ABSTRACT	O
:	O
In	O
a	O
model	O
of	O
acute	O
lung	O
injury	O
,	O
established	O
by	O
saline	O
lavage	O
of	O
isolated	O
perfused	O
rabbit	O
lungs	O
,	O
the	O
effect	O
of	O
ultrasonic	O
surfactant	O
nebulization	O
on	O
gas	B-ENZY
exchange	O
was	O
compared	O
with	O
that	O
of	O
tracheal	O
instillation	O
,	O
assessed	O
by	O
the	O
multiple	O
inert	O
gas	B-ENZY
elimination	O
technique	O
(	O
MIGET	O
).	O

We	O
confirmed	O
that	O
the	O
cells	O
cultured	O
in	O
horse	O
serum	O
were	O
devoid	O
of	O
Q	O
by	O
purifying	O
tRNAs	O
and	O
assessing	O
their	O
Q	O
-	O
content	O
by	O
tRNA	B-ENZY
transglycosylase	I-ENZY
assays	O
and	O
coupled	O
HPLC	O
-	O
mass	O
spectroscopy	O
.	O

Because	O
there	O
exist	O
normal	O
regions	O
in	O
the	O
lung	O
with	O
ARDS	O
and	O
because	O
PLV	O
in	O
the	O
normal	O
lung	O
results	O
in	O
worsened	O
gas	B-ENZY
exchange	O
,	O
we	O
postulated	O
that	O
the	O
optimal	O
dose	O
of	O
PFC	O
for	O
PLV	O
may	O
be	O
less	O
than	O
the	O
functional	O
residual	O
capacity	O
(	O
FRC	O
)	O
dose	O
in	O
the	O
lung	O
with	O
limited	O
disease	O
.	O

Our	O
modified	O
saline	O
solution	O
lavage	O
induced	O
atelectasis	O
and	O
hemorrhage	O
confined	O
to	O
the	O
dependent	O
lung	O
with	O
severe	O
hypoxia	O
(	O
PaO	B-ENZY
(	O
2	O
)/	O
fraction	O
of	O
inspired	O
oxygen	O
=	O
37	O
+/-	O

Peak	O
airway	O
pressure	O
(	O
Ppeak	O
)	O
and	O
inspiratory	O
pause	O
pressure	O
(	O
Ppause	O
)	O
with	O
PLV	O
were	O
lower	O
at	O
doses	O
of	O
3	O
to	O
15	O
mL	O
/	O
kg	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
),	O
but	O
not	O
different	O
at	O
a	O
dose	O
of	O
18	O
mL	O
/	O
kg	O
,	O
when	O
compared	O
with	O
gas	B-ENZY
ventilation	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
novel	O
cleavage	O
activity	O
of	O
the	O
first	O
papain	B-ENZY
-	O
like	O
proteinase	O
domain	O
encoded	O
by	O
open	O
reading	O
frame	O
1a	O
of	O
the	O
coronavirus	O
Avian	O
infectious	O
bronchitis	O
virus	O
and	O
characterization	O
of	O
the	O
cleavage	O
products	O
.	O

Previously	O
we	O
identified	O
the	O
first	O
cleavage	O
event	O
as	O
proteolysis	O
at	O
the	O
Gly	O
(	O
673	O
)-	O
Gly	O
(	O
674	O
)	O
dipeptide	O
bond	O
mediated	O
by	O
the	O
first	O
papain	B-ENZY
-	O
like	O
proteinase	O
domain	O
(	O
PLPD	O
-	O
1	O
)	O
to	O
release	O
an	O
87	O
-	O
kDa	O
mature	O
protein	O
.	O

If	O
the	O
binding	O
of	O
sialylated	O
macromolecules	O
was	O
prevented	O
by	O
neuraminidase	B-ENZY
treatment	O
,	O
the	O
parental	O
virus	O
was	O
as	O
sensitive	O
to	O
octylglucoside	O
as	O
were	O
the	O
HAD	O
mutants	O
.	O

There	O
was	O
a	O
strong	O
correlation	O
between	O
carbonyl	O
concentrations	O
in	O
lavage	O
fluid	O
and	O
plasma	O
,	O
and	O
between	O
protein	O
carbonyls	O
,	O
thiobarbituric	O
acid	O
-	O
reactive	O
substances	O
and	O
myeloperoxidase	B-ENZY
in	O
the	O
lungs	O
.	O

The	O
presence	O
of	O
pulmonary	O
edema	O
,	O
as	O
in	O
early	O
ARDS	O
and	O
HPE	O
predicts	O
a	O
beneficial	O
effect	O
of	O
the	O
prone	O
position	O
on	O
gas	B-ENZY
exchange	O
.	O

TITLE	O
:	O
Short	O
-	O
term	O
effect	O
of	O
inhaled	O
nitric	O
oxide	O
and	O
prone	O
positioning	O
on	O
gas	B-ENZY
exchange	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Lidocaine	O
attenuates	O
acute	O
lung	O
injury	O
induced	O
by	O
a	O
combination	O
of	O
phospholipase	B-ENZY
A2	I-ENZY
and	O
trypsin	B-ENZY
.	O

Acute	O
lung	O
injury	O
induced	O
by	O
phospholipase	B-ENZY
A2	I-ENZY
(	O
PLA2	O
)	O
or	O
trypsin	B-ENZY
,	O
a	O
pancreatic	O
enzyme	O
,	O
is	O
an	O
experimental	O
model	O
resembling	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Acute	O
lung	O
injury	O
was	O
induced	O
by	O
a	O
combination	O
of	O
PLA2	O
(	O
1000	O
units	O
/	O
kg	O
/	O
hr	O
)	O
and	O
trypsin	B-ENZY
(	O
5000	O
units	O
/	O
kg	O
/	O
hr	O
)	O
infused	O
intravenously	O
for	O
4	O
hrs	O
.	O

The	O
combination	O
of	O
PLA2	O
and	O
trypsin	B-ENZY
decreased	O
Pao2	O
,	O
lung	O
compliance	O
,	O
and	O
peripheral	O
counts	O
of	O
neutrophils	O
and	O
platelets	O
and	O
increased	O
alveolar	O
/	O
arterial	O
oxygen	O
tension	O
difference	O
,	O
lung	O
resistance	O
,	O
wet	O
weight	O
/	O
dry	O
weight	O
ratio	O
,	O
and	O
the	O
number	O
of	O
neutrophils	O
in	O
the	O
lung	O
.	O

In	O
this	O
particular	O
model	O
of	O
ARDS	O
the	O
monoclonal	O
antibody	O
against	O
the	O
CD11	O
-	O
CD18	O
complex	O
had	O
a	O
beneficial	O
effect	O
,	O
reducing	O
PMN	O
infiltration	O
and	O
oxygen	O
radical	O
release	O
in	O
the	O
lungs	O
,	O
preventing	O
alveolocapillary	O
membrane	O
damage	O
,	O
improving	O
gas	B-ENZY
exchange	O
and	O
,	O
finally	O
,	O
significantly	O
reducing	O
mortality	O
.	O

The	O
virus	O
neutralization	O
assay	O
was	O
performed	O
by	O
inoculating	O
24	O
-	O
to	O
-	O
25	O
-	O
day	O
-	O
old	O
turkey	O
embryos	O
via	O
the	O
amniotic	O
route	O
and	O
by	O
assessing	O
the	O
embryo	O
infectivity	O
on	O
the	O
basis	O
of	O
gross	O
intestinal	O
lesions	O
and	O
intestinal	O
maltase	B-ENZY
activity	O
at	O
72	O
hr	O
postinoculation	O
.	O

The	O
specificity	O
of	O
the	O
neuraminidase	B-ENZY
rapid	O
-	O
plate	O
HA	O
assay	O
was	O
examined	O
with	O
other	O
avian	O
viruses	O
in	O
individual	O
and	O
dual	O
embryonic	O
infections	O
.	O

Sensitivity	O
of	O
this	O
test	O
was	O
compared	O
with	O
embryo	O
lesions	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

The	O
rapid	O
-	O
plate	O
HA	O
assay	O
of	O
neuraminidase	B-ENZY
-	O
treated	O
allantoic	O
fluid	O
correlated	O
with	O
the	O
RT	O
-	O
PCR	O
during	O
the	O
early	O
stages	O
of	O
IBV	O
detection	O
,	O
identification	O
,	O
and	O
isolation	O
in	O
embryonated	O
eggs	O
.	O

We	O
show	O
that	O
TGEV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
,	O
-	O
6	O
,	O
-	O
7	O
,	O
-	O
8	O
,	O
and	O
-	O
9	O
and	O
cleavage	O
of	O
the	O
caspase	O
substrates	O
eIF4GI	O
,	O
gelsolin	O
,	O
and	O
alpha	O
-	O
fodrin	O
.	O

We	O
show	O
that	O
the	O
TGEV	O
nucleoprotein	O
is	O
a	O
substrate	O
for	O
both	O
caspase	B-ENZY
-	I-ENZY
6	I-ENZY
and	O
-	O
7	O
,	O
and	O
using	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
have	O
mapped	O
the	O
cleavage	O
site	O
to	O
VVPD	O
(	O
359	O
)	O
downward	O
arrow	O
.	O

The	O
depth	O
of	O
disorders	O
in	O
the	O
gas	B-ENZY
exchange	O
function	O
of	O
the	O
lungs	O
clearly	O
correlates	O
with	O
the	O
severity	O
of	O
burn	O
injury	O
and	O
the	O
terms	O
of	O
the	O
beginning	O
of	O
respiratory	O
support	O
.	O

TITLE	O
:	O
[	O
Effect	O
of	O
bronchial	O
drainage	O
on	O
the	O
improvement	O
in	O
gas	B-ENZY
exchange	O
observed	O
in	O
ventral	O
decubitus	O
in	O
ARDS	O
].	O

Haemodynamic	O
,	O
blood	O
gas	B-ENZY
and	O
respiratory	O
compliance	O
were	O
recorded	O
at	O
h0	O
,	O
h2	O
,	O
h3	O
,	O
h4	O
and	O
h6	O
.	O

CNI	O
-	O
1493	O
,	O
which	O
attenuates	O
mediator	O
production	O
through	O
p38	O
MAP	B-ENZY
kinase	I-ENZY
inhibition	O
,	O
was	O
administered	O
intraperitoneally	O
to	O
mice	O
while	O
control	O
animals	O
received	O
saline	O
.	O

Serum	O
hepatic	O
enzymes	O
and	O
hepatic	O
neutrophil	O
infiltration	O
by	O
myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
activity	O
were	O
measured	O
as	O
indicators	O
of	O
hepatic	O
insult	O
.	O

Exposure	O
of	O
the	O
liver	O
to	O
pancreatic	B-ENZY
elastase	I-ENZY
results	O
in	O
hepatic	O
inflammation	O
and	O
injury	O
which	O
appears	O
identical	O
to	O
that	O
seen	O
during	O
severe	O
AP	O
.	O

CONCLUSIONS	O
:	O
Exposure	O
of	O
the	O
liver	O
to	O
pancreatic	B-ENZY
elastase	I-ENZY
results	O
in	O
hepatic	O
inflammation	O
and	O
injury	O
which	O
appears	O
identical	O
to	O
that	O
seen	O
during	O
severe	O
AP	O
.	O

In	O
the	O
subgroup	O
of	O
four	O
trials	O
where	O
a	O
high	O
volume	O
strategy	O
(	O
HVS	B-ENZY
)	O
was	O
used	O
,	O
HFOV	O
results	O
in	O
more	O
favourable	O
pulmonary	O
outcomes	O
.	O

Of	O
the	O
four	O
trials	O
in	O
the	O
subgroup	O
using	O
surfactant	O
routinely	O
,	O
three	O
also	O
used	O
the	O
HVS	B-ENZY
.	O

In	O
the	O
subgroup	O
of	O
two	O
trials	O
(	O
HIFI	O
1989	O
,	O
Rettwitz	O
-	O
Volk	O
1998	O
)	O
not	O
using	O
a	O
HVS	B-ENZY
there	O
is	O
no	O
effect	O
of	O
HFOV	O
on	O
the	O
rate	O
of	O
CLD	O
;	O
however	O
,	O
there	O
is	O
an	O
increase	O
in	O
the	O
rate	O
of	O
PVL	O
[	O
summary	O
RR	O
1	O
.	O
64	O
(	O
1	O
.	O
02	O
,	O
2	O
.	O
64	O
).	O

The	O
overall	O
meta	O
-	O
analyses	O
is	O
dominated	O
by	O
the	O
large	O
HIFI	O
study	O
which	O
did	O
not	O
use	O
the	O
HVS	B-ENZY
recommended	O
on	O
the	O
basis	O
of	O
animal	O
studies	O
,	O
and	O
in	O
which	O
surfactant	O
was	O
not	O
available	O
.	O

Studies	O
which	O
used	O
HVS	B-ENZY
have	O
shown	O
some	O
benefits	O
in	O
short	O
term	O
measures	O
of	O
CLD	O
without	O
an	O
in	O

TITLE	O
:	O
Histoplasmosis	O
presenting	O
as	O
acute	O
respiratory	O
distress	O
syndrome	O
after	O
exposure	O
to	O
bat	B-ENZY
feces	O
in	O
a	O
home	O
basement	O
.	O

The	O
patient	O
had	O
severe	O
gas	B-ENZY
exchange	O
abnormalities	O
because	O
of	O
acute	O
lung	O
injury	O
and	O
marked	O
lung	O
collapse	O
.	O

With	O
the	O
recruitment	O
maneuvers	O
,	O
the	O
patient	O
had	O
a	O
dramatic	O
improvement	O
in	O
gas	B-ENZY
exchange	O
and	O
we	O
were	O
able	O
to	O
demonstrate	O
nearly	O
complete	O
recruitment	O
of	O
the	O
lung	O
by	O
computed	O
tomography	O
.	O

However	O
,	O
its	O
sequence	O
suggests	O
some	O
structural	O
relationship	O
to	O
the	O
chymotrypsin	B-ENZY
-	O
like	O
serine	O
proteases	O
of	O
arteriviruses	O
.	O

If	O
a	O
Pa	O
-	O
CO2	O
reached	O
>	O
75	O
torr	O
(	O
10	O
.	O
0	O
kPa	O
)	O
and	O
/	O
or	O
pH	O
<	O
7	O
.	O
20	O
,	O
tracheal	O
gas	B-ENZY
insufflation	O
(	O
TGI	O
)	O
was	O
instituted	O
.	O

TITLE	O
:	O
Isolation	O
of	O
respiratory	O
bovine	O
coronavirus	O
,	O
other	O
cytocidal	O
viruses	O
,	O
and	O
Pasteurella	O
spp	B-ENZY
from	O
cattle	O
involved	O
in	O
two	O
natural	O
outbreaks	O
of	O
shipping	O
fever	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
cytocidal	O
viruses	O
and	O
Pasteurella	O
spp	B-ENZY
that	O
could	O
be	O
isolated	O
from	O
cattle	O
involved	O
in	O
2	O
natural	O
outbreaks	O
of	O
shipping	O
fever	O
.	O

Pasteurella	O
spp	B-ENZY
was	O
cultured	O
from	O
4	O
and	O
6	O
cattle	O
at	O
the	O
order	O
-	O
buyer	O
'	O
s	O
barn	O
and	O
from	O
92	O
and	O
72	O
cattle	O
on	O
arrival	O
at	O
the	O
feedlot	O
during	O
the	O
1997	O
and	O
1998	O
outbreaks	O
,	O
respectively	O
.	O

More	O
than	O
80	O
%	O
of	O
the	O
sick	O
cattle	O
shed	O
RBCV	O
at	O
the	O
beginning	O
of	O
2	O
outbreaks	O
when	O
the	O
Pasteurella	O
spp	B-ENZY
infection	O
rate	O
was	O
low	O
.	O

Pasteurella	O
spp	B-ENZY
was	O
cultured	O
from	O
4	O
and	O
6	O
cattle	O
at	O
the	O
order	O
-	O
buyer	O
'	O
s	O
barn	O
and	O
from	O
92	O
and	O
72	O
cattle	O
on	O
arrival	O
at	O
the	O
feedlot	O
during	O
the	O
1997	O
and	O
1998	O
outbreaks	O
,	O
respectively	O
.	O

Since	O
mammal	O
lungs	O
are	O
evolutionary	O
specialised	O
to	O
gas	B-ENZY
exchange	O
using	O
atmospheric	O
oxygen	O
,	O
the	O
application	O
of	O
liquids	O
,	O
even	O
if	O
they	O
transport	O
respiratory	O
gases	O
very	O
well	O
is	O
not	O
physiologic	O
.	O

ABSTRACT	O
:	O
Faeces	O
samples	O
from	O
218	O
,	O
one	O
to	O
30	O
days	O
old	O
,	O
diarrheic	O
dairy	O
calves	O
in	O
65	O
dairy	O
herds	O
were	O
screened	O
for	O
the	O
presence	O
of	O
rotavirus	O
and	O
concurrent	O
infections	O
with	O
coronavirus	O
,	O
Cryptosporidium	O
,	O
F5	O
+	O
Escherichia	O
coli	O
and	O
Salmonella	O
spp	B-ENZY
.	O

ABSTRACT	O
:	O
The	O
defective	O
RNA	O
(	O
D	O
-	O
RNA	O
)	O
CD	O
-	O
61	O
,	O
derived	O
from	O
the	O
Beaudette	O
strain	O
of	O
the	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
was	O
used	O
as	O
an	O
RNA	O
vector	O
for	O
the	O
expression	O
of	O
two	O
reporter	O
genes	O
,	O
luciferase	B-ENZY
and	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
).	O

ABSTRACT	O
:	O
Abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
)	O
is	O
defined	O
as	O
cardiopulmonary	O
or	O
renal	O
dysfunction	O
caused	O
by	O
an	O
acute	O
increase	O
in	O
intraabdominal	O
pressure	O
.	O

Although	O
the	O
condition	O
is	O
well	O
described	O
in	O
adults	O
,	O
particularly	O
trauma	O
patients	O
,	O
little	O
is	O
known	O
about	O
ACS	B-ENZY
in	O
children	O
.	O

Three	O
girls	O
,	O
ages	O
4	O
,	O
5	O
,	O
and	O
5	O
years	O
,	O
were	O
treated	O
for	O
ACS	B-ENZY
by	O
silo	O
decompression	O
.	O

The	O
third	O
presented	O
with	O
shock	O
of	O
unknown	O
etiology	O
,	O
and	O
ACS	B-ENZY
developed	O
acutely	O
with	O
a	O
bladder	O
pressure	O
of	O
26	O
mm	O
Hg	O
.	O

ACS	B-ENZY
is	O
a	O
potentially	O
lethal	O
complication	O
of	O
severe	O
trauma	O
and	O
shock	O
in	O
children	O
.	O

ABSTRACT	O
:	O
Direct	O
automated	O
cycle	O
sequencing	O
(	O
DACS	B-ENZY
)	O
of	O
a	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
product	O
of	O
the	O
S	O
-	O
1	O
subunit	O
of	O
the	O
spike	O
peplomer	O
gene	O
was	O
used	O
to	O
identify	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
serotypes	O
.	O

The	O
S	O
-	O
1	O
nucleotide	O
sequences	O
generated	O
by	O
DACS	B-ENZY
were	O
aligned	O
and	O
analyzed	O
with	O
commercial	O
software	O
to	O
determine	O
their	O
relationship	O
to	O
the	O
S	O
-	O
1	O
nucleotide	O
sequences	O
of	O
IBV	O
strains	O
on	O
deposit	O
in	O
the	O
GenBank	O
and	O
EMBL	O
databases	O
.	O

Reference	O
strains	O
Massachusetts	O
(	O
Mass	O
)	O
41	O
,	O
Connecticut	O
(	O
Conn	O
),	O
Arkansas	O
(	O
Ark	O
)	O
DPI	O
,	O
JMK	O
,	O
and	O
DE	O
/	O
072	O
/	O
92	O
were	O
initially	O
tested	O
by	O
DACS	B-ENZY
to	O
establish	O
the	O
feasibility	O
of	O
the	O
procedure	O
.	O

The	O
DACS	B-ENZY
procedure	O
was	O
further	O
evaluated	O
with	O
a	O
panel	O
of	O
""""	O
unknowns	O
""""	O
comprised	O
of	O
IBV	O
reference	O
strains	O
,	O
field	O
isolates	O
,	O
and	O
variant	O
serotypes	O
collected	O
by	O
our	O
laboratory	O
.	O

The	O
S	O
-	O
1	O
nucleotide	O
sequences	O
for	O
the	O
amplified	O
PCR	O
products	O
of	O
reference	O
strains	O
Mass	O
41	O
,	O
Conn	O
,	O
Ark	O
DPI	O
,	O
JMK	O
,	O
and	O
DE	O
/	O
072	O
/	O
92	O
generated	O
by	O
DACS	B-ENZY
were	O
highly	O
homologous	O
(>	O
99	O
%	O
nucleotide	O
identity	O
)	O
with	O
their	O
respective	O
GenBank	O
database	O
sequences	O
.	O

In	O
the	O
unknown	O
panel	O
,	O
the	O
nucleotide	O
identities	O
of	O
the	O
DACS	B-ENZY
S	O
-	O
1	O
sequences	O
of	O
field	O
isolates	O
of	O
serotypes	O
previously	O
identified	O
by	O
virus	O
neutralization	O
were	O
also	O
found	O
to	O
be	O
very	O
high	O
(>	O
or	O
=	O
95	O
.	O
5	O
%)	O
after	O
alignment	O
with	O
database	O
sequences	O
.	O

DACS	B-ENZY
of	O
IBV	O
S	O
-	O
1	O
RT	O
-	O
PCR	O
products	O
will	O
enable	O
researchers	O
to	O
rapidly	O
identify	O
field	O
strains	O
,	O
including	O
new	O
,	O
previously	O
unrecognized	O
variant	O
virus	O
serotypes	O
.	O

Clinical	O
signs	O
,	O
virus	O
replication	O
and	O
(	O
histo	O
)	O
pathological	O
changes	O
in	O
the	O
lungs	O
,	O
percentage	O
of	O
neutrophils	O
and	O
bioactive	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1	O
in	O
broncho	O
-	O
alveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluids	O
were	O
examined	O
.	O

The	O
purified	O
recombinant	O
protein	O
had	O
in	O
vitro	O
ATPase	B-ENZY
activity	O
that	O
was	O
strongly	O
stimulated	O
by	O
poly	O
(	O
U	O
),	O
poly	O
(	O
dT	O
),	O
poly	O
(	O
C	O
),	O
and	O
poly	O
(	O
dA	O
),	O
but	O
not	O
by	O
poly	O
(	O
G	O
).	O

To	O
determine	O
the	O
separate	O
and	O
combined	O
effects	O
of	O
HFOV	O
and	O
PLV	O
when	O
initiated	O
after	O
the	O
establishment	O
of	O
acute	O
lung	O
injury	O
in	O
severe	O
respiratory	O
distress	O
syndrome	O
,	O
we	O
studied	O
the	O
effects	O
of	O
these	O
strategies	O
on	O
gas	B-ENZY
exchange	O
and	O
histologic	O
signs	O
of	O
acute	O
lung	O
injury	O
in	O
premature	O
lambs	O
.	O

Histologic	O
examination	O
and	O
myeloperoxidase	B-ENZY
assay	O
were	O
not	O
different	O
between	O
groups	O
.	O

Pulmonary	O
NF	O
-	O
kappaB	O
activation	O
,	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
gene	O
expression	O
,	O
and	O
neutrophil	O
infiltration	O
(	O
myeloperoxidase	B-ENZY
)	O
were	O
determined	O
and	O
myeloperoxidase	B-ENZY
experiments	O
repeated	O
in	O
p55	O
TNF	O
receptor	O
-	O
deficient	O
(	O
TNF	O
KO	O
)	O
animals	O
.	O

Pancreatic	B-ENZY
elastase	I-ENZY
induced	O
pulmonary	O
IkappaBalpha	O
/	O
IkappaBbeta	O
degradation	O
(	O
30	O
minutes	O
),	O
NF	O
-	O
kappaB	O
activation	O
(	O
60	O
minutes	O
),	O
and	O
TNF	O
gene	O
expression	O
(	O
60	O
minutes	O
)	O
with	O
subsequent	O
neutrophilic	O
inflammation	O
(	O
4	O
hours	O
)	O
and	O
microvascular	O
leakage	O
(	O
24	O
hours	O
),	O
whereas	O
amylase	O
,	O
lipase	B-ENZY
,	O
and	O
trypsin	B-ENZY
did	O
not	O
.	O

Pancreatic	B-ENZY
elastase	I-ENZY
induces	O
cytokine	O
-	O
mediated	O
lung	O
injury	O
and	O
this	O
pathway	O
involves	O
the	O
NF	O
-	O
kappaB	O
second	O
messenger	O
system	O
,	O
further	O
supporting	O
elastase	O
as	O
a	O
factor	O
linking	O
pancreatic	O
inflammation	O
to	O
systemic	O
illness	O
during	O
severe	O
acute	O
pancreatitis	O
.	O

TITLE	O
:	O
[	O
Inhalative	O
strategies	O
for	O
improvement	O
of	O
pulmonary	O
hemodynamics	O
and	O
gas	B-ENZY
exchange	O
in	O
sepsis	O
and	O
severe	O
pulmonary	O
hypertension	O
].	O

In	O
these	O
diseases	O
,	O
the	O
pulmonary	O
bloodflow	O
is	O
impaired	O
by	O
a	O
pathologic	O
constriction	O
of	O
blood	O
vessels	O
that	O
may	O
lead	O
to	O
right	O
ventricular	O
overloading	O
as	O
well	O
as	O
serious	O
worsening	O
of	O
gas	B-ENZY
exchange	O
mainly	O
caused	O
by	O
ventilation	O
/	O
perfusion	O
mismatch	O
.	O

Thus	O
,	O
the	O
decrease	O
in	O
pulmonary	O
-	O
vascular	O
resistance	O
is	O
paralleled	O
by	O
both	O
optimized	O
ventilation	O
-	O
perfusion	O
matching	O
and	O
subsequently	O
improved	O
gas	B-ENZY
exchange	O
.	O

TITLE	O
:	O
Identification	O
of	O
mouse	O
hepatitis	O
virus	O
papain	B-ENZY
-	O
like	O
proteinase	O
2	O
activity	O
.	O

Intracellular	O
M	O
protein	O
-	O
N	O
protein	O
interaction	O
was	O
maintained	O
after	O
removal	O
of	O
viral	O
RNAs	O
by	O
RNase	B-ENZY
treatment	O
.	O

Mycoplasma	O
spp	B-ENZY
.	O
are	O
regularly	O
found	O
in	O
an	O
upper	O
respiratory	O
disease	O
syndrome	O
complicated	O
by	O
opportunistic	O
bacterial	O
pathogens	O
.	O

ACE	B-ENZY
inhibitors	O
are	O
mainly	O
associated	O
with	O
cough	O
.	O

ABSTRACT	O
:	O
We	O
report	O
use	O
of	O
a	O
pumpless	O
extracorporeal	O
lung	O
assist	O
-	O
a	O
safe	O
and	O
effective	O
method	O
in	O
the	O
management	O
of	O
severe	O
acute	O
respiratory	O
failure	O
that	O
allows	O
an	O
extracorporal	O
gas	B-ENZY
-	O
exchange	O
without	O
the	O
use	O
of	O
a	O
pump	O
.	O

Mouse	O
eyes	O
harvested	O
at	O
varying	O
times	O
after	O
inoculation	O
were	O
evaluated	O
for	O
apoptotic	O
and	O
immunologic	O
events	O
by	O
hematoxylin	O
and	O
eosin	O
staining	O
,	O
immunohistochemical	O
staining	O
,	O
in	O
situ	O
terminal	B-ENZY
deoxynucleotidyltransferase	I-ENZY
dUTP	O
nick	O
-	O
end	O
labeling	O
(	O
TUNEL	O
)	O
assay	O
,	O
and	O
electron	O
microscopy	O
.	O

Reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
identified	O
the	O
upregulation	O
of	O
Fas	O
ligand	O
(	O
FasL	O
)	O
and	O
granzyme	B-ENZY
B	I-ENZY
mRNAs	O
within	O
the	O
infected	O
retinas	O
.	O

Two	O
and	O
17	O
cattle	O
nasally	O
shed	O
Pasteurella	O
spp	B-ENZY
.	O

ABSTRACT	O
:	O
A	O
54	O
-	O
year	O
-	O
old	O
patient	O
was	O
admitted	O
to	O
our	O
ICU	O
for	O
ketoacidosis	O
with	O
acute	O
respiratory	O
distress	O
(	O
ARD	B-ENZY
).	O

The	O
main	O
and	O
unusual	O
cause	O
of	O
ARD	B-ENZY
was	O
hypophosphataemia	O
.	O

Correction	O
of	O
the	O
metabolic	O
acidosis	O
by	O
insulin	O
therapy	O
resulted	O
in	O
intracellular	O
penetration	O
of	O
phosphate	O
and	O
potassium	O
,	O
causing	O
severe	O
hypophosphataemia	O
and	O
hypokaliaemia	O
responsible	O
for	O
ARD	B-ENZY
.	O

TITLE	O
:	O
RNase	B-ENZY
L	O
-	O
independent	O
specific	O
28S	O
rRNA	O
cleavage	O
in	O
murine	O
coronavirus	O
-	O
infected	O
cells	O
.	O

Furthermore	O
,	O
28S	O
rRNA	O
cleavage	O
occurred	O
in	O
an	O
MHV	O
-	O
infected	O
mouse	O
embryonic	O
fibroblast	O
cell	O
line	O
derived	O
from	O
RNase	B-ENZY
L	O
knockout	O
mice	O
.	O

Thus	O
,	O
MHV	O
-	O
induced	O
28S	O
rRNA	O
cleavage	O
was	O
independent	O
of	O
the	O
activation	O
of	O
RNase	B-ENZY
L	O
.	O
MHV	O
-	O
induced	O
28S	O
rRNA	O
cleavage	O
was	O
also	O
different	O
from	O
apoptosis	O
-	O
related	O
rRNA	O
degradation	O
,	O
which	O
usually	O
occurs	O
concomitantly	O
with	O
DNA	O
fragmentation	O
.	O

Using	O
immunohistochemistry	O
,	O
we	O
found	O
the	O
receptor	O
for	O
HCoV	O
-	O
229E	O
(	O
CD13	O
or	O
aminopeptidase	B-ENZY
N	I-ENZY
)	O
localized	O
mainly	O
to	O
the	O
apical	O
surface	O
of	O
airway	O
epithelia	O
.	O

RNase	B-ENZY
A	I-ENZY
treatment	O
of	O
the	O
purified	O
genome	O
-	O
length	O
RI	O
resulted	O
in	O
the	O
production	O
of	O
the	O
genome	O
-	O
length	O
replicative	O
form	O
RNA	O
,	O
indicating	O
that	O
the	O
genome	O
-	O
length	O
RI	O
included	O
genome	O
-	O
length	O
template	O
RNA	O
.	O

RNase	B-ENZY
protection	O
assays	O
using	O
the	O
purified	O
genome	O
-	O
length	O
RI	O
and	O
two	O
probes	O
,	O
which	O
corresponded	O
to	O
the	O
5	O
'	O
300	O
-	O
nt	O
region	O
of	O
mRNA	O
6	O
and	O
to	O
the	O
same	O
region	O
of	O
mRNA	O
7	O
,	O
showed	O
the	O
presence	O
of	O
nascent	O
leader	O
sequence	O
-	O
containing	O
subgenomic	O
mRNAs	O
in	O
the	O
genome	O
-	O
length	O
RI	O
.	O

The	O
protein	O
was	O
partially	O
purified	O
by	O
affinity	O
chromatography	O
and	O
shown	O
to	O
have	O
ATPase	B-ENZY
activity	O
that	O
was	O
strongly	O
stimulated	O
by	O
poly	O
(	O
dT	O
),	O
poly	O
(	O
U	O
),	O
and	O
poly	O
(	O
dA	O
)	O
but	O
not	O
by	O
poly	O
(	O
G	O
).	O

Goat	O
anti	O
-	O
turkey	O
immunoglobulin	O
G	O
(	O
light	O
plus	O
heavy	O
chains	O
)	O
conjugated	O
with	O
horseradish	O
peroxidase	B-ENZY
was	O
used	O
as	O
detector	O
antibody	O
.	O

TITLE	O
:	O
Comparison	O
of	O
virus	O
isolation	O
,	O
immunohistochemistry	O
,	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
procedures	O
for	O
detection	O
of	O
turkey	O
coronavirus	O
.	O

ABSTRACT	O
:	O
A	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
procedure	O
and	O
two	O
monoclonal	O
antibody	O
(	O
MAb	O
)-	O
based	O
immunohistochemical	O
procedures	O
were	O
developed	O
for	O
detection	O
of	O
turkey	O
coronavirus	O
(	O
TCV	O
)	O
in	O
tissues	O
and	O
intestinal	O
contents	O
/	O
dropping	O
samples	O
.	O

TITLE	O
:	O
Redesign	O
of	O
primer	O
and	O
application	O
of	O
the	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
test	O
to	O
the	O
DE072	O
strain	O
of	O
infectious	O
bronchitis	O
virus	O
.	O

ABSTRACT	O
:	O
Diagnosis	O
of	O
the	O
DE072	O
strain	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
by	O
the	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
serotype	O
identification	O
test	O
was	O
not	O
possible	O
because	O
the	O
primer	O
used	O
in	O
the	O
RT	O
-	O
PCR	O
did	O
not	O
amplify	O
the	O
S1	O
gene	O
of	O
the	O
DE072	O
strain	O
.	O

Although	O
there	O
are	O
significant	O
differences	O
among	O
species	O
in	O
the	O
basal	O
rates	O
of	O
sodium	O
and	O
fluid	O
transport	O
,	O
the	O
basic	O
mechanism	O
seems	O
to	O
depend	O
on	O
sodium	O
uptake	O
by	O
channels	O
on	O
the	O
apical	O
membrane	O
of	O
alveolar	O
type	O
II	O
cells	O
,	O
followed	O
by	O
extrusion	O
of	O
sodium	O
on	O
the	O
basolateral	O
surface	O
by	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
.	O

TITLE	O
:	O
Regional	O
distribution	O
of	O
gas	B-ENZY
and	O
tissue	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
Pulmonary	O
capillary	O
endothelium	O
-	O
bound	O
(	O
PCEB	O
)	O
angiotensin	O
-	O
converting	O
ectoenzyme	O
(	O
ACE	B-ENZY
)	O
activity	O
alteration	O
is	O
an	O
early	O
,	O
sensitive	O
,	O
and	O
quantifiable	O
lung	O
injury	O
index	O
in	O
animal	O
models	O
.	O

Applying	O
indicator	O
-	O
dilution	O
techniques	O
,	O
we	O
measured	O
single	O
-	O
pass	O
transpulmonary	O
hydrolysis	O
of	O
the	O
synthetic	O
ACE	B-ENZY
substrate	O
(	O
3	O
)	O
H	O
-	O
benzoyl	O
-	O
Phe	O
-	O
Ala	O
-	O
Pro	O
(	O
BPAP	O
)	O
in	O
33	O
mechanically	O
ventilated	O
,	O
critically	O
ill	O
patients	O
with	O
a	O
lung	O
injury	O
score	O
(	O
LIS	B-ENZY
)	O
ranging	O
from	O
0	O
(	O
no	O
lung	O
injury	O
)	O
to	O
3	O
.	O
7	O
(	O
severe	O
lung	O
injury	O
)	O
and	O
calculated	O
the	O
kinetic	O
parameter	O
A	O
(	O
max	O
)/	O
K	O
(	O
m	O
).	O

PCEB	O
-	O
ACE	B-ENZY
activity	O
decreases	O
early	O
during	O
ALI	O
,	O
correlates	O
with	O
the	O
clinical	O
severity	O
of	O
both	O
the	O
lung	O
injury	O
and	O
the	O
underlying	O
disease	O
,	O
and	O
may	O
be	O
used	O
as	O
a	O
quantifiable	O
marker	O
of	O
underlying	O
pulmonary	O
capillary	O
endothelial	O
dysfunction	O
.	O

ABSTRACT	O
:	O
Hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	B-ENZY
),	O
a	O
severe	O
respiratory	O
disease	O
with	O
high	O
mortality	O
caused	O
by	O
rodent	O
-	O
borne	O
hantaviruses	O
,	O
has	O
previously	O
been	O
identified	O
in	O
the	O
United	O
States	O
and	O
Canada	O
as	O
well	O
as	O
central	O
and	O
southern	O
South	O
America	O
.	O

In	O
late	O
1999	O
and	O
early	O
2000	O
,	O
an	O
outbreak	O
of	O
acute	O
illness	O
compatible	O
with	O
HPS	B-ENZY
was	O
reported	O
in	O
Los	O
Santos	O
,	O
Panama	O
,	O
with	O
the	O
death	O
of	O
3	O
of	O
the	O
12	O
(	O
25	O
%)	O
suspected	O
cases	O
.	O

Hantavirus	O
-	O
specific	O
antibodies	O
were	O
detected	O
in	O
patient	O
sera	O
,	O
and	O
virus	O
RNA	O
was	O
detected	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
.	O

Serologic	O
and	O
virus	O
genetic	O
analyses	O
of	O
rodents	O
trapped	O
in	O
the	O
area	O
showed	O
Oligoryzomys	O
fulvescens	O
to	O
be	O
the	O
likely	O
reservoir	O
for	O
the	O
HPS	B-ENZY
-	O
associated	O
Choclo	O
virus	O
.	O

Thereafter	O
the	O
calves	O
received	O
one	O
test	O
meal	O
of	O
whole	O
fresh	O
cow	O
'	O
s	O
milk	O
whose	O
lactose	O
had	O
been	O
hydrolysed	O
by	O
added	O
lactase	B-ENZY
and	O
one	O
test	O
meal	O
of	O
unprocessed	O
cow	O
'	O
s	O
milk	O
at	O
an	O
interval	O
of	O
24	O
h	O
in	O
a	O
cross	O
-	O
over	O
design	O
trial	O
.	O

We	O
have	O
developed	O
methods	O
to	O
quantify	O
the	O
haemagglutination	O
-	O
neuraminidase	B-ENZY
(	O
HN	O
)	O
and	O
fusion	O
(	O
F	O
)	O
proteins	O
of	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
),	O
the	O
viral	O
protein	O
3	O
(	O
VP3	O
)	O
of	O
the	O
infectious	O
bursal	O
disease	O
virus	O
(	O
IBDV	O
),	O
and	O
the	O
spike	O
-	O
1	O
(	O
S1	O
)	O
protein	O
of	O
the	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

Using	O
previously	O
described	O
BCV	O
primers	O
,	O
the	O
N	O
protein	O
gene	O
of	O
isolate	O
NC99	O
was	O
amplified	O
by	O
a	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
procedure	O
.	O

Animals	O
underwent	O
35	O
%	O
hepatic	O
resection	O
or	O
a	O
similar	O
volume	O
hepatic	O
cryo	O
and	O
were	O
sacrificed	O
at	O
1	O
,	O
2	O
,	O
6	O
,	O
and	O
24	O
h	O
.	O
Pulmonary	O
histologic	O
features	O
were	O
assessed	O
using	O
hematoxylin	O
and	O
eosin	O
and	O
immunoperoxidase	O
staining	O
with	O
a	O
macrophage	O
-	O
specific	O
antibody	O
(	O
anti	O
-	O
lysozyme	B-ENZY
,	O
1	O
:	O
200	O
dilution	O
,	O
Dako	O
,	O
Carpinteria	O
,	O
CA	O
).	O

TITLE	O
:	O
Temperature	O
-	O
sensitive	O
acetylesterase	B-ENZY
activity	O
of	O
haemagglutinin	O
-	O
esterase	O
specified	O
by	O
respiratory	O
bovine	O
coronaviruses	O
.	O

However	O
,	O
when	O
neuraminidase	B-ENZY
-	O
treated	O
virions	O
or	O
mutants	O
with	O
a	O
defective	O
sialic	O
acid	O
binding	O
activity	O
were	O
analyzed	O
,	O
the	O
S	O
protein	O
remained	O
in	O
the	O
supernatant	O
rather	O
than	O
in	O
the	O
pellet	O
fraction	O
.	O

For	O
scoring	O
the	O
severity	O
of	O
respiratory	O
failure	O
,	O
the	O
lung	O
injury	O
score	O
(	O
LIS	B-ENZY
)	O
according	O
to	O
Murray	O
and	O
the	O
SOFA	O
score	O
lung	O
(	O
sepsis	O
-	O
related	O
organ	O
failure	O
assessment	O
)	O
according	O
to	O
Vincent	O
were	O
evaluated	O
.	O

Direct	O
binding	O
of	O
the	O
M	O
protein	O
to	O
the	O
nucleoprotein	O
was	O
predicted	O
,	O
since	O
degradation	O
of	O
the	O
exposed	O
RNA	O
by	O
RNase	B-ENZY
treatment	O
did	O
not	O
affect	O
the	O
binding	O
.	O

ABSTRACT	O
:	O
The	O
specific	O
endothelial	O
cell	O
product	O
von	O
Willebrand	O
factor	O
antigen	O
(	O
vWf	O
:	O
Ag	O
)	O
was	O
measured	O
in	O
plasma	O
and	O
lung	O
function	O
tests	O
were	O
carried	O
out	O
and	O
the	O
following	O
lung	O
injury	O
parameters	O
measured	O
:	O
P	O
(	O
a	O
)	O
O2	O
/	O
F	O
(	O
i	O
)	O
O2	O
ratio	O
,	O
static	O
respiratory	O
compliance	O
and	O
Murray	O
'	O
s	O
lung	O
injury	O
score	O
(	O
LIS	B-ENZY
)	O
in	O
a	O
follow	O
-	O
up	O
study	O
of	O
36	O
severely	O
traumatized	O
patients	O
.	O

Significant	O
correlations	O
were	O
observed	O
between	O
initial	O
vWf	O
:	O
Ag	O
concentration	O
and	O
ISS	O
,	O
APACHE	O
II	O
,	O
LIS	B-ENZY
.	O

TITLE	O
:	O
Effects	O
of	O
surfactant	O
treatment	O
on	O
gas	B-ENZY
-	O
exchange	O
and	O
clinical	O
course	O
in	O
near	O
-	O
term	O
newborns	O
with	O
RDS	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
if	O
there	O
is	O
a	O
relationship	O
between	O
acute	O
improvement	O
in	O
pulmonary	O
gas	B-ENZY
exchange	O
and	O
surfactant	O
use	O
in	O
near	O
-	O
term	O
(	O
35	O
-	O
39	O
weeks	O
'	O
gestation	O
)	O
infants	O
with	O
respiratory	O
distress	O
syndrome	O
(	O
RDS	O
).	O

Digestion	O
with	O
RNase	B-ENZY
T1	O
at	O
1	O
-	O
10	O
units	O
/	O
microgram	O
RNA	O
resolved	O
RI	O
/	O
TIs	O
into	O
RF	O
/	O
TF	O
cores	O
and	O
left	O
native	O
RF	O
/	O
TFs	O
intact	O
,	O
whereas	O
RNase	B-ENZY
A	I-ENZY
at	O
concentrations	O
of	O
0	O
.	O
02	O
microgram	O
/	O
microgram	O
RNA	O
or	O
higher	O
degraded	O
both	O
native	O
RF	O
/	O
TFs	O
and	O
RI	O
/	O
TIs	O
.	O

Failure	O
originally	O
to	O
find	O
TIs	O
and	O
TF	O
cores	O
was	O
probably	O
due	O
to	O
overdigestion	O
with	O
RNase	B-ENZY
A	I-ENZY
.	O

TITLE	O
:	O
Nebulized	O
prostacyclin	O
(	O
PGI2	O
)	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
impact	O
of	O
primary	O
(	O
pulmonary	O
injury	O
)	O
and	O
secondary	O
(	O
extrapulmonary	O
injury	O
)	O
disease	O
on	O
gas	B-ENZY
exchange	O
response	O
.	O

To	O
fulfil	O
this	O
approach	O
,	O
sedation	O
,	O
neuromuscular	O
blocking	O
agents	O
and	O
full	O
mechanical	O
ventilatory	O
support	O
are	O
often	O
used	O
in	O
critical	O
failure	O
of	O
gas	B-ENZY
exchange	O
.	O

Improvement	O
of	O
gas	B-ENZY
exhange	O
occurred	O
after	O
application	O
of	O
combined	O
use	O
of	O
APRV	O
and	O
prone	O
positioning	O
.	O

APRV	O
and	O
maintenance	O
of	O
patients	O
'	O
spontaneous	O
ventilation	O
is	O
feasible	O
during	O
prone	O
positioning	O
,	O
and	O
this	O
approach	O
may	O
have	O
beneficial	O
synergistic	O
effects	O
on	O
gas	B-ENZY
exhange	O
in	O
patients	O
with	O
severe	O
acute	O
lung	O
injury	O
.	O

PLs	O
were	O
isolated	O
by	O
thin	O
-	O
layer	O
chromatography	O
,	O
and	O
the	O
FA	O
profile	O
of	O
each	O
PL	O
class	O
was	O
assessed	O
by	O
gas	B-ENZY
chromatography	O
.	O

Infection	O
was	O
confirmed	O
with	O
a	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
test	O
and	O
by	O
immunohistochemical	O
demonstration	O
of	O
coronavirus	O
antigen	O
in	O
the	O
affected	O
tissues	O
,	O
including	O
the	O
left	O
testicle	O
.	O

TITLE	O
:	O
Mitochondrial	O
aconitase	B-ENZY
binds	O
to	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
mouse	O
hepatitis	O
virus	O
genome	O
.	O

The	O
complex	O
observed	O
in	O
gel	O
shift	O
assays	O
has	O
been	O
resolved	O
by	O
second	O
-	O
dimension	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
into	O
four	O
proteins	O
of	O
approximately	O
90	O
,	O
70	O
,	O
58	O
,	O
and	O
40	O
kDa	O
after	O
RNase	B-ENZY
treatment	O
.	O

Protein	O
microsequencing	O
identified	O
the	O
90	O
-	O
kDa	O
protein	O
as	O
mitochondrial	O
aconitase	B-ENZY
.	O

Antibody	O
raised	O
against	O
purified	O
mitochondrial	O
aconitase	B-ENZY
recognizes	O
the	O
RNA	O
-	O
protein	O
complex	O
and	O
the	O
90	O
-	O
kDa	O
protein	O
,	O
which	O
can	O
be	O
released	O
from	O
the	O
complex	O
by	O
RNase	B-ENZY
digestion	O
.	O

Furthermore	O
,	O
UV	O
cross	O
-	O
linking	O
studies	O
indicate	O
that	O
highly	O
purified	O
mitochondrial	O
aconitase	B-ENZY
binds	O
specifically	O
to	O
the	O
MHV	O
3	O
'	O
protein	O
-	O
binding	O
element	O
.	O

The	O
binding	O
properties	O
of	O
mitochondrial	O
aconitase	B-ENZY
and	O
the	O
functional	O
relevance	O
of	O
RNA	O
binding	O
appear	O
to	O
parallel	O
those	O
of	O
cytoplasmic	O
aconitase	B-ENZY
.	O

TITLE	O
:	O
The	O
use	O
of	O
L	O
-	O
arginine	O
[	O
correction	O
of	O
F	O
-	O
arginine	O
]	O
and	O
phosphodiesterase	B-ENZY
inhibitor	O
(	O
dipyridamole	O
)	O
to	O
wean	O
from	O
inhaled	O
nitric	O
oxide	O
.	O

Exogeous	O
NO	O
may	O
lead	O
to	O
down	O
regulation	O
of	O
endogenous	O
NO	O
production	O
,	O
and	O
further	O
lead	O
to	O
rapid	O
hydrolization	O
of	O
cyclic	O
guanosine	O
3	O
',	O
5	O
'	O
monophosphate	O
(	O
cGMP	O
),	O
the	O
smooth	O
muscle	O
relaxant	O
,	O
by	O
the	O
enzyme	O
phosphodiesterase	B-ENZY
.	O

Moreover	O
L	O
-	O
Arginine	O
,	O
the	O
precursor	O
for	O
the	O
formation	O
of	O
endogenous	O
NO	O
,	O
has	O
been	O
found	O
to	O
be	O
deficient	O
in	O
neonates	O
with	O
PPHN	O
,	O
so	O
we	O
speculated	O
that	O
by	O
inhibiting	O
phosphodiesterase	B-ENZY
and	O
administrating	O
L	O
-	O
Arginine	O
smooth	O
muscle	O
relaxation	O
occurred	O
,	O
and	O
consequent	O
weaning	O
from	O
iNO	O
was	O
achieved	O
.	O

However	O
,	O
chest	O
radiography	O
and	O
arterial	O
blood	O
gas	B-ENZY
sampling	O
appear	O
to	O
be	O
useful	O
,	O
while	O
short	O
-	O
term	O
spirometry	O
measurements	O
do	O
not	O
.	O

TITLE	O
:	O
Meconium	O
aspiration	O
syndrome	O
:	O
a	O
role	O
for	O
phospholipase	B-ENZY
A2	I-ENZY
in	O
the	O
pathogenesis	O
?	O

TITLE	O
:	O
Role	O
of	O
stromelysin	B-ENZY
1	I-ENZY
and	O
gelatinase	B-ENZY
B	I-ENZY
in	O
experimental	O
acute	O
lung	O
injury	O
.	O

The	O
gelatinase	B-ENZY
B	I-ENZY
-	O
and	O
the	O
stromelysin	B-ENZY
1	I-ENZY
-	O
deficient	O
mice	O
had	O
less	O
severe	O
lung	O
injury	O
than	O
did	O
the	O
WT	O
controls	O
,	O
suggesting	O
that	O
both	O
MMPs	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
the	O
lung	O
injury	O
.	O

These	O
studies	O
indicate	O
,	O
first	O
,	O
that	O
both	O
gelatinase	B-ENZY
B	I-ENZY
and	O
stromelysin	B-ENZY
1	I-ENZY
are	O
involved	O
in	O
the	O
development	O
of	O
experimental	O
acute	O
lung	O
injury	O
,	O
and	O
second	O
,	O
that	O
the	O
mechanisms	O
by	O
which	O
these	O
individual	O
MMPs	O
function	O
appear	O
to	O
differ	O
.	O

33	O
ng	O
/	O
l	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
during	O
ANP	O
infusion	O
,	O
there	O
were	O
no	O
changes	O
in	O
mean	O
pulmonary	O
artery	O
pressure	O
,	O
pulmonary	O
vascular	O
resistance	O
index	O
,	O
extravascular	O
lung	O
water	O
index	O
,	O
or	O
in	O
pulmonary	O
gas	B-ENZY
exchange	O
.	O

Furthermore	O
,	O
NO	O
inhalation	O
improved	O
pulmonary	O
gas	B-ENZY
exchange	O
,	O
reflected	O
by	O
a	O
decrease	O
in	O
alveolar	O
-	O
arterial	O
oxygen	O
gradient	O
(	O
from	O
41	O
.	O
9	O
+/-	O

ABSTRACT	O
:	O
Partial	O
liquid	O
ventilation	O
with	O
the	O
perfluorochemical	O
,	O
perflubron	O
,	O
has	O
been	O
shown	O
to	O
improve	O
lung	O
mechanics	O
and	O
enhance	O
gas	B-ENZY
exchange	O
in	O
the	O
treatment	O
of	O
severe	O
acute	O
lung	O
injury	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
hemodynamic	O
variables	O
or	O
gas	B-ENZY
exchange	O
after	O
lung	O
injury	O
in	O
the	O
four	O
groups	O
.	O

Caspase	O
-	O
dependent	O
apoptosis	O
,	O
as	O
characterized	O
by	O
chromosomal	O
condensation	O
,	O
DNA	O
fragmentation	O
,	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
activation	O
,	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
degradation	O
,	O
was	O
detected	O
in	O
IBV	O
-	O
infected	O
Vero	O
cells	O
.	O

ABSTRACT	O
:	O
A	O
stable	O
recombinant	O
fowl	O
poxvirus	O
(	O
rFPV	O
)	O
expressing	O
the	O
C	O
-	O
terminal	O
region	O
(	O
119	O
amino	O
acids	O
)	O
of	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
an	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
strain	O
Ch3	O
was	O
constructed	O
by	O
inserting	O
the	O
coding	O
sequence	O
within	O
the	O
thymidine	B-ENZY
kinase	I-ENZY
gene	O
of	O
fowl	O
poxvirus	O
(	O
FPV	O
)	O
by	O
homologous	O
recombination	O
.	O

ABSTRACT	O
:	O
Eleven	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
isolates	O
foreign	O
to	O
the	O
United	O
States	O
were	O
analyzed	O
by	O
using	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)/	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
and	O
S1	O
glycoprotein	O
gene	O
sequencing	O
.	O

Blood	O
work	O
revealed	O
a	O
moderate	O
nonregenerative	O
anemia	O
,	O
leukocytosis	O
,	O
hypokalemia	O
,	O
hyperbilirubinemia	O
,	O
and	O
mildly	O
elevated	O
alanine	B-ENZY
aminotransferase	I-ENZY
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
.	O

ABSTRACT	O
:	O
To	O
explore	O
three	O
aspects	O
of	O
non	O
-	O
invasive	O
pressure	O
support	O
ventilation	O
(	O
NIPSV	O
)	O
applied	O
by	O
face	O
mask	O
to	O
patients	O
with	O
acute	O
respiratory	O
failure	O
(	O
ARF	O
)	O
due	O
to	O
severe	O
community	O
-	O
acquired	O
pneumonia	O
(	O
CAP	O
):	O
(	O
1	O
)	O
the	O
initial	O
acute	O
effects	O
on	O
respiratory	O
rate	O
,	O
gas	B-ENZY
exchange	O
and	O
hemodynamics	O
,	O
(	O
2	O
)	O
the	O
clinical	O
course	O
and	O
outcome	O
during	O
ICU	O
and	O
hospital	O
stay	O
,	O
(	O
3	O
)	O
the	O
nursing	O
workload	O
as	O
measured	O
by	O
the	O
daily	O
PRN	O
87	O
(	O
Project	O
Research	O
in	O
Nursing	O
)	O
score	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
effects	O
of	O
PFC	O
aerosol	O
compared	O
to	O
PGI2	O
aerosol	O
and	O
NaCl	O
aerosol	O
on	O
gas	B-ENZY
exchange	O
and	O
lung	O
mechanics	O
in	O
oleic	O
acid	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

The	O
inhalation	O
of	O
a	O
PFC	O
aerosol	O
led	O
to	O
a	O
significant	O
improvement	O
in	O
pulmonary	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
,	O
which	O
was	O
not	O
observed	O
in	O
the	O
other	O
two	O
groups	O
.	O

These	O
data	O
suggest	O
that	O
a	O
small	O
dose	O
of	O
perfluorocarbon	O
will	O
have	O
beneficial	O
effects	O
on	O
gas	B-ENZY
exchange	O
and	O
respiratory	O
mechanics	O
.	O

It	O
is	O
autocatalytically	O
released	O
from	O
the	O
precursors	O
pp1a	O
and	O
pp1ab	O
by	O
one	O
zinc	O
finger	O
-	O
containing	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
in	O
IBV	O
and	O
by	O
two	O
paralogous	O
PLpros	O
,	O
PL1pro	O
and	O
PL2pro	O
,	O
in	O
mouse	O
hepatitis	O
virus	O
.	O

One	O
specific	O
site	O
on	O
the	O
S	O
glycoprotein	O
of	O
bovine	O
coronavirus	O
must	O
be	O
cleaved	O
by	O
an	O
intracellular	O
protease	O
or	O
trypsin	B-ENZY
to	O
activate	O
viral	O
infectivity	O
and	O
cell	O
fusion	O
.	O

Because	O
the	O
N	O
-	O
terminal	O
was	O
blocked	O
,	O
we	O
digested	O
the	O
protein	O
in	O
-	O
gel	O
with	O
trypsin	B-ENZY
and	O
sequenced	O
various	O
peptides	O
.	O

Additionally	O
,	O
a	O
second	O
protein	O
recognized	O
by	O
the	O
autoAb	O
was	O
detected	O
during	O
FAH	O
purification	O
steps	O
and	O
was	O
identified	O
as	O
liver	O
alcohol	B-ENZY
dehydrogenase	I-ENZY
.	O

TITLE	O
:	O
Aerosolized	O
prostacyclin	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
caused	O
by	O
Chlamydiaceae	O
spp	B-ENZY
.	O

Although	O
the	O
initial	O
insult	O
may	O
cause	O
overwhelming	O
tissue	O
damage	O
with	O
subsequent	O
gas	B-ENZY
exchange	O
impairment	O
and	O
risk	O
of	O
death	O
,	O
several	O
strategies	O
of	O
management	O
may	O
also	O
add	O
substantial	O
toxicity	O
.	O

An	O
increased	O
understanding	O
of	O
both	O
the	O
benefits	O
and	O
hazards	O
has	O
led	O
to	O
a	O
general	O
consensus	O
regarding	O
the	O
optimal	O
techniques	O
to	O
ensure	O
adequate	O
gas	B-ENZY
exchange	O
.	O

Angioedema	O
is	O
well	O
documented	O
in	O
patients	O
taking	O
ACE	B-ENZY
inhibitors	O
.	O

Considering	O
that	O
35	O
to	O
40	O
million	O
patients	O
are	O
treated	O
worldwide	O
with	O
ACE	B-ENZY
inhibitors	O
,	O
this	O
drug	O
class	O
could	O
account	O
for	O
several	O
hundred	O
deaths	O
per	O
year	O
from	O
laryngeal	O
oedema	O
.	O

ACE	B-ENZY
inhibitors	O
certainly	O
do	O
not	O
mediate	O
angioedema	O
through	O
an	O
allergic	O
or	O
idiosyncratic	O
reaction	O
.	O

This	O
adverse	O
effect	O
seems	O
to	O
occur	O
less	O
frequently	O
with	O
angiotensin	O
II	O
receptor	O
antagonists	O
than	O
with	O
ACE	B-ENZY
inhibitors	O
.	O

Scattered	O
reports	O
suggest	O
the	O
possibility	O
of	O
angioedema	O
associated	O
with	O
the	O
use	O
of	O
estrogens	O
,	O
antihypertensive	O
drugs	O
other	O
than	O
ACE	B-ENZY
inhibitors	O
,	O
and	O
psychotropic	O
drugs	O
.	O

In	O
the	O
case	O
of	O
ACE	B-ENZY
inhibitors	O
,	O
the	O
appearance	O
of	O
angioedema	O
following	O
long	O
term	O
treatment	O
does	O
not	O
lessen	O
the	O
probability	O
that	O
such	O
an	O
agent	O
could	O
be	O
the	O
cause	O
.	O

Pulmonary	O
hemodynamics	O
and	O
gas	B-ENZY
exchange	O
are	O
related	O
to	O
changes	O
of	O
arterial	O
prostanoid	O
levels	O
in	O
ARDS	O
patients	O
,	O
depending	O
on	O
the	O
rate	O
of	O
fat	O
infusion	O
.	O

CONCLUSIONS	O
:	O
Pulmonary	O
hemodynamics	O
and	O
gas	B-ENZY
exchange	O
are	O
related	O
to	O
changes	O
of	O
arterial	O
prostanoid	O
levels	O
in	O
ARDS	O
patients	O
,	O
depending	O
on	O
the	O
rate	O
of	O
fat	O
infusion	O
.	O

ABSTRACT	O
:	O
Organophosphate	O
(	O
OP	O
)	O
insecticides	O
inhibit	O
both	O
cholinesterase	B-ENZY
and	O
pseudo	O
-	O
cholinesterase	B-ENZY
activities	O
.	O

PCT	O
was	O
detectable	O
in	O
BAL	B-ENZY
fluids	O
of	O
all	O
14	O
patients	O
.	O

PCT	O
and	O
interleukin	O
-	O
6	O
BAL	B-ENZY
levels	O
cannot	O
be	O
considered	O
as	O
reliable	O
parameters	O
to	O
assess	O
the	O
extent	O
of	O
lung	O
contusion	O
.	O

ABSTRACT	O
:	O
Aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
),	O
a	O
150	O
-	O
kDa	O
metalloprotease	O
also	O
called	O
CD13	O
,	O
serves	O
as	O
a	O
receptor	O
for	O
serologically	O
related	O
coronaviruses	O
of	O
humans	O
(	O
human	O
coronavirus	O
229E	O
[	O
HCoV	O
-	O
229E	O
]),	O
pigs	O
,	O
and	O
cats	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
and	O
sepsis	O
exhibit	O
decreased	O
plasma	O
selenium	O
and	O
glutathione	B-ENZY
peroxidase	I-ENZY
activity	O
.	O

In	O
a	O
patient	O
with	O
a	O
long	O
history	O
of	O
smoking	O
and	O
emphysema	O
,	O
PCP	O
may	O
trigger	O
-	O
macrophage	O
activation	O
and	O
an	O
excessive	O
release	O
of	O
leukocyte	B-ENZY
elastase	I-ENZY
,	O
leading	O
to	O
elastin	O
destruction	O
in	O
the	O
alveoli	O
.	O

In	O
the	O
subgroup	O
of	O
six	O
trials	O
where	O
a	O
high	O
volume	O
strategy	O
(	O
HVS	B-ENZY
)	O
was	O
used	O
for	O
HFOV	O
,	O
this	O
is	O
associated	O
with	O
significantly	O
lower	O
rates	O
of	O
CLD	O
in	O
survivors	O
at	O
28	O
-	O
30	O
days	O
[	O
three	O
trials	O
,	O
summary	O
RR	O
0	O
.	O
53	O
(	O
0	O
.	O
36	O
,	O
0	O
.	O
76	O
)],	O
of	O
'	O
death	O
or	O
CLD	O
at	O
28	O
-	O
30	O
days	O
'	O
[	O
three	O
trials	O
,	O
summary	O
RR	O
0	O
.	O
56	O
(	O
0	O
.	O
40	O
,	O
0	O
.	O
77	O
)	O
and	O
oxygen	O
use	O
at	O
36	O
-	O
37	O
weeks	O
postmenstrual	O
age	O
or	O
discharge	O
[	O
five	O
trials	O
,	O
summary	O
RR	O
0	O
.	O
72	O
(	O
0	O
.	O
56	O
,	O
0	O
.	O
93	O
)].	O

In	O
this	O
group	O
of	O
trials	O
HFOV	O
is	O
associated	O
with	O
a	O
strong	O
trend	O
for	O
an	O
increased	O
rate	O
of	O
gross	O
pulmonary	O
ALS	O
(	O
four	O
trials	O
,	O
summary	O
RR	O
1	O
.	O
54	O
(	O
0	O
.	O
98	O
,	O
2	O
.	O
42	O
)]	O
In	O
the	O
subgroup	O
of	O
two	O
trials	O
(	O
HIFI	O
1989	O
,	O
Rettwitz	O
-	O
Volk	O
1998	O
)	O
not	O
using	O
a	O
HVS	B-ENZY
there	O
is	O
no	O
effect	O
of	O
HFOV	O
on	O
the	O
rate	O
of	O
CLD	O
;	O
however	O
,	O
there	O
is	O
an	O
increase	O
in	O
the	O
rate	O
of	O
periventricular	O
leukomalacia	O
(	O
PVL	O
)	O
[	O
summary	O
RR	O
1	O
.	O
64	O
(	O
1	O
.	O
02	O
,	O
2	O
.	O
64	O
).	O

The	O
solution	O
could	O
be	O
the	O
use	O
of	O
tracheal	O
gas	B-ENZY
which	O
insufflation	O
(	O
TGI	O
)	O
allows	O
the	O
reduction	O
of	O
arterial	O
carbon	O
dioxide	O
tension	O
(	O
PaCO	O
(	O
2	O
))	O
while	O
controlling	O
airway	O
pressures	O
.	O

The	O
decrease	O
of	O
tidal	O
volume	O
(	O
by	O
60	O
and	O
25	O
%	O
respectively	O
)	O
in	O
association	O
with	O
tracheal	O
gas	B-ENZY
insufflation	O
allowed	O
to	O
reduce	O
plateau	O
airway	O
pressure	O
(<	O
35	O
cm	O
d	O
'	O
H	O
(	O
2	O
)	O
O	O
)	O
and	O
PaCO	O
(	O
2	O
)	O
(	O
in	O
the	O
first	O
case	O
by	O
23	O
%	O
and	O
in	O
the	O
second	O
case	O
,	O
by	O
11	O
%	O
for	O
the	O
second	O
hour	O
then	O
by	O
24	O
%),	O
while	O
intracranial	O
pressure	O
remained	O
constant	O
or	O
was	O
lowered	O
(	O
in	O
the	O
second	O
case	O
by	O
39	O
%	O
for	O
the	O
second	O
hour	O
).	O

To	O
determine	O
the	O
role	O
of	O
RNA	O
secondary	O
structures	O
within	O
these	O
two	O
host	O
protein	O
binding	O
elements	O
in	O
viral	O
replication	O
,	O
we	O
explored	O
the	O
secondary	O
structure	O
of	O
the	O
3	O
'-	O
terminal	O
166	O
nucleotides	O
of	O
the	O
MHV	O
strain	O
JHM	O
genome	O
using	O
limited	O
RNase	B-ENZY
digestion	O
assays	O
.	O

The	O
existence	O
of	O
a	O
population	O
of	O
M	O
molecules	O
adopting	O
a	O
Nexo	O
-	O
Cexo	O
topology	O
in	O
the	O
virion	O
envelope	O
was	O
demonstrated	O
by	O
(	O
i	O
)	O
immunopurification	O
of	O
(	O
35	O
)	O
S	O
-	O
labeled	O
TGEV	O
virions	O
using	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
specific	O
for	O
the	O
M	O
protein	O
carboxy	O
terminus	O
(	O
this	O
immunopurification	O
was	O
inhibited	O
only	O
by	O
deletion	O
mutant	O
M	O
proteins	O
that	O
maintained	O
an	O
intact	O
carboxy	O
terminus	O
),	O
(	O
ii	O
)	O
direct	O
binding	O
of	O
M	O
-	O
specific	O
MAbs	O
to	O
the	O
virus	O
surface	O
,	O
and	O
(	O
iii	O
)	O
mass	O
spectrometry	O
analysis	O
of	O
peptides	O
released	O
from	O
trypsin	B-ENZY
-	O
treated	O
virions	O
.	O

IL	O
-	O
8	O
and	O
other	O
proinflammatory	O
mediator	O
expression	O
was	O
measured	O
by	O
ELISA	O
,	O
northern	O
blotting	O
or	O
multi	O
-	O
probe	O
RNase	B-ENZY
protection	O
assay	O
.	O

Mean	O
systemic	O
arterial	O
pressure	O
,	O
mean	O
pulmonary	O
arterial	O
pressure	O
,	O
arterial	O
oxygen	O
tension	O
(	O
PO2	O
),	O
pulmonary	O
myeloperoxidase	B-ENZY
activity	O
,	O
and	O
neutrophil	O
respiratory	O
burst	O
activity	O
.	O

It	O
reduced	O
pulmonary	O
myeloperoxidase	B-ENZY
activity	O
and	O
peripheral	O
neutropenia	O
and	O
increased	O
neutrophil	O
respiratory	O
burst	O
activity	O
.	O

RESULTS	O
:	O
Endotoxin	O
induced	O
a	O
severe	O
lung	O
injury	O
characterised	O
by	O
a	O
decrease	O
in	O
mean	O
systemic	O
blood	O
pressure	O
and	O
an	O
increase	O
in	O
pulmonary	O
artery	O
pressure	O
,	O
hypoxia	O
,	O
and	O
an	O
increase	O
in	O
pulmonary	O
myeloperoxidase	B-ENZY
activity	O
.	O

It	O
reduced	O
pulmonary	O
myeloperoxidase	B-ENZY
activity	O
and	O
peripheral	O
neutropenia	O
and	O
increased	O
neutrophil	O
respiratory	O
burst	O
activity	O
.	O

TITLE	O
:	O
Immediate	O
effects	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
and	O
low	O
and	O
high	O
tidal	O
volume	O
ventilation	O
upon	O
gas	B-ENZY
exchange	O
and	O
compliance	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
The	O
surface	O
-	O
functionalization	O
of	O
shell	O
cross	O
-	O
linked	O
(	O
SCK	O
)	O
nanoparticles	O
with	O
the	O
oligomeric	O
peptide	O
sequence	O
YGRKKRRQRRR	O
,	O
the	O
protein	O
transduction	O
domain	O
(	O
PTD	O
)	O
from	O
the	O
human	O
immunodeficiency	O
virus	O
TAT	B-ENZY
protein	O
,	O
is	O
described	O
,	O
and	O
the	O
cell	O
binding	O
interactions	O
these	O
nanobioconjugates	O
exhibit	O
are	O
demonstrated	O
.	O

Serum	O
sES	O
and	O
plasma	O
vWF	O
:	O
Ag	O
concentrations	O
were	O
measured	O
and	O
PaO2	O
/	O
FiO2	O
ratio	O
,	O
Lung	O
Injury	O
Score	O
(	O
LIS	B-ENZY
)	O
and	O
APACHE	O
II	O
ratio	O
were	O
calculated	O
at	O
the	O
admission	O
to	O
IC	O
,	O
after	O
24	O
h	O
and	O
on	O
2	O
,	O
3	O
,	O
5	O
,	O
7	O
,	O
10th	O
day	O
.	O

Among	O
these	O
,	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitors	O
have	O
shown	O
the	O
most	O
promise	O
and	O
are	O
currently	O
undergoing	O
Phase	O
III	O
trials	O
.	O

ACE	B-ENZY
inhibitors	O
(	O
and	O
angiotensin	O
-	O
receptor	O
antagonists	O
)	O
should	O
be	O
discontinued	O
due	O
to	O
fetotoxicity	O
.	O

Although	O
the	O
serum	O
concentrations	O
of	O
both	O
organophosphate	O
compounds	O
rapidly	O
decreased	O
,	O
the	O
activity	O
of	O
cholinesterase	B-ENZY
showed	O
a	O
prolonged	O
inhibition	O
.	O

At	O
least	O
three	O
coronavirus	O
strains	O
within	O
group	O
2	O
expressed	O
a	O
structural	O
protein	O
with	O
sialate	O
-	O
4	O
-	O
O	O
-	O
acetylesterase	B-ENZY
activity	O
,	O
distinguishing	O
them	O
from	O
other	O
members	O
of	O
group	O
2	O
,	O
which	O
encode	O
an	O
enzyme	O
specific	O
for	O
5	O
-	O
N	O
-	O
acetyl	O
-	O
9	O
-	O
O	O
-	O
acetylneuraminic	O
acid	O
.	O

Expression	O
of	O
the	O
reporter	O
gene	O
beta	B-ENZY
-	I-ENZY
glucuronidase	I-ENZY
(	O
GUS	O
)	O
(	O
2	O
-	O
8	O
microg	O
per	O
10	O
(	O
6	O
)	O
cells	O
)	O
and	O
the	O
porcine	O
respiratory	O
and	O
reproductive	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
ORF5	O
(	O
1	O
-	O
2	O
microg	O
per	O
10	O
(	O
6	O
)	O
cells	O
)	O
has	O
been	O
shown	O
using	O
a	O
TGEV	O
-	O
derived	O
minigenome	O
.	O

Third	O
,	O
replacements	O
of	O
Gly	O
(	O
83	O
)	O
and	O
Asn	O
(	O
64	O
),	O
which	O
were	O
candidates	O
to	O
occupy	O
the	O
position	O
spatially	O
equivalent	O
to	O
that	O
of	O
the	O
catalytic	O
Asp	O
residue	O
of	O
chymotrypsin	B-ENZY
-	O
like	O
proteases	O
,	O
resulted	O
in	O
proteolytically	O
active	O
proteins	O
.	O

ABSTRACT	O
:	O
We	O
present	O
an	O
extremely	O
rare	O
case	O
of	O
hemophagocytic	O
syndrome	O
(	O
HPS	B-ENZY
)	O
induced	O
by	O
fulminant	O
Mycoplasma	O
pneumoniae	O
(	O
Mp	O
)	O
pneumonia	O
in	O
an	O
elderly	O
adult	O
.	O

Physicians	O
should	O
be	O
aware	O
of	O
HPS	B-ENZY
as	O
a	O
complication	O
in	O
Mp	O
infection	O
.	O

The	O
serum	O
alanine	B-ENZY
aminotransferase	I-ENZY
activity	O
of	O
infected	O
BALB	O
-	O
GKO	O
mice	O
were	O
higher	O
than	O
that	O
of	O
B6	O
-	O
GKO	O
mice	O
and	O
was	O
paralleled	O
with	O
the	O
severity	O
of	O
the	O
pathological	O
changes	O
and	O
viral	O
titers	O
in	O
infected	O
mice	O
.	O

TITLE	O
:	O
Vascular	O
immunotargeting	O
of	O
glucose	B-ENZY
oxidase	I-ENZY
to	O
the	O
endothelial	O
antigens	O
induces	O
distinct	O
forms	O
of	O
oxidant	O
acute	O
lung	O
injury	O
:	O
targeting	O
to	O
thrombomodulin	O
,	O
but	O
not	O
to	O
PECAM	O
-	O
1	O
,	O
causes	O
pulmonary	O
thrombosis	O
and	O
neutrophil	O
transmigration	O
.	O

Vascular	O
immunotargeting	O
of	O
the	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)-	O
generating	O
enzyme	O
glucose	B-ENZY
oxidase	I-ENZY
(	O
GOX	B-ENZY
)	O
to	O
the	O
pulmonary	O
endothelium	O
causes	O
an	O
acute	O
oxidative	O
lung	O
injury	O
in	O
mice	O
.(	O
1	O
)	O
In	O
the	O
present	O
study	O
we	O
compared	O
the	O
pulmonary	O
thrombosis	O
and	O
leukocyte	O
transmigration	O
caused	O
by	O
GOX	B-ENZY
targeting	O
to	O
the	O
endothelial	O
antigens	O
platelet	O
-	O
endothelial	O
cell	O
adhesion	O
molecule	O
(	O
PECAM	O
)	O
and	O
thrombomodulin	O
(	O
TM	O
).	O

CONCLUSIONS	O
:	O
Pharmacodynamics	O
of	O
iNO	O
in	O
this	O
model	O
was	O
related	O
to	O
improvement	O
in	O
gas	B-ENZY
exchange	O
,	O
Cdyn	O
,	O
PVRI	O
,	O
and	O
suppression	O
of	O
proinflammatory	O
cytokine	O
expression	O
in	O
the	O
lungs	O
,	O
and	O
its	O
adverse	O
effect	O
was	O
mainly	O
confined	O
to	O
MetHb	O
at	O
higher	O
NO	O
dose	O
.	O

However	O
,	O
MHV	O
was	O
not	O
detected	O
at	O
diagnostic	O
laboratories	O
by	O
use	O
of	O
viral	O
isolation	O
or	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
of	O
tissues	O
from	O
MHV	O
-	O
seropositive	O
animals	O
.	O

TITLE	O
:	O
Further	O
in	O
vitro	O
characterization	O
of	O
mouse	O
hepatitis	O
virus	O
papain	B-ENZY
-	O
like	O
proteinase	O
1	O
:	O
cleavage	O
sequence	O
requirements	O
within	O
pp1a	O
.	O

Hemodynamics	O
,	O
pulmonary	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
were	O
observed	O
before	O
,	O
during	O
,	O
and	O
2	O
min	O
,	O
5	O
min	O
after	O
applying	O
SI	O
.	O

When	O
the	O
pressure	O
of	O
SI	O
was	O
higher	O
than	O
3P	O
(	O
m	O
),	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
(	O
PaO	B-ENZY
(	O
2	O
))	O
and	O
arterial	O
oxygen	O
saturation	O
were	O
improved	O
.	O

RESULTS	O
:	O
When	O
the	O
pressure	O
of	O
SI	O
was	O
higher	O
than	O
3P	O
(	O
m	O
),	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
(	O
PaO	B-ENZY
(	O
2	O
))	O
and	O
arterial	O
oxygen	O
saturation	O
were	O
improved	O
.	O

As	O
his	O
clinical	O
situation	O
deteriorated	O
rapidly	O
,	O
BMT	B-ENZY
was	O
performed	O
with	O
unmanipulated	O
marrow	O
stem	O
cells	O
from	O
his	O
EBV	O
-	O
positive	O
HLA	O
-	O
identical	O
sister	O
after	O
conditioning	O
with	O
dexamethasone	O
(	O
1	O
.	O
75	O
mg	O
/	O
kg	O
/	O
day	O
),	O
cyclophosphamide	O
(	O
114	O
mg	O
/	O
kg	O
)	O
and	O
etoposide	O
(	O
10	O
mg	O
/	O
kg	O
),	O
with	O
no	O
immunosuppression	O
given	O
post	O
transplant	O
.	O

Thus	O
,	O
transplanted	O
T	O
cells	O
can	O
expand	O
very	O
rapidly	O
within	O
days	O
after	O
BMT	B-ENZY
and	O
clear	O
EBV	O
lymphoproliferative	O
disease	O
and	O
hemophagocytic	O
lymphohistiocytosis	O
.	O

There	O
was	O
a	O
progressive	O
improvement	O
in	O
PaO	B-ENZY
(	O
2	O
)/	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
FIO	O
(	O
2	O
))	O
ratio	O
which	O
reached	O
significance	O
after	O
12	O
h	O
[	O
121	O
(	O
81	O
-	O
151	O
)	O
to	O
258	O
(	O
187	O
-	O
329	O
)	O
torr	O
;	O
p	O
<	O
0	O
.	O
05	O
].	O

Over	O
the	O
18	O
h	O
period	O
studied	O
there	O
was	O
progressive	O
improvement	O
in	O
gas	B-ENZY
exchange	O
,	O
pulmonary	O
shunt	O
and	O
EVLW	O
.	O

Nasopharyngeal	O
secretion	O
obtained	O
at	O
onset	O
of	O
illness	O
was	O
cultured	O
for	O
bacterial	O
pathogens	O
of	O
otitis	O
media	O
using	O
selective	O
agars	O
and	O
tested	O
for	O
rhinovirus	O
,	O
coronavirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	O
A	O
and	O
B	O
,	O
and	O
parainfluenza	O
1	O
-	O
3	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
technology	O
.	O

TITLE	O
:	O
Kinetic	O
analysis	O
of	O
a	O
unique	O
direct	O
prothrombinase	B-ENZY
,	O
fgl2	O
,	O
and	O
identification	O
of	O
a	O
serine	O
residue	O
critical	O
for	O
the	O
prothrombinase	B-ENZY
activity	O
.	O

ABSTRACT	O
:	O
fgl2	O
prothrombinase	B-ENZY
,	O
by	O
its	O
ability	O
to	O
generate	O
thrombin	B-ENZY
,	O
has	O
been	O
shown	O
to	O
be	O
pivotal	O
to	O
the	O
pathogenesis	O
of	O
viral	O
-	O
induced	O
hepatitis	O
,	O
cytokine	O
-	O
induced	O
fetal	O
loss	O
syndrome	O
,	O
and	O
xeno	O
-	O
and	O
allograft	O
rejection	O
.	O

Purified	O
fgl2	O
protein	O
generated	O
in	O
a	O
baculovirus	O
expression	O
system	O
had	O
no	O
measurable	O
prothrombinase	B-ENZY
activity	O
,	O
whereas	O
the	O
activity	O
was	O
restored	O
when	O
the	O
purified	O
protein	O
was	O
reconstituted	O
into	O
phosphatidyl	O
-	O
L	O
-	O
serine	O
-	O
containing	O
vesicles	O
.	O

Furthermore	O
,	O
fgl2	O
prothrombinase	B-ENZY
activity	O
was	O
not	O
inhibited	O
by	O
antithrombin	O
III	O
,	O
soybean	O
trypsin	B-ENZY
inhibitor	O
,	O
4	O
-	O
aminobenzamidine	O
,	O
aprotinin	O
,	O
or	O
phenylmethylsulfonyl	O
fluoride	O
,	O
whereas	O
diisopropylfluorophosphate	O
completely	O
abrogated	O
the	O
activity	O
.	O

In	O
this	O
work	O
we	O
provide	O
direct	O
evidence	O
that	O
fgl2	O
cleaves	O
prothrombin	O
to	O
thrombin	B-ENZY
consistent	O
with	O
serine	O
protease	O
activity	O
and	O
requires	O
calcium	O
,	O
phospholipids	O
,	O
and	O
factor	O
Va	O
for	O
its	O
full	O
activity	O
.	O

ABSTRACT	O
:	O
Analyses	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPKs	O
)	O
in	O
a	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)-	O
infected	O
macrophage	O
-	O
derived	O
J774	O
.	O
1	O
cell	O
line	O
showed	O
activation	O
of	O
two	O
MAPKs	O
,	O
p38	O
MAPK	B-ENZY
and	O
c	B-ENZY
-	I-ENZY
Jun	I-ENZY
N	I-ENZY
-	I-ENZY
terminal	I-ENZY
kinase	I-ENZY
(	O
JNK	B-ENZY
),	O
but	O
not	O
of	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
(	O
ERK	B-ENZY
).	O

Several	O
other	O
MHV	O
-	O
permissive	O
cell	O
lines	O
also	O
showed	O
activation	O
of	O
both	O
p38	O
MAPK	B-ENZY
and	O
JNK	B-ENZY
,	O
which	O
indicated	O
that	O
the	O
MHV	O
-	O
induced	O
stress	O
-	O
kinase	O
activation	O
was	O
not	O
restricted	O
to	O
any	O
particular	O
cell	O
type	O
.	O

The	O
upstream	O
kinase	O
responsible	O
for	O
activating	O
MHV	O
-	O
induced	O
p38	O
MAPK	B-ENZY
was	O
the	O
MAPK	B-ENZY
kinase	O
3	O
.	O

Furthermore	O
,	O
the	O
upstream	O
kinase	O
responsible	O
for	O
eIF4E	O
phosphorylation	O
,	O
MAPK	B-ENZY
-	O
interacting	O
kinase	O
1	O
,	O
was	O
also	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
MHV	O
infection	O
.	O

(	O
i	O
)	O
Binding	O
to	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
is	O
essential	O
for	O
the	O
initiation	O
of	O
infection	O
.	O

The	O
attachment	O
of	O
parental	O
virus	O
was	O
reduced	O
to	O
levels	O
observed	O
with	O
the	O
mutants	O
when	O
sialic	O
acid	O
containing	O
inhibitors	O
was	O
present	O
or	O
when	O
the	O
cells	O
were	O
pretreated	O
with	O
neuraminidase	B-ENZY
.	O

TITLE	O
:	O
Detection	O
of	O
rodent	O
coronaviruses	O
by	O
use	O
of	O
fluorogenic	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

ABSTRACT	O
:	O
Reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
have	O
proved	O
useful	O
for	O
the	O
detection	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
rat	O
coronavirus	O
(	O
RCV	O
)	O
in	O
acutely	O
infected	O
animals	O
and	O
contaminated	O
biomaterials	O
.	O

ABSTRACT	O
:	O
As	O
bolus	O
instillation	O
of	O
surfactant	O
can	O
lead	O
to	O
acute	O
pulmonary	O
,	O
hemodynamic	O
and	O
cerebral	O
side	O
effects	O
,	O
we	O
tested	O
whether	O
pulmonary	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
differ	O
between	O
slow	O
surfactant	O
infusion	O
and	O
bolus	O
administration	O
.	O

After	O
90	O
min	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
had	O
increased	O
from	O
111	O
+/-	O
44	O
to	O
254	O
+/-	O
69	O
in	O
the	O
bolus	O
group	O
and	O
from	O
86	O
+/-	O
40	O
to	O
238	O
+/-	O
102	O
in	O
the	O
infusion	O
group	O
,	O
but	O
early	O
FIO	O
(	O
2	O
)	O
reduction	O
and	O
increase	O
in	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
seemed	O
delayed	O
in	O
the	O
infusion	O
group	O
.	O

However	O
,	O
until	O
90	O
min	O
the	O
course	O
of	O
C	O
(	O
stat	O
)	O
and	O
indices	O
of	O
gas	B-ENZY
exchange	O
seem	O
superior	O
after	O
bolus	O
therapy	O
.	O

TITLE	O
:	O
Bronchoscopic	O
administration	O
of	O
bovine	O
natural	O
surfactant	O
in	O
ARDS	O
and	O
septic	O
shock	O
:	O
impact	O
on	O
gas	B-ENZY
exchange	O
and	O
haemodynamics	O
.	O

No	O
untoward	O
effects	O
on	O
gas	B-ENZY
exchange	O
,	O
lung	O
mechanics	O
and	O
haemodynamics	O
were	O
noted	O
during	O
the	O
procedure	O
of	O
surfactant	O
administration	O
.	O

In	O
seven	O
patients	O
,	O
in	O
whom	O
gas	B-ENZY
exchange	O
again	O
deteriorated	O
with	O
further	O
progression	O
of	O
the	O
disease	O
,	O
a	O
second	O
surfactant	O
dose	O
of	O
200	O
mg	O
x	O
kg	O
(-	O
1	O
)	O
was	O
administered	O
18	O
-	O
24	O
h	O
after	O
the	O
first	O
application	O
,	O
again	O
improving	O
arterial	O
oxygenation	O
.	O

The	O
bronchoscopic	O
application	O
of	O
a	O
high	O
dose	O
of	O
natural	O
surfactant	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
septic	O
shock	O
is	O
both	O
feasible	O
and	O
safe	O
,	O
resulting	O
in	O
a	O
pronounced	O
improvement	O
in	O
gas	B-ENZY
exchange	O
.	O

Percutaneous	O
decompression	O
is	O
a	O
safe	O
and	O
effective	O
method	O
of	O
decreasing	O
IAH	O
and	O
preventing	O
ACS	B-ENZY
in	O
patients	O
with	O
less	O
than	O
80	O
%	O
TBSA	O
thermal	O
injury	O
.	O

Hepatopulmonary	O
syndrome	O
(	O
HPS	B-ENZY
)	O
was	O
considered	O
to	O
be	O
a	O
contraindication	O
to	O
transplantation	O
in	O
the	O
1980s	O
.	O

Intensive	O
respiratory	O
therapy	O
after	O
transplantation	O
with	O
NO	O
inhalation	O
allows	O
expansion	O
of	O
the	O
indications	O
for	O
transplantation	O
in	O
HPS	B-ENZY
.	O

Nerve	O
agents	O
inhibit	O
acetylcholinesterase	B-ENZY
and	O
thus	O
produce	O
symptoms	O
of	O
increased	O
cholinergic	O
activity	O
.	O

Ammonia	O
,	O
chlorine	O
,	O
vinyl	O
chloride	O
,	O
phosgene	O
,	O
sulfur	O
dioxide	O
,	O
and	O
nitrogen	O
dioxide	O
,	O
tear	O
gas	B-ENZY
,	O
and	O
zinc	O
chloride	O
primarily	O
injure	O
the	O
upper	O
respiratory	O
tract	O
and	O
the	O
lungs	O
.	O

It	O
is	O
defined	O
as	O
chronic	O
alveolar	O
hypoventilation	O
(	O
PaO	B-ENZY
(	O
2	O
)<	O
70	O
mmHg	O
,	O
PaCO	O
(	O
2	O
)	O
>	O
45	O
mmHg	O
)	O
in	O
obese	O
patient	O
with	O
a	O
body	O
mass	O
index	O
>	O
30	O
kg	O
/	O
m	O
(	O
2	O
)	O
who	O
have	O
no	O
other	O
respiratory	O
disease	O
explaining	O
the	O
gas	B-ENZY
anomalies	O
.	O

TITLE	O
:	O
Structure	O
of	O
coronavirus	O
main	O
proteinase	O
reveals	O
combination	O
of	O
a	O
chymotrypsin	B-ENZY
fold	O
with	O
an	O
extra	O
alpha	O
-	O
helical	O
domain	O
.	O

The	O
active	O
site	O
,	O
comprised	O
of	O
Cys144	O
and	O
His41	O
,	O
is	O
part	O
of	O
a	O
chymotrypsin	B-ENZY
-	O
like	O
fold	O
that	O
is	O
connected	O
by	O
a	O
16	O
residue	O
loop	O
to	O
an	O
extra	O
domain	O
featuring	O
a	O
novel	O
alpha	O
-	O
helical	O
fold	O
.	O

The	O
study	O
illustrates	O
that	O
RNA	O
viruses	O
have	O
evolved	O
unprecedented	O
variations	O
of	O
the	O
classical	O
chymotrypsin	B-ENZY
fold	O
.	O

We	O
conclude	O
that	O
low	O
-	O
dose	O
GM	O
-	O
CSF	O
was	O
associated	O
with	O
improved	O
gas	B-ENZY
exchange	O
without	O
pulmonary	O
neutrophil	O
infiltration	O
,	O
despite	O
functional	O
activation	O
of	O
both	O
circulating	O
neutrophils	O
and	O
pulmonary	O
phagocytes	O
.	O

Alternative	O
modes	O
of	O
supporting	O
gas	B-ENZY
exchange	O
,	O
such	O
as	O
with	O
partial	O
liquid	O
ventilation	O
and	O
extracorporeal	O
gas	B-ENZY
-	O
exchange	O
,	O
may	O
serve	O
as	O
rescue	O
therapies	O
.	O

A	O
repeat	O
screening	O
test	O
for	O
urine	O
porphyrins	O
was	O
positive	O
,	O
and	O
AIP	O
was	O
confirmed	O
by	O
specific	O
porphobilinogen	B-ENZY
deaminase	I-ENZY
in	O
the	O
blood	O
.	O

TITLE	O
:	O
Case	O
report	O
and	O
literature	O
review	O
of	O
chlorine	O
gas	B-ENZY
toxicity	O
.	O

ABSTRACT	O
:	O
Chlorine	O
gas	B-ENZY
exposure	O
is	O
uncommon	O
in	O
children	O
and	O
when	O
it	O
occurs	O
usually	O
results	O
in	O
mild	O
ocular	O
,	O
oropharyngeal	O
,	O
or	O
respiratory	O
symptoms	O
.	O

Occasionally	O
,	O
however	O
,	O
chlorine	O
gas	B-ENZY
poisoning	O
may	O
cause	O
severe	O
pulmonay	O
toxicity	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
14	O
-	O
y	O
-	O
old	O
boy	O
with	O
a	O
history	O
of	O
asthma	O
who	O
was	O
exposed	O
to	O
chlorine	O
gas	B-ENZY
as	O
a	O
result	O
of	O
an	O
ill	O
-	O
advised	O
science	O
experiment	O
.	O

TF	O
and	O
other	O
coagulation	O
proteins	O
,	O
including	O
Factor	O
Xa	O
,	O
thrombin	B-ENZY
,	O
and	O
fibrin	O
,	O
also	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
acute	O
lung	O
injury	O
through	O
multi	O
-	O
level	O
interactions	O
with	O
inflammatory	O
effectors	O
,	O
in	O
which	O
these	O
proteins	O
coordinately	O
act	O
as	O
regulators	O
of	O
tissue	O
injury	O
responses	O
.	O

Lung	O
injury	O
,	O
quantitated	O
by	O
measuring	O
lung	O
myeloperoxidase	B-ENZY
activity	O
(	O
an	O
indicator	O
of	O
neutrophil	O
sequestration	O
),	O
alveolar	O
-	O
capillary	O
permeability	O
,	O
and	O
alveolar	O
membrane	O
thickness	O
was	O
less	O
severe	O
in	O
GM	O
-	O
CSF	O
-/-	O
than	O
in	O
GM	O
-	O
CSF	O
+/+	O
mice	O
.	O

TITLE	O
:	O
Influence	O
of	O
respiratory	O
rate	O
on	O
gas	B-ENZY
trapping	O
during	O
low	O
volume	O
ventilation	O
of	O
patients	O
with	O
acute	O
lung	O
injury	O
.	O

PaO	B-ENZY
(	O
2	O
)	O
was	O
not	O
affected	O
but	O
the	O
alveolar	O
-	O
arterial	O
oxygen	O
tension	O
difference	O
slightly	O
worsened	O
with	O
the	O
high	O
respiratory	O
rate	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

An	O
increase	O
in	O
respiratory	O
rate	O
used	O
to	O
avoid	O
Vt	O
reduction	O
-	O
induced	O
hypercapnia	O
may	O
induce	O
substantial	O
gas	B-ENZY
trapping	O
and	O
PEEPi	O
in	O
patients	O
with	O
ALI	O
.	O

PaO	B-ENZY
(	O
2	O
)	O
was	O
not	O
affected	O
but	O
the	O
alveolar	O
-	O
arterial	O
oxygen	O
tension	O
difference	O
slightly	O
worsened	O
with	O
the	O
high	O
respiratory	O
rate	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

In	O
these	O
patients	O
,	O
inhaled	O
NO	O
improves	O
gas	B-ENZY
exchange	O
and	O
ventilation	O
-	O
perfusion	O
matching	O
,	O
reduces	O
the	O
length	O
of	O
hospitalization	O
and	O
is	O
without	O
severe	O
detrimental	O
effects	O
.	O

TITLE	O
:	O
Alveolar	O
macrophage	O
activation	O
after	O
trauma	O
-	O
hemorrhage	O
and	O
sepsis	O
is	O
dependent	O
on	O
NF	O
-	O
kappaB	O
and	O
MAPK	B-ENZY
/	O
ERK	B-ENZY
mechanisms	O
.	O

We	O
hypothesized	O
that	O
alveolar	O
macrophage	O
(	O
AMPhi	O
)	O
chemokine	O
and	O
cytokine	O
release	O
after	O
hemorrhage	O
and	O
sepsis	O
is	O
regulated	O
by	O
NF	O
-	O
kappaB	O
and	O
MAPK	B-ENZY
.	O

In	O
control	O
animals	O
,	O
AMPhi	O
were	O
stimulated	O
with	O
LPS	O
with	O
or	O
without	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
and	O
MAPK	B-ENZY
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
or	O
the	O
upstream	O
MAPK	B-ENZY
significantly	O
decreased	O
LPS	O
-	O
stimulated	O
AMPhi	O
activation	O
.	O

INTERVENTIONS	O
Pulmonary	O
(	O
with	O
muscle	O
as	O
control	O
)	O
leukocyte	O
accumulation	O
was	O
assessed	O
by	O
uptake	O
of	O
technetium	O
-	O
99m	O
-	O
labeled	O
chemotactic	O
peptide	O
(	O
fMLFK	O
)	O
and	O
confirmed	O
by	O
measurement	O
of	O
myeloperoxidase	B-ENZY
activity	O
.	O

Lung	O
myeloperoxidase	B-ENZY
activity	O
,	O
18FDG	O
,	O
and	O
peripheral	O
white	O
blood	O
cells	O
all	O
significantly	O
increased	O
in	O
both	O
mild	O
and	O
severe	O
pancreatitis	O
,	O
but	O
lung	O
fMLFK	O
only	O
increased	O
in	O
severe	O
pancreatitis	O
.	O

The	O
sheep	O
developed	O
a	O
hyperkinetic	O
cardiovascular	O
response	O
concomitant	O
with	O
a	O
decrease	O
in	O
Pao	B-ENZY
similar	O
to	O
severe	O
sepsis	O
in	O
human	O
patients	O
who	O
meet	O
the	O
criteria	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
PaO2	O
/	O
FIO2	O
<	O
200	O
).	O

ABSTRACT	O
:	O
Patients	O
with	O
severe	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
)	O
requiring	O
endotracheal	O
intubation	O
and	O
erythrocytopheresis	O
are	O
at	O
increased	O
risk	O
for	O
neurologic	O
morbidity	O
.	O

This	O
study	O
examines	O
patients	O
with	O
sickle	O
cell	O
disease	O
who	O
developed	O
severe	O
episodes	O
of	O
ACS	B-ENZY
,	O
leading	O
to	O
endotracheal	O
intubation	O
,	O
ventilatory	O
support	O
for	O
respiratory	O
failure	O
,	O
and	O
erythrocytapheresis	O
.	O

Five	O
consecutive	O
patients	O
,	O
aged	O
3	O
to	O
9	O
years	O
,	O
were	O
identified	O
with	O
severe	O
ACS	B-ENZY
.	O

ABSTRACT	O
:	O
To	O
improve	O
the	O
detection	O
and	O
molecular	O
identification	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
avian	O
coronavirus	O
),	O
two	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assays	O
were	O
developed	O
.	O

TITLE	O
:	O
Use	O
of	O
TaqMan	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
analysis	O
and	O
serologic	O
testing	O
to	O
eliminate	O
an	O
enzootic	O
infection	O
of	O
mouse	O
hepatitis	O
virus	O
.	O

A	O
cl	O
-	O
2	O
mutant	O
,	O
srr7	O
,	O
of	O
the	O
MHV	O
JHM	O
virus	O
(	O
JHMV	O
)	O
was	O
digested	O
with	O
proteinase	B-ENZY
K	I-ENZY
after	O
treatment	O
with	O
soMHVR	O
,	O
and	O
the	O
resultant	O
S	O
protein	O
was	O
analyzed	O
by	O
Western	O
blotting	O
using	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
10G	O
,	O
specific	O
for	O
the	O
membrane	O
-	O
anchored	O
S2	O
subunit	O
.	O

soMHVR	O
induced	O
conformational	O
changes	O
of	O
the	O
S	O
proteins	O
of	O
wild	O
-	O
type	O
(	O
wt	O
)	O
JHMV	O
cl	O
-	O
2	O
,	O
as	O
well	O
as	O
revertants	O
from	O
srr7	O
,	O
srr7A	O
and	O
srr7B	O
;	O
however	O
,	O
a	O
major	O
proportion	O
of	O
these	O
S	O
proteins	O
were	O
resistant	O
to	O
proteinase	B-ENZY
K	I-ENZY
even	O
without	O
soMHVR	O
treatment	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
feline	O
aminopeptidase	B-ENZY
N	I-ENZY
as	O
a	O
receptor	O
for	O
infectious	O
bronchitis	O
virus	O
.	O

Therefore	O
,	O
the	O
present	O
study	O
investigated	O
in	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
manner	O
the	O
effect	O
of	O
severe	O
trauma	O
on	O
the	O
alveolar	O
fibrinolytic	O
/	O
coagulation	O
balance	O
,	O
and	O
the	O
effect	O
here	O
-	O
upon	O
of	O
inhalation	O
of	O
single	O
-	O
chain	O
urokinase	B-ENZY
plasminogen	O
activator	O
(	O
scu	O
-	O
PA	O
)	O
in	O
pigs	O
.	O

The	O
study	O
shows	O
an	O
increased	O
concentration	O
of	O
scu	O
-	O
PA	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
of	O
the	O
treated	O
animals	O
in	O
association	O
with	O
an	O
increased	O
plasmin	B-ENZY
-	O
dependent	O
fibrinolytic	O
activity	O
without	O
increased	O
systemic	O
fibrinolytic	O
activity	O
,	O
the	O
transient	O
increase	O
in	O
the	O
concentration	O
of	O
scu	O
-	O
PA	O
in	O
the	O
plasma	O
being	O
minimal	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
-	O
induced	O
apoptosis	O
in	O
17Cl	O
-	O
1	O
cells	O
involves	O
a	O
mitochondria	O
-	O
mediated	O
pathway	O
and	O
its	O
downstream	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
activation	O
and	O
bid	O
cleavage	O
.	O

Activation	O
of	O
the	O
mitochondria	O
-	O
mediated	O
apoptotic	O
pathway	O
was	O
indicated	O
by	O
the	O
activation	O
of	O
caspase	B-ENZY
-	I-ENZY
9	I-ENZY
and	O
delay	O
of	O
apoptosis	O
by	O
Bcl	O
-	O
2	O
overexpression	O
.	O

An	O
increase	O
in	O
the	O
amount	O
of	O
Fas	O
(	O
APO	O
-	O
1	O
/	O
CD95	O
),	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
activation	O
,	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
-	O
mediated	O
Bid	O
cleavage	O
,	O
and	O
subsequent	O
translocation	O
of	O
truncated	O
Bid	O
to	O
mitochondria	O
,	O
all	O
of	O
which	O
relate	O
to	O
the	O
Fas	O
-	O
mediated	O
pathway	O
,	O
also	O
occurred	O
in	O
MHV	O
-	O
infected	O
17Cl	O
-	O
1	O
cells	O
,	O
whereas	O
the	O
formation	O
of	O
the	O
death	O
-	O
inducing	O
signaling	O
complex	O
,	O
a	O
direct	O
indication	O
of	O
the	O
activation	O
of	O
Fas	O
-	O
mediated	O
pathway	O
,	O
was	O
undetectable	O
.	O

Caspase	B-ENZY
-	I-ENZY
8	I-ENZY
and	O
Bid	O
activation	O
appeared	O
to	O
be	O
downstream	O
of	O
mitochondria	O
,	O
because	O
Bcl	O
-	O
2	O
overexpression	O
suppressed	O
both	O
events	O
,	O
suggesting	O
that	O
infected	O
17Cl	O
-	O
1	O
cells	O
might	O
have	O
activated	O
a	O
receptor	O
-	O
mediated	O
""""	O
type	O
II	O
""""	O
signaling	O
pathway	O
,	O
in	O
which	O
primary	O
and	O
low	O
levels	O
of	O
receptor	O
-	O
mediated	O
pathway	O
activation	O
lead	O
to	O
the	O
activation	O
of	O
the	O
mitochondria	O
-	O
mediated	O
pathway	O
.	O

We	O
found	O
that	O
the	O
change	O
in	O
Pao	B-ENZY
/	O
Fio	O
ratio	O
was	O
greatest	O
in	O
the	O
HFOV	O
plus	O
iNO	O
group	O
compared	O
with	O
the	O
other	O
treatment	O
groups	O
at	O
4	O
hrs	O
(	O
p	O
=.	O
02	O
)	O
and	O
12	O
hrs	O
(	O
p	O
=.	O
01	O
).	O

Consecutive	O
pediatric	O
patients	O
with	O
severe	O
ARDS	O
(	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
<	O
200	O
,	O
Murray	O
score	O
>	O
2	O
.	O
5	O
).	O

Changes	O
in	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
during	O
supine	O
-	O
prone	O
and	O
prone	O
-	O
supine	O
positioning	O
were	O
evaluated	O
.	O

The	O
responders	O
showed	O
an	O
increase	O
in	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
of	O
22	O
%,	O
from	O
91	O
+/-	O
33	O
to	O
112	O
+/-	O
43	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
when	O
they	O
were	O
placed	O
from	O
the	O
supine	O
to	O
the	O
prone	O
position	O
.	O

Instillation	O
of	O
a	O
modified	O
porcine	O
surfactant	O
(	O
Curosurf	O
)	O
improved	O
gas	B-ENZY
exchange	O
immediately	O
.	O

Surfactant	O
dysfunction	O
probably	O
plays	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
severe	O
paediatric	O
ARDS	O
triggered	O
by	O
pneumonia	O
,	O
as	O
it	O
was	O
found	O
that	O
surfactant	O
instillation	O
rapidly	O
improved	O
gas	B-ENZY
exchange	O
in	O
the	O
majority	O
of	O
the	O
affected	O
infants	O
in	O
our	O
study	O
.	O

CONCLUSIONS	O
:	O
Surfactant	O
dysfunction	O
probably	O
plays	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
severe	O
paediatric	O
ARDS	O
triggered	O
by	O
pneumonia	O
,	O
as	O
it	O
was	O
found	O
that	O
surfactant	O
instillation	O
rapidly	O
improved	O
gas	B-ENZY
exchange	O
in	O
the	O
majority	O
of	O
the	O
affected	O
infants	O
in	O
our	O
study	O
.	O

Despite	O
encouraging	O
results	O
,	O
however	O
,	O
the	O
use	O
of	O
prone	O
positioning	O
is	O
not	O
widely	O
accepted	O
as	O
an	O
adjunct	O
to	O
therapy	O
in	O
hypoxemic	O
patients	O
because	O
,	O
aside	O
from	O
temporarily	O
improving	O
gas	B-ENZY
exchange	O
,	O
it	O
does	O
not	O
seem	O
to	O
affect	O
the	O
outcome	O
of	O
these	O
patients	O
.	O

Oral	O
administration	O
of	O
IgY	O
has	O
proved	O
successful	O
for	O
treatment	O
of	O
a	O
variety	O
of	O
GI	O
infections	O
,	O
such	O
as	O
bovine	O
and	O
human	O
rotaviruses	O
,	O
bovine	O
coronavirus	O
,	O
Yersinia	O
ruckeri	O
,	O
enterotoxigenic	O
Escherichia	O
coli	O
,	O
Salmonella	O
spp	B-ENZY
.,	O
Edwardsiella	O
tarda	O
,	O
Staphylococcus	O
,	O
and	O
Pseudomonas	O
.	O

Receptor	O
binding	O
induced	O
a	O
profound	O
,	O
apparently	O
irreversible	O
conformational	O
change	O
in	O
S	O
on	O
the	O
viral	O
envelope	O
that	O
allowed	O
S2	O
,	O
but	O
not	O
S1	O
,	O
to	O
be	O
degraded	O
by	O
trypsin	B-ENZY
at	O
4	O
degrees	O
C	O
.	O
Various	O
murine	O
CEACAM	O
proteins	O
triggered	O
conformational	O
changes	O
in	O
S	O
on	O
recombinant	O
MHV	O
strains	O
expressing	O
S	O
glycoproteins	O
of	O
MHV	O
-	O
A59	O
or	O
MHV	O
-	O
4	O
(	O
MHV	O
-	O
JHM	O
)	O
with	O
the	O
same	O
specificities	O
as	O
seen	O
for	O
virus	O
neutralization	O
and	O
virus	O
-	O
receptor	O
activities	O
.	O

A	O
novel	O
120	O
-	O
kDa	O
subunit	O
was	O
formed	O
following	O
incubation	O
of	O
the	O
receptor	O
-	O
triggered	O
S	O
(	O
A59	O
)	O
H716D	O
virions	O
with	O
trypsin	B-ENZY
at	O
4	O
degrees	O
C	O
.	O
The	O
data	O
show	O
that	O
unlike	O
class	O
1	O
fusion	O
glycoproteins	O
of	O
other	O
enveloped	O
viruses	O
,	O
the	O
murine	O
coronavirus	O
S	O
protein	O
can	O
be	O
triggered	O
to	O
a	O
membrane	O
-	O
binding	O
conformation	O
at	O
37	O
degrees	O
C	O
either	O
by	O
soluble	O
receptor	O
at	O
neutral	O
pH	O
or	O
by	O
alkaline	O
pH	O
alone	O
,	O
without	O
requiring	O
previous	O
activation	O
by	O
cleavage	O
between	O
S1	O
and	O
S2	O
.	O

Serial	O
levels	O
of	O
soluble	O
L	O
-,	O
P	O
-,	O
and	O
E	O
-	O
selectins	O
,	O
ICAM	O
-	O
1	O
,	O
VCAM	O
-	O
1	O
,	O
thrombomodulin	O
,	O
and	O
neutrophil	B-ENZY
elastase	I-ENZY
were	O
measured	O
on	O
days	O
0	O
-	O
4	O
after	O
trauma	O
.	O

Maximum	O
DIC	O
scores	O
in	O
the	O
DIC	O
group	O
showed	O
good	O
correlations	O
with	O
peak	O
levels	O
of	O
sICAM	O
-	O
1	O
,	O
sVCAM	O
-	O
1	O
,	O
neutrophil	B-ENZY
elastase	I-ENZY
,	O
sThrombomodulin	O
,	O
and	O
the	O
number	O
of	O
dysfunctioning	O
organs	O
.	O

This	O
was	O
associated	O
with	O
an	O
increase	O
in	O
PaO	B-ENZY
(	O
2	O
)	O
and	O
a	O
decrease	O
in	O
total	O
static	O
compliance	O
.	O

Experimental	O
studies	O
have	O
shown	O
that	O
the	O
use	O
of	O
selective	O
tracheal	O
gas	B-ENZY
insufflation	O
and	O
partial	O
liquid	O
ventilation	O
facilitates	O
low	O
tidal	O
volume	O
with	O
appropriate	O
gas	B-ENZY
exchange	O
while	O
reducing	O
cyclic	O
lung	O
stretch	O
and	O
shear	O
stresses	O
.	O

Agents	O
with	O
zoonotic	O
potential	O
were	O
detected	O
in	O
feces	O
from	O
21	O
(	O
16	O
.	O
2	O
%)	O
of	O
130	O
dogs	O
and	O
included	O
Giardia	O
spp	B-ENZY
.	O

A	O
method	O
based	O
on	O
xylene	O
deparaffinization	O
followed	O
by	O
proteinase	B-ENZY
K	I-ENZY
digestion	O
yielded	O
RNA	O
of	O
a	O
suitable	O
quality	O
for	O
reliable	O
and	O
consistent	O
multiplex	O
RT	O
-	O
nPCR	O
analyses	O
.	O

Blood	O
gas	B-ENZY
measurements	O
were	O
obtained	O
10	O
-	O
15	O
mins	O
after	O
initiation	O
or	O
any	O
increase	O
in	O
INO	O
dosage	O
to	O
assess	O
the	O
effect	O
on	O
Pao2	O
/	O
Fio2	O
.	O

The	O
alveolar	O
epithelium	O
is	O
important	O
both	O
for	O
the	O
integrity	O
of	O
the	O
blood	O
-	O
gas	B-ENZY
barrier	O
and	O
for	O
repair	O
of	O
the	O
barrier	O
after	O
lung	O
injury	O
.	O

A	O
higher	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
was	O
observed	O
in	O
the	O
surfactant	O
group	O
2	O
h	O
after	O
the	O
first	O
dose	O
(	O
58	O
from	O
baseline	O
vs	O
.	O
9	O
),	O
at	O
48	O
h	O
there	O
was	O
a	O
trend	O
towards	O
a	O
higher	O
ratio	O
(	O
38	O
from	O
baseline	O
vs	O
.	O
22	O
).	O

This	O
improvement	O
is	O
sustained	O
only	O
in	O
the	O
subgroup	O
of	O
patients	O
without	O
pneumonia	O
and	O
that	O
with	O
an	O
initial	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
higher	O
than	O
65	O
RESULTS	O
:	O
In	O
the	O
pilot	O
study	O
the	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
increased	O
by	O
a	O
mean	O
of	O
100	O
at	O
48	O
h	O
(	O
n	O
=	O
19	O
).	O

This	O
improvement	O
is	O
sustained	O
only	O
in	O
the	O
subgroup	O
of	O
patients	O
without	O
pneumonia	O
and	O
that	O
with	O
an	O
initial	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
higher	O
than	O
65	O

Arterial	O
blood	O
gas	B-ENZY
tensions	O
were	O
measured	O
immediately	O
before	O
and	O
1	O
and	O
24	O
h	O
after	O
PDT	O
.	O

Nevertheless	O
,	O
PDT	O
did	O
not	O
significantly	O
decrease	O
oxygenation	O
in	O
either	O
group	O
1	O
and	O
24	O
h	O
after	O
PDT	O
(	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
):	O
223	O
+/-	O
83	O
and	O
260	O
+/-	O
86	O
mmHg	O
in	O
the	O
high	O
PEEP	O
group	O
and	O
280	O
+/-	O
88	O
and	O
302	O
+/-	O
82	O
mmHg	O
in	O
the	O
low	O
PEEP	O
group	O
,	O
respectively	O
).	O

Furthermore	O
,	O
oxygenation	O
did	O
not	O
deteriorate	O
with	O
PDT	O
even	O
in	O
patients	O
with	O
gravely	O
impaired	O
gas	B-ENZY
exchange	O
(	O
lowest	O
quartile	O
)	O
with	O
a	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
averaging	O
130	O
+/-	O
42	O
mmHg	O
(	O
range	O
45	O
-	O
192	O
mmHg	O
)	O
at	O
a	O
PEEP	O
of	O
17	O
+/-	O
4	O
mbar	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
SAR	O
,	O
and	O
molecular	O
modeling	O
studies	O
of	O
acylthiocarbamates	O
:	O
a	O
novel	O
series	O
of	O
potent	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
structurally	O
related	O
to	O
phenethylthiazolylthiourea	O
derivatives	O
.	O

TITLE	O
:	O
Induction	O
of	O
prothrombinase	B-ENZY
fgl2	O
by	O
the	O
nucleocapsid	O
protein	O
of	O
virulent	O
mouse	O
hepatitis	O
virus	O
is	O
dependent	O
on	O
host	O
hepatic	O
nuclear	O
factor	O
-	O
4	O
alpha	O
.	O

Collectively	O
,	O
the	O
results	O
of	O
this	O
study	O
define	O
both	O
viral	O
and	O
host	O
factors	O
necessary	O
for	O
induction	O
of	O
fgl2	O
prothrombinase	B-ENZY
gene	O
transcription	O
in	O
MHV	O
infection	O
and	O
may	O
provide	O
an	O
explanation	O
for	O
the	O
hepatotrophic	O
nature	O
of	O
MHV	O
-	O
induced	O
fulminant	O
hepatic	O
failure	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
229E	O
:	O
receptor	O
binding	O
domain	O
and	O
neutralization	O
by	O
soluble	O
receptor	O
at	O
37	O
degrees	O
C	O
.	O
ABSTRACT	O
:	O
Truncated	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
spike	O
glycoproteins	O
containing	O
amino	O
acids	O
407	O
to	O
547	O
bound	O
to	O
purified	O
,	O
soluble	O
virus	O
receptor	O
,	O
human	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
hAPN	O
).	O

We	O
evaluated	O
pulmonary	O
VEGF	O
expression	O
in	O
lung	O
autopsy	O
material	O
from	O
septic	O
patients	O
who	O
had	O
been	O
cared	O
for	O
by	O
intensive	O
care	O
medicine	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
immunohistochemical	O
methods	O
.	O

The	O
changes	O
in	O
blood	O
gas	B-ENZY
dynamics	O
,	O
blood	O
gas	B-ENZY
acid	O
-	O
base	O
status	O
and	O
electrolytes	O
,	O
along	O
with	O
the	O
histological	O
changes	O
in	O
the	O
lung	O
tissues	O
were	O
comparatively	O
analyzed	O
between	O
the	O
3	O
groups	O
.	O

The	O
values	O
of	O
PaO	B-ENZY
(	O
2	O
),	O
PaCO	O
(	O
2	O
),	O
pH	O
,	O
actual	O
bicarbonate	O
(	O
AB	O
),	O
base	O
excess	O
(	O
BE	O
),	O
tidal	O
volume	O
,	O
and	O
respiration	O
rate	O
in	O
groups	O
A	O
and	O
R	O
were	O
significantly	O
different	O
from	O
those	O
in	O
group	O
D	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
in	O
groups	O
A	O
and	O
R	O
,	O
the	O
above	O
measurements	O
at	O
every	O
stage	O
after	O
seawater	O
perfusion	O
were	O
significantly	O
different	O
from	O
those	O
before	O
perfusion	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

RESULTS	O
:	O
The	O
values	O
of	O
PaO	B-ENZY
(	O
2	O
),	O
PaCO	O
(	O
2	O
),	O
pH	O
,	O
actual	O
bicarbonate	O
(	O
AB	O
),	O
base	O
excess	O
(	O
BE	O
),	O
tidal	O
volume	O
,	O
and	O
respiration	O
rate	O
in	O
groups	O
A	O
and	O
R	O
were	O
significantly	O
different	O
from	O
those	O
in	O
group	O
D	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
in	O
groups	O
A	O
and	O
R	O
,	O
the	O
above	O
measurements	O
at	O
every	O
stage	O
after	O
seawater	O
perfusion	O
were	O
significantly	O
different	O
from	O
those	O
before	O
perfusion	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

These	O
included	O
decreased	O
pulmonary	O
gas	B-ENZY
exchange	O
,	O
increased	O
pulmonary	O
edema	O
,	O
abnormal	O
lung	O
compliance	O
,	O
and	O
extensive	O
airway	O
obstruction	O
.	O

Lymphopenia	O
(	O
in	O
89	O
percent	O
of	O
those	O
for	O
whom	O
data	O
were	O
available	O
),	O
elevated	O
lactate	O
dehydrogenase	O
levels	O
(	O
in	O
80	O
percent	O
),	O
elevated	O
aspartate	B-ENZY
aminotransferase	I-ENZY
levels	O
(	O
in	O
78	O
percent	O
),	O
and	O
elevated	O
creatinine	O
kinase	O
levels	O
(	O
in	O
56	O
percent	O
)	O
were	O
common	O
.	O

The	O
creatine	B-ENZY
kinase	I-ENZY
(	O
CK	O
)	O
value	O
was	O
high	O
in	O
14	O
of	O
22	O
patients	O
,	O
suggesting	O
the	O
presence	O
of	O
myositis	O
.	O

Other	O
common	O
findings	O
were	O
lymphopenia	O
(	O
in	O
69	O
.	O
6	O
percent	O
),	O
thrombocytopenia	O
(	O
44	O
.	O
8	O
percent	O
),	O
and	O
elevated	O
lactate	O
dehydrogenase	O
and	O
creatine	B-ENZY
kinase	I-ENZY
levels	O
(	O
71	O
.	O
0	O
percent	O
and	O
32	O
.	O
1	O
percent	O
,	O
respectively	O
).	O

This	O
article	O
reviews	O
some	O
of	O
the	O
physiologic	O
actions	O
of	O
proteases	O
,	O
specifically	O
elastase	O
,	O
the	O
evidence	O
for	O
neutrophil	B-ENZY
elastase	I-ENZY
involvement	O
in	O
ARDS	O
,	O
and	O
the	O
potential	O
therapeutic	O
use	O
of	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitors	O
in	O
lung	O
injury	O
.	O

Although	O
the	O
data	O
support	O
a	O
key	O
role	O
for	O
neutrophil	B-ENZY
elastase	I-ENZY
in	O
the	O
pathogenesis	O
of	O
ARDS	O
,	O
further	O
study	O
is	O
needed	O
to	O
fully	O
define	O
the	O
actions	O
of	O
neutrophil	B-ENZY
elastase	I-ENZY
,	O
and	O
how	O
these	O
actions	O
affect	O
host	O
functions	O
,	O
before	O
we	O
can	O
exploit	O
this	O
knowledge	O
for	O
therapeutic	O
benefit	O
.	O

A	O
recently	O
published	O
randomized	O
,	O
controlled	O
trial	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
(	O
n	O
=	O
148	O
)	O
comparing	O
HFOV	O
with	O
a	O
pressure	O
-	O
control	O
ventilation	O
strategy	O
(	O
Pao	B-ENZY
(	O
2	O
)/	O
Fio	O
(	O
2	O
)	O
ratio	O
of	O
<	O
or	O
=	O
200	O
mm	O
Hg	O
on	O
positive	O
end	O
-	O
expiratory	O
pressure	O
of	O
>	O
10	O
cm	O
H	O
(	O
2	O
)	O
O	O
)	O
demonstrated	O
early	O
(<	O
16	O
hrs	O
)	O
improvement	O
in	O
Pao	B-ENZY
(	O
2	O
)/	O
Fio	O
(	O
2	O
)	O
(	O
p	O
=.	O
008	O
)	O
in	O
the	O
HFOV	O
group	O
but	O
no	O
significant	O
difference	O
in	O
oxygenation	O
index	O
between	O
the	O
two	O
groups	O
during	O
the	O
initial	O
72	O
hrs	O
of	O
treatment	O
.	O

An	O
activated	O
complex	O
of	O
tissue	O
factor	O
and	O
factor	O
VIIa	O
triggers	O
procoagulant	O
activity	O
in	O
the	O
lung	O
,	O
with	O
subsequent	O
thrombin	B-ENZY
formation	O
and	O
fibrin	O
deposition	O
.	O

Finally	O
,	O
plasminogen	O
activators	O
may	O
improve	O
gas	B-ENZY
exchange	O
in	O
ALI	O
,	O
but	O
studies	O
in	O
humans	O
are	O
limited	O
.	O

After	O
smoke	O
inhalation	O
,	O
all	O
four	O
groups	O
displayed	O
similar	O
high	O
arterial	O
carboxyhemoglobin	O
levels	O
,	O
low	O
Pao	B-ENZY
(	O
2	O
)	O
(<	O
150	O
mm	O
Hg	O
),	O
and	O
low	O
dynamic	O
lung	O
compliance	O
(<	O
66	O
%	O
of	O
its	O
baseline	O
).	O

All	O
treatment	O
groups	O
demonstrated	O
a	O
significant	O
increase	O
in	O
Pao	B-ENZY
(	O
2	O
)	O
compared	O
with	O
the	O
CMV	O
group	O
.	O

MHV	O
-	O
2	O
was	O
injected	O
intraperitoneally	O
into	O
4	O
-	O
week	O
-	O
old	O
ICR	O
mice	O
,	O
IFN	O
or	O
the	O
vehicle	O
was	O
administered	O
intramuscularly	O
for	O
5	O
days	O
,	O
and	O
the	O
antiviral	O
effect	O
was	O
evaluated	O
based	O
on	O
survival	O
periods	O
,	O
liver	O
histology	O
,	O
serum	O
alanine	B-ENZY
transaminase	I-ENZY
(	O
ALT	O
)	O
levels	O
,	O
and	O
MHV	O
-	O
2	O
virus	O
titers	O
in	O
the	O
liver	O
tissues	O
.	O

Fecal	O
samples	O
collected	O
on	O
days	O
0	O
,	O
4	O
,	O
14	O
,	O
and	O
35	O
after	O
arrival	O
were	O
tested	O
for	O
BoTV	O
by	O
use	O
of	O
ELISA	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
.	O

Though	O
acute	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
(	O
GVHD	O
)	O
of	O
systemic	O
skin	O
(	O
grade	O
II	O
)	O
and	O
pneumonia	O
were	O
observed	O
during	O
neutropenia	O
due	O
to	O
the	O
post	O
-	O
conditioning	O
regimen	O
,	O
he	O
could	O
be	O
discharged	O
from	O
our	O
hospital	O
on	O
the	O
135th	O
day	O
after	O
BMT	B-ENZY
.	O

Despite	O
therapy	O
with	O
prednisolone	O
and	O
FK506	O
,	O
he	O
died	O
on	O
day	O
400	O
post	O
-	O
BMT	B-ENZY
because	O
of	O
respiratory	O
failure	O
due	O
to	O
BO	O
.	O

Animals	O
treated	O
with	O
site	O
inactivated	O
Factor	O
VIIa	O
had	O
less	O
severe	O
lung	O
injury	O
,	O
with	O
preserved	O
gas	B-ENZY
exchange	O
,	O
better	O
lung	O
compliance	O
and	O
histology	O
scores	O
,	O
and	O
decreased	O
lung	O
wet	O
/	O
dry	O
weight	O
.	O

HRV	O
RNA	O
was	O
detected	O
in	O
6	O
(	O
8	O
%)	O
of	O
77	O
patients	O
,	O
and	O
coronavirus	O
RNA	O
was	O
detected	O
in	O
0	O
of	O
46	O
of	O
BAL	B-ENZY
samples	O
from	O
HSCT	O
recipients	O
.	O

The	O
fatality	O
rate	O
in	O
HRV	O
-	O
infected	O
patients	O
was	O
high	O
(	O
83	O
%),	O
but	O
all	O
patients	O
had	O
significant	O
coinfections	O
,	O
and	O
the	O
overall	O
mortality	O
rate	O
was	O
not	O
different	O
from	O
that	O
of	O
patients	O
who	O
were	O
negative	O
for	O
HRV	O
in	O
BAL	B-ENZY
samples	O
.	O

These	O
results	O
suggest	O
that	O
HRV	O
may	O
be	O
a	O
cause	O
of	O
lower	O
respiratory	O
tract	O
infections	O
in	O
HSCT	O
recipients	O
and	O
that	O
its	O
detection	O
in	O
BAL	B-ENZY
samples	O
is	O
associated	O
with	O
frequent	O
copathogens	O
.	O

Frozen	O
sections	O
of	O
the	O
thrombotic	O
coronary	O
segment	O
,	O
analysed	O
for	O
different	O
infective	O
agents	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
PCR	O
,	O
showed	O
positive	O
amplification	O
for	O
an	O
enteroviral	O
genome	O
.	O

Granulocyte	O
colony	O
-	O
stimulating	O
factor	O
increased	O
alveolar	O
neutrophil	O
recruitment	O
,	O
pulmonary	O
edema	O
,	O
and	O
lung	O
myeloperoxidase	B-ENZY
activity	O
on	O
day	O
4	O
.	O

TITLE	O
:	O
Extracorporeal	O
gas	B-ENZY
exchange	O
with	O
the	O
DeltaStream	O
rotary	O
blood	O
pump	O
in	O
experimental	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
In	O
most	O
severe	O
cases	O
of	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
can	O
be	O
used	O
to	O
facilitate	O
gas	B-ENZY
exchange	O
.	O

In	O
controls	O
,	O
hemodynamics	O
and	O
gas	B-ENZY
exchange	O
remained	O
unchanged	O
.	O

Case	O
report	O
of	O
a	O
patient	O
with	O
severe	O
inhalation	O
injury	O
and	O
burns	O
in	O
an	O
intensive	O
care	O
unit	O
setting	O
,	O
undergoing	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	B-ENZY
),	O
nitric	O
oxide	O
(	O
NO	O
)-	O
inhalation	O
,	O
surfactant	O
-,	O
kinetic	O
-,	O
and	O
urodilatin	O
-	O
therapy	O
.	O

TITLE	O
:	O
Recombinant	O
platelet	B-ENZY
-	I-ENZY
activating	I-ENZY
factor	I-ENZY
acetylhydrolase	I-ENZY
to	O
prevent	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
mortality	O
in	O
severe	O
sepsis	O
:	O
Phase	O
IIb	O
,	O
multicenter	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
clinical	O
trial	O
.	O

One	O
of	O
the	O
regulatory	O
pathways	O
for	O
PAF	O
involves	O
degradation	O
to	O
the	O
inactive	O
metabolite	O
lyso	O
-	O
PAF	O
by	O
the	O
enzyme	O
PAF	B-ENZY
acetylhydrolase	I-ENZY
(	O
PAF	O
-	O
AH	O
).	O

TITLE	O
:	O
Novel	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitors	O
as	O
a	O
treatment	O
for	O
neutrophil	O
-	O
predominant	O
inflammatory	O
lung	O
diseases	O
.	O

This	O
review	O
mainly	O
focuses	O
upon	O
the	O
pathogenic	O
contribution	O
of	O
NE	O
to	O
these	O
neutrophil	O
-	O
predominant	O
inflammatory	O
lung	O
diseases	O
,	O
and	O
evaluates	O
the	O
experimental	O
and	O
clinical	O
efficacies	O
of	O
the	O
two	O
-	O
types	O
of	O
appropriate	O
small	O
molecular	O
weight	O
human	O
neutrophil	B-ENZY
elastase	I-ENZY
(	O
HNE	O
)	O
inhibitors	O
:	O
acyl	O
-	O
enzyme	O
inhibitors	O
and	O
transition	O
-	O
state	O
inhibitors	O
.	O

The	O
amino	O
acid	O
sequence	O
contained	O
seven	O
potential	O
sites	O
for	O
threonine	O
(	O
T	O
)-	O
or	O
serine	O
(	O
S	O
)-	O
linked	O
phosphorylation	O
by	O
each	O
protein	B-ENZY
kinase	I-ENZY
C	I-ENZY
and	O
casein	O
kinase	O
II	O
.	O

TITLE	O
:	O
Identification	O
of	O
the	O
murine	O
coronavirus	O
MP1	O
cleavage	O
site	O
recognized	O
by	O
papain	B-ENZY
-	O
like	O
proteinase	O
2	O
.	O

ABSTRACT	O
:	O
The	O
replicase	O
polyprotein	O
of	O
murine	O
coronavirus	O
is	O
extensively	O
processed	O
by	O
three	O
proteinases	O
,	O
two	O
papain	B-ENZY
-	O
like	O
proteinases	O
(	O
PLPs	O
),	O
termed	O
PLP1	O
and	O
PLP2	O
,	O
and	O
a	O
picornavirus	O
3C	O
-	O
like	O
proteinase	O
(	O
3CLpro	O
).	O

The	O
amino	O
terminal	O
half	O
of	O
the	O
S	O
glycoprotein	O
gene	O
including	O
antigenic	O
sites	O
A	O
,	O
B	O
,	O
C	O
and	O
D	O
,	O
were	O
amplified	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Dyspnea	O
was	O
present	O
in	O
12	O
patients	O
during	O
their	O
stay	O
in	O
hospital	O
,	O
and	O
all	O
developed	O
abnormalities	O
on	O
chest	O
radiograph	O
;	O
3	O
patients	O
developed	O
severe	O
hypoxemia	O
(	O
PaO	B-ENZY
(	O
2	O
)	O
<	O
50	O
mm	O
Hg	O
).	O

Common	O
laboratory	O
findings	O
included	O
lymphopenia	O
,	O
thrombocytopenia	O
,	O
and	O
mild	O
elevations	O
of	O
activated	O
partial	O
thromboplastin	O
time	O
,	O
alanine	B-ENZY
transaminase	I-ENZY
,	O
lactic	O
dehydrogenase	O
,	O
and	O
creatine	O
phosphokinase	O
.	O

Venoarterial	O
patients	O
had	O
significantly	O
greater	O
alveolar	O
-	O
arterial	O
oxygen	O
gradients	O
and	O
lower	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratios	O
than	O
venovenous	O
patients	O
(	O
p	O
<.	O
03	O
).	O

ABSTRACT	O
:	O
Chemical	O
modification	O
of	O
the	O
proteins	O
bovine	O
serum	O
albumin	O
,	O
alpha	O
-	O
lactalbumin	O
,	O
beta	O
-	O
lactoglobulin	O
and	O
chicken	O
lysozyme	B-ENZY
by	O
3	O
-	O
hydroxyphthalic	O
anhydride	O
(	O
3	O
-	O
HP	O
)	O
yielded	O
compounds	O
which	O
exerted	O
antiviral	O
activity	O
in	O
vitro	O
as	O
compared	O
with	O
the	O
native	O
unmodified	O
proteins	O
.	O

Proteolytical	O
digestion	O
of	O
albumin	O
,	O
alpha	O
-	O
lactalbumin	O
,	O
beta	O
-	O
lactoglobulin	O
and	O
lysozyme	B-ENZY
by	O
trypsin	B-ENZY
,	O
chymotrypsin	B-ENZY
and	O
pepsin	B-ENZY
yielded	O
several	O
peptide	O
fragments	O
with	O
antiherpetic	O
activity	O
.	O

ABSTRACT	O
:	O
Acute	O
Chest	O
Syndrome	O
(	O
ACS	B-ENZY
)	O
describes	O
a	O
syndrome	O
characterized	O
by	O
the	O
presence	O
of	O
a	O
new	O
pulmonary	O
infiltrate	O
on	O
a	O
chest	O
X	O
-	O
ray	O
,	O
fever	O
,	O
and	O
respiratory	O
symptoms	O
and	O
is	O
the	O
leading	O
cause	O
of	O
death	O
and	O
hospitalization	O
in	O
sickle	O
cell	O
disease	O
(	O
SCD	O
).	O

During	O
follow	O
up	O
(	O
14	O
-	O
32	O
months	O
),	O
none	O
of	O
the	O
6	O
patients	O
developed	O
viral	O
complications	O
related	O
to	O
transfusion	O
therapy	O
,	O
alloimmunization	O
or	O
recurrence	O
of	O
ACS	B-ENZY
.	O

In	O
conclusion	O
,	O
in	O
regard	O
to	O
the	O
pre	O
-	O
and	O
post	O
-	O
red	O
cell	O
-	O
exchange	O
clinical	O
and	O
laboratory	O
data	O
,	O
we	O
can	O
say	O
that	O
red	O
cell	O
-	O
exchange	O
provides	O
a	O
dramatic	O
resolution	O
of	O
the	O
episode	O
of	O
ACS	B-ENZY
,	O
minimizes	O
the	O
development	O
of	O
iron	O
overload	O
,	O
and	O
rapidly	O
decreases	O
HbS	O
and	O
hematocrit	O
levels	O
.	O

In	O
light	O
of	O
our	O
results	O
,	O
we	O
hypothesize	O
that	O
ACS	B-ENZY
episodes	O
are	O
secondary	O
to	O
pulmonary	O
damage	O
and	O
to	O
a	O
gradual	O
worsening	O
related	O
to	O
age	O
,	O
and	O
that	O
there	O
is	O
some	O
evidence	O
that	O
individuals	O
affected	O
by	O
SCD	O
in	O
the	O
third	O
to	O
fourth	O
decade	O
of	O
life	O
are	O
more	O
susceptible	O
to	O
ACS	B-ENZY
and	O
/	O
or	O
other	O
severe	O
disease	O
-	O
related	O
complications	O
,	O
needing	O
repeated	O
and	O
strict	O
clinical	O
follow	O
up	O
.	O

IFN	O
-	O
gamma	O
mRNA	O
was	O
detected	O
at	O
the	O
time	O
of	O
T	O
-	O
cell	O
infiltration	O
,	O
and	O
earlier	O
studies	O
have	O
shown	O
that	O
this	O
is	O
temporally	O
related	O
to	O
granzyme	B-ENZY
B	I-ENZY
gene	O
expression	O
and	O
the	O
clearance	O
of	O
infectious	O
virus	O
from	O
the	O
retina	O
.	O

TITLE	O
:	O
[	O
The	O
study	O
of	O
cis	O
-	O
element	O
HNF4	O
in	O
the	O
regulation	O
of	O
mfg12	O
prothrombinase	B-ENZY
/	O
fibroleukin	O
gene	O
expression	O
in	O
response	O
to	O
nucleocapsid	O
protein	O
of	O
MHV	O
-	O
3	O
].	O

ABSTRACT	O
:	O
To	O
identify	O
the	O
transcription	O
factor	O
(	O
s	O
)	O
that	O
is	O
essential	O
for	O
activation	O
of	O
mfgl2	O
prothrombinase	B-ENZY
/	O
fibroleukin	O
gene	O
in	O
response	O
to	O
nucleocapsid	O
protein	O
of	O
murine	O
hepatitis	O
virus	O
type	O
3	O
(	O
MHV	O
-	O
3	O
).	O

Other	O
common	O
findings	O
included	O
elevated	O
levels	O
of	O
serum	O
alanine	B-ENZY
aminotransferase	I-ENZY
,	O
lactate	O
dehydrogenase	O
and	O
erythrocyte	O
sedimentation	O
(	O
76	O
.	O
2	O
%,	O
28	O
.	O
6	O
%	O
and	O
47	O
.	O
8	O
%,	O
respectively	O
),	O
and	O
decreased	O
levels	O
of	O
serum	O
iron	O
and	O
albumin	O
(	O
63	O
.	O
2	O
%	O
and	O
47	O
.	O
8	O
%,	O
respectively	O
).	O

Other	O
rare	O
abnormalities	O
included	O
liver	O
injury	O
(	O
elevated	O
alanine	B-ENZY
aminotransferase	I-ENZY
in	O
7	O
.	O
6	O
%)	O
and	O
thrombocytopenia	O
(	O
3	O
.	O
8	O
%).	O

Almost	O
all	O
patients	O
suffered	O
from	O
hypoxemia	O
(	O
PaO	B-ENZY
(	O
2	O
)	O
less	O
than	O
90	O
mm	O
Hg	O
in	O
90	O
.	O
2	O
%,	O
less	O
than	O
70	O
mm	O
Hg	O
in	O
28	O
.	O
6	O
%).	O

The	O
antiviral	O
activity	O
may	O
be	O
mediated	O
in	O
part	O
by	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
synthetase	O
,	O
RNA	O
-	O
dependent	O
protein	B-ENZY
kinase	I-ENZY
,	O
and	O
Mx	O
protein	O
,	O
which	O
inhibit	O
viral	O
replication	O
or	O
degrade	O
viral	O
components	O
,	O
because	O
limitin	O
induced	O
their	O
mRNA	O
expression	O
and	O
enzyme	O
activity	O
.	O

TITLE	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
NTPase	B-ENZY
/	O
helicase	O
belongs	O
to	O
a	O
distinct	O
class	O
of	O
5	O
'	O
to	O
3	O
'	O
viral	O
helicases	O
.	O

ABSTRACT	O
:	O
The	O
putative	O
NTPase	B-ENZY
/	O
helicase	O
protein	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
postulated	O
to	O
play	O
a	O
number	O
of	O
crucial	O
roles	O
in	O
the	O
viral	O
life	O
cycle	O
,	O
making	O
it	O
an	O
attractive	O
target	O
for	O
anti	O
-	O
SARS	O
therapy	O
.	O

We	O
have	O
cloned	O
,	O
expressed	O
,	O
and	O
purified	O
this	O
protein	O
as	O
an	O
N	O
-	O
terminal	O
hexahistidine	O
fusion	O
in	O
Escherichia	O
coli	O
and	O
have	O
characterized	O
its	O
helicase	O
and	O
NTPase	B-ENZY
activities	O
.	O

Homopolynucleotides	O
significantly	O
stimulated	O
the	O
ATPase	B-ENZY
activity	O
(	O
15	O
-	O
25	O
-	O
fold	O
)	O
with	O
the	O
notable	O
exception	O
of	O
poly	O
(	O
G	O
)	O
and	O
poly	O
(	O
dG	O
),	O
which	O
were	O
non	O
-	O
stimulatory	O
.	O

Direct	O
sequencing	O
followed	O
by	O
phylogenetic	O
analysis	O
on	O
that	O
region	O
allowed	O
us	O
to	O
type	O
those	O
field	O
isolates	O
that	O
were	O
not	O
typable	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
).	O

Klenow	O
-	O
FragELTM	O
DNA	O
Fragmentation	O
Detection	O
Kit	O
and	O
immunohistochemical	O
alkaline	B-ENZY
phosphatase	I-ENZY
detection	O
reagent	O
kit	O
were	O
used	O
to	O
detect	O
cell	O
apoptosis	O
and	O
expressions	O
of	O
CD68	O
,	O
CD20	O
,	O
CD4	O
,	O
CD8	O
and	O
CD45RA	O
in	O
the	O
pathological	O
tissues	O
of	O
SARS	O
patients	O
.	O

The	O
serum	O
levels	O
of	O
creatine	B-ENZY
kinase	I-ENZY
(	O
CK	B-ENZY
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
),	O
aspartate	B-ENZY
transaminase	I-ENZY
(	O
AST	B-ENZY
),	O
troponin	O
I	O
(	O
TnI	O
),	O
creatine	B-ENZY
kinase	I-ENZY
-	O
MB	O
(	O
CK	B-ENZY
-	O
MB	O
)	O
and	O
myoglobin	O
(	O
MYO	O
)	O
were	O
measured	O
.	O

CK	O
,	O
LDH	O
and	O
AST	B-ENZY
levels	O
in	O
patients	O
were	O
higher	O
than	O
those	O
of	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
);	O
furthermore	O
,	O
among	O
patients	O
the	O
levels	O
were	O
higher	O
in	O
fatal	O
cases	O
than	O
in	O
survivors	O
.	O

RESULTS	O
:	O
CK	O
,	O
LDH	O
and	O
AST	B-ENZY
levels	O
in	O
patients	O
were	O
higher	O
than	O
those	O
of	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
);	O
furthermore	O
,	O
among	O
patients	O
the	O
levels	O
were	O
higher	O
in	O
fatal	O
cases	O
than	O
in	O
survivors	O
.	O

Abnormal	O
liver	O
function	O
mainly	O
resulted	O
from	O
ALT	O
elevation	O
(	O
70	O
.	O
7	O
%),	O
then	O
both	O
ALT	O
and	O
AST	B-ENZY
elevation	O
(	O
22	O
.	O
4	O
%).	O

TITLE	O
:	O
5	B-ENZY
-	I-ENZY
lipoxygenase	I-ENZY
knockout	O
mice	O
exhibit	O
a	O
resistance	O
to	O
acute	O
pancreatitis	O
induced	O
by	O
cerulein	O
.	O

ABSTRACT	O
:	O
Here	O
we	O
compare	O
the	O
degree	O
of	O
pancreatitis	O
caused	O
by	O
cerulein	O
in	O
mice	O
lacking	O
5	B-ENZY
-	I-ENZY
lipoxygenase	I-ENZY
(	O
5	O
-	O
LO	O
)	O
and	O
in	O
the	O
corresponding	O
wild	O
-	O
type	O
mice	O
.	O

Intraperitoneal	O
injection	O
of	O
cerulein	O
in	O
mice	O
resulted	O
in	O
severe	O
,	O
acute	O
pancreatitis	O
characterized	O
by	O
oedema	O
,	O
neutrophil	O
infiltration	O
and	O
necrosis	O
and	O
elevated	O
serum	O
levels	O
of	O
amylase	O
and	O
lipase	B-ENZY
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
the	O
impact	O
of	O
aerosolised	O
prostacyclin	O
(	O
PGI2	O
)	O
and	O
iloprost	O
in	O
the	O
absence	O
or	O
presence	O
of	O
subthreshold	O
intravascular	O
doses	O
of	O
the	O
dual	O
-	O
selective	O
phosphodiesterase	B-ENZY
-	O
3	O
/	O
4	O
inhibitor	O
zardaverine	O
was	O
investigated	O
in	O
an	O
experimental	O
model	O
of	O
acute	O
respiratory	O
failure	O
.	O

In	O
perfused	O
rabbit	O
lungs	O
,	O
continuous	O
infusion	O
of	O
the	O
thromboxane	O
-	O
A2	O
-	O
mimetic	O
U46619	O
provoked	O
pulmonary	O
hypertension	O
,	O
accompanied	O
by	O
progressive	O
lung	O
oedema	O
formation	O
and	O
severe	O
ventilation	O
-	O
perfusion	O
mismatch	O
with	O
predominance	O
of	O
shunt	O
flow	O
(	O
increasing	O
from	O
approximately	O
2	O
to	O
58	O
%,	O
as	O
assessed	O
by	O
the	O
multiple	O
inert	O
gas	B-ENZY
elimination	O
technique	O
).	O

TITLE	O
:	O
Protective	O
role	O
of	O
heme	B-ENZY
oxygenase	I-ENZY
-	O
1	O
induction	O
in	O
carbon	O
tetrachloride	O
-	O
induced	O
hepatotoxicity	O
.	O

Heme	B-ENZY
oxygenase	I-ENZY
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
(	O
EC	O
1	O
.	O
14	O
.	O
99	O
.	O
3	O
),	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
heme	O
catabolism	O
,	O
is	O
known	O
to	O
be	O
induced	O
by	O
oxidative	O
stress	O
and	O
to	O
confer	O
protection	O
against	O
oxidative	O
tissue	O
injuries	O
.	O

CCl	O
(	O
4	O
)	O
treatment	O
(	O
1	O
mL	O
/	O
kg	O
,	O
intraperitoneally	O
)	O
produced	O
severe	O
hepatic	O
injury	O
in	O
rats	O
as	O
revealed	O
by	O
significant	O
increases	O
in	O
serum	O
alanine	B-ENZY
transaminase	I-ENZY
(	O
ALT	O
)	O
(	O
EC	O
2	O
.	O
6	O
.	O
1	O
.	O
2	O
)	O
activity	O
and	O
hepatic	O
malondialdehyde	O
(	O
MDA	O
)	O
content	O
,	O
severe	O
liver	O
cell	O
injury	O
,	O
and	O
increases	O
in	O
hepatic	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
mRNA	O
expression	O
and	O
DNA	O
binding	O
activity	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
).	O

HO	O
-	O
1	O
induction	O
was	O
mediated	O
in	O
part	O
through	O
a	O
rapid	O
increase	O
in	O
microsomal	O
free	O
heme	O
concentration	O
presumably	O
derived	O
from	O
hepatic	O
cytochrome	B-ENZY
P450	I-ENZY
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
influence	O
of	O
the	O
acute	O
blood	O
gas	B-ENZY
analysis	O
index	O
change	O
on	O
the	O
prognosis	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

The	O
human	O
lysosomal	O
enzyme	O
beta	B-ENZY
-	I-ENZY
glucuronidase	I-ENZY
(	O
GUSB	B-ENZY
)	O
was	O
used	O
as	O
a	O
reporter	O
gene	O
,	O
because	O
it	O
can	O
be	O
distinguished	O
from	O
feline	O
GUSB	B-ENZY
by	O
heat	O
stability	O
.	O

The	O
clinical	O
course	O
,	O
laboratory	O
data	O
,	O
SARS	O
-	O
CoV	O
antibody	O
titers	O
,	O
and	O
results	O
of	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
were	O
studied	O
.	O

A	O
decrease	O
in	O
LVEF	O
correlated	O
moderately	O
with	O
an	O
elevated	O
lactate	O
dehydrogenase	O
level	O
(	O
r	O
=-	O
0	O
.	O
605	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
whereas	O
a	O
higher	O
IMP	O
correlated	O
weakly	O
with	O
an	O
increase	O
in	O
creatine	B-ENZY
kinase	I-ENZY
level	O
(	O
r	O
=	O
0	O
.	O
38	O
,	O
P	O
=	O
0	O
.	O
016	O
).	O

SARS	O
-	O
CoV	O
RNA	O
was	O
identified	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
in	O
7	O
of	O
8	O
cases	O
in	O
fresh	O
autopsy	O
tissue	O
and	O
in	O
8	O
of	O
8	O
cases	O
in	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
lung	O
tissue	O
,	O
including	O
the	O
1	O
negative	O
case	O
in	O
fresh	O
tissue	O
.	O

Pretreatment	O
with	O
a	O
FasL	O
antagonist	O
,	O
a	O
decoy	O
receptor	O
3	O
analogue	O
(	O
DcR3	O
analogue	O
),	O
reduced	O
neutrophil	O
infiltration	O
into	O
the	O
airspace	O
and	O
resulted	O
in	O
a	O
highly	O
significant	O
reduction	O
in	O
the	O
levels	O
of	O
GM	O
-	O
CSF	O
,	O
MIP	O
-	O
2	O
and	O
KC	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
.	O

The	O
crystal	O
structure	O
of	O
Clostridium	O
botulinum	B-ENZY
neurotoxin	I-ENZY
B	O
appeared	O
to	O
be	O
structurally	O
adaptable	O
to	O
human	O
and	O
canine	O
coronavirus	O
spike	O
protein	O
sequences	O
and	O
it	O
was	O
successfully	O
used	O
to	O
model	O
the	O
two	O
subunits	O
of	O
SARS	O
coronavirus	O
spike	O
glycoprotein	O
.	O

All	O
patients	O
had	O
fever	O
(	O
5	O
/	O
5	O
),	O
3	O
chills	O
or	O
rigor	O
,	O
4	O
cough	O
;	O
2	O
with	O
decreased	O
lymphocyte	O
,	O
2	O
decreased	O
platelet	O
,	O
3	O
elevated	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
),	O
4	O
hypoalbuminemia	O
,	O
5	O
abnormal	O
chest	O
radiographs	O
.	O

Lymphopenia	O
;	O
neutropenia	O
;	O
thrombocytopenia	O
;	O
and	O
elevated	O
alanine	B-ENZY
aminotransferase	I-ENZY
,	O
aspartate	B-ENZY
aminotransferase	I-ENZY
,	O
and	O
creatine	B-ENZY
kinase	I-ENZY
were	O
present	O
in	O
some	O
cases	O
.	O

Nasopharyngeal	O
swab	O
specimens	O
were	O
negative	O
for	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
by	O
an	O
in	O
-	O
house	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
in	O
all	O
25	O
children	O
.	O

Nasopharyngeal	O
swab	O
specimens	O
were	O
negative	O
for	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
by	O
an	O
in	O
-	O
house	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
in	O
all	O
25	O
children	O
.	O

Infection	O
with	O
MHV	O
was	O
confirmed	O
in	O
nude	O
sentinel	O
mice	O
by	O
use	O
of	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
detection	O
of	O
viral	O
RNA	O
in	O
ascending	O
colon	O
and	O
feces	O
.	O

Admission	O
radiographic	O
score	O
was	O
correlated	O
with	O
admission	O
AST	B-ENZY
level	O
(	O
r	O
=	O
0	O
.	O
53	O
,	O
P	O
=.	O
003	O
);	O
treatment	O
radiographic	O
score	O
,	O
with	O
treatment	O
ALT	O
and	O
AST	B-ENZY
levels	O
(	O
r	O
=	O
0	O
.	O
43	O
,	O
P	O
=.	O
007	O
;	O
r	O
=	O
0	O
.	O
42	O
,	O
P	O
=.	O
019	O
);	O
and	O
time	O
to	O
maximal	O
radiographic	O
score	O
,	O
with	O
AST	B-ENZY
level	O
at	O
maximal	O
radiographic	O
score	O
(	O
r	O
=	O
-	O
0	O
.	O
45	O
,	O
P	O
=.	O
006	O
),	O
admission	O
radiographic	O
score	O
(	O
r	O
=	O
-	O
0	O
.	O
55	O
,	O
P	O
<.	O
001	O
),	O
treatment	O
radiographic	O
score	O
(	O
r	O
=	O
-	O
0	O
.	O
58	O
,	O
P	O
<.	O
001	O
),	O
and	O
admission	O
ALT	O
and	O
AST	B-ENZY
levels	O
(	O
r	O
=	O
-	O
0	O
.	O
44	O
,	O
P	O
=.	O
007	O
;	O
r	O
=	O
-	O
0	O
.	O
58	O
,	O
P	O
=.	O
001	O
).	O

Renilla	O
and	O
firefly	B-ENZY
luciferase	I-ENZY
expression	O
cassettes	O
,	O
each	O
provided	O
with	O
viral	O
transcription	O
regulatory	O
sequences	O
(	O
TRSs	O
),	O
were	O
inserted	O
at	O
several	O
genomic	O
positions	O
,	O
both	O
independently	O
in	O
different	O
viruses	O
and	O
combined	O
within	O
one	O
viral	O
genome	O
.	O

The	O
primers	O
were	O
specific	O
and	O
did	O
not	O
amplify	O
New	O
Castle	O
disease	O
virus	O
,	O
Mycoplasma	O
spp	B-ENZY
.,	O
or	O
infectious	O
laryngotracheitis	O
virus	O
.	O

The	O
life	O
signs	O
,	O
pulmonary	O
ventilation	O
parameters	O
,	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
were	O
monitored	O
and	O
blood	O
levels	O
of	O
TXB2	O
,	O
6	O
-	O
keto	O
-	O
PGF1	O
alpha	O
in	O
both	O
groups	O
were	O
determined	O
in	O
the	O
fixed	O
time	O
points	O
.	O

TITLE	O
:	O
[	O
Genomic	O
variations	O
in	O
the	O
locus	O
for	O
aminopeptidase	B-ENZY
N	I-ENZY
:	O
a	O
putative	O
cellular	O
receptor	O
for	O
SARS	O
-	O
CoV	O
spike	O
glycoprotein	O
].	O

ABSTRACT	O
:	O
Aminopeptidase	B-ENZY
N	I-ENZY
has	O
been	O
identified	O
as	O
the	O
cellular	O
receptor	O
for	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
and	O
was	O
a	O
putative	O
receptor	O
for	O
the	O
spike	O
glycoprotein	O
encoded	O
by	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

We	O
report	O
here	O
identification	O
of	O
9	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
ANPEP	O
,	O
encoding	O
human	O
aminopeptidase	B-ENZY
N	I-ENZY
,	O
in	O
Chinese	O
.	O

All	O
were	O
having	O
positive	O
results	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
ribonucleic	O
acid	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
performed	O
on	O
their	O
nasopharyngeal	O
aspirates	O
or	O
stool	O
samples	O
.	O

Other	O
common	O
findings	O
were	O
lymphopenia	O
(	O
57	O
%,	O
26	O
/	O
46	O
),	O
thrombocytopenia	O
(	O
39	O
%,	O
18	O
/	O
46	O
),	O
elevated	O
lactate	O
dehydrogenase	O
(	O
63	O
%,	O
29	O
/	O
46	O
),	O
and	O
elevated	O
creatine	B-ENZY
kinase	I-ENZY
(	O
24	O
%,	O
11	O
/	O
46	O
).	O

A	O
further	O
73	O
BAL	B-ENZY
samples	O
were	O
obtained	O
from	O
20	O
infants	O
(	O
median	O
age	O
2	O
days	O
,	O
range	O
1	O
to	O
402	O
)	O
receiving	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
for	O
severe	O
respiratory	O
failure	O
.	O

Neutrophil	O
apoptosis	O
was	O
increased	O
in	O
the	O
RDS	O
group	O
(	O
mean	O
(	O
SEM	O
)	O
neutrophil	O
apoptosis	O
on	O
day	O
7	O
BAL	B-ENZY
:	O
RDS	O
17	O
.	O
0	O
(	O
8	O
.	O
6	O
)%	O
v	O
CLD	O
0	O
.	O
7	O
(	O
0	O
.	O
2	O
)%	O
(	O
p	O
<	O
0	O
.	O
05	O
)).	O

BAL	B-ENZY
fluid	O
obtained	O
from	O
RDS	O
but	O
not	O
CLD	O
patients	O
was	O
proapoptotic	O
to	O
neutrophils	O
(	O
apoptosis	O
ratio	O
BAL	B-ENZY
fluid	O
/	O
saline	O
control	O
:	O
day	O
1	O
,	O
RDS	O
9	O
.	O
8	O
(	O
5	O
.	O
5	O
)	O
v	O
CLD	O
1	O
.	O
2	O
(	O
0	O
.	O
1	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
);	O
day	O
2	O
,	O
RDS	O
4	O
.	O
32	O
(	O
2	O
.	O
8	O
)	O
v	O
CLD	O
0	O
.	O
5	O
(	O
0	O
.	O
4	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)).	O

There	O
were	O
similar	O
findings	O
in	O
the	O
ECMO	O
group	O
:	O
survivors	O
had	O
proapoptotic	O
BAL	B-ENZY
fluid	O
compared	O
with	O
non	O
-	O
survivors	O
(	O
apoptosis	O
ratio	O
day	O
1	O
,	O
survivors	O
7	O
.	O
9	O
(	O
2	O
.	O
1	O
)	O
v	O
non	O
-	O
survivors	O
2	O
.	O
1	O
(	O
0	O
.	O
7	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)).	O

There	O
were	O
similar	O
findings	O
in	O
the	O
ECMO	O
group	O
:	O
survivors	O
had	O
proapoptotic	O
BAL	B-ENZY
fluid	O
compared	O
with	O
non	O
-	O
survivors	O
(	O
apoptosis	O
ratio	O
day	O
1	O
,	O
survivors	O
7	O
.	O
9	O
(	O
2	O
.	O
1	O
)	O
v	O
non	O
-	O
survivors	O
2	O
.	O
1	O
(	O
0	O
.	O
7	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)).	O

This	O
finding	O
was	O
further	O
confirmed	O
by	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
,	O
Western	O
blot	O
analysis	O
,	O
and	O
BNip3	O
-	O
promoter	O
-	O
luciferase	B-ENZY
reporter	O
system	O
.	O

The	O
fourth	O
patient	O
did	O
not	O
carry	O
this	O
mutation	O
but	O
had	O
severely	O
decreased	O
activities	O
of	O
long	O
-	O
chain	O
3	B-ENZY
-	I-ENZY
hydroxyacyl	I-ENZY
-	I-ENZY
CoA	I-ENZY
dehydrogenase	I-ENZY
and	O
long	O
-	O
chain	O
3	B-ENZY
-	I-ENZY
ketoacyl	I-ENZY
-	I-ENZY
CoA	I-ENZY
thiolase	I-ENZY
.	O

Moreover	O
,	O
work	O
on	O
viral	O
neuraminidase	B-ENZY
has	O
led	O
to	O
the	O
licensing	O
of	O
potent	O
selective	O
antiviral	O
drugs	O
,	O
and	O
economic	O
decision	O
modelling	O
provides	O
further	O
justification	O
for	O
annual	O
vaccination	O
and	O
a	O
framework	O
for	O
the	O
use	O
of	O
neuraminidase	B-ENZY
inhibitors	O
.	O

ABSTRACT	O
:	O
We	O
report	O
here	O
that	O
fusions	O
of	O
single	O
-	O
chain	O
antibodies	O
(	O
scFvs	O
)	O
to	O
the	O
autotransporter	O
beta	O
domain	O
of	O
the	O
IgA	B-ENZY
protease	I-ENZY
of	O
Neisseria	O
gonorrhoeae	O
are	O
instrumental	O
in	O
locating	O
virus	O
-	O
neutralizing	O
activity	O
on	O
the	O
cell	O
surface	O
of	O
Escherichia	O
coli	O
.	O

Mechanically	O
-	O
ventilated	O
children	O
with	O
peak	O
inspiratory	O
pressure	O
greater	O
than	O
or	O
equal	O
to	O
30	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
FiO	O
(	O
2	O
)	O
greater	O
than	O
or	O
equal	O
to	O
0	O
.	O
5	O
,	O
and	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
less	O
than	O
or	O
equal	O
to	O
200	O
were	O
included	O
in	O
the	O
study	O
.	O

Patients	O
who	O
presented	O
an	O
increase	O
of	O
at	O
least	O
20	O
in	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
were	O
considered	O
responsive	O
.	O

RESULTS	O
:	O
Eighteen	O
children	O
(	O
10	O
males	O
),	O
whose	O
mean	O
age	O
was	O
11	O
.	O
5	O
-/+	O
11	O
.	O
5	O
months	O
,	O
with	O
initial	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
of	O
96	O
.	O
06	O
-/+	O
41	O
.	O
78	O
,	O
participated	O
in	O
the	O
study	O
.	O

After	O
one	O
hour	O
in	O
the	O
prone	O
position	O
,	O
27	O
.	O
7	O
%	O
of	O
the	O
patients	O
(	O
5	O
/	O
18	O
)	O
improved	O
their	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
(	O
P	O
=	O
0	O
.	O
045	O
).	O

CONCLUSION	O
:	O
Prone	O
positioning	O
during	O
mechanical	O
ventilation	O
of	O
children	O
with	O
severe	O
hypoxemia	O
may	O
improve	O
the	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
in	O
the	O
first	O
hour	O
.	O

The	O
ACs	B-ENZY
of	O
T	O
lymphocytes	O
including	O
CD4	O
and	O
CD8	O
subsets	O
in	O
different	O
phases	O
were	O
as	O
below	O
:	O
III	O
>	O
II	O
>	O
I	O
.	O
The	O
ACs	B-ENZY
of	O
subsets	O
involved	O
in	O
activation	O
such	O
as	O
CD3	O
+	O
HLA	O
-	O
DR	O
+/	O
lym	O
,	O
CD3	O
+	O
CD25	O
+/	O
lym	O
,	O
CD28	O
+	O
CD4	O
+/	O
CD4	O
,	O
CD28	O
+	O
CD8	O
+/	O
CD8	O
,	O
and	O
CD38	O
+	O
CD4	O
+/	O
CD4	O
all	O
were	O
highest	O
in	O
group	O
III	O
.	O

We	O
predict	O
important	O
structural	O
attributes	O
of	O
potential	O
anti	O
-	O
SARS	O
-	O
CoV	O
RdRp	O
nucleotide	O
analog	O
inhibitors	O
:	O
hydrogen	O
-	O
bonding	O
capability	O
for	O
the	O
2	O
'	O
and	O
3	O
'	O
groups	O
of	O
the	O
sugar	O
ring	O
and	O
C3	O
'	O
endo	O
sugar	O
puckering	O
,	O
and	O
the	O
absence	O
of	O
a	O
hydrophobic	O
binding	O
pocket	O
for	O
non	O
-	O
nucleoside	O
analog	O
inhibitors	O
similar	O
to	O
those	O
observed	O
in	O
hepatitis	O
C	O
virus	O
RdRp	O
and	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
.	O

The	O
present	O
study	O
demonstrated	O
that	O
N	O
protein	O
in	O
the	O
MHV	O
virion	O
nucleocapsid	O
and	O
in	O
the	O
intracellular	O
genome	O
-	O
length	O
RNP	O
complex	O
that	O
bound	O
to	O
viral	O
envelope	O
M	O
protein	O
was	O
tightly	O
self	O
-	O
associated	O
such	O
that	O
its	O
association	O
was	O
retained	O
even	O
after	O
extensive	O
RNase	B-ENZY
A	I-ENZY
-	O
treatment	O
of	O
the	O
RNP	O
complexes	O
.	O

The	O
RNase	B-ENZY
A	I-ENZY
-	O
resistant	O
tight	O
N	O
protein	O
association	O
in	O
the	O
virion	O
nucleocapsid	O
was	O
not	O
mediated	O
by	O
an	O
intermolecular	O
disulfide	O
bridge	O
between	O
N	O
proteins	O
.	O

In	O
contrast	O
,	O
N	O
protein	O
association	O
in	O
the	O
majority	O
of	O
the	O
intracellular	O
RNP	O
complexes	O
was	O
susceptible	O
to	O
RNase	B-ENZY
A	I-ENZY
-	O
treatment	O
.	O

Tissue	O
sections	O
were	O
stained	O
with	O
haematoxylin	O
and	O
eosin	O
(	O
H	O
&	O
E	O
),	O
and	O
in	O
situ	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
on	O
lung	O
sections	O
was	O
performed	O
using	O
SARS	O
coronavirus	O
-	O
specific	O
primers	O
.	O

The	O
risk	O
factors	O
associated	O
with	O
severe	O
disease	O
were	O
presence	O
of	O
diarrhoea	O
,	O
high	O
peak	O
LDH	O
and	O
CRP	O
,	O
high	O
AST	B-ENZY
and	O
creatine	B-ENZY
kinase	I-ENZY
on	O
admission	O
and	O
high	O
peak	O
values	O
.	O

The	O
risk	O
factors	O
associated	O
with	O
severe	O
disease	O
were	O
presence	O
of	O
diarrhoea	O
,	O
high	O
peak	O
LDH	O
and	O
CRP	O
,	O
high	O
AST	B-ENZY
and	O
creatine	B-ENZY
kinase	I-ENZY
on	O
admission	O
and	O
high	O
peak	O
values	O
.	O

Each	O
deletion	O
strain	O
was	O
transformed	O
to	O
express	O
BMV	O
replicase	O
proteins	O
and	O
a	O
BMV	O
RNA	O
replication	O
template	O
with	O
the	O
capsid	O
gene	O
replaced	O
by	O
a	O
luciferase	B-ENZY
reporter	O
.	O

Luciferase	B-ENZY
expression	O
,	O
which	O
is	O
dependent	O
on	O
viral	O
RNA	O
replication	O
and	O
RNA	O
-	O
dependent	O
mRNA	O
synthesis	O
,	O
was	O
measured	O
in	O
intact	O
yeast	O
cells	O
.	O

PEDV	O
occupies	O
an	O
intermediate	O
position	O
between	O
two	O
well	O
characterized	O
members	O
of	O
the	O
coronavirus	O
group	O
I	O
,	O
human	O
coronavirus	O
(	O
HCoV	O
-	O
229E	O
)	O
and	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
which	O
uses	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
),	O
a	O
150	O
kDa	O
protein	O
,	O
as	O
their	O
receptors	O
.	O

The	O
neuraminidase	B-ENZY
inhibitors	O
(	O
NAIs	O
)	O
are	O
a	O
new	O
class	O
of	O
antiviral	O
drug	O
targeting	O
a	O
viral	O
influenza	O
enzyme	O
,	O
the	O
neuraminidase	B-ENZY
,	O
which	O
acts	O
both	O
to	O
facilitate	O
virus	O
infection	O
of	O
cells	O
by	O
clearing	O
a	O
passage	O
through	O
otherwise	O
protective	O
respiratory	O
fluids	O
and	O
also	O
by	O
helping	O
release	O
of	O
the	O
virus	O
by	O
cutting	O
the	O
chemical	O
umbilical	O
cord	O
which	O
links	O
up	O
the	O
virus	O
to	O
the	O
infected	O
cell	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
mitochondrial	O
-	O
aconitase	B-ENZY
binds	O
specifically	O
to	O
the	O
3	O
'	O
terminal	O
42	O
nucleotides	O
of	O
the	O
Murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
RNA	O
along	O
with	O
three	O
additional	O
proteins	O
of	O
70	O
,	O
58	O
and	O
40	O
kDa	O
to	O
form	O
a	O
stable	O
RNA	O
-	O
protein	O
complex	O
.	O

We	O
believe	O
it	O
is	O
likely	O
that	O
MHV	O
RNA	O
interacts	O
with	O
m	O
-	O
aconitase	B-ENZY
prior	O
to	O
its	O
import	O
into	O
mitochondria	O
in	O
cooperation	O
with	O
extra	O
-	O
mitochondrial	O
mtHSP70	O
,	O
HSP60	O
,	O
and	O
HSP40	O
.	O

Salmonella	O
spp	B-ENZY
were	O
not	O
isolated	O
.	O

The	O
interferon	O
alfacon	O
-	O
1	O
treatment	O
group	O
had	O
a	O
shorter	O
time	O
to	O
50	O
%	O
resolution	O
of	O
lung	O
radiographic	O
abnormalities	O
(	O
median	O
time	O
,	O
4	O
days	O
vs	O
9	O
days	O
;	O
P	O
=.	O
001	O
),	O
had	O
better	O
oxygen	O
saturation	O
(	O
P	O
=.	O
02	O
),	O
resolved	O
their	O
need	O
for	O
supplemental	O
oxygen	O
more	O
rapidly	O
(	O
median	O
,	O
10	O
days	O
vs	O
16	O
days	O
;	O
P	O
=.	O
02	O
),	O
had	O
less	O
of	O
an	O
increase	O
in	O
creatine	B-ENZY
kinase	I-ENZY
levels	O
(	O
P	O
=.	O
03	O
),	O
and	O
showed	O
a	O
trend	O
toward	O
more	O
rapid	O
resolution	O
of	O
lactate	O
dehydrogenase	O
levels	O
compared	O
with	O
the	O
group	O
receiving	O
corticosteroids	O
alone	O
.	O

In	O
this	O
preliminary	O
,	O
uncontrolled	O
study	O
of	O
patients	O
with	O
SARS	O
,	O
use	O
of	O
interferon	O
alfacon	O
-	O
1	O
plus	O
corticosteroids	O
was	O
associated	O
with	O
reduced	O
disease	O
-	O
associated	O
impaired	O
oxygen	O
saturation	O
,	O
more	O
rapid	O
resolution	O
of	O
radiographic	O
lung	O
abnormalities	O
,	O
and	O
lower	O
levels	O
of	O
creatine	B-ENZY
kinase	I-ENZY
.	O

Pediatric	O
SARS	O
patients	O
have	O
markedly	O
elevated	O
circulating	O
IL	O
-	O
1beta	O
levels	O
,	O
which	O
suggests	O
selective	O
activation	O
of	O
the	O
caspase	B-ENZY
-	I-ENZY
1	I-ENZY
-	O
dependent	O
pathway	O
.	O

Serum	O
ALT	O
,	O
AST	B-ENZY
,	O
LDH	O
and	O
CK	O
were	O
elevated	O
in	O
45	O
.	O
2	O
%,	O
29	O
.	O
4	O
%,	O
42	O
.	O
1	O
%,	O
and	O
18	O
.	O
3	O
%	O
of	O
the	O
patients	O
respectively	O
.	O

Serum	O
amylase	O
activity	O
,	O
pancreatic	O
histopathology	O
,	O
myeloperoxidase	B-ENZY
enzyme	O
activity	O
(	O
MPO	O
),	O
and	O
pulmonary	O
changes	O
were	O
assessed	O
.	O

The	O
recombination	O
event	O
was	O
assessed	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
using	O
a	O
combination	O
of	O
specific	O
primers	O
designed	O
to	O
flank	O
a	O
known	O
recombination	O
hot	O
spot	O
of	O
the	O
viral	O
genomic	O
sequence	O
that	O
codes	O
for	O
the	O
S1	O
subunit	O
of	O
the	O
spike	O
envelope	O
protein	O
.	O

After	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
the	O
California	O
isolate	O
exhibited	O
an	O
identical	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
pattern	O
to	O
some	O
isolates	O
obtained	O
from	O
California	O
,	O
known	O
as	O
California	O
99	O
isolates	O
.	O

ABSTRACT	O
:	O
The	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
an	O
important	O
regulator	O
of	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
and	O
was	O
very	O
recently	O
identified	O
as	O
a	O
functional	O
receptor	O
for	O
the	O
SARS	O
virus	O
.	O

The	O
high	O
level	O
of	O
sequence	O
similarity	O
allowed	O
us	O
to	O
build	O
a	O
robust	O
homology	O
model	O
of	O
the	O
ACE2	O
structure	O
with	O
a	O
root	O
-	O
mean	O
-	O
square	O
deviation	O
from	O
the	O
aligned	O
crystal	O
structures	O
of	O
tACE	B-ENZY
and	O
AnCE	O
less	O
than	O
0	O
.	O
5A	O
.	O

The	O
blood	O
gas	B-ENZY
and	O
lung	O
mechanics	O
were	O
measured	O
during	O
the	O
experiments	O
every	O
2	O
h	O
.	O
(	O
1	O
)	O
Meconium	O
aspiration	O
induced	O
ALI	O
and	O
severe	O
HRF	O
(	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
<	O
200	O
mmHg	O
)	O
and	O
depressed	O
dynamic	O
compliance	O
of	O
respiratory	O
system	O
(	O
Cdyn	O
)	O
and	O
airway	O
resistance	O
(	O
Raw	O
).	O

After	O
the	O
rats	O
were	O
killed	O
,	O
lung	O
tissue	O
was	O
sampled	O
to	O
measured	O
expression	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
),	O
nitrotyrosine	O
(	O
NT	O
),	O
myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
activity	O
,	O
malondialdehyde	O
(	O
MDA	O
),	O
wet	O
-	O
to	O
-	O
dry	O
lung	O
weight	O
ratio	O
(	O
W	O
/	O
D	O
),	O
and	O
pulmonary	O
permeability	O
index	O
(	O
PPI	O
).	O

Based	O
on	O
seroconversion	O
to	O
BRSV	O
and	O
clinical	O
picture	O
,	O
67	O
pairs	O
of	O
sera	O
were	O
selected	O
from	O
calves	O
with	O
a	O
BRSV	O
-	O
associated	O
PRDS	O
for	O
circulating	O
MC	O
tryptase	B-ENZY
determination	O
.	O

Levels	O
of	O
tryptase	B-ENZY
were	O
significantly	O
higher	O
in	O
acute	O
sera	O
(	O
26	O
.	O
6	O
+/-	O

ABSTRACT	O
:	O
The	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)-	O
related	O
carboxypeptidase	O
,	O
ACE2	O
,	O
is	O
a	O
type	O
I	O
integral	O
membrane	O
protein	O
of	O
805	O
amino	O
acids	O
that	O
contains	O
one	O
HEXXH	O
+	O
E	O
zinc	O
-	O
binding	O
consensus	O
sequence	O
.	O

A	O
few	O
active	O
site	O
residue	O
substitutions	O
in	O
ACE2	O
relative	O
to	O
ACE	B-ENZY
appear	O
to	O
eliminate	O
the	O
S	O
(	O
2	O
)'	O
substrate	O
-	O
binding	O
subsite	O
and	O
account	O
for	O
the	O
observed	O
reactivity	O
change	O
from	O
the	O
peptidyl	O
dipeptidase	O
activity	O
of	O
ACE	B-ENZY
to	O
the	O
carboxypeptidase	O
activity	O
of	O
ACE2	O
.	O

For	O
further	O
confirmation	O
of	O
this	O
phenomenon	O
and	O
its	O
related	O
mechanism	O
,	O
recombinant	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
was	O
cleaved	O
in	O
vitro	O
by	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
-	O
6	O
respectively	O
.	O

The	O
results	O
demonstrated	O
that	O
these	O
shorter	O
isoforms	O
could	O
be	O
the	O
products	O
from	O
cleavage	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
rather	O
than	O
that	O
of	O
caspase	B-ENZY
-	I-ENZY
6	I-ENZY
.	O

During	O
the	O
acute	O
phase	O
of	O
SARS	O
,	O
lactate	O
dehydrogenase	O
level	O
,	O
degree	O
of	O
hypoxemia	O
,	O
respiratory	O
rate	O
,	O
alpha	O
-	O
hydroxybutyric	O
dehydrogenase	O
level	O
,	O
creatine	B-ENZY
kinase	I-ENZY
isoenzyme	O
-	O
MB	O
,	O
platelet	O
count	O
,	O
and	O
number	O
of	O
involved	O
lobes	O
noted	O
on	O
chest	O
radiographs	O
,	O
and	O
so	O
on	O
,	O
correlated	O
markedly	O
with	O
the	O
prognosis	O
(	O
r	O
=	O
0	O
.	O
257	O
-	O
0	O
.	O
788	O
;	O
P	O
<.	O
05	O
).	O

Three	O
patients	O
who	O
fulfilled	O
the	O
World	O
Health	O
Organization	O
case	O
definition	O
of	O
probable	O
SARS	O
and	O
developed	O
marked	O
elevation	O
of	O
alanine	B-ENZY
aminotransferase	I-ENZY
were	O
included	O
.	O

BAL	B-ENZY
was	O
performed	O
within	O
12	O
h	O
and	O
24	O
h	O
after	O
onset	O
of	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
We	O
report	O
on	O
the	O
role	O
of	O
specific	O
CD8	O
(+)	O
T	O
cells	O
in	O
the	O
pathogenesis	O
of	O
a	O
highly	O
lethal	O
human	O
viral	O
disease	O
,	O
hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	B-ENZY
).	O

HPS	B-ENZY
is	O
a	O
zoonotic	O
disease	O
caused	O
by	O
transmission	O
of	O
Sin	O
Nombre	O
virus	O
(	O
SNV	O
)	O
from	O
chronically	O
infected	O
deer	O
mice	O
.	O

Individuals	O
with	O
HLA	O
-	O
B	O
*	O
3501	O
have	O
an	O
increased	O
risk	O
of	O
developing	O
severe	O
HPS	B-ENZY
,	O
suggesting	O
that	O
CD8	O
(+)	O
T	O
cell	O
responses	O
to	O
SNV	O
contribute	O
to	O
pathogenesis	O
.	O

We	O
identified	O
three	O
CD8	O
(+)	O
T	O
cell	O
epitopes	O
in	O
SNV	O
presented	O
by	O
HLA	O
-	O
B	O
*	O
3501	O
and	O
quantitated	O
circulating	O
SNV	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	O
in	O
11	O
acute	O
HPS	B-ENZY
patients	O
using	O
HLA	O
/	O
peptide	O
tetramers	O
.	O

We	O
found	O
significantly	O
higher	O
frequencies	O
of	O
SNV	O
-	O
specific	O
T	O
cells	O
in	O
patients	O
with	O
severe	O
HPS	B-ENZY
requiring	O
mechanical	O
ventilation	O
(	O
up	O
to	O
44	O
.	O
2	O
%	O
of	O
CD8	O
(+)	O
T	O
cells	O
)	O
than	O
in	O
moderately	O
ill	O
HPS	B-ENZY
patients	O
hospitalized	O
but	O
not	O
requiring	O
mechanical	O
ventilation	O
(	O
up	O
to	O
9	O
.	O
8	O
%	O
of	O
CD8	O
(+)	O
T	O
cells	O
).	O

These	O
results	O
imply	O
that	O
virus	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	O
contribute	O
to	O
HPS	B-ENZY
disease	O
outcome	O
.	O

Physicians	O
must	O
establish	O
reasonable	O
therapeutic	O
goals	O
based	O
on	O
oxygen	O
delivery	O
rather	O
than	O
arbitrary	O
normal	O
values	O
of	O
blood	O
gas	B-ENZY
measurement	O
.	O

GA	O
did	O
not	O
inhibit	O
HSV	O
-	O
1	O
thymidine	B-ENZY
kinase	I-ENZY
.	O

ISAV	O
has	O
been	O
shown	O
earlier	O
to	O
exhibit	O
a	O
receptor	O
-	O
destroying	O
activity	O
,	O
which	O
was	O
defined	O
as	O
an	O
acetylesterase	B-ENZY
with	O
unknown	O
specificity	O
.	O

Improvement	O
in	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
,	O
complications	O
,	O
length	O
of	O
hospital	O
stay	O
,	O
early	O
48	O
-	O
h	O
and	O
overall	O
mortality	O
,	O
compared	O
between	O
the	O
CPAP	O
and	O
standard	O
treatment	O
groups	O
.	O

Within	O
1	O
h	O
,	O
noninvasive	O
continuous	O
positive	O
airway	O
pressure	O
led	O
to	O
decreased	O
respiratory	O
rate	O
(	O
respiratory	O
rate	O
,	O
27	O
+/-	O
7	O
vs	O
35	O
+/-	O
6	O
breaths	O
/	O
min	O
;	O
p	O
=	O
0	O
.	O
009	O
),	O
and	O
improved	O
oxygenation	O
(	O
PaO	B-ENZY
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
),	O
306	O
+/-	O
104	O
vs	O
157	O
+/-	O
71	O
;	O
p	O
=	O
0	O
.	O
004	O
)	O
compared	O
with	O
baseline	O
,	O
whereas	O
no	O
differences	O
were	O
observed	O
within	O
the	O
standard	O
treatment	O
group	O
.	O

An	O
improvement	O
in	O
gas	B-ENZY
exchange	O
parameters	O
,	O
but	O
not	O
a	O
defined	O
value	O
per	O
se	O
may	O
be	O
useful	O
as	O
a	O
prognostic	O
factor	O
for	O
favourable	O
outcome	O
.	O

A	O
subject	O
inhaled	O
saline	O
mist	O
and	O
exhaled	O
through	O
three	O
oxygen	O
masks	O
to	O
illustrate	O
the	O
pattern	O
of	O
dispersal	O
of	O
pulmonary	O
gas	B-ENZY
.	O

In	O
two	O
commonly	O
used	O
masks	O
,	O
exhaled	O
gas	B-ENZY
formed	O
a	O
plume	O
emanating	O
from	O
the	O
side	O
vents	O
,	O
while	O
a	O
third	O
mask	O
with	O
a	O
valved	O
manifold	O
,	O
which	O
was	O
modified	O
by	O
adding	O
a	O
respiratory	O
filter	O
,	O
retained	O
the	O
droplets	O
.	O

The	O
common	O
laboratory	O
findings	O
include	O
lymphopenia	O
,	O
thrombocytopenia	O
,	O
elevated	O
serum	O
alanine	O
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
,	O
lactate	O
dehydrogenase	O
,	O
creatine	O
phosphokinase	O
,	O
and	O
C	O
-	O
reactive	O
protein	O
.	O

However	O
,	O
neuraminidase	B-ENZY
inhibitors	O
can	O
only	O
be	O
applied	O
in	O
specific	O
infections	O
and	O
the	O
spectrum	O
of	O
agents	O
with	O
antiviral	O
activity	O
is	O
broad	O
.	O

Bilateral	O
femur	O
fracture	O
produced	O
a	O
significant	O
lung	O
injury	O
,	O
measured	O
by	O
increases	O
in	O
MPO	O
(	O
25	O
-	O
43	O
microg	O
/	O
g	O
tissue	O
)	O
and	O
BAL	B-ENZY
protein	O
(	O
460	O
-	O
605	O
microg	O
/	O
mL	O
).	O

This	O
effect	O
was	O
attenuated	O
by	O
treatment	O
with	O
N	O
-	O
acetylcysteine	O
(	O
MPO	O
43	O
-	O
9	O
microg	O
/	O
mL	O
,	O
BAL	B-ENZY
protein	O
605	O
-	O
198	O
microg	O
/	O
mL	O
).	O

RESULTS	O
:	O
Bilateral	O
femur	O
fracture	O
produced	O
a	O
significant	O
lung	O
injury	O
,	O
measured	O
by	O
increases	O
in	O
MPO	O
(	O
25	O
-	O
43	O
microg	O
/	O
g	O
tissue	O
)	O
and	O
BAL	B-ENZY
protein	O
(	O
460	O
-	O
605	O
microg	O
/	O
mL	O
).	O

The	O
ability	O
to	O
detect	O
MHV	O
-	O
Y	O
transmission	O
to	O
sentinel	O
mice	O
exposed	O
directly	O
to	O
infected	O
mice	O
or	O
to	O
soil	O
bedding	O
from	O
infected	O
mice	O
was	O
compared	O
with	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
-	O
based	O
detection	O
of	O
viral	O
RNA	O
in	O
the	O
feces	O
.	O

Attempts	O
at	O
virus	O
isolation	O
were	O
unsuccessful	O
;	O
however	O
,	O
viral	O
RNA	O
was	O
detected	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
in	O
blood	O
of	O
both	O
species	O
during	O
the	O
first	O
week	O
after	O
inoculation	O
,	O
and	O
in	O
chicken	O
organs	O
at	O
2	O
weeks	O
after	O
inoculation	O
.	O

After	O
its	O
causative	O
agent	O
,	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
was	O
confirmed	O
,	O
laboratory	O
methods	O
,	O
including	O
virus	O
isolation	O
,	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
serologic	O
methods	O
,	O
have	O
been	O
quickly	O
developed	O
.	O

Cerebrospinal	O
fluid	O
tested	O
positive	O
for	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
.	O

Lung	O
injury	O
was	O
quantified	O
in	O
terms	O
of	O
lung	O
microvascular	O
permeability	O
(	O
Evans	O
blue	O
dye	O
extravasation	O
),	O
tissue	O
lipid	O
peroxidation	O
(	O
thiobarbituric	O
acid	O
reactive	O
substances	O
),	O
and	O
tissue	O
polymorphonuclear	O
leukocyte	O
accumulation	O
(	O
myeloperoxidase	B-ENZY
activity	O
).	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
3C	O
-	O
like	O
protease	O
consists	O
of	O
two	O
distinct	O
folds	O
,	O
namely	O
the	O
N	O
-	O
terminal	O
chymotrypsin	B-ENZY
fold	O
containing	O
the	O
domains	O
I	O
and	O
II	O
hosting	O
the	O
complete	O
catalytic	O
machinery	O
and	O
the	O
C	O
-	O
terminal	O
extra	O
helical	O
domain	O
III	O
unique	O
for	O
the	O
coronavirus	O
3CL	O
proteases	O
.	O

Previously	O
the	O
functional	O
role	O
of	O
this	O
extra	O
domain	O
has	O
been	O
completely	O
unknown	O
,	O
and	O
it	O
was	O
believed	O
that	O
the	O
coronavirus	O
3CL	O
proteases	O
share	O
the	O
same	O
enzymatic	O
mechanism	O
with	O
picornavirus	O
3C	O
proteases	O
,	O
which	O
contain	O
the	O
chymotrypsin	B-ENZY
fold	O
but	O
have	O
no	O
extra	O
domain	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
secretory	O
phospholipase	B-ENZY
A2	I-ENZY
in	O
acute	O
chest	O
syndrome	O
.	O

ABSTRACT	O
:	O
Acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
)	O
is	O
the	O
leading	O
cause	O
of	O
death	O
in	O
sickle	O
cell	O
disease	O
.	O

Severe	O
ACS	B-ENZY
often	O
develops	O
in	O
the	O
course	O
of	O
a	O
vasoocclusive	O
crisis	O
(	O
VOC	O
),	O
and	O
frequently	O
involves	O
pulmonary	O
fat	O
embolism	O
.	O

The	O
data	O
indicate	O
that	O
measurement	O
of	O
sPLA2	O
can	O
be	O
useful	O
in	O
alerting	O
the	O
clinician	O
to	O
patients	O
with	O
impending	O
ACS	B-ENZY
,	O
and	O
suggest	O
that	O
instituting	O
early	O
therapies	O
based	O
on	O
sPLA2	O
levels	O
,	O
including	O
inhibition	O
of	O
sPLA2	O
activity	O
,	O
may	O
be	O
useful	O
to	O
prevent	O
or	O
reduce	O
the	O
clinical	O
morbidity	O
of	O
ACS	B-ENZY
in	O
sickle	O
cell	O
disease	O
.	O

For	O
prevention	O
of	O
health	O
-	O
care	O
--	O
associated	O
Legionnaires	O
disease	O
,	O
the	O
changes	O
include	O
maintaining	O
potable	O
hot	O
water	O
at	O
temperatures	O
not	O
suitable	O
for	O
amplification	O
of	O
Legionella	O
spp	B-ENZY
.,	O
considering	O
routine	O
culturing	O
of	O
water	O
samples	O
from	O
the	O
potable	O
water	O
system	O
of	O
a	O
facility	O
'	O
s	O
organ	O
-	O
transplant	O
unit	O
when	O
it	O
is	O
done	O
as	O
part	O
of	O
the	O
facility	O
'	O
s	O
comprehensive	O
program	O
to	O
prevent	O
and	O
control	O
health	O
-	O
care	O
--	O
associated	O
Legionnaires	O
disease	O
,	O
and	O
initiating	O
an	O
investigation	O
for	O
the	O
source	O
of	O
Legionella	O
spp	B-ENZY
.	O

Infection	O
was	O
diagnosed	O
by	O
serology	O
and	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
using	O
primers	O
directed	O
to	O
two	O
separate	O
but	O
highly	O
conserved	O
regions	O
of	O
the	O
MHV	O
genome	O
.	O

The	O
neuraminidase	B-ENZY
inhibitors	O
zanamivir	O
and	O
oseltamivir	O
,	O
and	O
the	O
M2	O
inhibitors	O
amantadine	O
and	O
rimantadine	O
,	O
remain	O
the	O
only	O
options	O
for	O
controlling	O
respiratory	O
disease	O
caused	O
by	O
influenza	O
viruses	O
,	O
although	O
the	O
latter	O
two	O
could	O
not	O
be	O
used	O
against	O
very	O
recent	O
H5N1	O
strains	O
.	O

The	O
following	O
is	O
an	O
overview	O
of	O
recent	O
papers	O
on	O
the	O
further	O
development	O
of	O
neuraminidase	B-ENZY
inhibitors	O
against	O
influenza	O
viruses	O
and	O
on	O
recent	O
development	O
of	O
newer	O
antivirals	O
against	O
RSV	O
and	O
rhinoviruses	O
.	O

Since	O
SARS	O
3CL	O
proteinase	O
belongs	O
to	O
the	O
cysteine	O
protease	O
family	O
(	O
family	O
C3	O
in	O
clan	O
CB	O
)	O
with	O
a	O
chymotrypsin	B-ENZY
fold	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
catalytic	O
mechanism	O
of	O
SARS	O
3CL	O
proteinase	O
to	O
determine	O
whether	O
the	O
proteolysis	O
proceeds	O
through	O
a	O
general	O
base	O
catalysis	O
mechanism	O
like	O
chymotrypsin	B-ENZY
or	O
an	O
ion	O
pair	O
mechanism	O
like	O
papain	B-ENZY
.	O

A	O
significant	O
association	O
between	O
the	O
history	O
of	O
positive	O
exposure	O
to	O
pesticides	O
(	O
i	O
.	O
e	O
.	O
the	O
women	O
themselves	O
or	O
their	O
newborns	O
who	O
showed	O
acetylcholinesterase	B-ENZY
activity	O
levels	O
lower	O
than	O
20	O
%)	O
and	O
the	O
presence	O
of	O
IUGR	O
was	O
found	O
.	O

Gas	B-ENZY
exchange	O
deteriorated	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
our	O
intensive	O
care	O
unit	O
(	O
ICU	O
).	O

Uncontrolled	O
studies	O
in	O
adults	O
have	O
shown	O
improvement	O
in	O
gas	B-ENZY
exchange	O
and	O
lung	O
compliance	O
with	O
partial	O
liquid	O
ventilation	O
A	O
single	O
uncontrolled	O
study	O
in	O
six	O
children	O
with	O
acute	O
respiratory	O
syndrome	O
showed	O
some	O
improvement	O
in	O
gas	B-ENZY
exchange	O
during	O
three	O
hours	O
of	O
partial	O
liquid	O
ventilation	O
.	O

These	O
are	O
:	O
Hendra	O
virus	O
,	O
formerly	O
named	O
equine	O
morbillivirus	O
,	O
which	O
was	O
responsible	O
for	O
an	O
outbreak	O
of	O
disease	O
in	O
horses	O
and	O
humans	O
in	O
Brisbane	O
,	O
Australia	O
,	O
in	O
1994	O
;	O
Australian	O
bat	B-ENZY
lyssavirus	O
,	O
the	O
cause	O
of	O
a	O
severe	O
acute	O
encephalitis	O
,	O
in	O
1996	O
;	O
and	O
Nipah	O
virus	O
,	O
the	O
cause	O
of	O
a	O
major	O
outbreak	O
of	O
encephalitis	O
and	O
pulmonary	O
disease	O
in	O
domestic	O
pigs	O
and	O
people	O
in	O
peninsula	O
Malaysia	O
in	O
1999	O
.	O

Hendra	O
and	O
Nipah	O
viruses	O
have	O
been	O
shown	O
to	O
be	O
the	O
first	O
two	O
members	O
of	O
a	O
new	O
genus	O
,	O
Henipavirus	O
,	O
in	O
the	O
family	O
Paramyxoviridae	O
,	O
subfamily	O
Paramyxovirinae	O
,	O
whereas	O
Australian	O
bat	B-ENZY
lyssavirus	O
is	O
closely	O
related	O
antigenically	O
to	O
classical	O
rabies	O
virus	O
in	O
the	O
genus	O
Lyssavirus	O
,	O
family	O
Rhabdoviridae	O
,	O
although	O
it	O
can	O
be	O
distinguished	O
on	O
genetic	O
grounds	O
.	O

Two	O
human	O
infections	O
with	O
Australian	O
bat	B-ENZY
lyssavirus	O
have	O
been	O
reported	O
,	O
the	O
clinical	O
signs	O
of	O
which	O
were	O
consistent	O
with	O
classical	O
rabies	O
infection	O
and	O
included	O
a	O
diffuse	O
,	O
non	O
-	O
suppurative	O
encephalitis	O
.	O

Stable	O
helper	O
cell	O
line	O
clones	O
have	O
been	O
established	O
by	O
transfection	O
of	O
CRFK	O
cells	O
with	O
FFV	O
tas	O
and	O
assessed	O
using	O
beta	B-ENZY
-	I-ENZY
galactosidase	I-ENZY
assays	O
,	O
PCR	O
,	O
immunofluorescence	O
and	O
western	O
blotting	O
.	O

TITLE	O
:	O
Reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
diagnostic	O
assay	O
for	O
the	O
coronavirus	O
associated	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Samples	O
were	O
analyzed	O
by	O
a	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
assay	O
.	O

Direct	O
reaction	O
bilirubin	O
(	O
DBil	O
),	O
total	O
bile	O
acid	O
(	O
TBA	O
),	O
gamma	B-ENZY
-	I-ENZY
glutamyltransferase	I-ENZY
(	O
GGT	O
)	O
and	O
alkaline	B-ENZY
phosphatase	I-ENZY
(	O
ALP	O
)	O
showed	O
no	O
marked	O
difference	O
between	O
SARS	O
patients	O
and	O
controls	O
,	O
all	O
P	O
>	O
0	O
.	O
05	O
.	O

ALT	O
,	O
AST	B-ENZY
,	O
GGT	O
and	O
LDH	O
were	O
always	O
4	O
to	O
9	O
times	O
of	O
normal	O
.	O

The	O
ratio	O
of	O
abnormality	O
of	O
ALT	O
,	O
AST	B-ENZY
and	O
PAB	O
were	O
more	O
than	O
80	O
.	O
0	O
percent	O
,	O
the	O
ratio	O
of	O
abnormality	O
of	O
ALB	O
was	O
42	O
.	O
7	O
percent	O
,	O
and	O
less	O
than	O
30	O
.	O
0	O
percent	O
for	O
other	O
indexes	O
.	O

Characterization	O
of	O
the	O
nsp13	O
-	O
associated	O
(	O
deoxy	O
)	O
nucleoside	O
triphosphatase	B-ENZY
([	O
dNTPase	O
)	O
activities	O
revealed	O
that	O
all	O
natural	O
nucleotides	O
and	O
deoxynucleotides	O
are	O
substrates	O
of	O
nsp13	O
,	O
with	O
ATP	O
,	O
dATP	O
,	O
and	O
GTP	O
being	O
hydrolyzed	O
slightly	O
more	O
efficiently	O
than	O
other	O
nucleotides	O
.	O

The	O
data	O
suggest	O
that	O
the	O
(	O
d	O
)	O
NTPase	B-ENZY
and	O
RNA	O
5	O
'-	O
triphosphatase	B-ENZY
activities	O
of	O
nsp13	O
have	O
a	O
common	O
active	O
site	O
.	O

While	O
the	O
amounts	O
of	O
the	O
cellular	O
cyclin	B-ENZY
-	I-ENZY
dependent	I-ENZY
kinase	I-ENZY
(	O
Cdk	O
)	O
inhibitors	O
p21	O
(	O
Cip1	O
),	O
p27	O
(	O
Kip1	O
),	O
and	O
p16	O
(	O
INK4a	O
)	O
did	O
not	O
change	O
in	O
infected	O
cells	O
,	O
MHV	O
infection	O
in	O
asynchronous	O
cultures	O
induced	O
a	O
clear	O
reduction	O
in	O
the	O
amounts	O
of	O
Cdk4	O
and	O
G	O
(	O
1	O
)	O
cyclins	O
(	O
cyclins	O
D1	O
,	O
D2	O
,	O
D3	O
,	O
and	O
E	O
)	O
in	O
both	O
DBT	O
and	O
17Cl	O
-	O
1	O
cells	O
and	O
a	O
reduction	O
in	O
Cdk6	O
levels	O
in	O
17Cl	O
-	O
1	O
cells	O
.	O

ABSTRACT	O
:	O
Conjugation	O
of	O
a	O
peptide	O
related	O
to	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
Tat	B-ENZY
represents	O
a	O
novel	O
method	O
for	O
delivery	O
of	O
antisense	O
morpholino	O
-	O
oligomers	O
.	O

The	O
treatment	O
was	O
lasted	O
for	O
13	O
days	O
to	O
investigate	O
the	O
changes	O
of	O
the	O
clinical	O
indexes	O
such	O
as	O
creatine	B-ENZY
kinase	I-ENZY
(	O
CK	O
),	O
lactate	O
dehydogenase	O
(	O
LDH	O
)	O
and	O
serum	O
sodium	O
levels	O
.	O

Droplet	O
aerosols	O
,	O
which	O
are	O
generated	O
from	O
water	O
,	O
oils	O
,	O
oil	O
-	O
water	O
emulsions	O
and	O
other	O
liquids	O
in	O
various	O
work	O
environments	O
,	O
may	O
contain	O
infectious	O
agents	O
(	O
Legionella	O
spp	B-ENZY
.)	O
as	O
well	O
as	O
allergic	O
and	O
/	O
or	O
toxic	O
agents	O
.	O

ABSTRACT	O
:	O
A	O
TaqMan	O
fluorogenic	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
was	O
developed	O
for	O
the	O
detection	O
and	O
quantitation	O
of	O
canine	O
coronavirus	O
(	O
CCoV	O
)	O
RNA	O
in	O
the	O
faeces	O
of	O
naturally	O
or	O
experimentally	O
infected	O
dogs	O
.	O

Liver	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
),	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
)	O
and	O
lactic	O
dehydrogenase	O
(	O
LDH	O
)	O
were	O
analyzed	O
in	O
these	O
patients	O
.	O

RESULTS	O
:	O
Of	O
the	O
182	O
patients	O
,	O
128	O
(	O
70	O
.	O
3	O
%)	O
had	O
abnormal	O
ALT	O
activity	O
,	O
57	O
(	O
31	O
.	O
3	O
%)	O
had	O
abnormal	O
AST	B-ENZY
activity	O
and	O
87	O
(	O
47	O
.	O
8	O
%)	O
had	O
abnormal	O
LDH	O
activity	O
.	O

ABSTRACT	O
:	O
For	O
a	O
long	O
time	O
fibrinopeptide	O
A	O
(	O
FPA	O
),	O
fibrinopeptide	O
B	O
(	O
FPB	O
),	O
D	O
-	O
dimer	O
,	O
FM	O
test	O
,	O
serum	O
FDP	O
,	O
and	O
thrombin	B-ENZY
anti	O
-	O
thrombin	B-ENZY
complex	O
(	O
TAT	B-ENZY
)	O
are	O
being	O
used	O
as	O
molecular	O
markers	O
to	O
for	O
sure	O
diagnose	O
hypercoagulable	O
state	O
and	O
thrombus	O
formation	O
.	O

Underlying	O
disease	O
includes	O
leukemia	O
,	O
malignant	O
lymphoma	O
,	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
),	O
multiple	O
injury	O
,	O
giant	O
ovarian	O
tumor	O
,	O
prostatic	O
cancer	O
with	O
multiple	O
bone	O
metastasis	O
,	O
lung	O
cancer	O
,	O
breast	O
cancer	O
with	O
multiple	O
lung	O
and	O
bone	O
metastasis	O
,	O
severe	O
pneumoniae	O
,	O
sepsis	O
,	O
hemophagocytic	O
syndrome	O
(	O
HPS	B-ENZY
),	O
and	O
rheumatoid	O
arthritis	O
.	O

As	O
the	O
level	O
of	O
SF	O
reflects	O
the	O
thrombin	B-ENZY
generation	O
activity	O
in	O
plasma	O
,	O
it	O
would	O
serve	O
as	O
a	O
strong	O
tool	O
to	O
selectively	O
kick	O
up	O
the	O
state	O
of	O
thrombin	B-ENZY
generation	O
.	O

Intraperitoneal	O
injection	O
of	O
cerulein	O
in	O
mice	O
resulted	O
in	O
severe	O
,	O
acute	O
pancreatitis	O
characterised	O
by	O
oedema	O
,	O
neutrophil	O
infiltration	O
,	O
tissue	O
haemorrhage	O
and	O
necrosis	O
and	O
elevated	O
serum	O
levels	O
of	O
amylase	O
and	O
lipase	B-ENZY
.	O

Although	O
effective	O
in	O
experimental	O
studies	O
no	O
clear	O
recommendation	O
can	O
be	O
made	O
in	O
view	O
to	O
the	O
use	O
of	O
other	O
vasodilators	O
such	O
as	O
phosphodiesterase	B-ENZY
inhibitors	O
or	O
endothelin	O
antagonists	O
.	O

Several	O
putative	O
functional	O
domains	O
such	O
as	O
a	O
papain	B-ENZY
-	O
like	O
proteinase	O
(	O
PL	O
(	O
pro	O
)),	O
main	O
protease	O
(	O
M	O
(	O
pro	O
)),	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
),	O
and	O
RNA	O
helicase	O
encoded	O
by	O
the	O
replicase	O
gene	O
are	O
important	O
for	O
virus	O
replication	O
.	O

TITLE	O
:	O
Altered	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
expression	O
in	O
different	O
leukocytes	O
with	O
increment	O
of	O
immunosuppressive	O
mediators	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Flow	O
cytometric	O
analysis	O
of	O
MAPKs	O
activation	O
by	O
phospho	O
-	O
p38	O
and	O
phospho	O
-	O
p44	O
/	O
42	O
(	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
)	O
expression	O
showed	O
that	O
augmented	O
p38	O
activation	O
(	O
p	O
=	O
0	O
.	O
044	O
)	O
of	O
CD14	O
monocytes	O
associated	O
with	O
suppressed	O
p38	O
activation	O
(	O
p	O
=	O
0	O
.	O
033	O
)	O
of	O
CD8	O
lymphocytes	O
was	O
found	O
in	O
SARS	O
patients	O
.	O

Furthermore	O
,	O
detection	O
of	O
DNA	O
ladder	O
and	O
cleaved	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
in	O
the	O
virus	O
-	O
infected	O
cells	O
at	O
24h	O
.	O
p	O
.	O
i	O
.	O
indicated	O
that	O
SARS	O
-	O
CoV	O
infection	O
induced	O
apoptotic	O
cell	O
death	O
.	O

Phosphorylation	O
of	O
p38	O
MAPK	B-ENZY
was	O
significantly	O
up	O
-	O
regulated	O
at	O
18	O
h	O
.	O
p	O
.	O
i	O
.	O

The	O
downstream	O
targets	O
of	O
p38	O
MAPK	B-ENZY
,	O
MAPKAPK	O
-	O
2	O
,	O
HSP	O
-	O
27	O
,	O
CREB	O
,	O
and	O
eIF4E	O
were	O
phosphorylated	O
in	O
virus	O
-	O
infected	O
cells	O
.	O

The	O
p38	O
MAPK	B-ENZY
inhibitor	O
,	O
SB203580	O
,	O
inhibited	O
effectively	O
phosphorylation	O
of	O
HSP	O
-	O
27	O
,	O
CREB	O
,	O
and	O
eIF4E	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

Gas	B-ENZY
insufflation	O
through	O
the	O
trachea	O
is	O
a	O
promising	O
therapeutic	O
option	O
for	O
correcting	O
hypercapnia	O
secondary	O
to	O
ventilation	O
for	O
lung	O
protection	O
in	O
such	O
patients	O
.	O

Tested	O
were	O
19	O
clinically	O
approved	O
compounds	O
from	O
several	O
major	O
antiviral	O
pharmacologic	O
classes	O
:	O
nucleoside	O
analogs	O
,	O
interferons	O
,	O
protease	O
inhibitors	O
,	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
,	O
and	O
neuraminidase	B-ENZY
inhibitors	O
.	O

ABSTRACT	O
:	O
In	O
California	O
,	O
molecular	O
testing	O
was	O
useful	O
in	O
decreasing	O
suspicion	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
by	O
detecting	O
common	O
respiratory	O
pathogens	O
(	O
influenza	O
A	O
/	O
B	O
,	O
human	O
metapneumovirus	O
,	O
picornavirus	O
,	O
Mycoplasma	O
pneumoniae	O
,	O
Chlamydia	O
spp	B-ENZY
.,	O
parainfluenza	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
and	O
adenovirus	O
)	O
in	O
23	O
(	O
45	O
%)	O
of	O
51	O
patients	O
with	O
suspected	O
SARS	O
and	O
9	O
(	O
47	O
%)	O
of	O
19	O
patients	O
with	O
probable	O
SARS	O
.	O

When	O
the	O
patient	O
was	O
turned	O
to	O
the	O
left	O
lateral	O
position	O
,	O
oxygen	O
saturation	O
suddenly	O
worsened	O
from	O
94	O
%	O
to	O
78	O
%,	O
with	O
Pao2	O
from	O
arterial	O
blood	O
gas	B-ENZY
measured	O
at	O
54	O
mm	O
Hg	O
.	O

An	O
hour	O
of	O
NPPV	O
therapy	O
led	O
to	O
significant	O
increases	O
in	O
PaO	B-ENZY
(	O
2	O
)	O
and	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
and	O
a	O
decrease	O
in	O
respiratory	O
rate	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Human	O
coronavirus	O
229E	O
nonstructural	O
protein	O
13	O
:	O
characterization	O
of	O
duplex	O
-	O
unwinding	O
,	O
nucleoside	O
triphosphatase	B-ENZY
,	O
and	O
RNA	O
5	O
'-	O
triphosphatase	B-ENZY
activities	O
.	O

Characterization	O
of	O
the	O
nsp13	O
-	O
associated	O
nucleoside	O
triphosphatase	B-ENZY
(	O
NTPase	B-ENZY
)	O
activities	O
revealed	O
that	O
all	O
natural	O
ribonucleotides	O
and	O
nucleotides	O
are	O
substrates	O
of	O
nsp13	O
,	O
with	O
ATP	O
,	O
dATP	O
,	O
and	O
GTP	O
being	O
hydrolyzed	O
most	O
efficiently	O
.	O

In	O
30	O
patients	O
with	O
ARDS	O
due	O
to	O
multitrauma	O
,	O
pneumonia	O
or	O
after	O
surgery	O
(	O
p	O
(	O
a	O
)	O
O	O
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)-	O
ratio	O
67	O
+/-	O
23	O
mmHg	O
)	O
pECLA	O
was	O
established	O
by	O
insertion	O
of	O
cannulae	O
to	O
the	O
femoral	O
artery	O
and	O
vein	O
followed	O
by	O
connection	O
with	O
a	O
membrane	O
gas	B-ENZY
exchanger	O
.	O

However	O
,	O
both	O
IBV	O
and	O
APV	O
could	O
be	O
detected	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
PCR	O
after	O
autoclaving	O
and	O
as	O
long	O
as	O
5	O
min	O
microwave	O
treatment	O
(	O
Newcastle	O
disease	O
virus	O
and	O
avian	O
influenza	O
viruses	O
were	O
not	O
tested	O
).	O

The	O
cDNA	O
derived	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
was	O
cloned	O
and	O
sequenced	O
.	O

ABSTRACT	O
:	O
High	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
improves	O
gas	B-ENZY
exchange	O
while	O
providing	O
lung	O
protective	O
effects	O
during	O
the	O
ventilation	O
of	O
patients	O
with	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

After	O
switching	O
from	O
CMV	O
to	O
HFOV	O
,	O
there	O
were	O
significant	O
improvements	O
in	O
the	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO2	O
ratio	O
within	O
1h	O
and	O
in	O
the	O
oxygenation	O
index	O
within	O
24	O
h	O
.	O
The	O
duration	O
of	O
HFOV	O
was	O
6	O
.	O
1	O
+/-	O

ABSTRACT	O
:	O
A	O
piezoelectric	O
immunosensor	O
was	O
developed	O
for	O
the	O
detection	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
sputum	O
in	O
the	O
gas	B-ENZY
phase	O
.	O

Common	O
laboratory	O
features	O
include	O
lymphopenia	O
,	O
thrombocytopenia	O
,	O
raised	O
alanine	O
transaminases	O
,	O
lactate	O
dehydrogenase	O
,	O
and	O
creatine	B-ENZY
kinase	I-ENZY
.	O

Measurement	O
of	O
serum	O
RNA	O
by	O
real	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
technique	O
has	O
a	O
detection	O
rate	O
of	O
75	O
%-	O
80	O
%	O
in	O
the	O
first	O
week	O
of	O
the	O
illness	O
.	O

The	O
receptor	O
for	O
group	O
I	O
and	O
III	O
CoV	O
is	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
CD13	O
).	O

ABSTRACT	O
:	O
The	O
importance	O
of	O
rapid	O
diagnosis	O
of	O
influenza	O
has	O
increased	O
with	O
the	O
availability	O
of	O
neuraminidase	B-ENZY
inhibitors	O
,	O
which	O
need	O
to	O
be	O
commenced	O
within	O
48	O
hr	O
of	O
symptom	O
onset	O
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
show	O
that	O
SARS	O
-	O
CoV	O
N	O
is	O
capable	O
of	O
inducing	O
apoptosis	O
of	O
COS	O
-	O
1	O
monkey	O
kidney	O
cells	O
in	O
the	O
absence	O
of	O
growth	O
factors	O
by	O
down	O
-	O
regulating	O
ERK	B-ENZY
(	O
extracellular	O
-	O
signal	O
-	O
regulated	O
kinase	O
),	O
up	O
-	O
regulating	O
JNK	B-ENZY
(	O
c	B-ENZY
-	I-ENZY
Jun	I-ENZY
N	I-ENZY
-	I-ENZY
terminal	I-ENZY
kinase	I-ENZY
)	O
and	O
p38	O
MAPK	B-ENZY
(	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
)	O
pathways	O
,	O
and	O
affecting	O
their	O
downstream	O
effectors	O
.	O

Common	O
laboratory	O
findings	O
included	O
lymphopenia	O
(	O
on	O
hospital	O
admission	O
,	O
70	O
%;	O
during	O
hospitalization	O
,	O
95	O
%),	O
thrombocytopenia	O
(	O
on	O
hospital	O
admission	O
,	O
28	O
%;	O
during	O
hospitalization	O
,	O
40	O
%),	O
elevated	O
lactate	O
dehydrogenase	O
(	O
on	O
hospital	O
admission	O
,	O
58	O
%;	O
during	O
hospitalization	O
,	O
88	O
%),	O
creatine	B-ENZY
kinase	I-ENZY
(	O
on	O
hospital	O
admission	O
,	O
18	O
%;	O
during	O
hospitalization	O
,	O
32	O
%),	O
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
or	O
alanine	B-ENZY
aminotransferase	I-ENZY
levels	O
(	O
on	O
hospital	O
admission	O
,	O
27	O
%;	O
during	O
hospitalization	O
,	O
62	O
%).	O

Throat	O
or	O
nasopharyngeal	O
swab	O
for	O
SARS	O
-	O
CoV	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
real	O
-	O
time	O
PCR	O
was	O
positive	O
in	O
40	O
of	O
the	O
47	O
patients	O
(	O
85	O
%)	O
in	O
whom	O
the	O
test	O
was	O
performed	O
.	O

Throat	O
or	O
nasopharyngeal	O
swab	O
for	O
SARS	O
-	O
CoV	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
real	O
-	O
time	O
PCR	O
was	O
positive	O
in	O
40	O
of	O
the	O
47	O
patients	O
(	O
85	O
%)	O
in	O
whom	O
the	O
test	O
was	O
performed	O
.	O

7	O
.	O
5	O
)	O
with	O
severe	O
ARDS	O
(	O
ie	O
,	O
mean	O
Pao	B-ENZY
(	O
2	O
)/	O
fraction	O
of	O
inspired	O
oxygen	O
[	O
Fio	O
(	O
2	O
)]	O
ratio	O
,	O
91	O
+/-	O

Pao	B-ENZY
(	O
2	O
)/	O
Fio	O
(	O
2	O
)	O
ratios	O
and	O
OI	O
([	O
Fio	O
(	O
2	O
)	O
x	O
mean	O
airway	O
pressure	O
x	O
100	O
]/	O
Pao	B-ENZY
(	O
2	O
))	O
improved	O
significantly	O
with	O
the	O
application	O
of	O
HFOV	O
,	O
and	O
this	O
benefit	O
persisted	O
for	O
the	O
72	O
-	O
h	O
study	O
duration	O
.	O

HFOV	O
has	O
beneficial	O
effects	O
on	O
Pao	B-ENZY
(	O
2	O
)/	O
Fio	O
(	O
2	O
)	O
ratios	O
and	O
OI	O
,	O
and	O
may	O
be	O
an	O
effective	O
rescue	O
therapy	O
for	O
adults	O
with	O
severe	O
oxygenation	O
failure	O
.	O

Serial	O
serum	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
)	O
and	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
levels	O
were	O
retrospectively	O
analyzed	O
and	O
hepatitis	O
B	O
surface	O
antigen	O
(	O
HBsAg	O
)	O
was	O
also	O
evaluated	O
to	O
correlate	O
with	O
the	O
progression	O
of	O
this	O
disease	O
.	O

ARDS	O
rabbit	O
models	O
were	O
established	O
by	O
injecting	O
oleic	O
acid	O
through	O
central	O
vein	O
,	O
and	O
the	O
results	O
of	O
effective	O
local	O
blood	O
perfusion	O
in	O
different	O
areas	O
of	O
rabbit	O
lung	O
(	O
upper	O
area	O
,	O
abdominal	O
area	O
,	O
and	O
dorsal	O
area	O
of	O
right	O
lung	O
)	O
with	O
PIM	O
-	O
II	O
laser	O
perfusion	O
imager	O
and	O
arterial	O
blood	O
gas	B-ENZY
under	O
different	O
ventilation	O
modes	O
[	O
large	O
tidal	O
volume	O
ventilation	O
,	O
low	O
tidal	O
volume	O
ventilation	O
+	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
),	O
prone	O
position	O
+	O
large	O
tidal	O
volume	O
ventilation	O
,	O
and	O
prone	O
position	O
+	O
low	O
tidal	O
volume	O
ventilation	O
+	O
PEEP	O
]	O
were	O
measured	O
.	O

ABSTRACT	O
:	O
Activated	O
protein	O
C	O
(	O
APC	O
),	O
a	O
natural	O
anticoagulant	O
,	O
is	O
formed	O
from	O
protein	O
C	O
by	O
the	O
action	O
of	O
thrombin	B-ENZY
bound	O
to	O
thrombomodulin	O
on	O
the	O
endothelial	O
cell	O
surface	O
.	O

The	O
maximal	O
Trp	B-ENZY
emission	O
wavelength	O
occurs	O
near	O
331	O
nm	O
,	O
suggesting	O
substantial	O
burial	O
of	O
Trp	B-ENZY
residues	O
.	O

ABSTRACT	O
:	O
The	O
features	O
of	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
fumarylacetoacetate	B-ENZY
hydrolase	I-ENZY
(	O
FAH	O
)	O
elicited	O
in	O
mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
were	O
studied	O
by	O
ELISA	O
and	O
western	O
-	O
blot	O
competition	O
assays	O
.	O

A	O
72	O
-	O
year	O
-	O
old	O
African	O
American	O
man	O
developed	O
an	O
acute	O
confusional	O
state	O
(	O
ACS	B-ENZY
)	O
one	O
month	O
after	O
receiving	O
celecoxib	O
for	O
osteoarthritis	O
of	O
his	O
knee	O
joints	O
.	O

There	O
was	O
no	O
other	O
identifiable	O
cause	O
of	O
ACS	B-ENZY
such	O
as	O
any	O
recognized	O
cause	O
of	O
metabolic	O
encephalopathy	O
,	O
meningoencephalitis	O
,	O
cerebrovascular	O
accident	O
,	O
or	O
drug	O
intoxication	O
.	O

Although	O
acute	O
methemoglobinemia	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
several	O
drugs	O
,	O
including	O
sulfonamides	O
,	O
as	O
of	O
August	O
13	O
,	O
2004	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
severe	O
methemoglobinemia	O
manifesting	O
as	O
ACS	B-ENZY
with	O
celecoxib	O
therapy	O
.	O

The	O
close	O
monitoring	O
of	O
the	O
blood	O
cell	O
counts	O
,	O
the	O
blood	O
gas	B-ENZY
analysis	O
and	O
chest	O
radiography	O
might	O
be	O
crucial	O
to	O
the	O
early	O
diagnosis	O
.	O

Vital	O
signs	O
,	O
clinical	O
symptoms	O
and	O
arterial	O
blood	O
gas	B-ENZY
measured	O
before	O
and	O
at	O
the	O
end	O
of	O
HD	O
were	O
compared	O
.	O

Our	O
recent	O
study	O
indicated	O
that	O
SARS	O
-	O
CoV	O
infection	O
induces	O
activation	O
of	O
the	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
signaling	O
pathway	O
and	O
the	O
p38	O
MAPK	B-ENZY
inhibitor	O
partially	O
inhibited	O
its	O
cytopathic	O
effect	O
in	O
Vero	O
E6	O
cells	O
.	O

Thus	O
,	O
the	O
phosphatidylinositol	B-ENZY
3	I-ENZY
-	I-ENZY
kinase	I-ENZY
(	O
PI3K	O
)/	O
Akt	O
pathway	O
is	O
activated	O
in	O
virus	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

A	O
downstream	O
target	O
of	O
Akt	O
,	O
glycogen	B-ENZY
synthase	I-ENZY
kinase	O
3beta	O
(	O
GSK	B-ENZY
-	O
3beta	O
),	O
was	O
slightly	O
phosphorylated	O
,	O
indicating	O
that	O
the	O
level	O
of	O
activation	O
of	O
Akt	O
was	O
very	O
low	O
.	O

Intratracheal	O
instillation	O
of	O
LPS	O
produced	O
a	O
severe	O
lung	O
injury	O
at	O
2	O
days	O
,	O
characterized	O
by	O
elevation	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
in	O
the	O
BAL	B-ENZY
fluid	O
,	O
and	O
by	O
histological	O
changes	O
consistent	O
with	O
increased	O
lung	O
vascular	O
permeability	O
and	O
neutrophil	O
infiltration	O
.	O

ABSTRACT	O
:	O
Ampligen	O
[	O
polyI	O
:	O
polyC12U	O
]	O
is	O
a	O
mismatched	O
double	O
-	O
stranded	O
RNA	O
that	O
acts	O
by	O
inducing	O
interferon	O
production	O
(	O
immunomodulator	O
)	O
and	O
by	O
activating	O
an	O
intracellular	O
enzyme	O
(	O
RNase	B-ENZY
-	O
L	O
)	O
against	O
viral	O
RNA	O
transcripts	O
(	O
antiviral	O
).	O

TITLE	O
:	O
Nucleocapsid	O
protein	O
of	O
SARS	O
coronavirus	O
tightly	O
binds	O
to	O
human	O
cyclophilin	B-ENZY
A	O
.	O
ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
responsible	O
for	O
SARS	O
infection	O
.	O

Protein	O
-	O
protein	O
interaction	O
analysis	O
using	O
bioinformatics	O
tools	O
indicated	O
that	O
SARS_NP	O
may	O
bind	O
to	O
human	O
cyclophilin	B-ENZY
A	O
(	O
hCypA	O
),	O
and	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
technology	O
revealed	O
this	O
binding	O
with	O
the	O
equilibrium	O
dissociation	O
constant	O
ranging	O
from	O
6	O
to	O
160nM	O
.	O
The	O
probable	O
binding	O
sites	O
of	O
these	O
two	O
proteins	O
were	O
detected	O
by	O
modeling	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
SARS_NP	O
-	O
hCypA	O
complex	O
,	O
from	O
which	O
the	O
important	O
interaction	O
residue	O
pairs	O
between	O
the	O
proteins	O
were	O
deduced	O
.	O

Characterization	O
of	O
various	O
cellular	O
proteins	O
that	O
are	O
involved	O
in	O
regulating	O
cell	O
cycle	O
progression	O
demonstrated	O
that	O
p28	O
expression	O
resulted	O
in	O
an	O
accumulation	O
of	O
hypophosphorylated	O
retinoblastoma	O
protein	O
(	O
pRb	O
),	O
tumor	O
suppressor	O
p53	O
,	O
and	O
cyclin	B-ENZY
-	I-ENZY
dependent	I-ENZY
kinase	I-ENZY
(	O
Cdk	O
)	O
inhibitor	O
p21	O
(	O
Cip1	O
).	O

TITLE	O
:	O
Effects	O
of	O
expiratory	O
tracheal	O
gas	B-ENZY
insufflation	O
in	O
patients	O
with	O
severe	O
head	O
trauma	O
and	O
acute	O
lung	O
injury	O
.	O

Patients	O
were	O
ventilated	O
in	O
assist	O
/	O
control	O
mode	O
with	O
a	O
ventilatory	O
strategy	O
providing	O
adequate	O
oxygenation	O
(	O
PaO	B-ENZY
(	O
2	O
)	O
>	O
70	O
mmHg	O
)	O
and	O
normocapnia	O
(	O
PaCO	O
(	O
2	O
)	O
between	O
35	O
-	O
40	O
mmHg	O
).	O

Mid	O
to	O
end	O
expiratory	O
tracheal	O
gas	B-ENZY
insufflation	O
at	O
8	O
l	O
/	O
min	O
flow	O
rate	O
was	O
delivered	O
for	O
90	O
min	O
while	O
normocapnia	O
was	O
maintained	O
by	O
simultaneous	O
reductions	O
in	O
tidal	O
volume	O
.	O

Tracheal	O
gas	B-ENZY
insufflation	O
allowed	O
a	O
significant	O
decrease	O
in	O
tidal	O
volume	O
from	O
9	O
.	O
1	O
to	O
7	O
.	O
2	O
ml	O
/	O
kg	O
,	O
with	O
associated	O
reduction	O
in	O
driving	O
pressure	O
(	O
plateau	O
pressure	O
minus	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
PEEP	O
)	O
from	O
18	O
.	O
1	O
to	O
13	O
.	O
2	O
cm	O
H	O
(	O
2	O
)	O
O	O
.	O
Total	O
PEEP	O
increased	O
from	O
9	O
.	O
3	O
to	O
12	O
.	O
7	O
cm	O
H	O
(	O
2	O
)	O
O	O
due	O
to	O
the	O
generation	O
of	O
lung	O
hyperinflation	O
.	O

Oxygenation	O
improved	O
slightly	O
during	O
tracheal	O
gas	B-ENZY
insufflation	O
,	O
and	O
this	O
improvement	O
remained	O
after	O
stopping	O
tracheal	O
insufflation	O
.	O

TITLE	O
:	O
The	O
central	O
role	O
of	O
angiotensin	B-ENZY
I	I-ENZY
-	I-ENZY
converting	I-ENZY
enzyme	I-ENZY
in	O
vertebrate	O
pathophysiology	O
.	O

ABSTRACT	O
:	O
Genomic	O
epidemiologic	O
data	O
,	O
increasingly	O
supported	O
by	O
clinical	O
outcomes	O
results	O
,	O
strongly	O
suggest	O
that	O
overactivity	O
of	O
angiotensin	B-ENZY
I	I-ENZY
-	I-ENZY
converting	I-ENZY
enzyme	I-ENZY
(	O
ACE	B-ENZY
)	O
may	O
underlie	O
most	O
age	O
-	O
related	O
diseases	O
.	O

Angiotensin	O
II	O
,	O
the	O
main	O
product	O
of	O
ACE	B-ENZY
,	O
is	O
a	O
pleiotropic	O
hormone	O
,	O
capable	O
of	O
serving	O
as	O
a	O
neurotransmitter	O
,	O
growth	O
factor	O
,	O
angiogenesis	O
factor	O
,	O
vasoconstrictor	O
,	O
pro	O
-	O
thrombotic	O
agent	O
,	O
and	O
cytokine	O
.	O

So	O
it	O
is	O
perhaps	O
not	O
surprising	O
that	O
the	O
ACE	B-ENZY
D	O
/	O
D	O
genotype	O
is	O
associated	O
with	O
several	O
major	O
psychiatric	O
diseases	O
,	O
most	O
cancers	O
except	O
prostate	O
cancer	O
(	O
where	O
the	O
D	O
/	O
D	O
genotype	O
is	O
actually	O
protective	O
),	O
most	O
cardiovascular	O
diseases	O
,	O
most	O
autoimmune	O
diseases	O
,	O
and	O
even	O
infectious	O
diseases	O
like	O
tuberculosis	O
and	O
HIV	O
.	O

The	O
ancestral	O
,	O
unduplicated	O
form	O
of	O
ACE	B-ENZY
is	O
still	O
expressed	O
during	O
the	O
terminal	O
differentiation	O
of	O
human	O
spermatocytes	O
,	O
suggesting	O
a	O
critical	O
role	O
in	O
reproduction	O
.	O

Computer	O
modeling	O
suggests	O
that	O
tACE	B-ENZY
may	O
be	O
activated	O
by	O
both	O
mechanical	O
forces	O
and	O
reducing	O
agents	O
.	O

The	O
duplicated	O
form	O
of	O
ACE	B-ENZY
(	O
somatic	O
ACE	B-ENZY
,	O
sACE	O
)	O
is	O
expressed	O
in	O
areas	O
of	O
high	O
fluid	O
flow	O
.	O

The	O
sACE	O
dimer	O
is	O
predicted	O
to	O
have	O
higher	O
catalytic	O
efficiency	O
and	O
redox	O
resistance	O
than	O
tACE	B-ENZY
.	O

ABSTRACT	O
:	O
Abnormally	O
increased	O
physiologic	O
deadspace	O
volume	O
(	O
Vd	O
(	O
phys	O
)),	O
consisting	O
of	O
alveolar	O
deadspace	O
volume	O
and	O
airway	O
deadspace	O
volume	O
,	O
is	O
one	O
of	O
several	O
causative	O
factors	O
predisposing	O
to	O
compromised	O
arterial	O
blood	O
gas	B-ENZY
exchange	O
.	O

Furthermore	O
,	O
isoflurane	O
inhalation	O
(	O
1	O
.	O
15	O
%	O
end	O
-	O
tidal	O
concentration	O
)	O
resulted	O
in	O
impaired	O
arterial	O
oxygenation	O
,	O
as	O
evidenced	O
by	O
a	O
significant	O
decrease	O
in	O
the	O
Pao	B-ENZY
(	O
2	O
)/	O
fractional	O
inspired	O
oxygen	O
concentration	O
ratio	O
compared	O
with	O
baseline	O
values	O
from	O
387	O
+/-	O

A	O
purification	O
scheme	O
to	O
isolate	O
the	O
recombinant	O
O	O
-	O
acetylesterase	B-ENZY
of	O
influenza	O
C	O
virus	O
was	O
developed	O
.	O

Uncontrolled	O
studies	O
in	O
adults	O
have	O
shown	O
improvement	O
in	O
gas	B-ENZY
exchange	O
and	O
lung	O
compliance	O
with	O
partial	O
liquid	O
ventilation	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
blood	O
gas	B-ENZY
features	O
and	O
short	O
-	O
term	O
outcomes	O
of	O
noninvasive	O
positive	O
pressure	O
ventilation	O
(	O
NPPV	O
)	O
treatment	O
for	O
acute	O
respiratory	O
failure	O
(	O
ARF	O
)	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
this	O
retrospective	O
case	O
series	O
study	O
sought	O
.	O

In	O
addition	O
to	O
phosphorylation	O
of	O
p38	O
MAPK	B-ENZY
in	O
virus	O
-	O
infected	O
cells	O
,	O
other	O
MAPKs	O
,	O
i	O
.	O
e	O
.,	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
(	O
ERK	B-ENZY
)	O
1	O
/	O
2	O
and	O
c	B-ENZY
-	I-ENZY
Jun	I-ENZY
N	I-ENZY
-	I-ENZY
terminal	I-ENZY
kinase	I-ENZY
(	O
JNK	B-ENZY
),	O
were	O
phosphorylated	O
.	O

Although	O
inhibitors	O
of	O
ERK1	O
/	O
2	O
and	O
JNK	B-ENZY
(	O
PD98059	O
and	O
SP600125	O
)	O
had	O
no	O
effect	O
on	O
phosphorylation	O
status	O
of	O
STAT3	O
,	O
inhibitors	O
of	O
p38	O
MAPK	B-ENZY
(	O
SB203580	O
and	O
SB202190	O
)	O
partially	O
inhibited	O
dephosphorylation	O
of	O
STAT3	O
at	O
Tyr	O
-	O
705	O
.	O

Both	O
patients	O
with	O
myopathy	O
had	O
elevated	O
serum	O
creatine	B-ENZY
kinase	I-ENZY
levels	O
.	O

And	O
32	O
.	O
76	O
%-	O
62	O
.	O
50	O
%	O
of	O
cases	O
were	O
found	O
to	O
have	O
high	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
above	O
40	O
U	O
/	O
L	O
),	O
13	O
.	O
04	O
%-	O
40	O
.	O
00	O
%	O
cases	O
with	O
high	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
above	O
40	O
U	O
/	O
L	O
)	O
and	O
40	O
.	O
35	O
%-	O
72	O
.	O
00	O
%	O
cases	O
with	O
low	O
albumin	O
content	O
.	O

Serum	O
total	O
protein	O
(	O
TP	O
),	O
albumin	O
(	O
Alb	O
),	O
total	O
cholesterol	O
(	O
TC	O
),	O
triglyceride	O
(	O
TG	O
),	O
calcium	O
(	O
Ca	O
),	O
ferrum	O
(	O
Fe	O
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
),	O
creatine	B-ENZY
kinase	I-ENZY
(	O
CK	O
),	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
)	O
between	O
SARS	O
and	O
other	O
viral	O
pneumonias	O
were	O
examined	O
by	O
Roche	O
Diagnostics	O
assay	O
,	O
HITACHI7600	O
automatic	O
analyzer	O
.	O

Compared	O
with	O
healthy	O
person	O
,	O
the	O
levels	O
of	O
serum	O
TC	O
,	O
Fe	O
,	O
Ca	O
,	O
Alb	O
were	O
significantly	O
lowered	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
),	O
while	O
the	O
activity	O
of	O
LDH	O
,	O
CK	O
,	O
ALT	O
,	O
AST	B-ENZY
were	O
elevated	O
,	O
the	O
increase	O
of	O
CK	O
and	O
the	O
decrease	O
of	O
Fe	O
were	O
the	O
most	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
),	O
the	O
changes	O
of	O
TP	O
and	O
TG	O
were	O
not	O
obvious	O
.	O

In	O
the	O
other	O
viral	O
pneumonias	O
patients	O
,	O
ALT	O
,	O
AST	B-ENZY
,	O
LDH	O
were	O
elevated	O
slightly	O
than	O
those	O
of	O
healthy	O
person	O
,	O
while	O
Fe	O
,	O
Ca	O
,	O
Alb	O
,	O
TC	O
,	O
CK	O
were	O
a	O
little	O
reduced	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O

In	O
convalescent	O
stage	O
,	O
all	O
the	O
tests	O
were	O
returned	O
to	O
normal	O
ranges	O
except	O
ALT	O
,	O
AST	B-ENZY
were	O
still	O
elevated	O
in	O
SARS	O
patients	O
.	O

Measured	O
variables	O
upon	O
admission	O
included	O
APACHE	O
II	O
score	O
,	O
the	O
ratio	O
of	O
the	O
partial	O
pressure	O
of	O
oxygen	O
in	O
arterial	O
blood	O
to	O
the	O
fraction	O
of	O
oxygen	O
in	O
inspired	O
gas	B-ENZY
(	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)),	O
and	O
plasma	O
levels	O
of	O
free	O
T3	O
(	O
fT3	O
)	O
and	O
free	O
thyroxine	O
(	O
fT4	O
),	O
and	O
TSH	O
levels	O
.	O

Plasma	O
fT3	O
was	O
correlated	O
with	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
with	O
APACHE	O
II	O
score	O
(	O
P	O
=	O
0	O
.	O
003	O
).	O

Normalization	O
of	O
thyroid	O
function	O
was	O
observed	O
at	O
discharge	O
with	O
a	O
significant	O
correlation	O
between	O
the	O
percent	O
increase	O
in	O
both	O
fT3	O
and	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
(	O
P	O
=	O
0	O
.	O
015	O
).	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
-	O
2	O
(	O
ACE2	O
)	O
is	O
the	O
first	O
human	O
homologue	O
of	O
ACE	B-ENZY
to	O
be	O
described	O
.	O

It	O
is	O
a	O
consequence	O
of	O
this	O
action	O
that	O
ACE2	O
participates	O
in	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
.	O

When	O
corrosion	O
,	O
bleaching	O
or	O
gas	B-ENZY
production	O
have	O
to	O
be	O
avoided	O
,	O
chlorine	O
compounds	O
may	O
be	O
substituted	O
by	O
phenolic	O
detergent	O
disinfectants	O
.	O

We	O
used	O
Cox	O
proportional	O
hazard	O
modelling	O
to	O
analyze	O
potential	O
predictors	O
of	O
survival	O
recorded	O
at	O
the	O
time	O
of	O
presentation	O
,	O
including	O
viral	O
load	O
from	O
nasopharyngeal	O
specimens	O
(	O
measured	O
by	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
[	O
PCR	O
]	O
of	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
).	O

TITLE	O
:	O
Identification	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
replicase	O
products	O
and	O
characterization	O
of	O
papain	B-ENZY
-	O
like	O
protease	O
activity	O
.	O

ABSTRACT	O
:	O
Gene	O
1	O
of	O
the	O
coronavirus	O
associated	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
encodes	O
replicase	O
polyproteins	O
that	O
are	O
predicted	O
to	O
be	O
processed	O
into	O
16	O
nonstructural	O
proteins	O
(	O
nsps	O
1	O
to	O
16	O
)	O
by	O
two	O
viral	O
proteases	O
,	O
a	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
and	O
a	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
).	O

Human	O
lung	O
fibroblasts	O
were	O
transfected	O
with	O
a	O
procollagen	O
I	O
promoter	O
-	O
luciferase	B-ENZY
construct	O
and	O
incubated	O
with	O
BALF	O
;	O
procollagen	O
I	O
promoter	O
activity	O
was	O
then	O
measured	O
.	O

Femoral	O
and	O
jugular	O
veins	O
,	O
and	O
femoral	O
and	O
carotid	O
arteries	O
were	O
instrumented	O
for	O
the	O
AV	O
-	O
ECMO	O
circuit	O
,	O
systemic	O
and	O
pulmonary	O
artery	O
blood	O
pressure	O
monitoring	O
,	O
gas	B-ENZY
exchange	O
,	O
and	O
cardiac	O
output	O
determination	O
(	O
thermodilution	O
technique	O
).	O

There	O
are	O
several	O
proteins	O
that	O
have	O
never	O
been	O
identified	O
in	O
plasma	O
before	O
using	O
2D	O
gel	O
electrophoresis	O
,	O
among	O
which	O
peroxiredoxin	B-ENZY
II	O
was	O
chosen	O
for	O
further	O
study	O
by	O
analyzing	O
additional	O
20	O
plasma	O
samples	O
from	O
patients	O
with	O
probable	O
and	O
suspected	O
SARS	O
and	O
patients	O
with	O
fever	O
,	O
respectively	O
.	O

The	O
results	O
showed	O
that	O
the	O
level	O
of	O
plasma	O
peroxiredoxin	B-ENZY
II	O
in	O
patients	O
with	O
SARS	O
is	O
significantly	O
high	O
and	O
could	O
be	O
secreted	O
by	O
T	O
cells	O
.	O

Multivariate	O
analysis	O
identified	O
3	O
laboratory	O
features	O
that	O
together	O
are	O
highly	O
predictive	O
of	O
a	O
diagnosis	O
of	O
dengue	O
and	O
able	O
to	O
rule	O
out	O
the	O
possibility	O
of	O
SARS	O
:	O
platelet	O
count	O
of	O
<	O
140	O
x	O
10	O
(	O
9	O
)	O
platelets	O
/	O
L	O
,	O
white	O
blood	O
cell	O
count	O
of	O
<	O
5x10	O
(	O
9	O
)	O
cells	O
/	O
L	O
,	O
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
level	O
of	O
>	O
34	O
IU	O
/	O
L	O
.	O
A	O
combination	O
of	O
these	O
parameters	O
has	O
a	O
sensitivity	O
of	O
75	O
%	O
and	O
a	O
specificity	O
of	O
100	O
%.	O

RESULTS	O
:	O
Multivariate	O
analysis	O
identified	O
3	O
laboratory	O
features	O
that	O
together	O
are	O
highly	O
predictive	O
of	O
a	O
diagnosis	O
of	O
dengue	O
and	O
able	O
to	O
rule	O
out	O
the	O
possibility	O
of	O
SARS	O
:	O
platelet	O
count	O
of	O
<	O
140	O
x	O
10	O
(	O
9	O
)	O
platelets	O
/	O
L	O
,	O
white	O
blood	O
cell	O
count	O
of	O
<	O
5x10	O
(	O
9	O
)	O
cells	O
/	O
L	O
,	O
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
level	O
of	O
>	O
34	O
IU	O
/	O
L	O
.	O
A	O
combination	O
of	O
these	O
parameters	O
has	O
a	O
sensitivity	O
of	O
75	O
%	O
and	O
a	O
specificity	O
of	O
100	O
%.	O

Cholinesterase	B-ENZY
(	O
ChE	O
)	O
activity	O
was	O
dynamically	O
monitored	O
.	O

Activations	O
of	O
AP	O
-	O
1	O
DNA	O
-	O
protein	O
binding	O
and	O
MAPKs	O
after	O
vAtEpGS688	O
transduction	O
were	O
demonstrated	O
,	O
and	O
SARS	O
-	O
CoV	O
S	O
protein	O
-	O
induced	O
IL	O
-	O
8	O
promoter	O
activity	O
was	O
inhibited	O
by	O
the	O
specific	O
inhibitors	O
of	O
MAPK	B-ENZY
cascades	O
.	O

The	O
membrane	O
-	O
bound	O
proprotein	O
convertases	O
(	O
PCs	O
)	O
furin	B-ENZY
,	O
PC7	O
or	O
PC5B	O
enhanced	O
the	O
production	O
of	O
the	O
approximately	O
80	O
kDa	O
protein	O
.	O

In	O
agreement	O
,	O
proS	O
processing	O
,	O
cytopathic	O
effects	O
,	O
and	O
viral	O
titers	O
were	O
enhanced	O
in	O
recombinant	O
Vero	O
E6	O
cells	O
overexpressing	O
furin	B-ENZY
,	O
PC7	O
or	O
PC5B	O
.	O

The	O
convertase	O
inhibitor	O
dec	O
-	O
RVKR	O
-	O
cmk	B-ENZY
significantly	O
reduced	O
proS	O
cleavage	O
and	O
viral	O
titers	O
of	O
SARS	O
-	O
CoV	O
infected	O
cells	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
processing	O
by	O
dec	O
-	O
RVKR	O
-	O
cmk	B-ENZY
completely	O
abrogated	O
the	O
virus	O
-	O
induced	O
cellular	O
cytopathicity	O
.	O

A	O
fluorogenically	O
quenched	O
synthetic	O
peptide	O
encompassing	O
Arg	O
(	O
761	O
)	O
of	O
the	O
spike	O
glycoprotein	O
was	O
efficiently	O
cleaved	O
by	O
furin	B-ENZY
and	O
the	O
cleavage	O
was	O
inhibited	O
by	O
EDTA	O
and	O
dec	O
-	O
RVKR	O
-	O
cmk	B-ENZY
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
furin	B-ENZY
or	O
PC	O
-	O
mediated	O
processing	O
plays	O
a	O
critical	O
role	O
in	O
SARS	O
-	O
CoV	O
spread	O
and	O
cytopathicity	O
,	O
and	O
inhibitors	O
of	O
the	O
PCs	O
represent	O
potential	O
therapeutic	O
anti	O
-	O
SARS	O
-	O
CoV	O
agents	O
.	O

TITLE	O
:	O
The	O
ubiquitin	O
-	O
proteasome	B-ENZY
system	O
facilitates	O
the	O
transfer	O
of	O
murine	O
coronavirus	O
from	O
endosome	O
to	O
cytoplasm	O
during	O
virus	O
entry	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
proteasome	B-ENZY
inhibitors	O
blocked	O
mouse	O
hepatitis	O
virus	O
replication	O
at	O
an	O
early	O
step	O
in	O
the	O
viral	O
life	O
cycle	O
.	O

Besides	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
,	O
RNA	O
helicase	O
,	O
and	O
protease	O
activities	O
,	O
which	O
are	O
common	O
to	O
RNA	O
viruses	O
,	O
the	O
coronavirus	O
replicase	O
was	O
recently	O
predicted	O
to	O
employ	O
a	O
variety	O
of	O
RNA	O
processing	O
enzymes	O
that	O
are	O
not	O
(	O
or	O
extremely	O
rarely	O
)	O
found	O
in	O
other	O
RNA	O
viruses	O
and	O
include	O
putative	O
sequence	O
-	O
specific	O
endoribonuclease	O
,	O
3	O
'-	O
to	O
-	O
5	O
'	O
exoribonuclease	O
,	O
2	O
'-	O
O	O
-	O
ribose	O
methyltransferase	O
,	O
ADP	O
ribose	O
1	O
"""-"	O
phosphatase	O
and	O
,	O
in	O
a	O
subset	O
of	O
group	O
2	O
coronaviruses	O
,	O
cyclic	O
phosphodiesterase	B-ENZY
activities	O
.	O

In	O
addition	O
to	O
viral	O
proteins	O
,	O
several	O
cellular	O
proteins	O
,	O
such	O
as	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
(	O
hnRNP	O
)	O
A1	O
,	O
polypyrimidine	O
-	O
tract	O
-	O
binding	O
(	O
PTB	O
)	O
protein	O
,	O
poly	O
(	O
A	O
)-	O
binding	O
protein	O
(	O
PABP	O
),	O
and	O
mitochondrial	O
aconitase	B-ENZY
(	O
m	O
-	O
aconitase	B-ENZY
),	O
have	O
been	O
identified	O
to	O
interact	O
with	O
the	O
critical	O
cis	O
-	O
acting	O
elements	O
of	O
coronavirus	O
replication	O
.	O

These	O
proteins	O
include	O
rennin	B-ENZY
,	O
amyloglucosidases	O
(	O
glucamylases	O
),	O
interferons	O
,	O
interleukins	O
,	O
insulin	O
,	O
monoclonal	O
antibodies	O
,	O
tissue	O
plasminogen	O
activators	O
(	O
t	O
-	O
PA	O
),	O
sexually	O
transmitted	O
disease	O
antigens	O
,	O
and	O
measles	O
,	O
mumps	O
and	O
rubella	O
antigens	O
,	O
growth	O
hormones	O
,	O
somatotropin	O
,	O
blood	O
clotting	O
factors	O
VIII	O
and	O
XIII	O
.	O

Here	O
,	O
we	O
characterized	O
the	O
ATPase	B-ENZY
and	O
helicase	O
activities	O
of	O
bacterially	O
expressed	O
mutant	O
forms	O
of	O
nsp10	O
and	O
its	O
human	O
coronavirus	O
229E	O
ortholog	O
,	O
nsp13	O
,	O
and	O
correlated	O
these	O
in	O
vitro	O
activities	O
with	O
specific	O
virus	O
phenotypes	O
.	O

TITLE	O
:	O
Effect	O
of	O
soluble	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
on	O
antibody	O
production	O
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Current	O
trends	O
in	O
the	O
management	O
of	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
consist	O
of	O
maintaining	O
acceptable	O
gas	B-ENZY
exchange	O
while	O
limiting	O
ventilator	O
-	O
associated	O
lung	O
injury	O
.	O

The	O
management	O
goal	O
in	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
challenges	O
clinicians	O
to	O
achieve	O
the	O
optimal	O
balance	O
that	O
both	O
limits	O
the	O
forms	O
of	O
alveolar	O
stress	O
failure	O
and	O
maintains	O
effective	O
gas	B-ENZY
exchange	O
.	O

Airway	O
pressure	O
release	O
ventilation	O
is	O
a	O
mode	O
of	O
mechanical	O
ventilation	O
that	O
maintains	O
lung	O
volume	O
to	O
limit	O
intra	O
tidal	O
recruitment	O
/	O
derecruitment	O
and	O
improves	O
gas	B-ENZY
exchange	O
while	O
limiting	O
over	O
distension	O
.	O

Eleven	O
highly	O
conserved	O
regions	O
in	O
RdRp	O
and	O
twelve	O
cleavage	O
sites	O
by	O
3CLP	O
(	O
chymotrypsin	B-ENZY
-	O
like	O
protein	O
)	O
have	O
been	O
identified	O
as	O
potential	O
drug	O
targets	O
.	O

Of	O
the	O
196	O
patients	O
,	O
34	O
(	O
17	O
.	O
3	O
%)	O
met	O
the	O
World	O
Health	O
Organization	O
criteria	O
for	O
probable	O
SARS	O
with	O
positive	O
results	O
of	O
serologic	O
testing	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
nasopharyngeal	O
or	O
throat	O
swabs	O
for	O
SARS	O
-	O
CoV	O
,	O
or	O
both	O
.	O

RESULTS	O
:	O
Of	O
the	O
196	O
patients	O
,	O
34	O
(	O
17	O
.	O
3	O
%)	O
met	O
the	O
World	O
Health	O
Organization	O
criteria	O
for	O
probable	O
SARS	O
with	O
positive	O
results	O
of	O
serologic	O
testing	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
nasopharyngeal	O
or	O
throat	O
swabs	O
for	O
SARS	O
-	O
CoV	O
,	O
or	O
both	O
.	O

Arginine	O
metabolism	O
in	O
activated	O
and	O
/	O
or	O
virus	O
infected	O
BMMphi	O
was	O
investigated	O
through	O
nitric	O
oxide	O
(	O
NO	O
)	O
and	O
arginase	B-ENZY
induction	O
as	O
well	O
as	O
the	O
consumption	O
of	O
arginine	O
and	O
synthesis	O
of	O
citrulline	O
,	O
ornithine	O
and	O
spermine	O
.	O

For	O
pneumonia	O
,	O
NAATs	O
offer	O
advantages	O
over	O
conventional	O
tests	O
for	O
the	O
detection	O
of	O
Mycoplasma	O
pneumoniae	O
,	O
Legionella	O
spp	B-ENZY
.	O

ABSTRACT	O
:	O
To	O
apply	O
fluorescent	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
in	O
detecting	O
influenza	O
viruses	O
.	O

The	O
basis	O
of	O
the	O
assay	O
is	O
the	O
cleavage	O
of	O
target	O
RNA	O
by	O
RNase	B-ENZY
H	I-ENZY
mediated	O
by	O
sequence	O
-	O
specific	O
chimeric	O
oligonucleotides	O
followed	O
by	O
sample	O
to	O
residual	O
ratio	O
quantitation	O
(	O
SRRQ	O
)	O
using	O
RRT	O
-	O
PCR	O
.	O

In	O
recruiters	O
(=	O
6	O
patients	O
),	O
elastance	O
decreased	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
PaO	B-ENZY
(	O
2	O
)	O
increased	O
(	O
P	O
<	O
0	O
.	O
005	O
),	O
while	O
in	O
non	O
-	O
recruiters	O
(=	O
6	O
patients	O
)	O
elastance	O
and	O
PaCO	O
(	O
2	O
)	O
significantly	O
increased	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

(	O
2	O
)	O
The	O
evidence	O
for	O
immune	O
implication	O
in	O
distress	O
strongly	O
supports	O
immunomodulators	O
for	O
therapy	O
:	O
phosphodiesterase	B-ENZY
inhibitors	O
(	O
due	O
to	O
their	O
down	O
-	O
modulating	O
activity	O
on	O
proinflammatory	O
cytokines	O
);	O
inhaled	O
corticoids	O
(	O
aimed	O
at	O
producing	O
a	O
local	O
immunomodulation	O
);	O
teophylline	O
or	O
nedocromil	O
sodium	O
(	O
which	O
prevents	O
inflammatory	O
cell	O
recruitment	O
into	O
the	O
airway	O
wall	O
).	O

In	O
situ	O
hybridization	O
was	O
used	O
to	O
identify	O
sites	O
of	O
virus	O
replication	O
,	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
analysis	O
was	O
used	O
to	O
detect	O
viral	O
RNA	O
in	O
feces	O
and	O
blood	O
.	O

Frameshifting	O
in	O
SARS	O
-	O
CoV	O
has	O
been	O
characterized	O
in	O
cultured	O
mammalian	O
cells	O
using	O
a	O
dual	O
luciferase	B-ENZY
reporter	O
system	O
and	O
mass	O
spectrometry	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
a	O
novel	O
bat	B-ENZY
coronavirus	O
through	O
surveillance	O
of	O
coronaviruses	O
in	O
wildlife	O
.	O

The	O
virus	O
was	O
detected	O
in	O
fecal	O
and	O
respiratory	O
samples	O
from	O
three	O
bat	B-ENZY
species	O
(	O
Miniopterus	O
spp	B-ENZY
.).	O

The	O
three	O
-	O
dimensional	O
model	O
was	O
also	O
used	O
to	O
explain	O
the	O
recently	O
published	O
experimental	O
results	O
of	O
S1	O
-	O
ACE	B-ENZY
-	O
2	O
binding	O
and	O
immunizations	O
.	O

TITLE	O
:	O
Three	O
-	O
dimensional	O
model	O
of	O
a	O
substrate	O
-	O
bound	O
SARS	O
chymotrypsin	B-ENZY
-	O
like	O
cysteine	O
proteinase	O
predicted	O
by	O
multiple	O
molecular	O
dynamics	O
simulations	O
:	O
catalytic	O
efficiency	O
regulated	O
by	O
substrate	O
binding	O
.	O

ABSTRACT	O
:	O
Reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
amplification	O
of	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
successfully	O
detected	O
36	O
strains	O
from	O
the	O
faeces	O
of	O
mice	O
that	O
had	O
been	O
housed	O
in	O
animal	O
facilities	O
in	O
Japan	O
from	O
2000	O
to	O
2003	O
.	O

Compared	O
with	O
pre	O
-	O
PPV	O
,	O
in	O
ARDSp	O
,	O
partial	O
pressure	O
of	O
oxygen	O
in	O
artery	O
(	O
PaO	B-ENZY
(	O
2	O
))/	O
inhaled	O
oxygen	O
concentration	O
(	O
FiO	O
(	O
2	O
))	O
was	O
not	O
increased	O
after	O
0	O
.	O
5	O
h	O
,	O
and	O
increased	O
only	O
after	O
2	O
h	O
in	O
the	O
prone	O
position	O
(	O
130	O
.	O
6	O
+/-	O

The	O
changes	O
of	O
the	O
PaO	B-ENZY
(	O
2	O
)	O
were	O
similar	O
to	O
the	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
).	O

It	O
improved	O
the	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
rapidly	O
in	O
ARDSexp	O
,	O
but	O
in	O
ARDSp	O
the	O
improvement	O
took	O
a	O
longer	O
time	O
.	O

RESULTS	O
:	O
Compared	O
with	O
pre	O
-	O
PPV	O
,	O
in	O
ARDSp	O
,	O
partial	O
pressure	O
of	O
oxygen	O
in	O
artery	O
(	O
PaO	B-ENZY
(	O
2	O
))/	O
inhaled	O
oxygen	O
concentration	O
(	O
FiO	O
(	O
2	O
))	O
was	O
not	O
increased	O
after	O
0	O
.	O
5	O
h	O
,	O
and	O
increased	O
only	O
after	O
2	O
h	O
in	O
the	O
prone	O
position	O
(	O
130	O
.	O
6	O
+/-	O

RESULTS	O
:	O
The	O
abnormalities	O
of	O
serum	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
were	O
52	O
.	O
5	O
%,	O
71	O
.	O
8	O
%,	O
85	O
.	O
7	O
%	O
and	O
85	O
.	O
2	O
%.	O

TITLE	O
:	O
Development	O
of	O
a	O
quantitative	O
assay	O
for	O
SARS	O
coronavirus	O
and	O
correlation	O
of	O
GAPDH	B-ENZY
mRNA	O
with	O
SARS	O
coronavirus	O
in	O
clinical	O
specimens	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
a	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
Q	O
-	O
RT	O
-	O
PCR	O
)	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
detection	O
and	O
explore	O
the	O
potential	O
of	O
using	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	B-ENZY
)	O
mRNA	O
as	O
an	O
internal	O
control	O
to	O
exclude	O
false	O
negative	O
results	O
.	O

SARS	O
-	O
CoV	O
and	O
GAPDH	B-ENZY
mRNA	O
were	O
both	O
measured	O
in	O
26	O
specimens	O
from	O
16	O
patients	O
with	O
SARS	O
,	O
40	O
follow	O
up	O
specimens	O
from	O
the	O
same	O
batch	O
of	O
patients	O
,	O
and	O
appropriate	O
control	O
subjects	O
.	O

The	O
relation	O
between	O
SARS	O
positivity	O
and	O
GAPDH	B-ENZY
mRNA	O
concentration	O
was	O
investigated	O
using	O
the	O
chi2	O
test	O
.	O

In	O
addition	O
,	O
concentrations	O
of	O
GAPDH	B-ENZY
mRNA	O
were	O
significantly	O
different	O
between	O
the	O
patients	O
with	O
SARS	O
,	O
follow	O
up	O
specimens	O
,	O
and	O
healthy	O
controls	O
(	O
Kruskal	O
-	O
Wallis	O
test	O
,	O
p	O
<	O
0	O
.	O
05	O
).	O

Moreover	O
,	O
GAPDH	B-ENZY
mRNA	O
concentrations	O
were	O
highly	O
correlated	O
with	O
SARS	O
-	O
CoV	O
positivity	O
(	O
chi2	O
=	O
5	O
.	O
43	O
;	O
p	O
<	O
0	O
.	O
05	O
).	O

Finally	O
,	O
SARS	O
-	O
CoV	O
and	O
GAPDH	B-ENZY
mRNA	O
were	O
both	O
detected	O
in	O
three	O
follow	O
up	O
urine	O
specimens	O
that	O
were	O
initially	O
negative	O
when	O
the	O
amount	O
of	O
cDNA	O
used	O
was	O
increased	O
from	O
5	O
microl	O
to	O
10	O
and	O
15	O
microl	O
.	O

Finally	O
,	O
SARS	O
-	O
CoV	O
and	O
GAPDH	B-ENZY
mRNA	O
were	O
both	O
detected	O
in	O
three	O
follow	O
up	O
urine	O
specimens	O
that	O
were	O
initially	O
negative	O
when	O
the	O
amount	O
of	O
cDNA	O
used	O
was	O
increased	O
from	O
5	O
microl	O
to	O
10	O
and	O
15	O
microl	O
.	O

There	O
is	O
a	O
need	O
to	O
improve	O
the	O
current	O
sanitary	O
drainage	O
design	O
and	O
maintenance	O
standards	O
to	O
avoid	O
any	O
leakage	O
of	O
foul	O
gas	B-ENZY
into	O
the	O
indoor	O
environments	O
.	O

Partitioned	O
respiratory	O
mechanics	O
were	O
determined	O
during	O
iso	O
-	O
flow	O
(	O
0	O
.	O
91	O
L	O
.	O
s	O
(-	O
1	O
))	O
experiments	O
(	O
V	O
(	O
T	O
)	O
varied	O
within	O
0	O
.	O
2	O
-	O
1	O
.	O
0	O
L	O
),	O
along	O
with	O
haemodynamics	O
,	O
gas	B-ENZY
exchange	O
,	O
and	O
EELV	O
.	O

During	O
hospitalization	O
,	O
lymphopenia	O
was	O
found	O
in	O
57	O
patients	O
(	O
85	O
.	O
1	O
%);	O
and	O
elevated	O
levels	O
of	O
lactate	O
dehydrogenase	O
(	O
LDH	O
;	O
n	O
=	O
55	O
;	O
83	O
.	O
3	O
%),	O
C	O
-	O
reactive	O
protein	O
(	O
n	O
=	O
55	O
;	O
83	O
.	O
3	O
%),	O
aminotransferases	O
(	O
n	O
=	O
44	O
;	O
65	O
.	O
7	O
%),	O
and	O
creatine	B-ENZY
kinase	I-ENZY
(	O
n	O
=	O
14	O
;	O
20	O
.	O
9	O
%)	O
were	O
also	O
noted	O
.	O

High	O
-	O
frequency	O
percussive	O
ventilation	O
has	O
been	O
shown	O
to	O
provide	O
favorable	O
gas	B-ENZY
exchange	O
in	O
several	O
well	O
-	O
defined	O
patient	O
populations	O
.	O

Using	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
pulmonary	O
permeability	O
changes	O
were	O
quantified	O
and	O
PMNL	O
activation	O
was	O
assessed	O
by	O
chemiluminescence	O
.	O

We	O
demonstrate	O
this	O
principle	O
by	O
using	O
14	O
isolates	O
of	O
9	O
diverse	O
Coronavirus	O
spp	B-ENZY
.,	O
including	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

TITLE	O
:	O
Attenuation	O
of	O
acute	O
lung	O
injury	O
in	O
mice	O
by	O
oxymatrine	O
is	O
associated	O
with	O
inhibition	O
of	O
phosphorylated	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
.	O

Furthermore	O
,	O
pretreatment	O
with	O
oxymatrine	O
significantly	O
alleviated	O
oleic	O
acid	O
-	O
induced	O
lung	O
injury	O
accompanied	O
by	O
reduction	O
of	O
lung	O
index	O
and	O
wet	O
-	O
to	O
-	O
dry	O
weight	O
ratio	O
,	O
decreases	O
in	O
serum	O
TNF	O
-	O
alpha	O
level	O
and	O
inhibition	O
of	O
phosphorylated	O
p38	O
MAPK	B-ENZY
.	O

These	O
findings	O
suggest	O
that	O
oxymatrine	O
has	O
a	O
beneficial	O
effect	O
on	O
acute	O
lung	O
injury	O
induced	O
by	O
oleic	O
acid	O
in	O
mice	O
and	O
may	O
inhibit	O
the	O
production	O
of	O
proinflammatory	O
cytokine	O
,	O
TNF	O
-	O
alpha	O
,	O
by	O
means	O
of	O
the	O
inhibition	O
of	O
p38	O
MAPK	B-ENZY
.	O

SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
was	O
demonstrated	O
using	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
in	O
all	O
4	O
patients	O
.	O

We	O
analyzed	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
synthetase	O
1	O
(	O
OAS	O
-	O
1	O
),	O
myxovirus	O
resistance	O
-	O
A	O
(	O
MxA	O
),	O
and	O
double	O
-	O
stranded	O
RNA	O
-	O
dependent	O
protein	B-ENZY
kinase	I-ENZY
in	O
44	O
Vietnamese	O
SARS	O
patients	O
with	O
103	O
controls	O
.	O

Serum	O
TAC	O
and	O
lung	O
tissue	O
Na	O
+-	O
K	O
+	O
ATPase	B-ENZY
activity	O
levels	O
were	O
found	O
to	O
be	O
increased	O
in	O
ILO	O
group	O
compared	O
to	O
IR	O
group	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
).	O

With	O
the	O
use	O
of	O
2	O
databases	O
,	O
we	O
compared	O
the	O
ability	O
of	O
the	O
absolute	O
lymphocyte	O
count	O
,	O
absolute	O
neutrophil	O
count	O
,	O
lactate	O
dehydrogenase	O
level	O
,	O
creatine	B-ENZY
kinase	I-ENZY
level	O
,	O
alanine	B-ENZY
aminotransferase	I-ENZY
level	O
,	O
and	O
serum	O
calcium	O
level	O
at	O
hospital	O
admission	O
to	O
discriminate	O
between	O
cases	O
of	O
SARS	O
and	O
cases	O
of	O
community	O
-	O
acquired	O
pneumonia	O
.	O

Bananin	O
,	O
iodobananin	O
,	O
vanillinbananin	O
,	O
and	O
eubananin	O
were	O
effective	O
inhibitors	O
of	O
the	O
ATPase	B-ENZY
activity	O
of	O
the	O
SCV	O
helicase	O
with	O
IC50	O
values	O
in	O
the	O
range	O
0	O
.	O
5	O
-	O
3	O
microM	O
.	O
A	O
similar	O
trend	O
,	O
though	O
at	O
slightly	O
higher	O
inhibitor	O
concentrations	O
,	O
was	O
observed	O
for	O
inhibition	O
of	O
the	O
helicase	O
activities	O
,	O
using	O
a	O
FRET	O
-	O
based	O
fluorescent	O
assay	O
.	O

Interaction	O
with	O
alkaline	B-ENZY
phosphatase	I-ENZY
-	O
labelled	O
streptavidin	O
permits	O
amplified	O
indirect	O
electrochemical	O
detection	O
.	O

A	O
newly	O
described	O
lesion	O
,	O
isolated	O
ductular	O
hyperplasia	O
(	O
IDH	B-ENZY
)	O
was	O
found	O
in	O
patients	O
with	O
prolonged	O
abnormalities	O
of	O
liver	O
function	O
tests	O
of	O
uncertain	O
origin	O
.	O

A	O
recent	O
study	O
has	O
suggested	O
that	O
the	O
deletion	O
allele	O
(	O
D	O
allele	O
)	O
of	O
the	O
angiotensin	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)	O
gene	O
is	O
associated	O
with	O
hypoxemia	O
in	O
SARS	O
patients	O
.	O

Moreover	O
,	O
the	O
ACE	B-ENZY
D	O
allele	O
has	O
been	O
shown	O
to	O
be	O
more	O
prevalent	O
in	O
patients	O
suffering	O
from	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
a	O
previous	O
study	O
.	O

Thus	O
,	O
we	O
have	O
investigated	O
the	O
association	O
between	O
ACE	B-ENZY
insertion	O
/	O
deletion	O
(	O
I	O
/	O
D	O
)	O
polymorphism	O
and	O
the	O
progression	O
to	O
ARDS	O
or	O
requirement	O
of	O
intensive	O
care	O
in	O
SARS	O
patients	O
.	O

The	O
ACE	B-ENZY
I	O
/	O
D	O
genotypes	O
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
and	O
agarose	O
gel	O
electrophoresis	O
.	O

There	O
is	O
no	O
significant	O
difference	O
in	O
the	O
genotypic	O
distributions	O
and	O
the	O
allelic	O
frequencies	O
of	O
the	O
ACE	B-ENZY
I	O
/	O
D	O
polymorphism	O
between	O
the	O
SARS	O
patients	O
and	O
the	O
healthy	O
control	O
subjects	O
.	O

Moreover	O
,	O
there	O
is	O
also	O
no	O
evidence	O
that	O
ACE	B-ENZY
I	O
/	O
D	O
polymorphism	O
is	O
associated	O
with	O
the	O
progression	O
to	O
ARDS	O
or	O
the	O
requirement	O
of	O
intensive	O
care	O
in	O
the	O
SARS	O
patients	O
.	O

The	O
ACE	B-ENZY
I	O
/	O
D	O
polymorphism	O
is	O
not	O
directly	O
related	O
to	O
increased	O
susceptibility	O
to	O
SARS	O
-	O
coronavirus	O
infection	O
and	O
is	O
not	O
associated	O
with	O
poor	O
outcomes	O
after	O
SARS	O
-	O
coronavirus	O
infection	O
.	O

The	O
ACE	B-ENZY
I	O
/	O
D	O
genotypes	O
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
and	O
agarose	O
gel	O
electrophoresis	O
.	O

RESULTS	O
:	O
There	O
is	O
no	O
significant	O
difference	O
in	O
the	O
genotypic	O
distributions	O
and	O
the	O
allelic	O
frequencies	O
of	O
the	O
ACE	B-ENZY
I	O
/	O
D	O
polymorphism	O
between	O
the	O
SARS	O
patients	O
and	O
the	O
healthy	O
control	O
subjects	O
.	O

Subsequently	O
detection	O
of	O
Rhizopus	O
spp	B-ENZY
.	O

Rhizopus	O
spp	B-ENZY
.	O
were	O
detected	O
by	O
microbiological	O
testing	O
in	O
the	O
empyema	O
fluid	O
.	O

The	O
very	O
rarely	O
seen	O
pulmonary	O
zygomycosis	O
caused	O
by	O
infection	O
with	O
Rhizopus	O
spp	B-ENZY
.	O

One	O
is	O
the	O
N	O
-	O
terminal	O
chymotrypsin	B-ENZY
-	O
like	O
fold	O
that	O
consists	O
of	O
two	O
structural	O
domains	O
and	O
constitutes	O
the	O
catalytic	O
machinery	O
;	O
the	O
other	O
is	O
the	O
C	O
-	O
terminal	O
helical	O
domain	O
,	O
which	O
has	O
an	O
unclear	O
function	O
and	O
is	O
not	O
found	O
in	O
other	O
RNA	O
virus	O
main	O
proteases	O
.	O

TITLE	O
:	O
Mutations	O
in	O
Sendai	O
virus	O
variant	O
F1	O
-	O
R	O
that	O
correlate	O
with	O
plaque	O
formation	O
in	O
the	O
absence	O
of	O
trypsin	B-ENZY
.	O

To	O
confirm	O
that	O
the	O
F	O
and	O
M	O
gene	O
mutations	O
described	O
above	O
are	O
solely	O
responsible	O
for	O
the	O
phenotypic	O
differences	O
seen	O
in	O
wild	O
-	O
type	O
versus	O
F1	O
-	O
R	O
infections	O
,	O
reverse	O
genetics	O
was	O
used	O
to	O
construct	O
recombinant	O
Sendai	O
viruses	O
with	O
various	O
combinations	O
of	O
the	O
mutations	O
found	O
in	O
the	O
M	O
and	O
F	O
genes	O
of	O
F1	O
-	O
R	O
.	O
Plaque	O
assays	O
were	O
performed	O
with	O
or	O
without	O
trypsin	B-ENZY
addition	O
.	O

A	O
recombinant	O
virus	O
containing	O
all	O
F1	O
-	O
R	O
M	O
and	O
F	O
mutations	O
formed	O
plaques	O
in	O
LLC	O
-	O
MK2	O
cells	O
and	O
underwent	O
multiple	O
cycles	O
of	O
replication	O
without	O
trypsin	B-ENZY
addition	O
.	O

Therefore	O
,	O
more	O
than	O
one	O
mutation	O
in	O
the	O
F	O
gene	O
contributes	O
to	O
the	O
ability	O
of	O
F1	O
-	O
R	O
to	O
form	O
plaques	O
without	O
trypsin	B-ENZY
addition	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
feasibility	O
of	O
using	O
Flinders	O
Technology	O
Associates	O
(	O
FTA	O
)	O
filter	O
cards	O
for	O
the	O
storage	O
of	O
allantoic	O
fluid	O
containing	O
an	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
such	O
as	O
Arkansas	O
-	O
DPI	O
,	O
Connecticut	O
,	O
and	O
Massachusetts	O
,	O
and	O
for	O
their	O
identification	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
characterization	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
or	O
nucleotide	O
sequencing	O
.	O

TITLE	O
:	O
Cells	O
of	O
human	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
CD13	O
)	O
transgenic	O
mice	O
are	O
infected	O
by	O
human	O
coronavirus	O
-	O
229E	O
in	O
vitro	O
,	O
but	O
not	O
in	O
vivo	O
.	O

We	O
found	O
that	O
the	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
and	O
a	O
felinized	O
murine	O
hepatitis	O
virus	O
(	O
fMHV	O
),	O
both	O
normally	O
incapable	O
of	O
infecting	O
human	O
cells	O
,	O
could	O
rapidly	O
and	O
effectively	O
kill	O
human	O
cancer	O
cells	O
artificially	O
expressing	O
the	O
feline	O
coronavirus	O
receptor	O
aminopeptidase	B-ENZY
N	I-ENZY
.	O
Also	O
3	O
-	O
D	O
multilayer	O
tumor	O
spheroids	O
established	O
from	O
such	O
cells	O
were	O
effectively	O
eradicated	O
.	O

APHS	O
did	O
not	O
affect	O
the	O
replication	O
of	O
feline	O
immunodeficiency	O
virus	O
,	O
HIV	O
-	O
2	O
and	O
a	O
HIV	O
-	O
1	O
strain	O
resistant	O
to	O
non	O
-	O
nucleoside	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
(	O
NNRTI	O
).	O

Significant	O
impairment	O
in	O
surface	O
area	O
for	O
gas	B-ENZY
exchange	O
was	O
noted	O
in	O
15	O
.	O
5	O
%	O
of	O
survivors	O
.	O

The	O
effects	O
of	O
class	O
-	O
specific	O
protease	O
inhibitors	O
on	O
the	O
trans	O
-	O
cleavage	O
activity	O
revealed	O
that	O
this	O
enzyme	O
worked	O
more	O
like	O
a	O
serine	O
protease	O
rather	O
than	O
the	O
papain	B-ENZY
protease	O
.	O

TITLE	O
:	O
Real	O
-	O
time	O
quantitative	O
fluorescent	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
for	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
RNA	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
construct	O
a	O
sensitive	O
and	O
specific	O
real	O
-	O
time	O
quantitative	O
fluorescent	O
(	O
QF	O
)	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
PCR	O
method	O
for	O
the	O
detection	O
of	O
SARS	O
-	O
CoV	O
RNA	O
.	O

Survival	O
studies	O
,	O
lung	O
weights	O
,	O
x	O
-	O
ray	O
computed	O
tomographic	O
scanning	O
,	O
light	O
and	O
electron	O
microscopy	O
,	O
bronchoalveolar	O
lavage	O
,	O
lung	O
uptake	O
of	O
((	O
18	O
)	O
F	O
)	O
fluorodeoxyglucose	O
,	O
tissue	O
myeloperoxidase	B-ENZY
,	O
arterial	O
blood	O
gases	O
,	O
mean	O
arterial	O
pressure	O
,	O
and	O
lung	O
tissue	O
prostanoids	O
were	O
measured	O
in	O
separate	O
groups	O
of	O
C57Bl	O
/	O
6	O
mice	O
(	O
normal	O
animals	O
,	O
endotoxin	O
only	O
[	O
20	O
microg	O
/	O
g	O
],	O
oleic	O
acid	O
only	O
[	O
0	O
.	O
15	O
microl	O
/	O
g	O
],	O
or	O
endotoxin	O
+	O
oleic	O
acid	O
).	O

When	O
given	O
together	O
,	O
endotoxin	O
and	O
oleic	O
acid	O
acted	O
synergistically	O
to	O
increase	O
pulmonary	O
edema	O
and	O
to	O
worsen	O
gas	B-ENZY
exchange	O
and	O
hemodynamics	O
,	O
thereby	O
increasing	O
mortality	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
also	O
known	O
as	O
noncardiogenic	O
pulmonary	O
edema	O
,	O
is	O
a	O
severe	O
complication	O
in	O
cirrhotic	O
patients	O
undergoing	O
microwave	O
coagulation	O
therapy	O
(	O
MCT	B-ENZY
)	O
for	O
liver	O
tumor	O
.	O

In	O
this	O
study	O
,	O
cirrhotic	O
patients	O
with	O
ARDS	O
after	O
MCT	B-ENZY
were	O
compared	O
with	O
others	O
without	O
ARDS	O
.	O

Four	O
patients	O
with	O
ARDS	O
after	O
open	O
MCT	B-ENZY
and	O
17	O
other	O
patients	O
without	O
ARDS	O
were	O
compared	O
in	O
terms	O
of	O
preoperative	O
status	O
,	O
intraoperative	O
findings	O
,	O
and	O
postoperative	O
management	O
.	O

The	O
water	O
balance	O
and	O
sodium	O
administration	O
have	O
to	O
be	O
closely	O
monitored	O
to	O
prevent	O
cirrhotic	O
patients	O
undergoing	O
MCT	B-ENZY
from	O
developing	O
ARDS	O
.	O

Furosemide	O
has	O
been	O
shown	O
to	O
improve	O
pulmonary	O
gas	B-ENZY
exchange	O
and	O
intrapulmonary	O
shunt	O
by	O
a	O
nondiuretic	O
mechanism	O
in	O
animal	O
models	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
JNK	B-ENZY
and	O
PI3k	O
/	O
Akt	O
signaling	O
pathways	O
are	O
required	O
for	O
establishing	O
persistent	O
SARS	O
-	O
CoV	O
infection	O
in	O
Vero	O
E6	O
cells	O
.	O

Our	O
previous	O
studies	O
demonstrated	O
that	O
signaling	O
pathways	O
of	O
extracellular	O
signal	O
-	O
related	O
kinase	O
(	O
ERK1	O
/	O
2	O
),	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
protein	B-ENZY
kinase	I-ENZY
(	O
JNK	B-ENZY
),	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
),	O
and	O
phosphatidylinositol	O
3	O
'-	O
kinase	O
(	O
PI3K	O
)/	O
Akt	O
were	O
activated	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

Previous	O
studies	O
also	O
showed	O
that	O
the	O
activation	O
of	O
p38	O
MAPK	B-ENZY
by	O
viral	O
infection	O
-	O
induced	O
apoptosis	O
,	O
and	O
a	O
weak	O
activation	O
of	O
Akt	O
was	O
not	O
sufficient	O
to	O
protect	O
from	O
apoptosis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
the	O
inhibitors	O
of	O
JNK	B-ENZY
and	O
PI3K	O
/	O
Akt	O
inhibited	O
the	O
establishment	O
of	O
persistence	O
,	O
but	O
those	O
of	O
MAPK	B-ENZY
/	O
ERK	B-ENZY
kinase	O
(	O
MEK	B-ENZY
;	O
as	O
an	O
inhibitor	O
for	O
ERK1	O
/	O
2	O
)	O
and	O
p38	O
MAPK	B-ENZY
did	O
not	O
.	O

These	O
results	O
indicated	O
that	O
two	O
signaling	O
pathways	O
of	O
JNK	B-ENZY
and	O
PI3K	O
/	O
Akt	O
were	O
important	O
for	O
the	O
establishment	O
of	O
persistence	O
in	O
Vero	O
E6	O
cells	O
.	O

All	O
patients	O
who	O
died	O
at	O
Sahlgrenska	O
University	O
Hospital	O
in	O
Goteborg	O
,	O
Sweden	O
,	O
in	O
whom	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	B-ENZY
)	O
was	O
not	O
attempted	O
during	O
a	O
period	O
of	O
one	O
year	O
.	O

The	O
low	O
rate	O
of	O
CPR	B-ENZY
attempts	O
after	O
in	O
-	O
hospital	O
cardiac	O
arrest	O
appears	O
to	O
be	O
justified	O
.	O

In	O
all	O
these	O
16	O
cases	O
,	O
it	O
was	O
regarded	O
retrospectively	O
as	O
ethically	O
justifiable	O
not	O
to	O
start	O
CPR	B-ENZY
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
who	O
died	O
at	O
a	O
Swedish	O
University	O
Hospital	O
,	O
we	O
did	O
not	O
find	O
a	O
single	O
case	O
in	O
which	O
it	O
was	O
regarded	O
as	O
unethical	O
not	O
to	O
start	O
CPR	B-ENZY
.	O

We	O
show	O
here	O
that	O
the	O
expression	O
of	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
,	O
also	O
termed	O
CD13	O
),	O
the	O
receptor	O
for	O
HCoV	O
-	O
229E	O
,	O
is	O
required	O
but	O
not	O
sufficient	O
to	O
confer	O
susceptibility	O
in	O
vivo	O
.	O

The	O
gene	O
expression	O
profiles	O
of	O
macrophages	O
infected	O
with	O
SARS	O
-	O
CoV	O
,	O
human	O
coronavirus	O
229E	O
,	O
and	O
influenza	O
A	O
(	O
H1N1	O
)	O
virus	O
were	O
compared	O
by	O
using	O
microarrays	O
and	O
real	O
-	O
time	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
.	O

With	O
this	O
vast	O
array	O
of	O
antibodies	O
,	O
no	O
signal	O
was	O
observed	O
in	O
other	O
cell	O
types	O
including	O
those	O
organs	O
in	O
which	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reactions	O
were	O
reported	O
to	O
be	O
positive	O
.	O

TITLE	O
:	O
[	O
Hypothesis	O
on	O
generating	O
and	O
tracer	O
gas	B-ENZY
study	O
regarding	O
transmission	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
through	O
ventilation	O
system	O
in	O
a	O
general	O
hospital	O
].	O

Tracer	O
gas	B-ENZY
was	O
detected	O
from	O
the	O
wards	O
of	O
8th	O
to	O
13th	O
floor	O
.	O

RESULTS	O
:	O
Tracer	O
gas	B-ENZY
was	O
detected	O
from	O
the	O
wards	O
of	O
8th	O
to	O
13th	O
floor	O
.	O

The	O
ACE	B-ENZY
method	O
used	O
here	O
could	O
be	O
developed	O
to	O
be	O
an	O
effective	O
and	O
simple	O
way	O
of	O
applying	O
large	O
-	O
scale	O
drug	O
screening	O
and	O
evaluation	O
.	O

Lung	O
injury	O
score	O
(	O
LIS	B-ENZY
),	O
which	O
is	O
composed	O
of	O
four	O
components	O
,	O
is	O
used	O
for	O
making	O
a	O
distinction	O
between	O
two	O
separate	O
but	O
rather	O
similar	O
syndromes	O
.	O

The	O
obtained	O
results	O
indicate	O
that	O
high	O
values	O
of	O
the	O
lung	O
injury	O
score	O
are	O
suggestive	O
of	O
the	O
severe	O
respiratory	O
dysfunction	O
as	O
well	O
as	O
that	O
lethal	O
outcome	O
is	O
dependent	O
on	O
LIS	B-ENZY
value	O
.	O

A	O
unique	O
feature	O
of	O
the	O
system	O
is	O
the	O
SUMO	O
tag	O
,	O
which	O
enhances	O
expression	O
,	O
facilitates	O
purification	O
,	O
and	O
can	O
be	O
efficiently	O
cleaved	O
by	O
a	O
SUMO	B-ENZY
-	I-ENZY
specific	I-ENZY
protease	I-ENZY
to	O
generate	O
native	O
protein	O
with	O
a	O
desired	O
N	O
-	O
terminus	O
.	O

Using	O
paired	O
ELISA	O
assay	O
,	O
three	O
mAbs	O
N1E8	O
,	O
N8E1	O
and	O
N10E4	O
were	O
selected	O
as	O
capturing	O
antibody	O
and	O
rabbit	O
polyclonal	O
antibodies	O
as	O
detecting	O
antibody	O
then	O
triple	O
antibodies	O
-	O
based	O
sandwich	O
ELISA	O
was	O
established	O
following	O
horseradish	O
peroxidase	B-ENZY
(	O
HRP	O
)-	O
conjugated	O
goat	O
anti	O
-	O
rabbit	O
immunoglobulin	O
G	O
.	O
The	O
recombinant	O
N	O
protein	O
was	O
used	O
as	O
a	O
standard	O
to	O
establish	O
a	O
detection	O
sensitivity	O
of	O
approximated	O
50	O
pg	O
/	O
ml	O
with	O
this	O
assay	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
a	O
topically	O
applied	O
nuclear	O
factor	O
-	O
kappaB	O
inhibitor	O
(	O
IkappaB	O
kinase	O
-	O
NF	O
-	O
kappaB	O
essential	O
modulator	O
binding	O
domain	O
[	O
IKK	B-ENZY
-	O
NBD	O
]	O
peptide	O
)	O
on	O
gas	B-ENZY
exchange	O
,	O
lung	O
function	O
,	O
lung	O
fluids	O
,	O
and	O
inflammation	O
in	O
a	O
piglet	O
model	O
of	O
repeated	O
airway	O
lavage	O
that	O
is	O
characterized	O
by	O
surfactant	O
deficiency	O
,	O
lung	O
edema	O
,	O
and	O
an	O
inflammatory	O
response	O
.	O

One	O
group	O
of	O
piglets	O
served	O
as	O
a	O
control	O
(	O
n	O
=	O
8	O
),	O
a	O
second	O
group	O
(	O
S	O
,	O
n	O
=	O
8	O
)	O
received	O
a	O
porcine	O
surfactant	O
preparation	O
(	O
Curosurf	O
),	O
and	O
a	O
third	O
group	O
received	O
IKK	B-ENZY
-	O
NBD	O
peptide	O
admixed	O
to	O
surfactant	O
(	O
S	O
+	O
IN	O
,	O
n	O
=	O
8	O
).	O

This	O
work	O
evaluated	O
if	O
RNase	B-ENZY
III	I-ENZY
-	O
prepared	O
short	O
interfering	O
RNAs	O
can	O
induce	O
specific	O
degradation	O
of	O
SARS	O
-	O
coronavirus	O
mRNAs	O
in	O
human	O
cells	O
.	O

Long	O
length	O
double	O
-	O
stranded	O
RNA	O
of	O
these	O
genes	O
were	O
transcribed	O
in	O
vitro	O
and	O
then	O
were	O
cleaved	O
to	O
<	O
30bp	O
length	O
short	O
interfering	O
RNA	O
with	O
E	O
.	O
coli	O
RNase	B-ENZY
III	I-ENZY
.	O

RdRp	O
,	O
spike	O
and	O
nucleocapsid	O
DNA	O
fragments	O
were	O
inserted	O
into	O
the	O
plasmid	O
pGL3	O
-	O
Control	O
,	O
obtained	O
plasmids	O
pGL	O
-	O
R	O
,	O
pGL	O
-	O
S	O
and	O
pGL	O
-	O
N	O
can	O
express	O
hybrid	O
mRNAs	O
luciferase	B-ENZY
-	O
RdRp	O
,	O
spike	O
and	O
-	O
nucleocapsid	O
in	O
cells	O
.	O

Firefly	B-ENZY
luciferase	I-ENZY
and	O
Renilla	O
luciferase	B-ENZY
activity	O
were	O
measured	O
.	O

Firefly	B-ENZY
luciferase	I-ENZY
expression	O
of	O
pGL	O
-	O
R	O
was	O
reduced	O
to	O
13	O
%	O
by	O
esiRNA	O
-	O
R	O
.	O
Expression	O
of	O
pGLS	O
was	O
reduced	O
to	O
11	O
%	O
by	O
esiRNA	O
-	O
S	O
.	O
Expression	O
of	O
pGL	O
-	O
N	O
was	O
reduced	O
to	O
40	O
%	O
by	O
esiRNA	O
-	O
N	O
.	O
Control	O
esiRNAs	O
didn	O
'	O
t	O
affect	O
luciferase	B-ENZY
expression	O
;	O
Hybrid	O
mRNAs	O
'	O
abundance	O
was	O
dramatically	O
reduced	O
by	O
corresponding	O
esiRNAs	O
.	O

RNase	B-ENZY
III	I-ENZY
-	O
prepared	O
short	O
interfering	O
RNAs	O
induce	O
robust	O
and	O
specific	O
degradation	O
of	O
SARS	O
-	O
coronavirus	O
mRNAs	O
in	O
HEK293F	O
cells	O
.	O

Here	O
,	O
to	O
extend	O
our	O
experimental	O
observation	O
,	O
we	O
have	O
incorporated	O
protein	O
structural	O
studies	O
(	O
with	O
positive	O
/	O
negative	O
controls	O
)	O
to	O
investigate	O
the	O
potential	O
binding	O
modes	O
/	O
sites	O
of	O
ATA	O
onto	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
from	O
SARS	O
-	O
CoV	O
and	O
other	O
pathogenic	O
positive	O
-	O
strand	O
RNA	O
-	O
viruses	O
,	O
as	O
well	O
as	O
other	O
proteins	O
in	O
SARS	O
-	O
CoV	O
based	O
on	O
the	O
fact	O
that	O
ATA	O
binds	O
to	O
Ca2	O
+-	O
activated	O
neutral	O
protease	O
(	O
m	B-ENZY
-	I-ENZY
calpain	I-ENZY
),	O
the	O
protein	O
tyrosine	O
phosphatase	O
(	O
PTP	O
)	O
and	O
HIV	O
integrase	O
which	O
have	O
existing	O
crystal	O
structures	O
.	O

The	O
existence	O
of	O
this	O
strictly	O
conserved	O
region	O
that	O
incorporated	O
catalytic	O
residues	O
,	O
coupled	O
with	O
the	O
homologous	O
ATA	O
binding	O
pockets	O
and	O
their	O
consistent	O
DeltaG	O
values	O
,	O
suggested	O
strongly	O
ATA	O
may	O
be	O
involved	O
in	O
an	O
analogous	O
inhibition	O
mechanism	O
of	O
SARS	O
-	O
COV	O
'	O
s	O
RdRp	O
in	O
concomitant	O
to	O
the	O
case	O
in	O
m	B-ENZY
-	I-ENZY
calpain	I-ENZY
,	O
PTP	O
and	O
HIV	O
integrase	O
.	O

TITLE	O
:	O
Heterogeneous	O
airway	O
versus	O
tissue	O
mechanics	O
and	O
their	O
relation	O
to	O
gas	B-ENZY
exchange	O
function	O
during	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
Artificial	O
lung	O
and	O
extracorporeal	O
gas	B-ENZY
exchange	O
.	O

Today	O
ECLA	O
is	O
used	O
only	O
as	O
a	O
rescue	O
therapy	O
in	O
life	O
threatening	O
gas	B-ENZY
exchange	O
disorders	O
if	O
maximal	O
conventional	O
therapy	O
fails	O
to	O
prevent	O
from	O
hypoxemia	O
.	O

Veno	O
-	O
venous	O
ECMO	O
therapy	O
at	O
present	O
is	O
an	O
important	O
therapeutic	O
option	O
in	O
severe	O
ARDS	O
with	O
persisiting	O
life	O
threatening	O
gas	B-ENZY
exchange	O
disorder	O
as	O
a	O
rescue	O
therapy	O
.	O

High	O
IgG	O
levels	O
were	O
detected	O
in	O
mice	O
immunized	O
with	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.)	O
recombinant	O
spike	O
polypeptide	O
generated	O
by	O
Escherichia	O
coli	O
(	O
S	O
-	O
peptide	O
),	O
mice	O
primed	O
with	O
intramuscular	O
(	O
i	O
.	O
m	O
.)	O
tPA	B-ENZY
-	O
optimize800	O
DNA	O
vaccine	O
(	O
tPA	B-ENZY
-	O
S	O
-	O
DNA	O
)	O
and	O
boosted	O
with	O
i	O
.	O
p	O
.	O

S	O
-	O
peptide	O
,	O
and	O
mice	O
primed	O
with	O
oral	O
live	O
-	O
attenuated	O
S	O
.	O
typhimurium	O
that	O
contained	O
CTLA4HingeSARS800	O
DNA	O
vaccine	O
(	O
Salmonella	O
-	O
tPA	B-ENZY
-	O
S	O
-	O
DNA	O
)	O
and	O
boosted	O
with	O
i	O
.	O
p	O
.	O

tPA	B-ENZY
-	O
S	O
-	O
DNA	O
,	O
i	O
.	O
m	O
.	O

S	O
-	O
peptide	O
,	O
oral	O
Salmonella	O
-	O
tPA	B-ENZY
-	O
S	O
-	O
DNA	O
,	O
oral	O
Salmonella	O
-	O
tPA	B-ENZY
-	O
S	O
-	O
DNA	O
boosted	O
with	O
i	O
.	O
p	O
S	O
-	O
peptide	O
,	O
oral	O
Salmonella	O
-	O
CTLA4	O
-	O
S	O
-	O
DNA	O
and	O
oral	O
Salmonella	O
-	O
CTLA4	O
-	O
S	O
-	O
DNA	O
boosted	O
with	O
i	O
.	O
p	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
report	O
clinical	O
,	O
radiological	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
findings	O
in	O
patients	O
with	O
pulmonary	O
manifestations	O
of	O
HIV	O
-	O
associated	O
multicentric	O
Castleman	O
'	O
s	O
disease	O
(	O
MCD	O
).	O

BAL	B-ENZY
analysis	O
showed	O
hypercellularity	O
(	O
n	O
=	O
6	O
)	O
and	O
/	O
or	O
lymphocytosis	O
(	O
n	O
=	O
6	O
),	O
and	O
human	O
herpesvirus	O
-	O
8	O
DNA	O
was	O
detected	O
in	O
two	O
out	O
of	O
two	O
cases	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
and	O
real	O
-	O
time	O
loop	O
-	O
mediated	O
amplification	O
assays	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
detection	O
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)	O
and	O
ACE2	O
are	O
homologues	O
with	O
different	O
key	O
functions	O
in	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
.	O

ACE	B-ENZY
cleaves	O
angiotensin	O
I	O
to	O
generate	O
angiotensin	O
II	O
,	O
whereas	O
ACE2	O
inactivates	O
angiotensin	O
II	O
and	O
is	O
a	O
negative	O
regulator	O
of	O
the	O
system	O
.	O

However	O
,	O
other	O
components	O
of	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
,	O
including	O
ACE	B-ENZY
,	O
angiotensin	O
II	O
and	O
the	O
angiotensin	O
II	O
type	O
1a	O
receptor	O
(	O
AT1a	O
),	O
promote	O
disease	O
pathogenesis	O
,	O
induce	O
lung	O
oedemas	O
and	O
impair	O
lung	O
function	O
.	O

We	O
show	O
that	O
mice	O
deficient	O
for	O
Ace	B-ENZY
show	O
markedly	O
improved	O
disease	O
,	O
and	O
also	O
that	O
recombinant	O
ACE2	O
can	O
protect	O
mice	O
from	O
severe	O
acute	O
lung	O
injury	O
.	O

The	O
most	O
prevalent	O
gas	B-ENZY
exchange	O
abnormality	O
in	O
cirrhosis	O
was	O
the	O
alteration	O
of	O
alveolar	O
-	O
arterial	O
oxygen	O
tension	O
gradient	O
,	O
directly	O
correlated	O
with	O
hepatocellur	O
disfunction	O
.	O

HPS	B-ENZY
was	O
confirmed	O
in	O
8	O
patients	O
(	O
16	O
%).	O

Notably	O
,	O
injection	O
of	O
SARS	O
-	O
CoV	O
Spike	O
into	O
mice	O
worsens	O
acute	O
lung	O
failure	O
in	O
vivo	O
that	O
can	O
be	O
attenuated	O
by	O
blocking	O
the	O
renin	B-ENZY
-	O
angiotensin	O
pathway	O
.	O

Salmonella	O
enterica	O
and	O
Brachyspira	O
spp	B-ENZY
were	O
not	O
common	O
,	O
whereas	O
other	O
pathogens	O
such	O
as	O
canine	O
coronavirus	O
and	O
Helicobacter	O
spp	B-ENZY
were	O
common	O
among	O
the	O
dogs	O
that	O
were	O
surveyed	O
.	O

RESULTS	O
:	O
Salmonella	O
enterica	O
and	O
Brachyspira	O
spp	B-ENZY
were	O
not	O
common	O
,	O
whereas	O
other	O
pathogens	O
such	O
as	O
canine	O
coronavirus	O
and	O
Helicobacter	O
spp	B-ENZY
were	O
common	O
among	O
the	O
dogs	O
that	O
were	O
surveyed	O
.	O

The	O
ACE2	O
active	O
-	O
site	O
model	O
and	O
its	O
crystal	O
structure	O
,	O
which	O
was	O
solved	O
recently	O
,	O
highlighted	O
key	O
differences	O
between	O
ACE2	O
and	O
its	O
counterpart	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
),	O
which	O
are	O
responsible	O
for	O
their	O
differing	O
substrate	O
and	O
inhibitor	O
sensitivities	O
.	O

Thus	O
ACE2	O
has	O
only	O
one	O
chloride	O
-	O
binding	O
site	O
(	O
CL1	O
)	O
whereas	O
ACE	B-ENZY
has	O
two	O
sites	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
address	O
the	O
differences	O
that	O
exist	O
between	O
ACE2	O
and	O
ACE	B-ENZY
at	O
the	O
molecular	O
level	O
.	O

The	O
results	O
can	O
be	O
applied	O
to	O
future	O
studies	O
aimed	O
at	O
unravelling	O
the	O
role	O
of	O
ACE2	O
,	O
relative	O
to	O
ACE	B-ENZY
,	O
in	O
vivo	O
.	O

Muscle	O
weakness	O
and	O
elevated	O
serum	O
creatine	B-ENZY
kinase	I-ENZY
levels	O
are	O
commonly	O
encountered	O
in	O
patients	O
with	O
SARS	O
.	O

Importantly	O
,	O
both	O
ACE	B-ENZY
-	O
2	O
and	O
viral	O
antigen	O
appeared	O
to	O
preferentially	O
colocalize	O
at	O
the	O
apical	O
domain	O
of	O
infected	O
cells	O
.	O

The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
genes	O
of	O
the	O
various	O
IBVs	O
were	O
amplified	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
were	O
cloned	O
and	O
sequenced	O
,	O
and	O
the	O
nucleotide	O
and	O
deduced	O
amino	O
acid	O
sequences	O
were	O
compared	O
with	O
published	O
sequences	O
for	O
non	O
-	O
Korean	O
IBV	O
strains	O
.	O

TITLE	O
:	O
Papain	B-ENZY
-	O
like	O
protease	O
2	O
(	O
PLP2	O
)	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
):	O
expression	O
,	O
purification	O
,	O
characterization	O
,	O
and	O
inhibition	O
.	O

Little	O
information	O
is	O
available	O
on	O
SARS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
(	O
PLP2	O
),	O
and	O
development	O
of	O
inhibitors	O
against	O
PLP2	O
is	O
attractive	O
for	O
antiviral	O
therapy	O
.	O

The	O
study	O
demonstrates	O
,	O
for	O
the	O
first	O
time	O
among	O
coronaviral	O
PLPs	O
,	O
that	O
the	O
reaction	O
mechanism	O
of	O
SARS	O
-	O
CoV	O
PLP2	O
is	O
characteristic	O
of	O
papain	B-ENZY
and	O
compatible	O
with	O
the	O
involvement	O
of	O
the	O
catalytic	O
dyad	O
(	O
Cys	O
)-	O
S	O
(-)/(	O
His	O
)-	O
Im	O
(+)	O
H	O
ion	O
pair	O
.	O

Furthermore	O
,	O
immunohistochemistry	O
of	O
frozen	O
HG	O
sections	O
showed	O
positive	O
stained	O
cells	O
for	O
both	O
H	O
-	O
PGDS	O
and	O
mast	B-ENZY
cell	I-ENZY
tryptase	I-ENZY
in	O
the	O
sub	O
-	O
epithelial	O
cell	O
layers	O
of	O
the	O
HG	O
ducts	O
.	O

TITLE	O
:	O
Membrane	O
-	O
associated	O
zinc	O
peptidase	O
families	O
:	O
comparing	O
ACE	B-ENZY
and	O
ACE2	O
.	O

Here	O
ACE2	O
is	O
poised	O
to	O
metabolise	O
circulating	O
peptides	O
which	O
may	O
include	O
angiotensin	O
II	O
,	O
a	O
potent	O
vasoconstrictor	O
and	O
the	O
product	O
of	O
angiotensin	O
I	O
cleavage	O
by	O
ACE	B-ENZY
.	O

The	O
recent	O
solution	O
of	O
the	O
structure	O
of	O
ACE2	O
,	O
and	O
ACE	B-ENZY
,	O
has	O
provided	O
new	O
insight	O
into	O
the	O
substrate	O
and	O
inhibitor	O
profiles	O
of	O
these	O
two	O
key	O
regulators	O
of	O
the	O
RAS	O
.	O

ABSTRACT	O
:	O
The	O
principal	O
goals	O
of	O
respiratory	O
therapy	O
for	O
acute	O
respiratory	O
failure	O
are	O
to	O
correct	O
gas	B-ENZY
exchange	O
and	O
to	O
lower	O
respiratory	O
performance	O
.	O

TITLE	O
:	O
Inhibitors	O
of	O
cathepsin	B-ENZY
L	I-ENZY
prevent	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
entry	O
.	O

The	O
requirement	O
for	O
cathepsin	B-ENZY
L	I-ENZY
proteolysis	O
identifies	O
a	O
previously	O
uncharacterized	O
class	O
of	O
inhibitor	O
for	O
SARS	O
-	O
CoV	O
infection	O
.	O

This	O
review	O
therefore	O
summarizes	O
the	O
current	O
pathophysiological	O
concepts	O
underlying	O
the	O
evolution	O
of	O
acute	O
hypoxemic	O
respiratory	O
failure	O
and	O
focuses	O
on	O
:	O
(	O
1	O
)	O
possible	O
reasons	O
for	O
the	O
development	O
of	O
ALI	O
/	O
ARDS	O
;	O
(	O
2	O
)	O
cellular	O
and	O
humoral	O
mediator	O
responses	O
leading	O
to	O
a	O
sustained	O
and	O
self	O
-	O
perpetuating	O
inflammation	O
of	O
the	O
lung	O
;	O
(	O
3	O
)	O
consequences	O
with	O
regard	O
to	O
fluid	O
balance	O
,	O
pulmonary	O
perfusion	O
,	O
ventilation	O
,	O
and	O
efficiency	O
of	O
gas	B-ENZY
exchange	O
;	O
and	O
(	O
4	O
)	O
mechanisms	O
underlying	O
the	O
aggravating	O
complications	O
commonly	O
seen	O
in	O
ARDS	O
,	O
especially	O
ventilator	O
-	O
associated	O
lung	O
injury	O
,	O
ventilator	O
-	O
associated	O
pneumonia	O
,	O
and	O
lung	O
fibrosis	O
.	O

TITLE	O
:	O
Protective	O
effects	O
of	O
a	O
selective	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
(	O
sivelestat	O
)	O
on	O
lipopolysaccharide	O
-	O
induced	O
acute	O
dysfunction	O
of	O
the	O
pulmonary	O
microcirculation	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
a	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
,	O
sivelestat	O
,	O
on	O
lipopolysaccharide	O
-	O
induced	O
acute	O
lung	O
injury	O
through	O
analysis	O
of	O
hemodynamic	O
changes	O
in	O
the	O
pulmonary	O
microcirculation	O
.	O

Twenty	O
-	O
seven	O
Wistar	O
rats	O
(	O
15	O
rats	O
for	O
microspectroscopic	O
observations	O
,	O
12	O
rats	O
for	O
measurements	O
of	O
neutrophil	B-ENZY
elastase	I-ENZY
activity	O
and	O
wet	O
-	O
to	O
-	O
dry	O
ratio	O
).	O

Blood	O
-	O
free	O
wet	O
-	O
to	O
-	O
dry	O
ratio	O
and	O
neutrophil	B-ENZY
elastase	I-ENZY
activity	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
serum	O
,	O
and	O
supernatant	O
of	O
lung	O
homogenate	O
were	O
measured	O
in	O
another	O
set	O
of	O
experiments	O
(	O
n	O
=	O
4	O
for	O
each	O
group	O
).	O

Neutrophil	B-ENZY
elastase	I-ENZY
activities	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
serum	O
,	O
and	O
lung	O
tissue	O
were	O
all	O
significantly	O
lower	O
in	O
the	O
sivelestat	O
group	O
than	O
in	O
the	O
lipopolysaccharide	O
group	O
(	O
p	O
<	O
.	O
05	O
).	O

To	O
date	O
,	O
molecular	O
assays	O
for	O
the	O
detection	O
of	O
SARS	O
-	O
CoV	O
has	O
focused	O
mainly	O
on	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
of	O
specimens	O
.	O

New	O
techniques	O
to	O
noninvasively	O
image	O
thrombin	B-ENZY
activation	O
(	O
by	O
using	O
magnetic	O
resonance	O
imaging	O
)	O
in	O
reperfused	O
limbs	O
may	O
coincide	O
with	O
the	O
pattern	O
of	O
murine	O
skeletal	O
muscle	O
chemokine	O
expression	O
in	O
humans	O
.	O

Further	O
,	O
we	O
show	O
that	O
the	O
phosphorylated	O
protein	O
is	O
translocated	O
to	O
the	O
cytoplasm	O
by	O
binding	O
to	O
14	O
-	O
3	O
-	O
3	O
(	O
tyrosine	B-ENZY
3	I-ENZY
-	I-ENZY
monooxygenase	I-ENZY
/	O
tryptophan	B-ENZY
5	I-ENZY
-	I-ENZY
monooxygenase	I-ENZY
activation	O
protein	O
).	O

Personal	O
protective	O
equipment	O
,	O
including	O
gas	B-ENZY
mask	O
,	O
impermeable	O
protective	O
clothing	O
,	O
and	O
3	O
layers	O
of	O
gloves	O
worn	O
during	O
autopsies	O
;	O
the	O
equipment	O
was	O
decontaminated	O
before	O
it	O
was	O
allowed	O
to	O
exit	O
the	O
facility	O
.	O

We	O
found	O
that	O
proteases	O
such	O
as	O
trypsin	B-ENZY
and	O
thermolysin	B-ENZY
enabled	O
SARS	O
-	O
CoV	O
adsorbed	O
onto	O
the	O
cell	O
surface	O
to	O
enter	O
cells	O
directly	O
from	O
that	O
site	O
.	O

The	O
geometric	O
mean	O
titer	O
(	O
GMT	B-ENZY
)	O
of	O
the	O
87	O
convalescent	O
sera	O
was	O
1	O
:	O
61	O
.	O

Compared	O
to	O
the	O
healthy	O
control	O
or	O
the	O
convalescent	O
case	O
,	O
plenty	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
IL	O
-	O
1	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
8	O
,	O
and	O
MAPK	B-ENZY
signaling	O
pathway	O
were	O
significantly	O
upregulated	O
in	O
the	O
acute	O
severe	O
case	O
.	O

A	O
total	O
of	O
295	O
patients	O
with	O
unexplained	O
respiratory	O
illnesses	O
,	O
admitted	O
to	O
Queen	O
Mary	O
Hospital	O
,	O
Hong	O
Kong	O
SAR	O
,	O
China	O
,	O
in	O
March	O
to	O
July	O
2003	O
,	O
were	O
evaluated	O
for	O
clinical	O
,	O
radiological	O
,	O
haematological	O
and	O
alanine	B-ENZY
transaminase	I-ENZY
(	O
ALT	O
)	O
data	O
daily	O
for	O
3	O
days	O
after	O
hospitalisation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
possible	O
regulatory	O
interaction	O
between	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
and	O
NF	O
-	O
kappaB	O
by	O
luciferase	B-ENZY
activity	O
assay	O
.	O

To	O
investigate	O
whether	O
a	O
neutralizing	O
antibody	O
against	O
SARS	O
-	O
CoV	O
raised	O
in	O
an	O
artiodactylous	O
host	O
can	O
have	O
a	O
protective	O
role	O
on	O
primate	O
cells	O
,	O
we	O
prepared	O
serum	O
IgGs	O
and	O
their	O
pepsin	B-ENZY
-	O
digested	O
F	O
(	O
ab	O
')	O
2	O
fragments	O
from	O
horses	O
inoculated	O
with	O
purified	O
SARS	O
-	O
CoV	O
(	O
BJ	O
-	O
01	O
strain	O
).	O

The	O
results	O
indicated	O
that	O
apart	O
from	O
the	O
two	O
subunits	O
of	O
cellular	O
RNA	O
polymerase	O
complex	O
,	O
BTF3	O
and	O
ATF5	O
,	O
this	O
nsp10	O
protein	O
was	O
also	O
able	O
to	O
interact	O
specifically	O
with	O
the	O
NADH	O
4L	O
subunit	O
and	O
cytochrome	B-ENZY
oxidase	I-ENZY
II	O
.	O

Phylogenetic	O
analysis	O
showed	O
that	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
formed	O
a	O
distinct	O
cluster	O
with	O
SARS	O
-	O
CoV	O
as	O
group	O
2b	O
CoV	O
,	O
distantly	O
related	O
to	O
known	O
group	O
2	O
CoV	O
.	O
Most	O
differences	O
between	O
the	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
and	O
SARS	O
-	O
CoV	O
genomes	O
were	O
observed	O
in	O
the	O
spike	O
genes	O
,	O
ORF	O
3	O
and	O
ORF	O
8	O
,	O
which	O
are	O
the	O
regions	O
where	O
most	O
variations	O
also	O
were	O
observed	O
between	O
human	O
and	O
civet	O
SARS	O
-	O
CoV	O
genomes	O
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
a	O
29	O
-	O
bp	O
insertion	O
in	O
ORF	O
8	O
of	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
genome	O
,	O
not	O
in	O
most	O
human	O
SARS	O
-	O
CoV	O
genomes	O
,	O
suggests	O
that	O
it	O
has	O
a	O
common	O
ancestor	O
with	O
civet	O
SARS	O
-	O
CoV	O
.	O
Antibody	O
against	O
recombinant	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
was	O
detected	O
in	O
84	O
%	O
of	O
Chinese	O
horseshoe	O
bats	O
by	O
using	O
an	O
enzyme	O
immunoassay	O
.	O

The	O
digestion	O
of	O
modified	O
oligodeoxynucleotides	O
by	O
snake	O
venom	B-ENZY
phosphodiesterase	I-ENZY
showed	O
that	O
an	O
isonucleotide	O
strongly	O
antagonizes	O
hydrolysis	O
.	O

Soluble	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
(	O
sVCAM	O
-	O
1	O
)	O
and	O
soluble	O
Fas	O
ligand	O
(	O
sFasL	O
)	O
in	O
plasma	O
were	O
measured	O
by	O
ELISA	O
,	O
and	O
intracellular	O
activated	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
fragment	O
in	O
different	O
leukocytes	O
was	O
determined	O
by	O
flow	O
cytometry	O
.	O

Intracellular	O
cleaved	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
expression	O
was	O
also	O
significantly	O
higher	O
in	O
lymphocytes	O
from	O
SARS	O
patients	O
in	O
acute	O
phase	O
than	O
in	O
convalescent	O
stage	O
.	O

Inhibition	O
of	O
cell	O
adhesion	O
and	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
activation	O
could	O
,	O
therefore	O
,	O
have	O
prevented	O
SARS	O
patients	O
from	O
developing	O
thrombocytopenia	O
and	O
lymphopenia	O
.	O

ABSTRACT	O
:	O
Replication	O
of	O
the	O
approximately	O
30	O
-	O
kb	O
plus	O
-	O
strand	O
RNA	O
genome	O
of	O
coronaviruses	O
and	O
synthesis	O
of	O
an	O
extensive	O
set	O
of	O
subgenome	O
-	O
length	O
RNAs	O
are	O
mediated	O
by	O
the	O
replicase	O
-	O
transcriptase	O
,	O
a	O
membrane	O
-	O
bound	O
protein	O
complex	O
containing	O
several	O
cellular	O
proteins	O
and	O
up	O
to	O
16	O
viral	O
nonstructural	O
proteins	O
(	O
nsps	O
)	O
with	O
multiple	O
enzymatic	O
activities	O
,	O
including	O
protease	O
,	O
polymerase	O
,	O
helicase	O
,	O
methyltransferase	O
,	O
and	O
RNase	B-ENZY
activities	O
.	O

The	O
loss	O
of	O
expression	O
of	O
the	O
firefly	B-ENZY
luciferase	I-ENZY
was	O
found	O
to	O
result	O
from	O
various	O
,	O
often	O
large	O
deletions	O
of	O
the	O
gene	O
,	O
probably	O
due	O
to	O
RNA	O
recombination	O
.	O

The	O
extent	O
of	O
this	O
process	O
appeared	O
to	O
depend	O
strongly	O
on	O
the	O
coronaviral	O
genomic	O
background	O
,	O
the	O
luciferase	B-ENZY
gene	O
being	O
much	O
more	O
stable	O
in	O
the	O
feline	O
than	O
in	O
the	O
mouse	O
coronavirus	O
genome	O
.	O

Oxidative	O
stress	O
was	O
assessed	O
by	O
measuring	O
the	O
levels	O
of	O
erythrocyte	O
reduced	O
glutathione	O
(	O
GSH	O
),	O
tissue	O
malondialdehyde	O
(	O
MDA	O
),	O
myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
and	O
Na	O
(+)-	O
K	O
(+)	O
ATPase	B-ENZY
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
membrane	O
protein	O
and	O
5	B-ENZY
-	I-ENZY
lipoxygenase	I-ENZY
-	O
activating	O
protein	O
(	O
FLAP	O
)	O
are	O
among	O
a	O
large	O
number	O
of	O
membrane	O
proteins	O
that	O
are	O
poorly	O
expressed	O
when	O
traditional	O
expression	O
systems	O
and	O
methods	O
are	O
employed	O
.	O

In	O
addition	O
to	O
these	O
advantages	O
,	O
we	O
found	O
that	O
SUMO	B-ENZY
Protease	I-ENZY
1	O
,	O
can	O
cleave	O
the	O
SUMO	O
fusion	O
high	O
specificity	O
to	O
generate	O
native	O
protein	O
.	O

The	O
main	O
clinical	O
features	O
of	O
ARDS	O
include	O
rapid	O
onset	O
of	O
dyspnea	O
,	O
severe	O
defects	O
in	O
gas	B-ENZY
exchange	O
,	O
and	O
imaging	O
studies	O
demonstrating	O
diffuse	O
pulmonary	O
infiltrates	O
.	O

ABSTRACT	O
:	O
Both	O
prone	O
position	O
and	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
have	O
the	O
potential	O
to	O
facilitate	O
lung	O
recruitment	O
,	O
and	O
their	O
combined	O
use	O
could	O
thus	O
be	O
synergetic	O
on	O
gas	B-ENZY
exchange	O
.	O

Spike	O
protein	O
,	O
especially	O
the	O
ACE	B-ENZY
-	O
2	O
binding	O
region	O
(	O
318	O
-	O
510aa	O
)	O
is	O
capable	O
of	O
producing	O
neutralizing	O
antibody	O
to	O
SARS	O
-	O
Cov	O
.	O

To	O
examine	O
the	O
efficiency	O
of	O
low	O
-	O
dose	O
PLV	O
with	O
with	O
HFO	O
on	O
pulmonary	O
gas	B-ENZY
exchange	O
and	O
lung	O
compliance	O
in	O
a	O
surfactant	O
-	O
depleted	O
rabbit	O
model	O
.	O

Physiological	O
and	O
blood	O
gas	B-ENZY
data	O
were	O
compared	O
between	O
the	O
two	O
groups	O
by	O
analysis	O
of	O
variance	O
.	O

RESULTS	O
:	O
The	O
HFO	O
-	O
PLV	O
group	O
showed	O
improved	O
total	O
lung	O
compliance	O
with	O
maintenance	O
of	O
significantly	O
lower	O
mean	O
airway	O
pressure	O
as	O
compared	O
with	O
the	O
HFO	O
-	O
GAS	B-ENZY
group	O
so	O
as	O
to	O
keep	O
SpO2	O
>	O
90	O
%.	O

TITLE	O
:	O
Binding	O
interaction	O
of	O
SARS	O
coronavirus	O
3CL	O
(	O
pro	O
)	O
protease	O
with	O
vacuolar	O
-	O
H	O
+	O
ATPase	B-ENZY
G1	O
subunit	O
.	O

In	O
addition	O
,	O
our	O
result	O
also	O
demonstrated	O
the	O
cleavage	O
of	O
the	O
V	O
-	O
ATPase	B-ENZY
G1	O
fusion	O
protein	O
and	O
the	O
immunoprecipitation	O
of	O
cellular	O
V	O
-	O
ATPase	B-ENZY
G1	O
by	O
the	O
3CL	O
(	O
pro	O
).	O

Increased	O
activation	O
of	O
the	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
protein	O
38	O
,	O
Akt	O
,	O
and	O
nuclear	O
factor	O
(	O
NF	O
)-	O
kappa	O
B	O
in	O
neutrophils	O
and	O
other	O
cell	O
populations	O
obtained	O
at	O
early	O
time	O
points	O
in	O
the	O
clinical	O
course	O
of	O
sepsis	O
-	O
induced	O
acute	O
lung	O
injury	O
or	O
after	O
accidental	O
trauma	O
is	O
associated	O
with	O
a	O
more	O
-	O
severe	O
clinical	O
course	O
,	O
suggesting	O
that	O
a	O
proinflammatory	O
cellular	O
phenotype	O
contributes	O
to	O
organ	O
system	O
dysfunction	O
in	O
such	O
settings	O
.	O

We	O
examined	O
the	O
effects	O
of	O
prone	O
position	O
on	O
inflation	O
PV	O
curves	O
and	O
their	O
potential	O
relationships	O
with	O
postural	O
alterations	O
in	O
gas	B-ENZY
exchange	O
.	O

In	O
each	O
posture	O
hemodynamics	O
,	O
gas	B-ENZY
exchange	O
,	O
and	O
lung	O
volumes	O
were	O
determined	O
before	O
/	O
during	O
removal	O
and	O
after	O
restoration	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
=	O
10	O
.	O
2	O
+/-	O
0	O
.	O
6	O
cmH2O	O
).	O

TITLE	O
:	O
Design	O
and	O
synthesis	O
of	O
peptidomimetic	O
severe	O
acute	O
respiratory	O
syndrome	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
inhibitors	O
.	O

Interestingly	O
,	O
this	O
property	O
mapped	O
to	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
protein	O
,	O
implying	O
that	O
the	O
difference	O
in	O
infection	O
efficiency	O
between	O
the	O
two	O
viruses	O
is	O
not	O
determined	O
at	O
the	O
level	O
of	O
receptor	O
usage	O
,	O
which	O
we	O
confirmed	O
by	O
showing	O
that	O
infection	O
by	O
both	O
viruses	O
was	O
equally	O
blocked	O
by	O
antibodies	O
directed	O
against	O
the	O
feline	O
aminopeptidase	B-ENZY
N	I-ENZY
receptor	O
.	O

One	O
such	O
virus	O
that	O
we	O
studied	O
had	O
acquired	O
two	O
putative	O
heparan	O
sulfate	O
-	O
binding	O
sites	O
while	O
preserving	O
another	O
site	O
in	O
the	O
furin	B-ENZY
-	O
cleavage	O
motif	O
.	O

The	O
adaptation	O
of	O
the	O
virus	O
through	O
the	O
use	O
of	O
heparan	O
sulfate	O
as	O
an	O
attachment	O
/	O
entry	O
receptor	O
was	O
demonstrated	O
by	O
increased	O
heparin	O
binding	O
as	O
well	O
as	O
by	O
inhibition	O
of	O
infection	O
through	O
treatment	O
of	O
cells	O
and	O
the	O
virus	O
with	O
heparinase	B-ENZY
and	O
heparin	O
,	O
respectively	O
.	O

The	O
first	O
qualitative	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
tests	O
for	O
SARS	O
-	O
coronavirus	O
(	O
CoV	O
)	O
were	O
sensitive	O
and	O
capable	O
of	O
detecting	O
1	O
to	O
10	O
genome	O
equivalents	O
.	O

Commercially	O
available	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
tests	O
for	O
SARS	O
have	O
recently	O
appeared	O
;	O
however	O
,	O
meaningful	O
evaluations	O
of	O
these	O
assays	O
have	O
not	O
yet	O
been	O
performed	O
and	O
their	O
true	O
performance	O
has	O
not	O
been	O
determined	O
.	O

The	O
ACE	B-ENZY
-	O
2	O
encoding	O
gene	O
was	O
then	O
cloned	O
into	O
pcDNA4	O
/	O
HisMax	O
-	O
TOPO	O
eukaryotic	O
expression	O
vector	O
to	O
construct	O
the	O
recombinant	O
plasmid	O
pcDNA4	O
/	O
ACE	B-ENZY
-	O
2	O
,	O
which	O
was	O
then	O
transfected	O
into	O
293	O
T	O
cell	O
and	O
ACE	B-ENZY
-	O
2	O
eukaryotic	O
transient	O
expression	O
was	O
detected	O
by	O
Western	O
Blot	O
.	O

The	O
recombinant	O
plasmid	O
pcDNA4	O
/	O
ACE	B-ENZY
-	O
2	O
could	O
express	O
ACE	B-ENZY
-	O
2	O
protein	O
in	O
eukaryotic	O
cells	O
and	O
induce	O
cell	O
-	O
cell	O
fusion	O
between	O
S	O
protein	O
-	O
and	O
ACE2	O
-	O
expressing	O
cells	O
.	O

SARS	O
-	O
CoV	O
receptor	O
ACE	B-ENZY
-	O
2	O
gene	O
was	O
successfully	O
cloned	O
and	O
eukaryotic	O
expressed	O
,	O
and	O
used	O
to	O
establish	O
syncytia	O
inhibition	O
assay	O
for	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	O
assay	O
.	O

RESULTS	O
:	O
The	O
recombinant	O
plasmid	O
pcDNA4	O
/	O
ACE	B-ENZY
-	O
2	O
could	O
express	O
ACE	B-ENZY
-	O
2	O
protein	O
in	O
eukaryotic	O
cells	O
and	O
induce	O
cell	O
-	O
cell	O
fusion	O
between	O
S	O
protein	O
-	O
and	O
ACE2	O
-	O
expressing	O
cells	O
.	O

CONCLUSIONS	O
:	O
SARS	O
-	O
CoV	O
receptor	O
ACE	B-ENZY
-	O
2	O
gene	O
was	O
successfully	O
cloned	O
and	O
eukaryotic	O
expressed	O
,	O
and	O
used	O
to	O
establish	O
syncytia	O
inhibition	O
assay	O
for	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	O
assay	O
.	O

The	O
time	O
of	O
disappearance	O
of	O
symptoms	O
,	O
the	O
recovery	O
time	O
of	O
acetyl	O
cholinesterase	B-ENZY
(	O
AChE	O
),	O
atropinization	O
time	O
,	O
atropine	O
dosage	O
,	O
pralidoxime	O
chloride	O
dosage	O
,	O
naloxone	O
dosage	O
,	O
hospitalization	O
days	O
and	O
other	O
targets	O
were	O
also	O
observed	O
.	O

Respiratory	O
symptom	O
,	O
spirometry	O
,	O
and	O
gas	B-ENZY
transfer	O
analyses	O
were	O
performed	O
longitudinally	O
in	O
adults	O
in	O
Papua	O
,	O
Indonesia	O
,	O
with	O
uncomplicated	O
(	O
n	O
=	O
50	O
)	O
and	O
severe	O
(	O
n	O
=	O
30	O
)	O
falciparum	O
malaria	O
;	O
normal	O
values	O
were	O
derived	O
from	O
109	O
control	O
subjects	O
.	O

Gas	B-ENZY
transfer	O
was	O
partitioned	O
into	O
its	O
alveolar	O
-	O
capillary	O
membrane	O
(	O
D	O
(	O
M	O
))	O
and	O
pulmonary	O
vascular	O
(	O
Vc	O
)	O
components	O
,	O
to	O
characterize	O
the	O
site	O
of	O
impaired	O
gas	B-ENZY
transfer	O
.	O

Gas	B-ENZY
transfer	O
was	O
significantly	O
impaired	O
in	O
patients	O
with	O
severe	O
malaria	O
.	O

TITLE	O
:	O
Development	O
of	O
one	O
-	O
step	O
,	O
real	O
-	O
time	O
,	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
assays	O
for	O
absolute	O
quantitation	O
of	O
human	O
coronaviruses	O
OC43	O
and	O
229E	O
.	O

TITLE	O
:	O
Elevated	O
plasma	O
tissue	B-ENZY
-	I-ENZY
type	I-ENZY
plasminogen	I-ENZY
activator	I-ENZY
(	O
t	O
-	O
PA	O
)	O
and	O
soluble	O
thrombomodulin	O
in	O
patients	O
suffering	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
as	O
a	O
possible	O
index	O
for	O
prognosis	O
and	O
treatment	O
strategy	O
.	O

ABSTRACT	O
:	O
To	O
detect	O
the	O
presence	O
of	O
endothelial	O
injury	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
via	O
enhanced	O
levels	O
of	O
tissue	B-ENZY
-	I-ENZY
type	I-ENZY
plasminogen	I-ENZY
activator	I-ENZY
(	O
t	O
-	O
PA	O
)	O
and	O
soluble	O
thrombomodulin	O
(	O
sTM	O
).	O

The	O
likelihood	O
ratio	O
analysis	O
indicated	O
the	O
excellent	O
discriminating	O
power	O
for	O
SARS	O
at	O
the	O
optimal	O
cut	O
-	O
point	O
of	O
0	O
.	O
49	O
nmol	O
/	O
L	O
for	O
tPA	B-ENZY
and	O
0	O
.	O
20	O
nmol	O
/	O
L	O
for	O
sTM	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Classic	O
plasma	O
markers	O
of	O
endothelial	O
injury	O
,	O
tPA	B-ENZY
and	O
sTM	O
significantly	O
elevated	O
in	O
SARS	O
patients	O
in	O
comparison	O
to	O
controls	O
[	O
t	O
-	O
PA	O
:	O
1	O
.	O
48	O
+/-	O

CONCLUSIONS	O
:	O
Increased	O
plasma	O
concentrations	O
of	O
tPA	B-ENZY
and	O
sTM	O
in	O
patients	O
with	O
SARS	O
suggest	O
the	O
possibility	O
of	O
endothelial	O
injury	O
.	O

TITLE	O
:	O
Specific	O
targeting	O
highly	O
conserved	O
residues	O
in	O
the	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
primer	O
grip	O
region	O
.	O

Disk	O
susceptibility	O
data	O
of	O
Escherichia	O
coli	O
,	O
Klebsiella	O
pneumoniae	O
,	O
Enterobacter	O
cloacae	O
,	O
Serratia	O
marcescens	O
,	O
Proteus	O
spp	B-ENZY
.,	O
Pseudomonas	O
aeruginosa	O
,	O
Acinetobacter	O
spp	B-ENZY
.,	O
Stenotrophomonas	O
maltophilia	O
and	O
other	O
non	O
-	O
fermentative	O
Gram	O
-	O
negative	O
bacilli	O
causing	O
nosocomial	O
infections	O
were	O
evaluated	O
.	O

Data	O
on	O
annual	O
patient	O
-	O
days	O
and	O
annual	O
consumption	O
(	O
defined	O
daily	O
dose	O
(	O
DDD	O
)	O
per	O
1000	O
patient	O
-	O
days	O
)	O
of	O
extended	O
-	O
spectrum	O
cephalosporins	O
(	O
cefotaxime	O
,	O
ceftriaxone	O
,	O
ceftazidime	O
,	O
flumoxef	O
,	O
cefepime	O
and	O
cefpirome	O
),	O
beta	O
-	O
lactam	O
-	O
beta	B-ENZY
-	I-ENZY
lactamase	I-ENZY
inhibitor	O
combinations	O
(	O
ticarcillin	O
/	O
clavulanic	O
acid	O
and	O
piperacillin	O
/	O
tazobactam	O
),	O
carbapenems	O
(	O
imipenem	O
and	O
meropenem	O
),	O
aminoglycosides	O
(	O
amikacin	O
,	O
gentamicin	O
and	O
tobramycin	O
),	O
fluoroquinolones	O
(	O
ciprofloxacin	O
(	O
oral	O
and	O
injectable	O
)	O
and	O
oral	O
levofloxacin	O
and	O
moxifloxacin	O
)	O
from	O
1991	O
to	O
2003	O
were	O
analysed	O
.	O

Increased	O
ciprofloxacin	O
-	O
resistant	O
K	O
.	O
pneumoniae	O
and	O
meropenem	O
-	O
resistant	O
Acinetobacter	O
spp	B-ENZY
.	O

PEDV	O
shedding	O
was	O
monitored	O
every	O
day	O
and	O
virus	O
levels	O
were	O
measured	O
using	O
a	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
method	O
.	O

This	O
position	O
is	O
predicted	O
to	O
map	O
in	O
the	O
N	O
-	O
terminal	O
polyprotein	O
papain	B-ENZY
-	O
like	O
proteinase	O
(	O
PLP	O
-	O
1	O
)	O
cleavage	O
site	O
at	O
the	O
p9	O
/	O
p87	O
junction	O
.	O

ABSTRACT	O
:	O
Group	O
2	O
coronaviruses	O
encode	O
an	O
accessory	O
envelope	O
glycoprotein	O
species	O
,	O
the	O
hemagglutinin	O
esterase	O
(	O
HE	O
),	O
which	O
possesses	O
sialate	O
-	O
O	O
-	O
acetylesterase	B-ENZY
activity	O
and	O
which	O
,	O
presumably	O
,	O
promotes	O
virus	O
spread	O
and	O
entry	O
in	O
vivo	O
by	O
facilitating	O
reversible	O
virion	O
attachment	O
to	O
O	O
-	O
acetylated	O
sialic	O
acids	O
.	O

One	O
produced	O
an	O
anchorless	O
HE	O
,	O
while	O
the	O
other	O
had	O
a	O
Gly	O
-	O
to	O
-	O
Trp	B-ENZY
substitution	O
at	O
the	O
predicted	O
C	O
-	O
terminal	O
residue	O
of	O
the	O
HE	O
signal	O
peptide	O
.	O

TITLE	O
:	O
The	O
papain	B-ENZY
-	O
like	O
protease	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
has	O
deubiquitinating	O
activity	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
SARS	O
-	O
CoV	O
PLpro	O
)	O
is	O
involved	O
in	O
the	O
processing	O
of	O
the	O
viral	O
polyprotein	O
and	O
,	O
thereby	O
,	O
contributes	O
to	O
the	O
biogenesis	O
of	O
the	O
virus	O
replication	O
complex	O
.	O

This	O
unexpected	O
activity	O
for	O
a	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
suggests	O
a	O
novel	O
viral	O
strategy	O
to	O
modulate	O
the	O
host	O
cell	O
ubiquitination	O
machinery	O
to	O
its	O
advantage	O
.	O

TITLE	O
:	O
Absence	O
of	O
heme	B-ENZY
oxygenase	I-ENZY
-	O
1	O
expression	O
in	O
the	O
lung	O
parenchyma	O
exacerbates	O
endotoxin	O
-	O
induced	O
acute	O
lung	O
injury	O
and	O
decreases	O
surfactant	O
protein	O
-	O
B	O
levels	O
.	O

In	O
this	O
study	O
we	O
assessed	O
the	O
role	O
of	O
the	O
cytoprotective	O
and	O
anti	O
-	O
inflammatory	O
enzyme	O
heme	B-ENZY
oxygenase	I-ENZY
(	O
HO	O
)-	O
1	O
in	O
a	O
model	O
of	O
nebulized	O
endotoxin	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

Significant	O
features	O
of	O
this	O
study	O
that	O
unique	O
to	O
the	O
contemporary	O
literature	O
are	O
i	O
)	O
the	O
over	O
-	O
representation	O
of	O
certain	O
breeds	O
(	O
Burmese	O
,	O
Australian	O
Mist	O
,	O
British	O
Shorthaired	O
,	O
and	O
Cornish	O
Rex	B-ENZY
)	O
and	O
the	O
under	O
-	O
representation	O
of	O
other	O
breeds	O
(	O
Domestic	O
Shorthaired	O
,	O
Persian	O
);	O
ii	O
)	O
the	O
overrepresentation	O
of	O
males	O
;	O
iii	O
)	O
the	O
tendency	O
for	O
effusive	O
disease	O
in	O
Australian	O
Mist	O
cats	O
and	O
non	O
-	O
effusive	O
disease	O
in	O
Burmese	O
;	O
iv	O
)	O
the	O
even	O
age	O
distribution	O
of	O
disease	O
seen	O
in	O
cats	O
older	O
than	O
2	O
years	O
-	O
of	O
-	O
age	O
;	O
and	O
v	O
)	O
the	O
presence	O
of	O
fulminant	O
immune	O
-	O
mediated	O
haemolytic	O
anaemia	O
in	O
two	O
cats	O
in	O
this	O
study	O
.	O

Significant	O
features	O
of	O
this	O
study	O
that	O
unique	O
to	O
the	O
contemporary	O
literature	O
are	O
i	O
)	O
the	O
over	O
-	O
representation	O
of	O
certain	O
breeds	O
(	O
Burmese	O
,	O
Australian	O
Mist	O
,	O
British	O
Shorthaired	O
,	O
and	O
Cornish	O
Rex	B-ENZY
)	O
and	O
the	O
under	O
-	O
representation	O
of	O
other	O
breeds	O
(	O
Domestic	O
Shorthaired	O
,	O
Persian	O
);	O
ii	O
)	O
the	O
overrepresentation	O
of	O
males	O
;	O
iii	O
)	O
the	O
tendency	O
for	O
effusive	O
disease	O
in	O
Australian	O
Mist	O
cats	O
and	O
non	O
-	O
effusive	O
disease	O
in	O
Burmese	O
;	O
iv	O
)	O
the	O
even	O
age	O
distribution	O
of	O
disease	O
seen	O
in	O
cats	O
older	O
than	O
2	O
years	O
-	O
of	O
-	O
age	O
;	O
and	O
v	O
)	O
the	O
presence	O
of	O
fulminant	O
immune	O
-	O
mediated	O
haemolytic	O
anaemia	O
in	O
two	O
cats	O
in	O
this	O
study	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
a	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
to	O
detect	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
from	O
commercially	O
-	O
raised	O
poultry	O
in	O
New	O
Zealand	O
and	O
compare	O
results	O
with	O
those	O
from	O
virus	O
isolation	O
.	O

Chem	O
.	O
2000	O
,	O
43	O
,	O
401	O
;	O
Miller	O
,	O
M	O
.	O
A	O
.	O
Nat	B-ENZY
.	O

The	O
use	O
of	O
commercially	O
available	O
rapid	O
diagnostic	O
tests	O
for	O
influenza	O
associated	O
pneumonia	O
,	O
allows	O
the	O
potential	O
use	O
of	O
new	O
specific	O
anti	O
-	O
neuraminidase	B-ENZY
drugs	O
,	O
which	O
can	O
be	O
efficient	O
during	O
the	O
30	O
hours	O
after	O
the	O
beginning	O
of	O
the	O
clinical	O
influenza	O
syndrome	O
.	O

Inhibitors	O
of	O
cathepsin	B-ENZY
L	I-ENZY
blocked	O
infection	O
by	O
SARS	O
-	O
CoV	O
and	O
by	O
a	O
retrovirus	O
pseudotyped	O
with	O
the	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
but	O
not	O
infection	O
by	O
HCoV	O
-	O
NL63	O
or	O
a	O
retrovirus	O
pseudotyped	O
with	O
the	O
HCoV	O
-	O
NL63	O
S	O
protein	O
.	O

Expression	O
of	O
exogenous	O
cathepsin	B-ENZY
L	I-ENZY
substantially	O
enhanced	O
infection	O
mediated	O
by	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
and	O
by	O
filovirus	O
GP	O
proteins	O
but	O
not	O
by	O
the	O
HCoV	O
-	O
NL63	O
S	O
protein	O
or	O
the	O
vesicular	O
stomatitis	O
virus	O
G	O
protein	O
.	O

We	O
report	O
a	O
24	O
years	O
old	O
male	O
with	O
HPS	B-ENZY
that	O
was	O
successfully	O
managed	O
when	O
an	O
arterio	O
-	O
venous	O
shunt	O
was	O
added	O
to	O
a	O
conventional	O
veno	O
-	O
arterial	O
ECLS	O
technique	O
.	O

We	O
found	O
that	O
caspase	B-ENZY
-	I-ENZY
9	I-ENZY
activity	O
was	O
12	O
-	O
fold	O
higher	O
in	O
virus	O
-	O
infected	O
cells	O
than	O
in	O
mock	O
-	O
infected	O
cells	O
at	O
24	O
h	O
postinfection	O
(	O
p	O
.	O
i	O
.).	O

Pretreatment	O
of	O
cells	O
with	O
a	O
caspase	B-ENZY
-	I-ENZY
9	I-ENZY
inhibitor	O
completely	O
blocked	O
caspase	B-ENZY
-	I-ENZY
9	I-ENZY
activation	O
and	O
partially	O
inhibited	O
the	O
apoptosis	O
mediated	O
by	O
MHV	O
infection	O
.	O

To	O
identify	O
upstream	O
signals	O
,	O
we	O
determined	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
activity	O
,	O
cleavage	O
of	O
Bid	O
,	O
and	O
expression	O
of	O
Bax	O
and	O
Bad	O
by	O
Western	O
blotting	O
.	O

We	O
found	O
a	O
drastic	O
increase	O
in	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
activity	O
and	O
cleavage	O
of	O
Bid	O
at	O
24	O
h	O
p	O
.	O
i	O
.	O

in	O
virus	O
-	O
infected	O
cells	O
,	O
suggesting	O
that	O
Bid	O
may	O
serve	O
as	O
a	O
messenger	O
to	O
relay	O
the	O
signals	O
from	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
to	O
mitochondria	O
.	O

in	O
cells	O
infected	O
with	O
both	O
live	O
and	O
UV	O
-	O
inactivated	O
viruses	O
and	O
that	O
Bax	O
activation	O
was	O
partially	O
blocked	O
by	O
treatment	O
with	O
the	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
inhibitor	O
.	O

TITLE	O
:	O
Binding	O
site	O
-	O
based	O
classification	O
of	O
coronaviral	O
papain	B-ENZY
-	O
like	O
proteases	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
replicase	O
gene	O
encodes	O
one	O
or	O
two	O
papain	B-ENZY
-	O
like	O
proteases	O
(	O
termed	O
PL1pro	O
and	O
PL2pro	O
)	O
implicated	O
in	O
the	O
N	O
-	O
terminal	O
processing	O
of	O
the	O
replicase	O
polyprotein	O
and	O
thus	O
contributing	O
to	O
the	O
formation	O
of	O
the	O
viral	O
replicase	O
complex	O
that	O
mediates	O
genome	O
replication	O
.	O

Using	O
consensus	O
fold	O
recognition	O
with	O
the	O
3D	O
-	O
JURY	O
meta	O
-	O
predictor	O
followed	O
by	O
model	O
building	O
and	O
refinement	O
,	O
we	O
developed	O
a	O
structural	O
model	O
for	O
the	O
single	O
PLpro	O
present	O
in	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SCoV	O
)	O
genome	O
,	O
based	O
on	O
significant	O
structural	O
relationships	O
to	O
the	O
catalytic	O
core	O
domain	O
of	O
HAUSP	O
,	O
a	O
ubiquitin	O
-	O
specific	O
protease	O
(	O
USP	B-ENZY
).	O

One	O
group	O
includes	O
all	O
PL2pros	O
and	O
some	O
of	O
the	O
PL1pros	O
,	O
which	O
are	O
characterized	O
by	O
a	O
restricted	O
USP	B-ENZY
-	O
like	O
binding	O
site	O
.	O

The	O
remaining	O
PL1pros	O
from	O
some	O
of	O
the	O
coronaviruses	O
form	O
the	O
other	O
group	O
,	O
featuring	O
a	O
more	O
open	O
papain	B-ENZY
-	O
like	O
binding	O
site	O
,	O
and	O
is	O
referred	O
to	O
as	O
the	O
O	O
-	O
group	O
.	O

TITLE	O
:	O
7a	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
inhibits	O
cellular	O
protein	O
synthesis	O
and	O
activates	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
.	O

7a	O
protein	O
inhibited	O
expression	O
of	O
luciferase	B-ENZY
from	O
an	O
mRNA	O
construct	O
that	O
specifically	O
measures	O
translation	O
,	O
whereas	O
inhibitors	O
of	O
transcription	O
and	O
nucleocytoplasmic	O
transport	O
did	O
not	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
induction	O
of	O
apoptosis	O
by	O
the	O
7a	O
protein	O
may	O
be	O
related	O
to	O
its	O
ability	O
to	O
inhibit	O
cellular	O
translation	O
and	O
activate	O
p38	O
MAPK	B-ENZY
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
an	O
Escherichia	O
coli	O
-	O
expressed	O
,	O
denatured	O
spike	O
(	O
S	O
)	O
protein	O
fragment	O
of	O
the	O
severe	O
acute	O
respiratory	O
coronavirus	O
,	O
containing	O
residues	O
1029	O
to	O
1192	O
which	O
include	O
the	O
heptad	O
repeat	O
2	O
(	O
HR2	O
)	O
domain	O
,	O
was	O
able	O
to	O
induce	O
neutralizing	O
polyclonal	O
antibodies	O
(	O
C	O
.	O
T	O
.	O
Keng	O
,	O
A	O
.	O
Zhang	O
,	O
S	O
.	O
Shen	O
,	O
K	O
.	O
M	O
.	O
Lip	B-ENZY
,	O
B	O
.	O
C	O
.	O
Fielding	O
,	O
T	O
.	O
H	O
.	O
Tan	O
,	O
C	O
.	O
F	O
.	O
Chou	O
,	O
C	O
.	O
B	O
.	O
Loh	O
,	O
S	O
.	O
Wang	O
,	O
J	O
.	O
Fu	O
,	O
X	O
.	O
Yang	O
,	O
S	O
.	O
G	O
.	O
Lim	O
,	O
W	O
.	O
Hong	O
,	O
and	O
Y	O
.	O
J	O
.	O
Tan	O
,	O
J	O
.	O
Virol	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
CNS	O
gene	O
transfer	O
of	O
AAV2	O
(	O
CU	O
)	O
hCLN2	O
(	O
an	O
AAV2	O
-	O
based	O
vector	O
expressing	O
the	O
human	O
CLN2	O
cDNA	O
)	O
in	O
rats	O
and	O
nonhuman	O
primates	O
mediates	O
long	O
-	O
term	O
TPP	B-ENZY
-	O
I	O
expression	O
in	O
the	O
CNS	O
neurons	O
[	O
Sondhi	O
,	O
D	O
.,	O
Peterson	O
,	O
D	O
.	O
A	O
.,	O
Giannaris	O
,	O
E	O
.	O
L	O
.,	O
Sanders	O
,	O
C	O
.	O
T	O
.,	O
Mendez	O
,	O
B	O
.	O
S	O
.,	O
De	O
,	O
B	O
.,	O
Rostkowski	O
,	O
A	O
.,	O
Blancard	O
,	O
B	O
.,	O
Bjugstad	O
,	O
K	O
.,	O
Sladek	O
,	O
J	O
.	O
R	O
.,	O
Redmond	O
,	O
D	O
.	O
E	O
.,	O
Leopold	O
,	O
P	O
.	O
L	O
.,	O
Kaminsky	O
,	O
S	O
.	O
M	O
.,	O
Hackett	O
,	O
N	O
.	O
R	O
.,	O
and	O
Crystal	O
,	O
R	O
.	O
G	O
.	O
(	O
2005	O
).	O

The	O
improvements	O
in	O
pulmonary	O
gas	B-ENZY
exchange	O
,	O
systemic	O
blood	O
flow	O
and	O
oxygen	O
supply	O
to	O
the	O
tissue	O
which	O
have	O
been	O
observed	O
when	O
spontaneous	O
breathing	O
has	O
been	O
maintained	O
during	O
mechanical	O
ventilation	O
are	O
reflected	O
in	O
the	O
clinical	O
improvement	O
in	O
the	O
patient	O
'	O
s	O
condition	O
.	O

Computer	O
tomography	O
observations	O
demonstrated	O
that	O
spontaneous	O
breathing	O
improves	O
gas	B-ENZY
exchange	O
by	O
redistribution	O
of	O
ventilation	O
and	O
end	O
-	O
expiratory	O
gas	B-ENZY
to	O
dependent	O
,	O
juxtadiaphragmatic	O
lung	O
regions	O
and	O
thereby	O
promotes	O
alveolar	O
recruitment	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
5	O
-	O
membered	O
iminocyclitol	O
derivative	O
was	O
found	O
to	O
be	O
a	O
potent	O
and	O
selective	O
inhibitor	O
of	O
the	O
glycoprotein	O
-	O
processing	O
alpha	B-ENZY
-	I-ENZY
glucosidase	I-ENZY
with	O
a	O
Ki	O
value	O
of	O
53	O
nM	O
.	O
This	O
compound	O
was	O
further	O
derivatized	O
to	O
antiviral	O
agents	O
against	O
Japanese	O
encephalitis	O
virus	O
,	O
dengue	O
virus	O
serotype	O
2	O
(	O
DEN	O
-	O
2	O
),	O
human	O
SARS	O
coronavirus	O
,	O
and	O
human	O
beta	B-ENZY
-	I-ENZY
hexosaminidase	I-ENZY
(	O
Ki	O
=	O
2	O
.	O
6	O
nM	O
),	O
a	O
new	O
target	O
for	O
the	O
development	O
of	O
osteoarthritis	O
therapeutics	O
.	O

This	O
method	O
uses	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
of	O
the	O
spike	O
gene	O
to	O
obtain	O
RFLP	O
patterns	O
that	O
correlate	O
with	O
serotype	O
.	O

ABSTRACT	O
:	O
Hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	B-ENZY
)	O
is	O
an	O
acute	O
disease	O
resulting	O
from	O
infection	O
with	O
any	O
one	O
of	O
a	O
number	O
of	O
New	O
World	O
hantaviruses	O
.	O

To	O
address	O
the	O
importance	O
of	O
these	O
fatty	O
acylations	O
to	O
coronavirus	O
infection	O
,	O
we	O
exposed	O
infected	O
cells	O
to	O
2	O
-	O
bromopalmitate	O
(	O
2	O
-	O
BP	O
),	O
a	O
specific	O
PAT	B-ENZY
inhibitor	O
.	O

The	O
N	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
bears	O
signature	O
motifs	O
for	O
binding	O
to	O
cyclin	O
and	O
phosphorylation	O
by	O
cyclin	B-ENZY
-	I-ENZY
dependent	I-ENZY
kinase	I-ENZY
(	O
CDK	B-ENZY
)	O
and	O
has	O
recently	O
been	O
reported	O
by	O
us	O
to	O
get	O
phosphorylated	O
by	O
the	O
cyclin	O
-	O
CDK	B-ENZY
complex	O
(	O
Surjit	O
,	O
M	O
.,	O
Kumar	O
,	O
R	O
.,	O
Mishra	O
,	O
R	O
.	O
N	O
.,	O
Reddy	O
,	O
M	O
.	O
K	O
.,	O
Chow	O
,	O
V	O
.	O
T	O
.,	O
and	O
Lal	O
,	O
S	O
.	O
K	O
.	O
(	O
2005	O
)	O
J	O
.	O
Virol	O
.	O
79	O
,	O
11476	O
-	O
11486	O
).	O

Procoagulant	O
activity	O
representing	O
functional	O
prothrombinase	B-ENZY
activity	O
in	O
PBMC	O
and	O
white	O
blood	O
cells	O
was	O
also	O
assayed	O
.	O

Alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
and	O
total	O
bilirubin	O
(	O
TBil	O
)	O
in	O
serum	O
were	O
measured	O
to	O
assess	O
the	O
severity	O
of	O
liver	O
injury	O
.	O

PCA	O
significantly	O
increased	O
in	O
PBMC	O
in	O
patients	O
with	O
severe	O
AOC	O
hepatitis	O
B	O
.	O
CONCLUSIONS	O
:	O
The	O
molecular	O
and	O
cellular	O
results	O
reported	O
here	O
in	O
both	O
mice	O
and	O
patients	O
with	O
severe	O
viral	O
hepatitis	O
suggest	O
that	O
virus	O
-	O
induced	O
hfgl2	O
prothrombinase	B-ENZY
/	O
fibroleukin	O
expression	O
and	O
the	O
coagulation	O
activity	O
associated	O
with	O
the	O
encoded	O
fgl2	O
protein	O
play	O
a	O
pivotal	O
role	O
in	O
initiating	O
severe	O
hepatitis	O
.	O

Common	O
laboratory	O
features	O
included	O
lymphopenia	O
and	O
elevated	O
aspartate	B-ENZY
aminotransferase	I-ENZY
,	O
alanine	B-ENZY
aminotransferase	I-ENZY
,	O
lactate	O
dehydrogenase	O
,	O
C	O
-	O
reactive	O
protein	O
and	O
creatine	B-ENZY
kinase	I-ENZY
values	O
.	O

ABSTRACT	O
:	O
The	O
time	O
course	O
of	O
impairment	O
of	O
respiratory	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
in	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
remains	O
poorly	O
defined	O
.	O

Severity	O
of	O
lung	O
injury	O
,	O
gas	B-ENZY
exchange	O
,	O
and	O
hemodynamics	O
were	O
assessed	O
.	O

Pressure	O
-	O
volume	O
(	O
PV	O
)	O
curves	O
of	O
the	O
respiratory	O
system	O
were	O
obtained	O
,	O
and	O
upper	O
and	O
lower	O
inflection	O
points	O
(	O
UIP	O
,	O
LIP	B-ENZY
)	O
and	O
recruitment	O
were	O
estimated	O
.	O

TITLE	O
:	O
Acute	O
and	O
sustained	O
effects	O
of	O
lucinactant	O
versus	O
poractant	O
-	O
alpha	O
on	O
pulmonary	O
gas	B-ENZY
exchange	O
and	O
mechanics	O
in	O
premature	O
lambs	O
with	O
respiratory	O
distress	O
syndrome	O
.	O

After	O
surfactant	O
instillation	O
,	O
similar	O
improvements	O
in	O
gas	B-ENZY
exchange	O
and	O
lung	O
mechanics	O
were	O
observed	O
for	O
the	O
lucinactant	O
and	O
poractant	O
-	O
alpha	O
groups	O
at	O
1	O
hour	O
(	O
pH	O
:	O
7	O
.	O
3	O
+/-	O
0	O
.	O
1	O
vs	O
7	O
.	O
4	O
+/-	O

Among	O
preterm	O
lambs	O
with	O
severe	O
RDS	O
,	O
lucinactant	O
produced	O
improvements	O
in	O
gas	B-ENZY
exchange	O
and	O
lung	O
mechanics	O
similar	O
to	O
those	O
observed	O
with	O
a	O
porcine	O
-	O
derived	O
surfactant	O
.	O

The	O
ATS	O
/	O
ERS	O
classification	O
of	O
2002	O
comprises	O
seven	O
entities	O
:	O
usual	O
interstitial	O
pneumonia	O
(	O
UIP	O
),	O
non	O
-	O
specific	O
interstitial	O
pneumonia	O
(	O
NSIP	O
),	O
desquamative	O
interstitial	O
pneumonia	O
(	O
DIP	O
),	O
respiratory	O
bronchiolitis	O
-	O
associated	O
interstitial	O
lung	O
disease	O
(	O
RB	O
-	O
ILD	O
),	O
cryptogenic	O
organizing	O
pneumonia	O
(	O
COP	O
),	O
lymphocyte	O
interstitial	O
pneumonia	O
(	O
LIP	B-ENZY
),	O
and	O
acute	O
interstitial	O
pneumonia	O
(	O
AIP	O
).	O

ABSTRACT	O
:	O
The	O
90	O
kDa	O
ribosomal	O
S6	O
kinases	O
(	O
p90RSKs	O
)	O
are	O
a	O
family	O
of	O
broadly	O
expressed	O
serine	O
/	O
threonine	O
kinases	O
with	O
two	O
kinase	O
domains	O
activated	O
by	O
extracellular	O
signal	O
-	O
regulated	O
protein	B-ENZY
kinase	I-ENZY
in	O
response	O
to	O
many	O
growth	O
factors	O
.	O

On	O
the	O
other	O
hand	O
,	O
Both	O
Thr573	O
and	O
Ser380	O
were	O
phosphorylated	O
by	O
treatment	O
with	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
in	O
the	O
absence	O
of	O
p38	O
MAPK	B-ENZY
activation	O
.	O

and	O
Haemophilus	O
parasuis	O
(	O
HPS	B-ENZY
)	O
throughout	O
Slovenia	O
during	O
the	O
hunting	O
season	O
2003	O
/	O
2004	O
.	O

By	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
antibodies	O
against	O
ADV	O
were	O
detected	O
in	O
55	O
sera	O
(	O
31	O
%),	O
against	O
PRCV	O
in	O
five	O
sera	O
(	O
3	O
%),	O
PPV	O
in	O
87	O
sera	O
(	O
49	O
%),	O
APP	O
in	O
93	O
sera	O
(	O
52	O
%),	O
M	O
.	O
hyopneumoniae	O
in	O
38	O
sera	O
(	O
21	O
%),	O
Salmonella	O
spp	B-ENZY
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
developed	O
a	O
test	O
for	O
the	O
diagnosis	O
and	O
prognostic	O
assessment	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
based	O
on	O
the	O
detection	O
of	O
the	O
SARS	O
-	O
coronavirus	O
RNA	O
in	O
serum	O
by	O
real	O
-	O
time	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Both	O
FIC	O
scales	O
correlated	O
stronger	O
with	O
physical	O
component	O
summary	O
(	O
PCS	O
)	O
(-	O
0	O
.	O
41	O
and	O
-	O
0	O
.	O
55	O
)	O
than	O
with	O
mental	O
component	O
summary	O
(	O
MCS	B-ENZY
)	O
(-	O
0	O
.	O
30	O
and	O
-	O
0	O
.	O
23	O
).	O

Then	O
the	O
recombinant	O
plasmids	O
were	O
transfected	O
into	O
HepG2	O
cells	O
and	O
the	O
luciferase	B-ENZY
activities	O
were	O
detected	O
.	O

The	O
luciferase	B-ENZY
activities	O
expressed	O
by	O
the	O
plasmids	O
were	O
measured	O
.	O

The	O
luciferase	B-ENZY
expressed	O
by	O
pGL3	O
-	O
5	O
'	O
UTR	O
in	O
various	O
cells	O
,	O
the	O
lung	O
carcinoma	O
cell	O
line	O
A549	O
,	O
hepatoma	O
cell	O
line	O
HepG2	O
,	O
kidney	O
cell	O
Vero	O
E6	O
,	O
cervical	O
cancer	O
cell	O
line	O
HeLa	O
and	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
line	O
ECV304	O
were	O
measured	O
and	O
compared	O
with	O
each	O
other	O
.	O

Comparing	O
with	O
pGL3	O
-	O
a	O
-	O
5	O
'	O
UTR	O
,	O
pGL3	O
-	O
5	O
'	O
UTR	O
expressed	O
luciferase	B-ENZY
obviously	O
.	O

Both	O
pGL3	O
-	O
5	O
'	O
UTR	O
containing	O
full	O
sequence	O
and	O
pGL3	O
-	O
5	O
'	O
UTR	O
-	O
1	O
containing	O
three	O
stem	O
-	O
loops	O
of	O
3	O
'	O
termini	O
expressed	O
the	O
luciferase	B-ENZY
well	O
.	O

However	O
,	O
when	O
lost	O
stem	O
-	O
loop	O
I	O
and	O
II	O
,	O
the	O
pGL3	O
-	O
5	O
'	O
UTR	O
-	O
2	O
,	O
pGL3	O
-	O
5	O
'	O
UTR	O
-	O
3	O
and	O
pGL3	O
-	O
5	O
'	O
UTR	O
-	O
4	O
almost	O
didn	O
'	O
t	O
express	O
luciferase	B-ENZY
.	O

Transfected	O
with	O
expression	O
luciferase	B-ENZY
plasmid	O
pGL3	O
-	O
5	O
'	O
UTR	O
in	O
which	O
SARS	O
-	O
CoV	O
5	O
'	O
UTR	O
acts	O
as	O
the	O
promoter	O
,	O
the	O
luciferase	B-ENZY
could	O
express	O
in	O
five	O
cell	O
lines	O
in	O
different	O
degrees	O
.	O

Ranked	O
by	O
the	O
luciferase	B-ENZY
activity	O
from	O
the	O
highest	O
to	O
the	O
lowest	O
,	O
the	O
order	O
is	O
A549	O
,	O
HepG2	O
,	O
ECV304	O
,	O
HeLa	O
and	O
Vero	O
E6	O
.	O

Additionally	O
,	O
we	O
provide	O
evidence	O
for	O
the	O
contribution	O
of	O
two	O
kinases	O
,	O
the	O
MAP	B-ENZY
kinase	I-ENZY
p38MAPK	O
,	O
and	O
protein	B-ENZY
kinase	I-ENZY
C	I-ENZY
(	O
PKC	B-ENZY
)	O
delta	O
to	O
antiviral	O
protection	O
from	O
MHV	O
-	O
1	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
protease	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
has	O
a	O
C	O
-	O
terminal	O
extra	O
domain	O
in	O
addition	O
to	O
the	O
chymotrypsin	B-ENZY
-	O
fold	O
adopted	O
by	O
picornavirus	O
3C	O
proteases	O
hosting	O
the	O
complete	O
catalytic	O
machinery	O
.	O

The	O
compliance	O
of	O
the	O
respiratory	O
system	O
obtained	O
from	O
the	O
pressure	O
-	O
volume	O
curves	O
was	O
significantly	O
correlated	O
with	O
markers	O
for	O
collagen	O
turn	O
-	O
over	O
(	O
type	O
III	O
procollagen	O
peptide	O
and	O
matrix	B-ENZY
metalloproteinase	I-ENZY
2	I-ENZY
)	O
and	O
with	O
markers	O
of	O
surfactant	O
degradation	O
(	O
type	O
-	O
IIA	O
secretory	O
phospholipase	B-ENZY
A2	I-ENZY
).	O

Phosphorylation	O
of	O
glycogen	B-ENZY
synthase	I-ENZY
kinase	O
-	O
3beta	O
,	O
which	O
is	O
one	O
of	O
the	O
downstream	O
targets	O
of	O
Akt	O
,	O
was	O
prevented	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

However	O
,	O
treatment	O
with	O
glycogen	B-ENZY
synthase	I-ENZY
kinase	O
-	O
3beta	O
small	O
interfering	O
RNA	O
indicated	O
that	O
the	O
glycogen	B-ENZY
synthase	I-ENZY
kinase	O
-	O
3beta	O
signaling	O
pathway	O
was	O
not	O
related	O
to	O
inhibition	O
of	O
cell	O
proliferation	O
.	O

Specifically	O
,	O
the	O
median	O
Coronase	O
antibody	O
titres	O
of	O
Siamese	O
,	O
Persians	O
,	O
Domestic	O
Shorthairs	O
and	O
Bengal	O
cats	O
(	O
100	O
)	O
were	O
significantly	O
lower	O
than	O
that	O
of	O
British	O
Shorthairs	O
,	O
Cornish	O
Rex	B-ENZY
and	O
Burmese	O
cats	O
(	O
400	O
,	O
P	O
<	O
0	O
.	O
0005	O
).	O

To	O
determine	O
whether	O
proteolytic	O
cleavage	O
of	O
the	O
S	O
glycoprotein	O
might	O
be	O
important	O
for	O
the	O
newly	O
emerged	O
SARS	O
-	O
CoV	O
,	O
we	O
introduced	O
a	O
furin	B-ENZY
recognition	O
site	O
at	O
single	O
basic	O
residues	O
within	O
the	O
putative	O
S1	O
-	O
S2	O
junctional	O
region	O
.	O

We	O
show	O
that	O
furin	B-ENZY
cleavage	O
at	O
the	O
modified	O
R667	O
position	O
generates	O
discrete	O
S1	O
and	O
S2	O
subunits	O
and	O
potentiates	O
membrane	O
fusion	O
activity	O
.	O

The	O
mechanisms	O
that	O
contribute	O
to	O
disturbed	O
alveolar	O
fibrin	O
turnover	O
are	O
localized	O
tissue	O
factor	O
-	O
mediated	O
thrombin	B-ENZY
generation	O
and	O
depression	O
of	O
bronchoalveolar	O
urokinase	B-ENZY
plasminogen	O
activator	O
-	O
mediated	O
fibrinolysis	O
,	O
caused	O
by	O
the	O
increase	O
of	O
plasminogen	O
activator	O
inhibitors	O
.	O

Modest	O
sequence	O
conservation	O
within	O
gene	O
1	O
has	O
enabled	O
the	O
design	O
of	O
oligonucleotide	O
primers	O
for	O
use	O
in	O
diagnostic	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reactions	O
,	O
which	O
will	O
be	O
useful	O
for	O
the	O
detection	O
of	O
new	O
coronaviruses	O
.	O

Drugs	O
that	O
selectively	O
inhibit	O
this	O
enzyme	O
,	O
when	O
used	O
in	O
combination	O
with	O
inhibitors	O
of	O
reverse	B-ENZY
transcriptase	I-ENZY
and	O
protease	O
,	O
are	O
believed	O
to	O
be	O
highly	O
effective	O
in	O
suppressing	O
the	O
viral	O
replication	O
.	O

ABSTRACT	O
:	O
Pump	O
-	O
driven	O
extracorporeal	O
gas	B-ENZY
exchange	O
systems	O
have	O
been	O
advocated	O
in	O
patients	O
suffering	O
from	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
who	O
are	O
at	O
risk	O
for	O
life	O
-	O
threatening	O
hypoxemia	O
and	O
/	O
or	O
hypercapnia	O
.	O

ABSTRACT	O
:	O
The	O
advantages	O
of	O
nucleic	O
acid	O
amplification	O
tests	O
(	O
NAT	B-ENZY
)	O
over	O
conventional	O
methods	O
for	O
the	O
detection	O
of	O
pathogens	O
in	O
lower	O
respiratory	O
tract	O
samples	O
have	O
not	O
been	O
established	O
.	O

NAT	B-ENZY
for	O
respiratory	O
pathogens	O
were	O
performed	O
on	O
439	O
endotracheal	O
tube	O
(	O
ETT	O
)	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
samples	O
.	O

An	O
additional	O
73	O
pathogens	O
were	O
detected	O
by	O
NAT	B-ENZY
in	O
65	O
samples	O
including	O
30	O
pathogens	O
that	O
were	O
missed	O
by	O
conventional	O
methods	O
(	O
19	O
adenovirus	O
,	O
6	O
respiratory	O
syncytial	O
virus	O
,	O
3	O
parainfluenza	O
virus	O
1	O
-	O
4	O
,	O
2	O
influenza	O
A	O
),	O
41	O
pathogens	O
not	O
routinely	O
identified	O
by	O
conventional	O
methods	O
in	O
most	O
laboratories	O
(	O
23	O
rhinovirus	O
,	O
8	O
human	O
coronavirus	O
OC43	O
,	O
5	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
2	O
human	O
coronavirus	O
229E	O
,	O
2	O
human	O
coronavirus	O
NL63	O
,	O
1	O
Chlamydophila	O
pneumoniae	O
)	O
and	O
2	O
pathogens	O
from	O
samples	O
where	O
no	O
respiratory	O
virus	O
testing	O
was	O
requested	O
(	O
1	O
influenza	O
A	O
,	O
1	O
parainfluenza	O
virus	O
).	O

Four	O
of	O
52	O
patients	O
who	O
had	O
multiple	O
BAL	B-ENZY
samples	O
submitted	O
on	O
the	O
same	O
day	O
had	O
negative	O
and	O
positive	O
results	O
by	O
NAT	B-ENZY
on	O
different	O
samples	O
.	O

The	O
median	O
Immunocomb	O
scores	O
of	O
DSH	O
,	O
Persian	O
,	O
Siamese	O
and	O
Devon	O
Rex	B-ENZY
cats	O
were	O
significantly	O
lower	O
than	O
that	O
of	O
Burmese	O
,	O
BSH	O
,	O
Abyssinian	O
,	O
Birman	O
,	O
Ragdoll	O
and	O
Russian	O
Blue	O
.	O

To	O
examine	O
the	O
mechanism	O
of	O
inhibition	O
of	O
dengue	O
virus	O
,	O
we	O
developed	O
two	O
replicon	O
systems	O
for	O
dengue	O
type	O
1	O
virus	O
:	O
(	O
i	O
)	O
a	O
stable	O
cell	O
line	O
that	O
harbored	O
replicons	O
containing	O
a	O
luciferase	B-ENZY
reporter	O
and	O
a	O
neomycin	O
phosphotransferase	O
selection	O
marker	O
and	O
(	O
ii	O
)	O
a	O
luciferase	B-ENZY
-	O
expressing	O
replicon	O
that	O
could	O
differentiate	O
between	O
viral	O
translation	O
and	O
RNA	O
replication	O
.	O

These	O
are	O
processed	O
primarily	O
by	O
the	O
chymotrypsin	B-ENZY
-	O
like	O
main	O
proteinases	O
(	O
M	O
(	O
pro	O
)	O
s	O
).	O

Using	O
a	O
sensitive	O
method	O
of	O
gas	B-ENZY
chromatography	O
coupled	O
to	O
mass	O
spectrometry	O
in	O
the	O
electron	O
impact	O
mode	O
of	O
ionization	O
this	O
manuscript	O
demonstrates	O
the	O
occurrence	O
of	O
13	O
different	O
sialic	O
acids	O
varying	O
in	O
their	O
alkyl	O
and	O
acyl	O
substituents	O
in	O
mouse	O
tissues	O
including	O
5	O
-	O
N	O
-	O
acetyl	O
-	O
4	O
-	O
O	O
-	O
acetyl	O
-	O
9	O
-	O
O	O
-	O
lactyl	O
-	O
neuraminic	O
acid	O
(	O
Neu4	O
,	O
5Ac	O
(	O
2	O
)	O
9Lt	O
),	O
5	O
-	O
N	O
-	O
acetyl	O
-	O
9	O
-	O
O	O
-	O
lactyl	O
-	O
neuraminic	O
acid	O
(	O
Neu5Ac9Lt	O
),	O
5	O
-	O
N	O
-	O
acetyl	O
-	O
8	O
-	O
O	O
-	O
methyl	O
-	O
neuraminic	O
acid	O
(	O
Neu5Ac8Me	O
)	O
and	O
the	O
1	O
,	O
7	O
-	O
lactone	O
(	O
Neu5Ac1	O
,	O
7L	O
)	O
of	O
neuraminic	O
acid	O
.	O

ABSTRACT	O
:	O
The	O
renin	B-ENZY
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
plays	O
a	O
key	O
role	O
in	O
maintaining	O
blood	O
pressure	O
homeostasis	O
,	O
as	O
well	O
as	O
fluid	O
and	O
salt	O
balance	O
.	O

ACE2	O
,	O
a	O
close	O
homologue	O
of	O
ACE	B-ENZY
,	O
functions	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
angiotensin	O
system	O
and	O
was	O
identified	O
as	O
a	O
key	O
receptor	O
for	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)	O
coronavirus	O
infections	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
:	O
structure	O
of	O
a	O
viral	O
deubiquitinating	O
enzyme	O
.	O

ABSTRACT	O
:	O
Replication	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
requires	O
proteolytic	O
processing	O
of	O
the	O
replicase	O
polyprotein	O
by	O
two	O
viral	O
cysteine	O
proteases	O
,	O
a	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
and	O
a	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
).	O

This	O
was	O
confirmed	O
using	O
a	O
pan	O
-	O
coronavirus	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
that	O
amplified	O
part	O
of	O
gene	O
1	O
that	O
encodes	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
.	O

Targets	O
for	O
the	O
prophylactic	O
or	O
therapeutic	O
interventions	O
include	O
interaction	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
(	O
S1	O
domain	O
)	O
with	O
the	O
host	O
cell	O
receptor	O
,	O
fusion	O
of	O
the	O
S2	O
domain	O
with	O
the	O
host	O
cell	O
membrane	O
,	O
processing	O
of	O
the	O
replicase	O
polyproteins	O
by	O
the	O
virus	O
-	O
encoded	O
proteases	O
(	O
3C	O
-	O
like	O
cysteine	O
protease	O
[	O
3CLpro	O
]	O
and	O
papain	B-ENZY
-	O
like	O
cysteine	O
protease	O
)	O
and	O
other	O
virus	O
-	O
encoded	O
enzymes	O
such	O
as	O
the	O
NTPase	B-ENZY
/	O
helicase	O
and	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
.	O

Neuraminidase	B-ENZY
treatment	O
rendered	O
Vero	O
,	O
baby	O
hamster	O
kidney	O
and	O
primary	O
chicken	O
kidney	O
cells	O
resistant	O
to	O
infection	O
by	O
the	O
IBV	O
-	O
Beaudette	O
strain	O
.	O

In	O
comparison	O
with	O
Influenza	O
A	O
virus	O
and	O
Sendai	O
virus	O
,	O
IBV	O
was	O
most	O
sensitive	O
to	O
pre	O
-	O
treatment	O
of	O
cells	O
with	O
neuraminidase	B-ENZY
.	O

Measurements	O
were	O
repeated	O
at	O
different	O
degrees	O
of	O
pulmonary	O
gas	B-ENZY
exchange	O
impairment	O
with	O
the	O
pulmonary	O
venous	O
admixture	O
ranging	O
from	O
35	O
.	O
0	O
%	O
to	O
70	O
.	O
6	O
%.	O

A	O
chymotrypsin	B-ENZY
-	O
like	O
cysteine	O
protease	O
named	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
is	O
essential	O
for	O
the	O
life	O
cycle	O
of	O
the	O
SARS	O
-	O
CoV	O
.	O
This	O
main	O
protease	O
is	O
responsible	O
for	O
maturation	O
of	O
functional	O
proteins	O
and	O
represents	O
a	O
key	O
anti	O
-	O
viral	O
target	O
.	O

The	O
diagnosis	O
of	O
pulmonary	O
hypertension	O
by	O
PAT	B-ENZY
diameter	O
measurements	O
was	O
incorrect	O
in	O
43	O
.	O
7	O
%	O
of	O
patients	O
with	O
ARDS	O
.	O

Measurement	O
of	O
PAT	B-ENZY
diameter	O
on	O
admission	O
CT	O
scan	O
is	O
an	O
unreliable	O
tool	O
for	O
identification	O
of	O
ARDS	O
patients	O
with	O
pulmonary	O
hypertension	O
.	O

TITLE	O
:	O
Enhancement	O
of	O
the	O
infectivity	O
of	O
SARS	O
-	O
CoV	O
in	O
BALB	O
/	O
c	O
mice	O
by	O
IMP	B-ENZY
dehydrogenase	I-ENZY
inhibitors	O
,	O
including	O
ribavirin	O
.	O

ABSTRACT	O
:	O
Because	O
of	O
the	O
conflicting	O
data	O
concerning	O
the	O
SARS	O
-	O
CoV	O
inhibitory	O
efficacy	O
of	O
ribavirin	O
,	O
an	O
inosine	O
monophosphate	O
(	O
IMP	O
)	O
dehydrogenase	O
inhibitor	O
,	O
studies	O
were	O
done	O
to	O
evaluate	O
the	O
efficacy	O
of	O
ribavirin	O
and	O
other	O
IMP	B-ENZY
dehydrogenase	I-ENZY
inhibitors	O
(	O
5	O
-	O
ethynyl	O
-	O
1	O
-	O
beta	O
-	O
D	O
-	O
ribofuranosylimidazole	O
-	O
4	O
-	O
carboxamide	O
(	O
EICAR	O
),	O
mizoribine	O
,	O
and	O
mycophenolic	O
acid	O
)	O
in	O
preventing	O
viral	O
replication	O
in	O
the	O
lungs	O
of	O
BALB	O
/	O
c	O
mice	O
,	O
a	O
replication	O
model	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
infections	O
(	O
Subbarao	O
,	O
K	O
.,	O
McAuliffe	O
,	O
J	O
.,	O
Vogel	O
,	O
L	O
.,	O
Fahle	O
,	O
G	O
.,	O
Fischer	O
,	O
S	O
.,	O
Tatti	O
,	O
K	O
.,	O
Packard	O
,	O
M	O
.,	O
Shieh	O
,	O
W	O
.	O
J	O
.,	O
Zaki	O
,	O
S	O
.,	O
Murphy	O
,	O
B	O
.,	O
2004	O
.	O

Other	O
IMP	B-ENZY
dehydrogenase	I-ENZY
inhibitors	O
administered	O
near	O
maximum	O
tolerated	O
doses	O
using	O
the	O
same	O
dosing	O
regimen	O
as	O
for	O
ribavirin	O
were	O
found	O
to	O
slightly	O
enhance	O
virus	O
replication	O
in	O
the	O
lungs	O
.	O

Our	O
data	O
do	O
not	O
support	O
the	O
use	O
of	O
ribavirin	O
or	O
other	O
IMP	B-ENZY
dehydrogenase	I-ENZY
inhibitors	O
for	O
treating	O
SARS	O
infections	O
in	O
humans	O
.	O

Partial	O
ventilatory	O
support	O
can	O
effectively	O
unload	O
the	O
respiratory	O
workload	O
and	O
improve	O
pulmonary	O
gas	B-ENZY
exchange	O
with	O
less	O
hemodynamic	O
compromise	O
.	O

This	O
study	O
compares	O
the	O
effects	O
of	O
assisted	O
ventilatory	O
techniques	O
on	O
breathing	O
pattern	O
,	O
gas	B-ENZY
exchange	O
,	O
hemodynamic	O
function	O
,	O
and	O
respiratory	O
effort	O
with	O
those	O
of	O
controlled	O
mechanical	O
ventilation	O
in	O
similarly	O
sedated	O
subjects	O
.	O

The	O
effects	O
of	O
P	O
-	O
ACV	O
,	O
BIPAP	O
,	O
and	O
PSV	O
were	O
comparable	O
with	O
respect	O
to	O
gas	B-ENZY
exchange	O
and	O
hemodynamic	O
function	O
,	O
except	O
for	O
a	O
more	O
pronounced	O
reduction	O
in	O
shunt	O
during	O
BIPAP	O
.	O

In	O
addition	O
,	O
the	O
following	O
agents	O
were	O
detected	O
in	O
bovine	O
faecal	O
samples	O
:	O
Bovine	O
coronavirus	O
,	O
25	O
.	O
7	O
%;	O
Escherichia	O
coli	O
,	O
17	O
%;	O
Cryptosporidium	O
spp	B-ENZY
.,	O
11	O
.	O
7	O
%;	O
Eimeria	O
spp	B-ENZY
.,	O
10	O
.	O
4	O
%;	O
Rotavirus	O
,	O
9	O
.	O
1	O
%;	O
Clostridium	O
perfringens	O
,	O
9	O
.	O
1	O
%	O
and	O
Giardia	O
spp	B-ENZY
.,	O
6	O
.	O
1	O
%.	O

Salmonella	O
spp	B-ENZY
.	O

ABSTRACT	O
:	O
The	O
existence	O
of	O
coronaviruses	O
in	O
bats	O
is	O
unknown	O
until	O
the	O
recent	O
discovery	O
of	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
in	O
Chinese	O
horseshoe	O
bats	O
and	O
a	O
novel	O
group	O
1	O
coronavirus	O
in	O
other	O
bat	B-ENZY
species	O
.	O

Among	O
the	O
six	O
novel	O
coronaviruses	O
,	O
four	O
were	O
group	O
1	O
coronaviruses	O
(	O
bat	B-ENZY
-	O
CoV	O
HKU2	O
from	O
Chinese	O
horseshoe	O
bat	B-ENZY
,	O
bat	B-ENZY
-	O
CoV	O
HKU6	O
from	O
rickett	O
'	O
s	O
big	O
-	O
footed	O
bat	B-ENZY
,	O
bat	B-ENZY
-	O
CoV	O
HKU7	O
from	O
greater	O
bent	O
-	O
winged	O
bat	B-ENZY
and	O
bat	B-ENZY
-	O
CoV	O
HKU8	O
from	O
lesser	O
bent	O
-	O
winged	O
bat	B-ENZY
)	O
and	O
two	O
were	O
group	O
2	O
coronaviruses	O
(	O
bat	B-ENZY
-	O
CoV	O
HKU4	O
from	O
lesser	O
bamboo	O
bats	O
and	O
bat	B-ENZY
-	O
CoV	O
HKU5	O
from	O
Japanese	O
pipistrelles	O
).	O

The	O
up	O
-	O
regulated	O
proteins	O
were	O
identified	O
as	O
alpha	O
-	O
1	O
acid	O
glycoprotein	O
,	O
haptoglobin	O
,	O
alpha	O
-	O
1	O
anti	O
-	O
chymotrypsin	B-ENZY
and	O
fetuin	O
.	O

Detection	O
of	O
rhinovirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
and	O
coronavirus	O
infections	O
in	O
acute	O
otitis	O
media	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
.	O

Extracorporeal	O
lung	O
assist	O
(	O
ECLA	O
)	O
or	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
using	O
capillary	O
membrane	O
oxygenators	O
can	O
provide	O
sufficient	O
gas	B-ENZY
exchange	O
and	O
lung	O
rest	O
.	O

In	O
this	O
report	O
,	O
we	O
study	O
the	O
membrane	O
topology	O
of	O
the	O
SARS	O
-	O
CoV	O
E	O
protein	O
by	O
immunofluorescent	O
staining	O
of	O
cells	O
differentially	O
permeabilized	O
with	O
detergents	O
and	O
proteinase	B-ENZY
K	I-ENZY
protection	O
assay	O
.	O

At	O
the	O
same	O
time	O
,	O
arterial	O
oxygen	O
tension	O
(	O
PaO	B-ENZY
2	O
),	O
cytokines	O
and	O
activated	O
NF	O
-	O
	O
B	O
levels	O
of	O
peripheral	O
blood	O
mononuclear	O
cell	O
were	O
measured	O
.	O

PaO	B-ENZY
(	O
2	O
)	O
was	O
significantly	O
higher	O
in	O
HV	O
group	O
than	O
in	O
LV	O
group	O
at	O
6	O
h	O
,	O
12	O
h	O
,	O
24	O
h	O
and	O
48	O
h	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
secondary	O
to	O
inhalation	O
of	O
chlorine	O
gas	B-ENZY
in	O
sheep	O
.	O

ABSTRACT	O
:	O
The	O
plasma	B-ENZY
kallikrein	I-ENZY
-	O
kinin	O
system	O
(	O
KKS	O
)	O
participates	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
reactions	O
involved	O
in	O
cellular	O
injury	O
,	O
coagulation	O
,	O
fibrinolysis	O
,	O
kinin	O
formation	O
,	O
complement	O
activation	O
,	O
cytokine	O
secretion	O
and	O
release	O
of	O
proteases	O
.	O

It	O
has	O
been	O
demostrated	O
that	O
therapy	O
with	O
a	O
specific	O
plasma	B-ENZY
kallikrein	I-ENZY
inhibitor	O
(	O
P8720	O
)	O
modulated	O
the	O
experimental	O
enterocolitis	O
,	O
arthritis	O
and	O
systemic	O
inflammation	O
.	O

The	O
most	O
recent	O
literature	O
is	O
reviewed	O
,	O
and	O
emphasis	O
is	O
placed	O
on	O
current	O
controversies	O
,	O
most	O
notably	O
the	O
risk	O
/	O
benefit	O
ratio	O
of	O
fiberoptic	O
bronchoscopy	O
and	O
BAL	B-ENZY
in	O
patients	O
with	O
severe	O
hypoxemia	O
.	O

In	O
contrast	O
,	O
trypsin	B-ENZY
treatment	O
can	O
both	O
overcome	O
ammonium	O
chloride	O
inhibition	O
and	O
promote	O
cell	O
-	O
cell	O
fusion	O
.	O

With	O
tapering	O
down	O
of	O
corticosteroid	O
dosage	O
,	O
CTx	O
started	O
to	O
return	O
to	O
previous	O
baseline	O
level	O
from	O
Day	O
51	O
onwards	O
,	O
while	O
other	O
bone	O
formation	O
markers	O
,	O
serum	O
osteocalcin	O
and	O
bone	O
-	O
specific	O
alkaline	B-ENZY
phosphatase	I-ENZY
concentrations	O
(	O
OC	O
and	O
BALP	O
,	O
respectively	O
),	O
started	O
to	O
increase	O
.	O

The	O
FIP1	O
-	O
like	O
1	O
(	O
FIP1L1	O
)-	O
platelet	O
-	O
derived	O
growth	O
factor	O
receptor	O
alpha	O
(	O
PDGFRalpha	O
)	O
fusion	O
transcript	O
was	O
found	O
with	O
the	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Saikosaponins	O
isolated	O
from	O
medicinal	O
plants	O
such	O
as	O
Bupleurum	O
spp	B-ENZY
.,	O
Heteromorpha	O
spp	B-ENZY
.	O

Using	O
the	O
2	O
,	O
3	O
-	O
bis	B-ENZY
[	O
2	O
-	O
methoxy	O
-	O
4	O
-	O
nitro	O
-	O
5	O
-	O
sulfophenyl	O
]-	O
5	O
-[(	O
phenylamino	O
)	O
carbonyl	O
-	O
2H	O
-	O
tetrazolium	O
hydroxide	O
]	O
(	O
XTT	O
)	O
assay	O
,	O
results	O
showed	O
that	O
all	O
saikosaponins	O
tested	O
demonstrated	O
antiviral	O
activity	O
at	O
concentrations	O
of	O
0	O
.	O
25	O
-	O
25	O
micromol	O
/	O
L	O
,	O
with	O
the	O
strongest	O
activity	O
being	O
noted	O
for	O
saikosaponin	O
B2	O
(	O
IC50	O
=	O
1	O
.	O
7	O
+/-	O

Gas	B-ENZY
exchange	O
and	O
hemodynamic	O
data	O
were	O
collected	O
at	O
each	O
step	O
.	O

Augmentation	O
of	O
mPaw	O
improved	O
gas	B-ENZY
exchange	O
and	O
pulmonary	O
shunt	O
fraction	O
in	O
both	O
groups	O
,	O
but	O
at	O
a	O
significant	O
lower	O
mPaw	O
in	O
the	O
HFOV	O
treated	O
animals	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
a	O
clinical	O
syndrome	O
in	O
which	O
patients	O
develop	O
severe	O
and	O
progressive	O
pulmonary	O
gas	B-ENZY
exchange	O
defects	O
and	O
pulmonary	O
mechanical	O
dysfunction	O
.	O

Using	O
initial	O
data	O
in	O
medical	O
records	O
reported	O
by	O
hospitals	O
to	O
the	O
Center	O
for	O
Disease	O
Control	O
in	O
Taiwan	O
,	O
we	O
analyzed	O
whether	O
hematological	O
,	O
biochemical	O
and	O
arterial	O
blood	O
gas	B-ENZY
measures	O
could	O
predict	O
fatality	O
in	O
346	O
SARS	O
patients	O
.	O

Factors	O
significantly	O
associated	O
with	O
initial	O
CRP	O
concentration	O
>	O
47	O
.	O
5	O
mg	O
/	O
L	O
included	O
dyspnea	O
(	O
OR	O
=	O
4	O
.	O
3	O
),	O
red	O
blood	O
cell	O
count	O
<	O
4	O
.	O
1	O
x	O
106	O
/	O
microL	O
(	O
OR	O
=	O
4	O
.	O
3	O
)	O
and	O
serum	O
aspartate	B-ENZY
aminotransferase	I-ENZY
>	O
57	O
IU	O
/	O
L	O
(	O
OR	O
=	O
3	O
.	O
1	O
).	O

ABSTRACT	O
:	O
Previously	O
,	O
we	O
reported	O
the	O
establishment	O
of	O
cells	O
with	O
persistent	O
SARS	O
-	O
CoV	O
infection	O
after	O
apoptotic	O
events	O
and	O
showed	O
that	O
both	O
JNK	B-ENZY
and	O
PI3K	O
/	O
Akt	O
signaling	O
pathways	O
are	O
important	O
for	O
persistence	O
by	O
treatment	O
with	O
inhibitors	O
at	O
the	O
early	O
stages	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
which	O
signaling	O
pathways	O
play	O
important	O
roles	O
in	O
escape	O
from	O
apoptosis	O
in	O
cells	O
infected	O
with	O
SARS	O
-	O
CoV	O
.	O
In	O
persistently	O
infected	O
cells	O
at	O
50h	O
.	O
p	O
.	O
i	O
.,	O
PI3K	O
/	O
Akt	O
,	O
JNK	B-ENZY
,	O
p38	O
MAPK	B-ENZY
and	O
Bcl	O
-	O
2	O
were	O
phosphorylated	O
and	O
the	O
protein	O
levels	O
of	O
Bcl	O
-	O
2	O
and	O
Bcl	O
-	O
xL	O
were	O
increased	O
.	O

When	O
surviving	O
cells	O
were	O
treated	O
with	O
the	O
JNK	B-ENZY
-	O
specific	O
inhibitor	O
,	O
SP600125	O
,	O
at	O
50h	O
.	O
p	O
.	O
i	O
.,	O
all	O
cells	O
died	O
,	O
suggesting	O
that	O
the	O
JNK	B-ENZY
signaling	O
pathway	O
is	O
necessary	O
for	O
maintenance	O
of	O
persistently	O
infected	O
cells	O
.	O

These	O
results	O
indicated	O
that	O
at	O
least	O
four	O
proteins	O
,	O
Akt	O
,	O
JNK	B-ENZY
,	O
Bcl	O
-	O
2	O
and	O
Bcl	O
-	O
xL	O
,	O
are	O
necessary	O
for	O
survival	O
of	O
persistently	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

Genome	O
analysis	O
also	O
revealed	O
various	O
numbers	O
of	O
tandem	O
copies	O
of	O
a	O
perfect	O
30	O
-	O
base	O
acidic	O
tandem	O
repeat	O
(	O
ATR	O
)	O
which	O
encodes	O
NDDEDVVTGD	O
and	O
various	O
numbers	O
and	O
sequences	O
of	O
imperfect	O
repeats	O
in	O
the	O
N	O
terminus	O
of	O
nsp3	O
inside	O
the	O
acidic	O
domain	O
upstream	O
of	O
papain	B-ENZY
-	O
like	O
protease	O
1	O
among	O
the	O
22	O
genomes	O
.	O

The	O
indexes	O
were	O
observed	O
among	O
the	O
three	O
groups	O
comprising	O
the	O
mortality	O
rate	O
,	O
the	O
change	O
of	O
arterial	O
blood	O
PaCO	O
(	O
2	O
)	O
and	O
PaO	B-ENZY
(	O
2	O
),	O
the	O
ratio	O
of	O
wet	O
to	O
dry	O
lung	O
tissue	O
(	O
W	O
/	O
D	O
),	O
the	O
change	O
of	O
the	O
lung	O
tissue	O
under	O
light	O
and	O
electric	O
microscope	O
respectively	O
,	O
and	O
the	O
expression	O
of	O
pulmonary	O
surfactant	O
associated	O
protein	O
A	O
.	O
The	O
mortality	O
rate	O
of	O
rats	O
in	O
the	O
PQ	O
group	O
was	O
50	O
.	O
0	O
%	O
on	O
the	O
seventh	O
day	O
while	O
the	O
mortality	O
rate	O
in	O
the	O
AT	O
group	O
was	O
25	O
.	O
0	O
%.	O

The	O
level	O
of	O
arterial	O
blood	O
PaO	B-ENZY
(	O
2	O
)	O
in	O
the	O
PQ	O
group	O
(	O
6	O
.	O
98	O
+/-	O

In	O
expressing	O
cells	O
,	O
7a	O
protein	O
exhibits	O
a	O
variety	O
of	O
biological	O
activities	O
,	O
including	O
induction	O
of	O
apoptosis	O
,	O
activation	O
of	O
the	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
signaling	O
pathway	O
,	O
inhibition	O
of	O
host	O
protein	O
translation	O
,	O
and	O
suppression	O
of	O
cell	O
growth	O
progression	O
.	O

Phylogenetic	O
analyses	O
of	O
the	O
spike	O
,	O
envelope	O
,	O
membrane	O
,	O
and	O
nucleoprotein	O
structural	O
proteins	O
and	O
the	O
two	O
conserved	O
replicase	O
domains	O
,	O
putative	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
and	O
RNA	O
helicase	O
,	O
revealed	O
that	O
bat	B-ENZY
coronaviruses	O
cluster	O
in	O
three	O
different	O
groups	O
:	O
group	O
1	O
,	O
another	O
group	O
that	O
includes	O
all	O
SARS	O
and	O
SARS	O
-	O
like	O
coronaviruses	O
(	O
putative	O
group	O
4	O
),	O
and	O
an	O
independent	O
bat	B-ENZY
coronavirus	O
group	O
(	O
putative	O
group	O
5	O
).	O

Further	O
genetic	O
analyses	O
showed	O
that	O
different	O
species	O
of	O
bats	O
maintain	O
coronaviruses	O
from	O
different	O
groups	O
and	O
that	O
a	O
single	O
bat	B-ENZY
species	O
from	O
different	O
geographic	O
locations	O
supports	O
similar	O
coronaviruses	O
.	O

Moreover	O
,	O
progress	O
in	O
the	O
drug	O
development	O
based	O
on	O
different	O
molecular	O
targets	O
is	O
also	O
summarized	O
,	O
including	O
1	O
)	O
Compounds	O
that	O
block	O
the	O
S	O
protein	O
-	O
ACE2	O
-	O
mediated	O
viral	O
entry	O
;	O
2	O
)	O
Compounds	O
targeting	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
);	O
3	O
)	O
Compounds	O
targeting	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
(	O
PLP2	O
);	O
4	O
)	O
Compounds	O
targeting	O
SARS	O
-	O
CoV	O
RdRp	O
;	O
5	O
)	O
Compounds	O
targeting	O
SARS	O
-	O
CoV	O
helicase	O
;	O
6	O
)	O
Active	O
compounds	O
with	O
unspecified	O
targets	O
;	O
and	O
7	O
)	O
Research	O
on	O
siRNA	O
.	O

TITLE	O
:	O
Bites	O
by	O
coral	O
snakes	O
(	O
Micrurus	O
spp	B-ENZY
.)	O
in	O
Campinas	O
,	O
State	O
of	O
So	O
Paulo	O
,	O
Southeastern	O
Brazil	O
.	O

ABSTRACT	O
:	O
Coral	O
snakes	O
(	O
Micrurus	O
spp	B-ENZY
.)	O
are	O
the	O
main	O
representatives	O
of	O
the	O
Elapidae	O
in	O
South	O
America	O
.	O

ABSTRACT	O
:	O
We	O
have	O
solved	O
the	O
crystal	O
and	O
molecular	O
structures	O
of	O
hepatitis	O
A	O
viral	O
(	O
HAV	O
)	O
3C	O
proteinase	O
,	O
a	O
cysteine	O
peptidase	O
having	O
a	O
chymotrypsin	B-ENZY
-	O
like	O
protein	O
fold	O
,	O
in	O
complex	O
with	O
each	O
of	O
three	O
tetrapeptidyl	O
-	O
based	O
methyl	O
ketone	O
inhibitors	O
to	O
resolutions	O
beyond	O
1	O
.	O
4	O
A	O
,	O
the	O
highest	O
resolution	O
to	O
date	O
for	O
a	O
3C	O
or	O
a	O
3C	O
-	O
Like	O
(	O
e	O
.	O
g	O
.	O
SARS	O
viral	O
main	O
proteinase	O
)	O
peptidase	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
extracorporeal	O
gas	B-ENZY
exchange	O
(	O
ECMO	O
)	O
on	O
mortality	O
of	O
patients	O
referred	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

NM	O
calves	O
had	O
a	O
high	O
geometric	O
mean	O
titer	O
for	O
BCV	O
antibody	O
at	O
arrival	O
(	O
GMT	B-ENZY
,	O
1	O
,	O
928	O
);	O
only	O
2	O
%	O
shed	O
BCV	O
in	O
nasal	O
secretions	O
and	O
1	O
%	O
in	O
feces	O
.	O

RESULTS	O
:	O
NM	O
calves	O
had	O
a	O
high	O
geometric	O
mean	O
titer	O
for	O
BCV	O
antibody	O
at	O
arrival	O
(	O
GMT	B-ENZY
,	O
1	O
,	O
928	O
);	O
only	O
2	O
%	O
shed	O
BCV	O
in	O
nasal	O
secretions	O
and	O
1	O
%	O
in	O
feces	O
.	O

The	O
structure	O
and	O
the	O
spatial	O
arrangement	O
of	O
the	O
catalytic	O
residues	O
into	O
an	O
RNase	B-ENZY
A	I-ENZY
-	O
like	O
active	O
site	O
define	O
a	O
separate	O
endonuclease	O
family	O
,	O
endoU	O
,	O
and	O
represent	O
another	O
spectacular	O
example	O
of	O
convergent	O
evolution	O
toward	O
an	O
enzymatic	O
function	O
that	O
is	O
critically	O
involved	O
in	O
the	O
coronavirus	O
replication	O
cycle	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
-	O
positive	O
samples	O
of	O
faeces	O
collected	O
in	O
an	O
Austrian	O
animal	O
shelter	O
from	O
12	O
cats	O
and	O
10	O
dogs	O
were	O
analysed	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
pcr	O
with	O
primers	O
amplifying	O
a	O
segment	O
of	O
the	O
M	O
protein	O
gene	O
,	O
and	O
by	O
sequence	O
analysis	O
.	O

We	O
conducted	O
a	O
multicenter	O
evaluation	O
of	O
four	O
automated	O
and	O
four	O
manual	O
extraction	O
methods	O
using	O
dilutions	O
of	O
viral	O
lysate	O
in	O
replicate	O
mock	O
stool	O
samples	O
,	O
followed	O
by	O
quantitation	O
of	O
SARS	O
CoV	O
RNA	O
using	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
.	O

TITLE	O
:	O
Coronaviruses	O
in	O
bent	O
-	O
winged	O
bats	O
(	O
Miniopterus	O
spp	B-ENZY
.).	O

ABSTRACT	O
:	O
A	O
novel	O
group	O
1	O
coronavirus	O
was	O
previously	O
identified	O
in	O
bent	O
-	O
winged	O
bats	O
(	O
Miniopterus	O
spp	B-ENZY
.).	O

These	O
findings	O
show	O
that	O
group	O
1	O
coronaviruses	O
are	O
endemic	O
in	O
these	O
bat	B-ENZY
populations	O
in	O
Hong	O
Kong	O
.	O

Phylogenetic	O
analysis	O
revealed	O
that	O
these	O
group	O
1	O
bat	B-ENZY
coronaviruses	O
have	O
descended	O
from	O
a	O
common	O
ancestor	O
and	O
that	O
these	O
viruses	O
have	O
been	O
established	O
in	O
these	O
bats	O
for	O
a	O
long	O
period	O
of	O
time	O
.	O

Both	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
of	O
the	O
role	O
of	O
the	O
coagulation	O
cascade	O
in	O
sepsis	O
and	O
lung	O
injury	O
will	O
be	O
discussed	O
,	O
including	O
initiation	O
of	O
coagulation	O
through	O
modulation	O
of	O
tissue	O
factor	O
and	O
tissue	O
factor	O
pathway	O
inhibitor	O
,	O
propagation	O
of	O
coagulation	O
via	O
protein	O
C	O
and	O
thrombomodulin	O
,	O
inhibition	O
of	O
thrombin	B-ENZY
generation	O
and	O
resolution	O
through	O
thrombolysis	O
by	O
plasminogen	O
activator	O
,	O
and	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
.	O

Although	O
not	O
currently	O
in	O
clinical	O
practice	O
,	O
liquid	O
ventilation	O
using	O
perfluorocarbons	O
to	O
provide	O
gas	B-ENZY
exchange	O
in	O
the	O
lungs	O
is	O
a	O
potentially	O
useful	O
adjunct	O
in	O
the	O
management	O
of	O
severe	O
respiratory	O
failure	O
.	O

Most	O
gram	O
-	O
positive	O
bacteria	O
,	O
such	O
as	O
Enterococcus	O
spp	B-ENZY
.	O

Many	O
gram	O
-	O
negative	O
species	O
,	O
such	O
as	O
Acinetobacter	O
spp	B-ENZY
.,	O
Escherichia	O
coli	O
,	O
Klebsiella	O
spp	B-ENZY
.,	O
Pseudomonas	O
aeruginosa	O
,	O
Serratia	O
marcescens	O
,	O
or	O
Shigella	O
spp	B-ENZY
.,	O
can	O
also	O
survive	O
for	O
months	O
.	O

RESULTS	O
:	O
Most	O
gram	O
-	O
positive	O
bacteria	O
,	O
such	O
as	O
Enterococcus	O
spp	B-ENZY
.	O

ABSTRACT	O
:	O
Three	O
commercially	O
available	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
assays	O
(	O
the	O
Artus	O
RealArt	O
HPA	O
coronavirus	O
LightCycler	O
,	O
the	O
Artus	O
RealArt	O
HPA	O
coronavirus	O
Rotor	O
-	O
Gene	O
,	O
and	O
the	O
EraGen	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
POL	O
assay	O
)	O
and	O
three	O
RNA	O
extraction	O
methodologies	O
were	O
evaluated	O
for	O
the	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
RNA	O
from	O
91	O
stool	O
specimens	O
.	O

To	O
identify	O
published	O
original	O
CEAs	B-ENZY
presenting	O
cost	O
/	O
quality	O
-	O
adjusted	O
life	O
year	O
or	O
cost	O
/	O
life	O
-	O
year	O
ratios	O
for	O
treatments	O
used	O
in	O
intensive	O
care	O
units	O
,	O
to	O
summarize	O
the	O
results	O
in	O
an	O
accessible	O
format	O
,	O
and	O
to	O
identify	O
areas	O
in	O
critical	O
care	O
medicine	O
that	O
merit	O
further	O
economic	O
evaluation	O
.	O

We	O
conducted	O
a	O
systematic	O
search	O
of	O
the	O
English	O
-	O
language	O
literature	O
for	O
original	O
CEAs	B-ENZY
of	O
critical	O
care	O
interventions	O
published	O
from	O
1993	O
through	O
2003	O
.	O

Recent	O
guidelines	O
for	O
the	O
conduct	O
of	O
CEAs	B-ENZY
in	O
critical	O
care	O
may	O
increase	O
the	O
number	O
and	O
improve	O
the	O
quality	O
of	O
future	O
CEAs	B-ENZY
.	O

RESULTS	O
:	O
We	O
identified	O
19	O
CEAs	B-ENZY
published	O
through	O
2003	O
with	O
48	O
cost	O
-	O
effectiveness	O
ratios	O
pertaining	O
to	O
treatment	O
of	O
severe	O
sepsis	O
,	O
acute	O
respiratory	O
failure	O
,	O
and	O
general	O
critical	O
care	O
interventions	O
.	O

We	O
studied	O
exhaled	O
air	O
and	O
particle	O
dispersion	O
through	O
an	O
oronasal	O
mask	O
attached	O
to	O
a	O
human	O
-	O
patient	O
simulator	O
(	O
HPS	B-ENZY
)	O
during	O
noninvasive	O
positive	O
-	O
pressure	O
ventilation	O
(	O
NPPV	O
).	O

The	O
leakage	O
plume	O
exposure	O
probability	O
was	O
highest	O
about	O
60	O
to	O
80	O
mm	O
lateral	O
to	O
the	O
median	O
sagittal	O
plane	O
of	O
the	O
HPS	B-ENZY
.	O

The	O
amino	O
acid	O
sequence	O
contained	O
seven	O
potential	O
protein	B-ENZY
kinase	I-ENZY
C	I-ENZY
phosphorylation	O
sites	O
,	O
nine	O
Casein	O
kinase	O
II	O
phosphorylation	O
sites	O
,	O
one	O
Tyrosine	O
kinase	O
phosphorylation	O
site	O
,	O
two	O
cAMP	O
-	O
and	O
cGMP	B-ENZY
-	I-ENZY
dependent	I-ENZY
protein	I-ENZY
kinase	I-ENZY
phosphorylation	O
sites	O
.	O

TITLE	O
:	O
Three	O
dimensional	O
model	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
helicase	O
ATPase	B-ENZY
catalytic	O
domain	O
and	O
molecular	O
design	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
helicase	O
inhibitors	O
.	O

ABSTRACT	O
:	O
The	O
modeling	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
helicase	O
ATPase	B-ENZY
catalytic	O
domain	O
was	O
performed	O
using	O
the	O
protein	O
structure	O
prediction	O
Meta	O
Server	O
and	O
the	O
3D	O
Jury	O
method	O
for	O
model	O
selection	O
,	O
which	O
resulted	O
in	O
the	O
identification	O
of	O
1JPR	O
,	O
1UAA	O
and	O
1W36	O
PDB	O
structures	O
as	O
suitable	O
templates	O
for	O
creating	O
a	O
full	O
atom	O
3D	O
model	O
.	O

On	O
the	O
contrary	O
,	O
a	O
G	O
-	O
C	O
and	O
a	O
G	O
-	O
A	O
point	O
mutations	O
at	O
nucleotide	O
positions	O
4330	O
and	O
9230	O
,	O
respectively	O
,	O
causing	O
Glu	O
-	O
Gln	O
and	O
Gly	O
-	O
Glu	O
mutations	O
in	O
or	O
near	O
the	O
catalytic	O
centers	O
of	O
the	O
papain	B-ENZY
-	O
like	O
(	O
Nsp3	O
)	O
and	O
3C	O
-	O
like	O
(	O
Nsp5	O
)	O
proteinases	O
,	O
did	O
not	O
show	O
detectable	O
detrimental	O
effect	O
on	O
the	O
rescue	O
of	O
infectious	O
viruses	O
and	O
the	O
infectivity	O
of	O
the	O
rescued	O
viruses	O
.	O

STAT1	O
tyrosine	O
phosphorylation	O
was	O
elevated	O
by	O
IFN	O
combination	O
treatment	O
,	O
however	O
,	O
only	O
the	O
hyper	O
-	O
transactivation	O
of	O
GAS	B-ENZY
but	O
not	O
ISRE	O
was	O
observed	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
a	O
second	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
),	O
regulates	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
by	O
counterbalancing	O
ACE	B-ENZY
activity	O
.	O

More	O
than	O
250	O
field	O
samples	O
were	O
tested	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
using	O
two	O
sets	O
of	O
primers	O
corresponding	O
to	O
the	O
most	O
conserved	O
3	O
'-	O
untranslated	O
region	O
and	O
the	O
most	O
variable	O
S1	O
gene	O
region	O
of	O
the	O
viral	O
genome	O
.	O

The	O
bat	B-ENZY
G2b	O
-	O
CoV	O
isolates	O
have	O
an	O
identical	O
genome	O
organization	O
and	O
share	O
an	O
overall	O
genome	O
sequence	O
identity	O
of	O
88	O
-	O
92	O
%	O
among	O
themselves	O
and	O
between	O
them	O
and	O
the	O
human	O
/	O
civet	O
isolates	O
.	O

The	O
most	O
variable	O
regions	O
are	O
located	O
in	O
the	O
genes	O
encoding	O
nsp3	O
,	O
ORF3a	O
,	O
spike	O
protein	O
and	O
ORF8	O
when	O
bat	B-ENZY
and	O
human	O
/	O
civet	O
G2b	O
-	O
CoV	O
isolates	O
are	O
compared	O
.	O

Genetic	O
analysis	O
demonstrated	O
that	O
a	O
diverse	O
G2b	O
-	O
CoV	O
population	O
exists	O
in	O
the	O
bat	B-ENZY
habitat	O
and	O
has	O
evolved	O
from	O
a	O
common	O
ancestor	O
of	O
SARS	O
-	O
CoV	O
.	O

TITLE	O
:	O
Genotypes	O
and	O
subtypes	O
of	O
Cryptosporidium	O
spp	B-ENZY
.	O

ABSTRACT	O
:	O
Cryptosporidium	O
spp	B-ENZY
.	O

This	O
work	O
demonstrates	O
the	O
utility	O
of	O
genotyping	O
and	O
subtyping	O
tools	O
in	O
characterizing	O
the	O
transmission	O
of	O
Cryptosporidium	O
spp	B-ENZY
.	O

into	O
IL	O
-	O
2	O
receptor	O
gamma	O
-	O
chain	O
-	O
disrupted	O
NOD	B-ENZY
-	O
SCID	O
mice	O
[	O
IL	O
-	O
2R	O
(-/-)	O
NOD	B-ENZY
-	O
SCID	O
].	O

The	O
association	O
between	O
the	O
bat	B-ENZY
coronaviruses	O
and	O
certain	O
lyssaviruses	O
with	O
particular	O
bat	B-ENZY
species	O
implies	O
co	O
-	O
evolution	O
between	O
specific	O
viruses	O
and	O
bat	B-ENZY
hosts	O
.	O

In	O
parallel	O
,	O
liver	O
histology	O
,	O
virus	O
titers	O
,	O
and	O
plasma	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
activity	O
were	O
monitored	O
.	O

On	O
day	O
5	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
in	O
both	O
groups	O
.	O

On	O
day	O
5	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
in	O
both	O
groups	O
.	O

The	O
PaO	B-ENZY
(	O
2	O
),	O
SaO	O
(	O
2	O
)	O
and	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
of	O
all	O
18	O
patients	O
were	O
improved	O
greatly	O
.	O

RESULTS	O
:	O
The	O
PaO	B-ENZY
(	O
2	O
),	O
SaO	O
(	O
2	O
)	O
and	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
of	O
all	O
18	O
patients	O
were	O
improved	O
greatly	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
of	O
human	O
coronavirus	O
strain	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
was	O
amplified	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
,	O
and	O
cloned	O
in	O
pENTR	O
/	O
D	O
-	O
TOPO	O
plasmid	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
Raf	O
/	O
MEK	B-ENZY
/	O
ERK	B-ENZY
signaling	O
pathway	O
is	O
involved	O
in	O
MHV	O
RNA	O
synthesis	O
.	O

ABSTRACT	O
:	O
Synthetic	O
decapeptides	O
(	O
N	O
=	O
206	O
)	O
covering	O
the	O
entire	O
sequence	O
of	O
mouse	O
liver	O
fumarylacetoacetate	B-ENZY
hydrolase	I-ENZY
(	O
FAH	O
)	O
were	O
used	O
to	O
analyze	O
the	O
specificities	O
of	O
the	O
autoantibodies	O
(	O
autoAb	O
)	O
elicited	O
towards	O
this	O
enzyme	O
in	O
mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

The	O
blood	O
gas	B-ENZY
,	O
clinical	O
biochemical	O
items	O
,	O
medium	O
molecule	O
substance	O
(	O
MMS	O
)	O
concentration	O
in	O
blood	O
as	O
well	O
as	O
capillary	O
refill	O
time	O
(	O
CRT	O
),	O
BP	O
,	O
urine	O
output	O
,	O
vasopressors	O
dosage	O
were	O
examined	O
at	O
a	O
set	O
of	O
time	O
points	O
from	O
the	O
beginning	O
to	O
the	O
end	O
of	O
the	O
CVVH	O
.	O

Mannheimia	O
spp	B-ENZY
.	O

The	O
effects	O
of	O
ligustrazine	O
on	O
the	O
severity	O
of	O
lung	O
injury	O
were	O
assessed	O
by	O
lung	O
wet	O
/	O
dry	O
weight	O
ratio	O
,	O
myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
activity	O
and	O
histopathological	O
changes	O
.	O

Acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHEII	O
)	O
scores	O
,	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
)	O
evaluation	O
scores	O
and	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
were	O
observed	O
before	O
and	O
after	O
HVHF	O
.	O

DO	O
(	O
2	O
),	O
VO	O
(	O
2	O
)	O
and	O
O	O
(	O
2	O
)	O
ER	O
were	O
stabilized	O
at	O
72	O
hours	O
with	O
amelioration	O
of	O
partial	O
pressure	O
of	O
oxygen	O
in	O
artery	O
(	O
PaO	B-ENZY
(	O
2	O
)),	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
and	O
peak	O
airway	O
pressure	O
(	O
Ppeak	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Mutational	O
analysis	O
of	O
aminopeptidase	B-ENZY
N	I-ENZY
,	O
a	O
receptor	O
for	O
several	O
group	O
1	O
coronaviruses	O
,	O
identifies	O
key	O
determinants	O
of	O
viral	O
host	O
range	O
.	O

Tissue	O
leukocyte	O
sequestration	O
was	O
assessed	O
by	O
myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
activity	O
.	O

ABSTRACT	O
:	O
Twelve	O
complete	O
genomes	O
of	O
three	O
novel	O
coronaviruses	O
-	O
bat	B-ENZY
coronavirus	O
HKU4	O
(	O
bat	B-ENZY
-	O
CoV	O
HKU4	O
),	O
bat	B-ENZY
-	O
CoV	O
HKU5	O
(	O
putative	O
group	O
2c	O
),	O
and	O
bat	B-ENZY
-	O
CoV	O
HKU9	O
(	O
putative	O
group	O
2d	O
)-	O
were	O
sequenced	O
.	O

Unique	O
genomic	O
features	O
distinguishing	O
between	O
these	O
four	O
subgroups	O
,	O
including	O
the	O
number	O
of	O
papain	B-ENZY
-	O
like	O
proteases	O
,	O
the	O
presence	O
or	O
absence	O
of	O
hemagglutinin	O
esterase	O
,	O
small	O
ORFs	O
between	O
the	O
membrane	O
and	O
nucleocapsid	O
genes	O
and	O
ORFs	O
(	O
NS7a	O
and	O
NS7b	O
),	O
bulged	O
stem	O
-	O
loop	O
and	O
pseudoknot	O
structures	O
downstream	O
of	O
the	O
nucleocapsid	O
gene	O
,	O
transcription	O
regulatory	O
sequence	O
,	O
and	O
ribosomal	O
recognition	O
signal	O
for	O
the	O
envelope	O
gene	O
,	O
were	O
also	O
observed	O
.	O

The	O
role	O
of	O
circulating	O
trypsin	B-ENZY
,	O
phospholipase	B-ENZY
A2	I-ENZY
,	O
platelet	O
activating	O
factor	O
,	O
release	O
of	O
free	O
fatty	O
acids	O
,	O
chemoattractants	O
such	O
as	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
fMet	O
-	O
leu	O
-	O
phe	O
(	O
a	O
bacterial	O
wall	O
product	O
),	O
nitric	O
oxide	O
,	O
substance	O
P	O
,	O
and	O
macrophage	O
inhibitor	O
factor	O
is	O
currently	O
studied	O
.	O

The	O
effects	O
of	O
adenovirus	O
-	O
delivered	O
small	O
hairpin	O
RNA	O
on	O
SARS	O
-	O
CoV	O
gene	O
expression	O
were	O
determined	O
by	O
RT	O
-	O
PCR	O
,	O
Western	O
blot	O
,	O
and	O
luciferase	B-ENZY
activity	O
assays	O
.	O

The	O
""""	O
progressive	O
docking	O
""""	O
has	O
been	O
tested	O
on	O
drug	O
-	O
like	O
substances	O
from	O
the	O
NCI	O
database	O
that	O
have	O
been	O
docked	O
into	O
several	O
unrelated	O
targets	O
,	O
including	O
human	O
sex	O
hormone	O
binding	O
globulin	O
(	O
SHBG	O
),	O
carbonic	B-ENZY
anhydrase	I-ENZY
,	O
corticosteroid	O
-	O
binding	O
globulin	O
,	O
SARS	O
3C	O
-	O
like	O
protease	O
,	O
and	O
HIV1	O
reverse	B-ENZY
transcriptase	I-ENZY
.	O

Treatment	O
with	O
a	O
Fas	O
/	O
Fc	O
chimera	O
,	O
which	O
blocks	O
Fas	O
-	O
Fas	O
ligand	O
-	O
mediated	O
apoptosis	O
,	O
inhibited	O
the	O
formation	O
of	O
the	O
complexes	O
and	O
blocked	O
the	O
activation	O
of	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
and	O
apoptosis	O
in	O
MHV	O
-	O
infected	O
cells	O
.	O

It	O
also	O
inhibited	O
the	O
release	O
of	O
cytochrome	O
c	O
from	O
mitochondria	O
and	O
the	O
activation	O
of	O
caspase	B-ENZY
-	I-ENZY
9	I-ENZY
.	O

First	O
,	O
the	O
receptor	O
of	O
HCoV	O
229E	O
,	O
human	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
hAPN	O
or	O
CD13	O
)	O
is	O
expressed	O
mainly	O
on	O
human	O
dendritic	O
cells	O
(	O
DCs	O
)	O
and	O
macrophages	O
indicating	O
that	O
targeting	O
of	O
HCoV	O
229E	O
-	O
based	O
vectors	O
to	O
professional	O
antigen	O
presenting	O
cells	O
can	O
be	O
achieved	O
by	O
receptor	O
-	O
mediated	O
transduction	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
with	O
diluted	O
porcine	O
surfactant	O
in	O
mechanically	O
ventilated	O
term	O
infants	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
due	O
to	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	O
).	O

Eight	O
consecutive	O
mechanically	O
ventilated	O
term	O
infants	O
with	O
severe	O
ARDS	O
due	O
to	O
MAS	O
underwent	O
BAL	B-ENZY
with	O
15	O
mL	O
/	O
kg	O
of	O
diluted	O
(	O
5	O
.	O
3mg	O
phospholipid	O
/	O
mL	O
)	O
surfactant	O
saline	O
suspension	O
(	O
porcine	O
surfactant	O
[	O
Curosurf	O
]).	O

Compared	O
with	O
pre	O
-	O
BAL	B-ENZY
values	O
,	O
significant	O
improvements	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
mean	O
values	O
for	O
partial	O
pressure	O
of	O
oxygen	O
in	O
arterial	O
blood	O
,	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
in	O
arterial	O
blood	O
,	O
pH	O
,	O
arterial	O
/	O
alveolar	O
O2	O
ratio	O
and	O
oxygenation	O
index	O
were	O
documented	O
at	O
3	O
and	O
6	O
hours	O
after	O
BAL	B-ENZY
.	O

In	O
all	O
patients	O
,	O
tracheal	O
fluids	O
that	O
had	O
been	O
meconium	O
-	O
stained	O
prior	O
to	O
BAL	B-ENZY
were	O
clear	O
of	O
meconium	O
after	O
BAL	B-ENZY
.	O

BAL	B-ENZY
with	O
dilute	O
porcine	O
surfactant	O
administered	O
slowly	O
in	O
2	O
.	O
5	O
mL	O
aliquots	O
improved	O
oxygenation	O
and	O
chest	O
x	O
-	O
ray	O
findings	O
,	O
without	O
causing	O
major	O
adverse	O
effects	O
,	O
in	O
mechanically	O
ventilated	O
term	O
infants	O
with	O
ARDS	O
due	O
to	O
MAS	O
.	O

Animals	O
in	O
GC1	O
and	O
GC2	O
survived	O
longer	O
than	O
those	O
in	O
C	O
group	O
,	O
but	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
among	O
them	O
(	O
both	O
P	O
>	O
0	O
.	O
05	O
).	O
Oxygen	O
index	O
(	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
))	O
and	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
were	O
improved	O
in	O
GC1	O
much	O
better	O
than	O
those	O
of	O
controls	O
(	O
both	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
the	O
same	O
was	O
true	O
in	O
GC2	O
as	O
compared	O
that	O
before	O
GC	O
treatment	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

Though	O
the	O
enzyme	O
is	O
a	O
cysteine	O
protease	O
with	O
a	O
chymotrypsin	B-ENZY
fold	O
,	O
SARS	O
3C	O
-	O
like	O
proteinase	O
follows	O
the	O
general	O
base	O
catalytic	O
mechanism	O
similar	O
to	O
chymotrypsin	B-ENZY
.	O

TITLE	O
:	O
[	O
Survival	O
by	O
a	O
young	O
woman	O
with	O
malnutrition	O
due	O
to	O
alcoholism	O
and	O
eating	O
disorders	O
and	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
severe	O
pneumonia	O
who	O
showed	O
increased	O
serum	O
neutrophil	B-ENZY
elastase	I-ENZY
activity	O
].	O

Treatment	O
with	O
sivelestat	O
sodium	O
hydrate	O
also	O
decreased	O
serum	O
neutrophil	B-ENZY
elastase	I-ENZY
activity	O
.	O

Protein	B-ENZY
kinase	I-ENZY
R	O
(	O
PKR	O
)	O
and	O
the	O
alpha	O
subunit	O
of	O
eukaryotic	O
translation	O
initiation	O
factor	O
are	O
not	O
phosphorylated	O
in	O
infected	O
cells	O
.	O

Several	O
bat	B-ENZY
species	O
are	O
reservoir	O
hosts	O
of	O
zoonotic	O
viruses	O
and	O
therefore	O
can	O
be	O
a	O
public	O
health	O
hazard	O
.	O

Lyssaviruses	O
of	O
different	O
genotypes	O
have	O
emerged	O
from	O
bats	O
in	O
America	O
(	O
Genotype	O
1	O
rabies	O
virus	O
;	O
RABV	O
),	O
Europe	O
(	O
European	O
bat	B-ENZY
lyssavirus	O
;	O
EBLV	O
),	O
and	O
Australia	O
(	O
Australian	O
bat	B-ENZY
lyssavirus	O
;	O
ABLV	O
),	O
whereas	O
Nipah	O
virus	O
is	O
the	O
most	O
important	O
recent	O
zoonosis	O
of	O
bat	B-ENZY
origin	O
in	O
Asia	O
.	O

Furthermore	O
,	O
some	O
insectivorous	O
bat	B-ENZY
species	O
may	O
be	O
important	O
reservoirs	O
of	O
SARS	O
coronavirus	O
,	O
whereas	O
Ebola	O
virus	O
has	O
been	O
detected	O
in	O
some	O
megachiropteran	O
fruit	O
bats	O
.	O

Thus	O
far	O
,	O
European	O
bat	B-ENZY
lyssavirus	O
(	O
EBLV	O
)	O
is	O
the	O
only	O
zoonotic	O
virus	O
that	O
has	O
been	O
detected	O
in	O
bats	O
in	O
Europe	O
.	O

First	O
,	O
ATA	O
blocks	O
the	O
phosphorylation	O
of	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
1	O
/	O
2	O
,	O
an	O
event	O
shown	O
to	O
be	O
essential	O
for	O
vaccinia	O
virus	O
replication	O
.	O

Under	O
apnoeic	O
oxygenation	O
,	O
variations	O
of	O
sweep	O
-	O
gas	B-ENZY
flow	O
were	O
performed	O
every	O
20	O
min	O
in	O
order	O
to	O
evaluate	O
the	O
membrane	O
lung	O
'	O
s	O
efficacy	O
,	O
in	O
terms	O
of	O
carbon	O
dioxide	O
(	O
CO2	O
)	O
removal	O
and	O
oxygen	O
(	O
O2	O
)	O
uptake	O
.	O

MHV	O
nsp3	O
contains	O
multiple	O
domains	O
including	O
two	O
papain	B-ENZY
-	O
like	O
protease	O
domains	O
,	O
PLP1	O
and	O
PLP2	O
,	O
and	O
a	O
predicted	O
transmembrane	O
(	O
TM	O
)	O
domain	O
.	O

Proteinase	B-ENZY
K	I-ENZY
digestion	O
experiments	O
indicate	O
that	O
the	O
TM	O
domain	O
of	O
nsp3	O
has	O
4	O
membrane	O
-	O
spanning	O
helices	O
.	O

ABSTRACT	O
:	O
Production	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
core	O
protein	O
requires	O
the	O
cleavages	O
of	O
polyprotein	O
by	O
signal	O
peptidase	O
and	O
signal	O
peptide	O
peptidase	O
(	O
SPP	B-ENZY
).	O

Cleavage	O
of	O
signal	O
peptide	O
at	O
the	O
C	O
-	O
terminus	O
of	O
HCV	O
core	O
protein	O
by	O
SPP	B-ENZY
was	O
characterized	O
in	O
this	O
study	O
.	O

The	O
cleavage	O
efficiency	O
of	O
SPP	B-ENZY
is	O
inversely	O
proportional	O
to	O
the	O
length	O
of	O
C	O
-	O
terminal	O
extension	O
of	O
the	O
signal	O
peptide	O
:	O
the	O
longer	O
the	O
extension	O
,	O
the	O
less	O
efficiency	O
the	O
cleavage	O
is	O
.	O

Thus	O
,	O
reducing	O
the	O
length	O
of	O
C	O
-	O
terminal	O
extension	O
of	O
signal	O
peptide	O
by	O
signal	O
peptidase	O
cleavage	O
could	O
facilitate	O
further	O
cleavage	O
by	O
SPP	B-ENZY
.	O

The	O
recombinant	O
core	O
protein	O
fused	O
with	O
signal	O
peptide	O
from	O
the	O
C	O
-	O
terminus	O
of	O
p7	O
protein	O
,	O
but	O
not	O
those	O
from	O
the	O
C	O
-	O
termini	O
of	O
E1	O
and	O
E2	O
,	O
could	O
be	O
cleaved	O
by	O
SPP	B-ENZY
.	O

Therefore	O
,	O
the	O
sequence	O
of	O
the	O
signal	O
peptide	O
is	O
important	O
but	O
not	O
the	O
sole	O
determinant	O
for	O
its	O
cleavage	O
by	O
SPP	B-ENZY
.	O

120	O
-	O
150	O
)	O
with	O
the	O
E	O
.	O
R	O
.-	O
associated	O
domain	O
(	O
a	O
.	O
a	O
.	O
1	O
-	O
50	O
)	O
of	O
SARS	O
-	O
CoV	O
membrane	O
protein	O
results	O
in	O
the	O
failure	O
of	O
cleavage	O
of	O
this	O
recombinant	O
protein	O
by	O
SPP	B-ENZY
,	O
though	O
this	O
protein	O
still	O
is	O
E	O
.	O
R	O
.-	O
associated	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
both	O
sequences	O
of	O
the	O
signal	O
peptide	O
and	O
the	O
E	O
.	O
R	O
.-	O
associated	O
domain	O
are	O
important	O
for	O
the	O
signal	O
peptide	O
cleavage	O
of	O
HCV	O
core	O
protein	O
by	O
SPP	B-ENZY
.	O

TITLE	O
:	O
Human	O
coronavirus	O
229E	O
papain	B-ENZY
-	O
like	O
proteases	O
have	O
overlapping	O
specificities	O
but	O
distinct	O
functions	O
in	O
viral	O
replication	O
.	O

ABSTRACT	O
:	O
Expression	O
of	O
the	O
exceptionally	O
large	O
RNA	O
genomes	O
of	O
CoVs	O
involves	O
multiple	O
regulatory	O
mechanisms	O
,	O
including	O
extensive	O
proteolytic	O
processing	O
of	O
the	O
large	O
replicase	O
polyproteins	O
,	O
pp1a	O
and	O
pp1ab	O
,	O
by	O
two	O
types	O
of	O
cysteine	O
proteases	O
:	O
the	O
chymotrypsin	B-ENZY
-	O
like	O
main	O
protease	O
and	O
papain	B-ENZY
-	O
like	O
accessory	O
proteases	O
(	O
PLpros	O
).	O

TITLE	O
:	O
Spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
stimulates	O
cyclooxygenase	O
-	O
2	O
expression	O
via	O
both	O
calcium	O
-	O
dependent	O
and	O
calcium	B-ENZY
-	I-ENZY
independent	I-ENZY
protein	I-ENZY
kinase	I-ENZY
C	I-ENZY
pathways	O
.	O

We	O
found	O
that	O
an	O
upstream	O
calcium	O
-	O
dependent	O
PKC	B-ENZY
isozyme	O
PKC	B-ENZY
alpha	O
that	O
modulates	O
the	O
downstream	O
ERK	B-ENZY
/	O
NF	O
-	O
kappaB	O
pathway	O
through	O
an	O
influx	O
of	O
extracellular	O
Ca2	O
+	O
is	O
induced	O
by	O
the	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
ERK	B-ENZY
/	O
NF	O
-	O
kappaB	O
was	O
identified	O
to	O
be	O
involved	O
in	O
the	O
activation	O
of	O
COX	O
-	O
2	O
promoter	O
and	O
production	O
of	O
COX	O
-	O
2	O
protein	O
in	O
HEK293T	O
cells	O
.	O

We	O
also	O
demonstrated	O
that	O
another	O
unusual	O
pathway	O
,	O
the	O
calcium	O
-	O
independent	O
PI3K	O
/	O
PKC	B-ENZY
epsilon	O
/	O
JNK	B-ENZY
/	O
CREB	O
pathway	O
,	O
functioned	O
in	O
cooperation	O
with	O
the	O
calcium	O
-	O
dependent	O
pathway	O
to	O
induce	O
COX	O
-	O
2	O
expression	O
upon	O
stimulation	O
by	O
spike	O
protein	O
.	O

This	O
pathway	O
can	O
be	O
blocked	O
by	O
PKC	B-ENZY
epsilon	O
-	O
specific	O
,	O
small	O
interfering	O
RNA	O
,	O
PI3K	O
/	O
JNK	B-ENZY
kinase	O
-	O
specific	O
inhibitors	O
as	O
well	O
as	O
dominant	O
negative	O
JNK	B-ENZY
.	O

PKC	B-ENZY
epsilon	O
-	O
specific	O
siRNA	O
also	O
attenuated	O
the	O
phosphorylation	O
of	O
JNK	B-ENZY
.	O

Dating	O
of	O
different	O
coronavirus	O
lineages	O
suggests	O
that	O
bat	B-ENZY
coronaviruses	O
are	O
older	O
than	O
those	O
recognized	O
in	O
other	O
animals	O
and	O
that	O
the	O
human	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
was	O
directly	O
derived	O
from	O
viruses	O
from	O
wild	O
animals	O
in	O
wet	O
markets	O
of	O
southern	O
China	O
.	O

Further	O
surveillance	O
of	O
bat	B-ENZY
and	O
other	O
animal	O
populations	O
is	O
needed	O
to	O
fully	O
describe	O
the	O
ecology	O
and	O
evolution	O
of	O
this	O
virus	O
family	O
.	O

TITLE	O
:	O
Therapeutic	O
effects	O
of	O
caspase	B-ENZY
-	I-ENZY
1	I-ENZY
inhibitors	O
on	O
acute	O
lung	O
injury	O
in	O
experimental	O
severe	O
acute	O
pancreatitis	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
therapeutic	O
effect	O
of	O
Caspase	B-ENZY
-	I-ENZY
1	I-ENZY
inhibitors	O
(	O
ICE	O
-	O
I	O
)	O
on	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
in	O
experimental	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
).	O

Intrapulmonary	O
expression	O
of	O
Caspase	B-ENZY
-	I-ENZY
1	I-ENZY
,	O
IL	O
-	O
1beta	O
and	O
IL	O
-	O
18	O
mRNA	O
were	O
detected	O
by	O
semi	O
-	O
quantitative	O
RT	O
-	O
PCR	O
.	O

Intrapulmonary	O
expression	O
of	O
Caspase	B-ENZY
-	I-ENZY
1	I-ENZY
,	O
IL	O
-	O
1beta	O
and	O
IL	O
-	O
18	O
mRNA	O
were	O
observed	O
in	O
the	O
HC	O
group	O
,	O
while	O
they	O
were	O
increased	O
significantly	O
in	O
the	O
SAP	O
-	O
S	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
,	O
vs	O
HC	O
).	O

Caspase	B-ENZY
-	I-ENZY
1	I-ENZY
inhibitors	O
ameliorated	O
the	O
severity	O
of	O
ALI	O
in	O
SAP	O
.	O

Caspase	B-ENZY
-	I-ENZY
1	I-ENZY
activation	O
,	O
and	O
overproduction	O
of	O
IL	O
-	O
1beta	O
and	O
IL	O
-	O
18	O
play	O
an	O
important	O
role	O
in	O
the	O
course	O
of	O
ALI	O
,	O
and	O
Caspase	B-ENZY
-	I-ENZY
1	I-ENZY
inhibition	O
is	O
effective	O
for	O
the	O
treatment	O
of	O
ALI	O
in	O
experimental	O
SAP	O
.	O

Caspase	B-ENZY
-	I-ENZY
1	I-ENZY
inhibitors	O
ameliorated	O
the	O
severity	O
of	O
ALI	O
in	O
SAP	O
.	O

Preliminary	O
data	O
suggest	O
that	O
such	O
differential	O
signalling	O
involves	O
p38	O
MAP	B-ENZY
kinase	I-ENZY
rather	O
than	O
NF	O
-	O
kappaB	O
.	O
SARS	O
coronavirus	O
infection	O
of	O
primary	O
human	O
macrophages	O
is	O
associated	O
with	O
a	O
strong	O
induction	O
of	O
chemokines	O
without	O
an	O
associated	O
type	O
1	O
interferon	O
response	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
introduces	O
our	O
work	O
on	O
how	O
to	O
use	O
image	O
mining	O
techniques	O
to	O
detect	O
SARS	O
,	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
automatically	O
as	O
the	O
prototype	O
of	O
computer	O
aided	O
detection	O
/	O
diagnosis	O
(	O
CAD	B-ENZY
)	O
system	O
.	O

By	O
performing	O
a	O
forward	O
genetic	O
modifier	O
screen	O
,	O
we	O
identified	O
phosphoinositide	O
-	O
dependent	O
kinase	O
-	O
1	O
(	O
PDK	B-ENZY
-	O
1	O
)	O
as	O
a	O
dominant	O
suppressor	O
of	O
M	O
-	O
induced	O
apoptotic	O
cell	O
death	O
.	O

In	O
univariate	O
analyses	O
,	O
daily	O
average	O
temperature	O
(	O
DAT	B-ENZY
),	O
daily	O
average	O
air	O
pressure	O
(	O
DAAP	O
),	O
and	O
daily	O
average	O
relative	O
humidity	O
(	O
DARH	O
)	O
were	O
inversely	O
associated	O
with	O
secondary	O
attack	O
rate	O
(	O
P	O
<	O
0	O
.	O
001	O
);	O
a	O
significant	O
positive	O
association	O
was	O
found	O
for	O
daily	O
hours	O
of	O
sunshine	O
(	O
DHS	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

ABSTRACT	O
:	O
Ranpirnase	O
[	O
Onconase	O
]	O
is	O
an	O
amphibian	O
oocyte	O
/	O
early	O
embryo	O
ribonuclease	O
(	O
RNase	B-ENZY
)	O
of	O
105	O
amino	O
acids	O
in	O
length	O
that	O
is	O
capable	O
of	O
controlling	O
tumour	O
growth	O
by	O
degrading	O
RNA	O
within	O
cancer	O
cells	O
,	O
resulting	O
in	O
inhibition	O
of	O
protein	O
synthesis	O
and	O
arresting	O
mitosis	O
in	O
G	O
(	O
1	O
)	O
phase	O
.	O

Preclinical	O
investigations	O
conducted	O
by	O
Alfacell	O
showed	O
synergistic	O
antitumour	O
effects	O
between	O
ranpirnase	O
and	O
proteasome	B-ENZY
inhibitors	O
.	O

TITLE	O
:	O
Feline	O
aminopeptidase	B-ENZY
N	I-ENZY
is	O
not	O
a	O
functional	O
receptor	O
for	O
avian	O
infectious	O
bronchitis	O
virus	O
.	O

Feline	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
fAPN	O
)	O
serves	O
as	O
a	O
functional	O
receptor	O
for	O
most	O
group	O
1	O
coronaviruses	O
including	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
),	O
canine	O
coronavirus	O
,	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
and	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
).	O

A	O
recent	O
report	O
has	O
also	O
suggested	O
a	O
role	O
for	O
fAPN	O
during	O
IBV	O
entry	O
(	O
Miguel	O
B	O
,	O
Pharr	O
GT	O
,	O
Wang	O
C	O
:	O
The	O
role	O
of	O
feline	O
aminopeptidase	B-ENZY
N	I-ENZY
as	O
a	O
receptor	O
for	O
infectious	O
bronchitis	O
virus	O
.	O

In	O
addition	O
to	O
SARS	O
-	O
like	O
coronaviruses	O
,	O
many	O
other	O
novel	O
bat	B-ENZY
coronaviruses	O
,	O
which	O
belong	O
to	O
groups	O
1	O
and	O
2	O
of	O
the	O
3	O
existing	O
coronavirus	O
groups	O
,	O
have	O
been	O
detected	O
by	O
PCR	O
.	O

The	O
discovery	O
of	O
bat	B-ENZY
SARS	O
-	O
like	O
coronaviruses	O
and	O
the	O
great	O
genetic	O
diversity	O
of	O
coronaviruses	O
in	O
bats	O
have	O
shed	O
new	O
light	O
on	O
the	O
origin	O
and	O
transmission	O
of	O
SARS	O
coronaviruses	O
.	O

Areas	O
reviewed	O
include	O
genomic	O
studies	O
and	O
the	O
identification	O
of	O
bat	B-ENZY
-	O
SARS	O
CoV	O
,	O
spike	O
protein	O
and	O
host	O
cell	O
entry	O
,	O
nucleocapsid	O
protein	O
,	O
accessory	O
proteins	O
,	O
non	O
-	O
structural	O
proteins	O
of	O
the	O
replicase	O
complex	O
,	O
viral	O
proteases	O
and	O
their	O
inhibitors	O
,	O
and	O
clinical	O
treatment	O
of	O
SARS	O
with	O
ribavirin	O
.	O

Arterial	O
blood	O
gas	B-ENZY
analysis	O
and	O
chest	O
X	O
-	O
rays	O
were	O
performed	O
in	O
all	O
patients	O
at	O
admission	O
and	O
at	O
intervals	O
,	O
when	O
clinically	O
indicated	O
.	O

A	O
consensus	O
sequence	O
of	O
the	O
jejunum	O
-	O
derived	O
genomic	O
RNA	O
(	O
FCoV	O
C1Je	O
)	O
was	O
determined	O
from	O
overlapping	O
cDNA	O
fragments	O
produced	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
amplification	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
used	O
the	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
to	O
detect	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
in	O
sick	O
poults	O
30	O
to	O
120	O
days	O
of	O
age	O
from	O
a	O
particular	O
producer	O
region	O
in	O
Brazil	O
.	O

Sixteen	O
ventilated	O
trauma	O
patients	O
with	O
severe	O
refractory	O
hypoxemia	O
(	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)<	O
150	O
mmHg	O
)	O
and	O
lung	O
contusions	O
.	O

In	O
the	O
surfactant	O
group	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
increased	O
from	O
100	O
+/-	O
20	O
mmHg	O
at	O
baseline	O
to	O
140	O
+/-	O
20	O
(	O
6	O
h	O
),	O
163	O
+/-	O
26	O
(	O
12	O
h	O
),	O
and	O
187	O
+/-	O
30	O
mmHg	O
(	O
24h	O
).	O

TITLE	O
:	O
TNF	O
-	O
alpha	O
,	O
produced	O
by	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)-	O
infected	O
macrophages	O
,	O
upregulates	O
expression	O
of	O
type	O
II	O
FIPV	O
receptor	O
feline	O
aminopeptidase	B-ENZY
N	I-ENZY
in	O
feline	O
macrophages	O
.	O

We	O
also	O
demonstrated	O
that	O
the	O
expression	O
level	O
of	O
the	O
FIPV	O
virus	O
receptor	O
,	O
feline	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
fAPN	O
),	O
was	O
increased	O
in	O
macrophages	O
of	O
FIP	O
cats	O
.	O

Reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
used	O
to	O
detect	O
and	O
quantify	O
SARS	O
-	O
CoV	O
in	O
934	O
sera	O
and	O
self	O
-	O
collected	O
throat	O
washes	O
and	O
fecal	O
samples	O
from	O
271	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
SARS	O
managed	O
at	O
a	O
single	O
institution	O
.	O

TITLE	O
:	O
Proteolytic	O
processing	O
and	O
deubiquitinating	O
activity	O
of	O
papain	B-ENZY
-	O
like	O
proteases	O
of	O
human	O
coronavirus	O
NL63	O
.	O

Here	O
,	O
we	O
identify	O
HCoV	O
-	O
NL63	O
replicase	O
gene	O
products	O
and	O
characterize	O
two	O
viral	O
papain	B-ENZY
-	O
like	O
proteases	O
(	O
PLPs	O
),	O
PLP1	O
and	O
PLP2	O
,	O
which	O
process	O
the	O
viral	O
replicase	O
polyprotein	O
.	O

Consequently	O
,	O
the	O
pressure	O
and	O
flow	O
generation	O
capabilities	O
of	O
standard	O
anesthesia	O
ventilators	O
may	O
be	O
inadequate	O
to	O
support	O
ventilation	O
and	O
gas	B-ENZY
exchange	O
.	O

The	O
human	O
diphtheria	O
toxin	O
(	O
DT	O
)	O
receptor	O
(	O
DTR	O
),	O
heparin	O
-	O
binding	O
epidermal	O
growth	O
factor	O
-	O
like	O
growth	O
factor	O
(	O
HB	O
-	O
EGF	O
),	O
was	O
expressed	O
under	O
the	O
control	O
of	O
the	O
lysozyme	B-ENZY
M	O
(	O
LysM	O
)	O
gene	O
promoter	O
in	O
the	O
mice	O
.	O

Previously	O
,	O
SARS	O
CoV	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
has	O
been	O
demonstrated	O
to	O
induce	O
apoptosis	O
via	O
the	O
activation	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
caspase	B-ENZY
-	I-ENZY
9	I-ENZY
(	O
Lin	O
,	O
C	O
.	O
W	O
.,	O
Lin	O
,	O
K	O
.	O
H	O
.,	O
Hsieh	O
,	O
T	O
.	O
H	O
.,	O
Shiu	O
,	O
S	O
.	O
Y	O
.	O
et	O
al	O
.,	O
FEMS	O
Immunol	O
.	O

Treatment	O
includes	O
starting	O
neuraminidase	B-ENZY
inhibitor	O
oseltamivir	O
as	O
early	O
as	O
possible	O
in	O
addition	O
to	O
the	O
standard	O
supportive	O
management	O
.	O

However	O
,	O
many	O
patients	O
with	O
severe	O
ARDS	O
remain	O
hypoxemic	O
and	O
more	O
aggressive	O
ventilation	O
is	O
necessary	O
to	O
maintain	O
sufficient	O
gas	B-ENZY
exchange	O
.	O

Conventional	O
mechanical	O
ventilation	O
(	O
CV	O
)	O
with	O
high	O
-	O
airway	O
pressures	O
and	O
low	O
VT	O
failed	O
to	O
improve	O
gas	B-ENZY
exchange	O
.	O

The	O
combination	O
of	O
two	O
innovative	O
treatment	O
modalities	O
resulted	O
in	O
rapid	O
stabilization	O
and	O
improvement	O
of	O
gas	B-ENZY
exchange	O
during	O
severe	O
ARDS	O
refractory	O
to	O
conventional	O
lung	O
protective	O
ventilation	O
.	O

TITLE	O
:	O
Acute	O
effects	O
of	O
combined	O
high	O
-	O
frequency	O
oscillation	O
and	O
tracheal	O
gas	B-ENZY
insufflation	O
in	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Alveolar	O
ventilation	O
is	O
improved	O
by	O
adding	O
tracheal	O
gas	B-ENZY
insufflation	O
(	O
TGI	O
)	O
to	O
CMV	O
.	O

Neutrophils	O
activated	O
by	O
TNF	O
release	O
a	O
huge	O
amount	O
of	O
neutrophil	B-ENZY
elastase	I-ENZY
that	O
is	O
capable	O
of	O
decreasing	O
endothelial	O
prostaglandin	O
production	O
.	O

ABSTRACT	O
:	O
Some	O
patients	O
with	O
severe	O
primary	O
graft	O
dysfunction	O
(	O
PGD	O
)	O
after	O
lung	O
transplantation	O
(	O
LTx	O
)	O
require	O
gas	B-ENZY
exchange	O
support	O
using	O
an	O
extracorporeal	O
membrane	O
oxygenator	O
(	O
ECMO	O
)	O
as	O
a	O
life	O
-	O
saving	O
therapy	O
.	O

After	O
removal	O
of	O
serum	O
in	O
COS	O
-	O
1	O
cells	O
,	O
we	O
observed	O
the	O
loss	O
of	O
DeltaPsim	O
,	O
the	O
increase	O
of	O
ROS	O
and	O
cytochrome	O
C	O
release	O
into	O
cytosol	O
and	O
subsequent	O
activation	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
PARP	O
cleavage	O
.	O

ABSTRACT	O
:	O
The	O
renin	B-ENZY
-	O
angiotensin	O
-	O
aldosterone	O
system	O
(	O
RAAS	O
)	O
is	O
a	O
key	O
regulator	O
of	O
systemic	O
blood	O
pressure	O
and	O
renal	O
function	O
and	O
a	O
key	O
player	O
in	O
renal	O
and	O
cardiovascular	O
disease	O
.	O

TITLE	O
:	O
Porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
is	O
a	O
functional	O
receptor	O
for	O
the	O
PEDV	O
coronavirus	O
.	O

It	O
was	O
reported	O
that	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
)	O
is	O
the	O
receptor	O
for	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
and	O
feline	O
coronavirus	O
(	O
FeCoV	O
)	O
which	O
all	O
belong	O
to	O
group	O
I	O
coronavirus	O
including	O
as	O
well	O
as	O
PEDV	O
.	O

It	O
was	O
also	O
confirmed	O
previously	O
that	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
can	O
bind	O
to	O
PEDV	O
,	O
and	O
anti	O
-	O
pAPN	O
antibodies	O
may	O
inhibit	O
the	O
combination	O
.	O

In	O
ARDS	O
patients	O
genotypes	O
differed	O
significantly	O
between	O
those	O
with	O
severe	O
ARDS	O
[	O
Lung	O
Injury	O
Score	O
(	O
LIS	B-ENZY
)>	O
or	O
=	O
3	O
;	O
23	O
homozygote	O
deletion	O
(	O
DD	O
),	O
heterozygote	O
(	O
ID	O
)	O
31	O
,	O
and	O
homozygote	O
insertion	O
wildtype	O
(	O
II	O
)	O
23	O
],	O
and	O
those	O
with	O
LIS	B-ENZY
below	O
3	O
(	O
1	O
DD	O
,	O
9	O
ID	O
,	O
16	O
II	O
).	O

Both	O
Akt	O
and	O
p38	O
MAPK	B-ENZY
are	O
keys	O
for	O
determination	O
of	O
cell	O
survival	O
or	O
death	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
in	O
vitro	O
.	O

We	O
observed	O
that	O
(	O
i	O
)	O
the	O
5	O
'-	O
terminal	O
186	O
nt	O
of	O
the	O
nsp1	O
coding	O
region	O
are	O
necessary	O
and	O
sufficient	O
for	O
DI	O
RNA	O
replication	O
,	O
(	O
ii	O
)	O
two	O
Mfold	O
-	O
predicted	O
stem	O
-	O
loops	O
within	O
the	O
186	O
-	O
nt	O
sequence	O
,	O
named	O
SLV	O
(	O
nt	O
239	O
to	O
310	O
)	O
and	O
SLVI	O
(	O
nt	O
311	O
to	O
340	O
),	O
are	O
supported	O
by	O
RNase	B-ENZY
structure	O
probing	O
and	O
by	O
nucleotide	O
covariation	O
among	O
closely	O
related	O
group	O
2	O
coronaviruses	O
,	O
and	O
(	O
iii	O
)	O
SLVI	O
is	O
a	O
required	O
higher	O
-	O
order	O
structure	O
for	O
DI	O
RNA	O
replication	O
based	O
on	O
mutation	O
analyses	O
.	O

Blood	O
samples	O
were	O
tested	O
for	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
by	O
an	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
which	O
has	O
previously	O
been	O
described	O
to	O
have	O
a	O
high	O
specificity	O
in	O
the	O
diagnosis	O
of	O
clinical	O
FIP	O
[	O
Simons	O
AF	O
,	O
Vennema	O
H	O
,	O
Rofina	O
JE	O
,	O
Pol	O
JM	O
,	O
Horzinek	O
MC	O
,	O
Rottier	O
PJM	O
,	O
Egberink	O
HF	O
(	O
2005	O
)	O
A	O
mRNA	O
PCR	O
for	O
the	O
diagnosis	O
of	O
feline	O
infectious	O
peritonitis	O
.	O

TITLE	O
:	O
Type	O
I	O
feline	O
coronavirus	O
spike	O
glycoprotein	O
fails	O
to	O
recognize	O
aminopeptidase	B-ENZY
N	I-ENZY
as	O
a	O
functional	O
receptor	O
on	O
feline	O
cell	O
lines	O
.	O

It	O
is	O
generally	O
accepted	O
that	O
feline	O
aminopeptidase	B-ENZY
N	I-ENZY
can	O
act	O
as	O
a	O
receptor	O
for	O
the	O
attachment	O
and	O
entry	O
of	O
type	O
II	O
strains	O
,	O
and	O
it	O
has	O
been	O
proposed	O
that	O
the	O
same	O
molecule	O
acts	O
as	O
a	O
receptor	O
for	O
type	O
I	O
viruses	O
.	O

The	O
aim	O
of	O
the	O
studies	O
reported	O
here	O
was	O
to	O
provide	O
evidence	O
for	O
or	O
against	O
the	O
involvement	O
of	O
feline	O
aminopeptidase	B-ENZY
N	I-ENZY
as	O
a	O
receptor	O
for	O
type	O
I	O
feline	O
coronaviruses	O
.	O

Quick	O
encouragement	O
of	O
ECMO	O
for	O
the	O
temporary	O
management	O
of	O
gas	B-ENZY
exchange	O
may	O
increase	O
survival	O
rates	O
in	O
trauma	O
patients	O
with	O
ARDS	O
.	O

A	O
coronavirus	O
was	O
detected	O
by	O
electron	O
microscopy	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
in	O
the	O
faeces	O
and	O
in	O
the	O
intestinal	O
content	O
of	O
the	O
dead	O
quails	O
.	O

ABSTRACT	O
:	O
The	O
implication	O
of	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
in	O
the	O
regulation	O
of	O
the	O
cardiovascular	O
system	O
has	O
been	O
well	O
known	O
for	O
many	O
years	O
.	O

For	O
instance	O
,	O
ACE	B-ENZY
has	O
been	O
shown	O
to	O
work	O
not	O
only	O
by	O
generating	O
angiotensin	O
-	O
II	O
but	O
also	O
by	O
interacting	O
with	O
receptors	O
outside	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
.	O

With	O
the	O
new	O
century	O
came	O
the	O
discovery	O
of	O
a	O
new	O
homolog	O
of	O
ACE	B-ENZY
,	O
called	O
ACE2	O
,	O
and	O
early	O
studies	O
suggest	O
that	O
it	O
may	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
RAS	O
by	O
controlling	O
the	O
balance	O
between	O
the	O
vasoconstrictor	O
effects	O
of	O
angiotensin	O
-	O
II	O
and	O
the	O
vasodilatory	O
properties	O
of	O
the	O
angiotensin	O
(	O
1	O
-	O
7	O
)	O
peptide	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
compare	O
the	O
structures	O
,	O
distributions	O
and	O
properties	O
of	O
ACE	B-ENZY
and	O
its	O
new	O
homologue	O
in	O
the	O
context	O
of	O
cardiovascular	O
function	O
,	O
focusing	O
on	O
the	O
autocrine	O
/	O
paracrine	O
cardiac	O
and	O
brain	O
renin	B-ENZY
-	O
angiotensin	O
systems	O
and	O
we	O
will	O
present	O
recent	O
data	O
from	O
the	O
literature	O
and	O
our	O
laboratory	O
offering	O
a	O
new	O
perspective	O
on	O
this	O
potential	O
target	O
for	O
the	O
treatment	O
of	O
cardiovascular	O
diseases	O
.	O

Cardiovascular	O
stability	O
is	O
essential	O
to	O
produce	O
sufficiently	O
high	O
blood	O
flow	O
rates	O
over	O
the	O
gas	B-ENZY
exchange	O
unit	O
.	O

During	O
the	O
experiment	O
,	O
blood	O
samples	O
were	O
taken	O
from	O
cervical	O
artery	O
and	O
subjected	O
to	O
blood	O
-	O
gas	B-ENZY
analysis	O
at	O
different	O
time	O
points	O
after	O
oleic	O
acid	O
injection	O
.	O

Differential	O
inhibition	O
of	O
intracellular	O
signaling	O
steps	O
suggested	O
significant	O
contribution	O
of	O
phosphatidylcholine	O
-	O
specific	O
phospholipase	B-ENZY
C	I-ENZY
and	O
protein	B-ENZY
kinase	I-ENZY
C	I-ENZY
and	O
of	O
the	O
Rho	O
/	O
Rho	O
-	O
kinase	O
pathway	O
to	O
PLY	O
-	O
induced	O
pulmonary	O
vasoconstriction	O
.	O

Postmortem	O
findings	O
in	O
8	O
clinically	O
affected	O
mice	O
included	O
a	O
small	O
,	O
poorly	O
differentiated	O
exocrine	O
pancreas	O
comprising	O
cytokeratin	O
-	O
negative	O
duct	O
-	O
like	O
structures	O
but	O
lacking	O
recognizable	O
acinar	O
cells	O
with	O
their	O
normal	O
carboxypeptidase	B-ENZY
B	I-ENZY
-	O
positive	O
zymogen	O
granules	O
.	O

In	O
addition	O
,	O
emerging	O
evidence	O
suggests	O
that	O
the	O
use	O
of	O
anticoagulants	O
,	O
such	O
as	O
tissue	O
factor	O
pathway	O
inhibitor	O
,	O
antithrombin	O
,	O
thrombomodulin	O
,	O
heparin	O
,	O
activated	O
protein	O
C	O
,	O
and	O
fibrinolytics	O
(	O
plasminogen	O
activators	O
and	O
particularly	O
tissue	B-ENZY
plasminogen	I-ENZY
activator	I-ENZY
),	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
ALI	O
and	O
ARDS	O
.	O

The	O
second	O
exemplar	O
involves	O
the	O
newly	O
appreciated	O
complexity	O
of	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
as	O
a	O
regulator	O
of	O
the	O
cardiovascular	O
system	O
.	O

The	O
application	O
of	O
functional	O
genomics	O
approaches	O
to	O
the	O
discovery	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
-	O
2	O
(	O
ACE2	O
)	O
as	O
a	O
counterbalance	O
to	O
the	O
well	O
known	O
hypertensive	O
target	O
ACE	B-ENZY
will	O
be	O
highlighted	O
and	O
their	O
differential	O
cellular	O
targeting	O
and	O
enzymology	O
addressed	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
a	O
technology	O
that	O
can	O
provide	O
extracorporeal	O
gas	B-ENZY
exchange	O
to	O
patients	O
with	O
severe	O
pulmonary	O
or	O
cardiac	O
dysfunction	O
.	O

The	O
majority	O
of	O
cases	O
of	O
pulmonary	O
-	O
renal	O
syndrome	O
are	O
associated	O
with	O
ANCAs	O
,	O
either	O
c	O
-	O
ANCA	O
or	O
p	O
-	O
ANCA	O
,	O
due	O
to	O
autoantibodies	O
against	O
the	O
target	O
antigens	O
proteinase	O
-	O
3	O
and	O
myeloperoxidase	B-ENZY
respectively	O
.	O

Diffuse	O
alveolar	O
haemorrhage	O
is	O
characterized	O
by	O
the	O
presence	O
of	O
a	O
haemorrhagic	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
in	O
serial	O
BAL	B-ENZY
samples	O
.	O

The	O
specimens	O
were	O
also	O
examined	O
for	O
the	O
presence	O
of	O
other	O
enteric	O
pathogens	O
,	O
bovine	O
rotavirus	O
,	O
coronavirus	O
and	O
Cryptosporidium	O
spp	B-ENZY
.	O

Rotavirus	O
was	O
confirmed	O
to	O
be	O
associated	O
with	O
calf	O
diarrhea	O
,	O
but	O
coronavirus	O
and	O
Cryptosporidium	O
spp	B-ENZY
.	O

The	O
S1	O
glycoprotein	O
gene	O
of	O
IBV	O
isolates	O
were	O
amplified	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
proved	O
to	O
be	O
S1	O
gene	O
by	O
sequencing	O
.	O

In	O
addition	O
,	O
AM	O
significantly	O
suppressed	O
apoptosis	O
of	O
alveolar	O
wall	O
cells	O
as	O
indicated	O
by	O
cleaved	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
staining	O
.	O

ACE	B-ENZY
cleaves	O
angiotensin	O
I	O
to	O
generate	O
angiotensin	O
II	O
,	O
whereas	O
ACE2	O
reduces	O
angiotensin	O
II	O
levels	O
.	O

ABSTRACT	O
:	O
Secondary	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
)	O
is	O
a	O
lethal	O
complication	O
after	O
resuscitation	O
from	O
burn	O
shock	O
,	O
even	O
after	O
abdominal	O
decompression	O
(	O
AD	O
)	O
is	O
performed	O
.	O

This	O
study	O
investigated	O
increased	O
susceptibility	O
to	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
)	O
in	O
extensively	O
burned	O
patients	O
with	O
ACS	B-ENZY
.	O

Hemodynamic	O
parameters	O
,	O
blood	O
gas	B-ENZY
analysis	O
,	O
and	O
intrabladder	O
pressure	O
as	O
intra	O
-	O
abdominal	O
pressure	O
were	O
recorded	O
.	O

Ventilatory	O
pattern	O
,	O
respiratory	O
system	O
compliance	O
,	O
blood	O
gas	B-ENZY
analysis	O
,	O
and	O
hemodynamic	O
profile	O
were	O
recorded	O
and	O
entered	O
in	O
a	O
stepwise	O
regression	O
model	O
.	O

Although	O
neuraminidase	B-ENZY
inhibitors	O
are	O
effective	O
in	O
treating	O
avian	O
influenza	O
,	O
especially	O
if	O
given	O
within	O
48	O
h	O
of	O
infection	O
,	O
it	O
is	O
harder	O
to	O
prevent	O
the	O
resultant	O
hypercytokinaemia	O
from	O
developing	O
if	O
the	O
patient	O
does	O
not	O
seek	O
timely	O
medical	O
assistance	O
.	O

Two	O
adverse	O
outcomes	O
were	O
examined	O
:	O
hospital	O
mortality	O
and	O
the	O
development	O
of	O
oxygenation	O
failure	O
based	O
on	O
the	O
estimated	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
of	O
<	O
200	O
mm	O
Hg	O
.	O

Blood	O
samples	O
were	O
obtained	O
for	O
the	O
determination	O
of	O
amylase	O
,	O
lipase	B-ENZY
,	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
macrophage	O
inflammatory	O
peptide	O
(	O
MIP	O
)-	O
2	O
and	O
soluble	O
intercellular	O
adhesion	O
molecule	O
(	O
sICAM	O
)-	O
1	O
levels	O
,	O
while	O
pancreatic	O
and	O
lung	O
tissues	O
were	O
removed	O
for	O
myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
activity	O
,	O
nitric	O
oxide	O
(	O
NOx	O
)	O
level	O
,	O
CD40	O
expression	O
and	O
histological	O
evaluation	O
.	O

Cerulein	O
injection	O
caused	O
severe	O
AP	O
,	O
confirmed	O
by	O
an	O
increase	O
in	O
serum	O
amylase	O
and	O
lipase	B-ENZY
levels	O
,	O
histopathological	O
findings	O
of	O
severe	O
AP	O
,	O
and	O
pancreatic	O
MPO	O
activity	O
,	O
compared	O
to	O
the	O
values	O
obtained	O
in	O
the	O
sham	O
group	O
.	O

ABSTRACT	O
:	O
An	O
incident	O
involving	O
the	O
release	O
of	O
chlorine	O
gas	B-ENZY
from	O
the	O
pump	O
room	O
at	O
a	O
local	O
swimming	O
pool	O
resulted	O
in	O
54	O
patients	O
seeking	O
treatment	O
in	O
the	O
emergency	O
departments	O
(	O
EDs	O
)	O
of	O
two	O
local	O
,	O
tertiary	O
-	O
level	O
hospitals	O
in	O
Singapore	O
.	O

SARS	O
-	O
CoV	O
viral	O
load	O
and	O
SARS	O
-	O
CoV	O
/	O
GAPDH	B-ENZY
RNA	O
ratio	O
for	O
each	O
organ	O
type	O
were	O
related	O
to	O
four	O
time	O
durations	O
:	O
onset	O
of	O
illness	O
to	O
death	O
,	O
death	O
to	O
post	O
-	O
mortem	O
tissue	O
sampling	O
,	O
and	O
total	O
durations	O
of	O
treatment	O
with	O
ribavirin	O
and	O
hydrocortisone	O
.	O

Outcomes	O
included	O
survival	O
and	O
parameters	O
of	O
systemic	O
inflammation	O
(	O
plasma	O
neutrophil	O
,	O
cytokine	O
,	O
chemokine	O
,	O
and	O
nitrite	O
/	O
nitrate	O
levels	O
),	O
pulmonary	O
inflammation	O
(	O
lung	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
myeloperoxidase	B-ENZY
activities	O
,	O
inducible	O
nitric	O
oxide	O
synthase	O
expression	O
,	O
inducible	O
nitric	O
oxide	O
synthase	O
-	O
Hsp90	O
complex	O
formation	O
,	O
and	O
leukocyte	O
infiltration	O
),	O
and	O
lung	O
injury	O
(	O
pulmonary	O
capillary	O
leak	O
and	O
lung	O
function	O
).	O

TITLE	O
:	O
Complete	O
genome	O
sequence	O
of	O
bat	B-ENZY
coronavirus	O
HKU2	O
from	O
Chinese	O
horseshoe	O
bats	O
revealed	O
a	O
much	O
smaller	O
spike	O
gene	O
with	O
a	O
different	O
evolutionary	O
lineage	O
from	O
the	O
rest	O
of	O
the	O
genome	O
.	O

ABSTRACT	O
:	O
Apart	O
from	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
,	O
we	O
have	O
identified	O
a	O
novel	O
group	O
1	O
coronavirus	O
,	O
bat	B-ENZY
-	O
CoV	O
HKU2	O
,	O
in	O
Rhinolophus	O
sinicus	O
(	O
Chinese	O
horseshoe	O
bats	O
).	O

This	O
spike	O
protein	O
,	O
sharing	O
similar	O
deletions	O
with	O
other	O
group	O
2	O
coronaviruses	O
in	O
its	O
C	O
-	O
terminus	O
,	O
also	O
contained	O
a	O
15	O
-	O
amino	O
acid	O
peptide	O
homologous	O
to	O
a	O
corresponding	O
peptide	O
within	O
the	O
RBM	O
of	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
,	O
which	O
was	O
absent	O
in	O
other	O
coronaviruses	O
except	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
.	O
These	O
suggest	O
a	O
common	O
evolutionary	O
origin	O
in	O
the	O
spike	O
protein	O
of	O
bat	B-ENZY
-	O
CoV	O
HKU2	O
,	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
,	O
and	O
SARS	O
-	O
CoV	O
.	O

Moreover	O
,	O
CXCL10	O
(-/-)	O
mice	O
infected	O
with	O
MHV	O
-	O
CXCL10	O
were	O
protected	O
from	O
severe	O
hepatitis	O
as	O
evidenced	O
by	O
reduced	O
pathology	O
and	O
serum	O
alanine	B-ENZY
aminotransferase	I-ENZY
levels	O
compared	O
with	O
MHV	O
-	O
infected	O
mice	O
.	O

In	O
contrast	O
,	O
treatment	O
of	O
MHV	O
-	O
CXCL10	O
-	O
infected	O
CXCL10	O
(-/-)	O
mice	O
with	O
anti	O
-	O
CXCL10	O
Ab	O
resulted	O
in	O
increased	O
clinical	O
disease	O
correlating	O
with	O
enhanced	O
viral	O
recovery	O
from	O
the	O
brain	O
and	O
liver	O
as	O
well	O
as	O
increased	O
serum	O
alanine	B-ENZY
aminotransferase	I-ENZY
levels	O
.	O

Trypsin	B-ENZY
was	O
not	O
the	O
determinant	O
for	O
the	O
viral	O
replication	O
,	O
suggesting	O
that	O
the	O
restriction	O
of	O
IBV	O
replication	O
in	O
HeLa	O
cells	O
is	O
the	O
result	O
of	O
intracellular	O
events	O
rather	O
than	O
the	O
binding	O
to	O
or	O
fusion	O
with	O
host	O
cells	O
.	O

The	O
presence	O
of	O
sialic	O
acid	O
on	O
HeLa	O
cells	O
contributed	O
to	O
efficient	O
virus	O
replication	O
,	O
while	O
human	O
aminopeptidase	B-ENZY
N	I-ENZY
was	O
not	O
involved	O
in	O
the	O
infection	O
.	O

In	O
the	O
absence	O
of	O
the	O
8a	O
region	O
,	O
protein	O
8b	O
undergoes	O
rapid	O
degradation	O
by	O
proteasomes	O
,	O
and	O
addition	O
of	O
proteasome	B-ENZY
inhibitors	O
inhibits	O
the	O
degradation	O
of	O
protein	O
8b	O
as	O
well	O
as	O
the	O
protein	O
8b	O
-	O
induced	O
rapid	O
degradation	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
E	O
protein	O
.	O

Acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
III	O
(	O
APACHE	O
III	O
),	O
multiple	O
organ	O
dysfunction	O
syndrome	O
score	O
(	O
MODS	O
score	O
),	O
and	O
lung	O
injury	O
score	O
(	O
LIS	B-ENZY
)	O
were	O
determined	O
on	O
the	O
onset	O
day	O
of	O
ARDS	O
for	O
all	O
the	O
patients	O
.	O

Other	O
recorded	O
variables	O
included	O
age	O
,	O
sex	O
,	O
biochemical	O
indicators	O
,	O
blood	O
gas	B-ENZY
analysis	O
,	O
length	O
of	O
stay	O
in	O
ICU	O
,	O
length	O
of	O
ventilation	O
,	O
presence	O
or	O
absence	O
of	O
tracheostomy	O
,	O
ventilation	O
variables	O
,	O
elective	O
operation	O
or	O
emergency	O
operation	O
.	O

Predictors	O
of	O
death	O
at	O
the	O
onset	O
of	O
ARDS	O
were	O
advanced	O
age	O
,	O
MODS	O
>	O
or	O
=	O
to	O
8	O
,	O
and	O
LIS	B-ENZY
>	O
or	O
=	O
2	O
.	O
76	O
.	O

Based	O
on	O
this	O
patient	O
population	O
,	O
advanced	O
age	O
,	O
MODS	O
score	O
,	O
and	O
LIS	B-ENZY
may	O
be	O
the	O
important	O
prognostic	O
indicators	O
for	O
ARDS	O
.	O

Predictors	O
of	O
death	O
at	O
the	O
onset	O
of	O
ARDS	O
were	O
advanced	O
age	O
,	O
MODS	O
>	O
or	O
=	O
to	O
8	O
,	O
and	O
LIS	B-ENZY
>	O
or	O
=	O
2	O
.	O
76	O
.	O

Phospholipid	O
-	O
to	O
-	O
protein	O
ratio	O
in	O
BAL	B-ENZY
fluids	O
,	O
phospholipid	O
class	O
profiles	O
,	O
phosphatidylcholine	O
(	O
PC	O
)	O
molecular	O
species	O
,	O
surfactant	O
proteins	O
(	O
SP	O
)-	O
A	O
,	O
-	O
B	O
,	O
-	O
C	O
,	O
-	O
D	O
,	O
and	O
relative	O
content	O
and	O
surface	O
tension	O
properties	O
of	O
large	O
surfactant	O
aggregates	O
(	O
LA	O
)	O
were	O
assessed	O
.	O

TITLE	O
:	O
Pseudomembranous	O
necrotizing	O
tracheobronchitis	O
caused	O
by	O
Aspergillus	O
spp	B-ENZY
--	O
contribution	O
of	O
one	O
case	O
with	O
acute	O
myeloid	O
leukemia	O
.	O

The	O
authors	O
report	O
on	O
a	O
case	O
of	O
pseudomembranous	O
necrotizing	O
form	O
of	O
histologically	O
proven	O
tracheobronchitis	O
,	O
caused	O
by	O
Aspergillus	O
spp	B-ENZY
in	O
the	O
time	O
of	O
induction	O
chemotherapy	O
in	O
a	O
patient	O
with	O
acute	O
myeloid	O
leukemia	O
.	O

Multiple	O
spontaneous	O
expectoration	O
of	O
a	O
part	O
of	O
the	O
bronchial	O
wall	O
was	O
observed	O
in	O
which	O
Aspergillus	O
spp	B-ENZY
hyphae	O
were	O
histologically	O
proven	O
.	O

TITLE	O
:	O
Selectivity	O
in	O
ISG15	O
and	O
ubiquitin	O
recognition	O
by	O
the	O
SARS	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
.	O

RNA	O
and	O
protein	O
composition	O
analysis	O
by	O
RNase	B-ENZY
-	O
gold	O
and	O
immunoelectron	O
microscopy	O
showed	O
that	O
rTGEV	O
-	O
DeltaE	O
virions	O
contained	O
RNA	O
and	O
also	O
all	O
the	O
structural	O
TGEV	O
proteins	O
,	O
except	O
the	O
deleted	O
E	O
protein	O
.	O

ABSTRACT	O
:	O
Pulmonary	O
complication	O
in	O
severe	O
Plasmodium	O
falciparum	O
malaria	O
is	O
manifested	O
as	O
a	O
prolonged	O
impairment	O
of	O
gas	B-ENZY
transfer	O
or	O
the	O
more	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Multiplex	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
PCR	O
was	O
developed	O
for	O
simultaneous	O
differential	O
quantification	O
of	O
each	O
virus	O
in	O
a	O
single	O
reaction	O
tube	O
,	O
using	O
Cy5	O
-	O
and	O
FAM	O
-	O
labeled	O
TaqMan	O
-	O
probes	O
based	O
on	O
sequences	O
from	O
the	O
TGEV	O
and	O
PEDV	O
nucleocapsid	O
genes	O
.	O

Inflammatory	O
stimuli	O
can	O
activate	O
IkappaB	O
kinase	O
(	O
IKK	B-ENZY
)	O
signalsome	O
and	O
subsequently	O
the	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
),	O
which	O
influences	O
gene	O
expression	O
of	O
cyclooxygenase	O
-	O
2	O
(	O
Cox	O
-	O
2	O
)	O
along	O
with	O
other	O
transcription	O
factors	O
.	O

Further	O
investigation	O
showed	O
M	O
protein	O
suppressed	O
Cox	O
-	O
2	O
expression	O
using	O
a	O
luciferase	B-ENZY
reporter	O
gene	O
assay	O
,	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
analysis	O
.	O

A	O
series	O
of	O
benzothiazolium	O
compounds	O
were	O
found	O
to	O
have	O
inhibitory	O
activity	O
against	O
TGEV	O
3CL	O
(	O
pro	O
)	O
and	O
to	O
exert	O
anti	O
-	O
TGEV	O
activities	O
in	O
terms	O
of	O
viral	O
protein	O
and	O
RNA	O
replication	O
in	O
TGEV	O
-	O
infected	O
ST	O
cells	O
,	O
with	O
consequent	O
protection	O
of	O
TGEV	O
-	O
infected	O
ST	O
cells	O
from	O
cytopathic	O
effect	O
by	O
blocking	O
the	O
activation	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
.	O

Prospective	O
,	O
clinical	O
study	O
of	O
consecutive	O
episodes	O
of	O
ACS	B-ENZY
in	O
patients	O
with	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
seen	O
at	O
Nizwa	O
Regional	O
Referral	O
Hospital	O
,	O
Oman	O
between	O
June	O
2001	O
and	O
May	O
2006	O
.	O

In	O
general	O
,	O
there	O
was	O
no	O
relationship	O
between	O
severity	O
of	O
SCD	O
and	O
the	O
incidence	O
of	O
ACS	B-ENZY
,	O
but	O
in	O
71	O
%	O
of	O
cases	O
a	O
vaso	O
-	O
occlusive	O
crisis	O
(	O
VOC	O
)	O
preceded	O
the	O
episodes	O
.	O

The	O
distribution	O
of	O
ACS	B-ENZY
during	O
the	O
year	O
was	O
bimodal	O
,	O
peaking	O
in	O
May	O
and	O
September	O
and	O
at	O
its	O
lowest	O
in	O
June	O
and	O
December	O
/	O
January	O
.	O

ACS	B-ENZY
is	O
common	O
in	O
SCD	O
.	O

RESULTS	O
:	O
Of	O
240	O
patients	O
registered	O
with	O
SCD	O
,	O
52	O
(	O
22	O
%)	O
developed	O
55	O
episodes	O
of	O
ACS	B-ENZY
.	O

In	O
September	O
2003	O
,	O
the	O
Colombian	O
epidemiological	O
surveillance	O
system	O
was	O
notified	O
of	O
several	O
deaths	O
from	O
an	O
acute	O
respiratory	O
disease	O
(	O
ARD	B-ENZY
).	O

In	O
order	O
to	O
identify	O
the	O
agents	O
associated	O
with	O
ARD	B-ENZY
cases	O
,	O
a	O
clinical	O
and	O
laboratory	O
-	O
based	O
surveillance	O
system	O
was	O
implemented	O
throughout	O
the	O
country	O
.	O

RESULTS	O
:	O
Between	O
September	O
19	O
and	O
December	O
31	O
,	O
2003	O
,	O
64	O
suspected	O
cases	O
of	O
ARD	B-ENZY
were	O
reported	O
;	O
of	O
these	O
reported	O
cases	O
,	O
21	O
(	O
33	O
%)	O
died	O
.	O

ABSTRACT	O
:	O
A	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
based	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
based	O
on	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
was	O
developed	O
to	O
differentiate	O
between	O
field	O
isolates	O
of	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
)	O
and	O
a	O
vaccine	O
strain	O
,	O
J	O
-	O
vac	O
.	O

TITLE	O
:	O
Regulation	O
of	O
IRF	O
-	O
3	O
-	O
dependent	O
innate	O
immunity	O
by	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
domain	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

In	O
searching	O
for	O
a	O
SARS	O
-	O
CoV	O
protein	O
capable	O
of	O
counteracting	O
innate	O
immunity	O
,	O
we	O
identified	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
domain	O
as	O
a	O
potent	O
IFN	O
antagonist	O
.	O

PCR	O
assays	O
for	O
Bartonella	O
species	O
and	O
FHV	O
-	O
1	O
and	O
a	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
assay	O
for	O
FCV	O
were	O
performed	O
on	O
blood	O
and	O
throat	O
swabs	O
.	O

Administration	O
of	O
MSCs	O
significantly	O
reduced	O
LPS	O
-	O
induced	O
pulmonary	O
inflammation	O
,	O
as	O
reflected	O
by	O
reductions	O
in	O
total	O
cell	O
and	O
neutrophil	O
counts	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
(	O
53	O
%,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
7	O
%-	O
101	O
%;	O
and	O
60	O
%,	O
CI	O
4	O
%-	O
116	O
%,	O
respectively	O
)	O
as	O
well	O
as	O
reducing	O
levels	O
of	O
proinflammatory	O
cytokines	O
in	O
both	O
BAL	B-ENZY
fluid	O
and	O
lung	O
parenchymal	O
homogenates	O
.	O

Clinicopathological	O
abnormalities	O
included	O
nonregenerative	O
anaemia	O
,	O
hypoalbuminaemia	O
,	O
increased	O
globulin	O
concentration	O
,	O
and	O
mildly	O
elevated	O
aspartate	B-ENZY
aminotransferase	I-ENZY
and	O
alkaline	B-ENZY
phosphatase	I-ENZY
activities	O
.	O

ABSTRACT	O
:	O
Structure	O
-	O
based	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
peptidomimetic	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
inhibitors	O
are	O
described	O
.	O

The	O
sequences	O
of	O
six	O
bat	B-ENZY
GHV	O
were	O
similarly	O
related	O
to	O
members	O
of	O
the	O
gammaherpesvirus	O
genera	O
Percavirus	O
and	O
Rhadinovirus	O
.	O

For	O
three	O
bat	B-ENZY
GHV	O
a	O
3	O
.	O
6	O
kbp	O
locus	O
was	O
amplified	O
and	O
sequenced	O
,	O
spanning	O
part	O
of	O
the	O
glycoprotein	O
B	O
gene	O
and	O
the	O
majority	O
of	O
the	O
DPOL	O
gene	O
.	O

In	O
phylogenetic	O
analysis	O
,	O
the	O
three	O
bat	B-ENZY
GHV	O
formed	O
a	O
separate	O
clade	O
with	O
similar	O
distance	O
to	O
the	O
Percavirus	O
and	O
Rhadinovirus	O
clades	O
.	O

Mechanisms	O
for	O
antiviral	O
activity	O
of	O
Glycyrrhiza	O
spp	B-ENZY
.	O
include	O
reduced	O
transport	O
to	O
the	O
membrane	O
and	O
sialylation	O
of	O
hepatitis	O
B	O
virus	O
surface	O
antigen	O
,	O
reduction	O
of	O
membrane	O
fluidity	O
leading	O
to	O
inhibition	O
of	O
fusion	O
of	O
the	O
viral	O
membrane	O
of	O
HIV	O
-	O
1	O
with	O
the	O
cell	O
,	O
induction	O
of	O
interferon	O
gamma	O
in	O
T	O
-	O
cells	O
,	O
inhibition	O
of	O
phosphorylating	O
enzymes	O
in	O
vesicular	O
stomatitis	O
virus	O
infection	O
and	O
reduction	O
of	O
viral	O
latency	O
.	O

In	O
this	O
study	O
,	O
two	O
recombinant	O
baculoviruses	O
,	O
vAc	O
-	O
N	O
and	O
vAc	O
-	O
S	O
,	O
were	O
constructed	O
,	O
which	O
contained	O
the	O
mammalian	O
-	O
cell	O
activate	O
promoter	O
element	O
,	O
human	O
elongation	O
factor	O
1alpha	O
-	O
subunit	O
(	O
EF	O
-	O
1alpha	O
),	O
the	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
immediate	O
-	O
early	O
promoter	O
,	O
and	O
the	O
nucleocapsid	O
(	O
N	O
)	O
or	O
spike	O
(	O
S	O
)	O
gene	O
of	O
bat	B-ENZY
SARS	O
-	O
like	O
CoV	O
(	O
SL	O
-	O
CoV	O
)	O
under	O
the	O
control	O
of	O
the	O
CMV	O
promoter	O
.	O

The	O
number	O
of	O
coronavirus	O
species	O
with	O
complete	O
genomes	O
available	O
has	O
increased	O
from	O
9	O
in	O
2003	O
to	O
25	O
in	O
2007	O
,	O
of	O
which	O
six	O
,	O
including	O
coronavirus	O
HKU1	O
,	O
bat	B-ENZY
SARS	O
coronavirus	O
,	O
group	O
1	O
bat	B-ENZY
coronavirus	O
HKU2	O
,	O
groups	O
2c	O
and	O
2d	O
coronaviruses	O
,	O
were	O
sequenced	O
by	O
our	O
laboratory	O
.	O

The	O
univariate	O
analysis	O
and	O
multivariate	O
analysis	O
demonstrated	O
that	O
the	O
clinical	O
conditions	O
such	O
as	O
elder	O
age	O
,	O
shock	O
,	O
dyspnea	O
,	O
abnormal	O
arterial	O
blood	O
gas	B-ENZY
,	O
hemopneumothorax	O
,	O
pulmonary	O
contusion	O
,	O
flail	O
chest	O
,	O
coexisting	O
pulmonary	O
diseases	O
,	O
multiple	O
abdominal	O
injury	O
and	O
high	O
ISS	O
score	O
were	O
the	O
independent	O
high	O
risk	O
factors	O
related	O
to	O
ARDS	O
.	O

Neuraminidase	B-ENZY
inhibitors	O
are	O
effective	O
in	O
the	O
treatment	O
of	O
avian	O
influenza	O
especially	O
when	O
given	O
early	O
,	O
in	O
the	O
first	O
48	O
hours	O
of	O
infection	O
.	O

In	O
both	O
groups	O
,	O
gas	B-ENZY
exchange	O
improved	O
in	O
the	O
course	O
of	O
the	O
study	O
(	O
p	O
<	O
.	O
05	O
).	O

The	O
effects	O
of	O
CNEP	O
combined	O
with	O
HFO	O
on	O
pulmonary	O
gas	B-ENZY
exchange	O
and	O
circulation	O
were	O
examined	O
in	O
a	O
surfactant	O
-	O
depleted	O
rabbit	O
model	O
.	O

Physiological	O
and	O
blood	O
gas	B-ENZY
data	O
were	O
compared	O
among	O
groups	O
using	O
analysis	O
of	O
variance	O
.	O

TITLE	O
:	O
Regulation	O
of	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
during	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
A	O
hallmark	O
of	O
acute	O
lung	O
injury	O
is	O
the	O
accumulation	O
of	O
a	O
protein	O
rich	O
edema	O
which	O
impairs	O
gas	B-ENZY
exchange	O
and	O
leads	O
to	O
hypoxemia	O
.	O

The	O
resolution	O
of	O
lung	O
edema	O
is	O
effected	O
by	O
active	O
sodium	O
transport	O
,	O
mostly	O
contributed	O
by	O
apical	O
Na	O
(+)	O
channels	O
and	O
the	O
basolateral	O
located	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
decrease	O
of	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
function	O
seen	O
during	O
lung	O
injury	O
is	O
due	O
to	O
its	O
endocytosis	O
from	O
the	O
cell	O
plasma	O
membrane	O
into	O
intracellular	O
pools	O
.	O

Cells	O
exposed	O
to	O
hypoxia	O
generate	O
reactive	O
oxygen	O
species	O
which	O
activate	O
PKC	B-ENZY
zeta	O
which	O
in	O
turn	O
phosphorylates	O
the	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
at	O
the	O
Ser18	O
residue	O
in	O
the	O
N	O
-	O
terminus	O
of	O
the	O
alpha1	O
-	O
subunit	O
leading	O
the	O
ubiquitination	O
of	O
any	O
of	O
the	O
four	O
lysines	O
(	O
K16	O
,	O
K17	O
,	O
K19	O
,	O
K20	O
)	O
adjacent	O
to	O
the	O
Ser18	O
residue	O
.	O

Finally	O
,	O
the	O
ubiquitinated	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
undergoes	O
degradation	O
via	O
a	O
lysosome	O
/	O
proteasome	B-ENZY
dependent	O
mechanism	O
.	O

The	O
MTD	B-ENZY
was	O
not	O
assessed	O
because	O
the	O
study	O
was	O
halted	O
due	O
to	O
slow	O
accrual	O
.	O

Moreover	O
,	O
domain	O
III	O
rotates	O
dramatically	O
against	O
the	O
chymotrypsin	B-ENZY
fold	O
compared	O
with	O
the	O
dimer	O
,	O
from	O
which	O
we	O
proposed	O
a	O
putative	O
dimerization	O
model	O
for	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

ABSTRACT	O
:	O
A	O
fraction	O
of	O
SIDS	O
cases	O
have	O
death	O
delayed	O
by	O
successful	O
CPR	B-ENZY
,	O
yet	O
they	O
have	O
not	O
been	O
compared	O
to	O
SIDS	O
cases	O
which	O
were	O
found	O
dead	O
or	O
not	O
successfully	O
resuscitated	O
.	O

Our	O
aims	O
were	O
to	O
:	O
(	O
1	O
)	O
determine	O
the	O
percent	O
of	O
SIDS	O
cases	O
in	O
the	O
San	O
Diego	O
SIDS	O
Research	O
Project	O
database	O
for	O
whom	O
death	O
was	O
delayed	O
by	O
CPR	B-ENZY
and	O
subsequent	O
life	O
support	O
;	O
(	O
2	O
)	O
compare	O
demographics	O
,	O
circumstances	O
of	O
death	O
and	O
autopsy	O
findings	O
of	O
delayed	O
death	O
SIDS	O
cases	O
(	O
delayed	O
SIDS	O
)	O
with	O
those	O
whose	O
deaths	O
were	O
not	O
delayed	O
(	O
non	O
-	O
delayed	O
SIDS	O
);	O
(	O
3	O
)	O
examine	O
the	O
evolution	O
of	O
pathologic	O
changes	O
in	O
delayed	O
SIDS	O
as	O
a	O
function	O
of	O
survival	O
interval	O
.	O

We	O
did	O
not	O
identify	O
factors	O
that	O
would	O
reliably	O
predict	O
which	O
SIDS	O
cases	O
might	O
be	O
discovered	O
soon	O
enough	O
to	O
allow	O
earlier	O
and	O
more	O
effective	O
CPR	B-ENZY
and	O
survival	O
without	O
permanent	O
brain	O
injury	O
.	O

Inhaled	O
nitric	O
oxide	O
(	O
iNO	O
)	O
can	O
improve	O
gas	B-ENZY
exchange	O
and	O
decrease	O
pulmonary	O
vascular	O
resistance	O
.	O

The	O
samples	O
were	O
screened	O
for	O
astrovirus	O
,	O
rotavirus	O
,	O
reovirus	O
,	O
and	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
by	O
a	O
reverse	B-ENZY
transcriptase	I-ENZY
and	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
for	O
groups	O
1	O
and	O
2	O
adenovirus	O
by	O
PCR	O
.	O

Urokinase	B-ENZY
potentiates	O
neutrophil	O
activation	O
and	O
contributes	O
to	O
the	O
severity	O
of	O
pulmonary	O
injury	O
in	O
preclinical	O
models	O
of	O
ALI	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
examine	O
associations	O
between	O
polymorphisms	O
and	O
haplotypes	O
of	O
urokinase	B-ENZY
with	O
risk	O
for	O
and	O
outcomes	O
from	O
ALI	O
.	O

Six	O
polymorphisms	O
,	O
rs1916341	O
,	O
rs2227562	O
,	O
rs2227564	O
,	O
rs2227566	O
,	O
rs2227571	O
,	O
and	O
rs4065	O
,	O
defining	O
98	O
%	O
of	O
all	O
urokinase	B-ENZY
haplotypes	O
,	O
were	O
analyzed	O
.	O

ABSTRACT	O
:	O
The	O
effect	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
outbreak	O
on	O
the	O
willingness	O
of	O
laypersons	O
to	O
provide	O
bystander	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	B-ENZY
)	O
using	O
standard	O
CPR	B-ENZY
(	O
SCPR	O
)	O
or	O
compression	O
-	O
only	O
CPR	B-ENZY
(	O
CCPR	O
)	O
was	O
evaluated	O
.	O

Persons	O
who	O
attended	O
a	O
CPR	B-ENZY
course	O
from	O
January	O
2000	O
through	O
February	O
2003	O
answered	O
a	O
structured	O
questionnaire	O
.	O

Next	O
in	O
order	O
of	O
frequency	O
were	O
adenovirus	O
(	O
116	O
/	O
312	O
:	O
37	O
%),	O
human	O
bocavirus	O
(	O
57	O
/	O
312	O
:	O
18	O
%),	O
rhinovirus	O
(	O
36	O
/	O
325	O
:	O
11	O
%),	O
Chlamydia	O
spp	B-ENZY
.	O

The	O
process	O
of	O
temperature	O
regulation	O
can	O
be	O
altered	O
by	O
drugs	O
such	O
as	O
succinylcholine	O
,	O
phenothiazines	O
,	O
monoamine	B-ENZY
oxidase	I-ENZY
inhibitors	O
,	O
atropine	O
,	O
benztropine	O
,	O
antihistamines	O
,	O
cocaine	O
,	O
Ecstasy	O
,	O
amphetamines	O
,	O
and	O
haloperidol	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
human	O
coronavirus	O
229E	O
infection	O
in	O
human	O
epithelial	O
lung	O
cells	O
(	O
L132	O
)	O
by	O
chloroquine	O
:	O
involvement	O
of	O
p38	O
MAPK	B-ENZY
and	O
ERK	B-ENZY
.	O

We	O
demonstrated	O
that	O
CQ	O
affects	O
the	O
activation	O
of	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
and	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
(	O
ERK	B-ENZY
).	O

However	O
,	O
previous	O
studies	O
suggested	O
that	O
none	O
of	O
the	O
currently	O
sampled	O
bat	B-ENZY
SLCoVs	O
is	O
the	O
descendant	O
of	O
the	O
direct	O
ancestor	O
of	O
SCoV	O
,	O
based	O
on	O
their	O
relatively	O
distant	O
phylogenetic	O
relationship	O
.	O

In	O
this	O
study	O
,	O
evidence	O
of	O
the	O
recombinant	O
origin	O
of	O
the	O
genome	O
of	O
a	O
bat	B-ENZY
SLCoV	O
is	O
demonstrated	O
.	O

Phylogenetic	O
analysis	O
of	O
its	O
parental	O
regions	O
suggests	O
the	O
presence	O
of	O
an	O
uncharacterized	O
SLCoV	O
lineage	O
that	O
is	O
phylogenetically	O
closer	O
to	O
SCoVs	O
than	O
any	O
of	O
the	O
currently	O
sampled	O
bat	B-ENZY
SLCoVs	O
.	O

In	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
coronary	O
artery	O
disease	O
,	O
or	O
acute	O
hemorrhage	O
,	O
target	O
a	O
hemoglobin	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
(	O
1B	O
);	O
a	O
low	O
tidal	O
volume	O
(	O
1B	O
)	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
strategy	O
(	O
1C	O
)	O
for	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
in	O
acute	O
lung	O
injury	O
(	O
1C	O
);	O
head	O
of	O
bed	O
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
avoiding	O
routine	O
use	O
of	O
pulmonary	O
artery	O
catheters	O
in	O
ALI	O
/	O
ARDS	O
(	O
1A	O
);	O
to	O
decrease	O
days	O
of	O
mechanical	O
ventilation	O
and	O
ICU	O
length	O
of	O
stay	O
,	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ALI	O
/	O
ARDS	O
who	O
are	O
not	O
in	O
shock	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	O
and	O
sedation	O
/	O
analgesia	O
(	O
1B	O
);	O
using	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
with	O
daily	O
interruptions	O
or	O
lightening	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
,	O
if	O
at	O
all	O
possible	O
(	O
1B	O
);	O
institution	O
of	O
glycemic	O
control	O
(	O
1B	O
)	O
targeting	O
a	O
blood	O
glucose	O
<	O
150	O
mg	O
/	O
dL	O
after	O
initial	O
stabilization	O
(	O
2C	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
veno	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	O
vein	O
thrombosis	O
(	O
1A	O
);	O
use	O
of	O
stress	O
ulcer	O
prophylaxis	O
to	O
prevent	O
upper	O
GI	O
bleeding	O
using	O
H2	O
blockers	O
(	O
1A	O
)	O
or	O
proton	B-ENZY
pump	I-ENZY
inhibitors	O
(	O
1B	O
);	O
and	O
consideration	O
of	O
limitation	O
of	O
support	O
where	O
appropriate	O
(	O
1D	O
).	O

ABSTRACT	O
:	O
The	O
insertion	O
/	O
deletion	O
(	O
I	O
/	O
D	O
)	O
of	O
a	O
289	O
base	O
pair	O
Alu	O
repeat	O
sequence	O
polymorphism	O
in	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
gene	O
(	O
ACE	B-ENZY
)	O
has	O
been	O
shown	O
to	O
predict	O
susceptibility	O
and	O
outcome	O
in	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ACE	B-ENZY
I	O
/	O
D	O
polymorphism	O
was	O
not	O
associated	O
with	O
severe	O
sepsis	O
susceptibility	O
or	O
mortality	O
.	O

Our	O
data	O
do	O
not	O
support	O
an	O
association	O
of	O
the	O
ACE	B-ENZY
gene	O
I	O
/	O
D	O
polymorphism	O
with	O
susceptibility	O
or	O
mortality	O
in	O
severe	O
sepsis	O
or	O
with	O
sepsis	O
-	O
induced	O
ARDS	O
in	O
Spanish	O
patients	O
.	O

Previously	O
proposed	O
mechanisms	O
of	O
IMS	O
include	O
different	O
susceptibility	O
of	O
various	O
cholinergic	O
receptors	O
,	O
muscle	O
necrosis	O
,	O
prolonged	O
acetylcholinesterase	B-ENZY
inhibition	O
,	O
inadequate	O
oxime	O
therapy	O
,	O
downregulation	O
or	O
desensitization	O
of	O
postsynaptic	O
acetylcholine	O
receptors	O
,	O
failure	O
of	O
postsynaptic	O
acetylcholine	O
release	O
,	O
and	O
oxidative	O
stress	O
-	O
related	O
myopathy	O
.	O

Nevertheless	O
,	O
because	O
IMS	O
generally	O
concurs	O
with	O
severe	O
organophosphate	O
toxicity	O
and	O
persistent	O
inhibition	O
of	O
acetylcholinesterase	B-ENZY
,	O
early	O
aggressive	O
decontamination	O
,	O
appropriate	O
antidotal	O
therapy	O
,	O
and	O
prompt	O
institution	O
of	O
ventilatory	O
support	O
should	O
be	O
helpful	O
in	O
ameliorating	O
the	O
magnitude	O
and	O
/	O
or	O
the	O
incidence	O
of	O
IMS	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
-	O
2	O
(	O
ACE2	O
)	O
is	O
a	O
regulatory	O
protein	O
of	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
and	O
a	O
receptor	O
for	O
the	O
causative	O
agent	O
of	O
severe	O
-	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
the	O
SARS	O
-	O
coronavirus	O
.	O

We	O
have	O
previously	O
shown	O
that	O
ACE2	O
can	O
be	O
shed	O
from	O
the	O
cell	O
surface	O
in	O
response	O
to	O
phorbol	O
esters	O
by	O
a	O
process	O
involving	O
TNF	O
-	O
alpha	O
converting	O
enzyme	O
(	O
TACE	B-ENZY
;	O
ADAM17	O
).	O

This	O
pathophysiology	O
included	O
decreased	O
pulmonary	O
gas	B-ENZY
exchange	O
and	O
lung	O
compliance	O
,	O
increased	O
pulmonary	O
edema	O
,	O
and	O
extensive	O
airway	O
obstruction	O
.	O

The	O
aerosolization	O
of	O
rhAT	O
or	O
heparin	O
alone	O
did	O
not	O
significantly	O
improve	O
deteriorated	O
pulmonary	O
gas	B-ENZY
exchange	O
.	O

Second	O
,	O
the	O
SARS	O
-	O
CoV	O
S	O
failed	O
to	O
enter	O
cells	O
expressing	O
the	O
bat	B-ENZY
ACE2	O
.	O

TITLE	O
:	O
Isolation	O
of	O
inhibitory	O
RNA	O
aptamers	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
NTPase	B-ENZY
/	O
Helicase	O
.	O

Isolated	O
RNAs	O
were	O
observed	O
to	O
efficiently	O
inhibit	O
double	O
-	O
stranded	O
DNA	O
unwinding	O
activity	O
of	O
the	O
helicase	O
by	O
up	O
to	O
approximately	O
85	O
%	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
1	O
.	O
2nM	O
but	O
show	O
a	O
slight	O
effect	O
on	O
ATPase	B-ENZY
activity	O
of	O
the	O
protein	O
in	O
the	O
presence	O
of	O
cofactor	O
,	O
poly	O
(	O
rU	O
).	O

Organophosphate	O
compounds	O
inhibit	O
acetylcholinesterase	B-ENZY
resulting	O
in	O
acute	O
toxicity	O
.	O

Using	O
a	O
sweep	O
gas	B-ENZY
flow	O
of	O
10	O
.	O
7	O
+/-	O

In	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
coronary	O
artery	O
disease	O
,	O
or	O
acute	O
hemorrhage	O
,	O
target	O
a	O
hemoglobin	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
(	O
1B	O
);	O
a	O
low	O
tidal	O
volume	O
(	O
1B	O
)	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
strategy	O
(	O
1C	O
)	O
for	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
in	O
acute	O
lung	O
injury	O
(	O
1C	O
);	O
head	O
of	O
bed	O
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
avoiding	O
routine	O
use	O
of	O
pulmonary	O
artery	O
catheters	O
in	O
ALI	O
/	O
ARDS	O
(	O
1A	O
);	O
to	O
decrease	O
days	O
of	O
mechanical	O
ventilation	O
and	O
ICU	O
length	O
of	O
stay	O
,	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ALI	O
/	O
ARDS	O
who	O
are	O
not	O
in	O
shock	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	O
and	O
sedation	O
/	O
analgesia	O
(	O
1B	O
);	O
using	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
with	O
daily	O
interruptions	O
or	O
lightening	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
,	O
if	O
at	O
all	O
possible	O
(	O
1B	O
);	O
institution	O
of	O
glycemic	O
control	O
(	O
1B	O
),	O
targeting	O
a	O
blood	O
glucose	O
<	O
150	O
mg	O
/	O
dL	O
after	O
initial	O
stabilization	O
(	O
2C	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
veno	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	O
vein	O
thrombosis	O
(	O
1A	O
);	O
use	O
of	O
stress	O
ulcer	O
prophylaxis	O
to	O
prevent	O
upper	O
gastrointestinal	O
bleeding	O
using	O
H2	O
blockers	O
(	O
1A	O
)	O
or	O
proton	B-ENZY
pump	I-ENZY
inhibitors	O
(	O
1B	O
);	O
and	O
consideration	O
of	O
limitation	O
of	O
support	O
where	O
appropriate	O
(	O
1D	O
).	O

ABSTRACT	O
:	O
We	O
intended	O
to	O
evaluate	O
the	O
diagnostic	O
usefulness	O
of	O
a	O
multiplex	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
(	O
mRT	O
-	O
PCR	O
)	O
assay	O
kit	O
under	O
dual	O
priming	O
oligonucleotide	O
system	O
(	O
DPO	O
)	O
for	O
the	O
childhood	O
acute	O
respiratory	O
tract	O
infections	O
.	O

The	O
open	O
reading	O
frame	O
7	O
(	O
ORF	O
7	O
)	O
gene	O
from	O
each	O
of	O
the	O
four	O
TGEVs	O
(	O
KT2	O
-	O
L	O
,	O
KT2	O
-	O
H	O
,	O
133	O
,	O
and	O
DAE	O
),	O
which	O
is	O
located	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
TGEV	O
genome	O
,	O
was	O
amplified	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Common	O
bacteria	O
of	O
cattle	O
were	O
recovered	O
only	O
from	O
2	O
outbreaks	O
of	O
BRD	O
:	O
Staphylococcus	O
spp	B-ENZY
.	O
and	O
Proteus	O
mirabilis	O
(	O
outbreak	O
1	O
)	O
and	O
Mannheimia	O
haemolytica	O
(	O
outbreak	O
4	O
).	O

BAL	B-ENZY
showed	O
a	O
predominance	O
of	O
neutrophils	O
,	O
lymphocytes	O
and	O
erythrocytes	O
but	O
not	O
eosinophils	O
.	O

In	O
one	O
design	O
,	O
a	O
biotinylated	O
target	O
is	O
used	O
and	O
the	O
detection	O
of	O
the	O
hybridization	O
reaction	O
is	O
monitored	O
using	O
alkaline	B-ENZY
phosphatase	I-ENZY
labeled	O
streptavidin	O
(	O
S	O
-	O
AP	O
).	O

The	O
membrane	O
(	O
M	O
)	O
protein	O
genes	O
of	O
six	O
PEDV	O
isolates	O
were	O
amplified	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
then	O
cloned	O
,	O
sequenced	O
,	O
and	O
compared	O
with	O
each	O
other	O
as	O
well	O
as	O
those	O
ten	O
PEDV	O
reference	O
strains	O
.	O

Patent	O
applications	O
for	O
cathepsin	B-ENZY
L	I-ENZY
inhibitors	O
have	O
taken	O
new	O
relevance	O
because	O
of	O
the	O
role	O
of	O
cathepsin	B-ENZY
L	I-ENZY
in	O
the	O
entry	O
of	O
SARS	O
-	O
CoV	O
into	O
host	O
cells	O
.	O

Subcutaneous	O
fasciotomy	O
may	O
be	O
effective	O
in	O
early	O
and	O
less	O
severe	O
cases	O
of	O
ACS	B-ENZY
but	O
it	O
is	O
always	O
accompanied	O
with	O
a	O
ventral	O
hernia	O
.	O

Transverse	O
subcostal	O
laparostomy	O
is	O
a	O
promising	O
alternative	O
decompression	O
technique	O
for	O
ACS	B-ENZY
in	O
SAP	O
.	O

Comparative	O
studies	O
are	O
needed	O
to	O
define	O
its	O
role	O
as	O
a	O
decompressive	O
technique	O
for	O
ACS	B-ENZY
.	O

Primary	O
outcome	O
measure	O
acute	O
respiratory	O
failure	O
was	O
defined	O
as	O
a	O
Pao	B-ENZY
(	O
2	O
)/	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
Fio	O
(	O
2	O
))	O
ratio	O
of	O
<	O
200	O
and	O
the	O
need	O
for	O
mechanical	O
respiratory	O
support	O
.	O

Moreover	O
,	O
as	O
is	O
commonly	O
observed	O
in	O
coronavirus	O
infection	O
in	O
other	O
animals	O
,	O
the	O
activities	O
of	O
effecter	O
caspases	O
-	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
/	O
7	O
-	O
and	O
initiator	O
caspases	O
-	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
and	O
caspase	B-ENZY
-	I-ENZY
9	I-ENZY
-	O
that	O
are	O
representative	O
factors	O
in	O
the	O
death	O
receptor	O
-	O
mediated	O
apoptotic	O
pathway	O
and	O
mitochondrial	O
apoptotic	O
pathway	O
,	O
respectively	O
,	O
were	O
increased	O
in	O
ECoV	O
-	O
infected	O
MDBK	O
cells	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
faecal	O
suspensions	O
and	O
FCoV	O
RNA	O
was	O
quantified	O
using	O
a	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
.	O

Samples	O
of	O
testis	O
,	O
trachea	O
,	O
and	O
lungs	O
from	O
breeder	O
males	O
aged	O
57	O
wk	O
were	O
positive	O
for	O
IBV	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
virus	O
isolation	O
and	O
testis	O
samples	O
were	O
also	O
positive	O
for	O
aMPV	O
by	O
RT	O
-	O
PCR	O
.	O

Because	O
of	O
the	O
potential	O
for	O
bat	B-ENZY
coronaviruses	O
to	O
cause	O
disease	O
in	O
humans	O
and	O
animals	O
,	O
further	O
surveillance	O
and	O
characterization	O
of	O
bat	B-ENZY
coronaviruses	O
in	O
North	O
America	O
are	O
needed	O
.	O

TITLE	O
:	O
Coronavirus	O
antibodies	O
in	O
African	O
bat	B-ENZY
species	O
.	O

TITLE	O
:	O
Evolutionary	O
relationships	O
between	O
bat	B-ENZY
coronaviruses	O
and	O
their	O
hosts	O
.	O

TITLE	O
:	O
Sequential	O
affinity	O
purification	O
of	O
peroxidase	B-ENZY
tagged	O
bispecific	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibodies	O
on	O
phenylboronic	O
acid	O
agarose	O
.	O

Using	O
a	O
dual	O
,	O
sequential	O
affinity	O
chromatography	O
(	O
Protein	O
-	O
G	O
chromatography	O
followed	O
by	O
m	O
-	O
aminophenyleboronic	O
acid	O
agarose	O
column	O
),	O
we	O
have	O
purified	O
bispecific	O
monoclonal	O
antibodies	O
(	O
BsMAb	O
)	O
as	O
a	O
preformed	O
HRPO	O
(	O
Horseradish	O
Peroxidase	B-ENZY
)	O
complex	O
(	O
BsMAb	O
-	O
HRPO	O
).	O

Recently	O
,	O
a	O
pumpless	O
extracorporeal	O
lung	O
support	O
system	O
was	O
developed	O
using	O
an	O
arterio	O
-	O
venous	O
bypass	O
into	O
which	O
a	O
gas	B-ENZY
exchange	O
membrane	O
is	O
integrated	O
"("""	O
interventional	O
lung	O
assist	O
""""	O
[	O
iLA	O
]).	O

Viral	O
gene	O
expression	O
and	O
viral	O
particle	O
production	O
of	O
glucose	B-ENZY
-	I-ENZY
6	I-ENZY
-	I-ENZY
phosphate	I-ENZY
dehydrogenase	I-ENZY
(	O
G6PD	B-ENZY
)-	O
deficient	O
and	O
G6PD	B-ENZY
-	O
knockdown	O
cells	O
were	O
much	O
higher	O
than	O
their	O
counterparts	O
when	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
229E	O
was	O
applied	O
at	O
0	O
.	O
1	O
multiplicity	O
of	O
infection	O
.	O

Plasma	O
levels	O
of	O
pseudo	O
cholinesterase	B-ENZY
were	O
initially	O
very	O
low	O
in	O
both	O
patients	O
.	O

Innate	O
and	O
Th1	O
cytokines	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
and	O
serum	O
were	O
elevated	O
in	O
PRCV	O
-	O
infected	O
pigs	O
compared	O
to	O
controls	O
,	O
but	O
were	O
decreased	O
after	O
DEX	O
treatment	O
in	O
the	O
PRCV	O
-	O
infected	O
,	O
DEX	O
-	O
treated	O
(	O
PRCV	O
/	O
DEX	O
)	O
pigs	O
.	O

Levels	O
of	O
the	O
proinflammatory	O
cytokine	O
interleukin	O
-	O
6	O
in	O
BAL	B-ENZY
and	O
serum	O
were	O
decreased	O
in	O
PRCV	O
/	O
DEX	O
pigs	O
early	O
but	O
increased	O
later	O
compared	O
to	O
those	O
in	O
phosphate	O
-	O
buffered	O
saline	O
-	O
treated	O
,	O
PRCV	O
-	O
infected	O
pigs	O
,	O
corresponding	O
to	O
a	O
similar	O
trend	O
for	O
lung	O
lesions	O
.	O

PRCV	O
infection	O
increased	O
T	O
-	O
cell	O
frequencies	O
in	O
BAL	B-ENZY
,	O
but	O
DEX	O
treatment	O
of	O
PRCV	O
-	O
infected	O
pigs	O
reduced	O
frequencies	O
of	O
T	O
cells	O
;	O
interestingly	O
B	O
and	O
SWC3a	O
(+)	O
(	O
monocytes	O
/	O
macrophages	O
/	O
granulocytes	O
)	O
cell	O
frequencies	O
were	O
increased	O
.	O

Dirofilaria	O
immitis	O
was	O
also	O
common	O
in	O
dogs	O
(	O
34	O
%),	O
with	O
lower	O
prevalences	O
of	O
Wolbachia	O
pipiens	O
(	O
22	O
%),	O
Bartonella	O
sp	O
.	O
(	O
13	O
%),	O
Ehrlichia	O
/	O
Anaplasma	O
spp	B-ENZY
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
virus	O
depends	O
on	O
a	O
chymotrypsin	B-ENZY
-	O
like	O
cysteine	O
proteinase	O
(	O
3CL	O
(	O
pro	O
))	O
to	O
process	O
the	O
translated	O
polyproteins	O
to	O
functional	O
viral	O
proteins	O
.	O

ABSTRACT	O
:	O
A	O
prospective	O
2	O
-	O
year	O
analysis	O
including	O
322	O
infant	O
patients	O
with	O
acute	O
respiratory	O
disease	O
(	O
ARD	B-ENZY
)	O
hospitalized	O
in	O
a	O
pediatric	O
department	O
in	O
northern	O
Italy	O
was	O
carried	O
out	O
to	O
evaluate	O
the	O
role	O
as	O
respiratory	O
pathogens	O
or	O
co	O
-	O
pathogens	O
of	O
recently	O
identified	O
viruses	O
.	O

However	O
,	O
we	O
detected	O
minimal	O
downstream	O
induction	O
of	O
UPR	O
target	O
genes	O
,	O
including	O
ERdj4	O
,	O
ER	O
degradation	O
-	O
enhancing	O
alpha	B-ENZY
-	I-ENZY
mannosidase	I-ENZY
-	O
like	O
protein	O
,	O
and	O
p58	O
(	O
IPK	O
),	O
or	O
expression	O
of	O
UPR	O
reporter	O
constructs	O
.	O

TITLE	O
:	O
RNase	B-ENZY
-	O
resistant	O
virus	O
-	O
like	O
particles	O
containing	O
long	O
chimeric	O
RNA	O
sequences	O
produced	O
by	O
two	O
-	O
plasmid	O
coexpression	O
system	O
.	O

ABSTRACT	O
:	O
In	O
the	O
past	O
few	O
years	O
,	O
the	O
classical	O
concept	O
of	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
has	O
experienced	O
substantial	O
conceptual	O
changes	O
.	O

TITLE	O
:	O
Thiopurine	O
analogues	O
inhibit	O
papain	B-ENZY
-	O
like	O
protease	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
papain	B-ENZY
-	O
like	O
protease	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
PLpro	O
)	O
(	O
EC	O
3	O
.	O
4	O
.	O
22	O
.	O
46	O
)	O
is	O
essential	O
for	O
the	O
viral	O
life	O
cycle	O
and	O
therefore	O
represents	O
an	O
important	O
antiviral	O
target	O
.	O

Our	O
findings	O
of	O
increased	O
TPO	B-ENZY
levels	O
in	O
the	O
plasma	O
of	O
SARS	O
patients	O
provide	O
a	O
possible	O
explanation	O
for	O
the	O
genesis	O
of	O
thrombocytosis	O
,	O
which	O
frequently	O
develops	O
from	O
thrombocytopenia	O
in	O
SARS	O
patients	O
.	O

We	O
found	O
that	O
(	O
1	O
)	O
amiodarone	O
associates	O
with	O
different	O
cell	O
membranes	O
and	O
accumulates	O
in	O
acidic	O
organelles	O
;	O
(	O
2	O
)	O
the	O
diethylamino	O
-	O
beta	O
-	O
ethoxy	O
group	O
is	O
an	O
important	O
determinant	O
of	O
uptake	O
;	O
(	O
3	O
)	O
vacuoles	O
forming	O
upon	O
exposure	O
to	O
amiodarone	O
are	O
enlarged	O
late	O
endosomes	O
;	O
(	O
4	O
)	O
amiodarone	O
inhibits	O
the	O
spreading	O
in	O
vitro	O
of	O
SARS	O
coronavirus	O
;	O
and	O
(	O
5	O
)	O
trypsin	B-ENZY
cleavage	O
of	O
the	O
viral	O
spike	O
protein	O
before	O
infection	O
,	O
which	O
permits	O
virus	O
entry	O
through	O
the	O
plasma	O
membrane	O
,	O
does	O
not	O
impair	O
amiodarone	O
antiviral	O
activity	O
.	O

Partial	O
genome	O
sequence	O
analysis	O
of	O
hemagglutinin	O
(	O
HA	O
),	O
neuraminidase	B-ENZY
(	O
NA	O
),	O
and	O
nonstructural	O
(	O
NS	O
)	O
genes	O
were	O
performed	O
in	O
54	O
influenza	O
B	O
isolates	O
during	O
the	O
study	O
period	O
,	O
and	O
nine	O
srandomly	O
chosen	O
isolates	O
during	O
2000	O
and	O
2003	O
.	O

Interestingly	O
,	O
a	O
novel	O
homologue	O
of	O
angiotensin	O
converting	O
-	O
enzyme	O
(	O
ACE	B-ENZY
),	O
termed	O
angiotensin	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
has	O
been	O
identified	O
as	O
a	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
ACE	B-ENZY
and	O
ACE2	O
share	O
homology	O
in	O
their	O
catalytic	O
domain	O
and	O
provide	O
different	O
key	O
functions	O
in	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
.	O

ACE	B-ENZY
cleaves	O
angiotensin	O
I	O
to	O
generate	O
angiotensin	O
II	O
that	O
is	O
a	O
key	O
effector	O
peptide	O
of	O
the	O
system	O
and	O
exerts	O
multiple	O
biological	O
functions	O
,	O
whereas	O
ACE2	O
reduces	O
angiotensin	O
II	O
levels	O
and	O
thus	O
is	O
a	O
negative	O
regulator	O
of	O
the	O
system	O
.	O

TITLE	O
:	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
expression	O
is	O
increased	O
in	O
the	O
lungs	O
of	O
alcohol	O
-	O
fed	O
rats	O
.	O

Gene	O
and	O
protein	O
expression	O
of	O
lung	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
alpha1	O
,	O
alpha2	O
,	O
and	O
beta1	O
subunits	O
were	O
quantified	O
via	O
real	O
-	O
time	O
PCR	O
and	O
immunobiological	O
analyses	O
,	O
respectively	O
.	O

Alcohol	O
-	O
induced	O
,	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
-	O
dependent	O
epithelial	O
barrier	O
dysfunction	O
was	O
determined	O
by	O
calculating	O
lung	O
tissue	O
wet	O
:	O
dry	O
ratios	O
following	O
an	O
ex	O
vivo	O
buffer	O
-	O
perfused	O
challenge	O
for	O
2	O
hours	O
in	O
the	O
presence	O
of	O
ouabain	O
(	O
10	O
(-	O
4	O
)	O
M	O
),	O
a	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
inhibitor	O
.	O

Chronic	O
alcohol	O
ingestion	O
significantly	O
increased	O
gene	O
and	O
protein	O
expression	O
of	O
each	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
subunit	O
in	O
rat	O
lungs	O
.	O

Immunohistochemical	O
analyses	O
of	O
the	O
alcoholic	O
lung	O
also	O
revealed	O
that	O
protein	O
expression	O
of	O
the	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
alpha1	O
subunit	O
was	O
increased	O
throughout	O
the	O
alveolar	O
epithelium	O
.	O

These	O
findings	O
indicate	O
that	O
chronic	O
alcohol	O
ingestion	O
,	O
which	O
is	O
known	O
to	O
increase	O
alveolar	O
epithelial	O
paracellular	O
permeability	O
,	O
actually	O
increases	O
the	O
expression	O
of	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
in	O
the	O
lung	O
as	O
a	O
compensatory	O
mechanism	O
.	O

To	O
help	O
elucidate	O
these	O
roles	O
,	O
we	O
have	O
characterized	O
the	O
first	O
virally	O
encoded	O
cyclophilin	B-ENZY
(	O
mimicyp	O
)	O
derived	O
from	O
the	O
largest	O
virus	O
discovered	O
to	O
date	O
(	O
the	O
Mimivirus	O
)	O
that	O
is	O
also	O
a	O
causative	O
agent	O
of	O
pneumonia	O
in	O
humans	O
.	O

We	O
investigated	O
the	O
following	O
unclear	O
points	O
concerning	O
ADE	O
of	O
FIPV	O
infection	O
:	O
(	O
i	O
)	O
involvement	O
of	O
the	O
virus	O
receptor	O
,	O
feline	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
fAPN	O
),	O
in	O
ADE	O
activity	O
in	O
FIPV	O
infection	O
;	O
(	O
ii	O
)	O
necessity	O
of	O
acidification	O
of	O
the	O
endosome	O
in	O
cellular	O
invasion	O
of	O
FIPV	O
.	O

All	O
bronchoalveolar	O
lavage	O
specimens	O
were	O
screened	O
using	O
a	O
set	O
of	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
assays	O
targeting	O
17	O
different	O
respiratory	O
viruses	O
.	O

Diagnosis	O
of	O
platypnea	O
-	O
orthodeoxia	O
syndrome	O
was	O
demonstrated	O
by	O
O2	O
saturation	O
and	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
in	O
the	O
supine	O
and	O
upright	O
positions	O
.	O

One	O
of	O
these	O
domains	O
is	O
located	O
within	O
the	O
previously	O
described	O
SARS	O
-	O
unique	O
domain	O
,	O
and	O
there	O
is	O
a	O
nucleic	O
acid	O
chaperone	O
-	O
like	O
domain	O
located	O
immediately	O
downstream	O
of	O
the	O
papain	B-ENZY
-	O
like	O
proteinase	O
domain	O
.	O

Most	O
adults	O
can	O
maintain	O
adequate	O
gas	B-ENZY
exchange	O
using	O
HFO	O
frequencies	O
well	O
above	O
5	O
-	O
6	O
Hz	O
.	O

We	O
monitored	O
the	O
arterial	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
blood	O
gas	B-ENZY
.	O

The	O
plasma	O
nitrate	O
/	O
nitrite	O
,	O
methylguanidine	O
,	O
cytokines	O
(	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
interleukin	O
-	O
1beta	O
,	O
interleukin	O
-	O
6	O
,	O
and	O
interleukin	O
-	O
10	O
),	O
neutrophil	B-ENZY
elastase	I-ENZY
,	O
myeloperoxidase	B-ENZY
,	O
malondialdehyde	O
,	O
and	O
sodium	O
-	O
and	O
potassium	O
-	O
activated	O
adenosine	O
triphosphatase	B-ENZY
(	O
Na	O
+-	O
K	O
+-	O
ATPase	B-ENZY
)	O
were	O
detected	O
.	O

Oleic	O
acid	O
caused	O
systemic	O
hypotension	O
and	O
severe	O
ALI	O
as	O
evidenced	O
by	O
the	O
increases	O
in	O
the	O
extent	O
of	O
ALI	O
,	O
impairment	O
of	O
pulmonary	O
functions	O
(	O
blood	O
gas	B-ENZY
variables	O
),	O
and	O
lung	O
pathology	O
.	O

Findings	O
on	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
assays	O
for	O
SARS	O
-	O
CoV	O
at	O
a	O
national	O
reference	O
laboratory	O
were	O
suspected	O
to	O
represent	O
false	O
positives	O
,	O
but	O
this	O
was	O
confounded	O
by	O
concurrent	O
identification	O
of	O
antibody	O
to	O
N	O
protein	O
on	O
serology	O
.	O

Subsequent	O
testing	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
confirmed	O
HCoV	O
-	O
OC43	O
infection	O
.	O

In	O
this	O
study	O
,	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
sequencing	O
of	O
the	O
RNA	O
genome	O
of	O
an	O
isolate	O
of	O
the	O
MHV	O
ts	O
virus	O
Alb	O
ts6	O
,	O
referred	O
to	O
as	O
Alb	O
/	O
ts	O
/	O
nsp5	O
/	O
V148A	O
,	O
identified	O
a	O
putative	O
ts	O
mutation	O
in	O
nsp5	O
(	O
T10651C	O
,	O
Val148Ala	O
),	O
the	O
viral	O
3C	O
-	O
like	O
proteinase	O
(	O
3CLpro	O
).	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	O
of	O
SARS	O
-	O
CoV	O
induces	O
transcription	O
of	O
hfgl2	O
prothrombinase	B-ENZY
gene	O
dependent	O
on	O
C	O
/	O
EBP	O
alpha	O
.	O

ABSTRACT	O
:	O
Fibrin	O
deposition	O
was	O
universal	O
in	O
the	O
lungs	O
of	O
SARS	O
patients	O
and	O
fgl2	O
prothrombinase	B-ENZY
gene	O
,	O
a	O
novel	O
procoagulant	O
,	O
was	O
demonstrated	O
to	O
express	O
highly	O
in	O
a	O
clinically	O
relevant	O
SARS	O
model	O
.	O

Luciferase	B-ENZY
assay	O
showed	O
that	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
could	O
activate	O
the	O
transcription	O
of	O
hfgl2	O
promoter	O
compared	O
with	O
the	O
pcDNA3	O
.	O
1	O
empty	O
vector	O
.	O

ABSTRACT	O
:	O
Real	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
is	O
now	O
used	O
commonly	O
for	O
the	O
detection	O
of	O
viral	O
pathogens	O
in	O
respiratory	O
samples	O
.	O

ABSTRACT	O
:	O
We	O
tested	O
315	O
bats	O
from	O
7	O
different	O
bat	B-ENZY
species	O
in	O
northern	O
Germany	O
for	O
coronaviruses	O
by	O
reverse	O
transcription	O
-	O
PCR	O
.	O

The	O
lineages	O
formed	O
a	O
monophyletic	O
clade	O
of	O
bat	B-ENZY
coronaviruses	O
found	O
in	O
northern	O
Germany	O
.	O

The	O
clade	O
of	O
bat	B-ENZY
coronaviruses	O
have	O
a	O
sister	O
relationship	O
with	O
a	O
clade	O
of	O
Chinese	O
type	O
I	O
coronaviruses	O
that	O
were	O
also	O
associated	O
with	O
the	O
Myotis	O
genus	O
(	O
M	O
.	O
ricketti	O
).	O

TITLE	O
:	O
Cleavage	O
of	O
group	O
1	O
coronavirus	O
spike	O
proteins	O
:	O
how	O
furin	B-ENZY
cleavage	O
is	O
traded	O
off	O
against	O
heparan	O
sulfate	O
binding	O
upon	O
cell	O
culture	O
adaptation	O
.	O

Here	O
,	O
however	O
,	O
we	O
show	O
that	O
some	O
group	O
1	O
coronavirus	O
spike	O
proteins	O
carry	O
a	O
furin	B-ENZY
enzyme	O
recognition	O
motif	O
and	O
can	O
actually	O
be	O
cleaved	O
,	O
as	O
demonstrated	O
for	O
a	O
feline	O
coronavirus	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
and	O
CT	O
severity	O
index	O
scales	O
,	O
the	O
activities	O
of	O
amylase	O
and	O
lipase	B-ENZY
,	O
the	O
incidence	O
rate	O
of	O
liver	O
function	O
failure	O
,	O
the	O
infection	O
rate	O
and	O
the	O
operability	O
between	O
the	O
PE	O
group	O
and	O
the	O
non	O
-	O
PE	O
group	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

The	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE	B-ENZY
-	O
2	O
)	O
has	O
been	O
identified	O
as	O
a	O
functional	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
ACE	B-ENZY
-	O
2	O
has	O
been	O
shown	O
to	O
be	O
expressed	O
at	O
the	O
apical	O
domain	O
of	O
polarized	O
Calu	O
-	O
3	O
cells	O
.	O

Using	O
species	O
-	O
specific	O
RT	O
-	O
PCR	O
assays	O
,	O
bat	B-ENZY
CoVs	O
1A	O
and	O
1B	O
were	O
confirmed	O
to	O
have	O
distinct	O
host	O
specificities	O
to	O
Miniopterus	O
magnater	O
and	O
Miniopterus	O
pusillus	O
,	O
respectively	O
.	O

Connecting	O
to	O
the	O
HR2	O
region	O
is	O
a	O
Trp	B-ENZY
-	O
rich	O
region	O
which	O
is	O
absolutely	O
conserved	O
in	O
members	O
of	O
coronaviruses	O
.	O

The	O
power	O
and	O
sensitivity	O
of	O
the	O
UBL	O
-	O
PLA	O
(	O
2	O
)	O
assay	O
are	O
demonstrated	O
by	O
its	O
ability	O
to	O
differentiate	O
the	O
contrasting	O
deISGylase	O
and	O
DUB	O
activities	O
of	O
two	O
coronavirus	O
proteases	O
:	O
severe	O
acute	O
respiratory	O
syndrome	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
SARS	O
-	O
CoV	O
PLpro	O
)	O
and	O
NL63	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
(	O
PLP2	O
).	O

Blood	O
gas	B-ENZY
and	O
hemodynamic	O
data	O
were	O
recorded	O
over	O
4	O
h	O
.	O
After	O
sacrifice	O
,	O
protein	O
analysis	O
from	O
lung	O
lavage	O
and	O
histologic	O
evaluation	O
were	O
performed	O
.	O

ABSTRACT	O
:	O
Waste	O
ashes	O
from	O
three	O
types	O
of	O
hospital	O
waste	O
(	O
HW	O
)	O
incinerators	O
,	O
built	O
in	O
SARS	O
(	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
)	O
period	O
and	O
currently	O
running	O
in	O
China	O
,	O
were	O
collected	O
and	O
polycyclic	O
aromatic	O
hydrocarbons	O
(	O
PAH	B-ENZY
)	O
properties	O
in	O
the	O
ashes	O
were	O
investigated	O
.	O

The	O
mean	O
summation	O
PAH	B-ENZY
levels	O
in	O
the	O
waste	O
ashes	O
varied	O
widely	O
from	O
4	O
.	O
16	O
mg	O
kg	O
(-	O
1	O
)	O
to	O
198	O
.	O
92	O
mg	O
kg	O
(-	O
1	O
),	O
and	O
the	O
mean	O
amounts	O
of	O
carcinogenic	O
PAHs	O
ranged	O
from	O
0	O
.	O
74	O
to	O
96	O
.	O
77	O
mg	O
kg	O
(-	O
1	O
),	O
exceeding	O
the	O
limits	O
regulated	O
by	O
several	O
countries	O
.	O

Among	O
the	O
three	O
types	O
of	O
incinerators	O
,	O
two	O
medium	O
-	O
scale	O
incinerators	O
generated	O
relatively	O
high	O
levels	O
of	O
PAHs	O
(	O
mean	O
summation	O
PAH	B-ENZY
22	O
.	O
50	O
and	O
198	O
.	O
92	O
mg	O
kg	O
(-	O
1	O
))	O
compared	O
to	O
small	O
-	O
scale	O
and	O
large	O
-	O
scale	O
incinerators	O
(	O
mean	O
summation	O
PAH	B-ENZY
4	O
.	O
16	O
and	O
16	O
.	O
43	O
mg	O
kg	O
(-	O
1	O
)).	O

Bottom	O
ashes	O
were	O
dominated	O
by	O
low	O
molecular	O
weight	O
PAHs	O
(	O
LM	O
-	O
PAH	B-ENZY
;	O
containing	O
two	O
-	O
to	O
three	O
-	O
ringed	O
PAHs	O
)	O
and	O
medium	O
molecular	O
weight	O
PAHs	O
(	O
MM	O
-	O
PAH	B-ENZY
;	O
containing	O
four	O
-	O
ringed	O
PAHs	O
),	O
while	O
fly	O
ashes	O
were	O
abundant	O
in	O
MM	O
-	O
PAH	B-ENZY
and	O
high	O
molecular	O
weight	O
PAHs	O
(	O
HM	O
-	O
PAH	B-ENZY
,	O
containing	O
five	O
-	O
to	O
six	O
-	O
ringed	O
PAHs	O
).	O

Moreover	O
,	O
it	O
was	O
found	O
that	O
PAHs	O
in	O
the	O
ashes	O
correlated	O
highly	O
with	O
some	O
metallic	O
elements	O
either	O
positively	O
(	O
e	O
.	O
g	O
.	O
Fe	O
,	O
Ti	O
,	O
Mg	O
)	O
or	O
negatively	O
(	O
Ca	O
),	O
indicating	O
that	O
these	O
elements	O
might	O
promote	O
or	O
prevent	O
PAH	B-ENZY
formation	O
during	O
HW	O
combustion	O
.	O

TITLE	O
:	O
Heme	B-ENZY
oxygenase	I-ENZY
-	O
1	O
upregulation	O
significantly	O
inhibits	O
TNF	O
-	O
alpha	O
and	O
Hmgb1	O
releasing	O
and	O
attenuates	O
lipopolysaccharide	O
-	O
induced	O
acute	O
lung	O
injury	O
in	O
mice	O
.	O

Interestingly	O
,	O
a	O
novel	O
homologue	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
,	O
termed	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
has	O
been	O
identified	O
as	O
a	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
Angiotensin	O
-	O
converting	O
enzyme	O
and	O
ACE2	O
share	O
homology	O
in	O
their	O
catalytic	O
domain	O
and	O
provide	O
different	O
key	O
functions	O
in	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
(	O
RAS	O
).	O

Notably	O
,	O
injection	O
of	O
SARS	O
-	O
CoV	O
Spike	O
into	O
mice	O
worsens	O
acute	O
lung	O
failure	O
in	O
vivo	O
,	O
which	O
can	O
be	O
attenuated	O
by	O
blocking	O
the	O
renin	B-ENZY
-	O
angiotensin	O
pathway	O
,	O
suggesting	O
that	O
the	O
activation	O
of	O
the	O
pulmonary	O
RAS	O
influences	O
the	O
pathogenesis	O
of	O
ALI	O
/	O
ARDS	O
and	O
SARS	O
.	O

There	O
were	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
in	O
age	O
,	O
body	O
mass	O
index	O
,	O
length	O
of	O
stay	O
,	O
APACHE	O
II	O
score	O
,	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
)	O
and	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
)	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Multiple	O
-	O
factor	O
Logistic	O
regression	O
analysis	O
indicated	O
that	O
the	O
MODS	O
(	O
OR	O
=	O
67	O
.	O
358	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
APACHE	O
II	O
score	O
(	O
OR	O
=	O
9	O
.	O
716	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
ACS	B-ENZY
(	O
OR	O
=	O
5	O
.	O
775	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
the	O
independent	O
risk	O
factors	O
affecting	O
the	O
prognosis	O
of	O
SAP	O
during	O
its	O
early	O
stage	O
,	O
whereas	O
pancreatic	O
infection	O
(	O
OR	O
=	O
9	O
.	O
652	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
MODS	O
(	O
OR	O
=	O
5	O
.	O
212	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
celiac	O
hemorrhage	O
(	O
OR	O
=	O
4	O
.	O
707	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
the	O
independent	O
risk	O
factors	O
during	O
the	O
advanced	O
stage	O
of	O
SAP	O
.	O

ABSTRACT	O
:	O
Direct	O
antigen	O
test	O
(	O
DAT	B-ENZY
)	O
and	O
culture	O
are	O
primary	O
tests	O
to	O
diagnose	O
infections	O
by	O
respiratory	O
viruses	O
,	O
but	O
are	O
mainly	O
available	O
for	O
the	O
traditional	O
viral	O
pathogens	O
such	O
as	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
influenza	O
virus	O
,	O
parainfluenza	O
virus	O
(	O
PIV	O
),	O
and	O
adenovirus	O
in	O
clinical	O
laboratories	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
a	O
multiplex	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
method	O
using	O
Seeplex	O
RV	O
Detection	O
kit	O
(	O
Seegene	O
,	O
Korea	O
)	O
for	O
the	O
detection	O
of	O
rhinovirus	O
,	O
coronavirus	O
,	O
and	O
human	O
metapneumovirus	O
(	O
hMPV	O
).	O

From	O
January	O
to	O
May	O
2007	O
,	O
nasopharyngeal	O
aspirates	O
(	O
NPAs	O
)	O
from	O
pediatric	O
patients	O
negative	O
for	O
culture	O
and	O
DAT	B-ENZY
of	O
traditional	O
viral	O
pathogens	O
were	O
tested	O
with	O
Seeplex	O
.	O

Multiplex	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
method	O
using	O
Seeplex	O
RV	O
Detection	O
kit	O
is	O
a	O
reliable	O
test	O
to	O
detect	O
rhinovirus	O
,	O
hMPV	O
,	O
and	O
coronavirus	O
.	O

The	O
culprit	O
,	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
was	O
detected	O
in	O
patient	O
specimens	O
by	O
traditional	O
cell	O
culture	O
using	O
an	O
unusual	O
cell	O
line	O
for	O
respiratory	O
viruses	O
,	O
Vero	O
E6	O
,	O
and	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
targeting	O
the	O
polymerase	O
1	O
B	O
region	O
of	O
the	O
genome	O
.	O

This	O
study	O
used	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
),	O
histopathology	O
and	O
gene	O
expression	O
analysis	O
to	O
examine	O
the	O
development	O
of	O
ALI	O
in	O
mice	O
infected	O
with	O
Plasmodium	O
berghei	O
ANKA	O
(	O
PbA	O
).	O

BAL	B-ENZY
fluid	O
of	O
PbA	O
-	O
infected	O
C57BL	O
/	O
6	O
mice	O
revealed	O
a	O
significant	O
increase	O
in	O
IgM	O
and	O
total	O
protein	O
prior	O
to	O
the	O
development	O
of	O
CM	O
,	O
indicating	O
disruption	O
of	O
the	O
alveolar	O
-	O
capillary	O
membrane	O
barrier	O
-	O
the	O
physiological	O
hallmark	O
of	O
ALI	O
.	O

We	O
found	O
that	O
the	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
(	O
SARS	O
-	O
S	O
)	O
induced	O
TNF	O
-	O
alpha	O
-	O
converting	O
enzyme	O
(	O
TACE	B-ENZY
)-	O
dependent	O
shedding	O
of	O
the	O
ACE2	O
ectodomain	O
.	O

The	O
modulation	O
of	O
TACE	B-ENZY
activity	O
by	O
SARS	O
-	O
S	O
depended	O
on	O
the	O
cytoplasmic	O
domain	O
of	O
ACE2	O
,	O
because	O
deletion	O
mutants	O
of	O
ACE2	O
lacking	O
the	O
carboxyl	O
-	O
terminal	O
region	O
did	O
not	O
induce	O
ACE2	O
shedding	O
or	O
TNF	O
-	O
alpha	O
production	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
feasibility	O
,	O
safety	O
,	O
and	O
efficacy	O
on	O
PaO	B-ENZY
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
ratio	O
of	O
prone	O
positioning	O
(	O
PP	O
)	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
after	O
cardiac	O
surgery	O
.	O

For	O
the	O
entire	O
population	O
,	O
median	O
PaO	B-ENZY
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
rose	O
from	O
87	O
(	O
range	O
,	O
56	O
-	O
161	O
)	O
before	O
PP	O
to	O
194	O
(	O
range	O
,	O
94	O
-	O
460	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
after	O
it	O
.	O

After	O
supine	O
repositioning	O
(	O
SR	O
),	O
PaO	B-ENZY
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
declined	O
to	O
146	O
(	O
range	O
,	O
72	O
-	O
320	O
;	O
not	O
significant	O
).	O

PaO	B-ENZY
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
at	O
the	O
end	O
of	O
PP	O
and	O
1	O
day	O
after	O
SR	O
were	O
comparable	O
,	O
respectively	O
,	O
194	O
(	O
range	O
,	O
94	O
-	O
460	O
)	O
and	O
184	O
(	O
range	O
,	O
105	O
-	O
342	O
).	O

Mortality	O
rates	O
were	O
comparable	O
regardless	O
of	O
whether	O
patients	O
were	O
PaO	B-ENZY
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
responders	O
or	O
their	O
PaCO	O
(	O
2	O
)	O
decreased	O
by	O
>	O
or	O
=	O
1	O
mmHg	O
.	O

RESULTS	O
:	O
Microscopic	O
examination	O
and	O
blood	O
gas	B-ENZY
analysis	O
indicated	O
severe	O
injury	O
of	O
the	O
lung	O
tissues	O
in	O
ALI	O
group	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
an	O
simple	O
and	O
sensitive	O
method	O
for	O
detecting	O
anti	O
-	O
coronavirus	O
IgG	O
antibodies	O
in	O
bat	B-ENZY
sera	O
based	O
on	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

A	O
commercial	O
ELISA	O
kit	O
for	O
detecting	O
SARS	O
-	O
CoV	O
antibody	O
was	O
modified	O
for	O
detecting	O
coronavirus	O
antibodies	O
in	O
bat	B-ENZY
serum	O
samples	O
.	O

Coronavirus	O
antibody	O
was	O
detected	O
in	O
2	O
out	O
of	O
the	O
55	O
bat	B-ENZY
serum	O
samples	O
.	O

This	O
SPA	O
-	O
ELISA	O
method	O
is	O
applicable	O
for	O
detecting	O
coronavirus	O
antibody	O
in	O
bat	B-ENZY
sera	O
.	O

CONCLUSIONS	O
:	O
This	O
SPA	O
-	O
ELISA	O
method	O
is	O
applicable	O
for	O
detecting	O
coronavirus	O
antibody	O
in	O
bat	B-ENZY
sera	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
leflunomide	O
,	O
an	O
immunomodulatory	O
agent	O
,	O
on	O
oxidant	O
/	O
antioxidant	O
status	O
with	O
nitric	O
oxide	O
(	O
NO	O
)	O
level	O
and	O
myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
activity	O
in	O
rats	O
with	O
sepsis	O
-	O
induced	O
ALI	O
.	O

The	O
lung	O
superoxide	B-ENZY
dismutase	I-ENZY
(	O
SOD	B-ENZY
),	O
catalase	B-ENZY
and	O
glutathione	B-ENZY
peroxidase	I-ENZY
activities	O
were	O
decreased	O
in	O
the	O
sepsis	O
group	O
as	O
compared	O
to	O
the	O
group	O
control	O
,	O
sham	O
,	O
leflunomide	O
and	O
sepsis	O
+	O
leflunomide	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
SOD	B-ENZY
activity	O
were	O
significantly	O
higher	O
in	O
group	O
sepsis	O
+	O
leflunomide	O
than	O
sham	O
,	O
control	O
,	O
leflunomide	O
and	O
sepsis	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

After	O
the	O
animals	O
were	O
euthanized	O
at	O
4	O
hours	O
treatment	O
time	O
point	O
,	O
the	O
right	O
middle	O
lobe	O
of	O
rabbit	O
lung	O
was	O
harvested	O
for	O
the	O
examination	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
p73	O
contents	O
and	O
relative	O
values	O
,	O
as	O
well	O
as	O
mRNA	O
expression	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
p73	O
.	O

(	O
1	O
)	O
Contents	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
p73	O
in	O
lung	O
tissue	O
homogenates	O
in	O
HFOV	O
group	O
and	O
HFOV	O
+	O
PS	O
group	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
CMV	O
group	O
and	O
CMV	O
+	O
PS	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
also	O
contents	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
p73	O
in	O
lung	O
tissue	O
homogenates	O
in	O
groups	O
with	O
exogenous	O
PS	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
groups	O
without	O
exogenous	O
PS	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

Caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
p73	O
mRNA	O
expression	O
in	O
lung	O
tissue	O
in	O
groups	O
with	O
exogenous	O
PS	O
group	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
the	O
corresponding	O
group	O
without	O
exogenous	O
PS	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

Compared	O
with	O
CMV	O
or	O
CMV	O
+	O
PS	O
,	O
HFOV	O
or	O
HFOV	O
+	O
PS	O
can	O
decrease	O
the	O
concentration	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
p73	O
,	O
reduce	O
the	O
mRNA	O
expression	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
p73	O
in	O
the	O
lung	O
homogenates	O
,	O
as	O
a	O
result	O
lung	O
tissue	O
apoptosis	O
in	O
inhalation	O
injury	O
may	O
be	O
suppressed	O
.	O

CONCLUSIONS	O
:	O
Compared	O
with	O
CMV	O
or	O
CMV	O
+	O
PS	O
,	O
HFOV	O
or	O
HFOV	O
+	O
PS	O
can	O
decrease	O
the	O
concentration	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
p73	O
,	O
reduce	O
the	O
mRNA	O
expression	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
p73	O
in	O
the	O
lung	O
homogenates	O
,	O
as	O
a	O
result	O
lung	O
tissue	O
apoptosis	O
in	O
inhalation	O
injury	O
may	O
be	O
suppressed	O
.	O

Virus	O
detection	O
rates	O
of	O
36	O
%	O
to	O
100	O
%	O
and	O
50	O
%	O
to	O
70	O
%	O
were	O
found	O
in	O
Miniopterus	O
magnater	O
and	O
Miniopterus	O
pusillus	O
bats	O
,	O
respectively	O
,	O
captured	O
within	O
a	O
single	O
bat	B-ENZY
habitat	O
during	O
four	O
consecutive	O
visits	O
spanning	O
1	O
year	O
.	O

Some	O
bat	B-ENZY
astroviruses	O
may	O
be	O
phylogenetically	O
related	O
to	O
human	O
astroviruses	O
,	O
and	O
further	O
studies	O
with	O
a	O
wider	O
range	O
of	O
bat	B-ENZY
species	O
in	O
different	O
geographic	O
locations	O
are	O
warranted	O
.	O

Whereas	O
the	O
structural	O
design	O
of	O
the	O
RDE	O
-	O
acetylesterase	B-ENZY
domain	O
remained	O
unaltered	O
,	O
the	O
HE	O
receptor	O
-	O
binding	O
domain	O
underwent	O
remodeling	O
to	O
such	O
extent	O
that	O
the	O
ligand	O
is	O
now	O
bound	O
in	O
opposite	O
orientation	O
.	O

TITLE	O
:	O
Cathepsin	B-ENZY
L	I-ENZY
functionally	O
cleaves	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
class	O
I	O
fusion	O
protein	O
upstream	O
of	O
rather	O
than	O
adjacent	O
to	O
the	O
fusion	O
peptide	O
.	O

Here	O
we	O
demonstrate	O
that	O
cathepsin	B-ENZY
L	I-ENZY
indeed	O
activates	O
the	O
membrane	O
fusion	O
function	O
of	O
the	O
spike	O
protein	O
.	O

Moreover	O
,	O
cleavage	O
was	O
mapped	O
to	O
the	O
same	O
region	O
where	O
,	O
in	O
coronaviruses	O
carrying	O
furin	B-ENZY
-	O
activated	O
spikes	O
,	O
the	O
receptor	O
binding	O
subunit	O
of	O
the	O
protein	O
is	O
separated	O
from	O
the	O
membrane	O
-	O
anchored	O
fusion	O
subunit	O
.	O

TITLE	O
:	O
A	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
survey	O
of	O
infectious	O
bronchitis	O
virus	O
genotypes	O
in	O
Western	O
Europe	O
from	O
2002	O
to	O
2006	O
.	O

Despite	O
using	O
a	O
protective	O
ventilatory	O
strategy	O
,	O
recruitment	O
maneuvers	O
,	O
prone	O
position	O
and	O
high	O
frequency	O
oscillatory	O
ventilation	O
,	O
her	O
gas	B-ENZY
exchange	O
became	O
worse	O
.	O

Mannose	O
-	O
binding	O
lectin	O
(	O
MBL	O
)	O
and	O
MBL	O
-	O
associated	O
serine	O
protease	O
2	O
(	O
MASP	B-ENZY
-	I-ENZY
2	I-ENZY
)	O
deficiencies	O
are	O
common	O
primary	O
immunodeficiencies	O
the	O
clinical	O
penetrance	O
of	O
which	O
remains	O
controversial	O
.	O

We	O
sought	O
to	O
evaluate	O
the	O
significance	O
of	O
MBL	O
deficiency	O
(	O
O	O
/	O
O	O
genotypes	O
)	O
and	O
insufficiency	O
(	O
O	O
/	O
O	O
plus	O
XA	O
/	O
O	O
genotypes	O
),	O
as	O
well	O
as	O
MASP	B-ENZY
-	I-ENZY
2	I-ENZY
deficiency	O
(	O
D105G	O
mutation	O
),	O
in	O
the	O
susceptibility	O
to	O
and	O
severity	O
and	O
outcome	O
of	O
CAP	O
in	O
adults	O
.	O

MBL	O
and	O
MASP	B-ENZY
-	I-ENZY
2	I-ENZY
serum	O
levels	O
,	O
as	O
well	O
as	O
lectin	O
pathway	O
activity	O
with	O
regard	O
to	O
MBL2	O
and	O
MASP2	B-ENZY
genotypes	O
,	O
were	O
measured	O
in	O
healthy	O
control	O
subjects	O
.	O

We	O
found	O
similar	O
frequencies	O
of	O
MBL2	O
and	O
MASP2	B-ENZY
alleles	O
and	O
genotypes	O
among	O
patients	O
and	O
control	O
subjects	O
.	O

RESULTS	O
:	O
We	O
found	O
similar	O
frequencies	O
of	O
MBL2	O
and	O
MASP2	B-ENZY
alleles	O
and	O
genotypes	O
among	O
patients	O
and	O
control	O
subjects	O
.	O

To	O
gain	O
insight	O
into	O
the	O
C	O
-	O
terminal	O
recognition	O
region	O
of	O
ubiquitin	O
by	O
DUBs	O
,	O
we	O
synthesized	O
positional	O
scanning	O
libraries	O
of	O
fluorigenic	O
tetrapeptides	O
and	O
tested	O
them	O
on	O
three	O
examples	O
of	O
human	O
DUBs	O
[	O
OTU	O
-	O
1	O
(	O
ovarian	O
tumour	O
1	O
),	O
Iso	O
-	O
T	O
(	O
isopeptidase	O
T	O
)	O
and	O
UCH	O
-	O
L3	O
(	O
ubiquitin	B-ENZY
C	I-ENZY
-	I-ENZY
terminal	I-ENZY
hydrolase	I-ENZY
L3	O
)]	O
and	O
one	O
viral	O
ubiquitin	O
-	O
specific	O
protease	O
,	O
namely	O
PLpro	O
(	O
papain	B-ENZY
-	O
like	O
protease	O
)	O
from	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)	O
virus	O
.	O

Here	O
we	O
show	O
that	O
the	O
FECV	O
strain	O
WSU	O
79	O
-	O
1683	O
(	O
FECV	O
-	O
1683	O
)	O
is	O
highly	O
dependent	O
on	O
host	O
cell	O
cathepsin	B-ENZY
B	I-ENZY
and	O
cathepsin	B-ENZY
L	I-ENZY
activity	O
for	O
entry	O
into	O
the	O
host	O
cell	O
,	O
as	O
well	O
as	O
on	O
the	O
low	O
pH	O
of	O
endocytic	O
compartments	O
.	O

In	O
contrast	O
,	O
host	O
cell	O
entry	O
by	O
the	O
FIPV	O
strains	O
WSU	O
79	O
-	O
1146	O
(	O
FIPV	O
-	O
1146	O
)	O
and	O
FIPV	O
-	O
DF2	O
proceeds	O
independently	O
of	O
cathepsin	B-ENZY
L	I-ENZY
activity	O
and	O
low	O
pH	O
,	O
but	O
is	O
still	O
highly	O
dependent	O
on	O
cathepsin	B-ENZY
B	I-ENZY
activity	O
.	O

In	O
the	O
case	O
of	O
FIPV	O
-	O
1146	O
and	O
FIPV	O
-	O
DF2	O
,	O
infection	O
of	O
primary	O
feline	O
monocytes	O
was	O
also	O
dependent	O
on	O
host	O
cell	O
cathepsin	B-ENZY
B	I-ENZY
activity	O
,	O
indicating	O
that	O
host	O
cell	O
cathepsins	O
may	O
play	O
a	O
role	O
in	O
the	O
distinct	O
tropisms	O
displayed	O
by	O
different	O
feline	O
coronavirus	O
biotypes	O
.	O

The	O
S2	O
domain	O
of	O
protein	O
S	O
has	O
been	O
suggested	O
to	O
have	O
two	O
fusion	O
peptides	O
,	O
one	O
located	O
at	O
its	O
N	O
-	O
terminus	O
,	O
downstream	O
of	O
the	O
furin	B-ENZY
cleavage	O
,	O
and	O
another	O
,	O
more	O
internal	O
,	O
located	O
immediately	O
upstream	O
of	O
the	O
HR1	O
.	O

Multivariate	O
analysis	O
revealed	O
that	O
the	O
necessity	O
of	O
renal	O
dialysis	O
was	O
an	O
independent	O
risk	O
factor	O
associated	O
with	O
failure	O
to	O
wean	O
and	O
non	O
-	O
survival	O
,	O
and	O
the	O
necessity	O
of	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	B-ENZY
)	O
before	O
ECLS	O
was	O
an	O
independent	O
risk	O
factor	O
for	O
non	O
-	O
survival	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	O
is	O
phosphorylated	O
primarily	O
within	O
the	O
RS	O
-	O
rich	O
region	O
in	O
cells	O
and	O
by	O
SR	O
protein	B-ENZY
kinase	I-ENZY
1	O
in	O
vitro	O
.	O

Deletion	O
or	O
mutations	O
of	O
the	O
RS	O
motif	O
enhanced	O
stress	O
granule	O
localization	O
of	O
the	O
nucleocapsid	O
protein	O
,	O
whereas	O
overexpression	O
of	O
SR	O
protein	B-ENZY
kinase	I-ENZY
1	O
inhibited	O
nucleocapsid	O
protein	O
localization	O
to	O
stress	O
granules	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3a	O
protein	O
activates	O
the	O
mitochondrial	O
death	O
pathway	O
through	O
p38	O
MAP	B-ENZY
kinase	I-ENZY
activation	O
.	O

Activation	O
of	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
through	O
extrinsic	O
signal	O
(	O
s	O
)	O
caused	O
Bid	O
activation	O
.	O

In	O
the	O
intrinsic	O
pathway	O
,	O
there	O
was	O
activation	O
of	O
caspase	B-ENZY
-	I-ENZY
9	I-ENZY
and	O
cytochrome	O
c	O
release	O
from	O
the	O
mitochondria	O
.	O

This	O
was	O
the	O
result	O
of	O
increased	O
Bax	O
oligomerization	O
and	O
higher	O
levels	O
of	O
p53	O
in	O
3a	O
protein	O
-	O
expressing	O
cells	O
,	O
which	O
depended	O
on	O
the	O
activation	O
of	O
p38	O
MAP	B-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
in	O
these	O
cells	O
.	O

Pumpless	O
extracorporeal	O
lung	O
assist	O
is	O
a	O
simple	O
and	O
efficient	O
method	O
to	O
support	O
patients	O
with	O
deteriorating	O
gas	B-ENZY
exchange	O
for	O
prolonged	O
periods	O
to	O
allow	O
the	O
lung	O
protective	O
ventilation	O
and	O
transportation	O
.	O

ABSTRACT	O
:	O
Twelve	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
isolates	O
obtained	O
from	O
commercial	O
chickens	O
in	O
China	O
between	O
2005	O
and	O
2006	O
were	O
characterized	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
the	O
sequencing	O
of	O
the	O
entire	O
S1	O
gene	O
.	O

Initial	O
in	O
vitro	O
studies	O
demonstrated	O
recombinant	O
human	O
PBEF	O
(	O
rhPBEF	O
)	O
as	O
a	O
direct	O
rat	O
neutrophil	O
chemotactic	O
factor	O
with	O
in	O
vivo	O
studies	O
demonstrating	O
marked	O
increases	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
leukocytes	O
(	O
PMNs	O
)	O
after	O
intratracheal	O
injection	O
in	O
C57BL	O
/	O
6J	O
mice	O
.	O

Heterozygous	O
PBEF	O
(+/-)	O
mice	O
were	O
significantly	O
protected	O
(	O
reduced	O
BAL	B-ENZY
protein	O
,	O
BAL	B-ENZY
IL	O
-	O
6	O
levels	O
,	O
peak	O
inspiratory	O
pressures	O
)	O
when	O
exposed	O
to	O
a	O
model	O
of	O
severe	O
VILI	O
(	O
4	O
h	O
,	O
40	O
ml	O
/	O
kg	O
tidal	O
volume	O
)	O
and	O
exhibited	O
significantly	O
reduced	O
expression	O
of	O
VILI	O
-	O
associated	O
gene	O
expression	O
modules	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
in	O
vitro	O
anti	O
-	O
HIV	O
evaluation	O
of	O
a	O
new	O
series	O
of	O
6	O
-	O
arylmethyl	O
-	O
substituted	O
S	O
-	O
DABOs	O
as	O
potential	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
.	O

The	O
LPS	O
challenge	O
also	O
increased	O
pulmonary	O
myeloperoxidase	B-ENZY
activity	O
and	O
chloramine	O
concentrations	O
indicative	O
of	O
neutrophil	O
infiltration	O
and	O
activation	O
of	O
the	O
inflammatory	O
response	O
.	O

ABSTRACT	O
:	O
Altered	O
protease	O
activity	O
is	O
considered	O
important	O
for	O
tumour	O
invasion	O
and	O
metastasis	O
,	O
processes	O
in	O
which	O
the	O
cysteine	O
proteases	O
cathepsin	B-ENZY
B	I-ENZY
and	O
L	O
are	O
involved	O
.	O

It	O
was	O
functionally	O
intact	O
and	O
extracts	O
of	O
cells	O
exposed	O
to	O
cystatin	O
C	O
showed	O
a	O
higher	O
capacity	O
to	O
inhibit	O
papain	B-ENZY
and	O
cathepsin	B-ENZY
B	I-ENZY
than	O
control	O
cells	O
(	O
decrease	O
in	O
enzyme	O
activity	O
of	O
34	O
%	O
and	O
37	O
%,	O
respectively	O
).	O

TITLE	O
:	O
A	O
SARS	O
-	O
CoV	O
protein	O
,	O
ORF	O
-	O
6	O
,	O
induces	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
mediated	O
,	O
ER	O
stress	O
and	O
JNK	B-ENZY
-	O
dependent	O
apoptosis	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
overexpression	O
of	O
ORF	O
-	O
6	O
also	O
induces	O
apoptosis	O
and	O
that	O
Caspase	B-ENZY
-	I-ENZY
3	I-ENZY
inhibitor	O
and	O
JNK	B-ENZY
inhibitor	O
block	O
ORF	O
-	O
6	O
induced	O
apoptosis	O
.	O

All	O
these	O
data	O
suggest	O
that	O
ORF	O
-	O
6	O
induces	O
apoptosis	O
via	O
Caspase	B-ENZY
-	I-ENZY
3	I-ENZY
mediated	O
,	O
ER	O
stress	O
and	O
JNK	B-ENZY
-	O
dependent	O
pathways	O
.	O

This	O
was	O
supported	O
by	O
in	O
vitro	O
binding	O
studies	O
that	O
demonstrated	O
homozygous	O
L	O
-	O
SIGN	O
,	O
compared	O
to	O
heterozygous	O
,	O
had	O
higher	O
binding	O
capacity	O
for	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
with	O
higher	O
proteasome	B-ENZY
-	O
dependent	O
viral	O
degradation	O
.	O

TITLE	O
:	O
RNA	O
viruses	O
and	O
the	O
mitogenic	O
Raf	O
/	O
MEK	B-ENZY
/	O
ERK	B-ENZY
signal	O
transduction	O
cascade	O
.	O

ABSTRACT	O
:	O
The	O
Raf	O
/	O
MEK	B-ENZY
/	O
ERK	B-ENZY
signal	O
transduction	O
cascade	O
belongs	O
to	O
the	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
cascades	O
.	O

Raf	O
/	O
MEK	B-ENZY
/	O
ERK	B-ENZY
signaling	O
leads	O
to	O
stimulus	O
-	O
specific	O
changes	O
in	O
gene	O
expression	O
,	O
alterations	O
in	O
cell	O
metabolism	O
or	O
induction	O
of	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
),	O
and	O
thus	O
controls	O
cell	O
differentiation	O
and	O
proliferation	O
.	O

In	O
contrast	O
,	O
the	O
consequences	O
of	O
RNA	O
virus	O
-	O
induced	O
Raf	O
/	O
MEK	B-ENZY
/	O
ERK	B-ENZY
signaling	O
were	O
less	O
clear	O
for	O
a	O
long	O
time	O
,	O
but	O
since	O
the	O
turn	O
of	O
the	O
century	O
the	O
number	O
of	O
publications	O
on	O
this	O
topic	O
has	O
rapidly	O
increased	O
.	O

We	O
propose	O
a	O
novel	O
combination	O
of	O
computational	O
and	O
adaptive	O
modeling	O
approaches	O
that	O
address	O
the	O
maintenance	O
of	O
emerging	O
diseases	O
in	O
bat	B-ENZY
colonies	O
through	O
individual	O
(	O
intra	O
-	O
host	O
)	O
models	O
of	O
the	O
response	O
of	O
the	O
host	O
to	O
a	O
viral	O
challenge	O
.	O

Applications	O
of	O
the	O
proposed	O
approach	O
to	O
modeling	O
the	O
effects	O
of	O
immunological	O
heterogeneity	O
on	O
the	O
dynamics	O
of	O
bat	B-ENZY
rabies	O
are	O
presented	O
.	O

ABSTRACT	O
:	O
Rapid	O
immunochromatographic	O
assays	O
for	O
detecting	O
infections	O
with	O
bovine	O
coronavirus	O
(	O
BCV	O
),	O
rotavirus	O
A	O
and	O
Cryptosporidium	O
parvum	O
in	O
calf	O
faeces	O
were	O
evaluated	O
using	O
as	O
gold	O
standards	O
a	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
BCV	O
and	O
rotavirus	O
)	O
and	O
a	O
sedimentation	O
-	O
flotation	O
technique	O
(	O
C	O
.	O
parvum	O
).	O

Sulfation	O
of	O
CDR	B-ENZY
tyrosine	O
residues	O
,	O
a	O
property	O
recently	O
shown	O
to	O
broaden	O
antibody	O
binding	O
affinity	O
and	O
antigen	O
recognition	O
was	O
also	O
demonstrated	O
.	O

This	O
suggests	O
that	O
SARS	O
-	O
CoV	O
bearing	O
a	O
cleaved	O
form	O
of	O
the	O
S	O
protein	O
can	O
enter	O
cells	O
directly	O
from	O
the	O
cell	O
surface	O
without	O
trypsin	B-ENZY
treatment	O
.	O

To	O
explore	O
this	O
possibility	O
,	O
we	O
introduced	O
a	O
furin	B-ENZY
-	O
like	O
cleavage	O
sequence	O
in	O
the	O
S	O
protein	O
at	O
amino	O
acids	O
798	O
to	O
801	O
and	O
found	O
that	O
the	O
mutated	O
S	O
protein	O
was	O
cleaved	O
and	O
induced	O
cell	O
fusion	O
without	O
trypsin	B-ENZY
treatment	O
when	O
expressed	O
on	O
the	O
cell	O
surface	O
.	O

TITLE	O
:	O
Loss	O
of	O
extracellular	O
superoxide	B-ENZY
dismutase	I-ENZY
leads	O
to	O
acute	O
lung	O
damage	O
in	O
the	O
presence	O
of	O
ambient	O
air	O
:	O
a	O
potential	O
mechanism	O
underlying	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
The	O
extracellular	O
superoxide	B-ENZY
dismutase	I-ENZY
3	O
(	O
SOD3	O
)	O
is	O
highly	O
expressed	O
in	O
both	O
blood	O
vessels	O
and	O
lungs	O
.	O

ABSTRACT	O
:	O
Design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
5	O
-	O
chloropyridine	O
ester	O
-	O
derived	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
inhibitors	O
is	O
described	O
.	O

ACS	B-ENZY
was	O
discussed	O
followed	O
by	O
a	O
short	O
review	O
of	O
the	O
literature	O
.	O

After	O
adjusting	O
for	O
confounders	O
and	O
excluding	O
patients	O
with	O
cirrhosis	O
,	O
the	O
risk	O
of	O
ALI	O
increased	O
with	O
HCV	O
(	O
adjusted	O
odds	O
ratio	O
[	O
aOR	B-ENZY
]	O
1	O
.	O
80	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]:	O
1	O
.	O
30	O
-	O
2	O
.	O
48	O
),	O
nonalcoholic	O
fatty	O
liver	O
disease	O
(	O
aOR	B-ENZY
7	O
.	O
43	O
;	O
95	O
%	O
CI	O
:	O
3	O
.	O
30	O
-	O
16	O
.	O
7	O
),	O
alcoholic	O
liver	O
disease	O
(	O
aOR	B-ENZY
6	O
.	O
46	O
;	O
95	O
%	O
CI	O
:	O
4	O
.	O
53	O
-	O
9	O
.	O
21	O
),	O
and	O
malnutrition	O
(	O
aOR	B-ENZY
3	O
.	O
84	O
;	O
95	O
%	O
CI	O
:	O
2	O
.	O
61	O
-	O
5	O
.	O
65	O
).	O

TITLE	O
:	O
Variation	O
in	O
the	O
myosin	B-ENZY
light	I-ENZY
chain	I-ENZY
kinase	I-ENZY
gene	O
is	O
associated	O
with	O
development	O
of	O
acute	O
lung	O
injury	O
after	O
major	O
trauma	O
.	O

ABSTRACT	O
:	O
Single	O
nucleotide	O
polymorphisms	O
in	O
the	O
myosin	B-ENZY
light	I-ENZY
chain	I-ENZY
kinase	I-ENZY
(	O
MYLK	O
)	O
gene	O
have	O
been	O
implicated	O
in	O
the	O
risk	O
of	O
sepsis	O
-	O
related	O
acute	O
lung	O
injury	O
and	O
asthma	O
.	O

These	O
data	O
reveal	O
a	O
role	O
for	O
apoD	O
in	O
the	O
regulation	O
of	O
inflammation	O
and	O
suggest	O
that	O
it	O
protects	O
from	O
HCoV	O
-	O
OC43	O
-	O
induced	O
encephalitis	O
,	O
most	O
likely	O
through	O
the	O
phospholipase	B-ENZY
A2	I-ENZY
signaling	O
pathways	O
.	O

These	O
contents	O
include	O
myoglobin	O
,	O
creatine	O
phosphokinase	O
,	O
potassium	O
,	O
aldolase	B-ENZY
,	O
lactate	O
dehydrogenase	O
and	O
glutamic	O
-	O
oxaloacetic	O
transaminase	O
.	O

Other	O
pertinent	O
laboratory	O
results	O
such	O
as	O
urea	O
,	O
creatinine	O
,	O
prothrombin	O
time	O
,	O
alanine	B-ENZY
aminotransferase	I-ENZY
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
were	O
also	O
changed	O
significantly	O
.	O

Cleavage	O
of	O
S	O
and	O
release	O
of	O
HCoV	O
-	O
HKU1	O
S	O
pseudotyped	O
virus	O
were	O
inhibited	O
by	O
furin	B-ENZY
or	O
furin	B-ENZY
-	O
like	O
enzyme	O
inhibitors	O
.	O

TITLE	O
:	O
A	O
noncovalent	O
class	O
of	O
papain	B-ENZY
-	O
like	O
protease	O
/	O
deubiquitinase	O
inhibitors	O
blocks	O
SARS	O
virus	O
replication	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
discovery	O
and	O
optimization	O
of	O
a	O
potent	O
inhibitor	O
against	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
from	O
the	O
coronavirus	O
that	O
causes	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
).	O

Hemodynamics	O
,	O
respiratory	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
were	O
measured	O
15	O
minutes	O
after	O
each	O
PEEP	O
level	O
was	O
applied	O
,	O
and	O
lung	O
specimens	O
for	O
pathological	O
examination	O
were	O
harvested	O
after	O
sacrifice	O
of	O
the	O
animals	O
.	O

ABSTRACT	O
:	O
Although	O
in	O
different	O
groups	O
,	O
the	O
coronaviruses	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
NL63	O
use	O
the	O
same	O
receptor	O
,	O
angiotensin	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)-	O
2	O
,	O
for	O
entry	O
into	O
the	O
host	O
cell	O
.	O

Using	O
a	O
wholly	O
recombinant	O
system	O
,	O
we	O
have	O
investigated	O
the	O
ability	O
of	O
each	O
virus	O
receptor	O
-	O
binding	O
protein	O
,	O
spike	O
or	O
S	O
protein	O
,	O
to	O
bind	O
to	O
ACE	B-ENZY
-	O
2	O
in	O
solution	O
and	O
on	O
the	O
cell	O
surface	O
.	O

We	O
also	O
confirm	O
that	O
the	O
ACE	B-ENZY
-	O
2	O
-	O
binding	O
site	O
of	O
NL63	O
S	O
lies	O
between	O
residues	O
190	O
and	O
739	O
.	O

Mycobacteria	O
were	O
identified	O
after	O
patient	O
'	O
s	O
death	O
on	O
the	O
smear	O
from	O
BAL	B-ENZY
,	O
from	O
blood	O
cultures	O
,	O
and	O
in	O
a	O
postmortem	O
liver	O
biopsy	O
.	O

TITLE	O
:	O
Novel	O
modifications	O
in	O
the	O
series	O
of	O
O	O
-(	O
2	O
-	O
phthalimidoethyl	O
)-	O
N	O
-	O
substituted	O
thiocarbamates	O
and	O
their	O
ring	O
-	O
opened	O
congeners	O
as	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
.	O

ABSTRACT	O
:	O
The	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
of	O
N	O
-	O
aryl	O
-	O
O	O
-(	O
2	O
-	O
phthalimidoethyl	O
)	O
thiocarbamates	O
(	O
C	O
-	O
TCs	O
)	O
and	O
their	O
imide	O
ring	O
-	O
opened	O
congeners	O
(	O
O	O
-	O
TCs	O
)	O
as	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
were	O
further	O
investigated	O
.	O

As	O
a	O
consequence	O
,	O
co	O
-	O
expression	O
of	O
PLP2	O
strongly	O
inhibits	O
CARDIF	O
-,	O
TBK1	B-ENZY
-	O
and	O
IRF3	O
-	O
mediated	O
IFNbeta	O
reporter	O
activities	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
229E	O
,	O
classified	O
as	O
a	O
group	O
I	O
coronavirus	O
,	O
utilizes	O
human	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
)	O
as	O
a	O
receptor	O
;	O
however	O
,	O
its	O
entry	O
mechanism	O
has	O
not	O
yet	O
been	O
fully	O
elucidated	O
.	O

In	O
addition	O
,	O
trypsin	B-ENZY
induced	O
cleavage	O
of	O
the	O
229E	O
S	O
protein	O
.	O

We	O
found	O
that	O
cathepsin	B-ENZY
L	I-ENZY
(	O
CPL	B-ENZY
)	O
inhibitors	O
blocked	O
229E	O
infection	O
the	O
most	O
remarkably	O
among	O
a	O
variety	O
of	O
protease	O
inhibitors	O
tested	O
.	O

However	O
,	O
its	O
inhibition	O
was	O
not	O
so	O
remarkable	O
as	O
that	O
found	O
with	O
SARS	O
-	O
CoV	O
infection	O
,	O
which	O
seems	O
to	O
indicate	O
that	O
while	O
CPL	B-ENZY
is	O
involved	O
in	O
the	O
fusogenic	O
activation	O
of	O
229E	O
S	O
protein	O
in	O
endosomal	O
infection	O
,	O
not	O
-	O
yet	O
-	O
identified	O
proteases	O
could	O
also	O
play	O
a	O
part	O
in	O
that	O
activity	O
.	O

Furthermore	O
,	O
as	O
with	O
SARS	O
-	O
CoV	O
,	O
229E	O
entered	O
cells	O
directly	O
from	O
the	O
cell	O
surface	O
when	O
cell	O
-	O
attached	O
viruses	O
were	O
treated	O
with	O
trypsin	B-ENZY
.	O

These	O
findings	O
suggest	O
that	O
229E	O
takes	O
an	O
endosomal	O
pathway	O
for	O
cell	O
entry	O
and	O
that	O
proteases	O
like	O
CPL	B-ENZY
are	O
involved	O
in	O
this	O
mode	O
of	O
entry	O
.	O

In	O
phylogenetic	O
trees	O
constructed	O
using	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
)),	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
Pol	O
),	O
helicase	O
,	O
spike	O
,	O
and	O
nucleocapsid	O
proteins	O
,	O
BuCoV	O
HKU11	O
,	O
ThCoV	O
HKU12	O
,	O
and	O
MuCoV	O
HKU13	O
formed	O
a	O
cluster	O
distantly	O
related	O
to	O
infectious	O
bronchitis	O
virus	O
and	O
turkey	O
CoV	O
(	O
group	O
3a	O
CoVs	O
).	O

Sequencing	O
of	O
two	O
independent	O
clones	O
revealed	O
cDNA	O
inserts	O
encoding	O
HLA	O
-	O
C	O
.	O
Inhibition	O
of	O
HLA	O
-	O
C	O
expression	O
or	O
function	O
by	O
RNAi	O
silencing	O
and	O
anti	O
-	O
HLA	O
-	O
C	O
antibody	O
decreased	O
HCoV	O
-	O
HKU1	O
S	O
pseudotyped	O
virus	O
infection	O
of	O
A549	O
cells	O
by	O
62	O
to	O
65	O
%,	O
whereas	O
pretreatment	O
of	O
cells	O
with	O
neuraminidase	B-ENZY
decreased	O
such	O
infection	O
by	O
only	O
13	O
%.	O

Recently	O
,	O
a	O
more	O
conserved	O
group	O
-	O
specific	O
open	O
reading	O
frame	O
(	O
ORF	O
),	O
the	O
3a	O
gene	O
,	O
was	O
found	O
in	O
both	O
SARS	O
-	O
CoV	O
and	O
SL	O
-	O
CoV	O
.	O
Here	O
,	O
we	O
studied	O
the	O
immunogenicity	O
of	O
human	O
SARS	O
-	O
CoV	O
3a	O
and	O
bat	B-ENZY
SL	O
-	O
CoV	O
3a	O
DNA	O
vaccines	O
in	O
mice	O
through	O
electroporation	O
immunization	O
followed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
,	O
enzyme	O
-	O
linked	O
immunospot	O
,	O
and	O
flow	O
cytometry	O
assays	O
.	O

Structure	O
-	O
based	O
amino	O
acid	O
changes	O
in	O
an	O
activation	O
-	O
induced	O
cytidine	B-ENZY
deaminase	I-ENZY
(	O
AID	O
)	O
""""	O
hot	O
spot	O
""""	O
in	O
a	O
light	O
chain	O
CDR	B-ENZY
(	O
complementarity	O
determining	O
region	O
)	O
alone	O
,	O
introduced	O
through	O
shuffling	O
of	O
naturally	O
occurring	O
non	O
-	O
immune	O
human	O
VL	O
chain	O
repertoire	O
or	O
by	O
targeted	O
mutagenesis	O
,	O
were	O
successful	O
in	O
generating	O
these	O
BnAbs	O
.	O

The	O
strategies	O
investigated	O
in	O
this	O
study	O
,	O
in	O
particular	O
the	O
use	O
of	O
structural	O
information	O
in	O
combination	O
of	O
chain	O
-	O
shuffling	O
as	O
well	O
as	O
hot	O
-	O
spot	O
CDR	B-ENZY
mutagenesis	O
,	O
can	O
be	O
exploited	O
to	O
broaden	O
neutralization	O
activity	O
,	O
to	O
improve	O
anti	O
-	O
viral	O
nAb	O
therapies	O
,	O
and	O
directly	O
manipulate	O
virus	O
evolution	O
.	O

Its	O
spike	O
glycoprotein	O
(	O
S	O
)	O
is	O
processed	O
by	O
host	O
furin	B-ENZY
enzyme	O
to	O
produce	O
S1	O
and	O
S2	O
fragments	O
,	O
the	O
latter	O
being	O
crucial	O
for	O
fusion	O
with	O
the	O
host	O
membrane	O
.	O

The	O
present	O
study	O
sought	O
to	O
evaluate	O
the	O
factors	O
determining	O
the	O
efficacy	O
of	O
iLA	O
and	O
calculate	O
its	O
contribution	O
to	O
gas	B-ENZY
exchange	O
.	O

In	O
a	O
cohort	O
of	O
96	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
haemodynamic	O
parameters	O
,	O
oxygen	O
consumption	O
and	O
carbon	O
dioxide	O
production	O
as	O
well	O
as	O
gas	B-ENZY
transfer	O
through	O
the	O
iLA	O
were	O
analysed	O
.	O

While	O
ECMO	O
enables	O
a	O
complete	O
extrapulmonary	O
gas	B-ENZY
exchange	O
,	O
iLA	O
provides	O
effective	O
CO	O
(	O
2	O
)-	O
elimination	O
.	O

All	O
of	O
the	O
aptamers	O
that	O
were	O
selected	O
stimulated	O
ATPase	B-ENZY
activity	O
of	O
the	O
SARS	O
-	O
CoV	O
helicase	O
with	O
low	O
-	O
nanomolar	O
apparent	O
K	O
(	O
m	O
)	O
values	O
.	O

7	O
days	O
due	O
to	O
an	O
increase	O
in	O
flow	O
resistance	O
and	O
an	O
impairment	O
of	O
the	O
gas	B-ENZY
exchange	O
capacity	O
.	O

TITLE	O
:	O
Synthetic	O
recombinant	O
bat	B-ENZY
SARS	O
-	O
like	O
coronavirus	O
is	O
infectious	O
in	O
cultured	O
cells	O
and	O
in	O
mice	O
.	O

Here	O
,	O
we	O
report	O
the	O
design	O
,	O
synthesis	O
,	O
and	O
recovery	O
of	O
the	O
largest	O
synthetic	O
replicating	O
life	O
form	O
,	O
a	O
29	O
.	O
7	O
-	O
kb	O
bat	B-ENZY
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
like	O
coronavirus	O
(	O
Bat	B-ENZY
-	O
SCoV	O
),	O
a	O
likely	O
progenitor	O
to	O
the	O
SARS	O
-	O
CoV	O
epidemic	O
.	O

To	O
test	O
a	O
possible	O
route	O
of	O
emergence	O
from	O
the	O
noncultivable	O
Bat	B-ENZY
-	O
SCoV	O
to	O
human	O
SARS	O
-	O
CoV	O
,	O
we	O
designed	O
a	O
consensus	O
Bat	B-ENZY
-	O
SCoV	O
genome	O
and	O
replaced	O
the	O
Bat	B-ENZY
-	O
SCoV	O
Spike	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
with	O
the	O
SARS	O
-	O
CoV	O
RBD	O
(	O
Bat	B-ENZY
-	O
SRBD	O
).	O

Bat	B-ENZY
-	O
SRBD	O
was	O
infectious	O
in	O
cell	O
culture	O
and	O
in	O
mice	O
and	O
was	O
efficiently	O
neutralized	O
by	O
antibodies	O
specific	O
for	O
both	O
bat	B-ENZY
and	O
human	O
CoV	O
Spike	O
proteins	O
.	O

TITLE	O
:	O
Acute	O
health	O
effects	O
after	O
exposure	O
to	O
chlorine	O
gas	B-ENZY
released	O
after	O
a	O
train	O
derailment	O
.	O

ABSTRACT	O
:	O
In	O
January	O
2005	O
,	O
a	O
train	O
derailment	O
on	O
the	O
premises	O
of	O
a	O
textile	O
mill	O
in	O
South	O
Carolina	O
released	O
42	O
to	O
60	O
tons	O
of	O
chlorine	O
gas	B-ENZY
in	O
the	O
middle	O
of	O
a	O
small	O
town	O
.	O

Medical	O
records	O
and	O
autopsy	O
reports	O
were	O
reviewed	O
to	O
describe	O
the	O
clinical	O
presentation	O
,	O
hospital	O
course	O
,	O
and	O
pathology	O
observed	O
in	O
persons	O
hospitalized	O
or	O
deceased	O
as	O
a	O
result	O
of	O
chlorine	O
gas	B-ENZY
exposure	O
.	O

This	O
community	O
release	O
of	O
chlorine	O
gas	B-ENZY
caused	O
widespread	O
exposure	O
and	O
resulted	O
in	O
significant	O
acute	O
health	O
effects	O
and	O
substantial	O
health	O
care	O
requirements	O
.	O

Pulse	O
oximetry	O
and	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
provided	O
early	O
indications	O
of	O
outcome	O
severity	O
.	O

Sivelestat	O
is	O
a	O
small	O
molecular	O
weight	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
.	O

ABSTRACT	O
:	O
Bat	B-ENZY
coronaviruses	O
(	O
Bt	O
-	O
CoVs	O
)	O
are	O
thought	O
to	O
be	O
the	O
precursors	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

We	O
detected	O
Bt	O
-	O
CoVs	O
in	O
2	O
bat	B-ENZY
species	O
from	O
Trinidad	O
.	O

TITLE	O
:	O
The	O
use	O
of	O
cross	O
-	O
foster	O
rederivation	O
to	O
eliminate	O
murine	O
norovirus	O
,	O
Helicobacter	O
spp	B-ENZY
.,	O
and	O
murine	O
hepatitis	O
virus	O
from	O
a	O
mouse	O
colony	O
.	O

ABSTRACT	O
:	O
Over	O
10	O
mo	O
,	O
287	O
mouse	O
litters	O
were	O
cross	O
-	O
fostered	O
by	O
using	O
1	O
of	O
2	O
paradigms	O
to	O
eliminate	O
murine	O
norovirus	O
(	O
MNV	O
),	O
Helicobacter	O
spp	B-ENZY
.,	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
and	O
Syphacia	O
obvelata	O
.	O

After	O
cross	O
-	O
foster	O
rederivation	O
,	O
mice	O
were	O
tested	O
for	O
the	O
presence	O
of	O
Helicobacter	O
spp	B-ENZY
.	O

The	O
presence	O
of	O
MNV	O
,	O
Helicobacter	O
spp	B-ENZY
.,	O
and	O
MHV	O
can	O
be	O
predicted	O
reliably	O
at	O
12	O
,	O
8	O
,	O
and	O
4	O
wk	O
,	O
respectively	O
.	O

Patients	O
with	O
positive	O
results	O
of	O
either	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
or	O
antibody	O
to	O
SARS	O
coronavirus	O
were	O
defined	O
as	O
SARS	O
cases	O
and	O
others	O
with	O
negative	O
results	O
as	O
control	O
cases	O
.	O

The	O
highest	O
leukocyte	O
and	O
neutrophil	O
counts	O
,	O
lactate	O
dehydrogenase	O
,	O
and	O
creatine	B-ENZY
kinase	I-ENZY
;	O
positive	O
end	O
-	O
expiratory	O
pressure	O
;	O
and	O
use	O
of	O
corticosteroids	O
,	O
ribavirin	O
,	O
and	O
intravenous	O
immunoglobulin	O
were	O
higher	O
in	O
the	O
SARS	O
group	O
.	O

In	O
contrast	O
,	O
the	O
lowest	O
lymphocyte	O
count	O
and	O
the	O
ratio	O
of	O
Pao	B-ENZY
(	O
2	O
)	O
to	O
the	O
fraction	O
of	O
inspired	O
oxygen	O
were	O
lower	O
in	O
the	O
SARS	O
group	O
.	O

The	O
VSVdeltaaG	O
*/	O
SEAP	O
system	O
,	O
which	O
secretes	O
alkaline	B-ENZY
phosphatase	I-ENZY
instead	O
of	O
GFP	O
,	O
was	O
also	O
generated	O
as	O
a	O
VSV	O
pseudotype	O
having	O
SARS	O
-	O
CoV	O
S	O
protein	O
(	O
VSV	O
-	O
SARS	O
-	O
CoV	O
-	O
St19	O
/	O
SEAP	O
).	O

Infectious	O
recombinant	O
IBVs	O
are	O
generated	O
in	O
situ	O
following	O
the	O
transfection	O
of	O
vaccinia	O
virus	O
DNA	O
containing	O
the	O
modified	O
IBV	O
cDNA	O
into	O
cells	O
infected	O
with	O
a	O
recombinant	O
fowlpox	O
virus	O
expressing	O
T7	O
DNA	B-ENZY
-	I-ENZY
dependent	I-ENZY
RNA	I-ENZY
polymerase	I-ENZY
.	O

Here	O
we	O
show	O
that	O
infection	O
of	O
primary	O
blood	O
-	O
derived	O
feline	O
mononuclear	O
cells	O
by	O
FIPV	O
WSU	O
79	O
-	O
1146	O
and	O
FIPV	O
-	O
DF2	O
leads	O
to	O
rapid	O
activation	O
of	O
the	O
p38	O
MAPK	B-ENZY
pathway	O
and	O
that	O
this	O
activation	O
regulates	O
production	O
of	O
the	O
pro	O
-	O
inflammatory	O
cytokine	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
interleukin	O
-	O
1	O
beta	O
(	O
IL	O
-	O
1	O
beta	O
).	O

FIPV	O
-	O
induced	O
p38	O
MAPK	B-ENZY
activation	O
was	O
observed	O
in	O
primary	O
feline	O
blood	O
-	O
derived	O
mononuclear	O
cells	O
individually	O
purified	O
from	O
multiple	O
SPF	O
cats	O
,	O
as	O
was	O
the	O
inhibition	O
of	O
TNF	O
-	O
alpha	O
production	O
by	O
pyridinyl	O
imidazole	O
inhibitors	O
.	O

TITLE	O
:	O
Parallel	O
synthesis	O
,	O
molecular	O
modelling	O
and	O
further	O
structure	O
-	O
activity	O
relationship	O
studies	O
of	O
new	O
acylthiocarbamates	O
as	O
potent	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
.	O

IL	O
-	O
15	O
deficiency	O
also	O
had	O
no	O
affect	O
on	O
IL	O
-	O
7	O
receptor	O
(	O
CD127	O
)	O
expression	O
,	O
Bcl	O
-	O
2	O
upregulation	O
,	O
granzyme	B-ENZY
B	I-ENZY
expression	O
,	O
or	O
IFN	O
-	O
gamma	O
secretion	O
in	O
CNS	O
persisting	O
CD8	O
(+)	O
T	O
cells	O
.	O

TITLE	O
:	O
Glycogen	B-ENZY
synthase	I-ENZY
kinase	O
-	O
3	O
regulates	O
the	O
phosphorylation	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	O
and	O
viral	O
replication	O
.	O

Mass	O
spectrometric	O
analysis	O
and	O
deletion	O
mapping	O
showed	O
that	O
the	O
major	O
phosphorylation	O
sites	O
were	O
located	O
at	O
the	O
central	O
serine	O
-	O
arginine	O
(	O
SR	O
)-	O
rich	O
motif	O
that	O
contains	O
several	O
glycogen	B-ENZY
synthase	I-ENZY
kinase	O
(	O
GSK	B-ENZY
)-	O
3	O
substrate	O
consensus	O
sequences	O
.	O

GSK	B-ENZY
-	O
3	O
-	O
specific	O
inhibitor	O
treatment	O
dephosphorylated	O
the	O
N	O
protein	O
,	O
and	O
this	O
could	O
be	O
recovered	O
by	O
the	O
constitutively	O
active	O
GSK	B-ENZY
-	O
3	O
kinase	O
.	O

Immunoprecipitation	O
brought	O
down	O
both	O
N	O
and	O
GSK	B-ENZY
-	O
3	O
proteins	O
in	O
the	O
same	O
complex	O
,	O
and	O
the	O
N	O
protein	O
could	O
be	O
phosphorylated	O
directly	O
at	O
its	O
SR	O
-	O
rich	O
motif	O
by	O
GSK	B-ENZY
-	O
3	O
using	O
an	O
in	O
vitro	O
kinase	O
assay	O
.	O

Mutation	O
of	O
the	O
two	O
priming	O
sites	O
critical	O
for	O
GSK	B-ENZY
-	O
3	O
phosphorylation	O
in	O
the	O
SR	O
-	O
rich	O
motif	O
abolished	O
N	O
protein	O
phosphorylation	O
.	O

Finally	O
,	O
GSK	B-ENZY
-	O
3	O
inhibitor	O
was	O
found	O
to	O
reduce	O
N	O
phosphorylation	O
in	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
-	O
infected	O
VeroE6	O
cells	O
and	O
decrease	O
the	O
viral	O
titer	O
and	O
cytopathic	O
effects	O
.	O

Our	O
results	O
indicate	O
that	O
GSK	B-ENZY
-	O
3	O
is	O
critical	O
for	O
CoV	O
N	O
protein	O
phosphorylation	O
and	O
suggest	O
that	O
it	O
plays	O
a	O
role	O
in	O
regulating	O
the	O
viral	O
life	O
cycle	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
triggers	O
apoptosis	O
via	O
protein	B-ENZY
kinase	I-ENZY
R	O
but	O
is	O
resistant	O
to	O
its	O
antiviral	O
activity	O
.	O

In	O
addition	O
,	O
two	O
of	O
the	O
three	O
cellular	O
eIF2alpha	O
kinases	O
known	O
to	O
be	O
virus	O
induced	O
,	O
protein	B-ENZY
kinase	I-ENZY
R	O
(	O
PKR	O
)	O
and	O
PKR	O
-	O
like	O
endoplasmic	O
reticulum	O
kinase	O
(	O
PERK	O
),	O
were	O
activated	O
by	O
SARS	O
-	O
CoV	O
.	O
The	O
third	O
kinase	O
,	O
general	O
control	O
nonderepressible	O
-	O
2	O
kinase	O
(	O
GCN2	O
),	O
was	O
not	O
activated	O
,	O
but	O
late	O
in	O
infection	O
the	O
level	O
of	O
GCN2	O
protein	O
was	O
significantly	O
reduced	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
proteins	O
decrease	O
levels	O
and	O
activity	O
of	O
human	O
ENaC	O
via	O
activation	O
of	O
distinct	O
PKC	B-ENZY
isoforms	O
.	O

These	O
findings	O
indicate	O
that	O
lung	O
edema	O
in	O
SARS	O
infection	O
may	O
be	O
due	O
at	O
least	O
in	O
part	O
to	O
activation	O
of	O
PKC	B-ENZY
by	O
SARS	O
proteins	O
,	O
leading	O
to	O
decreasing	O
levels	O
and	O
activity	O
of	O
ENaC	O
at	O
the	O
apical	O
surfaces	O
of	O
lung	O
epithelial	O
cells	O
.	O

ABSTRACT	O
:	O
Eight	O
isolates	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
were	O
obtained	O
from	O
various	O
prefectures	O
in	O
Japan	O
during	O
2003	O
-	O
2007	O
and	O
were	O
genetically	O
analyzed	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
coupled	O
with	O
direct	O
sequencing	O
.	O

TITLE	O
:	O
Induction	O
of	O
proinflammatory	O
cytokines	O
in	O
primary	O
human	O
macrophages	O
by	O
influenza	O
A	O
virus	O
(	O
H5N1	O
)	O
is	O
selectively	O
regulated	O
by	O
IFN	O
regulatory	O
factor	O
3	O
and	O
p38	O
MAPK	B-ENZY
.	O

In	O
picornavirus	O
,	O
a	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
(	O
3C	O
(	O
pro	O
))	O
is	O
required	O
for	O
viral	O
replication	O
by	O
processing	O
the	O
polyproteins	O
,	O
and	O
thus	O
it	O
is	O
regarded	O
as	O
an	O
antiviral	O
drug	O
target	O
.	O

We	O
have	O
recently	O
shown	O
that	O
like	O
ACE	B-ENZY
,	O
ACE2	O
undergoes	O
ectodomain	O
shedding	O
and	O
that	O
this	O
shedding	O
event	O
is	O
up	O
-	O
regulated	O
by	O
phorbol	O
esters	O
.	O

Neutrophil	O
infiltration	O
measured	O
by	O
myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
activity	O
in	O
the	O
lung	O
was	O
significantly	O
increased	O
at	O
2	O
days	O
after	O
blast	O
and	O
returned	O
to	O
controls	O
at	O
8	O
days	O
.	O

In	O
addition	O
,	O
expression	O
of	O
heme	B-ENZY
oxygenase	I-ENZY
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
mRNA	O
increased	O
at	O
2	O
days	O
after	O
exposure	O
.	O

No	O
changes	O
were	O
detected	O
in	O
the	O
lung	O
manganase	O
superoxide	B-ENZY
dismutase	I-ENZY
(	O
MnSOD	O
)	O
or	O
glutathione	B-ENZY
reductase	I-ENZY
(	O
GR	O
)	O
mRNA	O
expression	O
after	O
blast	O
.	O

TITLE	O
:	O
Organ	O
-	O
specific	O
attenuation	O
of	O
murine	O
hepatitis	O
virus	O
strain	O
A59	O
by	O
replacement	O
of	O
catalytic	O
residues	O
in	O
the	O
putative	O
viral	O
cyclic	O
phosphodiesterase	B-ENZY
ns2	O
.	O

ABSTRACT	O
:	O
We	O
report	O
on	O
recent	O
advances	O
and	O
achievements	O
on	O
the	O
use	O
of	O
extracorporeal	O
gas	B-ENZY
exchange	O
for	O
long	O
-	O
term	O
application	O
in	O
the	O
therapy	O
of	O
critically	O
ill	O
patients	O
with	O
various	O
forms	O
of	O
respiratory	O
failure	O
.	O

The	O
most	O
important	O
results	O
regarding	O
the	O
use	O
of	O
extracorporeal	O
gas	B-ENZY
exchange	O
are	O
expected	O
from	O
the	O
Conventional	O
Ventilatory	O
Support	O
vs	O
.	O
Extracorporeal	O
Membrane	O
Oxygenation	O
for	O
Severe	O
Adult	O
Respiratory	O
Failure	O
(	O
CESAR	O
)	O
study	O
,	O
a	O
randomized	O
clinical	O
trial	O
assessing	O
the	O
effectiveness	O
of	O
extracorporeal	O
lung	O
assist	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
.	O

Among	O
technical	O
progress	O
,	O
of	O
particular	O
interest	O
is	O
the	O
development	O
of	O
microfiber	O
,	O
microporous	O
polymethylpentene	O
membrane	O
lungs	O
,	O
which	O
offer	O
low	O
resistance	O
to	O
blood	O
flow	O
,	O
high	O
gas	B-ENZY
transfer	O
capability	O
,	O
and	O
high	O
leak	O
-	O
proof	O
performance	O
.	O

Results	O
of	O
recent	O
clinical	O
trials	O
,	O
widespread	O
use	O
of	O
clinical	O
applications	O
,	O
and	O
technical	O
progress	O
are	O
leading	O
to	O
reevaluation	O
and	O
extension	O
of	O
extracorporeal	O
gas	B-ENZY
exchange	O
in	O
critically	O
ill	O
patients	O
with	O
respiratory	O
failure	O
of	O
various	O
forms	O
.	O

Patients	O
with	O
AE	O
showed	O
acute	O
respiratory	O
deterioration	O
with	O
severe	O
hypoxemia	O
(	O
mean	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
,	O
131	O
).	O

ABSTRACT	O
:	O
Pumpless	O
interventional	O
lung	O
assist	O
(	O
iLA	O
)	O
is	O
used	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
aimed	O
at	O
improving	O
extracorporeal	O
gas	B-ENZY
exchange	O
with	O
a	O
membrane	O
integrated	O
in	O
a	O
passive	O
arteriovenous	O
shunt	O
.	O

Gas	B-ENZY
exchange	O
,	O
tidal	O
volumes	O
,	O
airway	O
pressures	O
,	O
breathing	O
patterns	O
and	O
sedation	O
requirements	O
before	O
(	O
baseline	O
)	O
and	O
after	O
(	O
2	O
-	O
4	O
days	O
)	O
initiation	O
of	O
treatment	O
with	O
p	O
-	O
ECLA	O
were	O
analysed	O
.	O

The	O
PCRs	O
,	O
or	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCRs	O
,	O
may	O
be	O
general	O
,	O
designed	O
to	O
detect	O
all	O
or	O
most	O
variants	O
of	O
a	O
pathogen	O
,	O
or	O
to	O
be	O
serotype	O
,	O
genotype	O
or	O
pathotype	O
specific	O
.	O

This	O
review	O
analyzes	O
the	O
effects	O
of	O
NMBAs	O
on	O
thoracopulmonary	O
mechanics	O
,	O
gas	B-ENZY
exchange	O
,	O
patient	O
outcome	O
and	O
their	O
potential	O
adverse	O
effects	O
.	O

However	O
,	O
APC	O
failed	O
to	O
prevent	O
the	O
decrease	O
in	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
.	O

Here	O
we	O
used	O
this	O
method	O
to	O
monitor	O
the	O
spatial	O
and	O
temporal	O
progression	O
of	O
mouse	O
hepatitis	O
coronavirus	O
(	O
MHV	O
)	O
infection	O
in	O
mice	O
using	O
luciferase	B-ENZY
-	O
expressing	O
viruses	O
.	O

TITLE	O
:	O
Aryl	O
diketoacids	O
(	O
ADK	O
)	O
selectively	O
inhibit	O
duplex	O
DNA	O
-	O
unwinding	O
activity	O
of	O
SARS	O
coronavirus	O
NTPase	B-ENZY
/	O
helicase	O
.	O

Furthermore	O
,	O
a	O
tight	O
positive	O
correlation	O
was	O
observed	O
between	O
lung	O
injury	O
score	O
(	O
LIS	B-ENZY
)	O
and	O
NO	O
production	O
level	O
in	O
lung	O
tissue	O
.	O

We	O
reported	O
previously	O
the	O
presence	O
of	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	B-ENZY
hydrolase	I-ENZY
(	O
FAH	O
)	O
in	O
sera	O
from	O
mice	O
infected	O
with	O
MHV	O
-	O
A59	O
.	O

The	O
modulation	O
of	O
UPR	O
by	O
S	O
protein	O
involves	O
activation	O
of	O
PERK	O
protein	B-ENZY
kinase	I-ENZY
.	O

When	O
different	O
forms	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
-	O
based	O
vaccines	O
for	O
generation	O
of	O
a	O
neutralising	O
antibody	O
response	O
to	O
SARS	O
-	O
CoV	O
were	O
injected	O
into	O
a	O
mouse	O
model	O
,	O
all	O
the	O
mice	O
immunised	O
with	O
intramuscular	O
tPA	B-ENZY
-	O
optimised	O
800	O
DNA	O
vaccine	O
boosted	O
with	O
intraperitoneal	O
recombinant	O
spike	O
polypeptide	O
generated	O
by	O
Escherichia	O
coli	O
and	O
intramuscular	O
CTLA4Hinge	O
SARS800	O
DNA	O
vaccine	O
boosted	O
with	O
intraperitoneal	O
S	O
-	O
peptide	O
had	O
neutralising	O
antibody	O
titres	O
of	O
>	O
1	O
:	O
1280	O
.	O
2	O
.	O

No	O
positive	O
selection	O
was	O
found	O
in	O
any	O
proteins	O
of	O
bat	B-ENZY
SARS	O
-	O
like	O
-	O
CoV	O
.	O
Furthermore	O
,	O
specific	O
amino	O
acid	O
sites	O
that	O
may	O
be	O
the	O
targets	O
of	O
positive	O
selection	O
in	O
each	O
group	O
are	O
identified	O
.	O

No	O
positive	O
selection	O
was	O
found	O
in	O
any	O
proteins	O
of	O
bat	B-ENZY
SARS	O
-	O
like	O
-	O
CoV	O
.	O
Furthermore	O
,	O
specific	O
amino	O
acid	O
sites	O
that	O
may	O
be	O
the	O
targets	O
of	O
positive	O
selection	O
in	O
each	O
group	O
are	O
identified	O
.	O

The	O
present	O
study	O
analyzed	O
the	O
activities	O
of	O
nsp1	O
proteins	O
from	O
the	O
group	O
2	O
bat	B-ENZY
CoV	O
strains	O
Rm1	O
,	O
133	O
,	O
and	O
HKU9	O
-	O
1	O
,	O
belonging	O
to	O
groups	O
2b	O
,	O
2c	O
,	O
and	O
2d	O
,	O
respectively	O
.	O

The	O
results	O
of	O
our	O
studies	O
suggested	O
a	O
conserved	O
function	O
among	O
nsp1	O
proteins	O
of	O
SARS	O
-	O
CoV	O
and	O
group	O
2	O
bat	B-ENZY
CoVs	O
.	O

The	O
patients	O
showed	O
a	O
statistically	O
significant	O
improvement	O
in	O
Pao	B-ENZY
(	O
2	O
)/	O
Fio	O
(	O
2	O
)	O
(	O
92	O
+/-	O
12	O
vs	O
227	O
+/-	O

ABSTRACT	O
:	O
This	O
article	O
reports	O
on	O
the	O
identification	O
of	O
a	O
group	O
2	O
coronavirus	O
(	O
BatCoV	O
DR	O
/	O
2007	O
)	O
in	O
a	O
Desmodus	O
rotundus	O
vampire	O
bat	B-ENZY
in	O
Brazil	O
.	O

Factors	O
independently	O
associated	O
with	O
multiple	O
-	O
type	O
HPV	O
were	O
Hispanic	O
ethnicity	O
[	O
adjusted	O
odds	O
ratio	O
(	O
AOR	B-ENZY
),	O
2	O
.	O
45	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
),	O
1	O
.	O
05	O
-	O
5	O
.	O
67	O
],	O
concurrent	O
detection	O
of	O
genital	O
warts	O
(	O
AOR	B-ENZY
,	O
10	O
.	O
40	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
12	O
-	O
96	O
.	O
6	O
),	O
smoking	O
>	O
or	O
=	O
10	O
cigarettes	O
/	O
d	O
(	O
AOR	B-ENZY
,	O
3	O
.	O
00	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
07	O
-	O
8	O
.	O
43	O
),	O
greater	O
lifetime	O
number	O
of	O
female	O
sexual	O
partners	O
(	O
AOR	B-ENZY
,	O
13	O
.	O
73	O
for	O
>	O
or	O
=	O
21	O
versus	O
1	O
-	O
5	O
;	O
95	O
%	O
CI	O
,	O
5	O
.	O
34	O
-	O
35	O
.	O
3	O
),	O
and	O
condom	O
use	O
less	O
than	O
half	O
the	O
time	O
(	O
AOR	B-ENZY
,	O
2	O
.	O
03	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
07	O
-	O
3	O
.	O
84	O
).	O

Mutation	O
of	O
R797	O
specifically	O
inhibited	O
trypsin	B-ENZY
-	O
dependent	O
fusion	O
in	O
both	O
cell	O
-	O
cell	O
fusion	O
and	O
pseudovirion	O
entry	O
assays	O
.	O

We	O
also	O
introduced	O
a	O
furin	B-ENZY
cleavage	O
site	O
at	O
both	O
the	O
S2	O
'	O
cleavage	O
site	O
within	O
S2	O
793	O
-	O
KPTKR	O
-	O
797	O
(	O
S2	O
'),	O
as	O
well	O
as	O
at	O
the	O
junction	O
of	O
S1	O
and	O
S2	O
.	O

Introduction	O
of	O
a	O
furin	B-ENZY
cleavage	O
site	O
at	O
the	O
S2	O
'	O
position	O
allowed	O
trypsin	B-ENZY
-	O
independent	O
cell	O
-	O
cell	O
fusion	O
,	O
which	O
was	O
strongly	O
increased	O
by	O
the	O
presence	O
of	O
a	O
second	O
furin	B-ENZY
cleavage	O
site	O
at	O
the	O
S1	O
-	O
S2	O
position	O
.	O

Significant	O
elevations	O
in	O
oxygen	O
saturation	O
,	O
serum	O
creatinine	O
,	O
lactate	O
dehydrogenase	O
,	O
creatine	B-ENZY
kinase	I-ENZY
MB	O
isoenzyme	O
,	O
and	O
fasting	O
plasma	O
glucose	O
(	O
FPG	O
),	O
but	O
not	O
in	O
alanine	B-ENZY
transaminase	I-ENZY
were	O
predictors	O
for	O
death	O
.	O

Chi	O
-	O
squared	O
tests	O
showed	O
adverse	O
outcome	O
in	O
MABC	O
scores	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
compared	O
with	O
the	O
reference	O
population	O
in	O
children	O
with	O
CDH	B-ENZY
,	O
sepsis	O
and	O
PPH	B-ENZY
,	O
but	O
not	O
in	O
children	O
with	O
MAS	O
.	O

Compared	O
with	O
the	O
Dutch	O
population	O
height	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
and	O
weight	O
for	O
height	O
were	O
lower	O
in	O
the	O
CDH	B-ENZY
group	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

TITLE	O
:	O
APOBEC3G	O
cytidine	B-ENZY
deaminase	I-ENZY
association	O
with	O
coronavirus	O
nucleocapsid	O
protein	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
genetic	O
diversity	O
of	O
the	O
S2	O
gene	O
of	O
infectious	O
bronchitis	O
viruses	O
(	O
IBV	O
)	O
isolated	O
in	O
Japan	O
,	O
we	O
determined	O
the	O
nucleotide	O
sequences	O
of	O
these	O
IBVs	O
using	O
the	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
method	O
coupled	O
with	O
direct	O
sequencing	O
.	O

Blood	O
gas	B-ENZY
analysis	O
demonstrated	O
severe	O
hypoxemia	O
(	O
PaO2	O
43	O
.	O
2Torr	O
with	O
6L	O
/	O
min	O
oxygen	O
).	O

Despite	O
several	O
intervention	O
options	O
,	O
the	O
mortality	O
in	O
patients	O
developing	O
ACS	B-ENZY
remains	O
high	O
:	O
50	O
-	O
75	O
%.	O

We	O
attempted	O
to	O
isolate	O
viruses	O
from	O
fresh	O
tissue	O
samples	O
taken	O
from	O
trapped	O
bats	O
in	O
cultured	O
cells	O
of	O
bat	B-ENZY
,	O
primate	O
,	O
rodent	O
,	O
porcine	O
,	O
ovine	O
and	O
avian	O
origin	O
.	O

In	O
this	O
study	O
,	O
we	O
focus	O
on	O
the	O
SARS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLP	O
),	O
which	O
engages	O
and	O
antagonizes	O
the	O
IFN	O
induction	O
and	O
NF	O
-	O
kappaB	O
signaling	O
pathways	O
.	O

TITLE	O
:	O
Thiopurine	O
analogue	O
inhibitors	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
,	O
a	O
deubiquitinating	O
and	O
deISGylating	O
enzyme	O
.	O

The	O
best	O
docking	O
score	O
and	O
binding	O
energy	O
for	O
6MP	O
and	O
6TG	O
is	O
against	O
ubiquitin	O
-	O
specific	O
protease	O
(	O
USP	B-ENZY
)	O
14	O
,	O
suggesting	O
that	O
6MP	O
and	O
6TG	O
are	O
potential	O
inhibitors	O
of	O
USP14	O
.	O

M	O
protein	O
potently	O
antagonizes	O
the	O
activation	O
of	O
interferon	O
-	O
stimulated	O
response	O
element	O
-	O
dependent	O
transcription	O
by	O
double	O
-	O
stranded	O
RNA	O
,	O
RIG	O
-	O
I	O
,	O
MDA5	O
,	O
TBK1	B-ENZY
,	O
IKKepsilon	O
,	O
and	O
virus	O
-	O
induced	O
signaling	O
adaptor	O
(	O
VISA	O
)	O
but	O
has	O
no	O
influence	O
on	O
the	O
transcriptional	O
activity	O
of	O
this	O
element	O
when	O
IRF3	O
or	O
IRF7	O
is	O
overexpressed	O
.	O

M	O
protein	O
physically	O
associates	O
with	O
RIG	O
-	O
I	O
,	O
TBK1	B-ENZY
,	O
IKKepsilon	O
,	O
and	O
TRAF3	O
and	O
likely	O
sequesters	O
some	O
of	O
them	O
in	O
membrane	O
-	O
associated	O
cytoplasmic	O
compartments	O
.	O

Consequently	O
,	O
the	O
expression	O
of	O
M	O
protein	O
prevents	O
the	O
formation	O
of	O
TRAF3	O
.	O
TANK	O
.	O
TBK1	B-ENZY
/	O
IKKepsilon	O
complex	O
and	O
thereby	O
inhibits	O
TBK1	B-ENZY
/	O
IKKepsilon	O
-	O
dependent	O
activation	O
of	O
IRF3	O
/	O
IRF7	O
transcription	O
factors	O
.	O

As	O
the	O
downstream	O
protein	O
of	O
MBL	O
,	O
variants	O
of	O
the	O
MBL	O
-	O
associated	O
serine	O
protease	O
-	O
2	O
(	O
MASP2	B-ENZY
)	O
gene	O
may	O
be	O
associated	O
with	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
in	O
the	O
same	O
population	O
.	O

Thirty	O
individuals	O
with	O
SARS	O
were	O
chosen	O
for	O
analysis	O
of	O
MASP2	B-ENZY
polymorphisms	O
by	O
means	O
of	O
PCR	O
direct	O
sequencing	O
.	O

There	O
is	O
no	O
significant	O
association	O
between	O
alleles	O
or	O
genotypes	O
of	O
the	O
MASP2	B-ENZY
tagSNP	O
and	O
susceptibility	O
to	O
SARS	O
-	O
CoV	O
in	O
both	O
Beijing	O
and	O
Guangzhou	O
populations	O
.	O

Our	O
data	O
do	O
not	O
suggest	O
a	O
role	O
for	O
MASP2	B-ENZY
polymorphisms	O
in	O
SARS	O
susceptibility	O
in	O
northern	O
and	O
southern	O
China	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
do	O
not	O
suggest	O
a	O
role	O
for	O
MASP2	B-ENZY
polymorphisms	O
in	O
SARS	O
susceptibility	O
in	O
northern	O
and	O
southern	O
China	O
.	O

By	O
using	O
an	O
infectious	O
cloning	O
system	O
developed	O
recently	O
for	O
the	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
the	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
gene	O
,	O
the	O
firefly	B-ENZY
luciferase	I-ENZY
gene	O
and	O
several	O
host	O
and	O
viral	O
genes	O
(	O
eIF3f	O
,	O
SARS	O
ORF6	O
,	O
Dengue	O
virus	O
1	O
core	O
protein	O
gene	O
)	O
were	O
inserted	O
into	O
various	O
positions	O
of	O
the	O
IBV	O
genome	O
,	O
and	O
the	O
effects	O
on	O
gene	O
expression	O
,	O
virus	O
recovery	O
,	O
and	O
stability	O
in	O
cell	O
culture	O
were	O
studied	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
carry	O
out	O
molecular	O
epidemiological	O
investigation	O
on	O
enterotoxigenic	O
Escherichia	O
coli	O
(	O
ETEC	O
)	O
K99	O
and	O
Salmonella	O
spp	B-ENZY
.	O

E	O
.	O
coli	O
and	O
Salmonella	O
spp	B-ENZY
.	O

isolates	O
were	O
examined	O
for	O
E	O
.	O
coli	O
K99	O
and	O
Salmonella	O
spp	B-ENZY
.	O

ETEC	O
K99	O
was	O
recovered	O
from	O
20	O
(	O
10	O
.	O
36	O
%)	O
out	O
of	O
193	O
isolates	O
,	O
whereas	O
Salmonella	O
spp	B-ENZY
.	O
was	O
recovered	O
from	O
nine	O
calves	O
(	O
4	O
.	O
09	O
%).	O

The	O
results	O
of	O
the	O
present	O
study	O
indicate	O
the	O
importance	O
of	O
PCR	O
as	O
rapid	O
,	O
effective	O
and	O
reliable	O
tool	O
for	O
screening	O
of	O
ETEC	O
and	O
Salmonella	O
spp	B-ENZY
.	O

N	O
protein	O
is	O
thought	O
to	O
dysregulate	O
cell	O
signalling	O
and	O
the	O
transcription	O
of	O
cellular	O
genes	O
,	O
including	O
FGL2	O
,	O
which	O
encodes	O
a	O
prothrombinase	B-ENZY
implicated	O
in	O
vascular	O
thrombosis	O
,	O
fibrin	O
deposition	O
and	O
pneumocyte	O
necrosis	O
.	O

TITLE	O
:	O
Expression	O
and	O
functional	O
analysis	O
of	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
produced	O
in	O
prokaryotic	O
expression	O
system	O
.	O

ABSTRACT	O
:	O
Porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
is	O
a	O
cellular	O
membrane	O
protein	O
and	O
a	O
functional	O
receptor	O
for	O
porcine	O
coronaviruses	O
.	O

Compared	O
with	O
seropositive	O
controls	O
,	O
the	O
concentration	O
of	O
TSA	B-ENZY
was	O
higher	O
in	O
cats	O
with	O
FIP	O
(	O
556	O
.	O
7	O
+/-	O

Consequently	O
,	O
TSA	B-ENZY
could	O
support	O
a	O
diagnosis	O
of	O
FIP	O
only	O
at	O
extremely	O
high	O
serum	O
concentration	O
(>	O
800	O
mg	O
/	O
L	O
)	O
or	O
when	O
the	O
pre	O
-	O
test	O
probability	O
of	O
FIP	O
is	O
high	O
.	O

ABSTRACT	O
:	O
The	O
effects	O
of	O
glycyrrhizin	O
diammonium	O
(	O
GD	O
)	O
and	O
lithium	O
chloride	O
(	O
LiCl	O
)	O
on	O
cell	O
infection	O
by	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
were	O
investigated	O
using	O
cytopathic	O
effect	O
observation	O
,	O
plaque	O
-	O
reduction	O
assay	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
.	O

ABSTRACT	O
:	O
Neutrophil	B-ENZY
elastase	I-ENZY
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	O
)	O
in	O
sepsis	O
.	O

Sivelestat	O
is	O
a	O
selective	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
.	O

In	O
two	O
children	O
DCT	B-ENZY
was	O
positive	O
with	O
the	O
peripheral	O
smear	O
showing	O
RBC	O
agglutinates	O
around	O
the	O
parasitised	O
RBC	O
.	O

Rats	O
with	O
LC	O
+	O
CASP	O
versus	O
LC	O
had	O
more	O
severe	O
inflammation	O
based	O
on	O
higher	O
levels	O
of	O
PMN	O
in	O
BAL	B-ENZY
at	O
5	O
h	O
,	O
increased	O
whole	O
lung	O
myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
activity	O
at	O
5	O
and	O
24	O
h	O
,	O
and	O
increased	O
levels	O
of	O
inflammatory	O
mediators	O
in	O
BAL	B-ENZY
(	O
TNFalpha	O
,	O
IL	O
-	O
1beta	O
,	O
and	O
MCP	O
-	O
1	O
at	O
5	O
and	O
24	O
h	O
;	O
IL	O
-	O
10	O
,	O
MIP	O
-	O
2	O
,	O
and	O
CINC	O
-	O
1	O
at	O
5	O
h	O
).	O

RESULTS	O
:	O
Rats	O
with	O
LC	O
+	O
CASP	O
had	O
lower	O
mean	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratios	O
compared	O
with	O
LC	O
alone	O
at	O
24	O
h	O
,	O
and	O
higher	O
BAL	B-ENZY
albumin	O
concentrations	O
compared	O
with	O
either	O
LC	O
or	O
CASP	O
alone	O
.	O

TITLE	O
:	O
Proteolytic	O
activation	O
of	O
the	O
spike	O
protein	O
at	O
a	O
novel	O
RRRR	O
/	O
S	O
motif	O
is	O
implicated	O
in	O
furin	B-ENZY
-	O
dependent	O
entry	O
,	O
syncytium	O
formation	O
,	O
and	O
infectivity	O
of	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
in	O
cultured	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
coronavirus	O
(	O
CoV	O
)	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
cleaved	O
into	O
S1	O
and	O
S2	O
subunits	O
at	O
the	O
furin	B-ENZY
consensus	O
motif	O
RRFRR	O
(	O
537	O
)/	O
S	O
in	O
virus	O
-	O
infected	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
observe	O
that	O
the	O
S2	O
subunit	O
of	O
the	O
IBV	O
Beaudette	O
strain	O
is	O
additionally	O
cleaved	O
at	O
the	O
second	O
furin	B-ENZY
site	O
(	O
RRRR	O
(	O
690	O
)/	O
S	O
)	O
in	O
cells	O
expressing	O
S	O
constructs	O
and	O
in	O
virus	O
-	O
infected	O
cells	O
.	O

Detailed	O
time	O
course	O
experiments	O
showed	O
that	O
a	O
peptide	O
furin	B-ENZY
inhibitor	O
,	O
decanoyl	O
-	O
Arg	O
-	O
Val	O
-	O
Lys	O
-	O
Arg	O
-	O
chloromethylketone	O
,	O
blocked	O
both	O
viral	O
entry	O
and	O
syncytium	O
formation	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
studies	O
revealed	O
that	O
the	O
S1	O
/	O
S2	O
cleavage	O
by	O
furin	B-ENZY
was	O
not	O
necessary	O
for	O
,	O
but	O
could	O
promote	O
,	O
syncytium	O
formation	O
by	O
and	O
infectivity	O
of	O
IBV	O
in	O
Vero	O
cells	O
.	O

Mutations	O
of	O
the	O
second	O
site	O
from	O
furin	B-ENZY
-	O
cleavable	O
RRRR	O
/	O
S	O
to	O
non	O
-	O
furin	B-ENZY
-	O
cleavable	O
PRRRS	O
and	O
AAARS	O
,	O
respectively	O
,	O
abrogated	O
the	O
furin	B-ENZY
dependence	O
of	O
IBV	O
entry	O
.	O

The	O
agents	O
isolated	O
were	O
the	O
following	O
:	O
Mannheimia	O
haemolytica	O
(	O
25	O
.	O
0	O
%),	O
Pasteurella	O
multocida	O
(	O
24	O
.	O
5	O
%),	O
Histophilus	O
somni	O
(	O
10	O
.	O
0	O
%),	O
Arcanobacterium	O
pyogenes	O
(	O
35	O
.	O
0	O
%),	O
Salmonella	O
spp	B-ENZY
.	O

(	O
0	O
.	O
5	O
%),	O
and	O
Mycoplasma	O
spp	B-ENZY
.	O

Other	O
common	O
findings	O
were	O
an	O
increased	O
creatine	B-ENZY
kinase	I-ENZY
level	O
(	O
in	O
62	O
%	O
of	O
patients	O
)	O
and	O
lymphopenia	O
(	O
in	O
61	O
%).	O

Blood	O
DNA	O
samples	O
were	O
evaluated	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
for	O
feline	O
leukemia	O
virus	O
(	O
FeLV	O
)	O
proviral	O
DNA	O
,	O
whereas	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
was	O
run	O
on	O
fecal	O
samples	O
for	O
detection	O
of	O
coronavirus	O
RNA	O
.	O

Gene	O
silencing	O
of	O
PABP	O
,	O
hnRNP	O
Q	O
,	O
and	O
glutamyl	O
-	O
prolyl	B-ENZY
-	I-ENZY
tRNA	I-ENZY
synthetase	I-ENZY
(	O
EPRS	O
)	O
caused	O
a	O
significant	O
2	O
to	O
3	O
-	O
fold	O
reduction	O
of	O
viral	O
RNA	O
synthesis	O
.	O

Interestingly	O
,	O
the	O
silencing	O
of	O
glyceraldehyde	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	B-ENZY
),	O
initially	O
used	O
as	O
a	O
control	O
gene	O
,	O
caused	O
a	O
2	O
to	O
3	O
-	O
fold	O
increase	O
in	O
viral	O
RNA	O
synthesis	O
in	O
both	O
systems	O
.	O

These	O
data	O
suggest	O
that	O
PABP	O
,	O
hnRNP	O
Q	O
,	O
and	O
EPRS	O
play	O
a	O
positive	O
role	O
in	O
virus	O
infection	O
that	O
could	O
be	O
mediated	O
through	O
their	O
interaction	O
with	O
the	O
viral	O
3	O
'	O
end	O
,	O
and	O
that	O
GAPDH	B-ENZY
has	O
a	O
negative	O
effect	O
on	O
viral	O
infection	O
.	O

After	O
adjusting	O
for	O
physiology	O
,	O
injury	O
severity	O
,	O
and	O
transfusion	O
,	O
etomidate	O
use	O
remained	O
associated	O
with	O
ARDS	O
(	O
aOR	B-ENZY
=	O
3	O
.	O
9	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
24	O
-	O
12	O
.	O
0	O
).	O

This	O
was	O
a	O
prospective	O
study	O
with	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
and	O
blood	O
sampling	O
.	O

Serum	O
and	O
BAL	B-ENZY
fluid	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
10	O
,	O
TNF	O
-	O
alpha	O
,	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
endotoxins	O
on	O
the	O
first	O
day	O
of	O
ICU	O
admission	O
were	O
obtained	O
.	O

Furthermore	O
,	O
in	O
the	O
ARDS	O
population	O
,	O
we	O
found	O
that	O
the	O
endotoxin	O
levels	O
in	O
the	O
BAL	B-ENZY
fluid	O
were	O
higher	O
in	O
the	O
survival	O
than	O
in	O
the	O
nonsurvival	O
group	O
and	O
BAL	B-ENZY
fluid	O
concentrations	O
of	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
IL	O
-	O
1beta	O
and	O
sera	O
levels	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
10	O
were	O
lower	O
in	O
the	O
survival	O
than	O
in	O
the	O
nonsurvival	O
group	O
,	O
and	O
they	O
were	O
associated	O
with	O
a	O
high	O
negative	O
predictive	O
value	O
.	O

Serum	O
and	O
BAL	B-ENZY
fluid	O
levels	O
of	O
the	O
studied	O
cytokines	O
on	O
admission	O
may	O
provide	O
valuable	O
prognostic	O
information	O
for	O
patients	O
with	O
severe	O
CAP	O
.	O

TITLE	O
:	O
Immunogenicity	O
difference	O
between	O
the	O
SARS	O
coronavirus	O
and	O
the	O
bat	B-ENZY
SARS	O
-	O
like	O
coronavirus	O
spike	O
(	O
S	O
)	O
proteins	O
.	O

ABSTRACT	O
:	O
Aryl	O
diketoacids	O
have	O
been	O
identified	O
as	O
the	O
first	O
SARS	O
-	O
CoV	O
NTPase	B-ENZY
/	O
helicase	O
inhibitors	O
with	O
a	O
distinct	O
pharmacophore	O
featuring	O
an	O
arylmethyl	O
group	O
attached	O
to	O
a	O
diketoacid	O
.	O

Based	O
on	O
SAR	O
study	O
,	O
an	O
extended	O
feature	O
of	O
the	O
pharmacophore	O
model	O
of	O
SARS	O
-	O
CoV	O
NTPase	B-ENZY
/	O
helicase	O
was	O
proposed	O
which	O
is	O
constituted	O
of	O
a	O
diketoacid	O
core	O
,	O
a	O
hydrophobic	O
arylmethyl	O
substituent	O
,	O
and	O
a	O
free	O
catechol	O
unit	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
rdACE2	O
has	O
identities	O
of	O
99	O
.	O
3	O
,	O
89	O
.	O
2	O
,	O
83	O
.	O
9	O
and	O
80	O
.	O
4	O
%	O
to	O
ACE2	O
proteins	O
from	O
dog	O
,	O
masked	O
palm	O
civet	O
(	O
pcACE2	O
),	O
human	O
(	O
huACE2	O
)	O
and	O
bat	B-ENZY
,	O
respectively	O
.	O

It	O
was	O
reported	O
that	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
)	O
was	O
the	O
receptor	O
for	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
Human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
and	O
Feline	O
coronavirus	O
(	O
FeCoV	O
)	O
which	O
all	O
belonged	O
to	O
group	O
I	O
coronavirus	O
including	O
PEDV	O
.	O

ABSTRACT	O
:	O
Patients	O
who	O
are	O
diagnosed	O
with	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ALI	O
/	O
ARDS	O
)	O
usually	O
have	O
ventilation	O
-	O
perfusion	O
mismatch	O
,	O
severe	O
decrease	O
in	O
lung	O
capacity	O
,	O
and	O
gas	B-ENZY
exchange	O
abnormalities	O
.	O

ABSTRACT	O
:	O
Red	O
cell	O
exchange	O
(	O
RCE	O
)	O
is	O
part	O
of	O
the	O
management	O
of	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
)	O
in	O
patients	O
with	O
sickle	O
cell	O
disease	O
.	O

We	O
retrospectively	O
reviewed	O
53	O
episodes	O
of	O
ACS	B-ENZY
in	O
44	O
patients	O
who	O
received	O
RCE	O
from	O
January	O
2003	O
to	O
October	O
2006	O
.	O

ACS	B-ENZY
was	O
diagnosed	O
at	O
presentation	O
in	O
66	O
%,	O
in	O
the	O
remainder	O
ACS	B-ENZY
was	O
diagnosed	O
after	O
a	O
median	O
of	O
2	O
days	O
.	O

RCE	O
appears	O
to	O
be	O
a	O
safe	O
and	O
effective	O
treatment	O
for	O
patients	O
with	O
sickle	O
cell	O
disease	O
and	O
ACS	B-ENZY
.	O

TITLE	O
:	O
Combining	O
""""	O
open	O
-	O
lung	O
""""	O
ventilation	O
and	O
arteriovenous	O
extracorporeal	O
lung	O
assist	O
:	O
influence	O
of	O
different	O
tidal	O
volumes	O
on	O
gas	B-ENZY
exchange	O
in	O
experimental	O
lung	O
failure	O
.	O

TITLE	O
:	O
Structure	O
-	O
based	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
novel	O
and	O
reversible	O
inhibitors	O
for	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
.	O

ABSTRACT	O
:	O
Nonthrombotic	O
pulmonary	O
embolism	O
(	O
NTPE	O
)	O
is	O
defined	O
as	O
embolisation	O
to	O
the	O
pulmonary	O
circulation	O
of	O
different	O
cell	O
types	O
(	O
adipocytes	O
,	O
haematopoietic	O
,	O
amniotic	O
,	O
trophoblastic	O
or	O
tumour	O
),	O
bacteria	O
,	O
fungi	O
,	O
foreign	O
material	O
or	O
gas	B-ENZY
.	O

Compared	O
to	O
low	O
PEEP	O
,	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
and	O
alveolar	O
recruitment	O
were	O
increased	O
with	O
high	O
PEEP	O
.	O

RESULTS	O
:	O
Compared	O
to	O
low	O
PEEP	O
,	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
and	O
alveolar	O
recruitment	O
were	O
increased	O
with	O
high	O
PEEP	O
.	O

Upon	O
receptor	O
binding	O
,	O
the	O
spike	O
(	O
S	O
)	O
proteins	O
of	O
both	O
viruses	O
are	O
activated	O
for	O
membrane	O
fusion	O
by	O
proteases	O
,	O
such	O
as	O
trypsin	B-ENZY
,	O
present	O
in	O
the	O
environment	O
,	O
facilitating	O
virus	O
entry	O
from	O
the	O
cell	O
surface	O
.	O

The	O
exposure	O
of	O
receptor	O
-	O
bound	O
S	O
protein	O
to	O
trypsin	B-ENZY
or	O
cathepsin	B-ENZY
L	I-ENZY
(	O
CPL	B-ENZY
)	O
induces	O
the	O
formation	O
of	O
six	O
-	O
helix	O
bundles	O
(	O
6HB	O
),	O
the	O
final	O
conformation	O
.	O

Although	O
trypsin	B-ENZY
treatment	O
enabled	O
receptor	O
-	O
bound	O
MHV	O
-	O
2	O
to	O
enter	O
from	O
the	O
cell	O
surface	O
,	O
CPL	B-ENZY
failed	O
to	O
do	O
so	O
.	O

Torovirus	O
HEs	O
form	O
homodimers	O
with	O
sialate	O
-	O
O	O
-	O
acetylesterase	B-ENZY
domains	O
almost	O
identical	O
to	O
corresponding	O
domains	O
in	O
orthomyxo	O
-	O
and	O
coronavirus	O
HEs	O
,	O
but	O
with	O
unique	O
lectin	O
sites	O
.	O

ABSTRACT	O
:	O
Asymmetric	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
microarrays	O
were	O
combined	O
to	O
distinguish	O
4	O
viruses	O
,	O
including	O
Avian	O
influenza	O
virus	O
(	O
AIV	O
),	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
),	O
Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
and	O
Infectious	O
bursal	O
disease	O
virus	O
(	O
IBDV	O
),	O
and	O
hemagglutinin	O
(	O
HA	O
)	O
subtypes	O
H5	O
,	O
H7	O
,	O
and	O
H9	O
,	O
and	O
neuraminidase	B-ENZY
(	O
NA	O
)	O
subtypes	O
N1	O
and	O
N2	O
of	O
AIV	O
.	O

Depending	O
on	O
mouse	O
strain	O
,	O
the	O
viral	O
fixation	O
to	O
heparan	O
sulfate	O
/	O
TLR2	O
stimulated	O
differently	O
the	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
and	O
nuclear	O
factor	O
(	O
NF	O
)-	O
kappaB	O
in	O
the	O
induction	O
of	O
IL	O
-	O
6	O
and	O
TNF	O
-	O
alpha	O
.	O

The	O
synergistic	O
IFN	O
-	O
gamma	O
production	O
involves	O
the	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
rather	O
than	O
the	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
-	O
1	O
/	O
2	O
MAPK	B-ENZY
signalling	O
pathway	O
.	O

CPR	B-ENZY
and	O
complications	O
while	O
on	O
ECMO	O
including	O
circuit	O
rupture	O
,	O
central	O
nervous	O
system	O
infarction	O
or	O
hemorrhage	O
,	O
gastrointestinal	O
or	O
pulmonary	O
hemorrhage	O
,	O
and	O
arterial	O
blood	O
pH	O
<	O
7	O
.	O
2	O
or	O
>	O
7	O
.	O
6	O
were	O
associated	O
with	O
increased	O
odds	O
of	O
death	O
.	O

CPR	B-ENZY
and	O
complications	O
while	O
on	O
ECMO	O
including	O
circuit	O
rupture	O
,	O
central	O
nervous	O
system	O
infarction	O
or	O
hemorrhage	O
,	O
gastrointestinal	O
or	O
pulmonary	O
hemorrhage	O
,	O
and	O
arterial	O
blood	O
pH	O
<	O
7	O
.	O
2	O
or	O
>	O
7	O
.	O
6	O
were	O
associated	O
with	O
increased	O
odds	O
of	O
death	O
.	O

Using	O
inhibitors	O
specific	O
for	O
three	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
,	O
we	O
showed	O
that	O
induction	O
of	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
6	O
by	O
MHV	O
-	O
A59	O
infection	O
was	O
mediated	O
through	O
activation	O
of	O
the	O
Janus	O
N	O
-	O
terminal	O
kinase	O
signaling	O
pathway	O
,	O
but	O
not	O
through	O
the	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
or	O
p38	O
signaling	O
pathway	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
protein	B-ENZY
kinase	I-ENZY
R	O
activation	O
and	O
upregulation	O
of	O
GADD34	O
expression	O
play	O
a	O
synergistic	O
role	O
in	O
facilitating	O
coronavirus	O
replication	O
by	O
maintaining	O
de	O
novo	O
protein	O
synthesis	O
in	O
virus	O
-	O
infected	O
cells	O
.	O

To	O
understand	O
whether	O
this	O
suppression	O
is	O
through	O
inhibition	O
of	O
protein	B-ENZY
kinase	I-ENZY
R	O
(	O
PKR	O
),	O
the	O
double	O
-	O
stranded	O
-	O
RNA	O
-	O
dependent	O
kinase	O
that	O
is	O
one	O
of	O
the	O
main	O
kinases	O
responsible	O
for	O
phosphorylation	O
of	O
eIF	O
-	O
2alpha	O
,	O
cells	O
infected	O
with	O
IBV	O
were	O
analyzed	O
by	O
Western	O
blotting	O
.	O

We	O
found	O
that	O
CCoV	O
-	O
II	O
triggers	O
apoptosis	O
in	O
A	O
-	O
72	O
cells	O
by	O
activating	O
initiator	O
(	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
and	O
-	O
9	O
)	O
and	O
executioner	O
(	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
-	O
6	O
)	O
caspases	O
.	O

ABSTRACT	O
:	O
We	O
tested	O
12	O
bat	B-ENZY
species	O
in	O
Ghana	O
for	O
coronavirus	O
(	O
CoV	O
)	O
RNA	O
.	O

Virus	O
concentrations	O
were	O
<	O
or	O
=	O
45	O
,	O
000	O
copies	O
/	O
100	O
mg	O
of	O
bat	B-ENZY
feces	O
.	O

The	O
role	O
of	O
RNase	B-ENZY
L	O
in	O
viral	O
encephalomyelitis	O
was	O
explored	O
based	O
on	O
its	O
functions	O
in	O
inhibiting	O
translation	O
,	O
inducing	O
apoptosis	O
,	O
and	O
propagating	O
the	O
IFN	O
-	O
alpha	O
/	O
beta	O
pathway	O
through	O
RNA	O
degradation	O
intermediates	O
.	O

Infection	O
of	O
RNase	B-ENZY
L	O
deficient	O
(	O
RL	O
(-/-))	O
mice	O
with	O
a	O
sub	O
-	O
lethal	O
,	O
demyelinating	O
mouse	O
hepatitis	O
virus	O
variant	O
revealed	O
that	O
the	O
majority	O
of	O
mice	O
succumbed	O
to	O
infection	O
by	O
day	O
12	O
p	O
.	O
i	O
.	O

ABSTRACT	O
:	O
Hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	B-ENZY
)	O
is	O
an	O
emerging	O
rodent	O
-	O
borne	O
disease	O
in	O
the	O
American	O
continent	O
,	O
characterized	O
by	O
acute	O
respiratory	O
distress	O
and	O
a	O
high	O
case	O
-	O
fatality	O
ratio	O
.	O

The	O
present	O
work	O
describes	O
a	O
case	O
of	O
HPS	B-ENZY
,	O
with	O
favorable	O
outcome	O
,	O
whose	O
initial	O
features	O
were	O
mistaken	O
for	O
leptospirosis	O
or	O
other	O
less	O
severe	O
acute	O
infections	O
.	O

The	O
case	O
of	O
a	O
32	O
-	O
year	O
-	O
old	O
male	O
with	O
an	O
uneventful	O
course	O
of	O
HPS	B-ENZY
is	O
reported	O
.	O

The	O
prognosis	O
for	O
HPS	B-ENZY
is	O
ominous	O
and	O
misdiagnoses	O
may	O
increase	O
mortality	O
.	O

Clinical	O
suspicion	O
favored	O
warning	O
local	O
health	O
authorities	O
about	O
a	O
new	O
case	O
of	O
HPS	B-ENZY
.	O

ABSTRACT	O
:	O
In	O
some	O
cases	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
hypoxemia	O
occurs	O
despite	O
optimized	O
conservative	O
therapy	O
;	O
however	O
,	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
can	O
assure	O
sufficient	O
gas	B-ENZY
exchange	O
.	O

Plasmatic	O
coagulation	O
was	O
slightly	O
activated	O
in	O
all	O
groups	O
demonstrated	O
by	O
increased	O
thrombin	B-ENZY
-	O
anti	O
-	O
thrombin	B-ENZY
III	O
-	O
complex	O
.	O

Time	O
from	O
hospital	O
to	O
ICU	O
admission	O
was	O
short	O
(	O
median	O
,	O
1	O
day	O
[	O
interquartile	O
range	O
{	O
IQR	O
},	O
0	O
-	O
3	O
days	O
]),	O
and	O
all	O
patients	O
but	O
2	O
received	O
mechanical	O
ventilation	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
refractory	O
hypoxemia	O
(	O
median	O
day	O
1	O
ratio	O
of	O
Pao	B-ENZY
(	O
2	O
)	O
to	O
fraction	O
of	O
inspired	O
oxygen	O
,	O
83	O
[	O
IQR	O
,	O
59	O
-	O
145	O
]	O
mm	O
Hg	O
).	O

After	O
adjusting	O
for	O
a	O
reduced	O
opportunity	O
of	O
patients	O
dying	O
early	O
to	O
receive	O
neuraminidase	B-ENZY
inhibitors	O
,	O
neuraminidase	B-ENZY
inhibitor	O
treatment	O
(	O
vs	O
no	O
treatment	O
)	O
was	O
associated	O
with	O
improved	O
survival	O
(	O
odds	O
ratio	O
,	O
8	O
.	O
5	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
2	O
-	O
62	O
.	O
8	O
).	O

All	O
patients	O
were	O
severely	O
hypoxemic	O
(	O
mean	O
[	O
SD	O
]	O
ratio	O
of	O
Pao	B-ENZY
(	O
2	O
)	O
to	O
fraction	O
of	O
inspired	O
oxygen	O
[	O
Fio	O
(	O
2	O
)]	O
of	O
147	O
[	O
128	O
]	O
mm	O
Hg	O
)	O
at	O
ICU	O
admission	O
.	O

Before	O
ECMO	O
,	O
patients	O
had	O
severe	O
respiratory	O
failure	O
despite	O
advanced	O
mechanical	O
ventilatory	O
support	O
with	O
a	O
median	O
(	O
IQR	O
)	O
Pao	B-ENZY
(	O
2	O
)/	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
Fio	O
(	O
2	O
))	O
ratio	O
of	O
56	O
(	O
48	O
-	O
63	O
),	O
positive	O
end	O
-	O
expiratory	O
pressure	O
of	O
18	O
(	O
15	O
-	O
20	O
)	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
and	O
an	O
acute	O
lung	O
injury	O
score	O
of	O
3	O
.	O
8	O
(	O
3	O
.	O
5	O
-	O
4	O
.	O
0	O
).	O

ABSTRACT	O
:	O
A	O
rare	O
side	O
effect	O
of	O
antipsychotic	O
medication	O
is	O
neuroleptic	O
malignant	O
syndrome	O
,	O
mainly	O
characterized	O
by	O
hyperthermia	O
,	O
altered	O
mental	O
state	O
,	O
haemodynamic	O
dysregulation	O
,	O
elevated	O
serum	O
creatine	B-ENZY
kinase	I-ENZY
and	O
rigor	O
.	O

TCoV	O
detection	O
was	O
accomplished	O
by	O
a	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
through	O
amplification	O
of	O
the	O
3	O
'	O
UTR	O
region	O
,	O
followed	O
by	O
amplification	O
of	O
genes	O
3	O
and	O
5	O
.	O

In	O
addition	O
,	O
ventilation	O
-	O
perfusion	O
distribution	O
of	O
the	O
lung	O
tissue	O
was	O
assessed	O
by	O
the	O
multiple	O
inert	O
gas	B-ENZY
elimination	O
technique	O
.	O

Multiple	O
inert	O
gas	B-ENZY
elimination	O
technique	O
revealed	O
a	O
more	O
homogeneous	O
pulmonary	O
blood	O
flow	O
after	O
treatment	O
with	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
.	O

TITLE	O
:	O
Safety	O
of	O
prolonged	O
,	O
repeated	O
administration	O
of	O
a	O
pulmonary	O
formulation	O
of	O
tissue	B-ENZY
plasminogen	I-ENZY
activator	I-ENZY
in	O
mice	O
.	O

We	O
have	O
developed	O
a	O
pulmonary	O
formulation	O
of	O
tissue	B-ENZY
plasminogen	I-ENZY
activator	I-ENZY
(	O
pf	O
-	O
tPA	B-ENZY
)	O
that	O
withstands	O
nebulization	O
and	O
reaches	O
the	O
lower	O
airways	O
.	O

This	O
study	O
established	O
a	O
safe	O
dose	O
range	O
and	O
demonstrated	O
the	O
feasibility	O
of	O
prolonged	O
,	O
repeated	O
dosing	O
of	O
pf	O
-	O
tPA	B-ENZY
.	O

CONCLUSIONS	O
:	O
This	O
study	O
established	O
a	O
safe	O
dose	O
range	O
and	O
demonstrated	O
the	O
feasibility	O
of	O
prolonged	O
,	O
repeated	O
dosing	O
of	O
pf	O
-	O
tPA	B-ENZY
.	O

Type	O
II	O
FCoVs	O
can	O
be	O
propagated	O
to	O
high	O
titers	O
by	O
employing	O
feline	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
fAPN	O
)	O
as	O
a	O
cellular	O
receptor	O
,	O
whereas	O
the	O
propagation	O
of	O
type	O
I	O
FCoVs	O
is	O
usually	O
difficult	O
,	O
and	O
the	O
involvement	O
of	O
fAPN	O
as	O
a	O
receptor	O
is	O
controversial	O
.	O

READILY	O
CLEAVED	O
IN	O
VITRO	O
BY	O
THREE	O
DIFFERENT	O
AIRWAY	O
PROTEASES	O
:	O
trypsin	B-ENZY
,	O
plasmin	B-ENZY
and	O
TMPRSS11a	O
.	O

Laboratory	O
:	O
signs	O
of	O
inflammation	O
;	O
blood	O
gas	B-ENZY
analysis	O
:	O
pronounced	O
hypoxemia	O
.	O

Recombinant	O
urate	B-ENZY
oxidase	I-ENZY
(	O
rasburicase	O
)	O
is	O
a	O
newer	O
agent	O
that	O
directly	O
cleaves	O
uric	O
acid	O
.	O

Real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
of	O
respiratory	O
sample	O
for	O
novel	O
H1N1	O
virus	O
revealed	O
positive	O
results	O
.	O

Clinical	O
signs	O
,	O
pathological	O
changes	O
and	O
viral	O
replication	O
in	O
lungs	O
,	O
arterial	O
blood	O
gas	B-ENZY
,	O
and	O
cytokines	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
observed	O
at	O
different	O
time	O
points	O
after	O
infection	O
.	O

Arterial	O
blood	O
gas	B-ENZY
analysis	O
,	O
peak	O
inflating	O
pressure	O
(	O
PIP	O
)	O
and	O
static	O
compliance	O
of	O
the	O
respiratory	O
system	O
(	O
Cst	O
)	O
were	O
measured	O
.	O

TITLE	O
:	O
[	O
Acute	O
respiratory	O
distress	O
syndrome	O
induced	O
by	O
hydrogen	O
fluoride	O
gas	B-ENZY
inhalation	O
].	O

Later	O
,	O
his	O
illness	O
was	O
diagnosed	O
as	O
acute	O
lung	O
damage	O
induced	O
by	O
hydrogen	O
fluoride	O
gas	B-ENZY
inhalation	O
based	O
on	O
the	O
findings	O
of	O
increased	O
fluoride	O
concentration	O
in	O
serum	O
and	O
urine	O
specimen	O
,	O
and	O
decreased	O
serum	O
calcium	O
level	O
.	O

TITLE	O
:	O
TACE	B-ENZY
antagonists	O
blocking	O
ACE2	O
shedding	O
caused	O
by	O
the	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
are	O
candidate	O
antiviral	O
compounds	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
the	O
cellular	O
factor	O
TNF	O
-	O
alpha	O
converting	O
enzyme	O
(	O
TACE	B-ENZY
),	O
activated	O
by	O
the	O
spike	O
protein	O
of	O
SARS	O
-	O
CoV	O
(	O
SARS	O
-	O
S	O
protein	O
),	O
was	O
positively	O
involved	O
in	O
viral	O
entry	O
,	O
implying	O
that	O
TACE	B-ENZY
is	O
a	O
possible	O
target	O
for	O
developing	O
antiviral	O
compounds	O
.	O

To	O
demonstrate	O
this	O
possibility	O
,	O
we	O
here	O
tested	O
the	O
effects	O
of	O
TACE	B-ENZY
inhibitors	O
on	O
viral	O
entry	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
data	O
revealed	O
that	O
the	O
TACE	B-ENZY
inhibitor	O
TAPI	O
-	O
2	O
attenuated	O
entry	O
of	O
both	O
pseudotyped	O
virus	O
expressing	O
the	O
SARS	O
-	O
S	O
protein	O
in	O
a	O
lentiviral	O
vector	O
backbone	O
and	O
infectious	O
SARS	O
-	O
CoV	O
.	O
TAPI	O
-	O
2	O
blocked	O
both	O
the	O
SARS	O
-	O
S	O
protein	O
-	O
induced	O
shedding	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
a	O
receptor	O
of	O
SARS	O
-	O
CoV	O
,	O
and	O
TNF	O
-	O
alpha	O
production	O
in	O
lung	O
tissues	O
.	O

Since	O
the	O
downregulation	O
of	O
ACE2	O
by	O
SARS	O
-	O
S	O
protein	O
was	O
proposed	O
as	O
an	O
etiological	O
event	O
in	O
the	O
severe	O
clinical	O
manifestations	O
,	O
our	O
data	O
suggest	O
that	O
TACE	B-ENZY
antagonists	O
block	O
SARS	O
-	O
CoV	O
infection	O
and	O
also	O
attenuate	O
its	O
severe	O
clinical	O
outcome	O
.	O

Impedance	O
tomography	O
has	O
been	O
increasingly	O
tested	O
,	O
whereas	O
gas	B-ENZY
exchange	O
is	O
the	O
less	O
reliable	O
indicator	O
of	O
recruitment	O
.	O

The	O
role	O
of	O
Mycoplasma	O
spp	B-ENZY
.,	O
particularly	O
Mycoplasma	O
bovis	O
in	O
BRD	O
,	O
has	O
been	O
more	O
extensively	O
studied	O
.	O

Rats	O
with	O
LC	O
,	O
CASP	O
,	O
LC	O
+	O
CASP	O
all	O
had	O
severe	O
lung	O
injury	O
compared	O
with	O
uninjured	O
controls	O
based	O
on	O
decreased	O
arterial	O
oxygenation	O
or	O
increased	O
BAL	B-ENZY
albumin	O
at	O
5	O
or	O
24	O
hours	O
postinsult	O
.	O

Since	O
the	O
discovery	O
of	O
SARS	O
-	O
like	O
coronaviruses	O
in	O
Chinese	O
horseshoe	O
bats	O
,	O
attempts	O
to	O
isolate	O
a	O
SL	O
-	O
CoV	O
from	O
bats	O
have	O
failed	O
and	O
attempts	O
to	O
isolate	O
other	O
bat	B-ENZY
-	O
borne	O
viruses	O
in	O
various	O
mammalian	O
cell	O
lines	O
have	O
been	O
similarly	O
unsuccessful	O
.	O

New	O
stable	O
bat	B-ENZY
cell	O
lines	O
are	O
needed	O
to	O
help	O
with	O
these	O
investigations	O
and	O
as	O
tools	O
to	O
assist	O
in	O
the	O
study	O
of	O
bat	B-ENZY
immunology	O
and	O
virus	O
-	O
host	O
interactions	O
.	O

We	O
are	O
in	O
the	O
process	O
of	O
generating	O
further	O
cell	O
lines	O
from	O
a	O
number	O
of	O
different	O
bat	B-ENZY
species	O
using	O
the	O
methodology	O
established	O
in	O
this	O
study	O
.	O

ABSTRACT	O
:	O
The	O
Chinese	O
rufous	O
horseshoe	O
bat	B-ENZY
(	O
Rhinolophus	O
sinicus	O
)	O
has	O
been	O
suggested	O
to	O
carry	O
the	O
direct	O
ancestor	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SCoV	O
),	O
and	O
the	O
diversity	O
of	O
SARS	O
-	O
like	O
CoVs	O
(	O
SLCoV	O
)	O
within	O
this	O
Rhinolophus	O
species	O
is	O
therefore	O
worth	O
investigating	O
.	O

Efficiency	O
,	O
side	O
effects	O
and	O
outcome	O
of	O
treatment	O
with	O
a	O
new	O
miniaturized	O
device	O
for	O
veno	O
-	O
venous	O
extracorporeal	O
gas	B-ENZY
transfer	O
were	O
analysed	O
in	O
60	O
consecutive	O
patients	O
with	O
life	O
-	O
threatening	O
respiratory	O
failure	O
.	O

Gas	B-ENZY
exchange	O
capacity	O
of	O
the	O
device	O
averaged	O
155	O
(	O
116	O
to	O
182	O
)	O
mL	O
/	O
min	O
for	O
oxygen	O
and	O
210	O
(	O
164	O
to	O
251	O
)	O
mL	O
/	O
min	O
for	O
carbon	O
dioxide	O
.	O

Prone	O
positioning	O
has	O
an	O
established	O
niche	O
as	O
an	O
intervention	O
to	O
improve	O
gas	B-ENZY
exchange	O
in	O
patients	O
with	O
severe	O
hypoxemia	O
refractory	O
to	O
standard	O
ventilatory	O
manipulations	O
.	O

Importantly	O
,	O
the	O
initial	O
specimen	O
evaluated	O
by	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
was	O
negative	O
for	O
novel	O
2009	O
H1N1	O
influenza	O
virus	O
.	O

For	O
the	O
first	O
time	O
,	O
a	O
group	O
2	O
CoV	O
was	O
found	O
in	O
a	O
bat	B-ENZY
,	O
Pipistrellus	O
pipistrellus	O
,	O
in	O
Europe	O
.	O

TITLE	O
:	O
Ecoepidemiology	O
and	O
complete	O
genome	O
comparison	O
of	O
different	O
strains	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
related	O
Rhinolophus	O
bat	B-ENZY
coronavirus	O
in	O
China	O
reveal	O
bats	O
as	O
a	O
reservoir	O
for	O
acute	O
,	O
self	O
-	O
limiting	O
infection	O
that	O
allows	O
recombination	O
events	O
.	O

The	O
Pao	B-ENZY
(	O
2	O
)/	O
inspired	O
fraction	O
of	O
oxygen	O
ratio	O
increased	O
from	O
61	O
(	O
47	O
-	O
86	O
)	O
to	O
98	O
(	O
67	O
-	O
116	O
)	O
within	O
2	O
hours	O
and	O
to	O
106	O
(	O
70	O
-	O
135	O
)	O
mm	O
Hg	O
at	O
24	O
hours	O
.	O

Community	O
-	O
acquired	O
RVIs	O
are	O
frequently	O
detected	O
in	O
BAL	B-ENZY
samples	O
from	O
lung	O
transplant	O
patients	O
.	O

CONCLUSIONS	O
:	O
Community	O
-	O
acquired	O
RVIs	O
are	O
frequently	O
detected	O
in	O
BAL	B-ENZY
samples	O
from	O
lung	O
transplant	O
patients	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
whether	O
selected	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
myosin	B-ENZY
light	I-ENZY
chain	I-ENZY
kinase	I-ENZY
gene	O
are	O
associated	O
with	O
more	O
severe	O
lung	O
injury	O
in	O
children	O
and	O
adults	O
with	O
community	O
-	O
acquired	O
pneumonia	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
association	O
between	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
myosin	B-ENZY
light	I-ENZY
chain	I-ENZY
kinase	I-ENZY
gene	O
and	O
increased	O
severity	O
of	O
acute	O
lung	O
injury	O
in	O
adults	O
.	O

No	O
associations	O
were	O
observed	O
between	O
the	O
myosin	B-ENZY
light	I-ENZY
chain	I-ENZY
kinase	I-ENZY
gene	O
single	O
nucleotide	O
polymorphisms	O
genotyped	O
in	O
children	O
with	O
community	O
-	O
acquired	O
pneumonia	O
and	O
increased	O
severity	O
of	O
lung	O
injury	O
.	O

Similarly	O
,	O
no	O
associations	O
were	O
observed	O
between	O
myosin	B-ENZY
light	I-ENZY
chain	I-ENZY
kinase	I-ENZY
gene	O
single	O
nucleotide	O
polymorphisms	O
genotyped	O
in	O
adults	O
with	O
community	O
-	O
acquired	O
pneumonia	O
and	O
increased	O
severity	O
of	O
lung	O
injury	O
.	O

No	O
association	O
between	O
the	O
selected	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
myosin	B-ENZY
light	I-ENZY
chain	I-ENZY
kinase	I-ENZY
gene	O
and	O
either	O
the	O
need	O
for	O
positive	O
-	O
pressure	O
ventilation	O
or	O
the	O
development	O
of	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
was	O
observed	O
in	O
children	O
with	O
community	O
-	O
acquired	O
pneumonia	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
we	O
attempted	O
to	O
establish	O
a	O
simple	O
detection	O
method	O
for	O
classification	O
of	O
IBV	O
S1	O
genotypes	O
by	O
direct	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

However	O
,	O
he	O
suffered	O
from	O
sudden	O
-	O
onset	O
severe	O
respiratory	O
distress	O
,	O
and	O
blood	O
gas	B-ENZY
analysis	O
showed	O
profound	O
hypoxemia	O
with	O
a	O
marked	O
arterial	O
-	O
alveolar	O
oxygen	O
difference	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
a	O
first	O
homolog	O
of	O
ACE	B-ENZY
,	O
regulates	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
by	O
counterbalancing	O
ACE	B-ENZY
activity	O
.	O

For	O
instance	O
,	O
in	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
ACE	B-ENZY
,	O
AngII	O
,	O
and	O
AT1R	O
promote	O
the	O
disease	O
pathogenesis	O
,	O
whereas	O
ACE2	O
and	O
the	O
AT2R	O
protect	O
from	O
ARDS	O
.	O

TITLE	O
:	O
Hexokinase	B-ENZY
II	O
gene	O
transfer	O
protects	O
against	O
neurodegeneration	O
in	O
the	O
rotenone	O
and	O
MPTP	O
mouse	O
models	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O

We	O
have	O
found	O
that	O
increasing	O
mitochondrial	O
hexokinase	B-ENZY
II	O
activity	O
can	O
prevent	O
cell	O
death	O
in	O
neuronal	O
cultures	O
treated	O
with	O
rotenone	O
.	O

Overexpression	O
of	O
hexokinase	B-ENZY
II	O
prevented	O
both	O
rotenone	O
and	O
MPTP	O
-	O
induced	O
dopaminergic	O
neuronal	O
cell	O
death	O
,	O
as	O
well	O
as	O
reducing	O
the	O
associated	O
motor	O
defects	O
.	O

Our	O
results	O
provide	O
the	O
first	O
proof	O
-	O
of	O
-	O
principle	O
that	O
hexokinase	B-ENZY
II	O
protects	O
against	O
dopaminergic	O
neurodegeneration	O
in	O
vivo	O
,	O
emphasizing	O
the	O
role	O
of	O
this	O
enzyme	O
in	O
promoting	O
neuronal	O
survival	O
.	O

Thus	O
,	O
the	O
increase	O
of	O
hexokinase	B-ENZY
II	O
expression	O
by	O
gene	O
transfer	O
or	O
other	O
means	O
represents	O
a	O
promising	O
approach	O
to	O
treat	O
Parkinson	O
'	O
s	O
and	O
other	O
neurodegenerative	O
diseases	O
.	O

The	O
7a	O
protein	O
is	O
present	O
in	O
the	O
virus	O
particle	O
and	O
has	O
been	O
shown	O
to	O
interact	O
with	O
several	O
host	O
proteins	O
;	O
thereby	O
implicating	O
it	O
as	O
being	O
involved	O
in	O
several	O
pathogenic	O
processes	O
including	O
apoptosis	O
,	O
inhibition	O
of	O
cellular	O
protein	O
synthesis	O
,	O
and	O
activation	O
of	O
p38	O
mitogen	O
activated	O
protein	B-ENZY
kinase	I-ENZY
.	O

TITLE	O
:	O
Induced	O
,	O
selective	O
proteolysis	O
of	O
MLK3	O
negatively	O
regulates	O
MLK3	O
/	O
JNK	B-ENZY
signalling	O
.	O

Whereas	O
numerous	O
mammalian	O
protease	O
inhibitors	O
have	O
no	O
effect	O
on	O
MLK3	O
proteolysis	O
,	O
blockade	O
of	O
the	O
proteasome	B-ENZY
through	O
epoxomicin	O
or	O
MG132	O
abolishes	O
PMA	O
-	O
induced	O
production	O
of	O
the	O
CTF	O
of	O
MLK3	O
.	O

This	O
CTF	O
is	O
able	O
to	O
heterodimerize	O
with	O
full	O
-	O
length	O
MLK3	O
,	O
and	O
interact	O
with	O
the	O
active	O
form	O
of	O
the	O
small	O
GTPase	O
Cdc42	O
,	O
resulting	O
in	O
diminished	O
activation	O
loop	O
phosphorylation	O
of	O
MLK3	O
and	O
reduced	O
signalling	O
to	O
JNK	B-ENZY
.	O

ABSTRACT	O
:	O
Twenty	O
1	O
-	O
day	O
-	O
old	O
specific	O
pathogen	O
free	O
chicks	O
and	O
20	O
1	O
-	O
day	O
-	O
old	O
commercially	O
derived	O
turkey	O
poults	O
were	O
inoculated	O
with	O
a	O
Brazilian	O
strain	O
of	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
to	O
study	O
the	O
pathogenicity	O
and	O
virus	O
distribution	O
up	O
to	O
14	O
days	O
post	O
-	O
inoculation	O
by	O
histopathology	O
,	O
immunohistochemistry	O
,	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
and	O
sequencing	O
.	O

TITLE	O
:	O
Deubiquitinating	O
and	O
interferon	O
antagonism	O
activities	O
of	O
coronavirus	O
papain	B-ENZY
-	O
like	O
proteases	O
.	O

One	O
such	O
multifunctional	O
domain	O
is	O
the	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLP	O
),	O
which	O
processes	O
the	O
viral	O
replicase	O
polyprotein	O
,	O
has	O
deubiquitinating	O
(	O
DUB	O
)	O
activity	O
,	O
and	O
antagonizes	O
the	O
induction	O
of	O
type	O
I	O
interferon	O
(	O
IFN	O
).	O

We	O
evaluated	O
the	O
meaning	O
of	O
early	O
gas	B-ENZY
exchange	O
in	O
patients	O
with	O
severe	O
ARDS	O
under	O
prolonged	O
(>	O
or	O
=	O
12	O
hours	O
)	O
prone	O
positioning	O
.	O

15	O
.	O
6	O
years	O
;	O
75	O
%	O
men	O
)	O
with	O
severe	O
ARDS	O
(	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO2	O
<	O
or	O
=	O
150	O
mmHg	O
)	O
admitted	O
to	O
a	O
medical	O
intensive	O
care	O
unit	O
(	O
MICU	O
).	O

Adjusted	O
for	O
sex	O
,	O
health	O
care	O
worker	O
status	O
and	O
nosocomial	O
setting	O
,	O
older	O
age	O
was	O
associated	O
with	O
a	O
higher	O
fatality	O
,	O
with	O
adjusted	O
odds	O
ratio	O
(	O
AOR	B-ENZY
):	O
2	O
.	O
10	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
45	O
,	O
3	O
.	O
04	O
)	O
for	O
those	O
aged	O
51	O
-	O
60	O
;	O
AOR	B-ENZY
:	O
4	O
.	O
57	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
3	O
.	O
32	O
,	O
7	O
.	O
30	O
)	O
for	O
those	O
aged	O
above	O
60	O
compared	O
to	O
those	O
aged	O
41	O
-	O
50	O
years	O
.	O

Presence	O
of	O
pre	O
-	O
existing	O
comorbid	O
conditions	O
was	O
also	O
associated	O
with	O
greater	O
mortality	O
(	O
AOR	B-ENZY
:	O
1	O
.	O
74	O
;	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
36	O
,	O
2	O
.	O
21	O
).	O

The	O
routine	O
examinations	O
of	O
prothrombin	O
time	O
,	O
thrombin	B-ENZY
time	O
,	O
prothrombin	O
activity	O
,	O
and	O
international	O
normalized	O
ratio	O
were	O
also	O
performed	O
.	O

TITLE	O
:	O
Trypsin	B-ENZY
-	O
induced	O
hemagglutination	O
activity	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Recently	O
,	O
a	O
large	O
number	O
of	O
viruses	O
closely	O
related	O
to	O
members	O
of	O
the	O
genus	O
Coronavirus	O
have	O
been	O
associated	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
detected	O
in	O
bat	B-ENZY
species	O
.	O

In	O
this	O
study	O
,	O
samples	O
were	O
collected	O
from	O
106	O
live	O
bats	O
of	O
seven	O
different	O
bat	B-ENZY
species	O
from	O
27	O
different	O
locations	O
in	O
Slovenia	O
.	O

Coronaviruses	O
were	O
detected	O
by	O
RT	O
-	O
PCR	O
in	O
14	O
out	O
of	O
36	O
horseshoe	O
bat	B-ENZY
(	O
Rhinolophus	O
hipposideros	O
)	O
fecal	O
samples	O
,	O
with	O
38	O
.	O
8	O
%	O
virus	O
prevalence	O
.	O

The	O
most	O
closely	O
related	O
virus	O
sequence	O
in	O
GenBank	O
was	O
SARS	O
bat	B-ENZY
isolate	O
Rp3	O
/	O
2004	O
(	O
DQ071615	O
)	O
within	O
the	O
SARS	O
-	O
like	O
CoV	O
cluster	O
,	O
sharing	O
85	O
%	O
nucleotide	O
identity	O
and	O
95	O
.	O
6	O
%	O
amino	O
acid	O
identity	O
.	O

The	O
potential	O
risk	O
of	O
a	O
new	O
group	O
of	O
bat	B-ENZY
coronaviruses	O
as	O
a	O
reservoir	O
for	O
human	O
infections	O
is	O
highly	O
suspected	O
,	O
and	O
further	O
molecular	O
epidemiologic	O
studies	O
of	O
these	O
bat	B-ENZY
coronaviruses	O
are	O
needed	O
.	O

TITLE	O
:	O
Extracorporeal	O
gas	B-ENZY
exchange	O
in	O
acute	O
lung	O
injury	O
:	O
step	O
by	O
step	O
towards	O
expanded	O
indications	O
?	O

From	O
a	O
strategic	O
perspective	O
,	O
this	O
is	O
another	O
small	O
but	O
useful	O
step	O
towards	O
implementing	O
extracorporeal	O
gas	B-ENZY
exchange	O
for	O
the	O
prevention	O
of	O
VILI	O
.	O

Modifications	O
in	O
a	O
patient	O
'	O
s	O
respiratory	O
assistance	O
were	O
made	O
depending	O
on	O
the	O
clinical	O
,	O
blood	O
gas	B-ENZY
,	O
and	O
radiologic	O
evolution	O
of	O
the	O
patient	O
.	O

TITLE	O
:	O
Identification	O
of	O
key	O
amino	O
acid	O
residues	O
required	O
for	O
horseshoe	O
bat	B-ENZY
angiotensin	O
-	O
I	O
converting	O
enzyme	O
2	O
to	O
function	O
as	O
a	O
receptor	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

A	O
previous	O
study	O
indicated	O
that	O
ACE2	O
from	O
a	O
horseshoe	O
bat	B-ENZY
,	O
the	O
host	O
of	O
a	O
highly	O
related	O
SARS	O
-	O
like	O
coronavirus	O
,	O
could	O
not	O
function	O
as	O
a	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
a	O
3	O
aa	O
change	O
from	O
SHE	O
(	O
aa	O
40	O
-	O
42	O
)	O
to	O
FYQ	O
was	O
sufficient	O
to	O
convert	O
the	O
bat	B-ENZY
ACE2	O
into	O
a	O
fully	O
functional	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
We	O
further	O
demonstrate	O
that	O
an	O
ACE2	O
molecule	O
from	O
a	O
fruit	O
bat	B-ENZY
,	O
which	O
contains	O
the	O
FYQ	O
motif	O
,	O
was	O
able	O
to	O
support	O
SARS	O
-	O
CoV	O
infection	O
,	O
indicating	O
a	O
potentially	O
much	O
wider	O
host	O
range	O
for	O
SARS	O
-	O
CoV	O
-	O
related	O
viruses	O
among	O
different	O
bat	B-ENZY
populations	O
.	O

ABSTRACT	O
:	O
Inhaled	O
nitric	O
oxide	O
(	O
iNO	O
)	O
improves	O
gas	B-ENZY
exchange	O
in	O
about	O
60	O
%	O
of	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Statistical	O
analysis	O
did	O
not	O
reveal	O
gas	B-ENZY
exchange	O
improvements	O
due	O
to	O
SB	O
alone	O
.	O

Significant	O
gas	B-ENZY
exchange	O
improvements	O
due	O
to	O
iNO	O
were	O
only	O
achieved	O
during	O
unassisted	O
SB	O
with	O
BIPAP	O
(	O
P	O
<.	O
05	O
)	O
but	O
not	O
during	O
CMV	O
or	O
assisted	O
SB	O
.	O

Thus	O
combined	O
iNO	O
and	O
unassisted	O
SB	O
is	O
possibly	O
most	O
effective	O
to	O
improve	O
gas	B-ENZY
exchange	O
in	O
severe	O
hypoxemic	O
ARDS	O
.	O

We	O
retrospectively	O
identified	O
HCT	O
recipients	O
with	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
parainfluenza	O
virus	O
,	O
influenza	O
virus	O
,	O
metapneumovirus	O
(	O
MPV	O
),	O
and	O
coronavirus	O
(	O
CoV	O
)	O
detected	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
samples	O
,	O
and	O
we	O
tested	O
stored	O
BAL	B-ENZY
and	O
/	O
or	O
serum	O
samples	O
by	O
quantitative	O
polymerase	O
chain	O
reaction	O
.	O

In	O
85	O
BAL	B-ENZY
samples	O
from	O
82	O
patients	O
,	O
median	O
viral	O
loads	O
were	O
as	O
follows	O
:	O
for	O
RSV	O
(	O
n	O
=	O
35	O
),	O
2	O
.	O
6	O
x	O
10	O
(	O
6	O
)	O
copies	O
/	O
mL	O
;	O
for	O
parainfluenza	O
virus	O
(	O
n	O
=	O
35	O
),	O
4	O
.	O
9	O
x	O
10	O
(	O
7	O
)	O
copies	O
/	O
mL	O
;	O
for	O
influenza	O
virus	O
(	O
n	O
=	O
9	O
),	O
6	O
.	O
8	O
x	O
10	O
(	O
5	O
)	O
copies	O
/	O
mL	O
;	O
for	O
MPV	O
(	O
n	O
=	O
7	O
),	O
3	O
.	O
9	O
x	O
10	O
(	O
7	O
)	O
copies	O
/	O
mL	O
;	O
and	O
for	O
CoV	O
(	O
n	O
=	O
4	O
),	O
1	O
.	O
8	O
x	O
10	O
(	O
5	O
)	O
copies	O
/	O
mL	O
.	O
Quantitative	O
viral	O
load	O
was	O
not	O
associated	O
with	O
mechanical	O
ventilation	O
or	O
death	O
.	O

RSV	O
detection	O
in	O
serum	O
was	O
associated	O
with	O
high	O
viral	O
load	O
in	O
BAL	B-ENZY
samples	O
(	O
p	O
=	O
.	O
05	O
),	O
and	O
viral	O
RNA	O
detection	O
in	O
serum	O
was	O
significantly	O
associated	O
with	O
death	O
(	O
adjusted	O
rate	O
ratio	O
,	O
1	O
.	O
8	O
;	O
(	O
p	O
=	O
.	O
02	O
).	O

Quantitative	O
polymerase	O
chain	O
reaction	O
detects	O
high	O
viral	O
loads	O
in	O
BAL	B-ENZY
samples	O
from	O
HCT	O
recipients	O
with	O
respiratory	O
virus	O
pneumonia	O
.	O

RESULTS	O
:	O
In	O
85	O
BAL	B-ENZY
samples	O
from	O
82	O
patients	O
,	O
median	O
viral	O
loads	O
were	O
as	O
follows	O
:	O
for	O
RSV	O
(	O
n	O
=	O
35	O
),	O
2	O
.	O
6	O
x	O
10	O
(	O
6	O
)	O
copies	O
/	O
mL	O
;	O
for	O
parainfluenza	O
virus	O
(	O
n	O
=	O
35	O
),	O
4	O
.	O
9	O
x	O
10	O
(	O
7	O
)	O
copies	O
/	O
mL	O
;	O
for	O
influenza	O
virus	O
(	O
n	O
=	O
9	O
),	O
6	O
.	O
8	O
x	O
10	O
(	O
5	O
)	O
copies	O
/	O
mL	O
;	O
for	O
MPV	O
(	O
n	O
=	O
7	O
),	O
3	O
.	O
9	O
x	O
10	O
(	O
7	O
)	O
copies	O
/	O
mL	O
;	O
and	O
for	O
CoV	O
(	O
n	O
=	O
4	O
),	O
1	O
.	O
8	O
x	O
10	O
(	O
5	O
)	O
copies	O
/	O
mL	O
.	O
Quantitative	O
viral	O
load	O
was	O
not	O
associated	O
with	O
mechanical	O
ventilation	O
or	O
death	O
.	O

RSV	O
detection	O
in	O
serum	O
was	O
associated	O
with	O
high	O
viral	O
load	O
in	O
BAL	B-ENZY
samples	O
(	O
p	O
=	O
.	O
05	O
),	O
and	O
viral	O
RNA	O
detection	O
in	O
serum	O
was	O
significantly	O
associated	O
with	O
death	O
(	O
adjusted	O
rate	O
ratio	O
,	O
1	O
.	O
8	O
;	O
(	O
p	O
=	O
.	O
02	O
).	O

CONCLUSIONS	O
:	O
Quantitative	O
polymerase	O
chain	O
reaction	O
detects	O
high	O
viral	O
loads	O
in	O
BAL	B-ENZY
samples	O
from	O
HCT	O
recipients	O
with	O
respiratory	O
virus	O
pneumonia	O
.	O

ABSTRACT	O
:	O
To	O
verify	O
if	O
secretory	O
phospholipase	B-ENZY
A2	I-ENZY
(	O
sPLA2	O
)	O
is	O
increased	O
in	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
triggered	O
or	O
not	O
by	O
respiratory	O
syncytial	O
virus	O
infection	O
and	O
to	O
clarify	O
how	O
the	O
enzyme	O
may	O
influence	O
the	O
disease	O
severity	O
and	O
the	O
degree	O
of	O
ventilatory	O
support	O
.	O

Cytochrome	B-ENZY
p450	I-ENZY
levels	O
in	O
phenobarbital	O
pre	O
-	O
treated	O
animals	O
were	O
significantly	O
higher	O
than	O
non	O
pre	O
-	O
treated	O
animals	O
(	O
300	O
vs	O
100	O
pmol	O
/	O
mg	O
protein	O
).	O

A	O
marked	O
increase	O
in	O
serum	O
AST	B-ENZY
(	O
471	O
.	O
5	O
+/-	O

Later	O
study	O
also	O
found	O
that	O
neutrophil	B-ENZY
elastase	I-ENZY
and	O
myeloperoxidase	B-ENZY
were	O
elevated	O
following	O
fat	O
embolism	O
.	O

This	O
case	O
report	O
describes	O
the	O
management	O
of	O
a	O
critically	O
ill	O
ventilated	O
patient	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
who	O
developed	O
clinically	O
significant	O
tongue	O
and	O
lip	B-ENZY
swelling	O
during	O
treatment	O
with	O
oseltamivir	O
.	O

ABSTRACT	O
:	O
The	O
maturation	O
of	O
SARS	O
coronavirus	O
involves	O
the	O
autocleavage	O
of	O
polyproteins	O
1a	O
and	O
1ab	O
by	O
the	O
main	O
protease	O
(	O
Mpro	O
)	O
and	O
a	O
papain	B-ENZY
-	O
like	O
protease	O
;	O
these	O
represent	O
attractive	O
targets	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	O
drugs	O
.	O

Cardiopulmonary	O
failure	O
was	O
treated	O
effectively	O
with	O
ECMO	O
and	O
systemic	O
gas	B-ENZY
exchange	O
and	O
blood	O
flow	O
improved	O
rapidly	O
within	O
2	O
h	O
on	O
ECMO	O
in	O
all	O
patients	O
(	O
median	O
OR	O
69	O
(	O
52	O
-	O
263	O
)	O
mmHg	O
,	O
median	O
paCO	O
(	O
2	O
)	O
41	O
(	O
22	O
-	O
85	O
)	O
mmHg	O
.	O

We	O
sought	O
to	O
describe	O
the	O
ventilation	O
strategies	O
in	O
anesthetized	O
patients	O
with	O
varying	O
degrees	O
of	O
hypoxemia	O
as	O
defined	O
by	O
the	O
Pao	B-ENZY
(	O
2	O
)	O
to	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
Fio	O
(	O
2	O
))	O
(	O
P	O
/	O
F	O
)	O
ratio	O
.	O

TITLE	O
:	O
A	O
multiplex	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
assay	O
for	O
the	O
genotyping	O
of	O
avian	O
infectious	O
bronchitis	O
viruses	O
.	O

This	O
work	O
reports	O
on	O
a	O
rapid	O
and	O
reliable	O
multiplex	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
mRT	O
-	O
PCR	O
)	O
assay	O
for	O
the	O
genotyping	O
of	O
IBVs	O
.	O

We	O
examined	O
NO	O
levels	O
by	O
Greiss	O
assay	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
of	O
pigs	O
infected	O
with	O
either	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
or	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
a	O
member	O
of	O
Nidovirales	O
,	O
like	O
CoV	O
.	O
The	O
antiviral	O
effects	O
of	O
NO	O
on	O
these	O
two	O
viruses	O
were	O
tested	O
in	O
an	O
in	O
vitro	O
system	O
using	O
a	O
NO	O
donor	O
,	O
S	O
-	O
nitroso	O
-	O
N	O
-	O
acetylpenicillamine	O
(	O
SNAP	O
).	O

We	O
detected	O
a	O
large	O
increase	O
in	O
NO	O
levels	O
in	O
BAL	B-ENZY
fluids	O
of	O
PRCV	O
-	O
infected	O
pigs	O
,	O
but	O
not	O
in	O
PRRSV	O
-	O
infected	O
pigs	O
.	O

Articles	O
for	O
review	O
were	O
selected	O
based	O
on	O
the	O
following	O
criteria	O
:	O
(	O
i	O
)	O
prospective	O
or	O
cross	O
-	O
sectional	O
study	O
,	O
(	O
ii	O
)	O
original	O
research	O
,	O
(	O
iii	O
)	O
viral	O
detection	O
used	O
the	O
highly	O
sensitive	O
techniques	O
of	O
PCR	O
and	O
/	O
or	O
Reverse	B-ENZY
Transcriptase	I-ENZY
PCR	O
(	O
RT	O
-	O
PCR	O
),	O
(	O
iv	O
)	O
viral	O
prevalence	O
in	O
AECOPD	O
defined	O
,	O
and	O
(	O
v	O
)	O
full	O
paper	O
available	O
in	O
English	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
nonstructural	O
proteins	O
1	O
to	O
3	O
are	O
processed	O
by	O
one	O
or	O
two	O
papain	B-ENZY
-	O
like	O
proteases	O
(	O
PLP1	O
and	O
PLP2	O
)	O
at	O
specific	O
cleavage	O
sites	O
(	O
CS1	O
to	O
-	O
3	O
).	O

A	O
formula	O
including	O
fish	O
oil	O
,	O
borage	O
oil	O
and	O
antioxidants	O
has	O
demonstrated	O
marked	O
benefits	O
on	O
gas	B-ENZY
exchange	O
,	O
ventilation	O
requirement	O
,	O
new	O
organ	O
failures	O
,	O
ICU	O
stay	O
and	O
mortality	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
acute	O
lung	O
injury	O
or	O
severe	O
sepsis	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
severe	O
lung	O
disease	O
characterized	O
by	O
inflammation	O
of	O
the	O
lung	O
parenchyma	O
leading	O
to	O
impaired	O
gas	B-ENZY
exchange	O
.	O

High	O
anti	O
-	O
TNF	O
-	O
alpha	O
activity	O
was	O
detected	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluids	O
,	O
peritoneal	O
lavage	O
fluids	O
and	O
serum	O
of	O
all	O
animals	O
for	O
at	O
least	O
8h	O
post	O
-	O
inoculation	O
(	O
HPI	O
).	O

No	O
clinical	O
symptoms	O
,	O
lung	O
lesions	O
,	O
lung	O
cell	O
infiltration	O
or	O
induction	O
of	O
IFN	O
-	O
alpha	O
,	O
IL	O
-	O
1	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
12	O
and	O
TNF	O
-	O
alpha	O
in	O
BAL	B-ENZY
were	O
detected	O
.	O

ABSTRACT	O
:	O
A	O
tetrahydroquinoline	O
oxocarbazate	O
(	O
PubChem	O
CID	O
23631927	O
)	O
was	O
tested	O
as	O
an	O
inhibitor	O
of	O
human	O
cathepsin	B-ENZY
L	I-ENZY
(	O
EC	O
3	O
.	O
4	O
.	O
22	O
.	O
15	O
)	O
and	O
as	O
an	O
entry	O
blocker	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
and	O
Ebola	O
pseudotype	O
virus	O
.	O

In	O
the	O
cathepsin	B-ENZY
L	I-ENZY
inhibition	O
assay	O
,	O
the	O
oxocarbazate	O
caused	O
a	O
time	O
-	O
dependent	O
17	O
-	O
fold	O
drop	O
in	O
IC	O
(	O
50	O
)	O
from	O
6	O
.	O
9	O
nM	O
(	O
no	O
preincubation	O
)	O
to	O
0	O
.	O
4	O
nM	O
(	O
4	O
-	O
h	O
preincubation	O
).	O

The	O
compound	O
also	O
displayed	O
cathepsin	B-ENZY
L	I-ENZY
/	O
B	O
selectivity	O
of	O
>	O
700	O
-	O
fold	O
and	O
was	O
nontoxic	O
to	O
human	O
aortic	O
endothelial	O
cells	O
at	O
100	O
muM	O
.	O
The	O
oxocarbazate	O
and	O
a	O
related	O
thiocarbazate	O
(	O
PubChem	O
CID	O
16725315	O
)	O
were	O
tested	O
in	O
a	O
SARS	O
coronavirus	O
(	O
CoV	O
)	O
and	O
Ebola	O
virus	O
-	O
pseudotype	O
infection	O
assay	O
with	O
the	O
oxocarbazate	O
but	O
not	O
the	O
thiocarbazate	O
,	O
demonstrating	O
activity	O
in	O
blocking	O
both	O
SARS	O
-	O
CoV	O
(	O
IC	O
(	O
50	O
)	O
=	O
273	O
+/-	O

To	O
trace	O
the	O
intracellular	O
action	O
of	O
the	O
inhibitors	O
with	O
intracellular	O
cathepsin	B-ENZY
L	I-ENZY
,	O
the	O
activity	O
-	O
based	O
probe	O
biotin	O
-	O
Lys	O
-	O
C5	O
alkyl	O
linker	O
-	O
Tyr	O
-	O
Leu	O
-	O
epoxide	O
(	O
DCG	O
-	O
04	O
)	O
was	O
used	O
to	O
label	O
the	O
active	O
site	O
of	O
cysteine	O
proteases	O
in	O
293T	O
lysates	O
.	O

Overall	O
,	O
the	O
oxocarbazate	O
CID	O
23631927	O
was	O
a	O
subnanomolar	O
,	O
slow	O
-	O
binding	O
,	O
reversible	O
inhibitor	O
of	O
human	O
cathepsin	B-ENZY
L	I-ENZY
that	O
blocked	O
SARS	O
-	O
CoV	O
and	O
Ebola	O
pseudotype	O
virus	O
entry	O
in	O
human	O
cells	O
.	O

A	O
luciferase	B-ENZY
-	O
based	O
reporter	O
gene	O
assay	O
was	O
used	O
to	O
validate	O
the	O
up	O
-	O
regulation	O
of	O
AP	O
-	O
1	O
-	O
and	O
NF	O
-	O
kappaB	O
-	O
dependent	O
transcription	O
in	O
IBV	O
-	O
infected	O
cells	O
and	O
confirmed	O
using	O
immunofluorescence	O
.	O

TITLE	O
:	O
Interactions	O
of	O
SARS	O
coronavirus	O
nucleocapsid	O
protein	O
with	O
the	O
host	O
cell	O
proteasome	B-ENZY
subunit	O
p42	O
.	O

Using	O
surface	O
plasmon	O
resonance	O
biomolecular	O
interaction	O
analysis	O
(	O
SPR	O
/	O
BIA	O
)	O
and	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
of	O
flight	O
(	O
MALDI	O
-	O
TOF	O
)	O
mass	O
spectrometry	O
,	O
we	O
found	O
that	O
only	O
the	O
proteasome	B-ENZY
subunit	O
p42	O
from	O
human	O
fetal	O
lung	O
diploid	O
fibroblast	O
(	O
2BS	O
)	O
cells	O
bound	O
to	O
SARS	O
-	O
CoV	O
NP	O
.	O

p42	O
is	O
a	O
subunit	O
of	O
the	O
26S	O
proteasome	B-ENZY
;	O
this	O
large	O
,	O
multi	O
-	O
protein	O
complex	O
is	O
a	O
component	O
of	O
the	O
ubiquitin	O
-	O
proteasome	B-ENZY
pathway	O
,	O
which	O
is	O
involved	O
in	O
a	O
variety	O
of	O
basic	O
cellular	O
processes	O
and	O
inflammatory	O
responses	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
that	O
SARS	O
-	O
CoV	O
NP	O
interacts	O
with	O
the	O
proteasome	B-ENZY
subunit	O
p42	O
within	O
host	O
cells	O
.	O

RESULTS	O
:	O
Using	O
surface	O
plasmon	O
resonance	O
biomolecular	O
interaction	O
analysis	O
(	O
SPR	O
/	O
BIA	O
)	O
and	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
of	O
flight	O
(	O
MALDI	O
-	O
TOF	O
)	O
mass	O
spectrometry	O
,	O
we	O
found	O
that	O
only	O
the	O
proteasome	B-ENZY
subunit	O
p42	O
from	O
human	O
fetal	O
lung	O
diploid	O
fibroblast	O
(	O
2BS	O
)	O
cells	O
bound	O
to	O
SARS	O
-	O
CoV	O
NP	O
.	O

CONCLUSIONS	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
that	O
SARS	O
-	O
CoV	O
NP	O
interacts	O
with	O
the	O
proteasome	B-ENZY
subunit	O
p42	O
within	O
host	O
cells	O
.	O

Improving	O
alveolar	O
ventilation	O
and	O
oxygenation	O
may	O
improve	O
the	O
outcome	O
of	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
).	O

Prospective	O
randomized	O
single	O
-	O
center	O
open	O
study	O
from	O
November	O
1998	O
to	O
February	O
2002	O
to	O
test	O
whether	O
noninvasive	O
ventilation	O
(	O
NIV	O
)	O
was	O
more	O
effective	O
than	O
oxygen	O
alone	O
in	O
improving	O
oxygenation	O
on	O
day	O
3	O
in	O
adults	O
with	O
ACS	B-ENZY
and	O
to	O
evaluate	O
the	O
effects	O
on	O
pain	O
,	O
transfusion	O
requirements	O
,	O
and	O
length	O
of	O
stay	O
.	O

Seventy	O
-	O
one	O
consecutive	O
ACS	B-ENZY
episodes	O
in	O
67	O
patients	O
were	O
randomly	O
allocated	O
to	O
oxygen	O
(	O
n	O
=	O
36	O
)	O
or	O
NIV	O
(	O
n	O
=	O
35	O
)	O
for	O
3	O
days	O
in	O
a	O
medical	O
step	O
-	O
down	O
unit	O
.	O

Respiratory	O
rate	O
and	O
gas	B-ENZY
exchange	O
improved	O
faster	O
with	O
NIV	O
.	O

RESULTS	O
:	O
Seventy	O
-	O
one	O
consecutive	O
ACS	B-ENZY
episodes	O
in	O
67	O
patients	O
were	O
randomly	O
allocated	O
to	O
oxygen	O
(	O
n	O
=	O
36	O
)	O
or	O
NIV	O
(	O
n	O
=	O
35	O
)	O
for	O
3	O
days	O
in	O
a	O
medical	O
step	O
-	O
down	O
unit	O
.	O

The	O
upregulation	O
of	O
CCL2	O
by	O
SARS	O
-	O
CoV	O
spike	O
protein	O
was	O
mainly	O
mediated	O
by	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
1	O
and	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
and	O
AP	O
-	O
1	O
but	O
not	O
the	O
IkappaBalpha	O
-	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
.	O

These	O
results	O
indicate	O
that	O
SARS	O
-	O
CoV	O
spike	O
protein	O
triggers	O
ACE2	O
signaling	O
and	O
activates	O
fibrosis	O
-	O
associated	O
CCL2	O
expression	O
through	O
the	O
Ras	O
-	O
ERK	B-ENZY
-	O
AP	O
-	O
1	O
pathway	O
.	O

TITLE	O
:	O
The	O
ubiquitin	O
-	O
proteasome	B-ENZY
system	O
plays	O
an	O
important	O
role	O
during	O
various	O
stages	O
of	O
the	O
coronavirus	O
infection	O
cycle	O
.	O

Inhibition	O
of	O
the	O
proteasome	B-ENZY
by	O
different	O
chemical	O
compounds	O
(	O
i	O
.	O
e	O
.,	O
MG132	O
,	O
epoxomicin	O
,	O
and	O
Velcade	O
)	O
appeared	O
to	O
not	O
only	O
impair	O
entry	O
but	O
also	O
RNA	O
synthesis	O
and	O
subsequent	O
protein	O
expression	O
of	O
different	O
CoVs	O
(	O
i	O
.	O
e	O
.,	O
mouse	O
hepatitis	O
virus	O
[	O
MHV	O
],	O
feline	O
infectious	O
peritonitis	O
virus	O
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
).	O

Stress	O
-	O
induced	O
phosphorylation	O
of	O
eukaryotic	O
translation	O
initiation	O
factor	O
2alpha	O
(	O
eIF2alpha	O
)	O
generally	O
results	O
in	O
impaired	O
initiation	O
of	O
protein	O
synthesis	O
,	O
but	O
the	O
sensitivity	O
of	O
MHV	O
infection	O
to	O
proteasome	B-ENZY
inhibitors	O
was	O
unchanged	O
in	O
cells	O
lacking	O
a	O
phosphorylatable	O
eIF2alpha	O
.	O

MHV	O
infection	O
was	O
affected	O
not	O
only	O
by	O
inhibition	O
of	O
the	O
proteasome	B-ENZY
but	O
also	O
by	O
interfering	O
with	O
protein	O
ubiquitination	O
.	O

Viral	O
protein	O
expression	O
was	O
reduced	O
in	O
cells	O
expressing	O
a	O
temperature	O
-	O
sensitive	O
ubiquitin	B-ENZY
-	I-ENZY
activating	I-ENZY
enzyme	I-ENZY
E1	O
at	O
the	O
restrictive	O
temperature	O
,	O
as	O
well	O
as	O
in	O
cells	O
in	O
which	O
ubiquitin	O
was	O
depleted	O
by	O
using	O
small	O
interfering	O
RNAs	O
.	O

TITLE	O
:	O
The	O
proteasome	B-ENZY
inhibitor	O
Velcade	O
enhances	O
rather	O
than	O
reduces	O
disease	O
in	O
mouse	O
hepatitis	O
coronavirus	O
-	O
infected	O
mice	O
.	O

ABSTRACT	O
:	O
Many	O
viruses	O
,	O
including	O
coronaviruses	O
(	O
CoVs	O
),	O
depend	O
on	O
a	O
functional	O
cellular	O
proteasome	B-ENZY
for	O
efficient	O
infection	O
in	O
vitro	O
.	O

Hence	O
,	O
the	O
proteasome	B-ENZY
inhibitor	O
Velcade	O
(	O
bortezomib	O
),	O
a	O
clinically	O
approved	O
anticancer	O
drug	O
,	O
shown	O
in	O
an	O
accompanying	O
study	O
(	O
M	O
.	O
Raaben	O
et	O
al	O
.,	O
J	O
.	O
Virol	O
.	O

Rather	O
,	O
inhibition	O
of	O
the	O
proteasome	B-ENZY
caused	O
enhanced	O
infection	O
with	O
lethal	O
outcome	O
,	O
calling	O
for	O
caution	O
when	O
using	O
this	O
type	O
of	O
drug	O
during	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
spectrum	O
of	O
the	O
clinical	O
presentation	O
and	O
severity	O
of	O
malaria	O
infections	O
is	O
broad	O
,	O
ranging	O
from	O
uncomplicated	O
febrile	O
illness	O
to	O
severe	O
forms	O
of	O
disease	O
such	O
as	O
cerebral	O
malaria	O
(	O
CM	O
),	O
acute	O
lung	O
injury	O
(	O
ALI	O
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
pregnancy	O
-	O
associated	O
malaria	O
(	O
PAM	B-ENZY
)	O
or	O
severe	O
anemia	O
(	O
SA	O
).	O

Rodent	O
models	O
that	O
mimic	O
human	O
CM	O
,	O
PAM	B-ENZY
and	O
SA	O
syndromes	O
have	O
been	O
established	O
.	O

Phosphorylation	O
levels	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
induced	O
by	O
tumor	O
necrosis	O
factor	O
,	O
bacterial	O
lipopolysaccharide	O
,	O
muramyl	O
dipeptide	O
,	O
Escherichia	O
coli	O
,	O
Staphylococcus	O
aureus	O
,	O
and	O
Staphylococcus	O
epidermidis	O
were	O
significantly	O
lower	O
in	O
patients	O
'	O
monocytes	O
than	O
monocytes	O
of	O
healthy	O
reference	O
subjects	O
,	O
whereas	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
p38	O
phosphorylation	O
levels	O
were	O
normal	O
.	O

Phosphorylation	O
levels	O
induced	O
by	O
interleukin	O
-	O
6	O
in	O
STAT1	O
and	O
STAT3	O
and	O
by	O
combination	O
of	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
calcium	O
ionophore	O
A23187	O
in	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
1	O
/	O
2	O
,	O
members	O
of	O
a	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
family	O
,	O
were	O
depressed	O
in	O
patients	O
'	O
monocytes	O
,	O
whereas	O
phosphorylation	O
levels	O
induced	O
by	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
in	O
STAT5	O
was	O
normal	O
.	O

Vaccinated	O
birds	O
that	O
were	O
challenged	O
with	O
10	O
(	O
4	O
.	O
5	O
)	O
median	O
embryo	O
infectious	O
doses	O
of	O
pathogenic	O
GA08	O
virus	O
/	O
bird	O
at	O
28	O
days	O
of	O
age	O
were	O
protected	O
from	O
the	O
disease	O
,	O
and	O
challenge	O
virus	O
was	O
only	O
detected	O
in	O
the	O
trachea	O
of	O
one	O
of	O
21	O
birds	O
by	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
at	O
5	O
days	O
post	O
challenge	O
.	O

Severe	O
viral	O
pneumonia	O
predominated	O
in	O
these	O
patients	O
,	O
mean	O
APACHE	O
was	O
18	O
,	O
average	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
on	O
admission	O
was	O
74	O
.	O
9	O
,	O
100	O
%	O
had	O
multisystemic	O
involvement	O
.	O

Creatine	B-ENZY
kinase	I-ENZY
peaked	O
in	O
all	O
patients	O
.	O

ABSTRACT	O
:	O
The	O
discovery	O
of	O
SARS	O
-	O
like	O
coronavirus	O
in	O
bats	O
suggests	O
that	O
bats	O
could	O
be	O
the	O
natural	O
reservoir	O
of	O
SARS	O
-	O
CoV	O
.	O
However	O
,	O
previous	O
studies	O
indicated	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
protein	O
,	O
a	O
known	O
SARS	O
-	O
CoV	O
receptor	O
,	O
from	O
a	O
horseshoe	O
bat	B-ENZY
was	O
unable	O
to	O
act	O
as	O
a	O
functional	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
Here	O
,	O
we	O
extended	O
our	O
previous	O
study	O
to	O
ACE2	O
molecules	O
from	O
seven	O
additional	O
bat	B-ENZY
species	O
and	O
tested	O
their	O
interactions	O
with	O
human	O
SARS	O
-	O
CoV	O
spike	O
protein	O
using	O
both	O
HIV	O
-	O
based	O
pseudotype	O
and	O
live	O
SARS	O
-	O
CoV	O
infection	O
assays	O
.	O

Further	O
,	O
the	O
alteration	O
of	O
several	O
key	O
residues	O
either	O
decreased	O
or	O
enhanced	O
bat	B-ENZY
ACE2	O
receptor	O
efficiency	O
,	O
as	O
predicted	O
from	O
a	O
structural	O
modeling	O
study	O
of	O
the	O
different	O
bat	B-ENZY
ACE2	O
molecules	O
.	O

Furthermore	O
,	O
our	O
current	O
study	O
also	O
demonstrates	O
that	O
the	O
genetic	O
diversity	O
of	O
ACE2	O
among	O
bats	O
is	O
greater	O
than	O
that	O
observed	O
among	O
known	O
SARS	O
-	O
CoV	O
susceptible	O
mammals	O
,	O
highlighting	O
the	O
possibility	O
that	O
there	O
are	O
many	O
more	O
uncharacterized	O
bat	B-ENZY
species	O
that	O
can	O
act	O
as	O
a	O
reservoir	O
of	O
SARS	O
-	O
CoV	O
or	O
its	O
progenitor	O
viruses	O
.	O

This	O
calls	O
for	O
continuation	O
and	O
expansion	O
of	O
field	O
surveillance	O
studies	O
among	O
different	O
bat	B-ENZY
populations	O
to	O
eventually	O
identify	O
the	O
true	O
natural	O
reservoir	O
of	O
SARS	O
-	O
CoV	O
.	O

Over	O
time	O
,	O
a	O
decreased	O
proportion	O
of	O
the	O
respondents	O
(	O
1	O
)	O
felt	O
susceptible	O
to	O
contracting	O
H5N1	O
,	O
(	O
2	O
)	O
expected	O
a	O
large	O
outbreak	O
would	O
eventually	O
occur	O
,	O
(	O
3	O
)	O
believed	O
that	O
the	O
impacts	O
of	O
H5N1	O
were	O
worse	O
than	O
those	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
(	O
4	O
)	O
anticipated	O
adopting	O
more	O
types	O
of	O
preventive	O
measures	O
and	O
experiencing	O
mental	O
distress	O
in	O
the	O
case	O
of	O
a	O
small	O
-	O
scale	O
outbreak	O
in	O
Hong	O
Kong	O
(	O
AOR	B-ENZY
from	O
0	O
.	O
27	O
to	O
0	O
.	O
43	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
but	O
the	O
public	O
remained	O
vigilant	O
on	O
public	O
health	O
behaviors	O
,	O
such	O
as	O
hand	O
-	O
washing	O
.	O

RESULTS	O
:	O
Over	O
time	O
,	O
a	O
decreased	O
proportion	O
of	O
the	O
respondents	O
(	O
1	O
)	O
felt	O
susceptible	O
to	O
contracting	O
H5N1	O
,	O
(	O
2	O
)	O
expected	O
a	O
large	O
outbreak	O
would	O
eventually	O
occur	O
,	O
(	O
3	O
)	O
believed	O
that	O
the	O
impacts	O
of	O
H5N1	O
were	O
worse	O
than	O
those	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
(	O
4	O
)	O
anticipated	O
adopting	O
more	O
types	O
of	O
preventive	O
measures	O
and	O
experiencing	O
mental	O
distress	O
in	O
the	O
case	O
of	O
a	O
small	O
-	O
scale	O
outbreak	O
in	O
Hong	O
Kong	O
(	O
AOR	B-ENZY
from	O
0	O
.	O
27	O
to	O
0	O
.	O
43	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
but	O
the	O
public	O
remained	O
vigilant	O
on	O
public	O
health	O
behaviors	O
,	O
such	O
as	O
hand	O
-	O
washing	O
.	O

Previously	O
,	O
the	O
domain	O
III	O
-	O
truncated	O
enzyme	O
was	O
demonstrated	O
to	O
fold	O
independently	O
into	O
an	O
intact	O
chymotrypsin	B-ENZY
-	O
like	O
fold	O
,	O
but	O
it	O
showed	O
no	O
enzyme	O
activity	O
.	O

TITLE	O
:	O
Trilogy	O
of	O
ACE2	O
:	O
a	O
peptidase	O
in	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
,	O
a	O
SARS	O
receptor	O
,	O
and	O
a	O
partner	O
for	O
amino	O
acid	O
transporters	O
.	O

First	O
ACE2	O
has	O
emerged	O
as	O
a	O
potent	O
negative	O
regulator	O
of	O
the	O
RAS	O
counterbalancing	O
the	O
multiple	O
functions	O
of	O
ACE	B-ENZY
.	O

Since	O
multiple	O
infectious	O
agents	O
can	O
be	O
involved	O
in	O
calf	O
diarrhea	O
,	O
and	O
the	O
detection	O
of	O
each	O
of	O
the	O
causative	O
agents	O
by	O
traditional	O
methods	O
is	O
laborious	O
and	O
expensive	O
,	O
a	O
panel	O
of	O
2	O
multiplex	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assays	O
was	O
developed	O
for	O
rapid	O
and	O
simultaneous	O
detection	O
of	O
the	O
5	O
major	O
bovine	O
enteric	O
pathogens	O
(	O
i	O
.	O
e	O
.,	O
Bovine	O
coronavirus	O
[	O
BCoV	O
;	O
formally	O
known	O
as	O
Betacoronavirus	O
1	O
],	O
group	O
A	O
Bovine	O
rotavirus	O
[	O
BRV	O
],	O
Salmonella	O
spp	B-ENZY
.,	O
Escherichia	O
coli	O
K99	O
(+),	O
and	O
Cryptosporidium	O
parvum	O
).	O

Glasgow	O
Coma	O
Scale	O
(	O
GCS	O
)	O
scores	O
and	O
the	O
need	O
for	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	B-ENZY
)	O
at	O
the	O
scene	O
of	O
injury	O
were	O
associated	O
with	O
eventual	O
patient	O
mortality	O
(	O
100	O
%	O
mortality	O
for	O
an	O
initial	O
GCS	O
score	O
of	O
3	O
and	O
75	O
%	O
mortality	O
for	O
on	O
-	O
scene	O
CPR	B-ENZY
).	O

Sequential	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluids	O
from	O
all	O
patients	O
hospitalised	O
with	O
acute	O
respiratory	O
illness	O
over	O
12	O
months	O
(	O
n	O
=	O
283	O
)	O
were	O
tested	O
for	O
the	O
presence	O
of	O
17	O
respiratory	O
viruses	O
by	O
multiplex	O
PCR	O
assay	O
and	O
for	O
newly	O
discovered	O
respiratory	O
viruses	O
(	O
bocavirus	O
,	O
WU	O
and	O
KI	O
polyomaviruses	O
)	O
by	O
single	O
-	O
target	O
PCR	O
.	O

BAL	B-ENZY
samples	O
also	O
underwent	O
conventional	O
testing	O
(	O
direct	O
immunoflorescence	O
and	O
viral	O
culture	O
)	O
for	O
respiratory	O
virus	O
at	O
the	O
clinician	O
'	O
s	O
discretion	O
.	O

The	O
presence	O
of	O
respiratory	O
virus	O
was	O
associated	O
with	O
increased	O
levels	O
of	O
interferon	O
gamma	O
-	O
inducible	O
protein	O
10	O
(	O
IP	O
-	O
10	O
)	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
eotaxin	O
-	O
1	O
(	O
p	O
=	O
0	O
.	O
017	O
)	O
in	O
BAL	B-ENZY
.	O

In	O
addition	O
,	O
the	O
Lung	O
Injury	O
Score	O
(	O
LIS	B-ENZY
)	O
and	O
the	O
APACHE	O
II	O
and	O
SOFA	O
scores	O
were	O
recorded	O
.	O

TITLE	O
:	O
Papain	B-ENZY
-	O
like	O
protease	O
1	O
from	O
transmissible	O
gastroenteritis	O
virus	O
:	O
crystal	O
structure	O
and	O
enzymatic	O
activity	O
toward	O
viral	O
and	O
cellular	O
substrates	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
encode	O
two	O
classes	O
of	O
cysteine	O
proteases	O
,	O
which	O
have	O
narrow	O
substrate	O
specificities	O
and	O
either	O
a	O
chymotrypsin	B-ENZY
-	O
or	O
papain	B-ENZY
-	O
like	O
fold	O
.	O

The	O
papain	B-ENZY
-	O
like	O
protease	O
1	O
(	O
PL1	O
(	O
pro	O
))	O
domain	O
is	O
present	O
in	O
nonstructural	O
protein	O
3	O
(	O
nsp3	O
)	O
of	O
alphacoronaviruses	O
and	O
subgroup	O
2a	O
betacoronaviruses	O
.	O

Other	O
problems	O
include	O
relative	O
hypoxia	O
,	O
gas	B-ENZY
expansion	O
,	O
air	O
dryness	O
,	O
ozone	O
,	O
cosmic	O
rays	O
,	O
airsickness	O
,	O
jet	O
lag	O
,	O
the	O
effects	O
of	O
alcohol	O
and	O
tobacco	O
,	O
and	O
,	O
more	O
recently	O
,	O
deep	O
vein	O
thrombosis	O
(	O
DVT	O
)	O
and	O
pulmonary	O
embolism	O
(	O
PE	O
),	O
collectively	O
known	O
as	O
""""	O
coach	O
class	O
syndrome	O
"""."	O

ABSTRACT	O
:	O
Fifty	O
-	O
two	O
bats	O
captured	O
during	O
July	O
2008	O
in	O
the	O
Philippines	O
were	O
tested	O
by	O
reverse	O
transcription	O
-	O
PCR	O
to	O
detect	O
bat	B-ENZY
coronavirus	O
(	O
CoV	O
)	O
RNA	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
gene	O
showed	O
that	O
groups	O
1	O
and	O
2	O
CoVs	O
were	O
similar	O
to	O
Bat	B-ENZY
-	O
CoV	O
/	O
China	O
/	O
A515	O
/	O
2005	O
(	O
95	O
%	O
nt	O
sequence	O
identity	O
)	O
and	O
Bat	B-ENZY
-	O
CoV	O
/	O
HKU9	O
-	O
1	O
/	O
China	O
/	O
2007	O
(	O
83	O
%	O
identity	O
),	O
respectively	O
.	O

After	O
virus	O
replication	O
in	O
the	O
bats	O
was	O
confirmed	O
,	O
an	O
additional	O
passage	O
of	O
the	O
virus	O
was	O
made	O
in	O
Leschenault	O
rousette	O
bats	O
,	O
and	O
bat	B-ENZY
pathogenesis	O
was	O
investigated	O
.	O

We	O
conducted	O
an	O
evaluation	O
of	O
CoV	O
in	O
rhinolophid	O
and	O
vespertilionid	O
bat	B-ENZY
species	O
common	O
in	O
Europe	O
.	O

An	O
additional	O
novel	O
Alphacoronavirus	O
clade	O
(	O
bat	B-ENZY
CoV	O
[	O
BtCoV	O
]/	O
BNM98	O
-	O
30	O
)	O
was	O
detected	O
in	O
Nyctalus	O
leisleri	O
.	O

Strict	O
associations	O
between	O
CoV	O
RGU	O
and	O
host	O
bat	B-ENZY
genera	O
were	O
confirmed	O
for	O
six	O
independent	O
RGU	O
represented	O
simultaneously	O
in	O
China	O
and	O
Europe	O
.	O

A	O
SARS	O
-	O
related	O
virus	O
(	O
BtCoV	O
/	O
BM48	O
-	O
31	O
/	O
Bulgaria	O
/	O
2008	O
)	O
from	O
a	O
Rhinolophus	O
blasii	O
(	O
Rhi	O
bla	O
)	O
bat	B-ENZY
was	O
fully	O
sequenced	O
.	O

Surface	O
expression	O
of	O
spike	O
and	O
staining	O
with	O
sera	O
of	O
SARS	O
survivors	O
suggested	O
low	O
antigenic	O
overlap	O
with	O
SARS	O
CoV	O
.	O
However	O
,	O
the	O
receptor	O
binding	O
domain	O
of	O
SARS	O
CoV	O
showed	O
higher	O
similarity	O
with	O
that	O
of	O
BtCoV	O
/	O
BM48	O
-	O
31	O
/	O
Bulgaria	O
/	O
2008	O
than	O
with	O
that	O
of	O
any	O
Chinese	O
bat	B-ENZY
-	O
borne	O
CoV	O
.	O
Critical	O
spike	O
domains	O
472	O
and	O
487	O
were	O
identical	O
and	O
similar	O
,	O
respectively	O
.	O

This	O
study	O
underlines	O
the	O
importance	O
of	O
assessments	O
of	O
the	O
zoonotic	O
potential	O
of	O
widely	O
distributed	O
bat	B-ENZY
-	O
borne	O
CoV	O
.	O

TITLE	O
:	O
Electrophoretic	O
fractionation	O
of	O
creatine	B-ENZY
kinase	I-ENZY
isoenzymes	O
and	O
macroenzymes	O
in	O
clinically	O
healthy	O
dogs	O
and	O
cats	O
and	O
preliminary	O
evaluation	O
in	O
central	O
neurologic	O
disease	O
.	O

ABSTRACT	O
:	O
Information	O
about	O
the	O
electrophoretic	O
distribution	O
of	O
CK	O
-	O
MM	O
,	O
CK	O
-	O
MB	O
,	O
and	O
CK	O
-	O
BB	O
,	O
serum	O
creatine	B-ENZY
kinase	I-ENZY
(	O
CK	B-ENZY
)	O
isoenzymes	O
that	O
are	O
indicators	O
of	O
skeletal	O
muscle	O
,	O
cardiac	O
muscle	O
,	O
and	O
brain	O
lesions	O
,	O
respectively	O
,	O
and	O
CK	B-ENZY
macroenzymes	O
(	O
macro	O
-	O
CK1	O
and	O
macro	O
-	O
CK2	O
)	O
in	O
dogs	O
and	O
cats	O
with	O
and	O
without	O
central	O
neurologic	O
disease	O
is	O
scant	O
and	O
equivocal	O
.	O

TITLE	O
:	O
Coexistence	O
of	O
different	O
genotypes	O
in	O
the	O
same	O
bat	B-ENZY
and	O
serological	O
characterization	O
of	O
Rousettus	O
bat	B-ENZY
coronavirus	O
HKU9	O
belonging	O
to	O
a	O
novel	O
Betacoronavirus	O
subgroup	O
.	O

ABSTRACT	O
:	O
Rousettus	O
bat	B-ENZY
coronavirus	O
HKU9	O
(	O
Ro	O
-	O
BatCoV	O
HKU9	O
),	O
a	O
recently	O
identified	O
coronavirus	O
of	O
novel	O
Betacoronavirus	O
subgroup	O
D	O
,	O
from	O
Leschenault	O
'	O
s	O
rousette	O
,	O
was	O
previously	O
found	O
to	O
display	O
marked	O
sequence	O
polymorphism	O
among	O
genomes	O
of	O
four	O
strains	O
.	O

Among	O
10	O
bats	O
with	O
complete	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
),	O
spike	O
(	O
S	O
),	O
and	O
nucleocapsid	O
(	O
N	O
)	O
genes	O
sequenced	O
,	O
three	O
and	O
two	O
sequence	O
clades	O
for	O
all	O
three	O
genes	O
were	O
codetected	O
in	O
two	O
and	O
five	O
bats	O
,	O
respectively	O
,	O
suggesting	O
the	O
coexistence	O
of	O
two	O
or	O
three	O
distinct	O
genotypes	O
of	O
Ro	O
-	O
BatCoV	O
HKU9	O
in	O
the	O
same	O
bat	B-ENZY
.	O

Recombination	O
analysis	O
using	O
eight	O
Ro	O
-	O
BatCoV	O
HKU9	O
genomes	O
showed	O
possible	O
recombination	O
events	O
between	O
strains	O
from	O
different	O
bat	B-ENZY
individuals	O
,	O
which	O
may	O
have	O
allowed	O
for	O
the	O
generation	O
of	O
different	O
genotypes	O
.	O

Acanthopanacis	O
cortex	O
and	O
Torilis	O
fructus	O
might	O
exert	O
their	O
antiviral	O
activities	O
in	O
MHV	O
-	O
A59	O
-	O
infected	O
cells	O
by	O
inducing	O
cyclooxygenase	O
-	O
2	O
expression	O
via	O
the	O
activation	O
of	O
extracellular	O
signal	O
-	O
related	O
kinase	O
(	O
ERK	B-ENZY
)	O
and	O
p38	O
or	O
ERK	B-ENZY
alone	O
,	O
respectively	O
.	O

Acanthopanacis	O
cortex	O
and	O
Torilis	O
fructus	O
might	O
exert	O
their	O
antiviral	O
activities	O
in	O
MHV	O
-	O
A59	O
-	O
infected	O
cells	O
by	O
inducing	O
cyclooxygenase	O
-	O
2	O
expression	O
via	O
the	O
activation	O
of	O
extracellular	O
signal	O
-	O
related	O
kinase	O
(	O
ERK	B-ENZY
)	O
and	O
p38	O
or	O
ERK	B-ENZY
alone	O
,	O
respectively	O
.	O

Significantly	O
better	O
oxygenation	O
with	O
higher	O
PaO	B-ENZY
(	O
2	O
)	O
and	O
alveolar	O
-	O
arterial	O
oxygen	O
difference	O
was	O
noted	O
in	O
the	O
Surf	O
and	O
Bude	O
+	O
Surf	O
groups	O
,	O
compared	O
with	O
the	O
control	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
Surf	O
and	O
Bude	O
+	O
Surf	O
groups	O
.	O

RESULTS	O
:	O
Significantly	O
better	O
oxygenation	O
with	O
higher	O
PaO	B-ENZY
(	O
2	O
)	O
and	O
alveolar	O
-	O
arterial	O
oxygen	O
difference	O
was	O
noted	O
in	O
the	O
Surf	O
and	O
Bude	O
+	O
Surf	O
groups	O
,	O
compared	O
with	O
the	O
control	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
Surf	O
and	O
Bude	O
+	O
Surf	O
groups	O
.	O

ABSTRACT	O
:	O
A	O
case	O
-	O
control	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
role	O
of	O
different	O
Cryptosporidium	O
spp	B-ENZY
.	O

Early	O
improvement	O
of	O
PaO	B-ENZY
(	O
2	O
)	O
to	O
FiO	O
ratio	O
was	O
greater	O
in	O
ECMO	O
survivors	O
than	O
non	O
-	O
survivors	O
after	O
ECMO	O
initiation	O
[	O
295	O
(	O
151	O
-	O
439	O
)	O
versus	O
131	O
(	O
106	O
-	O
144	O
)	O
mmHg	O
,	O
p	O
<	O
0	O
.	O
05	O
].	O

The	O
disease	O
was	O
diagnosed	O
by	O
clinical	O
symptoms	O
,	O
gross	O
and	O
histopathology	O
and	O
viral	O
detection	O
using	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
assay	O
.	O

We	O
have	O
recently	O
described	O
ANP	O
-	O
protective	O
effects	O
against	O
thrombin	B-ENZY
-	O
induced	O
barrier	O
dysfunction	O
in	O
pulmonary	O
endothelial	O
cells	O
(	O
EC	O
).	O

TITLE	O
:	O
Synthesis	O
,	O
biological	O
evaluation	O
and	O
molecular	O
modeling	O
studies	O
of	O
N	O
-	O
aryl	O
-	O
2	O
-	O
arylthioacetamides	O
as	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
N	O
-	O
aryl	O
-	O
2	O
-	O
arylthioacetamide	O
derivatives	O
(	O
2	O
-	O
4	O
)	O
designed	O
as	O
non	O
-	O
nucleoside	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
was	O
synthesized	O
and	O
evaluated	O
for	O
their	O
inhibitory	O
activity	O
against	O
HIV	O
-	O
1	O
(	O
IIIB	O
)	O
replication	O
in	O
MT	O
-	O
4	O
cell	O
cultures	O
.	O

Reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
has	O
been	O
used	O
to	O
detect	O
FCoV	O
and	O
is	O
rapid	O
and	O
sensitive	O
,	O
but	O
results	O
must	O
be	O
interpreted	O
in	O
the	O
context	O
of	O
clinical	O
findings	O
.	O

However	O
,	O
ACS	B-ENZY
has	O
been	O
only	O
rarely	O
described	O
in	O
this	O
population	O
.	O

Although	O
patients	O
with	O
fulminant	O
CDI	O
share	O
many	O
risk	O
factors	O
for	O
IAH	O
and	O
ACS	B-ENZY
,	O
these	O
conditions	O
were	O
rarely	O
reported	O
in	O
this	O
population	O
and	O
are	O
likely	O
under	O
recognized	O
,	O
as	O
was	O
the	O
case	O
with	O
the	O
present	O
patient	O
.	O

ALI	O
was	O
confirmed	O
with	O
lung	O
tissue	O
injury	O
(	O
histopathological	O
examination	O
),	O
enhanced	O
lung	O
edema	O
(	O
wet	O
-	O
to	O
-	O
dry	O
weight	O
ratio	O
),	O
and	O
neutrophil	O
infiltration	O
(	O
myeloperoxidase	B-ENZY
activity	O
)	O
at	O
6	O
h	O
after	O
LPS	O
exposure	O
.	O

Advances	O
in	O
the	O
standardisation	O
of	O
care	O
for	O
ARDS	O
patients	O
involving	O
innovative	O
therapeutic	O
procedures	O
such	O
as	O
extracorporeal	O
gas	B-ENZY
exchange	O
systems	O
will	O
lead	O
to	O
a	O
further	O
improvement	O
in	O
ARDS	O
management	O
and	O
outcome	O
.	O

Among	O
patients	O
who	O
developed	O
ALI	O
/	O
ARDS	O
,	O
there	O
was	O
no	O
evidence	O
to	O
support	O
a	O
difference	O
in	O
partial	O
pressure	O
of	O
oxygen	O
in	O
arterial	O
blood	O
to	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
Pao	B-ENZY
(	O
2	O
)/	O
Fio	O
(	O
2	O
))	O
(	O
P	O
=	O
.	O
33	O
),	O
lung	O
injury	O
score	O
(	O
P	O
=	O
.	O
67	O
),	O
or	O
mortality	O
(	O
P	O
=	O
.	O
78	O
)	O
by	O
race	O
.	O

Among	O
patients	O
who	O
developed	O
ALI	O
/	O
ARDS	O
,	O
there	O
was	O
no	O
evidence	O
to	O
support	O
a	O
difference	O
in	O
partial	O
pressure	O
of	O
oxygen	O
in	O
arterial	O
blood	O
to	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
Pao	B-ENZY
(	O
2	O
)/	O
Fio	O
(	O
2	O
))	O
(	O
P	O
=	O
.	O
33	O
),	O
lung	O
injury	O
score	O
(	O
P	O
=	O
.	O
67	O
),	O
or	O
mortality	O
(	O
P	O
=	O
.	O
78	O
)	O
by	O
race	O
.	O

Compared	O
with	O
model	O
group	O
,	O
blood	O
PaO	B-ENZY
(	O
2	O
)	O
and	O
pH	O
value	O
were	O
significantly	O
increased	O
[	O
PaO	B-ENZY
(	O
2	O
):	O
(	O
88	O
.	O
16	O
	O
5	O
.	O
07	O
)	O
mm	O
Hg	O
,	O
pH	O
value	O
:	O
7	O
.	O
322	O
	O
0	O
.	O
039	O
],	O
the	O
PaCO	O
(	O
2	O
),	O
the	O
serum	O
levels	O
of	O
AMY	O
,	O
W	O
/	O
D	O
ratio	O
and	O
the	O
serum	O
levels	O
of	O
sPLA	O
(	O
2	O
)	O
in	O
QYT	O
group	O
were	O
significantly	O
decreased	O
[	O
PaCO	O
(	O
2	O
):	O
(	O
33	O
.	O
13	O
	O
2	O
.	O
14	O
)	O
mm	O
Hg	O
,	O
AMY	O
:	O
(	O
4	O
283	O
.	O
51	O
	O
527	O
.	O
52	O
)	O
U	O
/	O
L	O
,	O
W	O
/	O
D	O
ratio	O
:	O
4	O
.	O
05	O
	O
0	O
.	O
52	O
,	O
sPLA	O
(	O
2	O
):	O
(	O
28	O
.	O
00	O
	O
4	O
.	O
78	O
)	O
nmol	O
	O
min	O
(-	O
1	O
)	O
	O
ml	O
(-	O
1	O
)],	O
and	O
the	O
expression	O
of	O
sPLA	O
(	O
2	O
)-	O
II	O
mRNA	O
(	O
0	O
.	O
89	O
	O
0	O
.	O
08	O
)	O
and	O
protein	O
were	O
significantly	O
decreased	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Proteasome	B-ENZY
inhibition	O
in	O
vivo	O
promotes	O
survival	O
in	O
a	O
lethal	O
murine	O
model	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

In	O
vitro	O
,	O
the	O
pretreatment	O
of	O
peritoneal	O
macrophages	O
with	O
inhibitors	O
of	O
the	O
proteasome	B-ENZY
(	O
pyrrolidine	O
dithiocarbamate	O
[	O
PDTC	O
],	O
MG132	O
,	O
and	O
PS	O
-	O
341	O
)	O
markedly	O
inhibited	O
MHV	O
-	O
1	O
replication	O
at	O
an	O
early	O
step	O
in	O
its	O
replication	O
cycle	O
,	O
as	O
evidenced	O
by	O
inhibition	O
of	O
viral	O
RNA	O
production	O
.	O

Treatment	O
of	O
A	O
/	O
J	O
mice	O
with	O
the	O
proteasome	B-ENZY
inhibitor	O
PDTC	O
,	O
MG132	O
,	O
or	O
PS	O
-	O
341	O
led	O
to	O
40	O
%	O
survival	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
with	O
a	O
concomitant	O
improvement	O
of	O
lung	O
histology	O
,	O
reduced	O
pulmonary	O
viral	O
replication	O
,	O
decreased	O
pulmonary	O
STAT	O
phosphorylation	O
,	O
and	O
reduced	O
pulmonary	O
inflammatory	O
cytokine	O
expression	O
.	O

The	O
results	O
further	O
suggest	O
that	O
targeting	O
the	O
proteasome	B-ENZY
may	O
be	O
an	O
effective	O
new	O
treatment	O
for	O
severe	O
coronavirus	O
infections	O
.	O

Increased	O
effector	O
function	O
at	O
the	O
single	O
-	O
cell	O
level	O
was	O
also	O
evident	O
by	O
elevated	O
granzyme	B-ENZY
B	I-ENZY
expression	O
specifically	O
in	O
virus	O
-	O
specific	O
CNS	O
CD8	O
T	O
cells	O
.	O

Lymphopenia	O
and	O
increased	O
creatine	B-ENZY
kinase	I-ENZY
levels	O
were	O
frequently	O
observed	O
(	O
83	O
%	O
and	O
65	O
%	O
among	O
PCR	O
+	O
and	O
PCR	O
-	O
respectively	O
).	O

TITLE	O
:	O
Metagenomic	O
analysis	O
of	O
the	O
viromes	O
of	O
three	O
North	O
American	O
bat	B-ENZY
species	O
:	O
viral	O
diversity	O
among	O
different	O
bat	B-ENZY
species	O
that	O
share	O
a	O
common	O
habitat	O
.	O

To	O
assess	O
the	O
virome	O
of	O
North	O
American	O
bats	O
,	O
we	O
collected	O
fecal	O
,	O
oral	O
,	O
urine	O
,	O
and	O
tissue	O
samples	O
from	O
individual	O
bats	O
captured	O
at	O
an	O
abandoned	O
railroad	O
tunnel	O
in	O
Maryland	O
that	O
is	O
cohabitated	O
by	O
7	O
to	O
10	O
different	O
bat	B-ENZY
species	O
.	O

Here	O
,	O
we	O
present	O
preliminary	O
characterization	O
of	O
the	O
virome	O
of	O
three	O
common	O
North	O
American	O
bat	B-ENZY
species	O
,	O
including	O
big	O
brown	O
bats	O
(	O
Eptesicus	O
fuscus	O
),	O
tricolored	O
bats	O
(	O
Perimyotis	O
subflavus	O
),	O
and	O
little	O
brown	O
myotis	O
(	O
Myotis	O
lucifugus	O
).	O

The	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
score	O
,	O
ECMO	O
flow	O
,	O
and	O
respiratory	O
parameters	O
,	O
such	O
as	O
PaO2	O
/	O
FiO2	O
(	O
P	O
/	O
F	O
ratio	O
),	O
pulmonary	O
compliance	O
,	O
and	O
Lung	O
Injury	O
Score	O
(	O
LIS	B-ENZY
)	O
before	O
and	O
after	O
the	O
introduction	O
of	O
ECMO	O
,	O
were	O
compared	O
among	O
patients	O
in	O
whom	O
ECMO	O
could	O
or	O
could	O
not	O
be	O
removed	O
.	O

In	O
all	O
cases	O
,	O
ARDS	O
was	O
diagnosed	O
by	O
the	O
presence	O
of	O
hypoxia	O
with	O
PaO	B-ENZY
(	O
2	O
)	O
/	O
FiO	O
(	O
2	O
)	O
ratio	O
<	O
200	O
and	O
bilateral	O
pulmonary	O
infiltration	O
,	O
and	O
by	O
excluding	O
cardiac	O
disease	O
by	O
echocardiography	O
.	O

Using	O
Luciferase	B-ENZY
Immunoprecipitation	O
Systems	O
(	O
LIPS	O
),	O
a	O
cohort	O
of	O
control	O
,	O
ARDS	O
and	O
sepsis	O
patients	O
were	O
tested	O
for	O
antibodies	O
to	O
a	O
panel	O
of	O
autoantigens	O
.	O

Frequent	O
high	O
titer	O
antibodies	O
were	O
detected	O
against	O
a	O
spectrum	O
of	O
autoantigens	O
including	O
potassium	O
channel	O
regulator	O
,	O
gastric	O
ATPase	B-ENZY
,	O
glutamic	O
decarboxylase	O
-	O
65	O
and	O
several	O
cytokines	O
.	O

Cholesterol	O
depletion	O
from	O
viral	O
membrane	O
may	O
not	O
affect	O
the	O
adsorption	O
process	O
as	O
neither	O
the	O
sialic	O
acid	O
binding	O
activity	O
nor	O
the	O
binding	O
to	O
aminopeptidase	B-ENZY
N	I-ENZY
was	O
reduced	O
post	O
-	O
MCD	O
treatment	O
.	O

TITLE	O
:	O
Immunogenicity	O
of	O
the	O
spike	O
glycoprotein	O
of	O
bat	B-ENZY
SARS	O
-	O
like	O
coronavirus	O
.	O

These	O
results	O
demonstrated	O
that	O
the	O
immunogenicity	O
of	O
the	O
SL	O
-	O
CoV	O
S	O
protein	O
is	O
distinct	O
from	O
that	O
of	O
SARS	O
-	O
CoV	O
,	O
which	O
may	O
cause	O
the	O
immunological	O
differences	O
between	O
human	O
SARS	O
-	O
CoV	O
and	O
bat	B-ENZY
SL	O
-	O
CoV	O
.	O
Furthermore	O
,	O
the	O
recombinant	O
virus	O
could	O
serve	O
as	O
a	O
potential	O
vaccine	O
candidate	O
against	O
bat	B-ENZY
SL	O
-	O
CoV	O
infection	O
.	O

In	O
these	O
cases	O
we	O
determined	O
H1N1	O
Inf	O
A	O
pandemic	O
variant	O
by	O
detection	O
of	O
Inf	O
A	O
Matrix	O
Protein	O
2	O
gene	O
M2	O
and	O
the	O
specific	O
H1	O
gene	O
for	O
influenza	O
pandemic	O
H1N1	O
2009	O
with	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
Inf	O
A	O
/	O
H1N1	O
(	O
Roche	O
).	O

Eleven	O
of	O
the	O
15	O
patients	O
had	O
increased	O
serum	O
lactate	O
dehydrogenase	O
levels	O
,	O
which	O
were	O
above	O
245	O
U	O
/	O
L	O
.	O
Three	O
patients	O
had	O
elevated	O
creatine	B-ENZY
kinase	I-ENZY
levels	O
at	O
admission	O
.	O

The	O
laboratory	O
study	O
included	O
blood	O
routine	O
,	O
blood	O
gas	B-ENZY
analysis	O
,	O
liver	O
and	O
renal	O
function	O
tests	O
,	O
myocardium	O
enzymology	O
,	O
chest	O
radiograph	O
and	O
CT	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
8b	O
reduces	O
viral	O
replication	O
by	O
down	O
-	O
regulating	O
E	O
via	O
an	O
ubiquitin	O
-	O
independent	O
proteasome	B-ENZY
pathway	O
.	O

Here	O
,	O
we	O
showed	O
that	O
the	O
down	O
-	O
regulation	O
of	O
E	O
is	O
not	O
dependent	O
on	O
the	O
lysine	O
residues	O
on	O
8b	O
and	O
the	O
reduction	O
of	O
polyubiquitination	O
of	O
E	O
mutants	O
is	O
not	O
correlated	O
with	O
their	O
down	O
-	O
regulation	O
by	O
8b	O
,	O
suggesting	O
an	O
ubiquitin	O
-	O
independent	O
proteasome	B-ENZY
pathway	O
is	O
involved	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
8b	O
negatively	O
modulates	O
virus	O
replication	O
by	O
down	O
-	O
regulating	O
E	O
via	O
an	O
ubiquitin	O
-	O
independent	O
proteasome	B-ENZY
pathway	O
.	O

A	O
positive	O
correlation	O
of	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
and	O
IL	O
-	O
15	O
levels	O
with	O
C	O
-	O
reactive	O
protein	O
and	O
with	O
>	O
5	O
-	O
day	O
interval	O
between	O
symptom	O
onset	O
and	O
admission	O
,	O
and	O
a	O
negative	O
correlation	O
with	O
the	O
PaO	B-ENZY
(	O
2	O
):	O
FiO	O
(	O
2	O
)	O
ratio	O
,	O
were	O
found	O
in	O
nvA	O
(	O
H1N1	O
)	O
groups	O
.	O

These	O
cytokines	O
,	O
except	O
TNF	O
,	O
had	O
a	O
positive	O
correlation	O
with	O
the	O
admission	O
delay	O
and	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
a	O
negative	O
correlation	O
with	O
the	O
PaO	B-ENZY
(	O
2	O
):	O
FiO	O
(	O
2	O
)	O
ratio	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
-	O
like	O
virus	O
in	O
a	O
leaf	O
-	O
nosed	O
bat	B-ENZY
in	O
Nigeria	O
.	O

In	O
the	O
course	O
of	O
a	O
project	O
focused	O
on	O
pathogen	O
discovery	O
in	O
contexts	O
where	O
human	O
-	O
bat	B-ENZY
contact	O
might	O
facilitate	O
more	O
efficient	O
interspecies	O
transmission	O
of	O
viruses	O
,	O
we	O
surveyed	O
gastrointestinal	O
tissue	O
obtained	O
from	O
bats	O
collected	O
in	O
caves	O
in	O
Nigeria	O
that	O
are	O
frequented	O
by	O
humans	O
.	O

It	O
is	O
caused	O
due	O
to	O
release	O
of	O
nitrogen	O
gas	B-ENZY
bubbles	O
that	O
impinge	O
the	O
blood	O
vessels	O
of	O
the	O
spinal	O
cord	O
and	O
brain	O
and	O
result	O
in	O
severe	O
neurodeficit	O
.	O

TITLE	O
:	O
Expression	O
of	O
neutral	B-ENZY
endopeptidase	I-ENZY
activity	O
during	O
clinical	O
and	O
experimental	O
acute	O
lung	O
injury	O
.	O

All	O
other	O
measures	O
of	O
lung	O
capacity	O
or	O
blood	O
gas	B-ENZY
assessments	O
were	O
less	O
valuable	O
than	O
V	O
(	O
T	O
)	O
in	O
predicting	O
survival	O
.	O

Thrombolysis	O
during	O
spontaneous	O
circulation	O
only	O
for	O
myocardial	O
infarction	O
or	O
massive	O
pulmonary	O
embolism	O
;	O
during	O
on	O
-	O
going	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	B-ENZY
)	O
only	O
when	O
indications	O
of	O
massive	O
pulmonary	O
embolism	O
.	O

Active	O
compression	O
-	O
decompression	O
(	O
ACD	O
-	O
CPR	B-ENZY
)	O
and	O
inspiratory	O
threshold	O
valve	O
(	O
ITV	O
-	O
CPR	B-ENZY
)	O
are	O
not	O
superior	O
to	O
good	O
standard	O
CPR	B-ENZY
.	O

Defibrillation	O
(	O
4	O
J	O
/	O
kgBW	O
;	O
monophasic	O
or	O
biphasic	O
)	O
followed	O
by	O
2	O
min	O
CPR	B-ENZY
,	O
then	O
ECG	O
and	O
pulse	O
check	O
.	O

Prediction	O
of	O
CPR	B-ENZY
outcome	O
is	O
not	O
possible	O
at	O
the	O
scene	O
,	O
determine	O
neurological	O
outcome	O
<	O
72	O
h	O
after	O
cardiac	O
arrest	O
with	O
somatosensory	O
evoked	O
potentials	O
,	O
biochemical	O
tests	O
and	O
neurological	O
examination	O
.	O

4000	O
IU	O
),	O
enoxaparin	O
,	O
bivalirudin	O
or	O
fondaparinux	O
depending	O
on	O
the	O
diagnosis	O
(	O
STEMI	O
or	O
non	O
-	O
STEMI	O
-	O
ACS	B-ENZY
)	O
and	O
the	O
planned	O
therapeutic	O
strategy	O
.	O

For	O
successful	O
CPR	B-ENZY
of	O
trauma	O
patients	O
a	O
minimal	O
intravascular	O
volume	O
status	O
and	O
management	O
of	O
hypoxia	O
are	O
essential	O
.	O

Any	O
CPR	B-ENZY
training	O
is	O
better	O
than	O
nothing	O
;	O
simplification	O
of	O
contents	O
and	O
processes	O
is	O
the	O
main	O
aim	O
.	O

Proximal	O
skeletal	O
muscle	O
symptoms	O
and	O
signs	O
,	O
elevation	O
of	O
creatine	B-ENZY
kinase	I-ENZY
,	O
and	O
myogenic	O
changes	O
in	O
electromyography	O
were	O
found	O
in	O
all	O
of	O
the	O
cases	O
,	O
and	O
magnetic	O
resonance	O
imaging	O
clearly	O
revealed	O
thickening	O
of	O
the	O
fascia	O
.	O

Neonates	O
who	O
received	O
opioid	O
infusion	O
had	O
higher	O
risk	O
for	O
mortality	O
(	O
adjusted	O
odds	O
ratio	O
[	O
AOR	B-ENZY
]	O
1	O
.	O
57	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1	O
.	O
13	O
,	O
2	O
.	O
18	O
),	O
severe	O
neurological	O
injury	O
(	O
AOR	B-ENZY
1	O
.	O
63	O
,	O
95	O
%	O
CI	O
1	O
.	O
30	O
,	O
2	O
.	O
04	O
),	O
severe	O
retinopathy	O
of	O
prematurity	O
(	O
AOR	B-ENZY
1	O
.	O
39	O
,	O
95	O
%	O
CI	O
1	O
.	O
08	O
,	O
1	O
.	O
79	O
),	O
and	O
bronchopulmonary	O
dysplasia	O
(	O
AOR	B-ENZY
1	O
.	O
36	O
,	O
95	O
%	O
CI	O
1	O
.	O
03	O
,	O
1	O
.	O
79	O
).	O

TITLE	O
:	O
Phage	O
displayed	O
peptides	O
recognizing	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
inhibit	O
transmissible	O
gastroenteritis	O
coronavirus	O
infection	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
is	O
a	O
cellular	O
receptor	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
a	O
porcine	O
coronavirus	O
.	O

Even	O
though	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
)	O
adopts	O
a	O
similar	O
chymotrypsin	B-ENZY
-	O
like	O
fold	O
as	O
that	O
of	O
piconavirus	O
3C	O
protease	O
,	O
the	O
extra	O
C	O
-	O
terminal	O
domain	O
is	O
required	O
for	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
)	O
to	O
be	O
enzymatically	O
active	O
.	O

To	O
evaluate	O
the	O
prevalence	O
and	O
clinical	O
presentations	O
of	O
HKU1	O
and	O
NL63	O
in	O
adults	O
with	O
acute	O
respiratory	O
tract	O
infections	O
,	O
an	O
investigation	O
of	O
HCoV	O
infections	O
in	O
Beijing	O
,	O
China	O
from	O
2005	O
to	O
2009	O
was	O
performed	O
by	O
using	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
assays	O
and	O
sequencing	O
analysis	O
.	O

The	O
packed	O
cell	O
volume	O
,	O
bilirubin	O
,	O
AST	B-ENZY
,	O
potassium	O
,	O
and	O
sodium	O
levels	O
were	O
established	O
to	O
predict	O
disease	O
staging	O
and	O
survival	O
time	O
.	O

The	O
most	O
N	O
-	O
terminal	O
portion	O
of	O
the	O
S1	O
region	O
,	O
which	O
comprises	O
antigenic	O
sites	O
C	O
and	O
B	O
,	O
is	O
needed	O
for	O
the	O
enteric	O
tropism	O
of	O
TGEV	O
,	O
whereas	O
the	O
major	O
antigenic	O
site	O
A	O
at	O
the	O
C	O
-	O
terminal	O
moiety	O
is	O
required	O
for	O
both	O
respiratory	O
and	O
enteric	O
cell	O
tropism	O
,	O
and	O
is	O
engaged	O
in	O
recognition	O
of	O
the	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
)	O
receptor	O
.	O

Papain	B-ENZY
treatment	O
identified	O
an	O
N	O
-	O
terminal	O
domain	O
(	O
D1	O
)	O
resistant	O
to	O
proteolysis	O
,	O
whereas	O
receptor	O
binding	O
defined	O
a	O
soluble	O
and	O
functional	O
APN	O
receptor	O
-	O
binding	O
domain	O
(	O
D3	O
).	O

ABSTRACT	O
:	O
Hantaviruses	O
have	O
previously	O
been	O
recognised	O
to	O
cause	O
two	O
separate	O
syndromes	O
:	O
hemorrhagic	O
fever	O
with	O
renal	O
syndrome	O
in	O
Eurasia	O
,	O
and	O
hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	B-ENZY
)	O
in	O
the	O
Americas	O
.	O

Herein	O
are	O
presented	O
three	O
cases	O
of	O
severe	O
European	O
Puumala	O
hantavirus	O
infection	O
that	O
meet	O
the	O
HPS	B-ENZY
case	O
definition	O
.	O

Myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
and	O
	O
-	O
defensins	O
were	O
monitored	O
as	O
indices	O
of	O
neutrophil	O
activity	O
.	O

The	O
herd	O
status	O
regarding	O
the	O
calves	O
'	O
passive	O
transfer	O
(	O
total	O
protein	O
),	O
levels	O
of	O
	O
-	O
tocopherol	O
,	O
	O
-	O
carotene	O
and	O
retinol	O
,	O
and	O
excretion	O
of	O
faecal	O
pathogens	O
(	O
Cryptosporidium	O
spp	B-ENZY
.,	O
Escherichia	O
coli	O
F5	O
,	O
rota	O
and	O
corona	O
virus	O
)	O
was	O
evaluated	O
based	O
on	O
targeted	O
sampling	O
of	O
high	O
risk	O
calf	O
groups	O
;	O
in	O
each	O
herd	O
,	O
blood	O
and	O
faecal	O
samples	O
were	O
collected	O
from	O
calves	O
1	O
-	O
7	O
and	O
1	O
-	O
14	O
days	O
old	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
),	O
a	O
deubiquitinating	O
enzyme	O
,	O
reportedly	O
blocks	O
poly	O
I	O
:	O
C	O
-	O
induced	O
activation	O
of	O
interferon	O
regulatory	O
factor	O
3	O
and	O
nuclear	O
factor	O
kappa	O
B	O
,	O
reducing	O
interferon	O
(	O
IFN	O
)	O
induction	O
.	O

A	O
proteomics	O
approach	O
demonstrated	O
downregulation	O
of	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
(	O
ERK	B-ENZY
)	O
1	O
and	O
upregulation	O
of	O
ubiquitin	B-ENZY
-	I-ENZY
conjugating	I-ENZY
enzyme	I-ENZY
(	O
UBC	O
)	O
E2	O
-	O
25k	O
as	O
inhibitory	O
mechanism	O
of	O
PLpro	O
on	O
IFN	O
-	O
	O
-	O
induced	O
responses	O
.	O

Combination	O
treatment	O
of	O
IFN	O
-	O
	O
and	O
the	O
proteasome	B-ENZY
inhibitor	O
MG	O
-	O
132	O
showed	O
a	O
time	O
-	O
dependent	O
restoration	O
of	O
ERK1	O
protein	O
levels	O
and	O
significant	O
increase	O
of	O
ERK1	O
,	O
STAT1	O
and	O
c	O
-	O
Jun	O
phosphorylation	O
in	O
PLpro	O
-	O
expressing	O
cells	O
.	O

Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
can	O
ensure	O
life	O
-	O
sustaining	O
gas	B-ENZY
exchange	O
in	O
patients	O
with	O
severe	O
vitally	O
compromised	O
pulmonary	O
failure	O
,	O
to	O
provide	O
time	O
for	O
lung	O
tissue	O
to	O
heal	O
and	O
reduce	O
ventilatory	O
stress	O
.	O

The	O
most	O
obvious	O
example	O
is	O
anti	O
-	O
AIDS	O
research	O
,	O
where	O
HIV	O
protease	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
have	O
triggered	O
enormous	O
efforts	O
in	O
developing	O
and	O
improving	O
computational	O
methods	O
.	O

We	O
discuss	O
the	O
role	O
of	O
computational	O
chemistry	O
in	O
the	O
development	O
of	O
small	O
molecules	O
as	O
agents	O
against	O
HIV	O
integrase	O
,	O
HIV	O
-	O
1	O
protease	O
,	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
,	O
the	O
influenza	O
virus	O
M2	O
channel	O
protein	O
,	O
influenza	O
virus	O
neuraminidase	B-ENZY
,	O
the	O
SARS	O
coronavirus	O
main	O
proteinase	O
and	O
spike	O
protein	O
,	O
thymidine	O
kinases	O
of	O
herpes	O
viruses	O
,	O
hepatitis	O
c	O
virus	O
proteins	O
and	O
other	O
flaviviruses	O
as	O
well	O
as	O
human	O
rhinovirus	O
coat	O
protein	O
and	O
proteases	O
,	O
and	O
other	O
picornaviridae	O
.	O

ABSTRACT	O
:	O
The	O
leader	O
proteinase	O
(	O
L	O
(	O
pro	O
))	O
of	O
foot	O
-	O
and	O
-	O
mouth	O
disease	O
virus	O
(	O
FMDV	O
)	O
is	O
a	O
papain	B-ENZY
-	O
like	O
proteinase	O
that	O
plays	O
an	O
important	O
role	O
in	O
FMDV	O
pathogenesis	O
.	O

Furthermore	O
,	O
Lb	O
(	O
pro	O
)	O
significantly	O
inhibited	O
ubiquitination	O
of	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
I	O
(	O
RIG	O
-	O
I	O
),	O
TANK	B-ENZY
-	I-ENZY
binding	I-ENZY
kinase	I-ENZY
1	I-ENZY
(	O
TBK1	B-ENZY
),	O
TNF	O
receptor	O
-	O
associated	O
factor	O
6	O
(	O
TRAF6	O
),	O
and	O
TRAF3	O
,	O
key	O
signaling	O
molecules	O
in	O
activation	O
of	O
type	O
I	O
IFN	O
response	O
.	O

ABSTRACT	O
:	O
Sixteen	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
field	O
isolates	O
obtained	O
from	O
vaccinated	O
commercial	O
broiler	O
chickens	O
showing	O
clinical	O
respiratory	O
disease	O
were	O
characterized	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
and	O
sequence	O
analysis	O
of	O
the	O
hypervariable	O
region	O
of	O
the	O
S1	O
spike	O
glycoprotein	O
gene	O
.	O

ABSTRACT	O
:	O
To	O
detect	O
the	O
presence	O
of	O
infectious	O
bronchitis	O
virus	O
or	O
avian	O
coronavirus	O
,	O
a	O
nested	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
method	O
was	O
developed	O
with	O
the	O
aim	O
of	O
amplifying	O
a	O
fragment	O
of	O
530	O
bases	O
,	O
comprising	O
the	O
gene	O
coding	O
S1	O
protein	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
can	O
achieve	O
sufficient	O
gas	B-ENZY
exchange	O
in	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Six	O
female	O
pigs	O
were	O
connected	O
to	O
venovenous	O
HEXMO	O
with	O
a	O
total	O
priming	O
volume	O
of	O
125	O
ml	O
for	O
4	O
hours	O
during	O
hypoxemia	O
induced	O
by	O
a	O
hypoxic	O
inspired	O
gas	B-ENZY
mixture	O
.	O

Subsequently	O
,	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
assays	O
for	O
the	O
detection	O
of	O
51	O
immune	O
-	O
related	O
and	O
four	O
internal	O
reference	O
genes	O
were	O
developed	O
.	O

TITLE	O
:	O
Alizarine	O
derivatives	O
as	O
new	O
dual	O
inhibitors	O
of	O
the	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
associated	O
DNA	O
polymerase	O
and	O
RNase	B-ENZY
H	I-ENZY
activities	O
effective	O
also	O
on	O
the	O
RNase	B-ENZY
H	I-ENZY
activity	O
of	O
non	O
-	O
nucleoside	O
resistant	O
reverse	O
transcriptases	O
.	O

ABSTRACT	O
:	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)	O
has	O
two	O
associated	O
activities	O
,	O
DNA	O
polymerase	O
and	O
RNase	B-ENZY
H	I-ENZY
,	O
both	O
essential	O
for	O
viral	O
replication	O
and	O
validated	O
drug	O
targets	O
.	O

When	O
tested	O
on	O
the	O
K103N	O
RT	O
,	O
both	O
derivatives	O
inhibited	O
the	O
RT	O
-	O
associated	O
functions	O
equally	O
,	O
whereas	O
when	O
tested	O
on	O
the	O
Y181C	O
RT	O
,	O
KNA	O
-	O
53	O
inhibited	O
the	O
RNase	B-ENZY
H	I-ENZY
function	O
and	O
was	O
inactive	O
on	O
the	O
polymerase	O
function	O
.	O

Kinetic	O
studies	O
demonstrated	O
that	O
they	O
are	O
noncompetitive	O
inhibitors	O
,	O
they	O
do	O
not	O
bind	O
to	O
the	O
RNase	B-ENZY
H	I-ENZY
active	O
site	O
or	O
to	O
the	O
classical	O
NNRTI	O
binding	O
pocket	O
,	O
even	O
though	O
efavirenz	O
binding	O
negatively	O
influenced	O
K	O
-	O
49	O
/	O
KNA	O
-	O
53	O
binding	O
and	O
vice	O
versa	O
.	O

TITLE	O
:	O
PLP2	O
of	O
mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
targets	O
TBK1	B-ENZY
to	O
negatively	O
regulate	O
cellular	O
type	O
I	O
interferon	O
signaling	O
pathway	O
.	O

Here	O
we	O
provide	O
further	O
evidence	O
that	O
PLP2	O
may	O
also	O
target	O
TANK	O
-	O
binding	O
kinase	O
-	O
1	O
(	O
TBK1	B-ENZY
),	O
the	O
upstream	O
kinase	O
of	O
IRF3	O
in	O
the	O
IFN	O
signaling	O
pathway	O
.	O

Albeit	O
promiscuous	O
in	O
deubiquitinating	O
cellular	O
proteins	O
,	O
PLP2	O
inactivated	O
TBK1	B-ENZY
and	O
IFN	O
-	O
	O
response	O
in	O
TNF	O
receptor	O
associated	O
factor	O
3	O
(	O
TRAF3	O
)	O
deficient	O
cells	O
,	O
suggesting	O
that	O
targeting	O
TBK1	B-ENZY
would	O
be	O
sufficient	O
for	O
PLP2	O
to	O
inhibit	O
IRF3	O
activation	O
.	O

This	O
notion	O
was	O
further	O
supported	O
by	O
in	O
vitro	O
kinase	O
assays	O
,	O
in	O
which	O
prior	O
treatment	O
of	O
TBK1	B-ENZY
with	O
PLP2	O
inhibited	O
its	O
kinase	O
activity	O
to	O
phosphorylate	O
IRF3	O
.	O

Intriguing	O
enough	O
,	O
results	O
of	O
PLP2	O
overexpression	O
system	O
and	O
MHV	O
-	O
A59	O
infection	O
system	O
proved	O
that	O
PLP2	O
formed	O
an	O
inactive	O
complex	O
with	O
TBK1	B-ENZY
and	O
IRF3	O
in	O
the	O
cytoplasm	O
and	O
the	O
presence	O
of	O
PLP2	O
stabilized	O
the	O
hypo	O
-	O
phosphorylated	O
IRF3	O
-	O
TBK1	B-ENZY
complex	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
results	O
suggest	O
that	O
PLP2	O
not	O
only	O
inactivates	O
TBK1	B-ENZY
,	O
but	O
also	O
prevents	O
IRF3	O
nuclear	O
translocation	O
hence	O
inhibits	O
IFN	O
transcription	O
activation	O
.	O

ABSTRACT	O
:	O
Since	O
1997	O
,	O
we	O
have	O
routinely	O
used	O
prone	O
positioning	O
(	O
PP	O
)	O
in	O
patients	O
who	O
have	O
a	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
below	O
100	O
mmHg	O
after	O
24	O
-	O
48	O
h	O
of	O
mechanical	O
ventilation	O
and	O
who	O
are	O
ventilated	O
using	O
a	O
low	O
stretch	O
ventilation	O
strategy	O
.	O

Of	O
these	O
patients	O
,	O
57	O
(	O
26	O
%)	O
were	O
positioned	O
prone	O
because	O
of	O
a	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
below	O
100	O
mmHg	O
after	O
24	O
-	O
48	O
h	O
of	O
mechanical	O
ventilation	O
.	O

In	O
patients	O
with	O
a	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
below	O
60	O
mmHg	O
,	O
the	O
60	O
-	O
day	O
mortality	O
was	O
28	O
%.	O

We	O
demonstrate	O
the	O
clinical	O
feasibility	O
of	O
routine	O
PP	O
in	O
patients	O
with	O
a	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
below	O
100	O
mmHg	O
after	O
24	O
-	O
48	O
h	O
and	O
suggest	O
that	O
,	O
when	O
combined	O
with	O
a	O
low	O
stretch	O
ventilation	O
strategy	O
,	O
it	O
is	O
protective	O
with	O
a	O
high	O
survival	O
rate	O
.	O

While	O
supportive	O
care	O
and	O
neuraminidase	B-ENZY
inhibitors	O
are	O
the	O
main	O
treatment	O
for	O
influenza	O
,	O
data	O
from	O
observational	O
and	O
interventional	O
studies	O
suggest	O
that	O
the	O
course	O
of	O
influenza	O
can	O
be	O
favorably	O
influenced	O
by	O
agents	O
not	O
classically	O
considered	O
as	O
influenza	O
treatments	O
.	O

ABSTRACT	O
:	O
Despite	O
utilizing	O
the	O
same	O
chymotrypsin	B-ENZY
fold	O
to	O
host	O
the	O
catalytic	O
machinery	O
,	O
coronavirus	O
3C	O
-	O
like	O
proteases	O
(	O
3CLpro	O
)	O
noticeably	O
differ	O
from	O
picornavirus	O
3C	O
proteases	O
in	O
acquiring	O
an	O
extra	O
helical	O
domain	O
in	O
evolution	O
.	O

TITLE	O
:	O
Amplification	O
of	O
emerging	O
viruses	O
in	O
a	O
bat	B-ENZY
colony	O
.	O

However	O
,	O
the	O
general	O
correlation	O
of	O
virus	O
and	O
bat	B-ENZY
population	O
dynamics	O
suggests	O
that	O
bats	O
control	O
infections	O
similar	O
to	O
other	O
mammals	O
and	O
that	O
they	O
may	O
well	O
experience	O
epidemics	O
of	O
viruses	O
under	O
certain	O
circumstances	O
.	O

Acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
)	O
is	O
an	O
acute	O
lung	O
injury	O
often	O
preceded	O
by	O
a	O
vaso	O
-	O
occlusive	O
crisis	O
and	O
triggered	O
by	O
different	O
factors	O
including	O
:	O
hypoventilation	O
,	O
pulmonary	O
infectious	O
disease	O
and	O
vascular	O
occlusions	O
.	O

Exchange	O
transfusion	O
may	O
be	O
indicated	O
in	O
severe	O
forms	O
of	O
ACS	B-ENZY
,	O
characterized	O
by	O
a	O
right	O
ventricular	O
dysfunction	O
and	O
acute	O
respiratory	O
failure	O
.	O

Studying	O
RVP	O
FAST	O
efficacy	O
in	O
detecting	O
respiratory	O
viruses	O
in	O
67	O
aspirate	O
samples	O
from	O
the	O
nasal	O
cavities	O
of	O
children	O
with	O
acute	O
respiratory	O
infection	O
,	O
we	O
compared	O
RVP	O
FAST	O
results	O
to	O
those	O
of	O
conventional	O
nucleic	O
acid	O
amplification	O
tests	O
(	O
NAT	B-ENZY
),	O
e	O
.	O
g	O
.,	O
real	O
-	O
time	O
PCR	O
,	O
targeting	O
8	O
strains	O
.	O

V	O
-	O
B	O
,	O
and	O
adenovirus	O
,	O
RS	O
virus	O
,	O
metapneumovirus	O
,	O
and	O
bocavirus	O
--	O
were	O
compared	O
to	O
NAT	B-ENZY
results	O
.	O

RVP	O
FAST	O
showed	O
higher	O
sensitivity	O
(	O
83	O
.	O
3	O
-	O
100	O
%)	O
and	O
specificity	O
(	O
98	O
.	O
2	O
-	O
100	O
%)	O
than	O
NAT	B-ENZY
.	O

A	O
case	O
-	O
control	O
study	O
was	O
carried	O
out	O
to	O
compare	O
the	O
carriage	O
of	O
some	O
common	O
canine	O
enteric	O
pathogens	O
(	O
enteric	O
coronavirus	O
,	O
parvovirus	O
,	O
distemper	O
,	O
endoparasites	O
,	O
Campylobacter	O
and	O
Salmonella	O
spp	B-ENZY
.),	O
as	O
well	O
as	O
lifestyle	O
factors	O
such	O
as	O
vaccination	O
history	O
,	O
diet	O
and	O
contact	O
with	O
other	O
species	O
,	O
in	O
dogs	O
presenting	O
at	O
first	O
opinion	O
veterinary	O
practices	O
with	O
and	O
without	O
diarrhoea	O
.	O

Laboratory	O
data	O
revealed	O
severe	O
renal	O
insufficiency	O
and	O
positive	O
titers	O
for	O
the	O
myeloperoxidase	B-ENZY
anti	O
-	O
neutrophil	O
cytoplasmic	O
and	O
anti	O
-	O
glomerular	O
basement	O
membrane	O
antibodies	O
.	O

Real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
was	O
used	O
for	O
detection	O
of	O
H1N1	O
virus	O
in	O
the	O
respiratory	O
specimens	O
.	O

To	O
determine	O
whether	O
the	O
activity	O
of	O
a	O
C	O
-	O
peptide	O
could	O
be	O
improved	O
by	O
increasing	O
its	O
intracellular	O
concentration	O
,	O
we	O
prepared	O
an	O
EboV	O
C	O
-	O
peptide	O
conjugated	O
to	O
the	O
arginine	O
-	O
rich	O
sequence	O
from	O
HIV	O
-	O
1	O
Tat	B-ENZY
,	O
which	O
is	O
known	O
to	O
accumulate	O
in	O
endosomes	O
.	O

We	O
determined	O
that	O
antiviral	O
activity	O
was	O
dependent	O
on	O
both	O
the	O
Tat	B-ENZY
sequence	O
and	O
the	O
native	O
EboV	O
CHR	O
sequence	O
.	O

The	O
rabbits	O
survived	O
in	O
poor	O
general	O
condition	O
,	O
and	O
arterial	O
partial	O
pressure	O
of	O
oxygen	O
(	O
PaO	B-ENZY
(	O
2	O
))	O
lowered	O
within	O
6	O
hours	O
.	O

Rotavirus	O
was	O
the	O
most	O
common	O
pathogen	O
identified	O
(	O
477	O
/	O
597	O
,	O
79	O
.	O
9	O
%)	O
followed	O
by	O
C	O
.	O
parvum	O
(	O
349	O
/	O
597	O
,	O
58	O
.	O
5	O
%),	O
Salmonella	O
spp	B-ENZY
.	O

Using	O
a	O
newly	O
designed	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
assay	O
specific	O
for	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
turkey	O
coronaviruses	O
(	O
TCoV	O
),	O
coronaviruses	O
were	O
identified	O
in	O
37	O
%	O
of	O
the	O
intestinal	O
samples	O
collected	O
from	O
diseased	O
turkey	O
flocks	O
.	O

While	O
no	O
inhibition	O
of	O
the	O
sialate	O
-	O
4	O
-	O
O	O
-	O
acetylesterases	O
from	O
mouse	O
hepatitis	O
virus	O
strain	O
S	O
or	O
sialodacryoadenitis	O
virus	O
was	O
found	O
,	O
a	O
9	O
-	O
O	O
-	O
methyl	O
derivative	O
displayed	O
inhibitory	O
activity	O
against	O
recombinant	O
sialate	O
-	O
9	O
-	O
O	O
-	O
acetylesterase	B-ENZY
from	O
influenza	O
C	O
virus	O
.	O

Tau	O
phosphorylation	O
was	O
increased	O
via	O
a	O
glycogen	B-ENZY
synthase	I-ENZY
kinase	O
-	O
3	O
-	O
dependent	O
mechanism	O
,	O
and	O
there	O
was	O
a	O
prominent	O
shift	O
of	O
tau	O
from	O
the	O
detergent	O
-	O
soluble	O
to	O
the	O
detergent	O
-	O
insoluble	O
fraction	O
.	O

During	O
chronic	O
inflammation	O
,	O
we	O
found	O
that	O
inhibiting	O
glycogen	B-ENZY
synthase	I-ENZY
kinase	O
-	O
3	O
activity	O
with	O
lithium	O
reduced	O
tau	O
phosphorylation	O
and	O
the	O
accumulation	O
of	O
insoluble	O
tau	O
and	O
reversed	O
memory	O
impairments	O
.	O

The	O
ribosomal	O
frameshifting	O
was	O
inhibited	O
by	O
the	O
PNA	O
,	O
which	O
bound	O
sequence	O
-	O
specifically	O
a	O
pseudoknot	O
structure	O
in	O
the	O
-	O
1	O
PRF	O
signal	O
,	O
in	O
cell	O
lines	O
as	O
assessed	O
using	O
a	O
dual	O
luciferase	B-ENZY
-	O
based	O
reporter	O
plasmid	O
containing	O
the	O
-	O
1	O
PRF	O
signal	O
.	O

Treatment	O
of	O
cells	O
,	O
which	O
were	O
transfected	O
with	O
a	O
SARS	O
-	O
CoV	O
-	O
replicon	O
expressing	O
firefly	B-ENZY
luciferase	I-ENZY
,	O
with	O
the	O
PNA	O
fused	O
to	O
a	O
cell	O
-	O
penetrating	O
peptide	O
(	O
CPP	O
)	O
resulted	O
in	O
suppression	O
of	O
the	O
replication	O
of	O
the	O
SARS	O
-	O
CoV	O
replicon	O
,	O
with	O
a	O
50	O
%	O
inhibitory	O
concentration	O
of	O
4	O
.	O
4M	O
.	O
There	O
was	O
no	O
induction	O
of	O
type	O
I	O
interferon	O
responses	O
by	O
PNA	O
treatment	O
,	O
suggesting	O
that	O
the	O
effect	O
of	O
PNA	O
is	O
not	O
due	O
to	O
innate	O
immune	O
responses	O
.	O

This	O
increase	O
in	O
activity	O
correlates	O
with	O
the	O
activation	O
of	O
ERK	B-ENZY
and	O
JNK	B-ENZY
pathways	O
.	O

The	O
ability	O
of	O
LiCl	O
to	O
inhibit	O
apoptosis	O
was	O
investigated	O
by	O
IF	O
analysis	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
expression	O
.	O

ABSTRACT	O
:	O
Two	O
potential	O
receptors	O
have	O
been	O
described	O
for	O
the	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
):	O
feline	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
fAPN	O
)	O
and	O
feline	O
dendritic	O
cell	O
-	O
specific	O
intercellular	O
adhesion	O
molecule	O
grabbing	O
non	O
-	O
integrin	O
(	O
fDC	O
-	O
SIGN	O
).	O

In	O
-	O
situ	O
hybridization	O
for	O
Pneumocystis	O
spp	B-ENZY
.,	O
Ziehl	O
-	O
Neelsen	O
staining	O
and	O
immunohistochemistry	O
for	O
distemper	O
,	O
coronavirus	O
and	O
influenza	O
antigen	O
were	O
negative	O
in	O
all	O
cases	O
.	O

ABSTRACT	O
:	O
We	O
have	O
shown	O
that	O
mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
A59	O
develop	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	B-ENZY
hydrolase	I-ENZY
(	O
FAH	O
).	O

In	O
order	O
to	O
explore	O
this	O
,	O
we	O
used	O
two	O
different	O
approaches	O
:	O
we	O
infected	O
either	O
Vero	O
cells	O
in	O
the	O
presence	O
of	O
trypsin	B-ENZY
or	O
Vero	O
cells	O
that	O
constitutively	O
express	O
the	O
membrane	O
-	O
associated	O
protease	O
TMPRSS2	O
(	O
Vero	O
/	O
TMPRSS2	O
cells	O
).	O

Under	O
electron	O
microscopy	O
,	O
PEDV	O
-	O
infected	O
Vero	O
cells	O
,	O
as	O
well	O
as	O
PEDV	O
-	O
infected	O
Vero	O
/	O
TMPRSS2	O
cells	O
treated	O
with	O
leupeptin	O
,	O
retained	O
huge	O
clusters	O
of	O
virions	O
on	O
their	O
surfaces	O
,	O
while	O
such	O
clusters	O
were	O
rarely	O
seen	O
in	O
the	O
presence	O
of	O
trypsin	B-ENZY
and	O
the	O
absence	O
of	O
leupeptin	O
in	O
Vero	O
and	O
Vero	O
/	O
TMPRSS2	O
cells	O
,	O
respectively	O
.	O

This	O
unique	O
observation	O
in	O
coronavirus	O
infection	O
suggests	O
that	O
the	O
actions	O
of	O
proteases	O
are	O
reminiscent	O
of	O
that	O
of	O
the	O
influenza	O
virus	O
neuraminidase	B-ENZY
protein	O
.	O

The	O
PEEP	O
was	O
then	O
progressively	O
reduced	O
until	O
the	O
PaO	B-ENZY
(	O
2	O
)	O
decreased	O
by	O
more	O
than	O
10	O
%	O
of	O
the	O
maximum	O
PaO	B-ENZY
(	O
2	O
);	O
the	O
PEEP	O
was	O
subsequently	O
set	O
to	O
2	O
cmH	O
(	O
2	O
)	O
O	O
above	O
this	O
level	O
.	O

Two	O
hours	O
after	O
the	O
RM	O
,	O
the	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
was	O
higher	O
than	O
at	O
baseline	O
(	O
187	O
	O
102	O
versus	O
339	O
	O
136	O
mmHg	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Seven	O
patients	O
did	O
not	O
reach	O
the	O
350	O
-	O
mmHg	O
PaO	B-ENZY
(	O
2	O
)	O
target	O
.	O

RESULTS	O
:	O
Two	O
hours	O
after	O
the	O
RM	O
,	O
the	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
was	O
higher	O
than	O
at	O
baseline	O
(	O
187	O
	O
102	O
versus	O
339	O
	O
136	O
mmHg	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
A59	O
)	O
induces	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
fumarylacetoacetate	B-ENZY
hydrolase	I-ENZY
(	O
FAH	O
),	O
a	O
soluble	O
cytosolic	O
enzyme	O
present	O
in	O
the	O
liver	O
and	O
kidneys	O
,	O
in	O
various	O
mouse	O
strains	O
.	O

We	O
found	O
that	O
an	O
export	O
signal	O
deficient	O
SARS	O
-	O
CoV	O
9b	O
protein	O
induces	O
apoptosis	O
in	O
transiently	O
transfected	O
cells	O
and	O
showed	O
elevated	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
activity	O
.	O

A	O
clinical	O
diagnosis	O
of	O
ACS	B-ENZY
was	O
made	O
.	O

TITLE	O
:	O
Host	O
and	O
viral	O
ecology	O
determine	O
bat	B-ENZY
rabies	O
seasonality	O
and	O
maintenance	O
.	O

Seasonal	O
variability	O
in	O
bat	B-ENZY
mortality	O
rates	O
,	O
specifically	O
low	O
mortality	O
during	O
hibernation	O
,	O
allows	O
long	O
-	O
term	O
bat	B-ENZY
population	O
viability	O
.	O

This	O
research	O
provides	O
a	O
context	O
to	O
explore	O
similar	O
host	O
ecology	O
and	O
viral	O
dynamics	O
that	O
may	O
explain	O
seasonal	O
patterns	O
and	O
maintenance	O
of	O
other	O
bat	B-ENZY
-	O
borne	O
diseases	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
infection	O
in	O
Vero	O
cells	O
is	O
facilitated	O
by	O
trypsin	B-ENZY
through	O
an	O
undefined	O
mechanism	O
.	O

Trypsin	B-ENZY
treatment	O
during	O
the	O
budding	O
stage	O
of	O
virus	O
infection	O
induces	O
an	O
obvious	O
cytopathic	O
effect	O
in	O
infected	O
cells	O
.	O

Furthermore	O
,	O
we	O
also	O
show	O
that	O
the	O
PEDV	O
spike	O
(	O
S	O
)	O
glycoprotein	O
is	O
cleaved	O
by	O
trypsin	B-ENZY
in	O
virions	O
that	O
are	O
bound	O
to	O
the	O
receptor	O
,	O
but	O
not	O
in	O
free	O
virions	O
.	O

These	O
findings	O
indicate	O
that	O
trypsin	B-ENZY
affects	O
only	O
cell	O
-	O
attached	O
PEDV	O
and	O
increases	O
infectivity	O
and	O
syncytium	O
formation	O
in	O
PEDV	O
-	O
infected	O
Vero	O
cells	O
by	O
cleavage	O
of	O
the	O
PEDV	O
S	O
protein	O
.	O

ABSTRACT	O
:	O
Acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
)	O
is	O
a	O
frequent	O
cause	O
of	O
morbidity	O
and	O
leading	O
cause	O
of	O
death	O
among	O
individuals	O
with	O
sickle	O
cell	O
disease	O
.	O

Yet	O
,	O
ACS	B-ENZY
in	O
hemoglobin	O
SC	O
disease	O
is	O
not	O
well	O
characterized	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
presentation	O
and	O
clinical	O
course	O
of	O
ACS	B-ENZY
in	O
individuals	O
with	O
hemoglobin	O
SC	O
disease	O
to	O
that	O
observed	O
in	O
individuals	O
with	O
hemoglobin	O
SS	O
disease	O
.	O

We	O
retrospectively	O
reviewed	O
71	O
inpatient	O
episodes	O
of	O
ACS	B-ENZY
in	O
patients	O
with	O
hemoglobin	O
SC	O
disease	O
over	O
a	O
20	O
-	O
year	O
period	O
.	O

In	O
our	O
multivariate	O
regression	O
model	O
,	O
time	O
to	O
ACS	B-ENZY
diagnosis	O
and	O
total	O
number	O
of	O
days	O
of	O
oxygen	O
supplementation	O
were	O
independent	O
predictors	O
of	O
length	O
of	O
hospitalization	O
in	O
both	O
hemoglobin	O
SC	O
and	O
SS	O
episodes	O
of	O
ACS	B-ENZY
.	O

ACS	B-ENZY
appears	O
to	O
be	O
less	O
severe	O
in	O
children	O
with	O
hemoglobin	O
SC	O
disease	O
compared	O
to	O
that	O
in	O
children	O
with	O
SS	O
disease	O
.	O

Asthma	O
and	O
wheezing	O
may	O
represent	O
more	O
significant	O
risk	O
factors	O
for	O
the	O
development	O
of	O
ACS	B-ENZY
in	O
children	O
with	O
hemoglobin	O
SC	O
disease	O
.	O

In	O
our	O
multivariate	O
regression	O
model	O
,	O
time	O
to	O
ACS	B-ENZY
diagnosis	O
and	O
total	O
number	O
of	O
days	O
of	O
oxygen	O
supplementation	O
were	O
independent	O
predictors	O
of	O
length	O
of	O
hospitalization	O
in	O
both	O
hemoglobin	O
SC	O
and	O
SS	O
episodes	O
of	O
ACS	B-ENZY
.	O

TITLE	O
:	O
Physiology	O
of	O
gas	B-ENZY
exchange	O
during	O
anaesthesia	O
.	O

Even	O
the	O
induction	O
of	O
anaesthesia	O
disturbs	O
the	O
physiological	O
lung	O
function	O
,	O
due	O
to	O
changes	O
in	O
chest	O
wall	O
mechanics	O
and	O
diaphragm	O
relaxation	O
,	O
generating	O
atelectases	O
,	O
gas	B-ENZY
exchange	O
disturbance	O
and	O
ventilation	O
-	O
perfusion	O
mismatch	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
are	O
associated	O
with	O
impaired	O
gas	B-ENZY
exchange	O
,	O
severe	O
inflammation	O
and	O
alveolar	O
damage	O
including	O
cell	O
death	O
.	O

Recent	O
developments	O
in	O
this	O
field	O
have	O
revealed	O
several	O
therapeutic	O
strategies	O
that	O
improve	O
gas	B-ENZY
exchange	O
,	O
increase	O
survival	O
and	O
minimize	O
the	O
deleterious	O
effects	O
of	O
mechanical	O
ventilation	O
.	O

pECLA	O
is	O
an	O
effective	O
and	O
manageable	O
technique	O
to	O
support	O
gas	B-ENZY
exchange	O
in	O
ARDS	O
patients	O
.	O

CONCLUSIONS	O
:	O
pECLA	O
is	O
an	O
effective	O
and	O
manageable	O
technique	O
to	O
support	O
gas	B-ENZY
exchange	O
in	O
ARDS	O
patients	O
.	O

In	O
this	O
review	O
,	O
those	O
variables	O
are	O
defined	O
as	O
PaO	B-ENZY
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
	O
100	O
mm	O
Hg	O
and	O
	O
15	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
respectively	O
.	O

The	O
meta	O
-	O
analysis	O
on	O
individual	O
data	O
of	O
these	O
three	O
studies	O
showed	O
that	O
the	O
hospital	O
mortality	O
was	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
of	O
patients	O
,	O
was	O
significantly	O
lower	O
in	O
the	O
higher	O
PEEP	O
group	O
in	O
the	O
subset	O
of	O
ARDS	O
patients	O
(	O
PaO	B-ENZY
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
	O
200	O
mm	O
Hg	O
),	O
and	O
tended	O
to	O
be	O
higher	O
in	O
the	O
higher	O
PEEP	O
group	O
in	O
the	O
subset	O
of	O
patients	O
with	O
acute	O
lung	O
injury	O
(	O
200	O
<	O
PaO	B-ENZY
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
	O
300	O
mm	O
Hg	O
).	O

All	O
the	O
patients	O
received	O
neuraminidase	B-ENZY
inhibitors	O
(	O
oseltaminir	O
),	O
while	O
60	O
patients	O
(	O
96	O
.	O
7	O
%)	O
were	O
treated	O
with	O
antibiotics	O
,	O
and	O
39	O
(	O
62	O
.	O
9	O
%)	O
with	O
corticosteroids	O
.	O

She	O
was	O
treated	O
for	O
influenza	O
,	O
which	O
was	O
isolated	O
repeatedly	O
from	O
oropharynx	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluids	O
,	O
and	O
later	O
empirically	O
for	O
lupus	O
pneumonitis	O
,	O
but	O
died	O
6	O
months	O
after	O
transplant	O
.	O

siRNA	O
-	O
mediated	O
knockdown	O
of	O
the	O
expression	O
of	O
the	O
prominent	O
CsA	O
targets	O
cyclophilin	B-ENZY
A	O
and	O
B	O
did	O
not	O
affect	O
SARS	O
-	O
CoV	O
replication	O
,	O
suggesting	O
either	O
that	O
these	O
specific	O
cyclophilin	B-ENZY
family	O
members	O
are	O
dispensable	O
or	O
that	O
the	O
reduced	O
expression	O
levels	O
suffice	O
to	O
support	O
replication	O
.	O

TITLE	O
:	O
Overexpression	O
of	O
pulmonary	O
extracellular	O
superoxide	B-ENZY
dismutase	I-ENZY
attenuates	O
endotoxin	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
Renin	B-ENZY
-	O
angiotensin	O
II	O
-	O
aldosterone	O
axis	O
has	O
long	O
been	O
known	O
as	O
a	O
regulator	O
of	O
blood	O
pressure	O
and	O
fluid	O
homeostasis	O
.	O

Yet	O
,	O
local	O
renin	B-ENZY
-	O
angiotensin	O
II	O
systems	O
have	O
been	O
discovered	O
and	O
novel	O
actions	O
of	O
angiotensin	O
II	O
(	O
AngII	O
)	O
have	O
emerged	O
among	O
which	O
its	O
ability	O
to	O
act	O
as	O
a	O
immunomodulator	O
and	O
profibrotic	O
molecule	O
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
review	O
data	O
from	O
studies	O
of	O
the	O
past	O
decade	O
that	O
implicate	O
AngII	O
and	O
functional	O
polymorphisms	O
of	O
the	O
ACE	B-ENZY
gene	O
that	O
increase	O
ACE	B-ENZY
activity	O
with	O
increased	O
susceptibility	O
for	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
and	O
for	O
pulmonary	O
hypertension	O
.	O

Moreover	O
,	O
drugs	O
that	O
inhibit	O
the	O
synthesis	O
of	O
AngII	O
(	O
ACE	B-ENZY
inhibitors	O
)	O
or	O
that	O
antagonize	O
its	O
actions	O
on	O
its	O
receptors	O
(	O
Angiotensin	O
II	O
receptor	O
blockers	O
-	O
ARBs	O
)	O
have	O
been	O
shown	O
to	O
provide	O
beneficial	O
effects	O
.	O

Another	O
recent	O
discovery	O
reviewed	O
is	O
the	O
presence	O
of	O
a	O
homologue	O
of	O
ACE	B-ENZY
,	O
ACE2	O
,	O
which	O
cleaves	O
a	O
single	O
amino	O
acid	O
from	O
AngII	O
and	O
forms	O
a	O
heptapeptide	O
with	O
vasodilatory	O
actions	O
,	O
Ang	O
1	O
-	O
7	O
.	O

ACE	B-ENZY
and	O
ACE2	O
also	O
appear	O
to	O
modify	O
the	O
severity	O
of	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
),	O
with	O
ACE2	O
playing	O
a	O
protective	O
role	O
.	O

TITLE	O
:	O
SARS	O
-	O
Coronavirus	O
ancestor	O
'	O
s	O
foot	O
-	O
prints	O
in	O
South	O
-	O
East	O
Asian	O
bat	B-ENZY
colonies	O
and	O
the	O
refuge	O
theory	O
.	O

Two	O
new	O
coronaviruses	O
were	O
detected	O
in	O
two	O
bat	B-ENZY
species	O
:	O
one	O
Betacoronavirus	O
in	O
Hipposideros	O
larvatus	O
and	O
one	O
Alphacoronavirus	O
in	O
Hipposiderosarmiger	O
.	O

Moreover	O
,	O
despite	O
its	O
probable	O
pathogenicity	O
,	O
we	O
found	O
that	O
a	O
Betacoronavirus	O
-	O
b	O
can	O
persistently	O
infect	O
a	O
medium	O
-	O
sized	O
hipposiderid	O
bat	B-ENZY
colony	O
.	O

We	O
included	O
190	O
consecutive	O
adults	O
treated	O
with	O
high	O
-	O
frequency	O
oscillation	O
and	O
retrospectively	O
abstracted	O
data	O
on	O
patient	O
demographics	O
,	O
gas	B-ENZY
exchange	O
,	O
hemodynamics	O
,	O
settings	O
during	O
conventional	O
ventilation	O
and	O
high	O
-	O
frequency	O
oscillation	O
,	O
adjunctive	O
therapies	O
,	O
and	O
outcomes	O
.	O

TITLE	O
:	O
Detection	O
of	O
alpha	O
and	O
betacoronaviruses	O
in	O
multiple	O
Iberian	O
bat	B-ENZY
species	O
.	O

ABSTRACT	O
:	O
Bat	B-ENZY
coronaviruses	O
(	O
CoV	O
)	O
are	O
putative	O
precursors	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
CoV	O
and	O
other	O
CoV	O
that	O
crossed	O
the	O
species	O
barrier	O
from	O
zoonotic	O
reservoirs	O
into	O
the	O
human	O
population	O
.	O

To	O
determine	O
the	O
presence	O
and	O
distribution	O
of	O
CoV	O
in	O
Iberian	O
bats	O
,	O
576	O
individuals	O
of	O
26	O
different	O
bat	B-ENZY
species	O
were	O
captured	O
in	O
13	O
locations	O
in	O
Spain	O
.	O

We	O
report	O
for	O
the	O
first	O
time	O
the	O
presence	O
of	O
14	O
coronaviruses	O
in	O
9	O
Iberian	O
bat	B-ENZY
species	O
.	O

Examination	O
of	O
the	O
cellular	O
PDZ	O
proteins	O
that	O
are	O
targets	O
of	O
viral	O
PBMs	O
reveals	O
that	O
the	O
viral	O
proteins	O
often	O
interact	O
with	O
the	O
same	O
or	O
similar	O
types	O
of	O
PDZ	O
proteins	O
,	O
most	O
notably	O
Dlg1	O
and	O
other	O
members	O
of	O
the	O
membrane	O
-	O
associated	O
guanylate	B-ENZY
kinase	I-ENZY
protein	O
family	O
,	O
as	O
well	O
as	O
Scribble	O
.	O

ABSTRACT	O
:	O
This	O
article	O
presents	O
experimental	O
results	O
that	O
illustrate	O
the	O
unsteady	O
characteristics	O
of	O
gas	B-ENZY
dispersion	O
around	O
a	O
complex	O
-	O
shaped	O
high	O
-	O
rise	O
building	O
for	O
different	O
incident	O
wind	O
directions	O
.	O

In	O
the	O
BAL	B-ENZY
samples	O
,	O
only	O
one	O
of	O
the	O
analysed	O
cytokines	O
,	O
IL	O
-	O
1	O
was	O
present	O
at	O
detectable	O
levels	O
in	O
two	O
patients	O
(	O
21	O
pg	O
/	O
ml	O
and	O
11	O
pg	O
/	O
ml	O
respectively	O
).	O

The	O
average	O
arterial	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
was	O
significantly	O
decreased	O
to	O
126	O
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
in	O
pain	O
or	O
ACS	B-ENZY
rate	O
,	O
lung	O
function	O
,	O
or	O
risk	O
of	O
death	O
between	O
adults	O
with	O
and	O
without	O
a	O
doctor	O
-	O
diagnosis	O
of	O
asthma	O
.	O

Further	O
disorders	O
in	O
term	O
neonates	O
include	O
meconium	O
aspiration	O
syndrome	O
and	O
congenital	O
diaphragmatic	O
hernia	O
leading	O
to	O
impaired	O
gas	B-ENZY
exchange	O
and	O
pulmonary	O
hypertension	O
.	O

In	O
preterm	O
neonates	O
,	O
respiratory	O
distress	O
syndrome	O
is	O
the	O
main	O
disorder	O
leading	O
to	O
severe	O
acute	O
and	O
long	O
-	O
term	O
impaired	O
gas	B-ENZY
exchange	O
.	O

The	O
following	O
results	O
were	O
obtained	O
:	O
pressure	O
catecholamine	O
index	O
significantly	O
decreased	O
at	O
3	O
h	O
after	O
initiation	O
of	O
septic	O
shock	O
,	O
PaO	B-ENZY
(	O
2	O
)/	O
F	O
(	O
IO2	O
)	O
significantly	O
increased	O
at	O
1	O
h	O
after	O
initiation	O
of	O
septic	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
a	O
significant	O
decrease	O
in	O
interleukin	O
(	O
IL	O
)-	O
6	O
level	O
for	O
3	O
days	O
was	O
observed	O
,	O
and	O
IL	O
-	O
6	O
was	O
effectively	O
adsorbed	O
in	O
one	O
pass	O
through	O
the	O
filter	O
.	O

TITLE	O
:	O
Complementary	O
roles	O
of	O
Fas	O
-	O
associated	O
death	O
domain	O
(	O
FADD	O
)	O
and	O
receptor	O
interacting	O
protein	B-ENZY
kinase	I-ENZY
-	O
3	O
(	O
RIPK3	O
)	O
in	O
T	O
-	O
cell	O
homeostasis	O
and	O
antiviral	O
immunity	O
.	O

ABSTRACT	O
:	O
Caspase	B-ENZY
-	I-ENZY
8	I-ENZY
(	O
casp8	O
)	O
is	O
required	O
for	O
extrinsic	O
apoptosis	O
,	O
and	O
mice	O
deficient	O
in	O
casp8	O
fail	O
to	O
develop	O
and	O
die	O
in	O
utero	O
while	O
ultimately	O
failing	O
to	O
maintain	O
the	O
proliferation	O
of	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
a	O
host	O
of	O
other	O
cell	O
types	O
.	O

In	O
this	O
study	O
,	O
bat	B-ENZY
coronaviruses	O
(	O
BtCoVs	O
)	O
were	O
detected	O
by	O
RT	O
-	O
PCR	O
from	O
intestinal	O
and	O
fecal	O
specimens	O
of	O
Miniopterus	O
fuliginosus	O
breeding	O
colonies	O
in	O
Wakayama	O
Prefecture	O
caves	O
,	O
where	O
we	O
previously	O
identified	O
bat	B-ENZY
betaherpesvirus	O
2	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
examined	O
the	O
role	O
of	O
cerebral	O
electron	O
transport	O
chain	O
complexes	O
,	O
including	O
complex	O
I	O
,	O
II	O
,	O
III	O
IV	O
,	O
and	O
pyruvate	B-ENZY
dehydrogenase	I-ENZY
in	O
the	O
non	O
-	O
synaptic	O
mitochondria	O
isolated	O
from	O
the	O
cortex	O
of	O
the	O
thioacetamide	O
-	O
induced	O
FHF	O
rats	O
.	O

Further	O
the	O
activity	O
of	O
pyruvate	B-ENZY
dehydrogenase	I-ENZY
at	O
18	O
and	O
24	O
h	O
after	O
the	O
induction	O
of	O
FHF	O
was	O
inhibited	O
by	O
29	O
and	O
43	O
%,	O
respectively	O
.	O

The	O
inhibition	O
of	O
the	O
respiratory	O
complexes	O
III	O
and	O
I	O
and	O
pyruvate	B-ENZY
dehydrogenase	I-ENZY
might	O
lead	O
to	O
the	O
increased	O
production	O
of	O
free	O
radical	O
resulting	O
in	O
oxidative	O
stress	O
and	O
cerebral	O
energy	O
disturbances	O
thereby	O
leading	O
to	O
mitochondrial	O
swelling	O
and	O
further	O
contributing	O
to	O
the	O
pathogenesis	O
of	O
FHF	O
.	O

TITLE	O
:	O
Intermittent	O
recruitment	O
with	O
high	O
-	O
frequency	O
oscillation	O
/	O
tracheal	O
gas	B-ENZY
insufflation	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
In	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
recruitment	O
sessions	O
of	O
high	O
-	O
frequency	O
oscillation	O
(	O
HFO	O
)	O
and	O
tracheal	O
gas	B-ENZY
insufflation	O
(	O
TGI	O
)	O
with	O
short	O
-	O
lasting	O
recruitment	O
manoeuvres	O
(	O
RMs	O
)	O
may	O
improve	O
oxygenation	O
and	O
enable	O
reduction	O
of	O
subsequent	O
conventional	O
mechanical	O
ventilation	O
(	O
CMV	O
)	O
pressures	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
different	O
tidal	O
volumes	O
with	O
associated	O
hypercapnia	O
on	O
lung	O
injury	O
and	O
gas	B-ENZY
exchange	O
in	O
a	O
model	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Cytochrome	B-ENZY
P450	I-ENZY
Family	O
3A	O
(	O
CYP4F3A	O
)	O
is	O
an	O
	O
-	O
oxidase	O
that	O
inactivates	O
Leukotriene	O
B4	O
(	O
LTB4	O
)	O
in	O
human	O
neutrophils	O
and	O
the	O
liver	O
.	O

In	O
the	O
Guangzhou	O
cohort	O
study	O
,	O
after	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
two	O
AHSG	O
SNPs	O
and	O
one	O
CYP4F3	O
SNP	O
were	O
found	O
to	O
be	O
associated	O
with	O
SARS	O
susceptibility	O
:	O
rs2248690	O
(	O
adjusted	O
odds	O
ratio	O
[	O
AOR	B-ENZY
]	O
2	O
.	O
42	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1	O
.	O
30	O
-	O
4	O
.	O
51	O
);	O
rs4917	O
(	O
AOR	B-ENZY
1	O
.	O
84	O
;	O
95	O
%	O
CI	O
1	O
.	O
02	O
-	O
3	O
.	O
34	O
);	O
and	O
rs3794987	O
(	O
AOR	B-ENZY
2	O
.	O
01	O
;	O
95	O
%	O
CI	O
1	O
.	O
10	O
-	O
3	O
.	O
68	O
).	O

The	O
combined	O
analysis	O
of	O
the	O
two	O
studies	O
confirmed	O
tag	O
SNP	O
rs2248690	O
in	O
AHSG	O
as	O
a	O
susceptibility	O
variant	O
(	O
AOR	B-ENZY
1	O
.	O
70	O
;	O
95	O
%	O
CI	O
1	O
.	O
37	O
-	O
2	O
.	O
09	O
).	O

Serologic	O
evidence	O
of	O
exposure	O
to	O
Ehrlichia	O
spp	B-ENZY
.,	O
Feline	O
immunodeficiency	O
virus	O
,	O
and	O
Feline	O
leukemia	O
virus	O
(	O
FeLV	O
)	O
was	O
detected	O
rarely	O
,	O
and	O
infections	O
with	O
FeLV	O
,	O
Ehrlichia	O
spp	B-ENZY
.,	O
and	O
Cytauxzoon	O
spp	B-ENZY
.	O
were	O
found	O
infrequently	O
.	O

Prior	O
to	O
infection	O
,	O
cultured	O
cells	O
were	O
either	O
treated	O
with	O
neuraminidase	B-ENZY
to	O
deplete	O
sialic	O
acids	O
from	O
the	O
cell	O
surface	O
,	O
or	O
mock	O
-	O
treated	O
.	O

Another	O
TGEV	O
strain	O
,	O
TGEV	O
Miller	O
,	O
and	O
IBV	O
Beaudette	O
showed	O
a	O
reduction	O
in	O
infectivity	O
after	O
neuraminidase	B-ENZY
treatment	O
of	O
the	O
cultured	O
cells	O
irrespective	O
of	O
the	O
virion	O
adsorption	O
time	O
.	O

Another	O
TGEV	O
strain	O
,	O
TGEV	O
Miller	O
,	O
and	O
IBV	O
Beaudette	O
showed	O
a	O
reduction	O
in	O
infectivity	O
after	O
neuraminidase	B-ENZY
treatment	O
of	O
the	O
cultured	O
cells	O
irrespective	O
of	O
the	O
virion	O
adsorption	O
time	O
.	O

Nasopharyngeal	O
specimens	O
from	O
children	O
less	O
than	O
16	O
years	O
old	O
who	O
were	O
suffering	O
from	O
acute	O
respiratory	O
diseases	O
were	O
tested	O
for	O
hMPV	O
and	O
HCoV	O
-	O
NL63	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
.	O

The	O
primary	O
endpoint	O
occurred	O
in	O
271	O
PAC	O
patients	O
versus	O
196	O
without	O
PAC	O
(	O
21	O
.	O
3	O
%	O
vs	O
.	O
15	O
.	O
4	O
%;	O
adjusted	O
odds	O
ratio	O
[	O
AOR	B-ENZY
],	O
1	O
.	O
68	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
24	O
to	O
2	O
.	O
26	O
;	O
P	O
<	O
0	O
.	O
001	O
).	O

Use	O
of	O
PAC	O
was	O
also	O
associated	O
with	O
prolonged	O
intensive	O
care	O
unit	O
stay	O
(	O
14	O
.	O
5	O
%	O
vs	O
10	O
.	O
1	O
%;	O
AOR	B-ENZY
,	O
1	O
.	O
55	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
06	O
to	O
2	O
.	O
27	O
;	O
P	O
=	O
0	O
.	O
02	O
).	O

Use	O
of	O
PAC	O
was	O
also	O
associated	O
with	O
prolonged	O
intensive	O
care	O
unit	O
stay	O
(	O
14	O
.	O
5	O
%	O
vs	O
10	O
.	O
1	O
%;	O
AOR	B-ENZY
,	O
1	O
.	O
55	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
06	O
to	O
2	O
.	O
27	O
;	O
P	O
=	O
0	O
.	O
02	O
).	O

Since	O
the	O
RNA	O
pseudoknot	O
located	O
in	O
the	O
frameshifting	O
region	O
of	O
IBV	O
was	O
used	O
as	O
bait	O
for	O
cellular	O
RBPs	O
,	O
we	O
tested	O
whether	O
ANXA2	O
could	O
regulate	O
the	O
frameshfting	O
of	O
IBV	O
pseudoknot	O
RNA	O
by	O
dual	O
luciferase	B-ENZY
assay	O
.	O

TITLE	O
:	O
2	O
,	O
6	O
-	O
Bis	B-ENZY
-	O
arylmethyloxy	O
-	O
5	O
-	O
hydroxychromones	O
with	O
antiviral	O
activity	O
against	O
both	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
and	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SCV	O
).	O

Among	O
those	O
,	O
3	O
-	O
iodobenzyloxy	O
-	O
substituted	O
derivative	O
5e	O
showed	O
the	O
most	O
potent	O
activity	O
against	O
HCV	O
(	O
EC	O
(	O
50	O
)	O
=	O
4	O
M	O
)	O
as	O
well	O
as	O
SCV	O
(	O
IC	O
(	O
50	O
)	O
=	O
4	O
M	O
for	O
ATPase	B-ENZY
activity	O
,	O
11	O
M	O
for	O
helicase	O
activity	O
)	O
and	O
this	O
might	O
be	O
used	O
as	O
a	O
platform	O
structure	O
for	O
future	O
development	O
of	O
the	O
multi	O
-	O
target	O
or	O
broad	O
-	O
spectrum	O
antivirals	O
.	O

Replication	O
of	O
picornaviruses	O
and	O
coronaviruses	O
requires	O
3Cpro	O
(	O
3C	O
protease	O
)	O
and	O
3CLpro	O
(	O
3C	O
-	O
like	O
protease	O
)	O
respectively	O
,	O
which	O
are	O
structurally	O
analogous	O
with	O
chymotrypsin	B-ENZY
-	O
fold	O
,	O
but	O
the	O
former	O
is	O
a	O
monomer	O
and	O
the	O
latter	O
is	O
dimeric	O
due	O
to	O
an	O
extra	O
third	O
domain	O
for	O
dimerization	O
.	O

In	O
this	O
study	O
,	O
the	O
authors	O
evaluated	O
whether	O
bronchoscopic	O
grading	O
of	O
injury	O
clinically	O
correlated	O
with	O
indices	O
of	O
gas	B-ENZY
exchange	O
over	O
the	O
first	O
72	O
hours	O
or	O
predicted	O
differences	O
in	O
hospitalization	O
outcomes	O
.	O

The	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
by	O
controlling	O
gas	B-ENZY
exchange	O
,	O
allowed	O
the	O
performing	O
of	O
a	O
successful	O
liver	O
transplantation	O
and	O
final	O
recovery	O
.	O

TITLE	O
:	O
Regulation	O
of	O
the	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
and	O
dual	O
-	O
specificity	O
phosphatase	O
1	O
feedback	O
loop	O
modulates	O
the	O
induction	O
of	O
interleukin	O
6	O
and	O
8	O
in	O
cells	O
infected	O
with	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
.	O

The	O
results	O
showed	O
that	O
IBV	O
infection	O
of	O
cultured	O
human	O
and	O
animal	O
cells	O
activated	O
the	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
pathway	O
and	O
induced	O
the	O
expression	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
.	O

Meanwhile	O
,	O
IBV	O
has	O
developed	O
a	O
strategy	O
to	O
counteract	O
the	O
induction	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
by	O
inducing	O
the	O
expression	O
of	O
dual	O
-	O
specificity	O
phosphatase	O
1	O
(	O
DUSP1	O
),	O
a	O
negative	O
regulator	O
of	O
the	O
p38	O
MAPK	B-ENZY
,	O
in	O
order	O
to	O
limit	O
the	O
production	O
of	O
an	O
excessive	O
amount	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
in	O
the	O
infected	O
cells	O
.	O

As	O
activation	O
of	O
the	O
p38	O
MAPK	B-ENZY
pathway	O
and	O
induction	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
may	O
have	O
multiple	O
pathogenic	O
effects	O
on	O
the	O
whole	O
host	O
as	O
well	O
as	O
on	O
individual	O
infected	O
cells	O
,	O
regulation	O
of	O
the	O
p38	O
MAPK	B-ENZY
and	O
DUSP1	O
feedback	O
loop	O
by	O
IBV	O
may	O
modulate	O
the	O
pathogenesis	O
of	O
the	O
virus	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
can	O
support	O
gas	B-ENZY
exchange	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
but	O
its	O
role	O
has	O
remained	O
controversial	O
.	O

Patient	O
data	O
were	O
collected	O
,	O
including	O
demographics	O
,	O
percentage	O
of	O
TBSA	O
burn	O
,	O
percentage	O
of	O
full	O
-	O
thickness	O
burn	O
,	O
mechanisms	O
of	O
burn	O
,	O
settings	O
on	O
conventional	O
mechanical	O
ventilation	O
and	O
HFOV	O
,	O
and	O
blood	O
gas	B-ENZY
data	O
before	O
initiation	O
of	O
HFOV	O
and	O
at	O
1	O
,	O
3	O
,	O
6	O
,	O
12	O
,	O
24	O
,	O
72	O
(	O
3	O
days	O
),	O
120	O
(	O
5	O
days	O
),	O
168	O
(	O
7	O
days	O
),	O
240	O
(	O
10	O
days	O
),	O
and	O
336	O
hours	O
(	O
14	O
days	O
).	O

TITLE	O
:	O
Cleavage	O
and	O
activation	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	O
by	O
human	O
airway	O
trypsin	B-ENZY
-	O
like	O
protease	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
role	O
of	O
the	O
type	O
II	O
transmembrane	O
serine	O
proteases	O
(	O
TTSPs	O
)	O
human	O
airway	O
trypsin	B-ENZY
-	O
like	O
protease	O
(	O
HAT	O
)	O
and	O
transmembrane	O
protease	O
,	O
serine	O
2	O
(	O
TMPRSS2	O
),	O
in	O
SARS	O
-	O
S	O
activation	O
.	O

All	O
HCoV	O
-	O
HKU1	O
genomes	O
contain	O
unique	O
tandem	O
copies	O
of	O
a	O
30	O
-	O
base	O
acidic	O
tandem	O
repeat	O
of	O
unknown	O
function	O
at	O
the	O
N	O
-	O
terminus	O
of	O
nsp3	O
inside	O
the	O
acidic	O
domain	O
upstream	O
of	O
papain	B-ENZY
-	O
like	O
protease	O
1	O
.	O

Surfactant	O
has	O
been	O
used	O
to	O
improve	O
pulmonary	O
gas	B-ENZY
exchange	O
for	O
severe	O
respiratory	O
distress	O
in	O
other	O
pediatric	O
populations	O
but	O
has	O
not	O
been	O
studied	O
in	O
pediatric	O
burn	O
-	O
injured	O
patients	O
.	O

Modes	O
of	O
ventilation	O
,	O
peak	O
inspiratory	O
pressure	O
,	O
oxygen	O
requirement	O
,	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
,	O
blood	O
pressure	O
,	O
and	O
heart	O
rate	O
were	O
analyzed	O
before	O
and	O
the	O
day	O
following	O
surfactant	O
therapy	O
.	O

The	O
remaining	O
four	O
patients	O
who	O
had	O
reduced	O
oxygen	O
requirements	O
received	O
surfactant	O
earlier	O
following	O
their	O
injury	O
(	O
4	O
.	O
8	O
	O
0	O
.	O
9	O
days	O
postinjury	O
vs	O
17	O
.	O
7	O
	O
8	O
days	O
postinjury	O
)	O
and	O
had	O
less	O
derangement	O
in	O
oxygenation	O
before	O
surfactant	O
dosing	O
(	O
PaO	B-ENZY
(	O
2	O
):	O
FiO	O
(	O
2	O
)	O
ratio	O
:	O
105	O
.	O
2	O
	O
26	O
.	O
4	O
vs	O
64	O
.	O
5	O
	O
5	O
.	O
2	O
).	O

The	O
papain	B-ENZY
-	O
like	O
cysteine	O
proteases	O
encoded	O
by	O
the	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
:	O
PLpro	O
;	O
NL63	O
:	O
PLP1	O
and	O
PLP2	O
)	O
represent	O
potential	O
targets	O
for	O
antiviral	O
drug	O
development	O
.	O

We	O
hypothesized	O
that	O
ACE	B-ENZY
I	O
/	O
D	O
genotype	O
in	O
pediatrics	O
is	O
associated	O
with	O
ARDS	O
and	O
plasma	O
levels	O
of	O
angiotensin	O
II	O
.	O

Association	O
between	O
ACE	B-ENZY
genotype	O
and	O
ARDS	O
was	O
evaluated	O
as	O
the	O
primary	O
outcome	O
;	O
mortality	O
and	O
severe	O
hypoxemia	O
were	O
examined	O
as	O
secondary	O
outcomes	O
.	O

Frequency	O
of	O
ACE	B-ENZY
I	O
/	O
D	O
genotype	O
was	O
similar	O
in	O
ARDS	O
and	O
control	O
groups	O
(	O
p	O
=	O
0	O
.	O
18	O
).	O

These	O
data	O
do	O
not	O
support	O
the	O
association	O
between	O
ACE	B-ENZY
I	O
/	O
D	O
genotype	O
and	O
ARDS	O
,	O
although	O
severe	O
hypoxemia	O
was	O
less	O
frequent	O
in	O
D	O
allele	O
carriers	O
.	O

ACE	B-ENZY
I	O
/	O
D	O
polymorphism	O
modified	O
angiotensin	O
-	O
II	O
levels	O
in	O
pediatric	O
ARDS	O
,	O
but	O
its	O
pathogenic	O
role	O
is	O
not	O
well	O
understood	O
and	O
needs	O
to	O
be	O
addressed	O
in	O
future	O
studies	O
.	O

RESULTS	O
:	O
Frequency	O
of	O
ACE	B-ENZY
I	O
/	O
D	O
genotype	O
was	O
similar	O
in	O
ARDS	O
and	O
control	O
groups	O
(	O
p	O
=	O
0	O
.	O
18	O
).	O

CONCLUSIONS	O
:	O
These	O
data	O
do	O
not	O
support	O
the	O
association	O
between	O
ACE	B-ENZY
I	O
/	O
D	O
genotype	O
and	O
ARDS	O
,	O
although	O
severe	O
hypoxemia	O
was	O
less	O
frequent	O
in	O
D	O
allele	O
carriers	O
.	O

TITLE	O
:	O
A	O
polyclonal	O
antibody	O
against	O
the	O
C	O
subunit	O
of	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
expressed	O
in	O
Escherichia	O
coli	O
.	O

HFOV	O
was	O
instituted	O
for	O
48	O
h	O
,	O
resulting	O
in	O
a	O
marked	O
improvement	O
in	O
gas	B-ENZY
exchange	O
,	O
however	O
any	O
manipulations	O
caused	O
immediate	O
deterioration	O
in	O
the	O
patient	O
'	O
s	O
condition	O
.	O

TITLE	O
:	O
Bat	B-ENZY
severe	O
acute	O
respiratory	O
syndrome	O
-	O
like	O
coronavirus	O
ORF3b	O
homologues	O
display	O
different	O
interferon	O
antagonist	O
activities	O
.	O

In	O
this	O
study	O
,	O
ORF3b	O
homologues	O
were	O
identified	O
from	O
three	O
bat	B-ENZY
SL	O
-	O
CoV	O
strains	O
.	O

These	O
results	O
indicate	O
that	O
different	O
ORF3b	O
proteins	O
display	O
different	O
IFN	O
antagonist	O
activities	O
and	O
this	O
function	O
is	O
independent	O
of	O
the	O
protein	O
'	O
s	O
nuclear	O
localization	O
,	O
suggesting	O
a	O
potential	O
link	O
between	O
bat	B-ENZY
SL	O
-	O
CoV	O
ORF3b	O
function	O
and	O
viral	O
pathogenesis	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
-	O
induced	O
neuronal	O
programmed	O
cell	O
death	O
is	O
cyclophilin	B-ENZY
d	O
dependent	O
and	O
potentially	O
caspase	O
dispensable	O
.	O

We	O
have	O
previously	O
reported	O
that	O
HCoV	O
-	O
OC43	O
infection	O
of	O
human	O
neurons	O
activates	O
the	O
unfolded	O
-	O
protein	O
response	O
and	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
induces	O
cell	O
death	O
and	O
that	O
the	O
viral	O
spike	O
(	O
S	O
)	O
glycoprotein	O
is	O
involved	O
in	O
the	O
process	O
.	O

Even	O
though	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
caspase	B-ENZY
-	I-ENZY
9	I-ENZY
were	O
both	O
activated	O
after	O
infection	O
,	O
the	O
use	O
of	O
caspase	O
inhibitors	O
neither	O
reduced	O
nor	O
delayed	O
virus	O
-	O
induced	O
PCD	O
,	O
suggesting	O
that	O
these	O
proteases	O
are	O
not	O
essential	O
in	O
the	O
process	O
.	O

Moreover	O
,	O
LA	O
-	O
N	O
-	O
5	O
neuronal	O
cells	O
treated	O
with	O
cyclosporine	O
(	O
CsA	O
),	O
an	O
inhibitor	O
of	O
the	O
mitochondrial	O
permeabilization	O
transition	O
pore	O
(	O
mPTP	O
),	O
or	O
knocked	O
down	O
for	O
cyclophilin	B-ENZY
D	O
(	O
CypD	O
)	O
were	O
completely	O
protected	O
from	O
rOC	O
/	O
ATCC	O
-	O
induced	O
neuronal	O
PCD	O
,	O
underlining	O
the	O
involvement	O
of	O
CypD	O
in	O
the	O
process	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
are	O
consistent	O
with	O
mitochondrial	O
AIF	O
and	O
cyclophilin	B-ENZY
D	O
being	O
central	O
in	O
HCoV	O
-	O
OC43	O
-	O
induced	O
PCD	O
,	O
while	O
caspases	O
appear	O
not	O
to	O
be	O
essential	O
.	O

During	O
the	O
first	O
24h	O
of	O
iLA	O
use	O
,	O
mean	O
blood	O
flow	O
was	O
1	O
.	O
08	O
	O
0	O
.	O
15L	O
/	O
min	O
,	O
PaCO	O
(	O
2	O
)	O
decreased	O
from	O
83	O
.	O
9	O
	O
23	O
.	O
4mmHg	O
to	O
40	O
.	O
7	O
	O
10	O
.	O
2mmHg	O
,	O
and	O
PaO	B-ENZY
(	O
2	O
)	O
/	O
FiO	O
(	O
2	O
)	O
ratio	O
increased	O
from	O
110	O
	O
37	O
to	O
141	O
	O
74	O
.	O

Their	O
PaO	B-ENZY
(	O
2	O
)/	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
)	O
ratio	O
was	O
<	O
150	O
at	O
a	O
tidal	O
volume	O
of	O
6	O
-	O
8	O
mL	O
	O
kg	O
(-	O
1	O
)	O
ideal	O
body	O
weight	O
and	O
a	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
	O
5	O
cm	O
H	O
(	O
2	O
)	O
O	O
for	O
<	O
48	O
hr	O
.	O

Among	O
the	O
most	O
potent	O
were	O
the	O
bis	B-ENZY
-	O
triazoloquinoline	O
1m	O
,	O
the	O
imidazoquinolines	O
2e	O
and	O
2h	O
,	O
and	O
the	O
pyridoquinoxalines	O
4h	O
,	O
4j	O
and	O
5n	O
(	O
EC	O
(	O
50	O
)	O
range	O
1	O
-	O
5	O
M	O
).	O

The	O
compounds	O
showed	O
antiparasitic	O
activities	O
against	O
T	O
.	O
brucei	O
and	O
time	O
-	O
dependent	O
inhibition	O
of	O
cathepsin	B-ENZY
L	I-ENZY
-	O
like	O
proteases	O
with	O
K	O
(	O
i	O
)	O
values	O
in	O
the	O
low	O
micromolar	O
range	O
.	O

In	O
total	O
,	O
ninety	O
7	O
-	O
d	O
-	O
old	O
poults	O
,	O
which	O
tested	O
negative	O
for	O
the	O
presence	O
of	O
astrovirus	O
,	O
rotavirus	O
,	O
coronavirus	O
,	O
and	O
reovirus	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)	O
PCR	O
,	O
were	O
divided	O
evenly	O
into	O
3	O
groups	O
:	O
A	O
,	O
B	O
,	O
and	O
C	O
.	O
Birds	O
in	O
group	O
A	O
were	O
inoculated	O
orally	O
with	O
turkey	O
astrovirus	O
-	O
positive	O
intestinal	O
contents	O
from	O
birds	O
affected	O
with	O
PES	O
.	O

By	O
western	O
blotting	O
and	O
ELISA	O
test	O
,	O
all	O
recombinant	O
proteins	O
were	O
recognized	O
by	O
the	O
antibody	O
against	O
native	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
.	O
Recombinant	O
proteins	O
,	O
rpAPN	O
-	O
C2	O
(	O
aa	O
623	O
-	O
722	O
)	O
and	O
rpAPN	O
-	O
C3	O
(	O
aa	O
673	O
-	O
772	O
),	O
had	O
the	O
highest	O
binding	O
activity	O
with	O
swine	O
transmissible	O
gastroenteritis	O
virus	O
among	O
the	O
truncated	O
pAPN	O
-	O
C	O
recombinant	O
proteins	O
.	O

Early	O
initiation	O
of	O
neuraminidase	B-ENZY
inhibitor	O
and	O
the	O
implementation	O
of	O
guidelines	O
for	O
management	O
of	O
severe	O
sepsis	O
and	O
septic	O
shock	O
should	O
be	O
considered	O
.	O

ABSTRACT	O
:	O
An	O
external	O
quality	O
assessment	O
(	O
EQA	O
)	O
panel	O
consisting	O
of	O
a	O
total	O
of	O
48	O
samples	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
or	O
transport	O
medium	O
was	O
prepared	O
in	O
collaboration	O
with	O
Quality	O
Control	O
for	O
Molecular	O
Diagnostics	O
(	O
QCMD	O
)	O
(	O
www	O
.	O
qcmd	O
.	O
org	O
).	O

Furthermore	O
,	O
three	O
commercially	O
available	O
multiplex	O
NAAT	B-ENZY
tests	O
-	O
the	O
ResPlex	O
(	O
Qiagen	O
GmbH	O
,	O
Hilden	O
,	O
Germany	O
),	O
RespiFinder	O
plus	O
(	O
PathoFinder	O
,	O
Maastricht	O
,	O
The	O
Netherlands	O
),	O
and	O
RespiFinder	O
Smart	O
21	O
(	O
PathoFinder	O
)	O
tests	O
-	O
were	O
evaluated	O
by	O
examination	O
of	O
the	O
same	O
EQA	O
panel	O
by	O
the	O
manufacturer	O
.	O

Criteria	O
for	O
ECMO	O
center	O
activation	O
were	O
:	O
potentially	O
reversibile	O
respiratory	O
failure	O
,	O
PaO	O
<	O
50	O
mmHg	O
with	O
FiO	O
>	O
0	O
.	O
6	O
for	O
>	O
12	O
hours	O
,	O
PEEP	O
>	O
5	O
cmH0	O
,	O
Lung	O
Injury	O
Score	O
(	O
LIS	B-ENZY
)	O
	O
3	O
or	O
respiratory	O
acidosis	O
with	O
pH	O
<	O
7	O
.	O
2	O
,	O
no	O
intracranial	O
bleeding	O
,	O
and	O
no	O
absolute	O
contraindication	O
to	O
anticoagulation	O
.	O

Nevertheless	O
,	O
the	O
absence	O
of	O
CNS	O
CD4	O
T	O
cells	O
was	O
associated	O
with	O
reduced	O
gamma	O
interferon	O
(	O
IFN	O
-	O
	O
)	O
and	O
granzyme	B-ENZY
B	I-ENZY
expression	O
by	O
infiltrating	O
CD8	O
T	O
cells	O
,	O
increased	O
CD8	O
T	O
cell	O
apoptosis	O
,	O
and	O
impaired	O
control	O
of	O
infectious	O
virus	O
.	O

The	O
BCV	O
was	O
identified	O
in	O
lung	O
samples	O
[	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
collection	O
]	O
as	O
well	O
as	O
in	O
nasal	O
swabs	O
.	O

TITLE	O
:	O
Contribution	O
of	O
neutrophil	O
-	O
derived	O
myeloperoxidase	B-ENZY
in	O
the	O
early	O
phase	O
of	O
fulminant	O
acute	O
respiratory	O
distress	O
syndrome	O
induced	O
by	O
influenza	O
virus	O
infection	O
.	O

We	O
focused	O
on	O
neutrophil	O
myeloperoxidase	B-ENZY
(	O
MPO	B-ENZY
)	O
as	O
a	O
potent	O
tissue	O
damage	O
factor	O
and	O
examined	O
its	O
contribution	O
in	O
influenza	O
pneumonia	O
by	O
using	O
mice	O
genetically	O
lacking	O
in	O
MPO	B-ENZY
.	O

ABSTRACT	O
:	O
Clinical	O
cases	O
of	O
hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	B-ENZY
)	O
can	O
be	O
challenging	O
to	O
differentiate	O
from	O
other	O
acute	O
respiratory	O
diseases	O
,	O
which	O
can	O
lead	O
to	O
delays	O
in	O
diagnosis	O
,	O
treatment	O
,	O
and	O
disease	O
reporting	O
.	O

This	O
study	O
'	O
s	O
objective	O
was	O
to	O
examine	O
the	O
clinical	O
characteristics	O
of	O
patients	O
that	O
would	O
indicate	O
HPS	B-ENZY
to	O
aid	O
in	O
detection	O
and	O
reporting	O
.	O

Test	O
results	O
of	O
blood	O
samples	O
from	O
U	O
.	O
S	O
.	O
patients	O
suspected	O
of	O
having	O
HPS	B-ENZY
submitted	O
to	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
from	O
1998	O
-	O
2010	O
were	O
reviewed	O
.	O

Of	O
567	O
patients	O
included	O
,	O
36	O
%	O
were	O
HPS	B-ENZY
-	O
confirmed	O
.	O

Thrombocytopenia	O
,	O
chest	O
x	O
-	O
rays	O
with	O
suggestive	O
signs	O
,	O
and	O
receiving	O
supplemental	O
oxygenation	O
were	O
highly	O
sensitive	O
(>	O
95	O
%),	O
while	O
elevated	O
hematocrit	O
was	O
highly	O
specific	O
(	O
83	O
%)	O
in	O
detecting	O
HPS	B-ENZY
.	O

Using	O
a	O
national	O
sample	O
of	O
suspect	O
patients	O
,	O
we	O
found	O
that	O
thrombocytopenia	O
was	O
a	O
highly	O
sensitive	O
indicator	O
of	O
HPS	B-ENZY
and	O
should	O
be	O
included	O
in	O
surveillance	O
definitions	O
for	O
suspected	O
HPS	B-ENZY
.	O

Using	O
a	O
sensitive	O
suspect	O
case	O
definition	O
to	O
identify	O
potential	O
HPS	B-ENZY
patients	O
that	O
are	O
confirmed	O
by	O
highly	O
specific	O
diagnostic	O
testing	O
will	O
ensure	O
accurate	O
reporting	O
of	O
this	O
disease	O
.	O

Cellular	O
pyruvate	B-ENZY
kinase	I-ENZY
activity	O
in	O
hepatoma	O
cells	O
was	O
repressed	O
by	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
in	O
either	O
transiently	O
transfected	O
or	O
stably	O
transfected	O
cells	O
.	O

It	O
is	O
reasonable	O
to	O
assume	O
that	O
an	O
inhibition	O
of	O
PKL	O
activity	O
due	O
to	O
interaction	O
with	O
SARS	O
-	O
CoV	O
N	O
protein	O
is	O
likely	O
to	O
cause	O
the	O
death	O
of	O
the	O
hepatocytes	O
,	O
which	O
results	O
in	O
the	O
elevation	O
of	O
serum	O
alanine	B-ENZY
aminotransferase	I-ENZY
and	O
liver	O
dysfunction	O
noted	O
in	O
most	O
SARS	O
patients	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
SARS	O
-	O
CoV	O
could	O
reduce	O
pyruvate	B-ENZY
kinase	I-ENZY
activity	O
via	O
its	O
nucleocapsid	O
protein	O
,	O
and	O
this	O
may	O
in	O
turn	O
cause	O
disease	O
.	O

We	O
show	O
here	O
that	O
whereas	O
antibody	O
-	O
or	O
B	O
cell	O
-	O
deficient	O
mice	O
failed	O
to	O
contain	O
MHV	O
CNS	O
infection	O
and	O
developed	O
progressive	O
demyelinating	O
disease	O
,	O
germline	O
IgM	O
produced	O
in	O
activation	O
-	O
induced	O
cytidine	B-ENZY
deaminase	I-ENZY
-	O
deficient	O
mice	O
(	O
aicda	O
(-/-))	O
provided	O
long	O
-	O
term	O
protection	O
against	O
the	O
chronic	O
multiple	O
sclerosis	O
-	O
like	O
disease	O
.	O

Arterial	O
blood	O
gas	B-ENZY
,	O
leukocyte	O
count	O
in	O
the	O
bronchial	O
alveolar	O
lavage	O
fluid	O
and	O
blood	O
,	O
virus	O
titers	O
,	O
and	O
cytokine	O
levels	O
in	O
the	O
lung	O
were	O
measured	O
at	O
various	O
times	O
post	O
-	O
inoculation	O
.	O

The	O
renin	B-ENZY
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
through	O
Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)-	O
generated	O
Angiotensin	O
II	O
contributes	O
to	O
lung	O
injury	O
.	O

ACE2	O
,	O
a	O
recently	O
discovered	O
ACE	B-ENZY
homologue	O
,	O
acts	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
RAS	O
and	O
counterbalances	O
the	O
function	O
of	O
ACE	B-ENZY
.	O

Cardiohelp	O
support	O
resulted	O
in	O
immediate	O
improvement	O
of	O
gas	B-ENZY
exchange	O
and	O
highly	O
protective	O
ventilation	O
.	O

The	O
compact	O
portable	O
ECMO	O
device	O
Cardiohelp	O
is	O
a	O
highly	O
effective	O
method	O
to	O
secure	O
vital	O
gas	B-ENZY
exchange	O
and	O
to	O
reduce	O
further	O
ventilator	O
-	O
induced	O
lung	O
injury	O
in	O
patients	O
with	O
acute	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
Phosphatidylinositol	B-ENZY
4	I-ENZY
-	I-ENZY
kinase	I-ENZY
III	O
is	O
required	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
-	O
mediated	O
cell	O
entry	O
.	O

Using	O
gene	O
knockdown	O
technology	O
,	O
we	O
demonstrate	O
that	O
phosphatidylinositol	B-ENZY
4	I-ENZY
-	I-ENZY
kinase	I-ENZY
III	O
(	O
PI4KB	O
)	O
is	O
required	O
for	O
cellular	O
entry	O
by	O
pseudoviruses	O
bearing	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
and	O
that	O
the	O
cell	O
entry	O
mediated	O
by	O
SARS	O
-	O
CoV	O
spike	O
protein	O
is	O
strongly	O
inhibited	O
by	O
knockdown	O
of	O
PI4KB	O
.	O

Kinase	O
assay	O
and	O
pharmacological	O
inhibitor	O
treatment	O
implied	O
that	O
3b	O
also	O
affect	O
RUNX1b	O
transcriptional	O
activity	O
by	O
regulating	O
its	O
ERK	B-ENZY
dependent	O
phosphorylation	O
levels	O
.	O

Chemically	O
modified	O
tetracycline	O
3	O
treatment	O
prevented	O
ARDS	O
as	O
indicated	O
by	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
,	O
static	O
compliance	O
,	O
and	O
plateau	O
airway	O
pressure	O
(	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
placebo	O
).	O

Alcohol	O
caused	O
an	O
increase	O
in	O
BAL	B-ENZY
fluid	O
adenosine	O
levels	O
.	O

RESULTS	O
:	O
Exposure	O
to	O
alcohol	O
reduced	O
alveolar	O
fluid	O
clearance	O
,	O
downregulated	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
in	O
the	O
lung	O
tissue	O
and	O
worsened	O
hyperoxia	O
-	O
induced	O
lung	O
injury	O
.	O

In	O
primary	O
rat	O
alveolar	O
type	O
II	O
cells	O
alcohol	O
and	O
adenosine	O
decreased	O
the	O
abundance	O
of	O
the	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
at	O
the	O
basolateral	O
membrane	O
via	O
a	O
mechanism	O
that	O
required	O
activation	O
of	O
the	O
AMPK	B-ENZY
.	O

Alphacoronavirus	O
strains	O
were	O
detected	O
in	O
two	O
of	O
seven	O
bat	B-ENZY
species	O
,	O
namely	O
Myotis	O
nattereri	O
and	O
M	O
.	O
daubentonii	O
.	O

TITLE	O
:	O
Discovery	O
of	O
seven	O
novel	O
Mammalian	O
and	O
avian	O
coronaviruses	O
in	O
the	O
genus	O
deltacoronavirus	O
supports	O
bat	B-ENZY
coronaviruses	O
as	O
the	O
gene	O
source	O
of	O
alphacoronavirus	O
and	O
betacoronavirus	O
and	O
avian	O
coronaviruses	O
as	O
the	O
gene	O
source	O
of	O
gammacoronavirus	O
and	O
deltacoronavirus	O
.	O

Since	O
moderate	O
oedema	O
does	O
not	O
necessarily	O
lead	O
to	O
hypoxemia	O
,	O
we	O
suggest	O
that	O
the	O
clinical	O
relevance	O
of	O
experimental	O
studies	O
can	O
be	O
further	O
improved	O
by	O
putting	O
greater	O
emphasis	O
on	O
gas	B-ENZY
exchange	O
.	O

Mini	O
bronchoalveolar	O
lavage	O
(	O
mini	O
BAL	B-ENZY
)	O
is	O
a	O
blind	O
,	O
non	O
bronchoscopic	O
procedure	O
,	O
used	O
to	O
obtain	O
samples	O
from	O
the	O
lower	O
respiratory	O
tract	O
from	O
patients	O
on	O
mechanical	O
ventilation	O
(	O
MV	O
).	O

To	O
assess	O
the	O
feasibility	O
,	O
complications	O
and	O
preliminary	O
results	O
of	O
mini	O
BAL	B-ENZY
among	O
patients	O
with	O
severe	O
ARF	O
on	O
MV	O
.	O

Mini	O
BAL	B-ENZY
is	O
a	O
safe	O
,	O
fast	O
and	O
easy	O
technique	O
for	O
obtaining	O
samples	O
from	O
the	O
inferior	O
airway	O
in	O
patients	O
with	O
ALI	O
or	O
ARDS	O
on	O
MV	O
.	O

They	O
do	O
so	O
through	O
concerted	O
action	O
of	O
distinct	O
receptor	O
-	O
binding	O
"("""	O
lectin	O
""")"	O
and	O
receptor	O
-	O
destroying	O
sialate	B-ENZY
O	I-ENZY
-	I-ENZY
acetylesterase	I-ENZY
"("""	O
esterase	O
""")"	O
domains	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
paediatric	O
case	O
of	O
survival	O
following	O
severe	O
hydrogen	O
sulfide	O
(	O
H2S	O
)	O
gas	B-ENZY
intoxication	O
.	O

Reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
is	O
useful	O
for	O
the	O
rapid	O
diagnosis	O
of	O
coronavirus	O
infections	O
.	O

Although	O
CoV	O
-	O
HKU1	O
was	O
not	O
identified	O
in	O
any	O
of	O
the	O
studied	O
animals	O
,	O
a	O
coronavirus	O
closely	O
related	O
to	O
SARS	O
-	O
CoV	O
(	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
)	O
was	O
identified	O
in	O
23	O
(	O
19	O
%)	O
of	O
118	O
wild	O
Chinese	O
horseshoe	O
bats	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Complete	O
genome	O
sequencing	O
and	O
phylogenetic	O
analysis	O
showed	O
that	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
formed	O
a	O
distinct	O
cluster	O
with	O
SARS	O
-	O
CoV	O
as	O
group	O
2b	O
coronaviruses	O
,	O
distantly	O
related	O
to	O
known	O
group	O
2	O
coronaviruses	O
.	O

The	O
presence	O
of	O
a29	O
-	O
bp	O
insertion	O
in	O
ORF	O
8	O
of	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
genome	O
,	O
not	O
in	O
most	O
human	O
SARS	O
-	O
CoV	O
genomes	O
,	O
suggests	O
that	O
it	O
has	O
a	O
common	O
ancestor	O
with	O
civet	O
SARS	O
-	O
CoV	O
.	O
4	O
.	O

Antibody	O
against	O
recombinant	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
was	O
detected	O
in	O
84	O
%	O
of	O
Chinese	O
horseshoe	O
bats	O
using	O
an	O
enzyme	O
immunoassay	O
.	O

TITLE	O
:	O
Coronavirus	O
papain	B-ENZY
-	O
like	O
proteases	O
negatively	O
regulate	O
antiviral	O
innate	O
immune	O
response	O
through	O
disruption	O
of	O
STING	O
-	O
mediated	O
signaling	O
.	O

Ectopic	O
expression	O
of	O
catalytically	O
active	O
PLP2	O
-	O
TM	O
blocks	O
STING	O
dimer	O
formation	O
and	O
negatively	O
regulates	O
assembly	O
of	O
STING	O
-	O
MAVS	O
-	O
TBK1	B-ENZY
/	O
IKK	O
complexes	O
required	O
for	O
activation	O
of	O
IRF	O
-	O
3	O
.	O

STING	O
dimerization	O
was	O
also	O
substantially	O
reduced	O
in	O
cells	O
infected	O
with	O
SARS	O
-	O
CoV	O
.	O
Furthermore	O
,	O
the	O
level	O
of	O
ubiquitinated	O
forms	O
of	O
STING	O
,	O
RIG	O
-	O
I	O
,	O
TBK1	B-ENZY
and	O
IRF	O
-	O
3	O
are	O
reduced	O
in	O
cells	O
expressing	O
wild	O
type	O
or	O
catalytic	O
mutants	O
of	O
PLP2	O
-	O
TM	O
,	O
likely	O
contributing	O
to	O
disruption	O
of	O
signaling	O
required	O
for	O
IFN	O
induction	O
.	O

ECMO	O
could	O
improve	O
gas	B-ENZY
exchange	O
,	O
oxygenation	O
and	O
partially	O
replace	O
pulmonary	O
function	O
.	O

Blood	O
routine	O
,	O
electrolytes	O
,	O
blood	O
gas	B-ENZY
analysis	O
,	O
hepatic	O
and	O
renal	O
function	O
tests	O
and	O
cardiac	O
enzymes	O
were	O
examined	O
before	O
and	O
after	O
treatment	O
.	O

Worsening	O
radiologic	O
infiltrate	O
24	O
h	O
after	O
admission	O
,	O
maximum	O
Sepsis	O
-	O
Related	O
Organ	O
Failure	O
Assessment	O
(	O
SOFA	O
)	O
score	O
and	O
,	O
after	O
1	O
h	O
of	O
NIV	O
,	O
higher	O
heart	O
rate	O
and	O
lower	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
and	O
bicarbonate	O
independently	O
predicted	O
NIV	O
failure	O
.	O

As	O
an	O
effective	O
measure	O
of	O
respiratory	O
supports	O
,	O
ECMO	O
may	O
provide	O
pulmonary	O
rest	O
and	O
improve	O
gas	B-ENZY
exchanges	O
in	O
severe	O
ARDS	O
induced	O
by	O
novel	O
H1N1	O
Influenza	O
.	O

TGEV	O
infection	O
up	O
-	O
regulated	O
FasL	O
,	O
activated	O
FasL	O
-	O
mediated	O
apoptotic	O
pathway	O
,	O
leading	O
to	O
activation	O
of	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
and	O
cleavage	O
of	O
Bid	O
.	O

In	O
addition	O
,	O
TGEV	O
infection	O
down	O
-	O
regulated	O
Bcl	O
-	O
2	O
,	O
up	O
-	O
regulated	O
Bax	O
expression	O
,	O
promoted	O
translocation	O
of	O
Bax	O
to	O
mitochondria	O
,	O
activated	O
mitochondria	O
-	O
mediated	O
apoptotic	O
pathway	O
,	O
which	O
in	O
turn	O
caused	O
the	O
release	O
of	O
cytochrome	O
c	O
and	O
the	O
activation	O
of	O
caspase	B-ENZY
-	I-ENZY
9	I-ENZY
.	O

Clinical	O
and	O
blood	O
gas	B-ENZY
features	O
,	O
complications	O
and	O
survival	O
of	O
patients	O
with	O
ECMO	O
.	O

The	O
nsp5	O
structure	O
contains	O
two	O
chymotrypsin	B-ENZY
-	O
like	O
domains	O
(	O
D1	O
and	O
D2	O
)	O
and	O
a	O
unique	O
domain	O
(	O
D3	O
),	O
and	O
forms	O
functional	O
dimers	O
.	O

TITLE	O
:	O
Metagenomic	O
analysis	O
of	O
viruses	O
from	O
bat	B-ENZY
fecal	O
samples	O
reveals	O
many	O
novel	O
viruses	O
in	O
insectivorous	O
bats	O
in	O
China	O
.	O

In	O
this	O
study	O
,	O
sequence	O
-	O
independent	O
amplification	O
and	O
high	O
-	O
throughput	O
sequencing	O
(	O
Solexa	O
)	O
were	O
applied	O
to	O
the	O
metagenomic	O
analysis	O
of	O
viruses	O
in	O
bat	B-ENZY
fecal	O
samples	O
collected	O
from	O
6	O
locations	O
in	O
China	O
.	O

This	O
study	O
provides	O
the	O
first	O
preliminary	O
understanding	O
of	O
the	O
virome	O
of	O
some	O
bat	B-ENZY
populations	O
in	O
China	O
,	O
which	O
may	O
guide	O
the	O
discovery	O
and	O
isolation	O
of	O
novel	O
viruses	O
in	O
the	O
future	O
.	O

As	O
shown	O
by	O
plaque	O
titration	O
,	O
qPCR	O
,	O
Luciferase	B-ENZY
-	O
and	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
reporter	O
gene	O
expression	O
,	O
replication	O
was	O
diminished	O
by	O
several	O
orders	O
of	O
magnitude	O
.	O

ABSTRACT	O
:	O
The	O
neuraminidase	B-ENZY
inhibitor	O
oseltamivir	O
is	O
a	O
recommended	O
treatment	O
for	O
influenza	O
A	O
(	O
H1N1	O
)	O
infection	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
timely	O
peritoneal	O
dialysis	O
(	O
PD	O
)	O
catheter	O
in	O
children	O
with	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
)	O
while	O
supported	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

We	O
present	O
a	O
case	O
series	O
of	O
four	O
patients	O
who	O
developed	O
significant	O
intraperitoneal	O
fluid	O
accumulation	O
and	O
ACS	B-ENZY
at	O
the	O
general	O
pediatric	O
and	O
cardiac	O
intensive	O
care	O
units	O
in	O
a	O
tertiary	O
children	O
'	O
s	O
hospital	O
.	O

In	O
each	O
of	O
these	O
patients	O
,	O
a	O
PD	O
catheter	O
was	O
placed	O
for	O
severe	O
abdominal	O
distension	O
and	O
proven	O
/	O
suspected	O
ACS	B-ENZY
.	O

After	O
ruling	O
out	O
common	O
causes	O
for	O
decreased	O
venous	O
return	O
,	O
ACS	B-ENZY
should	O
be	O
suspected	O
as	O
one	O
of	O
the	O
important	O
causes	O
,	O
especially	O
in	O
patients	O
with	O
massive	O
capillary	O
leak	O
and	O
increasing	O
abdominal	O
distension	O
,	O
among	O
patients	O
supported	O
on	O
ECMO	O
.	O

Timely	O
placement	O
of	O
a	O
PD	O
catheter	O
in	O
patients	O
who	O
develop	O
abdominal	O
distension	O
and	O
ACS	B-ENZY
can	O
substantially	O
improve	O
venous	O
return	O
and	O
thus	O
help	O
maintain	O
adequate	O
tissue	O
perfusion	O
by	O
improving	O
ECMO	O
flows	O
.	O

Ten	O
adult	O
patients	O
with	O
severe	O
ARDS	O
secondary	O
to	O
H1N1	O
infection	O
(	O
Pao	B-ENZY
(	O
2	O
)/	O
fraction	O
of	O
inspired	O
oxygen	O
,	O
69	O
mm	O
Hg	O
[	O
56	O
-	O
84	O
];	O
Murray	O
score	O
,	O
3	O
.	O
5	O
[	O
3	O
.	O
5	O
-	O
3	O
.	O
8	O
])	O
were	O
included	O
,	O
and	O
60	O
%	O
survived	O
to	O
hospital	O
discharge	O
.	O

TITLE	O
:	O
Differential	O
domain	O
structure	O
stability	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
.	O

ABSTRACT	O
:	O
Papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
is	O
one	O
of	O
the	O
two	O
proteases	O
involved	O
in	O
the	O
proteolytic	O
processing	O
of	O
the	O
virion	O
polyproteins	O
.	O

The	O
reverse	O
genetic	O
system	O
was	O
finally	O
used	O
to	O
generate	O
a	O
recSARS	O
-	O
CoV	O
reporter	O
virus	O
expressing	O
Renilla	O
luciferase	B-ENZY
in	O
order	O
to	O
facilitate	O
the	O
analysis	O
of	O
SARS	O
-	O
CoV	O
gene	O
expression	O
in	O
human	O
dendritic	O
cells	O
(	O
hDCs	O
).	O

In	O
parallel	O
,	O
a	O
Renilla	O
luciferase	B-ENZY
gene	O
was	O
also	O
inserted	O
into	O
the	O
genome	O
of	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
).	O

We	O
have	O
provided	O
evidence	O
for	O
the	O
involvement	O
of	O
recruited	O
neutrophils	O
,	O
their	O
toxic	O
enzymes	O
such	O
as	O
myeloperoxidase	B-ENZY
and	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
),	O
and	O
neutrophil	O
extracellular	O
traps	O
in	O
aggravating	O
alveolar	O
-	O
capillary	O
damage	O
.	O

Compared	O
with	O
nonobstetric	O
rabbits	O
,	O
obstetric	O
rabbits	O
had	O
more	O
severe	O
lung	O
injury	O
as	O
indicated	O
by	O
alveolar	O
and	O
interstitial	O
fluid	O
accumulation	O
and	O
marked	O
neutrophil	O
sequestration	O
and	O
greater	O
lung	O
injury	O
score	O
,	O
myeloperoxidase	B-ENZY
activity	O
,	O
expression	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
,	O
serum	O
tumor	O
necrosis	O
factor	O
-	O
	O
levels	O
,	O
and	O
nuclear	O
factor	O
-	O
B	O
activation	O
,	O
and	O
lower	O
serum	O
interleukin	O
-	O
10	O
levels	O
(	O
p	O
<.	O
05	O
for	O
all	O
).	O

ABSTRACT	O
:	O
In	O
2002	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
(	O
CoV	O
)	O
appeared	O
as	O
a	O
novel	O
human	O
virus	O
with	O
high	O
similarity	O
to	O
bat	B-ENZY
coronaviruses	O
.	O

Here	O
we	O
show	O
that	O
signatures	O
of	O
recurrent	O
positive	O
selection	O
in	O
the	O
bat	B-ENZY
ACE2	O
gene	O
map	O
almost	O
perfectly	O
to	O
known	O
SARS	O
-	O
CoV	O
interaction	O
surfaces	O
.	O

This	O
has	O
been	O
due	O
to	O
a	O
combination	O
of	O
factors	O
including	O
the	O
emergence	O
of	O
highly	O
virulent	O
zoonotic	O
pathogens	O
,	O
such	O
as	O
Hendra	O
,	O
Nipah	O
,	O
SARS	O
and	O
Ebola	O
viruses	O
,	O
and	O
the	O
high	O
rate	O
of	O
detection	O
of	O
a	O
large	O
number	O
of	O
previously	O
unknown	O
viral	O
sequences	O
in	O
bat	B-ENZY
specimens	O
.	O

So	O
the	O
question	O
'	O
Are	O
bats	O
different	O
,	O
special	O
or	O
exceptional	O
?'	O
has	O
become	O
a	O
focal	O
point	O
in	O
the	O
field	O
of	O
virology	O
,	O
bat	B-ENZY
biology	O
and	O
virus	O
-	O
host	O
co	O
-	O
evolution	O
.	O

A	O
subset	O
of	O
samples	O
was	O
screened	O
using	O
qRT	O
-	O
PCR	O
,	O
ELISA	O
and	O
a	O
commercial	O
LAT	B-ENZY
dipstick	O
(	O
132	O
faecal	O
samples	O
were	O
tested	O
for	O
coronavirus	O
and	O
122	O
samples	O
for	O
rotavirus	O
).	O

Using	O
LAT	B-ENZY
,	O
30	O
(	O
22	O
.	O
73	O
%)	O
and	O
43	O
(	O
35	O
.	O
35	O
%)	O
samples	O
were	O
positive	O
for	O
coronavirus	O
and	O
rotavirus	O
,	O
respectively	O
.	O

There	O
was	O
also	O
poor	O
agreement	O
between	O
the	O
LAT	B-ENZY
and	O
qRT	O
-	O
PCR	O
assays	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
commercial	O
ELISA	O
and	O
LAT	B-ENZY
assays	O
evaluated	O
in	O
this	O
study	O
were	O
low	O
compared	O
with	O
qRT	O
-	O
PCR	O
.	O

A	O
subset	O
of	O
samples	O
was	O
screened	O
using	O
qRT	O
-	O
PCR	O
,	O
ELISA	O
and	O
a	O
commercial	O
LAT	B-ENZY
dipstick	O
(	O
132	O
faecal	O
samples	O
were	O
tested	O
for	O
coronavirus	O
and	O
122	O
samples	O
for	O
rotavirus	O
).	O

There	O
was	O
also	O
poor	O
agreement	O
between	O
the	O
LAT	B-ENZY
and	O
qRT	O
-	O
PCR	O
assays	O
.	O

CONCLUSIONS	O
:	O
The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
commercial	O
ELISA	O
and	O
LAT	B-ENZY
assays	O
evaluated	O
in	O
this	O
study	O
were	O
low	O
compared	O
with	O
qRT	O
-	O
PCR	O
.	O

ABSTRACT	O
:	O
Porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
is	O
a	O
common	O
cellular	O
receptor	O
for	O
swine	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
and	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
).	O

We	O
assessed	O
the	O
role	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
support	O
in	O
adult	O
recipients	O
facing	O
acute	O
pulmonary	O
failure	O
and	O
refractory	O
to	O
conventional	O
mechanical	O
ventilation	O
and	O
concurrent	O
nitric	O
oxide	O
gas	B-ENZY
inhalation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
in	O
farmed	O
European	O
wild	O
boars	O
the	O
prevalence	O
of	O
and	O
risk	O
factors	O
associated	O
with	O
a	O
range	O
of	O
common	O
porcine	O
viral	O
and	O
bacterial	O
infections	O
,	O
namely	O
,	O
porcine	O
parvovirus	O
(	O
PPV	O
),	O
porcine	O
circovirus	O
type	O
2	O
(	O
PCV2	O
),	O
swine	O
influenza	O
virus	O
(	O
SIV	O
),	O
Aujeszky	O
'	O
s	O
disease	O
virus	O
(	O
ADV	O
),	O
classical	O
swine	O
fever	O
virus	O
(	O
CSFV	O
),	O
swine	O
vesicular	O
disease	O
virus	O
(	O
SVDV	O
),	O
coronavirus	O
causing	O
transmissible	O
gastroenteritis	O
(	O
TGEV	O
),	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
Mycoplasma	O
hyopneumoniae	O
,	O
Lawsonia	O
intracellularis	O
,	O
Brucella	O
spp	B-ENZY
.,	O
and	O
Leptospira	O
spp	B-ENZY
.	O

No	O
antibodies	O
were	O
detected	O
against	O
SIV	O
,	O
ADV	O
,	O
CSFV	O
,	O
SVDV	O
,	O
TGEV	O
,	O
PRSSV	O
,	O
Leptospira	O
spp	B-ENZY
.,	O
Brucella	O
spp	B-ENZY
.,	O
or	O
M	O
.	O
hyopneumoniae	O
.	O

TITLE	O
:	O
Genomic	O
characterization	O
of	O
seven	O
distinct	O
bat	B-ENZY
coronaviruses	O
in	O
Kenya	O
.	O

These	O
Kenya	O
bat	B-ENZY
CoVs	O
are	O
phylogenetically	O
distant	O
from	O
any	O
previously	O
described	O
human	O
and	O
animal	O
CoVs	O
.	O

However	O
,	O
because	O
of	O
the	O
examples	O
of	O
host	O
switching	O
among	O
CoVs	O
after	O
relatively	O
minor	O
sequence	O
changes	O
in	O
S1	O
domain	O
of	O
spike	O
protein	O
,	O
a	O
further	O
surveillance	O
in	O
animal	O
reservoirs	O
and	O
understanding	O
the	O
interface	O
between	O
host	O
susceptibility	O
is	O
critical	O
for	O
predicting	O
and	O
preventing	O
the	O
potential	O
threat	O
of	O
bat	B-ENZY
CoVs	O
to	O
public	O
health	O
.	O

The	O
substrate	O
used	O
is	O
a	O
quenched	O
peptide	O
(	O
bis	B-ENZY
-	O
AAF	O
-	O
R110	O
)	O
that	O
releases	O
a	O
fluorophore	O
upon	O
proteolytic	O
-	O
cleavage	O
by	O
proteases	O
;	O
the	O
latter	O
released	O
from	O
dead	O
cells	O
.	O

While	O
none	O
of	O
the	O
compounds	O
,	O
examined	O
in	O
our	O
study	O
inhibited	O
the	O
DNA	O
unwinding	O
activity	O
or	O
ATPase	B-ENZY
activity	O
of	O
human	O
HCV	O
helicase	O
protein	O
,	O
we	O
found	O
that	O
myricetin	O
and	O
scutellarein	O
potently	O
inhibit	O
the	O
SARS	O
-	O
CoV	O
helicase	O
protein	O
in	O
vitro	O
by	O
affecting	O
the	O
ATPase	B-ENZY
activity	O
,	O
but	O
not	O
the	O
unwinding	O
activity	O
,	O
nsP13	O
.	O

The	O
weaning	O
was	O
performed	O
while	O
keeping	O
the	O
blood	O
flow	O
unchanged	O
,	O
only	O
gas	B-ENZY
flows	O
were	O
gradually	O
decreased	O
.	O

Positive	O
specimens	O
were	O
used	O
to	O
develop	O
novel	O
reverse	B-ENZY
transcriptase	I-ENZY
real	O
-	O
time	O
PCRs	O
(	O
RT	O
-	O
rtPCRs	O
)	O
for	O
HCoV	O
detection	O
.	O

We	O
describe	O
the	O
unusual	O
presentation	O
of	O
an	O
11	O
-	O
year	O
-	O
old	O
boy	O
with	O
a	O
long	O
history	O
of	O
chronic	O
constipation	O
who	O
developed	O
acute	O
ACS	B-ENZY
requiring	O
resuscitative	O
measures	O
and	O
emergent	O
disimpaction	O
.	O

Although	O
ACS	B-ENZY
secondary	O
to	O
constipation	O
is	O
extremely	O
unusual	O
,	O
this	O
case	O
illustrates	O
the	O
need	O
to	O
actively	O
treat	O
constipation	O
and	O
what	O
can	O
happen	O
if	O
it	O
is	O
not	O
.	O

CCoV	O
-	O
A76	O
can	O
use	O
canine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
cAPN	O
)	O
receptor	O
for	O
infection	O
of	O
cells	O
,	O
but	O
was	O
unable	O
to	O
use	O
feline	O
APN	O
(	O
fAPN	O
).	O

TITLE	O
:	O
A	O
real	O
-	O
time	O
PCR	O
assay	O
for	O
bat	B-ENZY
SARS	O
-	O
like	O
coronavirus	O
detection	O
and	O
its	O
application	O
to	O
Italian	O
greater	O
horseshoe	O
bat	B-ENZY
faecal	O
sample	O
surveys	O
.	O

In	O
this	O
work	O
an	O
SYBR	O
Green	O
-	O
real	O
time	O
PCR	O
assay	O
was	O
developed	O
for	O
diagnosing	O
infection	O
with	O
SARS	O
-	O
related	O
coronaviruses	O
from	O
bat	B-ENZY
guano	O
and	O
was	O
applied	O
as	O
screening	O
tool	O
in	O
a	O
survey	O
carried	O
out	O
on	O
45	O
greater	O
horseshoe	O
bats	O
(	O
Rhinolophus	O
ferrumequinum	O
)	O
sampled	O
in	O
Italy	O
in	O
2009	O
.	O

This	O
method	O
could	O
be	O
suitable	O
as	O
screening	O
tool	O
in	O
epidemiological	O
surveys	O
about	O
the	O
presence	O
of	O
bat	B-ENZY
-	O
SARS	O
-	O
like	O
CoVs	O
,	O
consequently	O
to	O
obtain	O
a	O
more	O
realistic	O
scenario	O
of	O
the	O
viral	O
prevalence	O
in	O
the	O
population	O
.	O

Blood	O
gas	B-ENZY
analysis	O
(	O
BGA	O
)	O
however	O
showed	O
a	O
massive	O
increase	O
in	O
methemoglobinemia	O
from	O
0	O
.	O
5	O
%	O
just	O
prior	O
to	O
MCP	O
injection	O
to	O
53	O
.	O
1	O
%	O
after	O
MCP	O
injection	O
;	O
simultaneously	O
the	O
pO2	O
decreased	O
from	O
74	O
auf	O
54	O
mmHg	O
and	O
the	O
pCO2	O
from	O
37	O
.	O
7	O
to	O
34	O
.	O
1	O
mmHg	O
.	O

TITLE	O
:	O
Antagonism	O
of	O
the	O
interferon	O
-	O
induced	O
OAS	O
-	O
RNase	B-ENZY
L	O
pathway	O
by	O
murine	O
coronavirus	O
ns2	O
protein	O
is	O
required	O
for	O
virus	O
replication	O
and	O
liver	O
pathology	O
.	O

We	O
show	O
that	O
ns2	O
has	O
2	O
',	O
5	B-ENZY
'-	I-ENZY
phosphodiesterase	I-ENZY
activity	O
,	O
which	O
blocks	O
the	O
interferon	O
inducible	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
)-	O
RNase	B-ENZY
L	O
pathway	O
to	O
facilitate	O
hepatitis	O
development	O
.	O

Ns2	O
cleaves	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
,	O
the	O
product	O
of	O
OAS	O
,	O
to	O
prevent	O
activation	O
of	O
the	O
cellular	O
endoribonuclease	O
RNase	B-ENZY
L	O
and	O
consequently	O
block	O
viral	O
RNA	O
degradation	O
.	O

Thus	O
,	O
RNase	B-ENZY
L	O
is	O
a	O
critical	O
cellular	O
factor	O
for	O
protection	O
against	O
viral	O
infection	O
of	O
the	O
liver	O
and	O
the	O
resulting	O
hepatitis	O
.	O

The	O
expression	O
of	O
the	O
homologue	O
of	O
ACE2	O
,	O
the	O
ACE	B-ENZY
protein	O
not	O
used	O
as	O
a	O
receptor	O
by	O
HCoV	O
-	O
NL63	O
,	O
was	O
measured	O
as	O
a	O
control	O
.	O

Washes	O
and	O
flocked	O
swabs	O
collected	O
from	O
children	O
<	O
3	O
years	O
old	O
hospitalized	O
with	O
a	O
lower	O
respiratory	O
tract	O
infection	O
were	O
tested	O
for	O
parainfluenza	O
virus	O
1	O
-	O
3	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	O
A	O
and	O
B	O
and	O
metapneumovirus	O
(	O
Group	O
1	O
)	O
and	O
adenovirus	O
,	O
rhinovirus	O
and	O
coronavirus	O
(	O
Group	O
2	O
)	O
using	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
(	O
rRT	O
-	O
PCR	O
).	O

SSYA10	O
-	O
001	O
did	O
not	O
inhibit	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
helicase	O
,	O
other	O
bacterial	O
and	O
viral	O
RNA	O
-	O
dependent	O
RNA	O
polymerases	O
,	O
or	O
reverse	B-ENZY
transcriptase	I-ENZY
.	O

C	O
-	O
arm	O
CT	O
guidance	O
was	O
used	O
to	O
confirm	O
gas	B-ENZY
filling	O
of	O
the	O
target	O
vessels	O
.	O

All	O
patients	O
presented	O
with	O
fever	O
,	O
hemoptysis	O
,	O
bilateral	O
pulmonary	O
infiltrates	O
in	O
chest	O
radiographs	O
,	O
and	O
thrombocytopenia	O
and	O
had	O
compatible	O
epidemiological	O
history	O
with	O
leptospirosis	O
;	O
3	O
patients	O
had	O
anemia	O
,	O
3	O
had	O
renal	O
failure	O
,	O
2	O
had	O
increased	O
creatine	B-ENZY
kinase	I-ENZY
,	O
whereas	O
bilirubin	O
was	O
slightly	O
increased	O
in	O
only	O
1	O
patient	O
.	O

TITLE	O
:	O
HIV	O
-	O
1	O
Reverse	B-ENZY
Transcriptase	I-ENZY
Still	O
Remains	O
a	O
New	O
Drug	O
Target	O
:	O
Structure	O
,	O
Function	O
,	O
Classical	O
Inhibitors	O
,	O
and	O
New	O
Inhibitors	O
with	O
Innovative	O
Mechanisms	O
of	O
Actions	O
.	O

This	O
process	O
is	O
accomplished	O
by	O
the	O
virus	O
-	O
coded	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)	O
protein	O
,	O
which	O
is	O
a	O
primary	O
target	O
in	O
the	O
current	O
treatments	O
for	O
HIV	O
-	O
1	O
infection	O
.	O

These	O
include	O
translocation	O
-	O
defective	O
RTIs	O
,	O
delayed	O
chain	O
terminators	O
RTIs	O
,	O
lethal	O
mutagenesis	O
RTIs	O
,	O
dinucleotide	O
tetraphosphates	O
,	O
nucleotide	O
-	O
competing	O
RTIs	O
,	O
pyrophosphate	O
analogs	O
,	O
RT	O
-	O
associated	O
RNase	B-ENZY
H	I-ENZY
function	O
inhibitors	O
,	O
and	O
dual	O
activities	O
inhibitors	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
replication	O
is	O
severely	O
impaired	O
by	O
MG132	O
due	O
to	O
proteasome	B-ENZY
-	O
independent	O
inhibition	O
of	O
M	B-ENZY
-	I-ENZY
calpain	I-ENZY
.	O

ABSTRACT	O
:	O
The	O
ubiquitin	O
-	O
proteasome	B-ENZY
system	O
(	O
UPS	O
)	O
is	O
involved	O
in	O
the	O
replication	O
of	O
a	O
broad	O
range	O
of	O
viruses	O
.	O

Since	O
MG132	O
also	O
inhibits	O
the	O
cysteine	O
protease	O
m	B-ENZY
-	I-ENZY
calpain	I-ENZY
,	O
we	O
addressed	O
the	O
role	O
of	O
calpains	O
in	O
the	O
early	O
SARS	O
-	O
CoV	O
life	O
cycle	O
using	O
calpain	O
inhibitors	O
III	O
(	O
MDL28170	O
)	O
and	O
VI	O
(	O
SJA6017	O
).	O

Additional	O
m	B-ENZY
-	I-ENZY
calpain	I-ENZY
knockdown	O
experiments	O
confirmed	O
the	O
dependence	O
of	O
SARS	O
-	O
CoV	O
replication	O
on	O
the	O
activity	O
of	O
the	O
cysteine	O
protease	O
m	B-ENZY
-	I-ENZY
calpain	I-ENZY
.	O

Additionally	O
,	O
this	O
work	O
highlights	O
an	O
important	O
role	O
for	O
m	B-ENZY
-	I-ENZY
calpain	I-ENZY
during	O
early	O
steps	O
of	O
the	O
SARS	O
-	O
CoV	O
life	O
cycle	O
.	O

V	O
-	O
type	O
H	O
+	O
ATPase	B-ENZY
inhibition	O
in	O
the	O
renal	O
tubule	O
has	O
been	O
demonstrated	O
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
all	O
the	O
patients	O
,	O
and	O
blood	O
gas	B-ENZY
analysis	O
was	O
performed	O
every	O
6	O
hours	O
.	O

All	O
the	O
patients	O
on	O
admission	O
were	O
tested	O
for	O
H1N1	O
,	O
by	O
real	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Other	O
enteropathogens	O
identified	O
in	O
cats	O
with	O
and	O
without	O
diarrhea	O
included	O
Clostridium	O
perfringens	O
enterotoxin	O
A	O
(	O
42	O
%	O
and	O
50	O
%,	O
respectively	O
),	O
Cryptosporidium	O
spp	B-ENZY
(	O
10	O
%	O
and	O
20	O
%,	O
respectively	O
),	O
Giardia	O
spp	B-ENZY
(	O
20	O
%	O
and	O
8	O
%,	O
respectively	O
),	O
Cystoisospora	O
spp	B-ENZY
(	O
14	O
%	O
and	O
10	O
%,	O
respectively	O
),	O
hookworms	O
(	O
10	O
%	O
and	O
18	O
%,	O
respectively	O
),	O
ascarids	O
(	O
6	O
%	O
and	O
16	O
%,	O
respectively	O
),	O
Salmonella	O
spp	B-ENZY
(	O
6	O
%	O
and	O
4	O
%,	O
respectively	O
),	O
astrovirus	O
(	O
8	O
%	O
and	O
2	O
%,	O
respectively	O
),	O
feline	O
panleukopenia	O
virus	O
(	O
4	O
%	O
and	O
4	O
%,	O
respectively	O
),	O
calicivirus	O
(	O
0	O
%	O
and	O
2	O
%,	O
respectively	O
),	O
and	O
Spirometra	O
spp	B-ENZY
(	O
0	O
%	O
and	O
2	O
%,	O
respectively	O
).	O

Other	O
enteropathogens	O
identified	O
in	O
dogs	O
with	O
and	O
without	O
diarrhea	O
included	O
hookworms	O
(	O
58	O
%	O
and	O
48	O
%,	O
respectively	O
),	O
Giardia	O
spp	B-ENZY
(	O
22	O
%	O
and	O
16	O
%,	O
respectively	O
),	O
canine	O
enteric	O
coronavirus	O
(	O
2	O
%	O
and	O
18	O
%,	O
respectively	O
),	O
whipworms	O
(	O
12	O
%	O
and	O
8	O
%,	O
respectively	O
),	O
Cryptosporidium	O
spp	B-ENZY
(	O
12	O
%	O
and	O
2	O
%,	O
respectively	O
),	O
ascarids	O
(	O
8	O
%	O
and	O
8	O
%,	O
respectively	O
),	O
Salmonella	O
spp	B-ENZY
(	O
2	O
%	O
and	O
6	O
%,	O
respectively	O
),	O
Cystoisospora	O
spp	B-ENZY
(	O
2	O
%	O
and	O
4	O
%,	O
respectively	O
),	O
canine	O
distemper	O
virus	O
(	O
8	O
%	O
and	O
0	O
%,	O
respectively	O
),	O
Dipylidium	O
caninum	O
(	O
2	O
%	O
and	O
2	O
%,	O
respectively	O
),	O
canine	O
parvovirus	O
(	O
2	O
%	O
and	O
2	O
%,	O
respectively	O
),	O
and	O
rotavirus	O
(	O
2	O
%	O
and	O
0	O
%,	O
respectively	O
).	O

TITLE	O
:	O
Genomic	O
and	O
serological	O
detection	O
of	O
bat	B-ENZY
coronavirus	O
from	O
bats	O
in	O
the	O
Philippines	O
.	O

ABSTRACT	O
:	O
Bat	B-ENZY
coronavirus	O
(	O
BtCoV	O
)	O
is	O
assumed	O
to	O
be	O
a	O
progenitor	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
related	O
coronaviruses	O
.	O

Western	O
blotting	O
revealed	O
that	O
66	O
.	O
5	O
%	O
of	O
bat	B-ENZY
sera	O
had	O
antibodies	O
to	O
BtCoV	O
.	O
These	O
surveys	O
suggested	O
the	O
endemic	O
presence	O
of	O
BtCoVs	O
in	O
the	O
Philippines	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
the	O
aspiration	O
of	O
dead	O
space	O
(	O
ASPIDS	O
)	O
together	O
with	O
computer	O
simulation	O
can	O
help	O
maintain	O
gas	B-ENZY
exchange	O
at	O
these	O
settings	O
,	O
thus	O
promoting	O
protection	O
of	O
the	O
lungs	O
.	O

Luciferase	B-ENZY
activities	O
were	O
significantly	O
suppressed	O
in	O
cells	O
expressing	O
nsp1	O
together	O
with	O
the	O
mRNA	O
carrying	O
a	O
luciferase	B-ENZY
gene	O
,	O
while	O
nsp1	O
failed	O
to	O
suppress	O
luciferase	B-ENZY
activities	O
of	O
the	O
mRNA	O
flanked	O
by	O
the	O
5	O
'	O
UTR	O
of	O
SCoV	O
.	O
An	O
RNA	O
-	O
protein	O
binding	O
assay	O
and	O
RNA	O
decay	O
assay	O
revealed	O
that	O
nsp1	O
bound	O
to	O
stem	O
-	O
loop	O
1	O
(	O
SL1	O
)	O
in	O
the	O
5	O
'	O
UTR	O
of	O
SCoV	O
RNA	O
and	O
that	O
the	O
specific	O
interaction	O
with	O
nsp1	O
stabilized	O
the	O
mRNA	O
carrying	O
SL1	O
.	O

One	O
clinical	O
diagnostic	O
criterion	O
for	O
ARDS	O
is	O
the	O
P	O
(	O
a	O
)	O
O	O
(	O
2	O
):	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
)	O
ratio	O
,	O
which	O
is	O
an	O
index	O
of	O
alveolar	O
gas	B-ENZY
exchange	O
.	O

Influenza	O
infection	O
of	O
mice	O
results	O
in	O
impairment	O
of	O
alveolar	O
gas	B-ENZY
exchange	O
consistent	O
with	O
rapid	O
development	O
of	O
acute	O
lung	O
injury	O
and	O
progression	O
to	O
ARDS	O
.	O

ABSTRACT	O
:	O
Plasma	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
biomarkers	O
related	O
to	O
the	O
pathogenesis	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
have	O
previously	O
been	O
associated	O
with	O
poorer	O
clinical	O
outcomes	O
and	O
increased	O
disease	O
severity	O
among	O
patients	O
with	O
ALI	O
.	O

We	O
tested	O
the	O
association	O
of	O
plasma	O
and	O
BAL	B-ENZY
biomarkers	O
with	O
physiological	O
markers	O
of	O
ALI	O
severity	O
or	O
clinically	O
relevant	O
outcomes	O
in	O
a	O
secondary	O
analysis	O
of	O
a	O
clinical	O
trial	O
of	O
activated	O
protein	O
C	O
for	O
the	O
treatment	O
of	O
ALI	O
.	O

Plasma	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
and	O
mini	O
-	O
BAL	B-ENZY
protein	O
were	O
both	O
significantly	O
associated	O
with	O
increased	O
oxygenation	O
index	O
(	O
P	O
=	O
0	O
.	O
02	O
and	O
0	O
.	O
01	O
,	O
respectively	O
),	O
whereas	O
there	O
was	O
a	O
trend	O
toward	O
an	O
association	O
between	O
IL	O
-	O
6	O
and	O
oxygenation	O
index	O
(	O
P	O
=	O
0	O
.	O
057	O
).	O

High	O
plasma	O
IL	O
-	O
6	O
,	O
thrombomodulin	O
,	O
and	O
mini	O
-	O
BAL	B-ENZY
protein	O
were	O
all	O
significantly	O
associated	O
with	O
fewer	O
ventilator	O
-	O
free	O
days	O
(	O
VFDs	O
)	O
(	O
P	O
=	O
0	O
.	O
01	O
,	O
0	O
.	O
01	O
,	O
and	O
0	O
.	O
05	O
,	O
respectively	O
);	O
no	O
markers	O
were	O
associated	O
with	O
mortality	O
,	O
but	O
we	O
hypothesized	O
that	O
this	O
was	O
due	O
to	O
the	O
small	O
size	O
of	O
our	O
cohort	O
and	O
the	O
low	O
death	O
rate	O
.	O

Future	O
studies	O
should	O
be	O
focused	O
on	O
examining	O
larger	O
numbers	O
of	O
patients	O
with	O
less	O
severe	O
ALI	O
to	O
further	O
test	O
the	O
relative	O
predictive	O
value	O
of	O
plasma	O
and	O
mini	O
-	O
BAL	B-ENZY
biomarkers	O
for	O
clinically	O
relevant	O
outcomes	O
,	O
including	O
VFDs	O
and	O
mortality	O
,	O
and	O
for	O
their	O
prospective	O
utility	O
in	O
risk	O
stratification	O
for	O
future	O
clinical	O
trials	O
.	O

ABSTRACT	O
:	O
In	O
patients	O
with	O
severe	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
the	O
prone	O
position	O
has	O
been	O
shown	O
to	O
improve	O
survival	O
of	O
patients	O
who	O
are	O
severely	O
hypoxemic	O
with	O
an	O
arterial	O
oxygen	O
tension	O
to	O
inspiratory	O
oxygen	O
fraction	O
ratio	O
(	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
))<	O
100	O
.	O

TITLE	O
:	O
Structural	O
bases	O
of	O
coronavirus	O
attachment	O
to	O
host	O
aminopeptidase	B-ENZY
N	I-ENZY
and	O
its	O
inhibition	O
by	O
neutralizing	O
antibodies	O
.	O

A	O
subset	O
of	O
CoVs	O
uses	O
the	O
cell	O
surface	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
),	O
a	O
membrane	O
-	O
bound	O
metalloprotease	O
,	O
as	O
a	O
cell	O
entry	O
receptor	O
.	O

Analysis	O
of	O
immune	O
-	O
related	O
gene	O
expression	O
profiles	O
showed	O
that	O
at	O
24	O
h	O
after	O
SARS	O
-	O
CoV	O
infection	O
:	O
(	O
1	O
)	O
IFN	O
-	O
	O
/	O
	O
-	O
inducible	O
and	O
cathepsin	O
/	O
proteasome	B-ENZY
genes	O
were	O
downregulated	O
;	O
(	O
2	O
)	O
hypoxia	O
/	O
hyperoxia	O
-	O
related	O
genes	O
were	O
upregulated	O
;	O
and	O
(	O
3	O
)	O
TLR	O
/	O
TLR	O
-	O
signaling	O
,	O
cytokine	O
/	O
cytokine	O
receptor	O
-	O
related	O
,	O
chemokine	O
/	O
chemokine	O
receptor	O
-	O
related	O
,	O
lysosome	O
-	O
related	O
,	O
MHC	O
/	O
chaperon	O
-	O
related	O
,	O
and	O
fibrosis	O
-	O
related	O
genes	O
were	O
differentially	O
regulated	O
.	O

Histopathological	O
examination	O
,	O
a	O
hydrostatic	O
lung	O
test	O
and	O
blood	O
gas	B-ENZY
analysis	O
showed	O
positive	O
results	O
in	O
the	O
combination	O
therapy	O
group	O
.	O

Additionally	O
,	O
the	O
inhibition	O
is	O
selective	O
because	O
these	O
compounds	O
do	O
not	O
exert	O
significant	O
inhibitory	O
effects	O
against	O
other	O
proteases	O
including	O
chymotrysin	O
,	O
papain	B-ENZY
,	O
and	O
HIV	O
protease	O
.	O

The	O
isolated	O
strains	O
were	O
characterized	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
and	O
sequence	O
analysis	O
of	O
the	O
hypervariable	O
region	O
3	O
of	O
the	O
S1	O
spike	O
glycoprotein	O
gene	O
.	O

Multiple	O
pathogens	O
are	O
responsible	O
for	O
infectious	O
diarrhea	O
,	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
Bovine	O
coronavirus	O
(	O
BCV	O
),	O
bovine	O
Rotavirus	O
A	O
(	O
BRV	O
),	O
and	O
Cryptosporidium	O
spp	B-ENZY
.	O

Texas	O
Veterinary	O
Medical	O
Diagnostic	O
Laboratory	O
current	O
methods	O
for	O
calf	O
diarrhea	O
pathogen	O
identification	O
include	O
electron	O
microscopy	O
(	O
EM	O
)	O
for	O
BCV	O
and	O
BRV	O
and	O
a	O
direct	O
fluorescent	O
antibody	O
test	O
(	O
DFAT	O
)	O
for	O
organism	O
detection	O
of	O
Cryptosporidium	O
spp	B-ENZY
.	O

A	O
workflow	O
was	O
developed	O
consisting	O
of	O
an	O
optimized	O
fecal	O
nucleic	O
acid	O
purification	O
and	O
multiplex	O
reverse	O
transcription	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
for	O
single	O
tube	O
concurrent	O
detection	O
of	O
BCV	O
,	O
BRV	O
,	O
and	O
Cryptosporidium	O
spp	B-ENZY
.,	O
and	O
an	O
internal	O
control	O
to	O
monitor	O
nucleic	O
acid	O
purification	O
efficacy	O
and	O
PCR	O
reagent	O
functionality	O
.	O

Analytical	O
specificity	O
was	O
confirmed	O
using	O
Canine	O
and	O
Feline	O
coronavirus	O
,	O
Giardia	O
spp	B-ENZY
.,	O
and	O
noninfected	O
bovine	O
purified	O
nucleic	O
acid	O
.	O

These	O
viruses	O
possess	O
3C	O
or	O
3C	O
-	O
like	O
proteases	O
(	O
3Cpro	O
or	O
3CLpro	O
,	O
respectively	O
),	O
which	O
contain	O
a	O
typical	O
chymotrypsin	B-ENZY
-	O
like	O
fold	O
and	O
a	O
catalytic	O
triad	O
(	O
or	O
dyad	O
)	O
with	O
a	O
Cys	O
residue	O
as	O
a	O
nucleophile	O
.	O

A	O
minimum	O
level	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
and	O
mutually	O
exclusive	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
thresholds	O
were	O
chosen	O
for	O
the	O
different	O
levels	O
of	O
ARDS	O
severity	O
(	O
mild	O
,	O
moderate	O
,	O
severe	O
)	O
to	O
better	O
categorize	O
patients	O
with	O
different	O
outcomes	O
and	O
potential	O
responses	O
to	O
therapy	O
.	O

A	O
minimum	O
level	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
and	O
mutually	O
exclusive	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
thresholds	O
were	O
chosen	O
for	O
the	O
different	O
levels	O
of	O
ARDS	O
severity	O
(	O
mild	O
,	O
moderate	O
,	O
severe	O
)	O
to	O
better	O
categorize	O
patients	O
with	O
different	O
outcomes	O
and	O
potential	O
responses	O
to	O
therapy	O
.	O

An	O
observational	O
cohort	O
study	O
of	O
HIV	O
-	O
negative	O
adults	O
with	O
PJP	O
documented	O
by	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
through	O
Gomori	O
-	O
Grocott	O
staining	O
or	O
immunofluorescence	O
,	O
admitted	O
to	O
one	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
for	O
acute	O
respiratory	O
failure	O
,	O
was	O
undertaken	O
.	O

During	O
a	O
surveillance	O
study	O
from	O
2005	O
to	O
2010	O
,	O
a	O
novel	O
alphacoronavirus	O
,	O
BatCoV	O
HKU10	O
,	O
was	O
detected	O
in	O
two	O
very	O
different	O
bat	B-ENZY
species	O
,	O
Ro	O
-	O
BatCoV	O
HKU10	O
in	O
Leschenault	O
'	O
s	O
rousettes	O
(	O
Rousettus	O
leschenaulti	O
)	O
(	O
fruit	O
bats	O
in	O
the	O
suborder	O
Megachiroptera	O
)	O
in	O
Guangdong	O
and	O
Hi	O
-	O
BatCoV	O
HKU10	O
in	O
Pomona	O
leaf	O
-	O
nosed	O
bats	O
(	O
Hipposideros	O
pomona	O
)	O
(	O
insectivorous	O
bats	O
in	O
the	O
suborder	O
Microchiroptera	O
)	O
in	O
Hong	O
Kong	O
.	O

To	O
investigate	O
possible	O
interspecies	O
transmission	O
between	O
the	O
two	O
bat	B-ENZY
species	O
,	O
the	O
complete	O
genomes	O
of	O
two	O
Ro	O
-	O
BatCoV	O
HKU10	O
and	O
six	O
Hi	O
-	O
BatCoV	O
HKU10	O
strains	O
were	O
sequenced	O
.	O

syndrome	O
-	O
related	O
Rhinolophus	O
bat	B-ENZY
coronavirus	O
(	O
SARSr	O
-	O
CoV	O
)	O
in	O
bats	O
and	O
civets	O
.	O

TITLE	O
:	O
Correlation	O
between	O
TGF	O
-	O
1	O
expression	O
and	O
proteomic	O
profiling	O
induced	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
),	O
a	O
deubiquitinating	O
enzyme	O
,	O
demonstrates	O
inactivation	O
of	O
interferon	O
(	O
IFN	O
)	O
regulatory	O
factor	O
3	O
and	O
NF	O
-	O
B	O
,	O
reduction	O
of	O
IFN	O
induction	O
,	O
and	O
suppression	O
of	O
type	O
I	O
IFN	O
signaling	O
pathway	O
.	O

Proteomic	O
analysis	O
,	O
Western	O
blot	O
,	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O
assays	O
indicated	O
PLpro	O
upregulating	O
TGF	O
-	O
1	O
-	O
associated	O
genes	O
:	O
HSP27	O
,	O
protein	O
disulfide	O
isomerase	O
A3	O
precursor	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
vimentin	O
,	O
retinal	B-ENZY
dehydrogenase	I-ENZY
2	O
,	O
and	O
glutathione	B-ENZY
transferase	I-ENZY
omega	O
-	O
1	O
.	O

PLpro	O
-	O
activated	O
ubiquitin	O
proteasome	B-ENZY
pathway	O
via	O
upregulation	O
of	O
ubiquitin	B-ENZY
-	I-ENZY
conjugating	I-ENZY
enzyme	I-ENZY
E2	O
-	O
25k	O
and	O
proteasome	B-ENZY
subunit	O
alpha	O
type	O
5	O
.	O

Proteasome	B-ENZY
inhibitor	O
MG	O
-	O
132	O
significantly	O
reduced	O
expression	O
of	O
TGF	O
-	O
1	O
and	O
vimentin	O
.	O

The	O
emergence	O
or	O
re	O
-	O
emergence	O
of	O
bacterial	O
(	O
Mycobacterium	O
bovis	O
and	O
Brucella	O
spp	B-ENZY
)	O
or	O
viral	O
(	O
hepatitis	O
E	O
virus	O
)	O
infections	O
shows	O
that	O
zoonoses	O
should	O
be	O
considered	O
as	O
emerging	O
risks	O
in	O
agricultural	O
and	O
animal	O
breeding	O
and	O
should	O
be	O
addressed	O
by	O
specific	O
preventive	O
interventions	O
.	O

On	O
such	O
occasions	O
,	O
the	O
Respironics	O
V60	O
Ventilator	O
,	O
which	O
is	O
equipped	O
with	O
an	O
average	O
volume	O
-	O
assured	O
pressure	O
support	O
mode	O
,	O
may	O
be	O
useful	O
in	O
improving	O
gas	B-ENZY
exchange	O
and	O
may	O
achieve	O
good	O
patient	O
compliance	O
,	O
because	O
that	O
mode	O
allows	O
ventilation	O
to	O
be	O
maintained	O
by	O
automatically	O
adjusting	O
the	O
inspiratory	O
force	O
to	O
within	O
an	O
acceptable	O
range	O
whenever	O
ventilation	O
falls	O
below	O
target	O
levels	O
.	O

In	O
this	O
review	O
,	O
we	O
propose	O
a	O
novel	O
framework	O
for	O
the	O
holistic	O
and	O
interdisciplinary	O
investigation	O
of	O
zoonotic	O
disease	O
emergence	O
and	O
its	O
drivers	O
,	O
using	O
the	O
spillover	O
of	O
bat	B-ENZY
pathogens	O
as	O
a	O
case	O
study	O
.	O

We	O
revealed	O
that	O
administration	O
of	O
PGRN	O
significantly	O
reduced	O
LPS	O
-	O
induced	O
pulmonary	O
inflammation	O
,	O
as	O
reflected	O
by	O
reductions	O
in	O
total	O
cell	O
and	O
neutrophil	O
counts	O
,	O
proinflammatory	O
cytokines	O
,	O
as	O
well	O
as	O
chemokines	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
.	O

Furthermore	O
,	O
administration	O
of	O
PGRN	O
resulted	O
in	O
remarkable	O
reversal	O
of	O
LPS	O
-	O
induced	O
increases	O
in	O
lung	O
permeability	O
as	O
assessed	O
by	O
reductions	O
in	O
total	O
protein	O
,	O
albumin	O
,	O
and	O
IgM	O
in	O
BAL	B-ENZY
fluid	O
.	O

A	O
VRDAL	O
multiplex	O
PCR	O
for	O
10	O
common	O
respiratory	O
viruses	O
was	O
performed	O
on	O
collected	O
specimens	O
compared	O
with	O
the	O
Seeplex	O
	O
RV15	O
ACE	B-ENZY
Detection	O
kit	O
for	O
15	O
respiratory	O
viruses	O
.	O

Using	O
the	O
Seeplex	O
	O
RV15	O
ACE	B-ENZY
Detection	O
kit	O
,	O
viruses	O
were	O
detected	O
in	O
129	O
(	O
78	O
.	O
7	O
%)	O
patients	O
,	O
49	O
(	O
29	O
.	O
9	O
%)	O
were	O
co	O
-	O
infected	O
cases	O
.	O

The	O
Seeplex	O
	O
RV15	O
ACE	B-ENZY
detection	O
method	O
was	O
found	O
to	O
be	O
a	O
more	O
reliable	O
high	O
throughput	O
tool	O
than	O
VRDAL	O
method	O
to	O
simultaneously	O
detect	O
multiple	O
respiratory	O
viruses	O
.	O

TITLE	O
:	O
Diarylheptanoids	O
from	O
Alnus	O
japonica	O
inhibit	O
papain	B-ENZY
-	O
like	O
protease	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	O
)),	O
which	O
controls	O
replication	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
has	O
been	O
identified	O
as	O
a	O
potential	O
drug	O
target	O
for	O
the	O
treatment	O
of	O
SARS	O
.	O

ABSTRACT	O
:	O
The	O
relationship	O
between	O
bats	O
and	O
coronaviruses	O
(	O
CoVs	O
)	O
has	O
received	O
considerable	O
attention	O
since	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
like	O
CoV	O
was	O
identified	O
in	O
the	O
Chinese	O
horseshoe	O
bat	B-ENZY
(	O
Rhinolophidae	O
)	O
in	O
2005	O
.	O

Since	O
then	O
,	O
several	O
bats	O
throughout	O
the	O
world	O
have	O
been	O
shown	O
to	O
shed	O
CoV	O
sequences	O
,	O
and	O
presumably	O
CoVs	O
,	O
in	O
the	O
feces	O
;	O
however	O
,	O
no	O
bat	B-ENZY
CoVs	O
have	O
been	O
isolated	O
from	O
nature	O
.	O

Here	O
,	O
we	O
show	O
by	O
molecular	O
clock	O
analysis	O
that	O
alphacoronavirus	O
(	O
	O
-	O
CoV	O
)	O
sequences	O
derived	O
from	O
the	O
North	O
American	O
tricolored	O
bat	B-ENZY
(	O
Perimyotis	O
subflavus	O
)	O
are	O
predicted	O
to	O
share	O
common	O
ancestry	O
with	O
human	O
CoV	O
(	O
HCoV	O
)-	O
NL63	O
,	O
with	O
the	O
most	O
recent	O
common	O
ancestor	O
between	O
these	O
viruses	O
occurring	O
approximately	O
563	O
to	O
822	O
years	O
ago	O
.	O

TITLE	O
:	O
Characterization	O
of	O
cellular	O
furin	B-ENZY
content	O
as	O
a	O
potential	O
factor	O
determining	O
the	O
susceptibility	O
of	O
cultured	O
human	O
and	O
animal	O
cells	O
to	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
infection	O
.	O

Reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
employed	O
to	O
screen	O
for	O
coronavirus	O
NL63	O
,	O
which	O
is	O
a	O
255	O
bp	O
fragment	O
of	O
a	O
part	O
of	O
N	O
gene	O
.	O

Treatment	O
with	O
inhaled	O
epoprostenol	O
improved	O
gas	B-ENZY
exchange	O
in	O
severely	O
hypoxemic	O
surgical	O
patients	O
.	O

The	O
complication	O
rate	O
,	O
time	O
of	O
recovery	O
of	O
cholinesterase	B-ENZY
(	O
ChE	O
)	O
activity	O
to	O
70	O
,	O
hospital	O
stay	O
time	O
and	O
cost	O
,	O
the	O
cure	O
rate	O
,	O
mortality	O
rate	O
in	O
three	O
groups	O
were	O
analyzed	O
.	O

Genome	O
sequencing	O
showed	O
that	O
this	O
virus	O
belongs	O
to	O
the	O
group	O
C	O
species	O
of	O
the	O
genus	O
betacoronavirus	O
and	O
phylogenetically	O
related	O
to	O
the	O
bat	B-ENZY
coronaviruses	O
HKU4	O
and	O
HKU5	O
previously	O
found	O
in	O
lesser	O
bamboo	O
bat	B-ENZY
and	O
Japanese	O
Pipistrelle	O
bat	B-ENZY
of	O
Hong	O
Kong	O
respectively	O
.	O

Since	O
70	O
%	O
of	O
all	O
emerging	O
infectious	O
pathogens	O
came	O
from	O
animals	O
,	O
the	O
emergence	O
of	O
this	O
novel	O
virus	O
may	O
represent	O
another	O
instance	O
of	O
interspecies	O
jumping	O
of	O
betacoronavirus	O
from	O
animals	O
to	O
human	O
similar	O
to	O
the	O
group	O
A	O
coronavirus	O
OC43	O
possibly	O
from	O
a	O
bovine	O
source	O
in	O
the	O
1890s	O
and	O
the	O
group	O
B	O
SARS	O
coronavirus	O
in	O
2003	O
from	O
bat	B-ENZY
to	O
civet	O
and	O
human	O
.	O

Current	O
opinion	O
is	O
that	O
by	O
reducing	O
the	O
pressure	O
and	O
volume	O
of	O
gas	B-ENZY
delivered	O
to	O
the	O
lungs	O
during	O
mechanical	O
ventilation	O
,	O
the	O
stress	O
applied	O
to	O
the	O
lungs	O
is	O
eased	O
,	O
enabling	O
them	O
to	O
rest	O
and	O
recover	O
.	O

In	O
addition	O
,	O
mechanical	O
ventilation	O
may	O
fail	O
to	O
provide	O
adequate	O
gas	B-ENZY
exchange	O
,	O
thus	O
patients	O
may	O
suffer	O
from	O
severe	O
hypoxia	O
and	O
hypercapnea	O
.	O

The	O
objective	O
of	O
this	O
analysis	O
was	O
to	O
assess	O
the	O
effectiveness	O
,	O
safety	O
,	O
and	O
cost	O
-	O
effectiveness	O
of	O
extracorporeal	O
lung	O
support	O
technologies	O
in	O
the	O
improvement	O
of	O
pulmonary	O
gas	B-ENZY
exchange	O
and	O
the	O
survival	O
of	O
adult	O
patients	O
with	O
acute	O
pulmonary	O
failure	O
and	O
those	O
with	O
end	O
-	O
stage	O
chronic	O
progressive	O
lung	O
disease	O
as	O
a	O
bridge	O
to	O
lung	O
transplantation	O
(	O
LTx	O
).	O

These	O
techniques	O
do	O
not	O
treat	O
the	O
underlying	O
lung	O
condition	O
;	O
rather	O
,	O
they	O
improve	O
gas	B-ENZY
exchange	O
while	O
enabling	O
the	O
implantation	O
of	O
a	O
protective	O
ventilation	O
strategy	O
to	O
prevent	O
further	O
damage	O
to	O
the	O
lung	O
tissues	O
imposed	O
by	O
the	O
ventilator	O
.	O

The	O
system	O
is	O
characterized	O
by	O
a	O
novel	O
,	O
low	O
-	O
resistance	O
gas	B-ENZY
exchange	O
device	O
with	O
a	O
diffusion	O
membrane	O
composed	O
of	O
polymethylpentene	O
(	O
PMP	O
)	O
fibres	O
.	O

The	O
research	O
questions	O
addressed	O
in	O
this	O
report	O
are	O
:	O
Does	O
ILA	O
/	O
ECMO	O
facilitate	O
gas	B-ENZY
exchange	O
in	O
the	O
lungs	O
of	O
patients	O
with	O
severe	O
respiratory	O
failure	O
?	O
Does	O
ILA	O
/	O
ECMO	O
improve	O
the	O
survival	O
rate	O
of	O
patients	O
with	O
respiratory	O
failure	O
caused	O
by	O
a	O
range	O
of	O
underlying	O
conditions	O
including	O
patients	O
awaiting	O
LTx	O
?	O
What	O
are	O
the	O
possible	O
serious	O
adverse	O
events	O
associated	O
with	O
ILA	O
/	O
ECMO	O
therapy	O
?	O
To	O
address	O
these	O
questions	O
,	O
a	O
systematic	O
literature	O
search	O
was	O
performed	O
on	O
September	O
28	O
,	O
2009	O
using	O
OVID	O
MEDLINE	O
,	O
MEDLINE	O
In	O
-	O
Process	O
and	O
Other	O
Non	O
-	O
Indexed	O
Citations	O
,	O
EMBASE	O
,	O
the	O
Cumulative	O
Index	O
to	O
Nursing	O
&	O
Allied	O
Health	O
Literature	O
(	O
CINAHL	O
),	O
the	O
Cochrane	O
Library	O
,	O
and	O
the	O
International	O
Agency	O
for	O
Health	O
Technology	O
Assessment	O
(	O
INAHTA	O
)	O
for	O
studies	O
published	O
from	O
January	O
1	O
,	O
2005	O
to	O
September	O
28	O
,	O
2008	O
.	O

All	O
studies	O
reported	O
the	O
rate	O
of	O
gas	B-ENZY
exchange	O
and	O
respiratory	O
mechanics	O
before	O
ILA	O
and	O
for	O
up	O
to	O
7	O
days	O
of	O
ILA	O
therapy	O
.	O

Four	O
studies	O
reported	O
the	O
means	O
and	O
standard	O
deviations	O
of	O
blood	O
gas	B-ENZY
transfer	O
and	O
arterial	O
blood	O
pH	O
,	O
which	O
were	O
used	O
for	O
meta	O
-	O
analysis	O
.	O

The	O
closest	O
known	O
relatives	O
are	O
bat	B-ENZY
coronaviruses	O
HKU4	O
and	O
HKU5	O
.	O

Clinical	O
diagnosis	O
relies	O
on	O
the	O
following	O
4	O
criteria	O
stated	O
by	O
the	O
American	O
-	O
European	O
Consensus	O
Conference	O
:	O
acute	O
onset	O
of	O
impaired	O
gas	B-ENZY
exchange	O
,	O
severe	O
hypoxemia	O
defined	O
as	O
a	O
PaO2	O
to	O
FiO2	O
ratio	O
<	O
300	O
(	O
PaO2	O
in	O
mmHg	O
),	O
bilateral	O
diffuse	O
infiltration	O
on	O
chest	O
X	O
-	O
ray	O
;	O
pulmonary	O
artery	O
wedge	O
pressure	O
of	O
	O
18	O
mmHg	O
to	O
rule	O
out	O
cardiogenic	O
causes	O
of	O
pulmonary	O
edema	O
.	O

DAMPs	O
can	O
function	O
as	O
either	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
agonists	O
or	O
antagonists	O
,	O
and	O
can	O
modulate	O
both	O
TLR	O
and	O
nod	B-ENZY
-	O
like	O
receptor	O
(	O
NLR	O
)	O
signalling	O
cascades	O
.	O

ABSTRACT	O
:	O
In	O
patients	O
with	O
the	O
most	O
severe	O
forms	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
refractory	O
to	O
conventional	O
mechanical	O
ventilation	O
and	O
adjunctive	O
or	O
rescue	O
therapies	O
like	O
kinetic	O
therapy	O
,	O
inhaled	O
vasodilators	O
or	O
extracorporeal	O
CO2	O
-	O
elimination	O
(	O
extracorporeal	O
lung	O
assist	O
),	O
the	O
use	O
of	O
the	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
can	O
secure	O
gas	B-ENZY
exchange	O
.	O

TITLE	O
:	O
New	O
anthraquinone	O
derivatives	O
as	O
inhibitors	O
of	O
the	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
associated	O
ribonuclease	B-ENZY
H	I-ENZY
function	O
.	O

ABSTRACT	O
:	O
The	O
degradative	O
activity	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
),	O
termed	O
ribonuclease	B-ENZY
H	I-ENZY
(	O
RNase	B-ENZY
H	I-ENZY
),	O
which	O
hydrolyzes	O
the	O
RNA	O
component	O
of	O
the	O
heteroduplex	O
RNA	O
:	O
DNA	O
replication	O
intermediate	O
,	O
is	O
an	O
excellent	O
target	O
for	O
drug	O
discovery	O
.	O

We	O
have	O
assayed	O
new	O
AQ	O
derivatives	O
on	O
HIV	O
-	O
1	O
RNase	B-ENZY
H	I-ENZY
activities	O
in	O
biochemical	O
assays	O
.	O

Our	O
results	O
demonstrate	O
that	O
AQ	O
derivatives	O
are	O
promising	O
anti	O
-	O
RNase	B-ENZY
H	I-ENZY
inhibitors	O
.	O

RESULTS	O
:	O
The	O
limit	O
of	O
detection	O
(	O
LOD	B-ENZY
)	O
was	O
1	O
.	O
31	O
plaque	O
-	O
forming	O
units	O
(	O
PFU	O
)/	O
mL	O
for	O
human	O
rhinoviruses	O
(	O
hRVs	O
),	O
4	O
.	O
93	O
PFU	O
/	O
mL	O
for	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
/	O
NL63	O
,	O
2	O
.	O
67	O
PFU	O
/	O
mL	O
for	O
human	O
coronavirus	O
HCoV	O
-	O
OC43	O
,	O
18	O
.	O
20	O
PFU	O
/	O
mL	O
for	O
parainfluenza	O
virus	O
1	O
(	O
PIV	O
)-	O
1	O
,	O
24	O
.	O
57	O
PFU	O
/	O
mL	O
for	O
PIV	O
-	O
2	O
,	O
1	O
.	O
73	O
PFU	O
/	O
mL	O
for	O
PIV	O
-	O
3	O
,	O
1	O
.	O
79	O
PFU	O
/	O
mL	O
for	O
influenza	O
virus	O
group	O
(	O
Flu	O
)	O
A	O
,	O
59	O
.	O
51	O
PFU	O
/	O
mL	O
for	O
FluB	O
,	O
5	O
.	O
46	O
PFU	O
/	O
mL	O
for	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
hRSV	O
)-	O
A	O
,	O
17	O
.	O
23	O
PFU	O
/	O
mL	O
for	O
hRSV	O
-	O
B	O
,	O
9	O
.	O
99	O
PFU	O
/	O
mL	O
for	O
human	O
adenovirus	O
(	O
ADVs	O
).	O

Bortezomib	O
is	O
a	O
proteasome	B-ENZY
inhibitor	O
indicated	O
for	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
patients	O
.	O

Of	O
the	O
12	O
cases	O
,	O
3	O
were	O
established	O
ECMO	O
(	O
E	O
-	O
CPR	B-ENZY
)	O
while	O
underwent	O
chest	O
compression	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	B-ENZY
).	O

Phylogenetic	O
analysis	O
of	O
the	O
replicase	O
gene	O
of	O
coronaviruses	O
with	O
completely	O
sequenced	O
genomes	O
showed	O
that	O
HCoV	O
-	O
EMC	O
/	O
2012	O
is	O
most	O
closely	O
related	O
to	O
Tylonycteris	O
bat	B-ENZY
coronavirus	O
HKU4	O
(	O
BtCoV	O
-	O
HKU4	O
)	O
and	O
Pipistrellus	O
bat	B-ENZY
coronavirus	O
HKU5	O
(	O
BtCoV	O
-	O
HKU5	O
),	O
which	O
prototype	O
two	O
species	O
in	O
lineage	O
C	O
of	O
the	O
genus	O
Betacoronavirus	O
.	O

By	O
establishing	O
its	O
complete	O
genome	O
sequence	O
,	O
HCoV	O
-	O
EMC	O
/	O
2012	O
was	O
characterized	O
as	O
a	O
new	O
genotype	O
which	O
is	O
closely	O
related	O
to	O
bat	B-ENZY
coronaviruses	O
that	O
are	O
distant	O
from	O
SARS	O
-	O
CoV	O
.	O
We	O
expect	O
that	O
this	O
information	O
will	O
be	O
vital	O
to	O
rapid	O
advancement	O
of	O
both	O
clinical	O
and	O
vital	O
research	O
on	O
this	O
emerging	O
pathogen	O
.	O

Exogenous	O
surfactant	O
replacement	O
in	O
animal	O
models	O
of	O
ARDS	O
and	O
neonatal	O
respiratory	O
distress	O
syndrome	O
shows	O
consistent	O
improvements	O
in	O
gas	B-ENZY
exchange	O
and	O
survival	O
.	O

We	O
have	O
further	O
showed	O
that	O
the	O
peptidomimetic	O
inhibitor	O
,	O
Cbz	O
-	O
AVLQ	O
-	O
CN	O
,	O
has	O
broad	O
-	O
spectrum	O
inhibition	O
against	O
3CL	O
(	O
pro	O
)	O
from	O
human	O
coronavirus	O
strains	O
229E	O
,	O
NL63	O
,	O
OC43	O
,	O
HKU1	O
,	O
and	O
infectious	O
bronchitis	O
virus	O
,	O
with	O
IC	O
(	O
50	O
)	O
values	O
ranging	O
from	O
1	O
.	O
3	O
to	O
3	O
.	O
7	O
M	O
,	O
but	O
no	O
detectable	O
inhibition	O
against	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
.	O

We	O
compared	O
,	O
at	O
two	O
different	O
levels	O
of	O
pump	O
flow	O
,	O
SaO	O
(	O
2	O
)	O
and	O
the	O
oxygen	O
saturation	O
measured	O
in	O
the	O
pulmonary	O
artery	O
(	O
SpaO	O
(	O
2	O
))	O
with	O
the	O
predicted	O
saturation	O
using	O
the	O
formula	O
:	O
SpaO	O
(	O
2	O
)	O
=	O
(	O
EF	O
/	O
CO	O
)	O
SmO	B-ENZY
(	O
2	O
)	O
+	O
(	O
1	O
-	O
EF	O
/	O
CO	O
)	O
SvO	O
(	O
2	O
)	O
+	O
10	O
(-	O
2	O
)	O
PmO	O
(	O
2	O
),	O
where	O
PF	O
is	O
pump	O
flow	O
,	O
R	O
is	O
recirculation	O
,	O
EF	O
is	O
effective	O
flow	O
[=	O
(	O
1	O
-	O
R	O
)	O
PF	O
],	O
SmO	B-ENZY
(	O
2	O
)	O
is	O
saturation	O
of	O
the	O
oxygenator	O
outgoing	O
blood	O
,	O
CO	O
is	O
cardiac	O
output	O
,	O
SvO	O
(	O
2	O
)	O
is	O
saturation	O
of	O
mixed	O
venous	O
blood	O
,	O
and	O
PmO	O
(	O
2	O
)	O
is	O
oxygen	O
partial	O
pressure	O
of	O
the	O
oxygenator	O
outgoing	O
blood	O
.	O

Coronavirus	O
RNA	O
was	O
recovered	O
from	O
fresh	O
feces	O
from	O
spotted	O
hyena	O
and	O
silver	O
-	O
backed	O
jackal	O
,	O
but	O
not	O
bat	B-ENZY
-	O
eared	O
fox	O
.	O

During	O
the	O
replication	O
process	O
,	O
coronavirus	O
produces	O
viral	O
polyproteins	O
that	O
are	O
processed	O
into	O
mature	O
proteins	O
by	O
viral	O
proteases	O
,	O
the	O
main	O
protease	O
(	O
3C	O
-	O
like	O
[	O
3CL	O
]	O
protease	O
)	O
and	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
.	O

In	O
this	O
study	O
,	O
we	O
further	O
evaluated	O
the	O
antiviral	O
effects	O
of	O
the	O
peptidyl	O
inhibitors	O
against	O
feline	O
coronaviruses	O
,	O
and	O
investigated	O
the	O
interaction	O
between	O
our	O
protease	O
inhibitor	O
and	O
a	O
cathepsin	B-ENZY
B	I-ENZY
inhibitor	O
,	O
an	O
entry	O
blocker	O
,	O
against	O
a	O
feline	O
coronavirus	O
in	O
cell	O
culture	O
.	O

Herein	O
we	O
report	O
that	O
our	O
compounds	O
behave	O
as	O
reversible	O
,	O
competitive	O
inhibitors	O
of	O
3CL	O
protease	O
,	O
potently	O
inhibited	O
the	O
replication	O
of	O
feline	O
coronaviruses	O
(	O
EC	O
(	O
50	O
)	O
in	O
a	O
nanomolar	O
range	O
)	O
and	O
,	O
furthermore	O
,	O
combination	O
of	O
cathepsin	B-ENZY
B	I-ENZY
and	O
3CL	O
protease	O
inhibitors	O
led	O
to	O
a	O
strong	O
synergistic	O
interaction	O
against	O
feline	O
coronaviruses	O
in	O
a	O
cell	O
culture	O
system	O
.	O

Thirteen	O
effusions	O
,	O
one	O
plasma	O
and	O
three	O
undefined	O
samples	O
from	O
cats	O
with	O
FIP	O
,	O
which	O
gave	O
unexpectedly	O
low	O
FCoV	O
antibody	O
titres	O
,	O
were	O
examined	O
by	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

In	O
in	O
vitro	O
systems	O
,	O
histones	O
damaged	O
endothelial	O
cells	O
,	O
stimulated	O
cytokine	O
release	O
,	O
and	O
induced	O
neutrophil	O
extracellular	O
trap	O
formation	O
and	O
myeloperoxidase	B-ENZY
release	O
.	O

As	O
human	O
CoV	O
normally	O
cannot	O
replicate	O
in	O
bat	B-ENZY
cells	O
from	O
different	O
families	O
,	O
this	O
suggests	O
that	O
hCoV	O
-	O
EMC	O
might	O
use	O
a	O
receptor	O
molecule	O
that	O
is	O
conserved	O
in	O
bats	O
,	O
pigs	O
,	O
and	O
humans	O
,	O
implicating	O
a	O
low	O
barrier	O
against	O
cross	O
-	O
host	O
transmission	O
.	O

Coronaviruses	O
have	O
a	O
reservoir	O
in	O
bats	O
and	O
because	O
this	O
novel	O
virus	O
is	O
related	O
to	O
SARS	O
-	O
CoV	O
,	O
we	O
investigated	O
whether	O
it	O
might	O
replicate	O
in	O
bat	B-ENZY
cells	O
and	O
use	O
the	O
same	O
receptor	O
(	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
[	O
ACE2	O
]).	O

Moreover	O
,	O
the	O
virus	O
is	O
capable	O
of	O
infecting	O
human	O
,	O
pig	O
,	O
and	O
bat	B-ENZY
cells	O
.	O

This	O
is	O
remarkable	O
,	O
as	O
human	O
CoVs	O
normally	O
cannot	O
replicate	O
in	O
bat	B-ENZY
cells	O
as	O
a	O
consequence	O
of	O
host	O
adaptation	O
.	O

We	O
therefore	O
assessed	O
the	O
effects	O
on	O
gas	B-ENZY
exchange	O
and	O
lung	O
mechanics	O
and	O
the	O
possible	O
detrimental	O
effects	O
of	O
a	O
sequential	O
lung	O
RMs	O
and	O
decremental	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
titration	O
in	O
pediatric	O
ARDS	O
patients	O
.	O

Efficacy	O
was	O
evaluated	O
as	O
changes	O
in	O
lung	O
compliance	O
(	O
Cdyn	O
)	O
and	O
gas	B-ENZY
exchange	O
1	O
,	O
12	O
,	O
and	O
24	O
hr	O
after	O
the	O
RM	O
.	O

Gas	B-ENZY
exchange	O
worsening	O
over	O
the	O
next	O
24	O
hr	O
resulted	O
in	O
HFOV	O
use	O
in	O
36	O
%	O
of	O
patients	O
,	O
while	O
the	O
remaining	O
subjects	O
sustained	O
improvements	O
in	O
oxygenation	O
at	O
12	O
and	O
24	O
hr	O
.	O

In	O
the	O
presence	O
of	O
alveolar	O
capillary	O
damage	O
,	O
which	O
occurs	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
intra	O
-	O
abdominal	O
hypertension	O
promotes	O
lung	O
injury	O
as	O
well	O
as	O
edema	O
,	O
impedes	O
the	O
pulmonary	O
lymphatic	O
drainage	O
,	O
and	O
increases	O
intra	O
-	O
thoracic	O
pressures	O
,	O
leading	O
to	O
atelectasis	O
,	O
airway	O
closure	O
,	O
and	O
deterioration	O
of	O
respiratory	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
.	O

Comparison	O
of	O
bat	B-ENZY
genomes	O
with	O
other	O
mammalian	O
species	O
has	O
provided	O
new	O
insights	O
into	O
bat	B-ENZY
biology	O
and	O
evolution	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
focus	O
on	O
the	O
public	O
health	O
implications	O
of	O
bat	B-ENZY
derived	O
zoonotic	O
viral	O
disease	O
outbreaks	O
,	O
examine	O
the	O
drivers	O
and	O
risk	O
factors	O
of	O
past	O
disease	O
outbreaks	O
and	O
outline	O
research	O
directions	O
for	O
better	O
control	O
of	O
future	O
disease	O
events	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
mice	O
in	O
high	O
-	O
fat	O
diet	O
group	O
and	O
the	O
two	O
virus	O
infection	O
groups	O
had	O
significantly	O
increased	O
AST	B-ENZY
and	O
ALT	O
levels	O
with	O
also	O
elevated	O
TC	O
and	O
LDL	O
-	O
C	O
levels	O
.	O

To	O
investigate	O
and	O
analyze	O
the	O
reason	O
of	O
this	O
outbreak	O
,	O
the	O
M	O
and	O
ORF3	O
genes	O
of	O
15	O
porcine	O
epidemic	O
diarrhea	O
viruses	O
(	O
PEDV	O
),	O
which	O
were	O
collected	O
from	O
different	O
areas	O
of	O
central	O
China	O
during	O
October	O
2010	O
and	O
December	O
2011	O
,	O
were	O
amplified	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
,	O
cloned	O
,	O
sequenced	O
,	O
and	O
analyzed	O
.	O

Arterial	O
blood	O
gas	B-ENZY
,	O
including	O
pH	O
,	O
PaO2	O
and	O
PaCO2	O
were	O
significantly	O
improved	O
after	O
ECMO	O
running	O
24	O
and	O
48	O
hours	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Blood	O
gases	O
and	O
hemodynamic	O
parameters	O
were	O
evaluated	O
after	O
changing	O
one	O
of	O
three	O
ECMO	O
settings	O
,	O
namely	O
,	O
circuit	O
blood	O
flow	O
,	O
FiO	O
(	O
2ECMO	O
)	O
(	O
fraction	O
of	O
inspired	O
oxygen	O
in	O
circuit	O
),	O
or	O
sweep	O
gas	B-ENZY
flow	O
ventilating	O
the	O
membrane	O
,	O
while	O
leaving	O
the	O
other	O
two	O
parameters	O
at	O
their	O
maximum	O
setting	O
.	O

Alternatively	O
,	O
the	O
rate	O
of	O
sweep	O
gas	B-ENZY
flow	O
through	O
the	O
membrane	O
lung	O
determined	O
blood	O
decarboxylation	O
,	O
while	O
PaCO2	O
(	O
arterial	O
carbon	O
dioxide	O
tension	O
)	O
was	O
unaffected	O
when	O
the	O
ECMO	O
blood	O
flow	O
and	O
FiO	O
(	O
2ECMO	O
)	O
were	O
reduced	O
to	O
<	O
2	O
.	O
5	O
L	O
/	O
min	O
and	O
40	O
%,	O
respectively	O
.	O

For	O
severe	O
ARDS	O
patients	O
receiving	O
femoro	O
-	O
jugular	O
vv	O
-	O
ECMO	O
,	O
blood	O
flow	O
was	O
the	O
main	O
determinant	O
of	O
arterial	O
oxygenation	O
,	O
while	O
CO2	O
elimination	O
depended	O
on	O
sweep	O
gas	B-ENZY
flow	O
through	O
the	O
oxygenator	O
.	O

Sequencing	O
and	O
bioinformatic	O
analysis	O
of	O
the	O
viral	O
genomic	O
RNA	O
showed	O
that	O
it	O
is	O
a	O
novel	O
virus	O
not	O
previously	O
detected	O
in	O
any	O
other	O
species	O
and	O
that	O
its	O
closest	O
relatives	O
are	O
two	O
Asian	O
bat	B-ENZY
coronaviruses	O
.	O

Secondary	O
outcome	O
parameters	O
were	O
respiratory	O
mechanics	O
,	O
gas	B-ENZY
exchange	O
,	O
analgesic	O
/	O
sedation	O
use	O
,	O
complications	O
and	O
hospital	O
mortality	O
.	O

TITLE	O
:	O
Phenolic	O
phytochemical	O
displaying	O
SARS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
inhibition	O
from	O
the	O
seeds	O
of	O
Psoralea	O
corylifolia	O
.	O

Interleukin	O
1	O
(	O
IL	O
-	O
1	O
),	O
a	O
cytokine	O
released	O
within	O
the	O
airspace	O
in	O
ALI	O
,	O
downregulates	O
the	O
	O
subunit	O
of	O
the	O
epithelial	O
sodium	O
channel	O
(	O
ENaC	O
)	O
transcription	O
and	O
protein	O
expression	O
via	O
p38	O
MAP	B-ENZY
kinase	I-ENZY
-	O
dependent	O
signaling	O
.	O

ACE2	O
catalyzes	O
the	O
conversion	O
of	O
angiotensin	O
II	O
to	O
angiotensin	O
1	O
-	O
7	O
,	O
thereby	O
counterbalancing	O
ACE	B-ENZY
activity	O
.	O

In	O
addition	O
,	O
ACE2	O
is	O
structurally	O
a	O
chimeric	O
protein	O
that	O
has	O
emerged	O
from	O
the	O
duplication	O
of	O
2	O
genes	O
:	O
homology	O
with	O
ACE	B-ENZY
at	O
the	O
carboxypeptidase	O
domain	O
and	O
homology	O
with	O
Collectrin	O
in	O
the	O
transmembrane	O
C	O
-	O
terminal	O
domain	O
.	O

ABSTRACT	O
:	O
This	O
study	O
evaluates	O
the	O
effects	O
of	O
Sargassum	O
pallidum	O
polysaccharides	O
(	O
SPP	B-ENZY
)	O
on	O
the	O
immune	O
responses	O
in	O
a	O
chicken	O
model	O
.	O

The	O
ND	O
,	O
IB	O
and	O
AI	O
antibody	O
titers	O
and	O
the	O
lymphocyte	O
proliferation	O
were	O
enhanced	O
at	O
30	O
mg	O
/	O
mL	O
SPP	B-ENZY
.	O

Data	O
on	O
lung	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
were	O
taken	O
at	O
baseline	O
and	O
after	O
30	O
minutes	O
at	O
each	O
Vt	O
(	O
bedside	O
).	O

Key	O
recommendations	O
and	O
suggestions	O
,	O
listed	O
by	O
category	O
,	O
include	O
:	O
early	O
quantitative	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
h	O
after	O
recognition	O
(	O
1C	O
);	O
blood	O
cultures	O
before	O
antibiotic	O
therapy	O
(	O
1C	O
);	O
imaging	O
studies	O
performed	O
promptly	O
to	O
confirm	O
a	O
potential	O
source	O
of	O
infection	O
(	O
UG	O
);	O
administration	O
of	O
broad	O
-	O
spectrum	O
antimicrobials	O
therapy	O
within	O
1	O
h	O
of	O
the	O
recognition	O
of	O
septic	O
shock	O
(	O
1B	O
)	O
and	O
severe	O
sepsis	O
without	O
septic	O
shock	O
(	O
1C	O
)	O
as	O
the	O
goal	O
of	O
therapy	O
;	O
reassessment	O
of	O
antimicrobial	O
therapy	O
daily	O
for	O
de	O
-	O
escalation	O
,	O
when	O
appropriate	O
(	O
1B	O
);	O
infection	O
source	O
control	O
with	O
attention	O
to	O
the	O
balance	O
of	O
risks	O
and	O
benefits	O
of	O
the	O
chosen	O
method	O
within	O
12	O
h	O
of	O
diagnosis	O
(	O
1C	O
);	O
initial	O
fluid	O
resuscitation	O
with	O
crystalloid	O
(	O
1B	O
)	O
and	O
consideration	O
of	O
the	O
addition	O
of	O
albumin	O
in	O
patients	O
who	O
continue	O
to	O
require	O
substantial	O
amounts	O
of	O
crystalloid	O
to	O
maintain	O
adequate	O
mean	O
arterial	O
pressure	O
(	O
2C	O
)	O
and	O
the	O
avoidance	O
of	O
hetastarch	O
formulations	O
(	O
1B	O
);	O
initial	O
fluid	O
challenge	O
in	O
patients	O
with	O
sepsis	O
-	O
induced	O
tissue	O
hypoperfusion	O
and	O
suspicion	O
of	O
hypovolemia	O
to	O
achieve	O
a	O
minimum	O
of	O
30	O
mL	O
/	O
kg	O
of	O
crystalloids	O
(	O
more	O
rapid	O
administration	O
and	O
greater	O
amounts	O
of	O
fluid	O
may	O
be	O
needed	O
in	O
some	O
patients	O
(	O
1C	O
);	O
fluid	O
challenge	O
technique	O
continued	O
as	O
long	O
as	O
hemodynamic	O
improvement	O
is	O
based	O
on	O
either	O
dynamic	O
or	O
static	O
variables	O
(	O
UG	O
);	O
norepinephrine	O
as	O
the	O
first	O
-	O
choice	O
vasopressor	O
to	O
maintain	O
mean	O
arterial	O
pressure	O
	O
65	O
mmHg	O
(	O
1B	O
);	O
epinephrine	O
when	O
an	O
additional	O
agent	O
is	O
needed	O
to	O
maintain	O
adequate	O
blood	O
pressure	O
(	O
2B	O
);	O
vasopressin	O
(	O
0	O
.	O
03	O
U	O
/	O
min	O
)	O
can	O
be	O
added	O
to	O
norepinephrine	O
to	O
either	O
raise	O
mean	O
arterial	O
pressure	O
to	O
target	O
or	O
to	O
decrease	O
norepinephrine	O
dose	O
but	O
should	O
not	O
be	O
used	O
as	O
the	O
initial	O
vasopressor	O
(	O
UG	O
);	O
dopamine	O
is	O
not	O
recommended	O
except	O
in	O
highly	O
selected	O
circumstances	O
(	O
2C	O
);	O
dobutamine	O
infusion	O
administered	O
or	O
added	O
to	O
vasopressor	O
in	O
the	O
presence	O
of	O
(	O
a	O
)	O
myocardial	O
dysfunction	O
as	O
suggested	O
by	O
elevated	O
cardiac	O
filling	O
pressures	O
and	O
low	O
cardiac	O
output	O
,	O
or	O
(	O
b	O
)	O
ongoing	O
signs	O
of	O
hypoperfusion	O
despite	O
achieving	O
adequate	O
intravascular	O
volume	O
and	O
adequate	O
mean	O
arterial	O
pressure	O
(	O
1C	O
);	O
avoiding	O
use	O
of	O
intravenous	O
hydrocortisone	O
in	O
adult	O
septic	O
shock	O
patients	O
if	O
adequate	O
fluid	O
resuscitation	O
and	O
vasopressor	O
therapy	O
are	O
able	O
to	O
restore	O
hemodynamic	O
stability	O
(	O
2C	O
);	O
hemoglobin	O
target	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
in	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
ischemic	O
coronary	O
artery	O
disease	O
,	O
or	O
acute	O
hemorrhage	O
(	O
1B	O
);	O
low	O
tidal	O
volume	O
(	O
1A	O
)	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
(	O
1B	O
)	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
in	O
ARDS	O
(	O
1B	O
);	O
higher	O
rather	O
than	O
lower	O
level	O
of	O
PEEP	O
for	O
patients	O
with	O
sepsis	O
-	O
induced	O
moderate	O
or	O
severe	O
ARDS	O
(	O
2C	O
);	O
recruitment	O
maneuvers	O
in	O
sepsis	O
patients	O
with	O
severe	O
refractory	O
hypoxemia	O
due	O
to	O
ARDS	O
(	O
2C	O
);	O
prone	O
positioning	O
in	O
sepsis	O
-	O
induced	O
ARDS	O
patients	O
with	O
a	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
of	O
	O
100	O
mm	O
Hg	O
in	O
facilities	O
that	O
have	O
experience	O
with	O
such	O
practices	O
(	O
2C	O
);	O
head	O
-	O
of	O
-	O
bed	O
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ARDS	O
who	O
do	O
not	O
have	O
evidence	O
of	O
tissue	O
hypoperfusion	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	O
and	O
sedation	O
(	O
1A	O
);	O
minimizing	O
use	O
of	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
targeting	O
specific	O
titration	O
endpoints	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
if	O
possible	O
in	O
the	O
septic	O
patient	O
without	O
ARDS	O
(	O
1C	O
);	O
a	O
short	O
course	O
of	O
neuromuscular	O
blocker	O
(	O
no	O
longer	O
than	O
48	O
h	O
)	O
for	O
patients	O
with	O
early	O
ARDS	O
and	O
a	O
PaO	B-ENZY
(	O
2	O
)/	O
FI	O
O	O
(	O
2	O
)	O
<	O
150	O
mm	O
Hg	O
(	O
2C	O
);	O
a	O
protocolized	O
approach	O
to	O
blood	O
glucose	O
management	O
commencing	O
insulin	O
dosing	O
when	O
two	O
consecutive	O
blood	O
glucose	O
levels	O
are	O
>	O
180	O
mg	O
/	O
dL	O
,	O
targeting	O
an	O
upper	O
blood	O
glucose	O
	O
180	O
mg	O
/	O
dL	O
(	O
1A	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
venous	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	O
vein	O
thrombosis	O
(	O
1B	O
);	O
use	O
of	O
stress	O
ulcer	O
prophylaxis	O
to	O
prevent	O
upper	O
gastrointestinal	O
bleeding	O
in	O
patients	O
with	O
bleeding	O
risk	O
factors	O
(	O
1B	O
);	O
oral	O
or	O
enteral	O
(	O
if	O
necessary	O
)	O
feedings	O
,	O
as	O
tolerated	O
,	O
rather	O
than	O
either	O
complete	O
fasting	O
or	O
provision	O
of	O
only	O
intravenous	O
glucose	O
within	O
the	O
first	O
48	O
h	O
after	O
a	O
diagnosis	O
of	O
severe	O
sepsis	O
/	O
septic	O
shock	O
(	O
2C	O
);	O
and	O
addressing	O
goals	O
of	O
care	O
,	O
including	O
treatment	O
plans	O
and	O
end	O
-	O
of	O
-	O
life	O
planning	O
(	O
as	O
appropriate	O
)	O
(	O
1B	O
),	O
as	O
early	O
as	O
feasible	O
,	O
but	O
within	O
72	O
h	O
of	O
intensive	O
care	O
unit	O
admission	O
(	O
2C	O
).	O

RESULTS	O
:	O
Key	O
recommendations	O
and	O
suggestions	O
,	O
listed	O
by	O
category	O
,	O
include	O
:	O
early	O
quantitative	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
h	O
after	O
recognition	O
(	O
1C	O
);	O
blood	O
cultures	O
before	O
antibiotic	O
therapy	O
(	O
1C	O
);	O
imaging	O
studies	O
performed	O
promptly	O
to	O
confirm	O
a	O
potential	O
source	O
of	O
infection	O
(	O
UG	O
);	O
administration	O
of	O
broad	O
-	O
spectrum	O
antimicrobials	O
therapy	O
within	O
1	O
h	O
of	O
the	O
recognition	O
of	O
septic	O
shock	O
(	O
1B	O
)	O
and	O
severe	O
sepsis	O
without	O
septic	O
shock	O
(	O
1C	O
)	O
as	O
the	O
goal	O
of	O
therapy	O
;	O
reassessment	O
of	O
antimicrobial	O
therapy	O
daily	O
for	O
de	O
-	O
escalation	O
,	O
when	O
appropriate	O
(	O
1B	O
);	O
infection	O
source	O
control	O
with	O
attention	O
to	O
the	O
balance	O
of	O
risks	O
and	O
benefits	O
of	O
the	O
chosen	O
method	O
within	O
12	O
h	O
of	O
diagnosis	O
(	O
1C	O
);	O
initial	O
fluid	O
resuscitation	O
with	O
crystalloid	O
(	O
1B	O
)	O
and	O
consideration	O
of	O
the	O
addition	O
of	O
albumin	O
in	O
patients	O
who	O
continue	O
to	O
require	O
substantial	O
amounts	O
of	O
crystalloid	O
to	O
maintain	O
adequate	O
mean	O
arterial	O
pressure	O
(	O
2C	O
)	O
and	O
the	O
avoidance	O
of	O
hetastarch	O
formulations	O
(	O
1B	O
);	O
initial	O
fluid	O
challenge	O
in	O
patients	O
with	O
sepsis	O
-	O
induced	O
tissue	O
hypoperfusion	O
and	O
suspicion	O
of	O
hypovolemia	O
to	O
achieve	O
a	O
minimum	O
of	O
30	O
mL	O
/	O
kg	O
of	O
crystalloids	O
(	O
more	O
rapid	O
administration	O
and	O
greater	O
amounts	O
of	O
fluid	O
may	O
be	O
needed	O
in	O
some	O
patients	O
(	O
1C	O
);	O
fluid	O
challenge	O
technique	O
continued	O
as	O
long	O
as	O
hemodynamic	O
improvement	O
is	O
based	O
on	O
either	O
dynamic	O
or	O
static	O
variables	O
(	O
UG	O
);	O
norepinephrine	O
as	O
the	O
first	O
-	O
choice	O
vasopressor	O
to	O
maintain	O
mean	O
arterial	O
pressure	O
	O
65	O
mmHg	O
(	O
1B	O
);	O
epinephrine	O
when	O
an	O
additional	O
agent	O
is	O
needed	O
to	O
maintain	O
adequate	O
blood	O
pressure	O
(	O
2B	O
);	O
vasopressin	O
(	O
0	O
.	O
03	O
U	O
/	O
min	O
)	O
can	O
be	O
added	O
to	O
norepinephrine	O
to	O
either	O
raise	O
mean	O
arterial	O
pressure	O
to	O
target	O
or	O
to	O
decrease	O
norepinephrine	O
dose	O
but	O
should	O
not	O
be	O
used	O
as	O
the	O
initial	O
vasopressor	O
(	O
UG	O
);	O
dopamine	O
is	O
not	O
recommended	O
except	O
in	O
highly	O
selected	O
circumstances	O
(	O
2C	O
);	O
dobutamine	O
infusion	O
administered	O
or	O
added	O
to	O
vasopressor	O
in	O
the	O
presence	O
of	O
(	O
a	O
)	O
myocardial	O
dysfunction	O
as	O
suggested	O
by	O
elevated	O
cardiac	O
filling	O
pressures	O
and	O
low	O
cardiac	O
output	O
,	O
or	O
(	O
b	O
)	O
ongoing	O
signs	O
of	O
hypoperfusion	O
despite	O
achieving	O
adequate	O
intravascular	O
volume	O
and	O
adequate	O
mean	O
arterial	O
pressure	O
(	O
1C	O
);	O
avoiding	O
use	O
of	O
intravenous	O
hydrocortisone	O
in	O
adult	O
septic	O
shock	O
patients	O
if	O
adequate	O
fluid	O
resuscitation	O
and	O
vasopressor	O
therapy	O
are	O
able	O
to	O
restore	O
hemodynamic	O
stability	O
(	O
2C	O
);	O
hemoglobin	O
target	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
in	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
ischemic	O
coronary	O
artery	O
disease	O
,	O
or	O
acute	O
hemorrhage	O
(	O
1B	O
);	O
low	O
tidal	O
volume	O
(	O
1A	O
)	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
(	O
1B	O
)	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
in	O
ARDS	O
(	O
1B	O
);	O
higher	O
rather	O
than	O
lower	O
level	O
of	O
PEEP	O
for	O
patients	O
with	O
sepsis	O
-	O
induced	O
moderate	O
or	O
severe	O
ARDS	O
(	O
2C	O
);	O
recruitment	O
maneuvers	O
in	O
sepsis	O
patients	O
with	O
severe	O
refractory	O
hypoxemia	O
due	O
to	O
ARDS	O
(	O
2C	O
);	O
prone	O
positioning	O
in	O
sepsis	O
-	O
induced	O
ARDS	O
patients	O
with	O
a	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
of	O
	O
100	O
mm	O
Hg	O
in	O
facilities	O
that	O
have	O
experience	O
with	O
such	O
practices	O
(	O
2C	O
);	O
head	O
-	O
of	O
-	O
bed	O
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ARDS	O
who	O
do	O
not	O
have	O
evidence	O
of	O
tissue	O
hypoperfusion	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	O
and	O
sedation	O
(	O
1A	O
);	O
minimizing	O
use	O
of	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
targeting	O
specific	O
titration	O
endpoints	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
if	O
possible	O
in	O
the	O
septic	O
patient	O
without	O
ARDS	O
(	O
1C	O
);	O
a	O
short	O
course	O
of	O
neuromuscular	O
blocker	O
(	O
no	O
longer	O
than	O
48	O
h	O
)	O
for	O
patients	O
with	O
early	O
ARDS	O
and	O
a	O
PaO	B-ENZY
(	O
2	O
)/	O
FI	O
O	O
(	O
2	O
)	O
<	O
150	O
mm	O
Hg	O
(	O
2C	O
);	O
a	O
protocolized	O
approach	O
to	O
blood	O
glucose	O
management	O
commencing	O
insulin	O
dosing	O
when	O
two	O
consecutive	O
blood	O
glucose	O
levels	O
are	O
>	O
180	O
mg	O
/	O
dL	O
,	O
targeting	O
an	O
upper	O
blood	O
glucose	O
	O
180	O
mg	O
/	O
dL	O
(	O
1A	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
venous	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	O
vein	O
thrombosis	O
(	O
1B	O
);	O
use	O
of	O
stress	O
ulcer	O
prophylaxis	O
to	O
prevent	O
upper	O
gastrointestinal	O
bleeding	O
in	O
patients	O
with	O
bleeding	O
risk	O
factors	O
(	O
1B	O
);	O
oral	O
or	O
enteral	O
(	O
if	O
necessary	O
)	O
feedings	O
,	O
as	O
tolerated	O
,	O
rather	O
than	O
either	O
complete	O
fasting	O
or	O
provision	O
of	O
only	O
intravenous	O
glucose	O
within	O
the	O
first	O
48	O
h	O
after	O
a	O
diagnosis	O
of	O
severe	O
sepsis	O
/	O
septic	O
shock	O
(	O
2C	O
);	O
and	O
addressing	O
goals	O
of	O
care	O
,	O
including	O
treatment	O
plans	O
and	O
end	O
-	O
of	O
-	O
life	O
planning	O
(	O
as	O
appropriate	O
)	O
(	O
1B	O
),	O
as	O
early	O
as	O
feasible	O
,	O
but	O
within	O
72	O
h	O
of	O
intensive	O
care	O
unit	O
admission	O
(	O
2C	O
).	O

ABSTRACT	O
:	O
A	O
novel	O
multiplex	O
real	O
-	O
time	O
PCR	O
approach	O
(	O
Anyplex	O
II	O
RV16	O
[	O
RV16	O
];	O
Seegene	O
,	O
South	O
Korea	O
)	O
was	O
compared	O
with	O
a	O
multiplex	O
endpoint	O
PCR	O
kit	O
(	O
Seeplex	O
RV15	O
ACE	B-ENZY
detection	O
kit	O
[	O
RV15	O
];	O
Seegene	O
)	O
and	O
a	O
liquid	O
bead	O
-	O
based	O
assay	O
(	O
xTAG	O
respiratory	O
viral	O
panel	O
[	O
xTAG	O
];	O
Abbott	O
,	O
United	O
States	O
).	O

A	O
	O
-	O
CoV	O
with	O
96	O
.	O
5	O
%	O
amino	O
acid	O
identity	O
to	O
the	O
	O
-	O
CoV	O
associated	O
with	O
human	O
disease	O
in	O
the	O
Middle	O
East	O
was	O
found	O
in	O
a	O
Nyctinomops	O
laticaudatus	O
bat	B-ENZY
,	O
suggesting	O
that	O
efforts	O
to	O
identify	O
the	O
viral	O
reservoir	O
should	O
include	O
surveillance	O
of	O
the	O
bat	B-ENZY
families	O
Molossidae	O
/	O
Vespertilionidae	O
,	O
or	O
the	O
closely	O
related	O
Nycteridae	O
/	O
Emballonuridae	O
.	O

Variables	O
included	O
in	O
the	O
maximal	O
multivariate	O
model	O
were	O
male	O
sex	O
,	O
chronic	O
alcoholism	O
,	O
use	O
of	O
ACE	B-ENZY
inhibitors	O
or	O
angiotensin	O
-	O
receptor	O
blockers	O
,	O
Simplified	O
Acute	O
Physiology	O
Score	O
II	O
score	O
,	O
serum	O
glucose	O
concentration	O
at	O
ICU	O
admission	O
,	O
and	O
the	O
presence	O
of	O
the	O
allele	O
D	O
of	O
the	O
ACE	B-ENZY
gene	O
.	O

After	O
adjustment	O
for	O
those	O
variables	O
,	O
the	O
presence	O
of	O
the	O
allele	O
D	O
of	O
the	O
ACE	B-ENZY
gene	O
(	O
odds	O
ratio	O
,	O
4	O
.	O
75	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
02	O
-	O
22	O
.	O
20	O
;	O
P	O
=	O
0	O
.	O
048	O
)	O
was	O
significantly	O
associated	O
with	O
the	O
diagnosis	O
of	O
ARDS	O
.	O

CONCLUSIONS	O
:	O
The	O
presence	O
of	O
the	O
allele	O
D	O
of	O
the	O
ACE	B-ENZY
gene	O
is	O
associated	O
with	O
ARDS	O
in	O
patients	O
with	O
severe	O
sepsis	O
.	O

Kallistatin	O
,	O
an	O
endogenous	O
tissue	B-ENZY
kallikrein	I-ENZY
inhibitor	O
,	O
has	O
been	O
reported	O
to	O
be	O
protective	O
in	O
various	O
human	O
diseases	O
.	O

Plasma	O
kallistatin	O
,	O
kallikrein	O
,	O
and	O
other	O
biomarkers	O
of	O
inflammation	O
(	O
tumor	O
necrosis	O
factor	O
-	O
	O
(	O
TNF	O
-	O
	O
),	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)),	O
and	O
anti	O
-	O
coagulation	O
(	O
protein	O
C	O
,	O
anti	O
-	O
thrombin	B-ENZY
III	O
)	O
were	O
measured	O
on	O
days	O
1	O
and	O
4	O
of	O
ICU	O
admission	O
.	O

Arteriviruses	O
are	O
economically	O
important	O
positive	O
-	O
stranded	O
RNA	O
viruses	O
that	O
encode	O
an	O
ovarian	O
tumor	O
(	O
OTU	O
)	O
domain	O
DUB	O
known	O
as	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
(	O
PLP2	O
).	O

ABSTRACT	O
:	O
Surfactant	O
(	O
SF	O
)	O
instillation	O
may	O
produce	O
acute	O
deleterious	O
effects	O
on	O
gas	B-ENZY
exchange	O
and	O
both	O
systemic	O
and	O
cerebral	O
hemodynamics	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
the	O
effects	O
of	O
aerosolized	O
SF	O
(	O
SF	O
-	O
aero	O
)	O
with	O
those	O
of	O
bolus	O
SF	O
(	O
SF	O
-	O
bolus	O
)	O
administration	O
on	O
gas	B-ENZY
exchange	O
,	O
lung	O
mechanics	O
,	O
and	O
cardiovascular	O
function	O
in	O
premature	O
lambs	O
with	O
respiratory	O
distress	O
syndrome	O
(	O
RDS	O
).	O

SF	O
-	O
aero	O
produced	O
improvements	O
in	O
gas	B-ENZY
exchange	O
and	O
lung	O
mechanics	O
similar	O
to	O
those	O
produced	O
by	O
bolus	O
administration	O
but	O
with	O
less	O
lung	O
injury	O
and	O
fewer	O
cerebral	O
hemodynamic	O
changes	O
.	O

Bacterial	O
translocation	O
has	O
been	O
described	O
in	O
patients	O
with	O
ACS	B-ENZY
,	O
and	O
this	O
may	O
apply	O
to	O
patients	O
with	O
SAP	O
.	O

Approximately	O
30	O
-	O
40	O
%	O
of	O
SAP	O
patients	O
develop	O
ACS	B-ENZY
because	O
of	O
pancreatic	O
(	O
retroperitoneal	O
)	O
inflammation	O
,	O
peripancreatic	O
tissue	O
edema	O
,	O
formation	O
of	O
fluid	O
collections	O
or	O
abdominal	O
distension	O
.	O

Although	O
not	O
uncommon	O
in	O
ICU	O
,	O
CIP	O
and	O
CIM	O
as	O
severe	O
complications	O
of	O
percutaneous	O
nephrostolithotomy	O
(	O
PNL	B-ENZY
)	O
have	O
not	O
been	O
documented	O
in	O
literature	O
.	O

PNL	B-ENZY
was	O
indicated	O
and	O
performed	O
.	O

The	O
patient	O
developed	O
CIP	O
and	O
CIM	O
on	O
the	O
fourth	O
day	O
after	O
PNL	B-ENZY
.	O

This	O
case	O
expands	O
our	O
understanding	O
of	O
the	O
complications	O
of	O
PNL	B-ENZY
and	O
underscores	O
the	O
importance	O
of	O
differentiating	O
CIP	O
/	O
CIM	O
from	O
GBS	O
in	O
case	O
of	O
such	O
patients	O
developing	O
weakness	O
after	O
the	O
treatment	O
.	O

CONCLUSIONS	O
:	O
This	O
case	O
expands	O
our	O
understanding	O
of	O
the	O
complications	O
of	O
PNL	B-ENZY
and	O
underscores	O
the	O
importance	O
of	O
differentiating	O
CIP	O
/	O
CIM	O
from	O
GBS	O
in	O
case	O
of	O
such	O
patients	O
developing	O
weakness	O
after	O
the	O
treatment	O
.	O

Like	O
SARS	O
-	O
CoV	O
,	O
HCoV	O
-	O
EMC	O
is	O
of	O
zoonotic	O
origin	O
and	O
closely	O
related	O
to	O
bat	B-ENZY
coronaviruses	O
.	O

Patient	O
characteristics	O
,	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
cellularity	O
,	O
rates	O
of	O
respiratory	O
tract	O
infection	O
,	O
colonization	O
,	O
acute	O
rejection	O
,	O
and	O
lymphocytic	O
bronchiolitis	O
were	O
compared	O
between	O
BOS	O
,	O
RAS	O
,	O
and	O
stable	O
patients	O
.	O

BAL	B-ENZY
neutrophilia	O
in	O
BOS	O
and	O
RAS	O
were	O
elevated	O
at	O
days	O
360	O
,	O
540	O
,	O
and	O
720	O
versus	O
control	O
.	O

Acute	O
rejection	O
,	O
lymphocytic	O
bronchiolitis	O
,	O
colonization	O
with	O
pseudomonas	O
,	O
infection	O
,	O
and	O
BAL	B-ENZY
eosinophilia	O
and	O
neutrophilia	O
are	O
risk	O
factors	O
for	O
the	O
later	O
development	O
not	O
only	O
of	O
RAS	O
but	O
also	O
of	O
BOS	O
.	O

BOS	O
,	O
but	O
especially	O
RAS	O
patients	O
,	O
experienced	O
more	O
frequent	O
episodes	O
of	O
increased	O
BAL	B-ENZY
eosinophilia	O
(	O
2	O
%;	O
P	O
<	O
0	O
.	O
0001	O
).	O

Uncontrolled	O
studies	O
in	O
adults	O
have	O
shown	O
improvements	O
in	O
gas	B-ENZY
exchange	O
and	O
lung	O
compliance	O
with	O
partial	O
liquid	O
ventilation	O
.	O

A	O
single	O
uncontrolled	O
study	O
in	O
six	O
children	O
with	O
acute	O
respiratory	O
syndrome	O
showed	O
some	O
improvement	O
in	O
gas	B-ENZY
exchange	O
during	O
three	O
hours	O
of	O
partial	O
liquid	O
ventilation	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
14	O
kDa	O
endocan	O
fragment	O
generated	O
by	O
cathepsin	B-ENZY
G	I-ENZY
,	O
a	O
novel	O
circulating	O
biomarker	O
in	O
patients	O
with	O
sepsis	O
.	O

We	O
demonstrate	O
that	O
cathepsin	B-ENZY
G	I-ENZY
(	O
CG	O
),	O
neutrophil	B-ENZY
elastase	I-ENZY
(	O
NE	O
),	O
and	O
to	O
a	O
lesser	O
extent	O
proteinase	B-ENZY
3	I-ENZY
(	O
PR3	O
),	O
degrade	O
endocan	O
.	O

Antibody	O
titers	O
ranged	O
from	O
1	O
:	O
25	O
to	O
1	O
:	O
400	O
,	O
with	O
titers	O
of	O
1	O
:	O
200	O
detected	O
in	O
4	O
of	O
the	O
5	O
bat	B-ENZY
species	O
.	O

Expression	O
of	O
human	O
and	O
bat	B-ENZY
(	O
Pipistrellus	O
pipistrellus	O
)	O
DPP4	O
in	O
non	O
-	O
susceptible	O
COS	O
-	O
7	O
cells	O
enabled	O
infection	O
by	O
hCoV	O
-	O
EMC	O
.	O

ABSTRACT	O
:	O
A	O
survey	O
was	O
carried	O
out	O
in	O
search	O
for	O
bat	B-ENZY
coronaviruses	O
in	O
an	O
urban	O
maternity	O
roost	O
of	O
about	O
500	O
specimens	O
of	O
two	O
species	O
of	O
insectivorous	O
bats	O
,	O
Molossus	O
molossus	O
and	O
Tadarida	O
brasiliensis	O
,	O
in	O
Southern	O
Brazil	O
.	O

The	O
indications	O
included	O
acute	O
fulminant	O
myocarditis	O
(	O
AFM	O
)	O
(	O
n	O
=	O
6	O
),	O
congenital	O
diaphragmatic	O
hernia	O
(	O
CDH	B-ENZY
)	O
(	O
n	O
=	O
3	O
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
(	O
n	O
=	O
6	O
),	O
enterovirus	O
71	O
(	O
n	O
=	O
3	O
),	O
viral	O
sepsis	O
(	O
n	O
=	O
2	O
),	O
refractory	O
ventricular	O
fibrillation	O
due	O
to	O
long	O
QT	O
syndrome	O
(	O
n	O
=	O
1	O
),	O
and	O
pulmonary	O
edema	O
with	O
brain	O
herniation	O
(	O
n	O
=	O
1	O
).	O

External	O
primers	O
were	O
used	O
to	O
amplify	O
a	O
fragment	O
of	O
the	O
expected	O
size	O
(	O
441	O
bp	O
)	O
in	O
all	O
the	O
samples	O
evaluated	O
using	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
but	O
with	O
very	O
low	O
intensity	O
.	O

A	O
recent	O
cell	O
line	O
susceptibility	O
study	O
showed	O
that	O
HCoV	O
-	O
EMC	O
can	O
infect	O
primate	O
,	O
porcine	O
,	O
and	O
bat	B-ENZY
cells	O
and	O
therefore	O
may	O
jump	O
interspecies	O
barriers	O
.	O

Here	O
we	O
show	O
that	O
the	O
type	O
II	O
transmembrane	O
serine	O
proteases	O
TMPRSS2	O
and	O
HAT	O
cleave	O
the	O
HCoV	O
-	O
229E	O
S	O
-	O
protein	O
(	O
229E	O
-	O
S	O
)	O
and	O
augment	O
229E	O
-	O
S	O
-	O
driven	O
cell	O
-	O
cell	O
fusion	O
,	O
suggesting	O
that	O
TMPRSS2	O
and	O
HAT	O
can	O
activate	O
229E	O
-	O
S	O
.	O
Indeed	O
,	O
engineered	O
expression	O
of	O
TMPRSS2	O
and	O
HAT	O
rendered	O
229E	O
-	O
S	O
-	O
driven	O
virus	O
-	O
cell	O
fusion	O
insensitive	O
to	O
an	O
inhibitor	O
of	O
cathepsin	B-ENZY
L	I-ENZY
,	O
a	O
protease	O
previously	O
shown	O
to	O
facilitate	O
HCoV	O
-	O
229E	O
infection	O
.	O

The	O
present	O
study	O
for	O
the	O
first	O
time	O
has	O
documented	O
significantly	O
increased	O
MCs	B-ENZY
in	O
CPV	O
-	O
2	O
-	O
associated	O
ECA	O
as	O
was	O
previously	O
reported	O
for	O
IBD	O
,	O
showing	O
that	O
MCs	B-ENZY
may	O
also	O
play	O
an	O
important	O
role	O
in	O
CPV	O
-	O
2	O
-	O
associated	O
ECA	O
.	O

ABSTRACT	O
:	O
Bat	B-ENZY
SARS	O
-	O
like	O
coronavirus	O
(	O
SL	O
-	O
CoV	O
)	O
has	O
a	O
genome	O
organization	O
almost	O
identical	O
to	O
that	O
of	O
SARS	O
-	O
CoV	O
,	O
but	O
the	O
N	O
-	O
terminus	O
of	O
the	O
Spike	O
(	O
S	O
)	O
proteins	O
,	O
which	O
interacts	O
with	O
host	O
receptor	O
and	O
is	O
a	O
major	O
target	O
of	O
neutralizing	O
antibodies	O
against	O
CoVs	O
,	O
of	O
the	O
two	O
viruses	O
has	O
only	O
63	O
-	O
64	O
%	O
sequence	O
identity	O
.	O

A	O
deletion	O
of	O
five	O
amino	O
acids	O
in	O
the	O
neuraminidase	B-ENZY
(	O
NA	O
)	O
stalk	O
region	O
was	O
found	O
in	O
all	O
three	O
viruses	O
.	O

HCoV	O
-	O
EMC	O
is	O
phylogenetically	O
closely	O
related	O
to	O
Tylonycteris	O
-	O
bat	B-ENZY
-	O
coronavirus	O
-	O
HKU4	O
and	O
Pipistrellus	O
-	O
bat	B-ENZY
-	O
coronavirus	O
-	O
HKU5	O
in	O
Hong	O
Kong	O
.	O

TITLE	O
:	O
Respiratory	O
health	O
effect	O
of	O
persons	O
accidentally	O
expose	O
to	O
high	O
concentration	O
of	O
chlorine	O
gas	B-ENZY
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
short	O
term	O
and	O
long	O
term	O
respiratory	O
health	O
effects	O
of	O
subjects	O
who	O
accidentally	O
exposed	O
to	O
high	O
concentration	O
of	O
chlorine	O
gas	B-ENZY
.	O

Medical	O
records	O
of	O
those	O
who	O
developed	O
severe	O
symptoms	O
after	O
exposed	O
to	O
high	O
concentration	O
of	O
chlorine	O
gas	B-ENZY
were	O
reviewed	O
.	O

Among	O
1	O
,	O
434	O
persons	O
exposed	O
to	O
chlorine	O
gas	B-ENZY
,	O
92	O
developed	O
severe	O
symptoms	O
required	O
hospital	O
admission	O
and	O
21	O
participated	O
in	O
the	O
follow	O
-	O
up	O
study	O
at	O
2	O
months	O
there	O
after	O
.	O

RESULTS	O
:	O
Among	O
1	O
,	O
434	O
persons	O
exposed	O
to	O
chlorine	O
gas	B-ENZY
,	O
92	O
developed	O
severe	O
symptoms	O
required	O
hospital	O
admission	O
and	O
21	O
participated	O
in	O
the	O
follow	O
-	O
up	O
study	O
at	O
2	O
months	O
there	O
after	O
.	O

CONCLUSIONS	O
:	O
Acute	O
exposure	O
to	O
high	O
concentration	O
of	O
chlorine	O
gas	B-ENZY
causes	O
both	O
significant	O
short	O
and	O
long	O
term	O
respiratory	O
health	O
effects	O
.	O

TITLE	O
:	O
The	O
papain	B-ENZY
-	O
like	O
protease	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
negatively	O
regulates	O
type	O
I	O
interferon	O
pathway	O
by	O
acting	O
as	O
a	O
viral	O
deubiquitinase	O
.	O

We	O
identified	O
PEDV	O
replicase	O
encoded	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
(	O
PLP2	O
)	O
as	O
an	O
IFN	O
antagonist	O
that	O
depends	O
on	O
catalytic	O
activity	O
for	O
its	O
function	O
.	O

These	O
results	O
show	O
that	O
PEDV	O
infection	O
suppresses	O
production	O
of	O
IFN	O
-	O
	O
and	O
provides	O
evidence	O
indicating	O
that	O
the	O
PEDV	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
acts	O
as	O
a	O
viral	O
DUB	O
to	O
interfere	O
with	O
the	O
RIG	O
-	O
I	O
-	O
and	O
STING	O
-	O
mediated	O
signalling	O
pathway	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
are	O
found	O
in	O
a	O
diverse	O
array	O
of	O
bat	B-ENZY
and	O
bird	O
species	O
,	O
which	O
are	O
believed	O
to	O
act	O
as	O
natural	O
hosts	O
.	O

Complications	O
and	O
outcomes	O
including	O
respiratory	O
and	O
abdominal	O
infection	O
,	O
sepsis	O
,	O
abdominal	O
hemorrhage	O
,	O
intra	O
-	O
abdominal	O
hypertension	O
,	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
),	O
renal	O
failure	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
),	O
operation	O
intervention	O
,	O
length	O
of	O
intensive	O
care	O
unit	O
stay	O
,	O
length	O
of	O
hospital	O
stay	O
,	O
and	O
mortality	O
at	O
60	O
d	O
were	O
compared	O
.	O

Compared	O
to	O
the	O
NS	O
group	O
,	O
incidence	O
of	O
renal	O
dysfunction	O
,	O
ARDS	O
,	O
MODS	O
and	O
ACS	B-ENZY
in	O
the	O
SH	O
and	O
SHG	O
groups	O
was	O
obviously	O
lower	O
.	O

As	O
TCoV	O
does	O
not	O
induce	O
lesions	O
in	O
the	O
embryo	O
,	O
virus	O
replication	O
in	O
the	O
jejunum	O
and	O
ileum	O
of	O
the	O
embryos	O
was	O
detected	O
4	O
days	O
post	O
inoculation	O
,	O
using	O
RNA	O
extraction	O
and	O
a	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
based	O
on	O
the	O
nucleocapsid	O
gene	O
.	O

TITLE	O
:	O
Geranylated	O
flavonoids	O
displaying	O
SARS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
inhibition	O
from	O
the	O
fruits	O
of	O
Paulownia	O
tomentosa	O
.	O

ABSTRACT	O
:	O
SARS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
is	O
an	O
important	O
antiviral	O
target	O
due	O
to	O
its	O
key	O
roles	O
in	O
SARS	O
virus	O
replication	O
.	O

ABSTRACT	O
:	O
The	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
characterized	O
by	O
severe	O
impairment	O
of	O
gas	B-ENZY
exchange	O
and	O
remains	O
a	O
challenge	O
for	O
modern	O
intensive	O
care	O
medicine	O
.	O

In	O
extreme	O
,	O
life	O
threatening	O
cases	O
extracorporeal	O
membrane	O
oxygenation	O
can	O
stabilize	O
gas	B-ENZY
exchange	O
and	O
serve	O
as	O
a	O
bridge	O
to	O
recovery	O
and	O
means	O
to	O
enable	O
lung	O
protective	O
ventilation	O
.	O

Additionally	O
,	O
using	O
a	O
dual	O
luciferase	B-ENZY
assay	O
,	O
it	O
can	O
be	O
shown	O
that	O
a	O
hairpin	O
stimulated	O
+	O
1	O
frameshifting	O
when	O
placed	O
upstream	O
of	O
a	O
+	O
1	O
shifty	O
site	O
in	O
yeast	O
.	O

Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
used	O
to	O
achieve	O
gas	B-ENZY
exchange	O
independent	O
of	O
pulmonary	O
function	O
in	O
patients	O
with	O
severe	O
respiratory	O
failure	O
.	O

Seven	O
patients	O
presented	O
with	O
thrombocytopenia	O
and	O
hypoalbuminemia	O
,	O
five	O
of	O
which	O
had	O
hemoconcentration	O
and	O
increased	O
ALT	O
and	O
AST	B-ENZY
indicative	O
of	O
liver	O
damage	O
.	O

Here	O
,	O
we	O
report	O
a	O
severe	O
case	O
,	O
which	O
fulfilled	O
most	O
,	O
if	O
not	O
all	O
,	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
criteria	O
for	O
HPS	B-ENZY
,	O
needing	O
non	O
-	O
invasive	O
ventilation	O
and	O
subsequent	O
acute	O
hemodialysis	O
.	O

This	O
case	O
definitely	O
confirms	O
that	O
HPS	B-ENZY
can	O
be	O
encountered	O
during	O
PUUV	O
infections	O
.	O

Interestingly	O
,	O
special	O
findings	O
could	O
render	O
the	O
diagnosis	O
easier	O
,	O
such	O
as	O
greenish	O
homogeneous	O
cytoplasmic	O
inclusions	O
,	O
surrounded	O
by	O
a	O
fine	O
clear	O
halo	O
in	O
BAL	B-ENZY
macrophages	O
.	O

Therefore	O
,	O
although	O
the	O
diagnosis	O
remains	O
difficult	O
before	O
the	O
onset	O
of	O
renal	O
involvement	O
,	O
the	O
occurrence	O
of	O
severe	O
respiratory	O
failure	O
mimicking	O
community	O
-	O
acquired	O
pneumonia	O
must	O
alert	O
the	O
clinician	O
for	O
possible	O
HPS	B-ENZY
,	O
especially	O
in	O
endemic	O
areas	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
),	O
and	O
its	O
more	O
severe	O
form	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
are	O
syndromes	O
of	O
acute	O
hypoxemic	O
respiratory	O
failure	O
resulting	O
from	O
a	O
variety	O
of	O
direct	O
and	O
indirect	O
injuries	O
to	O
the	O
gas	B-ENZY
exchange	O
parenchyma	O
of	O
the	O
lungs	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
regulation	O
of	O
p53	O
and	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPK	B-ENZY
)	O
signalling	O
pathways	O
in	O
the	O
interaction	O
of	O
TGEV	O
with	O
host	O
cells	O
.	O

TGEV	O
infection	O
induced	O
the	O
transient	O
activation	O
of	O
p38	O
MAPK	B-ENZY
in	O
the	O
early	O
phase	O
of	O
inoculation	O
and	O
constant	O
activation	O
in	O
the	O
later	O
phase	O
of	O
infection	O
.	O

However	O
,	O
UV	O
-	O
irradiated	O
TGEV	O
did	O
not	O
promote	O
the	O
activation	O
of	O
p53	O
and	O
p38	O
MAPK	B-ENZY
in	O
the	O
later	O
phase	O
,	O
whereas	O
it	O
only	O
triggered	O
the	O
transient	O
activation	O
of	O
p38	O
MAPK	B-ENZY
in	O
the	O
early	O
phase	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
that	O
TGEV	O
infection	O
promoted	O
the	O
activation	O
of	O
p38	O
MAPK	B-ENZY
and	O
p53	O
signalling	O
,	O
and	O
p53	O
signalling	O
might	O
play	O
a	O
dominant	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
apoptosis	O
.	O

Studies	O
on	O
their	O
mechanisms	O
of	O
action	O
revealed	O
that	O
the	O
compounds	O
act	O
by	O
three	O
distinct	O
mechanisms	O
:	O
(	O
i	O
)	O
SSAA09E2	O
{	O
N	O
-[[	O
4	O
-(	O
4	O
-	O
methylpiperazin	O
-	O
1	O
-	O
yl	O
)	O
phenyl	O
]	O
methyl	O
]-	O
1	O
,	O
2	O
-	O
oxazole	O
-	O
5	O
-	O
carboxamide	O
}	O
acts	O
through	O
a	O
novel	O
mechanism	O
of	O
action	O
,	O
by	O
blocking	O
early	O
interactions	O
of	O
SARS	O
-	O
S	O
with	O
the	O
receptor	O
for	O
SARS	O
-	O
CoV	O
,	O
angiotensin	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
);	O
(	O
ii	O
)	O
SSAA09E1	O
{[(	O
Z	O
)-	O
1	O
-	O
thiophen	O
-	O
2	O
-	O
ylethylideneamino	O
]	O
thiourea	O
}	O
acts	O
later	O
,	O
by	O
blocking	O
cathepsin	B-ENZY
L	I-ENZY
,	O
a	O
host	O
protease	O
required	O
for	O
processing	O
of	O
SARS	O
-	O
S	O
during	O
viral	O
entry	O
;	O
and	O
(	O
iii	O
)	O
SSAA09E3	O
[	O
N	O
-(	O
9	O
,	O
10	O
-	O
dioxo	O
-	O
9	O
,	O
10	O
-	O
dihydroanthracen	O
-	O
2	O
-	O
yl	O
)	O
benzamide	O
]	O
also	O
acts	O
later	O
and	O
does	O
not	O
affect	O
interactions	O
of	O
SARS	O
-	O
S	O
with	O
ACE2	O
or	O
the	O
enzymatic	O
functions	O
of	O
cathepsin	B-ENZY
L	I-ENZY
but	O
prevents	O
fusion	O
of	O
the	O
viral	O
membrane	O
with	O
the	O
host	O
cellular	O
membrane	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
activation	O
of	O
the	O
protein	B-ENZY
kinase	I-ENZY
R	O
-	O
like	O
ER	O
kinase	O
(	O
PERK	O
)	O
pathway	O
of	O
UPR	O
in	O
cells	O
infected	O
with	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
its	O
relationship	O
with	O
IBV	O
-	O
induced	O
apoptosis	O
.	O

Interestingly	O
,	O
knockdown	O
of	O
protein	B-ENZY
kinase	I-ENZY
R	O
(	O
PKR	O
)	O
by	O
siRNA	O
and	O
inhibition	O
of	O
the	O
PKR	O
kinase	O
activity	O
by	O
2	O
-	O
aminopurine	O
(	O
2	O
-	O
AP	O
)	O
also	O
reduced	O
the	O
IBV	O
-	O
induced	O
upregulation	O
of	O
GADD153	O
and	O
apoptosis	O
induction	O
.	O

Analysis	O
of	O
the	O
pathways	O
downstream	O
of	O
GADD153	O
revealed	O
much	O
more	O
activation	O
of	O
the	O
extracellular	O
signal	O
-	O
related	O
kinase	O
(	O
ERK	B-ENZY
)	O
pathway	O
in	O
GADD153	O
-	O
knockdown	O
cells	O
during	O
IBV	O
infection	O
,	O
indicating	O
that	O
GADD153	O
may	O
modulate	O
apoptosis	O
through	O
suppression	O
of	O
the	O
pathway	O
.	O

Biochemistry	O
revealed	O
markedly	O
elevated	O
creatinine	O
kinase	O
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
which	O
indicated	O
a	O
myopathy	O
.	O

Patients	O
with	O
diethyl	O
-	O
OPs	O
required	O
intubation	O
significantly	O
earlier	O
and	O
showed	O
lower	O
and	O
more	O
sustained	O
inhibited	O
activity	O
of	O
the	O
plasma	O
-	O
cholinesterase	B-ENZY
on	O
admission	O
compared	O
with	O
patients	O
ingesting	O
dimethyl	O
-	O
OPs	O
.	O

Detailed	O
phylogenetic	O
analysis	O
of	O
the	O
virus	O
genome	O
(	O
England	O
/	O
Qatar	O
/	O
2012	O
)	O
revealed	O
its	O
close	O
relationship	O
to	O
European	O
bat	B-ENZY
coronaviruses	O
circulating	O
among	O
the	O
bat	B-ENZY
species	O
of	O
the	O
Vespertilionidae	O
family	O
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
nonstructural	O
protein	O
2	O
(	O
ns2	O
)	O
is	O
a	O
2	O
',	O
5	B-ENZY
'-	I-ENZY
phosphodiesterase	I-ENZY
that	O
inhibits	O
activation	O
of	O
the	O
interferon	O
-	O
induced	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
)-	O
RNase	B-ENZY
L	O
pathway	O
.	O

The	O
replication	O
of	O
wild	O
-	O
type	O
MHV	O
strain	O
A59	O
(	O
A59	O
)	O
and	O
a	O
mutant	O
with	O
an	O
inactive	O
phosphodiesterase	B-ENZY
(	O
ns2	O
-	O
H126R	O
)	O
was	O
assessed	O
in	O
primary	O
hepatocytes	O
and	O
primary	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
cell	O
types	O
-	O
neurons	O
,	O
astrocytes	O
,	O
and	O
oligodendrocytes	O
.	O

RNase	B-ENZY
L	O
activity	O
,	O
as	O
assessed	O
by	O
rRNA	O
cleavage	O
,	O
was	O
induced	O
by	O
ns2	O
-	O
H126R	O
,	O
but	O
not	O
by	O
A59	O
,	O
and	O
only	O
in	O
macrophages	O
and	O
microglia	O
.	O

Activation	O
of	O
RNase	B-ENZY
L	O
correlated	O
with	O
the	O
induction	O
of	O
type	O
I	O
interferon	O
and	O
the	O
consequent	O
high	O
levels	O
of	O
OAS	O
mRNA	O
induced	O
in	O
these	O
cell	O
types	O
.	O

Pretreatment	O
of	O
nonmyeloid	O
cells	O
with	O
interferon	O
restricted	O
A59	O
and	O
ns2	O
-	O
H126R	O
to	O
the	O
same	O
extent	O
and	O
failed	O
to	O
activate	O
RNase	B-ENZY
L	O
following	O
infection	O
,	O
despite	O
induction	O
of	O
OAS	O
expression	O
.	O

Thus	O
,	O
RNase	B-ENZY
L	O
activation	O
during	O
MHV	O
infection	O
is	O
cell	O
type	O
specific	O
and	O
correlates	O
with	O
relatively	O
high	O
levels	O
of	O
expression	O
of	O
OAS	O
genes	O
,	O
which	O
are	O
necessary	O
but	O
not	O
sufficient	O
for	O
induction	O
of	O
an	O
effective	O
RNase	B-ENZY
L	O
antiviral	O
response	O
.	O

Haematology	O
and	O
serum	O
biochemistry	O
revealed	O
severe	O
panleukopenia	O
,	O
thrombocytopenia	O
,	O
markedly	O
elevated	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
and	O
five	O
-	O
fold	O
increased	O
pre	O
-	O
prandial	O
bile	O
acids	O
.	O

Conventional	O
mechanical	O
ventilation	O
(	O
CMV	O
)	O
via	O
endotracheal	O
intubation	O
(	O
ETI	O
)	O
has	O
been	O
usually	O
considered	O
as	O
the	O
""""	O
golden	O
standard	O
""""	O
ventilator	O
treatment	O
in	O
ACS	B-ENZY
.	O

The	O
purpose	O
of	O
this	O
paper	O
was	O
to	O
review	O
rationale	O
,	O
clinical	O
feasibility	O
,	O
advantages	O
and	O
risks	O
correlated	O
with	O
the	O
use	O
of	O
NIV	O
in	O
ACS	B-ENZY
.	O

TITLE	O
:	O
Genetic	O
characterization	O
of	O
Betacoronavirus	O
lineage	O
C	O
viruses	O
in	O
bats	O
reveals	O
marked	O
sequence	O
divergence	O
in	O
the	O
spike	O
protein	O
of	O
pipistrellus	O
bat	B-ENZY
coronavirus	O
HKU5	O
in	O
Japanese	O
pipistrelle	O
:	O
implications	O
for	O
the	O
origin	O
of	O
the	O
novel	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Although	O
MERS	O
-	O
CoV	O
may	O
have	O
diverged	O
from	O
potential	O
lineage	O
C	O
betacoronaviruses	O
in	O
European	O
bats	O
more	O
recently	O
,	O
these	O
bat	B-ENZY
viruses	O
were	O
unlikely	O
to	O
be	O
the	O
direct	O
ancestor	O
of	O
MERS	O
-	O
CoV	O
.	O
Intensive	O
surveillance	O
for	O
lineage	O
C	O
betaCoVs	O
in	O
Pipistrellus	O
and	O
related	O
bats	O
with	O
diverse	O
habitats	O
and	O
other	O
animals	O
in	O
the	O
Middle	O
East	O
may	O
fill	O
the	O
evolutionary	O
gap	O
.	O

French	O
Institute	O
for	O
Public	O
Health	O
Surveillance	O
,	O
ANR	B-ENZY
grant	O
Labex	O
Integrative	O
Biology	O
of	O
Emerging	O
Infectious	O
Diseases	O
,	O
and	O
the	O
European	O
Community	O
'	O
s	O
Seventh	O
Framework	O
Programme	O
projects	O
EMPERIE	O
and	O
PREDEMICS	O
.	O

In	O
patients	O
as	O
well	O
as	O
in	O
mice	O
,	O
severe	O
edema	O
and	O
impaired	O
gas	B-ENZY
exchange	O
are	O
associated	O
with	O
abundant	O
inflammatory	O
infiltrates	O
consisting	O
of	O
mainly	O
mononuclear	O
cells	O
and	O
parasite	O
sequestration	O
,	O
and	O
the	O
pathogenesis	O
appears	O
different	O
from	O
cerebral	O
malaria	O
(	O
CM	O
).	O

To	O
compare	O
the	O
performance	O
of	O
RV16	O
with	O
those	O
of	O
culture	O
and	O
Seeplex	O
()	O
RV15	O
ACE	B-ENZY
[	O
RV15	O
]	O
by	O
determining	O
their	O
sensitivity	O
and	O
specificity	O
.	O

Amylase	O
and	O
lipase	B-ENZY
were	O
normal	O
.	O

There	O
is	O
only	O
limited	O
data	O
on	O
neotropical	O
bat	B-ENZY
CoVs	O
.	O

Our	O
study	O
expands	O
the	O
knowledge	O
on	O
CoV	O
diversity	O
in	O
neotropical	O
bats	O
and	O
emphasizes	O
the	O
association	O
of	O
distinct	O
CoVs	O
and	O
bat	B-ENZY
host	O
genera	O
.	O

Fluorogenic	O
peptide	O
assays	O
confirmed	O
that	O
the	O
substitutions	O
modulate	O
furin	B-ENZY
cleavage	O
.	O

Moreover	O
,	O
as	O
is	O
commonly	O
observed	O
for	O
coronavirus	O
infections	O
of	O
other	O
animals	O
,	O
the	O
activities	O
of	O
the	O
effecter	O
caspase	O
,	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
,	O
and	O
the	O
initiator	O
caspases	O
,	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
and	O
caspase	B-ENZY
-	I-ENZY
9	I-ENZY
,	O
which	O
are	O
representative	O
factors	O
in	O
the	O
death	O
receptor	O
-	O
mediated	O
apoptotic	O
pathway	O
and	O
the	O
mitochondrial	O
apoptotic	O
pathway	O
,	O
respectively	O
,	O
were	O
increased	O
in	O
PHEV	O
-	O
infected	O
PK	O
-	O
15	O
cells	O
.	O

Faecal	O
samples	O
were	O
analysed	O
for	O
9	O
infectious	O
agents	O
by	O
real	O
-	O
time	O
PCR	O
:	O
equine	O
rotavirus	O
,	O
equine	O
coronavirus	O
,	O
Clostridium	O
difficile	O
toxins	O
A	O
&	O
B	O
,	O
Neorickettsia	O
risticii	O
,	O
Clostridium	O
perfringens	O
alpha	O
toxin	O
,	O
Lawsonia	O
intracellularis	O
,	O
Rhodococcus	O
equi	O
,	O
Cryptosporidium	O
spp	B-ENZY
.,	O
and	O
Salmonella	O
spp	B-ENZY
.	O

We	O
used	O
sputum	O
and	O
blood	O
cultures	O
,	O
IgG	O
/	O
IgM	O
serology	O
and	O
molecular	O
diagnostic	O
techniques	O
(	O
PCR	O
,	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
)	O
for	O
detection	O
of	O
classical	O
and	O
atypical	O
bacteria	O
(	O
Mycoplasma	O
pneumoniae	O
,	O
Chlamydia	O
pneumoniae	O
,	O
Legionella	O
pneumoniae	O
)	O
and	O
respiratory	O
viruses	O
(	O
adenovirus	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
human	O
metapneumovirus	O
,	O
influenza	O
virus	O
,	O
parainfluenzavirus	O
,	O
rhinovirus	O
,	O
coronavirus	O
)	O
in	O
adults	O
>	O
18	O
years	O
old	O
presenting	O
with	O
CAP	O
in	O
Santiago	O
from	O
February	O
2005	O
to	O
September	O
2007	O
.	O

TITLE	O
:	O
Synergistic	O
inhibitor	O
binding	O
to	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
of	O
human	O
SARS	O
coronavirus	O
:	O
mechanistic	O
and	O
inhibitor	O
design	O
implications	O
.	O

TITLE	O
:	O
Hypericum	O
hircinum	O
L	O
.	O
components	O
as	O
new	O
single	O
-	O
molecule	O
inhibitors	O
of	O
both	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
associated	O
DNA	O
polymerase	O
and	O
ribonuclease	B-ENZY
H	I-ENZY
activities	O
.	O

ABSTRACT	O
:	O
Among	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
associated	O
functions	O
,	O
DNA	O
polymerase	O
and	O
Ribonuclease	B-ENZY
H	I-ENZY
(	O
RNase	B-ENZY
H	I-ENZY
)	O
are	O
both	O
essential	O
for	O
HIV	O
replication	O
and	O
excellent	O
targets	O
for	O
drug	O
development	O
.	O

While	O
all	O
RT	O
inhibitors	O
approved	O
for	O
therapy	O
target	O
the	O
DNA	O
polymerase	O
activity	O
,	O
there	O
is	O
the	O
pressing	O
need	O
for	O
new	O
RT	O
inhibitors	O
possibly	O
targeting	O
the	O
RNase	B-ENZY
H	I-ENZY
function	O
.	O

In	O
the	O
last	O
20	O
years	O
,	O
many	O
natural	O
substances	O
have	O
shown	O
antiviral	O
activity	O
against	O
HIV	O
-	O
1	O
,	O
but	O
only	O
a	O
few	O
against	O
the	O
RNase	B-ENZY
H	I-ENZY
function	O
.	O

ABSTRACT	O
:	O
In	O
Panama	O
,	O
hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	B-ENZY
)	O
is	O
caused	O
by	O
Choclo	O
virus	O
,	O
a	O
species	O
phylogenetically	O
related	O
to	O
Andes	O
and	O
Maporal	O
viruses	O
.	O

From	O
2006	O
to	O
2009	O
,	O
at	O
least	O
21	O
%	O
of	O
117	O
patients	O
diagnosed	O
with	O
HV	O
infection	O
had	O
HV	O
Fever	O
(	O
HF	O
)	O
with	O
no	O
evidence	O
of	O
pulmonary	O
edema	O
(	O
no	O
respiratory	O
distress	O
or	O
radiographic	O
lung	O
infiltrates	O
),	O
and	O
44	O
%	O
of	O
patients	O
had	O
very	O
mild	O
HPS	B-ENZY
(	O
radiographic	O
pulmonary	O
edema	O
but	O
no	O
respiratory	O
insufficiency	O
).	O

To	O
explore	O
the	O
potential	O
use	O
of	O
IBV	O
as	O
a	O
vaccine	O
vector	O
a	O
reverse	O
genetics	O
system	O
was	O
utilised	O
to	O
generate	O
infectious	O
recombinant	O
IBVs	O
(	O
rIBVs	O
)	O
expressing	O
the	O
reporter	O
genes	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
eGFP	O
)	O
or	O
humanised	O
Renilla	O
luciferase	B-ENZY
(	O
hRluc	O
).	O

Reporter	O
gene	O
expression	O
was	O
confirmed	O
by	O
fluorescence	O
microscopy	O
,	O
or	O
luciferase	B-ENZY
activity	O
assays	O
,	O
for	O
all	O
successfully	O
rescued	O
rIBVs	O
following	O
infection	O
of	O
primary	O
chick	O
kidney	O
(	O
CK	O
)	O
cells	O
.	O

TITLE	O
:	O
High	O
-	O
frequency	O
oscillation	O
and	O
tracheal	O
gas	B-ENZY
insufflation	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
traumatic	O
brain	O
injury	O
:	O
an	O
interventional	O
physiological	O
study	O
.	O

ABSTRACT	O
:	O
In	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
combined	O
high	O
-	O
frequency	O
oscillation	O
(	O
HFO	O
)	O
and	O
tracheal	O
gas	B-ENZY
insufflation	O
(	O
TGI	O
)	O
improves	O
gas	B-ENZY
exchange	O
compared	O
with	O
conventional	O
mechanical	O
ventilation	O
(	O
CMV	O
).	O

TITLE	O
:	O
A	O
sorghum	O
xylanase	B-ENZY
inhibitor	O
-	O
like	O
protein	O
with	O
highly	O
potent	O
antifungal	O
,	O
antitumor	O
and	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitory	O
activities	O
.	O

ABSTRACT	O
:	O
A	O
25	O
-	O
kDa	O
protein	O
,	O
with	O
an	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
homologous	O
to	O
that	O
of	O
xylanase	B-ENZY
inhibitor	O
and	O
designated	O
as	O
xylanase	B-ENZY
inbibitor	O
-	O
like	O
protein	O
(	O
XILP	O
)	O
was	O
purified	O
from	O
sorghum	O
seeds	O
.	O

In	O
conclusion	O
,	O
sorghum	O
XILP	O
is	O
thermostable	O
and	O
pH	O
stable	O
and	O
exhibits	O
potent	O
antifungal	O
,	O
antiproliferative	O
,	O
and	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitory	O
activities	O
.	O

In	O
the	O
serum	O
the	O
acute	O
phase	O
proteins	O
(	O
haptoglobin	O
and	O
serum	O
amyloid	O
A	O
),	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
interferon	O
-	O
	O
and	O
tumor	O
necrosis	O
factor	O
-	O
	O
),	O
and	O
serum	O
sialic	O
acid	O
(	O
total	O
,	O
TSA	B-ENZY
;	O
lipid	O
-	O
bound	O
,	O
LBSA	O
;	O
and	O
protein	O
-	O
bound	O
,	O
PBSA	O
)	O
concentrations	O
were	O
measured	O
using	O
validated	O
standard	O
procedures	O
.	O

Correlation	O
coefficients	O
were	O
significantly	O
positive	O
between	O
haptoglobin	O
and	O
interferon	O
-	O
	O
,	O
LBSA	O
and	O
TSA	B-ENZY
,	O
and	O
TSA	B-ENZY
and	O
LBSA	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
IFN	O
-	O
inducible	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
(	O
2	O
-	O
5A	O
)	O
synthetases	O
(	O
OASs	O
)	O
and	O
ribonuclease	O
(	O
RNase	B-ENZY
)	O
L	O
are	O
components	O
of	O
a	O
potent	O
host	O
antiviral	O
pathway	O
.	O

We	O
previously	O
showed	O
that	O
murine	O
coronavirus	O
(	O
MHV	O
)	O
accessory	O
protein	O
ns2	O
,	O
a	O
2H	O
phosphoesterase	O
superfamily	O
member	O
,	O
is	O
a	O
phosphodiesterase	B-ENZY
(	O
PDE	O
)	O
that	O
cleaves	O
2	O
-	O
5A	O
,	O
thereby	O
preventing	O
activation	O
of	O
RNase	B-ENZY
L	O
.	O
The	O
PDE	O
activity	O
of	O
ns2	O
is	O
required	O
for	O
MHV	O
replication	O
in	O
macrophages	O
and	O
for	O
hepatitis	O
.	O

Bacterially	O
expressed	O
VP3	O
-	O
CTD	O
exhibited	O
2	O
',	O
5	B-ENZY
'-	I-ENZY
PDE	I-ENZY
activity	O
,	O
which	O
cleaved	O
2	O
-	O
5A	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
VP3	O
-	O
CTD	O
expressed	O
transiently	O
in	O
mammalian	O
cells	O
depleted	O
2	O
-	O
5A	O
levels	O
induced	O
by	O
OAS	O
activation	O
with	O
poly	O
(	O
rI	O
):	O
poly	O
(	O
rC	O
),	O
preventing	O
RNase	B-ENZY
L	O
activation	O
.	O

In	O
addition	O
,	O
chimeric	O
viruses	O
expressing	O
either	O
active	O
ns2	O
or	O
VP3	O
-	O
CTD	O
,	O
but	O
not	O
nonfunctional	O
equivalents	O
,	O
were	O
able	O
to	O
protect	O
ribosomal	O
RNA	O
from	O
RNase	B-ENZY
L	O
-	O
mediated	O
degradation	O
.	O

Thus	O
,	O
VP3	O
-	O
CTD	O
is	O
a	O
2	O
',	O
5	B-ENZY
'-	I-ENZY
PDE	I-ENZY
able	O
to	O
functionally	O
substitute	O
for	O
ns2	O
in	O
MHV	O
infection	O
.	O

Although	O
PLV	O
has	O
been	O
shown	O
to	O
improve	O
gas	B-ENZY
exchange	O
and	O
to	O
reduce	O
inflammation	O
in	O
experimental	O
models	O
of	O
ALI	O
,	O
a	O
previous	O
systematic	O
review	O
did	O
not	O
find	O
any	O
evidence	O
to	O
support	O
or	O
refute	O
its	O
use	O
in	O
humans	O
with	O
ALI	O
and	O
ARDS	O
.	O

The	O
patient	O
was	O
immediately	O
treated	O
with	O
a	O
steroid	O
and	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
under	O
respiratory	O
supportive	O
therapy	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
lineage	O
C	O
betacoronavirus	O
,	O
originally	O
named	O
human	O
coronavirus	O
EMC	O
/	O
2012	O
(	O
HCoV	O
-	O
EMC	O
)	O
and	O
recently	O
renamed	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
that	O
is	O
phylogenetically	O
closely	O
related	O
to	O
Tylonycteris	O
bat	B-ENZY
coronavirus	O
HKU4	O
and	O
Pipistrellus	O
bat	B-ENZY
coronavirus	O
HKU5	O
,	O
which	O
we	O
discovered	O
in	O
2007	O
from	O
bats	O
in	O
Hong	O
Kong	O
,	O
has	O
recently	O
emerged	O
in	O
the	O
Middle	O
East	O
to	O
cause	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
like	O
infection	O
in	O
humans	O
.	O

Samples	O
were	O
tested	O
by	O
a	O
panel	O
of	O
multiplex	O
PCR	O
assays	O
for	O
11	O
enteric	O
pathogens	O
:	O
bovine	O
rotavirus	O
group	O
A	O
(	O
BRV	O
-	O
A	O
),	O
bovine	O
coronavirus	O
(	O
BCoV	O
),	O
bovine	O
viral	O
diarrhea	O
virus	O
(	O
BVDV	O
),	O
bovine	O
enterovirus	O
(	O
BEV	O
),	O
bovine	O
norovirus	O
(	O
BNoV	O
),	O
Nebovirus	O
,	O
bovine	O
torovirus	O
(	O
BToV	O
)	O
Salmonella	O
spp	B-ENZY
.	O

Supported	O
bilayers	O
are	O
formed	O
from	O
mammalian	O
cell	O
membrane	O
vesicles	O
that	O
express	O
feline	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
the	O
viral	O
receptor	O
)	O
using	O
a	O
cell	O
blebbing	O
technique	O
.	O

Meanwhile	O
,	O
the	O
CD69	O
expression	O
in	O
hepatic	O
NK	O
cells	O
was	O
highly	O
correlated	O
with	O
the	O
serum	O
level	O
of	O
ALT	O
and	O
AST	B-ENZY
.	O

First	O
,	O
the	O
full	O
-	O
length	O
gene	O
of	O
SARS	O
-	O
S	O
protein	O
was	O
PCR	O
amplified	O
,	O
purified	O
and	O
then	O
digested	O
with	O
DNase	B-ENZY
I	O
to	O
obtain	O
DNA	O
fragments	O
in	O
the	O
size	O
range	O
of	O
50	O
-	O
500	O
bp	O
.	O

Between	O
October	O
2008	O
and	O
September	O
2010	O
,	O
nose	O
and	O
throat	O
swabs	O
from	O
adults	O
and	O
children	O
(	O
approximately	O
20	O
per	O
week	O
)	O
presenting	O
with	O
an	O
acute	O
respiratory	O
illness	O
to	O
the	O
Ninh	O
Hoa	B-ENZY
General	O
Hospital	O
were	O
collected	O
.	O

MERS	O
-	O
CoV	O
infection	O
in	O
the	O
latter	O
2	O
patients	O
was	O
confirmed	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
testing	O
.	O

TITLE	O
:	O
Emerging	O
infectious	O
diseases	O
associated	O
with	O
bat	B-ENZY
viruses	O
.	O

The	O
number	O
of	O
identified	O
bat	B-ENZY
viruses	O
has	O
dramatically	O
increased	O
since	O
the	O
initial	O
SARS	O
outbreak	O
,	O
and	O
most	O
are	O
putative	O
novel	O
virus	O
species	O
or	O
genotypes	O
.	O

This	O
review	O
provides	O
a	O
brief	O
overview	O
of	O
bat	B-ENZY
viruses	O
associated	O
with	O
emerging	O
human	O
infectious	O
diseases	O
.	O

With	O
these	O
data	O
,	O
we	O
predicted	O
that	O
the	O
urokinase	B-ENZY
and	O
other	O
wound	O
repair	O
pathways	O
would	O
regulate	O
lethal	O
versus	O
sublethal	O
disease	O
following	O
SARS	O
-	O
CoV	O
infection	O
in	O
mice	O
.	O

The	O
results	O
of	O
these	O
studies	O
demonstrate	O
that	O
a	O
fine	O
balance	O
exists	O
between	O
host	O
coagulation	O
and	O
fibrinolysin	B-ENZY
pathways	O
regulating	O
pathological	O
disease	O
outcomes	O
,	O
including	O
diffuse	O
alveolar	O
damage	O
and	O
acute	O
lung	O
injury	O
,	O
following	O
infection	O
with	O
highly	O
pathogenic	O
respiratory	O
viruses	O
,	O
such	O
as	O
SARS	O
-	O
CoV	O
.	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
emerged	O
in	O
2002	O
and	O
2003	O
,	O
and	O
infected	O
patients	O
developed	O
an	O
atypical	O
pneumonia	O
,	O
acute	O
lung	O
injury	O
(	O
ALI	O
),	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
leading	O
to	O
pulmonary	O
fibrosis	O
and	O
death	O
.	O

By	O
infecting	O
Serpine1	O
-	O
knockout	O
mice	O
,	O
we	O
showed	O
that	O
the	O
urokinase	B-ENZY
pathway	O
had	O
a	O
significant	O
effect	O
on	O
both	O
lung	O
pathology	O
and	O
overall	O
SARS	O
-	O
CoV	O
pathogenesis	O
.	O

The	O
SARS	O
coronavirus	O
causes	O
lung	O
injury	O
and	O
inflammation	O
in	O
part	O
through	O
actions	O
on	O
the	O
nonclassical	O
renin	B-ENZY
angiotensin	O
pathway	O
.	O

In	O
addition	O
,	O
we	O
inserted	O
heterologous	O
genes	O
(	O
i	O
.	O
e	O
.	O
the	O
GFP	O
and	O
Renilla	O
luciferase	B-ENZY
genes	O
)	O
at	O
two	O
positions	O
in	O
the	O
viral	O
genome	O
,	O
either	O
as	O
an	O
extra	O
expression	O
cassette	O
or	O
as	O
a	O
replacement	O
for	O
the	O
ORF3	O
gene	O
.	O

We	O
demonstrated	O
the	O
expression	O
of	O
both	O
GFP	O
and	O
Renilla	O
luciferase	B-ENZY
as	O
well	O
as	O
the	O
application	O
of	O
these	O
viruses	O
by	O
establishing	O
a	O
convenient	O
and	O
rapid	O
virus	O
neutralization	O
assay	O
.	O

TITLE	O
:	O
ACE2	O
-	O
from	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
to	O
gut	O
microbiota	O
and	O
malnutrition	O
.	O

ABSTRACT	O
:	O
The	O
renin	B-ENZY
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
is	O
a	O
complex	O
network	O
that	O
regulates	O
blood	O
pressure	O
,	O
electrolyte	O
and	O
fluid	O
homeostasis	O
,	O
as	O
well	O
as	O
the	O
function	O
of	O
several	O
organs	O
.	O

Thus	O
,	O
ACE2	O
counteracts	O
the	O
role	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)	O
which	O
generates	O
Ang	O
II	O
from	O
Ang	O
I	O
.	O
ACE	B-ENZY
and	O
ACE2	O
have	O
been	O
implicated	O
in	O
several	O
pathologies	O
such	O
as	O
cardiovascular	O
and	O
renal	O
disease	O
or	O
acute	O
lung	O
injury	O
.	O

In	O
this	O
study	O
,	O
long	O
-	O
term	O
feline	O
intestinal	O
epithelial	O
cell	O
cultures	O
were	O
established	O
from	O
primary	O
ileocytes	O
and	O
colonocytes	O
by	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
T	O
-	O
antigen	O
-	O
and	O
human	O
Telomerase	O
Reverse	B-ENZY
Transcriptase	I-ENZY
(	O
hTERT	O
)-	O
induced	O
immortalization	O
.	O

The	O
integrity	O
of	O
epithelial	O
and	O
endothelial	O
barriers	O
in	O
the	O
lower	O
airspaces	O
of	O
the	O
lungs	O
has	O
to	O
be	O
tightly	O
regulated	O
,	O
in	O
order	O
to	O
prevent	O
leakage	O
and	O
to	O
assure	O
efficient	O
gas	B-ENZY
exchange	O
between	O
the	O
alveoli	O
and	O
capillaries	O
.	O

The	O
enzyme	O
arginase	B-ENZY
,	O
the	O
activity	O
of	O
which	O
can	O
be	O
regulated	O
by	O
the	O
redox	O
status	O
of	O
the	O
cell	O
,	O
exists	O
in	O
two	O
isoforms	O
-	O
arginase	B-ENZY
1	O
(	O
cytosolic	O
)	O
and	O
arginase	B-ENZY
2	O
(	O
mitochondrial	O
)	O
-	O
both	O
of	O
which	O
can	O
be	O
expressed	O
in	O
lung	O
microvascular	O
endothelial	O
cells	O
.	O

Both	O
viruses	O
also	O
have	O
close	O
relationships	O
with	O
bat	B-ENZY
coronaviruses	O
.	O

While	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
are	O
genetically	O
closely	O
related	O
to	O
bat	B-ENZY
coronaviruses	O
,	O
intermediate	O
host	O
(	O
s	O
)	O
is	O
(	O
are	O
)	O
likely	O
to	O
be	O
involved	O
in	O
the	O
emergence	O
and	O
cross	O
-	O
species	O
transmission	O
of	O
these	O
novel	O
human	O
viruses	O
.	O

In	O
this	O
study	O
,	O
we	O
produced	O
a	O
pseudovirus	O
bearing	O
the	O
full	O
-	O
length	O
spike	O
(	O
S	O
)	O
protein	O
of	O
MERS	O
-	O
CoV	O
in	O
the	O
Env	O
-	O
defective	O
,	O
luciferase	B-ENZY
-	O
expressing	O
HIV	O
-	O
1	O
backbone	O
.	O

ABSTRACT	O
:	O
Mechanical	O
circulatory	O
support	O
(	O
MCS	B-ENZY
)	O
is	O
a	O
rescue	O
therapy	O
for	O
infants	O
and	O
children	O
suffering	O
from	O
severe	O
cardiorespiratory	O
failure	O
with	O
specific	O
system	O
-	O
related	O
complications	O
like	O
bleeding	O
,	O
thromboembolism	O
and	O
device	O
failure	O
.	O

The	O
DP3	O
circuit	O
was	O
used	O
22	O
times	O
in	O
these	O
children	O
for	O
different	O
indications	O
:	O
(	O
I	O
)	O
extracorporeal	O
life	O
support	O
(	O
ECLS	O
)	O
in	O
post	O
-	O
cardiotomy	O
heart	O
failure	O
(	O
n	O
=	O
11	O
),	O
(	O
II	O
)	O
ECLS	O
in	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	B-ENZY
)	O
(	O
n	O
=	O
7	O
)	O
and	O
(	O
III	O
)	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
(	O
n	O
=	O
4	O
).	O

Mean	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
before	O
MCS	B-ENZY
was	O
700	O
(	O
384	O
)	O
U	O
/	O
l	O
,	O
and	O
increased	O
to	O
a	O
maximum	O
of	O
2279	O
(	O
2635	O
)	O
U	O
/	O
l	O
during	O
MCS	B-ENZY
(	O
P	O
=	O
0	O
.	O
04	O
).	O

The	O
mean	O
of	O
the	O
highest	O
plasma	O
-	O
free	O
haemoglobin	O
during	O
MCS	B-ENZY
was	O
21	O
.	O
0	O
(	O
42	O
.	O
9	O
)	O
mg	O
/	O
dl	O
.	O

The	O
increase	O
in	O
plasma	O
-	O
free	O
haemoglobin	O
correlated	O
moderately	O
with	O
the	O
duration	O
of	O
MCS	B-ENZY
(	O
Pearson	O
'	O
s	O
r	O
:	O
0	O
.	O
78	O
).	O

The	O
use	O
of	O
the	O
Deltastream	O
DP3	O
seems	O
to	O
be	O
safe	O
and	O
effective	O
for	O
MCS	B-ENZY
in	O
children	O
and	O
may	O
show	O
a	O
low	O
degree	O
of	O
haemolysis	O
.	O

RESULTS	O
:	O
Median	O
duration	O
of	O
MCS	B-ENZY
was	O
4	O
days	O
(	O
0	O
-	O
18	O
days	O
),	O
12	O
patients	O
(	O
75	O
%)	O
were	O
weaned	O
successfully	O
from	O
MCS	B-ENZY
,	O
4	O
of	O
these	O
children	O
(	O
25	O
%)	O
died	O
after	O
weaning	O
,	O
with	O
a	O
median	O
survival	O
time	O
of	O
15	O
days	O
(	O
6	O
-	O
28	O
days	O
).	O

The	O
increase	O
in	O
plasma	O
-	O
free	O
haemoglobin	O
correlated	O
moderately	O
with	O
the	O
duration	O
of	O
MCS	B-ENZY
(	O
Pearson	O
'	O
s	O
r	O
:	O
0	O
.	O
78	O
).	O

TITLE	O
:	O
High	O
-	O
frequency	O
oscillatory	O
ventilation	O
with	O
tracheal	O
gas	B-ENZY
insufflation	O
:	O
the	O
rescue	O
strategy	O
for	O
brain	O
-	O
lung	O
interaction	O
.	O

Venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
vvECMO	O
)	O
is	O
a	O
rescue	O
strategy	O
that	O
may	O
ensure	O
sufficient	O
gas	B-ENZY
exchange	O
in	O
ARDS	O
patients	O
failing	O
conventional	O
therapy	O
.	O

TITLE	O
:	O
Assessing	O
activity	O
and	O
inhibition	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-ENZY
-	O
like	O
and	O
3C	O
-	O
like	O
proteases	O
using	O
luciferase	B-ENZY
-	O
based	O
biosensors	O
.	O

To	O
investigate	O
MERS	O
-	O
CoV	O
3CLpro	O
activity	O
,	O
we	O
expressed	O
the	O
protease	O
in	O
context	O
with	O
flanking	O
nonstructural	O
protein	O
4	O
(	O
nsp4	O
)	O
and	O
the	O
amino	O
-	O
terminal	O
portion	O
of	O
nsp6	O
and	O
detected	O
processing	O
of	O
the	O
luciferase	B-ENZY
-	O
based	O
biosensors	O
containing	O
the	O
canonical	O
3CLpro	O
cleavage	O
site	O
VRLQS	O
.	O

Bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
specimen	O
was	O
indicated	O
of	O
AEP	O
.	O

TITLE	O
:	O
[	O
Evaluating	O
efficiency	O
of	O
influenza	O
vaccinal	O
prevention	O
among	O
oil	O
and	O
gas	B-ENZY
industry	O
workers	O
].	O

ABSTRACT	O
:	O
Explore	O
information	O
about	O
the	O
incidence	O
of	O
employees	O
of	O
enterprises	O
of	O
the	O
oil	O
and	O
gas	B-ENZY
industry	O
with	O
the	O
influenza	O
(	O
SARS	O
).	O

The	O
study	O
by	O
de	O
Prost	O
and	O
colleagues	O
in	O
the	O
current	O
issue	O
of	O
Critical	O
Care	O
provides	O
new	O
insights	O
into	O
the	O
impact	O
of	O
ventilation	O
strategies	O
on	O
pulmonary	O
function	O
,	O
gas	B-ENZY
exchange	O
,	O
and	O
regional	O
cellular	O
metabolic	O
activity	O
during	O
early	O
ALI	O
in	O
sheep	O
.	O

TITLE	O
:	O
Differential	O
sensitivity	O
of	O
bat	B-ENZY
cells	O
to	O
infection	O
by	O
enveloped	O
RNA	O
viruses	O
:	O
coronaviruses	O
,	O
paramyxoviruses	O
,	O
filoviruses	O
,	O
and	O
influenza	O
viruses	O
.	O

We	O
analyzed	O
six	O
different	O
cell	O
lines	O
from	O
either	O
Yinpterochiroptera	O
(	O
including	O
African	O
flying	O
foxes	O
and	O
a	O
rhinolophid	O
bat	B-ENZY
)	O
or	O
Yangochiroptera	O
(	O
genera	O
Carollia	O
and	O
Tadarida	O
)	O
for	O
susceptibility	O
to	O
infection	O
by	O
different	O
enveloped	O
RNA	O
viruses	O
.	O

The	O
resistance	O
to	O
infection	O
was	O
overcome	O
if	O
cells	O
were	O
transfected	O
to	O
express	O
the	O
respective	O
cellular	O
receptor	O
,	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
for	O
TGEV	O
or	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
for	O
SARS	O
-	O
CoV	O
.	O
VSV	O
pseudotypes	O
containing	O
the	O
S	O
proteins	O
of	O
two	O
bat	B-ENZY
SARS	O
-	O
related	O
CoV	O
(	O
Bg08	O
and	O
Rp3	O
)	O
were	O
unable	O
to	O
infect	O
any	O
of	O
the	O
six	O
tested	O
bat	B-ENZY
cell	O
lines	O
.	O

Nasopharyngeal	O
specimens	O
were	O
collected	O
systematically	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
was	O
performed	O
when	O
clinically	O
indicated	O
.	O

Picornavirus	O
was	O
identified	O
most	O
frequently	O
in	O
nasopharyngeal	O
(	O
85	O
/	O
140	O
;	O
60	O
.	O
7	O
%)	O
and	O
BAL	B-ENZY
specimens	O
(	O
20	O
/	O
34	O
;	O
59	O
%).	O

Simultaneous	O
treatment	O
with	O
inhibitors	O
of	O
cathepsin	B-ENZY
L	I-ENZY
and	O
TMPRSS2	O
completely	O
blocked	O
virus	O
entry	O
into	O
Vero	O
-	O
TMPRSS2	O
cells	O
,	O
indicating	O
that	O
MERS	O
-	O
CoV	O
employs	O
both	O
the	O
cell	O
surface	O
and	O
the	O
endosomal	O
pathway	O
to	O
infect	O
Vero	O
-	O
TMPRSS2	O
cells	O
.	O

TITLE	O
:	O
Sustained	O
improvement	O
of	O
gas	B-ENZY
exchange	O
and	O
lung	O
mechanics	O
by	O
vaporized	O
perfluorocarbon	O
inhalation	O
in	O
piglet	O
acute	O
lung	O
injury	O
model	O
.	O

This	O
study	O
aims	O
to	O
examine	O
the	O
effects	O
of	O
vaporized	O
PFC	O
on	O
gas	B-ENZY
exchange	O
and	O
lung	O
mechanics	O
in	O
a	O
piglet	O
model	O
with	O
ARDS	O
.	O

Inhalation	O
of	O
vaporized	O
PFC	O
results	O
in	O
sustained	O
improvement	O
of	O
pulmonary	O
gas	B-ENZY
exchange	O
and	O
lung	O
mechanics	O
in	O
a	O
detergent	O
-	O
induced	O
animal	O
model	O
of	O
lung	O
injury	O
.	O

The	O
preoperative	O
evaluation	O
showed	O
a	O
severe	O
alteration	O
of	O
diffusion	O
(	O
pO2	O
68	O
mm	O
Hg	O
),	O
without	O
hepatopulmonary	O
syndrome	O
or	O
portopulmonary	O
hypertension	O
(	O
PPH	B-ENZY
)	O
upon	O
basal	O
and	O
dobutamine	O
stress	O
echocardiography	O
.	O

On	O
postoperative	O
day	O
(	O
POD	O
)	O
3	O
,	O
we	O
observed	O
severe	O
worsening	O
of	O
PPH	B-ENZY
:	O
mPAP	O
60	O
mm	O
Hg	O
,	O
WP	O
10	O
mm	O
Hg	O
,	O
CO	O
9	O
.	O
8	O
L	O
/	O
min	O
,	O
PVR	O
395	O
dyne	O
s	O
/	O
cm	O
(	O
5	O
),	O
TPG	O
50	O
mm	O
Hg	O
even	O
with	O
maximal	O
pulmonary	O
vasodilatatory	O
therapy	O
(	O
ambrisentan	O
5	O
mg	O
,	O
intravenous	O
sildenafil	O
20	O
mg	O
	O
3	O
and	O
epoprostenol	O
22	O
ng	O
/	O
kg	O
/	O
min	O
,	O
iNO	O
).	O

TITLE	O
:	O
Thrombin	B-ENZY
selectively	O
engages	O
LIM	O
kinase	O
1	O
and	O
slingshot	O
-	O
1L	O
phosphatase	O
to	O
regulate	O
NF	O
-	O
B	O
activation	O
and	O
endothelial	O
cell	O
inflammation	O
.	O

However	O
,	O
TRT	O
in	O
healthy	O
older	O
men	O
in	O
near	O
physiological	O
doses	O
does	O
not	O
appear	O
to	O
incur	O
serious	O
adverse	O
events	O
,	O
although	O
regular	O
monitoring	O
of	O
prostate	B-ENZY
-	I-ENZY
specific	I-ENZY
antigen	I-ENZY
and	O
hematocrit	O
levels	O
is	O
required	O
.	O

Real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
),	O
multiplex	O
PCR	O
techniques	O
,	O
traditional	O
Sanger	O
Sequencing	O
and	O
classical	O
viral	O
culture	O
methods	O
were	O
used	O
.	O

Calves	O
that	O
were	O
fecal	O
positive	O
to	O
cryptosporidium	O
spp	B-ENZY
.	O

Computed	O
tomography	O
imaging	O
and	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
supported	O
a	O
diagnosis	O
of	O
acute	O
lung	O
injury	O
.	O

Codon	O
usage	O
(	O
CU	O
)	O
was	O
measured	O
for	O
the	O
viral	O
spike	O
(	O
S	O
),	O
nucleocapsid	O
(	O
N	O
),	O
nonstructural	O
protein	O
2	O
(	O
NSP2	O
)	O
and	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	O
))	O
genes	O
from	O
a	O
diverse	O
set	O
of	O
A	O
.	O
coronavirus	O
lineages	O
and	O
for	O
G	O
.	O
gallus	O
genes	O
(	O
lung	O
surfactant	O
protein	O
A	O
,	O
intestinal	O
cholecystokinin	O
,	O
oviduct	O
ovomucin	O
alpha	O
subunit	O
,	O
kidney	O
vitamin	O
D	O
receptor	O
and	O
the	O
ubiquitary	O
beta	O
-	O
actin	O
)	O
for	O
different	O
A	O
.	O
coronavirus	O
replicating	O
sites	O
.	O

ABSTRACT	O
:	O
Following	O
the	O
recognition	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
as	O
the	O
""""	O
endothelium	O
-	O
derived	O
relaxing	O
factor	O
","""	O
an	O
explosion	O
of	O
laboratory	O
and	O
clinical	O
research	O
led	O
to	O
the	O
development	O
of	O
inhaled	O
NO	O
as	O
a	O
potential	O
therapy	O
for	O
patients	O
with	O
pulmonary	O
arterial	O
hypertension	O
(	O
PAH	B-ENZY
).	O

Over	O
the	O
past	O
decades	O
,	O
inhaled	O
NO	O
remains	O
the	O
central	O
therapy	O
for	O
PPHN	O
and	O
is	O
commonly	O
used	O
for	O
acute	O
pulmonary	O
vasoreactivity	O
testing	O
during	O
right	O
heart	O
catheterization	O
and	O
for	O
treating	O
pediatric	O
and	O
adult	O
patients	O
with	O
PAH	B-ENZY
associated	O
with	O
postoperative	O
cardiac	O
surgery	O
,	O
severe	O
respiratory	O
failure	O
,	O
pulmonary	O
hypertension	O
crises	O
,	O
and	O
other	O
disorders	O
.	O

This	O
review	O
will	O
describe	O
the	O
current	O
use	O
of	O
inhaled	O
NO	O
in	O
clinical	O
practice	O
and	O
briefly	O
discuss	O
its	O
potential	O
role	O
for	O
the	O
treatment	O
of	O
chronic	O
PAH	B-ENZY
.	O

These	O
experiments	O
show	O
that	O
if	O
S	O
protein	O
on	O
MERS	O
pseudovirions	O
is	O
uncleaved	O
,	O
then	O
viruses	O
enter	O
by	O
endocytosis	O
in	O
a	O
cathepsin	B-ENZY
L	I-ENZY
-	O
dependent	O
manner	O
,	O
but	O
if	O
MERS	O
-	O
CoV	O
S	O
is	O
cleaved	O
,	O
either	O
during	O
virus	O
maturation	O
by	O
serine	O
proteases	O
or	O
on	O
pseudovirions	O
by	O
trypsin	B-ENZY
in	O
extracellular	O
fluids	O
,	O
then	O
viruses	O
enter	O
at	O
the	O
plasma	O
membrane	O
at	O
neutral	O
pH	O
and	O
cause	O
massive	O
syncytia	O
formation	O
even	O
in	O
cells	O
that	O
express	O
little	O
or	O
no	O
MERS	O
-	O
CoV	O
receptor	O
.	O

TITLE	O
:	O
Adaptive	O
evolution	O
of	O
bat	B-ENZY
dipeptidyl	O
peptidase	O
4	O
(	O
dpp4	O
):	O
implications	O
for	O
the	O
origin	O
and	O
emergence	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

We	O
show	O
that	O
bat	B-ENZY
DPP4	O
genes	O
have	O
been	O
subject	O
to	O
significant	O
adaptive	O
evolution	O
,	O
suggestive	O
of	O
a	O
long	O
-	O
term	O
arms	O
-	O
race	O
between	O
bats	O
and	O
MERS	O
related	O
CoVs	O
.	O

Neither	O
enterotoxigenic	O
E	O
.	O
coli	O
,	O
Clostridium	O
perfringens	O
type	O
A	O
or	O
C	O
,	O
Clostridium	O
difficile	O
,	O
rotavirus	O
,	O
coronavirus	O
,	O
Cryptosporidium	O
spp	B-ENZY
,	O
Giardia	O
spp	B-ENZY
,	O
Cystoisospora	O
suis	O
nor	O
Strongyloides	O
ransomi	O
were	O
associated	O
with	O
diarrhoea	O
in	O
the	O
investigated	O
outbreaks	O
.	O

Clinical	O
characteristics	O
and	O
distribution	O
of	O
respiratory	O
viruses	O
in	O
patients	O
with	O
and	O
without	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
)	O
were	O
evaluated	O
.	O

Logistic	O
regression	O
showed	O
no	O
association	O
between	O
ACS	B-ENZY
and	O
detection	O
of	O
HRV	O
,	O
hCoV	O
,	O
hBoV	O
,	O
hMPV	O
,	O
and	O
other	O
respiratory	O
pathogens	O
.	O

Co	O
-	O
infection	O
with	O
at	O
least	O
one	O
additional	O
respiratory	O
virus	O
was	O
seen	O
in	O
14	O
(	O
30	O
%)	O
infected	O
patients	O
,	O
and	O
was	O
not	O
significantly	O
higher	O
in	O
patients	O
with	O
ACS	B-ENZY
(	O
P	O
=	O
0	O
.	O
10	O
).	O

Co	O
-	O
infections	O
with	O
more	O
than	O
two	O
respiratory	O
viruses	O
were	O
seen	O
in	O
seven	O
patients	O
,	O
all	O
in	O
patients	O
without	O
ACS	B-ENZY
.	O

Larger	O
prospective	O
studies	O
with	O
asymptomatic	O
controls	O
are	O
needed	O
to	O
study	O
the	O
association	O
of	O
these	O
emerging	O
respiratory	O
viruses	O
with	O
ACS	B-ENZY
in	O
children	O
with	O
sickle	O
cell	O
disease	O
.	O

The	O
finding	O
that	O
the	O
emergent	O
U	O
.	O
S	O
.	O
PEDV	O
strains	O
share	O
unique	O
genetic	O
features	O
at	O
the	O
5	O
'-	O
untranslated	O
region	O
with	O
a	O
bat	B-ENZY
coronavirus	O
provided	O
further	O
support	O
of	O
the	O
evolutionary	O
origin	O
of	O
PEDV	O
from	O
bats	O
and	O
potential	O
cross	O
-	O
species	O
transmission	O
.	O

We	O
illustrate	O
the	O
power	O
of	O
these	O
methods	O
by	O
:	O
1	O
)	O
identifying	O
the	O
sites	O
explaining	O
SARS	O
coronavirus	O
differences	O
between	O
human	O
,	O
bat	B-ENZY
and	O
palm	O
civet	O
samples	O
;	O
2	O
)	O
showing	O
how	O
cross	O
species	O
jumps	O
of	O
rabies	O
virus	O
among	O
bat	B-ENZY
populations	O
can	O
be	O
readily	O
identified	O
;	O
and	O
3	O
)	O
de	O
novo	O
identification	O
of	O
likely	O
functional	O
influenza	O
host	O
discriminant	O
markers	O
.	O

As	O
RNA	O
viruses	O
may	O
coevolve	O
with	O
their	O
hosts	O
,	O
we	O
sought	O
to	O
investigate	O
the	O
closest	O
sister	O
taxon	O
to	O
bats	O
,	O
the	O
Eulipotyphla	O
,	O
and	O
screened	O
European	O
hedgehogs	O
(	O
Erinaceus	O
europaeus	O
)	O
from	O
Germany	O
for	O
CoV	O
by	O
nested	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
.	O

A	O
novel	O
betacoronavirus	O
species	O
in	O
a	O
phylogenetic	O
sister	O
relationship	O
to	O
MERS	O
-	O
CoV	O
and	O
clade	O
c	O
bat	B-ENZY
CoVs	O
was	O
detected	O
and	O
characterized	O
on	O
the	O
whole	O
-	O
genome	O
level	O
.	O

Thirteen	O
of	O
27	O
(	O
48	O
.	O
2	O
%)	O
hedgehog	O
sera	O
contained	O
non	O
-	O
neutralizing	O
antibodies	O
against	O
MERS	O
-	O
CoV	O
.	O
The	O
animal	O
origins	O
of	O
this	O
betacoronavirus	O
clade	O
that	O
includes	O
MERS	O
-	O
CoV	O
may	O
thus	O
include	O
both	O
bat	B-ENZY
and	O
nonbat	O
hosts	O
.	O

Two	O
authors	O
independently	O
selected	O
parallel	O
-	O
group	O
randomized	O
controlled	O
trials	O
comparing	O
nitric	O
oxide	O
with	O
control	O
(	O
placebo	O
or	O
no	O
gas	B-ENZY
)	O
in	O
mechanically	O
ventilated	O
adults	O
or	O
postneonatal	O
children	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
Although	O
intra	O
-	O
abdominal	O
hypertension	O
(	O
IAH	O
)	O
and	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
)	O
are	O
associated	O
with	O
substantial	O
morbidity	O
and	O
mortality	O
among	O
critically	O
ill	O
adults	O
,	O
it	O
remains	O
unknown	O
if	O
prevention	O
or	O
treatment	O
of	O
these	O
conditions	O
improves	O
patient	O
outcomes	O
.	O

We	O
sought	O
to	O
identify	O
evidence	O
-	O
based	O
risk	O
factors	O
for	O
IAH	O
and	O
ACS	B-ENZY
in	O
order	O
to	O
guide	O
identification	O
of	O
the	O
source	O
population	O
for	O
future	O
IAH	O
/	O
ACS	B-ENZY
treatment	O
trials	O
and	O
to	O
stratify	O
patients	O
into	O
risk	O
groups	O
based	O
on	O
prognosis	O
.	O

The	O
38	O
identified	O
risk	O
factors	O
for	O
IAH	O
and	O
24	O
for	O
ACS	B-ENZY
could	O
be	O
clustered	O
into	O
three	O
themes	O
and	O
eight	O
subthemes	O
.	O

Although	O
several	O
IAH	O
/	O
ACS	B-ENZY
risk	O
factors	O
transcend	O
across	O
presenting	O
patient	O
diagnoses	O
,	O
some	O
appear	O
specific	O
to	O
the	O
population	O
under	O
study	O
.	O

Among	O
trauma	O
and	O
surgical	O
patients	O
,	O
large	O
volume	O
crystalloid	O
resuscitation	O
and	O
markers	O
of	O
shock	O
/	O
hypotension	O
and	O
metabolic	O
derangement	O
/	O
organ	O
failure	O
were	O
risk	O
factors	O
for	O
IAH	O
and	O
ACS	B-ENZY
while	O
increased	O
disease	O
severity	O
scores	O
and	O
elevated	O
creatinine	O
were	O
risk	O
factors	O
for	O
ACS	B-ENZY
in	O
severe	O
acute	O
pancreatitis	O
patients	O
.	O

For	O
some	O
emerging	O
pathogens	O
the	O
bat	B-ENZY
origin	O
has	O
been	O
confirmed	O
(	O
such	O
as	O
lyssaviruses	O
,	O
henipaviruses	O
,	O
coronaviruses	O
),	O
for	O
other	O
it	O
has	O
been	O
suggested	O
(	O
filoviruses	O
).	O

In	O
the	O
present	O
review	O
we	O
summarize	O
information	O
on	O
major	O
bat	B-ENZY
-	O
associated	O
emerging	O
infections	O
and	O
discuss	O
specific	O
characteristics	O
of	O
bats	O
as	O
carriers	O
of	O
pathogens	O
(	O
from	O
evolutionary	O
,	O
ecological	O
,	O
and	O
immunological	O
positions	O
).	O

Gas	B-ENZY
diffusing	O
capacity	O
was	O
impaired	O
in	O
most	O
patients	O
,	O
significantly	O
improving	O
at	O
follow	O
-	O
up	O
but	O
still	O
subnormal	O
in	O
38	O
%.	O

NT	O
-	O
ProBNP	O
concentrations	O
were	O
markedly	O
increased	O
and	O
were	O
inversely	O
associated	O
with	O
gas	B-ENZY
diffusing	O
capacity	O
but	O
positively	O
correlated	O
to	O
pulmonary	O
vascular	O
resistance	O
.	O

The	O
results	O
demonstrate	O
vascular	O
leakage	O
in	O
the	O
lungs	O
that	O
most	O
likely	O
is	O
responsible	O
for	O
impaired	O
gas	B-ENZY
diffusing	O
capacity	O
and	O
increased	O
pulmonary	O
vascular	O
resistance	O
with	O
secondary	O
pulmonary	O
hypertension	O
and	O
right	O
heart	O
distress	O
.	O

Furthermore	O
,	O
patients	O
experiencing	O
impaired	O
general	O
condition	O
at	O
follow	O
-	O
up	O
had	O
significantly	O
lower	O
gas	B-ENZY
diffusing	O
capacity	O
and	O
higher	O
pulmonary	O
vascular	O
resistance	O
,	O
compared	O
to	O
those	O
feeling	O
fully	O
recovered	O
.	O

TITLE	O
:	O
Isolation	O
and	O
characterization	O
of	O
a	O
bat	B-ENZY
SARS	O
-	O
like	O
coronavirus	O
that	O
uses	O
the	O
ACE2	O
receptor	O
.	O

These	O
viruses	O
are	O
far	O
more	O
closely	O
related	O
to	O
SARS	O
-	O
CoV	O
than	O
any	O
previously	O
identified	O
bat	B-ENZY
coronaviruses	O
,	O
particularly	O
in	O
the	O
receptor	O
binding	O
domain	O
of	O
the	O
spike	O
protein	O
.	O

Most	O
importantly	O
,	O
we	O
report	O
the	O
first	O
recorded	O
isolation	O
of	O
a	O
live	O
SL	O
-	O
CoV	O
(	O
bat	B-ENZY
SL	O
-	O
CoV	O
-	O
WIV1	O
)	O
from	O
bat	B-ENZY
faecal	O
samples	O
in	O
Vero	O
E6	O
cells	O
,	O
which	O
has	O
typical	O
coronavirus	O
morphology	O
,	O
99	O
.	O
9	O
%	O
sequence	O
identity	O
to	O
Rs3367	O
and	O
uses	O
ACE2	O
from	O
humans	O
,	O
civets	O
and	O
Chinese	O
horseshoe	O
bats	O
for	O
cell	O
entry	O
.	O

Our	O
results	O
provide	O
the	O
strongest	O
evidence	O
to	O
date	O
that	O
Chinese	O
horseshoe	O
bats	O
are	O
natural	O
reservoirs	O
of	O
SARS	O
-	O
CoV	O
,	O
and	O
that	O
intermediate	O
hosts	O
may	O
not	O
be	O
necessary	O
for	O
direct	O
human	O
infection	O
by	O
some	O
bat	B-ENZY
SL	O
-	O
CoVs	O
.	O

Since	O
then	O
,	O
numerous	O
studies	O
have	O
described	O
novel	O
bat	B-ENZY
CoVs	O
,	O
including	O
close	O
relatives	O
of	O
the	O
newly	O
emerging	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
CoV	O
.	O
In	O
this	O
paper	O
we	O
discuss	O
CoV	O
genomic	O
properties	O
and	O
compare	O
different	O
taxonomic	O
approaches	O
in	O
light	O
of	O
the	O
technical	O
difficulties	O
of	O
obtaining	O
full	O
genomic	O
sequences	O
directly	O
from	O
bat	B-ENZY
specimens	O
.	O

We	O
first	O
present	O
an	O
overview	O
of	O
the	O
available	O
studies	O
on	O
bat	B-ENZY
CoVs	O
,	O
with	O
details	O
on	O
their	O
chiropteran	O
hosts	O
,	O
then	O
comparatively	O
analyze	O
the	O
increase	O
in	O
bat	B-ENZY
CoV	O
studies	O
and	O
novel	O
genomic	O
sequences	O
obtained	O
since	O
the	O
SARS	O
pandemic	O
.	O

We	O
next	O
discuss	O
preliminary	O
evidence	O
for	O
phylogenetic	O
co	O
-	O
segregation	O
of	O
CoVs	O
and	O
bat	B-ENZY
hosts	O
encompassing	O
the	O
Betacoronavirus	O
clades	O
b	O
and	O
d	O
,	O
with	O
an	O
emphasis	O
on	O
the	O
sampling	O
bias	O
that	O
exists	O
among	O
bat	B-ENZY
species	O
and	O
other	O
mammals	O
,	O
then	O
present	O
examples	O
of	O
CoVs	O
infecting	O
different	O
hosts	O
on	O
the	O
one	O
hand	O
and	O
viruses	O
apparently	O
confined	O
to	O
host	O
genera	O
on	O
the	O
other	O
.	O

We	O
also	O
demonstrate	O
a	O
geographic	O
bias	O
within	O
available	O
studies	O
on	O
bat	B-ENZY
CoVs	O
,	O
and	O
identify	O
a	O
critical	O
lack	O
of	O
information	O
from	O
biodiversity	O
hotspots	O
in	O
Africa	O
,	O
Asia	O
and	O
Latin	O
America	O
.	O

Finally	O
,	O
we	O
suggest	O
caution	O
with	O
conclusions	O
on	O
the	O
zoonotic	O
potential	O
of	O
bat	B-ENZY
viruses	O
,	O
based	O
only	O
on	O
genomic	O
sequence	O
data	O
,	O
and	O
emphasize	O
the	O
need	O
to	O
preserve	O
these	O
ecologically	O
highly	O
relevant	O
animals	O
.	O

This	O
study	O
fills	O
a	O
substantive	O
gap	O
in	O
the	O
knowledge	O
on	O
bat	B-ENZY
-	O
CoV	O
ecology	O
in	O
Italy	O
,	O
and	O
extends	O
the	O
current	O
knowledge	O
on	O
clade	O
2c	O
betacoronaviruses	O
with	O
new	O
sequences	O
obtained	O
from	O
bats	O
that	O
have	O
not	O
been	O
previously	O
described	O
as	O
hosts	O
of	O
these	O
viruses	O
.	O

Virus	O
from	O
1	O
bat	B-ENZY
showed	O
100	O
%	O
nucleotide	O
identity	O
to	O
virus	O
from	O
the	O
human	O
index	O
case	O
-	O
patient	O
.	O

Controls	O
(	O
2	O
:	O
1	O
ratio	O
)	O
were	O
ARDS	O
infants	O
weaned	O
with	O
pressure	O
support	O
ventilation	O
(	O
PSV	O
)	O
during	O
2008	O
-	O
2009	O
matched	O
for	O
age	O
,	O
gas	B-ENZY
exchange	O
impairment	O
,	O
and	O
weight	O
.	O

Patients	O
usually	O
receive	O
high	O
levels	O
of	O
supplemental	O
oxygen	O
to	O
counteract	O
the	O
hypoxemia	O
resulting	O
from	O
severe	O
gas	B-ENZY
exchange	O
abnormalities	O
.	O

Leukocytes	O
influx	O
into	O
the	O
lung	O
and	O
microvascular	O
leakage	O
were	O
assessed	O
by	O
lung	O
myeloperoxidase	B-ENZY
activity	O
and	O
Evans	O
blue	O
dye	O
extravasation	O
,	O
respectively	O
.	O

We	O
have	O
found	O
that	O
intestinal	O
I	O
/	O
R	O
increased	O
the	O
lung	O
myeloperoxidase	B-ENZY
activity	O
and	O
Evans	O
blue	O
dye	O
extravasation	O
,	O
which	O
were	O
reduced	O
by	O
treatment	O
of	O
rats	O
with	O
E2	O
.	O

Furthermore	O
,	O
the	O
two	O
scavengers	O
significantly	O
inhibited	O
the	O
activation	O
of	O
p38	O
MAPK	B-ENZY
and	O
p53	O
and	O
further	O
blocked	O
apoptosis	O
occurrence	O
through	O
suppressing	O
the	O
TGEV	O
-	O
induced	O
Bcl	O
-	O
2	O
reduction	O
,	O
Bax	O
redistribution	O
,	O
cytochrome	O
c	O
release	O
and	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
activation	O
.	O

Herein	O
,	O
we	O
show	O
that	O
glutamate	O
recycling	O
via	O
the	O
glial	O
transporter	O
1	O
protein	O
transporter	O
and	O
glutamine	B-ENZY
synthetase	I-ENZY
are	O
central	O
to	O
the	O
dysregulation	O
of	O
glutamate	O
homeostasis	O
and	O
development	O
of	O
motor	O
dysfunctions	O
and	O
paralytic	O
disease	O
in	O
HCoV	O
-	O
OC43	O
-	O
infected	O
mice	O
.	O

ABSTRACT	O
:	O
Myoclonic	O
status	O
epilepticus	O
(	O
MSE	O
)	O
within	O
the	O
first	O
24	O
hours	O
after	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	B-ENZY
)	O
predicts	O
poor	O
prognosis	O
,	O
enough	O
to	O
discontinue	O
the	O
treatment	O
.	O

In	O
contrast	O
,	O
chronic	O
MSE	O
appearing	O
a	O
few	O
days	O
after	O
CPR	B-ENZY
is	O
called	O
Lance	O
-	O
Adams	O
syndrome	O
(	O
LAS	O
),	O
which	O
is	O
characterized	O
by	O
preserved	O
intellect	O
and	O
a	O
favorable	O
prognosis	O
.	O

ABSTRACT	O
:	O
AlphaCoV	O
and	O
lineage	O
C	O
betaCoV	O
,	O
genetically	O
similar	O
to	O
those	O
identified	O
in	O
Spanish	O
related	O
bat	B-ENZY
species	O
,	O
have	O
been	O
detected	O
in	O
Italian	O
Myotis	O
blithii	O
and	O
Eptesicus	O
serotinus	O
,	O
respectively	O
,	O
out	O
of	O
75	O
anal	O
swabs	O
collected	O
from	O
Vespertilionidae	O
between	O
2009	O
and	O
2012	O
.	O

This	O
is	O
the	O
first	O
documented	O
occurrence	O
of	O
a	O
lineage	O
C	O
betaCoV	O
in	O
the	O
Italian	O
bat	B-ENZY
population	O
,	O
notably	O
in	O
E	O
.	O
serotinus	O
.	O

Using	O
synthetic	O
genomics	O
and	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
replicons	O
(	O
VRPs	O
)	O
expressing	O
spike	O
and	O
nucleocapsid	O
proteins	O
from	O
MERS	O
-	O
CoV	O
and	O
other	O
human	O
and	O
bat	B-ENZY
CoVs	O
,	O
we	O
characterize	O
the	O
antigenic	O
responses	O
(	O
using	O
Western	O
blot	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
)	O
and	O
serologic	O
responses	O
(	O
using	O
neutralization	O
assays	O
)	O
against	O
2	O
MERS	O
-	O
CoV	O
isolates	O
in	O
comparison	O
with	O
those	O
of	O
other	O
human	O
and	O
bat	B-ENZY
CoVs	O
.	O

TITLE	O
:	O
Adenosine	B-ENZY
deaminase	I-ENZY
acts	O
as	O
a	O
natural	O
antagonist	O
for	O
dipeptidyl	O
peptidase	O
4	O
-	O
mediated	O
entry	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Adenosine	B-ENZY
deaminase	I-ENZY
(	O
ADA	O
),	O
a	O
DPP4	O
binding	O
protein	O
,	O
competed	O
for	O
virus	O
binding	O
,	O
acting	O
as	O
a	O
natural	O
antagonist	O
for	O
MERS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Active	O
site	O
and	O
allosteric	O
inhibitors	O
of	O
the	O
ribonuclease	B-ENZY
H	I-ENZY
activity	O
of	O
HIV	O
reverse	B-ENZY
transcriptase	I-ENZY
.	O

ABSTRACT	O
:	O
Despite	O
the	O
wealth	O
of	O
information	O
available	O
for	O
the	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
associated	O
ribonuclease	B-ENZY
H	I-ENZY
(	O
RNaseH	O
)	O
domain	O
of	O
lentiviruses	O
,	O
gammaretroviruses	O
and	O
long	O
terminal	O
repeat	O
containing	O
retrotransposons	O
,	O
exploiting	O
this	O
information	O
in	O
the	O
form	O
of	O
an	O
RNaseH	O
inhibitor	O
with	O
high	O
specificity	O
and	O
low	O
cellular	O
toxicity	O
has	O
been	O
disappointing	O
.	O

Here	O
,	O
we	O
review	O
the	O
up	O
-	O
to	O
-	O
date	O
knowledge	O
on	O
SARS	O
-	O
CoV	O
replicative	O
enzymes	O
encoded	O
in	O
the	O
ORF1b	O
,	O
i	O
.	O
e	O
.,	O
the	O
main	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
nsp12	O
),	O
the	O
helicase	O
/	O
triphosphatase	B-ENZY
(	O
nsp13	O
),	O
two	O
unusual	O
ribonucleases	O
(	O
nsp14	O
,	O
nsp15	O
)	O
and	O
RNA	O
-	O
cap	O
methyltransferases	O
(	O
nsp14	O
,	O
nsp16	O
).	O

At	O
initial	O
review	O
all	O
patients	O
were	O
found	O
to	O
have	O
reduced	O
gas	B-ENZY
transfer	O
(	O
median	O
predicted	O
DLCO	O
74	O
%)	O
with	O
preservation	O
of	O
lung	O
volumes	O
and	O
normal	O
spirometrical	O
values	O
at	O
6	O
months	O
(	O
median	O
FVC	O
5	O
.	O
42L	O
[	O
101	O
%	O
predicted	O
]	O
and	O
FEV14	O
.	O
5L	O
[	O
101	O
.	O
2	O
%	O
predicted	O
]	O
respectively	O
),	O
with	O
improvements	O
in	O
gas	B-ENZY
transfer	O
(	O
median	O
predicted	O
DLCO	O
83	O
%)	O
at	O
subsequent	O
testing	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
strategies	O
aimed	O
at	O
either	O
enhancing	O
ATP	O
catabolism	O
(	O
ip	O
ecto	O
-	O
5	B-ENZY
'-	I-ENZY
nucleotidase	I-ENZY
administration	O
)	O
or	O
inhibiting	O
glycolytic	O
ATP	O
production	O
(	O
ip	O
2	O
-	O
deoxy	O
-	O
d	O
-	O
glucose	O
treatment	O
)	O
reduce	O
extracellular	O
ATP	O
accumulation	O
,	O
limit	O
vascular	O
leakage	O
,	O
and	O
effectively	O
block	O
the	O
late	O
,	O
but	O
not	O
the	O
early	O
,	O
stages	O
of	O
neutrophil	O
recruitment	O
to	O
the	O
lung	O
after	O
LPS	O
instillation	O
.	O

ABSTRACT	O
:	O
The	O
identification	O
of	O
pathogens	O
of	O
viral	O
(	O
Rotavirus	O
,	O
Coronavirus	O
),	O
parasitic	O
(	O
Toxocara	O
spp	B-ENZY
.)	O
and	O
bacterial	O
(	O
Escherichia	O
coli	O
,	O
Salmonella	O
spp	B-ENZY
.,	O
Rhodococcus	O
equi	O
)	O
origin	O
shed	O
in	O
feces	O
,	O
and	O
the	O
virulence	O
profile	O
of	O
R	O
.	O
equi	O
and	O
E	O
.	O
coli	O
isolates	O
were	O
investigated	O
in	O
200	O
samples	O
of	O
sand	O
obtained	O
from	O
40	O
parks	O
,	O
located	O
in	O
central	O
region	O
of	O
state	O
of	O
Sao	O
Paulo	O
,	O
Brazil	O
,	O
using	O
different	O
diagnostic	O
methods	O
.	O

TITLE	O
:	O
The	O
effect	O
of	O
Chaiqin	O
Chengqi	O
Decoction	O
()	O
on	O
modulating	O
serum	O
matrix	B-ENZY
metalloproteinase	I-ENZY
9	I-ENZY
in	O
patients	O
with	O
severe	O
acute	O
pancreatitis	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
Chaiqin	O
Chengqi	O
Decoction	O
(,	O
CQCQD	O
)	O
on	O
regulating	O
serum	O
matrix	B-ENZY
metalloproteinase	I-ENZY
9	I-ENZY
(	O
MMP	O
-	O
9	O
)	O
in	O
patients	O
with	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
).	O

ABSTRACT	O
:	O
The	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
is	O
a	O
serious	O
life	O
-	O
threatening	O
and	O
strikingly	O
mortal	O
respiratory	O
illness	O
caused	O
by	O
SARS	O
-	O
CoV	O
.	O
SARS	O
-	O
CoV	O
which	O
contains	O
a	O
chymotrypsin	B-ENZY
-	O
like	O
main	O
protease	O
analogous	O
to	O
that	O
of	O
the	O
main	O
picornavirus	O
protease	O
,	O
3CL	O
(	O
pro	O
).	O

TITLE	O
:	O
Identification	O
of	O
novel	O
drug	O
scaffolds	O
for	O
inhibition	O
of	O
SARS	O
-	O
CoV	O
3	O
-	O
Chymotrypsin	B-ENZY
-	O
like	O
protease	O
using	O
virtual	O
and	O
high	O
-	O
throughput	O
screenings	O
.	O

Gas	B-ENZY
status	O
data	O
improved	O
both	O
to	O
gas	B-ENZY
exchange	O
efficacy	O
in	O
patients	O
of	O
basic	O
group	O
.	O

ARDS	O
is	O
a	O
life	O
-	O
threatening	O
condition	O
that	O
is	O
characterized	O
by	O
severe	O
hypoxemia	O
,	O
defined	O
as	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
<	O
300	O
mmHg	O
.	O

Recently	O
,	O
however	O
,	O
it	O
has	O
been	O
shown	O
in	O
adults	O
with	O
ARDS	O
that	O
FiO	O
(	O
2	O
),	O
independently	O
of	O
the	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
predicts	O
mortality	O
.	O

Neither	O
baseline	O
PEEP	O
nor	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
correlated	O
with	O
outcome	O
.	O

TITLE	O
:	O
Proteolytic	O
processing	O
,	O
deubiquitinase	O
and	O
interferon	O
antagonist	O
activities	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
.	O

Genomic	O
studies	O
revealed	O
that	O
two	O
viral	O
proteases	O
,	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
and	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
),	O
process	O
the	O
polyproteins	O
encoded	O
by	O
the	O
MERS	O
-	O
CoV	O
genomic	O
RNA	O
.	O

Its	O
surface	O
receptor	O
glycoproteins	O
,	O
hemagglutinin	O
(	O
HA	O
)	O
and	O
neuraminidase	B-ENZY
(	O
NA	O
),	O
are	O
characterized	O
by	O
high	O
antigenic	O
variation	O
,	O
thus	O
a	O
host	O
organism	O
cannot	O
develop	O
permanent	O
resistance	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
human	O
neutrophil	B-ENZY
elastase	I-ENZY
by	O
pentacyclic	O
triterpenes	O
.	O

The	O
activities	O
of	O
ERK	B-ENZY
,	O
JNK	B-ENZY
,	O
and	O
p38MAPK	O
were	O
induced	O
by	O
LPS	O
stimulation	O
on	O
murine	O
macrophage	O
cell	O
line	O
,	O
but	O
only	O
p38MAPK	O
signaling	O
was	O
dramatically	O
suppressed	O
by	O
pretreatment	O
with	O
the	O
FJU	O
-	O
C4	O
compound	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
chimeric	O
VLP	O
was	O
composed	O
of	O
matrix	O
1	O
protein	O
from	O
avian	O
influenza	O
H5N1	O
virus	O
and	O
a	O
fusion	O
protein	O
neuraminidase	B-ENZY
(	O
NA	B-ENZY
)/	O
spike	O
1	O
(	O
S1	O
)	O
that	O
was	O
generated	O
by	O
fusing	O
IBV	O
S1	O
protein	O
to	O
the	O
cytoplasmic	O
and	O
transmembrane	O
domains	O
of	O
NA	B-ENZY
protein	O
of	O
avian	O
influenza	O
H5N1	O
virus	O
.	O

We	O
studied	O
enteropathogen	O
co	O
-	O
infection	O
in	O
diarrhoeic	O
UK	O
cats	O
using	O
results	O
of	O
a	O
real	O
time	O
PCR	O
assay	O
for	O
8	O
enteropathogenic	O
species	O
;	O
feline	O
coronavirus	O
(	O
Co	O
),	O
feline	O
panleukopenia	O
virus	O
(	O
Pa	O
),	O
Clostridium	O
perfringens	O
(	O
Cl	O
),	O
Salmonella	O
enterica	O
(	O
Sa	O
),	O
Giardia	O
spp	B-ENZY
.	O

(	O
Gi	O
),	O
Tritrichomonas	O
foetus	O
(	O
Tr	O
),	O
Cryptosporidium	O
spp	B-ENZY
.	O

Fluidigm	O
Dynamic	O
Array	O
nanofluidic	O
chip	O
96	O
.	O
96	O
was	O
used	O
to	O
analyze	O
the	O
mRNA	O
expression	O
of	O
21	O
TRP	B-ENZY
genes	O
and	O
two	O
control	O
genes	O
.	O

Although	O
all	O
the	O
extract	O
treatments	O
had	O
an	O
effect	O
on	O
IL	O
-	O
8	O
secretion	O
,	O
TRP	B-ENZY
gene	O
expression	O
and	O
virus	O
load	O
after	O
CoV	O
infection	O
,	O
it	O
was	O
the	O
Ah	O
extract	O
treatment	O
that	O
showed	O
the	O
biggest	O
difference	O
in	O
virus	O
load	O
.	O

The	O
data	O
(	O
experiment	O
SM001	O
)	O
are	O
publically	O
available	O
through	O
the	O
NIAID	O
Systems	O
Virology	O
(	O
https	O
://	O
www	O
.	O
systemsvirology	O
.	O
org	O
)	O
and	O
PNNL	O
(	O
http	O
://	O
omics	O
.	O
pnl	B-ENZY
.	O
gov	O
)	O
web	O
portals	O
.	O

Feces	O
samples	O
were	O
tested	O
for	O
canine	O
distemper	O
virus	O
,	O
canine	O
coronavirus	O
,	O
canine	O
parvovirus	O
type	O
2	O
(	O
CPV	O
-	O
2	O
),	O
Clostridium	O
perfringens	O
alpha	O
toxin	O
(	O
CPA	O
),	O
Cryptosporidium	O
spp	B-ENZY
.,	O
Giardia	O
spp	B-ENZY
.,	O
and	O
Salmonella	O
spp	B-ENZY
.	O

Scavenging	O
of	O
superoxide	O
by	O
pretreating	O
the	O
DKO	O
mice	O
with	O
MnTMPYP	O
(	O
a	O
superoxide	B-ENZY
dismutase	I-ENZY
mimetic	O
)	O
restored	O
the	O
inflammatory	O
responses	O
to	O
LPS	O
challenge	O
including	O
reduced	O
lung	O
myeloperoxidase	B-ENZY
activity	O
and	O
vascular	O
permeability	O
.	O

TITLE	O
:	O
The	O
ORF4b	O
-	O
encoded	O
accessory	O
proteins	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
and	O
two	O
related	O
bat	B-ENZY
coronaviruses	O
localize	O
to	O
the	O
nucleus	O
and	O
inhibit	O
innate	O
immune	O
signalling	O
.	O

ABSTRACT	O
:	O
Aluminium	O
phosphide	O
(	O
AlP	O
)	O
is	O
a	O
highly	O
toxic	O
pesticide	O
that	O
inhibits	O
cytochrome	B-ENZY
oxidase	I-ENZY
c	O
and	O
causes	O
oxidative	O
stress	O
.	O

ABSTRACT	O
:	O
Mutations	O
in	O
the	O
TMEM70	O
are	O
the	O
most	O
common	O
cause	O
of	O
nuclear	O
ATP	B-ENZY
synthase	I-ENZY
deficiency	O
resulting	O
in	O
a	O
distinctive	O
phenotype	O
characterized	O
by	O
severe	O
neonatal	O
hypotonia	O
,	O
hypertrophic	O
cardiomyopathy	O
(	O
HCMP	O
),	O
facial	O
dysmorphism	O
,	O
severe	O
lactic	O
acidosis	O
,	O
hyperammonemia	O
and	O
3	O
-	O
methylglutaconic	O
aciduria	O
(	O
3	O
-	O
MGA	O
).	O

Moreover	O
,	O
we	O
showed	O
that	O
the	O
expression	O
of	O
pulmonary	O
myeloperoxidase	B-ENZY
(	O
MPO	O
),	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
of	O
endothelial	O
cells	O
and	O
CD11b	O
of	O
polymorphonuclear	O
neutrophils	O
(	O
PMN	O
)	O
induced	O
by	O
LPS	O
were	O
significantly	O
decreased	O
by	O
PFC	O
treatment	O
in	O
vivo	O
.	O

These	O
viruses	O
depend	O
on	O
cathepsin	B-ENZY
L	I-ENZY
for	O
entry	O
into	O
their	O
target	O
cells	O
.	O

We	O
screened	O
a	O
library	O
of	O
5	O
,	O
000	O
small	O
molecules	O
and	O
discovered	O
a	O
small	O
molecule	O
that	O
can	O
inhibit	O
the	O
cathepsin	B-ENZY
L	I-ENZY
cleavage	O
of	O
all	O
viral	O
peptides	O
with	O
minimal	O
inhibition	O
of	O
cleavage	O
of	O
a	O
host	O
protein	O
-	O
derived	O
peptide	O
(	O
pro	O
-	O
neuropeptide	O
Y	O
).	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
small	O
molecule	O
is	O
a	O
mixed	O
inhibitor	O
of	O
cathepsin	B-ENZY
L	I-ENZY
.	O
Our	O
broad	O
-	O
spectrum	O
antiviral	O
small	O
molecule	O
appears	O
to	O
be	O
an	O
ideal	O
candidate	O
for	O
future	O
optimization	O
and	O
development	O
into	O
a	O
potent	O
antiviral	O
against	O
SARS	O
-	O
CoV	O
and	O
Ebola	O
,	O
Hendra	O
,	O
and	O
Nipah	O
viruses	O
.	O

We	O
developed	O
a	O
novel	O
high	O
-	O
throughput	O
screening	O
assay	O
to	O
identify	O
small	O
molecules	O
that	O
can	O
prevent	O
cathepsin	B-ENZY
L	I-ENZY
cleavage	O
of	O
viral	O
glycoproteins	O
derived	O
from	O
SARS	O
-	O
CoV	O
and	O
Ebola	O
,	O
Hendra	O
,	O
and	O
Nipah	O
viruses	O
that	O
are	O
required	O
for	O
their	O
entry	O
into	O
the	O
host	O
cell	O
.	O

We	O
identified	O
a	O
novel	O
broad	O
-	O
spectrum	O
small	O
molecule	O
that	O
could	O
block	O
cathepsin	B-ENZY
L	I-ENZY
-	O
mediated	O
cleavage	O
and	O
thus	O
inhibit	O
the	O
entry	O
of	O
pseudotypes	O
bearing	O
the	O
glycoprotein	O
derived	O
from	O
SARS	O
-	O
CoV	O
or	O
Ebola	O
,	O
Hendra	O
,	O
or	O
Nipah	O
virus	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
encode	O
papain	B-ENZY
-	O
like	O
proteases	O
(	O
PLpro	O
)	O
that	O
are	O
often	O
multifunctional	O
enzymes	O
with	O
protease	O
activity	O
to	O
process	O
the	O
viral	O
replicase	O
polyprotein	O
and	O
deubiquitinating	O
(	O
DUB	O
)/	O
deISGylating	O
activity	O
,	O
which	O
is	O
hypothesized	O
to	O
modify	O
the	O
innate	O
immune	O
response	O
to	O
infection	O
.	O

Gas	B-ENZY
exchange	O
was	O
more	O
severely	O
impaired	O
in	O
patients	O
with	O
H1N1	O
-	O
ARDS	O
over	O
course	O
of	O
time	O
.	O

Mechanistically	O
,	O
TM1	O
is	O
capable	O
of	O
binding	O
with	O
RIG	O
-	O
I	O
,	O
TRAF3	O
,	O
TBK1	B-ENZY
and	O
IKK	O
,	O
and	O
preventing	O
the	O
interaction	O
of	O
TRAF3	O
with	O
its	O
downstream	O
effectors	O
.	O

Direct	O
florescent	O
antibody	O
technique	O
(	O
dFAT	O
)	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
were	O
used	O
to	O
confirm	O
the	O
isolated	O
virus	O
strains	O
at	O
antigenic	O
and	O
genomic	O
levels	O
,	O
respectively	O
.	O

The	O
viral	O
papain	B-ENZY
-	O
like	O
proteases	O
(	O
PLPs	O
)	O
are	O
critical	O
for	O
processing	O
the	O
amino	O
-	O
terminal	O
end	O
of	O
the	O
replicase	O
and	O
are	O
attractive	O
targets	O
for	O
antiviral	O
therapies	O
.	O

With	O
the	O
analysis	O
of	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
came	O
the	O
realization	O
of	O
the	O
multifunctional	O
nature	O
of	O
these	O
enzymes	O
.	O

Coronavirus	O
surveillance	O
studies	O
in	O
different	O
populations	O
of	O
bats	O
have	O
suggested	O
that	O
they	O
are	O
probable	O
reservoirs	O
for	O
this	O
novel	O
virus	O
,	O
and	O
phylogenetic	O
analysis	O
of	O
both	O
the	O
spike	O
(	O
S1	O
)	O
and	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
proteins	O
of	O
MERS	O
-	O
CoV	O
have	O
revealed	O
that	O
it	O
is	O
related	O
to	O
bat	B-ENZY
viruses	O
.	O

Recombinant	O
FCoV	O
nucleocapsid	O
protein	O
(	O
rNP	O
)	O
was	O
used	O
as	O
a	O
conjugate	O
or	O
test	O
line	O
in	O
all	O
3	O
ICA	O
kits	O
(	O
CJIgG	O
/	O
TNP	O
,	O
CJNP	O
/	O
TNP	O
,	O
and	O
CJNP	O
/	O
TPA	B-ENZY
).	O

In	O
addition	O
,	O
the	O
specificity	O
and	O
sensitivity	O
of	O
ICA	O
(	O
CJNP	O
/	O
TPA	B-ENZY
)	O
were	O
equivalent	O
to	O
those	O
of	O
the	O
reference	O
ELISA	O
.	O

The	O
development	O
of	O
simple	O
antibody	O
test	O
methods	O
using	O
the	O
principle	O
of	O
ICA	O
(	O
CJNP	O
/	O
TPA	B-ENZY
)	O
for	O
other	O
coronavirus	O
and	O
feline	O
viral	O
infections	O
is	O
expected	O
in	O
the	O
future	O
.	O

TITLE	O
:	O
Myosins	O
1	O
and	O
6	O
,	O
myosin	B-ENZY
light	I-ENZY
chain	I-ENZY
kinase	I-ENZY
,	O
actin	O
and	O
microtubules	O
cooperate	O
during	O
antibody	O
-	O
mediated	O
internalisation	O
and	O
trafficking	O
of	O
membrane	O
-	O
expressed	O
viral	O
antigens	O
in	O
feline	O
infectious	O
peritonitis	O
virus	O
infected	O
monocytes	O
.	O

With	O
co	O
-	O
localisation	O
stainings	O
,	O
it	O
was	O
found	O
that	O
MLCK	B-ENZY
and	O
myosin	O
1	O
co	O
-	O
localise	O
with	O
antigens	O
even	O
before	O
internalisation	O
started	O
.	O

Intracellular	O
trafficking	O
over	O
microtubules	O
was	O
mediated	O
by	O
MLCK	B-ENZY
,	O
myosin	O
1	O
and	O
a	O
small	O
actin	O
tail	O
.	O

Since	O
inhibiting	O
MLCK	B-ENZY
with	O
ML	O
-	O
7	O
was	O
so	O
efficient	O
in	O
blocking	O
the	O
internalisation	O
pathway	O
,	O
this	O
target	O
can	O
be	O
used	O
for	O
the	O
development	O
of	O
a	O
new	O
treatment	O
for	O
FIPV	O
.	O

MERS	O
-	O
CoV	O
is	O
closely	O
related	O
to	O
bat	B-ENZY
coronaviruses	O
HKU4	O
and	O
HKU5	O
.	O

RNA	O
binding	O
of	O
MERS	O
-	O
CoV	O
4a	O
protein	O
was	O
required	O
for	O
IFN	O
antagonism	O
,	O
a	O
property	O
shared	O
by	O
4a	O
protein	O
of	O
bat	B-ENZY
coronavirus	O
HKU5	O
but	O
not	O
by	O
the	O
counterpart	O
in	O
bat	B-ENZY
coronavirus	O
HKU4	O
.	O

It	O
inhibited	O
PACT	O
-	O
induced	O
activation	O
of	O
RIG	O
-	O
I	O
and	O
MDA5	O
but	O
did	O
not	O
affect	O
the	O
activity	O
of	O
downstream	O
effectors	O
such	O
as	O
RIG	O
-	O
I	O
,	O
MDA5	O
,	O
MAVS	O
,	O
TBK1	B-ENZY
,	O
and	O
IRF3	O
.	O

TGEV	O
infection	O
induced	O
the	O
occurring	O
of	O
apoptosis	O
in	O
swine	O
testicle	O
(	O
ST	O
)	O
cells	O
,	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
Bcl	O
-	O
2	O
,	O
up	O
-	O
regulated	O
the	O
expression	O
of	O
Bax	O
,	O
altered	O
mitochondrial	O
membrane	O
potential	O
,	O
activated	O
p38	O
MAPK	B-ENZY
signal	O
pathway	O
,	O
and	O
increased	O
expression	O
of	O
p53	O
as	O
evidenced	O
by	O
immunofluorescence	O
assays	O
,	O
real	O
-	O
time	O
PCR	O
,	O
flow	O
cytometry	O
and	O
Western	O
blot	O
.	O

Moreover	O
,	O
further	O
results	O
showed	O
that	O
Ag	O
NPs	O
and	O
silver	O
nanowires	O
decreased	O
the	O
number	O
of	O
apoptotic	O
cells	O
induced	O
by	O
TGEV	O
through	O
regulating	O
p38	O
/	O
mitochondria	O
-	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
signaling	O
pathway	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
catalysis	O
and	O
ubiquitin	O
recognition	O
by	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
.	O

ABSTRACT	O
:	O
Papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
is	O
one	O
of	O
two	O
cysteine	O
proteases	O
involved	O
in	O
the	O
proteolytic	O
processing	O
of	O
the	O
polyproteins	O
of	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Moreover	O
,	O
the	O
expression	O
of	O
TGEV	O
N	O
gene	O
promoted	O
translocation	O
of	O
Bax	O
to	O
mitochondria	O
,	O
which	O
in	O
turn	O
caused	O
the	O
release	O
of	O
cytochrome	O
c	O
,	O
followed	O
by	O
activation	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
,	O
resulting	O
in	O
cell	O
apoptosis	O
in	O
the	O
transfected	O
PK	O
-	O
15	O
cells	O
following	O
cell	O
cycle	O
arrest	O
.	O

Quantitative	O
polymerase	O
chain	O
reaction	O
(	O
qRTPCR	O
)	O
was	O
performed	O
after	O
extraction	O
of	O
RNA	O
from	O
BAL	B-ENZY
cells	O
of	O
MERS	O
-	O
CoV	O
infected	O
patients	O
and	O
control	O
patients	O
.	O

BAL	B-ENZY
supernatants	O
and	O
sera	O
were	O
used	O
to	O
assess	O
cytokines	O
and	O
chemokines	O
secretion	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

We	O
compared	O
the	O
receptors	O
of	O
humans	O
and	O
Middle	O
Eastern	O
animals	O
and	O
found	O
that	O
human	O
,	O
camel	O
,	O
and	O
horse	O
receptors	O
sensitized	O
cells	O
to	O
MERS	O
-	O
CoV	O
infection	O
more	O
robustly	O
than	O
goat	O
and	O
bat	B-ENZY
receptors	O
.	O

Biochemical	O
blood	O
analyses	O
show	O
an	O
elevated	O
C	O
-	O
reactive	O
protein	O
,	O
but	O
creatine	B-ENZY
kinase	I-ENZY
is	O
often	O
normal	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
NL63	O
replication	O
is	O
cyclophilin	B-ENZY
A	O
-	O
dependent	O
and	O
inhibited	O
by	O
non	O
-	O
immunosuppressive	O
cyclosporine	O
A	O
-	O
derivatives	O
including	O
Alisporivir	O
.	O

Collectively	O
,	O
our	O
results	O
uncover	O
Cyclophilin	B-ENZY
A	O
as	O
a	O
host	O
target	O
for	O
CoV	O
infection	O
and	O
provide	O
new	O
strategies	O
for	O
urgently	O
needed	O
therapeutic	O
approaches	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
obtain	O
current	O
data	O
about	O
the	O
frequency	O
of	O
Giardia	O
spp	B-ENZY
.,	O
Cryptosporidium	O
spp	B-ENZY
.	O

and	O
Eimeria	O
spp	B-ENZY
.	O

Giardia	O
spp	B-ENZY
.	O

The	O
mean	O
age	O
was	O
46	O
.	O
5	O
days	O
and	O
the	O
odds	O
of	O
being	O
infected	O
with	O
Giardia	O
spp	B-ENZY
.	O

Cryptosporidium	O
spp	B-ENZY
.	O

The	O
odds	O
of	O
being	O
infected	O
with	O
Cryptosporidium	O
spp	B-ENZY
.	O

The	O
odds	O
of	O
being	O
infected	O
with	O
Eimeria	O
spp	B-ENZY
.	O

There	O
appeared	O
to	O
be	O
no	O
significant	O
seasonal	O
influence	O
on	O
the	O
frequency	O
of	O
Cryptosporidium	O
spp	B-ENZY
.;	O
but	O
there	O
was	O
one	O
for	O
Eimeria	O
spp	B-ENZY
.:	O
the	O
odds	O
of	O
being	O
infected	O
with	O
Eimeria	O
spp	B-ENZY
.	O

Additionally	O
,	O
as	O
requested	O
by	O
the	O
veterinarians	O
,	O
1282	O
of	O
those	O
samples	O
were	O
analysed	O
for	O
E	O
.	O
coli	O
,	O
Rota	O
-,	O
Coronavirus	O
and	O
Cryptosporidium	O
spp	B-ENZY
.	O

TITLE	O
:	O
X	O
-	O
ray	O
structural	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
potent	O
and	O
highly	O
selective	O
inhibitors	O
of	O
human	O
coronavirus	O
papain	B-ENZY
-	O
like	O
proteases	O
.	O

ABSTRACT	O
:	O
Structure	O
-	O
guided	O
design	O
was	O
used	O
to	O
generate	O
a	O
series	O
of	O
noncovalent	O
inhibitors	O
with	O
nanomolar	O
potency	O
against	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
from	O
the	O
SARS	O
coronavirus	O
(	O
CoV	O
).	O

Finally	O
,	O
the	O
less	O
lipophilic	O
bis	B-ENZY
(	O
amide	O
)	O
3e	O
and	O
methoxypyridine	O
5c	O
exhibit	O
significantly	O
improved	O
metabolic	O
stability	O
and	O
are	O
viable	O
candidates	O
for	O
advancing	O
to	O
in	O
vivo	O
studies	O
.	O

The	O
expression	O
of	O
CD31	O
,	O
CD61	O
,	O
CD62p	O
,	O
CD63	O
and	O
PAC	O
-	O
1	O
on	O
platelet	O
membrane	O
was	O
measured	O
respectively	O
by	O
flowcytometry	O
,	O
and	O
the	O
plasma	O
prothrombin	O
time	O
(	O
PT	O
),	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
),	O
thrombin	B-ENZY
time	O
(	O
TT	O
)	O
and	O
fibrinogen	O
(	O
Fbg	O
)	O
were	O
measured	O
by	O
blood	O
clotting	O
instrument	O
in	O
26	O
patients	O
with	O
ANFH	O
after	O
SARS	O
and	O
in	O
17	O
healthy	O
adults	O
.	O

We	O
compared	O
the	O
performance	O
of	O
AdvanSure	O
with	O
those	O
of	O
Seeplex	O
	O
RV	O
15	O
ACE	B-ENZY
and	O
culture	O
by	O
determining	O
their	O
sensitivities	O
and	O
specificities	O
against	O
a	O
composite	O
reference	O
standard	O
.	O

Four	O
hundred	O
thirty	O
-	O
seven	O
respiratory	O
samples	O
were	O
tested	O
by	O
modified	O
shell	O
vial	O
culture	O
method	O
,	O
RV	O
15	O
ACE	B-ENZY
,	O
and	O
AdvanSure	O
.	O

TITLE	O
:	O
The	O
potential	O
efficacy	O
of	O
noninvasive	O
ventilation	O
with	O
administration	O
of	O
a	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
aim	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
whether	O
the	O
combination	O
of	O
NIV	O
with	O
administration	O
of	O
a	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
could	O
improve	O
outcome	O
and	O
respiratory	O
conditions	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)-	O
patients	O
,	O
according	O
to	O
the	O
Berlin	O
definition	O
.	O

ARDS	O
-	O
patients	O
were	O
treated	O
with	O
NIV	O
and	O
a	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
.	O

The	O
survival	O
ratio	O
showed	O
statistically	O
significant	O
differences	O
in	O
mild	O
and	O
moderate	O
ARDS	O
-	O
patients	O
treated	O
with	O
the	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
.	O

Administration	O
of	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
with	O
NIV	O
may	O
be	O
associated	O
with	O
successful	O
outcome	O
in	O
mild	O
-	O
to	O
-	O
moderate	O
ARDS	O
-	O
patients	O
with	O
initial	O
PaO2	O
/	O
FiO2	O
>	O
150	O
.	O

The	O
survival	O
ratio	O
showed	O
statistically	O
significant	O
differences	O
in	O
mild	O
and	O
moderate	O
ARDS	O
-	O
patients	O
treated	O
with	O
the	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
.	O

This	O
virus	O
,	O
named	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
CoV	O
,	O
is	O
phylogenetically	O
related	O
to	O
bat	B-ENZY
CoVs	O
,	O
but	O
other	O
animal	O
species	O
like	O
dromedary	O
camels	O
may	O
potentially	O
act	O
as	O
intermediate	O
hosts	O
by	O
spreading	O
the	O
virus	O
to	O
humans	O
.	O

TITLE	O
:	O
Discovery	O
of	O
nitropyridine	O
derivatives	O
as	O
potent	O
HIV	O
-	O
1	O
non	O
-	O
nucleoside	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
via	O
a	O
structure	O
-	O
based	O
core	O
refining	O
approach	O
.	O

Gene	O
expression	O
of	O
IL	O
-	O
1	O
and	O
IL	O
-	O
6receptors	O
in	O
the	O
tubular	O
gland	O
cells	O
of	O
the	O
isthmus	O
and	O
uterus	O
was	O
analyzed	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
.	O

Nasopharyngeal	O
samples	O
were	O
collected	O
from	O
5235	O
adult	O
pilgrims	O
from	O
22	O
countries	O
and	O
screened	O
for	O
MERS	O
-	O
CoV	O
using	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
inhibits	O
the	O
type	O
I	O
interferon	O
signaling	O
pathway	O
through	O
interaction	O
with	O
the	O
STING	O
-	O
TRAF3	O
-	O
TBK1	B-ENZY
complex	O
.	O

We	O
found	O
that	O
expression	O
of	O
the	O
membrane	O
-	O
anchored	O
PLpro	O
domain	O
(	O
PLpro	O
-	O
TM	O
)	O
from	O
SARS	O
-	O
CoV	O
inhibits	O
STING	O
/	O
TBK1	B-ENZY
/	O
IKK	O
-	O
mediated	O
activation	O
of	O
type	O
I	O
IFNs	O
and	O
disrupts	O
the	O
phosphorylation	O
and	O
dimerization	O
of	O
IRF3	O
,	O
which	O
are	O
activated	O
by	O
STING	O
and	O
TBK1	B-ENZY
.	O

Meanwhile	O
,	O
we	O
showed	O
that	O
PLpro	O
-	O
TM	O
physically	O
interacts	O
with	O
TRAF3	O
,	O
TBK1	B-ENZY
,	O
IKK	O
,	O
STING	O
,	O
and	O
IRF3	O
,	O
the	O
key	O
components	O
that	O
assemble	O
the	O
STING	O
-	O
TRAF3	O
-	O
TBK1	B-ENZY
complex	O
for	O
activation	O
of	O
IFN	O
expression	O
.	O

These	O
results	O
collectively	O
point	O
to	O
a	O
new	O
mechanism	O
used	O
by	O
SARS	O
-	O
CoV	O
through	O
which	O
PLpro	O
negatively	O
regulates	O
IRF3	O
activation	O
by	O
interaction	O
with	O
STING	O
-	O
TRAF3	O
-	O
TBK1	B-ENZY
complex	O
,	O
yielding	O
a	O
SARS	O
-	O
CoV	O
countermeasure	O
against	O
host	O
innate	O
immunity	O
.	O

We	O
demonstrate	O
that	O
the	O
fusion	O
of	O
green	O
fluorescent	O
protein	O
and	O
firefly	B-ENZY
luciferase	I-ENZY
with	O
either	O
nonstructural	O
protein	O
2	O
or	O
3	O
is	O
tolerated	O
and	O
that	O
these	O
reporter	O
-	O
replicase	O
fusions	O
can	O
be	O
used	O
to	O
quantitate	O
replication	O
complex	O
formation	O
and	O
virus	O
replication	O
.	O

We	O
demonstrate	O
that	O
the	O
replicase	O
gene	O
tolerates	O
the	O
introduction	O
of	O
green	O
fluorescent	O
protein	O
or	O
firefly	B-ENZY
luciferase	I-ENZY
as	O
fusions	O
with	O
replicase	O
proteins	O
.	O

The	O
microorganisms	O
that	O
for	O
decades	O
have	O
been	O
associated	O
with	O
enteritis	O
and	O
diarrhea	O
in	O
suckling	O
piglets	O
are	O
:	O
rotavirus	O
A	O
,	O
coronavirus	O
,	O
enterotoxigenic	O
Escherichia	O
coli	O
(	O
ETEC	O
),	O
Clostridium	O
perfringens	O
type	O
C	O
,	O
Cryptosporidium	O
spp	B-ENZY
.,	O
Giardia	O
spp	B-ENZY
.,	O
Cystoisospora	O
suis	O
and	O
Strongyloides	O
ransomi	O
.	O

However	O
,	O
Enterococcus	O
spp	B-ENZY
.	O
was	O
primarily	O
detected	O
in	O
the	O
diarrheic	O
piglets	O
.	O

These	O
bacteria	O
were	O
identified	O
as	O
E	O
.	O
coli	O
and	O
Enterococcus	O
spp	B-ENZY
.	O

The	O
results	O
of	O
this	O
study	O
showed	O
that	O
simultaneous	O
colonization	O
of	O
the	O
intestinal	O
mucosa	O
by	O
adherent	O
non	O
-	O
ETEC	O
E	O
.	O
coli	O
and	O
Enterococcus	O
spp	B-ENZY
.	O
can	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
neonatal	O
porcine	O
diarrhea	O
.	O

Nasopharyngeal	O
aspirate	O
and	O
sputum	O
samples	O
should	O
be	O
collected	O
for	O
diagnosis	O
,	O
preferably	O
using	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
.	O

Early	O
treatment	O
with	O
neuraminidase	B-ENZY
inhibitors	O
improved	O
survival	O
,	O
but	O
the	O
efficacy	O
of	O
antivirals	O
was	O
hampered	O
by	O
resistant	O
mutants	O
.	O

ABSTRACT	O
:	O
Double	O
-	O
stranded	O
RNA	O
-	O
dependent	O
protein	B-ENZY
kinase	I-ENZY
(	O
PKR	O
)	O
regulates	O
antiviral	O
activity	O
,	O
immune	O
responses	O
,	O
apoptosis	O
and	O
neurotoxicity	O
.	O

Because	O
the	O
PEDV	O
host	O
cell	O
receptor	O
(	O
CD13	O
or	O
aminopeptidase	B-ENZY
N	I-ENZY
)	O
stimulates	O
cellular	O
signaling	O
pathways	O
in	O
the	O
absence	O
of	O
PEDV	O
infection	O
,	O
we	O
suspect	O
that	O
PEDV	O
co	O
-	O
infection	O
might	O
alter	O
CD13	O
function	O
and	O
induce	O
the	O
chlamydiae	O
to	O
enter	O
the	O
persistent	O
state	O
.	O

TITLE	O
:	O
A	O
mouse	O
model	O
for	O
Betacoronavirus	O
subgroup	O
2c	O
using	O
a	O
bat	B-ENZY
coronavirus	O
strain	O
HKU5	O
variant	O
.	O

MERS	O
-	O
CoV	O
and	O
Pipistrellus	O
bat	B-ENZY
coronavirus	O
(	O
BtCoV	O
)	O
strain	O
HKU5	O
of	O
Betacoronavirus	O
(	O
	O
-	O
CoV	O
)	O
subgroup	O
2c	O
share	O
>	O
65	O
%	O
identity	O
at	O
the	O
amino	O
acid	O
level	O
in	O
several	O
regions	O
,	O
including	O
nonstructural	O
protein	O
5	O
(	O
nsp5	O
)	O
and	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
which	O
are	O
significant	O
drug	O
and	O
vaccine	O
targets	O
.	O

However	O
,	O
in	O
the	O
Znhigh	O
group	O
,	O
we	O
found	O
a	O
prevention	O
of	O
villus	O
atrophy	O
and	O
decreased	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
-	O
mediated	O
apoptosis	O
of	O
jejunal	O
epithelium	O
.	O

The	O
USP	B-ENZY
-	O
10	O
isolate	O
,	O
of	O
enteric	O
origin	O
,	O
was	O
inoculated	O
via	O
the	O
oral	O
oroculonasal	O
routes	O
into	O
IBV	O
-	O
antibody	O
-	O
free	O
broilers	O
and	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
chickens	O
to	O
determine	O
tissue	O
tropism	O
and	O
pathogenicity	O
and	O
compared	O
with	O
an	O
IBV	O
variant	O
(	O
USP	B-ENZY
-	O
50	O
)	O
isolated	O
from	O
chickens	O
showing	O
signs	O
of	O
respiratory	O
disease	O
only	O
.	O

Both	O
USP	B-ENZY
-	O
10	O
and	O
USP	B-ENZY
-	O
50	O
strains	O
caused	O
similar	O
pathological	O
patterns	O
by	O
either	O
route	O
of	O
inoculation	O
.	O

Quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
confirmed	O
that	O
the	O
most	O
strongly	O
affected	O
of	O
these	O
,	O
the	O
nsp3	O
mutant	O
,	O
produced	O
more	O
viral	O
RNA	O
than	O
wild	O
-	O
type	O
virus	O
.	O

According	O
to	O
laboratory	O
examinations	O
,	O
increased	O
C	O
reactive	O
protein	O
(	O
CRP	O
),	O
Procalcitonin	O
(	O
PCT	O
),	O
Plasma	B-ENZY
thromboplastin	I-ENZY
antecedent	I-ENZY
(	O
PTA	O
)	O
and	O
virus	O
positive	O
time	O
(	O
days	O
)	O
were	O
indicative	O
of	O
patients	O
'	O
mortality	O
.	O

We	O
report	O
a	O
case	O
of	O
multiple	O
drug	O
poisoning	O
:	O
ACE	B-ENZY
inhibitor	O
(	O
ACE	B-ENZY
-	O
I	O
),	O
beta	O
-	O
blockers	O
and	O
calcium	O
channel	O
blockers	O
.	O

Specifically	O
,	O
the	O
potential	O
to	O
explore	O
and	O
exploit	O
this	O
newfound	O
relationship	O
to	O
study	O
coevolution	O
and	O
cross	O
species	O
transmission	O
together	O
with	O
fundamental	O
aspects	O
of	O
poxvirus	O
host	O
tropism	O
as	O
well	O
as	O
bat	B-ENZY
virology	O
and	O
immunology	O
.	O

Full	O
genomic	O
analysis	O
of	O
a	O
new	O
SARS	O
-	O
like	O
CoV	O
from	O
Baoshan	O
(	O
LYRa11	O
)	O
showed	O
that	O
it	O
was	O
29	O
,	O
805	O
nucleotides	O
(	O
nt	O
)	O
in	O
length	O
with	O
13	O
open	O
reading	O
frames	O
(	O
ORFs	O
),	O
sharing	O
91	O
%	O
nucleotide	O
identity	O
with	O
human	O
/	O
civet	O
SARS	O
CoVs	O
and	O
the	O
most	O
recently	O
reported	O
SARS	O
-	O
like	O
CoV	O
Rs3367	O
,	O
while	O
sharing	O
89	O
%	O
with	O
other	O
bat	B-ENZY
SARS	O
-	O
like	O
CoVs	O
.	O

Antigenic	O
analysis	O
showed	O
that	O
the	O
S1	O
domain	O
of	O
LYRa11	O
could	O
be	O
efficiently	O
recognized	O
by	O
SARS	O
-	O
convalescent	O
human	O
serum	O
,	O
indicating	O
that	O
LYRa11	O
is	O
a	O
novel	O
virus	O
antigenically	O
close	O
to	O
SARS	O
CoV	O
.	O
Recombination	O
analyses	O
indicate	O
that	O
LYRa11	O
is	O
likely	O
a	O
recombinant	O
descended	O
from	O
parental	O
lineages	O
that	O
had	O
evolved	O
into	O
a	O
number	O
of	O
bat	B-ENZY
SARS	O
-	O
like	O
CoVs	O
.	O

Notably	O
,	O
full	O
genomic	O
sequencing	O
and	O
antigenic	O
study	O
demonstrated	O
that	O
LYRa11	O
is	O
phylogenetically	O
and	O
antigenically	O
closely	O
related	O
to	O
SARS	O
CoV	O
.	O
Recombination	O
analyses	O
indicate	O
that	O
LYRa11	O
is	O
a	O
recombinant	O
from	O
certain	O
bat	B-ENZY
SARS	O
-	O
like	O
CoVs	O
circulating	O
in	O
Yunnan	O
Province	O
.	O

TITLE	O
:	O
Neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
reduces	O
ventilation	O
-	O
induced	O
lung	O
injury	O
via	O
nuclear	O
factor	O
-	O
B	O
and	O
NF	O
-	O
B	O
repressing	O
factor	O
in	O
mice	O
.	O

Neutrophil	B-ENZY
elastase	I-ENZY
,	O
nuclear	O
factor	O
-	O
B	O
(	O
NF	O
-	O
B	O
),	O
and	O
NF	O
-	O
B	O
repressing	O
factor	O
(	O
NRF	O
)	O
have	O
previously	O
been	O
shown	O
to	O
participate	O
in	O
the	O
regulation	O
of	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
(	O
MIP	O
-	O
2	O
)	O
during	O
airway	O
inflammation	O
.	O

Thus	O
,	O
we	O
hypothesized	O
that	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
attenuated	O
ventilation	O
-	O
induced	O
neutrophil	O
recruitment	O
and	O
MIP	O
-	O
2	O
production	O
through	O
inhibition	O
of	O
the	O
NF	O
-	O
B	O
/	O
NRF	O
pathway	O
.	O

Evan	O
blue	O
dye	O
,	O
lung	O
wet	O
-	O
to	O
-	O
dry	O
weight	O
ratio	O
,	O
free	O
radicals	O
,	O
myeloperoxidase	B-ENZY
,	O
histopathologic	O
grading	O
of	O
lung	O
tissue	O
,	O
inflammatory	O
cytokines	O
,	O
Western	O
blot	O
of	O
NF	O
-	O
B	O
and	O
NRF	O
,	O
and	O
gene	O
expression	O
of	O
NRF	O
were	O
measured	O
to	O
establish	O
the	O
extent	O
of	O
lung	O
injury	O
.	O

Infusion	O
of	O
AM	O
protected	O
against	O
MV	O
-	O
induced	O
lung	O
injury	O
(	O
66	O
%	O
reduction	O
of	O
pulmonary	O
permeability	O
p	O
<	O
0	O
.	O
01	O
;	O
prevention	O
of	O
pulmonary	O
restriction	O
)	O
and	O
against	O
VILI	O
-	O
induced	O
liver	O
and	O
gut	O
injury	O
in	O
pneumonia	O
(	O
91	O
%	O
reduction	O
of	O
AST	B-ENZY
levels	O
p	O
<	O
0	O
.	O
05	O
,	O
96	O
%	O
reduction	O
of	O
alanine	O
aminotransaminase	O
(	O
ALT	O
)	O
levels	O
p	O
<	O
0	O
.	O
05	O
,	O
abrogation	O
of	O
histopathological	O
changes	O
and	O
parenchymal	O
apoptosis	O
in	O
liver	O
and	O
gut	O
).	O

Infusion	O
of	O
AM	O
protected	O
against	O
MV	O
-	O
induced	O
lung	O
injury	O
(	O
66	O
%	O
reduction	O
of	O
pulmonary	O
permeability	O
p	O
<	O
0	O
.	O
01	O
;	O
prevention	O
of	O
pulmonary	O
restriction	O
)	O
and	O
against	O
VILI	O
-	O
induced	O
liver	O
and	O
gut	O
injury	O
in	O
pneumonia	O
(	O
91	O
%	O
reduction	O
of	O
AST	B-ENZY
levels	O
p	O
<	O
0	O
.	O
05	O
,	O
96	O
%	O
reduction	O
of	O
alanine	O
aminotransaminase	O
(	O
ALT	O
)	O
levels	O
p	O
<	O
0	O
.	O
05	O
,	O
abrogation	O
of	O
histopathological	O
changes	O
and	O
parenchymal	O
apoptosis	O
in	O
liver	O
and	O
gut	O
).	O

TITLE	O
:	O
Bat	B-ENZY
flight	O
and	O
zoonotic	O
viruses	O
.	O

NNPDS	O
is	O
a	O
diarrhoeic	O
syndrome	O
affecting	O
piglets	O
within	O
the	O
first	O
week	O
of	O
life	O
,	O
which	O
is	O
not	O
caused	O
by	O
enterotoxigenic	O
Escherichia	O
coli	O
(	O
ETEC	O
),	O
Clostridium	O
perfringens	O
(	O
C	O
.	O
perfringens	O
)	O
type	O
A	O
/	O
C	O
,	O
Clostridium	O
difficile	O
(	O
C	O
.	O
difficile	O
),	O
rotavirus	O
A	O
,	O
coronavirus	O
,	O
Cystoisospora	O
suis	O
,	O
Strongyloides	O
ransomi	O
,	O
Giardia	O
spp	B-ENZY
or	O
Cryptosporidium	O
spp	B-ENZY
.	O

Thus	O
far	O
three	O
membrane	O
ectopeptidases	O
,	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
),	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
and	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
),	O
have	O
been	O
identified	O
as	O
entry	O
receptors	O
for	O
four	O
human	O
-	O
infecting	O
coronaviruses	O
.	O

MERS	O
-	O
CoV	O
was	O
related	O
to	O
the	O
2C	O
betacoronavirus	O
clade	O
and	O
is	O
closely	O
related	O
to	O
Tylonycteris	O
bat	B-ENZY
coronavirus	O
HKU4	O
and	O
Pipistrellus	O
bat	B-ENZY
coronavirus	O
HKU5	O
.	O

ABSTRACT	O
:	O
The	O
pathophysiology	O
of	O
hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	B-ENZY
)	O
remains	O
unclear	O
because	O
of	O
a	O
lack	O
of	O
surrogate	O
disease	O
models	O
with	O
which	O
to	O
perform	O
pathogenesis	O
studies	O
.	O

Nonhuman	O
primates	O
(	O
NHP	O
)	O
are	O
considered	O
the	O
gold	O
standard	O
model	O
for	O
studying	O
the	O
underlying	O
immune	O
activation	O
/	O
suppression	O
associated	O
with	O
immunopathogenic	O
viruses	O
such	O
as	O
hantaviruses	O
;	O
however	O
,	O
to	O
date	O
an	O
NHP	O
model	O
for	O
HPS	B-ENZY
has	O
not	O
been	O
described	O
.	O

To	O
address	O
this	O
deficiency	O
,	O
high	O
-	O
throughput	O
real	O
time	O
RT	O
-	O
PCR	O
TaqMan	O
assays	O
were	O
developed	O
to	O
measure	O
the	O
expression	O
of	O
fifteen	O
immune	O
mediators	O
associated	O
with	O
the	O
innate	O
and	O
adaptive	O
immune	O
responses	O
(	O
IFN	O
,	O
IFN	O
,	O
IFN	O
,	O
IL1	O
,	O
IL1	O
,	O
IL2	O
,	O
IL4	O
,	O
IL6	O
,	O
IL8	O
,	O
IL10	O
,	O
IL12p40	O
,	O
IL17	O
,	O
Granzyme	B-ENZY
A	I-ENZY
,	O
MCP1	O
,	O
TNF	O
),	O
as	O
well	O
as	O
four	O
endogenous	O
housekeeping	O
genes	O
(	O
ATF4	O
,	O
HPRT	O
,	O
GAPDH	B-ENZY
,	O
L32	O
).	O

TITLE	O
:	O
Inhibition	O
of	O
foamy	O
virus	O
reverse	B-ENZY
transcriptase	I-ENZY
by	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
RNase	B-ENZY
H	I-ENZY
inhibitors	O
.	O

ABSTRACT	O
:	O
RNase	B-ENZY
H	I-ENZY
plays	O
an	O
essential	O
role	O
in	O
the	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
).	O

However	O
,	O
the	O
identification	O
of	O
HIV	O
-	O
1	O
RNase	B-ENZY
H	I-ENZY
inhibitors	O
(	O
RHIs	O
)	O
has	O
been	O
hampered	O
by	O
the	O
open	O
morphology	O
of	O
its	O
active	O
site	O
,	O
the	O
limited	O
number	O
of	O
available	O
RNase	B-ENZY
H	I-ENZY
crystal	O
structures	O
in	O
complex	O
with	O
inhibitors	O
,	O
and	O
the	O
fact	O
that	O
,	O
due	O
to	O
the	O
high	O
concentrations	O
of	O
Mg	O
(	O
2	O
+)	O
needed	O
for	O
protein	O
stability	O
,	O
HIV	O
-	O
1	O
RNase	B-ENZY
H	I-ENZY
is	O
not	O
suitable	O
for	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
inhibitor	O
studies	O
.	O

We	O
recently	O
showed	O
that	O
the	O
RNase	B-ENZY
H	I-ENZY
domains	O
of	O
HIV	O
-	O
1	O
and	O
prototype	O
foamy	O
virus	O
(	O
PFV	O
)	O
reverse	O
transcriptases	O
(	O
RTs	O
)	O
exhibit	O
a	O
high	O
degree	O
of	O
structural	O
similarity	O
.	O

Thus	O
,	O
we	O
examined	O
whether	O
PFV	O
RNase	B-ENZY
H	I-ENZY
can	O
serve	O
as	O
an	O
HIV	O
-	O
1	O
RNase	B-ENZY
H	I-ENZY
model	O
for	O
inhibitor	O
interaction	O
studies	O
.	O

Five	O
HIV	O
-	O
1	O
RHIs	O
inhibited	O
PFV	O
RNase	B-ENZY
H	I-ENZY
activity	O
at	O
low	O
-	O
micromolar	O
concentrations	O
similar	O
to	O
those	O
of	O
HIV	O
-	O
1	O
RNase	B-ENZY
H	I-ENZY
,	O
suggesting	O
pocket	O
similarity	O
of	O
the	O
RNase	B-ENZY
H	I-ENZY
domains	O
.	O

NMR	O
titration	O
experiments	O
with	O
the	O
PFV	O
RNase	B-ENZY
H	I-ENZY
domain	O
and	O
the	O
RHI	O
RDS1643	O
(	O
6	O
-[	O
1	O
-(	O
4	O
-	O
fluorophenyl	O
)	O
methyl	O
-	O
1H	O
-	O
pyrrol	O
-	O
2	O
-	O
yl	O
)]-	O
2	O
,	O
4	O
-	O
dioxo	O
-	O
5	O
-	O
hexenoic	O
acid	O
ethyl	O
ester	O
)	O
were	O
performed	O
to	O
determine	O
its	O
binding	O
site	O
.	O

Structural	O
overlays	O
were	O
performed	O
with	O
HIV	O
-	O
1	O
and	O
PFV	O
RNase	B-ENZY
H	I-ENZY
to	O
propose	O
the	O
RDS1643	O
binding	O
site	O
in	O
HIV	O
-	O
1	O
RNase	B-ENZY
H	I-ENZY
.	O
Our	O
results	O
suggest	O
that	O
this	O
approach	O
can	O
be	O
used	O
to	O
establish	O
PFV	O
RNase	B-ENZY
H	I-ENZY
as	O
a	O
model	O
system	O
for	O
HIV	O
-	O
1	O
RNase	B-ENZY
H	I-ENZY
in	O
order	O
to	O
identify	O
putative	O
inhibitor	O
binding	O
sites	O
in	O
HIV	O
-	O
1	O
RNase	B-ENZY
H	I-ENZY
.	O

TITLE	O
:	O
Proteolytic	O
activation	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
coronavirus	O
spike	O
fusion	O
protein	O
by	O
trypsin	B-ENZY
in	O
cell	O
culture	O
.	O

We	O
demonstrate	O
that	O
trypsin	B-ENZY
acts	O
on	O
the	O
wtPEDV	O
spike	O
protein	O
after	O
receptor	O
binding	O
.	O

We	O
mapped	O
the	O
genetic	O
determinant	O
for	O
trypsin	B-ENZY
-	O
dependent	O
cell	O
entry	O
to	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
fusion	O
subunit	O
of	O
this	O
class	O
I	O
fusion	O
protein	O
,	O
revealing	O
a	O
conserved	O
arginine	O
just	O
upstream	O
of	O
the	O
putative	O
fusion	O
peptide	O
as	O
the	O
potential	O
cleavage	O
site	O
.	O

The	O
changes	O
in	O
hemodynamics	O
,	O
respiratory	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
under	O
different	O
levels	O
of	O
PEEP	O
were	O
observed	O
.	O

ABSTRACT	O
:	O
Twenty	O
-	O
two	O
flocks	O
of	O
turkeys	O
affected	O
by	O
enteric	O
problems	O
,	O
with	O
ages	O
between	O
10	O
and	O
104	O
days	O
and	O
located	O
in	O
the	O
Southern	O
region	O
of	O
Brazil	O
,	O
were	O
surveyed	O
for	O
turkey	O
by	O
PCR	O
for	O
turkey	O
astrovirus	O
type	O
2	O
(	O
TAstV	O
-	O
2	O
),	O
turkey	O
coronavirus	O
(	O
TCoV	O
),	O
hemorrhagic	O
enteritis	O
virus	O
(	O
HEV	O
),	O
rotavirus	O
,	O
reovirus	O
,	O
Salmonella	O
spp	B-ENZY
.,	O
and	O
Lawsonia	O
intracellularis	O
(	O
Li	O
)	O
infections	O
.	O

Six	O
were	O
positive	O
for	O
Salmonella	O
spp	B-ENZY
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
1	O
,	O
3	O
-	O
diarylpropenones	O
as	O
dual	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
.	O

ABSTRACT	O
:	O
A	O
small	O
library	O
of	O
1	O
,	O
3	O
-	O
diarylpropenones	O
was	O
designed	O
and	O
synthesized	O
as	O
dual	O
inhibitors	O
of	O
both	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)	O
DNA	O
polymerase	O
(	O
DP	O
)	O
and	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
associated	O
functions	O
.	O

TITLE	O
:	O
Structural	O
Basis	O
for	O
the	O
Ubiquitin	O
-	O
Linkage	O
Specificity	O
and	O
deISGylating	O
activity	O
of	O
SARS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
.	O

Management	O
of	O
ARDS	O
remains	O
supportive	O
,	O
aimed	O
at	O
improving	O
gas	B-ENZY
exchange	O
and	O
preventing	O
complications	O
.	O

Pathogenic	O
trait	O
of	O
these	O
bat	B-ENZY
coronaviruses	O
remained	O
unexplored	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
PEDV	O
infection	O
inhibits	O
the	O
synthesis	O
of	O
type	O
I	O
interferon	O
(	O
IFN	O
),	O
and	O
viral	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
has	O
been	O
identified	O
as	O
an	O
IFN	O
antagonist	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
the	O
PEDV	O
-	O
encoded	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
also	O
inhibits	O
Sendai	O
virus	O
-	O
induced	O
IFN	O
-	O
	O
production	O
,	O
IFN	O
-	O
stimulated	O
gene	O
expression	O
,	O
and	O
activation	O
of	O
the	O
transcription	O
factors	O
IFN	O
regulatory	O
factor	O
3	O
(	O
IRF3	O
)	O
and	O
NF	O
-	O
B	O
.	O
We	O
also	O
found	O
that	O
N	O
protein	O
significantly	O
impedes	O
the	O
activation	O
of	O
the	O
IFN	O
-	O
	O
promoter	O
stimulated	O
by	O
TBK1	B-ENZY
or	O
its	O
upstream	O
molecules	O
(	O
RIG	O
-	O
I	O
,	O
MDA5	O
,	O
IPS	O
-	O
1	O
,	O
and	O
TRAF3	O
)	O
but	O
does	O
not	O
counteract	O
its	O
activation	O
by	O
IRF3	O
.	O

Here	O
,	O
we	O
identify	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
as	O
a	O
novel	O
PEDV	O
-	O
encoded	O
interferon	O
(	O
IFN	O
)	O
antagonist	O
and	O
demonstrate	O
that	O
N	O
protein	O
antagonizes	O
IFN	O
production	O
by	O
sequestering	O
the	O
interaction	O
between	O
IRF3	O
and	O
TBK1	B-ENZY
,	O
a	O
critical	O
step	O
in	O
type	O
I	O
IFN	O
signaling	O
.	O

Treatment	O
of	O
cells	O
with	O
neuraminidase	B-ENZY
(	O
NA	O
)	O
enhanced	O
infection	O
efficiency	O
,	O
showing	O
that	O
terminal	O
sialic	O
acid	O
residues	O
on	O
the	O
cell	O
surface	O
were	O
not	O
receptor	O
determinants	O
and	O
even	O
hampered	O
efficient	O
virus	O
-	O
receptor	O
engagement	O
.	O

Sodium	O
enters	O
through	O
apical	O
channels	O
,	O
primarily	O
the	O
epithelial	O
sodium	O
channel	O
,	O
and	O
is	O
pumped	O
into	O
the	O
lung	O
interstitium	O
by	O
basolaterally	O
located	O
Na	O
/	O
K	O
-	O
ATPase	B-ENZY
,	O
thus	O
creating	O
a	O
local	O
osmotic	O
gradient	O
to	O
reabsorb	O
the	O
water	O
fraction	O
of	O
the	O
edema	O
fluid	O
from	O
the	O
airspaces	O
of	O
the	O
lungs	O
.	O

Fluorescence	O
microscopy	O
and	O
real	O
-	O
time	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
were	O
utilized	O
to	O
assess	O
occurrence	O
and	O
consequences	O
of	O
infection	O
.	O

TITLE	O
:	O
A	O
phage	O
-	O
displayed	O
peptide	O
recognizing	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
is	O
a	O
potent	O
small	O
molecule	O
inhibitor	O
of	O
PEDV	O
entry	O
.	O

ABSTRACT	O
:	O
Three	O
phage	O
-	O
displayed	O
peptides	O
designated	O
H	O
,	O
S	O
and	O
F	O
that	O
recognize	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
),	O
the	O
cellular	O
receptor	O
of	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
were	O
able	O
to	O
inhibit	O
cell	O
infection	O
by	O
TGEV	O
.	O

Circular	O
dichroism	O
and	O
Tyr	O
/	O
Trp	B-ENZY
fluorescence	O
analyses	O
indicated	O
that	O
the	O
secondary	O
and	O
tertiary	O
structure	O
of	O
MERS	O
-	O
CoV	O
PLpro	O
is	O
well	O
organized	O
and	O
folded	O
.	O

RESULTS	O
:	O
Circular	O
dichroism	O
and	O
Tyr	O
/	O
Trp	B-ENZY
fluorescence	O
analyses	O
indicated	O
that	O
the	O
secondary	O
and	O
tertiary	O
structure	O
of	O
MERS	O
-	O
CoV	O
PLpro	O
is	O
well	O
organized	O
and	O
folded	O
.	O

TITLE	O
:	O
Glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	B-ENZY
)	O
prevents	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
,	O
sepsis	O
-	O
related	O
severe	O
acute	O
lung	O
injury	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
Glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	B-ENZY
)	O
is	O
an	O
energy	O
metabolism	O
-	O
related	O
enzyme	O
in	O
the	O
glycolytic	O
pathway	O
.	O

Recently	O
,	O
it	O
has	O
been	O
reported	O
that	O
GAPDH	B-ENZY
has	O
other	O
physiological	O
functions	O
,	O
such	O
as	O
apoptosis	O
,	O
DNA	O
repair	O
and	O
autophagy	O
.	O

Some	O
in	O
vitro	O
studies	O
have	O
indicated	O
immunological	O
aspects	O
of	O
GAPDH	B-ENZY
function	O
,	O
although	O
there	O
is	O
no	O
definite	O
study	O
discussing	O
the	O
advantage	O
of	O
GAPDH	B-ENZY
as	O
a	O
therapeutic	O
target	O
.	O

Here	O
,	O
we	O
show	O
that	O
GAPDH	B-ENZY
has	O
an	O
anti	O
-	O
inflammatory	O
function	O
by	O
using	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
,	O
sepsis	O
-	O
related	O
severe	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
mouse	O
model	O
,	O
which	O
is	O
referred	O
to	O
as	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
humans	O
.	O

GAPDH	B-ENZY
pre	O
-	O
injected	O
mice	O
were	O
protected	O
from	O
septic	O
death	O
,	O
and	O
their	O
serum	O
levels	O
of	O
proinflammatory	O
cytokines	O
were	O
significantly	O
suppressed	O
.	O

In	O
this	O
study	O
,	O
the	O
SARS	O
coronavirus	O
small	O
envelope	O
protein	O
(	O
SCVE	O
)	O
was	O
expressed	O
in	O
E	O
.	O
coli	O
cells	O
previously	O
engineered	O
for	O
periplasmic	O
expression	O
of	O
carbonic	B-ENZY
anhydrase	I-ENZY
(	O
CA	O
)	O
activity	O
.	O

There	O
was	O
no	O
effect	O
on	O
mortality	O
with	O
granulocyte	O
-	O
macrophage	O
colony	O
stimulating	O
factor	O
,	O
late	O
low	O
-	O
dose	O
methylprednisolone	O
,	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitors	O
,	O
intravenous	O
salbutamol	O
,	O
surfactant	O
,	O
or	O
N	O
-	O
acetylcysteine	O
;	O
each	O
meta	O
-	O
analysis	O
included	O
	O
1	O
trial	O
published	O
after	O
2003	O
.	O

There	O
was	O
a	O
close	O
correlation	O
between	O
hepatic	O
SOCS3	O
level	O
and	O
IL	O
-	O
6	O
,	O
and	O
the	O
severity	O
of	O
liver	O
injury	O
defined	O
by	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
)	O
levels	O
,	O
respectively	O
.	O

Here	O
,	O
we	O
report	O
the	O
characterization	O
of	O
a	O
novel	O
herpesvirus	O
isolated	O
from	O
an	O
Indonesian	O
pteropodid	O
bat	B-ENZY
.	O

Here	O
,	O
we	O
isolated	O
a	O
previously	O
unknown	O
alphaherpesvirus	O
from	O
an	O
Indonesian	O
fruit	O
bat	B-ENZY
.	O

FBAHV1	O
is	O
the	O
first	O
bat	B-ENZY
-	O
derived	O
alphaherpesvirus	O
whose	O
complete	O
genome	O
has	O
been	O
sequenced	O
.	O

Monitoring	O
included	O
standard	O
respiratory	O
,	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
and	O
electrical	O
impedance	O
tomography	O
(	O
EIT	O
)	O
images	O
.	O

TITLE	O
:	O
Murine	O
AKAP7	O
has	O
a	O
2	O
',	O
5	B-ENZY
'-	I-ENZY
phosphodiesterase	I-ENZY
domain	O
that	O
can	O
complement	O
an	O
inactive	O
murine	O
coronavirus	O
ns2	O
gene	O
.	O

To	O
determine	O
whether	O
AKAP7	O
could	O
substitute	O
for	O
a	O
viral	O
2	O
',	O
5	B-ENZY
'-	I-ENZY
PDE	I-ENZY
,	O
we	O
inserted	O
AKAP7	O
cDNA	O
into	O
an	O
MHV	O
genome	O
with	O
an	O
inactivated	O
ns2	O
gene	O
.	O

ns2	O
confers	O
virulence	O
by	O
cleaving	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
(	O
2	O
-	O
5A	O
)	O
activators	O
of	O
RNase	B-ENZY
L	O
in	O
macrophages	O
.	O

Here	O
we	O
report	O
that	O
a	O
cellular	O
protein	O
,	O
AKAP7	O
,	O
has	O
an	O
analogous	O
2	O
',	O
5	B-ENZY
'-	I-ENZY
phosphodiesterase	I-ENZY
(	O
2	O
',	O
5	B-ENZY
'-	I-ENZY
PDE	I-ENZY
)	O
domain	O
that	O
is	O
able	O
to	O
restore	O
the	O
growth	O
of	O
chimeric	O
MHV	O
expressing	O
inactive	O
ns2	O
.	O

We	O
speculate	O
that	O
AKAP7	O
is	O
the	O
ancestral	O
precursor	O
of	O
viral	O
proteins	O
,	O
such	O
as	O
ns2	O
and	O
VP3	O
,	O
that	O
degrade	O
2	O
-	O
5A	O
to	O
evade	O
the	O
antiviral	O
activity	O
of	O
RNase	B-ENZY
L	O
.	O

The	O
MERS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	O
))	O
is	O
a	O
potential	O
target	O
for	O
the	O
development	O
of	O
antiviral	O
drugs	O
.	O

These	O
molecules	O
inhibit	O
not	O
only	O
HIV	O
integrase	O
catalytic	O
activity	O
,	O
but	O
they	O
also	O
interfere	O
with	O
the	O
function	O
of	O
the	O
RNase	B-ENZY
H	I-ENZY
component	O
of	O
the	O
HIV	O
reverse	B-ENZY
transcriptase	I-ENZY
.	O

We	O
found	O
that	O
up	O
-	O
regulation	O
of	O
miR	O
-	O
125b	O
expression	O
maintained	O
the	O
body	O
weight	O
and	O
survival	O
of	O
ALI	O
mice	O
,	O
and	O
significantly	O
reduced	O
LPS	O
-	O
induced	O
pulmonary	O
inflammation	O
as	O
reflected	O
by	O
reductions	O
in	O
total	O
cell	O
and	O
neutrophil	O
counts	O
,	O
proinflammatory	O
cytokines	O
,	O
as	O
well	O
as	O
chemokines	O
in	O
BAL	B-ENZY
fluid	O
.	O

Further	O
,	O
enforced	O
expression	O
of	O
miR	O
-	O
125b	O
resulted	O
in	O
remarkable	O
reversal	O
of	O
LPS	O
-	O
induced	O
increases	O
in	O
lung	O
permeability	O
as	O
assessed	O
by	O
reductions	O
in	O
total	O
protein	O
,	O
albumin	O
and	O
IgM	O
in	O
BAL	B-ENZY
fluid	O
,	O
and	O
ameliorated	O
the	O
histopathology	O
changes	O
of	O
lung	O
in	O
LPS	O
-	O
induced	O
ALI	O
mice	O
.	O

Interestingly	O
,	O
mitochondrial	O
apoptosis	O
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
was	O
found	O
to	O
translocate	O
to	O
the	O
nucleus	O
during	O
PEDV	O
infection	O
,	O
and	O
AIF	O
relocalization	O
was	O
completely	O
abrogated	O
by	O
the	O
presence	O
of	O
cyclosporin	O
A	O
(	O
CsA	O
),	O
an	O
inhibitor	O
of	O
cyclophilin	B-ENZY
D	O
(	O
CypD	O
)	O
that	O
is	O
an	O
essential	O
component	O
of	O
the	O
mitochondrial	O
permeabilization	O
transition	O
pore	O
(	O
mPTP	O
)	O
complex	O
.	O

MAb	O
1A9	O
is	O
a	O
broadly	O
neutralizing	O
mAb	O
that	O
prevents	O
viral	O
entry	O
mediated	O
by	O
the	O
S	O
proteins	O
of	O
human	O
and	O
civet	O
SARS	O
-	O
CoVs	O
as	O
well	O
as	O
bat	B-ENZY
SL	O
-	O
CoVs	O
.	O

TITLE	O
:	O
Rooting	O
the	O
phylogenetic	O
tree	O
of	O
middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
by	O
characterization	O
of	O
a	O
conspecific	O
virus	O
from	O
an	O
African	O
bat	B-ENZY
.	O

We	O
determined	O
the	O
full	O
genome	O
sequence	O
of	O
a	O
CoV	O
directly	O
from	O
fecal	O
material	O
obtained	O
from	O
a	O
South	O
African	O
Neoromicia	O
capensis	O
bat	B-ENZY
(	O
NeoCoV	O
).	O

and	O
Eimeria	O
spp	B-ENZY
.	O
were	O
found	O
.	O

Diagnostic	O
viral	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
of	O
nose	O
and	O
throat	O
swabs	O
(	O
NTS	O
)	O
is	O
useful	O
for	O
patient	O
care	O
by	O
informing	O
antiviral	O
use	O
and	O
appropriate	O
isolation	O
.	O

Intravenous	O
immunization	O
with	O
peptide	O
-	O
loaded	O
dendritic	O
cells	O
(	O
DCs	O
)	O
followed	O
by	O
intranasal	O
boosting	O
with	O
recombinant	O
vaccinia	O
virus	O
(	O
rVV	O
)	O
encoding	O
S436	O
or	O
S525	O
resulted	O
in	O
accumulation	O
of	O
virus	O
-	O
specific	O
memory	O
CD8	O
T	O
cells	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BAL	B-ENZY
),	O
lungs	O
,	O
and	O
spleen	O
.	O

Upon	O
challenge	O
with	O
a	O
lethal	O
dose	O
of	O
SARS	O
-	O
CoV	O
,	O
virus	O
-	O
specific	O
memory	O
CD8	O
T	O
cells	O
efficiently	O
produced	O
multiple	O
effector	O
cytokines	O
(	O
gamma	O
interferon	O
[	O
IFN	O
-	O
	O
],	O
tumor	O
necrosis	O
factor	O
alpha	O
[	O
TNF	O
-	O
	O
],	O
and	O
interleukin	O
2	O
[	O
IL	O
-	O
2	O
])	O
and	O
cytolytic	O
molecules	O
(	O
granzyme	B-ENZY
B	I-ENZY
)	O
and	O
reduced	O
lung	O
viral	O
loads	O
.	O

Real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
assay	O
targeted	O
the	O
UpE	O
and	O
Orf1a	O
regions	O
of	O
the	O
MERS	O
-	O
CoV	O
genome	O
.	O

Nasal	O
/	O
Nasopharyngeal	O
swabs	O
were	O
tested	O
for	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
HCoV	O
-	O
22E	O
,	O
HCoV	O
-	O
OC43	O
,	O
HCoV	O
-	O
NL63	O
and	O
HCoV	O
-	O
HKU1	O
using	O
Reverse	B-ENZY
Transcriptase	I-ENZY
Real	O
-	O
Time	O
Polymerase	O
Chain	O
Reaction	O
.	O

ABSTRACT	O
:	O
Bronchoscopy	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
are	O
common	O
procedures	O
in	O
intensive	O
care	O
units	O
;	O
however	O
,	O
no	O
contemporaneous	O
safety	O
and	O
outcomes	O
data	O
have	O
been	O
reported	O
,	O
particularly	O
for	O
critically	O
ill	O
patients	O
.	O

One	O
hundred	O
mechanically	O
ventilated	O
patients	O
with	O
severe	O
sepsis	O
,	O
septic	O
shock	O
,	O
acute	O
lung	O
injury	O
(	O
ALI	O
),	O
and	O
/	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
underwent	O
bronchoscopy	O
with	O
unilateral	O
BAL	B-ENZY
.	O

Hypoxemia	O
during	O
or	O
immediately	O
after	O
the	O
BAL	B-ENZY
was	O
the	O
most	O
common	O
complication	O
.	O

Bronchoscopy	O
with	O
BAL	B-ENZY
in	O
critically	O
ill	O
patients	O
with	O
sepsis	O
and	O
ALI	O
is	O
well	O
tolerated	O
with	O
low	O
risk	O
of	O
complications	O
,	O
primarily	O
related	O
to	O
manageable	O
hypoxemia	O
.	O

TITLE	O
:	O
Identification	O
of	O
highly	O
conserved	O
residues	O
involved	O
in	O
inhibition	O
of	O
HIV	O
-	O
1	O
RNase	B-ENZY
H	I-ENZY
function	O
by	O
Diketo	O
acid	O
derivatives	O
.	O

ABSTRACT	O
:	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
associated	O
RNase	B-ENZY
H	I-ENZY
activity	O
is	O
an	O
essential	O
function	O
in	O
viral	O
genome	O
retrotranscription	O
.	O

RNase	B-ENZY
H	I-ENZY
is	O
a	O
promising	O
drug	O
target	O
for	O
which	O
no	O
inhibitor	O
is	O
available	O
for	O
therapy	O
.	O

Diketo	O
acid	O
(	O
DKA	O
)	O
derivatives	O
are	O
active	O
site	O
Mg	O
(	O
2	O
+)-	O
binding	O
inhibitors	O
of	O
both	O
HIV	O
-	O
1	O
RNase	B-ENZY
H	I-ENZY
and	O
integrase	O
(	O
IN	O
)	O
activities	O
.	O

Most	O
of	O
the	O
ester	O
derivatives	O
showed	O
selectivity	O
for	O
HIV	O
-	O
1	O
RNase	B-ENZY
H	I-ENZY
versus	O
IN	O
,	O
while	O
acids	O
inhibited	O
both	O
functions	O
.	O

Molecular	O
modeling	O
and	O
site	O
-	O
directed	O
mutagenesis	O
studies	O
on	O
the	O
RNase	B-ENZY
H	I-ENZY
domain	O
demonstrated	O
different	O
binding	O
poses	O
for	O
ester	O
and	O
acid	O
DKAs	O
and	O
proved	O
that	O
DKAs	O
interact	O
with	O
residues	O
(	O
R448	O
,	O
N474	O
,	O
Q475	O
,	O
Y501	O
,	O
and	O
R557	O
)	O
involved	O
not	O
in	O
the	O
catalytic	O
motif	O
but	O
in	O
highly	O
conserved	O
portions	O
of	O
the	O
RNase	B-ENZY
H	I-ENZY
primer	O
grip	O
motif	O
.	O

TITLE	O
:	O
No	O
evidence	O
of	O
coronavirus	O
infection	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
in	O
bats	O
in	O
Belgium	O
.	O

TITLE	O
:	O
A	O
chimeric	O
virus	O
-	O
mouse	O
model	O
system	O
for	O
evaluating	O
the	O
function	O
and	O
inhibition	O
of	O
papain	B-ENZY
-	O
like	O
proteases	O
of	O
emerging	O
coronaviruses	O
.	O

Here	O
,	O
we	O
exploit	O
a	O
biosafety	O
level	O
2	O
(	O
BSL	O
-	O
2	O
)	O
chimeric	O
Sindbis	O
virus	O
system	O
to	O
evaluate	O
protease	O
activities	O
and	O
the	O
efficacy	O
of	O
inhibitors	O
directed	O
against	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
a	O
biosafety	O
level	O
3	O
(	O
BSL	O
-	O
3	O
)	O
pathogen	O
.	O

We	O
extended	O
the	O
chimeric	O
-	O
virus	O
platform	O
to	O
evaluate	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
/	O
deISGylating	O
activity	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
to	O
provide	O
a	O
small	O
-	O
animal	O
model	O
to	O
evaluate	O
PLpro	O
inhibitors	O
of	O
this	O
recently	O
emerged	O
pathogen	O
.	O

We	O
used	O
this	O
system	O
to	O
demonstrate	O
the	O
in	O
vivo	O
efficacy	O
of	O
an	O
inhibitor	O
of	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Nitazoxanide	O
inhibits	O
a	O
broad	O
range	O
of	O
influenza	O
A	O
and	O
B	O
viruses	O
including	O
influenza	O
A	O
(	O
pH1N1	O
)	O
and	O
the	O
avian	O
A	O
(	O
H7N9	O
)	O
as	O
well	O
as	O
viruses	O
that	O
are	O
resistant	O
to	O
neuraminidase	B-ENZY
inhibitors	O
.	O

It	O
is	O
synergistic	O
with	O
neuraminidase	B-ENZY
inhibitors	O
,	O
and	O
combination	O
therapy	O
with	O
oseltamivir	O
is	O
being	O
studied	O
in	O
humans	O
as	O
part	O
of	O
ongoing	O
Phase	O
3	O
clinical	O
development	O
.	O

Fraction	O
of	O
inspired	O
oxygen	O
(	O
Fio	O
(	O
2	O
))	O
and	O
PEEP	O
are	O
typically	O
titrated	O
to	O
maintain	O
arterial	O
oxygen	O
saturation	O
(	O
Spo	O
(	O
2	O
))	O
of	O
88	O
to	O
95	O
%	O
(	O
Pao	B-ENZY
(	O
2	O
)	O
55	O
-	O
80	O
mm	O
Hg	O
).	O

Arterial	O
blood	O
gas	B-ENZY
analysis	O
at	O
ICU	O
admission	O
revealed	O
profound	O
hypoxia	O
.	O

TITLE	O
:	O
Receptor	O
usage	O
and	O
cell	O
entry	O
of	O
bat	B-ENZY
coronavirus	O
HKU4	O
provide	O
insight	O
into	O
bat	B-ENZY
-	O
to	O
-	O
human	O
transmission	O
of	O
MERS	O
coronavirus	O
.	O

Believed	O
to	O
have	O
originated	O
from	O
bats	O
,	O
MERS	O
-	O
CoV	O
is	O
genetically	O
related	O
to	O
bat	B-ENZY
coronaviruses	O
HKU4	O
and	O
HKU5	O
.	O

To	O
understand	O
how	O
bat	B-ENZY
coronaviruses	O
transmit	O
to	O
humans	O
,	O
we	O
investigated	O
the	O
receptor	O
usage	O
and	O
cell	O
entry	O
activity	O
of	O
the	O
virus	O
-	O
surface	O
spike	O
proteins	O
of	O
HKU4	O
and	O
HKU5	O
.	O

Second	O
,	O
in	O
the	O
absence	O
of	O
exogenous	O
proteases	O
,	O
both	O
MERS	O
-	O
CoV	O
and	O
HKU4	O
spikes	O
mediate	O
pseudovirus	O
entry	O
into	O
bat	B-ENZY
cells	O
,	O
whereas	O
only	O
MERS	O
-	O
CoV	O
spike	O
,	O
but	O
not	O
HKU4	O
spike	O
,	O
mediates	O
pseudovirus	O
entry	O
into	O
human	O
cells	O
.	O

They	O
also	O
suggest	O
that	O
DPP4	O
-	O
recognizing	O
bat	B-ENZY
coronaviruses	O
threaten	O
human	O
health	O
because	O
of	O
their	O
spikes	O
'	O
capability	O
to	O
adapt	O
to	O
human	O
cells	O
for	O
cross	O
-	O
species	O
transmissions	O
.	O

Sequence	O
analysis	O
suggests	O
that	O
the	O
orf3a	O
aligned	O
to	O
one	O
calcium	B-ENZY
pump	I-ENZY
present	O
in	O
Plasmodium	O
falciparum	O
and	O
the	O
enzyme	O
glutamine	B-ENZY
synthetase	I-ENZY
found	O
in	O
Leptospira	O
interrogans	O
.	O

ABSTRACT	O
:	O
Heliox	O
,	O
a	O
helium	O
-	O
oxygen	O
gas	B-ENZY
mixture	O
,	O
has	O
been	O
used	O
for	O
many	O
decades	O
to	O
treat	O
obstructive	O
pulmonary	O
disease	O
.	O

The	O
lower	O
density	O
and	O
higher	O
viscosity	O
of	O
heliox	O
relative	O
to	O
nitrogen	O
-	O
oxygen	O
mixtures	O
can	O
significantly	O
reduce	O
airway	O
resistance	O
when	O
an	O
anatomic	O
upper	O
air	O
-	O
flow	O
obstruction	O
is	O
present	O
and	O
gas	B-ENZY
flow	O
is	O
turbulent	O
.	O

Silencing	O
of	O
syntenin	O
using	O
siRNAs	O
led	O
to	O
a	O
decrease	O
in	O
p38	O
MAPK	B-ENZY
activation	O
in	O
SARS	O
-	O
CoV	O
infected	O
cells	O
,	O
further	O
reinforcing	O
their	O
functional	O
relationship	O
.	O

Active	O
p38	O
MAPK	B-ENZY
was	O
reduced	O
in	O
lungs	O
of	O
mice	O
infected	O
with	O
SARS	O
-	O
CoVs	O
lacking	O
E	O
protein	O
PBM	O
as	O
compared	O
with	O
the	O
parental	O
virus	O
,	O
leading	O
to	O
a	O
decreased	O
expression	O
of	O
inflammatory	O
cytokines	O
and	O
to	O
virus	O
attenuation	O
.	O

Therefore	O
,	O
the	O
E	O
protein	O
PBM	O
is	O
a	O
virulence	O
domain	O
that	O
activates	O
immunopathology	O
most	O
likely	O
by	O
using	O
syntenin	O
as	O
a	O
mediator	O
of	O
p38	O
MAPK	B-ENZY
induced	O
inflammation	O
.	O

This	O
study	O
describes	O
399	O
microRNAs	O
identified	O
by	O
deep	O
sequencing	O
of	O
small	O
RNA	O
isolated	O
from	O
tissues	O
of	O
the	O
Black	O
flying	O
fox	O
,	O
Pteropus	O
alecto	O
,	O
a	O
confirmed	O
natural	O
reservoir	O
of	O
the	O
human	O
pathogens	O
Hendra	O
virus	O
and	O
Australian	O
bat	B-ENZY
lyssavirus	O
.	O

Characterisation	O
of	O
the	O
bat	B-ENZY
microRNA	O
repertoire	O
is	O
an	O
essential	O
step	O
towards	O
understanding	O
transcriptional	O
regulation	O
during	O
viral	O
infection	O
,	O
and	O
will	O
assist	O
in	O
the	O
identification	O
of	O
mechanisms	O
that	O
enable	O
bats	O
to	O
act	O
as	O
natural	O
virus	O
reservoirs	O
.	O

RESULTS	O
:	O
This	O
study	O
describes	O
399	O
microRNAs	O
identified	O
by	O
deep	O
sequencing	O
of	O
small	O
RNA	O
isolated	O
from	O
tissues	O
of	O
the	O
Black	O
flying	O
fox	O
,	O
Pteropus	O
alecto	O
,	O
a	O
confirmed	O
natural	O
reservoir	O
of	O
the	O
human	O
pathogens	O
Hendra	O
virus	O
and	O
Australian	O
bat	B-ENZY
lyssavirus	O
.	O

Levels	O
of	O
brain	O
damage	O
markers	O
S100	O
calcium	O
binding	O
protein	O
B	O
and	O
neuron	O
-	O
specific	O
enolase	B-ENZY
,	O
interleukin	O
-	O
6	O
,	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
,	O
as	O
well	O
as	O
matrix	O
metalloproteinase	O
-	O
9	O
increased	O
significantly	O
after	O
treating	O
brain	O
cells	O
with	O
	O
2	O
%	O
conditioned	O
medium	O
.	O

TITLE	O
:	O
Catalytic	O
function	O
and	O
substrate	O
specificity	O
of	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
domain	O
of	O
nsp3	O
from	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Unlocking	O
the	O
secrets	O
of	O
how	O
coronavirus	O
(	O
CoV	O
)	O
papain	B-ENZY
-	O
like	O
proteases	O
(	O
PLpros	O
)	O
perform	O
their	O
multifunctional	O
roles	O
during	O
viral	O
replication	O
entails	O
a	O
complete	O
mechanistic	O
understanding	O
of	O
their	O
substrate	O
recognition	O
and	O
enzymatic	O
activities	O
.	O

Knockdown	O
and	O
overexpression	O
experiments	O
demonstrated	O
that	O
IRE1	O
protects	O
infected	O
cells	O
from	O
IBV	O
-	O
induced	O
apoptosis	O
,	O
which	O
required	O
both	O
its	O
kinase	O
and	O
RNase	B-ENZY
activities	O
.	O

Moreover	O
,	O
IRE1	O
antagonized	O
IBV	O
-	O
induced	O
apoptosis	O
by	O
modulating	O
the	O
phosphorylation	O
status	O
of	O
the	O
proapoptotic	O
c	B-ENZY
-	I-ENZY
Jun	I-ENZY
N	I-ENZY
-	I-ENZY
terminal	I-ENZY
kinase	I-ENZY
(	O
JNK	B-ENZY
)	O
and	O
the	O
prosurvival	O
RAC	O
-	O
alpha	O
serine	O
/	O
threonine	O
-	O
protein	B-ENZY
kinase	I-ENZY
(	O
Akt	O
).	O

Physicians	O
should	O
be	O
aware	O
that	O
acute	O
respiratory	O
distress	O
syndrome	O
not	O
responding	O
to	O
treatment	O
of	O
common	O
causes	O
could	O
be	O
a	O
manifestation	O
of	O
the	O
disease	O
,	O
even	O
with	O
negative	O
BAL	B-ENZY
or	O
biopsy	O
and	O
could	O
be	O
promptly	O
treated	O
with	O
salvage	O
therapy	O
.	O

Postoperative	O
NIV	O
improves	O
gas	B-ENZY
exchange	O
,	O
decreases	O
work	O
of	O
breathing	O
and	O
reduces	O
atelectasis	O
.	O

The	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
)	O
and	O
related	O
CoV	O
proteases	O
have	O
several	O
distinct	O
features	O
,	O
such	O
as	O
an	O
uncharged	O
Cys	O
-	O
His	O
catalytic	O
dyad	O
embedded	O
in	O
a	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
fold	O
,	O
that	O
clearly	O
separate	O
these	O
enzymes	O
from	O
archetypical	O
cysteine	O
proteases	O
.	O

Mechanical	O
ventilation	O
with	O
high	O
PEEP	O
improved	O
patient	O
'	O
s	O
gas	B-ENZY
exchange	O
parameters	O
within	O
3	O
weeks	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
SARs	O
of	O
indole	O
-	O
based	O
	O
-	O
amino	O
acids	O
as	O
potent	O
HIV	O
-	O
1	O
non	O
-	O
nucleoside	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
.	O

TITLE	O
:	O
Bat	B-ENZY
origins	O
of	O
MERS	O
-	O
CoV	O
supported	O
by	O
bat	B-ENZY
coronavirus	O
HKU4	O
usage	O
of	O
human	O
receptor	O
CD26	O
.	O

Finally	O
,	O
we	O
discuss	O
STING	O
antagonism	O
in	O
the	O
coronaviruses	O
SARS	O
coronavirus	O
and	O
human	O
coronavirus	O
NL63	O
,	O
which	O
disrupt	O
K63	O
-	O
linked	O
polyubiquitination	O
and	O
dimerisation	O
of	O
STING	O
(	O
both	O
of	O
which	O
are	O
required	O
for	O
STING	O
-	O
mediated	O
activation	O
of	O
IRF	O
-	O
3	O
)	O
via	O
their	O
papain	B-ENZY
-	O
like	O
proteases	O
.	O

The	O
oxygen	O
exchange	O
levels	O
of	O
the	O
two	O
groups	O
were	O
examined	O
based	O
on	O
the	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
at	O
different	O
times	O
(	O
0	O
,	O
24	O
,	O
72	O
hours	O
and	O
7	O
days	O
of	O
treatment	O
)	O
in	O
the	O
two	O
groups	O
.	O

In	O
this	O
study	O
,	O
nine	O
of	O
88	O
US	O
PEDV	O
strains	O
were	O
isolated	O
successfully	O
on	O
Vero	O
cells	O
with	O
supplemental	O
trypsin	B-ENZY
and	O
subjected	O
to	O
genomic	O
sequence	O
analysis	O
.	O

BMSCs	O
decreased	O
expression	O
of	O
cleaved	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
the	O
pro	O
-	O
apoptotic	O
protein	O
,	O
Bax	O
,	O
whilst	O
increased	O
levels	O
of	O
the	O
anti	O
-	O
apoptotic	O
protein	O
,	O
Bcl	O
-	O
2	O
,	O
prolonging	O
the	O
lifespan	O
of	O
AMs	O
in	O
vitro	O
.	O

Promotion	O
of	O
AMs	O
survival	O
by	O
BMSCs	O
required	O
down	O
-	O
regulation	O
of	O
p	O
-	O
GSK	B-ENZY
-	O
3	O
and	O
	O
-	O
catenin	O
in	O
AMs	O
.	O

ABSTRACT	O
:	O
To	O
conduct	O
a	O
country	O
-	O
wide	O
prevalence	O
study	O
of	O
bovine	O
group	O
A	O
rotavirus	O
,	O
coronavirus	O
,	O
Cryptosporidium	O
parvum	O
,	O
Salmonella	O
spp	B-ENZY
.	O
and	O
enterotoxigenic	O
K99	O
(+)	O
Escherichia	O
coli	O
(	O
K99	O
)	O
in	O
calves	O
on	O
New	O
Zealand	O
dairy	O
farms	O
.	O

Faecal	O
samples	O
(	O
n	O
=	O
1	O
,	O
283	O
)	O
were	O
collected	O
during	O
the	O
2011	O
calving	O
season	O
from	O
calves	O
that	O
were	O
1	O
-	O
5	O
and	O
9	O
-	O
21	O
days	O
-	O
old	O
on	O
97	O
dairy	O
farms	O
,	O
and	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
bovine	O
group	O
A	O
rotavirus	O
,	O
coronavirus	O
,	O
Cryptosporidium	O
and	O
Salmonella	O
spp	B-ENZY
.,	O
and	O
K99	O
.	O

Salmonella	O
spp	B-ENZY
.	O
were	O
found	O
in	O
three	O
and	O
four	O
samples	O
,	O
from	O
calves	O
that	O
were	O
1	O
-	O
5	O
and	O
9	O
-	O
21	O
days	O
-	O
old	O
,	O
respectively	O
.	O

Myeloid	O
cells	O
,	O
including	O
monocytes	O
and	O
macrophages	O
,	O
play	O
an	O
important	O
role	O
in	O
this	O
balance	O
,	O
particularly	O
through	O
the	O
activities	O
of	O
the	O
arginine	O
-	O
hydrolyzing	O
enzymes	O
nitric	O
oxide	O
synthase	O
2	O
(	O
Nos2	O
;	O
iNOS	O
)	O
and	O
arginase	B-ENZY
1	O
(	O
Arg1	O
).	O

Both	O
life	O
-	O
saving	O
gas	B-ENZY
exchange	O
and	O
a	O
reduction	O
of	O
ventilator	O
-	O
induced	O
lung	O
injury	O
by	O
means	O
of	O
a	O
more	O
protective	O
ventilation	O
can	O
be	O
achieved	O
.	O

CONCLUSIONS	O
:	O
Modern	O
extracorporeal	O
lung	O
support	O
devices	O
allow	O
an	O
effective	O
extracorporeal	O
gas	B-ENZY
exchange	O
and	O
have	O
become	O
an	O
inherent	O
component	O
of	O
intensive	O
care	O
treatment	O
of	O
critically	O
ill	O
patients	O
.	O

Arterial	O
blood	O
gas	B-ENZY
analysis	O
was	O
conducted	O
and	O
serum	O
cytokine	O
levels	O
,	O
including	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
	O
),	O
interleukin	O
4	O
(	O
IL	O
-	O
4	O
)	O
and	O
interleukin	O
6	O
(	O
IL	O
-	O
6	O
),	O
as	O
well	O
as	O
C	O
reactive	O
protein	O
(	O
CRP	O
)	O
were	O
evaluated	O
respectively	O
both	O
before	O
and	O
6h	O
,	O
12h	O
,	O
and	O
24h	O
after	O
CRRT	O
therapy	O
.	O

We	O
previously	O
reported	O
the	O
pro	O
-	O
apoptotic	O
property	O
of	O
the	O
SARS	O
-	O
CoV	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
)	O
M	O
(	O
membrane	O
)-	O
protein	O
and	O
a	O
down	O
-	O
regulation	O
of	O
the	O
phosphorylation	O
level	O
of	O
the	O
cell	O
-	O
survival	O
protein	O
PKB	O
(	O
protein	B-ENZY
kinase	I-ENZY
B	O
)/	O
Akt	O
in	O
cells	O
expressing	O
M	O
-	O
protein	O
.	O

We	O
also	O
showed	O
that	O
overexpression	O
of	O
PDK1	O
(	O
3	O
-	O
phosphoinositide	O
-	O
dependent	O
protein	B-ENZY
kinase	I-ENZY
1	O
),	O
the	O
immediate	O
upstream	O
kinase	O
of	O
PKB	O
/	O
Akt	O
,	O
suppressed	O
M	O
-	O
induced	O
apoptosis	O
.	O

Here	O
,	O
we	O
focused	O
on	O
the	O
role	O
of	O
Sprouty	O
-	O
related	O
EVH1	O
-	O
domain	O
-	O
containing	O
protein	O
(	O
Spred	O
)-	O
2	O
,	O
a	O
negative	O
regulator	O
of	O
the	O
Ras	O
-	O
Raf	O
-	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
(	O
ERK	B-ENZY
)-	O
MAPK	B-ENZY
pathway	O
,	O
in	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
acute	O
lung	O
inflammation	O
.	O

After	O
LPS	O
-	O
injection	O
,	O
the	O
lungs	O
were	O
harvested	O
to	O
assess	O
leukocyte	O
infiltration	O
,	O
cytokine	O
and	O
chemokine	O
production	O
,	O
ERK	B-ENZY
-	O
MAPK	B-ENZY
activation	O
and	O
immunopathology	O
.	O

U0126	O
,	O
a	O
selective	O
MEK	B-ENZY
/	O
ERK	B-ENZY
inhibitor	O
,	O
reduced	O
the	O
augmented	O
LPS	O
-	O
induced	O
inflammation	O
in	O
Spred	O
-	O
2	O
(-/-)	O
mice	O
.	O

The	O
ERK	B-ENZY
-	O
MAPK	B-ENZY
pathway	O
is	O
involved	O
in	O
LPS	O
-	O
induced	O
acute	O
lung	O
inflammation	O
.	O

Using	O
synthetic	O
genomics	O
,	O
we	O
were	O
unable	O
to	O
rescue	O
the	O
wild	O
type	O
bat	B-ENZY
virus	O
,	O
but	O
could	O
rescue	O
a	O
modified	O
bat	B-ENZY
-	O
influenza	O
virus	O
that	O
had	O
the	O
HA	O
and	O
NA	O
coding	O
regions	O
replaced	O
with	O
those	O
of	O
A	O
/	O
PR	O
/	O
8	O
/	O
1934	O
(	O
H1N1	O
).	O

This	O
modified	O
bat	B-ENZY
-	O
influenza	O
virus	O
replicated	O
efficiently	O
in	O
vitro	O
and	O
in	O
mice	O
,	O
resulting	O
in	O
severe	O
disease	O
.	O

Additional	O
studies	O
using	O
a	O
bat	B-ENZY
-	O
influenza	O
virus	O
that	O
had	O
the	O
HA	O
and	O
NA	O
of	O
A	O
/	O
swine	O
/	O
Texas	O
/	O
4199	O
-	O
2	O
/	O
1998	O
(	O
H3N2	O
)	O
showed	O
that	O
the	O
PR8	O
HA	O
and	O
NA	O
contributed	O
to	O
the	O
pathogenicity	O
in	O
mice	O
.	O

Unlike	O
other	O
influenza	O
viruses	O
,	O
engineering	O
truncations	O
hypothesized	O
to	O
reduce	O
interferon	O
antagonism	O
into	O
the	O
NS1	O
protein	O
didn	O
'	O
t	O
attenuate	O
bat	B-ENZY
-	O
influenza	O
.	O

In	O
contrast	O
,	O
substitution	O
of	O
a	O
putative	O
virulence	O
mutation	O
from	O
the	O
bat	B-ENZY
-	O
influenza	O
PB2	O
significantly	O
attenuated	O
the	O
virus	O
in	O
mice	O
and	O
introduction	O
of	O
a	O
putative	O
virulence	O
mutation	O
increased	O
its	O
pathogenicity	O
.	O

Mini	O
-	O
genome	O
replication	O
studies	O
and	O
virus	O
reassortment	O
experiments	O
demonstrated	O
that	O
bat	B-ENZY
-	O
influenza	O
has	O
very	O
limited	O
genetic	O
and	O
protein	O
compatibility	O
with	O
Type	O
A	O
or	O
Type	O
B	O
influenza	O
viruses	O
,	O
yet	O
it	O
readily	O
reassorts	O
with	O
another	O
divergent	O
bat	B-ENZY
-	O
influenza	O
virus	O
,	O
suggesting	O
that	O
the	O
bat	B-ENZY
-	O
influenza	O
lineage	O
may	O
represent	O
a	O
new	O
Genus	O
/	O
Species	O
within	O
the	O
Orthomyxoviridae	O
family	O
.	O

Collectively	O
,	O
our	O
data	O
indicate	O
that	O
the	O
bat	B-ENZY
-	O
influenza	O
viruses	O
recently	O
identified	O
are	O
authentic	O
viruses	O
that	O
pose	O
little	O
,	O
if	O
any	O
,	O
pandemic	O
threat	O
to	O
humans	O
;	O
however	O
,	O
they	O
provide	O
new	O
insights	O
into	O
the	O
evolution	O
and	O
basic	O
biology	O
of	O
influenza	O
viruses	O
.	O

TITLE	O
:	O
Host	O
cell	O
entry	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
after	O
two	O
-	O
step	O
,	O
furin	B-ENZY
-	O
mediated	O
activation	O
of	O
the	O
spike	O
protein	O
.	O

Here	O
,	O
we	O
have	O
uncovered	O
distinctive	O
characteristics	O
of	O
MERS	O
-	O
CoV	O
S	O
.	O
We	O
identify	O
,	O
by	O
bioinformatics	O
and	O
peptide	O
cleavage	O
assays	O
,	O
two	O
cleavage	O
sites	O
for	O
furin	B-ENZY
,	O
a	O
ubiquitously	O
expressed	O
protease	O
,	O
which	O
are	O
located	O
at	O
the	O
S1	O
/	O
S2	O
interface	O
and	O
at	O
the	O
S2	O
'	O
position	O
of	O
the	O
S	O
protein	O
.	O

We	O
show	O
that	O
although	O
the	O
S1	O
/	O
S2	O
site	O
is	O
proteolytically	O
processed	O
by	O
furin	B-ENZY
during	O
protein	O
biosynthesis	O
,	O
the	O
S2	O
'	O
site	O
is	O
cleaved	O
upon	O
viral	O
entry	O
.	O

MERS	O
-	O
CoV	O
pseudovirion	O
infection	O
was	O
shown	O
to	O
be	O
enhanced	O
by	O
elevated	O
levels	O
of	O
furin	B-ENZY
expression	O
,	O
and	O
entry	O
could	O
be	O
decreased	O
by	O
furin	B-ENZY
siRNA	O
silencing	O
.	O

Enhanced	O
furin	B-ENZY
activity	O
appeared	O
to	O
partially	O
override	O
the	O
low	O
pH	O
-	O
dependent	O
nature	O
of	O
MERS	O
-	O
CoV	O
entry	O
.	O

Inhibition	O
of	O
furin	B-ENZY
activity	O
was	O
shown	O
to	O
decrease	O
MERS	O
-	O
CoV	O
S	O
-	O
mediated	O
entry	O
,	O
as	O
well	O
as	O
infection	O
by	O
the	O
virus	O
.	O

Overall	O
,	O
we	O
show	O
that	O
MERS	O
-	O
CoV	O
has	O
evolved	O
an	O
unusual	O
two	O
-	O
step	O
furin	B-ENZY
activation	O
for	O
fusion	O
,	O
suggestive	O
of	O
a	O
role	O
during	O
the	O
process	O
of	O
emergence	O
into	O
the	O
human	O
population	O
.	O

The	O
ability	O
of	O
MERS	O
-	O
CoV	O
to	O
use	O
furin	B-ENZY
in	O
this	O
manner	O
,	O
along	O
with	O
other	O
proteases	O
,	O
may	O
explain	O
the	O
polytropic	O
nature	O
of	O
the	O
virus	O
.	O

We	O
find	O
that	O
phosphorylation	O
of	O
the	O
viral	O
nucleocapsid	O
(	O
N	O
)	O
by	O
host	O
glycogen	B-ENZY
synthase	I-ENZY
kinase	O
-	O
3	O
(	O
GSK	B-ENZY
-	O
3	O
)	O
is	O
required	O
for	O
template	O
switching	O
.	O

GSK	B-ENZY
-	O
3	O
inhibition	O
selectively	O
reduces	O
the	O
generation	O
of	O
gRNA	O
and	O
longer	O
sgmRNAs	O
,	O
but	O
not	O
shorter	O
sgmRNAs	O
.	O

The	O
possible	O
mechanism	O
of	O
the	O
inhibitory	O
action	O
on	O
the	O
male	O
immunity	O
was	O
associated	O
with	O
the	O
protein	B-ENZY
kinase	I-ENZY
cascade	O
,	O
including	O
protein	B-ENZY
kinase	I-ENZY
C	I-ENZY
,	O
activated	O
by	O
phorbolmyristate	O
in	O
the	O
cells	O
of	O
the	O
immune	O
system	O
.	O

UPR	O
is	O
mediated	O
by	O
three	O
ER	O
transmembrane	O
sensors	O
,	O
namely	O
the	O
PKR	O
-	O
like	O
ER	O
protein	B-ENZY
kinase	I-ENZY
(	O
PERK	O
),	O
the	O
inositol	O
-	O
requiring	O
protein	O
1	O
(	O
IRE1	O
)	O
and	O
the	O
activating	O
transcriptional	O
factor	O
6	O
(	O
ATF6	O
).	O

Noninvasive	O
mechanical	O
ventilation	O
can	O
reduce	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
,	O
improve	O
gas	B-ENZY
exchange	O
,	O
alleviate	O
symptoms	O
as	O
dyspnea	O
caused	O
by	O
fatigue	O
of	O
the	O
respiratory	O
muscles	O
,	O
reduce	O
duration	O
of	O
hospitalization	O
,	O
decrease	O
need	O
for	O
invasive	O
mechanical	O
ventilation	O
,	O
reduce	O
number	O
of	O
complications	O
and	O
also	O
lessen	O
hospital	O
mortality	O
.	O

Seropositivity	O
for	O
Leishmania	O
spp	B-ENZY
was	O
not	O
associated	O
with	O
signalment	O
,	O
living	O
conditions	O
,	O
season	O
of	O
sampling	O
and	O
health	O
status	O
of	O
the	O
cats	O
or	O
with	O
seropositivity	O
to	O
feline	O
leukemia	O
virus	O
,	O
feline	O
immunodeficiency	O
virus	O
,	O
feline	O
coronavirus	O
,	O
Toxoplasma	O
gondii	O
and	O
Bartonella	O
henselae	O
.	O

The	O
majority	O
of	O
respondents	O
set	O
permissive	O
blood	O
gas	B-ENZY
targets	O
(	O
hypoxia	O
(	O
92	O
%),	O
hypercapnia	O
(	O
58	O
%)	O
and	O
pH	O
(	O
90	O
%)).	O

It	O
causes	O
two	O
syndromes	O
:	O
hemorrhagic	O
fever	O
with	O
renal	O
syndrome	O
(	O
HFRS	O
),	O
endemic	O
in	O
Asia	O
and	O
Europe	O
and	O
the	O
Hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	B-ENZY
),	O
found	O
in	O
the	O
American	O
continent	O
,	O
including	O
Brazil	O
,	O
with	O
high	O
mortality	O
rates	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
report	O
a	O
case	O
of	O
HPS	B-ENZY
with	O
multiple	O
organ	O
failure	O
,	O
managed	O
with	O
early	O
goal	O
-	O
directed	O
therapy	O
guided	O
by	O
flow	O
and	O
tissue	O
perfusion	O
parameters	O
.	O

This	O
review	O
was	O
organized	O
as	O
follows	O
:	O
introduction	O
;	O
metabolism	O
and	O
biological	O
effects	O
;	O
clinical	O
applications	O
;	O
dosage	O
,	O
gas	B-ENZY
administration	O
and	O
weaning	O
process	O
;	O
warnings	O
and	O
side	O
-	O
effects	O
.	O

TITLE	O
:	O
Longitudinal	O
study	O
of	O
Salmonella	O
spp	B-ENZY
.,	O
diarrheagenic	O
Escherichia	O
coli	O
,	O
Rotavirus	O
,	O
and	O
Coronavirus	O
isolated	O
from	O
healthy	O
and	O
diarrheic	O
calves	O
in	O
a	O
Brazilian	O
dairy	O
herd	O
.	O

Seventeen	O
isolates	O
of	O
Salmonella	O
spp	B-ENZY
.	O
were	O
recovered	O
from	O
feces	O
of	O
11	O
calves	O
(	O
16	O
.	O
4	O
%),	O
and	O
statistical	O
analysis	O
revealed	O
no	O
association	O
between	O
the	O
presence	O
of	O
Salmonella	O
spp	B-ENZY
.	O

TITLE	O
:	O
Coronavirus	O
membrane	O
-	O
associated	O
papain	B-ENZY
-	O
like	O
proteases	O
induce	O
autophagy	O
through	O
interacting	O
with	O
Beclin1	O
to	O
negatively	O
regulate	O
antiviral	O
innate	O
immunity	O
.	O

These	O
results	O
suggested	O
that	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
induces	O
incomplete	O
autophagy	O
by	O
interacting	O
with	O
Beclin1	O
,	O
which	O
in	O
turn	O
modulates	O
coronavirus	O
replication	O
and	O
antiviral	O
innate	O
immunity	O
.	O

Clinical	O
signs	O
,	O
pathological	O
changes	O
,	O
virus	O
titration	O
in	O
tissues	O
of	O
mice	O
,	O
arterial	O
blood	O
gas	B-ENZY
,	O
and	O
cytokines	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
and	O
serum	O
were	O
observed	O
at	O
different	O
time	O
points	O
after	O
AIV	O
infection	O
.	O

Three	O
young	O
consecutive	O
patients	O
with	O
homozygous	O
sickle	O
cell	O
disease	O
were	O
admitted	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
due	O
to	O
ACS	B-ENZY
.	O

After	O
normalization	O
for	O
the	O
plasma	O
-	O
to	O
-	O
BAL	B-ENZY
urea	O
ratio	O
,	O
BALF	O
protein	O
and	O
lactate	O
dehydrogenase	O
levels	O
were	O
consistent	O
with	O
an	O
exudative	O
process	O
.	O

The	O
yellowish	O
coloration	O
of	O
tracheal	O
secretions	O
and	O
BALF	O
observed	O
during	O
ACS	B-ENZY
appears	O
to	O
be	O
related	O
to	O
an	O
intense	O
exudative	O
process	O
rather	O
than	O
to	O
the	O
presence	O
of	O
bilirubin	O
.	O

Twenty	O
-	O
three	O
pathogenic	O
respiratory	O
agents	O
,	O
18	O
respiratory	O
viruses	O
and	O
five	O
bacteria	O
were	O
investigated	O
using	O
multiplex	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
indirect	O
immunofluorescence	O
assay	O
(	O
IIF	O
).	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
papain	B-ENZY
-	O
like	O
protease	O
bound	O
to	O
ubiquitin	O
facilitates	O
targeted	O
disruption	O
of	O
deubiquitinating	O
activity	O
to	O
demonstrate	O
its	O
role	O
in	O
innate	O
immune	O
suppression	O
.	O

We	O
report	O
a	O
case	O
of	O
ACS	B-ENZY
in	O
a	O
patient	O
with	O
severe	O
acute	O
pancreatitis	O
.	O

With	O
a	O
presumptive	O
diagnosis	O
of	O
ACS	B-ENZY
,	O
abdominal	O
decompression	O
through	O
percutaneous	O
catheter	O
drainage	O
was	O
performed	O
immediately	O
.	O

After	O
incubation	O
with	O
RBCs	O
,	O
lung	O
ECs	O
underwent	O
regulated	O
necrotic	O
cell	O
death	O
(	O
necroptosis	O
)	O
and	O
released	O
the	O
essential	O
mediator	O
of	O
necroptosis	O
,	O
receptor	O
-	O
interacting	O
serine	O
/	O
threonine	O
-	O
protein	B-ENZY
kinase	I-ENZY
3	O
(	O
RIP3	O
),	O
and	O
HMGB1	O
.	O

After	O
72	O
h	O
of	O
LPS	O
stimulation	O
,	O
pulmonary	O
pathological	O
changes	O
,	O
lung	O
injury	O
scores	O
,	O
pulmonary	O
edema	O
,	O
myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
activity	O
,	O
total	O
cells	O
,	O
neutrophils	O
,	O
macrophages	O
,	O
TNF	O
-	O
	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
1	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
),	O
and	O
MCP	O
-	O
1	O
and	O
E	O
-	O
selectin	O
expression	O
were	O
notably	O
attenuated	O
by	O
emodin	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
Hantavirus	O
Pulmonary	O
Syndrome	O
(	O
HPS	B-ENZY
)	O
is	O
a	O
disease	O
of	O
viral	O
etiology	O
that	O
affects	O
humans	O
causing	O
severe	O
acute	O
respiratory	O
symptoms	O
.	O

In	O
contrast	O
,	O
MERS	O
-	O
CoV	O
,	O
which	O
contains	O
a	O
minimal	O
furin	B-ENZY
cleavage	O
site	O
just	O
upstream	O
of	O
the	O
fusion	O
peptide	O
,	O
was	O
negatively	O
affected	O
by	O
inhibition	O
of	O
furin	B-ENZY
,	O
but	O
not	O
of	O
lysosomal	O
proteases	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
life	O
-	O
threatening	O
critical	O
illness	O
,	O
characterised	O
by	O
qualitative	O
and	O
quantitative	O
surfactant	O
compositional	O
changes	O
associated	O
with	O
premature	O
airway	O
collapse	O
,	O
gas	B-ENZY
-	O
exchange	O
abnormalities	O
and	O
acute	O
hypoxic	O
respiratory	O
failure	O
.	O

We	O
isolated	O
RNA	O
from	O
frozen	O
samples	O
and	O
performed	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
using	O
a	O
published	O
universal	O
CoV	O
primer	O
set	O
.	O

ABSTRACT	O
:	O
We	O
present	O
the	O
results	O
of	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
performed	O
in	O
three	O
patients	O
with	O
severe	O
influenza	O
A	O
/	O
H1N1	O
pneumonia	O
complicated	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)	O
and	O
ACE2	O
are	O
involved	O
in	O
several	O
pathologies	O
such	O
as	O
cardiovascular	O
functions	O
,	O
renal	O
disease	O
,	O
and	O
acute	O
lung	O
injury	O
.	O

Two	O
hypotheses	O
may	O
explain	O
temporal	O
and	O
spatial	O
pulses	O
of	O
virus	O
shedding	O
in	O
bat	B-ENZY
populations	O
:	O
episodic	O
shedding	O
from	O
persistently	O
infected	O
bats	O
or	O
transient	O
epidemics	O
that	O
occur	O
as	O
virus	O
is	O
transmitted	O
among	O
bat	B-ENZY
populations	O
.	O

The	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHEII	O
)	O
score	O
,	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
score	O
,	O
oxygenation	O
index	O
(	O
PaO	O
/	O
FiO	O
),	O
lung	O
injury	O
score	O
(	O
LIS	B-ENZY
)	O
were	O
recorded	O
within	O
24	O
hours	O
after	O
admission	O
.	O

Compared	O
with	O
non	O
-	O
ARDS	O
group	O
,	O
APACHEII	O
score	O
,	O
SOFA	O
score	O
,	O
LIS	B-ENZY
score	O
,	O
mortality	O
were	O
significantly	O
increased	O
,	O
PaO2	O
/	O
FiO2	O
was	O
significantly	O
decreased	O
,	O
and	O
plasma	O
Ang	O
-	O
2	O
,	O
IL	O
-	O
6	O
,	O
CRP	O
were	O
significantly	O
elevated	O
[	O
APACHEII	O
score	O
:	O
20	O
.	O
7	O
	O
5	O
.	O
0	O
vs	O
.	O
14	O
.	O
1	O
	O
5	O
.	O
3	O
,	O
SOFA	O
score	O
:	O
7	O
.	O
7	O
	O
3	O
.	O
5	O
vs	O
.	O
3	O
.	O
5	O
	O
2	O
.	O
1	O
,	O
LIS	B-ENZY
score	O
:	O
1	O
.	O
69	O
	O
0	O
.	O
71	O
vs	O
.	O
0	O
.	O
28	O
	O
0	O
.	O
27	O
,	O
PaO	O
/	O
FiO	O
(	O
mmHg	O
,	O
1	O
mmHg	O
=	O
0	O
.	O
133	O
kPa	O
):	O
159	O
.	O
5	O
	O
61	O
.	O
3	O
vs	O
.	O
394	O
.	O
0	O
	O
3	O
.	O
2	O
,	O
mortality	O
:	O
45	O
.	O
3	O
%	O
(	O
24	O
/	O
53	O
)	O
vs	O
.	O
20	O
.	O
0	O
%	O
(	O
4	O
/	O
20	O
),	O
Ang	O
-	O
2	O
(	O
g	O
/	O
L	O
):	O
4	O
.	O
73	O
(	O
2	O
.	O
59	O
,	O
6	O
.	O
99	O
)	O
vs	O
.	O

It	O
was	O
shown	O
by	O
correlation	O
analysis	O
that	O
the	O
plasma	O
levels	O
of	O
Ang	O
-	O
2	O
was	O
significantly	O
positive	O
correlated	O
with	O
IL	O
-	O
6	O
(	O
r	O
=	O
0	O
.	O
468	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
CRP	O
(	O
r	O
=	O
0	O
.	O
492	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
APACHEII	O
score	O
(	O
r	O
=	O
0	O
.	O
560	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
SOFA	O
score	O
(	O
r	O
=	O
0	O
.	O
508	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
and	O
LIS	B-ENZY
score	O
(	O
r	O
=	O
0	O
.	O
588	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
significantly	O
negatively	O
correlated	O
with	O
PaO2	O
/	O
FiO2	O
(	O
r	O
=-	O
0	O
.	O
685	O
,	O
P	O
=	O
0	O
.	O
000	O
).	O

Factors	O
,	O
APACHEII	O
score	O
,	O
LIS	B-ENZY
score	O
,	O
PaO2	O
/	O
FiO2	O
,	O
Ang	O
-	O
2	O
and	O
IL	O
-	O
6	O
founded	O
statistical	O
significance	O
in	O
univariate	O
analysis	O
were	O
analyzed	O
using	O
multivariable	O
logistic	O
regression	O
.	O

RESULTS	O
:	O
Compared	O
with	O
non	O
-	O
ARDS	O
group	O
,	O
APACHEII	O
score	O
,	O
SOFA	O
score	O
,	O
LIS	B-ENZY
score	O
,	O
mortality	O
were	O
significantly	O
increased	O
,	O
PaO2	O
/	O
FiO2	O
was	O
significantly	O
decreased	O
,	O
and	O
plasma	O
Ang	O
-	O
2	O
,	O
IL	O
-	O
6	O
,	O
CRP	O
were	O
significantly	O
elevated	O
[	O
APACHEII	O
score	O
:	O
20	O
.	O
7	O
	O
5	O
.	O
0	O
vs	O
.	O
14	O
.	O
1	O
	O
5	O
.	O
3	O
,	O
SOFA	O
score	O
:	O
7	O
.	O
7	O
	O
3	O
.	O
5	O
vs	O
.	O
3	O
.	O
5	O
	O
2	O
.	O
1	O
,	O
LIS	B-ENZY
score	O
:	O
1	O
.	O
69	O
	O
0	O
.	O
71	O
vs	O
.	O
0	O
.	O
28	O
	O
0	O
.	O
27	O
,	O
PaO	O
/	O
FiO	O
(	O
mmHg	O
,	O
1	O
mmHg	O
=	O
0	O
.	O
133	O
kPa	O
):	O
159	O
.	O
5	O
	O
61	O
.	O
3	O
vs	O
.	O
394	O
.	O
0	O
	O
3	O
.	O
2	O
,	O
mortality	O
:	O
45	O
.	O
3	O
%	O
(	O
24	O
/	O
53	O
)	O
vs	O
.	O
20	O
.	O
0	O
%	O
(	O
4	O
/	O
20	O
),	O
Ang	O
-	O
2	O
(	O
g	O
/	O
L	O
):	O
4	O
.	O
73	O
(	O
2	O
.	O
59	O
,	O
6	O
.	O
99	O
)	O
vs	O
.	O

ABSTRACT	O
:	O
Bartonella	O
spp	B-ENZY
.	O

Most	O
Bartonella	O
spp	B-ENZY
.	O
have	O
adapted	O
to	O
a	O
specific	O
host	O
,	O
generally	O
a	O
domestic	O
or	O
wild	O
mammal	O
.	O

Nine	O
of	O
51	O
(	O
17	O
.	O
6	O
%)	O
camels	O
were	O
found	O
to	O
be	O
bacteremic	O
with	O
Bartonella	O
spp	B-ENZY
.;	O
bacteremia	O
levels	O
ranged	O
from	O
five	O
to	O
>	O
1000	O
colony	O
-	O
forming	O
units	O
/	O
mL	O
.	O
Phylogenetic	O
reconstruction	O
based	O
on	O
the	O
concatenated	O
sequences	O
of	O
gltA	O
and	O
rpoB	O
genes	O
demonstrated	O
that	O
the	O
dromedary	O
Bartonella	O
isolates	O
are	O
closely	O
related	O
to	O
other	O
ruminant	O
-	O
derived	O
Bartonella	O
spp	B-ENZY
.,	O
with	O
B	O
.	O
bovis	O
being	O
the	O
nearest	O
relative	O
.	O

TITLE	O
:	O
CD26	O
/	O
DPP4	O
cell	O
-	O
surface	O
expression	O
in	O
bat	B-ENZY
cells	O
correlates	O
with	O
bat	B-ENZY
cell	O
susceptibility	O
to	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
and	O
evolution	O
of	O
persistent	O
infection	O
.	O

For	O
this	O
study	O
,	O
ten	O
distinct	O
cell	O
lines	O
derived	O
from	O
bats	O
of	O
divergent	O
species	O
were	O
exposed	O
to	O
MERS	O
-	O
CoV	O
.	O
Plaque	O
assays	O
,	O
immunofluorescence	O
assays	O
,	O
and	O
transmission	O
electron	O
microscopy	O
confirmed	O
that	O
six	O
bat	B-ENZY
cell	O
lines	O
can	O
be	O
productively	O
infected	O
.	O

We	O
found	O
that	O
the	O
susceptibility	O
or	O
resistance	O
of	O
these	O
bat	B-ENZY
cell	O
lines	O
directly	O
correlates	O
with	O
the	O
presence	O
or	O
absence	O
of	O
cell	O
surface	O
-	O
expressed	O
CD26	O
/	O
DPP4	O
,	O
the	O
functional	O
human	O
receptor	O
for	O
MERS	O
-	O
CoV	O
.	O
Human	O
anti	O
-	O
CD26	O
/	O
DPP4	O
antibodies	O
inhibited	O
infection	O
of	O
susceptible	O
bat	B-ENZY
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Overexpression	O
of	O
human	O
CD26	O
/	O
DPP4	O
receptor	O
conferred	O
MERS	O
-	O
CoV	O
susceptibility	O
to	O
resistant	O
bat	B-ENZY
cell	O
lines	O
.	O

Before	O
combining	O
lung	O
recruitment	O
maneuver	O
,	O
24	O
h	O
after	O
combining	O
lung	O
recruitment	O
maneuver	O
,	O
and	O
at	O
the	O
end	O
of	O
combining	O
lung	O
recruitment	O
maneuver	O
,	O
variables	O
of	O
blood	O
gas	B-ENZY
analysis	O
(	O
pH	O
,	O
PaO2	O
,	O
and	O
PaCO2	O
)	O
were	O
obtained	O
by	O
blood	O
gas	B-ENZY
analyzer	O
,	O
and	O
the	O
OI	O
values	O
were	O
calculated	O
;	O
hemodynamic	O
parameters	O
including	O
heart	O
rate	O
,	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
),	O
central	O
venous	O
pressure	O
(	O
CVP	O
)	O
of	O
all	O
patients	O
and	O
the	O
cardiac	O
output	O
(	O
CO	O
),	O
extravascular	O
lung	O
water	O
index	O
(	O
EVLWI	O
)	O
of	O
4	O
patients	O
who	O
received	O
pulse	O
contour	O
cardiac	O
output	O
(	O
PiCCO	O
)	O
monitoring	O
were	O
monitored	O
.	O

Tryptase	B-ENZY
levels	O
are	O
seldom	O
increased	O
because	O
of	O
infant	O
anaphylaxis	O
,	O
although	O
baseline	O
tryptase	B-ENZY
levels	O
can	O
be	O
increased	O
in	O
the	O
first	O
few	O
months	O
of	O
life	O
,	O
reflecting	O
mast	O
cell	O
burden	O
in	O
the	O
developing	O
immune	O
system	O
.	O

These	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
endosomal	O
cathepsins	O
,	O
cell	O
surface	O
transmembrane	O
protease	O
/	O
serine	O
(	O
TMPRSS	O
)	O
proteases	O
,	O
furin	B-ENZY
,	O
and	O
trypsin	B-ENZY
.	O

In	O
an	O
effort	O
to	O
assist	O
rapid	O
development	O
of	O
anti	O
-	O
coronavirus	O
drugs	O
,	O
here	O
we	O
screened	O
the	O
NIH	O
Clinical	O
Collection	O
in	O
cell	O
culture	O
using	O
a	O
luciferase	B-ENZY
reporter	O
-	O
expressing	O
recombinant	O
murine	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
simian	O
hemorrhagic	O
fever	O
virus	O
(	O
SHFV	O
)	O
genome	O
differs	O
from	O
those	O
of	O
other	O
members	O
of	O
the	O
family	O
Arteriviridae	O
in	O
encoding	O
three	O
papain	B-ENZY
-	O
like	O
one	O
proteases	O
(	O
PLP1	O
,	O
PLP1	O
and	O
PLP1	O
)	O
at	O
the	O
5	O
'	O
end	O
and	O
two	O
adjacent	O
sets	O
of	O
four	O
minor	O
structural	O
proteins	O
at	O
the	O
3	O
'	O
end	O
.	O

TITLE	O
:	O
The	O
SARS	O
coronavirus	O
papain	B-ENZY
like	O
protease	O
can	O
inhibit	O
IRF3	O
at	O
a	O
post	O
activation	O
step	O
that	O
requires	O
deubiquitination	O
activity	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
SARS	O
-	O
CoV	O
Papain	B-ENZY
-	O
like	O
Protease	O
(	O
PLpro	O
)	O
inhibits	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
by	O
inhibiting	O
IRF3	O
phosphorylation	O
thereby	O
blocking	O
downstream	O
Interferon	O
induction	O
.	O

bioinformatics	O
analysis	O
of	O
our	O
kinome	O
data	O
,	O
including	O
pathway	O
overrepresentation	O
analysis	O
(	O
ORA	O
)	O
and	O
functional	O
network	O
analysis	O
,	O
suggested	O
that	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
(	O
ERK	B-ENZY
)/	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
and	O
phosphoinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)/	O
serine	O
-	O
threonine	O
kinase	O
(	O
AKT	O
)/	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
signaling	O
responses	O
were	O
specifically	O
modulated	O
in	O
response	O
to	O
MERS	O
-	O
CoV	O
infection	O
in	O
vitro	O
throughout	O
the	O
course	O
of	O
infection	O
.	O

Further	O
,	O
we	O
have	O
demonstrated	O
that	O
a	O
subset	O
of	O
licensed	O
kinase	O
inhibitors	O
targeting	O
the	O
ERK	B-ENZY
/	O
MAPK	B-ENZY
and	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
pathways	O
significantly	O
inhibited	O
MERS	O
-	O
CoV	O
replication	O
in	O
vitro	O
whether	O
they	O
were	O
added	O
before	O
or	O
after	O
viral	O
infection	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
ERK	B-ENZY
/	O
MAPK	B-ENZY
and	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
signaling	O
responses	O
play	O
important	O
roles	O
in	O
MERS	O
-	O
CoV	O
infection	O
and	O
may	O
represent	O
novel	O
drug	O
targets	O
for	O
therapeutic	O
intervention	O
strategies	O
.	O

Despite	O
the	O
importance	O
of	O
bats	O
as	O
reservoir	O
hosts	O
of	O
zoonotic	O
and	O
potentially	O
zoonotic	O
agents	O
,	O
virtually	O
nothing	O
is	O
known	O
about	O
the	O
host	O
/	O
virus	O
relationships	O
;	O
principally	O
because	O
few	O
colonies	O
of	O
bats	O
are	O
available	O
for	O
experimental	O
infections	O
,	O
a	O
lack	O
of	O
reagents	O
,	O
methods	O
and	O
expertise	O
for	O
studying	O
bat	B-ENZY
antiviral	O
responses	O
and	O
immunology	O
,	O
and	O
the	O
difficulty	O
of	O
conducting	O
meaningful	O
field	O
work	O
.	O

TITLE	O
:	O
p53	O
degradation	O
by	O
a	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
suppresses	O
type	O
I	O
interferon	O
signaling	O
.	O

To	O
start	O
gaining	O
information	O
about	O
bat	B-ENZY
-	O
transmitted	O
viruses	O
in	O
Hungary	O
,	O
we	O
tested	O
multiple	O
bat	B-ENZY
species	O
for	O
several	O
virus	O
groups	O
between	O
2012	O
and	O
2013	O
.	O

Bat	B-ENZY
-	O
transmitted	O
astroviruses	O
(	O
BtAstV	O
)	O
were	O
detected	O
in	O
eight	O
species	O
with	O
a	O
6	O
.	O
93	O
%	O
detection	O
rate	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
4	O
.	O
854	O
,	O
9	O
.	O
571	O
).	O

Coronaviruses	O
(	O
BtCoV	O
)	O
were	O
detected	O
in	O
seven	O
bat	B-ENZY
species	O
with	O
a	O
detection	O
rate	O
of	O
1	O
.	O
79	O
%	O
(	O
95	O
%	O
CI	O
0	O
.	O
849	O
,	O
3	O
.	O
348	O
),	O
whereas	O
novel	O
caliciviruses	O
(	O
BtCalV	O
)	O
were	O
detected	O
in	O
three	O
bat	B-ENZY
species	O
with	O
a	O
detection	O
rate	O
of	O
0	O
.	O
67	O
%	O
(	O
95	O
%	O
CI	O
0	O
.	O
189	O
,	O
1	O
.	O
780	O
).	O

We	O
have	O
successfully	O
confirmed	O
BtCoVs	O
in	O
numerous	O
bat	B-ENZY
species	O
.	O

Furthermore	O
,	O
we	O
have	O
described	O
new	O
bat	B-ENZY
species	O
harboring	O
BtAstVs	O
in	O
Europe	O
and	O
found	O
new	O
species	O
of	O
CalVs	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
447	O
fecal	O
samples	O
,	O
representing	O
24	O
European	O
bat	B-ENZY
species	O
were	O
tested	O
.	O

ABSTRACT	O
:	O
Real	O
-	O
time	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
assays	O
have	O
been	O
used	O
to	O
detect	O
the	O
presence	O
of	O
challenge	O
virus	O
when	O
the	O
efficacy	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
vaccine	O
against	O
field	O
viruses	O
is	O
being	O
experimentally	O
evaluated	O
.	O

TITLE	O
:	O
Thiopurine	O
analogs	O
and	O
mycophenolic	O
acid	O
synergistically	O
inhibit	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

This	O
has	O
resulted	O
in	O
an	O
urgent	O
need	O
to	O
identify	O
antiviral	O
drugs	O
that	O
are	O
active	O
against	O
MERS	O
-	O
CoV	O
.	O
The	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	O
))	O
of	O
MERS	O
-	O
CoV	O
represents	O
an	O
important	O
antiviral	O
target	O
as	O
it	O
is	O
not	O
only	O
essential	O
for	O
viral	O
maturation	O
,	O
but	O
also	O
antagonizes	O
interferon	O
stimulation	O
of	O
the	O
host	O
via	O
its	O
deubiquitination	O
activity	O
.	O

TITLE	O
:	O
Development	O
of	O
transgenic	O
mouse	O
model	O
expressing	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
and	O
its	O
susceptibility	O
to	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Since	O
the	O
only	O
endosomal	O
requirement	O
for	O
SARS	O
entry	O
is	O
cathepsin	B-ENZY
L	I-ENZY
activity	O
,	O
we	O
tested	O
and	O
provide	O
evidence	O
that	O
NPC1	O
(+)	O
LE	O
/	O
Lys	O
have	O
higher	O
cathepsin	B-ENZY
L	I-ENZY
activity	O
than	O
LE	O
,	O
with	O
no	O
detectable	O
activity	O
in	O
earlier	O
endosomes	O
.	O

TITLE	O
:	O
The	O
SARS	O
-	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
:	O
structure	O
,	O
function	O
and	O
inhibition	O
by	O
designed	O
antiviral	O
compounds	O
.	O

Values	O
for	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
),	O
bilirubin	O
,	O
platelets	O
(	O
Plt	O
),	O
urea	O
,	O
and	O
creatinine	O
at	O
0	O
,	O
8	O
,	O
16	O
,	O
24	O
,	O
48	O
,	O
and	O
72	O
hours	O
postpartum	O
in	O
both	O
groups	O
were	O
analyzed	O
and	O
compared	O
.	O

Women	O
with	O
HELLP	O
syndrome	O
without	O
clear	O
Plt	O
and	O
AST	B-ENZY
improvement	O
in	O
the	O
first	O
48	O
hours	O
and	O
with	O
acute	O
kidney	O
injury	O
,	O
neurological	O
impairment	O
,	O
or	O
respiratory	O
distress	O
syndrome	O
are	O
at	O
risk	O
of	O
progressing	O
to	O
PTMS	O
.	O

ABSTRACT	O
:	O
Mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
develop	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	B-ENZY
hydrolase	I-ENZY
(	O
FAH	O
)	O
with	O
a	O
concomitant	O
enhancement	O
of	O
transaminases	O
and	O
release	O
of	O
alarmins	O
such	O
as	O
uric	O
acid	O
and	O
high	O
-	O
mobility	O
group	O
box	O
protein	O
1	O
(	O
HMGB1	O
).	O

On	O
the	O
other	O
hand	O
,	O
the	O
ability	O
of	O
Aah	O
venom	O
to	O
increase	O
vascular	O
permeability	O
and	O
to	O
induce	O
edema	O
was	O
also	O
assessed	O
by	O
measuring	O
the	O
amount	O
of	O
Evans	O
blue	O
dye	O
(	O
EBD	O
)	O
extravasation	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
and	O
in	O
the	O
lungs	O
of	O
mice	O
.	O

TITLE	O
:	O
Structural	O
view	O
and	O
substrate	O
specificity	O
of	O
papain	B-ENZY
-	O
like	O
protease	O
from	O
avian	O
infectious	O
bronchitis	O
virus	O
.	O

ABSTRACT	O
:	O
Papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
of	O
coronaviruses	O
(	O
CoVs	O
)	O
carries	O
out	O
proteolytic	O
maturation	O
of	O
non	O
-	O
structural	O
proteins	O
that	O
play	O
a	O
role	O
in	O
replication	O
of	O
the	O
virus	O
and	O
performs	O
deubiquitination	O
of	O
host	O
cell	O
factors	O
to	O
scuttle	O
antiviral	O
responses	O
.	O

ABSTRACT	O
:	O
The	O
design	O
and	O
evaluation	O
of	O
a	O
novel	O
decahydroisoquinolin	O
scaffold	O
as	O
an	O
inhibitor	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
))	O
are	O
described	O
.	O

HIV	O
-	O
1	O
integrase	O
(	O
IN	O
)	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
associated	O
ribonuclease	B-ENZY
H	I-ENZY
(	O
RNase	B-ENZY
H	I-ENZY
)	O
are	O
both	O
selective	O
targets	O
for	O
HIV	O
-	O
1	O
chemotherapy	O
,	O
and	O
the	O
identification	O
of	O
dual	O
IN	O
/	O
RNase	B-ENZY
H	I-ENZY
inhibitors	O
is	O
an	O
attractive	O
strategy	O
for	O
new	O
drug	O
development	O
.	O

ABSTRACT	O
:	O
We	O
report	O
an	O
extremely	O
rare	O
case	O
of	O
pulmonary	O
lipiodol	O
embolism	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
after	O
transcatheter	O
arterial	O
chemoembolization	O
(	O
TACE	B-ENZY
)	O
for	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
).	O

A	O
77	O
-	O
year	O
-	O
old	O
man	O
who	O
was	O
diagnosed	O
with	O
a	O
huge	O
HCC	O
was	O
admitted	O
for	O
TACE	B-ENZY
.	O

We	O
suspected	O
that	O
his	O
symptoms	O
were	O
associated	O
with	O
a	O
pulmonary	O
lipiodol	O
embolism	O
after	O
TACE	B-ENZY
,	O
and	O
we	O
began	O
intensive	O
treatment	O
.	O

Phylogenetic	O
analysis	O
suggested	O
that	O
these	O
bat	B-ENZY
CoVs	O
are	O
related	O
to	O
members	O
of	O
the	O
genus	O
Betacoronavirus	O
.	O

TITLE	O
:	O
Insulated	O
Isothermal	O
Reverse	B-ENZY
Transcriptase	I-ENZY
PCR	O
(	O
iiRT	O
-	O
PCR	O
)	O
for	O
Rapid	O
and	O
Sensitive	O
Detection	O
of	O
Classical	O
Swine	O
Fever	O
Virus	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
validation	O
of	O
a	O
new	O
probe	O
-	O
based	O
insulated	O
isothermal	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
(	O
iiRT	O
-	O
PCR	O
)	O
assay	O
for	O
rapid	O
detection	O
of	O
classical	O
swine	O
fever	O
virus	O
(	O
CSFV	O
)	O
on	O
a	O
compact	O
,	O
user	O
-	O
friendly	O
device	O
(	O
POCKIT	O
()	O
Nucleic	O
Acid	O
Analyzer	O
)	O
that	O
does	O
not	O
need	O
data	O
interpretation	O
by	O
the	O
user	O
.	O

Several	O
CoVs	O
sequences	O
clustered	O
near	O
previously	O
described	O
CoVs	O
from	O
the	O
same	O
species	O
of	O
bat	B-ENZY
,	O
but	O
were	O
phylogenetically	O
distant	O
from	O
the	O
human	O
CoV	O
sequences	O
identified	O
to	O
date	O
,	O
suggesting	O
no	O
recent	O
spillover	O
events	O
.	O

The	O
Glossophaga	O
soricina	O
CoV	O
sequence	O
is	O
sufficiently	O
dissimilar	O
(	O
26	O
%	O
homology	O
to	O
the	O
closest	O
known	O
bat	B-ENZY
CoVs	O
)	O
to	O
represent	O
a	O
unique	O
coronavirus	O
not	O
clustering	O
near	O
other	O
CoVs	O
found	O
in	O
the	O
same	O
bat	B-ENZY
species	O
so	O
far	O
,	O
implying	O
an	O
even	O
higher	O
CoV	O
diversity	O
than	O
previously	O
suspected	O
.	O

Faecal	O
specimens	O
from	O
1283	O
calves	O
were	O
scored	O
as	O
liquid	O
,	O
semi	O
-	O
solid	O
or	O
solid	O
,	O
and	O
analysed	O
for	O
bovine	O
rotavirus	O
(	O
BRV	O
)	O
and	O
coronavirus	O
(	O
BCV	O
),	O
enterotoxigenic	O
K99	O
(+)	O
Escherichia	O
coli	O
(	O
K99	O
),	O
Salmonella	O
spp	B-ENZY
.	O

ABSTRACT	O
:	O
In	O
addition	O
to	O
transporting	O
ions	O
,	O
the	O
multisubunit	O
Na	O
(+),	O
K	O
(+)-	O
ATPase	B-ENZY
also	O
functions	O
by	O
relaying	O
cardiotonic	O
steroid	O
(	O
CTS	O
)-	O
binding	O
-	O
induced	O
signals	O
into	O
cells	O
.	O

Consistently	O
,	O
nanomolar	O
concentrations	O
of	O
the	O
cardiotonic	O
steroids	O
ouabain	O
and	O
bufalin	O
,	O
which	O
are	O
known	O
not	O
to	O
affect	O
the	O
transport	O
function	O
of	O
Na	O
(+),	O
K	O
(+)-	O
ATPase	B-ENZY
,	O
inhibited	O
infection	O
of	O
cells	O
with	O
MHV	O
,	O
FIPV	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
CoV	O
,	O
and	O
VSV	O
,	O
but	O
not	O
IAV	O
,	O
when	O
the	O
compounds	O
were	O
present	O
during	O
virus	O
inoculation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
the	O
ATP1A1	O
subunit	O
of	O
Na	O
(+),	O
K	O
(+)-	O
ATPase	B-ENZY
,	O
an	O
ion	O
transporter	O
and	O
signaling	O
transducer	O
,	O
supports	O
CoV	O
infection	O
.	O

These	O
results	O
suggest	O
that	O
targeting	O
the	O
Na	O
(+),	O
K	O
(+)-	O
ATPase	B-ENZY
using	O
cardiotonic	O
steroids	O
,	O
several	O
of	O
which	O
are	O
FDA	O
-	O
approved	O
compounds	O
,	O
may	O
be	O
an	O
attractive	O
therapeutic	O
approach	O
against	O
CoV	O
and	O
VSV	O
infections	O
.	O

The	O
UPLC	O
-	O
DAD	O
method	O
was	O
evaluated	O
with	O
linearity	O
,	O
limit	O
of	O
detection	O
(	O
LOD	B-ENZY
),	O
limit	O
of	O
quantification	O
(	O
LOQ	O
),	O
precision	O
,	O
stability	O
,	O
repeatability	O
,	O
and	O
recovery	O
tests	O
.	O

MERS	O
-	O
CoV	O
sequences	O
have	O
since	O
been	O
found	O
in	O
a	O
bat	B-ENZY
and	O
the	O
virus	O
appears	O
to	O
be	O
enzootic	O
among	O
dromedary	O
camels	O
across	O
the	O
Arabian	O
Peninsula	O
and	O
in	O
parts	O
of	O
Africa	O
.	O

High	O
frequency	O
oscillatory	O
ventilation	O
is	O
an	O
alternative	O
form	O
of	O
mechanical	O
ventilation	O
with	O
some	O
attractive	O
features	O
in	O
respect	O
to	O
attempting	O
to	O
improve	O
gas	B-ENZY
exchange	O
limiting	O
ventilator	O
induced	O
lung	O
injury	O
.	O

These	O
events	O
involve	O
structural	O
rearrangements	O
,	O
including	O
heteromerization	O
between	O
two	O
heptad	O
repeats	O
(	O
HR1	O
and	O
HR2	O
)	O
to	O
form	O
a	O
trimer	O
of	O
dimers	O
as	O
a	O
six	O
-	O
helix	O
bundle	O
(	O
6	O
-	O
HB	O
),	O
a	O
quaternary	O
protein	O
structure	O
that	O
brings	O
two	O
distant	O
clusters	O
of	O
hydrophobic	O
sequences	O
into	O
the	O
proximity	O
of	O
each	O
other	O
,	O
the	O
internal	O
fusion	O
peptide	O
(	O
IFP	O
)	O
preceding	O
HR1	O
,	O
and	O
the	O
highly	O
conserved	O
tryptophan	O
(	O
Trp	B-ENZY
)-	O
rich	O
membrane	O
proximal	O
external	O
region	O
(	O
MPER	O
)	O
following	O
HR2	O
.	O

To	O
delineate	O
the	O
roles	O
of	O
Trp	B-ENZY
residues	O
of	O
MPER	O
in	O
forming	O
these	O
quaternary	O
structures	O
and	O
interacting	O
with	O
membranes	O
,	O
we	O
employed	O
a	O
panel	O
of	O
synthetic	O
peptides	O
:	O
MPER	O
peptide	O
(	O
M	O
-	O
wt	O
)	O
and	O
its	O
alanine	O
(	O
Ala	O
)	O
and	O
phenylalanine	O
(	O
Phe	O
)	O
analogues	O
.	O

Ala	O
substitutions	O
of	O
Trp	B-ENZY
inhibited	O
its	O
association	O
with	O
cellular	O
membranes	O
.	O

Triple	O
-	O
Ala	O
substitutions	O
of	O
Trp	B-ENZY
in	O
M	O
-	O
wt	O
,	O
but	O
not	O
the	O
corresponding	O
triple	O
-	O
Phe	O
analogue	O
,	O
disrupted	O
oligomerization	O
of	O
M	O
-	O
wt	O
and	O
hetero	O
-	O
oligomerization	O
of	O
M	O
-	O
wt	O
with	O
IFP23	O
.	O

Overall	O
,	O
our	O
results	O
show	O
that	O
Trp	B-ENZY
residues	O
of	O
MPER	O
play	O
a	O
key	O
role	O
in	O
maintaining	O
the	O
structure	O
and	O
functions	O
of	O
MPER	O
,	O
allowing	O
it	O
to	O
interact	O
with	O
IFP	O
to	O
form	O
a	O
MPER	O
-	O
IFP	O
heteromer	O
,	O
a	O
putative	O
quaternary	O
structure	O
extending	O
from	O
the	O
6	O
-	O
HB	O
,	O
and	O
function	O
in	O
membrane	O
fusion	O
.	O

The	O
hemodynamics	O
were	O
monitored	O
by	O
pulse	O
-	O
indicated	O
continuous	O
cardiac	O
output	O
(	O
PiCCO	O
)	O
and	O
the	O
airway	O
pressure	O
changes	O
and	O
blood	O
gas	B-ENZY
analysis	O
indexes	O
were	O
recorded	O
at	O
different	O
time	O
points	O
.	O

TITLE	O
:	O
Molecular	O
characterization	O
of	O
RIG	O
-	O
I	O
,	O
STAT	O
-	O
1	O
and	O
IFN	O
-	O
beta	O
in	O
the	O
horseshoe	O
bat	B-ENZY
.	O

Our	O
results	O
demonstrated	O
that	O
bat	B-ENZY
RIG	O
-	O
I	O
,	O
STAT	O
-	O
1	O
and	O
IFN	O
-	O
	O
showed	O
close	O
homology	O
with	O
human	O
,	O
mouse	O
,	O
pig	O
and	O
rhesus	O
monkey	O
.	O

RIG	O
-	O
I	O
and	O
STAT	O
-	O
1	O
were	O
both	O
highly	O
expressed	O
in	O
bat	B-ENZY
spleen	O
.	O

Furthermore	O
,	O
IFN	O
-	O
	O
was	O
induced	O
by	O
polyI	O
:	O
C	O
and	O
VSV	O
in	O
both	O
bat	B-ENZY
and	O
mouse	O
cells	O
.	O

These	O
findings	O
have	O
provided	O
new	O
insight	O
into	O
the	O
potential	O
characteristics	O
of	O
the	O
bat	B-ENZY
innate	O
immune	O
system	O
against	O
viral	O
infection	O
.	O

TITLE	O
:	O
Chalcones	O
isolated	O
from	O
Angelica	O
keiskei	O
inhibit	O
cysteine	O
proteases	O
of	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Two	O
viral	O
proteases	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
a	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
))	O
and	O
a	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	O
))	O
are	O
attractive	O
targets	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	O
drugs	O
.	O

Structural	O
studies	O
of	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLP	O
)	O
domains	O
of	O
coronaviruses	O
(	O
CoVs	O
)	O
revealed	O
an	O
adjacent	O
Ubl	O
domain	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
CoV	O
,	O
and	O
the	O
murine	O
CoV	O
,	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

We	O
asked	O
if	O
changes	O
in	O
the	O
Ubl	O
domain	O
,	O
a	O
conserved	O
domain	O
adjacent	O
to	O
the	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
,	O
altered	O
the	O
viral	O
protease	O
activity	O
or	O
affected	O
viral	O
replication	O
or	O
pathogenesis	O
.	O

TITLE	O
:	O
Arbekacin	O
treatment	O
of	O
a	O
patient	O
infected	O
with	O
a	O
Pseudomonas	O
putida	O
producing	O
a	O
metallo	O
-	O
beta	B-ENZY
-	I-ENZY
lactamase	I-ENZY
.	O

Arbekacin	O
,	O
a	O
relatively	O
new	O
aminoglycoside	O
,	O
is	O
effective	O
against	O
Pseudomonas	O
spp	B-ENZY
.	O

We	O
encountered	O
a	O
case	O
of	O
pneumonia	O
caused	O
by	O
a	O
Pseudomonas	O
strain	O
producing	O
a	O
metallo	O
-	O
beta	B-ENZY
-	I-ENZY
lactamase	I-ENZY
;	O
the	O
patient	O
was	O
successfully	O
treated	O
with	O
arbekacin	O
.	O

The	O
causative	O
organism	O
was	O
a	O
strain	O
of	O
Pseudomonas	O
putida	O
that	O
produced	O
a	O
metallo	O
-	O
beta	B-ENZY
-	I-ENZY
lactamase	I-ENZY
.	O

TITLE	O
:	O
Using	O
common	O
spatial	O
distributions	O
of	O
atoms	O
to	O
relate	O
functionally	O
divergent	O
influenza	O
virus	O
N10	O
and	O
N11	O
protein	O
structures	O
to	O
functionally	O
characterized	O
neuraminidase	B-ENZY
structures	O
,	O
toxin	O
cell	O
entry	O
domains	O
,	O
and	O
non	O
-	O
influenza	O
virus	O
cell	O
entry	O
domains	O
.	O

We	O
identified	O
atoms	O
with	O
common	O
distributed	O
spatial	O
occupancy	O
in	O
PDB	O
structures	O
of	O
N10	O
protein	O
,	O
N11	O
protein	O
,	O
an	O
influenza	O
A	O
neuraminidase	B-ENZY
,	O
an	O
influenza	O
B	O
neuraminidase	B-ENZY
,	O
and	O
a	O
bacterial	O
neuraminidase	B-ENZY
.	O

Spatially	O
invariant	O
residues	O
in	O
the	O
N6	O
and	O
influenza	O
B	O
neuraminidase	B-ENZY
active	O
sites	O
were	O
found	O
in	O
previously	O
unidentified	O
spatially	O
equivalent	O
sites	O
in	O
the	O
N10	O
and	O
N11	O
proteins	O
.	O

We	O
found	O
structural	O
precedent	O
in	O
known	O
non	O
-	O
neuraminidase	B-ENZY
structures	O
for	O
residues	O
exhibiting	O
structural	O
and	O
sequence	O
divergence	O
in	O
the	O
aligned	O
structures	O
.	O

The	O
presence	O
of	O
active	O
site	O
components	O
common	O
to	O
the	O
N6	O
,	O
influenza	O
B	O
,	O
and	O
S	O
.	O
pneumoniae	O
neuraminidases	O
in	O
the	O
N10	O
and	O
N11	O
proteins	O
,	O
combined	O
with	O
the	O
absence	O
of	O
apparent	O
neuraminidase	B-ENZY
function	O
,	O
suggests	O
that	O
the	O
role	O
of	O
neuraminidases	O
in	O
H17N10	O
and	O
H18N11	O
emerging	O
influenza	O
A	O
viruses	O
may	O
have	O
changed	O
.	O

The	O
presentation	O
of	O
E2S	O
-	O
like	O
,	O
SARS	O
spike	O
protein	O
-	O
like	O
,	O
or	O
toxin	O
-	O
like	O
domains	O
by	O
the	O
N10	O
and	O
N11	O
proteins	O
in	O
these	O
emerging	O
viruses	O
may	O
indicate	O
that	O
H17N10	O
and	O
H18N11	O
sialidase	B-ENZY
-	O
facilitated	O
cell	O
entry	O
has	O
been	O
supplemented	O
or	O
replaced	O
by	O
sialidase	B-ENZY
-	O
independent	O
receptor	O
binding	O
to	O
an	O
expanded	O
cell	O
population	O
that	O
may	O
include	O
neurons	O
and	O
T	O
-	O
cells	O
.	O

To	O
determine	O
whether	O
the	O
utilization	O
of	O
cathepsins	O
by	O
bat	B-ENZY
-	O
borne	O
viruses	O
is	O
related	O
to	O
the	O
nature	O
of	O
proteases	O
in	O
their	O
natural	O
hosts	O
,	O
we	O
examined	O
proteolytic	O
processing	O
of	O
several	O
viral	O
fusion	O
proteins	O
in	O
cells	O
derived	O
from	O
two	O
fruit	O
bat	B-ENZY
species	O
,	O
Pteropus	O
alecto	O
and	O
Rousettus	O
aegyptiacus	O
.	O

Our	O
work	O
shows	O
that	O
fruit	O
bat	B-ENZY
cells	O
have	O
homologs	O
of	O
cathepsin	O
and	O
furin	B-ENZY
proteases	O
capable	O
of	O
cleaving	O
and	O
activating	O
both	O
the	O
cathepsin	O
-	O
dependent	O
Hendra	O
virus	O
F	O
and	O
the	O
furin	B-ENZY
-	O
dependent	O
parainfluenza	O
virus	O
5	O
F	O
proteins	O
.	O

However	O
,	O
kinetic	O
analysis	O
suggests	O
that	O
differences	O
may	O
exist	O
in	O
the	O
cellular	O
localization	O
of	O
furin	B-ENZY
between	O
different	O
species	O
.	O

Collectively	O
,	O
these	O
results	O
indicate	O
that	O
the	O
unusual	O
role	O
of	O
cathepsin	O
proteases	O
in	O
the	O
life	O
cycle	O
of	O
bat	B-ENZY
-	O
borne	O
viruses	O
is	O
not	O
due	O
to	O
the	O
lack	O
of	O
active	O
furin	B-ENZY
-	O
like	O
proteases	O
in	O
these	O
natural	O
reservoir	O
species	O
;	O
however	O
,	O
differences	O
may	O
exist	O
between	O
furin	B-ENZY
proteases	O
present	O
in	O
fruit	O
bats	O
compared	O
to	O
furins	O
in	O
other	O
mammalian	O
species	O
,	O
and	O
these	O
differences	O
may	O
impact	O
protease	O
usage	O
for	O
viral	O
glycoprotein	O
processing	O
.	O

A	O
technique	O
for	O
the	O
preparation	O
of	O
such	O
cell	O
cultures	O
,	O
using	O
a	O
combination	O
of	O
manual	O
and	O
trypsin	B-ENZY
disaggregation	O
of	O
kidneys	O
dissected	O
from	O
2	O
-	O
to	O
3	O
-	O
week	O
-	O
old	O
birds	O
is	O
described	O
.	O

Arterial	O
blood	O
gas	B-ENZY
analysis	O
was	O
done	O
before	O
and	O
after	O
iNO	O
treatment	O
.	O

TITLE	O
:	O
(	O
3Z	O
)-	O
3	O
-(	O
2	O
-[	O
4	O
-(	O
aryl	O
)-	O
1	O
,	O
3	O
-	O
thiazol	O
-	O
2	O
-	O
yl	O
]	O
hydrazin	O
-	O
1	O
-	O
ylidene	O
)-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1H	O
-	O
indol	O
-	O
2	O
-	O
one	O
derivatives	O
as	O
dual	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
.	O

These	O
compounds	O
are	O
active	O
towards	O
both	O
RT	O
-	O
associated	O
functions	O
,	O
DNA	O
polymerase	O
and	O
ribonuclease	B-ENZY
H	I-ENZY
.	O
The	O
structure	O
,	O
biological	O
activity	O
and	O
mode	O
of	O
action	O
of	O
the	O
new	O
derivatives	O
have	O
been	O
investigated	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
sensitivity	O
and	O
specificity	O
of	O
a	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
)	O
detecting	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
RNA	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
of	O
cats	O
with	O
and	O
without	O
neurological	O
and	O
/	O
or	O
ocular	O
signs	O
for	O
the	O
diagnosis	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

TITLE	O
:	O
From	O
the	O
traditional	O
Chinese	O
medicine	O
plant	O
Schisandra	O
chinensis	O
new	O
scaffolds	O
effective	O
on	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
resistant	O
to	O
non	O
-	O
nucleoside	O
inhibitors	O
.	O

TITLE	O
:	O
Inhibitor	O
recognition	O
specificity	O
of	O
MERS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
may	O
differ	O
from	O
that	O
of	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
The	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
blocking	O
loop	O
2	O
(	O
BL2	O
)	O
structure	O
differs	O
significantly	O
from	O
that	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
,	O
where	O
it	O
has	O
been	O
proven	O
to	O
play	O
a	O
crucial	O
role	O
in	O
SARS	O
-	O
CoV	O
PLpro	O
inhibitor	O
binding	O
.	O

ABSTRACT	O
:	O
A	O
32	O
-	O
nucleotide	O
(	O
nt	O
)	O
RNA	O
motif	O
located	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
genome	O
was	O
found	O
to	O
specifically	O
interact	O
with	O
the	O
host	O
proteins	O
glutamyl	O
-	O
prolyl	B-ENZY
-	I-ENZY
tRNA	I-ENZY
synthetase	I-ENZY
(	O
EPRS	O
)	O
and	O
arginyl	B-ENZY
-	I-ENZY
tRNA	I-ENZY
synthetase	I-ENZY
(	O
RRS	O
).	O

Seafarers	O
were	O
poisoned	O
by	O
phosphine	O
gas	B-ENZY
spreading	O
through	O
cabins	O
above	O
the	O
hold	O
.	O

Fumigation	O
performed	O
using	O
this	O
gas	B-ENZY
needs	O
to	O
be	O
done	O
with	O
extreme	O
care	O
.	O

Whether	O
higher	O
than	O
standard	O
doses	O
of	O
neuraminidase	B-ENZY
inhibitor	O
would	O
provide	O
greater	O
antiviral	O
effects	O
in	O
such	O
patients	O
requires	O
further	O
investigation	O
.	O

The	O
di	O
-	O
distributive	O
cleavage	O
mechanism	O
for	O
SARS	O
PLpro	O
appears	O
to	O
be	O
uncommon	O
among	O
USP	B-ENZY
(	O
Ub	O
-	O
specific	O
protease	O
)-	O
family	O
DUBs	O
,	O
as	O
related	O
USP	B-ENZY
family	O
members	O
from	O
humans	O
do	O
not	O
display	O
such	O
a	O
mechanism	O
.	O

TITLE	O
:	O
Eucalyptol	O
suppresses	O
matrix	O
metalloproteinase	O
-	O
9	O
expression	O
through	O
an	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
-	O
dependent	O
nuclear	O
factor	O
-	O
kappa	O
B	O
pathway	O
to	O
exert	O
anti	O
-	O
inflammatory	O
effects	O
in	O
an	O
acute	O
lung	O
inflammation	O
model	O
.	O

Eucalyptol	O
attenuated	O
inflammation	O
-	O
associated	O
increases	O
in	O
cell	O
numbers	O
,	O
matrix	O
metalloproteinase	O
-	O
9	O
(	O
MMP	O
-	O
9	O
)	O
expression	O
,	O
production	O
of	O
cytokines	O
(	O
tumour	O
necrosis	O
factor	O
-	O
	O
and	O
interleukin	O
-	O
6	O
)	O
and	O
nitric	O
oxide	O
,	O
and	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
B	O
)	O
and	O
phosphorylated	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
protein	O
levels	O
induced	O
by	O
LPS	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
from	O
ALI	O
mice	O
.	O

Collectively	O
,	O
these	O
results	O
indicate	O
that	O
eucalyptol	O
acts	O
through	O
a	O
mechanism	O
involving	O
decreased	O
MMP	O
-	O
9	O
expression	O
and	O
an	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
-	O
dependent	O
NF	O
-	O
B	O
pathway	O
to	O
exert	O
anti	O
-	O
inflammatory	O
actions	O
in	O
acute	O
lung	O
inflammation	O
.	O

Among	O
the	O
disease	O
-	O
related	O
functions	O
,	O
certain	O
anti	O
-	O
viral	O
pathways	O
and	O
proteins	O
,	O
such	O
as	O
the	O
RIG	O
-	O
I	O
-	O
like	O
receptor	O
,	O
Rap1	O
,	O
autophagy	O
,	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
,	O
PI3K	O
-	O
Akt	O
and	O
Jak	O
-	O
STAT	O
signaling	O
pathways	O
,	O
and	O
integrin	O
2	O
/	O
3	O
and	O
cystatin	O
-	O
C	O
proteins	O
,	O
represented	O
potential	O
factors	O
in	O
PEDV	O
infection	O
.	O

PEDV	O
recognizes	O
protein	O
receptor	O
aminopeptidase	B-ENZY
N	I-ENZY
from	O
pig	O
and	O
human	O
and	O
sugar	O
coreceptor	O
N	O
-	O
acetylneuraminic	O
acid	O
.	O

Moreover	O
,	O
PEDV	O
infects	O
cells	O
from	O
pig	O
,	O
human	O
,	O
monkey	O
,	O
and	O
bat	B-ENZY
.	O

Protective	O
ventilation	O
was	O
applied	O
,	O
and	O
RM	O
consisted	O
of	O
the	O
application	O
of	O
40	O
cmH2O	O
airway	O
pressure	O
for	O
40	O
s	O
.	O
Arterial	O
blood	O
was	O
sampled	O
for	O
gas	B-ENZY
analyses	O
and	O
sRAGE	O
measurements	O
,	O
5	O
min	O
pre	O
-	O
RM	O
(	O
or	O
40	O
-	O
s	O
-	O
long	O
sham	O
period	O
),	O
5	O
,	O
30	O
min	O
,	O
1	O
,	O
4	O
,	O
and	O
6	O
h	O
after	O
the	O
RM	O
(	O
or	O
40	O
-	O
s	O
-	O
long	O
sham	O
period	O
).	O

nsp3	O
comprises	O
multiple	O
structural	O
domains	O
,	O
including	O
two	O
papain	B-ENZY
-	O
like	O
proteases	O
(	O
PLPs	O
)	O
and	O
a	O
highly	O
conserved	O
ADP	O
-	O
ribose	O
-	O
1	O
-	O
phosphatase	O
(	O
ADRP	O
)	O
macrodomain	O
.	O

Canine	O
parainfluenza	O
virus	O
(	O
CPIV	O
),	O
canine	O
adenovirus	O
,	O
canine	O
herpes	O
virus	O
,	O
canine	O
influenzavirus	O
,	O
canine	O
distemper	O
virus	O
,	O
canine	O
respiratory	O
coronavirus	O
(	O
CRCoV	O
)	O
and	O
canine	O
pneumovirus	O
,	O
as	O
well	O
as	O
B	O
.	O
bronchiseptica	O
and	O
Mycoplasma	O
spp	B-ENZY
.	O
were	O
analyzed	O
in	O
respiratory	O
samples	O
using	O
PCR	O
assays	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
the	O
possible	O
presence	O
of	O
oxidative	O
stress	O
in	O
cats	O
naturally	O
affected	O
by	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
by	O
investigating	O
two	O
antioxidant	O
biomarkers	O
in	O
serum	O
:	O
paraoxonase	B-ENZY
-	O
1	O
(	O
PON1	O
)	O
and	O
total	O
antioxidant	O
capacity	O
(	O
TAC	O
).	O

ABSTRACT	O
:	O
Objective	O
Fibre	O
-	O
optic	O
bronchoscopy	O
with	O
bronchoalveolar	O
lavage	O
(	O
FOB	O
-	O
BAL	B-ENZY
)	O
is	O
an	O
important	O
tool	O
for	O
diagnosing	O
and	O
selecting	O
treatment	O
for	O
acutely	O
hypoxaemic	O
patients	O
with	O
diffuse	O
lung	O
infiltrates	O
.	O

However	O
,	O
FOB	O
-	O
BAL	B-ENZY
carries	O
a	O
risk	O
of	O
significant	O
hypoxaemia	O
and	O
subsequent	O
tracheal	O
intubation	O
during	O
and	O
after	O
the	O
procedure	O
.	O

The	O
application	O
of	O
FOB	O
-	O
BAL	B-ENZY
using	O
a	O
laryngeal	O
mask	O
airway	O
(	O
LMA	O
)	O
in	O
combination	O
with	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
may	O
minimize	O
the	O
incidence	O
of	O
hypoxaemia	O
;	O
however	O
,	O
the	O
safety	O
and	O
efficacy	O
of	O
this	O
procedure	O
have	O
not	O
been	O
investigated	O
.	O

Data	O
regarding	O
the	O
recovered	O
volume	O
of	O
BAL	B-ENZY
fluid	O
,	O
incidence	O
of	O
tracheal	O
intubation	O
within	O
eight	O
hours	O
after	O
the	O
completion	O
of	O
FOB	O
-	O
BAL	B-ENZY
,	O
respiratory	O
and	O
haemodynamic	O
parameters	O
and	O
treatment	O
modifications	O
were	O
collected	O
for	O
the	O
evaluation	O
.	O

Results	O
Ten	O
trials	O
of	O
FOB	O
-	O
BAL	B-ENZY
using	O
an	O
LMA	O
and	O
CPAP	O
were	O
performed	O
in	O
nine	O
patients	O
with	O
severe	O
acute	O
hypoxaemia	O
associated	O
with	O
diffuse	O
lung	O
infiltrates	O
.	O

The	O
BAL	B-ENZY
fluid	O
recovery	O
rate	O
was	O
56	O
%,	O
and	O
the	O
procedure	O
was	O
completed	O
without	O
subsequent	O
complications	O
.	O

Proteins	O
,	O
such	O
as	O
HIV	O
-	O
1	O
trans	O
-	O
activator	O
of	O
transcription	O
(	O
TAT	B-ENZY
)	O
and	O
Antennapedia	O
homeodomain	O
protein	O
,	O
are	O
capable	O
of	O
crossing	O
cellular	O
membranes	O
.	O

TITLE	O
:	O
Risk	O
factors	O
for	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
after	O
cardiac	O
surgery	O
.	O

Fifteen	O
patients	O
had	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
2	O
%),	O
199	O
(	O
27	O
.	O
75	O
%)	O
had	O
mild	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
,	O
402	O
(	O
56	O
.	O
1	O
%)	O
had	O
moderate	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
,	O
and	O
39	O
(	O
5	O
.	O
4	O
%)	O
had	O
severe	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
.	O

Pneumonia	O
was	O
present	O
in	O
8	O
.	O
9	O
%	O
of	O
cases	O
and	O
correlated	O
with	O
the	O
presence	O
of	O
moderate	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
(	O
P	O
=	O
0	O
.	O
001	O
).	O

Severe	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
was	O
associated	O
with	O
patients	O
who	O
had	O
renal	O
replacement	O
therapy	O
(	O
P	O
=	O
0	O
.	O
0005	O
),	O
hemotherapy	O
(	O
P	O
=	O
0	O
.	O
0001	O
),	O
enteral	O
nutrition	O
(	O
P	O
=	O
0	O
.	O
0012	O
),	O
or	O
cardiac	O
arrhythmia	O
(	O
P	O
=	O
0	O
.	O
0451	O
).	O

Preoperative	O
hypertension	O
and	O
cardiogenic	O
shock	O
were	O
associated	O
with	O
the	O
occurrence	O
of	O
postoperative	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
.	O

Postoperatively	O
,	O
pneumonia	O
,	O
ventilator	O
-	O
associated	O
pneumonia	O
,	O
renal	O
replacement	O
therapy	O
,	O
hemotherapy	O
,	O
and	O
cardiac	O
arrhythmia	O
were	O
associated	O
with	O
the	O
appearance	O
of	O
some	O
degree	O
of	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
,	O
which	O
was	O
a	O
risk	O
factor	O
for	O
reintubation	O
,	O
pneumonia	O
,	O
ventilator	O
-	O
associated	O
pneumonia	O
,	O
and	O
renal	O
replacement	O
therapy	O
in	O
the	O
postoperative	O
period	O
of	O
cardiac	O
surgery	O
and	O
cardiac	O
procedures	O
.	O

RESULTS	O
:	O
Fifteen	O
patients	O
had	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
2	O
%),	O
199	O
(	O
27	O
.	O
75	O
%)	O
had	O
mild	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
,	O
402	O
(	O
56	O
.	O
1	O
%)	O
had	O
moderate	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
,	O
and	O
39	O
(	O
5	O
.	O
4	O
%)	O
had	O
severe	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
.	O

CONCLUSIONS	O
:	O
Preoperative	O
hypertension	O
and	O
cardiogenic	O
shock	O
were	O
associated	O
with	O
the	O
occurrence	O
of	O
postoperative	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
.	O

ABSTRACT	O
:	O
Bats	O
are	O
reservoirs	O
for	O
a	O
diverse	O
range	O
of	O
coronaviruses	O
(	O
CoVs	O
),	O
including	O
those	O
closely	O
related	O
to	O
human	O
pathogens	O
such	O
as	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
CoV	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	O
CoV	O
.	O
There	O
are	O
approximately	O
139	O
bat	B-ENZY
species	O
reported	O
to	O
date	O
in	O
Thailand	O
,	O
of	O
which	O
two	O
are	O
endemic	O
species	O
.	O

A	O
total	O
of	O
626	O
bats	O
from	O
19	O
different	O
bat	B-ENZY
species	O
were	O
individually	O
sampled	O
from	O
5	O
provinces	O
in	O
Eastern	O
Thailand	O
between	O
2008	O
and	O
2013	O
(	O
84	O
fecal	O
and	O
542	O
rectal	O
swabs	O
).	O

Six	O
new	O
bat	B-ENZY
CoV	O
reservoirs	O
were	O
identified	O
in	O
our	O
study	O
,	O
namely	O
Cynopterus	O
sphinx	O
,	O
Taphozous	O
melanopogon	O
,	O
Hipposideros	O
lekaguli	O
,	O
Rhinolophus	O
shameli	O
,	O
Scotophilus	O
heathii	O
and	O
Megaderma	O
lyra	O
.	O

CoVs	O
from	O
the	O
same	O
genetic	O
lineage	O
were	O
found	O
in	O
different	O
bat	B-ENZY
species	O
roosting	O
in	O
similar	O
or	O
different	O
locations	O
.	O

Outpatients	O
with	O
ARI	O
were	O
assayed	O
for	O
presence	O
of	O
18	O
viruses	O
using	O
multiplex	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
MRT	O
-	O
PCR	O
)	O
to	O
simultaneously	O
detect	O
multiple	O
viruses	O
.	O

ARDS	O
was	O
defined	O
by	O
the	O
Berlin	O
definition	O
and	O
lung	O
injury	O
score	O
(	O
LIS	B-ENZY
).	O

Low	O
baseline	O
albumin	O
levels	O
were	O
moderately	O
associated	O
with	O
maximum	O
Berlin	O
and	O
LIS	B-ENZY
categories	O
within	O
7	O
days	O
;	O
an	O
elevated	O
CRP	O
level	O
was	O
moderately	O
associated	O
with	O
maximum	O
Berlin	O
categories	O
only	O
.	O

RESULTS	O
:	O
At	O
baseline	O
,	O
48	O
patients	O
had	O
mild	O
to	O
severe	O
ARDS	O
according	O
to	O
Berlin	O
and	O
87	O
according	O
to	O
LIS	B-ENZY
(	O
Rs	O
=	O
0	O
.	O
54	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

A	O
recent	O
study	O
in	O
South	O
Africa	O
isolated	O
a	O
genetic	O
variant	O
closely	O
related	O
to	O
MERS	O
-	O
CoV	O
from	O
an	O
insectivorous	O
bat	B-ENZY
.	O

Though	O
Madagascar	O
is	O
home	O
to	O
44	O
bat	B-ENZY
species	O
(	O
41	O
insectivorous	O
and	O
3	O
frugivorous	O
)	O
of	O
which	O
34	O
are	O
endemic	O
,	O
no	O
data	O
exists	O
concerning	O
the	O
circulation	O
of	O
CoVs	O
in	O
the	O
island	O
'	O
s	O
chiropteran	O
fauna	O
.	O

Furthermore	O
,	O
the	O
active	O
compound	O
c26	O
dose	O
-	O
dependently	O
inhibited	O
ERK	B-ENZY
phosphorylation	O
.	O

However	O
,	O
pretreatment	O
with	O
c26	O
attenuated	O
the	O
LPS	O
induced	O
increase	O
through	O
ERK	B-ENZY
pathway	O
in	O
vivo	O
.	O

We	O
next	O
demonstrated	O
that	O
enzymatic	O
removal	O
of	O
the	O
highly	O
sulfated	O
domain	O
of	O
heparan	O
sulfate	O
by	O
heparinase	B-ENZY
I	O
treatment	O
inhibited	O
PEDV	O
infection	O
.	O

The	O
results	O
showed	O
that	O
DON	O
reduced	O
(	O
p	O
=	O
0	O
.	O
032	O
)	O
the	O
titre	O
against	O
IBV	O
,	O
decreased	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
the	O
level	O
of	O
alanine	B-ENZY
transaminase	I-ENZY
(	O
ALT	O
)	O
(	O
4	O
.	O
2	O
	O
0	O
.	O
5	O
U	O
/	O
l	O
)	O
compared	O
with	O
control	O
birds	O
(	O
6	O
.	O
4	O
	O
0	O
.	O
5	O
U	O
/	O
l	O
),	O
increased	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
the	O
serum	O
cholesterol	O
concentration	O
(	O
144	O
	O
6	O
mg	O
/	O
dl	O
)	O
compared	O
with	O
their	O
control	O
counterparts	O
(	O
123	O
	O
5	O
mg	O
/	O
dl	O
)	O
and	O
increased	O
(	O
p	O
=	O
0	O
.	O
074	O
)	O
the	O
amount	O
of	O
circulating	O
triglycerides	O
(	O
62	O
.	O
25	O
	O
7	O
.	O
50	O
mg	O
/	O
dl	O
)	O
compared	O
with	O
controls	O
(	O
39	O
.	O
55	O
	O
4	O
.	O
74	O
).	O

A	O
total	O
of	O
360	O
chicken	O
flocks	O
suspected	O
of	O
being	O
infected	O
by	O
IBV	O
were	O
screened	O
for	O
the	O
IBV	O
N	O
gene	O
using	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Pretreatment	O
of	O
RD	O
cells	O
with	O
neuraminidase	B-ENZY
(	O
NA	O
)	O
and	O
trypsin	B-ENZY
greatly	O
reduced	O
the	O
binding	O
,	O
suggesting	O
that	O
the	O
binding	O
was	O
mediated	O
by	O
sialic	O
acids	O
on	O
glycoproteins	O
.	O

In	O
addition	O
,	O
we	O
determined	O
that	O
the	O
HKU1	O
-	O
HE	O
protein	O
is	O
an	O
O	O
-	O
acetylesterase	B-ENZY
and	O
acts	O
as	O
a	O
receptor	O
-	O
destroying	O
enzyme	O
(	O
RDE	O
)	O
for	O
hCoV	O
-	O
HKU1	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
that	O
hCoV	O
-	O
HKU1	O
uses	O
certain	O
types	O
of	O
O	O
-	O
acetylated	O
sialic	O
acid	O
residues	O
on	O
glycoproteins	O
to	O
initiate	O
the	O
infection	O
of	O
host	O
cells	O
and	O
that	O
the	O
HKU1	O
-	O
HE	O
protein	O
possesses	O
sialate	O
-	O
O	O
-	O
acetylesterase	B-ENZY
RDE	O
activity	O
.	O

We	O
established	O
a	O
miniaturized	O
luciferase	B-ENZY
gene	O
reporter	O
assay	O
in	O
A549	O
cells	O
that	O
measures	O
IFN	O
-	O
	O
induction	O
by	O
viral	O
dsRNA	O
and	O
is	O
dose	O
-	O
dependently	O
inhibited	O
by	O
VP35	O
expression	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
3	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
))	O
is	O
a	O
validated	O
target	O
in	O
the	O
design	O
of	O
potential	O
anticoronavirus	O
inhibitors	O
.	O

TITLE	O
:	O
Differential	O
Effects	O
of	O
Endotracheal	O
Suctioning	O
on	O
Gas	B-ENZY
Exchanges	O
in	O
Patients	O
with	O
Acute	O
Respiratory	O
Failure	O
under	O
Pressure	O
-	O
Controlled	O
and	O
Volume	O
-	O
Controlled	O
Ventilation	O
.	O

Ninety	O
-	O
six	O
ARF	O
patients	O
were	O
treated	O
with	O
open	O
endotracheal	O
suctioning	O
and	O
their	O
variations	O
in	O
respiratory	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
after	O
the	O
suctions	O
were	O
compared	O
.	O

Bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
was	O
performed	O
at	O
72	O
h	O
after	O
treatment	O
.	O

The	O
bacterial	O
load	O
in	O
BAL	B-ENZY
from	O
ALI	O
mice	O
was	O
increased	O
fivefold	O
(	O
P	O
=	O
0	O
.	O
03	O
).	O

Metabolic	O
profiling	O
of	O
BAL	B-ENZY
detected	O
the	O
presence	O
of	O
bacterial	O
substrates	O
suitable	O
for	O
both	O
isolates	O
.	O

Neuraminidase	B-ENZY
inhibitors	O
for	O
viral	O
pneumonia	O
have	O
been	O
shown	O
to	O
reduce	O
transmission	O
in	O
cases	O
of	O
exposure	O
and	O
to	O
improve	O
the	O
clinical	O
progress	O
of	O
patients	O
in	O
intensive	O
care	O
;	O
their	O
use	O
in	O
common	O
infections	O
is	O
not	O
recommended	O
.	O

He	O
was	O
treated	O
with	O
non	O
-	O
invasive	O
positive	O
pressure	O
ventilation	O
and	O
a	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
,	O
which	O
dramatically	O
alleviated	O
his	O
symptoms	O
and	O
improved	O
his	O
oxygenation	O
.	O

TITLE	O
:	O
A	O
Single	O
Point	O
Mutation	O
Creating	O
a	O
Furin	B-ENZY
Cleavage	O
Site	O
in	O
the	O
Spike	O
Protein	O
Renders	O
Porcine	O
Epidemic	O
Diarrhea	O
Coronavirus	O
Trypsin	B-ENZY
Independent	O
for	O
Cell	O
Entry	O
and	O
Fusion	O
.	O

ABSTRACT	O
:	O
The	O
emerging	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
requires	O
trypsin	B-ENZY
supplementation	O
to	O
activate	O
its	O
S	O
protein	O
for	O
membrane	O
fusion	O
and	O
virus	O
propagation	O
in	O
cell	O
culture	O
.	O

By	O
substitution	O
of	O
a	O
single	O
amino	O
acid	O
in	O
the	O
S	O
protein	O
,	O
we	O
created	O
a	O
recombinant	O
PEDV	O
with	O
an	O
artificial	O
furin	B-ENZY
protease	O
cleavage	O
site	O
N	O
terminal	O
of	O
the	O
putative	O
fusion	O
peptide	O
(	O
PEDV	O
-	O
SFCS	O
).	O

Using	O
next	O
-	O
generation	O
transcriptome	O
sequencing	O
(	O
mRNA	O
-	O
seq	O
),	O
we	O
profiled	O
the	O
transcriptional	O
response	O
of	O
Pteropus	O
vampyrus	O
bat	B-ENZY
kidney	O
(	O
PVK	O
)	O
cells	O
to	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
),	O
an	O
avian	O
paramyxovirus	O
known	O
to	O
elicit	O
a	O
strong	O
innate	O
immune	O
response	O
in	O
mammalian	O
cells	O
.	O

The	O
association	O
was	O
first	O
described	O
as	O
a	O
syndrome	O
by	O
Cottin	O
in	O
2005	O
,	O
named	O
""""	O
combined	O
pulmonary	O
fibrosis	O
and	O
emphysema	O
(	O
CPFE	O
")"","	O
which	O
is	O
characterized	O
by	O
exertional	O
dyspnea	O
,	O
upper	O
-	O
lobe	O
emphysema	O
and	O
lower	O
-	O
lobe	O
fibrosis	O
,	O
preserved	O
lung	O
volume	O
and	O
severely	O
diminished	O
capacity	O
of	O
gas	B-ENZY
exchange	O
.	O

TITLE	O
:	O
In	O
vivo	O
assessment	O
of	O
equine	O
arteritis	O
virus	O
vaccine	O
improvement	O
by	O
disabling	O
the	O
deubiquitinase	O
activity	O
of	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
.	O

We	O
have	O
recently	O
shown	O
that	O
the	O
deubiquitinase	O
(	O
DUB	O
)	O
activity	O
of	O
EAV	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
(	O
PLP2	O
)	O
is	O
important	O
for	O
the	O
inhibition	O
of	O
innate	O
immune	O
activation	O
during	O
infection	O
.	O

Detailed	O
physiological	O
measurements	O
revealed	O
severe	O
disruption	O
of	O
blood	O
/	O
alveolar	O
gas	B-ENZY
exchange	O
.	O

Biological	O
characterization	O
of	O
two	O
representative	O
isolates	O
revealed	O
trypsin	B-ENZY
resistance	O
and	O
thermostability	O
at	O
90	O
	O
C	O
.	O

NextGen	O
sequencing	O
of	O
ultrapurified	O
viruses	O
indicated	O
a	O
strong	O
homology	O
of	O
the	O
S1	O
segment	O
to	O
mammalian	O
and	O
bat	B-ENZY
MRV3	O
.	O

Humans	O
may	O
also	O
become	O
infected	O
with	O
viruses	O
through	O
aerosol	O
by	O
intruding	O
into	O
bat	B-ENZY
roosting	O
caves	O
or	O
via	O
direct	O
contact	O
with	O
bats	O
,	O
such	O
as	O
catching	O
bats	O
or	O
been	O
bitten	O
by	O
bats	O
.	O

The	O
addition	O
of	O
noninvasive	O
positive	O
pressure	O
ventilation	O
can	O
improve	O
gas	B-ENZY
exchange	O
and	O
potentially	O
prevent	O
intubation	O
and	O
mechanical	O
ventilation	O
in	O
some	O
children	O
with	O
mild	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Topics	O
included	O
ventilator	O
mode	O
,	O
tidal	O
volume	O
delivery	O
,	O
inspiratory	O
plateau	O
pressure	O
,	O
high	O
-	O
frequency	O
ventilation	O
,	O
cuffed	O
endotracheal	O
tubes	O
,	O
and	O
gas	B-ENZY
exchange	O
goals	O
.	O

TITLE	O
:	O
Genetic	O
relatedness	O
of	O
the	O
novel	O
human	O
group	O
C	O
betacoronavirus	O
to	O
Tylonycteris	O
bat	B-ENZY
coronavirus	O
HKU4	O
and	O
Pipistrellus	O
bat	B-ENZY
coronavirus	O
HKU5	O
.	O

TITLE	O
:	O
A	O
Kinome	O
-	O
Wide	O
Small	O
Interfering	O
RNA	O
Screen	O
Identifies	O
Proviral	O
and	O
Antiviral	O
Host	O
Factors	O
in	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
Replication	O
,	O
Including	O
Double	O
-	O
Stranded	O
RNA	O
-	O
Activated	O
Protein	B-ENZY
Kinase	I-ENZY
and	O
Early	O
Secretory	O
Pathway	O
Proteins	O
.	O

Depletion	O
of	O
the	O
antiviral	O
double	O
-	O
stranded	O
RNA	O
-	O
activated	O
protein	B-ENZY
kinase	I-ENZY
(	O
PKR	B-ENZY
)	O
enhanced	O
virus	O
replication	O
in	O
the	O
primary	O
screen	O
,	O
and	O
validation	O
experiments	O
confirmed	O
increased	O
SARS	O
-	O
CoV	O
protein	O
expression	O
and	O
virus	O
production	O
upon	O
PKR	B-ENZY
depletion	O
.	O

ABSTRACT	O
:	O
Porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
is	O
a	O
functional	O
receptor	O
for	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
(	O
PEDV	O
).	O

,	O
we	O
compared	O
the	O
virus	O
surface	O
spikes	O
of	O
MERS	O
-	O
CoV	O
and	O
a	O
related	O
bat	B-ENZY
coronavirus	O
,	O
HKU4	O
.	O

These	O
mutations	O
therefore	O
played	O
critical	O
roles	O
in	O
the	O
bat	B-ENZY
-	O
to	O
-	O
human	O
transmission	O
of	O
MERS	O
-	O
CoV	O
,	O
either	O
directly	O
or	O
through	O
intermediate	O
hosts	O
.	O

Recently	O
,	O
we	O
showed	O
that	O
LeTx	O
inactivation	O
of	O
p38	O
MAP	B-ENZY
kinase	I-ENZY
signaling	O
via	O
degradation	O
of	O
MKK3	O
in	O
pulmonary	O
vascular	O
endothelial	O
cells	O
can	O
be	O
linked	O
to	O
compromise	O
of	O
the	O
endothelial	O
permeability	O
barrier	O
.	O

Here	O
we	O
reported	O
that	O
ET	O
-	O
1	O
stimulated	O
expression	O
of	O
VCAM	O
-	O
1	O
gene	O
on	O
HTSMCs	O
,	O
which	O
was	O
blocked	O
by	O
pretreatment	O
with	O
the	O
inhibitors	O
of	O
ET	O
receptors	O
,	O
Src	O
,	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
),	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
),	O
platelet	O
-	O
derived	O
growth	O
factor	O
receptor	O
(	O
PDGFR	O
),	O
phosphatidylinositol	B-ENZY
3	I-ENZY
-	I-ENZY
kinase	I-ENZY
(	O
PI3K	O
),	O
AKT	O
,	O
MEK1	O
/	O
2	O
,	O
and	O
p300	O
,	O
suggesting	O
the	O
participation	O
of	O
these	O
signaling	O
components	O
in	O
ET	O
-	O
1	O
-	O
regulated	O
HTSMC	O
responses	O
.	O

Furthermore	O
,	O
transfection	O
with	O
small	O
-	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
of	O
Src	O
,	O
AKT	O
,	O
p42	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
),	O
or	O
p300	O
downregulated	O
the	O
respective	O
proteins	O
and	O
significantly	O
attenuated	O
ET	O
-	O
1	O
-	O
induced	O
VCAM	O
-	O
1	O
expression	O
.	O

ET	O
-	O
1	O
also	O
stimulated	O
phosphorylation	O
of	O
Src	O
,	O
EGFR	O
,	O
PDGFR	O
,	O
AKT	O
,	O
p42	O
/	O
p44	O
MAPK	B-ENZY
,	O
and	O
Elk	O
-	O
1	O
and	O
acetylation	O
of	O
histone	O
H4	O
on	O
HTSMCs	O
.	O

Adhesion	O
assay	O
revealed	O
that	O
the	O
adhesion	O
of	O
THP	O
-	O
1	O
to	O
HTSMCs	O
challenged	O
with	O
ET	O
-	O
1	O
was	O
increased	O
,	O
which	O
was	O
attenuated	O
by	O
the	O
inhibitors	O
of	O
ET	O
receptors	O
,	O
Src	O
,	O
MMPs	O
,	O
EGFR	O
,	O
PDGFR	O
,	O
PI3K	O
,	O
AKT	O
,	O
p42	O
/	O
p44	O
MAPK	B-ENZY
,	O
and	O
p300	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggested	O
that	O
ET	O
-	O
1	O
promotes	O
occurrence	O
and	O
amplification	O
of	O
pathology	O
-	O
related	O
airway	O
inflammation	O
via	O
enhancing	O
VCAM	O
-	O
1	O
expression	O
in	O
an	O
ET	O
receptor	O
/	O
Src	O
/	O
MMP	O
/	O
EGFR	O
,	O
PDGFR	O
/	O
PI3K	O
/	O
AKT	O
/	O
p42	O
/	O
p44	O
MAPK	B-ENZY
/	O
Elk	O
-	O
1	O
/	O
p300	O
pathway	O
in	O
HTSMCs	O
.	O

We	O
treated	O
human	O
lung	O
fibroblasts	O
(	O
HLF	O
)	O
with	O
PDGF	O
,	O
or	O
TGF1	O
,	O
or	O
combined	O
,	O
and	O
examined	O
the	O
activation	O
of	O
p38	O
MAPK	B-ENZY
,	O
p42	O
/	O
p44	O
MAPK	B-ENZY
and	O
SMAD3	O
.	O

We	O
used	O
a	O
specific	O
inhibitor	O
PD98059	O
to	O
antagonize	O
phosphorylation	O
of	O
p42	O
/	O
p44	O
MAPK	B-ENZY
,	O
or	O
used	O
a	O
specific	O
inhibitor	O
SN203580	O
to	O
antagonize	O
phosphorylation	O
of	O
p38	O
MAPK	B-ENZY
,	O
or	O
used	O
a	O
specific	O
inhibitor	O
SIS3	O
to	O
antagonize	O
phosphorylation	O
of	O
SMAD3	O
.	O

PDGF	O
activated	O
p38	O
MAPK	B-ENZY
and	O
p42	O
/	O
p44	O
MAPK	B-ENZY
,	O
but	O
not	O
SMAD3	O
in	O
HLF	O
cells	O
.	O

TGF1	O
activated	O
p38	O
MAPK	B-ENZY
and	O
SMAD3	O
,	O
but	O
not	O
p42	O
/	O
p44	O
MAPK	B-ENZY
in	O
HLF	O
cells	O
.	O

Activation	O
of	O
p38	O
MAPK	B-ENZY
by	O
either	O
PDGF	O
or	O
TGF1	O
induced	O
	O
-	O
SMA	O
but	O
not	O
collagen	O
I	O
in	O
HLF	O
cells	O
,	O
while	O
activation	O
of	O
p42	O
/	O
p44	O
MAPK	B-ENZY
by	O
PDGF	O
induced	O
collagen	O
I	O
but	O
not	O
	O
-	O
SMA	O
in	O
HLF	O
cells	O
.	O

RESULTS	O
:	O
PDGF	O
activated	O
p38	O
MAPK	B-ENZY
and	O
p42	O
/	O
p44	O
MAPK	B-ENZY
,	O
but	O
not	O
SMAD3	O
in	O
HLF	O
cells	O
.	O

In	O
this	O
study	O
,	O
PEDV	O
strain	O
HN1303	O
was	O
isolated	O
successfully	O
on	O
Vero	O
cells	O
with	O
supplemental	O
trypsin	B-ENZY
,	O
and	O
the	O
isolate	O
has	O
been	O
serially	O
propagated	O
in	O
cell	O
culture	O
for	O
over	O
95	O
passages	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
prognostic	O
value	O
of	O
plasma	O
soluble	O
urokinase	B-ENZY
plasminogen	O
activator	O
receptor	O
(	O
suPAR	O
)	O
on	O
day	O
1	O
in	O
patients	O
with	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
for	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
mortality	O
and	O
compared	O
it	O
with	O
established	O
disease	O
severity	O
scores	O
on	O
day	O
1	O
.	O

TITLE	O
:	O
A	O
Randomized	O
Dose	O
-	O
Escalation	O
Study	O
of	O
the	O
Safety	O
and	O
Anti	O
-	O
Inflammatory	O
Activity	O
of	O
the	O
p38	O
Mitogen	B-ENZY
-	I-ENZY
Activated	I-ENZY
Protein	I-ENZY
Kinase	I-ENZY
Inhibitor	O
Dilmapimod	O
in	O
Severe	O
Trauma	O
Subjects	O
at	O
Risk	O
for	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

TITLE	O
:	O
Elevated	O
level	O
of	O
renal	O
xanthine	B-ENZY
oxidase	I-ENZY
mRNA	O
transcription	O
after	O
nephropathogenic	O
infectious	O
bronchitis	O
virus	O
infection	O
in	O
growing	O
layers	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
relationships	O
between	O
xanthine	B-ENZY
oxidase	I-ENZY
(	O
XOD	O
)	O
and	O
nephropathogenic	O
infectious	O
bronchitis	O
virus	O
(	O
NIBV	O
)	O
infection	O
,	O
240	O
growing	O
layers	O
(	O
35	O
days	O
old	O
)	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
(	O
infected	O
and	O
control	O
)	O
of	O
120	O
chickens	O
each	O
.	O

The	O
results	O
showed	O
that	O
serum	O
glutathione	B-ENZY
peroxidase	I-ENZY
and	O
superoxide	B-ENZY
dismutase	I-ENZY
activities	O
in	O
the	O
infected	O
group	O
were	O
significantly	O
lower	O
than	O
in	O
the	O
control	O
group	O
at	O
8	O
and	O
15	O
dpi	O
(	O
p	O
<	O
0	O
.	O
01	O
),	O
while	O
serum	O
malondialdehyde	O
concentrations	O
were	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

In	O
SIRS	O
,	O
the	O
substantial	O
activation	O
of	O
endothelial	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
)	O
and	O
smooth	O
muscle	O
guanylate	B-ENZY
cyclase	I-ENZY
(	O
GC	O
)	O
is	O
observed	O
,	O
which	O
can	O
produce	O
severe	O
hypotension	O
that	O
is	O
unresponsive	O
to	O
conventional	O
vasopressors	O
.	O

To	O
this	O
end	O
,	O
Renilla	O
luciferase	B-ENZY
-	O
encoding	O
SARS	O
-	O
CoV	O
replicons	O
with	O
selectively	O
deleted	O
macrodomains	O
were	O
constructed	O
and	O
their	O
ability	O
to	O
modulate	O
the	O
RTC	O
activity	O
was	O
examined	O
.	O

TITLE	O
:	O
Human	O
-	O
Bat	B-ENZY
Interactions	O
in	O
Rural	O
West	O
Africa	O
.	O

Nearly	O
half	O
(	O
46	O
.	O
6	O
%)	O
of	O
respondents	O
regularly	O
visited	O
bat	B-ENZY
caves	O
;	O
37	O
.	O
4	O
%	O
had	O
been	O
bitten	O
,	O
scratched	O
,	O
or	O
exposed	O
to	O
bat	B-ENZY
urine	O
;	O
and	O
45	O
.	O
6	O
%	O
ate	O
bat	B-ENZY
meat	O
.	O

Human	O
-	O
bat	B-ENZY
interactions	O
in	O
rural	O
Ghana	O
are	O
frequent	O
and	O
diverse	O
.	O

The	O
aeration	O
score	O
of	O
the	O
lung	O
at	O
T1	O
,	O
T2	O
,	O
T3	O
,	O
T4	O
was	O
significantly	O
reduced	O
than	O
T0	O
all	O
,	O
the	O
ventilation	O
situation	O
of	O
mainly	O
areas	O
was	O
improved	O
after	O
2	O
h	O
PPV	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
4	O
h	O
later	O
it	O
was	O
not	O
distinguished	O
(	O
P	O
>	O
0	O
.	O
05	O
);	O
the	O
value	O
of	O
PaO	B-ENZY
(	O
2	O
),	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
was	O
greater	O
at	O
T1	O
,	O
T2	O
,	O
T3	O
,	O
T4	O
than	O
T0	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
the	O
value	O
of	O
the	O
oxygen	O
fraction	O
was	O
significant	O
increased	O
at	O
T2	O
than	O
T1	O
(	O
t	O
=	O
2	O
.	O
840	O
,	O
P	O
<	O
0	O
.	O
05	O
);	O
the	O
number	O
of	O
patients	O
with	O
oxygen	O
fractions	O
>	O
300	O
mmHg	O
after	O
5	O
days	O
PPV	O
was	O
65	O
(	O
83	O
.	O
3	O
%);	O
there	O
were	O
30	O
(	O
38	O
.	O
5	O
%)	O
patients	O
free	O
of	O
mechanical	O
ventilation	O
after	O
7	O
days	O
;	O
the	O
28	O
-	O
day	O
mortality	O
was	O
7	O
(	O
8	O
.	O
97	O
%).	O

RESULTS	O
:	O
The	O
aeration	O
score	O
of	O
the	O
lung	O
at	O
T1	O
,	O
T2	O
,	O
T3	O
,	O
T4	O
was	O
significantly	O
reduced	O
than	O
T0	O
all	O
,	O
the	O
ventilation	O
situation	O
of	O
mainly	O
areas	O
was	O
improved	O
after	O
2	O
h	O
PPV	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
4	O
h	O
later	O
it	O
was	O
not	O
distinguished	O
(	O
P	O
>	O
0	O
.	O
05	O
);	O
the	O
value	O
of	O
PaO	B-ENZY
(	O
2	O
),	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
was	O
greater	O
at	O
T1	O
,	O
T2	O
,	O
T3	O
,	O
T4	O
than	O
T0	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
the	O
value	O
of	O
the	O
oxygen	O
fraction	O
was	O
significant	O
increased	O
at	O
T2	O
than	O
T1	O
(	O
t	O
=	O
2	O
.	O
840	O
,	O
P	O
<	O
0	O
.	O
05	O
);	O
the	O
number	O
of	O
patients	O
with	O
oxygen	O
fractions	O
>	O
300	O
mmHg	O
after	O
5	O
days	O
PPV	O
was	O
65	O
(	O
83	O
.	O
3	O
%);	O
there	O
were	O
30	O
(	O
38	O
.	O
5	O
%)	O
patients	O
free	O
of	O
mechanical	O
ventilation	O
after	O
7	O
days	O
;	O
the	O
28	O
-	O
day	O
mortality	O
was	O
7	O
(	O
8	O
.	O
97	O
%).	O

ABSTRACT	O
:	O
Genotyping	O
of	O
seven	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
strains	O
isolated	O
in	O
Brazil	O
showed	O
that	O
all	O
belonged	O
to	O
the	O
common	O
Brazilian	O
genotype	O
and	O
that	O
these	O
strains	O
were	O
closest	O
to	O
the	O
subcluster	O
of	O
strain	O
IBV	O
/	O
Brazil	O
/	O
2007	O
/	O
USP	B-ENZY
-	O
19	O
.	O

ABSTRACT	O
:	O
The	O
bat	B-ENZY
coronavirus	O
HKU4	O
belongs	O
to	O
the	O
same	O
2c	O
lineage	O
as	O
that	O
of	O
the	O
deadly	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
shows	O
high	O
sequence	O
similarity	O
,	O
therefore	O
potentiating	O
a	O
threat	O
to	O
the	O
human	O
population	O
through	O
a	O
zoonotic	O
shift	O
or	O
'	O
spill	O
over	O
'	O
event	O
.	O

ABSTRACT	O
:	O
Necrotizing	O
tracheobronchitis	O
due	O
to	O
Aspergillus	O
spp	B-ENZY
is	O
a	O
rare	O
form	O
of	O
invasive	O
aspergillosis	O
.	O

TITLE	O
:	O
Bat	B-ENZY
-	O
to	O
-	O
human	O
:	O
spike	O
features	O
determining	O
'	O
host	O
jump	O
'	O
of	O
coronaviruses	O
SARS	O
-	O
CoV	O
,	O
MERS	O
-	O
CoV	O
,	O
and	O
beyond	O
.	O

ABSTRACT	O
:	O
Prone	O
position	O
is	O
used	O
to	O
recruit	O
collapsed	O
dependent	O
lung	O
regions	O
during	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
improving	O
lung	O
elastance	O
and	O
lung	O
gas	B-ENZY
content	O
.	O

We	O
hypothesised	O
that	O
,	O
in	O
the	O
absence	O
of	O
recruitment	O
,	O
prone	O
position	O
would	O
not	O
result	O
in	O
any	O
improvement	O
in	O
lung	O
mechanical	O
properties	O
or	O
gas	B-ENZY
content	O
compared	O
to	O
supine	O
position	O
.	O

A	O
lung	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
was	O
performed	O
in	O
the	O
two	O
positions	O
to	O
compute	O
gas	B-ENZY
content	O
(	O
i	O
.	O
e	O
.	O
functional	O
residual	O
capacity	O
(	O
FRC	O
))	O
and	O
the	O
distribution	O
of	O
aeration	O
.	O

Alogliptin	O
is	O
mainly	O
metabolized	O
by	O
cytochrome	B-ENZY
P450	I-ENZY
(	O
CYP2D6	O
)	O
and	O
CYP3A4	O
.	O

The	O
changes	O
of	O
hemodynamics	O
,	O
biochemical	O
variables	O
,	O
and	O
arterial	O
blood	O
gas	B-ENZY
were	O
examined	O
during	O
the	O
experimental	O
period	O
.	O

The	O
lung	O
from	O
rats	O
with	O
endotoxic	O
shock	O
exhibited	O
significant	O
decreases	O
in	O
the	O
levels	O
of	O
Wnt3a	O
,	O
Fzd1	O
,	O
Dsh1	O
,	O
phosphorylated	O
GSK	B-ENZY
-	O
3	O
at	O
Ser9	O
,	O
and	O
	O
-	O
catenin	O
.	O

In	O
contrast	O
,	O
the	O
expressions	O
of	O
Wnt5a	O
,	O
Fzd5	O
,	O
and	O
CaMKII	B-ENZY
were	O
up	O
-	O
regulated	O
in	O
the	O
lung	O
of	O
endotoxemic	O
rats	O
.	O

TITLE	O
:	O
NMR	O
and	O
MD	O
Studies	O
Reveal	O
That	O
the	O
Isolated	O
Dengue	O
NS3	O
Protease	O
Is	O
an	O
Intrinsically	O
Disordered	O
Chymotrypsin	B-ENZY
Fold	O
Which	O
Absolutely	O
Requests	O
NS2B	O
for	O
Correct	O
Folding	O
and	O
Functional	O
Dynamics	O
.	O

Here	O
as	O
facilitated	O
by	O
our	O
previous	O
discovery	O
,	O
the	O
isolated	O
NS3pro	O
has	O
been	O
surprisingly	O
deciphered	O
by	O
NMR	O
to	O
be	O
the	O
first	O
intrinsically	O
-	O
disordered	O
chymotrypsin	B-ENZY
-	O
like	O
fold	O
,	O
which	O
exists	O
in	O
a	O
loosely	O
-	O
packed	O
state	O
with	O
non	O
-	O
native	O
long	O
-	O
range	O
interactions	O
as	O
revealed	O
by	O
paramagnetic	O
relaxation	O
enhancement	O
(	O
PRE	O
).	O

There	O
were	O
no	O
detrimental	O
effects	O
in	O
terms	O
of	O
lung	O
mechanics	O
,	O
auto	O
-	O
PEEP	O
generation	O
,	O
hemodynamics	O
,	O
or	O
gas	B-ENZY
exchange	O
.	O

Although	O
two	O
SARS	O
-	O
related	O
Rhinolophus	O
sinicus	O
bat	B-ENZY
CoVs	O
(	O
SARSr	O
-	O
Rs	O
-	O
BatCoVs	O
)	O
previously	O
detected	O
in	O
Chinese	O
horseshoe	O
bats	O
(	O
Rhinolophus	O
sinicus	O
)	O
in	O
Yunnan	O
,	O
RsSHC014	O
and	O
Rs3367	O
,	O
possessed	O
95	O
%	O
genome	O
identities	O
to	O
human	O
and	O
civet	O
SARSr	O
-	O
CoVs	O
,	O
their	O
ORF8	O
protein	O
exhibited	O
only	O
32	O
.	O
2	O
to	O
33	O
%	O
amino	O
acid	O
identities	O
to	O
that	O
of	O
human	O
/	O
civet	O
SARSr	O
-	O
CoVs	O
.	O

Although	O
horseshoe	O
bats	O
are	O
the	O
primary	O
reservoir	O
of	O
SARS	O
-	O
related	O
coronaviruses	O
(	O
SARSr	O
-	O
CoVs	O
),	O
it	O
is	O
still	O
unclear	O
how	O
these	O
bat	B-ENZY
viruses	O
have	O
evolved	O
to	O
cross	O
the	O
species	O
barrier	O
to	O
infect	O
civets	O
and	O
humans	O
.	O

We	O
detected	O
diverse	O
alphacoronaviruses	O
and	O
betacoronaviruses	O
among	O
various	O
bat	B-ENZY
species	O
in	O
Yunnan	O
,	O
China	O
,	O
including	O
two	O
SARSr	O
-	O
Rf	O
-	O
BatCoVs	O
from	O
greater	O
horseshoe	O
bats	O
that	O
possessed	O
ORF8	O
proteins	O
with	O
exceptionally	O
high	O
amino	O
acid	O
identities	O
to	O
that	O
of	O
human	O
/	O
civet	O
SARSr	O
-	O
CoVs	O
.	O

In	O
the	O
upstream	O
of	O
IRF	O
-	O
3	O
,	O
TANK	B-ENZY
-	I-ENZY
binding	I-ENZY
kinase	I-ENZY
1	I-ENZY
(	O
TBK1	B-ENZY
)-	O
or	O
inhibitor	O
of	O
B	O
kinase	O
-	O
	O
(	O
IKK	O
)-	O
mediated	O
IFN	O
-	O
	O
production	O
was	O
not	O
blocked	O
by	O
PEDV	O
,	O
while	O
RIG	O
-	O
I	O
-	O
and	O
its	O
adapter	O
molecule	O
IFN	O
-	O
	O
promoter	O
stimulator	O
1	O
(	O
IPS	O
-	O
1	O
)-	O
mediated	O
IFN	O
-	O
	O
production	O
were	O
completely	O
inhibited	O
after	O
PEDV	O
infection	O
.	O

In	O
the	O
upstream	O
of	O
IRF	O
-	O
3	O
,	O
TANK	B-ENZY
-	I-ENZY
binding	I-ENZY
kinase	I-ENZY
1	I-ENZY
(	O
TBK1	B-ENZY
)-	O
or	O
inhibitor	O
of	O
B	O
kinase	O
-	O
	O
(	O
IKK	O
)-	O
mediated	O
IFN	O
-	O
	O
production	O
was	O
not	O
blocked	O
by	O
PEDV	O
,	O
while	O
RIG	O
-	O
I	O
-	O
and	O
its	O
adapter	O
molecule	O
IFN	O
-	O
	O
promoter	O
stimulator	O
1	O
(	O
IPS	O
-	O
1	O
)-	O
mediated	O
IFN	O
-	O
	O
production	O
were	O
completely	O
inhibited	O
after	O
PEDV	O
infection	O
.	O

Common	O
pathophysiological	O
indicators	O
of	O
ARDS	O
in	O
mice	O
include	O
impaired	O
pulmonary	O
gas	B-ENZY
exchange	O
and	O
histological	O
evidence	O
of	O
inflammatory	O
infiltrates	O
into	O
the	O
lung	O
.	O

We	O
report	O
here	O
the	O
x	O
-	O
ray	O
structure	O
of	O
three	O
tandemly	O
linked	O
domains	O
of	O
MHV	O
nsp3	O
,	O
including	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
(	O
PLP2	O
)	O
catalytic	O
domain	O
,	O
the	O
ubiquitin	O
-	O
like	O
domain	O
2	O
(	O
Ubl2	O
),	O
and	O
a	O
third	O
domain	O
that	O
we	O
call	O
the	O
DPUP	O
(	O
domain	O
preceding	O
Ubl2	O
and	O
PLP2	O
)	O
domain	O
.	O

TITLE	O
:	O
Genetic	O
deficiency	O
and	O
polymorphisms	O
of	O
cyclophilin	B-ENZY
A	O
reveal	O
its	O
essential	O
role	O
for	O
Human	O
Coronavirus	O
229E	O
replication	O
.	O

Here	O
,	O
we	O
summarize	O
present	O
knowledge	O
on	O
the	O
role	O
of	O
cyclophilin	B-ENZY
A	O
during	O
coronavirus	O
replication	O
.	O

We	O
present	O
data	O
on	O
the	O
effect	O
of	O
cyclophilin	B-ENZY
A	O
single	O
nucleotide	O
polymorphism	O
mutants	O
on	O
the	O
replication	O
of	O
human	O
CoV	O
-	O
229E	O
demonstrating	O
the	O
requirement	O
of	O
proper	O
cyclophilin	B-ENZY
A	O
function	O
for	O
virus	O
propagation	O
.	O

Results	O
define	O
cellular	O
cyclophilin	B-ENZY
A	O
as	O
a	O
host	O
target	O
for	O
inhibition	O
of	O
coronaviruses	O
ranging	O
from	O
relatively	O
mild	O
common	O
cold	O
to	O
highly	O
pathogenic	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
viruses	O
with	O
the	O
perspective	O
of	O
disclosing	O
non	O
-	O
immunosuppressive	O
cyclosporin	O
A	O
analogs	O
to	O
broadly	O
inactivate	O
the	O
coronavirus	O
family	O
.	O

TITLE	O
:	O
Pulmonary	O
ultrasound	O
and	O
pulse	O
oximetry	O
versus	O
chest	O
radiography	O
and	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
for	O
the	O
diagnosis	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
pilot	O
study	O
.	O

For	O
these	O
zoonotic	O
viruses	O
,	O
a	O
number	O
of	O
bat	B-ENZY
species	O
are	O
considered	O
as	O
important	O
reservoir	O
hosts	O
,	O
efficient	O
disseminators	O
or	O
even	O
directly	O
responsible	O
of	O
the	O
transmission	O
.	O

Some	O
of	O
these	O
bat	B-ENZY
-	O
borne	O
viruses	O
cause	O
highly	O
pathogenic	O
diseases	O
while	O
others	O
are	O
of	O
potential	O
significance	O
for	O
humans	O
and	O
domestic	O
or	O
wild	O
animals	O
;	O
so	O
,	O
bats	O
are	O
an	O
important	O
risk	O
in	O
human	O
and	O
animal	O
public	O
health	O
.	O

The	O
various	O
bioecology	O
of	O
the	O
different	O
bat	B-ENZY
populations	O
allows	O
exchange	O
of	O
virus	O
between	O
migrating	O
and	O
non	O
-	O
migrating	O
conspecific	O
species	O
.	O

It	O
is	O
also	O
necessary	O
to	O
get	O
a	O
better	O
knowledge	O
of	O
the	O
interactions	O
between	O
bats	O
and	O
ecologic	O
changes	O
induced	O
by	O
man	O
and	O
to	O
attentively	O
follow	O
bat	B-ENZY
populations	O
and	O
their	O
viruses	O
through	O
surveillance	O
networks	O
involving	O
human	O
and	O
veterinary	O
physicians	O
,	O
specialists	O
of	O
wild	O
fauna	O
,	O
ecologists	O
,	O
etc	O
.	O

In	O
this	O
study	O
,	O
6	O
duplex	O
real	O
-	O
time	O
PCR	O
assays	O
,	O
using	O
EvaGreen	O
intercalating	O
dye	O
,	O
were	O
developed	O
to	O
detect	O
12	O
major	O
viruses	O
responsible	O
for	O
respiratory	O
diseases	O
:	O
influenza	O
A	O
and	O
B	O
viruses	O
,	O
enteroviruses	O
(	O
including	O
enterovirus	O
spp	B-ENZY
,	O
and	O
rhinovirus	O
spp	B-ENZY
),	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
coronaviruses	O
group	O
I	O
(	O
of	O
which	O
CoV	O
229E	O
and	O
CoV	O
NL63	O
are	O
part	O
)	O
and	O
II	O
(	O
including	O
CoV	O
OC43	O
and	O
CoV	O
HKU1	O
),	O
parainfluenza	O
viruses	O
type	O
1	O
,	O
2	O
,	O
3	O
and	O
4	O
,	O
human	O
adenoviruses	O
and	O
human	O
bocaviruses	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
defined	O
as	O
the	O
acute	O
onset	O
of	O
noncardiogenic	O
edema	O
and	O
subsequent	O
gas	B-ENZY
-	O
exchange	O
impairment	O
due	O
to	O
a	O
severe	O
inflammatory	O
process	O
.	O

Here	O
,	O
we	O
developed	O
an	O
IC	O
assay	O
that	O
detected	O
PEDV	O
antigens	O
with	O
96	O
.	O
0	O
%	O
(	O
218	O
/	O
227	O
)	O
sensitivity	O
and	O
98	O
.	O
5	O
%	O
(	O
262	O
/	O
266	O
)	O
specificity	O
when	O
compared	O
with	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
PCR	O
using	O
FAM	O
-	O
labeled	O
probes	O
based	O
on	O
sequences	O
from	O
nucleocapsid	O
genes	O
.	O

Multivariate	O
analysis	O
demonstrated	O
an	O
association	O
between	O
the	O
NL	O
group	O
and	O
development	O
of	O
pulmonary	O
complications	O
(	O
adjusted	O
odds	O
ratio	O
[	O
aOR	B-ENZY
],	O
2	O
.	O
1	O
;	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
15	O
-	O
3	O
.	O
78	O
).	O

Emergency	O
department	O
mechanical	O
ventilation	O
was	O
independently	O
associated	O
with	O
development	O
of	O
ARDS	O
(	O
aOR	B-ENZY
,	O
3	O
.	O
5	O
;	O
1	O
.	O
8	O
-	O
7	O
.	O
0	O
).	O

ABSTRACT	O
:	O
Here	O
we	O
designed	O
and	O
tested	O
two	O
highly	O
specific	O
quantitative	O
TaqMan	O
()-	O
MGB	O
-	O
based	O
reverse	B-ENZY
transcriptase	I-ENZY
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
assays	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
).	O

Moreover	O
,	O
viral	O
infected	O
animals	O
in	O
deficiencies	O
of	O
NLRP3	O
and	O
Caspase	B-ENZY
-	I-ENZY
1	I-ENZY
,	O
two	O
essential	O
components	O
of	O
the	O
inflammasome	O
complex	O
,	O
also	O
have	O
reduced	O
IL	O
-	O
1	O
induction	O
along	O
with	O
ameliorated	O
hepatitis	O
.	O

Through	O
an	O
in	O
vitro	O
screen	O
,	O
we	O
identified	O
four	O
potential	O
BST	O
-	O
2	O
modulators	O
encoded	O
by	O
the	O
SARS	O
-	O
CoV	O
genome	O
:	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLPro	O
),	O
nonstructural	O
protein	O
1	O
(	O
nsp1	O
),	O
ORF6	O
,	O
and	O
ORF7a	O
.	O

Here	O
,	O
we	O
tested	O
2	O
,	O
087	O
fecal	O
specimens	O
from	O
11	O
bat	B-ENZY
species	O
sampled	O
in	O
Ghana	O
for	O
HCoV	O
-	O
229E	O
-	O
related	O
viruses	O
by	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
).	O

To	O
compare	O
the	O
genetic	O
diversity	O
of	O
bat	B-ENZY
viruses	O
and	O
HCoV	O
-	O
229E	O
,	O
we	O
tested	O
historical	O
isolates	O
and	O
diagnostic	O
specimens	O
sampled	O
globally	O
over	O
10	O
years	O
.	O

Bat	B-ENZY
viruses	O
were	O
5	O
-	O
and	O
6	O
-	O
fold	O
more	O
diversified	O
than	O
HCoV	O
-	O
229E	O
in	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
and	O
spike	O
genes	O
.	O

A	O
recently	O
described	O
229E	O
-	O
related	O
alpaca	O
virus	O
occupied	O
an	O
intermediate	O
phylogenetic	O
position	O
between	O
bat	B-ENZY
and	O
human	O
viruses	O
.	O

According	O
to	O
taxonomic	O
criteria	O
,	O
human	O
,	O
alpaca	O
,	O
and	O
bat	B-ENZY
viruses	O
form	O
a	O
single	O
CoV	O
species	O
showing	O
evidence	O
for	O
multiple	O
recombination	O
events	O
.	O

Analyses	O
of	O
four	O
full	O
genomes	O
from	O
229E	O
-	O
related	O
bat	B-ENZY
CoVs	O
revealed	O
an	O
eighth	O
open	O
reading	O
frame	O
(	O
ORF8	O
)	O
located	O
at	O
the	O
genomic	O
3	O
'	O
end	O
.	O

We	O
reanalyze	O
a	O
previously	O
described	O
genetically	O
related	O
alpaca	O
virus	O
and	O
discuss	O
the	O
role	O
of	O
camelids	O
as	O
potential	O
intermediate	O
hosts	O
between	O
bat	B-ENZY
and	O
human	O
viruses	O
.	O

TITLE	O
:	O
Critical	O
role	O
of	O
phospholipase	B-ENZY
A2	I-ENZY
group	O
IID	O
in	O
age	O
-	O
related	O
susceptibility	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
CoV	O
infection	O
.	O

FTY720	O
treatment	O
of	O
cultured	O
NPCs	O
resulted	O
in	O
increased	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
phosphorylation	O
and	O
migration	O
after	O
exposure	O
to	O
the	O
chemokine	O
CXCL12	O
.	O

ABSTRACT	O
:	O
Electrical	O
impedance	O
tomography	O
(	O
EIT	O
)	O
is	O
a	O
noninvasive	O
technique	O
used	O
to	O
assess	O
regional	O
gas	B-ENZY
distribution	O
in	O
the	O
lung	O
.	O

Uncommon	O
fungal	O
pathogens	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
respiratory	O
failure	O
,	O
especially	O
if	O
diagnostic	O
markers	O
such	O
as	O
galactomannan	O
(	O
from	O
BAL	B-ENZY
and	O
serum	O
)	O
or	O
1	O
,	O
3	O
-	O
beta	O
-	O
D	O
-	O
glucan	O
are	O
elevated	O
.	O

From	O
cloacal	O
swabs	O
and	O
intestines	O
,	O
TCoV	O
was	O
consistently	O
detected	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
throughout	O
the	O
experimental	O
period	O
(	O
1	O
-	O
21	O
days	O
postinoculation	O
[	O
DPI	O
])	O
from	O
all	O
age	O
groups	O
.	O

TITLE	O
:	O
Feline	O
coronavirus	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
on	O
effusion	O
samples	O
in	O
cats	O
with	O
and	O
without	O
feline	O
infectious	O
peritonitis	O
.	O

Feline	O
coronavirus	O
RNA	O
was	O
detected	O
using	O
a	O
reverse	B-ENZY
transcriptase	I-ENZY
quantitative	O
polymerase	O
chain	O
reaction	O
assay	O
(	O
qRT	O
-	O
PCR	O
),	O
and	O
positive	O
samples	O
underwent	O
pyrosequencing	O
of	O
position	O
1058	O
with	O
or	O
without	O
Sanger	O
sequencing	O
of	O
position	O
1060	O
in	O
the	O
FCoV	O
spike	O
protein	O
.	O

Serum	O
levels	O
of	O
alanine	B-ENZY
aminotransferase	I-ENZY
,	O
aspartate	B-ENZY
aminotransferase	I-ENZY
and	O
total	O
bilirubin	O
increased	O
,	O
accompanied	O
by	O
massive	O
hepatocyte	O
necrosis	O
.	O

Combining	O
adjunctive	O
therapies	O
(	O
high	O
PEEP	O
,	O
recruitment	O
maneuvers	O
,	O
and	O
inhaled	O
vasodilators	O
)	O
with	O
PP	O
has	O
an	O
additive	O
effect	O
in	O
improving	O
oxygenation	O
and	O
may	O
be	O
particularly	O
helpful	O
in	O
stabilizing	O
gas	B-ENZY
exchange	O
in	O
very	O
severe	O
ARDS	O
.	O

ABSTRACT	O
:	O
The	O
study	O
aimed	O
at	O
exploring	O
bereavement	O
and	O
complicated	O
grief	O
(	O
CG	O
)	O
symptoms	O
among	O
subjects	O
without	O
a	O
history	O
of	O
coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
at	O
the	O
time	O
of	O
a	O
first	O
acute	O
coronary	O
syndrome	O
(	O
ACS	B-ENZY
)	O
and	O
to	O
evaluate	O
the	O
relationship	O
of	O
CG	O
symptoms	O
and	O
ACS	B-ENZY
.	O

Of	O
the	O
total	O
sample	O
of	O
149	O
subjects	O
with	O
ACS	B-ENZY
,	O
118	O
(	O
79	O
.	O
2	O
%)	O
met	O
criteria	O
for	O
DSM	O
-	O
5	O
persistent	O
complex	O
bereavement	O
disorder	O
.	O

Among	O
these	O
,	O
subjects	O
who	O
lost	O
a	O
partner	O
,	O
child	O
,	O
or	O
sibling	O
were	O
older	O
(	O
P	O
=	O
0	O
.	O
008	O
),	O
less	O
likely	O
to	O
be	O
working	O
(	O
P	O
=	O
0	O
.	O
032	O
),	O
and	O
more	O
likely	O
to	O
be	O
suffering	O
from	O
hypertension	O
(	O
P	O
=	O
0	O
.	O
021	O
),	O
returned	O
higher	O
scores	O
on	O
the	O
SCI	O
-	O
CG	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
developed	O
the	O
index	O
ACS	B-ENZY
more	O
frequently	O
between	O
12	O
and	O
48	O
months	O
after	O
the	O
death	O
than	O
those	O
who	O
lost	O
a	O
parent	O
or	O
another	O
relative	O
(	O
P	O
	O
0	O
.	O
0001	O
).	O

A	O
great	O
proportion	O
of	O
subjects	O
with	O
ACS	B-ENZY
report	O
the	O
loss	O
of	O
a	O
loved	O
one	O
.	O

METHODS	O
:	O
Overall	O
,	O
149	O
subjects	O
with	O
ACS	B-ENZY
(	O
namely	O
,	O
acute	O
myocardial	O
infarct	O
with	O
or	O
without	O
ST	O
-	O
segment	O
elevation	O
or	O
unstable	O
angina	O
),	O
with	O
no	O
previous	O
history	O
of	O
CHD	O
,	O
admitted	O
to	O
three	O
cardiac	O
intensive	O
care	O
units	O
were	O
included	O
and	O
evaluated	O
by	O
the	O
Structured	O
Clinical	O
Interview	O
for	O
Complicated	O
Grief	O
(	O
SCI	O
-	O
CG	O
),	O
Hamilton	O
Depression	O
Rating	O
Scale	O
,	O
Hamilton	O
Anxiety	O
Rating	O
Scale	O
,	O
and	O
the	O
36	O
-	O
item	O
Short	O
-	O
Form	O
Health	O
Survey	O
(	O
MOS	O
-	O
SF	O
-	O
36	O
).	O

Non	O
-	O
survivors	O
had	O
a	O
significantly	O
higher	O
AAST	O
grade	O
(	O
p	O
=	O
0	O
.	O
0001	O
),	O
higher	O
aspartate	B-ENZY
aminotransferase	I-ENZY
level	O
(	O
p	O
=	O
0	O
.	O
01	O
),	O
lower	O
hemoglobin	O
level	O
(	O
p	O
=	O
0	O
.	O
0001	O
),	O
associated	O
brain	O
injury	O
(	O
p	O
=	O
0	O
.	O
0001	O
),	O
perioperative	O
complications	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
higher	O
transfusion	O
score	O
(	O
p	O
=	O
0	O
.	O
0001	O
).	O

The	O
RT	O
-	O
Bst	O
method	O
amplifies	O
cDNA	O
through	O
reverse	O
transcription	O
of	O
viral	O
RNA	O
using	O
reverse	B-ENZY
transcriptase	I-ENZY
and	O
amplification	O
of	O
cDNA	O
using	O
Bst	O
DNA	O
polymerase	O
.	O

We	O
identified	O
one	O
predominant	O
mutation	O
at	O
amino	O
acid	O
758	O
(	O
from	O
RRSR	O
	O
G758	O
to	O
RRSR	O
	O
R758	O
),	O
which	O
introduces	O
a	O
putative	O
furin	B-ENZY
-	O
like	O
cleavage	O
()	O
site	O
.	O

TITLE	O
:	O
A	O
SARS	O
-	O
like	O
cluster	O
of	O
circulating	O
bat	B-ENZY
coronaviruses	O
shows	O
potential	O
for	O
human	O
emergence	O
.	O

Here	O
we	O
examine	O
the	O
disease	O
potential	O
of	O
a	O
SARS	O
-	O
like	O
virus	O
,	O
SHC014	O
-	O
CoV	O
,	O
which	O
is	O
currently	O
circulating	O
in	O
Chinese	O
horseshoe	O
bat	B-ENZY
populations	O
.	O

Using	O
the	O
SARS	O
-	O
CoV	O
reverse	O
genetics	O
system	O
,	O
we	O
generated	O
and	O
characterized	O
a	O
chimeric	O
virus	O
expressing	O
the	O
spike	O
of	O
bat	B-ENZY
coronavirus	O
SHC014	O
in	O
a	O
mouse	O
-	O
adapted	O
SARS	O
-	O
CoV	O
backbone	O
.	O

Our	O
work	O
suggests	O
a	O
potential	O
risk	O
of	O
SARS	O
-	O
CoV	O
re	O
-	O
emergence	O
from	O
viruses	O
currently	O
circulating	O
in	O
bat	B-ENZY
populations	O
.	O

acute	O
respiratory	O
distress	O
syndrome	O
and	O
acute	O
lung	O
injury	O
were	O
determined	O
based	O
on	O
chest	O
imaging	O
and	O
arterial	O
blood	O
gas	B-ENZY
results	O
.	O

Serology	O
was	O
consistently	O
completed	O
for	O
feline	O
leukemia	O
virus	O
(	O
FeLV	O
),	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
),	O
feline	O
coronavirus	O
(	O
FCoV	O
),	O
Toxoplasma	O
gondii	O
,	O
and	O
Bartonella	O
spp	B-ENZY
.	O

Seroprevalence	O
of	O
FeLV	O
(	O
2	O
.	O
7	O
%),	O
FIV	O
(	O
7	O
.	O
3	O
%),	O
FCoV	O
(	O
34	O
.	O
7	O
%),	O
T	O
.	O
gondii	O
(	O
23	O
.	O
7	O
%),	O
and	O
Bartonella	O
spp	B-ENZY
.	O

In	O
this	O
article	O
,	O
we	O
review	O
the	O
evidence	O
supporting	O
a	O
bat	B-ENZY
/	O
camel	O
origin	O
of	O
human	O
MERS	O
-	O
CoV	O
infection	O
and	O
current	O
knowledge	O
on	O
the	O
modes	O
of	O
camel	O
-	O
to	O
-	O
human	O
transmission	O
of	O
MERS	O
-	O
CoV	O
.	O

ABSTRACT	O
:	O
Design	O
of	O
inhibitors	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
)	O
)	O
is	O
a	O
potentially	O
important	O
approach	O
to	O
fight	O
against	O
SARS	O
.	O

Five	O
necropsied	O
cats	O
that	O
were	O
naturally	O
infected	O
with	O
FIP	O
virus	O
,	O
confirmed	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
and	O
immunohistochemistry	O
,	O
with	O
different	O
intensities	O
of	O
CNS	O
lesions	O
,	O
were	O
studied	O
.	O

However	O
,	O
there	O
is	O
still	O
a	O
lack	O
of	O
knowledge	O
on	O
the	O
transmission	O
dynamics	O
within	O
and	O
between	O
bat	B-ENZY
species	O
,	O
as	O
well	O
as	O
from	O
bats	O
to	O
other	O
mammals	O
.	O

TITLE	O
:	O
Benchmark	O
Study	O
for	O
the	O
Cysteine	O
-	O
Histidine	O
Proton	O
Transfer	O
Reaction	O
in	O
a	O
Protein	O
Environment	O
:	O
Gas	B-ENZY
Phase	O
,	O
COSMO	O
,	O
QM	O
/	O
MM	O
Approaches	O
.	O

We	O
have	O
investigated	O
the	O
accuracy	O
of	O
commonly	O
used	O
quantum	O
chemical	O
methods	O
for	O
the	O
description	O
of	O
proton	O
transfer	O
reactions	O
in	O
different	O
environments	O
(	O
gas	B-ENZY
phase	O
,	O
COSMO	O
,	O
QM	O
/	O
MM	O
)	O
using	O
the	O
proton	O
transfer	O
between	O
the	O
catalytic	O
dyad	O
residues	O
cysteine	O
145	O
and	O
histidine	O
41	O
of	O
SARS	O
coronavirus	O
main	O
protease	O
as	O
a	O
case	O
study	O
.	O

As	O
an	O
example	O
HF	O
,	O
CC2	O
,	O
MP2	O
,	O
and	O
their	O
SCS	O
variants	O
show	O
similar	O
errors	O
for	O
gas	B-ENZY
phase	O
,	O
COSMO	O
,	O
or	O
QM	O
/	O
MM	O
computations	O
.	O

In	O
contrast	O
for	O
semiempirical	O
methods	O
,	O
the	O
errors	O
strongly	O
diversify	O
if	O
one	O
goes	O
from	O
gas	B-ENZY
phase	O
to	O
COSMO	O
or	O
QM	O
/	O
MM	O
.	O

Particular	O
problems	O
are	O
observed	O
for	O
the	O
recent	O
semiempirical	O
methods	O
PM6	O
and	O
RM1	O
,	O
which	O
show	O
the	O
best	O
performance	O
for	O
gas	B-ENZY
phase	O
calculations	O
but	O
possess	O
larger	O
errors	O
in	O
conjunction	O
with	O
COSMO	O
.	O

The	O
resulting	O
limits	O
of	O
detection	O
(	O
LOD	B-ENZY
)	O
for	O
virus	O
-	O
spiked	O
samples	O
,	O
bacteria	O
and	O
DNA	O
fragments	O
were	O
0	O
.	O
16	O
-	O
1	O
.	O
6	O
TCID50	O
(	O
PFU	O
/	O
reaction	O
),	O
1	O
.	O
3	O
-	O
13	O
CFU	O
/	O
reaction	O
and	O
10	O
-	O
100	O
copies	O
/	O
reaction	O
,	O
respectively	O
.	O

We	O
found	O
that	O
intravenous	O
LPS	O
induced	O
a	O
significant	O
increase	O
in	O
the	O
activity	O
of	O
lung	O
xanthine	B-ENZY
oxidoreductase	I-ENZY
(	O
XOR	O
),	O
an	O
enzyme	O
which	O
is	O
a	O
major	O
source	O
of	O
reactive	O
oxygen	O
species	O
and	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
acute	O
lung	O
injury	O
.	O

However	O
,	O
pretreatment	O
of	O
mice	O
with	O
imatinib	O
increased	O
lung	O
catalase	B-ENZY
activity	O
and	O
decreased	O
intravenous	O
LPS	O
-	O
induced	O
lung	O
oxidant	O
injury	O
as	O
measured	O
by	O
	O
-	O
H2AX	O
,	O
a	O
marker	O
of	O
oxidant	O
-	O
induced	O
DNA	O
damage	O
,	O
lung	O
apoptosis	O
,	O
and	O
pulmonary	O
edema	O
.	O

The	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
of	O
Plasmodium	O
berghei	O
NK65	O
infected	O
mice	O
was	O
characterized	O
by	O
high	O
levels	O
of	O
plasma	O
proteins	O
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
an	O
altered	O
lipid	O
composition	O
of	O
lung	O
tissue	O
and	O
BAL	B-ENZY
fluid	O
,	O
partially	O
ascribed	O
to	O
oedema	O
and	O
lipoprotein	O
infiltration	O
,	O
is	O
a	O
characteristic	O
feature	O
of	O
murine	O
MA	O
-	O
ALI	O
/	O
ARDS	O
and	O
possibly	O
contribute	O
to	O
lung	O
dysfunction	O
.	O

Changes	O
in	O
haemodynamics	O
,	O
pulmonary	O
compliance	O
,	O
gas	B-ENZY
exchange	O
and	O
extravascular	O
lung	O
water	O
index	O
(	O
EVLWI	O
)	O
were	O
monitored	O
before	O
RM	O
(	O
pre	O
-	O
RM	O
),	O
10	O
minutes	O
after	O
each	O
RM	O
,	O
and	O
four	O
hours	O
after	O
RM3	O
(	O
4	O
hours	O
post	O
-	O
RRM	O
).	O

Here	O
,	O
we	O
found	O
that	O
ORF4b	O
in	O
the	O
cytoplasm	O
could	O
specifically	O
bind	O
to	O
TANK	O
binding	O
kinase	O
1	O
(	O
TBK1	B-ENZY
)	O
and	O
IB	O
kinase	O
epsilon	O
(	O
IKK	O
),	O
suppress	O
the	O
molecular	O
interaction	O
between	O
mitochondrial	O
antiviral	O
signaling	O
protein	O
(	O
MAVS	O
)	O
and	O
IKK	O
,	O
and	O
inhibit	O
IFN	O
regulatory	O
factor	O
3	O
(	O
IRF3	O
)	O
phosphorylation	O
and	O
subsequent	O
IFN	O
-	O
	O
production	O
.	O

Collectively	O
,	O
these	O
results	O
indicate	O
that	O
MERS	O
-	O
CoV	O
ORF4b	O
inhibits	O
the	O
induction	O
of	O
type	O
I	O
IFN	O
through	O
a	O
direct	O
interaction	O
with	O
IKK	O
/	O
TBK1	B-ENZY
in	O
the	O
cytoplasm	O
,	O
and	O
also	O
in	O
the	O
nucleus	O
with	O
unknown	O
mechanism	O
.	O

We	O
present	O
for	O
the	O
first	O
time	O
the	O
presence	O
of	O
alpha	O
-	O
CoVs	O
in	O
French	O
Pipistrellus	O
pipistrellus	O
bat	B-ENZY
species	O
with	O
an	O
estimated	O
prevalence	O
of	O
4	O
.	O
2	O
%.	O

Phylogeographic	O
analyses	O
of	O
RdRp	O
sequences	O
show	O
that	O
several	O
CoVs	O
strains	O
circulate	O
in	O
European	O
bats	O
:	O
(	O
i	O
)	O
old	O
strains	O
detected	O
that	O
have	O
probably	O
diverged	O
a	O
long	O
time	O
ago	O
and	O
are	O
detected	O
in	O
different	O
bat	B-ENZY
subspecies	O
;	O
(	O
ii	O
)	O
strains	O
detected	O
in	O
Myotis	O
and	O
Pipistrellus	O
bat	B-ENZY
species	O
that	O
have	O
more	O
recently	O
diverged	O
.	O

As	O
the	O
ILIAS	O
prototype	O
provided	O
excellent	O
gas	B-ENZY
exchange	O
with	O
hemodynamic	O
stability	O
comparable	O
with	O
a	O
standard	O
ECMO	O
system	O
,	O
we	O
believe	O
this	O
study	O
serves	O
as	O
a	O
proof	O
of	O
concept	O
.	O

Besides	O
providing	O
adequate	O
gas	B-ENZY
exchange	O
,	O
extracorporeal	O
assist	O
devices	O
may	O
be	O
helpful	O
in	O
ameliorating	O
right	O
ventricular	O
dysfunction	O
during	O
ARDS	O
.	O

During	O
the	O
first	O
5	O
days	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
therapy	O
,	O
prothrombin	O
fragment	O
1	O
.	O
2	O
(	O
F1	O
.	O
2	O
)	O
(	O
1	O
.	O
36	O
-	O
2	O
.	O
4	O
M	O
),	O
thrombin	B-ENZY
-	O
antithrombin	O
complex	O
(	O
14	O
.	O
5	O
-	O
50	O
g	O
/	O
L	O
),	O
and	O
D	O
-	O
dimers	O
(	O
6	O
.	O
00	O
-	O
27	O
.	O
0	O
mg	O
/	O
L	O
)	O
increased	O
,	O
whereas	O
fibrinogen	O
values	O
dropped	O
from	O
5	O
.	O
8	O
to	O
4	O
.	O
1	O
g	O
/	O
L	O
.	O
The	O
three	O
different	O
extracorporeal	O
membrane	O
oxygenation	O
systems	O
did	O
not	O
show	O
any	O
differences	O
with	O
regard	O
to	O
hemostasis	O
,	O
anticoagulation	O
,	O
hemolysis	O
,	O
and	O
inflammatory	O
parameters	O
within	O
the	O
first	O
5	O
days	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
therapy	O
.	O

At	O
least	O
two	O
proteins	O
encoded	O
by	O
PEDV	O
have	O
been	O
identified	O
as	O
interferon	O
(	O
IFN	O
)	O
antagonists	O
,	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLP	O
)	O
and	O
N	O
protein	O
.	O

The	O
crystal	O
structure	O
of	O
MERS	O
-	O
CoV	O
Mpro	O
indicates	O
that	O
it	O
shares	O
a	O
similar	O
scaffold	O
to	O
that	O
of	O
other	O
coronaviral	O
Mpro	O
and	O
consists	O
of	O
chymotrypsin	B-ENZY
-	O
like	O
domains	O
I	O
and	O
II	O
and	O
a	O
helical	O
domain	O
III	O
of	O
five	O
helices	O
.	O

In	O
this	O
study	O
,	O
a	O
novel	O
prototype	O
automated	O
microarray	O
that	O
integrates	O
and	O
automates	O
all	O
steps	O
of	O
post	O
-	O
PCR	O
microarray	O
processing	O
for	O
the	O
simultaneous	O
detection	O
and	O
typing	O
of	O
eight	O
bacteria	O
and	O
viruses	O
commonly	O
associated	O
with	O
PRDC	O
is	O
described	O
along	O
with	O
associated	O
multiplex	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
.	O

Samples	O
were	O
screened	O
for	O
paramyxovirus	O
type	O
1	O
,	O
avian	O
influenza	O
,	O
poxvirus	O
,	O
coronavirus	O
,	O
psittacine	O
herpesvirus	O
1	O
,	O
Chlamydia	O
psittaci	O
,	O
enteropathogenic	O
Escherichia	O
coli	O
(	O
EPEC	O
),	O
Salmonella	O
spp	B-ENZY
.,	O
and	O
endoparasites	O
.	O

The	O
majority	O
of	O
samples	O
returned	O
negative	O
results	O
,	O
with	O
the	O
exception	O
of	O
two	O
individuals	O
that	O
tested	O
positive	O
for	O
C	O
.	O
psittaci	O
in	O
the	O
first	O
sampling	O
and	O
for	O
Ascaridia	O
spp	B-ENZY
.	O

Both	O
Cyp	O
and	O
FKBP	O
have	O
peptidyl	B-ENZY
-	I-ENZY
prolyl	I-ENZY
cis	I-ENZY
-	I-ENZY
trans	I-ENZY
isomerase	I-ENZY
(	O
PPIase	B-ENZY
)	O
activity	O
.	O

Special	O
attention	O
has	O
been	O
paid	O
to	O
bat	B-ENZY
coronaviruses	O
as	O
the	O
two	O
emerging	O
coronaviruses	O
which	O
have	O
caused	O
unexpected	O
human	O
disease	O
outbreaks	O
in	O
the	O
21st	O
century	O
,	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
are	O
suggested	O
to	O
be	O
originated	O
from	O
bats	O
.	O

TITLE	O
:	O
Glucose	B-ENZY
-	I-ENZY
6	I-ENZY
-	I-ENZY
Phosphate	I-ENZY
Dehydrogenase	I-ENZY
Enhances	O
Antiviral	O
Response	O
through	O
Downregulation	O
of	O
NADPH	O
Sensor	O
HSCARG	O
and	O
Upregulation	O
of	O
NF	O
-	O
B	O
Signaling	O
.	O

Molecular	O
analysis	O
revealed	O
that	O
the	O
promoter	O
activities	O
of	O
TNF	O
-	O
	O
and	O
MX1	O
were	O
downregulated	O
in	O
G6PD	B-ENZY
-	O
knockdown	O
cells	O
,	O
and	O
that	O
the	O
IB	O
degradation	O
and	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
B	O
were	O
decreased	O
.	O

Exogenous	O
G6PD	B-ENZY
or	O
IDH1	O
expression	O
inhibited	O
the	O
expression	O
of	O
HSCARG	O
,	O
resulting	O
in	O
increased	O
expression	O
of	O
TNF	O
-	O
	O
and	O
MX1	O
and	O
reduced	O
viral	O
gene	O
expression	O
upon	O
virus	O
infection	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
increased	O
susceptibility	O
of	O
the	O
G6PD	B-ENZY
-	O
knockdown	O
cells	O
to	O
viral	O
infection	O
was	O
due	O
to	O
impaired	O
NF	O
-	O
B	O
signaling	O
and	O
antiviral	O
response	O
mediated	O
by	O
HSCARG	O
.	O

Since	O
then	O
,	O
MERS	O
-	O
CoV	O
sequences	O
have	O
been	O
found	O
in	O
a	O
bat	B-ENZY
and	O
in	O
many	O
dromedary	O
camels	O
(	O
DC	O
).	O

Sensitive	O
,	O
validated	O
reverse	B-ENZY
transcriptase	I-ENZY
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
rtPCR	O
)-	O
based	O
diagnostics	O
have	O
been	O
available	O
almost	O
from	O
the	O
start	O
of	O
the	O
emergence	O
of	O
MERS	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
use	O
of	O
a	O
combined	O
reverse	B-ENZY
transcriptase	I-ENZY
nested	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
nPCR	O
)	O
and	O
sequencing	O
approach	O
in	O
the	O
diagnosis	O
of	O
FIP	O
,	O
detecting	O
mutations	O
at	O
two	O
different	O
nucleotide	O
positions	O
within	O
the	O
spike	O
(	O
S	O
)	O
gene	O
.	O

Management	O
of	O
IL	O
-	O
17	O
could	O
modulate	O
LPS	O
-	O
induced	O
pulmonary	O
inflammation	O
,	O
as	O
reflected	O
by	O
the	O
total	O
cell	O
and	O
neutrophil	O
counts	O
,	O
proinflammatory	O
cytokines	O
,	O
as	O
well	O
as	O
chemokines	O
in	O
BAL	B-ENZY
fluid	O
.	O

The	O
median	O
turnaround	O
time	O
(	O
TAT	B-ENZY
)	O
was	O
5	O
.	O
29	O
hr	O
(	O
first	O
and	O
third	O
quartile	O
,	O
4	O
.	O
11	O
and	O
7	O
.	O
48	O
hr	O
)	O
in	O
26	O
medical	O
institutions	O
.	O

Similar	O
comparative	O
assays	O
were	O
done	O
on	O
LLC	O
-	O
PK	O
and	O
ST	O
cells	O
inoculated	O
with	O
the	O
cell	O
-	O
adapted	O
PDCoV	O
strain	O
OH	O
-	O
FD22	O
-	O
P44	O
(	O
passage	O
44	O
)	O
in	O
cell	O
culture	O
medium	O
with	O
2	O
.	O
5	O
-	O
10	O
g	O
/	O
ml	O
of	O
trypsin	B-ENZY
and	O
1	O
%	O
pancreatin	O
,	O
respectively	O
.	O

To	O
determine	O
if	O
AHR	O
was	O
associated	O
with	O
asthma	O
-	O
like	O
symptoms	O
,	O
we	O
compared	O
the	O
results	O
of	O
the	O
MCT	B-ENZY
to	O
a	O
validated	O
asthma	O
questionnaire	O
.	O

AHR	O
was	O
identified	O
with	O
a	O
positive	O
MCT	B-ENZY
defined	O
as	O
a	O
provocation	O
concentration	O
(	O
PC20	O
)	O
<	O
4	O
mg	O
/	O
ml	O
.	O

Among	O
MCT	B-ENZY
positive	O
subjects	O
,	O
those	O
on	O
hydroxyurea	O
had	O
significantly	O
less	O
severe	O
AHR	O
as	O
quantified	O
by	O
PC20	O
(	O
P	O
=	O
0	O
.	O
014	O
).	O

Wiley	O
Periodicals	O
,	O
Inc	O
.	O
RESULTS	O
:	O
Twenty	O
-	O
nine	O
of	O
forty	O
children	O
(	O
72	O
.	O
5	O
%)	O
had	O
a	O
positive	O
MCT	B-ENZY
.	O

Among	O
MCT	B-ENZY
positive	O
subjects	O
,	O
those	O
on	O
hydroxyurea	O
had	O
significantly	O
less	O
severe	O
AHR	O
as	O
quantified	O
by	O
PC20	O
(	O
P	O
=	O
0	O
.	O
014	O
).	O

Our	O
results	O
provide	O
further	O
evidence	O
of	O
the	O
bat	B-ENZY
origin	O
of	O
the	O
SARS	O
-	O
CoV	O
and	O
highlight	O
the	O
likelihood	O
of	O
future	O
bat	B-ENZY
coronavirus	O
emergence	O
in	O
humans	O
.	O

ABSTRACT	O
:	O
The	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
)-	O
RNase	B-ENZY
L	O
pathway	O
is	O
a	O
potent	O
interferon	O
(	O
IFN	O
)-	O
induced	O
antiviral	O
activity	O
.	O

Upon	O
sensing	O
double	O
-	O
stranded	O
RNA	O
,	O
OAS	O
produces	O
2	O
',	O
5	O
'-	O
oligoadenylates	O
(	O
2	O
-	O
5A	O
),	O
which	O
activate	O
RNase	B-ENZY
L	O
.	O
Murine	O
coronavirus	O
(	O
mouse	O
hepatitis	O
virus	O
[	O
MHV	O
])	O
nonstructural	O
protein	O
2	O
(	O
ns2	O
)	O
is	O
a	O
2	O
',	O
5	B-ENZY
'-	I-ENZY
phosphodiesterase	I-ENZY
(	O
PDE	O
)	O
that	O
cleaves	O
2	O
-	O
5A	O
,	O
thereby	O
antagonizing	O
RNase	B-ENZY
L	O
activation	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
contributions	O
of	O
Oas	O
gene	O
expression	O
,	O
basal	O
IFN	O
signaling	O
,	O
and	O
virus	O
-	O
induced	O
IFN	O
to	O
RNase	B-ENZY
L	O
activation	O
.	O

Thus	O
,	O
activation	O
of	O
RNase	B-ENZY
L	O
does	O
not	O
require	O
virus	O
-	O
induced	O
IFN	O
but	O
rather	O
correlates	O
with	O
adequate	O
levels	O
of	O
basal	O
Oas	O
gene	O
expression	O
,	O
maintained	O
by	O
basal	O
IFN	O
signaling	O
.	O

The	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
)-	O
RNase	B-ENZY
L	O
pathway	O
is	O
a	O
potent	O
antiviral	O
activity	O
.	O

Activation	O
of	O
RNase	B-ENZY
L	O
during	O
murine	O
coronavirus	O
(	O
mouse	O
hepatitis	O
virus	O
[	O
MHV	O
])	O
infection	O
of	O
myeloid	O
cells	O
correlates	O
with	O
high	O
basal	O
Oas	O
gene	O
expression	O
and	O
is	O
independent	O
of	O
virus	O
-	O
induced	O
interferon	O
secretion	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
cells	O
with	O
high	O
basal	O
Oas	O
gene	O
expression	O
levels	O
can	O
activate	O
RNase	B-ENZY
L	O
and	O
thereby	O
inhibit	O
virus	O
replication	O
early	O
in	O
infection	O
upon	O
exposure	O
to	O
viral	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
before	O
the	O
induction	O
of	O
interferon	O
and	O
prior	O
to	O
transcription	O
of	O
interferon	O
-	O
stimulated	O
antiviral	O
genes	O
.	O

These	O
findings	O
challenge	O
the	O
notion	O
that	O
activation	O
of	O
the	O
OAS	O
-	O
RNase	B-ENZY
L	O
pathway	O
requires	O
virus	O
to	O
induce	O
type	O
I	O
IFN	O
,	O
which	O
in	O
turn	O
upregulates	O
OAS	O
gene	O
expression	O
,	O
as	O
well	O
as	O
to	O
provide	O
dsRNA	O
to	O
activate	O
OAS	O
.	O

A	O
diagnosis	O
of	O
bilateral	O
pneumonia	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
due	O
to	O
an	O
infection	O
by	O
rhinovirus	O
spp	B-ENZY
was	O
made	O
.	O

Respiratory	O
variables	O
,	O
end	O
-	O
expiratory	O
volume	O
(	O
EELV	O
)	O
and	O
gas	B-ENZY
exchange	O
were	O
assessed	O
during	O
mechanical	O
ventilation	O
.	O

Knowledge	O
and	O
appreciation	O
of	O
the	O
circuit	O
,	O
cannulae	O
,	O
and	O
the	O
physiology	O
of	O
gas	B-ENZY
exchange	O
with	O
ECMO	O
are	O
necessary	O
to	O
ensure	O
lung	O
rest	O
,	O
efficiency	O
of	O
oxygenation	O
,	O
and	O
ventilation	O
as	O
well	O
as	O
troubleshooting	O
problems	O
.	O

Several	O
pathogenic	O
agents	O
such	O
as	O
Campylobacter	O
spp	B-ENZY
.,	O
Clostridium	O
perfringens	O
,	O
Escherichia	O
coli	O
,	O
Salmonella	O
spp	B-ENZY
.,	O
group	O
A	O
rotavirus	O
(	O
RV	O
-	O
A	O
),	O
coronaviruses	O
(	O
transmissible	O
gastroenteritis	O
virus	O
;	O
porcine	O
epidemic	O
diarrhea	O
virus	O
),	O
as	O
well	O
as	O
nematode	O
and	O
protozoan	O
parasites	O
,	O
can	O
be	O
associated	O
with	O
disease	O
cases	O
.	O

All	O
bacterial	O
,	O
viral	O
,	O
protozoan	O
,	O
and	O
parasitic	O
agents	O
here	O
investigated	O
,	O
with	O
the	O
exception	O
of	O
Salmonella	O
spp	B-ENZY
.	O

RESULTS	O
:	O
All	O
bacterial	O
,	O
viral	O
,	O
protozoan	O
,	O
and	O
parasitic	O
agents	O
here	O
investigated	O
,	O
with	O
the	O
exception	O
of	O
Salmonella	O
spp	B-ENZY
.	O

Compound	O
showed	O
selective	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
thanks	O
to	O
its	O
ability	O
to	O
inhibit	O
the	O
reverse	B-ENZY
transcriptase	I-ENZY
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
the	O
mouse	O
hepatitis	O
virus	O
ns2	O
phosphodiesterase	B-ENZY
domain	O
that	O
antagonizes	O
RNase	B-ENZY
L	O
activation	O
.	O

During	O
the	O
IFN	O
antiviral	O
response	O
,	O
ns2	O
cleaves	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
(	O
2	O
-	O
5A	O
),	O
a	O
key	O
mediator	O
of	O
RNase	B-ENZY
L	O
activation	O
,	O
thereby	O
subverting	O
the	O
activation	O
of	O
RNase	B-ENZY
L	O
and	O
evading	O
host	O
innate	O
immunity	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
crenatoside	O
analogues	O
as	O
novel	O
influenza	O
neuraminidase	B-ENZY
inhibitors	O
.	O

Our	O
study	O
showed	O
an	O
acceptable	O
agreement	O
of	O
P	O
(	O
tcCO2	O
)	O
monitoring	O
with	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
.	O

TITLE	O
:	O
Comparison	O
of	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
serum	O
and	O
cell	O
-	O
free	O
body	O
cavity	O
effusion	O
for	O
the	O
diagnosis	O
of	O
feline	O
infectious	O
peritonitis	O
.	O

A	O
single	O
therapeutic	O
dose	O
of	O
VIS410	O
given	O
24	O
h	O
after	O
virus	O
inoculation	O
resulted	O
in	O
dose	O
-	O
dependent	O
protection	O
of	O
up	O
to	O
100	O
%	O
of	O
mice	O
inoculated	O
with	O
neuraminidase	B-ENZY
inhibitor	O
-	O
susceptible	O
or	O
-	O
resistant	O
A	O
(	O
H7N9	O
)	O
viruses	O
.	O

IHC	O
did	O
not	O
reveal	O
the	O
presence	O
of	O
antigen	O
from	O
feline	O
calicivirus	O
,	O
coronavirus	O
,	O
feline	O
leukaemia	O
virus	O
,	O
feline	O
parvovirus	O
,	O
Chlamydia	O
spp	B-ENZY
.	O

TITLE	O
:	O
Ribonuclease	B-ENZY
H	I-ENZY
/	O
DNA	O
Polymerase	O
HIV	O
-	O
1	O
Reverse	B-ENZY
Transcriptase	I-ENZY
Dual	O
Inhibitor	O
:	O
Mechanistic	O
Studies	O
on	O
the	O
Allosteric	O
Mode	O
of	O
Action	O
of	O
Isatin	O
-	O
Based	O
Compound	O
RMNC6	O
.	O

ABSTRACT	O
:	O
The	O
DNA	O
polymerase	O
and	O
ribonuclease	B-ENZY
H	I-ENZY
(	O
RNase	B-ENZY
H	I-ENZY
)	O
activities	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
are	O
needed	O
for	O
the	O
replication	O
of	O
the	O
viral	O
genome	O
and	O
are	O
validated	O
drug	O
targets	O
.	O

We	O
report	O
on	O
the	O
mechanisms	O
of	O
allosteric	O
inhibition	O
of	O
a	O
newly	O
synthesized	O
isatin	O
-	O
based	O
compound	O
designated	O
as	O
RMNC6	O
that	O
showed	O
IC50	O
values	O
of	O
1	O
.	O
4	O
and	O
9	O
.	O
8	O
M	O
on	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNase	B-ENZY
H	I-ENZY
and	O
polymerase	O
activities	O
,	O
respectively	O
.	O

Blind	O
docking	O
studies	O
predict	O
that	O
RMNC6	O
could	O
bind	O
two	O
different	O
pockets	O
in	O
the	O
RT	O
:	O
one	O
in	O
the	O
DNA	O
polymerase	O
domain	O
(	O
partially	O
overlapping	O
the	O
non	O
-	O
nucleoside	O
RT	O
inhibitor	O
[	O
NNRTI	O
]	O
binding	O
pocket	O
),	O
and	O
a	O
second	O
one	O
close	O
to	O
the	O
RNase	B-ENZY
H	I-ENZY
active	O
site	O
.	O

Mutagenesis	O
studies	O
showed	O
that	O
RT	O
RNase	B-ENZY
H	I-ENZY
domain	O
residues	O
Asn474	O
and	O
Tyr501	O
,	O
and	O
in	O
a	O
lesser	O
extent	O
Ala502	O
and	O
Ala508	O
,	O
are	O
critical	O
for	O
RMNC6	O
inhibition	O
of	O
the	O
endonuclease	O
activity	O
of	O
the	O
RT	O
,	O
without	O
affecting	O
its	O
DNA	O
polymerization	O
activity	O
.	O

TITLE	O
:	O
[	O
The	O
value	O
of	O
determination	O
of	O
serum	O
cholinesterase	B-ENZY
levels	O
in	O
judgment	O
of	O
severity	O
and	O
prognosis	O
in	O
patients	O
with	O
severe	O
pneumonia	O
].	O

With	O
the	O
increase	O
of	O
disease	O
severity	O
,	O
LIS	B-ENZY
and	O
lactic	O
acid	O
gradually	O
increased	O
,	O
the	O
difference	O
was	O
significant	O
among	O
the	O
three	O
groups	O
of	O
Mild	O
,	O
Moderate	O
and	O
Severe	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
addition	O
,	O
there	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
EVLWI	O
and	O
OI	O
or	O
between	O
PVPI	O
and	O
OI	O
(	O
r	O
=-	O
0	O
.	O
666	O
,	O
-	O
0	O
.	O
763	O
,	O
all	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
a	O
significant	O
positive	O
correlation	O
between	O
EVLWI	O
and	O
PVPI	O
,	O
the	O
APACHE	O
II	O
score	O
or	O
LIS	B-ENZY
(	O
r	O
=	O
0	O
.	O
929	O
,	O
0	O
.	O
895	O
,	O
0	O
.	O
661	O
,	O
all	O
P	O
<	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
effect	O
of	O
mehanical	O
ventilation	O
(	O
MV	O
)	O
guided	O
by	O
transpulmonary	O
pressure	O
(	O
Ptp	O
)	O
on	O
respiratory	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
in	O
severe	O
acute	O
pancreatitis	O
patient	O
with	O
intraabdominal	O
hypertension	O
.	O

By	O
means	O
of	O
histological	O
examination	O
and	O
biochemical	O
assays	O
,	O
the	O
severity	O
of	O
lung	O
injury	O
was	O
assessed	O
in	O
the	O
aspects	O
of	O
tissue	O
damages	O
,	O
myeloperoxidase	B-ENZY
activity	O
,	O
and	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

We	O
measured	O
plasma	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
biomarkers	O
of	O
inflammation	O
and	O
lung	O
injury	O
in	O
smokers	O
and	O
non	O
-	O
smokers	O
in	O
two	O
distinct	O
cohorts	O
of	O
healthy	O
volunteers	O
,	O
one	O
unstimulated	O
(	O
n	O
=	O
20	O
)	O
and	O
one	O
undergoing	O
50	O
g	O
LPS	O
inhalation	O
(	O
n	O
=	O
30	O
).	O

After	O
LPS	O
inhalation	O
,	O
cigarette	O
smokers	O
had	O
increased	O
alveolar	O
-	O
capillary	O
membrane	O
permeability	O
as	O
measured	O
by	O
BAL	B-ENZY
total	O
protein	O
,	O
compared	O
with	O
non	O
-	O
smokers	O
(	O
median	O
274	O
vs	O
208	O
g	O
/	O
mL	O
,	O
p	O
=	O
0	O
.	O
04	O
).	O

Smokers	O
had	O
exaggerated	O
inflammation	O
compared	O
with	O
non	O
-	O
smokers	O
,	O
with	O
increased	O
BAL	B-ENZY
interleukin	O
-	O
1	O
(	O
p	O
=	O
0	O
.	O
002	O
),	O
neutrophils	O
(	O
p	O
=	O
0	O
.	O
02	O
),	O
plasma	O
interleukin	O
-	O
8	O
(	O
p	O
=	O
0	O
.	O
003	O
),	O
and	O
plasma	O
matrix	O
metalloproteinase	O
-	O
8	O
(	O
p	O
=	O
0	O
.	O
006	O
).	O

Alveolar	O
epithelial	O
injury	O
after	O
LPS	O
was	O
more	O
severe	O
in	O
smokers	O
than	O
non	O
-	O
smokers	O
,	O
with	O
increased	O
plasma	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
and	O
decreased	O
BAL	B-ENZY
(	O
p	O
=	O
0	O
.	O
02	O
)	O
surfactant	O
protein	O
D	O
.	O
Finally	O
,	O
smokers	O
had	O
decreased	O
BAL	B-ENZY
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
with	O
increased	O
soluble	O
VEGF	O
receptor	O
-	O
1	O
(	O
p	O
=	O
0	O
.	O
0001	O
).	O

ABSTRACT	O
:	O
In	O
patients	O
who	O
developed	O
a	O
combined	O
situation	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
refractory	O
hypoxemia	O
and	O
acute	O
cardiac	O
failure	O
with	O
circulatory	O
collapse	O
,	O
traditional	O
veno	O
-	O
venous	O
or	O
veno	O
-	O
arterial	O
extracorporeal	O
membrane	O
oxygenation	O
approach	O
alone	O
may	O
not	O
be	O
sufficient	O
enough	O
to	O
maintain	O
both	O
an	O
acceptable	O
range	O
of	O
gas	B-ENZY
exchange	O
and	O
a	O
hemodynamic	O
stability	O
.	O

In	O
this	O
study	O
,	O
diverse	O
coronaviruses	O
(	O
CoVs	O
)	O
were	O
detected	O
in	O
50	O
of	O
951	O
(	O
positive	O
rate	O
5	O
.	O
3	O
%)	O
intestinal	O
specimens	O
of	O
eight	O
bat	B-ENZY
species	O
collected	O
in	O
four	O
provinces	O
and	O
the	O
Tibet	O
Autonomous	O
Region	O
of	O
China	O
by	O
pan	O
-	O
coronavirus	O
RT	O
-	O
PCR	O
screening	O
.	O

Two	O
new	O
species	O
of	O
bat	B-ENZY
CoV	O
,	O
identified	O
through	O
sequence	O
comparison	O
and	O
phylogenetic	O
analysis	O
,	O
are	O
proposed	O
.	O

ABSTRACT	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
lung	O
assist	O
(	O
ECLA	O
)	O
can	O
provide	O
sufficient	O
gas	B-ENZY
exchange	O
even	O
in	O
most	O
severe	O
cases	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Therefore	O
,	O
we	O
developed	O
a	O
demonstrator	O
with	O
an	O
integrated	O
control	O
algorithm	O
to	O
keep	O
continuously	O
measured	O
peripheral	O
oxygen	O
saturation	O
and	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
constant	O
by	O
automatically	O
adjusting	O
extracorporeal	O
blood	O
and	O
gas	B-ENZY
flow	O
.	O

The	O
""""	O
SmartECLA	O
""""	O
system	O
was	O
tested	O
in	O
six	O
animal	O
experiments	O
with	O
increasing	O
pulmonary	O
hypoventilation	O
and	O
hypoxic	O
inspiratory	O
gas	B-ENZY
mixture	O
to	O
simulate	O
progressive	O
acute	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
Biochemical	O
characterization	O
of	O
a	O
multi	O
-	O
drug	O
resistant	O
HIV	O
-	O
1	O
subtype	O
AG	O
reverse	B-ENZY
transcriptase	I-ENZY
:	O
antagonism	O
of	O
AZT	O
discrimination	O
and	O
excision	O
pathways	O
and	O
sensitivity	O
to	O
RNase	B-ENZY
H	I-ENZY
inhibitors	O
.	O

All	O
MR	O
-	O
RTs	O
exhibited	O
similar	O
sensitivity	O
toward	O
RNase	B-ENZY
H	I-ENZY
inhibitors	O
belonging	O
to	O
different	O
inhibitor	O
classes	O
,	O
indicating	O
the	O
importance	O
of	O
developing	O
RNase	B-ENZY
H	I-ENZY
inhibitors	O
further	O
as	O
anti	O
-	O
HIV	O
drugs	O
.	O

Aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
)	O
and	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
levels	O
were	O
highest	O
on	O
the	O
day	O
that	O
the	O
patient	O
developed	O
ALF	O
.	O

Lactate	O
dehydrogenase	O
levels	O
had	O
positive	O
correlations	O
with	O
AST	B-ENZY
(	O
r	O
=	O
0	O
.	O
95	O
)	O
and	O
ALT	O
(	O
r	O
=	O
0	O
.	O
87	O
)	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
).	O

The	O
median	O
(	O
interquartile	O
range	O
)	O
days	O
before	O
the	O
AST	B-ENZY
and	O
ALT	O
levels	O
returned	O
to	O
lower	O
than	O
200	O
U	O
/	O
L	O
after	O
the	O
ALF	O
were	O
10	O
.	O
5	O
(	O
8	O
.	O
8	O
,	O
12	O
.	O
8	O
)	O
and	O
10	O
.	O
5	O
(	O
7	O
.	O
8	O
,	O
14	O
.	O
0	O
)	O
days	O
,	O
respectively	O
.	O

Anti	O
-	O
infectious	O
therapy	O
was	O
escalated	O
to	O
additional	O
linezolid	O
and	O
liposomal	O
amphotericine	O
-	O
B	O
.	O
BAL	B-ENZY
revealed	O
a	O
significant	O
viral	O
load	O
of	O
HCoV	O
-	O
NL63	O
.	O

Virus	O
targets	O
included	O
the	O
influenza	O
haemagglutinin	O
,	O
neuraminidase	B-ENZY
and	O
M2	O
proteins	O
,	O
and	O
both	O
the	O
respiratory	O
syncytial	O
virus	O
and	O
influenza	O
polymerases	O
and	O
nucleoproteins	O
.	O

TITLE	O
:	O
Recombinant	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
H120	O
vaccine	O
strain	O
expressing	O
the	O
hemagglutinin	O
-	O
neuraminidase	B-ENZY
(	O
HN	O
)	O
protein	O
of	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
)	O
protects	O
chickens	O
against	O
IBV	O
and	O
NDV	O
challenge	O
.	O

In	O
this	O
study	O
,	O
using	O
a	O
previously	O
established	O
reverse	O
genetics	O
system	O
,	O
we	O
generated	O
a	O
recombinant	O
IBV	O
virus	O
based	O
on	O
the	O
IBV	O
H120	O
vaccine	O
strain	O
expressing	O
the	O
haemagglutinin	O
-	O
neuraminidase	B-ENZY
(	O
HN	O
)	O
protein	O
of	O
NDV	O
.	O

Primaquine	O
(	O
for	O
eradication	O
of	O
P	O
.	O
vivax	O
or	O
P	O
.	O
ovale	O
hypnozoites	O
)	O
is	O
contraindicated	O
in	O
pregnancy	O
and	O
when	O
breastfeeding	O
(	O
until	O
the	O
G6PD	B-ENZY
status	O
of	O
child	O
is	O
known	O
);	O
after	O
initial	O
treatment	O
for	O
these	O
infections	O
a	O
pregnant	O
woman	O
should	O
take	O
weekly	O
chloroquine	O
prophylaxis	O
until	O
after	O
delivery	O
or	O
cessation	O
of	O
breastfeeding	O
when	O
hypnozoite	O
eradication	O
can	O
be	O
considered	O
.	O

During	O
ALI	O
,	O
the	O
NLRP3	O
inflammasome	O
is	O
significantly	O
activated	O
with	O
a	O
large	O
amount	O
of	O
IL	O
-	O
1	O
and	O
the	O
activated	O
caspase	B-ENZY
-	I-ENZY
1	I-ENZY
occurring	O
in	O
the	O
lung	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
of	O
bats	O
as	O
a	O
potential	O
reservoir	O
for	O
MERS	O
-	O
CoV	O
.	O
In	O
vitro	O
,	O
the	O
MERS	O
-	O
CoV	O
spike	O
glycoprotein	O
interacted	O
with	O
Jamaican	O
fruit	O
bat	B-ENZY
(	O
Artibeus	O
jamaicensis	O
)	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
)	O
receptor	O
and	O
MERS	O
-	O
CoV	O
replicated	O
efficiently	O
in	O
Jamaican	O
fruit	O
bat	B-ENZY
cells	O
,	O
suggesting	O
there	O
is	O
no	O
restriction	O
at	O
the	O
receptor	O
or	O
cellular	O
level	O
for	O
MERS	O
-	O
CoV	O
.	O
To	O
shed	O
light	O
on	O
the	O
intrinsic	O
host	O
-	O
virus	O
relationship	O
,	O
we	O
inoculated	O
10	O
Jamaican	O
fruit	O
bats	O
with	O
MERS	O
-	O
CoV	O
.	O
Although	O
all	O
bats	O
showed	O
evidence	O
of	O
infection	O
,	O
none	O
of	O
the	O
bats	O
showed	O
clinical	O
signs	O
of	O
disease	O
.	O

Herein	O
,	O
we	O
investigated	O
the	O
interactions	O
between	O
the	O
S	O
protein	O
and	O
its	O
receptor	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
or	O
co	O
-	O
receptor	O
sugars	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
wet	O
/	O
dry	O
ratio	O
and	O
gas	B-ENZY
exchange	O
levels	O
.	O

In	O
archived	O
formalin	O
-	O
fixed	O
and	O
paraffin	O
wax	O
-	O
embedded	O
lung	O
samples	O
from	O
68	O
cases	O
with	O
the	O
clinical	O
and	O
histologic	O
diagnosis	O
of	O
pneumonia	O
the	O
histological	O
pattern	O
of	O
pneumonia	O
was	O
re	O
-	O
evaluated	O
and	O
the	O
samples	O
were	O
further	O
investigated	O
for	O
the	O
following	O
infectious	O
agents	O
:	O
canine	O
distemper	O
virus	O
(	O
CDV	O
),	O
canine	O
adenovirus	O
type	O
2	O
(	O
CAV	O
-	O
2	O
),	O
canine	O
respiratory	O
coronavirus	O
(	O
CRCoV	O
),	O
Bordetella	O
(	O
B	O
.)	O
bronchiseptica	O
,	O
Pasteurella	O
(	O
P	O
.)	O
multocida	O
,	O
Mycoplasma	O
spp	B-ENZY
.,	O
and	O
Pneumocystis	O
spp	B-ENZY
.	O

TITLE	O
:	O
Coexistence	O
of	O
multiple	O
coronaviruses	O
in	O
several	O
bat	B-ENZY
colonies	O
in	O
an	O
abandoned	O
mineshaft	O
.	O

Bats	O
are	O
likely	O
the	O
natural	O
reservoir	O
of	O
alpha	O
-	O
and	O
betacoronaviruses	O
,	O
and	O
due	O
to	O
the	O
rich	O
diversity	O
and	O
global	O
distribution	O
of	O
bats	O
,	O
the	O
number	O
of	O
bat	B-ENZY
coronaviruses	O
will	O
likely	O
increase	O
.	O

Six	O
bat	B-ENZY
species	O
were	O
frequently	O
detected	O
in	O
the	O
cave	O
:	O
Rhinolophus	O
sinicus	O
,	O
Rhinolophus	O
affinis	O
,	O
Hipposideros	O
pomona	O
,	O
Miniopterus	O
schreibersii	O
,	O
Miniopterus	O
fuliginosus	O
,	O
and	O
Miniopterus	O
fuscus	O
.	O

By	O
sequencing	O
PCR	O
products	O
of	O
the	O
coronavirus	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
gene	O
(	O
RdRp	O
),	O
we	O
found	O
a	O
high	O
frequency	O
of	O
infection	O
by	O
a	O
diverse	O
group	O
of	O
coronaviruses	O
in	O
different	O
bat	B-ENZY
species	O
in	O
the	O
mineshaft	O
.	O

Moreover	O
,	O
melanoma	O
differentiation	O
-	O
associated	O
protein	O
5	O
(	O
MDA5	O
),	O
laboratory	O
of	O
genetics	O
and	O
physiology	O
2	O
(	O
LGP2	O
),	O
stimulator	O
of	O
IFN	O
genes	O
(	O
STING	O
),	O
and	O
mitochondrial	O
antiviral	O
signaling	O
protein	O
(	O
MAVS	O
),	O
as	O
well	O
as	O
TANK	O
binding	O
kinase	O
1	O
(	O
TBK1	B-ENZY
),	O
inhibitor	O
of	O
kappaB	O
kinase	O
(	O
IKK	B-ENZY
)	O
	O
,	O
IKK	O
,	O
IKK	O
,	O
IFN	O
regulatory	O
factor	O
(	O
IRF	O
)	O
7	O
,	O
nuclear	O
factor	O
of	O
kappaB	O
(	O
NF	O
-	O
B	O
),	O
IFN	O
-	O
	O
,	O
IFN	O
-	O
	O
,	O
various	O
interleukins	O
(	O
ILs	O
),	O
and	O
macrophage	O
inflammatory	O
protein	O
-	O
1	O
(	O
MIP	O
-	O
1	O
)	O
were	O
significantly	O
upregulated	O
in	O
the	O
trachea	O
and	O
downregulated	O
in	O
the	O
kidney	O
.	O

Phylogenetic	O
and	O
sequencing	O
data	O
strongly	O
suggest	O
that	O
MERS	O
-	O
CoV	O
originated	O
from	O
bat	B-ENZY
ancestors	O
after	O
undergoing	O
a	O
recombination	O
event	O
in	O
the	O
spike	O
protein	O
,	O
possibly	O
in	O
dromedary	O
camels	O
in	O
Africa	O
,	O
before	O
its	O
exportation	O
to	O
the	O
Arabian	O
Peninsula	O
along	O
the	O
camel	O
trading	O
routes	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
HIV	O
-	O
1	O
Reverse	B-ENZY
Transcriptase	I-ENZY
Dimerization	O
by	O
Small	O
Molecules	O
.	O

ABSTRACT	O
:	O
Because	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
is	O
an	O
enzyme	O
whose	O
catalytic	O
activity	O
depends	O
on	O
its	O
heterodimeric	O
structure	O
,	O
this	O
system	O
could	O
be	O
a	O
target	O
for	O
inhibitors	O
that	O
perturb	O
the	O
interactions	O
between	O
the	O
protein	O
subunits	O
,	O
p51	O
and	O
p66	O
.	O

TITLE	O
:	O
Glycopeptide	O
Antibiotics	O
Potently	O
Inhibit	O
Cathepsin	B-ENZY
L	I-ENZY
in	O
the	O
Late	O
Endosome	O
/	O
Lysosome	O
and	O
Block	O
the	O
Entry	O
of	O
Ebola	O
Virus	O
,	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
and	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

The	O
re	O
-	O
emergence	O
of	O
SARS	O
-	O
CoV	O
remains	O
a	O
valid	O
concern	O
due	O
to	O
the	O
continual	O
persistence	O
of	O
zoonotic	O
SARS	O
-	O
CoVs	O
and	O
SARS	O
-	O
like	O
CoVs	O
(	O
SL	O
-	O
CoVs	O
)	O
in	O
bat	B-ENZY
reservoirs	O
.	O

TITLE	O
:	O
Conserved	O
antigenic	O
sites	O
between	O
MERS	O
-	O
CoV	O
and	O
Bat	B-ENZY
-	O
coronavirus	O
are	O
revealed	O
through	O
sequence	O
analysis	O
.	O

ABSTRACT	O
:	O
MERS	O
-	O
CoV	O
is	O
a	O
newly	O
emerged	O
human	O
coronavirus	O
reported	O
closely	O
related	O
with	O
HKU4	O
and	O
HKU5	O
Bat	B-ENZY
coronaviruses	O
.	O

It	O
is	O
of	O
importance	O
to	O
elucidate	O
the	O
shared	O
antigenic	O
-	O
sites	O
and	O
extent	O
of	O
conservation	O
between	O
them	O
to	O
understand	O
the	O
evolutionary	O
dynamics	O
of	O
MERS	O
-	O
CoV	O
.	O
Multiple	O
sequence	O
alignment	O
of	O
the	O
spike	O
(	O
S	O
),	O
membrane	O
(	O
M	O
),	O
enveloped	O
(	O
E	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	O
was	O
employed	O
to	O
identify	O
the	O
sequence	O
conservation	O
among	O
MERS	O
and	O
Bat	B-ENZY
(	O
HKU4	O
,	O
HKU5	O
)	O
coronaviruses	O
.	O

This	O
sharing	O
suggests	O
that	O
in	O
case	O
of	O
pathogenicity	O
MERS	O
-	O
CoV	O
is	O
more	O
closely	O
related	O
to	O
HKU5	O
bat	B-ENZY
-	O
CoV	O
than	O
HKU4	O
bat	B-ENZY
-	O
CoV	O
.	O
The	O
conserved	O
epitopes	O
indicates	O
their	O
evolutionary	O
relationship	O
and	O
ancestry	O
of	O
pathogenicity	O
.	O

CONCLUSIONS	O
:	O
This	O
sharing	O
suggests	O
that	O
in	O
case	O
of	O
pathogenicity	O
MERS	O
-	O
CoV	O
is	O
more	O
closely	O
related	O
to	O
HKU5	O
bat	B-ENZY
-	O
CoV	O
than	O
HKU4	O
bat	B-ENZY
-	O
CoV	O
.	O
The	O
conserved	O
epitopes	O
indicates	O
their	O
evolutionary	O
relationship	O
and	O
ancestry	O
of	O
pathogenicity	O
.	O

The	O
subsequent	O
effects	O
of	O
inbreeding	O
were	O
measured	O
using	O
42	O
genome	O
-	O
wide	O
STR	B-ENZY
markers	O
.	O

The	O
animals	O
were	O
then	O
ventilated	O
with	O
either	O
HFJV	O
or	O
CMV	O
for	O
4	O
h	O
.	O
Ventilatory	O
pressures	O
,	O
blood	O
gases	O
,	O
and	O
indexes	O
of	O
gas	B-ENZY
exchange	O
were	O
assessed	O
.	O

Novel	O
kinase	O
inhibitors	O
SB203580	O
(	O
MAPK	B-ENZY
-	O
2	O
antagonist	O
)	O
and	O
LY294002	O
(	O
phosphoinositide	O
-	O
3	O
kinases	O
antagonist	O
)	O
exhibit	O
promising	O
anti	O
-	O
MERS	O
-	O
CoV	O
activity	O
.	O

In	O
this	O
issue	O
of	O
the	O
JCI	O
,	O
Peteranderl	O
and	O
colleagues	O
define	O
a	O
paracrine	O
communication	O
between	O
macrophages	O
and	O
type	O
II	O
alveolar	O
epithelial	O
cells	O
during	O
influenza	O
infection	O
where	O
IFN	O
induces	O
macrophage	O
secretion	O
of	O
TRAIL	O
that	O
causes	O
endocytosis	O
of	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
by	O
the	O
alveolar	O
epithelium	O
.	O

This	O
reduction	O
of	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
expression	O
decreases	O
alveolar	O
fluid	O
clearance	O
,	O
which	O
in	O
turn	O
leads	O
to	O
pulmonary	O
edema	O
.	O

To	O
modulate	O
carbon	O
dioxide	O
extraction	O
,	O
ECMO	O
gas	B-ENZY
flow	O
(	O
GF	O
)	O
was	O
decreased	O
from	O
baseline	O
resting	O
protective	O
conditions	O
(	O
i	O
.	O
e	O
.,	O
GF100	O
%,	O
set	O
to	O
obtain	O
pressure	O
generated	O
in	O
the	O
first	O
100	O
ms	O
of	O
inspiration	O
against	O
an	O
occluded	O
airway	O
less	O
than	O
2	O
cm	O
H2O	O
,	O
respiratory	O
rate	O
less	O
than	O
or	O
equal	O
to	O
25	O
bpm	O
,	O
tidal	O
volume	O
less	O
than	O
6	O
ml	O
/	O
kg	O
,	O
and	O
peak	O
airway	O
pressure	O
less	O
than	O
25	O
cm	O
H2O	O
)	O
to	O
GF50	O
%-	O
GF25	O
%-	O
GF0	O
%	O
during	O
both	O
PSV	O
and	O
NAVA	O
(	O
random	O
order	O
for	O
ventilation	O
mode	O
).	O

We	O
evaluated	O
respiratory	O
indexes	O
(	O
PaO2	O
,	O
PaO2	O
/	O
FiO2	O
,	O
alveolar	O
-	O
arterial	O
oxygen	O
difference	O
,	O
intrapulmonary	O
arteriovenous	O
shunt	O
percentage	O
,	O
and	O
respiratory	O
rate	O
),	O
blood	O
biochemical	O
(	O
creatinine	O
,	O
blood	O
urea	O
nitrogen	O
,	O
alanine	B-ENZY
aminotransferase	I-ENZY
,	O
and	O
lactate	O
levels	O
)	O
and	O
inflammatory	O
(	O
CRP	O
,	O
IL	O
-	O
10	O
,	O
TNF	O
-	O
	O
,	O
and	O
IL	O
-	O
10	O
/	O
TNF	O
-	O
	O
ratio	O
)	O
markers	O
,	O
and	O
prognostic	O
outcomes	O
(	O
multiple	O
organ	O
dysfunction	O
syndrome	O
[	O
MODS	O
]	O
and	O
APACHE	O
II	O
scores	O
)	O
before	O
and	O
72	O
hours	O
after	O
the	O
treatment	O
.	O

Serum	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
)	O
was	O
raised	O
>	O
3	O
-	O
fold	O
in	O
17	O
.	O
16	O
%	O
and	O
serum	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
in	O
4	O
.	O
47	O
%	O
cases	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
NS4b	O
Protein	O
Inhibits	O
Host	O
RNase	B-ENZY
L	O
Activation	O
.	O

Activated	O
RNase	B-ENZY
L	O
cleaves	O
viral	O
and	O
host	O
single	O
-	O
stranded	O
RNA	O
(	O
ssRNA	O
),	O
which	O
leads	O
to	O
translational	O
arrest	O
and	O
subsequent	O
cell	O
death	O
,	O
preventing	O
viral	O
replication	O
and	O
spread	O
.	O

Here	O
we	O
report	O
that	O
MERS	O
-	O
CoV	O
,	O
a	O
lineage	O
CBetacoronavirus	O
,	O
and	O
related	O
bat	B-ENZY
CoV	O
NS4b	O
accessory	O
proteins	O
have	O
phosphodiesterase	B-ENZY
(	O
PDE	O
)	O
activity	O
and	O
antagonize	O
OAS	O
-	O
RNase	B-ENZY
L	O
by	O
enzymatically	O
degrading	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
(	O
2	O
-	O
5A	O
),	O
activators	O
of	O
RNase	B-ENZY
L	O
.	O
This	O
is	O
a	O
novel	O
function	O
for	O
NS4b	O
,	O
which	O
has	O
previously	O
been	O
reported	O
to	O
antagonize	O
IFN	O
signaling	O
.	O

However	O
,	O
the	O
expression	O
level	O
of	O
cytoplasmic	O
MERS	O
-	O
CoV	O
NS4b	O
protein	O
is	O
sufficient	O
to	O
prevent	O
activation	O
of	O
RNase	B-ENZY
L	O
.	O
Finally	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
RNase	B-ENZY
L	O
antagonist	O
expressed	O
by	O
a	O
human	O
or	O
bat	B-ENZY
coronavirus	O
and	O
provides	O
a	O
specific	O
mechanism	O
by	O
which	O
this	O
occurs	O
.	O

We	O
found	O
that	O
MERS	O
-	O
CoV	O
NS4b	O
and	O
homologs	O
from	O
related	O
lineage	O
C	O
bat	B-ENZY
betacoronaviruses	O
BtCoV	O
-	O
SC2013	O
(	O
SC2013	O
)	O
and	O
BtCoV	O
-	O
HKU5	O
(	O
HKU5	O
)	O
are	O
members	O
of	O
the	O
2H	O
-	O
phosphoesterase	O
(	O
2H	O
-	O
PE	O
)	O
enzyme	O
family	O
with	O
phosphodiesterase	B-ENZY
(	O
PDE	O
)	O
activity	O
.	O

Like	O
murine	O
coronavirus	O
NS2	O
,	O
a	O
previously	O
characterized	O
PDE	O
,	O
MERS	O
NS4b	O
,	O
can	O
antagonize	O
activation	O
of	O
the	O
OAS	O
-	O
RNase	B-ENZY
L	O
pathway	O
,	O
an	O
interferon	O
-	O
induced	O
potent	O
antiviral	O
activity	O
.	O

Furthermore	O
,	O
MERS	O
-	O
CoV	O
mutants	O
with	O
deletion	O
of	O
genes	O
encoding	O
accessory	O
proteins	O
NS3	O
to	O
NS5	O
or	O
NS4b	O
alone	O
or	O
inactivation	O
of	O
the	O
PDE	O
can	O
activate	O
RNase	B-ENZY
L	O
during	O
infection	O
of	O
Calu	O
-	O
3	O
cells	O
.	O

The	O
VEEV	O
nsP2	O
protease	O
is	O
a	O
member	O
of	O
MEROPS	O
Clan	O
CN	O
and	O
characteristically	O
contains	O
a	O
papain	B-ENZY
-	O
like	O
protease	O
linked	O
to	O
an	O
S	O
-	O
adenosyl	O
-	O
l	O
-	O
methionine	O
-	O
dependent	O
RNA	O
methyltransferase	O
(	O
SAM	O
MTase	O
)	O
domain	O
.	O

The	O
protease	O
contains	O
an	O
alternative	O
active	O
site	O
motif	O
,	O
(	O
475	O
)	O
NVCWAK	O
(	O
480	O
),	O
which	O
differs	O
from	O
papain	B-ENZY
'	O
s	O
(	O
CGS	O
(	O
25	O
)	O
CWAFS	O
),	O
and	O
the	O
enzyme	O
lacks	O
a	O
transition	O
state	O
-	O
stabilizing	O
residue	O
homologous	O
to	O
Gln	O
-	O
19	O
in	O
papain	B-ENZY
.	O

An	O
Asn	O
homologous	O
to	O
N475	O
is	O
similarly	O
found	O
in	O
coronaviral	O
papain	B-ENZY
-	O
like	O
proteases	O
(	O
PLpro	O
)	O
of	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
virus	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
)	O
virus	O
.	O

Of	O
these	O
50	O
alpaca	O
crias	O
,	O
20	O
presented	O
with	O
a	O
single	O
infection	O
(	O
19	O
positive	O
for	O
Eimeria	O
spp	B-ENZY
.	O
and	O
1	O
positive	O
for	O
rotavirus	O
).	O

RESULTS	O
:	O
Laboratory	O
testing	O
of	O
the	O
50	O
crias	O
included	O
in	O
this	O
study	O
revealed	O
that	O
80	O
%	O
were	O
infected	O
with	O
Eimeria	O
spp	B-ENZY
.,	O
40	O
%	O
with	O
coronavirus	O
,	O
34	O
%	O
with	O
E	O
.	O
coli	O
,	O
32	O
%	O
with	O
rotavirus	O
,	O
22	O
%	O
with	O
Clostridium	O
spp	B-ENZY
.,	O
and	O
20	O
%	O
with	O
Cryptosporidium	O
spp	B-ENZY
.	O

His	O
respiratory	O
sounds	O
were	O
clear	O
and	O
chest	O
radiography	O
did	O
not	O
show	O
any	O
abnormal	O
shadows	O
,	O
but	O
his	O
arterial	O
blood	O
gas	B-ENZY
examination	O
showed	O
type	O
II	O
respiratory	O
failure	O
.	O

Our	O
findings	O
support	O
the	O
virus	O
-	O
host	O
co	O
-	O
evolution	O
hypothesis	O
,	O
with	O
the	O
detection	O
of	O
Miniopterus	O
bat	B-ENZY
coronavirus	O
HKU8	O
(	O
previously	O
reported	O
in	O
Miniopterus	O
species	O
in	O
China	O
,	O
Hong	O
Kong	O
and	O
Bulgaria	O
)	O
in	O
Australian	O
Miniopterus	O
species	O
.	O

Similarly	O
,	O
we	O
detected	O
a	O
novel	O
betacoronavirus	O
genotype	O
from	O
Pteropus	O
alecto	O
which	O
is	O
most	O
closely	O
related	O
to	O
Bat	B-ENZY
coronavirus	O
HKU9	O
identified	O
in	O
other	O
pteropodid	O
bats	O
in	O
China	O
,	O
Kenya	O
and	O
the	O
Philippines	O
.	O

We	O
also	O
detected	O
possible	O
cross	O
-	O
species	O
transmission	O
of	O
bat	B-ENZY
coronaviruses	O
,	O
and	O
the	O
apparent	O
enteric	O
tropism	O
of	O
these	O
viruses	O
.	O

To	O
maintain	O
viable	O
gas	B-ENZY
exchange	O
,	O
the	O
mechanical	O
ventilation	O
becomes	O
progressively	O
more	O
risky	O
going	O
from	O
mild	O
to	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Fecal	O
samples	O
were	O
tested	O
by	O
PEDV	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
.	O

TITLE	O
:	O
Roles	O
of	O
neurally	O
adjusted	O
ventilatory	O
assist	O
in	O
improving	O
gas	B-ENZY
exchange	O
in	O
a	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
patient	O
after	O
weaning	O
from	O
extracorporeal	O
membrane	O
oxygenation	O
:	O
a	O
case	O
report	O
.	O

Dynamic	O
compliance	O
at	O
withdrawal	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
decreased	O
to	O
20	O
ml	O
/	O
cmH2O	O
or	O
less	O
,	O
but	O
gas	B-ENZY
exchange	O
was	O
maintained	O
by	O
full	O
support	O
with	O
assist	O
/	O
control	O
mode	O
.	O

Arterial	O
blood	O
gas	B-ENZY
and	O
ventilator	O
setting	O
on	O
Days	O
0	O
and	O
1	O
were	O
obtained	O
.	O

Jejunum	O
GLUT2	O
mRNA	O
abundance	O
and	O
sucrase	B-ENZY
,	O
maltase	B-ENZY
,	O
and	O
Na	O
+/	O
K	O
+	O
adenosine	O
triphosphatase	B-ENZY
activities	O
tended	O
to	O
be	O
increased	O
in	O
PRRS	O
pigs	O
compared	O
with	O
CON	O
pigs	O
(	O
<	O
0	O
.	O
06	O
).	O

The	O
renin	B-ENZY
-	O
angiotensin	O
system	O
(	O
RAS	O
),	O
one	O
of	O
the	O
primary	O
cardiovascular	O
regulatory	O
systems	O
,	O
has	O
been	O
proposed	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
lung	O
disease	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
M	O
protein	O
suppresses	O
type	O
I	O
interferon	O
expression	O
through	O
the	O
inhibition	O
of	O
TBK1	B-ENZY
-	O
dependent	O
phosphorylation	O
of	O
IRF3	O
.	O

This	O
suppressive	O
effect	O
was	O
found	O
to	O
be	O
specific	O
for	O
the	O
activation	O
of	O
IFN	O
regulatory	O
factor	O
3	O
(	O
IRF3	O
)	O
but	O
not	O
nuclear	O
factor	O
-	O
B	O
.	O
MERS	O
-	O
CoV	O
M	O
protein	O
interacted	O
with	O
TRAF3	O
and	O
disrupted	O
TRAF3	O
-	O
TBK1	B-ENZY
association	O
leading	O
to	O
reduced	O
IRF3	O
activation	O
.	O

Collectively	O
,	O
our	O
findings	O
suggest	O
a	O
common	O
and	O
conserved	O
mechanism	O
through	O
which	O
highly	O
pathogenic	O
MERS	O
-	O
CoV	O
and	O
SARS	O
-	O
CoV	O
harness	O
their	O
M	O
proteins	O
to	O
suppress	O
type	O
I	O
IFN	O
expression	O
at	O
the	O
level	O
of	O
TBK1	B-ENZY
-	O
dependent	O
phosphorylation	O
and	O
activation	O
of	O
IRF3	O
resulting	O
in	O
evasion	O
of	O
the	O
host	O
innate	O
antiviral	O
response	O
.	O

TITLE	O
:	O
Diminished	O
COX	O
-	O
2	O
/	O
PGE2	O
-	O
Mediated	O
Antiviral	O
Response	O
Due	O
to	O
Impaired	O
NOX	O
/	O
MAPK	B-ENZY
Signaling	O
in	O
G6PD	B-ENZY
-	O
Knockdown	O
Lung	O
Epithelial	O
Cells	O
.	O

G6PD	B-ENZY
-	O
deficient	O
cells	O
experience	O
a	O
high	O
level	O
of	O
oxidative	O
stress	O
and	O
an	O
increased	O
susceptibility	O
to	O
viral	O
infections	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
role	O
of	O
G6PD	B-ENZY
on	O
the	O
inflammatory	O
response	O
was	O
determined	O
in	O
both	O
scramble	O
control	O
and	O
G6PD	B-ENZY
-	O
knockdown	O
(	O
G6PD	B-ENZY
-	O
kd	O
)	O
A549	O
cells	O
upon	O
tumor	O
necrosis	O
factor	O
-	O
	O
(	O
TNF	O
-	O
	O
)	O
stimulation	O
.	O

A	O
decreased	O
expression	O
pattern	O
of	O
induced	O
COX	O
-	O
2	O
and	O
reduced	O
production	O
of	O
downstream	O
PGE2	O
occurred	O
upon	O
TNF	O
-	O
	O
stimulation	O
in	O
G6PD	B-ENZY
-	O
kd	O
A549	O
cells	O
compared	O
with	O
scramble	O
control	O
A549	O
cells	O
.	O

TNF	O
-	O
	O
-	O
induced	O
antiviral	O
activity	O
revealed	O
that	O
decreased	O
COX	O
-	O
2	O
expression	O
enhanced	O
the	O
susceptibility	O
to	O
coronavirus	O
229E	O
infection	O
in	O
G6PD	B-ENZY
-	O
kd	O
A549	O
cells	O
and	O
was	O
a	O
result	O
of	O
the	O
decreased	O
phosphorylation	O
levels	O
of	O
MAPK	B-ENZY
(	O
p38	O
and	O
ERK1	O
/	O
2	O
)	O
and	O
NF	O
-	O
B	O
.	O
The	O
impaired	O
inflammatory	O
response	O
in	O
G6PD	B-ENZY
-	O
kd	O
A549	O
cells	O
was	O
found	O
to	O
be	O
mediated	O
through	O
NADPH	O
oxidase	O
(	O
NOX	O
)	O
signaling	O
as	O
elucidated	O
by	O
cell	O
pretreatment	O
with	O
a	O
NOX2	O
-	O
siRNA	O
or	O
NOX	O
inhibitor	O
,	O
diphenyleneiodonium	O
chloride	O
(	O
DPI	O
).	O

In	O
addition	O
,	O
NOX	O
activity	O
with	O
TNF	O
-	O
	O
treatment	O
in	O
G6PD	B-ENZY
-	O
kd	O
A549	O
cells	O
was	O
not	O
up	O
-	O
regulated	O
and	O
was	O
coupled	O
with	O
a	O
decrease	O
in	O
NOX	O
subunit	O
expression	O
at	O
the	O
transcriptional	O
level	O
,	O
implying	O
that	O
TNF	O
-	O
	O
-	O
mediated	O
NOX	O
signaling	O
requires	O
the	O
participation	O
of	O
G6PD	B-ENZY
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
G6PD	B-ENZY
deficiency	O
affects	O
the	O
cellular	O
inflammatory	O
response	O
and	O
the	O
decreased	O
TNF	O
-	O
	O
-	O
mediated	O
antiviral	O
response	O
in	O
G6PD	B-ENZY
-	O
kd	O
A549	O
cells	O
is	O
a	O
result	O
of	O
dysregulated	O
NOX	O
/	O
MAPK	B-ENZY
/	O
NF	O
-	O
B	O
/	O
COX	O
-	O
2	O
signaling	O
.	O

In	O
this	O
study	O
,	O
an	O
easy	O
-	O
to	O
-	O
perform	O
SYBR	O
green	O
I	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
targeting	O
the	O
nucleocapsid	O
gene	O
of	O
IBV	O
was	O
developed	O
and	O
compared	O
with	O
conventional	O
agarose	O
gel	O
-	O
based	O
RT	O
-	O
PCR	O
for	O
the	O
detection	O
of	O
IBV	O
infection	O
.	O

Swabs	O
and	O
tissue	O
homogenates	O
were	O
tested	O
by	O
gel	O
based	O
PCR	O
(	O
G	O
-	O
PCR	O
),	O
quantitative	O
-	O
PCR	O
(	O
qPCR	O
)	O
and	O
quantitative	O
real	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
and	O
viral	O
culture	O
.	O

ABSTRACT	O
:	O
In	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
gas	B-ENZY
exchange	O
and	O
respiratory	O
system	O
mechanics	O
(	O
compliance	O
)	O
are	O
severely	O
impaired	O
.	O

So	O
,	O
they	O
represent	O
a	O
significative	O
risk	O
for	O
human	O
and	O
animal	O
public	O
health	O
,	O
that	O
justifies	O
to	O
set	O
up	O
surveillance	O
of	O
bat	B-ENZY
-	O
associated	O
viruses	O
and	O
research	O
programs	O
about	O
the	O
particular	O
immunity	O
mechanisms	O
of	O
bats	O
.	O

RVA	O
isolation	O
was	O
carried	O
out	O
on	O
MA104	O
cells	O
after	O
inoculates	O
were	O
treated	O
with	O
different	O
concentrations	O
of	O
trypsin	B-ENZY
TPCK	O
.	O

At	O
lower	O
TPCK	O
concentration	O
(	O
3	O
-	O
10	O
g	O
/	O
inoculum	O
),	O
no	O
changes	O
at	O
the	O
cellular	O
level	O
were	O
observed	O
,	O
while	O
cells	O
activated	O
with	O
25	O
-	O
30	O
g	O
of	O
trypsin	B-ENZY
/	O
inoculums	O
,	O
they	O
degenerated	O
and	O
trypsin	B-ENZY
cytotoxicity	O
was	O
enhanced	O
.	O

Appreciable	O
changes	O
in	O
cell	O
'	O
s	O
morphology	O
were	O
detected	O
with	O
optimal	O
trypsin	B-ENZY
concentration	O
of	O
15	O
-	O
20	O
g	O
trypsin	B-ENZY
/	O
inoculums	O
.	O

Current	O
evidence	O
strongly	O
supports	O
that	O
prone	O
positioning	O
has	O
beneficial	O
effects	O
on	O
gas	B-ENZY
exchange	O
,	O
respiratory	O
mechanics	O
,	O
lung	O
protection	O
and	O
hemodynamics	O
as	O
it	O
redistributes	O
transpulmonary	O
pressure	O
,	O
stress	O
and	O
strain	O
throughout	O
the	O
lung	O
and	O
unloads	O
the	O
right	O
ventricle	O
.	O

ABSTRACT	O
:	O
Hantavirus	O
diseases	O
are	O
emerging	O
human	O
diseases	O
caused	O
by	O
Hantavirus	O
spp	B-ENZY
.	O

Hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	B-ENZY
)	O
has	O
been	O
detected	O
in	O
the	O
Federal	O
District	O
(	O
DF	O
)	O
of	O
Brazil	O
since	O
2004	O
.	O

In	O
the	O
DF	O
,	O
the	O
cumulative	O
incidence	O
of	O
HPS	B-ENZY
was	O
one	O
of	O
the	O
highest	O
worldwide	O
.	O

TITLE	O
:	O
SARS	O
Coronavirus	O
Papain	B-ENZY
-	O
Like	O
Protease	O
Inhibits	O
the	O
TLR7	O
Signaling	O
Pathway	O
through	O
Removing	O
Lys63	O
-	O
Linked	O
Polyubiquitination	O
of	O
TRAF3	O
and	O
TRAF6	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLPro	O
)	O
reportedly	O
inhibits	O
the	O
production	O
of	O
type	O
I	O
interferons	O
(	O
IFNs	O
)	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
in	O
Toll	O
-	O
like	O
receptor	O
3	O
(	O
TLR3	O
)	O
and	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
1	O
(	O
RIG	O
-	O
I	O
)	O
pathways	O
.	O

TLR7	O
agonist	O
(	O
imiquimod	O
(	O
IMQ	O
))	O
concentration	O
-	O
dependently	O
induced	O
activation	O
of	O
ISRE	O
-,	O
NF	O
-	O
B	O
-	O
and	O
AP	O
-	O
1	O
-	O
luciferase	B-ENZY
reporters	O
,	O
as	O
well	O
as	O
the	O
production	O
of	O
IFN	O
-	O
	O
,	O
IFN	O
-	O
	O
,	O
TNF	O
-	O
	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
in	O
human	O
promonocyte	O
cells	O
.	O

The	O
results	O
revealed	O
that	O
the	O
antagonism	O
of	O
SARS	O
-	O
CoV	O
PLPro	O
on	O
TLR7	O
-	O
mediated	O
innate	O
immunity	O
was	O
associated	O
with	O
the	O
negative	O
regulation	O
of	O
TRAF3	O
/	O
6	O
-	O
TBK1	B-ENZY
-	O
IRF3	O
/	O
NF	O
-	O
B	O
/	O
AP1	O
signals	O
.	O

ABSTRACT	O
:	O
[	O
This	O
corrects	O
the	O
article	O
DOI	O
:	O
10	O
.	O
1371	O
/	O
journal	O
.	O
ppat	B-ENZY
.	O
1005531	O
.].	O

TITLE	O
:	O
Bat	B-ENZY
Severe	O
Acute	O
Respiratory	O
Syndrome	O
-	O
Like	O
Coronavirus	O
WIV1	O
Encodes	O
an	O
Extra	O
Accessory	O
Protein	O
,	O
ORFX	O
,	O
Involved	O
in	O
Modulation	O
of	O
the	O
Host	O
Immune	O
Response	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
induces	O
Egr	O
-	O
1	O
-	O
dependent	O
up	O
-	O
regulation	O
of	O
TGF	O
-	O
1	O
via	O
ROS	O
/	O
p38	O
MAPK	B-ENZY
/	O
STAT3	O
pathway	O
.	O

ABSTRACT	O
:	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
has	O
been	O
identified	O
in	O
TGF	O
-	O
1	O
up	O
-	O
regulation	O
in	O
human	O
promonocytes	O
(	O
Proteomics	O
2012	O
,	O
12	O
:	O
3193	O
-	O
205	O
).	O

Dual	O
luciferase	B-ENZY
reporter	O
assays	O
with	O
TGF	O
-	O
1	O
promoter	O
plasmids	O
indicated	O
that	O
TGF	O
-	O
1	O
promoter	O
region	O
between	O
-	O
175	O
to	O
-	O
60	O
,	O
the	O
Egr	O
-	O
1	O
binding	O
site	O
,	O
was	O
responsible	O
for	O
TGF	O
-	O
1	O
promoter	O
activation	O
induced	O
by	O
SARS	O
-	O
CoV	O
PLpro	O
.	O

Furthermore	O
,	O
the	O
inhibitors	O
for	O
ROS	O
(	O
YCG063	O
),	O
p38	O
MAPK	B-ENZY
(	O
SB203580	O
),	O
and	O
STAT3	O
(	O
Stattic	O
)	O
revealed	O
ROS	O
/	O
p38	O
MAPK	B-ENZY
/	O
STAT3	O
pathway	O
involving	O
in	O
Egr	O
-	O
1	O
dependent	O
activation	O
of	O
TGF	O
-	O
1	O
promoter	O
induced	O
by	O
PLpro	O
.	O

TITLE	O
:	O
Andrographolide	O
sulfonate	O
ameliorates	O
lipopolysaccharide	O
-	O
induced	O
acute	O
lung	O
injury	O
in	O
mice	O
by	O
down	O
-	O
regulating	O
MAPK	B-ENZY
and	O
NF	O
-	O
B	O
pathways	O
.	O

Moreover	O
,	O
andrographolide	O
sulfonate	O
markedly	O
suppressed	O
the	O
activation	O
of	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
as	O
well	O
as	O
p65	O
subunit	O
of	O
nuclear	O
factor	O
-	O
B	O
(	O
NF	O
-	O
B	O
).	O

In	O
summary	O
,	O
these	O
results	O
suggest	O
that	O
andrographolide	O
sulfonate	O
ameliorated	O
LPS	O
-	O
induced	O
ALI	O
in	O
mice	O
by	O
inhibiting	O
NF	O
-	O
B	O
and	O
MAPK	B-ENZY
-	O
mediated	O
inflammatory	O
responses	O
.	O

TITLE	O
:	O
Qingfei	O
Xiaoyan	O
Wan	O
,	O
a	O
traditional	O
Chinese	O
medicine	O
formula	O
,	O
ameliorates	O
Pseudomonas	O
aeruginosa	O
-	O
induced	O
acute	O
lung	O
inflammation	O
by	O
regulation	O
of	O
PI3K	O
/	O
AKT	O
and	O
Ras	O
/	O
MAPK	B-ENZY
pathways	O
.	O

In	O
addition	O
,	O
ATG	O
was	O
identified	O
as	O
the	O
primary	O
anti	O
-	O
inflammatory	O
agent	O
with	O
action	O
on	O
the	O
PI3K	O
/	O
AKT	O
and	O
Ras	O
/	O
MAPK	B-ENZY
pathways	O
.	O

CLA	O
and	O
CGA	O
enhanced	O
the	O
actions	O
of	O
ATG	O
and	O
exhibited	O
synergistic	O
NF	O
-	O
B	O
inactivation	O
effects	O
possibly	O
via	O
the	O
Ras	O
/	O
MAPK	B-ENZY
signaling	O
pathway	O
.	O

Moreover	O
,	O
CLA	O
is	O
speculated	O
to	O
target	O
FGFR	O
and	O
MEK	B-ENZY
firstly	O
.	O

Overall	O
,	O
QF	O
regulated	O
the	O
PI3K	O
/	O
AKT	O
and	O
Ras	O
/	O
MAPK	B-ENZY
pathways	O
to	O
inhibit	O
pathogenic	O
bacterial	O
infections	O
effectively	O
.	O

Pre	O
-	O
treatment	O
with	O
the	O
phosphodiesterase	B-ENZY
antagonist	O
pentoxifyllinum	O
(	O
PTX	O
)	O
obviously	O
attenuated	O
lung	O
injury	O
and	O
reduced	O
the	O
mortality	O
of	O
mice	O
with	O
cecal	O
ligature	O
and	O
puncture	O
(	O
CLP	O
)	O
induced	O
ARDS	O
,	O
while	O
raising	O
cAMP	O
levels	O
.	O

TITLE	O
:	O
Detection	O
of	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
-	O
Related	O
Coronavirus	O
and	O
Alphacoronavirus	O
in	O
the	O
Bat	B-ENZY
Population	O
of	O
Taiwan	O
.	O

ABSTRACT	O
:	O
Bats	O
have	O
been	O
demonstrated	O
to	O
be	O
natural	O
reservoirs	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
CoV	O
.	O
Faecal	O
samples	O
from	O
248	O
individuals	O
of	O
20	O
bat	B-ENZY
species	O
were	O
tested	O
for	O
partial	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
gene	O
of	O
CoV	O
and	O
57	O
faecal	O
samples	O
from	O
eight	O
bat	B-ENZY
species	O
were	O
tested	O
positive	O
.	O

Phylogenetic	O
analysis	O
classified	O
the	O
positive	O
samples	O
into	O
SARS	O
-	O
related	O
(	O
SARSr	O
)	O
CoV	O
,	O
Scotophilus	O
bat	B-ENZY
CoV	O
512	O
close	O
to	O
those	O
from	O
China	O
and	O
Philippines	O
,	O
and	O
Miniopterus	O
bat	B-ENZY
CoV	O
1A	O
-	O
related	O
lineages	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
Antigen	O
Processing	O
Machinery	O
and	O
Endogenous	O
Peptide	O
Presentation	O
of	O
a	O
Bat	B-ENZY
MHC	O
Class	O
I	O
Molecule	O
.	O

In	O
particular	O
,	O
little	O
is	O
known	O
about	O
bat	B-ENZY
adaptive	O
immunity	O
,	O
and	O
the	O
presence	O
of	O
functional	O
MHC	O
molecules	O
is	O
mostly	O
inferred	O
from	O
recently	O
described	O
genomes	O
.	O

We	O
identified	O
several	O
bat	B-ENZY
MHC	O
class	O
I	O
-	O
binding	O
partners	O
,	O
including	O
calnexin	O
,	O
calreticulin	O
,	O
protein	O
disulfide	O
isomerase	O
A3	O
,	O
tapasin	O
,	O
TAP1	O
,	O
and	O
TAP2	O
.	O

Additionally	O
,	O
endogenous	O
peptide	O
ligands	O
isolated	O
from	O
Ptal	B-ENZY
-	O
N	O
*	O
01	O
:	O
01	O
displayed	O
a	O
relatively	O
broad	O
length	O
distribution	O
and	O
an	O
unusual	O
preference	O
for	O
a	O
C	O
-	O
terminal	O
proline	O
residue	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
this	O
preference	O
for	O
C	O
-	O
terminal	O
proline	O
residues	O
was	O
observed	O
in	O
Hendra	O
virus	O
-	O
derived	O
peptides	O
presented	O
by	O
Ptal	B-ENZY
-	O
N	O
*	O
01	O
:	O
01	O
on	O
the	O
surface	O
of	O
infected	O
cells	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
to	O
identify	O
endogenous	O
and	O
viral	O
MHC	O
class	O
I	O
ligands	O
for	O
any	O
bat	B-ENZY
species	O
and	O
,	O
as	O
such	O
,	O
provides	O
an	O
important	O
avenue	O
for	O
monitoring	O
and	O
development	O
of	O
vaccines	O
against	O
major	O
bat	B-ENZY
-	O
borne	O
viruses	O
both	O
in	O
the	O
reservoir	O
and	O
spillover	O
hosts	O
.	O

Additionally	O
,	O
it	O
will	O
provide	O
a	O
foundation	O
to	O
understand	O
the	O
role	O
of	O
adaptive	O
immunity	O
in	O
bat	B-ENZY
antiviral	O
responses	O
.	O

Levels	O
of	O
TNF	O
-	O
a	O
,	O
Interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
1	O
,	O
IL	O
-	O
10	O
and	O
HMGB1	O
,	O
tissue	O
myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
activity	O
,	O
neutrophil	O
counts	O
and	O
total	O
protein	O
concentration	O
were	O
measured	O
.	O

Viral	O
infection	O
was	O
detected	O
by	O
multiplex	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
with	O
primers	O
specific	O
to	O
the	O
subtypes	O
HCoV	O
-	O
229E	O
/	O
NL63	O
and	O
OC43	O
/	O
HKU1	O
.	O

TITLE	O
:	O
Recognition	O
of	O
Lys48	O
-	O
Linked	O
Di	O
-	O
ubiquitin	O
and	O
Deubiquitinating	O
Activities	O
of	O
the	O
SARS	O
Coronavirus	O
Papain	B-ENZY
-	O
like	O
Protease	O
.	O

The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
is	O
a	O
DUB	O
that	O
cleaves	O
ISG15	O
,	O
a	O
two	O
-	O
domain	O
Ub	O
-	O
like	O
protein	O
,	O
and	O
Lys48	O
-	O
linked	O
polyUb	O
chains	O
,	O
releasing	O
diUb	O
(	O
Lys48	O
)	O
products	O
.	O

Heliox	O
might	O
prevent	O
intubation	O
or	O
improve	O
gas	B-ENZY
flow	O
in	O
mechanically	O
ventilated	O
patients	O
with	O
severe	O
asthma	O
.	O

ABSTRACT	O
:	O
Acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
)	O
is	O
the	O
most	O
common	O
cause	O
of	O
death	O
among	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
adult	O
patients	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
prevalence	O
and	O
prognosis	O
of	O
PVD	O
and	O
ACP	O
during	O
ACS	B-ENZY
-	O
ARDS	O
.	O

ARDS	O
episodes	O
were	O
assigned	O
to	O
ACS	B-ENZY
-	O
ARDS	O
or	O
nonACS	O
-	O
ARDS	O
group	O
according	O
to	O
whether	O
the	O
clinical	O
insult	O
was	O
ACS	B-ENZY
or	O
not	O
,	O
respectively	O
.	O

A	O
total	O
of	O
362	O
patients	O
were	O
analyzed	O
,	O
including	O
24	O
ACS	B-ENZY
-	O
ARDS	O
.	O

PVD	O
and	O
ACP	O
were	O
identified	O
,	O
respectively	O
,	O
in	O
24	O
(	O
100	O
%)	O
and	O
20	O
(	O
83	O
%)	O
ACS	B-ENZY
-	O
ARDS	O
patients	O
,	O
as	O
compared	O
with	O
204	O
(	O
60	O
%)	O
and	O
68	O
(	O
20	O
%)	O
nonACS	O
-	O
ARDS	O
patients	O
(	O
P	O
<	O
0	O
.	O
0001	O
).	O

The	O
mortality	O
did	O
not	O
differ	O
between	O
ACS	B-ENZY
-	O
ARDS	O
and	O
nonACS	O
-	O
ARDS	O
patients	O
.	O

Both	O
the	O
crude	O
(	O
odds	O
ratio	O
[	O
OR	O
],	O
19	O
.	O
9	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
6	O
.	O
6	O
-	O
60	O
;	O
P	O
<	O
0	O
.	O
0001	O
),	O
multivariable	O
adjustment	O
(	O
OR	O
,	O
27	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
8	O
.	O
2	O
-	O
91	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
propensity	O
-	O
matched	O
(	O
OR	O
,	O
11	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
110	O
.	O
8	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
analyses	O
found	O
a	O
significant	O
association	O
between	O
ACS	B-ENZY
-	O
ARDS	O
and	O
ACP	O
.	O

All	O
SCD	O
patients	O
presenting	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
as	O
a	O
consequence	O
of	O
ACS	B-ENZY
experienced	O
PVD	O
and	O
more	O
than	O
80	O
%	O
of	O
them	O
exhibited	O
ACP	O
.	O

These	O
results	O
suggest	O
a	O
predominant	O
role	O
for	O
PVD	O
in	O
the	O
pathogenesis	O
of	O
severe	O
forms	O
of	O
ACS	B-ENZY
.	O

RESULTS	O
:	O
A	O
total	O
of	O
362	O
patients	O
were	O
analyzed	O
,	O
including	O
24	O
ACS	B-ENZY
-	O
ARDS	O
.	O

Both	O
the	O
crude	O
(	O
odds	O
ratio	O
[	O
OR	O
],	O
19	O
.	O
9	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
6	O
.	O
6	O
-	O
60	O
;	O
P	O
<	O
0	O
.	O
0001	O
),	O
multivariable	O
adjustment	O
(	O
OR	O
,	O
27	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
8	O
.	O
2	O
-	O
91	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
propensity	O
-	O
matched	O
(	O
OR	O
,	O
11	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
110	O
.	O
8	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
analyses	O
found	O
a	O
significant	O
association	O
between	O
ACS	B-ENZY
-	O
ARDS	O
and	O
ACP	O
.	O

TITLE	O
:	O
Detection	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
-	O
Like	O
,	O
Middle	O
East	O
Respiratory	O
Syndrome	O
-	O
Like	O
Bat	B-ENZY
Coronaviruses	O
and	O
Group	O
H	O
Rotavirus	O
in	O
Faeces	O
of	O
Korean	O
Bats	O
.	O

In	O
this	O
study	O
,	O
consensus	O
primer	O
-	O
based	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reactions	O
(	O
RT	O
-	O
PCRs	O
)	O
and	O
high	O
-	O
throughput	O
sequencing	O
were	O
performed	O
to	O
investigate	O
viruses	O
in	O
bat	B-ENZY
faecal	O
samples	O
collected	O
at	O
11	O
natural	O
bat	B-ENZY
habitat	O
sites	O
from	O
July	O
to	O
December	O
2015	O
in	O
Korea	O
.	O

Diverse	O
coronaviruses	O
were	O
first	O
detected	O
in	O
Korean	O
bat	B-ENZY
faeces	O
,	O
including	O
alphacoronaviruses	O
,	O
SARS	O
-	O
CoV	O
-	O
like	O
and	O
MERS	O
-	O
CoV	O
-	O
like	O
betacoronaviruses	O
.	O

ABSTRACT	O
:	O
The	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
pathways	O
,	O
which	O
are	O
central	O
building	O
blocks	O
in	O
the	O
intracellular	O
signaling	O
network	O
,	O
are	O
often	O
manipulated	O
by	O
viruses	O
of	O
diverse	O
families	O
to	O
favor	O
their	O
replication	O
.	O

Among	O
the	O
MAPK	B-ENZY
family	O
,	O
the	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
(	O
ERK	B-ENZY
)	O
pathway	O
is	O
known	O
to	O
be	O
modulated	O
during	O
the	O
infection	O
with	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
);	O
however	O
,	O
involvement	O
of	O
stress	O
-	O
activated	O
protein	O
kinases	O
(	O
SAPKs	O
)	O
comprising	O
p38	O
MAPK	B-ENZY
and	O
c	O
-	O
Jun	O
NH2	O
-	O
terminal	O
kinase	O
(	O
JNK	B-ENZY
)	O
remains	O
to	O
be	O
determined	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
activation	O
of	O
p38	O
MAPK	B-ENZY
and	O
JNK	B-ENZY
cascades	O
is	O
required	O
for	O
PEDV	O
replication	O
.	O

Notably	O
,	O
UV	O
-	O
irradiated	O
inactivated	O
PEDV	O
,	O
which	O
can	O
enter	O
cells	O
but	O
cannot	O
replicate	O
inside	O
them	O
,	O
failed	O
to	O
induce	O
phosphorylation	O
of	O
p38	O
MAPK	B-ENZY
and	O
JNK1	O
/	O
2	O
suggesting	O
that	O
viral	O
biosynthesis	O
is	O
essential	O
for	O
activation	O
of	O
these	O
kinases	O
.	O

Treatment	O
of	O
cells	O
with	O
selective	O
p38	O
or	O
JNK	B-ENZY
inhibitors	O
markedly	O
impaired	O
PEDV	O
replication	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
these	O
antiviral	O
effects	O
were	O
found	O
to	O
be	O
maximal	O
during	O
the	O
early	O
times	O
of	O
the	O
infection	O
.	O

Furthermore	O
,	O
direct	O
pharmacological	O
inhibition	O
of	O
p38	O
MAPK	B-ENZY
or	O
JNK1	O
/	O
2	O
activation	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
viral	O
RNA	O
synthesis	O
,	O
viral	O
protein	O
expression	O
,	O
and	O
progeny	O
release	O
.	O

However	O
,	O
independent	O
treatments	O
with	O
either	O
SAPK	B-ENZY
inhibitor	O
did	O
not	O
inhibit	O
PEDV	O
-	O
induced	O
apoptotic	O
cell	O
death	O
mediated	O
by	O
activation	O
of	O
mitochondrial	O
apoptosis	O
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
suggesting	O
that	O
SAPKs	O
are	O
irrelevant	O
to	O
the	O
apoptosis	O
pathway	O
during	O
PEDV	O
infection	O
.	O

Based	O
on	O
a	O
scaffold	O
we	O
reported	O
for	O
inhibiting	O
neuraminidase	B-ENZY
(	O
NA	O
),	O
we	O
synthesized	O
the	O
analogues	O
and	O
identified	O
compounds	O
with	O
low	O
micromolar	O
inhibitory	O
activity	O
against	O
3CL	O
(	O
pro	O
)	O
of	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O
Docking	O
studies	O
show	O
that	O
a	O
carboxylate	O
present	O
at	O
either	O
R	O
(	O
1	O
)	O
or	O
R	O
(	O
4	O
)	O
destabilizes	O
the	O
oxyanion	O
hole	O
in	O
the	O
3CL	O
(	O
pro	O
).	O

There	O
was	O
no	O
impairment	O
in	O
arterial	O
blood	O
gas	B-ENZY
and	O
cardiopulmonary	O
parameters	O
after	O
FOB	O
.	O

TITLE	O
:	O
Structural	O
and	O
mutational	O
analysis	O
of	O
the	O
interaction	O
between	O
the	O
Middle	O
-	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
papain	B-ENZY
-	O
like	O
protease	O
and	O
human	O
ubiquitin	O
.	O

ABSTRACT	O
:	O
The	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	O
))	O
of	O
Middle	O
-	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
proteolytic	O
,	O
deubiquitinating	O
,	O
and	O
deISGylating	O
activities	O
.	O

Severe	O
ARDS	O
patients	O
should	O
receive	O
a	O
holistic	O
framework	O
of	O
respiratory	O
and	O
hemodynamic	O
support	O
aimed	O
to	O
ensure	O
adequate	O
gas	B-ENZY
exchange	O
while	O
minimizing	O
the	O
risk	O
of	O
VILI	O
,	O
by	O
promoting	O
lung	O
recruitment	O
and	O
setting	O
protective	O
mechanical	O
ventilation	O
.	O

CONCLUSIONS	O
:	O
Severe	O
ARDS	O
patients	O
should	O
receive	O
a	O
holistic	O
framework	O
of	O
respiratory	O
and	O
hemodynamic	O
support	O
aimed	O
to	O
ensure	O
adequate	O
gas	B-ENZY
exchange	O
while	O
minimizing	O
the	O
risk	O
of	O
VILI	O
,	O
by	O
promoting	O
lung	O
recruitment	O
and	O
setting	O
protective	O
mechanical	O
ventilation	O
.	O

MHV3	O
infection	O
provoked	O
a	O
fulminant	O
hepatitis	O
in	O
WT	O
mice	O
,	O
characterized	O
by	O
early	O
mortality	O
and	O
high	O
alanine	O
and	O
aspartate	B-ENZY
transaminase	I-ENZY
levels	O
,	O
histopathological	O
lesions	O
and	O
viral	O
replication	O
whereas	O
infection	O
of	O
TLR2	O
KO	O
mice	O
was	O
markedly	O
less	O
severe	O
.	O

Our	O
observation	O
suggests	O
that	O
AEC2	O
attenuates	O
LPS	O
-	O
induced	O
ARDS	O
via	O
the	O
Ang	O
-(	O
1	O
-	O
7	O
)/	O
Mas	O
pathway	O
by	O
inhibiting	O
ERK	B-ENZY
/	O
NF	O
-	O
B	O
activation	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
antioxidant	O
,	O
antimicrobial	O
,	O
anti	O
-	O
HIV	O
,	O
and	O
cholinesterase	B-ENZY
inhibitory	O
activities	O
of	O
aqueous	O
and	O
alcoholic	O
extracts	O
from	O
leaves	O
,	O
stems	O
,	O
and	O
flowers	O
of	O
Euphorbia	O
characias	O
.	O

Ethanolic	O
extracts	O
from	O
leaves	O
and	O
flowers	O
displayed	O
the	O
highest	O
inhibitory	O
activity	O
against	O
acetylcholinesterase	B-ENZY
and	O
butyrylcholinesterase	O
,	O
showing	O
potential	O
properties	O
against	O
Alzheimer	O
'	O
s	O
disease	O
.	O

The	O
ethanolic	O
flower	O
extract	O
was	O
the	O
most	O
potent	O
inhibitor	O
of	O
HIV	O
-	O
1	O
RT	O
DNA	O
polymerase	O
RNA	O
-	O
dependent	O
and	O
Ribonuclease	B-ENZY
H	I-ENZY
with	O
IC50	O
values	O
of	O
0	O
.	O
26	O
and	O
0	O
.	O
33	O
g	O
/	O
mL	O
,	O
respectively	O
.	O

PEDV	O
propagation	O
in	O
vitro	O
requires	O
the	O
presence	O
of	O
trypsin	B-ENZY
(-	O
like	O
)	O
proteases	O
in	O
the	O
culture	O
medium	O
,	O
which	O
capacitates	O
the	O
fusion	O
function	O
of	O
the	O
S	O
protein	O
.	O

Veno	O
-	O
venous	O
ECMO	O
was	O
initiated	O
for	O
respiratory	O
support	O
and	O
the	O
patient	O
'	O
s	O
clinical	O
condition	O
as	O
well	O
as	O
the	O
gas	B-ENZY
exchange	O
improved	O
within	O
the	O
next	O
few	O
days	O
.	O

Three	O
hundred	O
five	O
enteric	O
contents	O
of	O
29	O
bat	B-ENZY
species	O
were	O
tested	O
using	O
a	O
panCoV	O
nested	O
RT	O
-	O
PCR	O
.	O

Viral	O
isolation	O
was	O
performed	O
in	O
Vero	O
cells	O
with	O
trypsin	B-ENZY
.	O

ABSTRACT	O
:	O
Aluminum	O
phosphide	O
has	O
high	O
toxicity	O
when	O
it	O
is	O
ingested	O
,	O
and	O
in	O
case	O
of	O
contact	O
with	O
moisture	O
,	O
phosphine	O
gas	B-ENZY
is	O
released	O
.	O

Severe	O
metabolic	O
acidosis	O
was	O
determined	O
in	O
the	O
arterial	O
blood	O
gas	B-ENZY
,	O
and	O
metabolic	O
acidosis	O
was	O
corrected	O
by	O
sodium	O
bicarbonate	O
treatment	O
.	O

We	O
evaluated	O
the	O
following	O
three	O
sputum	O
-	O
homogenization	O
methods	O
:	O
proteinase	B-ENZY
K	I-ENZY
and	O
DNase	B-ENZY
I	O
(	O
PK	O
-	O
DNase	B-ENZY
)	O
treatment	O
,	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
treatment	O
,	O
and	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
and	O
sodium	O
citrate	O
(	O
NALC	O
)	O
treatment	O
.	O

Gas	B-ENZY
exchange	O
,	O
ventilation	O
,	O
and	O
outcome	O
data	O
were	O
collected	O
and	O
analyzed	O
.	O

IRV	O
was	O
initiated	O
on	O
4	O
.	O
4	O
ventilation	O
days	O
when	O
gas	B-ENZY
exchange	O
could	O
not	O
be	O
maintained	O
.	O

Pressure	O
-	O
controlled	O
IRV	O
provided	O
acceptable	O
gas	B-ENZY
exchange	O
without	O
apparent	O
complications	O
and	O
served	O
as	O
a	O
successful	O
bridge	O
to	O
conventional	O
treatment	O
when	O
used	O
as	O
a	O
rescue	O
therapy	O
for	O
moderate	O
to	O
severe	O
ARDS	O
.	O

CPV	O
co	O
-	O
infection	O
with	O
coccidium	O
(	O
10	O
.	O
00	O
%),	O
canine	O
distemper	O
virus	O
(	O
4	O
.	O
79	O
%),	O
hookworm	O
(	O
2	O
.	O
40	O
%),	O
canine	O
coronavirus	O
(	O
1	O
.	O
11	O
%),	O
roundworm	O
(	O
1	O
.	O
03	O
%),	O
tapeworm	O
(	O
0	O
.	O
17	O
%)	O
and	O
Babesia	O
spp	B-ENZY
.	O

Here	O
,	O
we	O
developed	O
four	O
infectious	O
recombinant	O
HCoVs	O
-	O
OC43	O
(	O
rHCoVs	O
-	O
OC43	O
)	O
which	O
express	O
the	O
Renilla	O
luciferase	B-ENZY
(	O
Rluc	O
)	O
reporter	O
gene	O
.	O

Among	O
these	O
four	O
rHCoVs	O
-	O
OC43	O
,	O
rOC43	O
-	O
ns2DelRluc	O
(	O
generated	O
by	O
replacing	O
ns2	O
with	O
the	O
Rluc	O
gene	O
)	O
showed	O
robust	O
luciferase	B-ENZY
activity	O
with	O
only	O
a	O
slight	O
impact	O
on	O
its	O
growth	O
characteristics	O
.	O

We	O
showed	O
that	O
chloroquine	O
strongly	O
inhibited	O
HCoV	O
-	O
OC43	O
replication	O
in	O
vitro	O
,	O
with	O
a	O
50	O
%	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
of	O
0	O
.	O
33	O
M	O
.	O
However	O
,	O
ribavirin	O
showed	O
inhibition	O
of	O
HCoV	O
-	O
OC43	O
replication	O
only	O
at	O
high	O
concentrations	O
which	O
may	O
not	O
be	O
applicable	O
to	O
humans	O
in	O
clinical	O
treatment	O
,	O
with	O
an	O
IC50	O
of	O
10	O
M	O
.	O
Furthermore	O
,	O
using	O
a	O
luciferase	B-ENZY
-	O
based	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
screening	O
assay	O
,	O
we	O
identified	O
double	O
-	O
stranded	O
-	O
RNA	O
-	O
activated	O
protein	B-ENZY
kinase	I-ENZY
(	O
PKR	O
)	O
and	O
DEAD	O
box	O
RNA	O
helicases	O
(	O
DDX3X	O
)	O
that	O
exhibited	O
antiviral	O
activities	O
,	O
which	O
were	O
further	O
verified	O
by	O
the	O
use	O
of	O
HCoV	O
-	O
OC43	O
-	O
WT	O
.	O

Beraprost	O
and	O
silvestat	O
,	O
phosphodiesterase	B-ENZY
3	O
(	O
PDE3	O
)	O
inhibitors	O
,	O
are	O
often	O
administered	O
in	O
clinical	O
practice	O
.	O

To	O
determine	O
hypercoagulopathy	O
,	O
plasma	O
levels	O
of	O
thrombin	B-ENZY
-	O
antithrombin	O
complex	O
and	O
plasmin	B-ENZY
-	O
plasmin	B-ENZY
inhibitor	O
complex	O
are	O
continuously	O
monitored	O
in	O
patients	O
with	O
suspected	O
sepsis	O
.	O

Therefore	O
,	O
the	O
present	O
study	O
seeks	O
to	O
design	O
a	O
valid	O
and	O
reliable	O
questionnaire	O
to	O
assess	O
sleep	O
disturbance	O
in	O
patients	O
with	O
acute	O
coronary	O
syndrome	O
(	O
ACS	B-ENZY
)	O
hospitalized	O
in	O
CCUs	O
.	O

Sleep	O
disturbance	O
questionnaire	O
for	O
patients	O
with	O
ACS	B-ENZY
hospitalized	O
in	O
coronary	O
care	O
unit	O
(	O
CCU	O
)	O
was	O
identified	O
in	O
5	O
dimensions	O
and	O
assessed	O
for	O
validity	O
and	O
reliability	O
.	O

The	O
patients	O
with	O
severe	O
acidosis	O
also	O
exhibited	O
worse	O
arterial	O
blood	O
gas	B-ENZY
parameters	O
:	O
the	O
PaCO2	O
levels	O
were	O
87	O
	O
22	O
and	O
70	O
	O
15	O
in	O
the	O
ACPE	O
patients	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
87	O
	O
21	O
and	O
76	O
	O
14	O
in	O
the	O
COPD	O
patients	O
,	O
and	O
83	O
	O
17	O
and	O
74	O
	O
14	O
in	O
the	O
OHS	O
patients	O
(	O
NS	O
).,	O
respectively	O
Further	O
,	O
the	O
patients	O
with	O
severe	O
acidosis	O
required	O
a	O
longer	O
duration	O
to	O
achieve	O
pH	O
normalization	O
than	O
those	O
with	O
non	O
-	O
severe	O
acidosis	O
(	O
patients	O
with	O
a	O
normalized	O
pH	O
after	O
the	O
first	O
hour	O
:	O
ACPE	O
,	O
8	O
%	O
vs	O
.	O
43	O
%,	O
p	O
<	O
0	O
.	O
001	O
;	O
COPD	O
,	O
11	O
%	O
vs	O
.	O
43	O
%,	O
p	O
<	O
0	O
.	O
001	O
;	O
and	O
OHS	O
,	O
13	O
%	O
vs	O
.	O
51	O
%,	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
they	O
had	O
longer	O
RICU	O
stays	O
,	O
particularly	O
those	O
in	O
the	O
COPD	O
group	O
(	O
ACPE	O
,	O
4	O
	O
3	O
.	O
1	O
vs	O
.	O
3	O
.	O
6	O
	O
2	O
.	O
5	O
,	O
NS	O
;	O
COPD	O
,	O
5	O
.	O
1	O
	O
3	O
vs	O
.	O
3	O
.	O
6	O
	O
2	O
.	O
1	O
,	O
p	O
<	O
0	O
.	O
001	O
;	O
and	O
OHS	O
,	O
4	O
.	O
3	O
	O
2	O
.	O
6	O
vs	O
.	O
3	O
.	O
7	O
	O
3	O
.	O
2	O
,	O
NS	O
).	O

ECMO	O
can	O
stabilize	O
gas	B-ENZY
exchange	O
and	O
haemodynamic	O
compromise	O
,	O
consequently	O
preventing	O
further	O
hypoxic	O
organ	O
damage	O
.	O

Six	O
days	O
later	O
,	O
further	O
deterioration	O
of	O
gas	B-ENZY
exchange	O
prompted	O
the	O
decision	O
to	O
intubate	O
.	O

ABSTRACT	O
:	O
Transient	O
receptor	O
potential	O
ion	O
channels	O
(	O
TRP	B-ENZY
)	O
are	O
a	O
superfamily	O
of	O
non	O
-	O
selective	O
ion	O
channels	O
which	O
are	O
opened	O
in	O
response	O
to	O
a	O
diverse	O
range	O
of	O
stimuli	O
.	O

The	O
TRP	B-ENZY
vanilloid	O
4	O
(	O
TRPV4	O
)	O
ion	O
channel	O
is	O
opened	O
in	O
response	O
to	O
heat	O
,	O
mechanical	O
stimuli	O
,	O
hypo	O
-	O
osmolarity	O
and	O
arachidonic	O
acid	O
metabolites	O
.	O

At	O
admission	O
,	O
leukopenia	O
(	O
42	O
.	O
6	O
%),	O
thrombocytopenia	O
(	O
46	O
.	O
6	O
%),	O
and	O
elevation	O
of	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
42	O
.	O
7	O
%)	O
were	O
observed	O
.	O

12	O
hrs	O
after	O
DH	O
in	O
mice	O
the	O
local	O
and	O
systemic	O
cytokines	O
and	O
chemokines	O
were	O
quantified	O
by	O
multiplex	O
bead	O
array	O
or	O
ELISA	O
,	O
activated	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
by	O
western	O
blot	O
.	O

In	O
lung	O
tissue	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
monocyte	O
chemo	O
attractant	O
protein	O
-	O
1	O
(	O
MCP	O
-	O
1	O
)	O
and	O
granulocyte	O
-	O
colony	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
was	O
elevated	O
in	O
both	O
C5	O
-/-	O
mice	O
and	O
wildtype	O
littermates	O
(	O
wt	O
),	O
whereas	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
was	O
reduced	O
in	O
lungs	O
after	O
DH	O
in	O
C5	O
-/-	O
mice	O
.	O

Locally	O
,	O
lung	O
myeloperoxidase	B-ENZY
(	O
MPO	O
),	O
protein	O
,	O
IL	O
-	O
6	O
,	O
MCP	O
-	O
1	O
and	O
G	O
-	O
CSF	O
in	O
brochoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
elevated	O
after	O
DH	O
in	O
C5	O
-/-	O
compared	O
to	O
wt	O
.	O

RESULTS	O
:	O
In	O
lung	O
tissue	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
monocyte	O
chemo	O
attractant	O
protein	O
-	O
1	O
(	O
MCP	O
-	O
1	O
)	O
and	O
granulocyte	O
-	O
colony	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
was	O
elevated	O
in	O
both	O
C5	O
-/-	O
mice	O
and	O
wildtype	O
littermates	O
(	O
wt	O
),	O
whereas	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
was	O
reduced	O
in	O
lungs	O
after	O
DH	O
in	O
C5	O
-/-	O
mice	O
.	O

Locally	O
,	O
lung	O
myeloperoxidase	B-ENZY
(	O
MPO	O
),	O
protein	O
,	O
IL	O
-	O
6	O
,	O
MCP	O
-	O
1	O
and	O
G	O
-	O
CSF	O
in	O
brochoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
elevated	O
after	O
DH	O
in	O
C5	O
-/-	O
compared	O
to	O
wt	O
.	O

TITLE	O
:	O
Porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
is	O
not	O
a	O
cellular	O
receptor	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
,	O
but	O
promotes	O
its	O
infectivity	O
via	O
aminopeptidase	O
activity	O
.	O

Compared	O
with	O
nonobese	O
women	O
,	O
super	O
obese	O
women	O
had	O
twofold	O
odds	O
of	O
acute	O
(	O
5	O
vs	O
.	O
10	O
%;	O
adjusted	O
odds	O
ratio	O
[	O
aOR	B-ENZY
]:	O
1	O
.	O
81	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]:	O
1	O
.	O
59	O
-	O
2	O
.	O
73	O
)	O
and	O
severe	O
(	O
3	O
vs	O
.	O
6	O
%;	O
aOR	B-ENZY
:	O
2	O
.	O
08	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
59	O
-	O
2	O
.	O
73	O
)	O
neonatal	O
morbidity	O
.	O

We	O
specifically	O
identified	O
the	O
imatinib	O
target	O
,	O
Abelson	O
tyrosine	O
-	O
protein	B-ENZY
kinase	I-ENZY
2	O
(	O
Abl2	O
),	O
as	O
required	O
for	O
efficient	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
replication	O
in	O
vitro	O
These	O
data	O
demonstrate	O
that	O
specific	O
approved	O
drugs	O
can	O
be	O
characterized	O
in	O
vitro	O
for	O
their	O
anticoronavirus	O
activity	O
and	O
used	O
to	O
identify	O
host	O
proteins	O
required	O
for	O
coronavirus	O
replication	O
.	O

In	O
this	O
report	O
,	O
we	O
identified	O
and	O
characterized	O
previously	O
unknown	O
and	O
diverse	O
genetic	O
clusters	O
of	O
bat	B-ENZY
coronaviruses	O
in	O
the	O
Atlantic	O
Forest	O
Biome	O
,	O
Brazil	O
.	O

ABSTRACT	O
:	O
Coronary	O
artery	O
disease	O
(	O
CAD	B-ENZY
)	O
is	O
a	O
leading	O
cause	O
of	O
death	O
and	O
identification	O
of	O
risk	O
factors	O
for	O
CAD	B-ENZY
is	O
crucial	O
.	O

This	O
prospective	O
cohort	O
study	O
investigated	O
the	O
prevalence	O
of	O
SDB	O
and	O
determined	O
risk	O
factors	O
for	O
the	O
presence	O
of	O
SDB	O
in	O
a	O
large	O
CAD	B-ENZY
cohort	O
undergoing	O
cardiac	O
rehabilitation	O
.	O

A	O
total	O
of	O
1408	O
patients	O
were	O
included	O
;	O
69	O
.	O
5	O
%	O
were	O
male	O
,	O
78	O
%	O
had	O
acute	O
coronary	O
syndrome	O
,	O
and	O
22	O
%	O
had	O
stable	O
CAD	B-ENZY
.	O

SDB	O
severity	O
did	O
not	O
vary	O
significantly	O
in	O
patients	O
with	O
stable	O
CAD	B-ENZY
or	O
on	O
the	O
basis	O
of	O
left	O
ventricular	O
ejection	O
fraction	O
.	O

SDB	O
is	O
a	O
highly	O
prevalent	O
comorbidity	O
in	O
patients	O
with	O
CAD	B-ENZY
,	O
particularly	O
those	O
who	O
have	O
undergone	O
CABG	O
.	O

These	O
results	O
strengthen	O
existing	O
associations	O
and	O
emphasize	O
the	O
importance	O
of	O
diagnosing	O
and	O
monitoring	O
SDB	O
in	O
patients	O
with	O
CAD	B-ENZY
entering	O
a	O
cardiac	O
rehabilitation	O
program	O
.	O

69	O
.	O
5	O
%	O
were	O
male	O
,	O
78	O
%	O
had	O
acute	O
coronary	O
syndrome	O
,	O
and	O
22	O
%	O
had	O
stable	O
CAD	B-ENZY
.	O

CONCLUSIONS	O
:	O
SDB	O
is	O
a	O
highly	O
prevalent	O
comorbidity	O
in	O
patients	O
with	O
CAD	B-ENZY
,	O
particularly	O
those	O
who	O
have	O
undergone	O
CABG	O
.	O

CCL2	O
and	O
CCL7	O
protein	O
levels	O
were	O
measured	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
obtained	O
from	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
challenged	O
human	O
volunteers	O
and	O
two	O
separate	O
cohorts	O
of	O
patients	O
with	O
ARDS	O
.	O

Neutrophil	O
chemotaxis	O
to	O
ARDS	O
BAL	B-ENZY
fluid	O
was	O
evaluated	O
and	O
the	O
contribution	O
of	O
each	O
was	O
assessed	O
and	O
compared	O
with	O
chemokine	O
(	O
C	O
-	O
X	O
-	O
C	O
motif	O
)	O
ligand	O
8	O
(	O
CXCL8	O
).	O

CCL2	O
and	O
CCL7	O
were	O
significantly	O
elevated	O
in	O
BAL	B-ENZY
fluid	O
recovered	O
from	O
LPS	O
-	O
challenged	O
volunteers	O
and	O
patients	O
with	O
ARDS	O
.	O

RESULTS	O
:	O
CCL2	O
and	O
CCL7	O
were	O
significantly	O
elevated	O
in	O
BAL	B-ENZY
fluid	O
recovered	O
from	O
LPS	O
-	O
challenged	O
volunteers	O
and	O
patients	O
with	O
ARDS	O
.	O

Furthermore	O
,	O
neutrophils	O
isolated	O
from	O
the	O
blood	O
or	O
BAL	B-ENZY
fluid	O
differentially	O
regulated	O
the	O
cell	O
surface	O
expression	O
of	O
chemokine	O
(	O
C	O
-	O
X	O
-	O
C	O
motif	O
)	O
receptor	O
1	O
and	O
C	O
-	O
C	O
chemokine	O
receptor	O
type	O
2	O
during	O
ARDS	O
.	O

TITLE	O
:	O
Sphingomyelin	B-ENZY
synthase	I-ENZY
2	O
affects	O
CD14	O
	O
associated	O
induction	O
of	O
NF	O
	O
B	O
by	O
lipopolysaccharides	O
in	O
acute	O
lung	O
injury	O
in	O
mice	O
.	O

TITLE	O
:	O
Association	O
Between	O
Train	O
-	O
of	O
-	O
Four	O
Values	O
and	O
Gas	B-ENZY
Exchange	O
Indices	O
in	O
Moderate	O
to	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

The	O
goal	O
of	O
this	O
evaluation	O
was	O
to	O
determine	O
if	O
the	O
depth	O
of	O
paralysis	O
,	O
determined	O
by	O
train	O
-	O
of	O
-	O
four	O
(	O
TOF	O
)	O
monitoring	O
,	O
correlates	O
with	O
gas	B-ENZY
exchange	O
in	O
moderate	O
to	O
severe	O
ARDS	O
.	O

This	O
was	O
a	O
retrospective	O
review	O
of	O
moderate	O
to	O
severe	O
ARDS	O
patients	O
who	O
were	O
prescribed	O
>	O
12	O
hours	O
of	O
continuous	O
infusion	O
cisatracurium	O
between	O
January	O
1	O
,	O
2013	O
,	O
and	O
December	O
31	O
,	O
2014	O
,	O
with	O
a	O
PaO	B-ENZY
A	O
total	O
of	O
378	O
patients	O
were	O
screened	O
for	O
inclusion	O
,	O
with	O
107	O
evaluable	O
patients	O
meeting	O
criteria	O
at	O
baseline	O
.	O

This	O
evaluation	O
demonstrates	O
that	O
the	O
use	O
of	O
TOF	O
monitoring	O
for	O
neuromuscular	O
blockade	O
does	O
not	O
correlate	O
with	O
gas	B-ENZY
exchange	O
markers	O
in	O
moderate	O
to	O
severe	O
ARDS	O
.	O

The	O
diagnosis	O
of	O
eosinophilic	O
pneumonia	O
is	O
based	O
on	O
characteristic	O
clinical	O
-	O
imaging	O
features	O
and	O
the	O
demonstration	O
of	O
alveolar	O
eosinophilia	O
,	O
defined	O
as	O
at	O
least	O
25	O
%	O
eosinophils	O
at	O
BAL	B-ENZY
.	O

General	O
strategies	O
to	O
design	O
specific	O
and	O
selective	O
drugs	O
targeting	O
helicase	O
for	O
the	O
treatment	O
of	O
viral	O
infections	O
could	O
act	O
via	O
one	O
or	O
more	O
of	O
the	O
following	O
mechanisms	O
:	O
inhibition	O
of	O
the	O
NTPase	B-ENZY
activity	O
,	O
by	O
interferences	O
with	O
ATP	O
binding	O
and	O
therefore	O
by	O
limiting	O
the	O
energy	O
required	O
for	O
the	O
unwinding	O
and	O
translocation	O
,	O
or	O
by	O
allosteric	O
mechanism	O
and	O
therefore	O
by	O
stabilizing	O
the	O
conformation	O
of	O
the	O
enzyme	O
in	O
low	O
helicase	O
activity	O
state	O
;	O
inhibition	O
of	O
nucleic	O
acids	O
binding	O
to	O
the	O
helicase	O
;	O
inhibition	O
of	O
coupling	O
of	O
ATP	O
hydrolysis	O
to	O
unwinding	O
;	O
inhibition	O
of	O
unwinding	O
by	O
sterically	O
blocking	O
helicase	O
translocation	O
.	O

The	O
constituents	O
of	O
garlic	O
extract	O
were	O
detected	O
by	O
gas	B-ENZY
chromatography	O
.	O

We	O
identify	O
cellular	O
E3	O
ubiquitin	O
ligase	O
ring	O
-	O
finger	O
and	O
CHY	O
zinc	O
-	O
finger	O
domain	O
-	O
containing	O
1	O
(	O
RCHY1	O
)	O
as	O
an	O
interacting	O
partner	O
of	O
the	O
viral	O
SARS	O
-	O
unique	O
domain	O
(	O
SUD	O
)	O
and	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	O
)),	O
and	O
,	O
as	O
a	O
consequence	O
,	O
the	O
involvement	O
of	O
cellular	O
p53	O
as	O
antagonist	O
of	O
coronaviral	O
replication	O
.	O

The	O
SARS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
is	O
encoded	O
next	O
to	O
SUD	O
within	O
nonstructural	O
protein	O
3	O
.	O

The	O
viruses	O
used	O
the	O
human	O
entry	O
receptor	O
aminopeptidase	B-ENZY
N	I-ENZY
and	O
replicated	O
in	O
human	O
hepatoma	O
cells	O
,	O
suggesting	O
a	O
principal	O
ability	O
to	O
cause	O
human	O
infections	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
study	O
the	O
effect	O
of	O
ROS	O
produced	O
by	O
hypoxanthine	B-ENZY
-	I-ENZY
xanthine	I-ENZY
oxidase	I-ENZY
(	O
Hx	O
-	O
XO	O
)	O
on	O
the	O
adhesion	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
and	O
on	O
the	O
signaling	O
pathways	O
involved	O
.	O

Wortmannin	O
,	O
a	O
PI3	B-ENZY
-	I-ENZY
kinase	I-ENZY
inhibitor	O
,	O
inhibited	O
ROS	O
-	O
induced	O
cell	O
adhesion	O
and	O
FAK	O
phosphorylation	O
.	O

This	O
study	O
shows	O
that	O
ROS	O
could	O
have	O
both	O
stimulatory	O
and	O
inhibitory	O
effects	O
on	O
HUVEC	O
adhesion	O
and	O
FAK	O
phosphorylation	O
and	O
suggests	O
that	O
PI3	B-ENZY
-	I-ENZY
kinase	I-ENZY
and	O
tyrosine	O
phosphatase	O
control	O
these	O
effects	O
.	O

Multiple	O
proteolysis	O
by	O
host	O
proteases	O
,	O
such	O
as	O
furin	B-ENZY
,	O
transmembrane	O
protease	O
serine	O
2	O
(	O
TMPRSS2	O
),	O
and	O
cathepsins	O
,	O
causes	O
the	O
S	O
protein	O
to	O
become	O
fusion	O
competent	O
.	O

Here	O
,	O
we	O
developed	O
a	O
cell	O
-	O
based	O
fusion	O
assay	O
for	O
S	O
in	O
a	O
TMPRSS2	O
-	O
dependent	O
manner	O
using	O
cell	O
lines	O
expressing	O
Renilla	O
luciferase	B-ENZY
(	O
RL	O
)-	O
based	O
split	O
reporter	O
proteins	O
.	O

This	O
review	O
focuses	O
on	O
the	O
different	O
approaches	O
available	O
to	O
monitor	O
RNA	O
packaging	O
:	O
Northern	O
blot	O
analysis	O
,	O
ribonuclease	O
protection	O
assay	O
and	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
coupled	O
polymerase	O
chain	O
reaction	O
as	O
well	O
as	O
the	O
most	O
recent	O
RNA	O
imaging	O
and	O
sequencing	O
technologies	O
.	O

TITLE	O
:	O
Antagonism	O
of	O
RNase	B-ENZY
L	O
Is	O
Required	O
for	O
Murine	O
Coronavirus	O
Replication	O
in	O
Kupffer	O
Cells	O
and	O
Liver	O
Sinusoidal	O
Endothelial	O
Cells	O
but	O
Not	O
in	O
Hepatocytes	O
.	O

Many	O
intracellular	O
signaling	O
pathways	O
,	O
including	O
the	O
phosphatidylinositol	B-ENZY
3	I-ENZY
-	I-ENZY
kinase	I-ENZY
(	O
PI3K	O
)/	O
Akt	O
pathway	O
,	O
are	O
activated	O
by	O
viral	O
infection	O
.	O

Inhibiting	O
GSK	B-ENZY
-	O
3	O
/	O
	O
,	O
one	O
of	O
the	O
downstream	O
effectors	O
of	O
PI3K	O
/	O
Akt	O
pathway	O
and	O
regulated	O
by	O
Akt	O
during	O
PEDV	O
infected	O
Vero	O
cells	O
,	O
also	O
enhanced	O
PEDV	O
replication	O
.	O

Collectively	O
,	O
our	O
data	O
suggest	O
that	O
PI3K	O
/	O
Akt	O
/	O
GSK	B-ENZY
-	O
3	O
/	O
	O
signaling	O
pathway	O
is	O
activated	O
by	O
PEDV	O
and	O
functions	O
in	O
inhibiting	O
PEDV	O
replication	O
.	O

Samples	O
were	O
pre	O
-	O
screened	O
,	O
using	O
a	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
multiprobe	O
for	O
coronavirus	O
,	O
and	O
subjected	O
to	O
confirmatory	O
pancoronavirus	O
and	O
/	O
or	O
strain	O
-	O
specific	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
PCR	O
followed	O
by	O
sequence	O
analysis	O
.	O

TITLE	O
:	O
[	O
Relationship	O
between	O
changes	O
of	O
increased	O
amylase	O
or	O
lipase	B-ENZY
levels	O
and	O
pancreas	O
injury	O
in	O
critically	O
ill	O
children	O
].	O

ABSTRACT	O
:	O
To	O
observe	O
the	O
occurrence	O
rate	O
of	O
elevated	O
serum	O
amylase	O
and	O
lipase	B-ENZY
in	O
critically	O
ill	O
children	O
,	O
to	O
explore	O
the	O
relationship	O
between	O
elevated	O
pancreatic	O
enzymes	O
and	O
pancreatic	O
injury	O
,	O
and	O
the	O
effect	O
of	O
elevated	O
pancreatic	O
enzymes	O
on	O
state	O
of	O
illness	O
and	O
the	O
prognosis	O
.	O

The	O
cases	O
were	O
divided	O
into	O
three	O
groups	O
:	O
the	O
control	O
group	O
(	O
amylase	O
or	O
lipase	B-ENZY
were	O
normal	O
),	O
mildly	O
elevated	O
group	O
(	O
1	O
time	O
<	O
increase	O
of	O
serum	O
amylase	O
or	O
<	O
3	O
times	O
increase	O
of	O
lipase	B-ENZY
),	O
highly	O
elevated	O
group	O
(	O
serum	O
amylase	O
or	O
lipase	B-ENZY
increased	O
>	O
3	O
times	O
).	O

The	O
occurrence	O
rate	O
of	O
elevated	O
serum	O
amylase	O
and	O
lipase	B-ENZY
in	O
critically	O
ill	O
children	O
was	O
22	O
.	O
87	O
%	O
(	O
773	O
/	O
3	O
380	O
).	O

(	O
6	O
)	O
The	O
median	O
of	O
survival	O
table	O
of	O
children	O
with	O
normal	O
pancreas	O
was	O
75	O
days	O
,	O
the	O
median	O
of	O
survival	O
table	O
of	O
children	O
with	O
elevated	O
amylase	O
or	O
lipase	B-ENZY
was	O
24	O
days	O
.(	O
7	O
)	O

The	O
risk	O
factors	O
of	O
elevated	O
amylase	O
or	O
lipase	B-ENZY
were	O
analyzed	O
by	O
Logistic	O
regression	O
analysis	O
.	O

To	O
assess	O
whether	O
sevoflurane	O
would	O
improve	O
gas	B-ENZY
exchange	O
and	O
inflammation	O
in	O
ARDS	O
.	O

TITLE	O
:	O
Isolation	O
of	O
Tioman	O
virus	O
from	O
Pteropus	O
giganteus	O
bat	B-ENZY
in	O
North	O
-	O
East	O
region	O
of	O
India	O
.	O

ABSTRACT	O
:	O
Bat	B-ENZY
-	O
borne	O
viral	O
diseases	O
are	O
a	O
major	O
public	O
health	O
concern	O
among	O
newly	O
emerging	O
infectious	O
diseases	O
which	O
includes	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
Nipah	O
,	O
Marburg	O
and	O
Ebola	O
virus	O
disease	O
.	O

Bat	B-ENZY
-	O
borne	O
viruses	O
have	O
become	O
serious	O
concern	O
world	O
-	O
wide	O
.	O

Our	O
studies	O
also	O
showed	O
that	O
SIRT1	O
,	O
histone	B-ENZY
acetyltransferase	I-ENZY
,	O
and	O
NF	O
-	O
B	O
regulated	O
the	O
acetylation	O
and	O
release	O
of	O
HMGB1	O
.	O

Establishing	O
a	O
well	O
-	O
characterized	O
bat	B-ENZY
cell	O
line	O
supporting	O
the	O
replication	O
of	O
bat	B-ENZY
-	O
borne	O
viruses	O
would	O
facilitate	O
the	O
analysis	O
of	O
virus	O
-	O
host	O
interactions	O
in	O
an	O
in	O
vitro	O
model	O
.	O

Currently	O
,	O
few	O
bat	B-ENZY
cell	O
lines	O
have	O
been	O
developed	O
and	O
only	O
Tb1	O
-	O
Lu	O
,	O
derived	O
from	O
Tadarida	O
brasiliensis	O
is	O
commercially	O
available	O
.	O

Here	O
we	O
describe	O
a	O
method	O
to	O
establish	O
and	O
immortalize	O
big	O
brown	O
bat	B-ENZY
(	O
Eptesicus	O
fuscus	O
)	O
kidney	O
(	O
Efk3	O
)	O
cells	O
using	O
the	O
Myotis	O
polyomavirus	O
T	O
-	O
antigen	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
bat	B-ENZY
cell	O
line	O
from	O
a	O
northern	O
latitude	O
insectivorous	O
bat	B-ENZY
developed	O
using	O
a	O
novel	O
technology	O
.	O

The	O
cell	O
line	O
has	O
the	O
potential	O
to	O
be	O
used	O
for	O
isolation	O
of	O
bat	B-ENZY
viruses	O
and	O
for	O
studying	O
virus	O
-	O
bat	B-ENZY
interactions	O
in	O
culture	O
.	O

TITLE	O
:	O
Understanding	O
bat	B-ENZY
SARS	O
-	O
like	O
coronaviruses	O
for	O
the	O
preparation	O
of	O
future	O
coronavirus	O
outbreaks	O
-	O
Implications	O
for	O
coronavirus	O
vaccine	O
development	O
.	O

A	O
total	O
of	O
250	O
swabs	O
were	O
randomly	O
selected	O
and	O
analyzed	O
by	O
multiplex	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
including	O
research	O
of	O
18	O
viruses	O
and	O
4	O
bacteria	O
.	O

TITLE	O
:	O
New	O
insights	O
into	O
the	O
interaction	O
between	O
pyrrolyl	O
diketoacids	O
and	O
HIV	O
-	O
1	O
integrase	O
active	O
site	O
and	O
comparison	O
with	O
RNase	B-ENZY
H	I-ENZY
.	O
ABSTRACT	O
:	O
HIV	O
-	O
1	O
integrase	O
(	O
IN	O
)	O
inhibitors	O
are	O
one	O
of	O
the	O
most	O
recent	O
innovations	O
in	O
the	O
treatment	O
of	O
HIV	O
infection	O
.	O

ABSTRACT	O
:	O
Certain	O
bat	B-ENZY
species	O
serve	O
as	O
natural	O
reservoirs	O
for	O
pathogens	O
in	O
several	O
key	O
viral	O
families	O
including	O
henipa	O
-,	O
lyssa	O
-,	O
corona	O
-,	O
and	O
filoviruses	O
,	O
which	O
may	O
pose	O
serious	O
threats	O
to	O
human	O
health	O
.	O

The	O
Common	O
Vampire	O
Bat	B-ENZY
(	O
Desmodus	O
rotundus	O
),	O
due	O
to	O
its	O
abundance	O
,	O
sanguivorous	O
feeding	O
habit	O
involving	O
humans	O
and	O
domestic	O
animals	O
,	O
and	O
highly	O
social	O
behavioral	O
ecology	O
,	O
may	O
have	O
an	O
unusually	O
high	O
potential	O
for	O
interspecies	O
disease	O
transmission	O
.	O

Blood	O
samples	O
from	O
all	O
lions	O
were	O
negative	O
for	O
Trypanosoma	O
,	O
Anaplasma	O
,	O
Theileria	O
,	O
and	O
Ehrlichia	O
spp	B-ENZY
.	O

by	O
molecular	O
testing	O
;	O
however	O
,	O
all	O
lions	O
were	O
positive	O
for	O
Babesia	O
spp	B-ENZY
.	O

Sequencing	O
of	O
amplicons	O
from	O
four	O
lions	O
revealed	O
four	O
groups	O
of	O
Babesia	O
spp	B-ENZY
.	O

Both	O
AST	B-ENZY
,	O
and	O
ALT	O
values	O
were	O
significantly	O
higher	O
in	O
MERS	O
-	O
CoV	O
infected	O
group	O
(	O
AST	B-ENZY
median	O
42	O
vs	O
36	O
,	O
P	O
:	O
0	O
.	O
03	O
,	O
and	O
ALT	O
median	O
33	O
vs	O
28	O
,	O
P	O
:	O
0	O
.	O
003	O
).	O

TITLE	O
:	O
A	O
Bat	B-ENZY
-	O
Derived	O
Putative	O
Cross	O
-	O
Family	O
Recombinant	O
Coronavirus	O
with	O
a	O
Reovirus	O
Gene	O
.	O

Although	O
the	O
virus	O
is	O
similar	O
to	O
Rousettus	O
bat	B-ENZY
coronavirus	O
HKU9	O
(	O
Ro	O
-	O
BatCoV	O
HKU9	O
)	O
in	O
genome	O
characteristics	O
,	O
it	O
is	O
sufficiently	O
distinct	O
to	O
be	O
classified	O
as	O
a	O
new	O
species	O
according	O
to	O
the	O
criteria	O
defined	O
by	O
the	O
International	O
Committee	O
of	O
Taxonomy	O
of	O
Viruses	O
(	O
ICTV	O
).	O

Severe	O
lung	O
injury	O
with	O
a	O
reproducible	O
deterioration	O
of	O
pulmonary	O
gas	B-ENZY
exchange	O
and	O
hemodynamics	O
can	O
be	O
induced	O
in	O
anesthetized	O
pigs	O
using	O
repeated	O
lung	O
lavages	O
with	O
warmed	O
0	O
.	O
9	O
%	O
saline	O
(	O
50	O
ml	O
/	O
kg	O
body	O
weight	O
).	O

TITLE	O
:	O
Putative	O
Receptor	O
Binding	O
Domain	O
of	O
Bat	B-ENZY
-	O
Derived	O
Coronavirus	O
HKU9	O
Spike	O
Protein	O
:	O
Evolution	O
of	O
Betacoronavirus	O
Receptor	O
Binding	O
Motifs	O
.	O

ABSTRACT	O
:	O
The	O
suggested	O
bat	B-ENZY
origin	O
for	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
revitalized	O
the	O
studies	O
of	O
other	O
bat	B-ENZY
-	O
derived	O
coronaviruses	O
with	O
respect	O
to	O
interspecies	O
transmission	O
potential	O
.	O

Bat	B-ENZY
coronavirus	O
(	O
BatCoV	O
)	O
HKU9	O
is	O
an	O
important	O
betacoronavirus	O
(	O
betaCoV	O
)	O
that	O
is	O
phylogenetically	O
affiliated	O
with	O
the	O
same	O
genus	O
as	O
MERS	O
-	O
CoV	O
.	O
The	O
bat	B-ENZY
surveillance	O
data	O
indicated	O
that	O
BatCoV	O
HKU9	O
has	O
been	O
widely	O
spreading	O
and	O
circulating	O
in	O
bats	O
.	O

Elevated	O
lactate	O
dehydrogenase	O
(>	O
1	O
,	O
000	O
U	O
/	O
l	O
)	O
was	O
detected	O
in	O
4	O
(	O
66	O
.	O
7	O
%)	O
patients	O
and	O
elevated	O
alanine	B-ENZY
aminotransferase	I-ENZY
was	O
exhibited	O
by	O
5	O
(	O
83	O
/	O
3	O
%)	O
patients	O
.	O

A	O
cross	O
-	O
sectional	O
survey	O
was	O
conducted	O
among	O
406	O
dental	O
health	O
professionals	O
(	O
DHPs	B-ENZY
)	O
working	O
in	O
selected	O
dental	O
facilities	O
in	O
Riyadh	O
city	O
,	O
Saudi	O
Arabia	O
during	O
the	O
outbreak	O
of	O
MERS	O
(	O
April	O
-	O
June	O
2013	O
).	O

Elevated	O
C	O
-	O
creative	O
protein	O
,	O
aspartate	B-ENZY
aminotransferase	I-ENZY
,	O
creatine	B-ENZY
kinase	I-ENZY
,	O
and	O
lymphocytopenia	O
predicted	O
a	O
higher	O
risk	O
of	O
developing	O
ARDS	O
.	O

TITLE	O
:	O
Cathepsin	B-ENZY
L	I-ENZY
Helps	O
to	O
Defend	O
Mice	O
from	O
Infection	O
with	O
Influenza	O
A	O
.	O
ABSTRACT	O
:	O
Host	O
-	O
derived	O
proteases	O
can	O
augment	O
or	O
help	O
to	O
clear	O
infections	O
.	O

This	O
dichotomy	O
is	O
exemplified	O
by	O
cathepsin	B-ENZY
L	I-ENZY
(	O
CTSL	O
),	O
which	O
helps	O
Hendra	O
virus	O
and	O
SARS	O
coronavirus	O
to	O
invade	O
cells	O
,	O
but	O
is	O
essential	O
for	O
survival	O
in	O
mice	O
with	O
mycoplasma	O
pneumonia	O
.	O

Extracellular	O
trypsin	B-ENZY
activates	O
PEDV	O
entry	O
when	O
lysosomal	O
cysteine	O
proteases	O
are	O
inhibited	O
.	O

Research	O
has	O
shown	O
that	O
the	O
entry	O
into	O
these	O
cells	O
is	O
through	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
receptor	O
.	O

We	O
found	O
that	O
,	O
compared	O
with	O
a	O
laboratory	O
strain	O
isolated	O
in	O
1966	O
and	O
passaged	O
for	O
a	O
half	O
century	O
,	O
clinical	O
isolates	O
of	O
HCoV	O
-	O
229E	O
were	O
less	O
likely	O
to	O
utilize	O
cathepsin	B-ENZY
L	I-ENZY
;	O
rather	O
,	O
they	O
showed	O
a	O
preference	O
for	O
TMPRSS2	O
.	O

Two	O
amino	O
acid	O
substitutions	O
(	O
R642M	O
and	O
N714K	O
)	O
in	O
the	O
S	O
protein	O
of	O
HCoV	O
-	O
229E	O
clinical	O
isolates	O
altered	O
their	O
sensitivity	O
to	O
a	O
cathepsin	B-ENZY
L	I-ENZY
inhibitor	O
,	O
suggesting	O
that	O
these	O
amino	O
acids	O
were	O
responsible	O
for	O
cathepsin	B-ENZY
L	I-ENZY
use	O
.	O

Human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
utilizes	O
endosomal	O
cathepsin	B-ENZY
L	I-ENZY
to	O
activate	O
the	O
spike	O
protein	O
after	O
receptor	O
binding	O
.	O

They	O
were	O
most	O
commonly	O
detected	O
in	O
ball	O
pythons	O
(	O
Python	O
[	O
P	O
.]	O
regius	O
)	O
and	O
Indian	O
rock	O
pythons	O
(	O
P	O
.	O
molurus	O
),	O
but	O
were	O
also	O
detected	O
for	O
the	O
first	O
time	O
in	O
other	O
python	O
species	O
,	O
including	O
Morelia	O
spp	B-ENZY
.	O

ABSTRACT	O
:	O
To	O
further	O
explore	O
the	O
chemical	O
space	O
around	O
the	O
entrance	O
channel	O
of	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
),	O
a	O
series	O
of	O
novel	O
indolylarylsulfones	O
(	O
IASs	O
)	O
bearing	O
N	O
-	O
substituted	O
piperidine	O
at	O
indole	O
-	O
2	O
-	O
carboxamide	O
were	O
identified	O
as	O
potent	O
HIV	O
NNRTIs	O
by	O
structure	O
-	O
guided	O
scaffold	O
morphing	O
and	O
fragment	O
rearrangement	O
.	O

Severity	O
of	O
illness	O
indices	O
including	O
lower	O
pH	O
,	O
lower	O
PaO	B-ENZY
Higher	O
PEEP	O
,	O
lower	O
peak	O
,	O
plateau	O
,	O
and	O
driving	O
pressures	O
,	O
and	O
lower	O
respiratory	O
rate	O
are	O
associated	O
with	O
improved	O
survival	O
from	O
ARDS	O
.	O

Severity	O
of	O
illness	O
indices	O
including	O
lower	O
pH	O
,	O
lower	O
PaO	B-ENZY

extracts	O
along	O
with	O
their	O
main	O
single	O
isolated	O
constituents	O
anthraquinone	O
derivatives	O
were	O
tested	O
on	O
both	O
HIV	O
-	O
1	O
Reverse	B-ENZY
Transcriptase	I-ENZY
(	O
RT	O
)-	O
associated	O
DNA	O
Polymerase	O
(	O
RDDP	O
)	O
and	O
Ribonuclease	B-ENZY
H	I-ENZY
(	O
RNase	B-ENZY
H	I-ENZY
)	O
activities	O
in	O
biochemical	O
assays	O
.	O

extracts	O
inhibited	O
the	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNase	B-ENZY
H	I-ENZY
activity	O
.	O

Among	O
the	O
isolated	O
constituents	O
,	O
Sennoside	O
A	O
and	O
B	O
were	O
effective	O
on	O
both	O
RDDP	O
and	O
RNase	B-ENZY
H	I-ENZY
RT	O
-	O
associated	O
functions	O
in	O
biochemical	O
assays	O
.	O

TITLE	O
:	O
Nur77	O
attenuates	O
endothelin	O
-	O
1	O
expression	O
via	O
downregulation	O
of	O
NF	O
-	O
B	O
and	O
p38	O
MAPK	B-ENZY
in	O
A549	O
cells	O
and	O
in	O
an	O
ARDS	O
rat	O
model	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
characterized	O
by	O
inflammatory	O
injury	O
to	O
the	O
alveolar	O
and	O
capillary	O
barriers	O
that	O
results	O
in	O
impaired	O
gas	B-ENZY
exchange	O
and	O
severe	O
acute	O
respiratory	O
failure	O
.	O

LPS	O
-	O
induced	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
NF	O
-	O
B	O
and	O
p38	O
MAPK	B-ENZY
were	O
blocked	O
by	O
Nur77	O
overexpression	O
and	O
augmented	O
by	O
Nur77	O
knockdown	O
in	O
A549	O
cells	O
.	O

Pharmacological	O
activation	O
of	O
Nur77	O
by	O
cytosporone	O
B	O
(	O
CsnB	O
)	O
inhibited	O
ET	O
-	O
1	O
expression	O
in	O
ARDS	O
rats	O
,	O
decreased	O
LPS	O
-	O
induced	O
phosphorylation	O
of	O
NF	O
-	O
B	O
and	O
p38	O
MAPK	B-ENZY
,	O
and	O
relieved	O
lung	O
,	O
liver	O
,	O
and	O
kidney	O
injury	O
.	O

Pharmacological	O
deactivation	O
of	O
Nur77	O
by	O
1	O
,	O
1	O
-	O
bis	B-ENZY
-(	O
3	O
'-	O
indolyl	O
)-	O
1	O
-(	O
p	O
-	O
hydroxyphenyl	O
)	O
methane	O
(	O
DIM	O
-	O
C	O
-	O
pPhOH	O
,	O
C	O
-	O
DIM8	O
)	O
had	O
no	O
effect	O
on	O
ET	O
-	O
1	O
expression	O
and	O
lung	O
injury	O
.	O

TITLE	O
:	O
Isatin	O
thiazoline	O
hybrids	O
as	O
dual	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
3	O
-	O
3	O
-{	O
2	O
-[	O
2	O
-	O
3	O
-	O
methyl	O
-	O
4	O
-	O
phenyl	O
-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1	O
,	O
3	O
-	O
thiazol	O
-	O
2	O
-	O
ylidene	O
]	O
hydrazin	O
-	O
1	O
-	O
ylidene	O
-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1H	O
-	O
indol	O
-	O
2	O
-	O
one	O
derivatives	O
has	O
been	O
designed	O
and	O
synthesized	O
to	O
study	O
their	O
activity	O
on	O
both	O
HIV	O
-	O
1	O
(	O
Human	O
Immunodeficiency	O
Virus	O
type	O
1	O
)	O
RT	O
(	O
Reverse	B-ENZY
Transcriptase	I-ENZY
)	O
associated	O
functions	O
.	O

Faecal	O
samples	O
from	O
puppies	O
with	O
(	O
n	O
=	O
113	O
)	O
and	O
without	O
(	O
n	O
=	O
56	O
)	O
acute	O
diarrhoea	O
were	O
collected	O
and	O
screened	O
for	O
Canine	O
Parvovirus	O
(	O
CPV	O
),	O
Canine	O
Coronavirus	O
(	O
CCoV	O
),	O
Salmonella	O
spp	B-ENZY
.,	O
Campylobacter	O
spp	B-ENZY
.,	O
Clostridium	O
perfringens	O
,	O
Clostridium	O
difficile	O
,	O
	O
-	O
hemolytic	O
Eschericha	O
coli	O
(	O
hEC	O
),	O
Giardia	O
spp	B-ENZY
.,	O
Toxocara	O
spp	B-ENZY
.,	O
Cystoisospora	O
spp	B-ENZY
.,	O
and	O
Cyniclomyces	O
guttulatus	O
.	O

Significant	O
positive	O
associations	O
were	O
found	O
between	O
CPV	O
and	O
CCoV	O
,	O
CPV	O
and	O
Cystoisospora	O
spp	B-ENZY
.,	O
Toxocara	O
spp	B-ENZY
.	O
and	O
hEC	O
,	O
Giardia	O
spp	B-ENZY
.	O

Puppies	O
from	O
high	O
-	O
volume	O
dog	O
breeders	O
were	O
significantly	O
at	O
increased	O
risk	O
for	O
CPV	O
(	O
OR	O
4	O
.	O
20	O
),	O
CCoV	O
(	O
OR	O
4	O
.	O
50	O
)	O
and	O
Cystoisospora	O
spp	B-ENZY
.	O

We	O
tested	O
in	O
a	O
prospective	O
physiological	O
study	O
the	O
hypothesis	O
that	O
continuous	O
administration	O
of	O
NMB	O
agents	O
in	O
mechanically	O
ventilated	O
children	O
with	O
severe	O
acute	O
hypoxemic	O
respiratory	O
failure	O
(	O
AHRF	O
)	O
improves	O
the	O
oxygenation	O
index	O
without	O
a	O
redistribution	O
of	O
tidal	O
volume	O
V	O
Oxygenation	O
index	O
,	O
PaO	B-ENZY
Twenty	O
-	O
two	O
patients	O
were	O
studied	O
(	O
N	O
=	O
18	O
met	O
the	O
criteria	O
for	O
pediatric	O
ARDS	O
).	O

Subgroup	O
analysis	O
showed	O
that	O
OI	O
decreased	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
PaO	B-ENZY
NMB	O
resulted	O
in	O
an	O
improved	O
oxygenation	O
index	O
in	O
pediatric	O
patients	O
with	O
AHRF	O
.	O

TITLE	O
:	O
Pivotal	O
Role	O
of	O
Receptor	O
-	O
Interacting	O
Protein	B-ENZY
Kinase	I-ENZY
1	O
and	O
Mixed	O
Lineage	O
Kinase	O
Domain	O
-	O
Like	O
in	O
Neuronal	O
Cell	O
Death	O
Induced	O
by	O
the	O
Human	O
Neuroinvasive	O
Coronavirus	O
OC43	O
.	O

The	O
arterial	O
partial	O
pressure	O
of	O
oxygen	O
(	O
PaO	B-ENZY
HFOV	O
as	O
an	O
efficient	O
alternative	O
therapy	O
could	O
significantly	O
improve	O
hypoxemia	O
and	O
promote	O
CO	O
RESULTS	O
:	O
The	O
arterial	O
partial	O
pressure	O
of	O
oxygen	O
(	O
PaO	B-ENZY
CONCLUSIONS	O
:	O
HFOV	O
as	O
an	O
efficient	O
alternative	O
therapy	O
could	O
significantly	O
improve	O
hypoxemia	O
and	O
promote	O
CO	O

TITLE	O
:	O
Molecular	O
Detection	O
of	O
Circovirus	O
and	O
Adenovirus	O
in	O
Feces	O
of	O
Fur	O
Seals	O
(	O
Arctocephalus	O
spp	B-ENZY
.).	O

At	O
the	O
beginning	O
of	O
the	O
mock	O
loop	O
experiments	O
,	O
the	O
septic	O
blood	O
showed	O
significantly	O
increased	O
thrombin	B-ENZY
-	O
antithrombin	O
complexes	O
(	O
76	O
.	O
9	O
vs	O
27	O
.	O
7	O
g	O
/	O
l	O
),	O
D	O
-	O
dimers	O
(	O
1	O
.	O
2	O
vs	O
0	O
.	O
3	O
mg	O
/	O
l	O
)	O
and	O
fibrinogen	O
concentration	O
(	O
1	O
.	O
8	O
vs	O
1	O
.	O
5	O
g	O
/	O
l	O
),	O
as	O
well	O
as	O
elevated	O
extrinsic	O
coagulation	O
activity	O
(	O
shorter	O
EXTEM	O
-	O
CT	O
:	O
44	O
.	O
2	O
vs	O
57	O
s	O
)	O
and	O
higher	O
lactate	O
(	O
3	O
.	O
4	O
vs	O
1	O
.	O
5	O
mmol	O
/	O
l	O
)	O
and	O
cytokine	O
levels	O
(	O
interleukin	O
-	O
6	O
:	O
827	O
vs	O
31	O
pg	O
/	O
ml	O
)	O
when	O
compared	O
with	O
the	O
blood	O
from	O
healthy	O
animals	O
.	O

Blood	O
and	O
bronchial	O
alveolar	O
lavage	O
fluid	O
(	O
BAL	B-ENZY
)	O
from	O
humans	O
(	O
n	O
=	O
10	O
-	O
13	O
)	O
with	O
ARDS	O
and	O
controls	O
(	O
n	O
=	O
5	O
-	O
10	O
)	O
as	O
well	O
as	O
a	O
murine	O
model	O
of	O
ARDS	O
(	O
n	O
=	O
5	O
-	O
6	O
)	O
with	O
controls	O
(	O
n	O
=	O
6	O
-	O
7	O
)	O
were	O
studied	O
.	O

Levels	O
of	O
sPD	O
-	O
1	O
are	O
increased	O
in	O
both	O
the	O
serum	O
(	O
11	O
,	O
429	O
.	O
3	O
pg	O
/	O
mL	O
(	O
SD	O
2133	O
.	O
3	O
)	O
vs	O
.	O
8061	O
.	O
4	O
(	O
SD	O
4187	O
.	O
8	O
),	O
p	O
=	O
0	O
.	O
036	O
)	O
and	O
bronchial	O
alveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
(	O
6	O
,	O
311	O
.	O
1	O
pg	O
/	O
mL	O
(	O
SD	O
3758	O
.	O
0	O
)	O
vs	O
.	O
90	O
.	O
7	O
pg	O
/	O
mL	O
(	O
SD	O
202	O
.	O
8	O
),	O
p	O
=	O
0	O
.	O
002	O
)	O
of	O
humans	O
with	O
ARDS	O
.	O

Similar	O
results	O
are	O
seen	O
in	O
the	O
serum	O
(	O
9396	O
.	O
1	O
pg	O
/	O
mL	O
(	O
SD	O
1546	O
.	O
0	O
)	O
vs	O
.	O
3464	O
.	O
5	O
pg	O
/	O
mL	O
(	O
SD	O
2511	O
.	O
8	O
),	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
BAL	B-ENZY
fluid	O
(	O
2891	O
.	O
7	O
pg	O
/	O
mL	O
(	O
SD	O
868	O
.	O
1	O
)	O
vs	O
.	O
1385	O
.	O
9	O
pg	O
/	O
mL	O
(	O
SD	O
927	O
.	O
8	O
),	O
p	O
=	O
0	O
.	O
012	O
)	O
of	O
mice	O
.	O

sPD	O
-	O
1	O
levels	O
in	O
murine	O
blood	O
(	O
AUC	O
=	O
1	O
(	O
1	O
-	O
1	O
),	O
p	O
=	O
0	O
.	O
006	O
),	O
murine	O
BAL	B-ENZY
fluid	O
(	O
AUC	O
=	O
0	O
.	O
905	O
(	O
0	O
.	O
717	O
-	O
1	O
.	O
093	O
),	O
p	O
=	O
0	O
.	O
015	O
),	O
and	O
human	O
BAL	B-ENZY
(	O
AUC	O
=	O
1	O
(	O
1	O
-	O
1	O
),	O
p	O
=	O
0	O
.	O
001	O
)	O
fluid	O
predicted	O
ARDS	O
.	O

RESULTS	O
:	O
Levels	O
of	O
sPD	O
-	O
1	O
are	O
increased	O
in	O
both	O
the	O
serum	O
(	O
11	O
,	O
429	O
.	O
3	O
pg	O
/	O
mL	O
(	O
SD	O
2133	O
.	O
3	O
)	O
vs	O
.	O
8061	O
.	O
4	O
(	O
SD	O
4187	O
.	O
8	O
),	O
p	O
=	O
0	O
.	O
036	O
)	O
and	O
bronchial	O
alveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
(	O
6	O
,	O
311	O
.	O
1	O
pg	O
/	O
mL	O
(	O
SD	O
3758	O
.	O
0	O
)	O
vs	O
.	O
90	O
.	O
7	O
pg	O
/	O
mL	O
(	O
SD	O
202	O
.	O
8	O
),	O
p	O
=	O
0	O
.	O
002	O
)	O
of	O
humans	O
with	O
ARDS	O
.	O

BAL	B-ENZY
fluid	O
from	O
mice	O
with	O
ARDS	O
dampens	O
the	O
TNF	O
-	O
	O
production	O
compared	O
to	O
cells	O
cultured	O
with	O
BAL	B-ENZY
lacking	O
sPD	O
-	O
1	O
(	O
2	O
.	O
7	O
pg	O
/	O
mL	O
(	O
SD	O
3	O
.	O
8	O
)	O
vs	O
.	O
52	O
.	O
38	O
pg	O
/	O
mL	O
(	O
SD	O
25	O
.	O
1	O
),	O
p	O
=	O
0	O
.	O
002	O
).	O

Extracorporeal	O
gas	B-ENZY
exchange	O
is	O
an	O
accepted	O
rescue	O
therapy	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
select	O
patients	O
.	O

This	O
article	O
hopes	O
to	O
inform	O
decisions	O
about	O
the	O
use	O
of	O
extracorporeal	O
support	O
by	O
increasing	O
understanding	O
concerning	O
the	O
past	O
and	O
present	O
practice	O
of	O
extracorporeal	O
gas	B-ENZY
exchange	O
.	O

ABSTRACT	O
:	O
Tripterygium	O
wilfordii	O
(	O
lei	O
gong	O
teng	O
;	O
Thunder	O
of	O
God	B-ENZY
Vine	O
),	O
a	O
member	O
of	O
the	O
Celastraceae	O
family	O
,	O
is	O
a	O
medicinal	O
plant	O
used	O
to	O
treat	O
a	O
range	O
of	O
illnesses	O
.	O

Using	O
real	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
of	O
pediatric	O
patients	O
revealed	O
that	O
9	O
out	O
of	O
552	O
(	O
1	O
.	O
6	O
%)	O
was	O
positive	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
.	O

The	O
PaO	B-ENZY
This	O
study	O
investigated	O
the	O
usefulness	O
of	O
the	O
PiCCO	O
system	O
in	O
improving	O
outcomes	O
for	O
patient	O
with	O
severe	O
thoracic	O
trauma	O
and	O
ARDS	O
and	O
provided	O
new	O
evidence	O
for	O
fluid	O
management	O
in	O
critical	O
care	O
settings	O
.	O

RESULTS	O
:	O
The	O
PaO	B-ENZY

Laboratory	O
exams	O
on	O
the	O
second	O
day	O
of	O
hospitalization	O
showed	O
elevated	O
creatine	B-ENZY
kinase	I-ENZY
(	O
CK	O
)	O
and	O
troponin	O
-	O
I	O
levels	O
while	O
his	O
electrocardiography	O
(	O
ECG	O
)	O
showed	O
J	O
-	O
point	O
elevation	O
in	O
V1	O
,	O
V2	O
,	O
and	O
V3	O
precordial	O
leads	O
.	O

TITLE	O
:	O
Feline	O
coronavirus	O
replication	O
is	O
affected	O
by	O
both	O
cyclophilin	B-ENZY
A	O
and	O
cyclophilin	B-ENZY
B	O
.	O
ABSTRACT	O
:	O
Feline	O
coronavirus	O
(	O
FCoV	O
)	O
causes	O
the	O
fatal	O
disease	O
feline	O
infectious	O
peritonitis	O
,	O
which	O
is	O
currently	O
incurable	O
by	O
drug	O
treatment	O
,	O
and	O
no	O
effective	O
vaccines	O
are	O
available	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
),	O
a	O
cyclophilin	B-ENZY
(	O
Cyp	O
)	O
inhibitor	O
,	O
inhibits	O
the	O
replication	O
of	O
FCoV	O
in	O
vitro	O
and	O
in	O
vivo	O
as	O
well	O
as	O
the	O
replication	O
of	O
human	O
and	O
animal	O
coronaviruses	O
.	O

Cholinesterase	B-ENZY
inhibitors	O
should	O
be	O
discontinued	O
,	O
but	O
resumed	O
prior	O
to	O
extubation	O
,	O
and	O
steroid	O
dosage	O
could	O
be	O
increased	O
once	O
the	O
airway	O
is	O
secured	O
.	O

In	O
addition	O
,	O
mice	O
with	O
ALI	O
/	O
ARDS	O
produced	O
more	O
neutrophil	O
-	O
attracting	O
chemokines	O
,	O
myeloperoxidase	B-ENZY
and	O
reactive	O
oxygen	O
species	O
.	O

The	O
depletion	O
of	O
neutrophils	O
,	O
treatment	O
with	O
AMD3100	O
(	O
a	O
CXCR4	O
antagonist	O
),	O
Pulmozyme	O
(	O
human	O
recombinant	O
DNase	B-ENZY
)	O
or	O
Sivelestat	O
(	O
inhibitor	O
of	O
neutrophil	B-ENZY
elastase	I-ENZY
)	O
decreased	O
the	O
development	O
of	O
malaria	O
-	O
associated	O
ALI	O
/	O
ARDS	O
and	O
significantly	O
increased	O
mouse	O
survival	O
.	O

TITLE	O
:	O
Characterization	O
and	O
phylogenetic	O
analysis	O
of	O
new	O
bat	B-ENZY
astroviruses	O
detected	O
in	O
Gabon	O
,	O
Central	O
Africa	O
.	O

Moreover	O
,	O
these	O
astroviruses	O
showed	O
an	O
important	O
genetic	O
diversity	O
and	O
low	O
host	O
restriction	O
in	O
bat	B-ENZY
species	O
.	O

Coronaviruses	O
(	O
CoVs	O
)	O
have	O
been	O
reported	O
in	O
bat	B-ENZY
species	O
from	O
Thailand	O
,	O
China	O
,	O
Indonesia	O
,	O
Taiwan	O
and	O
the	O
Philippines	O
.	O

The	O
CoVs	O
group	O
is	O
known	O
to	O
include	O
some	O
coronaviruses	O
highly	O
pathogenic	O
to	O
human	O
,	O
such	O
as	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O
All	O
coronavirus	O
sequences	O
generated	O
from	O
frugivorous	O
bats	O
(	O
family	O
Pteropodidae	O
)	O
(	O
n	O
=	O
55	O
)	O
clustered	O
with	O
other	O
bat	B-ENZY
CoVs	O
of	O
lineage	O
D	O
,	O
whereas	O
one	O
coronavirus	O
from	O
Pipistrellus	O
coromandra	O
fell	O
in	O
the	O
lineage	O
C	O
of	O
CoVs	O
which	O
also	O
includes	O
the	O
MERS	O
-	O
CoV	O
.	O
CoVs	O
were	O
all	O
detected	O
in	O
various	O
genera	O
of	O
insectivorous	O
bats	O
and	O
clustered	O
with	O
diverse	O
bat	B-ENZY
CoV	O
sequences	O
previously	O
published	O
.	O

TITLE	O
:	O
Unlocking	O
bat	B-ENZY
immunology	O
:	O
establishment	O
of	O
Pteropus	O
alecto	O
bone	O
marrow	O
-	O
derived	O
dendritic	O
cells	O
and	O
macrophages	O
.	O

Bat	B-ENZY
epithelial	O
or	O
fibroblast	O
cell	O
lines	O
were	O
previously	O
established	O
to	O
study	O
the	O
bat	B-ENZY
immune	O
response	O
against	O
viral	O
infection	O
.	O

Using	O
Pteropus	O
alecto	O
(	O
P	O
.	O
alecto	O
)	O
GM	O
-	O
CSF	O
plus	O
IL4	O
,	O
FLT3L	O
and	O
CSF	O
-	O
1	O
,	O
we	O
successfully	O
generated	O
bat	B-ENZY
bone	O
marrow	O
-	O
derived	O
DC	O
and	O
macrophages	O
.	O

The	O
successful	O
generation	O
of	O
the	O
first	O
bat	B-ENZY
bone	O
marrow	O
-	O
derived	O
immune	O
cells	O
paves	O
the	O
way	O
to	O
unlocking	O
the	O
immune	O
mechanisms	O
that	O
confer	O
host	O
resilience	O
to	O
pathogens	O
in	O
bats	O
.	O

Feces	O
were	O
tested	O
by	O
PEDV	O
real	O
-	O
time	O
,	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
(	O
rRT	O
-	O
PCR	O
).	O

TITLE	O
:	O
Association	O
of	O
Heme	B-ENZY
Oxygenase	I-ENZY
1	O
with	O
Lung	O
Protection	O
in	O
Malaria	O
-	O
Associated	O
ALI	O
/	O
ARDS	O
.	O

RESULTS	O
:	O
At	O
the	O
time	O
of	O
diagnosis	O
,	O
39	O
patients	O
(	O
57	O
%)	O
had	O
respiratory	O
failure	O
(	O
partial	O
pressure	O
of	O
oxygen	O
/	O
inspiratory	O
oxygen	O
fraction	O
ratio	O
,	O
PaO	B-ENZY
CONCLUSIONS	O
:	O
Soluble	O
TM	O
in	O
BALF	O
is	O
an	O
independent	O
predictor	O
of	O
severe	O
DLI	O
.	O

Developing	O
therapies	O
to	O
protect	O
endothelial	O
barrier	O
integrity	O
and	O
stabilizing	O
gas	B-ENZY
exchange	O
is	O
getting	O
more	O
and	O
more	O
attention	O
.	O

The	O
substitutions	O
resulted	O
in	O
a	O
loss	O
of	O
furin	B-ENZY
-	O
mediated	O
cleavage	O
,	O
as	O
shown	O
by	O
fluorogenic	O
peptide	O
cleavage	O
and	O
western	O
blot	O
assays	O
.	O

However	O
,	O
cathepsin	O
and	O
trypsin	B-ENZY
-	O
like	O
protease	O
activation	O
were	O
retained	O
,	O
albeit	O
with	O
much	O
reduced	O
efficiency	O
compared	O
with	O
the	O
prototypical	O
EMC	O
/	O
2012	O
human	O
strain	O
.	O

Lineage	O
A	O
Betacoronavirus	O
NS2	O
Proteins	O
and	O
the	O
Homologous	O
Torovirus	O
Berne	O
pp1a	O
Carboxy	O
-	O
Terminal	O
Domain	O
Are	O
Phosphodiesterases	O
That	O
Antagonize	O
Activation	O
of	O
RNase	B-ENZY
L	O
.	O
ABSTRACT	O
:	O
Viruses	O
in	O
the	O
family	O

ABSTRACT	O
:	O
Dilmapimod	O
is	O
a	O
potent	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
inhibitor	O
and	O
was	O
investigated	O
in	O
a	O
study	O
(	O
NCT00996840	O
)	O
for	O
its	O
anti	O
-	O
inflammatory	O
effect	O
in	O
non	O
-	O
head	O
injury	O
trauma	O
patients	O
at	O
risk	O
for	O
developing	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

TITLE	O
:	O
Fluorescent	O
Inhibitors	O
as	O
Tools	O
To	O
Characterize	O
Enzymes	O
:	O
Case	O
Study	O
of	O
the	O
Lipid	O
Kinase	O
Phosphatidylinositol	B-ENZY
4	I-ENZY
-	I-ENZY
Kinase	I-ENZY
III	O
(	O
PI4KB	O
).	O

The	O
lavage	O
procedure	O
was	O
repeated	O
until	O
the	O
paO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
index	O
after	O
stabilization	O
remained	O
below	O
100	O
at	O
PEEP	O
5	O
cm	O
H	O
(	O
2	O
)	O
O	O
.	O
In	O
33	O
pigs	O
we	O
have	O
achieved	O
the	O
desired	O
degree	O
of	O
severe	O
ARDS	O
(	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)<	O
100	O
).	O

So	O
far	O
,	O
the	O
most	O
commonly	O
used	O
techniques	O
to	O
ameliorate	O
gas	B-ENZY
exchange	O
in	O
the	O
postextubation	O
period	O
were	O
low	O
-	O
flow	O
oxygen	O
therapy	O
and	O
non	O
-	O
invasive	O
ventilation	O
(	O
NIV	O
).	O

These	O
can	O
be	O
engineered	O
to	O
contain	O
reporter	O
genes	O
such	O
as	O
luciferase	B-ENZY
,	O
enabling	O
quantification	O
of	O
virus	O
entry	O
events	O
upon	O
pseudotyped	O
particle	O
infection	O
with	O
susceptible	O
cells	O
.	O

We	O
also	O
describe	O
how	O
these	O
particles	O
are	O
used	O
to	O
infect	O
susceptible	O
cells	O
and	O
to	O
perform	O
a	O
quantitative	O
infectivity	O
readout	O
by	O
a	O
luciferase	B-ENZY
assay	O
.	O

The	O
new	O
definition	O
of	O
ARDS	O
requires	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
to	O
assess	O
gas	B-ENZY
exchange	O
and	O
has	O
better	O
predictive	O
validity	O
for	O
short	O
-	O
term	O
mortality	O
compared	O
with	O
the	O
previous	O
definition	O
.	O

At	O
the	O
time	O
of	O
diagnosis	O
,	O
PaO	B-ENZY
We	O
identified	O
62	O
consecutive	O
patients	O
with	O
AE	O
-	O
IPF	O
.	O

The	O
median	O
PaO	B-ENZY
Evaluation	O
of	O
oxygenation	O
with	O
PEEP	O
may	O
provide	O
useful	O
information	O
for	O
predicting	O
short	O
-	O
term	O
mortality	O
in	O
patients	O
with	O
AE	O
-	O
IPF	O
.	O

The	O
median	O
PaO	B-ENZY
CONCLUSIONS	O
:	O
Evaluation	O
of	O
oxygenation	O
with	O
PEEP	O
may	O
provide	O
useful	O
information	O
for	O
predicting	O
short	O
-	O
term	O
mortality	O
in	O
patients	O
with	O
AE	O
-	O
IPF	O
.	O

We	O
will	O
underline	O
how	O
a	O
holistic	O
framework	O
of	O
respiratory	O
and	O
hemodynamic	O
support	O
should	O
be	O
provided	O
to	O
patients	O
with	O
ARDS	O
,	O
aiming	O
to	O
ensure	O
adequate	O
gas	B-ENZY
exchange	O
by	O
promoting	O
lung	O
recruitment	O
while	O
minimizing	O
the	O
risk	O
of	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

The	O
MV	O
and	O
NIV	O
groups	O
did	O
not	O
differ	O
in	O
age	O
,	O
medical	O
history	O
,	O
etiology	O
of	O
CS	O
,	O
PaO	B-ENZY

TITLE	O
:	O
Surveillance	O
of	O
Bat	B-ENZY
Coronaviruses	O
in	O
Kenya	O
Identifies	O
Relatives	O
of	O
Human	O
Coronaviruses	O
NL63	O
and	O
229E	O
and	O
Their	O
Recombination	O
History	O
.	O

Our	O
screening	O
of	O
bat	B-ENZY
samples	O
collected	O
in	O
Kenya	O
from	O
2007	O
to	O
2010	O
not	O
only	O
detected	O
RNA	O
from	O
several	O
novel	O
CoVs	O
but	O
,	O
more	O
significantly	O
,	O
identified	O
sequences	O
that	O
were	O
closely	O
related	O
to	O
human	O
CoVs	O
NL63	O
and	O
229E	O
,	O
suggesting	O
that	O
these	O
two	O
human	O
viruses	O
originate	O
from	O
bats	O
.	O

TITLE	O
:	O
Clinical	O
validation	O
of	O
3	O
commercial	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
assays	O
for	O
the	O
detection	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
from	O
upper	O
respiratory	O
tract	O
specimens	O
.	O

ABSTRACT	O
:	O
Since	O
discovery	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
a	O
novel	O
betacoronavirus	O
first	O
isolated	O
and	O
characterized	O
in	O
2012	O
,	O
MERS	O
-	O
CoV	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
)	O
assays	O
represent	O
one	O
of	O
the	O
most	O
rapidly	O
expanding	O
commercial	O
tests	O
.	O

The	O
plasma	O
concentrations	O
of	O
aspartate	B-ENZY
aminotransferase	I-ENZY
and	O
alanine	B-ENZY
aminotransferase	I-ENZY
were	O
significantly	O
increased	O
in	O
the	O
infected	O
group	O
.	O

TITLE	O
:	O
Reverse	B-ENZY
transcriptase	I-ENZY
loop	O
-	O
mediated	O
isothermal	O
amplification	O
for	O
the	O
detection	O
of	O
feline	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
current	O
study	O
was	O
designed	O
to	O
assess	O
the	O
inhibitory	O
activity	O
of	O
Broussonetia	O
papyrifera	O
-	O
derived	O
polyphenols	O
against	O
3	O
-	O
chymotrypsin	B-ENZY
-	O
like	O
and	O
papain	B-ENZY
-	O
like	O
coronavirus	O
cysteine	O
proteases	O
.	O

FmoPV	O
RNA	O
-	O
positive	O
cats	O
had	O
lower	O
median	O
red	O
blood	O
cell	O
count	O
,	O
haemoglobin	O
,	O
albumin	O
,	O
albumin	O
/	O
globulin	O
and	O
urobilinogen	O
and	O
higher	O
alanine	B-ENZY
transaminase	I-ENZY
,	O
alkaline	B-ENZY
phosphatase	I-ENZY
and	O
bilirubin	O
compared	O
with	O
non	O
-	O
infected	O
cats	O
.	O

In	O
macrophages	O
we	O
found	O
immediate	O
induction	O
of	O
IFN	O
-	O
I	O
expression	O
and	O
RNase	B-ENZY
L	O
-	O
mediated	O
breakdown	O
of	O
ribosomal	O
RNA	O
.	O

However	O
,	O
residents	O
of	O
KSA	O
(	O
aOR	B-ENZY
:	O
0	O
.	O
03	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
01	O
-	O
0	O
.	O
07	O
,	O
p	O
<	O
0	O
.	O
01	O
),	O
UAE	O
(	O
aOR	B-ENZY
:	O
0	O
.	O
01	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
004	O
-	O
0	O
.	O
02	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
Kuwait	O
(	O
aOR	B-ENZY
:	O
0	O
.	O
03	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
01	O
-	O
0	O
.	O
07	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
were	O
less	O
likely	O
to	O
believe	O
that	O
camels	O
are	O
the	O
main	O
zoonotic	O
source	O
compared	O
to	O
respondents	O
from	O
the	O
other	O
countries	O
.	O

The	O
univariate	O
logistic	O
regression	O
analysis	O
showed	O
that	O
the	O
patients	O
with	O
hemoglobin	O
<	O
90	O
g	O
/	O
L	O
,	O
plasma	O
albumin	O
<	O
30	O
g	O
/	O
L	O
,	O
C	O
-	O
reactive	O
protein	O
>	O
30	O
mg	O
/	O
L	O
,	O
procalcitonin	O
>	O
10	O
ng	O
/	O
mL	O
,	O
alanine	B-ENZY
aminotransferase	I-ENZY
>	O
100	O
U	O
/	O
L	O
,	O
or	O
aspartate	B-ENZY
aminotransferase	I-ENZY
>	O
100	O
U	O
/	O
L	O
had	O
poor	O
prognosis	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
that	O
those	O
with	O
congenital	O
dysplasia	O
of	O
the	O
airway	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
circulatory	O
complications	O
,	O
electrolyte	O
and	O
acid	O
-	O
base	O
disturbance	O
,	O
or	O
more	O
than	O
three	O
complications	O
also	O
had	O
poor	O
prognosis	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

RESULTS	O
:	O
The	O
univariate	O
logistic	O
regression	O
analysis	O
showed	O
that	O
the	O
patients	O
with	O
hemoglobin	O
<	O
90	O
g	O
/	O
L	O
,	O
plasma	O
albumin	O
<	O
30	O
g	O
/	O
L	O
,	O
C	O
-	O
reactive	O
protein	O
>	O
30	O
mg	O
/	O
L	O
,	O
procalcitonin	O
>	O
10	O
ng	O
/	O
mL	O
,	O
alanine	B-ENZY
aminotransferase	I-ENZY
>	O
100	O
U	O
/	O
L	O
,	O
or	O
aspartate	B-ENZY
aminotransferase	I-ENZY
>	O
100	O
U	O
/	O
L	O
had	O
poor	O
prognosis	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
that	O
those	O
with	O
congenital	O
dysplasia	O
of	O
the	O
airway	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
circulatory	O
complications	O
,	O
electrolyte	O
and	O
acid	O
-	O
base	O
disturbance	O
,	O
or	O
more	O
than	O
three	O
complications	O
also	O
had	O
poor	O
prognosis	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Thrombotic	O
microangiopathy	O
caused	O
by	O
methionine	B-ENZY
synthase	I-ENZY
deficiency	O
:	O
diagnosis	O
and	O
treatment	O
pitfalls	O
.	O

However	O
,	O
there	O
has	O
only	O
been	O
a	O
single	O
published	O
case	O
of	O
TMA	O
associated	O
to	O
Cbl	O
deficiency	O
type	O
G	O
(	O
CblG	O
),	O
also	O
known	O
as	O
methionine	B-ENZY
synthase	I-ENZY
deficiency	O
(	O
MSD	O
).	O

Methionine	B-ENZY
synthase	I-ENZY
deficiency	O
is	O
very	O
rare	O
and	O
characterized	O
by	O
megaloblastic	O
anemia	O
and	O
neurological	O
symptoms	O
.	O

The	O
three	O
svRNAs	O
were	O
derived	O
from	O
the	O
nsp3	O
(	O
svRNA	O
-	O
nsp3	O
.	O
1	O
and	O
-	O
nsp3	O
.	O
2	O
)	O
and	O
N	O
(	O
svRNA	O
-	O
N	O
)	O
genomic	O
regions	O
of	O
SARS	O
-	O
CoV	O
.	O
Biogenesis	O
of	O
CoV	O
svRNAs	O
was	O
RNase	B-ENZY
III	I-ENZY
,	O
cell	O
type	O
,	O
and	O
host	O
species	O
independent	O
,	O
but	O
it	O
was	O
dependent	O
on	O
the	O
extent	O
of	O
viral	O
replication	O
.	O

TITLE	O
:	O
Simultaneous	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
,	O
and	O
related	O
bat	B-ENZY
coronaviruses	O
by	O
real	O
-	O
time	O
reverse	O
transcription	O
PCR	O
.	O

Primers	O
and	O
probes	O
that	O
target	O
the	O
conserved	O
spike	O
S2	O
region	O
of	O
human	O
SARS	O
-	O
CoV	O
,	O
MERS	O
-	O
CoV	O
,	O
and	O
their	O
related	O
bat	B-ENZY
CoVs	O
were	O
designed	O
.	O

In	O
addition	O
,	O
this	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
system	O
was	O
able	O
to	O
detect	O
the	O
target	O
viruses	O
SARS	O
-	O
like	O
bat	B-ENZY
CoV	O
and	O
MERS	O
-	O
CoV	O
in	O
bat	B-ENZY
fecal	O
samples	O
and	O
sputum	O
of	O
MERS	O
patients	O
,	O
respectively	O
.	O

Therefore	O
,	O
this	O
newly	O
developed	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
method	O
is	O
expected	O
to	O
detect	O
not	O
only	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
in	O
humans	O
but	O
also	O
several	O
bat	B-ENZY
CoVs	O
that	O
are	O
closely	O
related	O
to	O
these	O
viruses	O
in	O
bats	O
.	O

The	O
first	O
prone	O
session	O
significantly	O
increased	O
PaO	B-ENZY
Prone	O
position	O
of	O
ARDS	O
patients	O
after	O
abdominal	O
surgery	O
was	O
not	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
surgical	O
complication	O
.	O

The	O
first	O
prone	O
session	O
significantly	O
increased	O
PaO	B-ENZY
CONCLUSIONS	O
:	O
Prone	O
position	O
of	O
ARDS	O
patients	O
after	O
abdominal	O
surgery	O
was	O
not	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
surgical	O
complication	O
.	O

MERS	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
Plpro	O
)	O
was	O
more	O
conformationally	O
flexible	O
than	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
CoV	O
(	O
SARS	O
)	O
CoV	O
Plpro	O
.	O

TITLE	O
:	O
Natural	O
product	O
-	O
inspired	O
esters	O
and	O
amides	O
of	O
ferulic	O
and	O
caffeic	O
acid	O
as	O
dual	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
.	O

ABSTRACT	O
:	O
Using	O
an	O
HIV	O
-	O
1	O
Reverse	B-ENZY
Transcriptase	I-ENZY
(	O
RT	O
)-	O
associated	O
RNase	B-ENZY
H	I-ENZY
inhibition	O
assay	O
as	O
lead	O
,	O
bioguided	O
fractionation	O
of	O
the	O
dichloromethane	O
extract	O
of	O
the	O
Ocimum	O
sanctum	O
leaves	O
led	O
to	O
the	O
isolation	O
of	O
five	O
triterpenes	O
(	O
1	O
-	O
5	O
)	O
along	O
with	O
three	O
3	O
-	O
methoxy	O
-	O
4	O
-	O
hydroxy	O
phenyl	O
derivatives	O
(	O
6	O
-	O
8	O
).	O

Tetradecyl	O
ferulate	O
(	O
8	O
)	O
showed	O
an	O
interesting	O
RNase	B-ENZY
H	I-ENZY
IC	O

Group	O
A	O
streptococcus	O
(	O
GAS	B-ENZY
)	O
is	O
the	O
only	O
established	O
pathogen	O
in	O
PTA	O
.	O

However	O
,	O
GAS	B-ENZY
is	O
only	O
recovered	O
from	O
approximately	O
20	O
%	O
of	O
PTA	O
patients	O
.	O

Furthermore	O
,	O
identification	O
of	O
pathogens	O
other	O
than	O
GAS	B-ENZY
,	O
may	O
lead	O
the	O
way	O
for	O
earlier	O
bacterial	O
diagnosis	O
and	O
timely	O
intervention	O
before	O
abscess	O
formation	O
in	O
sore	O
throat	O
patients	O
.	O

In	O
addition	O
to	O
the	O
involvement	O
of	O
GAS	B-ENZY
,	O
the	O
following	O
findings	O
suggest	O
a	O
pathogenic	O
role	O
for	O
FN	O
in	O
PTA	O
:	O
1	O
.	O

However	O
,	O
the	O
microbiology	O
of	O
PTA	O
fluctuated	O
with	O
seasons	O
:	O
GAS	B-ENZY
-	O
positive	O
PTA	O
cases	O
were	O
significantly	O
more	O
prevalent	O
in	O
the	O
winter	O
and	O
spring	O
compared	O
to	O
the	O
summer	O
,	O
while	O
FN	O
-	O
positive	O
PTA	O
patients	O
exhibited	O
a	O
more	O
even	O
distribution	O
over	O
the	O
year	O
,	O
but	O
with	O
a	O
trend	O
towards	O
higher	O
prevalence	O
in	O
the	O
summer	O
than	O
in	O
the	O
winter	O
.	O

Although	O
PEDV	O
was	O
long	O
believed	O
to	O
replicate	O
in	O
the	O
intestinal	O
epithelium	O
by	O
using	O
aminopeptidase	B-ENZY
N	I-ENZY
as	O
a	O
receptor	O
,	O
the	O
mechanisms	O
of	O
PEDV	O
infection	O
are	O
not	O
fully	O
characterized	O
.	O

Agreement	O
among	O
TTW	O
and	O
NS	O
,	O
NPS	O
,	O
or	O
BAL	B-ENZY
was	O
evaluated	O
by	O
calculating	O
the	O
kappa	O
statistic	O
and	O
percent	O
positive	O
agreement	O
.	O

For	O
bovine	O
respiratory	O
syncytial	O
virus	O
(	O
BRSV	O
),	O
agreement	O
with	O
TTW	O
was	O
moderate	O
for	O
NS	O
,	O
good	O
for	O
NPS	O
,	O
and	O
very	O
good	O
for	O
BAL	B-ENZY
.	O

Mechanistically	O
,	O
neuraminidase	B-ENZY
inhibition	O
assay	O
and	O
hemagglutination	O
inhibition	O
assay	O
suggested	O
that	O
N30	O
did	O
not	O
directly	O
target	O
the	O
two	O
envelope	O
glycoproteins	O
required	O
for	O
viral	O
adsorption	O
or	O
release	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
the	O
miR	O
-	O
21a	O
-	O
5p	O
is	O
notably	O
up	O
-	O
regulated	O
in	O
the	O
brains	O
of	O
mice	O
and	O
N2a	O
cells	O
infected	O
with	O
PHEV	O
,	O
and	O
it	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
CASK	O
-	O
interactive	O
protein1	O
(	O
Caskin1	O
)	O
by	O
directly	O
targeting	O
the	O
3	O
'-	O
UTR	O
of	O
Caskin1	O
using	O
a	O
Dual	O
-	O
Luciferase	B-ENZY
reporter	O
assay	O
.	O

TITLE	O
:	O
The	O
papain	B-ENZY
-	O
like	O
protease	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
has	O
deubiquitinating	O
activity	O
.	O

We	O
conducted	O
a	O
retrospective	O
review	O
of	O
HCT	O
/	O
HM	O
patients	O
with	O
HCoV	O
detected	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
).	O

Among	O
23	O
available	O
BAL	B-ENZY
samples	O
,	O
48	O
%	O
were	O
strain	O
OC43	O
,	O
22	O
%	O
were	O
NL63	O
,	O
17	O
%	O
were	O
229E	O
,	O
and	O
13	O
%	O
were	O
HKU1	O
.	O

It	O
is	O
ingested	O
as	O
an	O
oral	O
prodrug	O
that	O
is	O
rapidly	O
metabolized	O
by	O
carboxylesterase	B-ENZY
1	O
(	O
CES1	O
)	O
to	O
its	O
active	O
form	O
,	O
oseltamivir	O
carboxylate	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
bat	B-ENZY
coronaviruses	O
(	O
CoVs	O
),	O
we	O
collected	O
132	O
rectal	O
swabs	O
and	O
urine	O
samples	O
from	O
five	O
bat	B-ENZY
species	O
in	O
three	O
countries	O
in	O
southwestern	O
China	O
.	O

Samples	O
from	O
other	O
bat	B-ENZY
species	O
were	O
negative	O
for	O
these	O
viruses	O
,	O
indicating	O
that	O
the	O
least	O
horseshoe	O
bat	B-ENZY
represents	O
one	O
of	O
the	O
natural	O
reservoirs	O
and	O
mixers	O
for	O
strains	O
of	O
CoVs	O
and	O
has	O
a	O
pivotal	O
role	O
in	O
the	O
evolution	O
and	O
dissemination	O
of	O
these	O
viruses	O
.	O

Whole	O
-	O
genome	O
sequencing	O
of	O
a	O
new	O
isolate	O
(	O
F46	O
)	O
from	O
a	O
rectal	O
swab	O
from	O
a	O
least	O
horseshoe	O
bat	B-ENZY
showed	O
that	O
it	O
contained	O
29	O
699	O
nucleotides	O
,	O
excluding	O
the	O
poly	O
(	O
A	O
)	O
tail	O
,	O
with	O
13	O
open	O
reading	O
frames	O
(	O
ORFs	O
).	O

Phylogenetic	O
and	O
recombination	O
analyses	O
of	O
F46	O
provided	O
evidence	O
of	O
natural	O
recombination	O
between	O
bat	B-ENZY
SARS	O
-	O
like	O
CoVs	O
(	O
Rs3367	O
and	O
LYRa11	O
)	O
or	O
SARS	O
-	O
CoV	O
(	O
BJ01	O
),	O
suggesting	O
that	O
F46	O
could	O
be	O
a	O
new	O
recombinant	O
virus	O
from	O
SARS	O
-	O
like	O
CoVs	O
or	O
SARS	O
-	O
CoVs	O
.	O

Compared	O
to	O
treatment	O
with	O
the	O
prototypical	O
inflammatory	O
cytokine	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
HCoV	O
-	O
229E	O
replication	O
was	O
found	O
to	O
attenuate	O
the	O
inducible	O
activity	O
of	O
the	O
transcription	O
factor	O
(	O
TF	O
)	O
NF	O
-	O
B	O
and	O
to	O
restrict	O
the	O
nuclear	O
concentration	O
of	O
NF	O
-	O
B	O
subunits	O
by	O
(	O
i	O
)	O
an	O
unusual	O
mechanism	O
involving	O
partial	O
degradation	O
of	O
IKK	O
,	O
NEMO	O
and	O
IB	O
and	O
(	O
ii	O
)	O
upregulation	O
of	O
TNFAIP3	O
(	O
A20	O
),	O
although	O
constitutive	O
IKK	B-ENZY
activity	O
and	O
basal	O
TNFAIP3	O
expression	O
levels	O
were	O
shown	O
to	O
be	O
required	O
for	O
efficient	O
virus	O
replication	O
.	O

Second	O
,	O
we	O
characterized	O
actively	O
transcribed	O
genomic	O
regions	O
and	O
enhancers	O
in	O
HCoV	O
-	O
229E	O
-	O
infected	O
cells	O
and	O
systematically	O
correlated	O
the	O
genome	O
-	O
wide	O
gene	O
expression	O
changes	O
with	O
the	O
recruitment	O
of	O
Ser5	O
-	O
phosphorylated	O
RNA	B-ENZY
polymerase	I-ENZY
II	I-ENZY
and	O
prototypical	O
histone	O
modifications	O
(	O
H3K9ac	O
,	O
H3K36ac	O
,	O
H4K5ac	O
,	O
H3K27ac	O
,	O
H3K4me1	O
).	O

Chemical	O
inhibition	O
of	O
protein	B-ENZY
kinase	I-ENZY
RNA	O
-	O
like	O
endoplasmic	O
reticulum	O
kinase	O
,	O
an	O
upstream	O
regulator	O
of	O
the	O
pathway	O
,	O
resulted	O
in	O
decreased	O
injury	O
signaling	O
and	O
improved	O
barrier	O
function	O
after	O
prolonged	O
cyclic	O
stretch	O
and	O
injurious	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
Aminopeptidase	B-ENZY
N	I-ENZY
is	O
not	O
required	O
for	O
porcine	O
epidemic	O
diarrhea	O
virus	O
cell	O
entry	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
nanoparticle	O
drug	O
carriers	O
that	O
interact	O
with	O
cells	O
specifically	O
in	O
the	O
mildly	O
acidic	O
tumor	O
microenvironment	O
,	O
we	O
produced	O
polymeric	O
nanoparticles	O
modified	O
with	O
amidated	O
TAT	B-ENZY
peptide	O
via	O
a	O
simple	O
surface	O
modification	O
method	O
.	O

Two	O
types	O
of	O
core	O
poly	O
(	O
lactic	O
-	O
co	O
-	O
glycolic	O
acid	O
)	O
nanoparticles	O
(	O
NL	O
and	O
NP	O
)	O
were	O
prepared	O
with	O
a	O
phospholipid	O
shell	O
as	O
an	O
optional	O
feature	O
and	O
covered	O
with	O
polydopamine	O
that	O
enabled	O
the	O
conjugation	O
of	O
TAT	B-ENZY
peptide	O
on	O
the	O
surface	O
.	O

Subsequent	O
treatment	O
with	O
acid	O
anhydrides	O
such	O
as	O
cis	O
-	O
aconitic	O
anhydride	O
(	O
CA	O
)	O
and	O
succinic	O
anhydride	O
(	O
SA	O
)	O
converted	O
amines	O
of	O
lysine	O
residues	O
in	O
TAT	B-ENZY
peptide	O
to	O
	O
-	O
carboxylic	O
amides	O
,	O
introducing	O
carboxylic	O
groups	O
that	O
undergo	O
pH	O
-	O
dependent	O
protonation	O
and	O
deprotonation	O
.	O

The	O
nanoparticles	O
modified	O
with	O
amidated	O
TAT	B-ENZY
peptide	O
(	O
NLpT	O
-	O
CA	O
and	O
NPpT	O
-	O
CA	O
)	O
avoided	O
interactions	O
with	O
LS174T	O
colon	O
cancer	O
cells	O
and	O
J774A	O
.	O
1	O
macrophages	O
at	O
pH	O
7	O
.	O
4	O
but	O
restored	O
the	O
ability	O
to	O
interact	O
with	O
LS174T	O
cells	O
at	O
pH	O
6	O
.	O
5	O
,	O
delivering	O
paclitaxel	O
efficiently	O
to	O
the	O
cells	O
following	O
a	O
brief	O
contact	O
time	O
.	O

After	O
adjusting	O
for	O
severity	O
of	O
illness	O
,	O
risk	O
factors	O
for	O
mortality	O
were	O
:	O
hospital	O
acquired	O
pneumonia	O
(	O
HAP	O
)	O
(	O
aOR	B-ENZY
:	O
2	O
.	O
92	O
[	O
95	O
%	O
CI	O
1	O
.	O
15	O
,	O
7	O
.	O
40	O
];	O
P	O
=	O
0	O
.	O
024	O
)	O
and	O
bacteremia	O
(	O
aOR	B-ENZY
:	O
5	O
.	O
03	O
[	O
95	O
%	O
CI	O
1	O
.	O
77	O
,	O
14	O
.	O
35	O
];	O
P	O
=	O
0	O
.	O
003	O
).	O

HIV	O
-	O
1	O
IN	O
and	O
Reverse	B-ENZY
Transcriptase	I-ENZY
-	O
associated	O
Ribonuclease	B-ENZY
H	I-ENZY
(	O
RNase	B-ENZY
H	I-ENZY
)	O
active	O
sites	O
show	O
structural	O
homologies	O
,	O
with	O
the	O
presence	O
of	O
two	O
Mg	O
(	O
II	O
)	O
cofactors	O
,	O
hence	O
it	O
seems	O
possible	O
to	O
inhibit	O
both	O
enzymes	O
by	O
means	O
of	O
chelating	O
ligands	O
with	O
analogous	O
structural	O
features	O
.	O

Body	O
temperature	O
of	O
	O
38	O
.	O
5	O
	O
C	O
(	O
adjusted	O
odds	O
ratio	O
[	O
aOR	B-ENZY
],	O
5	O
.	O
54	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
38	O
-	O
22	O
.	O
30	O
;	O
P	O
=	O
0	O
.	O
016	O
),	O
pulmonary	O
infiltration	O
of	O
	O
3	O
lung	O
zones	O
(	O
aOR	B-ENZY
,	O
7	O
.	O
33	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
93	O
-	O
27	O
.	O
79	O
;	O
P	O
=	O
0	O
.	O
003	O
),	O
and	O
a	O
more	O
nonisolated	O
in	O
-	O
hospital	O
days	O
(	O
aOR	B-ENZY
,	O
1	O
.	O
32	O
per	O
1	O
day	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
09	O
-	O
1	O
.	O
60	O
;	O
P	O
=	O
0	O
.	O
004	O
)	O
were	O
significant	O
risk	O
factors	O
in	O
the	O
spreader	O
group	O
.	O

For	O
classification	O
,	O
sensitivities	O
and	O
specificities	O
for	O
ACR	O
classification	O
criteria	O
were	O
,	O
respectively	O
,	O
81	O
.	O
1	O
%	O
and	O
94	O
.	O
9	O
%	O
for	O
GCA	B-ENZY
;	O
73	O
.	O
6	O
%	O
and	O
98	O
.	O
3	O
%	O
for	O
Takayasu	O
'	O
s	O
arteritis	O
;	O
65	O
.	O
6	O
%	O
and	O
88	O
.	O
7	O
%	O
for	O
granulomatosis	O
with	O
polyangiitis	O
;	O
57	O
.	O
0	O
%	O
and	O
99	O
.	O
8	O
%	O
for	O
eosinophilic	O
granulomatosis	O
with	O
polyangiitis	O
;	O
40	O
.	O
6	O
%	O
and	O
87	O
.	O
8	O
%	O
for	O
polyarteritis	O
nodosa	O
;	O
28	O
.	O
9	O
%	O
and	O
88	O
.	O
5	O
%	O
for	O
microscopic	O
polyangiitis	O
;	O
and	O
72	O
.	O
7	O
%	O
and	O
96	O
.	O
3	O
%	O
for	O
IgA	O
-	O
vasculitis	O
.	O

However	O
,	O
all	O
the	O
data	O
were	O
mainly	O
based	O
on	O
detection	O
of	O
RVA	O
RNA	O
,	O
present	O
only	O
during	O
acute	O
infections	O
,	O
which	O
does	O
not	O
permit	O
assessment	O
of	O
the	O
true	O
exposure	O
of	O
a	O
bat	B-ENZY
population	O
to	O
RVA	O
.	O

To	O
systematically	O
investigate	O
the	O
genetic	O
diversity	O
of	O
RVAs	O
,	O
547	O
bat	B-ENZY
anal	O
swabs	O
or	O
gut	O
samples	O
along	O
with	O
448	O
bat	B-ENZY
sera	O
were	O
collected	O
from	O
five	O
South	O
Chinese	O
provinces	O
.	O

RVA	O
-	O
specific	O
antibodies	O
were	O
detected	O
in	O
10	O
.	O
7	O
%	O
(	O
48	O
/	O
448	O
)	O
of	O
bat	B-ENZY
sera	O
by	O
an	O
indirect	O
immunofluorescence	O
assay	O
(	O
IIFA	O
).	O

All	O
newly	O
-	O
identified	O
betacoronaviruses	O
were	O
SARS	O
-	O
related	O
Rhinolophus	O
bat	B-ENZY
coronaviruses	O
(	O
SARSr	O
-	O
Rh	O
-	O
BatCoV	O
).	O

Our	O
phylogenetic	O
analyses	O
also	O
provided	O
insights	O
into	O
the	O
transmission	O
of	O
these	O
viruses	O
among	O
bat	B-ENZY
species	O
,	O
revealing	O
a	O
general	O
clustering	O
by	O
geographic	O
location	O
rather	O
than	O
by	O
bat	B-ENZY
species	O
.	O

Overall	O
,	O
these	O
data	O
suggest	O
that	O
high	O
contact	O
rates	O
among	O
specific	O
bat	B-ENZY
species	O
enable	O
the	O
acquisition	O
and	O
spread	O
of	O
coronaviruses	O
.	O

Additionally	O
,	O
229E	O
-	O
like	O
bat	B-ENZY
CoVs	O
were	O
detected	O
in	O
samples	O
originating	O
from	O
Hipposideros	O
bats	O
roosting	O
in	O
sites	O
with	O
high	O
human	O
activity	O
.	O

Our	O
findings	O
confirm	O
the	O
presence	O
of	O
diverse	O
viruses	O
in	O
Kenyan	O
bats	O
while	O
providing	O
extended	O
knowledge	O
on	O
bat	B-ENZY
virus	O
distribution	O
.	O

TITLE	O
:	O
Allosteric	O
inhibition	O
of	O
aminopeptidase	B-ENZY
N	I-ENZY
functions	O
related	O
to	O
tumor	O
growth	O
and	O
virus	O
infection	O
.	O

ABSTRACT	O
:	O
Cell	O
surface	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
)	O
is	O
a	O
membrane	O
-	O
bound	O
ectoenzyme	O
that	O
hydrolyzes	O
proteins	O
and	O
peptides	O
and	O
regulates	O
numerous	O
cell	O
functions	O
.	O

Gas	B-ENZY
Exchange	O
in	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
characterized	O
by	O
severe	O
impairment	O
of	O
gas	B-ENZY
exchange	O
.	O

We	O
hypothesized	O
that	O
lower	O
airway	O
symptoms	O
in	O
ENS	O
could	O
be	O
explained	O
by	O
HVS	B-ENZY
.	O

Patients	O
completed	O
the	O
Nijmegen	O
score	O
and	O
underwent	O
a	O
hyperventilation	O
provocation	O
test	O
(	O
HVPT	O
)	O
and	O
arterial	O
blood	O
gas	B-ENZY
and	O
cardiopulmonary	O
tests	O
.	O

Patients	O
with	O
HVS	B-ENZY
were	O
asked	O
to	O
complete	O
the	O
Sinonasal	O
Outcome	O
Test	O
(	O
SNOT	O
)-	O
16	O
questionnaire	O
before	O
and	O
after	O
a	O
specific	O
eight	O
-	O
session	O
respiratory	O
rehabilitation	O
program	O
.	O

This	O
study	O
suggests	O
that	O
HVS	B-ENZY
is	O
frequent	O
in	O
patients	O
with	O
ENS	O
,	O
and	O
that	O
symptoms	O
can	O
be	O
improved	O
by	O
respiratory	O
rehabilitation	O
.	O

Pathophysiological	O
links	O
between	O
ENS	O
and	O
HVS	B-ENZY
deserve	O
to	O
be	O
further	O
explored	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
up	O
-	O
regulates	O
the	O
collagen	O
expression	O
through	O
non	O
-	O
Samd	O
TGF	O
-	O
1	O
signaling	O
.	O

Various	O
studies	O
have	O
investigated	O
bat	B-ENZY
viruses	O
in	O
tropical	O
regions	O
,	O
but	O
to	O
date	O
there	O
are	O
no	O
data	O
regarding	O
viruses	O
with	O
zoonotic	O
potential	O
that	O
circulate	O
in	O
bat	B-ENZY
and	O
rat	O
populations	O
in	O
Viet	O
Nam	O
.	O

To	O
address	O
this	O
paucity	O
of	O
data	O
,	O
we	O
sampled	O
three	O
bat	B-ENZY
farms	O
and	O
three	O
wet	O
markets	O
trading	O
in	O
rat	O
meat	O
in	O
the	O
Mekong	O
Delta	O
region	O
of	O
southern	O
Viet	O
Nam	O
.	O

Phylogenetic	O
analysis	O
revealed	O
that	O
the	O
bat	B-ENZY
paramyxoviruses	O
and	O
bat	B-ENZY
and	O
rat	O
coronaviruses	O
were	O
related	O
to	O
viruses	O
circulating	O
in	O
bat	B-ENZY
and	O
rodent	O
populations	O
globally	O
,	O
but	O
showed	O
no	O
cross	O
-	O
species	O
mixing	O
of	O
viruses	O
between	O
bat	B-ENZY
and	O
rat	O
populations	O
within	O
Viet	O
Nam	O
.	O

TITLE	O
:	O
Synonymous	O
and	O
Biased	O
Codon	O
Usage	O
by	O
MERS	O
CoV	O
Papain	B-ENZY
-	O
Like	O
and	O
3CL	O
-	O
Proteases	O
.	O

After	O
sacrifice	O
,	O
lung	O
inflammation	O
,	O
edema	O
and	O
injury	O
were	O
assessed	O
with	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
and	O
histology	O
.	O

TITLE	O
:	O
Structural	O
Insights	O
into	O
the	O
Interaction	O
of	O
Coronavirus	O
Papain	B-ENZY
-	O
Like	O
Proteases	O
and	O
Interferon	O
-	O
Stimulated	O
Gene	O
Product	O
15	O
from	O
Different	O
Species	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
encode	O
multifunctional	O
papain	B-ENZY
-	O
like	O
proteases	O
(	O
PLPs	O
)	O
that	O
have	O
the	O
ability	O
to	O
process	O
the	O
viral	O
polyprotein	O
to	O
facilitate	O
RNA	O
replication	O
and	O
antagonize	O
the	O
host	O
innate	O
immune	O
response	O
.	O

In	O
order	O
to	O
gain	O
insight	O
on	O
the	O
tropism	O
of	O
these	O
viruses	O
in	O
bats	O
,	O
we	O
studied	O
the	O
DPP4	O
distribution	O
in	O
the	O
respiratory	O
and	O
extra	O
-	O
respiratory	O
tissues	O
of	O
two	O
frugivorous	O
bat	B-ENZY
species	O
(	O
Epomophorus	O
gambianus	O
and	O
Rousettus	O
aegyptiacus	O
)	O
and	O
two	O
insectivorous	O
bat	B-ENZY
species	O
(	O
Pipistrellus	O
pipistrellus	O
and	O
Eptesicus	O
serotinus	O
).	O

Based	O
on	O
oxygenation	O
index	O
(	O
PaO	B-ENZY
After	O
excluding	O
patients	O
who	O
did	O
not	O
meet	O
the	O
inclusion	O
criteria	O
and	O
loss	O
to	O
follow	O
-	O
up	O
,	O
the	O
final	O
89	O
patients	O
were	O
enrolled	O
in	O
the	O
analysis	O
.	O

HFNC	O
can	O
provide	O
well	O
heated	O
and	O
humidified	O
high	O
flow	O
gas	B-ENZY
with	O
a	O
high	O
concentration	O
of	O
oxygen	O
,	O
which	O
can	O
improve	O
the	O
oxygenation	O
and	O
degree	O
of	O
comfort	O
of	O
patients	O
after	O
extubation	O
.	O

The	O
respiratory	O
parameters	O
by	O
means	O
of	O
blood	O
gas	B-ENZY
results	O
,	O
measurements	O
of	O
lung	O
injury	O
,	O
inflammatory	O
responses	O
,	O
and	O
integrity	O
of	O
the	O
alveolar	O
capillary	O
barrier	O
after	O
the	O
infusion	O
of	O
these	O
cells	O
were	O
analyzed	O
.	O

One	O
member	O
of	O
this	O
family	O
that	O
has	O
been	O
well	O
studied	O
is	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
),	O
a	O
multifunctional	O
protease	O
known	O
to	O
cleave	O
biologically	O
active	O
peptides	O
and	O
aide	O
in	O
coronavirus	O
entry	O
.	O

Furthermore	O
,	O
we	O
revealed	O
that	O
aminopeptidase	B-ENZY
N	I-ENZY
was	O
involved	O
in	O
PEDV	O
infection	O
in	O
HEK293	O
cells	O
.	O

Finally	O
,	O
we	O
constructed	O
a	O
p47phox	O
3	O
'	O
UTR	O
luciferase	B-ENZY
reporter	O
plasmid	O
to	O
provide	O
direct	O
confirmation	O
that	O
miR	O
-	O
19	O
targets	O
p47phox	O
expression	O
.	O

It	O
may	O
ameliorate	O
obesity	O
-	O
related	O
comorbidities	O
,	O
counteract	O
upper	O
airway	O
obstruction	O
,	O
reduce	O
hypoventilation	O
and	O
atelectasis	O
,	O
improve	O
gas	B-ENZY
exchange	O
and	O
respiratory	O
function	O
,	O
relieve	O
dyspnea	O
,	O
and	O
decrease	O
breathing	O
effort	O
in	O
obese	O
patients	O
in	O
the	O
perioperative	O
period	O
.	O

Infection	O
of	O
macrophages	O
with	O
N15m1	O
,	O
which	O
expresses	O
an	O
unstable	O
nsp15	O
,	O
or	O
N15m3	O
,	O
which	O
expresses	O
a	O
catalysis	O
-	O
deficient	O
nsp15	O
,	O
activated	O
MDA5	O
,	O
PKR	O
,	O
and	O
the	O
OAS	O
/	O
RNase	B-ENZY
L	O
system	O
,	O
resulting	O
in	O
an	O
early	O
,	O
robust	O
induction	O
of	O
type	O
I	O
IFN	O
,	O
PKR	O
-	O
mediated	O
apoptosis	O
,	O
and	O
RNA	O
degradation	O
.	O

Of	O
the	O
severe	O
ARDS	O
survivors	O
enrolled	O
,	O
1	O
-	O
year	O
postdischarge	O
,	O
HRQoL	O
assessment	O
using	O
the	O
Short	O
-	O
Form	O
36	O
(	O
SF	O
-	O
36	O
)	O
and	O
EuroQol	O
questionnaire	O
dimensions	O
,	O
6	O
-	O
min	O
walking	O
distance	O
,	O
chest	O
computed	O
tomography	O
scan	O
,	O
pulmonary	O
function	O
,	O
and	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
were	O
compared	O
for	O
ARDS	O
patients	O
with	O
or	O
without	O
ECMO	O
.	O

Here	O
,	O
we	O
tested	O
in	O
a	O
paleotropical	O
forest	O
with	O
ongoing	O
logging	O
and	O
fragmentation	O
,	O
whether	O
habitat	O
disturbance	O
influences	O
the	O
occurrence	O
of	O
astro	O
-	O
and	O
coronaviruses	O
in	O
eight	O
bat	B-ENZY
species	O
.	O

After	O
a	O
proposed	O
bat	B-ENZY
to	O
camel	O
switching	O
event	O
,	O
transmission	O
of	O
MERS	O
-	O
CoV	O
to	O
humans	O
is	O
likely	O
to	O
have	O
been	O
the	O
result	O
of	O
multiple	O
zoonotic	O
transfers	O
from	O
dromedary	O
camels	O
.	O

Secretory	O
phospholipase	B-ENZY
A2	I-ENZY
plays	O
an	O
important	O
role	O
in	O
inflammation	O
and	O
possible	O
dysfunction	O
of	O
surfactants	O
in	O
ARDS	O
.	O

BAL	B-ENZY
with	O
diluted	O
surfactant	O
allows	O
rapid	O
absorption	O
of	O
the	O
surfactant	O
at	O
the	O
air	O
/	O
liquid	O
interface	O
,	O
which	O
blocks	O
the	O
progression	O
of	O
pathological	O
lung	O
disease	O
and	O
in	O
turn	O
disrupts	O
the	O
inflammatory	O
cycle	O
.	O

TITLE	O
:	O
TMPRSS2	O
and	O
MSPL	O
Facilitate	O
Trypsin	B-ENZY
-	O
Independent	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Replication	O
in	O
Vero	O
Cells	O
.	O

While	O
bat	B-ENZY
-	O
borne	O
viruses	O
are	O
of	O
concern	O
to	O
public	O
health	O
,	O
investigations	O
into	O
their	O
dynamics	O
have	O
been	O
limited	O
by	O
a	O
lack	O
of	O
longitudinal	O
data	O
from	O
individual	O
bats	O
.	O

Here	O
,	O
we	O
examine	O
capture	O
-	O
mark	O
-	O
recapture	O
(	O
CMR	O
)	O
data	O
from	O
a	O
species	O
of	O
Australian	O
bat	B-ENZY
(	O
Myotis	O
macropus	O
)	O
infected	O
with	O
a	O
putative	O
novel	O
Alphacoronavirus	O
within	O
a	O
Bayesian	O
framework	O
.	O

These	O
findings	O
,	O
using	O
rare	O
CMR	O
data	O
from	O
longitudinal	O
samples	O
of	O
individual	O
bats	O
,	O
increase	O
our	O
understanding	O
of	O
transmission	O
dynamics	O
of	O
bat	B-ENZY
viral	O
infectious	O
diseases	O
.	O

Simultaneous	O
SpO2	O
,	O
oximeter	O
characteristics	O
,	O
receipt	O
of	O
vasopressors	O
,	O
and	O
skin	O
pigmentation	O
were	O
recorded	O
at	O
the	O
time	O
of	O
a	O
clinical	O
arterial	O
blood	O
gas	B-ENZY
.	O

In	O
the	O
present	O
work	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
Uvaria	O
angolensis	O
extracts	O
on	O
the	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
associated	O
DNA	O
polymerase	O
and	O
ribonuclease	B-ENZY
H	I-ENZY
activities	O
.	O

Run	O
Rat	O
	O
is	O
a	O
commonly	O
used	O
rodenticide	O
and	O
the	O
toxic	O
effects	O
are	O
mediated	O
through	O
conversion	O
of	O
phosphide	O
to	O
phosphine	O
gas	B-ENZY
.	O

CONCLUSIONS	O
:	O
Run	O
Rat	O
	O
is	O
a	O
commonly	O
used	O
rodenticide	O
and	O
the	O
toxic	O
effects	O
are	O
mediated	O
through	O
conversion	O
of	O
phosphide	O
to	O
phosphine	O
gas	B-ENZY
.	O

The	O
correlation	O
between	O
serum	O
CC16	O
levels	O
and	O
the	O
severity	O
of	O
ARDS	O
as	O
quantified	O
by	O
PaO	B-ENZY
The	O
serum	O
CC16	O
levels	O
in	O
ARDS	O
patients	O
were	O
significantly	O
higher	O
than	O
that	O
in	O
non	O
-	O
ARDS	O
patients	O
(	O
54	O
.	O
44	O
	O
19	O
.	O
62	O
vs	O
24	O
.	O
13	O
	O
12	O
.	O
32	O
ng	O
/	O
mL	O
,	O
P	O
=.	O
001	O
).	O

The	O
AcCoV	O
-	O
JC34	O
genome	O
was	O
27	O
,	O
649	O
nucleotides	O
long	O
and	O
showed	O
a	O
structure	O
similar	O
to	O
the	O
HKU2	O
bat	B-ENZY
coronavirus	O
.	O

Further	O
cell	O
-	O
based	O
assays	O
indicated	O
that	O
FA	O
-	O
613	O
interfer	O
with	O
the	O
de	O
novo	O
pyrimidine	O
biosynthesis	O
pathway	O
by	O
targeting	O
the	O
dihydroorotate	B-ENZY
dehydrogenase	I-ENZY
.	O

Positive	O
BDR	O
according	O
to	O
the	O
GOLD	O
criteria	O
was	O
significantly	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
severe	O
AE	O
(	O
adjusted	O
odds	O
ratio	O
(	O
aOR	B-ENZY
)	O
=	O
0	O
.	O
38	O
;	O
95	O
%	O
Confidence	O
interval	O
(	O
CI	O
)	O
=	O
0	O
.	O
15	O
-	O
0	O
.	O
93	O
).	O

TITLE	O
:	O
Gas	B-ENZY
Exchange	O
in	O
the	O
Prone	O
Posture	O
.	O

ABSTRACT	O
:	O
The	O
prone	O
posture	O
is	O
known	O
to	O
have	O
numerous	O
effects	O
on	O
gas	B-ENZY
exchange	O
,	O
both	O
under	O
normal	O
conditions	O
and	O
in	O
patients	O
with	O
ARDS	O
.	O

Improvements	O
in	O
gas	B-ENZY
exchange	O
occur	O
via	O
several	O
mechanisms	O
:	O
alterations	O
in	O
the	O
distribution	O
of	O
alveolar	O
ventilation	O
,	O
redistribution	O
of	O
blood	O
flow	O
,	O
improved	O
matching	O
of	O
local	O
ventilation	O
and	O
perfusion	O
,	O
and	O
reduction	O
in	O
regions	O
of	O
low	O
ventilation	O
/	O
perfusion	O
ratios	O
.	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PL	O
ABSTRACT	O
:	O
Within	O
a	O
decade	O
,	O
MERS	O
-	O
CoV	O
emerged	O
with	O
nearly	O
four	O
times	O
higher	O
case	O
fatality	O
rate	O
than	O
an	O
earlier	O
outbreak	O
of	O
SARS	O
-	O
CoV	O
and	O
spread	O
out	O
in	O
27	O
countries	O
in	O
short	O
span	O
of	O
time	O
.	O

In	O
this	O
study	O
,	O
MERS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PL	O

HPS	B-ENZY
is	O
endemic	O
in	O
Argentina	O
,	O
as	O
well	O
as	O
other	O
countries	O
of	O
North	O
and	O
South	O
American	O
.	O

HFRS	O
and	O
HPS	B-ENZY
are	O
usually	O
acquired	O
via	O
the	O
upper	O
respiratory	O
tract	O
by	O
inhalation	O
of	O
virus	O
-	O
contaminated	O
aerosol	O
.	O

Although	O
the	O
pathogenesis	O
of	O
HFRS	O
and	O
HPS	B-ENZY
remains	O
largely	O
unknown	O
,	O
postmortem	O
tissue	O
studies	O
have	O
identified	O
endothelial	O
cells	O
as	O
the	O
primary	O
target	O
of	O
infection	O
.	O

Since	O
no	O
single	O
factor	O
has	O
been	O
identified	O
that	O
explains	O
the	O
complexity	O
of	O
HFRS	O
or	O
HPS	B-ENZY
pathogenesis	O
,	O
it	O
has	O
been	O
suggested	O
that	O
a	O
cytokine	O
storm	O
may	O
play	O
a	O
crucial	O
role	O
in	O
the	O
manifestation	O
of	O
both	O
diseases	O
.	O

Furthermore	O
,	O
HPS	B-ENZY
was	O
strictly	O
characterized	O
by	O
the	O
upregulation	O
of	O
cytokine	O
levels	O
,	O
in	O
contrast	O
to	O
HFRS	O
where	O
cases	O
were	O
distinguished	O
by	O
a	O
dichotomy	O
in	O
serum	O
cytokine	O
levels	O
.	O

The	O
severe	O
form	O
of	O
hantavirus	O
zoonosis	O
,	O
HPS	B-ENZY
,	O
was	O
characterized	O
by	O
the	O
upregulation	O
of	O
a	O
higher	O
number	O
of	O
cytokines	O
than	O
HFRS	O
(	O
40	O
vs	O
21	O
).	O

In	O
general	O
,	O
our	O
analysis	O
indicates	O
that	O
,	O
although	O
HPS	B-ENZY
and	O
HFRS	O
share	O
many	O
characteristic	O
features	O
,	O
there	O
are	O
distinct	O
cytokine	O
profiles	O
for	O
these	O
diseases	O
.	O

Finally	O
,	O
the	O
results	O
of	O
our	O
analysis	O
suggest	O
that	O
serum	O
cytokines	O
profiles	O
of	O
HPS	B-ENZY
and	O
HFRS	O
cases	O
are	O
consistent	O
with	O
the	O
presence	O
of	O
extracellular	O
matrix	O
degradation	O
,	O
increased	O
mononuclear	O
leukocyte	O
proliferation	O
,	O
and	O
transendothelial	O
migration	O
.	O

All	O
vaccines	O
contained	O
the	O
full	O
-	O
length	O
spike	O
gene	O
of	O
MERS	O
-	O
CoV	O
;	O
ChAdOx1	O
MERS	O
vaccines	O
were	O
produced	O
with	O
or	O
without	O
the	O
leader	O
sequence	O
of	O
the	O
human	O
tissue	B-ENZY
plasminogen	I-ENZY
activator	I-ENZY
gene	O
(	O
tPA	B-ENZY
)	O
where	O
MVA	O
MERS	O
vaccines	O
were	O
produced	O
with	O
tPA	B-ENZY
,	O
but	O
either	O
the	O
mH5	O
or	O
F11	O
promoter	O
driving	O
expression	O
of	O
the	O
spike	O
gene	O
.	O

ChAdOx1	O
MERS	O
with	O
tPA	B-ENZY
induced	O
higher	O
neutralising	O
antibodies	O
than	O
ChAdOx1	O
MERS	O
without	O
tPA	B-ENZY
.	O

A	O
single	O
dose	O
of	O
ChAdOx1	O
MERS	O
with	O
tPA	B-ENZY
elicited	O
cellular	O
immune	O
responses	O
as	O
well	O
as	O
neutralising	O
antibodies	O
that	O
were	O
boosted	O
to	O
a	O
significantly	O
higher	O
level	O
by	O
MVA	O
MERS	O
.	O

The	O
humoral	O
immunogenicity	O
of	O
a	O
single	O
dose	O
of	O
ChAdOx1	O
MERS	O
with	O
tPA	B-ENZY
was	O
equivalent	O
to	O
two	O
doses	O
of	O
MVA	O
MERS	O
(	O
also	O
with	O
tPA	B-ENZY
).	O

TITLE	O
:	O
SARS	O
-	O
unique	O
fold	O
in	O
the	O
Rousettus	O
bat	B-ENZY
coronavirus	O
HKU9	O
.	O

Here	O
,	O
we	O
report	O
the	O
solution	O
NMR	O
structure	O
of	O
a	O
protein	O
from	O
the	O
""""	O
SARS	O
-	O
unique	O
region	O
""""	O
of	O
the	O
bat	B-ENZY
coronavirus	O
HKU9	O
.	O

Co	O
-	O
infections	O
are	O
not	O
common	O
in	O
those	O
bat	B-ENZY
species	O
,	O
but	O
coronavirus	O
HKU6	O
and	O
adenovirus	O
can	O
be	O
found	O
commonly	O
occurred	O
in	O
Myotis	O
ricketti	O
.	O

Half	O
the	O
patients	O
received	O
mechanical	O
ventilation	O
within	O
1	O
(	O
1	O
-	O
2	O
)	O
day	O
following	O
ICU	O
admission	O
(	O
the	O
ratio	O
of	O
arterial	O
oxygen	O
partial	O
pressure	O
to	O
fractional	O
inspired	O
oxygen	O
(	O
PaO	B-ENZY

TITLE	O
:	O
Computational	O
modeling	O
of	O
the	O
bat	B-ENZY
HKU4	O
coronavirus	O
3CL	O
ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
an	O
emerging	O
virus	O
that	O
poses	O
a	O
major	O
challenge	O
to	O
clinical	O
management	O
.	O

Although	O
the	O
typical	O
genome	O
structure	O
of	O
NS1	O
-	O
NP1	O
-	O
VP1	O
/	O
VP2	O
was	O
observed	O
in	O
DBoV1	O
and	O
DBoV2	O
,	O
no	O
phospholipase	B-ENZY
A2	I-ENZY
motif	O
and	O
associated	O
calcium	O
binding	O
site	O
were	O
observed	O
in	O
the	O
predicted	O
VP1	O
sequences	O
for	O
any	O
of	O
the	O
18	O
sequenced	O
DBoV2	O
,	O
and	O
no	O
start	O
codons	O
were	O
found	O
for	O
their	O
VP1	O
.	O

We	O
found	O
significantly	O
greater	O
maximum	O
activity	O
of	O
aspartate	B-ENZY
transaminase	I-ENZY
(	O
p	O
=	O
0	O
.	O
048	O
),	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
p	O
=	O
0	O
.	O
003	O
),	O
and	O
direct	O
bilirubin	O
concentration	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
in	O
the	O
moxifloxacin	O
treated	O
groups	O
over	O
the	O
first	O
10	O
-	O
20	O
days	O
.	O

In	O
the	O
subsequent	O
years	O
,	O
a	O
suite	O
of	O
zoonotic	O
viruses	O
including	O
Australian	O
bat	B-ENZY
lyssavirus	O
,	O
Nipah	O
virus	O
,	O
SARS	O
coronavirus	O
,	O
and	O
Ebola	O
and	O
Marburg	O
viruses	O
have	O
been	O
detected	O
in	O
bats	O
.	O

In	O
addition	O
,	O
we	O
identify	O
bat	B-ENZY
species	O
which	O
overlap	O
(	O
or	O
neighbour	O
)	O
the	O
range	O
of	O
the	O
Australian	O
camel	O
population	O
with	O
a	O
higher	O
likelihood	O
of	O
carrying	O
CoVs	O
of	O
the	O
same	O
lineage	O
as	O
MERS	O
-	O
CoV	O
.	O
Both	O
of	O
these	O
proposed	O
follow	O
-	O
on	O
studies	O
are	O
examples	O
of	O
""""	O
proactive	O
surveillance	O
""","	O
a	O
concept	O
that	O
has	O
particular	O
relevance	O
to	O
a	O
One	O
Health	O
approach	O
to	O
emerging	O
zoonotic	O
diseases	O
with	O
a	O
complex	O
epidemiology	O
and	O
aetiology	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
severe	O
ARDS	O
or	O
with	O
ratios	O
of	O
the	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
(	O
PaO	B-ENZY
Important	O
geo	O
-	O
economic	O
differences	O
exist	O
in	O
the	O
severity	O
,	O
clinician	O
recognition	O
,	O
and	O
management	O
of	O
ARDS	O
,	O
and	O
in	O
patients	O
'	O
outcomes	O
.	O

We	O
identified	O
sequences	O
representing	O
100	O
discrete	O
phylogenetic	O
clusters	O
,	O
ninety	O
-	O
one	O
of	O
which	O
were	O
found	O
in	O
bats	O
,	O
and	O
used	O
ecological	O
and	O
epidemiologic	O
analyses	O
to	O
show	O
that	O
patterns	O
of	O
CoV	O
diversity	O
correlate	O
with	O
those	O
of	O
bat	B-ENZY
diversity	O
.	O

The	O
results	O
showed	O
that	O
administration	O
of	O
tea	O
saponins	O
significantly	O
increased	O
total	O
antioxidant	O
capacity	O
,	O
total	O
superoxide	B-ENZY
dismutase	I-ENZY
,	O
catalase	B-ENZY
,	O
glutathione	B-ENZY
peroxidase	I-ENZY
,	O
glutathione	O
,	O
ascorbic	O
acid	O
,	O
and	O
	O
-	O
tocopherol	O
,	O
and	O
decreased	O
malondialdehyde	O
and	O
protein	O
carbonyl	O
.	O

We	O
found	O
that	O
SARS	O
S	O
residue	O
R667	O
,	O
a	O
previously	O
identified	O
trypsin	B-ENZY
cleavage	O
site	O
,	O
is	O
also	O
required	O
for	O
S	O
protein	O
cleavage	O
by	O
TMPRSS2	O
.	O

Among	O
them	O
,	O
there	O
are	O
the	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
associated	O
ribonuclease	B-ENZY
H	I-ENZY
(	O
RNase	B-ENZY
H	I-ENZY
)	O
function	O
and	O
the	O
cellular	O
	O
-	O
glucosidase	O
,	O
involved	O
in	O
the	O
control	O
mechanisms	O
of	O
N	O
-	O
linked	O
glycoproteins	O
formation	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O

Hence	O
,	O
here	O
we	O
tested	O
the	O
pentacyclic	O
triterpene	O
Lupeol	O
,	O
showing	O
that	O
it	O
inhibits	O
the	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNase	B-ENZY
H	I-ENZY
function	O
.	O

NF	O
-	O
B	O
activation	O
induced	O
by	O
TGEV	O
infection	O
was	O
found	O
to	O
be	O
associated	O
with	O
two	O
convergent	O
pathways	O
,	O
IKK	B-ENZY
-	O
2_IB	O
/	O
p65	O
and	O
JAK2	O
mediated	O
p65	O
phosphorylation	O
,	O
in	O
swine	O
testicular	O
cells	O
.	O

JAK2	O
inhibition	O
either	O
by	O
CYT387	O
(	O
a	O
JAK	O
family	O
inhibitor	O
)	O
or	O
by	O
silencing	O
JAK2	O
-	O
expression	O
revealed	O
a	O
dominant	O
JAK2	O
mediated	O
p65	O
phosphorylation	O
pathway	O
for	O
NF	O
-	O
B	O
activation	O
and	O
resulted	O
in	O
NF	O
-	O
B	O
inhibition	O
,	O
which	O
overrode	O
the	O
IB	O
regulation	O
via	O
the	O
IKK	B-ENZY
-	I-ENZY
2	I-ENZY
.	O

The	O
protocol	O
below	O
regards	O
exclusively	O
veno	O
-	O
venous	O
ECMO	O
treatment	O
as	O
a	O
support	O
for	O
blood	O
gas	B-ENZY
conditioning	O
by	O
means	O
of	O
extracorporeal	O
circuit	O
in	O
adult	O
patients	O
with	O
severe	O
ARDS	O
.	O

Alone	O
,	O
resveratrol	O
does	O
not	O
inhibit	O
HIV	O
-	O
1	O
infection	O
of	O
activated	O
T	O
cells	O
,	O
but	O
it	O
does	O
synergize	O
with	O
nucleoside	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
in	O
these	O
cells	O
to	O
inhibit	O
reverse	O
transcription	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
reported	O
ability	O
of	O
resveratrol	O
to	O
inhibit	O
ribonucleotide	B-ENZY
reductase	I-ENZY
and	O
to	O
lower	O
dNTP	O
levels	O
in	O
cells	O
.	O

The	O
GDS04	O
strain	O
of	O
this	O
coronavirus	O
shares	O
high	O
aa	O
identities	O
(>	O
90	O
%)	O
with	O
the	O
reported	O
bat	B-ENZY
-	O
HKU2	O
strains	O
in	O
Coronaviridae	O
-	O
wide	O
conserved	O
domains	O
,	O
suggesting	O
that	O
the	O
GDS04	O
strain	O
belongs	O
to	O
the	O
same	O
species	O
as	O
HKU2	O
.	O

Prone	O
positioning	O
as	O
a	O
means	O
of	O
improving	O
gas	B-ENZY
exchange	O
has	O
shown	O
benefit	O
in	O
refractory	O
cases	O
of	O
ARDS	O
,	O
but	O
it	O
is	O
not	O
well	O
described	O
in	O
the	O
burn	O
population	O
.	O

A	O
rapidly	O
deteriorating	O
clinical	O
course	O
in	O
a	O
patient	O
with	O
SCD	O
presenting	O
with	O
ACS	B-ENZY
or	O
severe	O
vaso	O
-	O
occlusive	O
crisis	O
should	O
trigger	O
a	O
high	O
index	O
of	O
suspicion	O
for	O
FES	O
.	O

Here	O
,	O
we	O
describe	O
a	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)-	O
	O
-	O
triggered	O
mechanism	O
,	O
in	O
which	O
megalin	O
,	O
the	O
primary	O
mediator	O
of	O
alveolar	O
protein	O
transport	O
,	O
is	O
negatively	O
regulated	O
by	O
glycogen	B-ENZY
synthase	I-ENZY
kinase	O
(	O
GSK	B-ENZY
)	O
3	O
,	O
with	O
protein	O
phosphatase	O
1	O
and	O
nuclear	O
inhibitor	O
of	O
protein	O
phosphatase	O
1	O
being	O
involved	O
in	O
the	O
signaling	O
cascade	O
.	O

We	O
evaluated	O
variability	O
in	O
delayed	O
fixation	O
(	O
24	O
hours	O
)	O
between	O
trauma	O
centers	O
participating	O
in	O
the	O
American	O
College	O
of	O
Surgeons	O
(	O
ACS	B-ENZY
)	O

A	O
retrospective	O
cohort	O
study	O
was	O
performed	O
using	O
data	O
derived	O
from	O
the	O
ACS	B-ENZY
TQIP	O
database	O
.	O

	O
-	O
bisabolol	O
(	O
	O
-	O
bis	B-ENZY
),	O
a	O
constituent	O
of	O
the	O
essential	O
oil	O
from	O
chamomile	O
,	O
has	O
elicited	O
pharmacological	O
interest	O
.	O

We	O
found	O
that	O
	O
-	O
bis	B-ENZY
-	O
LNCs	O
(	O
30	O
,	O
50	O
,	O
and	O
100	O
mg	O
kg	O

Using	O
next	O
-	O
generation	O
sequencing	O
,	O
we	O
discovered	O
a	O
novel	O
ledantevirus	O
(	O
mononegaviral	O
family	O
Rhabdoviridae	O
,	O
genus	O
Ledantevirus	O
)	O
in	O
nycteribiid	O
bat	B-ENZY
flies	O
infesting	O
pteropodid	O
bats	O
in	O
western	O
Uganda	O
.	O

Mitochondrial	O
DNA	O
analyses	O
revealed	O
that	O
both	O
the	O
bat	B-ENZY
flies	O
and	O
their	O
bat	B-ENZY
hosts	O
belong	O
to	O
putative	O
new	O
species	O
.	O

The	O
coding	O
-	O
complete	O
genome	O
of	O
the	O
new	O
virus	O
,	O
named	O
Kanyawara	O
virus	O
(	O
KYAV	O
),	O
is	O
only	O
distantly	O
related	O
to	O
that	O
of	O
its	O
closest	O
known	O
relative	O
,	O
Mount	O
Elgon	O
bat	B-ENZY
virus	O
,	O
and	O
was	O
found	O
at	O
high	O
titers	O
in	O
bat	B-ENZY
flies	O
but	O
not	O
in	O
blood	O
or	O
on	O
mucosal	O
surfaces	O
of	O
host	O
bats	O
.	O

Our	O
findings	O
highlight	O
the	O
possibility	O
of	O
a	O
yet	O
-	O
to	O
-	O
be	O
-	O
discovered	O
diversity	O
of	O
potentially	O
pathogenic	O
viruses	O
in	O
bat	B-ENZY
ectoparasites	O
.	O

In	O
this	O
study	O
from	O
Luxembourg	O
,	O
the	O
genetic	O
diversity	O
and	O
epidemiology	O
of	O
paramyxoviruses	O
and	O
coronaviruses	O
shed	O
by	O
the	O
bat	B-ENZY
species	O

There	O
was	O
a	O
limited	O
availability	O
of	O
arterial	O
blood	O
gas	B-ENZY
analyzers	O
(	O
13	O
.	O
7	O
%),	O
oseltamivir	O
(	O
42	O
.	O
2	O
%)	O
and	O
N95	O
respirators	O
(	O
54	O
.	O
6	O
%)	O
across	O
all	O
hospitals	O
surveyed	O
.	O

There	O
was	O
a	O
limited	O
availability	O
of	O
arterial	O
blood	O
gas	B-ENZY
analyzers	O
(	O
13	O
.	O
7	O
%),	O
oseltamivir	O
(	O
42	O
.	O
2	O
%)	O
and	O
N95	O
respirators	O
(	O
54	O
.	O
6	O
%)	O
across	O
all	O
hospitals	O
surveyed	O
.	O

However	O
,	O
little	O
research	O
has	O
been	O
conducted	O
on	O
bat	B-ENZY
coronaviruses	O
in	O
South	O
Korea	O
.	O

In	O
this	O
study	O
,	O
bat	B-ENZY
samples	O
(	O
332	O
oral	O
swabs	O
,	O
245	O
fecal	O
samples	O
,	O
38	O
urine	O
samples	O
,	O
and	O
57	O
bat	B-ENZY
carcasses	O
)	O
were	O
collected	O
at	O
33	O
natural	O
bat	B-ENZY
habitat	O
sites	O
in	O
South	O
Korea	O
.	O

Thirteen	O
sequences	O
belonging	O
to	O
SARS	O
-	O
like	O
betacoronaviruses	O
showed	O
the	O
highest	O
nucleotide	O
identity	O
(	O
97	O
.	O
1	O
-	O
99	O
.	O
7	O
%)	O
with	O
Bat	B-ENZY
-	O
CoV	O
-	O
JTMC15	O
reported	O
in	O
China	O
.	O

Four	O
nucleotide	O
sequences	O
displayed	O
the	O
highest	O
identity	O
(	O
94	O
.	O
1	O
-	O
95	O
.	O
1	O
%)	O
with	O
Bat	B-ENZY
-	O
CoV	O
-	O
HKU5	O
from	O
Hong	O
Kong	O
.	O

The	O
one	O
sequence	O
from	O
a	O
carcass	O
showed	O
the	O
highest	O
nucleotide	O
identity	O
(	O
99	O
%)	O
with	O
Bat	B-ENZY
-	O
CoV	O
-	O
SC2013	O
from	O
China	O
.	O

These	O
results	O
suggest	O
that	O
careful	O
surveillance	O
of	O
coronaviruses	O
from	O
bats	O
should	O
be	O
continued	O
,	O
because	O
animal	O
and	O
human	O
infections	O
may	O
result	O
from	O
the	O
genetic	O
variants	O
present	O
in	O
bat	B-ENZY
coronavirus	O
reservoirs	O
.	O

The	O
multivariable	O
linear	O
regression	O
analysis	O
of	O
the	O
relationship	O
between	O
peak	O
cTnI	O
value	O
and	O
patient	O
group	O
,	O
age	O
,	O
sex	O
,	O
and	O
type	O
of	O
ACS	B-ENZY
showed	O
that	O
the	O
presence	O
or	O
absence	O
of	O
OSA	O
significantly	O
contributed	O
to	O
the	O
peak	O
cTnI	O
level	O
,	O
which	O
was	O
54	O
%	O
lower	O
in	O
patients	O
with	O
OSA	O
than	O
in	O
those	O
without	O
OSA	O
.	O

While	O
bat	B-ENZY
,	O
camel	O
,	O
and	O
human	O
DPP4	O
support	O
MERS	O
-	O
CoV	O
infection	O
,	O
several	O
DPP4	O
orthologs	O
,	O
including	O
mouse	O
,	O
ferret	O
,	O
hamster	O
,	O
and	O
guinea	O
pig	O
DPP4	O
,	O
do	O
not	O
.	O

PPV	O
increased	O
PaO	B-ENZY
Our	O
findings	O
suggest	O
that	O
PPV	O
may	O
improve	O
oxygenation	O
and	O
partially	O
improve	O
hemodynamic	O
parameters	O
during	O
acute	O
exacerbations	O
of	O
ILD	O
.	O

The	O
majority	O
of	O
the	O
literature	O
regarding	O
LIS	B-ENZY
is	O
based	O
on	O
case	O
reports	O
that	O
utilized	O
multidisciplinary	O
interventions	O
focused	O
on	O
improving	O
functional	O
communication	O
and	O
respiratory	O
care	O
with	O
minimal	O
focus	O
on	O
motor	O
retraining	O
.	O

We	O
also	O
detected	O
one	O
novel	O
variant	O
with	O
an	O
8	O
-	O
amino	O
acid	O
insertion	O
located	O
in	O
the	O
receptor	O
-	O
binding	O
region	O
for	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
.	O
Compared	O
to	O
the	O
commercial	O
vaccine	O
strains	O
,	O
the	O
emerging	O
Vietnamese	O
strains	O
were	O
genetically	O
distant	O
and	O
had	O
various	O
amino	O
acid	O
differences	O
in	O
epitope	O
regions	O
and	O
N	O
-	O
glycosylation	O
sites	O
in	O
the	O
S	O
protein	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
sensitivity	O
and	O
specificity	O
of	O
a	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
specifically	O
designed	O
to	O
detect	O
FCoV	O
spike	O
gene	O
mutations	O
at	O
two	O
nucleotide	O
positions	O
.	O

However	O
,	O
there	O
was	O
a	O
higher	O
expression	O
of	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
lymphocytes	O
,	O
CD83	O
+	O
dendritic	O
cells	O
,	O
granzyme	B-ENZY
A	O
+	O
and	O
natural	O
killer	O
+	O
cell	O
density	O
in	O
the	O
lung	O
parenchyma	O
of	O
the	O
H1N1	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

In	O
the	O
small	O
airways	O
,	O
there	O
was	O
a	O
lower	O
cell	O
density	O
of	O
tryptase	B-ENZY
+	O
mast	O
cells	O
and	O
dendritic	O
+	O
cells	O
and	O
an	O
increase	O
of	O
IL	O
-	O
17	O
in	O
both	O
DAD	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

In	O
the	O
small	O
airways	O
,	O
there	O
was	O
a	O
lower	O
cell	O
density	O
of	O
tryptase	B-ENZY
+	O
mast	O
cells	O
and	O
dendritic	O
+	O
cells	O
and	O
an	O
increase	O
of	O
IL	O
-	O
17	O
in	O
both	O
DAD	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Surprisingly	O
,	O
the	O
antiviral	O
activity	O
of	O
U18666A	O
was	O
suppressed	O
by	O
the	O
histone	B-ENZY
deacetylase	I-ENZY
inhibitor	O
(	O
HDACi	O
),	O
Vorinostat	O
.	O

We	O
therefore	O
started	O
mechanical	O
ventilation	O
,	O
but	O
still	O
the	O
gas	B-ENZY
exchange	O
did	O
not	O
improve	O
.	O

Almost	O
instantaneously	O
the	O
gas	B-ENZY
exchange	O
ameliorated	O
.	O

AMD3100	O
significantly	O
reduced	O
PaO	B-ENZY

The	O
median	O
SOFA	O
Score	O
was	O
13	O
(	O
10	O
to	O
19	O
)	O
and	O
the	O
median	O
LIS	B-ENZY
was	O
3	O
.	O
5	O
(	O
2	O
.	O
67	O
to	O
4	O
).	O

At	O
the	O
end	O
,	O
significant	O
improvement	O
in	O
survival	O
has	O
been	O
demonstrated	O
in	O
the	O
most	O
severe	O
ARDS	O
patients	O
,	O
at	O
a	O
threshold	O
of	O
100	O
-	O
150	O
mmHg	O
PaO	B-ENZY

TITLE	O
:	O
A	O
persistently	O
infecting	O
coronavirus	O
in	O
hibernating	O
Myotis	O
lucifugus	O
,	O
the	O
North	O
American	O
little	O
brown	O
bat	B-ENZY
.	O

Although	O
there	O
have	O
been	O
several	O
studies	O
on	O
the	O
pathogenesis	O
of	O
coronaviruses	O
in	O
humans	O
and	O
surrogate	O
animals	O
,	O
there	O
is	O
little	O
information	O
on	O
the	O
interactions	O
of	O
these	O
viruses	O
with	O
their	O
natural	O
bat	B-ENZY
hosts	O
.	O

The	O
detection	O
and	O
identification	O
of	O
an	O
apparently	O
persistent	O
coronavirus	O
in	O
a	O
local	O
bat	B-ENZY
species	O
creates	O
opportunities	O
to	O
understand	O
the	O
dynamics	O
of	O
coronavirus	O
circulation	O
in	O
bat	B-ENZY
populations	O
.	O

Preliminary	O
laboratory	O
analysis	O
ruled	O
out	O
important	O
enteropathogens	O
(	O
Cryptosporidium	O
spp	B-ENZY
;	O
Eimeria	O
spp	B-ENZY
.,	O
E	O
.	O
coli	O
F5	O
,	O
and	O
bovine	O
coronavirus	O
).	O

Dual	O
luciferase	B-ENZY
reporter	O
gene	O
assay	O
results	O
indicated	O
that	O
nsp1	O
strongly	O
inhibited	O
the	O
IFN	O
-	O
	O
promoter	O
activity	O
,	O
and	O
the	O
inhibitory	O
effect	O
was	O
nsp1	O
dose	O
-	O
dependent	O
.	O

These	O
include	O
viral	O
S	O
protein	O
targeting	O
;	O
inhibitors	O
of	O
host	O
proteases	O
,	O
including	O
TMPRSS2	O
,	O
cathepsin	B-ENZY
L	I-ENZY
and	O
furin	B-ENZY
protease	O
,	O
and	O
of	O
viral	O
M	O
(	O
pro	O
)	O
and	O
the	O
PL	O
(	O
pro	O
)	O
proteases	O
;	O
convalescent	O
plasma	O
;	O
and	O
vaccine	O
candidates	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
and	O
antiviral	O
evaluation	O
of	O
novel	O
heteroarylcarbothioamide	O
derivatives	O
as	O
dual	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
associated	O
RNase	B-ENZY
H	I-ENZY
and	O
RDDP	O
functions	O
.	O

The	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
associated	O
ribonuclease	B-ENZY
H	I-ENZY
(	O
RNase	B-ENZY
H	I-ENZY
)	O
is	O
the	O
only	O
viral	O
-	O
encoded	O
enzymatic	O
activity	O
that	O
still	O
lacks	O
an	O
efficient	O
inhibitor	O
.	O

We	O
synthesized	O
a	O
library	O
of	O
3	O
,	O
5	O
-	O
diamino	O
-	O
N	O
-	O
aryl	O
-	O
1H	O
-	O
pyrazole	O
-	O
4	O
-	O
carbothioamide	O
and	O
4	O
-	O
amino	O
-	O
5	O
-	O
benzoyl	O
-	O
N	O
-	O
phenyl	O
-	O
2	O
-(	O
substituted	O
-	O
amino	O
)-	O
1H	O
-	O
pyrrole	O
-	O
3	O
-	O
carbothioamide	O
derivatives	O
and	O
tested	O
them	O
against	O
RNase	B-ENZY
H	I-ENZY
activity	O
.	O

We	O
identified	O
the	O
pyrazolecarbothioamide	O
derivative	O
A15	O
,	O
able	O
to	O
inhibit	O
viral	O
replication	O
and	O
both	O
RNase	B-ENZY
H	I-ENZY
and	O
RNA	O
-	O
dependent	O
DNA	O
polymerase	O
(	O
RDDP	O
)	O
RT	O
-	O
associated	O
activities	O
in	O
the	O
low	O
micromolar	O
range	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
experiments	O
showed	O
that	O
,	O
with	O
respect	O
to	O
wt	O
RT	O
,	O
V108A	O
substitution	O
strongly	O
reduced	O
A15	O
IC50	O
values	O
(	O
12	O
.	O
6	O
-	O
fold	O
for	O
RNase	B-ENZY
H	I-ENZY
inhibition	O
and	O
4	O
.	O
7	O
-	O
fold	O
for	O
RDDP	O
),	O
while	O
substitution	O
A502F	O
caused	O
a	O
9	O
.	O
0	O
-	O
fold	O
increase	O
in	O
its	O
IC50	O
value	O
for	O
RNase	B-ENZY
H	I-ENZY
,	O
not	O
affecting	O
the	O
RDDP	O
inhibition	O
,	O
reinforcing	O
the	O
hypothesis	O
of	O
a	O
dual	O
-	O
site	O
inhibition	O
.	O

All	O
bat	B-ENZY
samples	O
were	O
screened	O
by	O
specific	O
PCR	O
and	O
phylogenetic	O
analysis	O
.	O

Mice	O
lacking	O
all	O
inflammasome	O
signaling	O
due	O
to	O
the	O
absence	O
of	O
caspase	B-ENZY
-	I-ENZY
1	I-ENZY
and	O
-	O
11	O
were	O
more	O
vulnerable	O
to	O
infection	O
,	O
with	O
poor	O
survival	O
and	O
elevated	O
viral	O
replication	O
compared	O
to	O
wild	O
-	O
type	O
mice	O
.	O

The	O
immune	O
evasion	O
mechanism	O
including	O
type	O
1	O
interferon	O
and	O
protein	B-ENZY
kinase	I-ENZY
R	O
-	O
mediated	O
antiviral	O
stress	O
responses	O
has	O
been	O
recently	O
attributed	O
to	O
the	O
involvement	O
of	O
MERS	O
-	O
CoV	O
protein	O
4a	O
(	O
p4a	O
)	O
that	O
masks	O
the	O
viral	O
dsRNA	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
respiratory	O
support	O
,	O
also	O
known	O
as	O
extracorporeal	O
gas	B-ENZY
exchange	O
,	O
may	O
be	O
used	O
to	O
rescue	O
the	O
most	O
severe	O
forms	O
of	O
acute	O
hypoxemic	O
respiratory	O
failure	O
with	O
high	O
blood	O
flow	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

The	O
probability	O
for	O
severe	O
illness	O
originated	O
from	O
delayed	O
utilization	O
of	O
health	O
services	O
,	O
delayed	O
prescription	O
of	O
neuraminidase	B-ENZY
inhibitors	O
(	O
NAIs	O
)	O
and	O
inappropriate	O
use	O
of	O
antibiotics	O
was	O
assessed	O
.	O

As	O
part	O
of	O
its	O
viral	O
genome	O
,	O
MERS	O
-	O
CoV	O
encodes	O
a	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
that	O
has	O
been	O
observed	O
to	O
act	O
as	O
a	O
deubiquitinase	O
and	O
deISGylase	O
to	O
antagonize	O
type	O
I	O
interferon	O
(	O
IFN	O
-	O
I	O
)	O
immune	O
pathways	O
.	O

We	O
also	O
discuss	O
various	O
cellular	O
processes	O
,	O
such	O
as	O
apoptosis	O
,	O
innate	O
immunity	O
,	O
ER	O
stress	O
response	O
,	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
pathway	O
and	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
B	O
)	O
pathway	O
that	O
may	O
be	O
modulated	O
by	O
HCoVs	O
.	O

We	O
suggest	O
the	O
use	O
of	O
IV	O
methylprednisolone	O
1	O
mg	O
/	O
kg	O
/	O
day	O
in	O
patients	O
with	O
early	O
moderate	O
to	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
PaO	B-ENZY
Evidence	O
-	O
based	O
recommendations	O
for	O
the	O
use	O
of	O
corticosteroids	O
in	O
critically	O
ill	O
patients	O
with	O
sepsis	O
and	O
septic	O
shock	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
major	O
trauma	O
have	O
been	O
developed	O
by	O
a	O
multispecialty	O
task	O
force	O
.	O

We	O
suggest	O
the	O
use	O
of	O
IV	O
methylprednisolone	O
1	O
mg	O
/	O
kg	O
/	O
day	O
in	O
patients	O
with	O
early	O
moderate	O
to	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
PaO	B-ENZY

Results	O
from	O
reverse	O
transcription	O
	O
quantitative	O
polymerase	O
chain	O
reaction	O
,	O
western	O
blotting	O
and	O
ELISA	O
analysis	O
demonstrated	O
that	O
calcitriol	O
also	O
modulated	O
the	O
expression	O
of	O
members	O
of	O
the	O
renin	O
	O
angiotensin	O
system	O
(	O
RAS	O
),	O
including	O
angiotensin	O
(	O
Ang	O
)	O
I	O
	O
converting	O
enzymes	O
(	O
ACE	B-ENZY
and	O
ACE2	O
),	O
renin	B-ENZY
and	O
Ang	O
II	O
,	O
which	O
indicates	O
that	O
calcitriol	O
may	O
exert	O
protective	O
effects	O
on	O
LPS	O
	O
induced	O
lung	O
injury	O
,	O
at	O
least	O
partially	O
,	O
by	O
regulating	O
the	O
balance	O
between	O
the	O
expression	O
of	O
members	O
of	O
the	O
RAS	O
.	O

Here	O
,	O
we	O
review	O
the	O
progresses	O
of	O
different	O
reverse	O
genetics	O
platforms	O
developed	O
for	O
PEDV	O
and	O
their	O
applications	O
,	O
covering	O
the	O
roles	O
of	O
trypsin	B-ENZY
in	O
PEDV	O
propagation	O
,	O
functions	O
of	O
S	O
and	O
ORF3	O
protein	O
and	O
the	O
development	O
of	O
next	O
generation	O
PED	O
vaccines	O
,	O
and	O
the	O
perspectives	O
of	O
reverse	O
genetics	O
for	O
PEDV	O
.	O

Three	O
selected	O
isolates	O
were	O
identified	O
as	O
IBV	O
using	O
a	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
assay	O
targeted	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
and	O
further	O
characterized	O
by	O
partial	O
spike	O
(	O
S	O
)	O
gene	O
sequence	O
analysis	O
.	O

There	O
were	O
no	O
detrimental	O
effects	O
in	O
terms	O
of	O
lung	O
mechanics	O
,	O
hemodynamics	O
,	O
or	O
gas	B-ENZY
exchange	O
.	O

stigmatosoma	O
,	O
collected	O
from	O
30	O
sites	O
in	O
southern	O
California	O
from	O
2009	O
-	O
2012	O
,	O
were	O
processed	O
for	O
vertebrate	O
host	O
identification	O
by	O
nucleotide	O
sequencing	O
following	O
polymerase	O
chain	O
reaction	O
to	O
amplify	O
portions	O
of	O
the	O
cytochrome	B-ENZY
oxidase	I-ENZY
I	O
and	O
cytochrome	O
b	O
genes	O
of	O
vertebrate	O
animals	O
.	O

The	O
separate	O
sampling	O
of	O
tracheas	O
and	O
kidneys	O
for	O
IBV	O
detection	O
using	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
was	O
very	O
useful	O
,	O
as	O
different	O
genotypes	O
or	O
significant	O
differences	O
in	O
sequences	O
of	O
the	O
same	O
genotype	O
were	O
detected	O
between	O
both	O
organs	O
.	O

TITLE	O
:	O
Nanoparticulate	O
vacuolar	O
ATPase	B-ENZY
blocker	O
exhibits	O
potent	O
host	O
-	O
targeted	O
antiviral	O
activity	O
against	O
feline	O
coronavirus	O
.	O

Their	O
median	O
Sequential	O
Organ	O
Failure	O
Assessment	O
score	O
was	O
12	O
,	O
PaO	B-ENZY
CONCLUSIONS	O
:	O
Cytokine	O
levels	O
,	O
on	O
average	O
,	O
fall	O
rapidly	O
after	O
initiation	O
of	O
VV	O
ECMO	O
,	O
which	O
may	O
be	O
related	O
to	O
the	O
reduction	O
of	O
invasiveness	O
of	O
mechanical	O
ventilation	O
.	O

Isolation	O
and	O
propagation	O
of	O
the	O
pathogen	O
in	O
cell	O
culture	O
resulted	O
in	O
discovery	O
of	O
a	O
novel	O
swine	O
enteric	O
alphacoronavirus	O
(	O
tentatively	O
named	O
SeACoV	O
)	O
related	O
to	O
the	O
bat	B-ENZY
coronavirus	O
HKU2	O
identified	O
in	O
the	O
same	O
region	O
a	O
decade	O
ago	O
.	O

However	O
,	O
eight	O
domains	O
of	O
Nsp3	O
exist	O
in	O
all	O
known	O
CoVs	O
:	O
the	O
ubiquitin	O
-	O
like	O
domain	O
1	O
(	O
Ubl1	O
),	O
the	O
Glu	O
-	O
rich	O
acidic	O
domain	O
(	O
also	O
called	O
""""	O
hypervariable	O
region	O
"""),"	O
a	O
macrodomain	O
(	O
also	O
named	O
""""	O
X	O
domain	O
"""),"	O
the	O
ubiquitin	O
-	O
like	O
domain	O
2	O
(	O
Ubl2	O
),	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
(	O
PL2	O

The	O
healthcare	O
worker	O
,	O
a	O
nurse	O
,	O
was	O
infected	O
while	O
performing	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	B-ENZY
)	O
for	O
a	O
MERS	O
patient	O
in	O
an	O
isolation	O
room	O
.	O

She	O
suggested	O
that	O
she	O
was	O
contaminated	O
with	O
the	O
MERS	O
patient	O
'	O
s	O
body	O
fluids	O
by	O
wiping	O
away	O
the	O
sweat	O
from	O
her	O
face	O
during	O
the	O
CPR	B-ENZY
.	O

The	O
MERS	O
guidelines	O
should	O
reflect	O
this	O
case	O
to	O
decrease	O
the	O
risk	O
of	O
infection	O
during	O
CPR	B-ENZY
.	O

RESULTS	O
:	O
The	O
healthcare	O
worker	O
,	O
a	O
nurse	O
,	O
was	O
infected	O
while	O
performing	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	B-ENZY
)	O
for	O
a	O
MERS	O
patient	O
in	O
an	O
isolation	O
room	O
.	O

She	O
suggested	O
that	O
she	O
was	O
contaminated	O
with	O
the	O
MERS	O
patient	O
'	O
s	O
body	O
fluids	O
by	O
wiping	O
away	O
the	O
sweat	O
from	O
her	O
face	O
during	O
the	O
CPR	B-ENZY
.	O

Interferon	O
(	O
IFN	O
)	O
beta	O
-	O
1a	O
up	O
-	O
regulates	O
the	O
cell	O
surface	O
ecto	O
-	O
5	B-ENZY
'-	I-ENZY
nucleotidase	I-ENZY
cluster	O
of	O
differentiation	O
73	O
(	O
CD73	O
),	O
which	O
increases	O
adenosine	O
levels	O
,	O
and	O
IFN	O
beta	O
-	O
1	O
may	O
,	O
therefore	O
,	O
be	O
a	O
potential	O
treatment	O
for	O
ARDS	O
.	O

Subjects	O
underwent	O
impedance	O
-	O
based	O
platelet	O
aggregometry	O
in	O
response	O
to	O
platelet	O
agonists	O
arachidonic	O
acid	O
,	O
adenosine	O
diphosphate	O
,	O
collagen	O
,	O
and	O
thrombin	B-ENZY
receptor	O
activating	O
peptide	O
-	O
6	O
.	O

Finally	O
,	O
elimination	O
of	O
peripheral	O
Ly6G	O
+	O
neutrophils	O
and	O
pharmacological	O
blockade	O
of	O
the	O
miR	O
-	O
223	O
-	O
NLRP3	O
-	O
IL	O
-	O
1	O
signalling	O
axis	O
could	O
alleviate	O
MTD	B-ENZY
-	O
induced	O
ALI	O
.	O

ABSTRACT	O
:	O
To	O
clarify	O
the	O
effect	O
of	O
single	O
-	O
session	O
multivessel	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
strategy	O
relative	O
to	O
the	O
staged	O
multivessel	O
strategy	O
on	O
clinical	O
outcomes	O
in	O
patients	O
with	O
stable	O
coronary	O
artery	O
disease	O
(	O
CAD	B-ENZY
)	O
or	O
non	O
-	O
ST	O
-	O
elevation	O
acute	O
coronary	O
syndrome	O
.	O

For	O
the	O
subgroup	O
analyses	O
including	O
age	O
,	O
gender	O
,	O
extent	O
of	O
CAD	B-ENZY
,	O
severe	O
chronic	O
kidney	O
disease	O
and	O
heart	O
failure	O
,	O
there	O
was	O
no	O
significant	O
interaction	O
between	O
the	O
subgroup	O
factors	O
and	O
the	O
effect	O
of	O
the	O
single	O
-	O
session	O
strategy	O
relative	O
to	O
the	O
staged	O
strategy	O
for	O
the	O
primary	O
outcome	O
measure	O
.	O

For	O
the	O
subgroup	O
analyses	O
including	O
age	O
,	O
gender	O
,	O
extent	O
of	O
CAD	B-ENZY
,	O
severe	O
chronic	O
kidney	O
disease	O
and	O
heart	O
failure	O
,	O
there	O
was	O
no	O
significant	O
interaction	O
between	O
the	O
subgroup	O
factors	O
and	O
the	O
effect	O
of	O
the	O
single	O
-	O
session	O
strategy	O
relative	O
to	O
the	O
staged	O
strategy	O
for	O
the	O
primary	O
outcome	O
measure	O
.	O

The	O
fewer	O
tacrolimus	O
daily	O
dosage	O
,	O
the	O
lower	O
APACHE	O
II	O
score	O
and	O
levels	O
of	O
PCT	O
and	O
BNP	O
,	O
the	O
more	O
effective	O
promotion	O
of	O
PaO	B-ENZY
RESULTS	O
:	O
The	O
two	O
groups	O
were	O
similar	O
in	O
gender	O
,	O
age	O
,	O
and	O
underlying	O
diseases	O
.	O

Histological	O
examination	O
revealed	O
MERS	O
-	O
CoV	O
enteric	O
infection	O
in	O
all	O
inoculated	O
mice	O
,	O
as	O
shown	O
by	O
the	O
presence	O
of	O
virus	O
-	O
positive	O
cells	O
,	O
progressive	O
inflammation	O
,	O
and	O
epithelial	O
degeneration	O
in	O
small	O
intestines	O
,	O
which	O
were	O
exaggerated	O
in	O
the	O
mice	O
pretreated	O
with	O
the	O
proton	B-ENZY
pump	I-ENZY
inhibitor	O
pantoprazole	O
.	O

The	O
lung	O
gas	B-ENZY
volume	O
was	O
significantly	O
lower	O
in	O
severe	O
ARDS	O
compared	O
to	O
CPE	O
(	O
830	O
[	O
462	O
]	O
vs	O
1120	O
[	O
832	O
]	O
mL	O
).	O

Updates	O
were	O
also	O
given	O
on	O
the	O
use	O
of	O
the	O
currently	O
licensed	O
neuraminidase	B-ENZY
inhibitors	O
.	O

GI	O
symptoms	O
were	O
more	O
likely	O
declared	O
in	O
case	O
of	O
laboratory	O
confirmed	O
-	O
enteric	O
infection	O
(	O
adjusted	O
odds	O
ratio	O
(	O
aOR	B-ENZY
)	O
=	O
3	O
.	O
2	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
[	O
1	O
.	O
2	O
-	O
9	O
.	O
9	O
];	O
p	O
=	O
0	O
.	O
02	O
)	O
or	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
infection	O
(	O
aOR	B-ENZY
=	O
2	O
.	O
7	O
;	O
[	O
1	O
.	O
2	O
-	O
6	O
.	O
8	O
];	O
p	O
=	O
0	O
.	O
02	O
).	O

Consumption	O
of	O
antipyretic	O
medication	O
before	O
the	O
consultation	O
seemed	O
to	O
reduce	O
the	O
risk	O
of	O
developing	O
GI	O
symptoms	O
for	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
influenza	O
(	O
aOR	B-ENZY
=	O
0	O
.	O
3	O
;	O
[	O
0	O
.	O
1	O
-	O
0	O
.	O
6	O
];	O
p	O
=	O
0	O
.	O
002	O
).	O

TITLE	O
:	O
Trypsin	B-ENZY
-	O
independent	O
porcine	O
epidemic	O
diarrhea	O
virus	O
US	O
strain	O
with	O
altered	O
virus	O
entry	O
mechanism	O
.	O

Mice	O
(	O
C57BL	O
/	O
6	O
)	O
had	O
50	O
	O
10	O
BAL	B-ENZY
IL	O
-	O
6	O
and	O
tumor	O
necrosis	O
factor	O
as	O
well	O
as	O
plasma	O
IL	O
-	O
6	O
were	O
significantly	O
lower	O
in	O
the	O
animals	O
administered	O
VPA	O
within	O
3	O
h	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
but	O
not	O
when	O
administered	O
later	O
(	O
4	O
,	O
6	O
,	O
9	O
h	O
).	O

There	O
was	O
no	O
difference	O
in	O
the	O
BAL	B-ENZY
E	O
coli	O
colony	O
-	O
forming	O
units	O
,	O
macrophage	O
,	O
or	O
neutrophil	O
numbers	O
at	O
any	O
time	O
point	O
.	O

RESULTS	O
:	O
BAL	B-ENZY
IL	O
-	O
6	O
and	O
tumor	O
necrosis	O
factor	O
as	O
well	O
as	O
plasma	O
IL	O
-	O
6	O
were	O
significantly	O
lower	O
in	O
the	O
animals	O
administered	O
VPA	O
within	O
3	O
h	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
but	O
not	O
when	O
administered	O
later	O
(	O
4	O
,	O
6	O
,	O
9	O
h	O
).	O

ABSTRACT	O
:	O
Mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
develop	O
hepatitis	O
and	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	B-ENZY
hydrolase	I-ENZY
(	O
FAH	O
),	O
a	O
fact	O
closely	O
related	O
to	O
the	O
release	O
of	O
alarmins	O
such	O
as	O
uric	O
acid	O
and	O
/	O
or	O
high	O
-	O
mobility	O
group	O
box	O
protein	O
1	O
(	O
HMGB1	O
).	O

TITLE	O
:	O
Discovery	O
of	O
a	O
rich	O
gene	O
pool	O
of	O
bat	B-ENZY
SARS	O
-	O
related	O
coronaviruses	O
provides	O
new	O
insights	O
into	O
the	O
origin	O
of	O
SARS	O
coronavirus	O
.	O

However	O
,	O
these	O
bat	B-ENZY
SARSr	O
-	O
CoVs	O
show	O
sequence	O
differences	O
from	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
different	O
genes	O
(	O
S	O
,	O
ORF8	O
,	O
ORF3	O
,	O
etc	O
)	O
and	O
are	O
considered	O
unlikely	O
to	O
represent	O
the	O
direct	O
progenitor	O
of	O
SARS	O
-	O
CoV	O
.	O
Herein	O
,	O
we	O
report	O
the	O
findings	O
of	O
our	O
5	O
-	O
year	O
surveillance	O
of	O
SARSr	O
-	O
CoVs	O
in	O
a	O
cave	O
inhabited	O
by	O
multiple	O
species	O
of	O
horseshoe	O
bats	O
in	O
Yunnan	O
Province	O
,	O
China	O
.	O

TITLE	O
:	O
Transmissible	O
Gastroenteritis	O
Virus	O
Papain	B-ENZY
-	O
Like	O
Protease	O
1	O
Antagonizes	O
Production	O
of	O
Interferon	O
-	O
ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
),	O
such	O
as	O
human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
(	O
SARS	O
-	O
CoV	O
),	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
encode	O
papain	B-ENZY
-	O
like	O
(	O
PL	O
)	O
proteases	O
that	O
inhibit	O
Sendai	O
virus	O
-	O
(	O
SeV	O
-)	O
induced	O
interferon	O
(	O
IFN	O
-	O

We	O
previously	O
reported	O
that	O
clinical	O
isolates	O
of	O
HCoV	O
-	O
229E	O
preferred	O
cell	O
-	O
surface	O
TMPRSS2	O
to	O
endosomal	O
cathepsin	O
for	O
cell	O
entry	O
,	O
and	O
that	O
they	O
acquired	O
the	O
ability	O
to	O
use	O
cathepsin	B-ENZY
L	I-ENZY
by	O
repeated	O
passage	O
in	O
cultured	O
cells	O
and	O
were	O
then	O
able	O
to	O
enter	O
cells	O
via	O
the	O
endosomal	O
pathway	O
.	O

TITLE	O
:	O
microRNA	O
-	O
4331	O
Promotes	O
Transmissible	O
Gastroenteritis	O
Virus	O
(	O
TGEV	O
)-	O
induced	O
Mitochondrial	O
Damage	O
Via	O
Targeting	O
RB1	O
,	O
Upregulating	O
Interleukin	O
-	O
1	O
Receptor	O
Accessory	O
Protein	O
(	O
IL1RAP	O
),	O
and	O
Activating	O
p38	O
MAPK	B-ENZY
Pathway	O
ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
a	O
member	O
of	O
the	O
coronaviridae	O
family	O
,	O
could	O
cause	O
fatal	O
diarrhea	O
of	O
piglets	O
and	O
result	O
in	O
numerous	O
economic	O
losses	O
.	O

Measured	O
with	O
the	O
patient	O
in	O
the	O
supine	O
position	O
before	O
and	O
at	O
the	O
end	O
of	O
the	O
first	O
PP	O
session	O
,	O
PaO	B-ENZY
In	O
conclusion	O
,	O
this	O
prospective	O
international	O
prevalence	O
study	O
found	O
that	O
PP	O
was	O
used	O
in	O
32	O
.	O
9	O
%	O
of	O
patients	O
with	O
severe	O
ARDS	O
,	O
and	O
was	O
associated	O
with	O
low	O
complication	O
rates	O
,	O
significant	O
increase	O
in	O
oxygenation	O
and	O
a	O
significant	O
decrease	O
in	O
driving	O
pressure	O
.	O

Measured	O
with	O
the	O
patient	O
in	O
the	O
supine	O
position	O
before	O
and	O
at	O
the	O
end	O
of	O
the	O
first	O
PP	O
session	O
,	O
PaO	B-ENZY

The	O
medians	O
of	O
PaO	B-ENZY
CONCLUSIONS	O
:	O
Since	O
the	O
duration	O
of	O
MV	O
before	O
ECMO	O
institution	O
was	O
strongly	O
correlated	O
to	O
the	O
outcome	O
of	O
adult	O
respiratory	O
ECMO	O
,	O
medical	O
centers	O
are	O
suggested	O
to	O
find	O
a	O
suitable	O
prognosticating	O
tool	O
to	O
determine	O
the	O
starting	O
point	O
of	O
respiratory	O
ECMO	O
among	O
their	O
candidates	O
with	O
different	O
duration	O
of	O
MV	O
.	O

Previously	O
,	O
activation	O
of	O
the	O
JNK	B-ENZY
pathway	O
has	O
been	O
detected	O
in	O
cells	O
infected	O
with	O
several	O
coronaviruses	O
.	O

Here	O
we	O
report	O
that	O
the	O
JNK	B-ENZY
pathway	O
was	O
activated	O
in	O
cells	O
infected	O
with	O
the	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

Taken	O
together	O
,	O
JNK	B-ENZY
constitutes	O
an	O
important	O
aspect	O
of	O
coronavirus	O
-	O
host	O
interaction	O
,	O
along	O
with	O
other	O
MAPKs	O
.	O

Multiple	O
surveillance	O
and	O
phylogenetic	O
studies	O
suggest	O
a	O
bat	B-ENZY
origin	O
.	O

Both	O
samples	O
resulted	O
positive	O
to	O
the	O
pan	O
-	O
coronavirus	O
RT	O
-	O
PCR	O
(	O
IT	O
-	O
batCoVs	O
)	O
and	O
their	O
genome	O
organization	O
showed	O
identical	O
pattern	O
of	O
MERS	O
CoV	O
.	O
Phylogenetic	O
analysis	O
showed	O
a	O
monophyletic	O
group	O
placed	O
in	O
the	O
Beta2c	O
clade	O
formed	O
by	O
MERS	O
-	O
CoV	O
sequences	O
originating	O
from	O
humans	O
and	O
camels	O
and	O
bat	B-ENZY
-	O
related	O
sequences	O
from	O
Africa	O
,	O
Italy	O
and	O
China	O
.	O

The	O
comparison	O
of	O
the	O
secondary	O
and	O
3DMMS	O
of	O
the	O
RBD	O
of	O
IT	O
-	O
batCoVs	O
with	O
MERS	O
,	O
HKU4	O
and	O
HKU5	O
bat	B-ENZY
sequences	O
showed	O
two	O
aa	O
deletions	O
located	O
in	O
a	O
region	O
corresponding	O
to	O
the	O
external	O
subdomain	O
of	O
MERS	O
-	O
RBD	O
in	O
IT	O
-	O
batCoV	O
and	O
HKU5	O
RBDs	O
.	O

RESULTS	O
:	O
Both	O
samples	O
resulted	O
positive	O
to	O
the	O
pan	O
-	O
coronavirus	O
RT	O
-	O
PCR	O
(	O
IT	O
-	O
batCoVs	O
)	O
and	O
their	O
genome	O
organization	O
showed	O
identical	O
pattern	O
of	O
MERS	O
CoV	O
.	O
Phylogenetic	O
analysis	O
showed	O
a	O
monophyletic	O
group	O
placed	O
in	O
the	O
Beta2c	O
clade	O
formed	O
by	O
MERS	O
-	O
CoV	O
sequences	O
originating	O
from	O
humans	O
and	O
camels	O
and	O
bat	B-ENZY
-	O
related	O
sequences	O
from	O
Africa	O
,	O
Italy	O
and	O
China	O
.	O

The	O
comparison	O
of	O
the	O
secondary	O
and	O
3DMMS	O
of	O
the	O
RBD	O
of	O
IT	O
-	O
batCoVs	O
with	O
MERS	O
,	O
HKU4	O
and	O
HKU5	O
bat	B-ENZY
sequences	O
showed	O
two	O
aa	O
deletions	O
located	O
in	O
a	O
region	O
corresponding	O
to	O
the	O
external	O
subdomain	O
of	O
MERS	O
-	O
RBD	O
in	O
IT	O
-	O
batCoV	O
and	O
HKU5	O
RBDs	O
.	O

All	O
microbiological	O
tests	O
were	O
negative	O
except	O
multiplex	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
using	O
respiratory	O
specimen	O
,	O
which	O
was	O
positive	O
for	O
human	O
adenovirus	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
the	O
plant	O
compound	O
silvestrol	O
,	O
a	O
specific	O
inhibitor	O
of	O
the	O
DEAD	O
-	O
box	O
RNA	O
helicase	O
eIF4A	O
,	O
on	O
viral	O
translation	O
using	O
a	O
dual	O
luciferase	B-ENZY
assay	O
and	O
virus	O
-	O
infected	O
primary	O
cells	O
.	O

Compared	O
with	O
severe	O
pneumonia	O
without	O
ARDS	O
development	O
,	O
patients	O
with	O
ARDS	O
development	O
had	O
shorter	O
disease	O
duration	O
before	O
admission	O
,	O
higher	O
lung	O
injury	O
score	O
(	O
LIS	B-ENZY
),	O
serum	O
fibrinogen	O
(	O
FiB	O
),	O
and	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
),	O
lower	O
Marshall	O
score	O
,	O
sequential	O
organ	O
failure	O
assessment	O
score	O
and	O
proportion	O
of	O
cardiovascular	O
and	O
gastrointestinal	O
diseases	O
,	O
but	O
similar	O
mortality	O
.	O

ABSTRACT	O
:	O
Bat	B-ENZY
-	O
borne	O
virus	O
surveillance	O
is	O
necessary	O
for	O
determining	O
inter	O
-	O
species	O
transmission	O
risks	O
and	O
is	O
important	O
due	O
to	O
the	O
wide	O
-	O
range	O
of	O
bat	B-ENZY
species	O
which	O
may	O
harbour	O
potential	O
pathogens	O
.	O

Family	O
-	O
wide	O
PCR	O
screenings	O
were	O
used	O
to	O
test	O
302	O
bats	O
belonging	O
to	O
19	O
different	O
bat	B-ENZY
species	O
.	O

CoV	O
RNA	O
was	O
found	O
in	O
36	O
bats	O
belonging	O
to	O
eight	O
species	O
,	O
while	O
PMV	O
RNA	O
in	O
three	O
Pipistrellus	O
spp	B-ENZY
.	O

The	O
23	O
new	O
bat	B-ENZY
genetic	O
sequences	O
presented	O
will	O
expand	O
the	O
current	O
molecular	O
bat	B-ENZY
-	O
borne	O
virus	O
databases	O
.	O

Considering	O
the	O
amount	O
of	O
novel	O
bat	B-ENZY
-	O
borne	O
PMVs	O
associated	O
with	O
the	O
emergence	O
of	O
zoonotic	O
infections	O
in	O
animals	O
and	O
humans	O
in	O
the	O
last	O
years	O
,	O
the	O
definition	O
of	O
viral	O
diversity	O
within	O
European	O
bat	B-ENZY
species	O
is	O
needed	O
.	O

Turning	O
off	O
the	O
sweep	O
gas	B-ENZY
flow	O
immediately	O
led	O
to	O
EAdi	O
elevation	O
,	O
followed	O
by	O
hypoxia	O
.	O

TITLE	O
:	O
Distribution	O
of	O
bat	B-ENZY
-	O
borne	O
viruses	O
and	O
environment	O
patterns	O
.	O

ABSTRACT	O
:	O
Acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
)	O
is	O
a	O
frequent	O
cause	O
of	O
acute	O
lung	O
disease	O
in	O
children	O
with	O
sickle	O
cell	O
disease	O
(	O
SCD	O
).	O

Patients	O
may	O
present	O
with	O
ACS	B-ENZY
or	O
may	O
develop	O
this	O
complication	O
during	O
the	O
course	O
of	O
a	O
hospitalization	O
for	O
acute	O
vaso	O
-	O
occlusive	O
crises	O
(	O
VOC	O
).	O

ACS	B-ENZY
is	O
associated	O
with	O
prolonged	O
hospitalization	O
,	O
increased	O
risk	O
of	O
respiratory	O
failure	O
,	O
and	O
the	O
potential	O
for	O
developing	O
chronic	O
lung	O
disease	O
.	O

The	O
etiology	O
of	O
ACS	B-ENZY
is	O
often	O
multifactorial	O
.	O

Several	O
risk	O
factors	O
have	O
been	O
identified	O
in	O
children	O
to	O
be	O
associated	O
with	O
increased	O
incidence	O
of	O
ACS	B-ENZY
.	O

As	O
of	O
November	O
2017	O
,	O
MERS	O
-	O
CoV	O
had	O
infected	O
at	O
least	O
2102	O
people	O
with	O
a	O
fatality	O
rate	O
of	O
about	O
35	O
%	O
globally	O
,	O
and	O
hence	O
there	O
is	O
an	O
urgent	O
need	O
to	O
identify	O
antiviral	O
drugs	O
that	O
are	O
active	O
against	O
MERS	O
-	O
CoV	O
.	O
Here	O
we	O
show	O
that	O
a	O
clinically	O
available	O
alcohol	O
-	O
aversive	O
drug	O
,	O
disulfiram	O
,	O
can	O
inhibit	O
the	O
papain	B-ENZY
-	O
like	O
proteases	O
(	O
PL	O

In	O
this	O
study	O
,	O
we	O
screened	O
a	O
library	O
of	O
1000	O
compounds	O
and	O
identified	O
two	O
specific	O
inhibitors	O
,	O
designated	O
compounds	O
2	O
and	O
3	O
,	O
which	O
target	O
the	O
PRRSV	O
3C	B-ENZY
-	I-ENZY
like	I-ENZY
serine	I-ENZY
protease	I-ENZY
(	O
3CLSP	B-ENZY
).	O

This	O
counteracting	O
effect	O
was	O
partially	O
mediated	O
by	O
protein	O
8b	O
/	O
8ab	O
-	O
induced	O
degradation	O
of	O
IRF3	O
in	O
a	O
ubiquitin	O
-	O
proteasome	B-ENZY
-	O
dependent	O
manner	O
.	O

Coronaviruses	O
are	O
one	O
of	O
the	O
most	O
common	O
viruses	O
discovered	O
in	O
bats	O
,	O
which	O
were	O
considered	O
as	O
the	O
natural	O
source	O
of	O
recent	O
human	O
-	O
susceptible	O
coronaviruses	O
,	O
i	O
.	O
e	O
.	O
SARS	O
-	O
COV	O
and	O
MERS	O
-	O
CoV	O
.	O
Our	O
previous	O
study	O
reported	O
the	O
discovery	O
of	O
a	O
bat	B-ENZY
-	O
derived	O
putative	O
cross	O
-	O
family	O
recombinant	O
coronavirus	O
with	O
a	O
reovirus	O
gene	O
p10	O
,	O
named	O
as	O
Ro	O
-	O
BatCoV	O
GCCDC1	O
.	O

In	O
this	O
report	O
,	O
through	O
a	O
two	O
-	O
year	O
follow	O
-	O
up	O
of	O
a	O
special	O
bat	B-ENZY
population	O
in	O
one	O
specific	O
cave	O
of	O
south	O
China	O
,	O
we	O
illustrate	O
that	O
Ro	O
-	O
BatCoV	O
GCCDC1	O
persistently	O
circulates	O
among	O
bats	O
.	O

Our	O
study	O
provides	O
the	O
first	O
glimpse	O
of	O
the	O
virus	O
evolution	O
in	O
one	O
longitudinally	O
observed	O
bat	B-ENZY
population	O
cohort	O
and	O
underlines	O
the	O
surveillance	O
and	O
pre	O
-	O
warning	O
of	O
potential	O
interspecies	O
transmittable	O
viruses	O
in	O
bats	O
.	O

The	O
gender	O
,	O
age	O
,	O
onset	O
to	O
diagnosis	O
time	O
,	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
score	O
,	O
oxygenation	O
index	O
(	O
PaO	B-ENZY
There	O
was	O
no	O
significant	O
difference	O
in	O
gender	O
,	O
age	O
,	O
onset	O
to	O
diagnosis	O
time	O
,	O
APACHE	O
II	O
score	O
,	O
PaO	B-ENZY
Early	O
bundle	O
therapy	O
has	O
a	O
significant	O
effect	O
on	O
severe	O
human	O
infection	O
by	O
avian	O
influenza	O
H7N9	O
,	O
which	O
can	O
improve	O
the	O
prognosis	O
and	O
reduce	O
the	O
mortality	O
of	O
patients	O
.	O

The	O
localization	O
of	O
more	O
negative	O
Ppl	O
proportionally	O
increases	O
dependent	O
lung	O
stretch	O
by	O
drawing	O
gas	B-ENZY
either	O
from	O
other	O
lung	O
regions	O
(	O
e	O
.	O
g	O
.,	O
nondependent	O
lung	O
[	O
pendelluft	O
])	O
or	O
from	O
the	O
ventilator	O
.	O

UTI	O
significantly	O
protected	O
animals	O
from	O
LPS	O
-	O
induced	O
ALI	O
,	O
decreasing	O
the	O
lung	O
wet	O
/	O
dry	O
weight	O
ratio	O
,	O
ALI	O
score	O
,	O
total	O
cells	O
,	O
neutrophils	O
,	O
macrophages	O
,	O
myeloperoxidase	B-ENZY
activity	O
,	O
and	O
malondialdehyde	O
content	O
,	O
factors	O
associated	O
with	O
lung	O
histological	O
damage	O
.	O

We	O
investigated	O
NET	O
production	O
in	O
plasma	O
and	O
supernatant	O
of	O
cultured	O
neutrophils	O
by	O
measuring	O
cell	O
-	O
free	O
deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
and	O
myeloperoxidase	B-ENZY
(	O
MPO	O
)-	O
DNA	O
complexes	O
with	O
PicoGreen	O
dye	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
methods	O
,	O
respectively	O
.	O

The	O
most	O
common	O
adverse	O
events	O
were	O
headache	O
(	O
n	O
=	O
6	O
[	O
21	O
%]	O
in	O
participants	O
who	O
received	O
SAB	O
-	O
301	O
and	O
n	O
=	O
2	O
[	O
20	O
%]	O
in	O
those	O
receiving	O
placebo	O
),	O
albuminuria	O
(	O
n	O
=	O
5	O
[	O
18	O
%]	O
vs	O
n	O
=	O
2	O
[	O
20	O
%]),	O
myalgia	O
(	O
n	O
=	O
3	O
[	O
11	O
%]	O
vs	O
n	O
=	O
1	O
[	O
10	O
%]),	O
increased	O
creatine	B-ENZY
kinase	I-ENZY
(	O
n	O
=	O
3	O
[	O
11	O
%]	O
vs	O
1	O
[	O
10	O
%]),	O
and	O
common	O
cold	O
(	O
n	O
=	O
3	O
[	O
11	O
%]	O
vs	O
n	O
=	O
2	O
[	O
20	O
%]).	O

TITLE	O
:	O
Circulation	O
of	O
Alphacoronavirus	O
,	O
Betacoronavirus	O
and	O
Paramyxovirus	O
in	O
Hipposideros	O
bat	B-ENZY
species	O
in	O
Zimbabwe	O
.	O

In	O
this	O
study	O
,	O
we	O
screened	O
bat	B-ENZY
faecal	O
samples	O
for	O
the	O
presence	O
of	O
Coronavirus	O
and	O
Paramyxovirus	O
in	O
two	O
caves	O
frequently	O
visited	O
by	O
local	O
people	O
to	O
collect	O
manure	O
and	O
/	O
or	O
to	O
hunt	O
bats	O
in	O
Zimbabwe	O
.	O

A	O
severe	O
ARDS	O
with	O
a	O
PaO	B-ENZY
RESULTS	O
:	O
Out	O
of	O
1234	O
ARDS	O
patients	O
,	O
431	O
(	O
34	O
.	O
9	O
%)	O
were	O
transported	O
,	O
and	O
52	O
of	O
these	O
(	O
12	O
.	O
1	O
%)	O
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

When	O
a	O
critical	O
event	O
occurred	O
,	O
the	O
PaO	B-ENZY

Most	O
of	O
the	O
patients	O
(	O
88	O
.	O
1	O
%)	O
had	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
,	O
and	O
the	O
median	O
PaO	B-ENZY
CONCLUSIONS	O
:	O
The	O
outcome	O
of	O
ARDS	O
in	O
patients	O
with	O
hematological	O
malignancies	O
is	O
associated	O
with	O
the	O
severity	O
of	O
the	O
underlying	O
diseases	O
,	O
the	O
presence	O
of	O
multidrug	O
-	O
resistance	O
pathogens	O
,	O
and	O
the	O
amount	O
of	O
transfusion	O
;	O
however	O
,	O
strict	O
application	O
of	O
low	O
tidal	O
volume	O
ventilation	O
may	O
improve	O
the	O
outcome	O
of	O
these	O
patients	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

This	O
study	O
focuses	O
on	O
a	O
new	O
mechanism	O
of	O
SPC	O
as	O
an	O
anti	O
-	O
inflammatory	O
molecule	O
using	O
SPC	O
-	O
TK	O
/	O
SPC	O
-	O
KO	O
(	O
surfactant	O
protein	O
C	O
-	O
thymidine	B-ENZY
kinase	I-ENZY
/	O
surfactant	O
protein	O
C	O
knockout	O
)	O
mice	O
,	O
which	O
represent	O
a	O
novel	O
sterile	O
injury	O
model	O
that	O
mimics	O
clinical	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

SPC	O
-	O
TK	O
mice	O
express	O
the	O
inducible	O
suicide	O
gene	O
thymidine	B-ENZY
kinase	I-ENZY
from	O
by	O
the	O
SPC	O
promoter	O
,	O
which	O
targets	O
alveolar	O
type	O
2	O
(	O
AT2	O
)	O
cells	O
for	O
depletion	O
in	O
response	O
to	O
ganciclovir	O
(	O
GCV	O
).	O

SPC	O
-	O
TK	O
/	O
SPC	O
-	O
KO	O
mice	O
had	O
highly	O
elevated	O
inflammatory	O
cytokines	O
and	O
granulocyte	O
infiltration	O
in	O
the	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
.	O

The	O
level	O
of	O
suppressor	O
of	O
cytokine	O
signaling	O
3	O
,	O
an	O
anti	O
-	O
inflammatory	O
mediator	O
that	O
decreases	O
pSTAT3	O
signaling	O
,	O
was	O
significantly	O
decreased	O
in	O
the	O
BAL	B-ENZY
fluid	O
of	O
SPC	O
-	O
TK	O
/	O
SPC	O
-	O
KO	O
mice	O
.	O

Our	O
findings	O
support	O
a	O
bat	B-ENZY
origin	O
of	O
MERS	O
-	O
CoV	O
and	O
suggest	O
that	O
bat	B-ENZY
CoV	O
spike	O
proteins	O
may	O
have	O
evolved	O
in	O
a	O
stepwise	O
manner	O
for	O
binding	O
to	O
hDPP4	O
.	O

TITLE	O
:	O
Interplay	O
between	O
co	O
-	O
divergence	O
and	O
cross	O
-	O
species	O
transmission	O
in	O
the	O
evolutionary	O
history	O
of	O
bat	B-ENZY
coronaviruses	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
have	O
been	O
documented	O
in	O
almost	O
every	O
species	O
of	O
bat	B-ENZY
sampled	O
.	O

Bat	B-ENZY
CoVs	O
exhibit	O
both	O
extensive	O
genetic	O
diversity	O
and	O
a	O
broad	O
geographic	O
range	O
,	O
indicative	O
of	O
a	O
long	O
-	O
standing	O
host	O
association	O
.	O

Despite	O
this	O
,	O
the	O
respective	O
roles	O
of	O
long	O
-	O
term	O
virus	O
-	O
host	O
co	O
-	O
divergence	O
and	O
cross	O
-	O
species	O
transmission	O
(	O
host	O
-	O
jumping	O
)	O
in	O
the	O
evolution	O
of	O
bat	B-ENZY
coronaviruses	O
are	O
unclear	O
.	O

Using	O
a	O
phylogenetic	O
approach	O
we	O
provide	O
evidence	O
that	O
CoV	O
diversity	O
in	O
bats	O
is	O
shaped	O
by	O
both	O
species	O
richness	O
and	O
their	O
geographical	O
distribution	O
,	O
and	O
that	O
CoVs	O
exhibit	O
clustering	O
at	O
the	O
level	O
of	O
bat	B-ENZY
genera	O
,	O
with	O
these	O
genus	O
-	O
specific	O
clusters	O
largely	O
associated	O
with	O
distinct	O
CoV	O
species	O
.	O

Co	O
-	O
phylogenetic	O
analyses	O
revealed	O
that	O
cross	O
-	O
species	O
transmission	O
has	O
been	O
more	O
common	O
than	O
co	O
-	O
divergence	O
across	O
coronavirus	O
evolution	O
as	O
a	O
whole	O
,	O
and	O
that	O
cross	O
-	O
species	O
transmission	O
events	O
were	O
more	O
likely	O
between	O
sympatric	O
bat	B-ENZY
hosts	O
.	O

For	O
each	O
case	O
,	O
data	O
were	O
extracted	O
pertaining	O
to	O
age	O
,	O
sex	O
,	O
type	O
of	O
medication	O
associated	O
with	O
the	O
disease	O
,	O
time	O
from	O
the	O
onset	O
of	O
symptoms	O
to	O
diagnosis	O
,	O
eosinophil	O
counts	O
in	O
the	O
blood	O
,	O
eosinophil	O
fractions	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
,	O
initial	O
chest	O
radiograph	O
and	O
computed	O
tomography	O
results	O
,	O
use	O
of	O
mechanical	O
ventilation	O
,	O
and	O
use	O
of	O
steroid	O
treatment	O
and	O
recurrence	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
has	O
supported	O
gas	B-ENZY
exchange	O
in	O
children	O
with	O
severe	O
respiratory	O
failure	O
for	O
more	O
than	O
40	O
years	O
,	O
without	O
ECMO	O
efficacy	O
studies	O
.	O

ABSTRACT	O
:	O
Group	O
A	O
Streptococcus	O
(	O
GAS	B-ENZY
)	O
are	O
pathogenic	O
bacteria	O
of	O
the	O
genus	O
Streptococcus	O
and	O
cause	O
severe	O
invasive	O
infections	O
that	O
comprise	O
a	O
wide	O
range	O
of	O
diverse	O
diseases	O
,	O
including	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
renal	O
failure	O
,	O
toxic	O
shock	O
-	O
like	O
syndrome	O
,	O
sepsis	O
,	O
cellulitis	O
and	O
necrotizing	O
fasciitis	O
.	O

The	O
essential	O
virulence	O
,	O
infected	O
host	O
and	O
external	O
environmental	O
factors	O
required	O
for	O
invasive	O
GAS	B-ENZY
infections	O
have	O
not	O
yet	O
been	O
determined	O
.	O

Superinfection	O
with	O
influenza	O
virus	O
and	O
GAS	B-ENZY
induced	O
invasive	O
GAS	B-ENZY
infections	O
was	O
demonstrated	O
by	O
our	O
team	O
in	O
a	O
mouse	O
model	O
,	O
after	O
which	O
clinical	O
cases	O
of	O
invasive	O
GAS	B-ENZY
infections	O
secondary	O
to	O
influenza	O
virus	O
infection	O
were	O
reported	O
by	O
other	O
investigators	O
in	O
Japan	O
,	O
USA	O
,	O
Canada	O
,	O
UK	O
China	O
,	O
and	O
other	O
countries	O
.	O

The	O
present	O
review	O
describes	O
the	O
current	O
knowledge	O
about	O
invasive	O
GAS	B-ENZY
infections	O
by	O
superinfection	O
.	O

Topics	O
addressed	O
include	O
the	O
bacteriological	O
,	O
virological	O
and	O
immunological	O
mechanisms	O
impacting	O
invasion	O
upon	O
superinfection	O
on	O
top	O
of	O
underlying	O
influenza	O
virus	O
infection	O
by	O
GAS	B-ENZY
and	O
other	O
bacteria	O
(	O
i	O
.	O
e	O
.,	O
Streptococcus	O
pneumoniae	O
and	O
Staphylococcus	O
aureus	O
).	O

TITLE	O
:	O
Dual	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
and	O
integrase	O
inhibitors	O
from	O
ABSTRACT	O
:	O
During	O
our	O
search	O
for	O
potential	O
templates	O
of	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)	O
and	O
integrase	O
(	O
IN	O
)	O
dual	O
inhibitors	O
,	O
the	O
methanolic	O
extract	O
obtained	O
from	O
aerial	O
parts	O
of	O

Lastly	O
,	O
we	O
observed	O
in	O
humans	O
that	O
increased	O
plasma	O
NETs	O
were	O
associated	O
with	O
ARDS	O
severity	O
and	O
mortality	O
,	O
and	O
lower	O
plasma	O
DNase	B-ENZY
I	O
levels	O
were	O
associated	O
with	O
the	O
development	O
of	O
sepsis	O
-	O
induced	O
ARDS	O
.	O

He	O
complained	O
of	O
numbness	O
and	O
weakness	O
in	O
the	O
distal	O
extremities	O
at	O
114	O
days	O
after	O
BMT	B-ENZY
.	O

He	O
developed	O
an	O
acute	O
kidney	O
injury	O
requiring	O
supportive	O
treatment	O
and	O
on	O
day	O
3	O
of	O
his	O
illness	O
was	O
noted	O
to	O
have	O
developed	O
severe	O
rhabdomyolysis	O
(	O
creatine	B-ENZY
kinase	I-ENZY
level	O
132	O
040	O
U	O
/	O
L	O
(	O
normal	O
<	O
320	O
U	O
/	O
L	O
)).	O

ABSTRACT	O
:	O
Continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
is	O
an	O
effective	O
treatment	O
for	O
obstructive	O
sleep	O
apnoea	O
(	O
OSA	O
),	O
but	O
an	O
evaluation	O
of	O
CPAP	O
adherence	O
is	O
rarely	O
carried	O
out	O
among	O
patients	O
with	O
acute	O
coronary	O
syndrome	O
(	O
ACS	B-ENZY
).	O

The	O
goals	O
of	O
the	O
study	O
are	O
to	O
analyse	O
long	O
-	O
term	O
adherence	O
and	O
identify	O
the	O
predictors	O
of	O
non	O
-	O
compliance	O
with	O
CPAP	O
treatment	O
for	O
patients	O
with	O
non	O
-	O
sleepy	O
OSA	O
and	O
ACS	B-ENZY
.	O

Protective	O
factors	O
against	O
non	O
-	O
compliance	O
with	O
CPAP	O
treatment	O
in	O
non	O
-	O
sleepy	O
patients	O
with	O
ACS	B-ENZY
were	O
illness	O
severity	O
(	O
high	O
values	O
of	O
AHI	O
or	O
ICU	O
stay	O
length	O
)	O
or	O
smoking	O
amount	O
.	O

Patients	O
with	O
no	O
previous	O
history	O
of	O
ACS	B-ENZY
showed	O
lower	O
odds	O
of	O
CPAP	O
non	O
-	O
compliance	O
than	O
patients	O
with	O
a	O
recurrent	O
ACS	B-ENZY
with	O
younger	O
age	O
.	O

The	O
co	O
-	O
evolutionary	O
history	O
of	O
bats	O
with	O
viruses	O
has	O
been	O
hypothesized	O
to	O
have	O
shaped	O
the	O
bat	B-ENZY
-	O
virus	O
relationship	O
,	O
allowing	O
both	O
to	O
exist	O
in	O
equilibrium	O
.	O

Progress	O
in	O
understanding	O
bat	B-ENZY
-	O
virus	O
interactions	O
and	O
the	O
isolation	O
of	O
bat	B-ENZY
-	O
borne	O
viruses	O
has	O
been	O
accelerated	O
in	O
recent	O
years	O
by	O
the	O
development	O
of	O
susceptible	O
bat	B-ENZY
cell	O
lines	O
.	O

In	O
this	O
review	O
,	O
we	O
highlight	O
the	O
current	O
progress	O
in	O
understanding	O
bat	B-ENZY
-	O
virus	O
interactions	O
in	O
bat	B-ENZY
cell	O
line	O
systems	O
and	O
some	O
of	O
the	O
challenges	O
and	O
limitations	O
associated	O
with	O
cell	O
lines	O
.	O

ABSTRACT	O
:	O
Hyperventilation	O
syndrome	O
(	O
HVS	B-ENZY
)	O
sometimes	O
occurs	O
in	O
patients	O
under	O
stressful	O
conditions	O
and	O
may	O
provoke	O
severe	O
complications	O
such	O
as	O
myocardial	O
infarction	O
and	O
death	O
.	O

TITLE	O
:	O
Metalloprotease	O
ADAM17	O
regulates	O
porcine	O
epidemic	O
diarrhea	O
virus	O
infection	O
by	O
modifying	O
aminopeptidase	B-ENZY
N	I-ENZY
.	O
ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
is	O
a	O
causative	O
agent	O
of	O
porcine	O
epidemic	O
diarrhea	O
(	O
PED	O
).	O

TITLE	O
:	O
Development	O
and	O
Validation	O
of	O
a	O
Novel	O
Dual	O
Luciferase	B-ENZY
Reporter	O
Gene	O
Assay	O
to	O
Quantify	O
Ebola	O
Virus	O
VP24	O
Inhibition	O
of	O
IFN	O
Signaling	O
.	O

Accordingly	O
,	O
we	O
developed	O
a	O
dual	O
signal	O
firefly	O
and	O
Renilla	O
luciferase	B-ENZY
cell	O
-	O
based	O
drug	O
screening	O
assay	O
able	O
to	O
quantify	O
IFN	O
-	O
mediated	O
induction	O
of	O
Interferon	O
Stimulated	O
Genes	O
(	O
ISGs	O
)	O
and	O
its	O
inhibition	O
by	O
VP24	O
.	O

Human	O
Embryonic	O
Kidney	O
293T	O
(	O
HEK293T	O
)	O
cells	O
were	O
transiently	O
transfected	O
with	O
a	O
luciferase	B-ENZY
reporter	O
gene	O
construct	O
driven	O
by	O
the	O
promoter	O
of	O
ISGs	O
,	O
Interferon	O
-	O
Stimulated	O
Response	O
Element	O
(	O
ISRE	O
).	O

To	O
accomplish	O
this	O
,	O
we	O
transfected	O
an	O
adherent	O
dihydrofolate	B-ENZY
reductase	I-ENZY
-	O
deficient	O
CHO	O
cell	O
line	O
(	O
adCHO	O
)	O
with	O
a	O
plasmid	O
encoding	O
S377	O
-	O
588	O
fused	O
with	O
the	O
human	O
IgG	O
Fc	O
fragment	O
(	O
S377	O
-	O
588	O
-	O
Fc	O
).	O

With	O
current	O
rates	O
of	O
deforestation	O
and	O
urbanization	O
,	O
redistribution	O
of	O
bat	B-ENZY
habitats	O
to	O
urban	O
and	O
suburban	O
areas	O
may	O
bring	O
bats	O
into	O
closer	O
contact	O
with	O
livestock	O
and	O
humans	O
.	O

This	O
report	O
describes	O
the	O
detection	O
of	O
coronavirus	O
RNA	O
in	O
P	O
.	O
medius	O
bat	B-ENZY
guano	O
collected	O
in	O
Peradeniya	O
,	O
Sri	O
Lanka	O
.	O

A	O
total	O
of	O
59	O
(	O
10	O
.	O
63	O
%)	O
bat	B-ENZY
samples	O
were	O
positive	O
for	O
the	O
two	O
betacorona	O
-	O
viruses	O
,	O
46	O
(	O
8	O
.	O
29	O
%)	O
for	O
HKU9	O
and	O
13	O
(	O
2	O
.	O
34	O
%)	O
for	O
GCCDC1	O
,	O
or	O
closely	O
related	O
viruses	O
.	O

The	O
rapid	O
MERS	O
-	O
CoV	O
nucleocapsid	O
protein	O
detection	O
assay	O
was	O
tested	O
positive	O
in	O
24	O
(	O
88	O
.	O
9	O
%)	O
of	O
27	O
Tylonycteris	O
bat	B-ENZY
CoV	O
HKU4	O
(	O
Ty	O
-	O
BatCoV	O
-	O
HKU4	O
)	O
RNA	O
-	O
positive	O
alimentary	O
samples	O
of	O
Tylonycteris	O
pachypus	O
and	O
4	O
(	O
19	O
.	O
0	O
%)	O
of	O
21	O
Pipistrellus	O
bat	B-ENZY
CoV	O
HKU5	O
(	O
Pi	O
-	O
BatCoV	O
-	O
HKU5	O
)	O
RNA	O
-	O
positive	O
alimentary	O
samples	O
of	O
Pipistrellus	O
abramus	O
.	O

This	O
assay	O
will	O
facilitate	O
rapid	O
on	O
-	O
site	O
mass	O
screening	O
of	O
animal	O
samples	O
for	O
ancestors	O
of	O
MERS	O
-	O
CoV	O
and	O
tracking	O
transmission	O
in	O
the	O
related	O
bat	B-ENZY
species	O
.	O

Arterial	O
blood	O
gas	B-ENZY
analysis	O
confirmed	O
a	O
severe	O
respiratory	O
failure	O
(	O
type	O
I	O
).	O

All	O
cases	O
underwent	O
autopsy	O
,	O
histopathology	O
and	O
immunohistochemistry	O
(	O
IHC	O
)	O
for	O
FCoV	O
.	O
Furthermore	O
,	O
a	O
genotype	O
-	O
discriminating	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
(	O
RT	O
-	O
qPCR	O
)	O
was	O
performed	O
on	O
shavings	O
of	O
paraffin	O
-	O
embedded	O
tissues	O
to	O
discriminate	O
between	O
cats	O
with	O
FIP	O
and	O
controls	O
,	O
and	O
the	O
sensitivity	O
and	O
specificity	O
of	O
this	O
discriminating	O
RT	O
-	O
qPCR	O
were	O
calculated	O
using	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
).	O

CS	O
exposure	O
alone	O
caused	O
no	O
detectable	O
lung	O
injury	O
or	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
inflammation	O
.	O

However	O
,	O
when	O
mice	O
were	O
treated	O
with	O
antibiotics	O
after	O
infection	O
to	O
improve	O
clinical	O
relevance	O
,	O
the	O
survival	O
benefit	O
was	O
lost	O
,	O
and	O
CS	O
-	O
exposed	O
mice	O
had	O
more	O
pulmonary	O
edema	O
,	O
increased	O
numbers	O
of	O
BAL	B-ENZY
monocytes	O
,	O
and	O
elevated	O
monocyte	O
and	O
lymphocyte	O
chemokines	O
.	O

This	O
study	O
assessed	O
the	O
efficacy	O
and	O
safety	O
of	O
bivalirudin	O
compared	O
with	O
UFH	O
with	O
or	O
without	O
GPIs	O
in	O
patients	O
with	O
acute	O
coronary	O
syndrome	O
(	O
ACS	B-ENZY
)	O
who	O
underwent	O
invasive	O
management	O
.	O

In	O
patients	O
with	O
ACS	B-ENZY
,	O
the	O
rates	O
of	O
MACEs	O
and	O
NACEs	O
were	O
not	O
significantly	O
lower	O
with	O
bivalirudin	O
than	O
with	O
UFH	O
,	O
irrespective	O
of	O
planned	O
GPI	O
use	O
.	O

ABSTRACT	O
:	O
Clinical	O
samples	O
were	O
evaluated	O
with	O
the	O
Mobile	O
Analysis	O
Platform	O
(	O
MAP	O
)	O
to	O
determine	O
platform	O
performance	O
for	O
detecting	O
respiratory	O
viruses	O
in	O
samples	O
previously	O
characterized	O
using	O
clinical	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
assays	O
.	O

The	O
model	O
included	O
male	O
sex	O
,	O
contact	O
with	O
a	O
sick	O
patient	O
or	O
camel	O
,	O
diabetes	O
,	O
severe	O
illness	O
,	O
low	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
count	O
,	O
low	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
),	O
and	O
high	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
).	O

HCoV	O
-	O
NL63	O
and	O
-	O
229E	O
may	O
originate	O
from	O
bat	B-ENZY
reservoirs	O
as	O
assumed	O
for	O
many	O
other	O
coronaviruses	O
,	O
but	O
HCoV	O
-	O
OC43	O
and	O
-	O
HKU1	O
seem	O
more	O
likely	O
to	O
have	O
speciated	O
from	O
rodent	O
-	O
associated	O
viruses	O
.	O

Blood	O
serum	O
samples	O
were	O
tested	O
by	O
an	O
electrophoretic	O
method	O
for	O
the	O
assessment	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
concentration	O
,	O
whereas	O
fecal	O
samples	O
were	O
submitted	O
to	O
ELISA	O
test	O
for	O
positivity	O
to	O
Escherichia	O
coli	O
K99	O
,	O
rotavirus	O
,	O
coronavirus	O
,	O
and	O
Cryptosporidium	O
spp	B-ENZY
.	O

95	O
%	O
CI	O
=	O
1	O
-	O
137	O
)	O
and	O
Cryptosporidium	O
spp	B-ENZY
.	O

ABSTRACT	O
:	O
By	O
means	O
of	O
structure	O
-	O
based	O
molecular	O
hybridization	O
strategy	O
,	O
a	O
series	O
of	O
novel	O
diarylpyri	O
(	O
mi	O
)	O
dine	O
derivatives	O
targeting	O
the	O
entrance	O
channel	O
of	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)	O
were	O
designed	O
,	O
synthesized	O
and	O
evaluated	O
as	O
potent	O
non	O
-	O
nucleoside	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
(	O
NNRTIs	O
).	O

ABSTRACT	O
:	O
Species	O
within	O
the	O
Neoromicia	O
bat	B-ENZY
genus	O
are	O
abundant	O
and	O
widely	O
distributed	O
in	O
Africa	O
.	O

With	O
the	O
exception	O
of	O
the	O
coronaviruses	O
,	O
the	O
study	O
represents	O
the	O
first	O
report	O
of	O
sequence	O
data	O
from	O
several	O
viral	O
families	O
within	O
a	O
Southern	O
African	O
insectivorous	O
bat	B-ENZY
genus	O
;	O
highlighting	O
the	O
need	O
for	O
continued	O
investigations	O
in	O
this	O
regard	O
.	O

TITLE	O
:	O
Porcine	O
Deltacoronavirus	O
Engages	O
the	O
Transmissible	O
Gastroenteritis	O
Virus	O
Functional	O
Receptor	O
Porcine	O
Aminopeptidase	B-ENZY
N	I-ENZY
for	O
Infectious	O
Cellular	O
Entry	O
.	O

TITLE	O
:	O
Fatal	O
swine	O
acute	O
diarrhoea	O
syndrome	O
caused	O
by	O
an	O
HKU2	O
-	O
related	O
coronavirus	O
of	O
bat	B-ENZY
origin	O
.	O

Quantitation	O
of	O
the	O
challenge	O
pathogens	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
and	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
determined	O
that	O
MGC	O
was	O
shed	O
in	O
much	O
higher	O
titers	O
from	O
the	O
trachea	O
than	O
MG	O
,	O
when	O
co	O
-	O
infected	O
with	O
IBV	O
.	O

Prompt	O
initiation	O
of	O
this	O
modality	O
may	O
improve	O
outcomes	O
in	O
adult	O
patients	O
with	O
sickle	O
cell	O
disease	O
complicated	O
by	O
life	O
threatening	O
ACS	B-ENZY
.	O

Phylogenetic	O
analysis	O
showed	O
that	O
PDCoV	O
spike	O
(	O
S	O
)	O
protein	O
was	O
close	O
to	O
the	O
cluster	O
containing	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
which	O
utilizes	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
as	O
a	O
functional	O
receptor	O
.	O

TITLE	O
:	O
A	O
novel	O
mechanism	O
of	O
RNase	B-ENZY
L	O
inhibition	O
:	O
Theiler	O
'	O
s	O
virus	O
L	O
*	O
protein	O
prevents	O
2	O
-	O
5A	O
from	O
binding	O
to	O
RNase	B-ENZY
L	O
.	O
ABSTRACT	O
:	O
The	O
OAS	O
/	O
RNase	B-ENZY
L	O
pathway	O
is	O
one	O
of	O
the	O
best	O
-	O
characterized	O
effector	O
pathways	O
of	O
the	O
IFN	O
antiviral	O
response	O
.	O

Previously	O
we	O
found	O
that	O
L	O
*	O
was	O
the	O
first	O
viral	O
protein	O
binding	O
directly	O
RNase	B-ENZY
L	O
.	O
Our	O
current	O
data	O
show	O
that	O
L	O
*	O
binds	O
the	O
ankyrin	O
repeats	O
R1	O
and	O
R2	O
of	O
RNase	B-ENZY
L	O
and	O
inhibits	O
2	O
'-	O
5	O
'	O
oligoadenylates	O
(	O
2	O
-	O
5A	O
)	O
binding	O
to	O
RNase	B-ENZY
L	O
.	O
Thereby	O
,	O
L	O
*	O
prevents	O
dimerization	O
and	O
oligomerization	O
of	O
RNase	B-ENZY
L	O
in	O
response	O
to	O
2	O
-	O
5A	O
.	O

Interestingly	O
,	O
those	O
data	O
show	O
that	O
L	O
*	O
can	O
functionally	O
substitute	O
for	O
the	O
MHV	O
-	O
encoded	O
phosphodiesterase	B-ENZY
ns2	O
,	O
which	O
acts	O
upstream	O
of	O
L	O
*	O
in	O
the	O
OAS	O
/	O
RNase	B-ENZY
L	O
pathway	O
,	O
by	O
degrading	O
2	O
-	O
5A	O
.	O

Analysis	O
of	O
cultured	O
patient	O
fibroblasts	O
demonstrated	O
deficient	O
pyruvate	B-ENZY
dehydrogenase	I-ENZY
(	O
PDH	B-ENZY
)	O
activity	O
and	O
reduced	O
quantity	O
of	O
protein	O
subunits	O
of	O
mitochondrial	O
complexes	O
I	O
and	O
II	O
,	O
consistent	O
with	O
BOLA3	O
dysfunction	O
.	O

Independent	O
predictors	O
of	O
MERS	O
-	O
CoV	O
infection	O
were	O
identified	O
,	O
including	O
chest	O
pain	O
(	O
OR	O
=	O
24	O
.	O
194	O
;	O
P	O
=	O
0	O
.	O
011	O
),	O
leukopenia	O
(	O
OR	O
=	O
6	O
.	O
080	O
;	O
P	O
=	O
0	O
.	O
049	O
),	O
and	O
elevated	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
)	O
(	O
OR	O
=	O
11	O
.	O
179	O
;	O
P	O
=	O
0	O
.	O
013	O
).	O

Discussion	O
This	O
risk	O
-	O
prediction	O
model	O
in	O
dialysis	O
patients	O
appears	O
to	O
depend	O
markedly	O
on	O
chest	O
pain	O
,	O
leukopenia	O
,	O
and	O
elevated	O
AST	B-ENZY
.	O

The	O
respiratory	O
system	O
(	O
71	O
.	O
6	O
%)	O
was	O
the	O
most	O
common	O
site	O
of	O
infection	O
,	O
and	O
Acinetobacter	O
spp	B-ENZY
.	O

Approximately	O
,	O
74	O
.	O
9	O
%,	O
39	O
.	O
1	O
%,	O
and	O
26	O
.	O
5	O
%	O
of	O
Acinetobacter	O
,	O
Klebsiella	O
,	O
and	O
Pseudomonas	O
spp	B-ENZY
.	O

Age	O
,	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
score	O
at	O
ICU	O
admission	O
,	O
sequential	O
organ	O
failure	O
assessment	O
score	O
on	O
study	O
day	O
,	O
solid	O
organ	O
malignancy	O
,	O
presence	O
of	O
severe	O
sepsis	O
or	O
shock	O
,	O
Candida	O
spp	B-ENZY
.	O

TITLE	O
:	O
Discovery	O
of	O
Novel	O
Bat	B-ENZY
Coronaviruses	O
in	O
South	O
China	O
That	O
Use	O
the	O
Same	O
Receptor	O
as	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
.	O

Here	O
,	O
we	O
screened	O
1	O
,	O
059	O
bat	B-ENZY
samples	O
from	O
at	O
least	O
30	O
bat	B-ENZY
species	O
collected	O
in	O
different	O
regions	O
in	O
south	O
China	O
and	O
identified	O
89	O
strains	O
of	O
lineage	O
C	O
betacoronaviruses	O
,	O
including	O

Bat	B-ENZY
-	O
Origin	O
Coronaviruses	O
Expand	O
Their	O
Host	O
Range	O
to	O
Pigs	O
.	O

Recently	O
,	O
novel	O
bat	B-ENZY
-	O
origin	O
coronaviruses	O
were	O
found	O
in	O
pigs	O
.	O

Luciferase	B-ENZY
reporter	O
assays	O
revealed	O
that	O
miR	O
-	O
146a	O
-	O
5p	O
could	O
bind	O
to	O
the	O
3	O
'-	O
UTRs	O
of	O
IRAK2	O
and	O
TNFRSF18	O
.	O

The	O
novel	O
PEAV	O
sequence	O
was	O
most	O
identical	O
to	O
that	O
of	O
bat	B-ENZY
-	O
HKU2	O
,	O
and	O
the	O
differences	O
between	O
them	O
were	O
comprehensively	O
compared	O
,	O
especially	O
the	O
uniform	O
features	O
of	O
the	O
S	O
protein	O
,	O
which	O
was	O
shown	O
to	O
have	O
a	O
close	O
relationship	O
with	O
betacoronaviruses	O
and	O
to	O
perhaps	O
represent	O
unrecognized	O
betacoronaviruses	O
.	O

TITLE	O
:	O
Sevoflurane	O
improves	O
respiratory	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
in	O
a	O
case	O
series	O
of	O
infants	O
with	O
severe	O
bronchiolitis	O
-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
This	O
report	O
describes	O
the	O
successful	O
use	O
of	O
a	O
new	O
intervention	O
to	O
improve	O
respiratory	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
in	O
a	O
relatively	O
homogeneous	O
group	O
of	O
infants	O
with	O
severe	O
bronchiolitis	O
-	O
induced	O
PARDS	O
after	O
failure	O
of	O
conventional	O
treatment	O
.	O

In	O
severe	O
cases	O
,	O
maintaining	O
adequate	O
gas	B-ENZY
exchange	O
aiming	O
to	O
avoid	O
further	O
lung	O
damage	O
and	O
other	O
neonatal	O
morbidities	O
associated	O
with	O
systemic	O
/	O
pulmonary	O
hypoperfusion	O
,	O
prolonged	O
hypoxia	O
,	O
and	O
respiratory	O
acidosis	O
can	O
be	O
challenging	O
and	O
requires	O
in	O
-	O
depth	O
knowledge	O
into	O
the	O
pathophysiology	O
of	O
the	O
disease	O
.	O

Here	O
,	O
we	O
found	O
that	O
ectopic	O
expression	O
of	O
accessory	O
protein	O
NS6	O
significantly	O
inhibits	O
Sendai	O
virus	O
-	O
induced	O
interferon	O
beta	O
(	O
IFN	O
-	O
	O
)	O
production	O
as	O
well	O
as	O
the	O
activation	O
of	O
transcription	O
factors	O
IRF3	O
and	O
NF	O
-	O
B	O
.	O
Interestingly	O
,	O
NS6	O
does	O
not	O
impede	O
the	O
IFN	O
-	O
	O
promoter	O
activation	O
mediated	O
via	O
key	O
molecules	O
in	O
the	O
RIG	O
-	O
I	O
-	O
like	O
receptor	O
(	O
RLR	O
)	O
signaling	O
pathway	O
,	O
specifically	O
RIG	O
-	O
I	O
,	O
MDA5	O
,	O
and	O
their	O
downstream	O
molecules	O
MAVS	O
,	O
TBK1	B-ENZY
,	O
IKK	O
,	O
and	O
IRF3	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aims	O
to	O
evaluate	O
the	O
knowledge	O
and	O
attitude	O
of	O
practicing	O
dental	O
health	O
professionals	O
(	O
DHPs	B-ENZY
)	O
(	O
dentist	O
and	O
dental	O
auxiliaries	O
)	O
toward	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
Saudi	O
Arabia	O
.	O

A	O
cross	O
-	O
sectional	O
descriptive	O
study	O
was	O
undertaken	O
among	O
practicing	O
DHPs	B-ENZY
in	O
Saudi	O
Arabia	O
.	O

A	O
total	O
of	O
202	O
DHPs	B-ENZY
participated	O
in	O
this	O
study	O
.	O

In	O
vitro	O
,	O
the	O
experiments	O
revealed	O
that	O
PFD	O
significantly	O
suppressed	O
LPS	O
/	O
ATP	O
-	O
induced	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
decreased	O
caspase	B-ENZY
-	I-ENZY
1	I-ENZY
activation	O
and	O
the	O
level	O
of	O
IL	O
-	O
1	O
in	O
J774	O
A	O
.	O
1	O
cells	O
.	O

TITLE	O
:	O
HCoV	O
-	O
229E	O
spike	O
protein	O
fusion	O
activation	O
by	O
trypsin	B-ENZY
-	O
like	O
serine	O
proteases	O
is	O
mediated	O
by	O
proteolytic	O
processing	O
in	O
the	O
S2	O
'	O
region	O
.	O

We	O
analysed	O
the	O
proteolytic	O
processing	O
of	O
the	O
HCoV	O
-	O
229E	O
spike	O
protein	O
by	O
trypsin	B-ENZY
-	O
like	O
serine	O
proteases	O
leading	O
to	O
activation	O
of	O
the	O
fusion	O
process	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
interaction	O
between	O
recombinant	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
and	O
spike	O
glycoprotein	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Infection	O
by	O
its	O
causative	O
agent	O
PED	O
virus	O
(	O
PEDV	O
),	O
an	O
Alpha	O
-	O
coronavirus	O
,	O
was	O
previously	O
proven	O
to	O
be	O
mediated	O
by	O
its	O
spike	O
(	O
S	O
)	O
glycoprotein	O
and	O
a	O
cellular	O
receptor	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
).	O

ABSTRACT	O
:	O
Mechanical	O
ventilation	O
is	O
a	O
life	O
-	O
saving	O
intervention	O
that	O
maintains	O
gas	B-ENZY
exchange	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
);	O
however	O
,	O
it	O
is	O
associated	O
with	O
high	O
mortality	O
and	O
it	O
may	O
augment	O
,	O
or	O
even	O
initiate	O
,	O
lung	O
injury	O
.	O

Furthermore	O
APN	O
and	O
EGFR	O
synergistically	O
stimulate	O
PI3K	O
/	O
AKT	O
as	O
well	O
as	O
MEK	B-ENZY
/	O
ERK1	O
/	O
2	O
endocytosis	O
signaling	O
pathways	O
.	O

Patients	O
with	O
AKI	O
had	O
significantly	O
lower	O
PaO	B-ENZY

A	O
bronchoscopy	O
with	O
BAL	B-ENZY
and	O
transbronchial	O
biopsies	O
did	O
not	O
show	O
acute	O
cellular	O
rejection	O
,	O
but	O
the	O
BAL	B-ENZY
fluid	O
was	O
positive	O
for	O
coronavirus	O
.	O

Moreover	O
,	O
metabolic	O
profiling	O
of	O
mice	O
serum	O
and	O
subsequent	O
Ingenuity	O
Pathway	O
Analysis	O
suggested	O
that	O
ACGs	O
activated	O
protective	O
protein	O
networks	O
and	O
pathways	O
involving	O
inflammatory	O
regulators	O
and	O
apoptosis	O
-	O
related	O
factors	O
,	O
such	O
as	O
JNK	B-ENZY
,	O
ERK1	O
/	O
2	O
and	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
/	O
7	O
,	O
suggesting	O
that	O
ACGs	O
-	O
dependent	O
effects	O
were	O
related	O
to	O
MAPKs	O
and	O
mitochondrial	O
apoptosis	O
pathways	O
.	O

These	O
results	O
were	O
further	O
supported	O
by	O
evaluation	O
of	O
protein	O
expression	O
,	O
showing	O
that	O
ACGs	O
blocked	O
LPS	O
-	O
activated	O
phosphorylation	O
of	O
p38	O
,	O
ERK1	O
/	O
2	O
and	O
JNK	B-ENZY
on	O
the	O
MAPKs	O
signaling	O
,	O
and	O
significantly	O
upregulated	O
the	O
expression	O
of	O
Bcl	O
-	O
2	O
whilst	O
down	O
-	O
regulated	O
Bax	O
and	O
cleaved	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
.	O

Sixty	O
patients	O
had	O
severe	O
LIS	B-ENZY
,	O
out	O
of	O
which	O
45	O
(	O
75	O
%)	O
patients	O
expired	O
,	O
as	O
compared	O
to	O
56	O
patients	O
with	O
moderate	O
LIS	B-ENZY
out	O
of	O
which	O
22	O
(	O
39	O
.	O
3	O
%)	O
expired	O
.	O

LIS	B-ENZY
,	O
Modified	O
LIS	B-ENZY
and	O
PaO2	O
/	O
FiO2	O
ratio	O
predicted	O
outcome	O
as	O
well	O
as	O
need	O
for	O
mechanical	O
ventilation	O
.	O

ACTB	O
-	O
actin	O
beta	O
;	O
ATG13	O
-	O
autophagy	O
related	O
13	O
;	O
ATG14	O
-	O
autophagy	O
related	O
14	O
;	O
ATG101	O
-	O
autophagy	O
related	O
101	O
;	O
BECN1	O
-	O
beclin	O
1	O
;	O
CVB3	O
-	O
coxsackievirus	O
B3	O
;	O
DMV	O
-	O
double	O
-	O
membraned	O
vesicles	O
;	O
EM	O
-	O
electron	O
microscopy	O
;	O
EMCV	O
-	O
encephalomyocarditis	O
virus	O
;	O
EV	O
-	O
71	O
-	O
enterovirus	O
71	O
;	O
FMDV	O
-	O
foot	O
and	O
mouth	O
disease	O
virus	O
;	O
GFP	O
-	O
green	O
fluorescent	O
protein	O
;	O
MAP1LC3B	O
/	O
LC3B	O
-	O
microtubule	O
associated	O
protein	O
1	O
light	O
chain	O
3	O
beta	O
;	O
MOI	O
-	O
multiplicity	O
of	O
infection	O
;	O
MTOR	O
-	O
mechanistic	O
target	O
of	O
rapamycin	O
kinase	O
;	O
PIK3C3	O
-	O
phosphatidylinositol	B-ENZY
3	I-ENZY
-	I-ENZY
kinase	I-ENZY
catalytic	O
subunit	O
type	O
3	O
;	O
PRKAA2	O
-	O
protein	B-ENZY
kinase	I-ENZY
AMP	O
-	O
activated	O
catalytic	O
subunit	O
alpha	O
2	O
;	O
PSMG1	O
-	O
proteasome	B-ENZY
assembly	O
chaperone	O
1	O
;	O
PSMG2	O
-	O
proteasome	B-ENZY
assembly	O
chaperone	O
2PV	O
-	O
poliovirus	O
;	O
RB1CC1	O
-	O
RB1	O
inducible	O
coiled	O
-	O
coil	O
1	O
;	O
SQSTM1	O
-	O
sequestosome	O
1	O
;	O
ULK1	O
-	O
unc	O
-	O
51	O
like	O
autophagy	O
activating	O
kinase	O
1	O
;	O
ULK2	O
-	O
unc	O
-	O
51	O
like	O
autophagy	O
activating	O
kinase	O
2	O
;	O
WIPI1	O
-	O
WD	O
repeat	O
domain	O
,	O
phosphoinositide	O
interacting	O
1	O
.	O

We	O
found	O
no	O
evidence	O
of	O
exposure	O
to	O
M	O
.	O
bovis	O
or	O
Brucella	O
spp	B-ENZY
.,	O
but	O
antibodies	O
were	O
present	O
to	O
bovine	O
parainfluenza	O
virus	O
3	O
,	O
bovine	O
coronavirus	O
,	O
Leptospira	O
interrogans	O
,	O
and	O
Neospora	O
caninum	O
,	O
with	O
seroprevalences	O
of	O
87	O
,	O
7	O
,	O
61	O
,	O
and	O
7	O
%	O
of	O
the	O
tested	O
animals	O
,	O
respectively	O
.	O

All	O
the	O
compounds	O
showed	O
no	O
inhibition	O
of	O
cytochrome	B-ENZY
P450	I-ENZY
enzymes	O
,	O
no	O
blood	O
-	O
brain	O
barrier	O
permeability	O
and	O
no	O
toxic	O
structure	O
in	O
medicinal	O
chemistry	O
profile	O
.	O

All	O
the	O
compounds	O
are	O
not	O
a	O
substrate	O
of	O
P	B-ENZY
-	I-ENZY
glycoprotein	I-ENZY
.	O

All	O
the	O
compounds	O
are	O
not	O
a	O
substrate	O
of	O
P	B-ENZY
-	I-ENZY
glycoprotein	I-ENZY
.	O

In	O
the	O
present	O
study	O
,	O
to	O
mimic	O
the	O
native	O
spike	O
(	O
S	O
)	O
glycoprotein	O
,	O
a	O
stable	O
cell	O
line	O
producing	O
the	O
trimeric	O
ectodomain	O
of	O
S	O
glycoprotein	O
of	O
the	O
PEDV	O
Pintung	O
-	O
52	O
(	O
PEDV	O
-	O
PT	O
)	O
strain	O
was	O
successfully	O
established	O
by	O
incorporating	O
T4	O
bacteriophage	O
foldon	O
sequence	O
of	O
fibritin	O
trimerization	O
domains	O
at	O
the	O
C	O
-	O
terminal	O
end	O
and	O
replacing	O
the	O
signal	O
peptide	O
of	O
S	O
protein	O
with	O
the	O
tissue	B-ENZY
plasminogen	I-ENZY
activator	I-ENZY
signal	O
peptide	O
sequence	O
at	O
the	O
N	O
terminal	O
end	O
.	O

Finally	O
,	O
we	O
show	O
that	O
HA	O
activation	O
by	O
the	O
TMPRSS11A	O
-	O
related	O
enzymes	O
human	O
airway	O
tryptase	B-ENZY
and	O
DESC1	O
,	O
but	O
not	O
TMPRSS11A	O
itself	O
,	O
is	O
blocked	O
by	O
the	O
cellular	O
serine	O
protease	O
inhibitor	O
hepatocyte	O
growth	O
factor	O
activator	O
inhibitor	O
type	O
-	O
1	O
(	O
HAI	O
-	O
1	O
).	O

We	O
conducted	O
quantification	O
of	O
infectious	O
virus	O
or	O
viral	O
RNA	O
,	O
immunofluorescent	O
(	O
IF	O
)	O
staining	O
for	O
the	O
detection	O
of	O
PDCoV	O
antigens	O
,	O
and	O
TUNEL	O
assay	O
in	O
IPEC	O
-	O
J2	O
cells	O
inoculated	O
with	O
the	O
strain	O
OH	O
-	O
FD22	O
-	O
P8	O
grown	O
in	O
LLC	O
-	O
PK	O
cells	O
,	O
and	O
supplemented	O
with	O
10	O
g	O
/	O
ml	O
of	O
trypsin	B-ENZY
in	O
the	O
cell	O
culture	O
medium	O
.	O

Heatmap	O
cluster	O
analysis	O
showed	O
that	O
the	O
vast	O
majority	O
of	O
the	O
viral	O
groups	O
were	O
differentially	O
expressed	O
in	O
miRNA	O
compared	O
with	O
the	O
control	O
group	O
,	O
Go	O
analysis	O
showed	O
that	O
miRNAs	O
are	O
widely	O
involved	O
in	O
combination	O
,	O
binding	O
protein	O
,	O
protein	B-ENZY
kinase	I-ENZY
activity	O
,	O
transfer	O
enzyme	O
activity	O
,	O
phosphorus	O
containing	O
radicals	O
transfer	O
,	O
phosphotransferase	O
enzyme	O
activity	O
and	O
other	O
biological	O
effects	O
.	O

PEDV	O
-	O
positive	O
samples	O
were	O
inoculated	O
in	O
Vero	O
cells	O
with	O
different	O
concentrations	O
of	O
trypsin	B-ENZY
.	O

Our	O
results	O
showed	O
that	O
these	O
two	O
isolates	O
could	O
proliferate	O
effectively	O
in	O
Vero	O
cells	O
with	O
a	O
specific	O
concentration	O
of	O
trypsin	B-ENZY
.	O

The	O
oxygenation	O
index	O
(	O
PaO	B-ENZY
A	O
total	O
of	O
32	O
patients	O
with	O
ARDS	O
were	O
selected	O
,	O
with	O
16	O
in	O
each	O
group	O
,	O
and	O
their	O
baseline	O
data	O
were	O
balanced	O
and	O
comparable	O
.	O

As	O
time	O
went	O
on	O
,	O
PaO	B-ENZY
The	O
Qingfeihuayutongfu	O
prescription	O
may	O
improve	O
oxygenation	O
of	O
ARDS	O
patients	O
,	O
reduce	O
the	O
levels	O
of	O
serum	O
PC	O
III	O
and	O
PLD	O
,	O
and	O
inhibit	O
pulmonary	O
fibrosis	O
,	O
thus	O
improve	O
prognosis	O
.	O

As	O
time	O
went	O
on	O
,	O
PaO	B-ENZY

Empirical	O
treatment	O
with	O
neuraminidase	B-ENZY
inhibitors	O
and	O
an	O
association	O
of	O
antibiotics	O
effective	O
against	O
S	O
.	O
pneumoniae	O
and	O
L	O
.	O
pneumophila	O
are	O
the	O
cornerstones	O
of	O
the	O
management	O
of	O
patients	O
hospitalized	O
for	O
suspected	O
MERS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Cyclophilins	O
and	O
cyclophilin	B-ENZY
inhibitors	O
in	O
nidovirus	O
replication	O
.	O

The	O
PPIase	B-ENZY
activity	O
of	O
most	O
Cyps	O
is	O
inhibited	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporin	O
A	O
and	O
several	O
of	O
its	O
non	O
-	O
immunosuppressive	O
analogs	O
,	O
which	O
can	O
also	O
block	O
the	O
replication	O
of	O
nidoviruses	O
(	O
arteriviruses	O
and	O
coronaviruses	O
).	O

Nucleic	O
acid	O
testing	O
(	O
NAT	B-ENZY
)	O
is	O
the	O
preferred	O
method	O
for	O
the	O
detection	O
of	O
MERS	O
-	O
CoV	O
.	O
A	O
single	O
round	O
of	O
a	O
Proficiency	O
Testing	O
Program	O
(	O
PTP	O
)	O
was	O
used	O
to	O
assess	O
the	O
capability	O
of	O
laboratories	O
globally	O
to	O
accurately	O
detect	O
the	O
presence	O
of	O
MERS	O
-	O
CoV	O
using	O
NAT	B-ENZY
.	O

All	O
patients	O
who	O
did	O
not	O
require	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	B-ENZY
),	O
or	O
only	O
basic	O
CPR	B-ENZY
,	O
had	O
good	O
outcomes	O
;	O
96	O
.	O
3	O
%	O
of	O
those	O
who	O
required	O
advanced	O
CPR	B-ENZY
with	O
epinephrine	O
administration	O
had	O
poor	O
outcomes	O
.	O

A	O
previous	O
report	O
shows	O
that	O
furin	B-ENZY
,	O
which	O
is	O
distributed	O
mainly	O
in	O
the	O
Golgi	O
apparatus	O
and	O
cycled	O
to	O
the	O
cell	O
surface	O
and	O
endosomes	O
,	O
proteolytically	O
activates	O
the	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
following	O
receptor	O
binding	O
to	O
mediate	O
fusion	O
between	O
the	O
viral	O
and	O
cellular	O
membranes	O
.	O

In	O
this	O
study	O
,	O
we	O
reexamined	O
furin	B-ENZY
usage	O
by	O
MERS	O
-	O
CoV	O
using	O
a	O
real	O
-	O
time	O
PCR	O
-	O
based	O
virus	O
cell	O
entry	O
assay	O
after	O
inhibition	O
of	O
cellular	O
proteases	O
.	O

In	O
addition	O
,	O
dec	O
-	O
RVKR	O
-	O
CMK	B-ENZY
inhibited	O
not	O
only	O
the	O
enzymatic	O
activity	O
of	O
furin	B-ENZY
but	O
also	O
those	O
of	O
cathepsin	B-ENZY
L	I-ENZY
,	O
cathepsin	B-ENZY
B	I-ENZY
,	O
trypsin	B-ENZY
,	O
papain	B-ENZY
,	O
and	O
TMPRSS2	O
.	O

The	O
transcriptional	O
activation	O
of	O
antiviral	O
response	O
elements	O
was	O
assessed	O
by	O
measuring	O
the	O
levels	O
of	O
firefly	B-ENZY
luciferase	I-ENZY
expressed	O
under	O
the	O
control	O
of	O
interferon	O
(	O
IFN	O
)-	O
stimulated	O
response	O
element	O
(	O
ISRE	O
),	O
IFN	O
-	O
	O
promoter	O
,	O
or	O
nuclear	O
factor	O
kappa	O
B	O
response	O
element	O
(	O
NF	O
-	O
B	O
-	O
RE	O
).	O

ABSTRACT	O
:	O
Since	O
being	O
first	O
described	O
more	O
than	O
60	O
years	O
ago	O
,	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
has	O
been	O
extensively	O
studied	O
,	O
while	O
novel	O
concepts	O
about	O
its	O
structure	O
,	O
physiology	O
,	O
and	O
biological	O
roles	O
continue	O
to	O
be	O
elucidated	O
.	O

Recently	O
,	O
antiviral	O
effects	O
have	O
been	O
described	O
as	O
a	O
novel	O
feature	O
of	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
inhibition	O
with	O
the	O
use	O
of	O
cardiac	O
glycosides	O
.	O

Limitations	O
of	O
standard	O
treatment	O
modalities	O
,	O
which	O
largely	O
rely	O
on	O
conventional	O
mechanical	O
ventilation	O
,	O
emphasize	O
the	O
urgent	O
,	O
unmet	O
clinical	O
need	O
for	O
developing	O
novel	O
(	O
bio	O
)	O
artificial	O
respiratory	O
assist	O
devices	O
that	O
provide	O
extracorporeal	O
gas	B-ENZY
exchange	O
with	O
a	O
focus	O
on	O
direct	O
extracorporeal	O
CO2	O
removal	O
from	O
the	O
blood	O
.	O

ABSTRACT	O
:	O
There	O
have	O
been	O
occasional	O
reports	O
of	O
respiratory	O
dysfunction	O
associated	O
with	O
acute	O
chlorine	O
gas	B-ENZY
inhalation	O
.	O

The	O
patient	O
was	O
diagnosed	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
chlorine	O
gas	B-ENZY
exposure	O
.	O

All	O
patients	O
with	O
influenza	O
>	O
18	O
-	O
years	O
-	O
old	O
hospitalized	O
to	O
the	O
ICU	O
department	O
of	O
Tunisian	O
University	O
hospital	O
of	O
Sousse	O
,	O
between	O
December	O
1	O
,	O
2009	O
and	O
March	O
31	O
,	O
2016	O
,	O
with	O
a	O
positive	O
influenza	O
A	O
/	O
H1N1	O
/	O
09	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
a	O
nasopharyngeal	O
specimen	O
were	O
included	O
,	O
were	O
included	O
.	O

As	O
others	O
have	O
examined	O
O	O
A	O
model	O
of	O
the	O
cardiorespiratory	O
system	O
during	O
vv	O
-	O
ECMO	O
was	O
developed	O
,	O
incorporating	O
O	O
P	O
This	O
mathematical	O
model	O
of	O
gas	B-ENZY
exchange	O
during	O
vv	O
-	O
ECMO	O
found	O
that	O
the	O
main	O
determinants	O
of	O
P	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
docking	O
studies	O
and	O
biological	O
screening	O
of	O
2	O
-	O
thiazolyl	O
substituted	O
-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1H	O
-	O
naphtho	O
[	O
1	O
,	O
2	O
-	O
e	O
][	O
1	O
,	O
3	O
]	O
oxazines	O
as	O
potent	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
.	O

These	O
derivatives	O
were	O
first	O
evaluated	O
for	O
their	O
inhibitory	O
effect	O
on	O
HIV	O
-	O
1	O
Reverse	B-ENZY
Transcriptase	I-ENZY
(	O
RT	O
)	O
enzyme	O
activity	O
.	O

Feed	O
was	O
then	O
analyzed	O
for	O
PEDV	O
RNA	O
by	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
semiquantitative	O
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
)	O
as	O
measured	O
by	O
cycle	O
threshold	O
(	O
Ct	O
)	O
and	O
for	O
infectivity	O
by	O
bioassay	O
.	O

According	O
to	O
Berlin	O
definition	O
of	O
ARDS	O
,	O
this	O
is	O
defined	O
based	O
on	O
the	O
timings	O
,	O
radiographic	O
changes	O
,	O
edema	O
formation	O
,	O
and	O
severity	O
on	O
the	O
PaO	B-ENZY

The	O
survival	O
days	O
of	O
mice	O
,	O
and	O
the	O
serum	O
levels	O
of	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
)	O
were	O
examined	O
.	O

Based	O
on	O
our	O
published	O
preliminary	O
data	O
,	O
we	O
hypothesized	O
that	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
response	O
molecule	O
Protein	B-ENZY
Kinase	I-ENZY
R	O
-	O
like	O
Endoplasmic	O
Reticulum	O
Kinase	O
(	O
PERK	O
)	O
plays	O
a	O
role	O
in	O
transmitting	O
mechanosensory	O
signals	O
the	O
alveolar	O
epithelium	O
.	O

Moreover	O
,	O
the	O
infectivity	O
of	O
scIAV	O
-	O
S	O
was	O
associated	O
with	O
the	O
degree	O
of	O
cell	O
adaptation	O
of	O
PEDV	O
-	O
S	O
.	O
Intriguingly	O
,	O
scIAV	O
-	O
S	O
lacking	O
functional	O
neuraminidase	B-ENZY
(	O
NA	O
)	O
exhibited	O
substantially	O
higher	O
infectivity	O
,	O
suggesting	O
a	O
pivotal	O
role	O
of	O
the	O
sialic	O
acid	O
in	O
the	O
binding	O
/	O
entry	O
of	O
PEDV	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
can	O
be	O
noncompetitively	O
inhibited	O
by	O
6	O
-	O
thioguanine	O
.	O

Coronaviral	O
proteases	O
,	O
including	O
main	O
proteases	O
and	O
papain	B-ENZY
-	O
like	O
proteases	O
,	O
are	O
ideal	O
antiviral	O
targets	O
because	O
of	O
their	O
essential	O
roles	O
in	O
viral	O
maturation	O
.	O

Here	O
we	O
provide	O
a	O
first	O
description	O
of	O
the	O
expression	O
,	O
purification	O
and	O
structural	O
characteristics	O
of	O
recombinant	O
PEDV	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
,	O
moreover	O
present	O
our	O
finding	O
that	O
6	O
-	O
thioguanine	O
,	O
a	O
chemotherapeutic	O
drug	O
,	O
in	O
contrast	O
to	O
its	O
competitive	O
inhibition	O
on	O
SARS	O
-	O
and	O
MERS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
proteases	O
,	O
is	O
a	O
noncompetitive	O
inhibitor	O
of	O
PEDV	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
.	O

The	O
selected	O
sdAb	O
-	O
Mcs	B-ENZY
were	O
solubly	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
functional	O
characteristics	O
analysis	O
revealed	O
that	O
the	O
recombinant	O
sdAb	O
-	O
Mcs	B-ENZY
have	O
excellent	O
binding	O
activity	O
and	O
specificity	O
to	O
M	O
protein	O
but	O
have	O
no	O
neutralizing	O
activity	O
to	O
PEDV	O
.	O

Three	O
series	O
of	O
derivatives	O
bearing	O
two	O
lipophilic	O
groups	O
were	O
synthesized	O
by	O
attaching	O
bis	B-ENZY
-	O
alkylthio	O
maleimides	O
directly	O
or	O
through	O
linkers	O
of	O
different	O
lengths	O
to	O
the	O
glycopeptide	O
.	O

We	O
screened	O
and	O
obtained	O
two	O
new	O
complete	O
genomes	O
,	O
five	O
N	O
and	O
five	O
S	O
genes	O
of	O
SADS	O
-	O
CoV	O
.	O
Phylogenetic	O
analysis	O
based	O
on	O
these	O
sequences	O
revealed	O
that	O
all	O
SADS	O
-	O
CoV	O
sequences	O
in	O
this	O
study	O
clustered	O
with	O
previously	O
reported	O
SADS	O
-	O
CoV	O
strains	O
to	O
form	O
a	O
well	O
defined	O
branch	O
that	O
grouped	O
with	O
the	O
bat	B-ENZY
coronavirus	O
HKU2	O
strains	O
.	O

Finally	O
,	O
SARS	O
3a	O
activates	O
caspase	B-ENZY
-	I-ENZY
1	I-ENZY
either	O
directly	O
or	O
via	O
an	O
enhanced	O
potassium	O
efflux	O
,	O
which	O
triggers	O
NLRP3	O
inflammasome	O
assembly	O
.	O

The	O
phylogenetic	O
analysis	O
supported	O
that	O
this	O
DNA	O
complemented	O
palindrome	O
originated	O
from	O
bat	B-ENZY
betacoronavirus	O
.	O

Moreover	O
,	O
HRG	O
suppressed	O
tumor	O
necrosis	O
factor	O
	O
,	O
inducible	O
nitric	O
oxide	O
synthase	O
,	O
interleukin	O
6	O
,	O
and	O
neutrophil	B-ENZY
elastase	I-ENZY
mRNA	O
expression	O
and	O
myeloperoxidase	B-ENZY
activity	O
in	O
the	O
lung	O
.	O

We	O
hypothesized	O
that	O
HFO	O
strategies	O
aimed	O
at	O
averting	O
/	O
attenuating	O
hypercapnia	O
,	O
such	O
as	O
""""	O
low	O
-	O
frequency	O
""""	O
(	O
i	O
.	O
e	O
.,	O
4	O
Hz	O
)	O
HFO	O
and	O
4	O
-	O
Hz	O
HFO	O
with	O
tracheal	O
-	O
gas	B-ENZY
insufflation	O
(	O
HFO	O
-	O
TGI	O
),	O
may	O
result	O
in	O
an	O
improved	O
RV	O
function	O
relative	O
to	O
""""	O
high	O
-	O
frequency	O
""""	O
(	O
i	O
.	O
e	O
.,	O
7	O
Hz	O
)	O
HFO	O
(	O
which	O
may	O
promote	O
hypercapnia	O
)	O
and	O
similar	O
RV	O
function	O
relative	O
to	O
lung	O
protective	O
CV	O
.	O

Proportion	O
of	O
patients	O
with	O
creatine	B-ENZY
kinase	I-ENZY
	O
2N	O
was	O
20	O
%	O
(	O
n	O
=	O
9	O
/	O
47	O
).	O

TITLE	O
:	O
Detection	O
and	O
Characterization	O
of	O
Distinct	O
Alphacoronaviruses	O
in	O
Five	O
Different	O
Bat	B-ENZY
Species	O
in	O
Denmark	O
.	O

These	O
results	O
revealed	O
81	O
%	O
shared	O
nucleotide	O
identity	O
with	O
human	O
/	O
civet	O
SARS	O
CoVs	O
,	O
which	O
was	O
more	O
distant	O
than	O
that	O
observed	O
previously	O
for	O
bat	B-ENZY
SL	O
-	O
CoVs	O
in	O
China	O
.	O

TITLE	O
:	O
Structurally	O
-	O
and	O
dynamically	O
-	O
driven	O
allostery	O
of	O
the	O
chymotrypsin	B-ENZY
-	O
like	O
proteases	O
of	O
SARS	O
,	O
Dengue	O
and	O
Zika	O
viruses	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
3C	O
-	O
like	O
and	O
Flavivirus	O
NS2B	O
-	O
NS3	O
proteases	O
utilize	O
the	O
chymotrypsin	B-ENZY
fold	O
to	O
harbor	O
their	O
catalytic	O
machineries	O
but	O
also	O
contain	O
additional	O
domains	O
/	O
co	O
-	O
factors	O
.	O

Over	O
the	O
past	O
decade	O
,	O
we	O
aimed	O
to	O
decipher	O
how	O
the	O
extra	O
domains	O
/	O
co	O
-	O
factors	O
mediate	O
the	O
catalytic	O
machineries	O
of	O
SARS	O
3C	O
-	O
like	O
,	O
Dengue	O
and	O
Zika	O
NS2B	O
-	O
NS3	O
proteases	O
by	O
characterizing	O
their	O
folding	O
,	O
structures	O
,	O
dynamics	O
and	O
inhibition	O
with	O
NMR	O
,	O
X	O
-	O
ray	O
crystallography	O
and	O
MD	O
simulations	O
,	O
and	O
the	O
results	O
revealed	O
:	O
1	O
)	O
the	O
chymotrypsin	B-ENZY
fold	O
of	O
the	O
SARS	O
3C	O
-	O
like	O
protease	O
can	O
independently	O
fold	O
,	O
while	O
,	O
by	O
contrast	O
,	O
those	O
of	O
Dengue	O
and	O
Zika	O
proteases	O
lack	O
the	O
intrinsic	O
capacity	O
to	O
fold	O
without	O
co	O
-	O
factors	O
.	O

Therefore	O
,	O
by	O
introducing	O
extra	O
domains	O
/	O
cofactors	O
,	O
nature	O
develops	O
diverse	O
strategies	O
to	O
regulate	O
the	O
catalytic	O
machinery	O
embedded	O
on	O
the	O
chymotrypsin	B-ENZY
fold	O
through	O
folding	O
,	O
structurally	O
-	O
and	O
dynamically	O
-	O
driven	O
allostery	O
,	O
all	O
of	O
which	O
might	O
be	O
exploited	O
to	O
develop	O
antiviral	O
drugs	O
.	O

TGEV	O
infection	O
induced	O
activation	O
of	O
phospho	O
-	O
protein	B-ENZY
kinase	I-ENZY
C	I-ENZY
	O
(	O
p	O
-	O
PKC	B-ENZY
	O
),	O
phospho	O
-	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
p	O
-	O
EGFR	O
),	O
and	O
enhanced	O
the	O
expression	O
of	O
caveolin	O
-	O
1	O
,	O
all	O
of	O
which	O
appear	O
to	O
be	O
involved	O
in	O
down	O
-	O
regulating	O
arginine	O
uptake	O
and	O
CAT	O
-	O
1	O
expression	O
.	O

RESULTS	O
:	O
OLA	O
significantly	O
improved	O
lung	O
aeration	O
,	O
arterial	O
oxygenation	O
,	O
and	O
gas	B-ENZY
exchange	O
.	O

Eimeria	O
spp	B-ENZY
.	O

TITLE	O
:	O
The	O
papain	B-ENZY
-	O
like	O
protease	O
determines	O
a	O
virulence	O
trait	O
that	O
varies	O
among	O
members	O
of	O
the	O
SARS	O
-	O
coronavirus	O
species	O
.	O

To	O
understand	O
the	O
influence	O
of	O
a	O
viral	O
factor	O
in	O
relation	O
to	O
interspecies	O
spillover	O
,	O
we	O
studied	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLP	O
)	O
of	O
SARS	O
-	O
CoV	O
.	O
This	O
key	O
enzyme	O
drives	O
the	O
early	O
stages	O
of	O
infection	O
as	O
it	O
cleaves	O
the	O
viral	O
polyprotein	O
,	O
deubiquitinates	O
viral	O
and	O
cellular	O
proteins	O
,	O
and	O
antagonizes	O
the	O
interferon	O
(	O
IFN	O
)	O
response	O
.	O

We	O
identified	O
a	O
bat	B-ENZY
SARS	O
-	O
CoV	O
PLP	O
,	O
which	O
shared	O
86	O
%	O
amino	O
acid	O
identity	O
with	O
SARS	O
-	O
CoV	O
PLP	O
,	O
and	O
used	O
reverse	O
genetics	O
to	O
insert	O
it	O
into	O
the	O
SARS	O
-	O
CoV	O
genome	O
.	O

Using	O
ectopically	O
-	O
expressed	O
PLP	O
variants	O
as	O
well	O
as	O
full	O
SARS	O
-	O
CoV	O
infectious	O
clones	O
chimerized	O
for	O
PLP	O
,	O
we	O
found	O
that	O
a	O
protease	O
-	O
independent	O
,	O
anti	O
-	O
IFN	O
function	O
exists	O
in	O
SARS	O
-	O
CoV	O
,	O
but	O
not	O
in	O
a	O
SARS	O
-	O
related	O
,	O
bat	B-ENZY
-	O
borne	O
virus	O
.	O

Our	O
results	O
showed	O
that	O
lysosomal	O
proteases	O
from	O
bat	B-ENZY
cells	O
support	O
coronavirus	O
spike	O
-	O
mediated	O
pseudovirus	O
entry	O
and	O
cell	O
-	O
cell	O
fusion	O
more	O
effectively	O
than	O
their	O
counterparts	O
from	O
human	O
cells	O
.	O

Moreover	O
,	O
purified	O
lysosomal	O
extracts	O
from	O
bat	B-ENZY
cells	O
cleave	O
cell	O
surface	O
-	O
expressed	O
coronavirus	O
spikes	O
more	O
efficiently	O
than	O
their	O
counterparts	O
from	O
human	O
cells	O
.	O

ABSTRACT	O
:	O
A	O
32	O
-	O
month	O
-	O
old	O
spayed	O
female	O
Singapura	O
cat	O
presented	O
with	O
a	O
non	O
-	O
pruritic	O
erythematous	O
nodule	O
on	O
the	O
upper	O
lip	B-ENZY
.	O

Assuming	O
an	O
improved	O
overall	O
status	O
,	O
PaO	B-ENZY

Further	O
in	O
silico	O
studies	O
identified	O
the	O
key	O
molecular	O
interactions	O
between	O
those	O
compounds	O
and	O
the	O
3	O
-	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
,	O
which	O
is	O
essential	O
to	O
the	O
intracellular	O
replication	O
of	O
the	O
virus	O
,	O
supporting	O
the	O
hypothesis	O
that	O
the	O
protease	O
is	O
the	O
target	O
molecule	O
of	O
the	O
potential	O
antiviral	O
derivatives	O
.	O

TITLE	O
:	O
Going	O
to	O
Bat	B-ENZY
(	O
s	O
)	O
for	O
Studies	O
of	O
Disease	O
Tolerance	O
.	O

Replication	O
of	O
the	O
resulting	O
viruses	O
was	O
compared	O
in	O
primate	O
cell	O
cultures	O
as	O
well	O
as	O
Rhinolophus	O
bat	B-ENZY
cells	O
made	O
permissive	O
for	O
SARS	O
-	O
CoV	O
replication	O
by	O
lentiviral	O
transduction	O
of	O
the	O
human	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
receptor	O
.	O

ENaC	O
,	O
CFTR	O
,	O
and	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
activities	O
and	O
protein	O
levels	O
were	O
also	O
reduced	O
in	O
virally	O
infected	O
human	O
airway	O
epithelial	O
cells	O
.	O

He	O
was	O
in	O
respiratory	O
failure	O
with	O
a	O
PaO	B-ENZY
Despite	O
broad	O
-	O
spectrum	O
antibiotics	O
,	O
the	O
patient	O
'	O
s	O
oxygenation	O
deteriorated	O
,	O
necessitating	O
ECMO	O
.	O

TITLE	O
:	O
Prolyl	B-ENZY
Hydroxylase	I-ENZY
Domain	O
-	O
2	O
Protein	O
Regulates	O
Lipopolysaccharide	O
-	O
Induced	O
Vascular	O
Inflammation	O
.	O

Additionally	O
,	O
the	O
intestines	O
of	O
bats	O
infected	O
with	O
fungus	O
exhibited	O
different	O
expression	O
of	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
pathway	O
and	O
cytokine	O
related	O
transcripts	O
,	O
irrespective	O
of	O
viral	O
presence	O
.	O

Initial	O
laboratory	O
investigations	O
were	O
significant	O
for	O
a	O
lipase	B-ENZY
level	O
of	O
4143	O
U	O
/	O
L	O
and	O
a	O
triglyceride	O
level	O
of	O
600	O
mg	O
/	O
dL	O
.	O
Computed	O
tomography	O
(	O
CT	O
)	O
of	O
the	O
abdomen	O
showed	O
diffuse	O
enlargement	O
of	O
the	O
pancreas	O
consistent	O
with	O
pancreatitis	O
.	O

Neither	O
binding	O
to	O
ACE2	O
nor	O
cleavage	O
by	O
trypsin	B-ENZY
at	O
the	O
S1	O
/	O
S2	O
cleavage	O
site	O
impart	O
large	O
conformational	O
changes	O
within	O
stabilized	O
SARS	O
-	O
CoV	O
S	O
or	O
expose	O
the	O
secondary	O
cleavage	O
site	O
,	O
S2	O
'.	O

ABSTRACT	O
:	O
The	O
paper	O
focussed	O
on	O
a	O
step	O
-	O
by	O
-	O
step	O
structural	O
modification	O
of	O
a	O
cycloheptathiophene	O
-	O
3	O
-	O
carboxamide	O
derivative	O
recently	O
identified	O
by	O
us	O
as	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
associated	O
ribonuclease	B-ENZY
H	I-ENZY
(	O
RNase	B-ENZY
H	I-ENZY
)	O
inhibitor	O
.	O

In	O
particular	O
,	O
its	O
conversion	O
to	O
a	O
2	O
-	O
aryl	O
-	O
cycloheptathienoozaxinone	O
derivative	O
and	O
the	O
successive	O
thorough	O
exploration	O
of	O
both	O
2	O
-	O
aromatic	O
and	O
cycloheptathieno	O
moieties	O
led	O
to	O
identify	O
oxazinone	O
-	O
based	O
compounds	O
as	O
new	O
anti	O
-	O
RNase	B-ENZY
H	I-ENZY
chemotypes	O
.	O

The	O
presence	O
of	O
the	O
catechol	O
moiety	O
at	O
the	O
C	O
-	O
2	O
position	O
of	O
the	O
scaffold	O
emerged	O
as	O
critical	O
to	O
achieve	O
potent	O
anti	O
-	O
RNase	B-ENZY
H	I-ENZY
activity	O
,	O
which	O
also	O
encompassed	O
anti	O
-	O
RNA	O
dependent	O
DNA	O
polymerase	O
(	O
RDDP	O
)	O
activity	O
for	O
the	O
tricyclic	O
derivatives	O
.	O

Furthermore	O
,	O
we	O
also	O
found	O
that	O
YQFM	O
significantly	O
inhibited	O
the	O
PM	O
-	O
induced	O
myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
activity	O
in	O
lung	O
tissues	O
,	O
decreased	O
the	O
PM	O
-	O
induced	O
inflammatory	O
cytokines	O
including	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
and	O
tumor	O
necrosis	O
factor	O
-	O
	O
(	O
TNF	O
-	O
	O
),	O
reduced	O
nitric	O
oxide	O
(	O
NO	O
)	O
and	O
total	O
protein	O
in	O
bronchoalveolar	O
lavage	O
fluids	O
(	O
BALF	O
),	O
and	O
effectively	O
attenuated	O
PM	O
-	O
induced	O
increases	O
lymphocytes	O
in	O
BALF	O
.	O

The	O
use	O
of	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
for	O
correction	O
of	O
gas	B-ENZY
exchange	O
can	O
cause	O
worsening	O
of	O
this	O
inflammatory	O
response	O
,	O
called	O
""""	O
ventilator	O
-	O
induced	O
lung	O
injury	O
""""	O
(	O
VILI	O
).	O

The	O
activation	O
or	O
cleavage	O
of	O
main	O
apoptosis	O
-	O
associated	O
molecular	O
such	O
as	O
AIFM1	O
,	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
,	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
,	O
caspase	B-ENZY
-	I-ENZY
9	I-ENZY
and	O
PARP	O
in	O
PEDV	O
infected	O
host	O
cells	O
were	O
analyzed	O
by	O
western	O
blotting	O
.	O

Arterial	O
blood	O
gas	B-ENZY
showed	O
PH	O
7	O
.	O
17	O
,	O
PCO2	O
155	O
,	O
PO2	O
95	O
and	O
O2	O
saturation	O
of	O
97	O
%	O
on	O
2	O
L	O
nasal	O
cannulae	O
.	O

TITLE	O
:	O
Diagnosis	O
of	O
non	O
-	O
effusive	O
feline	O
infectious	O
peritonitis	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
quantitative	O
PCR	O
from	O
mesenteric	O
lymph	O
node	O
fine	O
-	O
needle	O
aspirates	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
a	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
reverse	B-ENZY
transcriptase	I-ENZY
quantitative	O
PCR	O
(	O
RT	O
-	O
qPCR	O
)	O
on	O
fine	O
-	O
needle	O
aspirates	O
(	O
FNAs	O
)	O
from	O
mesenteric	O
lymph	O
nodes	O
(	O
MLNs	O
)	O
collected	O
in	O
sterile	O
saline	O
for	O
the	O
purpose	O
of	O
diagnosing	O
non	O
-	O
effusive	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
in	O
cats	O
.	O

The	O
cellular	O
proteases	O
furin	B-ENZY
,	O
cathepsin	B-ENZY
L	I-ENZY
and	O
TMPRSS2	O
can	O
activate	O
MERS	O
-	O
S	O
and	O
may	O
cleave	O
the	O
S	O
protein	O
at	O
two	O
distinct	O
sites	O
,	O
termed	O
S1	O
/	O
S2	O
and	O
S2	O
'.	O

Moreover	O
,	O
a	O
potential	O
cathepsin	B-ENZY
L	I-ENZY
cleavage	O
site	O
in	O
MERS	O
-	O
S	O
has	O
been	O
reported	O
.	O

These	O
findings	O
suggest	O
that	O
cleavage	O
at	O
S2	O
'	O
is	O
carried	O
out	O
by	O
proteases	O
recognizing	O
a	O
single	O
arginine	O
,	O
most	O
likely	O
TMPRSS2	O
and	O
cathepsin	B-ENZY
L	I-ENZY
.	O
Finally	O
,	O
mutation	O
of	O
the	O
proposed	O
cathepsin	B-ENZY
L	I-ENZY
site	O
did	O
not	O
impact	O
viral	O
entry	O
and	O
double	O
mutation	O
of	O
S1	O
/	O
S2	O
and	O
S2	O
'	O
site	O
was	O
compatible	O
with	O
cathepsin	B-ENZY
L	I-ENZY
-	O
but	O
not	O
TMPRSS2	O
-	O
dependent	O
host	O
cell	O
entry	O
,	O
indicating	O
that	O
cathepsin	B-ENZY
L	I-ENZY
can	O
process	O
the	O
S	O
protein	O
at	O
auxiliary	O
sites	O
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
a	O
rigid	O
sequence	O
requirement	O
for	O
S	O
protein	O
activation	O
by	O
TMPRSS2	O
but	O
not	O
cathepsin	B-ENZY
L	I-ENZY
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
driven	O
by	O
a	O
severe	O
pro	O
-	O
inflammatory	O
response	O
resulting	O
in	O
lung	O
damage	O
,	O
impaired	O
gas	B-ENZY
exchange	O
and	O
severe	O
respiratory	O
failure	O
.	O

We	O
developed	O
a	O
sealed	O
air	O
-	O
tight	O
chamber	O
in	O
which	O
plates	O
with	O
human	O
alveolar	O
epithelial	O
immortalized	O
cells	O
could	O
be	O
exposed	O
to	O
a	O
precise	O
,	O
controlled	O
fraction	O
of	O
sevoflurane	O
or	O
isoflurane	O
using	O
a	O
continuous	O
gas	B-ENZY
flow	O
provided	O
by	O
an	O
anesthetic	O
machine	O
circuit	O
.	O

The	O
recent	O
emergence	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
humans	O
,	O
with	O
evidence	O
that	O
these	O
viruses	O
may	O
have	O
their	O
ancestry	O
in	O
bats	O
,	O
highlights	O
the	O
importance	O
of	O
virus	O
surveillance	O
in	O
bat	B-ENZY
populations	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
and	O
molecular	O
characterization	O
of	O
a	O
bat	B-ENZY
	O
-	O
Coronavirus	O
,	O
detected	O
during	O
a	O
viral	O
survey	O
carried	O
out	O
on	O
different	O
bat	B-ENZY
species	O
in	O
the	O
island	O
of	O
Sardinia	O
(	O
Italy	O
).	O

Coronavirus	O
RNA	O
was	O
detected	O
in	O
faecal	O
samples	O
from	O
three	O
different	O
species	O
:	O
the	O
greater	O
horseshoe	O
bat	B-ENZY
(	O
Rhinolophus	O
ferrumequinum	O
),	O
the	O
brown	O
long	O
-	O
eared	O
bat	B-ENZY
(	O
Plecotus	O
auritus	O
),	O
and	O
the	O
European	O
free	O
-	O
tailed	O
bat	B-ENZY
(	O
Tadarida	O
teniotis	O
).	O

Phylogenetic	O
analyses	O
based	O
on	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
sequences	O
assigned	O
the	O
detected	O
CoV	O
to	O
clade	O
2b	O
within	O
betacoronaviruses	O
,	O
clustering	O
with	O
SARS	O
-	O
like	O
bat	B-ENZY
CoVs	O
previously	O
reported	O
.	O

These	O
findings	O
point	O
to	O
the	O
need	O
for	O
continued	O
surveillance	O
of	O
bat	B-ENZY
CoV	O
circulating	O
in	O
Sardinian	O
bats	O
,	O
and	O
extend	O
the	O
current	O
knowledge	O
on	O
CoV	O
ecology	O
with	O
novel	O
sequences	O
detected	O
in	O
bat	B-ENZY
species	O
not	O
previously	O
described	O
as	O
	O
-	O
Coronavirus	O
hosts	O
.	O

Compared	O
with	O
the	O
non	O
-	O
ARDS	O
group	O
,	O
the	O
ARDS	O
group	O
had	O
older	O
age	O
,	O
higher	O
rates	O
of	O
traffic	O
injuries	O
,	O
endotracheal	O
intubation	O
and	O
infection	O
,	O
higher	O
blood	O
sugar	O
,	O
PaO	B-ENZY
The	O
traumatic	O
patients	O
on	O
admission	O
with	O
hyperglycemia	O
,	O
abnormal	O
PaO	B-ENZY
RESULTS	O
:	O
A	O
total	O
of	O
303	O
patients	O
with	O
severe	O
trauma	O
,	O
including	O
223	O
males	O
and	O
80	O
females	O
,	O
were	O
enrolled	O
.	O

Compared	O
with	O
the	O
non	O
-	O
ARDS	O
group	O
,	O
the	O
ARDS	O
group	O
had	O
older	O
age	O
,	O
higher	O
rates	O
of	O
traffic	O
injuries	O
,	O
endotracheal	O
intubation	O
and	O
infection	O
,	O
higher	O
blood	O
sugar	O
,	O
PaO	B-ENZY

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
have	O
been	O
detected	O
worldwide	O
in	O
several	O
bat	B-ENZY
species	O
,	O
which	O
are	O
considered	O
the	O
main	O
reservoir	O
.	O

Phylogenetic	O
analysis	O
conducted	O
on	O
bat	B-ENZY
Alpha	O
-	O
CoV	O
strains	O
revealed	O
their	O
evolutive	O
correlation	O
to	O
human	O
strains	O
,	O
suggesting	O
their	O
origin	O
in	O
bats	O
.	O

The	O
analysis	O
of	O
a	O
fragment	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
showed	O
the	O
correlation	O
of	O
the	O
Italian	O
strains	O
with	O
CoVs	O
that	O
was	O
only	O
detected	O
in	O
the	O
bat	B-ENZY
Pipistrellus	O
genera	O
(	O
Pipistrellus	O
kuhlii	O
and	O
Pipistrellus	O
Pipistrellus	O
)	O
in	O
European	O
countries	O
.	O

ABSTRACT	O
:	O
Pulmonary	O
veno	O
-	O
occlusive	O
disease	O
(	O
PVOD	O
)	O
is	O
a	O
rare	O
cause	O
of	O
pulmonary	O
arterial	O
hypertension	O
(	O
PAH	B-ENZY
)	O
in	O
humans	O
and	O
can	O
be	O
classified	O
in	O
idiopathic	O
,	O
heritable	O
,	O
drug	O
and	O
radiation	O
-	O
induced	O
,	O
and	O
associated	O
with	O
connective	O
tissue	O
disease	O
or	O
human	O
immunodeficiency	O
virus	O
infection	O
.	O

In	O
dogs	O
,	O
PAH	B-ENZY
is	O
poorly	O
characterized	O
and	O
is	O
generally	O
considered	O
to	O
be	O
idiopathic	O
or	O
secondary	O
to	O
(	O
for	O
example	O
)	O
congenital	O
left	O
-	O
to	O
right	O
cardiovascular	O
shunts	O
or	O
heartworm	O
disease	O
.	O

No	O
causal	O
variants	O
were	O
found	O
in	O
the	O
genes	O
that	O
are	O
known	O
to	O
be	O
involved	O
in	O
human	O
PVOD	O
and	O
PAH	B-ENZY
.	O

In	O
the	O
present	O
case	O
,	O
no	O
casual	O
genetic	O
mutations	O
known	O
to	O
be	O
involved	O
in	O
humans	O
with	O
PVOD	O
and	O
PAH	B-ENZY
were	O
found	O
.	O

Importantly	O
,	O
TRIM8	O
could	O
negatively	O
meditate	O
AMP	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
-	O
	O
(	O
AMPK	O
)	O
activation	O
to	O
modulate	O
LPS	O
-	O
triggered	O
inflammatory	O
response	O
and	O
ROS	O
generation	O
in	O
vitro	O
.	O

Additionally	O
,	O
our	O
in	O
vivo	O
findings	O
suggested	O
that	O
TRIM8	O
knockdown	O
effectively	O
attenuated	O
LPS	O
-	O
induced	O
lung	O
injury	O
nu	O
decrease	O
of	O
lung	O
wet	O
/	O
dry	O
(	O
W	O
/	O
T	O
)	O
ratio	O
,	O
protein	O
concentrations	O
,	O
neutrophil	O
infiltration	O
,	O
myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
activity	O
,	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
and	O
superoxide	B-ENZY
dismutase	I-ENZY
(	O
SOD	O
)	O
depletion	O
.	O

Furthermore	O
,	O
TRIM8	O
knockdown	O
evidently	O
improved	O
nuclear	O
factor	O
-	O
erythroid	O
2	O
related	O
factor	O
2	O
(	O
Nrf2	O
)	O
and	O
heme	B-ENZY
oxygenase	I-ENZY
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
expressions	O
in	O
lung	O
of	O
LPS	O
-	O
treated	O
mice	O
.	O

In	O
this	O
Review	O
,	O
we	O
summarize	O
the	O
current	O
knowledge	O
on	O
the	O
origin	O
and	O
evolution	O
of	O
these	O
two	O
pathogenic	O
coronaviruses	O
and	O
discuss	O
their	O
receptor	O
usage	O
;	O
we	O
also	O
highlight	O
the	O
diversity	O
and	O
potential	O
of	O
spillover	O
of	O
bat	B-ENZY
-	O
borne	O
coronaviruses	O
,	O
as	O
evidenced	O
by	O
the	O
recent	O
spillover	O
of	O
swine	O
acute	O
diarrhoea	O
syndrome	O
coronavirus	O
(	O
SADS	O
-	O
CoV	O
)	O
to	O
pigs	O
.	O

TITLE	O
:	O
Replication	O
of	O
MERS	O
and	O
SARS	O
coronaviruses	O
in	O
bat	B-ENZY
cells	O
offers	O
insights	O
to	O
their	O
ancestral	O
origins	O
.	O

ABSTRACT	O
:	O
Previous	O
findings	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)-	O
related	O
viruses	O
in	O
bats	O
,	O
and	O
the	O
ability	O
of	O
Tylonycteris	O
-	O
BatCoV	O
HKU4	O
spike	O
protein	O
to	O
utilize	O
MERS	O
-	O
CoV	O
receptor	O
,	O
human	O
dipeptidyl	O
peptidase	O
4	O
hDPP4	O
,	O
suggest	O
a	O
bat	B-ENZY
ancestral	O
origin	O
of	O
MERS	O
-	O
CoV	O
.	O
We	O
developed	O
12	O
primary	O
bat	B-ENZY
cell	O
lines	O
from	O
seven	O
bat	B-ENZY
species	O
,	O
including	O
Tylonycteris	O
pachypus	O
,	O
Pipistrellus	O
abramus	O
and	O
Rhinolophus	O
sinicus	O
(	O
hosts	O
of	O
Tylonycteris	O
-	O
BatCoV	O
HKU4	O
,	O
Pipistrellus	O
-	O
BatCoV	O
HKU5	O
,	O
and	O
SARS	O
-	O
related	O
-	O
CoV	O
respectively	O
),	O
and	O
tested	O
their	O
susceptibilities	O
to	O
MERS	O
-	O
CoVs	O
,	O
SARS	O
-	O
CoV	O
,	O
and	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
).	O

SARS	O
-	O
CoV	O
can	O
only	O
replicate	O
in	O
R	O
.	O
sinicus	O
cells	O
,	O
while	O
HCoV	O
-	O
229E	O
cannot	O
replicate	O
in	O
any	O
bat	B-ENZY
cells	O
.	O

Bat	B-ENZY
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
)	O
sequences	O
were	O
closely	O
related	O
to	O
those	O
of	O
human	O
and	O
non	O
-	O
human	O
primates	O
but	O
distinct	O
from	O
dromedary	O
DPP4	O
sequence	O
.	O

DPP4	O
was	O
expressed	O
in	O
the	O
five	O
bat	B-ENZY
cells	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
,	O
with	O
significantly	O
higher	O
mRNA	O
expression	O
levels	O
than	O
those	O
in	O
non	O
-	O
susceptible	O
cells	O
(	O
P	O
=	O
0	O
.	O
0174	O
),	O
supporting	O
that	O
DPP4	O
expression	O
is	O
critical	O
for	O
MERS	O
-	O
CoV	O
infection	O
in	O
bats	O
.	O

Here	O
,	O
we	O
study	O
the	O
implication	O
of	O
HIV	O
-	O
1	O
transactivator	O
of	O
transcription	O
(	O
TAT	B-ENZY
)-	O
derived	O
peptides	O
inserted	O
on	O
PEGylated	O
liposomal	O
doxorubicin	O
(	O
PLD	O
)	O
and	O
followed	O
in	O
vitro	O
and	O
in	O
vivo	O
fate	O
.	O

PLDs	O
were	O
installed	O
with	O
25	O
-	O
400	O
TAT	B-ENZY
peptides	O
per	O
liposome	O
without	O
an	O
effect	O
on	O
PLD	O
stability	O
.	O

While	O
TAT	B-ENZY
peptides	O
facilitate	O
active	O
endocytosis	O
of	O
the	O
carriers	O
,	O
we	O
observed	O
that	O
these	O
peptides	O
did	O
not	O
promote	O
endosomal	O
escape	O
or	O
enhanced	O
intracellular	O
availability	O
of	O
doxorubicin	O
.	O

Interestingly	O
,	O
incorporation	O
of	O
TAT	B-ENZY
peptides	O
did	O
not	O
change	O
pharmacokinetics	O
or	O
biodistribution	O
,	O
which	O
we	O
found	O
to	O
result	O
from	O
a	O
dysopsonization	O
of	O
the	O
TAT	B-ENZY
-	O
modified	O
liposomes	O
by	O
serum	O
proteins	O
.	O

At	O
200	O
TAT	B-ENZY
peptides	O
,	O
the	O
preparation	O
appeared	O
to	O
be	O
least	O
effective	O
,	O
which	O
likely	O
results	O
from	O
augmented	O
interaction	O
with	O
tumor	O
cells	O
directly	O
upon	O
extravasation	O
.	O

The	O
indel	O
sites	O
of	O
the	O
spike	O
(	O
S	O
)	O
gene	O
of	O
CH	O
/	O
FJWT	O
/	O
2018	O
were	O
most	O
similar	O
to	O
those	O
of	O
bat	B-ENZY
-	O
origin	O
SADS	O
-	O
related	O
coronaviruses	O
.	O

ANCA	O
is	O
a	O
disease	O
-	O
labeled	O
antibody	O
of	O
AAV	O
,	O
and	O
myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
and	O
proteinase	B-ENZY
3	I-ENZY
are	O
the	O
main	O
targeted	O
antigens	O
of	O
ANCA	O
.	O

ABSTRACT	O
:	O
A	O
non	O
-	O
prime	O
site	O
substituent	O
and	O
warheads	O
combined	O
with	O
a	O
decahydroisoquinolin	O
scaffold	O
was	O
evaluated	O
as	O
a	O
novel	O
inhibitor	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
(	O
3CL	O

The	O
tracer	O
gas	B-ENZY
concentration	O
of	O
room	O
8110	O
,	O
which	O
was	O
the	O
farthest	O
room	O
,	O
was	O
7	O
.	O
56	O
%	O
of	O
room	O
8104	O
,	O
indicating	O
that	O
a	O
high	O
concentration	O
of	O
gas	B-ENZY
has	O
spread	O
from	O
room	O
8104	O
to	O
rooms	O
across	O
the	O
corridor	O
.	O

The	O
aim	O
was	O
to	O
identify	O
risk	O
factors	O
that	O
influence	O
in	O
-	O
hospital	O
mortality	O
for	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
blunt	O
multiple	O
trauma	O
(	O
BMT	B-ENZY
)	O
who	O
survive	O
initial	O
resuscitation	O
.	O

The	O
prospective	O
study	O
involved	O
195	O
adult	O
patients	O
with	O
BMT	B-ENZY
who	O
were	O
admitted	O
to	O
a	O
referral	O
hospital	O
'	O
s	O
emergency	O
department	O
(	O
ED	O
)	O
between	O
May	O
1	O
,	O
2015	O
,	O
and	O
May	O
31	O
,	O
2016	O
.	O

The	O
discovery	O
and	O
exploitation	O
of	O
oil	O
and	O
gas	B-ENZY
led	O
to	O
a	O
5	O
-	O
fold	O
increase	O
in	O
Qatar	O
GDP	O
coupled	O
with	O
a	O
7	O
-	O
fold	O
population	O
growth	O
in	O
the	O
past	O
30	O
years	O
.	O

Patients	O
with	O
G6PD	B-ENZY
deficiency	O
have	O
a	O
decreased	O
tolerance	O
to	O
oxidative	O
stress	O
and	O
are	O
therefore	O
at	O
a	O
greater	O
risk	O
of	O
hemolysis	O
and	O
methemoglobinemia	O
with	O
rasburicase	O
.	O

He	O
also	O
had	O
a	O
discrepancy	O
of	O
the	O
transcutaneous	O
saturation	O
(	O
75	O
%)	O
and	O
the	O
saturation	O
in	O
an	O
arterial	O
blood	O
gas	B-ENZY
value	O
(	O
99	O
%).	O

We	O
were	O
aware	O
that	O
methylene	O
blue	O
is	O
a	O
contraindication	O
in	O
patients	O
with	O
G6PD	B-ENZY
deficiency	O
but	O
considering	O
patient	O
being	O
Caucasian	O
and	O
low	O
risk	O
for	O
it	O
and	O
his	O
deteriorating	O
respiratory	O
condition	O
,	O
it	O
was	O
decided	O
to	O
offer	O
the	O
treatment	O
and	O
patient	O
received	O
1	O
dose	O
of	O
methylene	O
blue	O
which	O
failed	O
to	O
improve	O
his	O
methemoglobinemia	O
.	O

ABSTRACT	O
:	O
The	O
protein	B-ENZY
kinase	I-ENZY
RIPK1	O
plays	O
a	O
crucial	O
role	O
at	O
the	O
crossroad	O
of	O
stress	O
-	O
induced	O
signaling	O
pathways	O
that	O
affects	O
cell	O
'	O
s	O
decision	O
to	O
live	O
or	O
die	O
.	O

Forty	O
-	O
three	O
horses	O
>	O
1	O
year	O
of	O
age	O
with	O
results	O
of	O
CBC	O
,	O
serum	O
biochemistry	O
,	O
and	O
fecal	O
diagnostic	O
testing	O
for	O
ECoV	O
and	O
Salmonella	O
spp	B-ENZY
.	O

We	O
hope	O
that	O
this	O
review	O
will	O
enable	O
readers	O
to	O
identify	O
gaps	O
in	O
knowledge	O
that	O
currently	O
exist	O
and	O
initiate	O
a	O
dialogue	O
amongst	O
bat	B-ENZY
researchers	O
to	O
share	O
resources	O
to	O
overcome	O
present	O
limitations	O
.	O

The	O
hDPP4	O
-	O
Tg	O
mice	O
infected	O
with	O
MERS	O
-	O
CoV	O
overexpressed	O
caspase	B-ENZY
-	I-ENZY
1	I-ENZY
in	O
the	O
spleen	O
and	O
showed	O
high	O
IL	O
-	O
1	O
levels	O
in	O
serum	O
,	O
suggesting	O
that	O
pyroptosis	O
occurred	O
after	O
infection	O
.	O

However	O
,	O
when	O
the	O
C5a	O
-	O
C5aR1	O
axis	O
was	O
blocked	O
by	O
an	O
anti	O
-	O
C5aR1	O
antibody	O
(	O
Ab	O
),	O
expression	O
of	O
caspase	B-ENZY
-	I-ENZY
1	I-ENZY
and	O
IL	O
-	O
1	O
fell	O
.	O

In	O
Vero	O
cells	O
infected	O
with	O
PEDV	O
,	O
we	O
found	O
that	O
apoptosis	O
was	O
mediated	O
by	O
activation	O
of	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
and	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
in	O
the	O
late	O
stage	O
of	O
infection	O
.	O

In	O
addition	O
,	O
the	O
findings	O
suggest	O
that	O
L	O
.	O
acidophilus	O
S	O
-	O
layer	O
protein	O
protects	O
against	O
PEDV	O
-	O
induced	O
apoptosis	O
through	O
reduced	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
and	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
activation	O
in	O
the	O
later	O
stages	O
of	O
infection	O
.	O

Here	O
,	O
the	O
structure	O
of	O
ISG15	O
from	O
the	O
bat	B-ENZY
species	O
Myotis	O
davidii	O
solved	O
to	O
1	O
.	O
37	O
	O
resolution	O
is	O
reported	O
.	O

Using	O
the	O
papain	B-ENZY
-	O
like	O
deISGylase	O
from	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
as	O
a	O
probe	O
,	O
the	O
biochemical	O
importance	O
of	O
this	O
motif	O
in	O
ISG15	O
-	O
protein	O
engagements	O
was	O
illuminated	O
.	O

Sequence	O
analyses	O
suggest	O
that	O
PEDV	O
and	O
SADS	O
-	O
CoV	O
may	O
have	O
originated	O
from	O
bat	B-ENZY
CoVs	O
and	O
PDCoV	O
from	O
a	O
sparrow	O
CoV	O
,	O
reaffirming	O
the	O
interspecies	O
transmission	O
of	O
CoVs	O
.	O

Twenty	O
-	O
four	O
severe	O
ARDS	O
patients	O
(	O
arterial	O
oxygen	O
partial	O
pressure	O
to	O
fractional	O
inspired	O
oxygen	O
ratio	O
,	O
PaO	B-ENZY
Patients	O
in	O
the	O
EIT	O
group	O
were	O
younger	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
their	O
mean	O
plateau	O
pressure	O
was	O
1	O
.	O
5	O
cmH	O
In	O
severe	O
ARDS	O
patients	O
,	O
it	O
was	O
feasible	O
and	O
safe	O
to	O
guide	O
PEEP	O
titration	O
with	O
EIT	O
at	O
the	O
bedside	O
.	O

Results	O
indicated	O
that	O
the	O
limit	O
of	O
detection	O
(	O
LOD	B-ENZY
)	O
of	O
the	O
new	O
ICA	O
was	O
0	O
.	O
47	O
g	O
/	O
mL	O
(	O
5	O
.	O
9	O
	O
10	O
A	O
new	O
ICA	O
based	O
on	O
mAbs	O
prepared	O
by	O
CSFIA	O
was	O
developed	O
in	O
this	O
study	O
.	O

Results	O
indicated	O
that	O
the	O
limit	O
of	O
detection	O
(	O
LOD	B-ENZY
)	O
of	O
the	O
new	O
ICA	O
was	O
0	O
.	O
47	O
g	O
/	O
mL	O
(	O
5	O
.	O
9	O
	O
10	O

ABSTRACT	O
:	O
In	O
the	O
last	O
two	O
decades	O
,	O
several	O
high	O
impact	O
zoonotic	O
disease	O
outbreaks	O
have	O
been	O
linked	O
to	O
bat	B-ENZY
-	O
borne	O
viruses	O
.	O

Dromedary	O
camels	O
remain	O
the	O
only	O
documented	O
zoonotic	O
source	O
of	O
human	O
infection	O
,	O
but	O
MERS	O
-	O
like	O
CoVs	O
have	O
been	O
detected	O
in	O
bat	B-ENZY
species	O
globally	O
,	O
as	O
well	O
as	O
in	O
dromedary	O
camels	O
throughout	O
the	O
Middle	O
East	O
and	O
Africa	O
.	O

We	O
also	O
used	O
this	O
method	O
in	O
combination	O
with	O
bioinformatics	O
to	O
test	O
furin	B-ENZY
cleavage	O
activity	O
of	O
feline	O
coronavirus	O
spike	O
proteins	O
from	O
different	O
serotypes	O
and	O
strains	O
.	O

Considering	O
the	O
most	O
recent	O
randomized	O
controlled	O
trials	O
(	O
RCTs	O
)	O
and	O
recent	O
change	O
in	O
administration	O
strategies	O
,	O
the	O
aim	O
of	O
this	O
updated	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
was	O
to	O
evaluate	O
clinical	O
benefits	O
of	O
	O
-	O
3	O
PUFA	O
administration	O
on	O
gas	B-ENZY
exchange	O
and	O
clinical	O
outcomes	O
in	O
ARDS	O
patients	O
.	O

The	O
outcomes	O
assessed	O
were	O
PaO	B-ENZY
Twelve	O
RCTs	O

Omega	O
-	O
3	O
PUFAs	O
administration	O
was	O
associated	O
with	O
a	O
significant	O
improvement	O
in	O
early	O
PaO	B-ENZY
In	O
critically	O
ill	O
patients	O
with	O
ARDS	O
,	O
	O
-	O
3	O
PUFAs	O
in	O
enteral	O
immunomodulatory	O
diets	O
may	O
be	O
associated	O
with	O
an	O
improvement	O
in	O
early	O
and	O
late	O
PaO	B-ENZY
RESULTS	O
:	O
Twelve	O
RCTs	O
(	O
n	O
=	O
1280	O
patients	O
)	O
met	O
our	O
inclusion	O
criteria	O
.	O

It	O
is	O
a	O
variant	O
of	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
)	O
causing	O
an	O
abrupt	O
increase	O
in	O
intra	O
-	O
abdominal	O
pressure	O
.	O

We	O
present	O
a	O
case	O
of	O
pneumoperitoneum	O
,	O
after	O
an	O
endoscopic	O
mucosal	O
resection	O
with	O
the	O
development	O
of	O
ACS	B-ENZY
.	O

Decompressive	O
laparotomy	O
is	O
the	O
first	O
treatment	O
option	O
for	O
both	O
most	O
forms	O
of	O
pneumoperitoneum	O
and	O
ACS	B-ENZY
;	O
nevertheless	O
,	O
this	O
issue	O
is	O
controversial	O
.	O

If	O
a	O
severe	O
impairment	O
of	O
gas	B-ENZY
exchange	O
is	O
present	O
,	O
prone	O
posi	O
-	O
tioning	O
lessens	O
mortality	O
(	O
QoE	O
:	O
high	O
).	O

Recommendations	O
for	O
patients	O
undergoing	O
mechanical	O
ventilation	O
include	O
lung	O
-	O
protective	O
ventilation	O
,	O
early	O
sponta	O
-	O
neous	O
breathing	O
and	O
mobilization	O
,	O
weaning	O
protocols	O
,	O
and	O
,	O
for	O
those	O
with	O
severe	O
impairment	O
of	O
gas	B-ENZY
exchange	O
,	O
prone	O
positioning	O
.	O

It	O
is	O
further	O
recommended	O
that	O
patients	O
with	O
ARDS	O
and	O
refractory	O
impairment	O
of	O
gas	B-ENZY
exchange	O
should	O
be	O
transferred	O
to	O
an	O
ARDS	O
/	O
ECMO	O
center	O
,	O
where	O
extracorporeal	O
methods	O
should	O
be	O
applied	O
only	O
after	O
application	O
of	O
all	O
other	O
therapeutic	O
options	O
.	O

TITLE	O
:	O
StatPearls	O
ABSTRACT	O
:	O
Blood	O
gas	B-ENZY
analysis	O
is	O
a	O
commonly	O
used	O
diagnostic	O
tool	O
to	O
evaluate	O
the	O
partial	O
pressures	O
of	O
gas	B-ENZY
in	O
blood	O
as	O
well	O
as	O
acid	O
-	O
base	O
content	O
.	O

Understanding	O
and	O
use	O
of	O
blood	O
gas	B-ENZY
analysis	O
enables	O
providers	O
to	O
interpret	O
respiratory	O
,	O
circulatory	O
and	O
metabolic	O
disorders	O
.	O

Arterial	O
blood	O
gas	B-ENZY
analysis	O
assesses	O
a	O
patient	O
	O
s	O
partial	O
pressure	O
of	O
oxygen	O
(	O
PaO2	O
),	O
providing	O
information	O
on	O
the	O
oxygenation	O
status	O
;	O
the	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
(	O
PaCO2	O
),	O
providing	O
information	O
on	O
the	O
ventilation	O
status	O
(	O
chronic	O
or	O
acute	O
respiratory	O
failure	O
,	O
and	O
is	O
changed	O
by	O
hyperventilation	O
(	O
rapid	O
or	O
deep	O
breathing	O
)	O
and	O
hypoventilation	O
(	O
slow	O
or	O
shallow	O
breathing	O
);	O
and	O
acid	O
-	O
base	O
status	O
.	O

Although	O
oxygenation	O
and	O
ventilation	O
can	O
be	O
assessed	O
non	O
-	O
invasively	O
via	O
pulse	O
oximetry	O
and	O
end	O
-	O
tidal	O
carbon	O
dioxide	O
monitoring	O
,	O
respectively	O
,	O
blood	O
gas	B-ENZY
analysis	O
is	O
the	O
standard	O
.	O

We	O
introduce	O
the	O
genetic	O
diversity	O
of	O
SARS	O
-	O
related	O
coronaviruses	O
(	O
SARSr	O
-	O
CoVs	O
)	O
discovered	O
in	O
bats	O
and	O
provide	O
insights	O
on	O
the	O
bat	B-ENZY
origin	O
of	O
human	O
SARS	O
.	O

Granulomas	O
manifest	O
primarily	O
in	O
lungs	O
and	O
lung	O
-	O
draining	O
lymph	O
nodes	O
(	O
LLNs	O
)	O
but	O
these	O
compartments	O
are	O
less	O
studied	O
compared	O
to	O
blood	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
).	O

From	O
each	O
patient	O
,	O
blood	O
,	O
BAL	B-ENZY
,	O
endobronchial	O
biopsies	O
(	O
EBBs	O
),	O
and	O
LLN	O
samples	O
obtained	O
by	O
EBUS	O
-	O
TBNA	O
were	O
collected	O
and	O
MNPs	O
characterized	O
using	O
multicolor	O
flow	O
cytometry	O
.	O

Importantly	O
,	O
monocytes	O
and	O
DCs	O
were	O
most	O
mature	O
with	O
migratory	O
potential	O
in	O
BAL	B-ENZY
and	O
EBBs	O
but	O
not	O
in	O
the	O
LLNs	O
suggesting	O
heterogeneity	O
in	O
MNPs	O
in	O
the	O
compartments	O
typically	O
affected	O
in	O
sarcoidosis	O
.	O

TITLE	O
:	O
First	O
Complete	O
Genome	O
Sequence	O
of	O
Human	O
Coronavirus	O
HKU1	O
from	O
a	O
Nonill	O
Bat	B-ENZY
Guano	O
Miner	O
in	O
Thailand	O
.	O

Here	O
,	O
we	O
report	O
the	O
first	O
complete	O
genome	O
sequence	O
of	O
HCoV	O
-	O
HKU1	O
from	O
Thailand	O
,	O
obtained	O
from	O
a	O
nonill	O
person	O
who	O
worked	O
in	O
a	O
bat	B-ENZY
cave	O
.	O

ABSTRACT	O
:	O
Nod	B-ENZY
-	O
like	O
receptor	O
family	O
,	O
pyrin	O
domain	O
-	O
containing	O
3	O
(	O
NLRP3	O
)	O
regulates	O
the	O
secretion	O
of	O
proinflammatory	O
cytokines	O
interleukin	O
1	O
beta	O
(	O
IL	O
-	O
1	O
)	O
and	O
IL	O
-	O
18	O
.	O

The	O
plasma	O
metabolites	O
were	O
detected	O
with	O
gas	B-ENZY
chromatography	O
-	O
mass	O
spectrometry	O
(	O
GC	O
-	O
MS	O
),	O
and	O
the	O
relevant	O
metabolic	O
pathways	O
were	O
predicted	O
using	O
the	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
database	O
.	O

We	O
infected	O
human	O
and	O
bat	B-ENZY
(	O

The	O
engineered	O
oligomeric	O
Nbs	O
were	O
very	O
stable	O
under	O
extreme	O
conditions	O
,	O
including	O
low	O
or	O
high	O
pH	O
,	O
protease	O
(	O
pepsin	B-ENZY
),	O
chaotropic	O
denaturant	O
(	O
urea	O
),	O
and	O
high	O
temperature	O
.	O

TITLE	O
:	O
Global	O
Epidemiology	O
of	O
Bat	B-ENZY
Coronaviruses	O
.	O

Finally	O
,	O
a	O
dual	O
-	O
luciferase	B-ENZY
reporter	O
assay	O
showed	O
that	O
nsp4	O
contributed	O
to	O
the	O
expression	O
of	O
IL	O
-	O
1	O
,	O
IL	O
-	O
1	O
,	O
TNF	O
-	O
	O
,	O
CCL2	O
,	O
CCL5	O
and	O
CXCL8	O
via	O
the	O
NF	O
-	O
B	O
pathway	O
.	O

Here	O
,	O
we	O
report	O
significantly	O
dampened	O
activation	O
of	O
the	O
NLRP3	O
inflammasome	O
in	O
bat	B-ENZY
primary	O
immune	O
cells	O
compared	O
to	O
human	O
or	O
mouse	O
counterparts	O
.	O

Treatment	O
with	O
neuraminidase	B-ENZY
inhibitors	O
and	O
other	O
antivirals	O
is	O
reviewed	O
.	O

Risk	O
factors	O
associated	O
with	O
mortality	O
found	O
by	O
bivariate	O
analysis	O
were	O
Severity	O
Acute	O
Physiology	O
Score	O
II	O
(	O
p	O
=	O
0	O
.	O
01	O
),	O
Sequential	O
Organ	O
Failure	O
Assessment	O
(	O
p	O
=	O
0	O
.	O
01	O
),	O
base	O
excess	O
(	O
p	O
=	O
0	O
.	O
002	O
),	O
kaliemia	O
(	O
p	O
=	O
0	O
.	O
004	O
),	O
bilirubinemia	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
level	O
of	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
p	O
=	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Bat	B-ENZY
Coronaviruses	O
in	O
China	O
.	O

Therefore	O
,	O
the	O
investigation	O
of	O
bat	B-ENZY
coronaviruses	O
becomes	O
an	O
urgent	O
issue	O
for	O
the	O
detection	O
of	O
early	O
warning	O
signs	O
,	O
which	O
in	O
turn	O
minimizes	O
the	O
impact	O
of	O
such	O
future	O
outbreaks	O
in	O
China	O
.	O

The	O
purpose	O
of	O
the	O
review	O
is	O
to	O
summarize	O
the	O
current	O
knowledge	O
on	O
viral	O
diversity	O
,	O
reservoir	O
hosts	O
,	O
and	O
the	O
geographical	O
distributions	O
of	O
bat	B-ENZY
coronaviruses	O
in	O
China	O
,	O
and	O
eventually	O
we	O
aim	O
to	O
predict	O
virus	O
hotspots	O
and	O
their	O
cross	O
-	O
species	O
transmission	O
potential	O
.	O

ABSTRACT	O
:	O
Bats	O
are	O
known	O
to	O
harbor	O
and	O
transmit	O
many	O
emerging	O
and	O
re	O
-	O
emerging	O
viruses	O
,	O
many	O
of	O
which	O
are	O
extremely	O
pathogenic	O
in	O
humans	O
but	O
do	O
not	O
cause	O
overt	O
pathology	O
in	O
their	O
bat	B-ENZY
reservoir	O
hosts	O
:	O
henipaviruses	O
(	O
Nipah	O
and	O
Hendra	O
),	O
filoviruses	O
(	O
Ebola	O
and	O
Marburg	O
),	O
and	O
coronaviruses	O
(	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
).	O

Direct	O
transmission	O
cycles	O
are	O
often	O
implicated	O
in	O
these	O
outbreaks	O
,	O
with	O
virus	O
shed	O
in	O
bat	B-ENZY
feces	O
,	O
urine	O
,	O
and	O
saliva	O
.	O

Subsequently	O
,	O
SARS	O
-	O
related	O
CoVs	O
(	O
SARSr	O
-	O
CoVs	O
)	O
were	O
found	O
in	O
palm	O
civets	O
from	O
live	O
animal	O
markets	O
in	O
Guangdong	O
and	O
in	O
various	O
horseshoe	O
bat	B-ENZY
species	O
,	O
which	O
were	O
believed	O
to	O
be	O
the	O
ultimate	O
reservoir	O
of	O
SARSr	O
-	O
CoV	O
.	O
Till	O
November	O
2018	O
,	O
339	O
SARSr	O
-	O
CoV	O
genomes	O
have	O
been	O
sequenced	O
,	O
including	O
274	O
from	O
human	O
,	O
18	O
from	O
civets	O
and	O
47	O
from	O
bats	O
[	O
mostly	O
from	O
Chinese	O
horseshoe	O
bats	O
(	O
Rhinolophus	O
sinicus	O
),	O
n	O
=	O
30	O
;	O
and	O
greater	O
horseshoe	O
bats	O
(	O
Rhinolophus	O
ferrumequinum	O
),	O
n	O
=	O
9	O
].	O

Areas	O
covered	O
:	O
The	O
risks	O
of	O
re	O
-	O
emergence	O
of	O
SARS	O
-	O
CoV	O
from	O
bat	B-ENZY
reservoir	O
hosts	O
,	O
the	O
persistence	O
of	O
MERS	O
-	O
CoV	O
circulation	O
,	O
and	O
the	O
potential	O
for	O
future	O
emergence	O
of	O
novel	O
coronaviruses	O
indicate	O
antiviral	O
drug	O
discovery	O
will	O
require	O
activity	O
against	O
multiple	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
The	O
protocol	O
aims	O
to	O
generate	O
coronavirus	O
(	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
fusion	O
protein	O
pseudotyped	O
particles	O
with	O
a	O
murine	O
leukemia	O
virus	O
(	O
MLV	O
)	O
core	O
and	O
luciferase	B-ENZY
reporter	O
,	O
using	O
a	O
simple	O
transfection	O
procedure	O
of	O
the	O
widely	O
available	O
HEK	O
-	O
293T	O
cell	O
line	O
.	O

Once	O
formed	O
and	O
released	O
from	O
producer	O
cells	O
,	O
these	O
pseudovirions	O
incorporate	O
a	O
luciferase	B-ENZY
reporter	O
gene	O
.	O

Moreover	O
,	O
recombinant	O
PEDV	O
viruses	O
bearing	O
S	O
of	O
the	O
G2	O
strain	O
with	O
the	O
single	O
V672F	O
substitution	O
could	O
induce	O
extensive	O
syncytium	O
formation	O
and	O
replicate	O
efficiently	O
in	O
VeroE6	O
cells	O
stably	O
expressing	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
VeroE6	O
-	O
APN	O
).	O

Serology	O
was	O
performed	O
on	O
38	O
serum	O
samples	O
,	O
nested	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
(	O
nRT	O
-	O
PCR	O
)	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
quantitative	O
PCR	O
(	O
RT	O
-	O
qPCR	O
)	O
were	O
performed	O
on	O
39	O
blood	O
samples	O
and	O
on	O
17	O
semen	O
samples	O
,	O
and	O
histology	O
,	O
immunohistochemistry	O
and	O
nRT	O
-	O
PCR	O
were	O
performed	O
on	O
39	O
testicles	O
.	O

These	O
include	O
interferon	O
(	O
IFN	O
),	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
)-	O
RNase	B-ENZY
L	O
,	O
and	O
protein	B-ENZY
kinase	I-ENZY
R	O
(	O
PKR	O
).	O

NS4a	O
has	O
been	O
previously	O
characterized	O
as	O
a	O
dsRNA	O
binding	O
protein	O
,	O
while	O
NS4b	O
is	O
a	O
2	O
',	O
5	B-ENZY
'-	I-ENZY
phosphodiesterase	I-ENZY
with	O
structural	O
and	O
enzymatic	O
similarity	O
to	O
NS2	O
encoded	O
by	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

Here	O
,	O
we	O
report	O
genetic	O
analysis	O
of	O
a	O
ts	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
tsNC11	O
,	O
focusing	O
on	O
the	O
role	O
of	O
mutations	O
in	O
the	O
macrodomain	O
(	O
MAC	O
)	O
and	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
(	O
PLP2	O
)	O
domain	O
of	O
nonstructural	O
protein	O
3	O
(	O
nsp3	O
),	O
a	O
component	O
of	O
the	O
viral	O
replication	O
complex	O
.	O

Expression	O
studies	O
of	O
the	O
macrodomain	O
-	O
PLP2	O
portion	O
of	O
nsp3	O
indicate	O
that	O
the	O
ts	O
mutations	O
enhance	O
proteasome	B-ENZY
-	O
mediated	O
degradation	O
of	O
the	O
protein	O
.	O

Three	O
days	O
after	O
initiation	O
of	O
ECMO	O
,	O
the	O
patient	O
developed	O
jaundice	O
,	O
with	O
increase	O
of	O
bilirubin	O
,	O
Gamma	B-ENZY
-	I-ENZY
glutamyltransferase	I-ENZY
and	O
Alkaline	B-ENZY
phosphatase	I-ENZY
,	O
without	O
elevation	O
of	O
alanine	B-ENZY
aminotransferase	I-ENZY
and	O
INR	O
.	O

The	O
American	O
College	O
of	O
Surgeons	O
-	O
National	O
Surgical	O
Quality	O
Improvement	O
Program	O
(	O
ACS	B-ENZY
-	O
NSQIP	O
)	O
database	O
was	O
reviewed	O
retrospectively	O
.	O

Bivalirudin	O
is	O
a	O
direct	O
thrombin	B-ENZY
inhibitor	O
that	O
can	O
be	O
used	O
as	O
an	O
alternative	O
anticoagulant	O
in	O
neonates	O
and	O
infants	O
demonstrating	O
inaccurate	O
heparin	O
monitoring	O
.	O

TITLE	O
:	O
Arterivirus	B-ENZY
nsp4	I-ENZY
Antagonizes	O
Interferon	O
Beta	O
Production	O
by	O
Proteolytically	O
Cleaving	O
NEMO	O
at	O
Multiple	O
Sites	O
.	O

TITLE	O
:	O
Cholesterol	B-ENZY
25	I-ENZY
-	I-ENZY
hydroxylase	I-ENZY
negatively	O
regulates	O
porcine	O
intestinal	O
coronavirus	O
replication	O
by	O
the	O
production	O
of	O
25	O
-	O
hydroxycholesterol	O
.	O

It	O
is	O
important	O
to	O
develop	O
stable	O
and	O
safe	O
reference	O
materials	O
for	O
assessing	O
the	O
quality	O
of	O
NAT	B-ENZY
kits	O
and	O
performing	O
an	O
external	O
quality	O
assessment	O
(	O
EQA	O
)	O
in	O
different	O
laboratories	O
.	O

The	O
general	O
anesthetic	O
at	O
this	O
time	O
consisted	O
of	O
a	O
nonspecific	O
mixture	O
of	O
gas	B-ENZY
,	O
oxygen	O
,	O
and	O
ether	O
.	O

Unbiased	O
high	O
throughput	O
sequencing	O
of	O
fecal	O
samples	O
from	O
72	O
bat	B-ENZY
individuals	O
comprising	O
four	O
species	O
;	O
lesser	O
mouse	O
-	O
tailed	O
bat	B-ENZY
(	O
Rhinopoma	O
hardwickii	O
),	O
Egyptian	O
tomb	O
bat	B-ENZY
(	O
Taphozous	O
perforatus	O
),	O
straw	O
-	O
colored	O
fruit	O
bat	B-ENZY
(	O
Eidolon	O
helvum	O
),	O
and	O
Egyptian	O
fruit	O
bat	B-ENZY
(	O
Rousettus	O
aegyptiacus	O
)	O
revealed	O
molecular	O
evidence	O
of	O
a	O
diverse	O
set	O
of	O
viral	O
families	O
:	O
Picornaviridae	O
(	O
hepatovirus	O
,	O
teschovirus	O
,	O
parechovirus	O
),	O
Reoviridae	O
(	O
rotavirus	O
),	O
Polyomaviridae	O
(	O
polyomavirus	O
),	O
Papillomaviridae	O
(	O
papillomavirus	O
),	O
Astroviridae	O
(	O
astrovirus	O
),	O
Caliciviridae	O
(	O
sapovirus	O
),	O
Coronaviridae	O
(	O
coronavirus	O
),	O
Adenoviridae	O
(	O
adenovirus	O
),	O
Paramyxoviridae	O
(	O
paramyxovirus	O
),	O
and	O
unassigned	O
mononegavirales	O
(	O
chuvirus	O
).	O

All	O
of	O
the	O
patients	O
were	O
initially	O
hypoxic	O
and	O
some	O
had	O
PaO	B-ENZY

Kazakhstan	O
is	O
the	O
world	O
'	O
s	O
ninth	O
largest	O
country	O
;	O
however	O
,	O
little	O
is	O
understood	O
about	O
the	O
prevalence	O
and	O
diversity	O
of	O
bat	B-ENZY
-	O
borne	O
viruses	O
.	O

Our	O
phylogenetic	O
reconstruction	O
indicates	O
these	O
are	O
novel	O
bat	B-ENZY
coronaviruses	O
that	O
belong	O
to	O
the	O
genus	O

Considering	O
the	O
diversity	O
of	O
bat	B-ENZY
coronaviruses	O
,	O
bat	B-ENZY
species	O
and	O
populations	O
,	O
we	O
expect	O
to	O
discover	O
more	O
bat	B-ENZY
CoVs	O
through	O
virus	O
surveillance	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
infections	O
induce	O
apoptosis	O
in	O
Vero	O
cells	O
via	O
a	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)/	O
p53	O
,	O
but	O
not	O
p38	O
MAPK	B-ENZY
and	O
SAPK	B-ENZY
/	O
JNK	B-ENZY
signalling	O
pathways	O
.	O

However	O
,	O
treatment	O
with	O
the	O
p38	O
MAPK	B-ENZY
inhibitor	O
SB203580	O
,	O
and	O
the	O
SAPK	B-ENZY
/	O
JNK	B-ENZY
inhibitor	O
SP600125	O
reversed	O
PEDV	O
-	O
induced	O
apoptosis	O
.	O

Activated	O
p38	O
MAPK	B-ENZY
and	O
SAPK	B-ENZY
/	O
JNK	B-ENZY
exerted	O
no	O
influence	O
on	O
PEDV	O
-	O
induced	O
apoptosis	O
.	O

The	O
gene	O
succinate	B-ENZY
dehydrogenase	I-ENZY
complex	O
,	O
subunit	O
A	O
,	O
flavoprotein	O
variant	O
(	O
SDHA	O
)	O
was	O
down	O
-	O
regulated	O
in	O
the	O
shell	O
gland	O
by	O
IBV	O
challenge	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
while	O
other	O
genes	O
being	O
studied	O
did	O
not	O
show	O
responses	O
to	O
the	O
challenge	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

The	O
expression	O
levels	O
of	O
citrate	B-ENZY
synthase	I-ENZY
(	O
CS	O
),	O
cytochrome	O
C	O
,	O
somatic	O
(	O
CYC	O
,	O
S	O
)	O
and	O
sodium	O
-	O
potassium	O
adenosine	O
triphosphatase	B-ENZY
(	O
Na	O

Eighty	O
-	O
nine	O
patients	O
(	O
71	O
.	O
2	O
%)	O
showed	O
normal	O
intra	O
-	O
abdominal	O
pressure	O
since	O
31	O
patients	O
(	O
24	O
.	O
8	O
%),	O
and	O
5	O
patients	O
(	O
4	O
%)	O
developed	O
IAH	O
and	O
ACS	B-ENZY
.	O

Intra	O
-	O
abdominal	O
pressure	O
test	O
,	O
as	O
a	O
valuable	O
prognosis	O
test	O
for	O
the	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
)	O
and	O
Intra	O
-	O
abdominal	O
hypertension	O
(	O
IAH	O
),	O
may	O
offer	O
better	O
results	O
when	O
added	O
to	O
the	O
routine	O
medical	O
checkup	O
of	O
ICU	O
patients	O
.	O

The	O
ceruloplasmin	B-ENZY
activity	O
and	O
the	O
transferrin	O
saturation	O
in	O
blood	O
plasma	O
by	O
iron	O
were	O
determined	O
by	O
G	O
.	O
Babenko	O
'	O
s	O
method	O
.	O

We	O
also	O
found	O
the	O
activity	O
increase	O
of	O
ceruloplasmin	B-ENZY
in	O
1	O
,	O
8	O
times	O
in	O
patients	O
with	O
severe	O
course	O
of	O
disease	O
.	O

The	O
most	O
common	O
use	O
of	O
this	O
tool	O
is	O
to	O
determine	O
whether	O
acute	O
coronary	O
syndrome	O
(	O
ACS	B-ENZY
)	O
is	O
occurring	O
,	O
but	O
other	O
differentials	O
include	O
cardiomyopathy	O
,	O
pulmonary	O
embolism	O
,	O
and	O
even	O
acute	O
heart	O
failure	O
.	O

A	O
coronary	O
angiogram	O
showed	O
severe	O
CAD	B-ENZY
and	O
he	O
underwent	O
staged	O
a	O
percutaneous	O
coronary	O
intervention	O
with	O
the	O
resolution	O
of	O
symptoms	O
.	O

CAD	B-ENZY
and	O
viral	O
myocarditis	O
,	O
at	O
times	O
,	O
can	O
share	O
common	O
presenting	O
symptoms	O
,	O
EKG	O
changes	O
,	O
and	O
laboratory	O
findings	O
.	O

The	O
Berlin	O
Definition	O
of	O
ARDS	O
specifies	O
three	O
severity	O
classifications	O
:	O
mild	O
,	O
moderate	O
,	O
and	O
severe	O
based	O
on	O
the	O
PaO	B-ENZY

Extracorporeal	O
life	O
support	O
(	O
ECLS	O
)	O
may	O
be	O
used	O
to	O
rescue	O
patients	O
with	O
severely	O
impaired	O
gas	B-ENZY
exchange	O
and	O
provide	O
time	O
for	O
injured	O
lungs	O
to	O
recover	O
while	O
treating	O
the	O
underlying	O
disease	O
.	O

TITLE	O
:	O
Novel	O
Bat	B-ENZY
Alphacoronaviruses	O
in	O
Southern	O
China	O
Support	O
Chinese	O
Horseshoe	O
Bats	O
as	O
an	O
Important	O
Reservoir	O
for	O
Potential	O
Novel	O
Coronaviruses	O
.	O

ABSTRACT	O
:	O
While	O
bats	O
are	O
increasingly	O
recognized	O
as	O
a	O
source	O
of	O
coronavirus	O
epidemics	O
,	O
the	O
diversity	O
and	O
emergence	O
potential	O
of	O
bat	B-ENZY
coronaviruses	O
remains	O
to	O
be	O
fully	O
understood	O
.	O

Among	O
1779	O
bat	B-ENZY
samples	O
collected	O
in	O
China	O
,	O
diverse	O
coronaviruses	O
were	O
detected	O
in	O
32	O
samples	O
from	O
five	O
different	O
bat	B-ENZY
species	O
by	O
RT	O
-	O
PCR	O
.	O

TITLE	O
:	O
Complete	O
genome	O
analysis	O
of	O
a	O
SARS	O
-	O
like	O
bat	B-ENZY
coronavirus	O
identified	O
in	O
the	O
Republic	O
of	O
Korea	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
whole	O
genomic	O
sequence	O
of	O
a	O
SARS	O
-	O
like	O
bat	B-ENZY
CoV	O
(	O
16BO133	O
)	O
and	O
found	O
it	O
to	O
be	O
29	O
,	O
075	O
nt	O
in	O
length	O
with	O
a	O
40	O
.	O
9	O
%	O
G	O
+	O
C	O
content	O
.	O

The	O
spike	O
region	O
of	O
16BO133	O
showed	O
84	O
.	O
7	O
%	O
and	O
75	O
.	O
2	O
%	O
amino	O
acid	O
identity	O
with	O
Rf1	O
(	O
SARS	O
-	O
like	O
bat	B-ENZY
CoV	O
)	O
and	O
Tor2	O
(	O
human	O
SARS	O
CoV	O
),	O
respectively	O
.	O

TITLE	O
:	O
The	O
ER	O
stress	O
sensor	O
IRE1	O
and	O
MAP	B-ENZY
kinase	I-ENZY
ERK	B-ENZY
modulate	O
autophagy	O
induction	O
in	O
cells	O
infected	O
with	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
.	O

Finally	O
,	O
the	O
anti	O
-	O
apoptotic	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
1	O
/	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
also	O
contributed	O
to	O
IBV	O
-	O
induced	O
autophagy	O
.	O

ABSTRACT	O
:	O
BACKGROUND	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
),	O
also	O
known	O
as	O
extracorporeal	O
life	O
support	O
(	O
ECLS	O
),	O
is	O
a	O
technique	O
used	O
to	O
provide	O
prolonged	O
cardiac	O
and	O
respiratory	O
support	O
to	O
persons	O
whose	O
heart	O
and	O
lungs	O
are	O
unable	O
to	O
deliver	O
adequate	O
perfusion	O
or	O
gas	B-ENZY
exchange	O
to	O
sustain	O
life	O
.	O

ADAMTS13	O
-	O
and	O
plasmin	B-ENZY
-	O
independent	O
reductions	O
of	O
high	O
molecular	O
weight	O
VWF	O
multimers	O
were	O
observed	O
at	O
the	O
end	O
stage	O
of	O
disease	O
.	O

If	O
influenza	O
pneumonia	O
is	O
diagnosed	O
,	O
neuraminidase	B-ENZY
inhibitors	O
are	O
the	O
preferred	O
approved	O
drugs	O
.	O

The	O
gender	O
,	O
age	O
,	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
within	O
24	O
hours	O
of	O
admission	O
,	O
neutral	O
red	O
phagocytosis	O
and	O
alkaline	B-ENZY
phosphatase	I-ENZY
activity	O
of	O
macrophages	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
the	O
length	O
of	O
ICU	O
stay	O
,	O
total	O
hospitalization	O
time	O
,	O
hospitalization	O
expenses	O
,	O
and	O
prognosis	O
were	O
recorded	O
.	O

The	O
prognosis	O
was	O
analyzed	O
by	O
binary	O
Logistic	O
regression	O
combined	O
with	O
neutral	O
red	O
phagocytosis	O
and	O
alkaline	B-ENZY
phosphatase	I-ENZY
activity	O
in	O
patients	O
,	O
and	O
the	O
predictive	O
value	O
of	O
both	O
subjects	O
on	O
prognosis	O
was	O
analyzed	O
by	O
the	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
.	O

Compared	O
with	O
the	O
survival	O
group	O
,	O
the	O
death	O
group	O
was	O
older	O
(	O
years	O
old	O
:	O
58	O
.	O
50	O
	O
14	O
.	O
86	O
vs	O
.	O
46	O
.	O
67	O
	O
13	O
.	O
40	O
),	O
APACHE	O
II	O
score	O
was	O
higher	O
(	O
21	O
.	O
50	O
	O
3	O
.	O
93	O
vs	O
.	O
13	O
.	O
58	O
	O
4	O
.	O
12	O
),	O
neutral	O
red	O
phagocytosis	O
ability	O
and	O
alkaline	B-ENZY
phosphatase	I-ENZY
activity	O
of	O
alveolar	O
macrophages	O
were	O
significantly	O
decreased	O
(	O
A	O
value	O
:	O
0	O
.	O
265	O
	O
0	O
.	O
050	O
vs	O
.	O
0	O
.	O
338	O
	O
0	O
.	O
016	O
;	O
mol	O
/	O
L	O
:	O
12	O
.	O
06	O
	O
1	O
.	O
24	O
vs	O
.	O
17	O
.	O
96	O
	O
3	O
.	O
90	O
),	O
and	O
the	O
length	O
of	O
ICU	O
stay	O
was	O
significantly	O
longer	O
(	O
days	O
:	O
22	O
.	O
00	O
	O
14	O
.	O
59	O
vs	O
.	O
11	O
.	O
50	O
	O
3	O
.	O
17	O
),	O
hospitalization	O
cost	O
was	O
significantly	O
increased	O
(	O
10	O
thousand	O
Yuan	O
:	O
24	O
.	O
17	O
	O
11	O
.	O
02	O
vs	O
.	O
13	O
.	O
44	O
	O
3	O
.	O
53	O
),	O
the	O
total	O
hospitalization	O
time	O
was	O
shorter	O
(	O
days	O
:	O
25	O
.	O
25	O
	O
15	O
.	O
01	O
vs	O
.	O
35	O
.	O
67	O
	O
8	O
.	O
58	O
),	O
and	O
the	O
difference	O
was	O
statistically	O
significant	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
neutral	O
red	O
phagocytosis	O
ability	O
of	O
alveolar	O
macrophages	O
in	O
ARDS	O
patients	O
caused	O
by	O
abdominal	O
infection	O
was	O
negatively	O
correlated	O
with	O
age	O
,	O
APACHE	O
II	O
score	O
and	O
the	O
length	O
of	O
ICU	O
stay	O
(	O
r	O
value	O
was	O
-	O
0	O
.	O
328	O
,	O
-	O
0	O
.	O
572	O
,	O
-	O
0	O
.	O
809	O
,	O
respectively	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
);	O
alkaline	B-ENZY
phosphatase	I-ENZY
activity	O
was	O
negatively	O
correlated	O
with	O
age	O
,	O
APACHE	O
II	O
score	O
,	O
the	O
length	O
of	O
ICU	O
stay	O
and	O
hospitalization	O
expenses	O
(	O
r	O
value	O
was	O
-	O
0	O
.	O
334	O
,	O
-	O
0	O
.	O
583	O
,	O
-	O
0	O
.	O
470	O
,	O
-	O
0	O
.	O
517	O
,	O
respectively	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
AUC	O
of	O
alkaline	B-ENZY
phosphatase	I-ENZY
for	O
the	O
prognosis	O
of	O
ARDS	O
patients	O
caused	O
by	O
abdominal	O
infection	O
was	O
0	O
.	O
813	O
;	O
when	O
the	O
cut	O
-	O
off	O
value	O
was	O
19	O
.	O
72	O
mol	O
/	O
L	O
,	O
the	O
sensitivity	O
was	O
75	O
.	O
0	O
%,	O
and	O
the	O
specificity	O
was	O
87	O
.	O
5	O
%.	O

Furthermore	O
,	O
study	O
revealed	O
that	O
PDCoV	O
N	O
protein	O
interacted	O
with	O
RIG	O
-	O
I	O
and	O
MDA5	O
in	O
an	O
in	O
vitro	O
overexpression	O
system	O
and	O
evident	O
interactions	O
between	O
N	O
protein	O
and	O
RIG	O
-	O
I	O
could	O
be	O
detected	O
in	O
the	O
context	O
of	O
PDCoV	O
infection	O
,	O
which	O
interfered	O
with	O
the	O
binding	O
of	O
dsRNA	O
and	O
protein	O
activator	O
of	O
protein	B-ENZY
kinase	I-ENZY
R	O
(	O
PACT	O
)	O
to	O
RIG	O
-	O
I	O
.	O
Together	O
,	O
our	O
results	O
demonstrate	O
that	O
PDCoV	O
N	O
protein	O
is	O
an	O
IFN	O
antagonist	O
and	O
utilizes	O
diverse	O
strategies	O
to	O
attenuate	O
RIG	O
-	O
I	O
recognition	O
and	O
activation	O
.	O

Laboratory	O
investigation	O
showed	O
high	O
erythrocyte	O
sedimentation	O
rate	O
and	O
C	O
reactive	O
protein	O
,	O
leucocytosis	O
,	O
anaemia	O
,	O
mild	O
thrombocytopaenia	O
,	O
renal	O
impairment	O
,	O
hyperbilirubinaemia	O
and	O
abnormal	O
liver	O
function	O
tests	O
;	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
showed	O
respiratory	O
alkalosis	O
with	O
severe	O
hypoxia	O
.	O

ABSTRACT	O
:	O
The	O
introduction	O
of	O
blood	O
donor	O
screening	O
by	O
virus	O
nucleic	O
acid	O
amplification	O
technology	O
(	O
NAT	B-ENZY
)	O
in	O
the	O
mid	O
to	O
late	O
1990s	O
was	O
driven	O
by	O
the	O
so	O
-	O
called	O
AIDS	O
and	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
epidemic	O
,	O
with	O
thousands	O
of	O
recipients	O
of	O
infected	O
blood	O
products	O
and	O
components	O
.	O

To	O
achieve	O
a	O
similar	O
safety	O
standard	O
,	O
NAT	B-ENZY
was	O
then	O
also	O
introduced	O
for	O
labile	O
blood	O
components	O
.	O

German	O
transfusion	O
centres	O
were	O
the	O
first	O
to	O
start	O
in	O
-	O
house	O
NAT	B-ENZY
testing	O
of	O
their	O
donations	O
in	O
pools	O
of	O
up	O
to	O
96	O
samples	O
for	O
HCV	O
,	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
),	O
and	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
).	O

When	O
severe	O
acute	O
respiratory	O
syndrome	O
corona	O
virus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
West	O
Nile	O
Virus	O
emerged	O
it	O
was	O
the	O
NAT	B-ENZY
that	O
enabled	O
the	O
manufacturers	O
and	O
transfusion	O
centres	O
to	O
instantly	O
introduce	O
sensitive	O
and	O
specific	O
screening	O
tests	O
.	O

Currently	O
more	O
than	O
60	O
million	O
donations	O
per	O
year	O
are	O
NAT	B-ENZY
tested	O
worldwide	O
and	O
the	O
remaining	O
residual	O
risk	O
of	O
virus	O
transmission	O
by	O
blood	O
components	O
and	O
products	O
could	O
be	O
reduced	O
to	O
almost	O
zero	O
.	O

Thus	O
,	O
antibody	O
and	O
antigen	O
testing	O
may	O
be	O
dispensable	O
in	O
the	O
long	O
run	O
,	O
particularly	O
in	O
the	O
combination	O
of	O
NAT	B-ENZY
testing	O
with	O
pathogen	O
reduction	O
.	O

However	O
,	O
each	O
of	O
these	O
has	O
limitations	O
,	O
either	O
in	O
throughput	O
,	O
costs	O
,	O
automation	O
,	O
time	O
to	O
result	O
,	O
specificity	O
,	O
or	O
the	O
need	O
for	O
NAT	B-ENZY
as	O
an	O
integral	O
part	O
of	O
the	O
technology	O
.	O

Thus	O
,	O
NAT	B-ENZY
is	O
still	O
the	O
shortest	O
and	O
most	O
efficient	O
means	O
to	O
the	O
result	O
.	O

Donor	O
screening	O
NAT	B-ENZY
also	O
contributed	O
significantly	O
to	O
our	O
knowledge	O
on	O
how	O
fast	O
viruses	O
replicate	O
,	O
and	O
on	O
the	O
respective	O
diagnostic	O
window	O
.	O

The	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
),	O
injury	O
severity	O
score	O
(	O
ISS	O
)	O
and	O
oxygenation	O
index	O
(	O
PaO	B-ENZY
115	O
patients	O
were	O
enrolled	O
in	O
the	O
final	O
analysis	O
,	O
72	O
survived	O
in	O
28	O
days	O
,	O
43	O
died	O
,	O
and	O
the	O
mortality	O
rate	O
was	O
37	O
.	O
4	O
%.	O

The	O
levels	O
of	O
EVLWI	O
,	O
Ang	O
-	O
2	O
and	O
PaO	B-ENZY
EVLWI	O
and	O
Ang	O
-	O
2	O
can	O
be	O
used	O
as	O
independent	O
risk	O
factors	O
for	O
28	O
-	O
day	O
mortality	O
of	O
severe	O
multiple	O
trauma	O
patients	O
with	O
ARDS	O
,	O
and	O
the	O
predictive	O
value	O
of	O
EVLWI	O
was	O
better	O
than	O
Ang	O
-	O
2	O
and	O
APACHE	O
II	O
.	O

The	O
levels	O
of	O
EVLWI	O
,	O
Ang	O
-	O
2	O
and	O
PaO	B-ENZY

Aim	O
of	O
this	O
multicenter	O
retrospective	O
observational	O
study	O
was	O
to	O
evaluate	O
whether	O
poractant	O
alfa	O
use	O
in	O
pediatric	O
ARDS	O
might	O
improve	O
gas	B-ENZY
exchange	O
in	O
children	O
less	O
than	O
2	O
years	O
old	O
,	O
according	O
to	O
a	O
shared	O
protocol	O
.	O

Blood	O
gas	B-ENZY
exchange	O
variations	O
before	O
and	O
after	O
surfactant	O
use	O
were	O
recorded	O
.	O

Data	O
collection	O
consisted	O
of	O
patient	O
demographics	O
,	O
respiratory	O
variables	O
and	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
.	O

The	O
prototype	O
compound	O
of	O
this	O
family	O
is	O
a	O
derivative	O
of	O
pentaerythritol	O
with	O
12	O
peripheral	O
Trp	B-ENZY
groups	O
and	O
trivalent	O
spacer	O
arms	O
.	O

Our	O
findings	O
demonstrate	O
that	O
only	O
compounds	O
with	O
tetravalent	O
branched	O
arms	O
showed	O
the	O
same	O
anti	O
-	O
HIV	O
and	O
anti	O
-	O
EV71	O
activity	O
of	O
the	O
prototype	O
(	O
low	O
micromolar	O
)	O
and	O
even	O
gain	O
significant	O
antiviral	O
activity	O
against	O
new	O
pathogens	O
such	O
as	O
HSV	O
-	O
2	O
,	O
adenovirus	O
-	O
2	O
,	O
human	O
corona	O
virus	O
and	O
respiratory	O
syncytial	O
virus	O
,	O
being	O
the	O
first	O
members	O
of	O
the	O
Trp	B-ENZY
dendrimer	O
family	O
that	O
showed	O
activity	O
against	O
those	O
viruses	O
.	O

These	O
results	O
support	O
the	O
interest	O
of	O
this	O
new	O
series	O
of	O
Trp	B-ENZY
dendrimers	O
and	O
qualify	O
them	O
as	O
useful	O
prototypes	O
for	O
the	O
development	O
of	O
novel	O
inhibitors	O
of	O
viral	O
entry	O
with	O
broad	O
antiviral	O
spectrum	O
.	O

A	O
PCR	O
targeting	O
a	O
fragment	O
of	O
the	O
18S	O
rRNA	O
gene	O
of	O
Hepatozoon	O
spp	B-ENZY
.	O
and	O
DNA	O
sequencing	O
allowed	O
the	O
diagnosis	O
of	O
H	O
.	O
felis	O
-	O
DNA	O
in	O
blood	O
samples	O
.	O

Multiplex	O
polymerase	O
chain	O
reaction	O
assay	O
(	O
multiplex	O
-	O
PCR	O
)	O
can	O
detect	O
dozens	O
of	O
pathogens	O
simultaneously	O
,	O
greatly	O
reducing	O
turnaround	O
time	O
(	O
TAT	B-ENZY
)	O
and	O
improving	O
detection	O
sensitivity	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
identified	O
PEPCK	B-ENZY
-	O
M	O
(	O
encoded	O
by	O
the	O
Pck2	O
gene	O
)	O
to	O
be	O
highly	O
up	O
-	O
regulated	O
in	O
skeletal	O
muscle	O
of	O
pigs	O
treated	O
with	O
Ractopamine	O
,	O
an	O
anabolic	O
beta	O
-	O
adrenergic	O
receptor	O
agonist	O
.	O

To	O
determine	O
whether	O
PEPCK	B-ENZY
-	O
M	O
had	O
a	O
causative	O
role	O
in	O
modulating	O
the	O
skeletal	O
muscle	O
growth	O
response	O
to	O
Ractopamine	O
,	O
we	O
used	O
adeno	O
-	O
associated	O
virus	O
1	O
(	O
AAV1	O
)	O
to	O
over	O
-	O
express	O
Pck2	O
(	O
AAV	O
-	O
Pck2	O
)	O
in	O
murine	O
skeletal	O
muscle	O
.	O

When	O
skeletal	O
muscle	O
growth	O
was	O
induced	O
by	O
daily	O
administration	O
of	O
Clenbuterol	O
(	O
for	O
21	O
days	O
),	O
overexpression	O
of	O
AAV	O
-	O
Pck2	O
had	O
no	O
effect	O
on	O
the	O
growth	O
response	O
,	O
nor	O
did	O
it	O
alter	O
the	O
expression	O
of	O
Phosphoserine	B-ENZY
Aminotransferase	I-ENZY
-	O
1	O
(	O
Psat1	O
)	O
or	O
Asparagine	B-ENZY
Synthetase	I-ENZY
(	O
Asns	O
)	O
mRNA	O
or	O
the	O
Clenbuterol	O
-	O
induced	O
decreases	O
in	O
MyHC	O
IIa	O
and	O
IIx	O
mRNA	O
expression	O
(	O
p	O
=	O
0	O
.	O
0065	O
and	O
p	O
=	O
0	O
.	O
0267	O
respectively	O
).	O

However	O
AAV	O
-	O
Pck2	O
overexpression	O
reduced	O
TA	O
muscle	O
weights	O
(	O
p	O
=	O
0	O
.	O
0434	O
),	O
particularly	O
in	O
the	O
Control	O
(	O
vehicle	O
treated	O
)	O
mice	O
(	O
p	O
=	O
0	O
.	O
059	O
for	O
AAV	O
x	O
Clenbuterol	O
interaction	O
)	O
and	O
increased	O
the	O
expression	O
of	O
Seryl	B-ENZY
-	I-ENZY
tRNA	I-ENZY
Synthetase	I-ENZY
(	O
Sars	O
)	O
mRNA	O
(	O
p	O
=	O
0	O
.	O
0477	O
).	O

ABSTRACT	O
:	O
The	O
identification	O
and	O
analysis	O
of	O
viral	O
etiological	O
agents	O
from	O
suspected	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
cases	O
admitted	O
to	O
Prof	O
.	O
Dr	O
.	O
Sulianti	O
Saroso	O
Infectious	O
Disease	O
Hospital	O
(	O
IDH	B-ENZY
)	O
using	O
molecular	O
assays	O
.	O

Biological	O
samples	O
were	O
collected	O
from	O
13	O
hospitalized	O
patients	O
suspected	O
of	O
MERS	O
-	O
CoV	O
infection	O
in	O
Prof	O
.	O
Dr	O
.	O
Sulianti	O
Saroso	O
IDH	B-ENZY
from	O
July	O
2015	O
to	O
December	O
2016	O
.	O

In	O
the	O
CT	O
the	O
two	O
separate	O
precursors	O
of	O
lymphoid	O
dendritic	O
cells	O
provide	O
some	O
'	O
autonomy	O
'	O
for	O
the	O
GALT	B-ENZY
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
viral	O
and	O
bacterial	O
etiology	O
and	O
epidemiology	O
of	O
patients	O
with	O
acute	O
febrile	O
respiratory	O
syndrome	O
(	O
AFRS	O
)	O
in	O
Qinghai	O
using	O
a	O
commercial	O
routine	O
multiplex	O
-	O
ligation	O
-	O
nucleic	O
acid	O
amplification	O
test	O
(	O
NAT	B-ENZY
)-	O
based	O
assay	O
.	O

Sixty	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
(	O
PaO	B-ENZY
The	O
ICU	O
at	O
Beni	O
-	O
Suef	O
University	O
Hospital	O
.	O

Sixty	O
patients	O
with	O
severe	O
ARDS	O
(	O
PaO	B-ENZY
Nebulized	O
heparin	O
(	O
10	O
,	O
000	O
IU	O
/	O
4	O
h	O
),	O
nebulized	O
streptokinase	O
(	O
250	O
,	O
000	O
IU	O
/	O
4	O
h	O
),	O
and	O
conservative	O
management	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
change	O
in	O
PaO	B-ENZY
Inhaled	O
streptokinase	O
serves	O
as	O
rescue	O
therapy	O
in	O
patients	O
with	O
severe	O
ARDS	O
with	O
improving	O
oxygenation	O
and	O
lung	O
mechanics	O
more	O
quickly	O
than	O
heparin	O
or	O
conventional	O
management	O
.	O

ABSTRACT	O
:	O
A	O
high	O
diversity	O
of	O
corona	O
-	O
and	O
paramyxoviruses	O
have	O
been	O
detected	O
in	O
different	O
bat	B-ENZY
species	O
at	O
study	O
sites	O
worldwide	O
,	O
including	O
Africa	O
,	O
however	O
no	O
biosurveillance	O
studies	O
from	O
Rwanda	O
have	O
been	O
reported	O
.	O

In	O
addition	O
to	O
morphological	O
identification	O
of	O
bat	B-ENZY
species	O
,	O
we	O
also	O
did	O
molecular	O
confirmation	O
of	O
species	O
identities	O
,	O
contributing	O
to	O
the	O
known	O
genetic	O
database	O
available	O
for	O
African	O
bat	B-ENZY
species	O
.	O

To	O
compare	O
the	O
prognosis	O
between	O
the	O
titrated	O
PEEP	O
and	O
low	O
PEEP	O
groups	O
on	O
patients	O
with	O
moderate	O
-	O
severe	O
ARDS	O
(	O
PaO	B-ENZY
No	O
difference	O
was	O
found	O
in	O
28	O
-	O
day	O
mortality	O
and	O
ICU	O
mortality	O
(	O
OR	O
=	O
0	O
.	O
97	O
,	O
95	O
%	O
CI	O
(	O
0	O
.	O
61	O
-	O
1	O
.	O
52	O
),	O
No	O
difference	O
was	O
observed	O
in	O
the	O
RM	O
between	O
the	O
titrated	O
PEEP	O
and	O
the	O
low	O
PEEP	O
in	O
28	O
-	O
day	O
mortality	O
and	O
ICU	O
mortality	O
on	O
patients	O
with	O
moderate	O
-	O
severe	O
ARDS	O
.	O

ELISA	O
and	O
Western	O
blot	O
results	O
revealed	O
that	O
fraxin	O
might	O
inhibit	O
the	O
production	O
of	O
inflammatory	O
factors	O
,	O
namely	O
,	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
	O
,	O
and	O
IL	O
-	O
1	O
,	O
and	O
the	O
activation	O
of	O
NF	O
-	O
B	O
and	O
MAPK	B-ENZY
signaling	O
pathways	O
in	O
the	O
lungs	O
.	O

Outcome	O
measures	O
included	O
blood	O
gas	B-ENZY
criteria	O
and	O
oxygenation	O
state	O
at	O
ARDS	O
onset	O
,	O
mechanical	O
ventilation	O
duration	O
,	O
length	O
of	O
stay	O
in	O
the	O
ICU	O
and	O
in	O
the	O
hospital	O
,	O
ventilation	O
-	O
free	O
time	O
and	O
mortality	O
rate	O
until	O
28	O
days	O
postburn	O
.	O

Further	O
analysis	O
showed	O
that	O
the	O
actin	O
cytoskeleton	O
and	O
MAPK	B-ENZY
signal	O
pathway	O
were	O
related	O
to	O
the	O
target	O
genes	O
of	O
IBV	O
-	O
stimulated	O
miRNAs	O
.	O

TITLE	O
:	O
Staphylococcal	O
phosphatidylinositol	O
-	O
specific	O
phospholipase	B-ENZY
C	I-ENZY
potentiates	O
lung	O
injury	O
via	O
complement	O
sensitisation	O
.	O

ARDS	O
is	O
associated	O
with	O
staphylococcal	O
phosphatidylinositol	O
-	O
specific	O
phospholipase	B-ENZY
C	I-ENZY
(	O
PI	B-ENZY
-	I-ENZY
PLC	I-ENZY
);	O
however	O
,	O
the	O
role	O
of	O
PI	B-ENZY
-	I-ENZY
PLC	I-ENZY
in	O
the	O
pathogenesis	O
and	O
progression	O
of	O
ARDS	O
remains	O
unknown	O
.	O

Here	O
,	O
we	O
showed	O
that	O
recombinant	O
staphylococcal	O
PI	B-ENZY
-	I-ENZY
PLC	I-ENZY
possesses	O
enzyme	O
activity	O
that	O
causes	O
shedding	O
of	O
glycosylphosphatidylinositol	O
-	O
anchored	O
CD55	O
and	O
CD59	O
from	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
surfaces	O
and	O
triggers	O
cell	O
lysis	O
via	O
complement	O
activity	O
.	O

Intranasal	O
infection	O
with	O
PI	B-ENZY
-	I-ENZY
PLC	I-ENZY
-	O
positive	O
S	O
.	O
aureus	O
resulted	O
in	O
greater	O
neutrophil	O
infiltration	O
and	O
increased	O
pulmonary	O
oedema	O
compared	O
with	O
a	O
plc	O
-	O
isogenic	O
mutant	O
.	O

ABSTRACT	O
:	O
The	O
presence	O
of	O
lung	O
injury	O
and	O
the	O
factors	O
that	O
contribute	O
to	O
it	O
in	O
infants	O
with	O
congenital	O
diaphragmatic	O
hernia	O
(	O
CDH	B-ENZY
)	O
have	O
not	O
been	O
objectively	O
measured	O
during	O
their	O
clinical	O
course	O
.	O

We	O
hypothesized	O
that	O
serum	O
SP	O
-	O
D	O
levels	O
would	O
be	O
elevated	O
in	O
CDH	B-ENZY
infants	O
and	O
that	O
the	O
levels	O
would	O
correlate	O
to	O
the	O
amount	O
of	O
lung	O
injury	O
present	O
.	O

In	O
this	O
retrospective	O
cohort	O
study	O
,	O
serum	O
SP	O
-	O
D	O
levels	O
were	O
analyzed	O
in	O
37	O
CDH	B-ENZY
infants	O
and	O
5	O
control	O
infants	O
using	O
a	O
commercially	O
available	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
kit	O
.	O

Infants	O
with	O
more	O
severe	O
CDH	B-ENZY
had	O
a	O
statistically	O
significant	O
increase	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
serum	O
SP	O
-	O
D	O
over	O
their	O
first	O
month	O
of	O
life	O
.	O

SP	O
-	O
D	O
levels	O
in	O
CDH	B-ENZY
infants	O
were	O
similar	O
to	O
control	O
infants	O
while	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
but	O
were	O
2	O
.	O
5	O
-	O
fold	O
higher	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
than	O
controls	O
following	O
ECMO	O
termination	O
.	O

These	O
results	O
demonstrate	O
that	O
CDH	B-ENZY
infants	O
experience	O
lung	O
injury	O
during	O
the	O
first	O
week	O
of	O
life	O
,	O
around	O
the	O
time	O
of	O
surgery	O
,	O
and	O
at	O
the	O
time	O
of	O
ECMO	O
termination	O
.	O

RESULTS	O
:	O
Infants	O
with	O
more	O
severe	O
CDH	B-ENZY
had	O
a	O
statistically	O
significant	O
increase	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
serum	O
SP	O
-	O
D	O
over	O
their	O
first	O
month	O
of	O
life	O
.	O

ABSTRACT	O
:	O
Introducing	O
mathematically	O
derived	O
variability	O
(	O
MVV	O
)	O
into	O
the	O
otherwise	O
monotonous	O
conventional	O
mechanical	O
ventilation	O
has	O
been	O
suggested	O
to	O
improve	O
lung	O
recruitment	O
and	O
gas	B-ENZY
exchange	O
.	O

However	O
,	O
a	O
greater	O
benefit	O
on	O
respiratory	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
could	O
be	O
obtained	O
by	O
elevating	O
PEEP	O
,	O
compared	O
to	O
the	O
ventilation	O
mode	O
in	O
severe	O
ARDS	O
.	O

Serum	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)	O
levels	O
have	O
been	O
studied	O
in	O
non	O
-	O
trauma	O
-	O
related	O
ARDS	O
.	O

The	O
aim	O
of	O
this	O
prospective	O
observational	O
study	O
was	O
to	O
evaluate	O
the	O
role	O
of	O
ACE	B-ENZY
levels	O
as	O
a	O
prognostic	O
marker	O
in	O
thoracic	O
trauma	O
.	O

The	O
mean	O
ACE	B-ENZY
level	O
in	O
the	O
study	O
population	O
was	O
66	O
.	O
54	O
+-	O
11	O
.	O
18	O
.	O

A	O
strong	O
positive	O
correlation	O
was	O
found	O
among	O
serum	O
ACE	B-ENZY
levels	O
and	O
Thoracic	O
Trauma	O
Severity	O
Score	O
(	O
TTSS	O
).	O

Our	O
study	O
demonstrates	O
that	O
serum	O
ACE	B-ENZY
levels	O
are	O
increased	O
in	O
thoracic	O
trauma	O
patients	O
with	O
higher	O
levels	O
,	O
indicating	O
the	O
severe	O
nature	O
of	O
trauma	O
in	O
concordance	O
with	O
increased	O
TTSS	O
scores	O
.	O

RESULTS	O
:	O
The	O
mean	O
ACE	B-ENZY
level	O
in	O
the	O
study	O
population	O
was	O
66	O
.	O
54	O
+-	O
11	O
.	O
18	O
.	O

A	O
strong	O
positive	O
correlation	O
was	O
found	O
among	O
serum	O
ACE	B-ENZY
levels	O
and	O
Thoracic	O
Trauma	O
Severity	O
Score	O
(	O
TTSS	O
).	O

The	O
patients	O
were	O
subgrouped	O
according	O
to	O
whether	O
the	O
PaO	B-ENZY
Eight	O
hundred	O
and	O
thirty	O
-	O
six	O
patients	O
with	O
ARDS	O
were	O
enrolled	O
(	O
345	O
in	O
the	O
high	O
P	O
/	O
F	O
subgroup	O
[>	O
150	O
mmHg	O
]	O
and	O
491	O
in	O
the	O
low	O
P	O
/	O
F	O
subgroup	O
[	O
150	O
mmHg	O
]).	O

In	O
the	O
short	O
-	O
term	O
,	O
colonies	O
under	O
nutritional	O
stress	O
(	O
which	O
consumed	O
mainly	O
E	O
.	O
grandis	O
pollen	O
)	O
showed	O
higher	O
infection	O
level	O
with	O
Nosema	O
spp	B-ENZY
.	O

In	O
conclusion	O
,	O
nutritional	O
stress	O
and	O
Nosema	O
spp	B-ENZY
.	O

Although	O
only	O
11	O
%	O
of	O
total	O
beds	O
were	O
disinfected	O
,	O
the	O
isolation	O
and	O
vancomycin	O
-	O
resistance	O
rates	O
of	O
Enterococcus	O
spp	B-ENZY
significantly	O
decreased	O
for	O
2	O
months	O
,	O
whereas	O
other	O
multidrug	O
-	O
resistant	O
organisms	O
did	O
not	O
.	O

ABSTRACT	O
:	O
Although	O
lung	O
protection	O
with	O
low	O
tidal	O
volume	O
and	O
limited	O
plateau	O
pressure	O
(	O
P	O
This	O
study	O
aimed	O
to	O
compare	O
two	O
strategies	O
using	O
individual	O
PEEP	O
based	O
on	O
a	O
maximum	O
P	O
Nineteen	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	O
(	O
PaO	B-ENZY
There	O
is	O
a	O
great	O
heterogeneity	O
of	O
P	O
RESULTS	O
:	O
Nineteen	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	O
(	O
PaO	B-ENZY

Then	O
the	O
MP	O
and	O
LUS	O
were	O
analyzed	O
by	O
bivariate	O
correlation	O
analysis	O
,	O
and	O
their	O
correlations	O
with	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
),	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
),	O
oxygenation	O
index	O
(	O
PaO	B-ENZY
At	O
the	O
end	O
,	O
83	O
patients	O
were	O
enrolled	O
,	O
with	O
32	O
died	O
and	O
51	O
survived	O
in	O
28	O
-	O
day	O
.	O

The	O
Lac	O
level	O
,	O
APACHE	O
II	O
and	O
SOFA	O
in	O
the	O
death	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
the	O
survival	O
group	O
,	O
while	O
PaO	B-ENZY
There	O
was	O
a	O
significant	O
correlation	O
between	O
MP	O
and	O
LUS	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	O
.	O

The	O
Lac	O
level	O
,	O
APACHE	O
II	O
and	O
SOFA	O
in	O
the	O
death	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
the	O
survival	O
group	O
,	O
while	O
PaO	B-ENZY

At	O
the	O
time	O
when	O
he	O
was	O
transferred	O
to	O
our	O
hospital	O
,	O
his	O
chest	O
computed	O
tomography	O
showed	O
bilateral	O
,	O
diffuse	O
and	O
consolidative	O
shadows	O
all	O
over	O
the	O
lungs	O
,	O
the	O
ratio	O
of	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
to	O
the	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
PaO	B-ENZY

RESULTS	O
Patients	O
with	O
ARDS	O
who	O
had	O
unconsciousness	O
(	O
OR	O
=	O
2	O
.	O
778	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
396	O
-	O
5	O
.	O
528	O
),	O
hypertension	O
(	O
OR	O
=	O
1	O
.	O
771	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
089	O
-	O
2	O
.	O
881	O
),	O
ARDS	O
(	O
moderate	O
-	O
severe	O
)	O
(	O
OR	O
=	O
1	O
.	O
630	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
027	O
-	O
2	O
.	O
588	O
),	O
AST	B-ENZY
(	O
OR	O
=	O
2	O
.	O
093	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
251	O
-	O
3	O
.	O
499	O
),	O
and	O
D	O
-	O
dimer	O
(	O
OR	O
=	O
2	O
.	O
372	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
316	O
-	O
4	O
.	O
275	O
)	O
were	O
more	O
likely	O
to	O
also	O
have	O
AKI	O
.	O

The	O
score	O
was	O
allocated	O
in	O
proportion	O
to	O
the	O
corresponding	O
adjusted	O
OR	O
,	O
hypertension	O
,	O
ARDS	O
(	O
moderate	O
-	O
severe	O
),	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
),	O
D	O
-	O
dimer	O
(	O
2	O
points	O
each	O
),	O
and	O
unconsciousness	O
(	O
3	O
points	O
).	O

The	O
research	O
findings	O
showed	O
that	O
serum	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
-	O
	O
),	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
),	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
diamine	B-ENZY
oxidase	I-ENZY
(	O
DAO	O
),	O
endotoxin	O
,	O
D	O
-	O
lactic	O
acid	O
levels	O
and	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
(	O
APACHE	O
II	O
)	O
and	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
scores	O
of	O
group	O
B	O
were	O
lower	O
than	O
those	O
of	O
group	O
A	O
(	O
all	O
p	O
<	O
0	O
.	O
001	O
)	O
after	O
treatment	O
.	O

It	O
is	O
unclear	O
whether	O
OSA	O
is	O
a	O
risk	O
factor	O
for	O
acute	O
coronary	O
syndrome	O
(	O
ACS	B-ENZY
)	O
and	O
might	O
affect	O
its	O
outcome	O
.	O

On	O
the	O
one	O
hand	O
,	O
OSA	O
in	O
patients	O
with	O
ACS	B-ENZY
may	O
worsen	O
prognosis	O
;	O
on	O
the	O
other	O
hand	O
,	O
OSA	O
-	O
related	O
hypoxaemia	O
could	O
favour	O
the	O
development	O
of	O
coronary	O
collaterals	O
,	O
thereby	O
exerting	O
a	O
protective	O
effect	O
.	O

Fewer	O
data	O
are	O
available	O
in	O
subjects	O
with	O
ACS	B-ENZY
and	O
OSA	O
,	O
and	O
results	O
of	O
randomised	O
controlled	O
studies	O
on	O
the	O
effects	O
of	O
CPAP	O
are	O
expected	O
shortly	O
.	O

The	O
picture	O
is	O
still	O
incomplete	O
,	O
and	O
the	O
potential	O
role	O
of	O
OSA	O
in	O
patients	O
with	O
ACS	B-ENZY
awaits	O
confirmation	O
,	O
as	O
well	O
as	O
clear	O
definition	O
of	O
subgroups	O
with	O
different	O
degrees	O
of	O
risk	O
.	O

TITLE	O
:	O
Rapid	O
breath	O
analysis	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
diagnostics	O
using	O
a	O
portable	O
two	O
-	O
dimensional	O
gas	B-ENZY
chromatography	O
device	O
.	O

A	O
fully	O
automated	O
portable	O
2	O
-	O
dimensional	O
gas	B-ENZY
chromatography	O
device	O
with	O
high	O
peak	O
capacity	O
(>	O
200	O
at	O
the	O
resolution	O
of	O
1	O
),	O
high	O
sensitivity	O
(	O
sub	O
-	O
ppb	O
),	O
and	O
rapid	O
analysis	O
capability	O
(~	O
30	O
min	O
)	O
was	O
designed	O
and	O
made	O
in	O
-	O
house	O
for	O
on	O
-	O
site	O
analysis	O
of	O
patients	O
'	O
breath	O
.	O

The	O
reported	O
isolate	O
was	O
identified	O
by	O
a	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
assay	O
targeting	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
and	O
,	O
further	O
characterized	O
by	O
full	O
-	O
length	O
spike	O
(	O
S1	O
)	O
gene	O
sequencing	O
.	O

In	O
this	O
study	O
,	O
a	O
dual	O
luciferase	B-ENZY
reporter	O
assay	O
was	O
used	O
to	O
confirm	O
the	O
inhibition	O
of	O
NF	O
-	O
B	O
by	O
TGEV	O
infection	O
and	O
to	O
identify	O
the	O
major	O
viral	O
proteins	O
involved	O
in	O
the	O
inhibition	O
of	O
NF	O
-	O
B	O
signaling	O
.	O

In	O
addition	O
,	O
miR	O
-	O
150	O
or	O
si	O
-	O
AKT3	O
effectively	O
inhibited	O
the	O
phosphorylation	O
levels	O
of	O
c	B-ENZY
-	I-ENZY
Jun	I-ENZY
N	I-ENZY
-	I-ENZY
terminal	I-ENZY
kinase	I-ENZY
(	O
JNK	B-ENZY
)	O
and	O
nuclear	O
factor	O
-	O
B	O
(	O
NF	O
-	O
B	O
)	O
(	O
p65	O
and	O
IB	O
).	O

In	O
conclusion	O
,	O
miR	O
-	O
150	O
alleviated	O
LPS	O
-	O
induced	O
acute	O
lung	O
injury	O
via	O
directly	O
targeting	O
AKT3	O
expression	O
or	O
regulating	O
JNK	B-ENZY
and	O
NF	O
-	O
B	O
pathways	O
,	O
which	O
may	O
be	O
a	O
promising	O
therapeutic	O
strategy	O
to	O
treat	O
ALI	O
/	O
ARDS	O
.	O

Furthermore	O
,	O
HY	O
inhibited	O
IBV	O
-	O
induced	O
apoptosis	O
in	O
CEK	O
cells	O
,	O
and	O
significantly	O
reduced	O
the	O
mRNA	O
expression	O
levels	O
of	O
Fas	O
,	O
FasL	O
,	O
JNK	B-ENZY
,	O
Bax	O
,	O
Caspase	O
3	O
,	O
and	O
Caspase	O
8	O
,	O
and	O
significantly	O
increased	O
Bcl	O
-	O
2	O
mRNA	O
expression	O
level	O
in	O
CEK	O
cells	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
show	O
that	O
the	O
incorporation	O
of	O
the	O
Rho	O
-	O
associated	O
protein	B-ENZY
kinase	I-ENZY
(	O
ROCK	O
)	O
inhibitor	O
(	O
Y	O
-	O
27632	O
)	O
during	O
cell	O
propagation	O
extends	O
the	O
life	O
span	O
of	O
primary	O
human	O
cells	O
in	O
vitro	O
and	O
thereby	O
facilitates	O
the	O
incorporation	O
of	O
lentivirus	O
-	O
based	O
expression	O
systems	O
.	O

TITLE	O
:	O
Detection	O
and	O
characterization	O
of	O
a	O
novel	O
bat	B-ENZY
-	O
borne	O
coronavirus	O
in	O
Singapore	O
using	O
multiple	O
molecular	O
approaches	O
.	O

Screening	O
of	O
guano	O
samples	O
collected	O
during	O
the	O
survey	O
uncovered	O
a	O
bat	B-ENZY
coronavirus	O
(	O

ABSTRACT	O
:	O
Swine	O
enteric	O
alphacoronavirus	O
(	O
SeACoV	O
),	O
also	O
known	O
as	O
swine	O
acute	O
diarrhea	O
syndrome	O
coronavirus	O
(	O
SADS	O
-	O
CoV	O
),	O
belongs	O
to	O
the	O
species	O
Rhinolophus	O
bat	B-ENZY
coronavirus	O
HKU2	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
-	O
Encoded	O
Accessory	O
Proteins	O
Impair	O
MDA5	O
-	O
and	O
TBK1	B-ENZY
-	O
Mediated	O
Activation	O
of	O
NF	O
-	O
B	O
.	O
ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
newly	O
emerging	O
coronavirus	O
which	O
is	O
zoonotic	O
from	O
bats	O
and	O
camels	O
.	O

TITLE	O
:	O
Chromenone	O
derivatives	O
as	O
a	O
versatile	O
scaffold	O
with	O
dual	O
mode	O
of	O
inhibition	O
of	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
associated	O
Ribonuclease	B-ENZY
H	I-ENZY
function	O
and	O
integrase	O
activity	O
.	O

Coumarin	O
-	O
based	O
molecules	O
already	O
proved	O
to	O
act	O
as	O
HIV	O
-	O
1	O
Protease	O
(	O
PR	O
)	O
or	O
Integrase	O
(	O
IN	O
)	O
inhibitors	O
and	O
also	O
to	O
target	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
),	O
blocking	O
the	O
DNA	O
-	O
dependent	O
DNA	O
-	O
polymerase	O
activity	O
or	O
the	O
RNA	O
-	O
dependent	O
DNA	O
-	O
polymerase	O
activity	O
working	O
as	O
common	O
NNRTIs	O
.	O

The	O
modeling	O
studies	O
calculated	O
the	O
theoretical	O
binding	O
affinity	O
of	O
the	O
synthesized	O
compounds	O
on	O
both	O
HIV	O
-	O
1	O
IN	O
and	O
RT	O
-	O
associated	O
Ribonuclease	B-ENZY
H	I-ENZY
(	O
RNase	B-ENZY
H	I-ENZY
)	O
active	O
sites	O
,	O
which	O
was	O
confirmed	O
by	O
biological	O
assays	O
.	O

Because	O
of	O
their	O
origin	O
in	O
the	O
bat	B-ENZY
enteric	O
system	O
,	O
we	O
wondered	O
if	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
or	O
Middle	O
East	O
respiratory	O
syndrome	O
CoV	O
(	O
MERS	O
-	O
CoV	O
)	O
also	O
use	O
bacterial	O
components	O
to	O
modulate	O
infectivity	O
.	O

Older	O
age	O
,	O
oxygen	O
saturation	O
level	O
of	O
<	O
90	O
%	O
at	O
admission	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
pneumorrhagia	O
,	O
influenza	O
-	O
associated	O
encephalopathy	O
(	O
IEA	O
),	O
septic	O
shock	O
,	O
low	O
ratio	O
of	O
partial	O
pressure	O
of	O
oxygen	O
in	O
arterial	O
blood	O
(	O
PaO2	O
,	O
<	O
60	O
mm	O
Hg	O
)	O
to	O
the	O
fraction	O
concentration	O
of	O
oxygen	O
in	O
inspired	O
air	O
(	O
FiO2	O
;	O
P	O
/	O
F	O
),	O
higher	O
oxygenation	O
index	O
,	O
increased	O
alanine	B-ENZY
aminotransferase	I-ENZY
level	O
(>	O
100	O
IU	O
/	O
L	O
),	O
increased	O
aspartate	B-ENZY
aminotransferase	I-ENZY
level	O
(>	O
100	O
IU	O
/	O
L	O
),	O
increased	O
lactate	O
dehydrogenase	O
level	O
(>	O
500	O
IU	O
/	O
L	O
),	O
high	O
fraction	O
concentration	O
of	O
oxygen	O
in	O
inspired	O
air	O
(	O
FiO2	O
>	O
60	O
%),	O
and	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(>	O
8	O
cmH2O	O
)	O
were	O
associated	O
with	O
poor	O
outcome	O
.	O

TITLE	O
:	O
Identification	O
of	O
Diverse	O
Bat	B-ENZY
Alphacoronaviruses	O
and	O
Betacoronaviruses	O
in	O
China	O
Provides	O
New	O
Insights	O
Into	O
the	O
Evolution	O
and	O
Origin	O
of	O
Coronavirus	O
-	O
Related	O
Diseases	O
.	O

Neuraminidase	B-ENZY
inhibitors	O
are	O
currently	O
the	O
treatment	O
of	O
choice	O
for	O
IV	O
infections	O
.	O

ABSTRACT	O
:	O
Our	O
pilot	O
study	O
suggested	O
that	O
noninvasive	O
ventilation	O
(	O
NIV	O
)	O
reduced	O
the	O
need	O
for	O
intubation	O
compared	O
with	O
conventional	O
administration	O
of	O
oxygen	O
on	O
patients	O
with	O
""""	O
early	O
""""	O
stage	O
of	O
mild	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
,	O
PaO	B-ENZY
To	O
evaluate	O
whether	O
early	O
NIV	O
can	O
reduce	O
the	O
need	O
for	O
invasive	O
ventilation	O
in	O
patients	O
with	O
pneumonia	O
-	O
induced	O
early	O
mild	O
ARDS	O
.	O

In	O
the	O
NIV	O
group	O
,	O
PaO	B-ENZY
Treatment	O
with	O
NIV	O
did	O
not	O
reduce	O
the	O
need	O
for	O
intubation	O
among	O
patients	O
with	O
pneumonia	O
-	O
induced	O
early	O
mild	O
ARDS	O
,	O
despite	O
the	O
improved	O
PaO	B-ENZY
NCT01581229	O
.	O

In	O
the	O
NIV	O
group	O
,	O
PaO	B-ENZY

Notably	O
,	O
the	O
features	O
of	O
bat	B-ENZY
MHC	O
I	O
may	O
be	O
shared	O
by	O
MHC	O
I	O
from	O
various	O
marsupials	O
.	O

Acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
)	O
is	O
a	O
serious	O
complication	O
of	O
SCD	O
and	O
an	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
.	O

We	O
present	O
herein	O
the	O
case	O
of	O
a	O
young	O
female	O
adult	O
(	O
19	O
y	O
.	O
o	O
.)	O
with	O
SCD	O
who	O
developed	O
severe	O
respiratory	O
failure	O
due	O
to	O
ACS	B-ENZY
occurring	O
twice	O
within	O
15	O
months	O
and	O
treated	O
by	O
VV	O
-	O
ECMO	O
.	O

We	O
describe	O
the	O
management	O
of	O
ACS	B-ENZY
with	O
VV	O
-	O
ECMO	O
using	O
two	O
different	O
approaches	O
,	O
namely	O
with	O
and	O
without	O
mechanical	O
ventilation	O
.	O

This	O
review	O
aimed	O
to	O
provide	O
a	O
clear	O
knowledge	O
on	O
the	O
recent	O
development	O
of	O
indoles	O
as	O
anti	O
-	O
cancer	O
agents	O
,	O
such	O
as	O
myeloid	O
cell	O
leukemia	O
-	O
1	O
(	O
Mcl	O
-	O
1	O
)	O
inhibitors	O
,	O
proviral	O
insertion	O
site	O
in	O
moloney	O
murine	O
leukemia	O
virus	O
(	O
Pim	O
)	O
inhibitors	O
,	O
histone	B-ENZY
deacetylase	I-ENZY
(	O
HDAC	B-ENZY
)	O
inhibitors	O
,	O
silent	O
mating	O
type	O
information	O
regulation	O
2	O
homolog	O
(	O
SIRT	O
)	O
inhibitors	O
and	O
tubulin	O
inhibitors	O
,	O
and	O
made	O
an	O
insight	O
into	O
the	O
corresponding	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
).	O

ABSTRACT	O
:	O
In	O
a	O
multicenter	O
cohort	O
study	O
including	O
22	O
oseltamivir	O
-	O
treated	O
patients	O
with	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
prevalence	O
of	O
the	O
H275Y	O
substitution	O
in	O
the	O
neuraminidase	B-ENZY
,	O
responsible	O
for	O
highly	O
reduced	O
sensitivity	O
to	O
oseltamivir	O
,	O
was	O
23	O
%.	O

We	O
hypothesized	O
that	O
VT	O
could	O
be	O
reduced	O
down	O
to	O
4	O
ml	O
/	O
kg	O
,	O
with	O
clinically	O
significant	O
decrease	O
in	O
driving	O
pressure	O
,	O
without	O
the	O
need	O
for	O
extracorporeal	O
CO	O
We	O
conducted	O
a	O
non	O
-	O
experimental	O
before	O
-	O
and	O
-	O
after	O
multicenter	O
study	O
on	O
35	O
ARDS	O
patients	O
with	O
PaO	B-ENZY
From	O
inclusion	O
to	O
day	O
2	O
,	O
driving	O
pressure	O
decreased	O
significantly	O
from	O
12	O
[	O
9	O
-	O
15	O
]	O
to	O
8	O
[	O
6	O
-	O
11	O
]	O
cmH	O
Ultra	O
-	O
low	O
tidal	O
volume	O
ventilation	O
may	O
be	O
applied	O
in	O
approximately	O
2	O
/	O
3	O
of	O
moderately	O
severe	O
-	O
to	O
-	O
severe	O
ARDS	O
patients	O
,	O
with	O
a	O
4	O
cmH	O
RESULTS	O
:	O
From	O
inclusion	O
to	O
day	O
2	O
,	O
driving	O
pressure	O
decreased	O
significantly	O
from	O
12	O
[	O
9	O
-	O
15	O
]	O
to	O
8	O
[	O
6	O
-	O
11	O
]	O
cmH	O
CONCLUSIONS	O
:	O
Ultra	O
-	O
low	O
tidal	O
volume	O
ventilation	O
may	O
be	O
applied	O
in	O
approximately	O
2	O
/	O
3	O
of	O
moderately	O
severe	O
-	O
to	O
-	O
severe	O
ARDS	O
patients	O
,	O
with	O
a	O
4	O
cmH	O

TITLE	O
:	O
Ribonuclease	B-ENZY
H	I-ENZY
,	O
an	O
unexploited	O
target	O
for	O
antiviral	O
intervention	O
against	O
HIV	O
and	O
hepatitis	O
B	O
virus	O
.	O

During	O
reverse	O
transcription	O
,	O
the	O
RNase	B-ENZY
H	I-ENZY
activity	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
and	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
degrades	O
the	O
viral	O
genomic	O
RNA	O
to	O
facilitate	O
the	O
synthesis	O
of	O
viral	O
double	O
-	O
stranded	O
DNA	O
.	O

HIV	O
and	O
HBV	O
reverse	O
transcriptases	O
contain	O
DNA	O
polymerase	O
and	O
RNase	B-ENZY
H	I-ENZY
domains	O
that	O
act	O
in	O
a	O
coordinated	O
manner	O
to	O
produce	O
double	O
-	O
stranded	O
viral	O
DNA	O
.	O

Among	O
them	O
,	O
	O
-	O
hydroxytropolones	O
,	O
N	O
-	O
hydroxyisoquinolinediones	O
and	O
N	O
-	O
hydroxypyridinediones	O
represent	O
chemotypes	O
active	O
against	O
both	O
HIV	O
and	O
HBV	O
RNases	O
H	O
.	O
In	O
this	O
review	O
we	O
summarize	O
recent	O
developments	O
in	O
the	O
field	O
including	O
the	O
identification	O
of	O
novel	O
RNase	B-ENZY
H	I-ENZY
inhibitors	O
,	O
compounds	O
with	O
dual	O
inhibitory	O
activity	O
,	O
broad	O
specificity	O
and	O
efforts	O
to	O
decrease	O
their	O
toxicity	O
.	O

TITLE	O
:	O
Broad	O
Cross	O
-	O
Species	O
Infection	O
of	O
Cultured	O
Cells	O
by	O
Bat	B-ENZY
HKU2	O
-	O
Related	O
Swine	O
Acute	O
Diarrhea	O
Syndrome	O
Coronavirus	O
and	O
Identification	O
of	O
Its	O
Replication	O
in	O
Murine	O
Dendritic	O
Cells	O
ABSTRACT	O
:	O
Outbreaks	O
of	O
severe	O
diarrhea	O
in	O
neonatal	O
piglets	O
in	O
Guangdong	O
,	O
China	O
,	O
in	O
2017	O
resulted	O
in	O
the	O
isolation	O
and	O
discovery	O
of	O
a	O
novel	O
swine	O
enteric	O
alphacoronavirus	O
(	O
SeACoV	O
)	O
derived	O
from	O
the	O
species	O

Of	O
289	O
feline	O
faecal	O
samples	O
reviewed	O
,	O
Salmonella	O
spp	B-ENZY
.	O

(	O
47	O
.	O
6	O
%),	O
Clostridium	O
perfringens	O
(	O
81	O
.	O
3	O
%),	O
Giardia	O
spp	B-ENZY
.	O

In	O
dogs	O
,	O
Salmonella	O
spp	B-ENZY
.	O

(	O
36	O
.	O
3	O
%),	O
C	O
.	O
perfringens	O
(	O
85	O
.	O
4	O
%),	O
Giardia	O
spp	B-ENZY
.	O

It	O
was	O
possible	O
to	O
conclude	O
that	O
the	O
prevalence	O
of	O
Coronavirus	O
,	O
Rotavirus	O
,	O
Cryptosporidium	O
spp	B-ENZY
.,	O
Eimeria	O
spp	B-ENZY
.,	O
and	O
nematodes	O
was	O
7	O
.	O
20	O
%	O
(	O
95	O
%	O
CI	O
4	O
.	O
54	O
-	O
9	O
.	O
78	O
),	O
6	O
.	O
37	O
%	O
(	O
95	O
%	O
CI	O
3	O
.	O
85	O
-	O
8	O
.	O
89	O
),	O
51	O
.	O
52	O
%	O
(	O
95	O
%	O
CI	O
45	O
.	O
26	O
-	O
55	O
.	O
57	O
),	O
3	O
.	O
46	O
%	O
(	O
95	O
%	O
CI	O
2	O
.	O
24	O
-	O
4	O
.	O
67	O
),	O
and	O
3	O
.	O
46	O
%	O
(	O
95	O
%	O
CI	O
2	O
.	O
24	O
-	O
4	O
.	O
67	O
),	O
respectively	O
.	O

Calves	O
that	O
drink	O
water	O
from	O
rivers	O
,	O
streams	O
,	O
and	O
ponds	O
had	O
a	O
higher	O
chance	O
of	O
being	O
infected	O
by	O
Eimeria	O
spp	B-ENZY
.	O

Hexokinase	B-ENZY
2	O
(	O
HK2	B-ENZY
)	O
and	O
interleukin	O
6	O
(	O
IL	O
-	O
6	O
)	O
were	O
identified	O
as	O
the	O
targets	O
of	O
miR	O
-	O
22	O
.	O

Silencing	O
HK2	B-ENZY
enhanced	O
TGEV	O
-	O
induced	O
mPTP	O
opening	O
,	O
while	O
no	O
effect	O
on	O
NF	O
-	O
B	O
pathway	O
.	O

The	O
data	O
revealed	O
that	O
TGEV	O
-	O
induced	O
mPTP	O
opening	O
was	O
regulated	O
via	O
two	O
pathways	O
:	O
circEZH2	O
/	O
miR	O
-	O
22	O
/	O
HK2	B-ENZY
axis	O
and	O
circEZH2	O
/	O
miR	O
-	O
22	O
/	O
IL	O
-	O
6	O
/	O
NF	O
-	O
B	O
axis	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
Group	O
A	O
streptococcal	O
infection	O
-	O
induced	O
toxic	O
shock	O
syndrome	O
(	O
GAS	B-ENZY
-	O
TSS	O
)	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
successfully	O
treated	O
with	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
V	O
-	O
A	O
ECMO	O
).	O

V	O
-	O
A	O
ECMO	O
should	O
be	O
considered	O
as	O
an	O
effective	O
therapeutic	O
option	O
against	O
ARDS	O
and	O
circulation	O
failure	O
in	O
GAS	B-ENZY
-	O
TSS	O
during	O
pregnancy	O
.	O

TITLE	O
:	O
Generation	O
of	O
a	O
Nebulizable	O
CDR	B-ENZY
-	O
Modified	O
MERS	O
-	O
CoV	O
Neutralizing	O
Human	O
Antibody	O
.	O

Here	O
we	O
demonstrate	O
the	O
interaction	O
between	O
the	O
N	O
protein	O
of	O
HCoV	O
-	O
229E	O
and	O
cyclophilin	B-ENZY
A	O
,	O
not	O
cyclophilin	B-ENZY
B	O
.	O
Cyclophilin	B-ENZY
inhibitors	O
abolish	O
this	O
interaction	O
.	O

Upon	O
infection	O
,	O
cyclophilin	B-ENZY
A	O
stays	O
evenly	O
distributed	O
throughout	O
the	O
cell	O
,	O
whereas	O
cyclophilin	B-ENZY
B	O
concentrates	O
at	O
ER	O
-	O
bleb	O
-	O
like	O
structures	O
.	O

We	O
further	O
show	O
the	O
inhibitory	O
potential	O
of	O
non	O
-	O
immunosuppressive	O
CsA	O
derivatives	O
Alisporivir	O
,	O
NIM811	O
,	O
compound	O
3	O
on	O
HCoV	O
-	O
229E	O
-	O
GFP	O
and	O
-	O
Luciferase	B-ENZY
replication	O
in	O
human	O
Huh	O
-	O
7	O
.	O
5	O
hepatoma	O
cells	O
at	O
18	O
and	O
48	O
h	O
time	O
points	O
post	O
infection	O
with	O
EC	O

Out	O
of	O
45	O
necropscid	O
calves	O
,	O
three	O
(	O
6	O
.	O
66	O
%)	O
cases	O
were	O
positive	O
for	O
BRoV	O
and	O
four	O
(	O
8	O
.	O
88	O
%)	O
cases	O
were	O
found	O
positive	O
for	O
BCoV	O
,	O
screened	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Engagement	O
of	O
the	O
opiate	O
receptors	O
generates	O
a	O
series	O
of	O
intracellular	O
signals	O
,	O
including	O
inhibition	O
of	O
adenylate	B-ENZY
cyclase	I-ENZY
,	O
decreased	O
opening	O
of	O
calcium	O
channels	O
,	O
increased	O
potassium	O
currents	O
and	O
activation	O
of	O
protein	B-ENZY
kinase	I-ENZY
C	I-ENZY
(	O
PKC	B-ENZY
).	O

Like	O
the	O
natural	O
penicillins	O
,	O
aminopenicillins	O
have	O
a	O
thiazolidine	O
ring	O
structure	O
connected	O
to	O
a	O
beta	O
-	O
lactam	O
ring	O
which	O
makes	O
these	O
agents	O
susceptible	O
to	O
inactivation	O
by	O
beta	B-ENZY
-	I-ENZY
lactamase	I-ENZY
,	O
the	O
usual	O
cause	O
of	O
bacterial	O
resistance	O
to	O
the	O
penicillins	O
.	O

They	O
have	O
activity	O
against	O
Escherichia	O
coli	O
,	O
Hemophilis	O
influenzae	O
,	O
Listeria	O
monocytogenesis	O
,	O
Neisseria	O
gonorrhoeae	O
,	O
Proteus	O
mirabilis	O
,	O
Salmonella	O
,	O
Shigella	O
,	O
Staphylococcus	O
aureus	O
(	O
non	O
-	O
penicillinase	B-ENZY
producing	O
),	O
Staphyloccocus	O
epidermidis	O
,	O
and	O
Streptococcus	O
pneumoniae	O
.	O

Ampicillin	O
is	O
also	O
used	O
as	O
a	O
combination	O
antibiotic	O
with	O
sulbactam	O
(	O
sul	O
bak	O
'	O
tam	O
)	O
sodium	O
which	O
provides	O
coverage	O
against	O
penicillinase	B-ENZY
-	O
resistant	O
bacteria	O
.	O

CoV	O
genomes	O
regularly	O
undergo	O
recombination	O
during	O
infection	O
as	O
observed	O
in	O
bat	B-ENZY
SARS	O
-	O
related	O
CoVs	O
.	O

In	O
contrast	O
,	O
many	O
of	O
them	O
contain	O
antibodies	O
against	O
bat	B-ENZY
HKU8	O
-	O
related	O
(	O
HKU8r	O
)-	O
CoVs	O
.	O

Furthermore	O
,	O
we	O
found	O
bat	B-ENZY
HKU8r	O
-	O
CoV	O
NP	O
antibody	O
in	O
73	O
(	O
12	O
.	O
5	O
%)	O
of	O
the	O
MERS	O
-	O
CoV	O
RBD	O
positive	O
and	O
NP	O
negative	O
samples	O
,	O
yet	O
found	O
only	O
3	O
(	O
0	O
.	O
43	O
%)	O
of	O
the	O
HKU8r	O
-	O
CoV	O
S1	O
antibody	O
in	O
the	O
same	O
samples	O
.	O

Reported	O
are	O
the	O
X	O
-	O
ray	O
crystal	O
structures	O
of	O
Class	O
III	O
-	O
V	O
RBDs	O
in	O
complex	O
with	O
human	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
hAPN	O
),	O
as	O
well	O
as	O
the	O
electron	O
cryomicroscopy	O
structure	O
of	O
the	O
229E	O
S	O
-	O
protein	O
.	O

ABSTRACT	O
:	O
Some	O
coronaviruses	O
(	O
CoVs	O
)	O
have	O
an	O
extra	O
furin	B-ENZY
cleavage	O
site	O
(	O
RRKR	O
/	O
S	O
,	O
furin	B-ENZY
-	O
S2	O
'	O
site	O
)	O
upstream	O
of	O
the	O
fusion	O
peptide	O
in	O
the	O
spike	O
protein	O
,	O
which	O
plays	O
roles	O
in	O
virion	O
adsorption	O
and	O
fusion	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
evidence	O
suggesting	O
that	O
recombinant	O
IBV	O
with	O
a	O
mutant	O
S2	O
'	O
site	O
(	O
furin	B-ENZY
-	O
S2	O
'	O
site	O
)	O
leads	O
to	O
higher	O
mortality	O
.	O

TITLE	O
:	O
Protostemonine	O
alleviates	O
heat	O
-	O
killed	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
-	O
induced	O
acute	O
lung	O
injury	O
through	O
MAPK	B-ENZY
and	O
NF	O
-	O
B	O
signaling	O
pathways	O
.	O

Furthermore	O
,	O
treatment	O
with	O
PSN	O
suppressed	O
the	O
activation	O
of	O
MAPKs	O
(	O
e	O
.	O
g	O
.	O
p38	O
MAPK	B-ENZY
,	O
JNK	B-ENZY
and	O
ERK	B-ENZY
)	O
and	O
NF	O
-	O
B	O
.	O
Collectively	O
,	O
our	O
results	O
suggest	O
that	O
PSN	O
ameliorates	O
gram	O
-	O
positive	O
bacteria	O
-	O
induced	O
ALI	O
in	O
mice	O
by	O
inhibition	O
of	O
the	O
MAPK	B-ENZY
and	O
NF	O
-	O
B	O
signaling	O
pathways	O
,	O
and	O
our	O
studies	O
suggest	O
that	O
PSN	O
might	O
be	O
a	O
novel	O
candidate	O
for	O
treating	O
ALI	O
/	O
ARDS	O
.	O

Many	O
differentially	O
expressed	O
lncRNAs	O
act	O
as	O
elements	O
to	O
competitively	O
attach	O
microRNAs	O
(	O
miRNAs	O
)	O
which	O
target	O
to	O
messenger	O
RNA	O
(	O
mRNAs	O
)	O
to	O
mediate	O
expression	O
of	O
genes	O
that	O
related	O
to	O
toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
),	O
NOD	B-ENZY
-	O
like	O
receptors	O
(	O
NLRs	O
),	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
),	O
and	O
RIG	O
-	O
I	O
-	O
like	O
receptors	O
(	O
RLRs	O
)	O
pathways	O
.	O

To	O
combine	O
the	O
safety	O
and	O
efficacy	O
advantages	O
of	O
inactivated	O
and	O
attenuated	O
PEDV	O
vaccines	O
,	O
respectively	O
,	O
in	O
this	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
subjecting	O
PEDV	O
virions	O
to	O
heat	O
treatment	O
at	O
44	O
	O
C	O
for	O
10	O
min	O
to	O
reversibly	O
unfold	O
structural	O
proteins	O
,	O
followed	O
by	O
exposure	O
to	O
RNAse	B-ENZY
to	O
fragment	O
the	O
genome	O
,	O
would	O
result	O
in	O
a	O
vaccine	O
preparation	O
with	O
intact	O
viral	O
structure	O
/	O
antigenicity	O
but	O
highly	O
diminished	O
replicative	O
abilities	O
.	O

Following	O
the	O
heat	O
and	O
RNAse	B-ENZY
treatment	O
,	O
PEDV	O
virions	O
had	O
an	O
intact	O
electron	O
microscopic	O
ultrastructure	O
and	O
were	O
amplified	O
only	O
in	O
the	O
3rd	O
passage	O
in	O
Vero	O
cells	O
,	O
indicating	O
that	O
diminished	O
replication	O
was	O
achieved	O

Active	O
malignancy	O
,	O
male	O
gender	O
,	O
PaO	B-ENZY

Here	O
,	O
we	O
verified	O
the	O
replication	O
ability	O
and	O
pathogenicity	O
of	O
a	O
reporter	O
HCoV	O
-	O
OC43	O
strain	O
expressing	O
Renilla	O
luciferase	B-ENZY
(	O
Rluc	O
;	O
rOC43	O
-	O
ns2DelRluc	O
)	O
in	O
mice	O
with	O
different	O
genetic	O
backgrounds	O
(	O
C57BL	O
/	O
6	O
and	O
BALB	O
/	O
c	O
).	O

In	O
this	O
article	O
,	O
we	O
present	O
a	O
case	O
of	O
Cryptosporodiosis	O
with	O
hepatobiliary	O
system	O
involvement	O
who	O
were	O
admitted	O
to	O
the	O
pediatric	O
emergency	O
clinic	O
with	O
the	O
complaints	O
of	O
severe	O
diarrhea	O
and	O
Cryptosporidium	O
spp	B-ENZY
.	O

We	O
would	O
like	O
to	O
emphasize	O
that	O
Cryptosporodium	O
spp	B-ENZY
.	O
may	O
be	O
the	O
cause	O
of	O
severe	O
acute	O
diarrhea	O
in	O
non	O
-	O
immunocompromised	O
patients	O
and	O
may	O
also	O
involve	O
hepatobiliary	O
system	O
involvement	O
.	O

Arterial	O
blood	O
gas	B-ENZY
analysis	O
revealed	O
severe	O
hypoxemia	O
with	O
respiratory	O
and	O
metabolic	O
alkalosis	O
.	O

TITLE	O
:	O
Decoupling	O
deISGylating	O
and	O
deubiquitinating	O
activities	O
of	O
the	O
MERS	O
virus	O
papain	B-ENZY
-	O
like	O
protease	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
papain	B-ENZY
-	O
like	O
proteases	O
(	O
PLPs	O
or	O
PLpro	O
),	O
such	O
as	O
the	O
one	O
encoded	O
in	O
the	O
genome	O
of	O
the	O
infectious	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
)	O
virus	O
,	O
have	O
multiple	O
enzymatic	O
activities	O
that	O
promote	O
viral	O
infection	O
.	O

TITLE	O
:	O
Molecular	O
Basis	O
of	O
Binding	O
between	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
and	O
CD26	O
from	O
Seven	O
Bat	B-ENZY
Species	O
.	O

Further	O
structural	O
analysis	O
indicated	O
that	O
in	O
the	O
bat	B-ENZY
receptor	O
,	O
compared	O
to	O
the	O
human	O
receptor	O
,	O
substitutions	O
of	O
key	O
residues	O
and	O
their	O
adjacent	O
amino	O
acids	O
leads	O
to	O
decreased	O
binding	O
affinity	O
to	O
the	O
MERS	O
-	O
RBD	O
.	O

We	O
retrospectively	O
reviewed	O
data	O
from	O
60	O
children	O
(	O
median	O
age	O
of	O
6	O
.	O
2	O
months	O
,	O
range	O
0	O
.	O
6	O
-	O
70	O
.	O
9	O
)	O
hospitalized	O
for	O
acute	O
respiratory	O
symptoms	O
,	O
with	O
HBoV	O
detected	O
from	O
a	O
respiratory	O
sample	O
,	O
using	O
a	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
for	O
14	O
respiratory	O
viruses	O
(	O
including	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
influenza	O
virus	O
A	O
and	O
B	O
,	O
human	O
coronavirus	O
OC43	O
,	O
229E	O
,	O
NL	O
-	O
63	O
and	O
HUK1	O
,	O
adenovirus	O
,	O
rhinovirus	O
,	O
parainfluenza	O
virus1	O
-	O
3	O
,	O
and	O
human	O
metapneumovirus	O
).	O

TITLE	O
:	O
Trypsin	B-ENZY
Treatment	O
Unlocks	O
Barrier	O
for	O
Zoonotic	O
Bat	B-ENZY
Coronavirus	O
Infection	O
.	O

We	O
found	O
that	O
the	O
spike	O
protein	O
of	O
PDF2180	O
-	O
CoV	O
,	O
a	O
MERS	O
-	O
like	O
virus	O
found	O
in	O
a	O
Ugandan	O
bat	B-ENZY
,	O
could	O
mediate	O
infection	O
of	O
Vero	O
and	O
human	O
cells	O
in	O
the	O
presence	O
of	O
exogenous	O
trypsin	B-ENZY
.	O

We	O
subsequently	O
show	O
that	O
the	O
bat	B-ENZY
virus	O
spike	O
can	O
mediate	O
the	O
infection	O
of	O
human	O
gut	O
cells	O
but	O
is	O
unable	O
to	O
infect	O
human	O
lung	O
cells	O
.	O

Coupled	O
with	O
receptor	O
binding	O
,	O
proteolytic	O
activation	O
offers	O
a	O
new	O
parameter	O
to	O
evaluate	O
the	O
emergence	O
potential	O
of	O
bat	B-ENZY
CoVs	O
and	O
offers	O
a	O
means	O
to	O
recover	O
previously	O
unrecoverable	O
zoonotic	O
CoV	O
strains	O
.	O

Known	O
coronaviruses	O
detected	O
included	O
the	O
betacorona	O
viruses	O
:	O
Kenya	O
bat	B-ENZY
coronaviruses	O
,	O
Eidolon	O
bat	B-ENZY
coronavirus	O
,	O
and	O
Bat	B-ENZY
coronavirus	O
HKU9	O
,	O
as	O
well	O
as	O
an	O
alphacoronavirus	O
,	O
Chaerephon	O
Bat	B-ENZY
coronavirus	O
.	O

ABSTRACT	O
:	O
Choking	O
agent	O
exposure	O
,	O
among	O
them	O
chlorine	O
gas	B-ENZY
,	O
occurs	O
in	O
household	O
or	O
industrial	O
accidents	O
,	O
chemical	O
warfare	O
and	O
terrorist	O
attacks	O
.	O

Chlorine	O
gas	B-ENZY
has	O
a	O
medium	O
solubility	O
,	O
also	O
causing	O
delayed	O
lower	O
airway	O
symptoms	O
,	O
mainly	O
due	O
to	O
its	O
oxidizing	O
potential	O
by	O
releasing	O
hypochlorous	O
and	O
hydrochloric	O
acid	O
,	O
but	O
also	O
by	O
interacting	O
with	O
Transient	O
Receptor	O
Potential	O
channels	O
.	O

Sodium	O
bicarbonate	O
inhalation	O
after	O
chlorine	O
gas	B-ENZY
inhalation	O
is	O
discussed	O
controversially	O
.	O

Moreover	O
,	O
compound	O
5	O
also	O
inhibited	O
HIV	O
-	O
1	O
RNase	B-ENZY
H	I-ENZY
function	O
,	O
classifying	O
this	O
molecule	O
as	O
a	O
dual	O
HIV	O
-	O
1	O
IN	O
and	O
RNase	B-ENZY
H	I-ENZY
inhibitor	O
able	O
to	O
impair	O
the	O
HIV	O
-	O
1	O
virus	O
replication	O
in	O
cell	O
culture	O
.	O

TITLE	O
:	O
Discovery	O
of	O
novel	O
1	O
,	O
2	O
,	O
3	O
-	O
triazole	O
oseltamivir	O
derivatives	O
as	O
potent	O
influenza	O
neuraminidase	B-ENZY
inhibitors	O
targeting	O
the	O
430	O
-	O
cavity	O
.	O

ABSTRACT	O
:	O
Bats	O
are	O
known	O
reservoirs	O
of	O
a	O
wide	O
variety	O
of	O
viruses	O
that	O
rarely	O
result	O
in	O
overt	O
clinical	O
disease	O
in	O
the	O
bat	B-ENZY
host	O
.	O

The	O
cumulative	O
result	O
is	O
a	O
disturbance	O
of	O
bat	B-ENZY
-	O
pathogen	O
dynamics	O
,	O
which	O
facilitate	O
spillover	O
events	O
to	O
sympatric	O
species	O
,	O
and	O
may	O
threaten	O
bat	B-ENZY
communities	O
already	O
facing	O
synergistic	O
stressors	O
through	O
ecological	O
change	O
.	O

Phylogenetic	O
analysis	O
indicated	O
complex	O
ecological	O
interactions	O
including	O
virus	O
-	O
host	O
associations	O
,	O
cross	O
-	O
species	O
infections	O
,	O
and	O
multiple	O
viral	O
strains	O
circulating	O
concurrently	O
within	O
selected	O
bat	B-ENZY
populations	O
.	O

Lung	O
mechanics	O
,	O
gas	B-ENZY
exchange	O
,	O
diaphragm	O
electrical	O
activity	O
,	O
ultrasound	O
,	O
electrical	O
impedance	O
tomography	O
could	O
be	O
integrated	O
into	O
clinical	O
management	O
to	O
define	O
lung	O
and	O
diaphragm	O
protection	O
and	O
guide	O
personalized	O
ventilation	O
settings	O
.	O

The	O
patients	O
were	O
considered	O
to	O
turn	O
prone	O
if	O
PaO	B-ENZY
Eleven	O
adult	O
patients	O
with	O
severe	O
ARDS	O
were	O
ventilated	O
in	O
prone	O
position	O
.	O

The	O
worst	O
PaO	B-ENZY
PPV	O
improves	O
oxygenation	O
when	O
started	O
early	O
with	O
adequate	O
duration	O
and	O
should	O
be	O
considered	O
in	O
all	O
severe	O
ARDS	O
cases	O
secondary	O
to	O
H1N1	O
viral	O
infection	O
.	O

Coronavirus	O
spike	O
proteins	O
are	O
typically	O
proteolytically	O
processed	O
and	O
activated	O
by	O
host	O
cell	O
enzymes	O
such	O
as	O
trypsin	B-ENZY
-	O
like	O
proteases	O
,	O
cathepsins	O
,	O
or	O
proprotein	O
-	O
convertases	O
.	O

Here	O
,	O
we	O
present	O
a	O
method	O
based	O
on	O
western	O
blot	O
analysis	O
to	O
investigate	O
spike	O
protein	O
proteolytic	O
cleavage	O
by	O
transient	O
transfection	O
of	O
HEK	O
-	O
293	O
T	O
cells	O
allowing	O
expression	O
of	O
the	O
spike	O
protein	O
of	O
the	O
highly	O
pathogenic	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
cellular	O
trypsin	B-ENZY
-	O
like	O
transmembrane	O
serine	O
protease	O
,	O
matriptase	B-ENZY
.	O

Though	O
the	O
gold	O
standard	O
for	O
diagnosing	O
MERS	O
-	O
CoV	O
infection	O
in	O
humans	O
is	O
still	O
nucleic	O
acid	O
amplification	O
test	O
(	O
NAAT	B-ENZY
)	O
of	O
the	O
up	O
-	O
E	O
region	O
,	O
an	O
antigen	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
could	O
also	O
be	O
of	O
use	O
for	O
early	O
diagnosis	O
in	O
less	O
developed	O
locations	O
.	O

TITLE	O
:	O
Host	O
AAA	O
+	O
ATPase	B-ENZY
TER94	O
Plays	O
Critical	O
Roles	O
in	O
Building	O
the	O
Baculovirus	O
Viral	O
Replication	O
Factory	O
and	O
Virion	O
Morphogenesis	O
.	O

ABSTRACT	O
:	O
TER94	O
is	O
a	O
multifunctional	O
AAA	O
+	O
ATPase	B-ENZY
crucial	O
for	O
diverse	O
cellular	O
processes	O
,	O
especially	O
protein	O
quality	O
control	O
and	O
chromatin	O
dynamics	O
in	O
eukaryotic	O
organisms	O
.	O

Improvement	O
in	O
the	O
Oxygenation	O
Index	O
(	O
OI	O
)	O
at	O
48	O
h	O
of	O
initiation	O
of	O
HFOV	O
along	O
with	O
percent	O
increase	O
in	O
PaO	B-ENZY
Survival	O
in	O
pediatric	O
ARDS	O
patients	O
treated	O
with	O
HFOV	O
could	O
be	O
predicted	O
by	O
using	O
trends	O
of	O
OI	O
-	O
with	O
survivors	O
showing	O
a	O
more	O
rapid	O
decline	O
in	O
OI	O
between	O
24	O
and	O
48	O
h	O
of	O
initiation	O
compared	O
to	O
non	O
-	O
survivors	O
.	O

Improvement	O
in	O
the	O
Oxygenation	O
Index	O
(	O
OI	O
)	O
at	O
48	O
h	O
of	O
initiation	O
of	O
HFOV	O
along	O
with	O
percent	O
increase	O
in	O
PaO	B-ENZY

Results	O
obtained	O
from	O
our	O
analyses	O
suggest	O
that	O
the	O
2019	O
-	O
nCoV	O
may	O
appear	O
to	O
be	O
a	O
recombinant	O
virus	O
between	O
the	O
bat	B-ENZY
coronavirus	O
and	O
an	O
origin	O
-	O
unknown	O
coronavirus	O
.	O

Additionally	O
,	O
our	O
findings	O
suggest	O
that	O
2019	O
-	O
nCoV	O
has	O
most	O
similar	O
genetic	O
information	O
with	O
bat	B-ENZY
coronovirus	O
and	O
most	O
similar	O
codon	O
usage	O
bias	O
with	O
snake	O
.	O

The	O
immune	O
response	O
is	O
essential	O
to	O
control	O
and	O
eliminate	O
CoV	O
infections	O
,	O
however	O
,	O
maladjusted	O
immune	O
responses	O
may	O
result	O
in	O
immunopathology	O
and	O
impaired	O
pulmonary	O
gas	B-ENZY
exchange	O
.	O

Results	O
of	O
hematologic	O
analyses	O
and	O
serum	O
concentrations	O
of	O
intestinal	O
fatty	O
acid	O
-	O
binding	O
protein	O
(	O
I	O
-	O
FABP	O
),	O
liver	O
fatty	O
acid	O
-	O
binding	O
protein	O
(	O
L	O
-	O
FABP	O
),	O
trefoil	O
factor	O
3	O
(	O
TFF	O
-	O
3	O
),	O
Claudin	O
-	O
3	O
(	O
CLDN	O
-	O
3	O
),	O
	O
-	O
enteric	O
smooth	O
muscle	O
actin	O
(	O
ACTG2	O
),	O
intestinal	O
alkaline	B-ENZY
phosphatase	I-ENZY
(	O
IAP	O
),	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
),	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
),	O
and	O
leptin	O
(	O
LP	O
)	O
were	O
compared	O
among	O
calves	O
grouped	O
according	O
to	O
whether	O
they	O
were	O
healthy	O
(	O
control	O
group	O
;	O
G	O
-	O
1	O
)	O
or	O
had	O
diarrhea	O
caused	O
by	O
K99	O
Across	O
the	O
3	O
time	O
points	O
at	O
which	O
blood	O
samples	O
were	O
obtained	O
and	O
evaluated	O
,	O
the	O
groups	O
of	O
calves	O
with	O
diarrhea	O
generally	O
had	O
markedly	O
higher	O
mean	O
serum	O
concentrations	O
of	O
L	O
-	O
FABP	O
,	O
TFF	O
-	O
3	O
,	O
IAP	O
,	O
IL	O
-	O
8	O
,	O
and	O
LP	O
,	O
compared	O
with	O
the	O
control	O
group	O
.	O

Phylogenetic	O
analysis	O
of	O
these	O
five	O
patients	O
'	O
RT	O
-	O
PCR	O
amplicons	O
and	O
two	O
full	O
genomes	O
by	O
next	O
-	O
generation	O
sequencing	O
showed	O
that	O
this	O
is	O
a	O
novel	O
coronavirus	O
,	O
which	O
is	O
closest	O
to	O
the	O
bat	B-ENZY
severe	O
acute	O
respiatory	O
syndrome	O
(	O
SARS	O
)-	O
related	O
coronaviruses	O
found	O
in	O
Chinese	O
horseshoe	O
bats	O
.	O

Overall	O
,	O
the	O
genome	O
of	O
2019	O
-	O
nCoV	O
has	O
89	O
%	O
nucleotide	O
identity	O
with	O
bat	B-ENZY
SARS	O
-	O
like	O
-	O
CoVZXC21	O
and	O
82	O
%	O
with	O
that	O
of	O
human	O
SARS	O
-	O
CoV	O
.	O
The	O
phylogenetic	O
trees	O
of	O
their	O
orf1a	O
/	O
b	O
,	O
Spike	O
,	O
Envelope	O
,	O
Membrane	O
and	O
Nucleoprotein	O
also	O
clustered	O
closely	O
with	O
those	O
of	O
the	O
bat	B-ENZY
,	O
civet	O
and	O
human	O
SARS	O
coronaviruses	O
.	O

A	O
phylogenetic	O
tree	O
has	O
been	O
built	O
using	O
the	O
15	O
available	O
whole	O
genome	O
sequences	O
of	O
2019	O
-	O
nCoV	O
,	O
12	O
whole	O
genome	O
sequences	O
of	O
2019	O
-	O
nCoV	O
,	O
and	O
12	O
highly	O
similar	O
whole	O
genome	O
sequences	O
available	O
in	O
gene	O
bank	O
(	O
five	O
from	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
two	O
from	O
Middle	O
East	O
respiratory	O
syndrome	O
,	O
and	O
five	O
from	O
bat	B-ENZY
SARS	O
-	O
like	O
coronavirus	O
).	O

TITLE	O
:	O
Discovery	O
of	O
Bat	B-ENZY
Coronaviruses	O
through	O
Surveillance	O
and	O
Probe	O
Capture	O
-	O
Based	O
Next	O
-	O
Generation	O
Sequencing	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
of	O
bat	B-ENZY
origin	O
have	O
caused	O
two	O
pandemics	O
in	O
this	O
century	O
.	O

Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
CoV	O
both	O
originated	O
from	O
bats	O
,	O
and	O
it	O
is	O
highly	O
likely	O
that	O
bat	B-ENZY
coronaviruses	O
will	O
cause	O
future	O
outbreaks	O
.	O

Next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
is	O
currently	O
the	O
preferred	O
methodology	O
for	O
virus	O
discovery	O
to	O
ensure	O
unbiased	O
sequencing	O
of	O
bat	B-ENZY
CoVs	O
,	O
considering	O
their	O
high	O
genetic	O
diversity	O
.	O

Last	O
,	O
while	O
phylogenetic	O
analysis	O
indicates	O
a	O
bat	B-ENZY
origin	O
of	O
2019	O
-	O
nCoV	O
,	O
2019	O
-	O
nCoV	O
also	O
potentially	O
recognizes	O
ACE2	O
from	O
a	O
diversity	O
of	O
animal	O
species	O
(	O
except	O
mice	O
and	O
rats	O
),	O
implicating	O
these	O
animal	O
species	O
as	O
possible	O
intermediate	O
hosts	O
or	O
animal	O
models	O
for	O
2019	O
-	O
nCoV	O
infections	O
.	O

Even	O
in	O
cases	O
in	O
which	O
life	O
-	O
threatening	O
hypoxemia	O
and	O
severe	O
hypercapnia	O
/	O
acidosis	O
last	O
for	O
>	O
1	O
hours	O
during	O
CPR	B-ENZY
for	O
cardiac	O
arrest	O
,	O
VV	O
-	O
ECMO	O
could	O
be	O
considered	O
a	O
potential	O
lifesaving	O
treatment	O
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
suggest	O
that	O
prone	O
positioning	O
(	O
PP	O
)	O
can	O
increase	O
PaO	B-ENZY
This	O
prospective	O
observational	O
cohort	O
study	O
was	O
performed	O
in	O
two	O
teaching	O
hospitals	O
.	O

The	O
efficacy	O
in	O
improving	O
oxygenation	O
with	O
four	O
support	O
methods	O
-	O
HFNC	O
,	O
HFNC	O
+	O
PP	O
,	O
NIV	O
,	O
NIV	O
+	O
PP	O
-	O
were	O
evaluated	O
by	O
blood	O
gas	B-ENZY
analysis	O
.	O

All	O
7	O
patients	O
with	O
a	O
PaO	B-ENZY
Early	O
application	O
of	O
PP	O
with	O
HFNC	O
,	O
especially	O
in	O
patients	O
with	O
moderate	O
ARDS	O
and	O
baseline	O
SpO	O
ChiCTR	O
,	O
ChiCTR1900023564	O
.	O

All	O
7	O
patients	O
with	O
a	O
PaO	B-ENZY

We	O
collected	O
clinical	O
data	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
specimens	O
from	O
five	O
patients	O
with	O
severe	O
pneumonia	O
from	O
Jin	O
Yin	O
-	O
tan	O
Hospital	O
of	O
Wuhan	O
,	O
Hubei	O
province	O
,	O
China	O
.	O

Nucleic	O
acids	O
of	O
the	O
BAL	B-ENZY
were	O
extracted	O
and	O
subjected	O
to	O
next	O
-	O
generation	O
sequencing	O
.	O

A	O
novel	O
bat	B-ENZY
-	O
borne	O
CoV	O
was	O
identified	O
that	O
is	O
associated	O
with	O
severe	O
and	O
fatal	O
respiratory	O
disease	O
in	O
humans	O
.	O

CONCLUSIONS	O
:	O
A	O
novel	O
bat	B-ENZY
-	O
borne	O
CoV	O
was	O
identified	O
that	O
is	O
associated	O
with	O
severe	O
and	O
fatal	O
respiratory	O
disease	O
in	O
humans	O
.	O

Notably	O
,	O
2019	O
-	O
nCoV	O
was	O
closely	O
related	O
(	O
with	O
88	O
%	O
identity	O
)	O
to	O
two	O
bat	B-ENZY
-	O
derived	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
like	O
coronaviruses	O
,	O
bat	B-ENZY
-	O
SL	O
-	O
CoVZC45	O
and	O
bat	B-ENZY
-	O
SL	O
-	O
CoVZXC21	O
,	O
collected	O
in	O
2018	O
in	O
Zhoushan	O
,	O
eastern	O
China	O
,	O
but	O
were	O
more	O
distant	O
from	O
SARS	O
-	O
CoV	O
(	O
about	O
79	O
%)	O
and	O
MERS	O
-	O
CoV	O
(	O
about	O
50	O
%).	O

TITLE	O
:	O
Accelerated	O
viral	O
dynamics	O
in	O
bat	B-ENZY
cell	O
lines	O
,	O
with	O
implications	O
for	O
zoonotic	O
emergence	O
.	O

We	O
carried	O
out	O
virus	O
infectivity	O
assays	O
on	O
bat	B-ENZY
cell	O
lines	O
expressing	O
induced	O
and	O
constitutive	O
immune	O
phenotypes	O
,	O
then	O
developed	O
a	O
theoretical	O
model	O
of	O
our	O
Bats	O
can	O
carry	O
viruses	O
that	O
are	O
deadly	O
to	O
other	O
mammals	O
without	O
themselves	O
showing	O
serious	O
symptoms	O
.	O

Now	O
,	O
Brook	O
et	O
al	O
.	O
have	O
studied	O
this	O
exact	O
question	O
using	O
bat	B-ENZY
cells	O
grown	O
in	O
the	O
laboratory	O
.	O

The	O
experiments	O
made	O
use	O
of	O
cells	O
from	O
one	O
bat	B-ENZY
species	O
	O
the	O
black	O
flying	O
fox	O
	O
in	O
which	O
the	O
interferon	O
pathway	O
is	O
always	O
on	O
,	O
and	O
another	O
	O
the	O
Egyptian	O
fruit	O
bat	B-ENZY
	O
in	O
which	O
this	O
pathway	O
is	O
only	O
activated	O
during	O
an	O
infection	O
.	O

The	O
bat	B-ENZY
cells	O
were	O
infected	O
with	O
three	O
different	O
viruses	O
,	O
and	O
then	O
Brook	O
et	O
al	O
.	O
observed	O
how	O
the	O
interferon	O
pathway	O
helped	O
keep	O
the	O
infections	O
in	O
check	O
,	O
before	O
creating	O
a	O
computer	O
model	O
of	O
this	O
response	O
.	O

In	O
both	O
bat	B-ENZY
species	O
,	O
the	O
strongest	O
antiviral	O
responses	O
were	O
countered	O
by	O
the	O
virus	O
spreading	O
more	O
quickly	O
from	O
cell	O
to	O
cell	O
.	O

This	O
suggests	O
that	O
bat	B-ENZY
immune	O
defenses	O
may	O
drive	O
the	O
evolution	O
of	O
faster	O
transmitting	O
viruses	O
,	O
and	O
while	O
bats	O
are	O
well	O
protected	O
from	O
the	O
harmful	O
effects	O
of	O
their	O
own	O
prolific	O
viruses	O
,	O
other	O
creatures	O
like	O
humans	O
are	O
not	O
.	O

Coronavirus	O
infection	O
(	O
regardless	O
of	O
the	O
various	O
types	O
of	O
corona	O
virus	O
)	O
is	O
primarily	O
attacked	O
by	O
immune	O
cells	O
including	O
mast	O
cells	O
(	O
MCs	B-ENZY
),	O
which	O
are	O
located	O
in	O
the	O
submucosa	O
of	O
the	O
respiratory	O
tract	O
and	O
in	O
the	O
nasal	O
cavity	O
and	O
represent	O
a	O
barrier	O
of	O
protection	O
against	O
microorganisms	O
.	O

Viral	O
activate	O
MCs	B-ENZY
release	O
early	O
inflammatory	O
chemical	O
copounds	O
including	O
histamine	O
and	O
protease	O
;	O
while	O
late	O
activation	O
provoke	O
the	O
generation	O
of	O
pro	O
-	O
inflammatory	O
IL	O
-	O
1	O
family	O
members	O
including	O
IL	O
-	O
1	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
33	O
.	O

TITLE	O
:	O
A	O
pneumonia	O
outbreak	O
associated	O
with	O
a	O
new	O
coronavirus	O
of	O
probable	O
bat	B-ENZY
origin	O
.	O

From	O
2675	O
studies	O
,	O
we	O
included	O
five	O
RCTs	O
in	O
the	O
analysis	O
,	O
for	O
a	O
total	O
of	O
1461	O
patients	O
with	O
a	O
mean	O
PaO	B-ENZY
NMBA	O
improves	O
oxygenation	O
only	O
after	O
48	O
h	O
in	O
moderate	O
,	O
severe	O
ARDS	O
patients	O
and	O
has	O
a	O
lower	O
barotrauma	O
risk	O
without	O
affecting	O
ICU	O
weakness	O
.	O

Phylogenetic	O
analysis	O
indicates	O
that	O
2019	O
-	O
nCoV	O
is	O
close	O
to	O
coronaviruses	O
(	O
CoVs	O
)	O
circulating	O
in	O
Rhinolophus	O
(	O
Horseshoe	O
bats	O
),	O
such	O
as	O
98	O
.	O
7	O
%	O
nucleotide	O
identity	O
to	O
partial	O
RdRp	O
gene	O
of	O
bat	B-ENZY
coronavirus	O
strain	O
BtCoV	O
/	O
4991	O
(	O
GenBank	O
KP876546	O
,	O
370	O
nt	O
sequence	O
of	O
RdRp	O
and	O
lack	O
of	O
other	O
genome	O
sequence	O
)	O
and	O
87	O
.	O
9	O
%	O
nucleotide	O
identity	O
to	O
bat	B-ENZY
coronavirus	O
strain	O
bat	B-ENZY
-	O
SL	O
-	O
CoVZC45	O
and	O
bat	B-ENZY
-	O
SL	O
-	O
CoVZXC21	O
.	O

A	O
maximum	O
clade	O
credibility	O
tree	O
has	O
been	O
built	O
using	O
a	O
dataset	O
of	O
54	O
genome	O
sequences	O
of	O
2019	O
-	O
nCoV	O
plus	O
two	O
closely	O
related	O
bat	B-ENZY
strains	O
(	O
SARS	O
-	O
like	O
CoV	O
)	O
available	O
in	O
GenBank	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
outbreak	O
of	O
respiratory	O
illness	O
in	O
Wuhan	O
,	O
China	O
is	O
caused	O
by	O
a	O
novel	O
coronavirus	O
,	O
named	O
2019	O
-	O
nCoV	O
,	O
which	O
is	O
genetically	O
close	O
to	O
a	O
bat	B-ENZY
-	O
derived	O
coronavirus	O
.	O

Taking	O
advantage	O
of	O
all	O
the	O
genomic	O
information	O
currently	O
available	O
,	O
we	O
constructed	O
a	O
phylogenetic	O
tree	O
including	O
also	O
representatives	O
of	O
other	O
coronaviridae	O
,	O
such	O
as	O
Bat	B-ENZY
coronavirus	O
(	O
BCoV	O
)	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
determine	O
the	O
prognostic	O
capacity	O
of	O
changes	O
in	O
PaO	B-ENZY
This	O
was	O
a	O
post	O
hoc	O
analysis	O
of	O
the	O
conveniently	O
-	O
sized	O
'	O
Molecular	O
Diagnosis	O
and	O
Risk	O
Stratification	O
of	O
Sepsis	O
'	O
study	O
(	O
MARS	O
).	O

This	O
virus	O
is	O
genetically	O
similar	O
to	O
SARS	O
coronavirus	O
and	O
bat	B-ENZY
SARS	O
-	O
like	O
coronaviruses	O
.	O

Exosomes	O
were	O
isolated	O
via	O
ultracentrifugation	O
;	O
purity	O
was	O
determined	O
using	O
sucrose	O
cushion	O
;	O
and	O
presence	O
of	O
lung	O
self	O
-	O
antigens	O
,	O
20S	O
proteasome	B-ENZY
,	O
and	O
viral	O
antigens	O
for	O
rhinovirus	O
,	O
coronavirus	O
,	O
and	O
respiratory	O
syncytial	O
virus	O
were	O
determined	O
using	O
immunoblot	O
.	O

Circulating	O
exosomes	O
isolated	O
from	O
lung	O
transplant	O
recipients	O
diagnosed	O
with	O
respiratory	O
viral	O
infections	O
contained	O
lung	O
self	O
-	O
antigens	O
,	O
viral	O
antigens	O
,	O
and	O
20S	O
proteasome	B-ENZY
and	O
elicited	O
immune	O
responses	O
to	O
lung	O
self	O
-	O
antigens	O
that	O
resulted	O
in	O
development	O
of	O
chronic	O
lung	O
allograft	O
dysfunction	O
in	O
immunized	O
mice	O
.	O

RESULTS	O
:	O
Exosomes	O
containing	O
self	O
-	O
antigens	O
,	O
20S	O
proteasome	B-ENZY
,	O
and	O
viral	O
antigens	O
were	O
detected	O
at	O
significantly	O
higher	O
levels	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
serum	O
of	O
recipients	O
with	O
symptomatic	O
respiratory	O
viral	O
infections	O
(	O
n	O
=	O
35	O
)	O
as	O
compared	O
with	O
stable	O
controls	O
(	O
n	O
=	O
32	O
).	O

MERS	O
-	O
CoV	O
infection	O
was	O
associated	O
with	O
age	O
(	O
adjusted	O
odds	O
ratio	O
[	O
AOR	B-ENZY
]	O
=	O
1	O
.	O
06	O
;	O
95	O
%	O
CI	O
[	O
1	O
.	O
02	O
-	O
1	O
.	O
098	O
],	O
P	O
-	O
value	O
=	O
0	O
.	O
004	O
),	O
male	O
gender	O
(	O
AOR	B-ENZY
=	O
1	O
.	O
617	O
;	O
95	O
%	O
CI	O
[	O
1	O
.	O
365	O
-	O
1	O
.	O
77	O
],	O
P	O
-	O
value	O
<	O
0	O
.	O
001	O
)	O
and	O
diabetes	O
(	O
AOR	B-ENZY
=	O
1	O
.	O
68	O
;	O
95	O
%	O
CI	O
[	O
1	O
.	O
346	O
-	O
1	O
.	O
848	O
],	O
P	O
-	O
value	O
=	O
0	O
.	O
002	O
.	O

A	O
Maximum	O
Clade	O
Credibility	O
tree	O
has	O
been	O
built	O
using	O
the	O
29	O
available	O
whole	O
genome	O
sequences	O
of	O
2019	O
-	O
nCoV	O
and	O
two	O
whole	O
genome	O
sequences	O
that	O
are	O
highly	O
similar	O
sequences	O
from	O
Bat	B-ENZY
SARS	O
-	O
like	O
Coronavirus	O
available	O
in	O
GeneBank	O
.	O

The	O
Bayesian	O
phylogeographic	O
reconstruction	O
shows	O
that	O
the	O
2019	O
-	O
2020	O
nCoV	O
most	O
probably	O
originated	O
from	O
the	O
Bat	B-ENZY
SARS	O
-	O
like	O
Coronavirus	O
circulating	O
in	O
the	O

TITLE	O
:	O
Feasibility	O
,	O
reproducibility	O
and	O
diagnostic	O
usefulness	O
of	O
right	O
ventricular	O
strain	O
by	O
2	O
-	O
dimensional	O
speckle	O
-	O
tracking	O
echocardiography	O
in	O
ARDS	O
patients	O
:	O
the	O
ARD	B-ENZY
strain	O
study	O
.	O

TITLE	O
:	O
The	O
spike	O
glycoprotein	O
of	O
the	O
new	O
coronavirus	O
2019	O
-	O
nCoV	O
contains	O
a	O
furin	B-ENZY
-	O
like	O
cleavage	O
site	O
absent	O
in	O
CoV	O
of	O
the	O
same	O
clade	O
.	O

Despite	O
a	O
high	O
similarity	O
with	O
the	O
genome	O
sequence	O
of	O
SARS	O
-	O
CoV	O
and	O
SARS	O
-	O
like	O
CoVs	O
,	O
we	O
identified	O
a	O
peculiar	O
furin	B-ENZY
-	O
like	O
cleavage	O
site	O
in	O
the	O
Spike	O
protein	O
of	O
the	O
2019	O
-	O
nCoV	O
,	O
lacking	O
in	O
the	O
other	O
SARS	O
-	O
like	O
CoVs	O
.	O

ABSTRACT	O
:	O
Based	O
on	O
the	O
announcement	O
of	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
in	O
2018	O
,	O
the	O
Wuhan	O
pneumonia	O
caused	O
by	O
an	O
unknown	O
etiology	O
should	O
be	O
recognized	O
as	O
the	O
first	O
Disease	O
X	O
.	O
Later	O
,	O
the	O
pathogen	O
was	O
identified	O
to	O
be	O
a	O
novel	O
coronavirus	O
denoted	O
2019	O
-	O
nCoV	O
,	O
which	O
has	O
79	O
.	O
5	O
%	O
and	O
96	O
%	O
whole	O
genome	O
sequence	O
identify	O
to	O
SARS	O
-	O
CoV	O
and	O
bat	B-ENZY
SARS	O
-	O
related	O
coronavirus	O
(	O
SARSr	O
-	O
CoV	O
-	O
RaTG13	O
),	O
respectively	O
,	O
suggesting	O
its	O
potential	O
bat	B-ENZY
origin	O
.	O

A	O
number	O
of	O
coronavirus	O
genomes	O
have	O
been	O
published	O
that	O
were	O
obtained	O
from	O
such	O
bat	B-ENZY
species	O
.	O

Although	O
bats	O
are	O
the	O
likely	O
natural	O
host	O
of	O
2019_nCoV	O
,	O
the	O
exact	O
bat	B-ENZY
species	O
that	O
serves	O
as	O
the	O
natural	O
host	O
of	O
the	O
virus	O
remains	O
as	O
yet	O
unknown	O
.	O

Increased	O
ACE	B-ENZY
and	O
Ang	O
II	O
are	O
poor	O
prognostic	O
factors	O
for	O
severe	O
pneumonia	O
.	O

The	O
activation	O
of	O
RIPK3	O
-	O
MLKL	O
by	O
tumour	O
necrosis	O
factor	O
receptor	O
1	O
(	O
TNFR1	O
)	O
and	O
TNFR1	O
-	O
associated	O
death	O
domain	O
protein	O
(	O
TRADD	O
)	O
required	O
catalytically	O
active	O
RIPK1	O
and	O
the	O
inhibition	O
of	O
Fas	O
-	O
associated	O
protein	O
with	O
death	O
domain	O
(	O
FADD	O
)/	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
catalytic	O
activity	O
.	O

SARS	O
-	O
CoV	O
-	O
2	O
is	O
closely	O
related	O
to	O
two	O
bat	B-ENZY
-	O
derived	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
like	O
coronaviruses	O
,	O
bat	B-ENZY
-	O
SL	O
-	O
CoVZC45	O
and	O
bat	B-ENZY
-	O
SL	O
-	O
CoVZXC21	O
.	O

The	O
positive	O
selective	O
pressure	O
could	O
account	O
for	O
some	O
clinical	O
features	O
of	O
this	O
virus	O
compared	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
Bat	B-ENZY
SARS	O
-	O
like	O
CoV	O
.	O
The	O
stabilizing	O
mutation	O
falling	O
in	O
the	O
endosome	O
-	O
associated	O
-	O
protein	O
-	O
like	O
domain	O
of	O
the	O
nsp2	O
protein	O
could	O
account	O
for	O
COVID	O
-	O
2019	O
high	O
ability	O
of	O
contagious	O
,	O
while	O
the	O
destabilizing	O
mutation	O
in	O
nsp3	O
proteins	O
could	O
suggest	O
a	O
potential	O
mechanism	O
differentiating	O
COVID	O
-	O
2019	O
from	O
SARS	O
.	O

Based	O
on	O
the	O
limited	O
initial	O
human	O
-	O
to	O
-	O
human	O
transmission	O
and	O
timely	O
clustering	O
of	O
cases	O
in	O
Huanan	O
market	O
among	O
elderly	O
men	O
,	O
coupled	O
with	O
knowledge	O
that	O
coronaviruses	O
are	O
derived	O
from	O
animals	O
and	O
relationship	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
to	O
bat	B-ENZY
coronavirus	O
,	O
zoonotic	O
transmission	O
in	O
the	O
first	O
instance	O
is	O
probable	O
.	O

Clinical	O
isolates	O
were	O
found	O
to	O
contain	O
a	O
novel	O
coronavirus	O
with	O
similarity	O
to	O
bat	B-ENZY
coronaviruses	O
.	O

PDCoV	O
has	O
been	O
successfully	O
isolated	O
using	O
various	O
medium	O
additives	O
including	O
trypsin	B-ENZY
,	O
and	O
although	O
we	O
know	O
it	O
is	O
important	O
for	O
viral	O
replication	O
,	O
the	O
mechanism	O
has	O
not	O
been	O
fully	O
elucidated	O
.	O

Here	O
,	O
we	O
systematically	O
investigated	O
the	O
role	O
of	O
trypsin	B-ENZY
in	O
PDCoV	O
replication	O
including	O
cell	O
entry	O
,	O
cell	O
-	O
to	O
-	O
cell	O
membrane	O
fusion	O
and	O
virus	O
release	O
.	O

Using	O
pseudovirus	O
entry	O
assays	O
,	O
we	O
demonstrated	O
that	O
PDCoV	O
entry	O
is	O
not	O
trypsin	B-ENZY
dependent	O
.	O

Furthermore	O
,	O
unlike	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
in	O
which	O
trypsin	B-ENZY
is	O
important	O
for	O
the	O
release	O
of	O
virus	O
from	O
infected	O
cells	O
,	O
PDCoV	O
release	O
was	O
not	O
affected	O
by	O
trypsin	B-ENZY
.	O

Overall	O
,	O
these	O
results	O
clarify	O
that	O
trypsin	B-ENZY
promotes	O
PDCoV	O
replication	O
by	O
mediating	O
cell	O
-	O
to	O
-	O
cell	O
fusion	O
transmission	O
but	O
is	O
not	O
crucial	O
for	O
viral	O
entry	O
.	O

Where	O
blood	O
gas	B-ENZY
analyzers	O
are	O
unavailable	O
,	O
it	O
can	O
be	O
replaced	O
by	O
the	O
plethysmographic	O
oxygen	O
saturation	O
/	O
fractional	O
inspirational	O
oxygen	O
concentration	O
(	O
SpO	O

We	O
evaluated	O
ARDS	O
incidence	O
,	O
and	O
determined	O
ARDS	O
severity	O
from	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
.	O

Results	O
from	O
the	O
current	O
study	O
showed	O
that	O
pretreatment	O
with	O
nafithromycin	O
significantly	O
reduced	O
the	O
total	O
cell	O
count	O
,	O
total	O
protein	O
,	O
MPO	O
,	O
TNF	O
-	O
	O
and	O
IL	O
-	O
6	O
levels	O
in	O
BAL	B-ENZY
fluid	O
compared	O
to	O
LPS	O
control	O
group	O
.	O

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
craniotomy	O
(	O
CO	O
)	O
and	O
decompressive	O
craniectomy	O
(	O
DC	O
)	O
for	O
evacuation	O
of	O
acute	O
subdural	O
hematoma	O
(	O
SDH	B-ENZY
)	O
on	O
pulmonary	O
complications	O
and	O
sepsis	O
.	O

Some	O
differences	O
were	O
found	O
between	O
the	O
CO	O
and	O
DC	O
groups	O
regarding	O
age	O
(	O
mean	O
[	O
standard	O
deviation	O
(	O
SD	O
)]:	O
47	O
.	O
9	O
years	O
[	O
22	O
.	O
8	O
]	O
versus	O
39	O
.	O
6	O
years	O
[	O
20	O
.	O
1	O
];	O
CONCLUSIONS	O
:	O
Although	O
most	O
of	O
the	O
patients	O
underwent	O
CO	O
for	O
acute	O
SDH	B-ENZY
,	O
no	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
incidence	O
of	O
ARDS	O
,	O
pneumonia	O
,	O
PE	O
,	O
or	O
systemic	O
sepsis	O
when	O
compared	O
with	O
patients	O
who	O
underwent	O
DC	O
.	O

The	O
primary	O
end	O
point	O
was	O
to	O
compare	O
the	O
mean	O
change	O
in	O
partial	O
arterial	O
oxygen	O
pressure	O
to	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
Pao	B-ENZY
A	O
total	O
of	O
239	O
patients	O
were	O
included	O
with	O
139	O
(	O
58	O
.	O
2	O
%)	O
and	O
100	O
(	O
41	O
.	O
8	O
%)	O
in	O
the	O
iEPO	O
and	O
iNO	O
groups	O
,	O
respectively	O
.	O

The	O
mean	O
change	O
in	O
Pao	B-ENZY
CONCLUSIONS	O
:	O
Fixed	O
-	O
dose	O
iEPO	O
was	O
comparable	O
to	O
iNO	O
in	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
for	O
oxygenation	O
and	O
ventilation	O
parameters	O
as	O
well	O
as	O
clinical	O
outcomes	O
.	O

Females	O
(	O
adjusted	O
OR	O
(	O
aOR	B-ENZY
)	O
1	O
.	O
72	O
-	O
2	O
.	O
00	O
;	O
95	O
%	O
CI	O
1	O
.	O
14	O
to	O
2	O
.	O
86	O
)	O
and	O
lower	O
self	O
-	O
reported	O
household	O
economic	O
status	O
respondents	O
were	O
more	O
likely	O
to	O
perceive	O
the	O
affective	O
risk	O
.	O

The	O
respondents	O
who	O
had	O
low	O
trust	O
in	O
the	O
government	O
had	O
higher	O
affective	O
(	O
aOR	B-ENZY
2	O
.	O
19	O
-	O
3	O
.	O
11	O
;	O
95	O
CI	O
1	O
.	O
44	O
to	O
4	O
.	O
67	O
)	O
and	O
cognitive	O
(	O
aOR	B-ENZY
3	O
.	O
55	O
-	O
5	O
.	O
41	O
;	O
95	O
CI	O
1	O
.	O
44	O
to	O
9	O
.	O
01	O
)	O
risk	O
perceptions	O
.	O

The	O
respondents	O
who	O
had	O
low	O
trust	O
in	O
the	O
government	O
had	O
higher	O
affective	O
(	O
aOR	B-ENZY
2	O
.	O
19	O
-	O
3	O
.	O
11	O
;	O
95	O
CI	O
1	O
.	O
44	O
to	O
4	O
.	O
67	O
)	O
and	O
cognitive	O
(	O
aOR	B-ENZY
3	O
.	O
55	O
-	O
5	O
.	O
41	O
;	O
95	O
CI	O
1	O
.	O
44	O
to	O
9	O
.	O
01	O
)	O
risk	O
perceptions	O
.	O

Our	O
analysis	O
reliably	O
suggests	O
that	O
2019	O
-	O
nCoV	O
is	O
most	O
closely	O
related	O
to	O
BatCoV	O
RaTG13	O
and	O
belongs	O
to	O
subgenus	O
Sarbecovirus	O
of	O
Betacoronavirus	O
,	O
together	O
with	O
SARS	O
coronavirus	O
and	O
Bat	B-ENZY
-	O
SARS	O
-	O
like	O
coronavirus	O
.	O

A	O
60	O
-	O
year	O
-	O
old	O
nonalcoholic	O
man	O
,	O
with	O
normal	O
baseline	O
liver	O
function	O
tests	O
,	O
was	O
admitted	O
with	O
diffuse	O
abdominal	O
pain	O
and	O
AST	B-ENZY
=	O
499	O
U	O
/	O
L	O
and	O
ALT	O
=	O
539	O
U	O
/	O
L	O
,	O
six	O
days	O
after	O
completing	O
a	O
7	O
-	O
day	O
course	O
of	O
clarithromycin	O
500	O
mg	O
twice	O
daily	O
for	O
suspected	O
upper	O
respiratory	O
infection	O
.	O

AST	B-ENZY
and	O
ALT	O
each	O
rose	O
to	O
about	O
1	O
,	O
000	O
U	O
/	O
L	O
on	O
day	O
-	O
2	O
of	O
admission	O
,	O
and	O
rose	O
to	O
	O
6	O
,	O
000	O
U	O
/	O
L	O
on	O
day	O
-	O
3	O
,	O
with	O
development	O
of	O
severe	O
hepatic	O
encephalopathy	O
and	O
severe	O
coagulopathy	O
.	O

Rise	O
of	O
AST	B-ENZY
/	O
ALT	O
to	O
about	O
1	O
,	O
000	O
U	O
/	O
L	O
each	O
was	O
temporally	O
incompatible	O
with	O
shock	O
liver	O
because	O
this	O
rise	O
preceded	O
the	O
hemorrhagic	O
shock	O
,	O
but	O
the	O
subsequent	O
AST	B-ENZY
/	O
ALT	O
rise	O
to	O
	O
6	O
,	O
000	O
U	O
/	O
L	O
each	O
may	O
have	O
had	O
a	O
component	O
of	O
shock	O
liver	O
.	O

Review	O
of	O
6	O
previously	O
reported	O
and	O
current	O
case	O
of	O
clarithromycin	O
-	O
associated	O
ALF	O
revealed	O
that	O
patients	O
had	O
AST	B-ENZY
and	O
ALT	O
values	O
in	O
the	O
thousands	O
.	O

The	O
role	O
of	O
fibrinolytic	O
components	O
such	O
as	O
Urokinase	B-ENZY
Plasminogen	O
activator	O
(	O
uPA	O
),	O
uPA	O
receptor	O
(	O
uPAR	O
)	O
and	O
Plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
has	O
been	O
detailed	O
in	O
I	O
.	O
Curcumin	O
is	O
known	O
to	O
possess	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
fibrotic	O
effects	O
.	O

In	O
this	O
context	O
,	O
the	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
associated	O
ribonuclease	B-ENZY
H	I-ENZY
(	O
RNase	B-ENZY
H	I-ENZY
),	O
which	O
is	O
one	O
of	O
the	O
few	O
HIV	O
-	O
1	O
encoded	O
enzymatic	O
function	O
still	O
not	O
targeted	O
by	O
any	O
current	O
drug	O
,	O
can	O
be	O
considered	O
as	O
an	O
appealing	O
target	O
.	O

We	O
found	O
that	O
the	O
SARS	O
-	O
CoV	O
-	O
2	O
S	O
glycoprotein	O
harbors	O
a	O
furin	B-ENZY
cleavage	O
site	O
at	O
the	O
boundary	O
between	O
the	O
S	O

The	O
RT	O
-	O
PCR	O
detection	O
of	O
viral	O
nucleic	O
acid	O
test	O
(	O
NAT	B-ENZY
)	O
was	O
one	O
of	O
the	O
most	O
quickly	O
established	O
laboratory	O
diagnosis	O
method	O
in	O
a	O
novel	O
viral	O
pandemic	O
,	O
just	O
as	O
in	O
this	O
COVID	O
-	O
19	O
outbreak	O
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
viral	O
NAT	B-ENZY
played	O
an	O
important	O
role	O
in	O
identifying	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
.	O

The	O
genome	O
composition	O
,	O
nucleotide	O
analysis	O
,	O
codon	O
usage	O
indices	O
,	O
relative	O
synonymous	O
codons	O
usage	O
,	O
and	O
effective	O
number	O
of	O
codons	O
(	O
ENc	O
)	O
were	O
analyzed	O
in	O
the	O
four	O
structural	O
genes	O
;	O
Spike	O
(	O
S	O
),	O
Envelope	O
(	O
E	O
),	O
membrane	O
(	O
M	O
),	O
and	O
Nucleocapsid	O
(	O
N	O
)	O
genes	O
,	O
and	O
two	O
of	O
the	O
most	O
important	O
nonstructural	O
genes	O
comprising	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
and	O
main	O
protease	O
(	O
Mpro	O
)	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
Beta	O
-	O
CoV	O
from	O
pangolins	O
,	O
bat	B-ENZY
SARS	O
,	O
MERS	O
,	O
and	O
SARS	O
CoVs	O
.	O

Most	O
high	O
-	O
frequency	O
codons	O
were	O
ending	O
with	O
A	O
or	O
T	O
,	O
while	O
the	O
low	O
frequency	O
and	O
rare	O
codons	O
were	O
ending	O
with	O
G	O
or	O
C	O
.	O
SARS	O
-	O
CoV	O
-	O
2	O
structural	O
proteins	O
showed	O
5	O
to	O
20	O
lower	O
ENc	O
values	O
,	O
compared	O
with	O
SARS	O
,	O
bat	B-ENZY
SARS	O
,	O
and	O
MERS	O
CoVs	O
.	O

Pangolin	O
Beta	O
-	O
CoV	O
showed	O
little	O
differences	O
with	O
SARS	O
-	O
CoV	O
-	O
2	O
ENc	O
values	O
,	O
compared	O
with	O
SARS	O
,	O
bat	B-ENZY
SARS	O
,	O
and	O
MERS	O
CoV	O
.	O
Extreme	O
bias	O
and	O
lower	O
ENc	O
values	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
especially	O
in	O
Spike	O
,	O
Envelope	O
,	O
and	O
Mpro	O
genes	O
,	O
are	O
suggestive	O
for	O
higher	O
gene	O
expression	O
efficiency	O
,	O
compared	O
with	O
SARS	O
,	O
bat	B-ENZY
SARS	O
,	O
and	O
MERS	O
CoVs	O
.	O

Pangolin	O
Beta	O
-	O
CoV	O
showed	O
little	O
differences	O
with	O
SARS	O
-	O
CoV	O
-	O
2	O
ENc	O
values	O
,	O
compared	O
with	O
SARS	O
,	O
bat	B-ENZY
SARS	O
,	O
and	O
MERS	O
CoV	O
.	O
CONCLUSIONS	O
:	O
Extreme	O
bias	O
and	O
lower	O
ENc	O
values	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
especially	O
in	O
Spike	O
,	O
Envelope	O
,	O
and	O
Mpro	O
genes	O
,	O
are	O
suggestive	O
for	O
higher	O
gene	O
expression	O
efficiency	O
,	O
compared	O
with	O
SARS	O
,	O
bat	B-ENZY
SARS	O
,	O
and	O
MERS	O
CoVs	O
.	O

Compared	O
to	O
NON	O
-	O
NCOVID	O
-	O
19	O
,	O
NCOVID	O
-	O
19	O
present	O
remarkably	O
more	O
abnormal	O
laboratory	O
tests	O
including	O
AST	B-ENZY
,	O
ALT	O
,	O
	O
-	O
GT	O
,	O
LDH	O
and	O
	O
-	O
HBDH	O
.	O

Compared	O
to	O
NON	O
-	O
NCOVID	O
-	O
19	O
,	O
NCOVID	O
-	O
19	O
present	O
remarkably	O
more	O
abnormal	O
laboratory	O
tests	O
including	O
AST	B-ENZY
,	O
ALT	O
,	O
	O
-	O
GT	O
,	O
LDH	O
and	O
	O
-	O
HBDH	O
.	O

We	O
studied	O
children	O
at	O
a	O
large	O
tertiary	O
-	O
care	O
hospital	O
in	O
China	O
,	O
during	O
the	O
period	O
from	O
28	O
January	O
2019	O
to	O
8	O
February	O
2020	O
,	O
who	O
had	O
positive	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
COVID	O
-	O
19	O
.	O

Decrease	O
of	O
the	O
inflammatory	O
biomarkers	O
(	O
ferritin	O
,	O
interleukin	O
-	O
6	O
,	O
interleukin	O
-	O
10	O
)	O
in	O
the	O
first	O
96	O
hours	O
associated	O
with	O
a	O
progressive	O
improvement	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
Pao	B-ENZY
This	O
case	O
suggests	O
that	O
hemoadsorption	O
with	O
cartridge	O
column	O
in	O
combination	O
with	O
continuous	O
renal	O
replacement	O
therapy	O
and	O
tocilizumab	O
is	O
safe	O
and	O
potentially	O
effective	O
in	O
pediatric	O
patients	O
with	O
severe	O
cytokine	O
release	O
syndrome	O
.	O

The	O
AS	O
-	O
SCoV2	O
located	O
in	O
the	O
acidic	O
-	O
domain	O
of	O
papain	B-ENZY
-	O
like	O
protein	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
and	O
bat	B-ENZY
-	O
SL	O
-	O
CoV	O
-	O
RatG13	O
guided	O
us	O
to	O
suggest	O
that	O
the	O
novel	O
2019	O
coronavirus	O
probably	O
emerged	O
by	O
genetic	O
drift	O
from	O
bat	B-ENZY
-	O
SL	O
-	O
CoV	O
-	O
RaTG13	O
.	O

The	O
implication	O
of	O
this	O
amino	O
acid	O
signature	O
in	O
papain	B-ENZY
-	O
like	O
protein	O
structure	O
arrangement	O
and	O
function	O
is	O
something	O
worth	O
to	O
be	O
explored	O
.	O

Meanwhile	O
,	O
several	O
independent	O
research	O
groups	O
have	O
identified	O
that	O
SARS	O
-	O
CoV	O
-	O
2	O
belongs	O
to	O
	O
-	O
coronavirus	O
,	O
with	O
highly	O
identical	O
genome	O
to	O
bat	B-ENZY
coronavirus	O
,	O
pointing	O
to	O
bat	B-ENZY
as	O
the	O
natural	O
host	O
.	O

RESULTS	O
:	O
Compared	O
with	O
general	O
COVID	O
-	O
19	O
patients	O
(	O
45	O
.	O
2	O
%),	O
refractory	O
patients	O
had	O
an	O
older	O
age	O
,	O
male	O
sex	O
,	O
more	O
underlying	O
comorbidities	O
,	O
lower	O
incidence	O
of	O
fever	O
,	O
higher	O
levels	O
of	O
maximum	O
temperature	O
among	O
fever	O
cases	O
,	O
higher	O
incidence	O
of	O
breath	O
shortness	O
and	O
anorexia	O
,	O
severer	O
disease	O
assessment	O
on	O
admission	O
,	O
high	O
levels	O
of	O
neutrophil	O
,	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
and	O
C	O
-	O
reactive	O
protein	O
,	O
lower	O
levels	O
of	O
platelets	O
and	O
albumin	O
,	O
and	O
higher	O
incidence	O
of	O
bilateral	O
pneumonia	O
and	O
pleural	O
effusion	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

GA	O
has	O
shown	O
pleiotropic	O
effects	O
in	O
vitro	O
,	O
including	O
:	O
antitumor	O
effects	O
through	O
inhibition	O
of	O
lipogenesis	O
;	O
decreased	O
expression	O
of	O
invasion	O
associated	O
proteins	O
through	O
AMPK	B-ENZY
activation	O
;	O
and	O
potential	O
rescue	O
of	O
amyloid	O
-	O
	O
(	O
A	O
)	O
induced	O
synaptic	O
impairment	O
.	O

In	O
this	O
work	O
,	O
we	O
searched	O
the	O
homologous	O
templates	O
of	O
all	O
nonstructural	O
and	O
structural	O
proteins	O
of	O
2019	O
-	O
nCoV	O
.	O
Among	O
the	O
nonstructural	O
proteins	O
,	O
the	O
leader	O
protein	O
(	O
nsp1	O
),	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
nsp3	O
),	O
the	O
nsp4	O
,	O
the	O
3C	O
-	O
like	O
protease	O
(	O
nsp5	O
),	O
the	O
nsp7	O
,	O
the	O
nsp8	O
,	O
the	O
nsp9	O
,	O
the	O
nsp10	O
,	O
the	O
RNA	B-ENZY
-	I-ENZY
directed	I-ENZY
RNA	I-ENZY
polymerase	I-ENZY
(	O
nsp12	O
),	O
the	O
helicase	O
(	O
nsp13	O
),	O
the	O
guanine	O
-	O
N7	O
methyltransferase	O
(	O
nsp14	O
),	O
the	O
uridylate	O
-	O
specific	O
endoribonuclease	O
(	O
nsp15	O
),	O
the	O
2	O
'-	O
O	O
-	O
methyltransferase	O
(	O
nsp16	O
),	O
and	O
the	O
ORF7a	O
protein	O
could	O
be	O
built	O
on	O
the	O
basis	O
of	O
homology	O
templates	O
.	O

Dornase	O
alfa	O
is	O
a	O
US	O
Food	O
and	O
Drug	O
Administration	O
-	O
approved	O
recombinant	O
DNase	B-ENZY
,	O
which	O
cleaves	O
extracellular	O
DNA	O
and	O
may	O
therefore	O
break	O
up	O
the	O
backbone	O
of	O
NETs	O
and	O
DAMPs	O
.	O

TITLE	O
:	O
COVID	O
-	O
19	O
:	O
social	O
distancing	O
,	O
ACE	B-ENZY
2	O
receptors	O
,	O
protease	O
inhibitors	O
and	O
beyond	O
?	O

ABSTRACT	O
:	O
Lung	O
injury	O
caused	O
by	O
chemical	O
gas	B-ENZY
inhalation	O
is	O
a	O
common	O
clinically	O
severe	O
disease	O
that	O
very	O
easily	O
progresses	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

The	O
laboratory	O
results	O
showed	O
that	O
compared	O
to	O
the	O
normal	O
values	O
,	O
the	O
patients	O
'	O
lymphocytes	O
were	O
reduced	O
(	O
4	O
[	O
80	O
%]	O
patients	O
),	O
and	O
liver	O
function	O
ALT	O
and	O
AST	B-ENZY
(	O
2	O
[	O
40	O
%]	O
patients	O
,	O
2	O
[	O
40	O
%]	O
patients	O
)	O
and	O
C	O
-	O
reactive	O
protein	O
(	O
4	O
[	O
80	O
%]	O
patients	O
)	O
were	O
increased	O
when	O
admitted	O
to	O
hospital	O
.	O

Both	O
Pangolin	O
-	O
CoV	O
and	O
RaTG13	O
lost	O
the	O
putative	O
furin	B-ENZY
recognition	O
sequence	O
motif	O
at	O
S1	O
/	O
S2	O
cleavage	O
site	O
that	O
can	O
be	O
observed	O
in	O
the	O
SARS	O
-	O
CoV	O
-	O
2	O
.	O

Compared	O
with	O
the	O
mild	O
cases	O
,	O
the	O
severe	O
cases	O
had	O
lower	O
lymphocyte	O
counts	O
and	O
higher	O
plasma	O
levels	O
of	O
Pt	O
,	O
APTT	O
,	O
D	O
-	O
dimer	O
,	O
LDH	O
,	O
PCT	O
,	O
ALB	O
,	O
CRP	O
,	O
and	O
AST	B-ENZY
.	O

Compared	O
with	O
the	O
mild	O
cases	O
,	O
the	O
severe	O
cases	O
had	O
lower	O
lymphocyte	O
counts	O
and	O
higher	O
plasma	O
levels	O
of	O
Pt	O
,	O
APTT	O
,	O
D	O
-	O
dimer	O
,	O
LDH	O
,	O
PCT	O
,	O
ALB	O
,	O
CRP	O
,	O
and	O
AST	B-ENZY
.	O

TITLE	O
:	O
Renin	B-ENZY
-	O
angiotensin	O
system	O
in	O
human	O
coronavirus	O
pathogenesis	O
.	O

Here	O
,	O
we	O
identified	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
SARS	O
-	O
CoV	O
-	O
2	O
S	O
protein	O
and	O
found	O
that	O
the	O
RBD	O
protein	O
bound	O
strongly	O
to	O
human	O
and	O
bat	B-ENZY
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
receptors	O
.	O

TITLE	O
:	O
Renin	B-ENZY
-	O
Angiotensin	O
System	O
Blockers	O
and	O
the	O
COVID	O
-	O
19	O
Pandemic	O
:	O

At	O
Present	O
There	O
Is	O
No	O
Evidence	O
to	O
Abandon	O
Renin	B-ENZY
-	O
Angiotensin	O
System	O
Blockers	O
.	O

Because	O
the	O
ACE2	O
(	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
)	O
protein	O
is	O
the	O
receptor	O
that	O
facilitates	O
coronavirus	O
entry	O
into	O
cells	O
,	O
the	O
notion	O
has	O
been	O
popularized	O
that	O
treatment	O
with	O
renin	B-ENZY
-	O
angiotensin	O
system	O
blockers	O
might	O
increase	O
the	O
risk	O
of	O
developing	O
a	O
severe	O
and	O
fatal	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
-	O
2	O
infection	O
.	O

Moreover	O
,	O
there	O
are	O
no	O
data	O
to	O
support	O
the	O
notion	O
that	O
ACE	B-ENZY
inhibitor	O
or	O
angiotensin	O
II	O
type	O
1	O
receptor	O
blocker	O
administration	O
facilitates	O
coronavirus	O
entry	O
by	O
increasing	O
ACE2	O
expression	O
in	O
either	O
animals	O
or	O
humans	O
.	O

In	O
summary	O
,	O
based	O
on	O
the	O
currently	O
available	O
evidence	O
,	O
treatment	O
with	O
renin	B-ENZY
-	O
angiotensin	O
system	O
blockers	O
should	O
not	O
be	O
discontinued	O
because	O
of	O
concerns	O
with	O
coronavirus	O
infection	O
.	O

SARS	O
-	O
CoV	O
-	O
2	O
with	O
potential	O
origin	O
of	O
bat	B-ENZY
is	O
still	O
circulating	O
in	O
China	O
.	O

Alanine	B-ENZY
transaminase	I-ENZY
(	O
ALT	O
)	O
(	O
22	O
.	O
00	O
[	O
15	O
.	O
00	O
,	O
34	O
.	O
00	O
]	O
U	O
/	O
L	O
vs	O
.	O
18	O
.	O
70	O
[	O
13	O
.	O
00	O
,	O
30	O
.	O
38	O
]	O
U	O
/	O
L	O
,	O
Z	O
=	O
2	O
.	O
592	O
,	O
P	O
=	O
0	O
.	O
010	O
),	O
aspartate	B-ENZY
transaminase	I-ENZY
(	O
AST	B-ENZY
)	O
(	O
34	O
.	O
00	O
[	O
27	O
.	O
00	O
,	O
47	O
.	O
00	O
]	O
U	O
/	O
L	O
vs	O
.	O
22	O
.	O
00	O
[	O
17	O
.	O
65	O
,	O
31	O
.	O
75	O
]	O
U	O
/	O
L	O
,	O
Z	O
=	O
7	O
.	O
308	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
creatinine	O
levels	O
(	O
89	O
.	O
00	O
[	O
72	O
.	O
00	O
,	O
133	O
.	O
50	O
]	O
mol	O
/	O
L	O
vs	O
.	O
65	O
.	O
00	O
[	O
54	O
.	O
60	O
,	O
78	O
.	O
75	O
]	O
mol	O
/	O
L	O
,	O
Z	O
=	O
6	O
.	O
478	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
were	O
significantly	O
higher	O
in	O
the	O
death	O
group	O
that	O
those	O
in	O
the	O
recovered	O
group	O
.	O

A	O
total	O
of	O
82	O
patients	O
(	O
19	O
.	O
7	O
%)	O
had	O
cardiac	O
injury	O
,	O
and	O
compared	O
with	O
patients	O
without	O
cardiac	O
injury	O
,	O
these	O
patients	O
were	O
older	O
(	O
median	O
[	O
range	O
]	O
age	O
,	O
74	O
[	O
34	O
-	O
95	O
]	O
vs	O
60	O
[	O
21	O
-	O
90	O
]	O
years	O
;	O
P	O
<	O
.	O
001	O
);	O
had	O
more	O
comorbidities	O
(	O
eg	O
,	O
hypertension	O
in	O
49	O
of	O
82	O
[	O
59	O
.	O
8	O
%]	O
vs	O
78	O
of	O
334	O
[	O
23	O
.	O
4	O
%];	O
P	O
<	O
.	O
001	O
);	O
had	O
higher	O
leukocyte	O
counts	O
(	O
median	O
[	O
interquartile	O
range	O
(	O
IQR	O
)],	O
9400	O
[	O
6900	O
-	O
13	O
800	O
]	O
vs	O
5500	O
[	O
4200	O
-	O
7400	O
]	O
cells	O
/	O
L	O
)	O
and	O
levels	O
of	O
C	O
-	O
reactive	O
protein	O
(	O
median	O
[	O
IQR	O
],	O
10	O
.	O
2	O
[	O
6	O
.	O
4	O
-	O
17	O
.	O
0	O
]	O
vs	O
3	O
.	O
7	O
[	O
1	O
.	O
0	O
-	O
7	O
.	O
3	O
]	O
mg	O
/	O
dL	O
),	O
procalcitonin	O
(	O
median	O
[	O
IQR	O
],	O
0	O
.	O
27	O
[	O
0	O
.	O
10	O
-	O
1	O
.	O
22	O
]	O
vs	O
0	O
.	O
06	O
[	O
0	O
.	O
03	O
-	O
0	O
.	O
10	O
]	O
ng	O
/	O
mL	O
),	O
creatinine	O
kinase	O
-	O
myocardial	O
band	O
(	O
median	O
[	O
IQR	O
],	O
3	O
.	O
2	O
[	O
1	O
.	O
8	O
-	O
6	O
.	O
2	O
]	O
vs	O
0	O
.	O
9	O
[	O
0	O
.	O
6	O
-	O
1	O
.	O
3	O
]	O
ng	O
/	O
mL	O
),	O
myohemoglobin	O
(	O
median	O
[	O
IQR	O
],	O
128	O
[	O
68	O
-	O
305	O
]	O
vs	O
39	O
[	O
27	O
-	O
65	O
]	O
g	O
/	O
L	O
),	O
high	O
-	O
sensitivity	O
troponin	O
I	O
(	O
median	O
[	O
IQR	O
],	O
0	O
.	O
19	O
[	O
0	O
.	O
08	O
-	O
1	O
.	O
12	O
]	O
vs	O
<	O
0	O
.	O
006	O
[<	O
0	O
.	O
006	O
-	O
0	O
.	O
009	O
]	O
g	O
/	O
L	O
),	O
N	O
-	O
terminal	O
pro	O
-	O
B	O
-	O
type	O
natriuretic	O
peptide	O
(	O
median	O
[	O
IQR	O
],	O
1689	O
[	O
698	O
-	O
3327	O
]	O
vs	O
139	O
[	O
51	O
-	O
335	O
]	O
pg	O
/	O
mL	O
),	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
median	O
[	O
IQR	O
],	O
40	O
[	O
27	O
-	O
60	O
]	O
vs	O
29	O
[	O
21	O
-	O
40	O
]	O
U	O
/	O
L	O
),	O
and	O
creatinine	O
(	O
median	O
[	O
IQR	O
],	O
1	O
.	O
15	O
[	O
0	O
.	O
72	O
-	O
1	O
.	O
92	O
]	O
vs	O
0	O
.	O
64	O
[	O
0	O
.	O
54	O
-	O
0	O
.	O
78	O
]	O
mg	O
/	O
dL	O
);	O
and	O
had	O
a	O
higher	O
proportion	O
of	O
multiple	O
mottling	O
and	O
ground	O
-	O
glass	O
opacity	O
in	O
radiographic	O
findings	O
(	O
53	O
of	O
82	O
patients	O
[	O
64	O
.	O
6	O
%]	O
vs	O
15	O
of	O
334	O
patients	O
[	O
4	O
.	O
5	O
%]).	O

ABSTRACT	O
:	O
Ventilation	O
/	O
perfusion	O
inequalities	O
impair	O
gas	B-ENZY
exchange	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

